PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Dunlop, JA; Anderson, LI; Kerp, H; Hass, H				Dunlop, JA; Anderson, LI; Kerp, H; Hass, H			Preserved organs of Devonian harvestmen	NATURE			English	Article							ABERDEENSHIRE; SCOTLAND; OPILIONES; ARACHNIDA; SYSTEM; CHERTS; RHYNIE		Humboldt Univ, Museum Nat Kunde, Inst Systemat Zool, D-10115 Berlin, Germany; Natl Museums Scotland, Dept Geol & Zool, Edinburgh EH1 1JF, Midlothian, Scotland; Univ Munster, Forsch Stelle Palaobot, D-48143 Munster, Germany	Humboldt University of Berlin; Leibniz Institut fur Evolutions und Biodiversitatsforschung; University of Munster	Dunlop, JA (corresponding author), Humboldt Univ, Museum Nat Kunde, Inst Systemat Zool, D-10115 Berlin, Germany.		Dunlop, Jason A./AAC-8042-2019; Kerp, Hans/AAJ-1102-2020	Dunlop, Jason/0000-0002-0179-6640				Anderson LI, 2003, PALAEONTOLOGY, V46, P467, DOI 10.1111/1475-4983.00308; CLARIDGE MF, 1961, NATURE, V191, P1190, DOI 10.1038/1911190b0; Edgecombe GD, 1998, NATURE, V394, P172, DOI 10.1038/28156; Giribet G, 2002, CLADISTICS, V18, P5, DOI 10.1006/clad.2001.0185; Hofer AM, 2000, ARTHROPOD STRUCT DEV, V29, P13, DOI 10.1016/S1467-8039(00)00009-8; Martens J., 1981, Zoologische Jahrbuecher Abteilung fuer Anatomie und Ontogenie der Tiere, V105, P13; MARTENS J, 1976, Entomologica Germanica, V3, P51; Rice CM, 2002, J GEOL SOC LONDON, V159, P203, DOI 10.1144/0016-764900-181; TREWIN NH, 1994, T ROY SOC EDIN-EARTH, V84, P433	9	50	50	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	2003	425	6961					916	916		10.1038/425916a	http://dx.doi.org/10.1038/425916a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14586459				2022-12-28	WOS:000186230600031
J	Murphy, JG; Wright, RS; Bruce, GK; Baddour, LM; Farrell, MA; Edwards, WD; Kita, H; Cooper, LT				Murphy, JG; Wright, RS; Bruce, GK; Baddour, LM; Farrell, MA; Edwards, WD; Kita, H; Cooper, LT			Eosinophilic-lymphocytic myocarditis after smallpox vaccination	LANCET			English	Article							MYOPERICARDITIS	Smallpox is an eradicated viral disease that has re-emerged as a potential bioterrorism threat. Smallpox vaccination was historically the most effective defence measure against wild smallpox virus. The risk of myopericarditis after vaccination might limit this option. We report a case of biopsy-proven eosinophilic-lymphocytic myocarditis diagnosed in vivo with histological evidence for eosinophil-mediated cardiac myocyte necrosis shortly after smallpox vaccination. Furthermore, we report a beneficial haemodynamic response to high-dose corticosteroids. A better understanding of the aberrant immune mechanism of myocyte injury after smallpox vaccination might improve the risk/benefit assessment for people considering smallpox vaccination and better smallpox vaccines in the future.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Infect Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Diagnost Radiol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Anat Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Allerg Dis, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Murphy, JG (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.			Cooper, Leslie/0000-0003-1002-3313				Boccara F, 2001, CHEST, V120, P671, DOI 10.1378/chest.120.2.671; FEERY BJ, 1977, MED J AUSTRALIA, V2, P180, DOI 10.5694/j.1326-5377.1977.tb114544.x; GORE I, 1968, PATHOLOGY HEART BLOO, P737; Halsell JS, 2003, JAMA-J AM MED ASSOC, V289, P3283, DOI 10.1001/jama.289.24.3283; KARJALAINEN J, 1983, ACTA MED SCAND, V213, P65	5	48	48	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 25	2003	362	9393					1378	1380		10.1016/S0140-6736(03)14635-1	http://dx.doi.org/10.1016/S0140-6736(03)14635-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	735YX	14585641				2022-12-28	WOS:000186143300013
J	Beier, DR; Dluhy, RG				Beier, DR; Dluhy, RG			Bench and bedside - The G protein-coupled receptor GPR54 and puberty	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Beier, DR (corresponding author), Brigham & Womens Hosp, Dept Med, Div Genet, 75 Francis St, Boston, MA 02115 USA.								0	16	17	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	2003	349	17					1589	1592		10.1056/NEJMp038155	http://dx.doi.org/10.1056/NEJMp038155			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734ZT	14573729				2022-12-28	WOS:000186088400002
J	Patel, V				Patel, V			Recruiting doctors from poor countries: the great brain robbery?	BRITISH MEDICAL JOURNAL			English	Article									Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Patel, V (corresponding author), Sangath Ctr, 841-1 Alto, Porvorim 403521, Goa, India.			Patel, Vikram/0000-0003-1066-8584				*DEP HLTH, 2001, COD PRACT NHS EMPL I; GOLDBERG D., 2003, NEWSLETTER FACULTY G, V6, P5; *NAT HLTH SERV, 2002, CAR OPP DOCT ENGL NH; PATEL V, 1992, LANCET, V339, P110, DOI 10.1016/0140-6736(92)91010-6; WHO, 2001, ATL COUNTR PROF MENT	5	49	49	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 18	2003	327	7420					926	928		10.1136/bmj.327.7420.926	http://dx.doi.org/10.1136/bmj.327.7420.926			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734RV	14563760	Green Accepted, Green Published			2022-12-28	WOS:000186072100035
J	Barnes, JW; Tischkau, SA; Barnes, JA; Mitchell, JW; Burgoon, PW; Hickok, JR; Gillette, MU				Barnes, JW; Tischkau, SA; Barnes, JA; Mitchell, JW; Burgoon, PW; Hickok, JR; Gillette, MU			Requirement of mammalian Timeless for circadian rhythmicity	SCIENCE			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; DROSOPHILA TIMELESS; CLOCK; MPER1; EXPRESSION; ANTAGONISM; ORTHOLOG; GENETICS; LOOP; RNA	Despite a central circadian role in Drosophila for the transcriptional regulator Timeless (dTim), the relevance of mammalian Timeless (mTim) remains equivocal. Conditional knockdown of mTim protein expression in the rat suprachiasmatic nucleus (SCN) disrupted SCN neuronal activity rhythms, and altered levels of known core clock elements. Full-length mTim protein (mTIM-fl) exhibited a 24-hour oscillation, whereas a truncated isoform (mTIM-s) was constitutively expressed. mTIM-fl associated with the mammalian clock Period proteins (mPERs) in oscillating SCN cells. These data suggest that mTim is required for rhythmicity and is a functional homolog of dTim on the negative-feedback arm of the mammalian molecular clockwork.	Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Vet Biosci, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Gillette, MU (corresponding author), Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022155, F32NS011134, F32NS010170, F32NS011158, R01NS035859] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL067007, HL67007] Funding Source: Medline; NIGMS NIH HHS [GM07143] Funding Source: Medline; NINDS NIH HHS [NS22155, NS11134, R01 NS035859, R01 NS022155, NS11158, NS10170, NS35859] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akiyama M, 1999, J NEUROSCI, V19, P1115; Albrecht U, 2002, J APPL PHYSIOL, V92, P1348, DOI 10.1152/japplphysiol.00759.2001; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Earnest DJ, 1999, SCIENCE, V283, P693, DOI 10.1126/science.283.5402.693; Field MD, 2000, NEURON, V25, P437, DOI 10.1016/S0896-6273(00)80906-X; Gerhold LM, 2002, J COMP NEUROL, V450, P135, DOI 10.1002/cne.10307; Gotter AL, 2000, NAT NEUROSCI, V3, P755, DOI 10.1038/77653; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Harney JP, 1996, ENDOCRINOLOGY, V137, P3696, DOI 10.1210/en.137.9.3696; Hastings M H, 1999, J Neurosci, V19, pRC11; King DP, 2000, ANNU REV NEUROSCI, V23, P713, DOI 10.1146/annurev.neuro.23.1.713; Koike N, 1998, FEBS LETT, V441, P427, DOI 10.1016/S0014-5793(98)01597-X; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Li ZX, 2000, P NATL ACAD SCI USA, V97, P10038, DOI 10.1073/pnas.97.18.10038; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; Sakamoto S, 2000, BIOCHEM BIOPH RES CO, V279, P131, DOI 10.1006/bbrc.2000.3927; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Takumi T, 1999, GENES CELLS, V4, P67, DOI 10.1046/j.1365-2443.1999.00238.x; Tischkau S A, 1999, J Neurosci, V19, pRC15; Tischkau SA, 2003, J BIOL CHEM, V278, P718, DOI 10.1074/jbc.M209241200; Wakamatsu H, 2001, NEUROREPORT, V12, P127, DOI 10.1097/00001756-200101220-00033; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Zylka MJ, 1998, NEURON, V21, P1115, DOI 10.1016/S0896-6273(00)80628-5	24	153	162	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					439	442		10.1126/science.1086593	http://dx.doi.org/10.1126/science.1086593			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564007				2022-12-28	WOS:000185963200041
J	Orlitsky, A; Santhanam, NP; Zhang, JN				Orlitsky, A; Santhanam, NP; Zhang, JN			Always good Turing: Asymptotically optimal probability estimation	SCIENCE			English	Article								While deciphering the Enigma code, Good and Turing derived an unintuitive, yet effective, formula for estimating a probability distribution from a sample of data. We de. ne the attenuation of a probability estimator as the largest possible ratio between the per-symbol probability assigned to an arbitrarily long sequence by any distribution, and the corresponding probability assigned by the estimator. We show that some common estimators have infinite attenuation and that the attenuation of the Good-Turing estimator is low, yet greater than 1. We then derive an estimator whose attenuation is 1; that is, asymptotically it does not underestimate the probability of any sequence.	Univ Calif San Diego, Dept Elect & Comp Engn, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Comp Sci & Engn, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Orlitsky, A (corresponding author), Univ Calif San Diego, Dept Elect & Comp Engn, La Jolla, CA 92093 USA.	alon@ucsd.edu						ABERG J, 1997, P COMPR COMPL SEQ; Cesa-Bianchi N., 1999, Proceedings of the Twelfth Annual Conference on Computational Learning Theory, P12, DOI 10.1145/307400.307407; Chen S. F., 1996, P 34 ANN M ASS COMP, V34, P310, DOI DOI 10.3115/981863.981904; Church K.W., 1991, STAT COMPUTING, V1, P93, DOI [10.1007/BF01889984, DOI 10.1007/BF01889984]; CLARKE BS, 1994, J STAT PLAN INFER, V41, P37, DOI 10.1016/0378-3758(94)90153-8; Cover TM, 1991, MATH FINANCE, V1, P1, DOI DOI 10.1111/J.1467-9965.1991.TB00002.X; Csiszar I, 1996, IEEE T INFORM THEORY, V42, P2065, DOI 10.1109/18.556596; GALE W, 1994, GOOD TURING SMOOTHIN; Gale W., 1994, CORPUSBASED RES LANG, P189; GOOD IJ, 1953, BIOMETRIKA, V40, P237, DOI 10.2307/2333344; Good IJ, 2000, J STAT COMPUT SIM, V66, P101, DOI 10.1080/00949650008812016; Hardy GH, 1918, P LOND MATH SOC, V17, P75; HAYMAN W. K., 1956, J REINE ANGEW MATH, V196, P67; Hinsley F.H, 1993, CODEBREAKERS INSIDE; Jelinek F., 1998, STAT METHODS SPEECH; JEVTIC N, 2002, P IEEE S INF THEOR; Laplace P.S., 1995, PHILOS ESSAYS PROBAB, V5th; LITTLESTONE N, 1992, IEEE S FDN COMP SCI; McAllester D. A., 2000, P 13 ANN C COMP LEAR; Merhav N, 1998, IEEE T INFORM THEORY, V44, P2124, DOI 10.1109/18.720534; NADAS A, 1985, IEEE T ACOUST SPEECH, V33, P1414, DOI 10.1109/TASSP.1985.1164728; NADAS A, 1991, AM J MATH MANAGE SCI, V11, P229; ORLITSKY A, UNPUB; Rissanen JJ, 1996, IEEE T INFORM THEORY, V42, P40, DOI 10.1109/18.481776; Shtarkov J., 1977, COLL MATH SOC J BOLY, V16, P559; Song F, 1999, SIGIR'99: PROCEEDINGS OF 22ND INTERNATIONAL CONFERENCE ON RESEARCH AND DEVELOPMENT IN INFORMATION RETRIEVAL, P279, DOI 10.1145/312624.312698; Vovk V, 1998, J COMPUT SYST SCI, V56, P153, DOI 10.1006/jcss.1997.1556; WILF H, 1990, GENERATING FUNCTIONO, P91; WITTEN IH, 1991, IEEE T INFORM THEORY, V37, P1085, DOI 10.1109/18.87000	31	70	70	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 17	2003	302	5644					427	431		10.1126/science.1088284	http://dx.doi.org/10.1126/science.1088284			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564004				2022-12-28	WOS:000185963200037
J	Ferguson, NM; Keeling, MJ; Edmunds, WJ; Gant, R; Grenfell, BT; Amderson, RM; Leach, S				Ferguson, NM; Keeling, MJ; Edmunds, WJ; Gant, R; Grenfell, BT; Amderson, RM; Leach, S			Planning for smallpox outbreaks	NATURE			English	Review							MOUTH EPIDEMIC; TRANSMISSION DYNAMICS; VACCINATION; FOOT; IMPACT; MEASLES; SPREAD	Mathematical models of viral transmission and control are important tools for assessing the threat posed by deliberate release of the smallpox virus and the best means of containing an outbreak. Models must balance biological realism against limitations of knowledge, and uncertainties need to be accurately communicated to policy-makers. Smallpox poses the particular challenge that key biological, social and spatial factors affecting disease spread in contemporary populations must be elucidated largely from historical studies undertaken before disease eradication in 1979. We review the use of models in smallpox planning within the broader epidemiological context set by recent outbreaks of both novel and re-emerging pathogens.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, London W2 1PG, England; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Univ Warwick, Inst Math, Coventry CV4 7AL, W Midlands, England; CDSC, Hlth Protect Agcy, London NW9 5EQ, England; CAMR, Hlth Protect Agcy, Salisbury SP4 0JG, Wilts, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	Imperial College London; University of Warwick; University of Warwick; Health Protection Agency; Health Protection Agency; University of Cambridge	Ferguson, NM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, St Marys Campus,Norfolk Pl, London W2 1PG, England.	neil.ferguson@imperial.ac.uk	Keeling, Matt J/J-9280-2012; Ferguson, Neil/B-8578-2008	Keeling, Matt J/0000-0003-4639-4765; Ferguson, Neil/0000-0002-1154-8093; Anderson, Roy/0000-0002-9528-3175	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON R M, 1991; ANDERSON RM, 1988, NATURE, V332, P228, DOI 10.1038/332228a0; ANDERSON RM, 1982, SCIENCE, V215, P1053, DOI 10.1126/science.7063839; Bailey N., 1967, MATH APPROACH BIOL M, DOI [10.2307/2982529, DOI 10.2307/2982529]; BAILEY NTJ, 1980, J MATH BIOL, V10, P113, DOI 10.1007/BF00275837; Bozzette SA, 2003, NEW ENGL J MED, V348, P416, DOI 10.1056/NEJMsa025075; DIXON C.W, 1962, SMALLPOX; Eichner M, 2003, AM J EPIDEMIOL, V158, P110, DOI 10.1093/aje/kwg103; Eichner M, 2003, AM J EPIDEMIOL, V158, P118, DOI 10.1093/aje/kwg104; Ferguson NM, 2001, NATURE, V413, P542, DOI 10.1038/35097116; Ferguson NM, 2001, SCIENCE, V292, P1155, DOI 10.1126/science.1061020; Gani R, 2001, NATURE, V414, P748, DOI 10.1038/414748a; Grenfell BT, 2001, NATURE, V414, P716, DOI 10.1038/414716a; Halloran ME, 2002, SCIENCE, V298, P1428, DOI 10.1126/science.1074674; Isham Valerie, 1996, MODELS INFECT HUMAN; Jezek Z, 1988, HUMAN MONKEYPOX; Kaplan EH, 2002, P NATL ACAD SCI USA, V99, P10935, DOI 10.1073/pnas.162282799; Keeling MJ, 2001, SCIENCE, V294, P813, DOI 10.1126/science.1065973; Keeling MJ, 2003, NATURE, V421, P136, DOI 10.1038/nature01343; Kemper Alex R, 2002, Eff Clin Pract, V5, P84; Koopman J, 2002, SCIENCE, V298, P1342; Lane HC, 2001, NAT MED, V7, P1271, DOI 10.1038/nm1201-1271; Lane JM, 2003, ANN INTERN MED, V138, P488, DOI 10.7326/0003-4819-138-6-200303180-00014; Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616; Meltzer MI, 2001, EMERG INFECT DIS, V7, P959, DOI 10.3201/eid0706.010607; MOLLISON D, 1984, NATURE, V310, P224, DOI 10.1038/310224a0; O'Neill PD, 2002, MATH BIOSCI, V180, P103, DOI 10.1016/S0025-5564(02)00109-8; Riley S, 2003, SCIENCE, V300, P1961, DOI 10.1126/science.1086478; Wallinga J, 2001, EPIDEMIOL INFECT, V127, P281, DOI 10.1017/S095026880100601X; 1999, NATURE, V399, P628	30	253	264	1	57	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 16	2003	425	6959					681	685		10.1038/nature02007	http://dx.doi.org/10.1038/nature02007			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562094	Bronze, Green Published			2022-12-28	WOS:000185924500032
J	Arvanitidis, J; Papagelis, K; Margadonna, S; Prassides, K; Fitch, AN				Arvanitidis, J; Papagelis, K; Margadonna, S; Prassides, K; Fitch, AN			Temperature-induced valence transition and associated lattice collapse in samarium fulleride	NATURE			English	Article							CRYSTAL-STRUCTURE; PHASE-TRANSITION; SUPERCONDUCTIVITY	The different degrees of freedom of a given system are usually independent of each other but can in some materials be strongly coupled, giving rise to phase equilibria sensitively susceptible to external perturbations. Such systems often exhibit unusual physical properties that are difficult to treat theoretically, as exemplified by strongly correlated electron systems such as intermediate-valence rare-earth heavy fermions and Kondo insulators, colossal magnetoresistive manganites and high-transition temperature (high-T-c) copper oxide superconductors. Metal fulleride salts(1)-metal intercalation compounds of C-60- and materials based on rare-earth metals also exhibit strong electronic correlations. Rare-earth fullerides thus constitute a particularly intriguing system-they contain highly correlated cation (rare-earth) and anion (C-60) sublattices. Here we show, using high-resolution synchrotron X-ray diffraction and magnetic susceptibility measurements, that cooling the rare-earth fulleride Sm-2.75 C-60 induces an isosymmetric phase transition near 32 K, accompanied by a dramatic isotropic volume increase and a samarium valence transition from (2 + epsilon) + to nearly 2+. The negative thermal expansion-heating from 4.2 to 32 K leads to contraction rather than expansion-occurs at a rate about 40 times larger than in ternary metal oxides typically exhibiting such behaviour(2). We attribute the large negative thermal expansion, unprecedented in fullerene or other molecular systems, to a quasi-continuous valence transition from Sm2+ towards the smaller Sm(2+epsilon)+, analogous to the valence or configuration transitions encountered in intermediate-valence Kondo insulators like SmS (ref. 3).	Univ Sussex, Dept Chem, Brighton BN1 9QJ, E Sussex, England; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; European Synchrotron Radiat Facil, F-38042 Grenoble, France	University of Sussex; University of Cambridge; European Synchrotron Radiation Facility (ESRF)	Papagelis, K (corresponding author), Univ Sussex, Dept Chem, Brighton BN1 9QJ, E Sussex, England.	K.Prassides@sussex.ac.uk; sm413@cam.ac.uk	Papagelis, Konstantinos/ABB-8981-2020; Prassides, Kosmas/C-9804-2009; Prassides, Kosmas/GVU-9219-2022	Papagelis, Konstantinos/0000-0001-5094-9837; Prassides, Kosmas/0000-0003-4524-3084; Arvanitidis, John/0000-0003-3241-1720				Chen XH, 1995, PHYS REV B, V52, P15534, DOI 10.1103/PhysRevB.52.15534; Claves D, 1999, SOLID STATE COMMUN, V113, P357, DOI 10.1016/S0038-1098(99)00481-0; Gunnarsson O, 1997, REV MOD PHYS, V69, P575, DOI 10.1103/RevModPhys.69.575; Iwasa Y, 2003, J PHYS-CONDENS MAT, V15, pR495, DOI 10.1088/0953-8984/15/13/202; JAYARAMA.A, 1970, PHYS REV LETT, V25, P1430, DOI 10.1103/PhysRevLett.25.1430; JAYARAMAN A, 1973, PHYS REV LETT, V31, P700, DOI 10.1103/PhysRevLett.31.700; MAPLE MB, 1971, PHYS REV LETT, V27, P511, DOI 10.1103/PhysRevLett.27.511; Margadonna S, 2000, CHEM MATER, V12, P2736, DOI 10.1021/cm000330i; Margadonna S, 2002, J SOLID STATE CHEM, V168, P639, DOI 10.1006/jssc.2002.9762; OZDAS E, 1995, NATURE, V375, P126, DOI 10.1038/375126a0; PRASSIDES K, 1994, SCIENCE, V263, P950, DOI 10.1126/science.263.5149.950; Rabe KM, 1998, PHYS REV B, V58, pR551, DOI 10.1103/PhysRevB.58.R551; Rosseinsky MJ, 1998, CHEM MATER, V10, P2665, DOI 10.1021/cm980226p; Sun Z, 2000, J PHYS-CONDENS MAT, V12, P8919, DOI 10.1088/0953-8984/12/41/318	15	126	130	3	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 9	2003	425	6958					599	602		10.1038/nature01994	http://dx.doi.org/10.1038/nature01994			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534581				2022-12-28	WOS:000185801000031
J	Emanuel, EJ				Emanuel, EJ			The lessons of SARS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PHYSICIANS; AIDS	Given the low mortality and morbidity of the severe acute respiratory syndrome (SARS) compared with other public health scourges, is the attention devoted to it misdirected? The SARS experience has provided at least 4 enduring lessons. First, by providing a test of the capacity of each part of the public health system, from national to local and hospital responses, it has better prepared the world for the anticipated and much-feared next real pandemic. Second, SARS has reemphasized that from housing, sexual practices, and slaughtering techniques to health care capacity, the situation in other, especially developing, countries affects us. Global cooperation is necessary not only for justice but to ensure our own health. Third, despite trends toward commercialization, easier lives, and self-centered individualism, the response of health care professionals to SARS reaffirmed dedication to caring for the sick even at great personal risks as the core ethical principle of medicine. Finally, SARS also emphasized the importance of the duty of health care administrators and senior physicians to rapidly institute procedures to maximize the safety of frontline physicians and nurses. These lessons will be valuable far beyond the SARS episode.	NIH, Warren G Magnuson Clin Ctr, Dept Clin Bioeth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Emanuel, EJ (corresponding author), NIH, Warren G Magnuson Clin Ctr, Dept Clin Bioeth, Bldg 10,1C118, Bethesda, MD 20892 USA.							Billings M., INFLUENZA PANDEMIC 1; *CAN ASS EM PHYS, GUID MAN SEV AC RESP; *CDCP, 2002, REP TUB US 2001 ATL; *COUNC ETH JUD AFF, 2002, AM MED ASS COD MED E; CROSBY AW, 1990, AM FORGOTTEN PANDEMI; DEFOE D, 1987, J PLAGUE YEAR; EMANUEL EJ, 1988, NEW ENGL J MED, V318, P1686, DOI 10.1056/NEJM198806233182511; FREEDMAN B, 1988, HASTINGS CENT REP, V18, pS20, DOI 10.2307/3562422; *HLTH CAN, 2003, CAN SARS NUMB AUG 12; KOLOTA F, 1999, FLU STORY GREAT INFL; Park Katharine., 1985, DOCTORS MED EARLY RE; Reilley B, 2003, NEW ENGL J MED, V348, P1951, DOI 10.1056/NEJMp030080; *UNAIDS, 2002, AIDS EP UPD 2002; VIETS J, 1989, SURG URGES AIDS TEST, P1; *WHO, WHAT MAL; *WHO, 2002, TUB FACT SHEET 104; World Health Organization, 2003, SEV AC RESP SYNDR SA; ZUGER A, 1987, JAMA-J AM MED ASSOC, V258, P1924, DOI 10.1001/jama.258.14.1924	19	51	53	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 7	2003	139	7					589	591		10.7326/0003-4819-139-7-200310070-00011	http://dx.doi.org/10.7326/0003-4819-139-7-200310070-00011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729AP	14530230				2022-12-28	WOS:000185748800007
J	Rubin, CD; Stieglitz, H; Vicioso, B; Kirk, L				Rubin, CD; Stieglitz, H; Vicioso, B; Kirk, L			Development of geriatrics-oriented faculty in general internal medicine	ANNALS OF INTERNAL MEDICINE			English	Article							SOCIETY; MODEL	The need for adequate geriatrics training for the physician work-force has been recognized for decades. However, there are not enough academic geriatricians to provide for the educational needs of trainees, and this situation is not expected to change in the future. General internists are often responsible for teaching medical students and internal medicine residents to care for elderly patients in inpatient and ambulatory settings. These academic general internists could play a pivotal role in providing geriatrics instruction. To characterize what is being done to develop geriatrics-oriented general internal medicine faculty, we identified current practices, "best practices," goals and targets, and barriers to achieving those goals and targets. We reviewed the literature on faculty-development programs for general internal medicine faculty, and we held focus groups and structured interviews with general internal medicine unit chiefs and directors of Geriatric Centers of Excellence at 46 medical schools throughout the United States. We found a need for programs to develop geriatrics-oriented academic general internists. Although general internal medicine faculties seem receptive to further geriatrics training, important obstacles exist. These include inadequate time and resources as well as motivational and attitudinal challenges. We discuss potential solutions for overcoming these barriers and the implications of these solutions for stakeholders.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rubin, CD (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	craig.rubin@utsouthwestern.edu						*BUR HLTH PROF HLT, 2000, GEN PRIM CAR FAC DEV; DANS PE, 1979, NEW ENGL J MED, V300, P228, DOI 10.1056/NEJM197902013000504; EMANUEL LL, 1999, EPEC ED PHYSICIANS E; Fasser C E, 1988, Gerontol Geriatr Educ, V8, P37, DOI 10.1300/J021v08n03_05; Feather J, 1988, Gerontol Geriatr Educ, V8, P165, DOI 10.1300/J021v08n03_14; Fihn SD, 2000, J GEN INTERN MED, V15, P451, DOI 10.1046/j.1525-1497.2000.07001.x; FLEMING M, 1992, ACAD MED, V67, P691, DOI 10.1097/00001888-199210000-00015; Hazzard WR, 1997, J AM GERIATR SOC, V45, P638, DOI 10.1111/j.1532-5415.1997.tb03102.x; Institute of Medicine, 1978, AG MED ED; Larson EB, 2001, ANN INTERN MED, V134, P997, DOI 10.7326/0003-4819-134-10-200105150-00013; REUBEN DB, 1993, J AM GERIATR SOC, V41, P560, DOI 10.1111/j.1532-5415.1993.tb01896.x; REUBEN DB, 1991, J AM GERIATR SOC, V39, P799, DOI 10.1111/j.1532-5415.1991.tb02703.x; REUBEN DB, 1994, TRAINING PHYSICIANS; ROBBINS LJ, 1993, J AM GERIATR SOC, V41, P570, DOI 10.1111/j.1532-5415.1993.tb01897.x; RUBIN C, 2001, DEV GERIATRICALLY OR; Sox HC, 2001, AM J MED, V110, P745, DOI 10.1016/S0002-9343(01)00756-2; Swagerty D, 2000, J AM GERIATR SOC, V48, P1513, DOI 10.1111/jgs.2000.48.11.1513	17	29	29	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 7	2003	139	7					615	620		10.7326/0003-4819-139-7-200310070-00035	http://dx.doi.org/10.7326/0003-4819-139-7-200310070-00035			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729AP	14530245				2022-12-28	WOS:000185748800027
J	Dorresteijn, LDA; Portegies, P; van Kasteren, M; Bloem, BR				Dorresteijn, LDA; Portegies, P; van Kasteren, M; Bloem, BR			A gait disorder with an unexpected twist	LANCET			English	Editorial Material							INFECTION		Univ Med Ctr St Radboud, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr St Radboud, Dept Internal Med, NL-6500 HB Nijmegen, Netherlands; OLVG Hosp, Dept Neurol, Amsterdam, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Bloem, BR (corresponding author), Univ Med Ctr St Radboud, Dept Neurol, NL-6500 HB Nijmegen, Netherlands.		Bloem, Bastiaan/H-8013-2014; Bloem, Bastiaan R/E-3812-2010	Bloem, Bastiaan/0000-0002-6371-3337; 				Beckley DJ, 1998, ELECTROMYOGR MOTOR C, V109, P402, DOI 10.1016/S0924-980X(98)00040-X; Chang L, 1999, NEUROLOGY, V53, P782, DOI 10.1212/WNL.53.4.782; Di Rocco A, 1999, SEMIN NEUROL, V19, P151, DOI 10.1055/s-2008-1040832; NATH A, 1987, NEUROLOGY, V37, P37, DOI 10.1212/WNL.37.1.37	4	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 4	2003	362	9390					1120	1120		10.1016/S0140-6736(03)14468-6	http://dx.doi.org/10.1016/S0140-6736(03)14468-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728HA	14550700				2022-12-28	WOS:000185710700012
J	Kurisu, G; Zhang, HM; Smith, JL; Cramer, WA				Kurisu, G; Zhang, HM; Smith, JL; Cramer, WA			Structure of the cytochrome b(6)f complex of oxygenic photosynthesis: Tuning the cavity	SCIENCE			English	Article							IRON-SULFUR PROTEIN; ELECTRON-TRANSFER; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; BC(1) COMPLEX; MEMBRANE-PROTEINS; PHOTOSYSTEM-II; BOVINE HEART; BC COMPLEXES; B/F COMPLEX	The cytochrome b(6)f complex provides the electronic connection between the photosystem I and photosystem II reaction centers of oxygenic photosynthesis and generates a transmembrane electrochemical proton gradient for adenosine triphosphate synthesis. A 3.0 angstrom crystal structure of the dimeric b(6)f complex from the thermophilic cyanobacterium Mastigocladus laminosus reveals a large quinone exchange cavity, stabilized by lipid, in which plastoquinone, a quinone-analog inhibitor, and a novel heme are bound. The core of the b(6)f complex is similar to the analogous respiratory cytochrome bc(1) complex, but the domain arrangement outside the core and the complement of prosthetic groups are strikingly different. The motion of the Rieske iron-sulfur protein extrinsic domain, essential for electron transfer, must also be different in the b(6)f complex.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Osaka University	Cramer, WA (corresponding author), Purdue Univ, Dept Biol Sci, 915 W State St, W Lafayette, IN 47907 USA.	wac@bilbo.bio.purdue.edu	KURISU, GENJI/AAD-7109-2022; KURISU, GENJI/ABA-5960-2020	KURISU, GENJI/0000-0002-5354-0807; KURISU, GENJI/0000-0002-5354-0807	NIGMS NIH HHS [GM-38323] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM038323, R01GM038323] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; Carrell CJ, 1999, BIOCHEMISTRY-US, V38, P9590, DOI 10.1021/bi9903190; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; CRAMER WA, 1991, ENERGY TRANSDUCTION, pCH6; Gao XG, 2002, BIOCHEMISTRY-US, V41, P11692, DOI 10.1021/bi026252p; Garavito RM, 2001, J BIOL CHEM, V276, P32403, DOI 10.1074/jbc.R100031200; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; HAUSKA G, 1996, OXYGENIC PHOTOSYNTHE; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JOLIOT P, 1994, P NATL ACAD SCI USA, V91, P1034, DOI 10.1073/pnas.91.3.1034; JOLIOT P, 1988, BIOCHIM BIOPHYS ACTA, V933, P319, DOI 10.1016/0005-2728(88)90039-4; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kallas T, 1994, MOL BIOL CYANOBACTER, V1, P259, DOI DOI 10.1007/978-94-011-0227-8_9; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; KRAMER DM, 1993, BIOCHIM BIOPHYS ACTA, V1183, P72, DOI 10.1016/0005-2728(93)90006-2; LAVERGNE J, 1983, BIOCHIM BIOPHYS ACTA, V725, P25, DOI 10.1016/0005-2728(83)90220-7; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Pierre Y, 1997, J BIOL CHEM, V272, P21901, DOI 10.1074/jbc.272.35.21901; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; RIEDEL A, 1991, J BIOL CHEM, V266, P17838; Roberts AG, 2001, BIOCHEMISTRY-US, V40, P13407, DOI 10.1021/bi015774m; Sainz G, 2000, BIOCHEMISTRY-US, V39, P9164, DOI 10.1021/bi0004596; Schunemann V, 1999, BIOCHEMISTRY-US, V38, P8981, DOI 10.1021/bi990080n; STROEBEL D, COMMUNICATION; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TURRO NJ, 1965, MOL PHOTOCHEM, P92; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; Whitelegge JP, 2002, MOL CELL PROTEOMICS, V1, P816, DOI 10.1074/mcp.M200045-MCP200; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yan JS, 2003, J BIOL CHEM, V278, P20925, DOI 10.1074/jbc.M212616200; ZHANG H, UNPUB; Zhang HM, 1999, J BIOL CHEM, V274, P1581, DOI 10.1074/jbc.274.3.1581; Zhang HM, 2003, P NATL ACAD SCI USA, V100, P5160, DOI 10.1073/pnas.0931431100; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; ZHAO J, 1993, MOL MICROBIOL, V9, P183, DOI 10.1111/j.1365-2958.1993.tb01680.x; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	42	579	622	7	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	2003	302	5647					1009	1014		10.1126/science.1090165	http://dx.doi.org/10.1126/science.1090165			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14526088				2022-12-28	WOS:000186396300037
J	Agerbo, E				Agerbo, E			Risk of suicide, and spouse's psychiatric illness or suicide: nested case-control study	BRITISH MEDICAL JOURNAL			English	Article									Aarhus Univ, Natl Ctr Register Based Res, DK-8000 Aarhus C, Denmark	Aarhus University	Agerbo, E (corresponding author), Aarhus Univ, Natl Ctr Register Based Res, DK-8000 Aarhus C, Denmark.		Agerbo, Esben/A-2645-2012	Agerbo, Esben/0000-0002-2849-524X				Agerbo E, 2002, BMJ-BRIT MED J, V325, P74, DOI 10.1136/bmj.325.7355.74; Clark Sheila E., 2000, INT HDB SUICIDE ATTE, P467, DOI DOI 10.1002/9780470698976.CH26; Hippisley-Cox J, 2002, BMJ-BRIT MED J, V325, P636, DOI 10.1136/bmj.325.7365.636; Qin P, 2003, AM J PSYCHIAT, V160, P765, DOI 10.1176/appi.ajp.160.4.765; SCHAEFER C, 1995, AM J EPIDEMIOL, V141, P1142, DOI 10.1093/oxfordjournals.aje.a117387	5	32	33	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 1	2003	327	7422					1025	1026		10.1136/bmj.327.7422.1025	http://dx.doi.org/10.1136/bmj.327.7422.1025			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738NE	14593038	Green Published, Bronze			2022-12-28	WOS:000186294100023
J	[Anonymous]				[Anonymous]			2003 grand prize winner	SCIENCE			English	Biographical-Item																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	2003	302	5646					801	801						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593161				2022-12-28	WOS:000186258000031
J	Akahane, Y; Asano, T; Song, BS; Noda, S				Akahane, Y; Asano, T; Song, BS; Noda, S			High-Q photonic nanocavity in a two-dimensional photonic crystal	NATURE			English	Article							BAND-GAP; CAVITIES; LASER; MODE; MICROCAVITY; EMISSION; DEFECT	Photonic cavities that strongly confine light are finding applications in many areas of physics and engineering, including coherent electron - photon interactions(1), ultra-small filters(2,3), low-threshold lasers(4), photonic chips(5), nonlinear optics(6) and quantum information processing(7). Critical for these applications is the realization of a cavity with both high quality factor, Q, and small modal volume, V. The ratio Q/V determines the strength of the various cavity interactions, and an ultra-small cavity enables large-scale integration and single-mode operation for a broad range of wavelengths. However, a high-Q cavity of optical wavelength size is difficult to fabricate, as radiation loss increases in inverse proportion to cavity size. With the exception of a few recent theoretical studies(8-10), definitive theories and experiments for creating high-Q nanocavities have not been extensively investigated. Here we use a silicon-based two-dimensional photonic-crystal slab to fabricate a nanocavity with Q = 45,000 and V = 7.0 x 10(-14) cm(3); the value of Q/V is 10-100 times larger than in previous studies(4,11 - 14). Underlying this development is the realization that light should be confined gently in order to be confined strongly. Integration with other photonic elements is straightforward, and a large free spectral range of 100 nm has been demonstrated.	Kyoto Univ, Dept Elect Sci & Engn, Nishikyo Ku, Kyoto 6158510, Japan; Sumitomo Elect Ind Ltd, Adv Mat R&D Labs, Itami, Hyogo 6640016, Japan	Kyoto University; Sumitomo Electric Industries	Noda, S (corresponding author), Kyoto Univ, Dept Elect Sci & Engn, Nishikyo Ku, Kyoto 6158510, Japan.	snoda@kuee.kyoto-u.ac.jp						Akahane Y, 2003, APPL PHYS LETT, V83, P1512, DOI 10.1063/1.1604179; Armani DK, 2003, NATURE, V421, P925, DOI 10.1038/nature01371; Gayral B, 1999, APPL PHYS LETT, V75, P1908, DOI 10.1063/1.124894; Johnson SG, 2001, APPL PHYS LETT, V78, P3388, DOI 10.1063/1.1375838; Khitrova G, 1999, REV MOD PHYS, V71, P1591, DOI 10.1103/RevModPhys.71.1591; Michler P, 2000, SCIENCE, V290, P2282, DOI 10.1126/science.290.5500.2282; Noda S, 2000, NATURE, V407, P608, DOI 10.1038/35036532; Noda S, 2000, SCIENCE, V289, P604, DOI 10.1126/science.289.5479.604; Painter O, 1999, SCIENCE, V284, P1819, DOI 10.1126/science.284.5421.1819; Ryu HY, 2002, APPL PHYS LETT, V80, P3883, DOI 10.1063/1.1480103; Song BS, 2003, SCIENCE, V300, P1537, DOI 10.1126/science.1083066; Spillane SM, 2002, NATURE, V415, P621, DOI 10.1038/415621a; Srinivasan K, 2002, OPT EXPRESS, V10, P670, DOI 10.1364/OE.10.000670; Vernooy DW, 1998, OPT LETT, V23, P247, DOI 10.1364/OL.23.000247; Vuckovic J, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.016608; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059; Yoshie T, 2001, APPL PHYS LETT, V79, P4289, DOI 10.1063/1.1427748	17	2196	2247	28	826	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 30	2003	425	6961					944	947		10.1038/nature02063	http://dx.doi.org/10.1038/nature02063			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14586465				2022-12-28	WOS:000186230600037
J	Coupland, RM				Coupland, RM			Incapacitating chemical weapons: a year after the Moscow theatre siege	LANCET			English	Editorial Material							FENTANYL; TOXICOLOGY		Int Comm Red Cross, Legal Div, CH-1202 Geneva, Switzerland		Coupland, RM (corresponding author), Int Comm Red Cross, Legal Div, CH-1202 Geneva, Switzerland.	rcoupland@icrc.org						Bartfield JM, 2003, ACAD EMERG MED, V10, P215, DOI 10.1111/j.1553-2712.2003.tb01993.x; Coupland RM, 1997, BRIT MED J, V315, P72, DOI 10.1136/bmj.315.7100.72; Enserink M, 2002, SCIENCE, V298, P1150, DOI 10.1126/science.298.5596.1150; *ICRC, 2003, 1 SPEC SESS C STAT P; Lakoski J. M., 2000, ADVANTAGES LIMITATIO; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; *NAT RES COUNC COM, 2003, ASS NONL WEAP SCI TE; Schiermeier Q, 2002, NATURE, V420, P7, DOI 10.1038/420007a; Wax PM, 2003, ANN EMERG MED, V41, P700, DOI 10.1067/mem.2003.148; Wheelis M, 2003, ISSUES SCI TECHNOL, V19, P74; *WORLD MED ASS, 1996, WORLD MED ASS 48 GEN; WORSLEY MH, 1990, ANAESTHESIA, V45, P449, DOI 10.1111/j.1365-2044.1990.tb14331.x; 2002, BBC NEWS        1029	13	11	13	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 25	2003	362	9393					1346	1346		10.1016/S0140-6736(03)14684-3	http://dx.doi.org/10.1016/S0140-6736(03)14684-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	735YX	14585634				2022-12-28	WOS:000186143300006
J	Lord, JM; Flight, IHK; Norman, RJ				Lord, JM; Flight, IHK; Norman, RJ			Metformin in polycystic ovary syndrome: systematic review and meta-analysis	BRITISH MEDICAL JOURNAL			English	Review							INSULIN-SENSITIZING DRUGS; CLOMIPHENE CITRATE; OVULATION INDUCTION; METABOLIC PROFILES; PREGNANCY RATES; RESISTANT WOMEN; DOUBLE-BLIND; TRIAL; INFERTILITY; INCREASES	Objective To assess the effectiveness of metformin in improving clinical and biochemical features of polycystic ovary syndrome. Design Systematic review and meta-analysis. Data sources Randomised controlled trials that investigated the effect of metformin compared with either placebo or no treatment, or compared with an ovulation induction agent. Selection of studies 13 trials were included for analysis, including 543 women with polycystic ovary syndrome that was defined by using biochemical or ultrasound evidence. Main outcome measure Pregnancy and ovulation rates. Secondary outcomes of clinical and biochemical features of polycystic ovary syndrome. Results Meta-analysis showed that metformin is effective in achieving ovulation in women with polycystic ovary syndrome, with odds ratios of 3.88 (95% confidence interval 2.25 to 6.69) for metformin compared with placebo and 4.41 (2.37 to 8.22) for metformin and clomifene compared with clomifene alone. An analysis of pregnancy rates shows a significant treatment effect for metformin and clomifene (odds ratio 4.40,1.96 to 9.85). Metformin has an effect in reducing fasting insulin concentrations, blood pressure, and low density lipoprotein cholesterol. We found no evidence of any effect on body mass index or waist:hip ratio. Metformin was associated with a higher incidence of nausea, vomiting, and other gastrointestinal disturbance. Conclusions Metformin is an effective treatment for anovulation in women with polycystic ovary syndrome. Its choice as a first line agent seems justified, and there is some evidence of benefit on variables of the metabolic syndrome. No data are available regarding the safety of metformin in long term use in young women and only limited data on its safety in early pregnancy It should be used as an adjuvant to general lifestyle improvements and not as a replacement for increased exercise and improved diet.	Derriford Hosp, SW Ctr Reprod Med, Peninsula Med Sch, Dept Endocrinol & Metab, Plymouth PL6 8DH, Devon, England; Univ Adelaide, Queen Elizabeth Hosp, Dept Obstet & Gynaecol, Reprod Med Unit, Woodville, SA 5005, Australia; CSIRO, Hlth Sci & Nutr, Consumer Sci Program, Adelaide, SA 5000, Australia	Derriford Hospital; University of Plymouth; University of Adelaide; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Lord, JM (corresponding author), Derriford Hosp, SW Ctr Reprod Med, Peninsula Med Sch, Dept Endocrinol & Metab, Plymouth PL6 8DH, Devon, England.		Norman, Robert J/A-1155-2007; Flight, Ingrid/H-8768-2013	Norman, Robert J/0000-0002-3118-3896; Flight, Ingrid/0000-0001-7704-0869				Clark AM, 1998, HUM REPROD, V13, P1502, DOI 10.1093/humrep/13.6.1502; Costello MF, 2003, FERTIL STERIL, V79, P1, DOI 10.1016/S0015-0282(02)04554-5; El-Biely MM, 2001, MIDDLE E FERTIL SOC, V6, P43; Fleming R, 2002, J CLIN ENDOCR METAB, V87, P569, DOI 10.1210/jc.87.2.569; Hague WM, 2003, BMJ-BRIT MED J, V326, P762; Harborne L, 2003, LANCET, V361, P1894, DOI 10.1016/S0140-6736(03)13493-9; Homburg R, 2002, HUM REPROD, V17, P853, DOI 10.1093/humrep/17.4.853; Hull M., 1987, GYN ENDOCRINOL, V1, P233; Jakubowicz DJ, 2001, J CLIN ENDOCR METAB, V86, P1126, DOI 10.1210/jc.86.3.1126; Kocak M, 2002, FERTIL STERIL, V77, P101, DOI 10.1016/S0015-0282(01)02941-7; Kousta E, 1997, HUM REPROD UPDATE, V3, P359, DOI 10.1093/humupd/3.4.359; Legro RS, 2001, OBSTET GYN CLIN N AM, V28, P99, DOI 10.1016/S0889-8545(05)70188-1; LEVENE MI, 1992, BRIT J OBSTET GYNAEC, V99, P607, DOI 10.1111/j.1471-0528.1992.tb13831.x; Malkawi HY, 2002, SAUDI MED J, V23, P663; Messinis IE, 1997, HUM REPROD UPDATE, V3, P235, DOI 10.1093/humupd/3.3.235; Michelmore KF, 1999, CLIN ENDOCRINOL, V51, P779, DOI 10.1046/j.1365-2265.1999.00886.x; Moghetti P, 2000, J CLIN ENDOCR METAB, V85, P139, DOI 10.1210/jc.85.1.139; Nestler JE, 1996, NEW ENGL J MED, V335, P617, DOI 10.1056/NEJM199608293350902; Nestler JE, 1998, NEW ENGL J MED, V338, P1876, DOI 10.1056/NEJM199806253382603; Nestler JE, 2002, FERTIL STERIL, V77, P209, DOI 10.1016/S0015-0282(01)02963-6; Nestler JE, 2001, J CLIN ENDOCR METAB, V86, P1430, DOI 10.1210/jc.86.3.1430; Ng EHY, 2001, HUM REPROD, V16, P1625, DOI 10.1093/humrep/16.8.1625; Norman RJ, 2002, TRENDS ENDOCRIN MET, V13, P251, DOI 10.1016/S1043-2760(02)00612-4; Pasquali R, 2000, J CLIN ENDOCR METAB, V85, P2767, DOI 10.1210/jc.85.8.2767; POLSON DW, 1988, LANCET, V1, P870; Reaven G, 1999, DRUGS, V58, P19, DOI 10.2165/00003495-199958001-00006; Reaven GM, 1999, ANN NY ACAD SCI, V892, P45, DOI 10.1111/j.1749-6632.1999.tb07784.x; *ROYAL COLL OBST G, 2003, LONG TERM CONS POL O; Royal College of Obstetricians and Gynaecologists, 1998, EV BAS CLIN GUID; Seli E, 2002, HUM REPROD, V17, P2230, DOI 10.1093/humrep/17.9.2230; Stadtmauer LA, 2002, HUM REPROD, V17, P3016, DOI 10.1093/humrep/17.12.3016; Sturrock NDC, 2002, BRIT J CLIN PHARMACO, V53, P469, DOI 10.1046/j.1365-2125.2002.01575.x; Vandermolen DT, 2001, FERTIL STERIL, V75, P310, DOI 10.1016/S0015-0282(00)01675-7; Yarali H, 2002, HUM REPROD, V17, P289, DOI 10.1093/humrep/17.2.289	34	505	535	1	68	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 25	2003	327	7421					951	955		10.1136/bmj.327.7421.951	http://dx.doi.org/10.1136/bmj.327.7421.951			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	736AL	14576245	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000186147800015
J	Yla-Herttuala, S				Yla-Herttuala, S			Percutaneous transcoronary venous access for cellular cardiomyoplasty	LANCET			English	Editorial Material							GENE-TRANSFER; TRANSPLANTATION; REGENERATION; CELLS		Univ Kuopio, Kuopio Univ Hosp, Gene Therapy Unit, AI Virtanen Inst, FIN-70211 Kuopio, Finland; Univ Kuopio, Kuopio Univ Hosp, Gene Therapy Unit, Dept Med, FIN-70211 Kuopio, Finland	Kuopio University Hospital; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland	Yla-Herttuala, S (corresponding author), Univ Kuopio, Kuopio Univ Hosp, Gene Therapy Unit, AI Virtanen Inst, FIN-70211 Kuopio, Finland.			Yla-Herttuala, Seppo/0000-0001-7593-2708				Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Boekstegers P, 2000, GENE THER, V7, P232, DOI 10.1038/sj.gt.3301079; Losordo DW, 2002, CIRCULATION, V105, P2012, DOI 10.1161/01.CIR.0000015982.70785.B7; Orlic D, 2002, CIRC RES, V91, P1092, DOI 10.1161/01.RES.0000046045.00846.B0; Thompson CA, 2003, J AM COLL CARDIOL, V41, P1964, DOI 10.1016/S0735-1097(03)00397-8; Yla-Herttuala S, 2000, LANCET, V355, P213, DOI 10.1016/S0140-6736(99)04180-X; Yla-Herttuala S, 2003, NAT MED, V9, P694, DOI 10.1038/nm0603-694	7	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 18	2003	362	9392					1252	1252		10.1016/S0140-6736(03)14614-4	http://dx.doi.org/10.1016/S0140-6736(03)14614-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575965				2022-12-28	WOS:000186036900004
J	Plutzky, J				Plutzky, J			PPARs as therapeutic targets: Reverse cardiology?	SCIENCE			English	Editorial Material							ATHEROSCLEROSIS; CELL; INFLAMMATION; RECEPTORS; GAMMA		Brigham & Womens Hosp, Dept Cardiovasc Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Plutzky, J (corresponding author), Brigham & Womens Hosp, Dept Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA.		Plutzky, Jorge/V-3410-2019					Buchanan TA, 2002, DIABETES, V51, P2796, DOI 10.2337/diabetes.51.9.2796; CASTRILLO A, 2003, MOL CELL; Chawla A, 2003, P NATL ACAD SCI USA, V100, P1268, DOI 10.1073/pnas.0337331100; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Epstein SE, 2002, CIRC RES, V90, P2, DOI 10.1161/res.90.1.2; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Haffner SM, 2002, CIRCULATION, V106, P679, DOI 10.1161/01.CIR.0000025403.20953.23; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; Lee CH, 2003, SCIENCE, V302, P453, DOI 10.1126/science.1087344; Li AC, 2002, NAT MED, V8, P1235, DOI 10.1038/nm1102-1235; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Plutzky J, 2001, CURR OPIN LIPIDOL, V12, P511, DOI 10.1097/00041433-200110000-00006; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Ziouzenkova O, 2003, P NATL ACAD SCI USA, V100, P2730, DOI 10.1073/pnas.0538015100	15	70	80	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					406	407		10.1126/science.1091172	http://dx.doi.org/10.1126/science.1091172			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14563997				2022-12-28	WOS:000185963200030
J	Zhang, OH; Yoshimatsu, Y; Hildebrand, J; Frisch, SM; Goodman, RH				Zhang, OH; Yoshimatsu, Y; Hildebrand, J; Frisch, SM; Goodman, RH			Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP	CELL			English	Article							TERMINAL-BINDING-PROTEIN; DROSOPHILA EMBRYO; ACTIVATION; REPRESSOR; RECEPTOR; KINASE; CREB; PHOSPHORYLATION; ACETYLATION; ASSOCIATION	Genetic knockout of the transcriptional corepressor CtBP in mouse embryo fibroblasts upregulates several genes involved in apoptosis. We predicted, therefore, that a propensity toward apoptosis might be regulated through changes in cellular CtBP. To identify pathways involved in this regulation, we screened a mouse embryo cDNA library with an E1A-CtBP complex and identified the homeodomain interacting protein kinase 2 (HIPK2), which had previously been linked to UV-directed apoptosis through its ability to phosphorylate p53. Expression of HIPK2 or exposure to UV irradiation reduced CtBP levels via a proteosome-mediated pathway. The UV effect was prevented by coexpression of kinase-inactive HIPK2 or reduction in HIPK2 levels via siRNA. Mutation of the residue phosphorylated by HIPK2 prevented UV- and HIPK2-directed CtBP clearance. Finally, reduction in CtBP levels, either by genetic knockout or siRNA, promoted apoptosis in p53-deficient cells. These findings provide a pathway for UV-induced apoptosis in cells lacking p53.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Burnham Inst, La Jolla, CA 92037 USA	Oregon Health & Science University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Sanford Burnham Prebys Medical Discovery Institute	Zhang, OH (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	zhangq@ohsu.edu	Yoshimatsu, Yasuhiro/AAY-2259-2020	Yoshimatsu, Yasuhiro/0000-0002-3571-1596	NATIONAL CANCER INSTITUTE [K01CA096561, R01CA115468] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA096561, R01 CA115468-05, R01 CA115468] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnes CJ, 2003, NAT STRUCT BIOL, V10, P622, DOI 10.1038/nsb957; BODE AM, 2003, SCI STKE; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Iordanov MS, 2002, MOL CELL BIOL, V22, P5380, DOI 10.1128/MCB.22.15.5380-5394.2002; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; La Rosee-Borggreve A, 1999, MECH DEVELOP, V89, P133, DOI 10.1016/S0925-4773(99)00219-1; Lai ZC, 1999, GENETICS, V152, P299; Landon, 1977, Methods Enzymol, V47, P145; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Melhuish TA, 2000, J BIOL CHEM, V275, P39762, DOI 10.1074/jbc.C000416200; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Shih HM, 1996, P NATL ACAD SCI USA, V93, P13896, DOI 10.1073/pnas.93.24.13896; Vo N, 2001, MOL CELL BIOL, V21, P6181, DOI 10.1128/MCB.21.18.6181-6188.2001; Zhang HL, 1999, P NATL ACAD SCI USA, V96, P535, DOI 10.1073/pnas.96.2.535; Zhang QH, 2000, MOL CELL BIOL, V20, P4970, DOI 10.1128/MCB.20.14.4970-4978.2000; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598	31	186	194	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	2003	115	2					177	186		10.1016/S0092-8674(03)00802-X	http://dx.doi.org/10.1016/S0092-8674(03)00802-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567915	Bronze			2022-12-28	WOS:000186039200009
J	Shapira, OM; Kasznica, JM				Shapira, OM; Kasznica, JM			Spindle-cell thymoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Med Ctr, Boston, MA 02118 USA	Boston Medical Center	Shapira, OM (corresponding author), Boston Med Ctr, Boston, MA 02118 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	2003	349	15					1442	1442		10.1056/NEJMicm990389	http://dx.doi.org/10.1056/NEJMicm990389			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729JF	14534337				2022-12-28	WOS:000185769500007
J	Biteau, B; Labarre, J; Toledano, MB				Biteau, B; Labarre, J; Toledano, MB			ATP-dependent reduction of cysteine-sulphinic acid by S-cerevisiae sulphiredoxin	NATURE			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; OXIDATIVE STRESS; THIOREDOXIN PEROXIDASE; 2-CYS PEROXIREDOXIN; CRYSTAL-STRUCTURE; SULFENIC ACID; YEAST; IDENTIFICATION; CATALYSIS; SITE	Proteins contain thiol-bearing cysteine residues that are sensitive to oxidation, and this may interfere with biological function either as 'damage' or in the context of oxidant-dependent signal transduction. Cysteine thiols oxidized to sulphenic acid are generally unstable, either forming a disulphide with a nearby thiol or being further oxidized to a stable sulphinic acid(1,2). Cysteine - sulphenic acids and disulphides are known to be reduced by glutathione or thioredoxin in biological systems, but cysteine - sulphinic acid derivatives have been viewed as irreversible protein modifications. Here we identify a yeast protein of relative molecular mass M-r = 13,000, which we have named sulphiredoxin ( identified by the US spelling 'sulfiredoxin', in the Saccharomyces Genome Database), that is conserved in higher eukaryotes and reduces cysteine - sulphinic acid in the yeast peroxiredoxin Tsa1. Peroxiredoxins are ubiquitous thiol-containing antioxidants that reduce hydroperoxides(3-5) and control hydroperoxide-mediated signalling in mammals(6-8). The reduction reaction catalysed by sulphiredoxin requires ATP hydrolysis and magnesium, involving a conserved active-site cysteine residue which forms a transient disulphide linkage with Tsa1. We propose that reduction of cysteine - sulphinic acids by sulphiredoxin involves activation by phosphorylation followed by a thiol-mediated reduction step. Sulphiredoxin is important for the antioxidant function of peroxiredoxins, and is likely to be involved in the repair of proteins containing cysteine sulphinic acid modifications, and in signalling pathways involving protein oxidation.	CEA Saclay, DBJC, SBGM, Lab Stress Oxydants & Canc, F-91191 Gif Sur Yvette, France; CEA Saclay, DBJC, SBGM, Lab Physiogenom, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay	Toledano, MB (corresponding author), CEA Saclay, DBJC, SBGM, Lab Stress Oxydants & Canc, F-91191 Gif Sur Yvette, France.							CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Claiborne A, 2001, ADV PROTEIN CHEM, V58, P215; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; Fujii J, 2002, REDOX REP, V7, P123, DOI 10.1179/135100002125000352; FURUKAWA M, 1980, SYNTHESIS-STUTTGART, P937; Giles GI, 2002, BIOL CHEM, V383, P375, DOI 10.1515/BC.2002.042; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KICE JL, 1979, J ORG CHEM, V44, P1918, DOI 10.1021/jo01326a005; KICE JL, 1980, ADV PHYS ORG CHEM, V17, P65; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; Maillet I, 1996, J BIOL CHEM, V271, P10263, DOI 10.1074/jbc.271.17.10263; NOGUCHI Y, 1983, B CHEM SOC JPN, V56, P349, DOI 10.1246/bcsj.56.349; Park SG, 2000, J BIOL CHEM, V275, P5723, DOI 10.1074/jbc.275.8.5723; Poole LB, 2002, METHOD ENZYMOL, V348, P122, DOI 10.1016/S0076-6879(02)48632-6; Prouzet-Mauleon V, 2002, J BIOL CHEM, V277, P4823, DOI 10.1074/jbc.M109614200; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; SIKORSKI RS, 1989, GENETICS, V122, P19; Wong CM, 2002, J BIOL CHEM, V277, P5385, DOI 10.1074/jbc.M106846200; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200	30	745	781	2	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	2003	425	6961					980	984		10.1038/nature02075	http://dx.doi.org/10.1038/nature02075			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14586471				2022-12-28	WOS:000186230600046
J	Freedman, R				Freedman, R			Schizophrenia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DOPAMINE RECEPTOR-BINDING; WORKING-MEMORY DEFICITS; ANTIPSYCHOTIC-DRUGS; SCHIZOAFFECTIVE DISORDER; FLUPHENAZINE DECANOATE; THERAPEUTIC RESPONSE; ONSET SCHIZOPHRENIA; GRAY-MATTER; CLOZAPINE; HALOPERIDOL		Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Inst Childrens Mental Disorders, Denver, CO 80262 USA; Vet Affairs Med Ctr, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Freedman, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Inst Childrens Mental Disorders, C-268-71, Denver, CO 80262 USA.	freedman@uchsc.edu			NIMH NIH HHS [MH-38321, MH-61412, MH-59565] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038321, R01MH059565, R37MH038321, R01MH061412] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abi-Dargham A, 2000, P NATL ACAD SCI USA, V97, P8104, DOI 10.1073/pnas.97.14.8104; ADLER LE, 1993, AM J PSYCHIAT, V150, P1856; Aghajanian GK, 2000, BRAIN RES REV, V31, P302, DOI 10.1016/S0165-0173(99)00046-6; Akbarian S, 1996, ARCH GEN PSYCHIAT, V53, P425; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Benes FM, 1998, BIOL PSYCHIAT, V44, P88, DOI 10.1016/S0006-3223(98)00138-3; BIEDERMAN J, 1979, ARCH GEN PSYCHIAT, V36, P327; Bilder RM, 2002, AM J PSYCHIAT, V159, P1018, DOI 10.1176/appi.ajp.159.6.1018; Bressan RA, 2002, SCHIZOPHR RES, V56, P31, DOI 10.1016/S0920-9964(01)00185-2; Buchanan RW, 2002, SCHIZOPHRENIA BULL, V28, P63, DOI 10.1093/oxfordjournals.schbul.a006927; Buchanan RW, 1998, AM J PSYCHIAT, V155, P751; CARLSSON A, 1978, AM J PSYCHIAT, V135, P164, DOI 10.1176/ajp.135.2.164; CAROFF SN, 1993, MED CLIN N AM, V77, P185, DOI 10.1016/S0025-7125(16)30278-4; Castner SA, 2000, SCIENCE, V287, P2020, DOI 10.1126/science.287.5460.2020; Cecil KM, 1999, NEUROPSYCHOPHARMACOL, V20, P131, DOI 10.1016/S0893-133X(98)00063-3; Chowdari KV, 2002, HUM MOL GENET, V11, P1373, DOI 10.1093/hmg/11.12.1373; Chumakov I, 2002, P NATL ACAD SCI USA, V99, P13675, DOI 10.1073/pnas.182412499; Chumakov I, 2002, P NATL ACAD SCI USA, V99, P17221, DOI 10.1073/pnas.262645899; Conley RR, 1999, BIOL PSYCHIAT, V46, P73, DOI 10.1016/S0006-3223(99)00029-3; Cornblatt BA, 2001, SCHIZOPHR RES, V51, P31, DOI 10.1016/S0920-9964(01)00236-5; COX B, 1977, BRIT J PHARMACOL, V61, P83, DOI 10.1111/j.1476-5381.1977.tb09742.x; Cramer J, 2001, SCHIZOPHRENIA BULL, V27, P227, DOI 10.1093/oxfordjournals.schbul.a006869; CREESE I, 1976, SCIENCE, V192, P481, DOI 10.1126/science.3854; Csernansky JG, 2002, NEW ENGL J MED, V346, P16, DOI 10.1056/NEJMoa002028; Csernansky JG, 2002, NEW ENGL J MED, V346, P1424; Czobor P, 2002, J CLIN PSYCHOPHARM, V22, P244, DOI 10.1097/00004714-200206000-00003; Daniel DG, 1999, NEUROPSYCHOPHARMACOL, V20, P491, DOI 10.1016/S0893-133X(98)00090-6; de Haan L, 2002, J CLIN PSYCHIAT, V63, P104, DOI 10.4088/JCP.v63n0203; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Erlenmeyer-Kimling L, 2001, AM J MED GENET, V105, P23, DOI 10.1002/1096-8628(20010108)105:1<23::AID-AJMG1048>3.0.CO;2-0; FARDE L, 1986, SCIENCE, V231, P258, DOI 10.1126/science.2867601; Frazier CJ, 1998, J NEUROSCI, V18, P8228; FREEDMAN R, 1979, PSYCHIAT RES, V1, P31, DOI 10.1016/0165-1781(79)90025-8; GARDOS G, 1994, AM J PSYCHIAT, V151, P836; Gearon JS, 2003, PSYCHIAT SERV, V54, P523, DOI 10.1176/appi.ps.54.4.523; Gilmore JH, 1998, SCHIZOPHR RES, V33, P133, DOI 10.1016/S0920-9964(98)00073-5; Glassman AH, 2001, AM J PSYCHIAT, V158, P1774, DOI 10.1176/appi.ajp.158.11.1774; GOODMAN LS, 1965, PHARMACOL BASIS THER, P165; GRACE AA, 1986, J PHARMACOL EXP THER, V238, P1092; Green MF, 2002, BIOL PSYCHIAT, V51, P972, DOI 10.1016/S0006-3223(02)01370-7; Green MF, 1996, AM J PSYCHIAT, V153, P321; Greene R, 2001, HIPPOCAMPUS, V11, P569, DOI 10.1002/hipo.1072.abs; Hagg S, 2001, J CLIN PSYCHOPHARM, V21, P382, DOI 10.1097/00004714-200108000-00005; HERSHMAN KM, 1995, NEUROSCI LETT, V190, P133, DOI 10.1016/0304-3940(95)11523-Y; Herz MI, 1997, AM J PSYCHIAT, V154, P1; HERZ MI, 2002, SCHIZOPHRENIA COMPRE; Hoek HW, 1998, SOC PSYCH PSYCH EPID, V33, P373, DOI 10.1007/s001270050068; HOGARTY GE, 1974, ARCH GEN PSYCHIAT, V31, P603; HOGARTY GE, 1979, ARCH GEN PSYCHIAT, V36, P1283; Honigfeld G, 1998, J CLIN PSYCHIAT, V59, P3; Ichikawa J, 2002, NEUROPSYCHOPHARMACOL, V26, P325, DOI 10.1016/S0893-133X(01)00312-8; JESTE DV, 1989, ARCH GEN PSYCHIAT, V46, P1019; JOHNSON SW, 1983, NEUROPHARMACOLOGY, V22, P843, DOI 10.1016/0028-3908(83)90130-2; Jordan S, 2002, EUR J PHARMACOL, V441, P137, DOI 10.1016/S0014-2999(02)01532-7; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; Kane JM, 2002, J CLIN PSYCHIAT, V63, P763, DOI 10.4088/JCP.v63n0903; Kane JM, 2001, ARCH GEN PSYCHIAT, V58, P965, DOI 10.1001/archpsyc.58.10.965; Kane JM, 2002, AM J PSYCHIAT, V159, P554, DOI 10.1176/appi.ajp.159.4.554; Kapur S, 2002, NEUROREPORT, V13, P831, DOI 10.1097/00001756-200205070-00019; Keefe RSE, 1999, SCHIZOPHRENIA BULL, V25, P201, DOI 10.1093/oxfordjournals.schbul.a033374; KRAMER M S, 1989, Hillside Journal of Clinical Psychiatry, V11, P107; Kubicki M, 2002, NEUROIMAGE, V17, P1711, DOI 10.1006/nimg.2002.1296; Leonard S, 2002, ARCH GEN PSYCHIAT, V59, P1085, DOI 10.1001/archpsyc.59.12.1085; Leucht S, 2002, AM J PSYCHIAT, V159, P180, DOI 10.1176/appi.ajp.159.2.180; Levinson DF, 1999, AM J PSYCHIAT, V156, P1138; Lindenmayer JP, 2003, AM J PSYCHIAT, V160, P290, DOI 10.1176/appi.ajp.160.2.290; MADISON DV, 1988, BRAIN RES, V442, P131, DOI 10.1016/0006-8993(88)91440-0; Marder SR, 2002, SCHIZOPHRENIA BULL, V28, P5, DOI 10.1093/oxfordjournals.schbul.a006926; MARDER SR, 1987, ARCH GEN PSYCHIAT, V44, P518; McEvoy JP, 1999, BIOL PSYCHIAT, V46, P125, DOI 10.1016/S0006-3223(98)00377-1; McGorry PD, 2002, ARCH GEN PSYCHIAT, V59, P921, DOI 10.1001/archpsyc.59.10.921; McGuffin P, 2001, SCIENCE, V291, P1232, DOI 10.1126/science.1057264; Meltzer HY, 2003, ARCH GEN PSYCHIAT, V60, P82, DOI 10.1001/archpsyc.60.1.82; MELTZER HY, 1989, PSYCHOPHARMACOLOGY, V99, pS18, DOI 10.1007/BF00442554; NORDSTROM AL, 1992, PSYCHOPHARMACOLOGY, V106, P433, DOI 10.1007/BF02244811; PARK S, 1995, ARCH GEN PSYCHIAT, V52, P821; PICKAR D, 1986, ARCH GEN PSYCHIAT, V43, P669; Pisani F, 2002, DRUG SAFETY, V25, P91, DOI 10.2165/00002018-200225020-00004; SATANOVE A, 1967, J AMER MED ASSOC, V200, P209, DOI 10.1001/jama.200.3.209; Schaeffer JL, 2002, J AM ACAD CHILD PSY, V41, P538, DOI 10.1097/00004583-200205000-00011; SELEMON LD, 1995, ARCH GEN PSYCHIAT, V52, P805; Sernyak MJ, 2002, AM J PSYCHIAT, V159, P561, DOI 10.1176/appi.ajp.159.4.561; Sernyak MJ, 2001, AM J PSYCHIAT, V158, P931, DOI 10.1176/appi.ajp.158.987.931; Siris SG, 2001, J PSYCHOPHARMACOL, V15, P127, DOI 10.1177/026988110101500209; Small JG, 1997, ARCH GEN PSYCHIAT, V54, P549; Smith S, 2002, J CLIN PSYCHOPHARM, V22, P109, DOI 10.1097/00004714-200204000-00002; SPOHN HE, 1977, ARCH GEN PSYCHIAT, V34, P633; Stefansson H, 2002, AM J HUM GENET, V71, P877, DOI 10.1086/342734; Straub, 2002, AM J HUM GENET, V71, P1007; Straub RE, 2002, AM J HUM GENET, V71, P337, DOI 10.1086/341750; Suzuki A, 2001, AM J PSYCHIAT, V158, P1714, DOI 10.1176/appi.ajp.158.10.1714; SWANSON JW, 1990, HOSP COMMUNITY PSYCH, V41, P761; SWANSON JW, 1991, HOSP COMMUNITY PSYCH, V42, P954; TAMMINGA CA, 1992, ARCH GEN PSYCHIAT, V49, P522; Thompson PM, 2001, P NATL ACAD SCI USA, V98, P11650, DOI 10.1073/pnas.201243998; Tran PV, 1997, J CLIN PSYCHOPHARM, V17, P407, DOI 10.1097/00004714-199710000-00010; Tsuang M, 2000, BIOL PSYCHIAT, V47, P210, DOI 10.1016/S0006-3223(99)00289-9; VENABLES P H, 1964, Prog Exp Pers Res, V72, P1; Volavka, 2002, AM J PSYCHIAT, V159, P2132; Volavka J, 2002, AM J PSYCHIAT, V159, P255, DOI 10.1176/appi.ajp.159.2.255; WOLKOWITZ OM, 1991, AM J PSYCHIAT, V148, P714; Woo TU, 1998, P NATL ACAD SCI USA, V95, P5341, DOI 10.1073/pnas.95.9.5341; Wyatt RJ, 1998, J PSYCHIATR RES, V32, P169, DOI 10.1016/S0022-3956(97)00014-9	103	541	578	3	51	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 30	2003	349	18					1738	1749		10.1056/NEJMra035458	http://dx.doi.org/10.1056/NEJMra035458			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	737FJ	14585943				2022-12-28	WOS:000186219500010
J	Schulman, S; Wahlander, K; Lundstrom, T; Clason, SB; Eriksson, H				Schulman, S; Wahlander, K; Lundstrom, T; Clason, SB; Eriksson, H		THRIVE III Investigators	Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; INTENSITY WARFARIN THERAPY; ANTICOAGULANT-THERAPY; KNEE REPLACEMENT; FIRST EPISODE; LONG-TERM; PHARMACOKINETICS; ABSORPTION; MELAGATRAN	BACKGROUND: For many patients with venous thromboembolism, secondary prevention with vitamin K antagonists is not extended beyond six months, since the risk of recurrence may be outweighed by the risk of major bleeding. METHODS: In a double-blind, multicenter trial, we randomly assigned 1233 patients with venous thromboembolism who had undergone six months of anticoagulant therapy to extended secondary prevention with the oral direct thrombin inhibitor ximelagatran (24 mg) or placebo, taken twice daily, for 18 months without monitoring of coagulation. At base line, bilateral ultrasonography of the legs and perfusion lung scanning were performed. RESULTS: Data from 612 patients in the ximelagatran group and 611 in the placebo group were analyzed. The occurrence of the primary end point, symptomatic recurrent venous thromboembolism, was confirmed in 12 patients assigned to ximelagatran and 71 patients assigned to placebo (hazard ratio, 0.16; 95 percent confidence interval, 0.09 to 0.30; P<0.001). Death from any cause occurred in 6 patients in the ximelagatran group and 7 patients in the placebo group, and bleeding occurred in 134 patients and 111 patients, respectively (hazard ratio, 1.19; 95 percent confidence interval, 0.93 to 1.53; P=0.17). The incidence of major hemorrhage was low (six events in the ximelagatran group and five in the placebo group), and none of these hemorrhages were fatal. The cumulative risk of a transient elevation of the alanine aminotransferase level to more than three times the upper limit of normal was 6.4 percent in the ximelagatran group, as compared with 1.2 percent in the placebo group (P<0.001). CONCLUSIONS: Oral ximelagatran was superior to placebo for the extended prevention of venous thromboembolism. There was no significant increase in the frequency of bleeding complications, but there was an increase in the number of patients with a transient elevation in the alanine aminotransferase level.	Karolinska Hosp, Dept Med, Coagulat Unit, S-17176 Stockholm, Sweden; AstraZeneca R&D, Molndal, Sweden; Sahlgrens Univ Hosp, Dept Clin Chem & Transfus Med, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Med, Gothenburg, Sweden	Karolinska Institutet; Karolinska University Hospital; AstraZeneca; Sahlgrenska University Hospital; Sahlgrenska University Hospital	Schulman, S (corresponding author), Karolinska Hosp, Dept Med, Coagulat Unit, S-17176 Stockholm, Sweden.	sam.schulman@ks.se	Kovacs, Michael/G-3315-2011; Blanc, François-Xavier/D-7425-2015; Miranda, Fausto/N-9780-2018; Schulman, Sam/I-7559-2019	Blanc, François-Xavier/0000-0001-7644-2188; Miranda, Fausto/0000-0003-2954-8638; Schulman, Sam/0000-0002-8512-9043				Agnelli G, 2001, NEW ENGL J MED, V345, P165, DOI 10.1056/NEJM200107193450302; Elg M, 1999, THROMB RES, V94, P187, DOI 10.1016/S0049-3848(98)00213-8; Eriksson B, 2002, LANCET, V360, P1441, DOI 10.1016/S0140-6736(02)11469-3; Eriksson H, 2003, J THROMB HAEMOST, V1, P41, DOI 10.1046/j.1538-7836.2003.00034.x; Eriksson UG, 2003, DRUG METAB DISPOS, V31, P294, DOI 10.1124/dmd.31.3.294; Eriksson UG, 2003, EUR J CLIN PHARMACOL, V59, P35, DOI 10.1007/s00228-003-0565-7; Eriksson-Lepkowska M, 2001, BLOOD, V98, p89B; Francis CW, 2002, ANN INTERN MED, V137, P648, DOI 10.7326/0003-4819-137-8-200210150-00008; Gustafsson D, 2001, THROMB RES, V101, P171, DOI 10.1016/S0049-3848(00)00399-6; Heit JA, 2001, THROMB HAEMOSTASIS, V86, P452, DOI 10.1161/ATVBAHA.108.162545; Heit JA, 2001, ARCH INTERN MED, V161, P2215, DOI 10.1001/archinte.161.18.2215; Hyers TM, 2001, CHEST, V119, p176S, DOI 10.1378/chest.119.1_suppl.176S; Kearon C, 1999, NEW ENGL J MED, V341, P298; Kearon C, 2003, NEW ENGL J MED, V349, P631, DOI 10.1056/NEJMoa035422; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; Petersen P, 2003, J AM COLL CARDIOL, V41, P1445, DOI 10.1016/S0735-1097(03)00255-9; Pinede L, 2001, CIRCULATION, V103, P2453; Ridker PM, 2003, NEW ENGL J MED, V348, P1425, DOI 10.1056/NEJMoa035029; Schulman S, 1997, NEW ENGL J MED, V336, P393, DOI 10.1056/NEJM199702063360601; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; SOSTMAN HD, 1994, RADIOLOGY, V193, P103, DOI 10.1148/radiology.193.1.8090877	23	352	362	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 30	2003	349	18					1713	1721		10.1056/NEJMoa030104	http://dx.doi.org/10.1056/NEJMoa030104			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	737FJ	14585939				2022-12-28	WOS:000186219500005
J	Einsele, H; Hamprecht, K				Einsele, H; Hamprecht, K			Immunotherapy of cytomegalovirus infection after stem-cell transplantation: a new option?	LANCET			English	Editorial Material							GANCICLOVIR-RESISTANT CYTOMEGALOVIRUS; MARROW-TRANSPLANTATION; CMV INFECTION; BONE-MARROW; THERAPY; DISEASE; RECONSTITUTION; RECIPIENTS; IMMUNITY; CHILDREN		Univ Tubingen Hosp, Dept Haematol Oncol, D-72076 Tubingen, Germany; Univ Tubingen Hosp, Inst Med Virol & Epidemiol Viral Dis, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Einsele, H (corresponding author), Univ Tubingen Hosp, Dept Haematol Oncol, D-72076 Tubingen, Germany.							BOCCKH M, 2003, TRANSPLANT INFECT, P277; Boeckh M, 1996, BLOOD, V88, P4063, DOI 10.1182/blood.V88.10.4063.bloodjournal88104063; Eckle T, 2000, BLOOD, V96, P3286; Eckle T, 2002, BONE MARROW TRANSPL, V30, P433, DOI 10.1038/sj.bmt.1703666; EINSELE H, 1995, BLOOD, V86, P2815; Einsele H, 2002, BLOOD, V99, P3916, DOI 10.1182/blood.V99.11.3916; Einsele H, 2000, BONE MARROW TRANSPL, V25, P757, DOI 10.1038/sj.bmt.1702226; Gilbert C, 2002, DRUG RESIST UPDATE, V5, P88, DOI 10.1016/S1368-7646(02)00021-3; GOODRICH JM, 1993, ANN INTERN MED, V118, P173, DOI 10.7326/0003-4819-118-3-199302010-00003; Hakki M, 2003, BLOOD, V102, P3060, DOI 10.1182/blood-2002-11-3472; Hamprecht K, 2003, J INFECT DIS, V187, P139, DOI 10.1086/346240; Limaye AP, 2002, CLIN INFECT DIS, V35, P866, DOI 10.1086/342385; RIDDELL SR, 1992, SCIENCE, V257, P238; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603	14	15	15	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 25	2003	362	9393					1343	1344		10.1016/S0140-6736(03)14673-9	http://dx.doi.org/10.1016/S0140-6736(03)14673-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	735YX	14585632				2022-12-28	WOS:000186143300004
J	Grakoui, A; Shoukry, NH; Woollard, DJ; Han, JH; Hanson, HL; Ghrayeb, J; Murthy, KK; Rice, CM; Walker, CM				Grakoui, A; Shoukry, NH; Woollard, DJ; Han, JH; Hanson, HL; Ghrayeb, J; Murthy, KK; Rice, CM; Walker, CM			HCV persistence and immune evasion in the absence of memory T cell help	SCIENCE			English	Article							HEPATITIS-C VIRUS; PROTECTIVE IMMUNITY; CD8-T-CELL MEMORY; VIRAL CLEARANCE; CD4-T-CELL HELP; INFECTION; RESPONSES; CHIMPANZEES; CD8(+); DETERMINANTS	Spontaneous resolution of hepatitis C virus (HCV) infection in humans usually affords long-term immunity to persistent viremia and associated liver diseases. Here, we report that memory CD4+ T cells are essential for this protection. Antibody-mediated depletion of CD4+ T cells before reinfection of two immune chimpanzees resulted in persistent, low-level viremia despite functional intrahepatic memory CD8+ T cell responses. Incomplete control of HCV replication by memory CD8+ T cells in the absence of adequate CD4+ T cell help was associated with emergence of viral escape mutations in class I major histocompatibility complex-restricted epitopes and failure to resolve HCV infection.	Cilumbus Childrens Res Inst, Ctr Vaccines & Immun, Columbus, OH 43205 USA; Rockefeller Univ, Ctr Study Hepatitis C, New York, NY 10021 USA; Centocor Inc, Malvern, PA 19355 USA; SW Fdn Biomed Res, Dept Virol & Immunol, San Antonio, TX 78227 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Pediat, Columbus, OH 43205 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; Rockefeller University; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; Texas Biomedical Research Institute; University System of Ohio; Ohio State University	Walker, CM (corresponding author), Cilumbus Childrens Res Inst, Ctr Vaccines & Immun, 700 Childrens Dr,W503, Columbus, OH 43205 USA.		Yang, Chen/G-1379-2010		DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB027091] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA057973, R01CA085883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI048231] Funding Source: NIH RePORTER; NCI NIH HHS [CA85883, CA57973] Funding Source: Medline; NHLBI NIH HHS [N01 HB27091] Funding Source: Medline; NIAID NIH HHS [AI48231, AI40034] Funding Source: Medline; PHS HHS [A14736] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; Bassett SE, 2001, HEPATOLOGY, V33, P1479, DOI 10.1053/jhep.2001.24371; Chang KM, 1997, J CLIN INVEST, V100, P2376, DOI 10.1172/JCI119778; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Cooper S, 1999, IMMUNITY, V10, P439, DOI 10.1016/S1074-7613(00)80044-8; DIEPOLDER HM, 1995, LANCET, V346, P1006, DOI 10.1016/S0140-6736(95)91691-1; Erickson AL, 2001, IMMUNITY, V15, P883, DOI 10.1016/S1074-7613(01)00245-X; FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; Gerlach JT, 1999, GASTROENTEROLOGY, V117, P933, DOI 10.1016/S0016-5085(99)70353-7; Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950; Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441; JONKER M, 1993, CLIN EXP IMMUNOL, V93, P301, DOI 10.1111/j.1365-2249.1993.tb08176.x; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Looney James E., 1992, Human Antibodies and Hybridomas, V3, P191; Major ME, 2002, J VIROL, V76, P6586, DOI 10.1128/JVI.76.13.6586-6595.2002; Mehta SH, 2002, LANCET, V359, P1478, DOI 10.1016/S0140-6736(02)08435-0; Missale G, 1996, J CLIN INVEST, V98, P706, DOI 10.1172/JCI118842; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; PRINCE AM, 1992, J INFECT DIS, V165, P438, DOI 10.1093/infdis/165.3.438; Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305; Shoukry NH, 2003, J EXP MED, V197, P1645, DOI 10.1084/jem.20030239; Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317; Takaki A, 2000, NAT MED, V6, P578, DOI 10.1038/75063; Thimme R, 2002, P NATL ACAD SCI USA, V99, P15661, DOI 10.1073/pnas.202608299; Thimme R, 2001, J EXP MED, V194, P1395, DOI 10.1084/jem.194.10.1395; WALKER CM, UNPUB; Weiner AJ, 2001, J VIROL, V75, P7142, DOI 10.1128/JVI.75.15.7142-7148.2001	28	651	679	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					659	662		10.1126/science.1088774	http://dx.doi.org/10.1126/science.1088774			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576438				2022-12-28	WOS:000186119900063
J	Lorenz, R				Lorenz, R			The glitter of distant seas	SCIENCE			English	Editorial Material							TITANS SURFACE		Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	University of Arizona	Lorenz, R (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA.		Lorenz, Ralph D/B-8759-2016	Lorenz, Ralph D/0000-0001-8528-4644				BLACK GJ, 2002, B AM ASTRON SOC, V34, P882; Campbell DB, 2003, SCIENCE, V302, P431, DOI 10.1126/science.1088969; Gibbard SG, 1999, ICARUS, V139, P189, DOI 10.1006/icar.1999.6095; Griffith CA, 2003, SCIENCE, V300, P628, DOI 10.1126/science.1081897; Lorenz R. D., 2002, LIFTING TITANS VEIL; Lorenz RD, 1997, PLANET SPACE SCI, V45, P1009, DOI 10.1016/S0032-0633(97)00085-8; Lorenz RD, 1997, PLANET SPACE SCI, V45, P981, DOI 10.1016/S0032-0633(97)00087-1; LUNINE JI, 1983, SCIENCE, V222, P1229, DOI 10.1126/science.222.4629.1229; MUHLEMAN DO, 1990, SCIENCE, V248, P975, DOI 10.1126/science.248.4958.975; MUHLEMAN DO, 1995, ANNU REV EARTH PL SC, V23, P337, DOI 10.1146/annurev.earth.23.1.337; SAGAN C, 1982, NATURE, V300, P731, DOI 10.1038/300731a0; Smith PH, 1996, ICARUS, V119, P336, DOI 10.1006/icar.1996.0023; [No title captured]	13	6	6	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					403	404		10.1126/science.1090464	http://dx.doi.org/10.1126/science.1090464			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14526089				2022-12-28	WOS:000185963200028
J	Pellino, JL; Sontheimer, EJ				Pellino, JL; Sontheimer, EJ			R2D2 leads the silencing trigger to mRNA's death star	CELL			English	Editorial Material							REQUIREMENTS; INTERFERENCE; RDE-1; GENE	During RNA interference (RNAi), Dicer generates short interfering RNAs (siRNAs), which then guide target mRNA cleavage by the RISC complex. Now, Liu et al. identify R2D2, a Dicer-associated protein that is important for siRNA incorporation into RISC, thus linking the initiation and execution phases of RNAi.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Pellino, JL (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA.			Sontheimer, Erik/0000-0002-0881-0310				Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	10	6	12	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	2003	115	2					132	133		10.1016/S0092-8674(03)00806-7	http://dx.doi.org/10.1016/S0092-8674(03)00806-7			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567910	Bronze			2022-12-28	WOS:000186039200004
J	Barzilai, N; Atzmon, G; Schechter, C; Schaefer, EJ; Cupples, AL; Lipton, R; Cheng, S; Shuldiner, AR				Barzilai, N; Atzmon, G; Schechter, C; Schaefer, EJ; Cupples, AL; Lipton, R; Cheng, S; Shuldiner, AR			Unique lipoprotein phenotype and genotype associated with exceptional longevity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTER TRANSFER PROTEIN; HIGH-DENSITY-LIPOPROTEINS; CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; PARTICLE-SIZE; GENE POLYMORPHISMS; HEPATIC LIPASE; HDL; ATHEROSCLEROSIS; CHOLESTEROL	Context Individuals with exceptional longevity have a lower incidence and/or significant delay in the onset of age-related disease, and their family members may inherit biological factors that modulate aging processes and disease susceptibility. Objective To identify specific biological and genetic factors that are associated with or reliably define a human longevity phenotype. Design, Setting, and Participants In a case-control design, 213 Ashkenazi Jewish probands with exceptional longevity (mean [SDI age, 98.2 [5.3] years) and their offspring (n=216; mean [SD] age, 68.3 [6.7] years) were recruited from 1998 to 2002, while an age-matched control group of Ashkenazi Jews (n=258) and participants from the Framingham Offspring Study (n = 589) were accepted as control groups. Main Outcome Measures Detailed questionnaires, physical examination, and blood samples were taken, including assessment of lipids and lipoprotein subclass levels and particle sizes by proton nuclear magnetic resonance. Samples were also genotyped for the codon 405 isoleucine to valine (1405V) variation in the cholesteryl ester transfer protein (CETP) gene, which is involved in regulation of lipoprotein and its particle sizes. Results High-density lipoprotein (HDL) and low-density lipoprotein (LDL) particle sizes were significantly higher in probands compared with both control groups (P=.001 for both), independent of plasma levels of HDL and LDL cholesterol and apolipoprotein A1 and B. This phenotype was also typical of the proband's offspring but not of the age-matched controls. The HDL and LDL particle sizes were significantly larger in offspring and controls without hypertension or cardiovascular disease, (P=.001 and P=.008, respectively). Furthermore, lipoprotein particle sizes, but not plasma LDL levels, were significantly higher in offspring and controls without the metabolic syndrome (P<.001). Probands and offspring had a 2.9- and 3.6-fold (in men) and 2.7- and 1.5-fold (in women) increased frequency, respectively, of homozygosity for the 405 valine allele of CETP (VV genotype), respectively, compared with controls (P<.001 for both). Those probands with the VV genotype had increased lipoprotein sizes and lower serum CETP concentrations. Conclusions Individuals with exceptional longevity and their offspring have significantly larger HDL and LDL particle sizes. This phenotype is associated with a lower prevalence of hypertension, cardiovascular disease, the metabolic syndrome, and increased homozygosity for the 1405V variant in CETP. These findings suggest that lipoprotein particle sizes are heritable and promote a healthy aging phenotype.	Yeshiva Univ Albert Einstein Coll Med, Inst Aging Res, Ctr Diabet Res & Training, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Community & Family Med, Bronx, NY 10461 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Baltimore Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Baltimore, MD USA; Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Roche Mol Syst Inc, Dept Human Genet, Alameda, CA USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University System of Maryland; University of Maryland Baltimore; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center; Tufts University; United States Department of Agriculture (USDA); Boston University; Roche Holding	Barzilai, N (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Inst Aging Res, Ctr Diabet Res & Training, Belfer Bldg 701,1300 Morris Pk Ave, Bronx, NY 10461 USA.	barzilai@aecom.yu.edu		Cupples, L. Adrienne/0000-0003-0273-7965; Shuldiner, Alan/0000-0001-9921-4305	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR012248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020541, P60DK020541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018728] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR12248] Funding Source: Medline; NIA NIH HHS [R01 AG-18728-01A1] Funding Source: Medline; NIDDK NIH HHS [DK 20541] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arai T, 2000, CLIN CHIM ACTA, V301, P103, DOI 10.1016/S0009-8981(00)00328-4; Arai Y, 2003, J MOL MED, V81, P102, DOI 10.1007/s00109-002-0407-6; Asztalos BF, 2002, J LIPID RES, V43, P1701, DOI 10.1194/jlr.M200037-JLR200; Atzmon G, 2002, J GERONTOL A-BIOL, V57, pM712, DOI 10.1093/gerona/57.11.M712; ATZMON G, IN PRESS J AM GERIAT; Austin M A, 2000, Curr Atheroscler Rep, V2, P200, DOI 10.1007/s11883-000-0021-4; AUSTIN MA, 1993, GENET EPIDEMIOL, V10, P599, DOI 10.1002/gepi.1370100645; Barzilai N, 1999, J GERONTOL A-BIOL, V54, pB89, DOI 10.1093/gerona/54.3.B89; Barzilai N, 2001, J AM GERIATR SOC, V49, P76, DOI 10.1046/j.1532-5415.2001.49013.x; Barzilai N, 2001, J GERONTOL A-BIOL, V56, pM83, DOI 10.1093/gerona/56.2.M83; Blake GJ, 2002, CIRCULATION, V106, P1930, DOI 10.1161/01.CIR.0000033222.75187.B9; Boekholdt SM, 2003, J LIPID RES, V44, P1080, DOI 10.1194/jlr.R200018-JLR200; Bruce C, 1998, J LIPID RES, V39, P1071; Cheng S, 1999, GENOME RES, V9, P936, DOI 10.1101/gr.9.10.936; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Falconer D. S., 1996, INTRO QUANTATIVE GEN; FUNKE H, 1994, CIRCULATION, V90, P241; Garvey WT, 2003, DIABETES, V52, P453, DOI 10.2337/diabetes.52.2.453; Goto A, 2001, ATHEROSCLEROSIS, V159, P153, DOI 10.1016/S0021-9150(01)00476-2; Grundy SM, 1999, J LIPID RES, V40, P229; Gudnason V, 1999, EUR J CLIN INVEST, V29, P116, DOI 10.1046/j.1365-2362.1999.00412.x; Herrera VLM, 1999, NAT MED, V5, P1383, DOI 10.1038/70956; IKEWAKI K, 1995, J CLIN INVEST, V96, P1573, DOI 10.1172/JCI118196; Kakko S, 2000, EUR J CLIN INVEST, V30, P18; Kakko S, 2001, EUR J CLIN INVEST, V31, P593, DOI 10.1046/j.1365-2362.2001.00859.x; Kraus WE, 2002, NEW ENGL J MED, V347, P1483, DOI 10.1056/NEJMoa020194; Kuivenhoven JA, 1997, ARTERIOSCL THROM VAS, V17, P560, DOI 10.1161/01.ATV.17.3.560; Lakka HM, 2002, JAMA-J AM MED ASSOC, V288, P2709, DOI 10.1001/jama.288.21.2709; Lamarche B, 1997, CIRCULATION, V95, P69, DOI 10.1161/01.CIR.95.1.69; Lancaster, 1997, Medscape Womens Health, V2, P7; Libby P, 2001, AM J CARDIOL, V88, p3N; Okumura K, 2002, ATHEROSCLEROSIS, V161, P425, DOI 10.1016/S0021-9150(01)00653-0; Otvos James D, 2002, Clin Lab, V48, P171; OTVOS JD, 1992, CLIN CHEM, V38, P1632; Pascot A, 2002, ATHEROSCLEROSIS, V160, P399, DOI 10.1016/S0021-9150(01)00579-2; Perls T, 2002, MECH AGEING DEV, V123, P231, DOI 10.1016/S0047-6374(01)00348-7; Perls TT, 2002, P NATL ACAD SCI USA, V99, P8442, DOI 10.1073/pnas.122587599; Puca AA, 2001, P NATL ACAD SCI USA, V98, P10505, DOI 10.1073/pnas.181337598; Rader DJ, 2000, MOL MED TODAY, V6, P170, DOI 10.1016/S1357-4310(00)01673-7; SAKAI N, 1995, EUR J CLIN INVEST, V25, P332, DOI 10.1111/j.1365-2362.1995.tb01710.x; SCHAEFER EJ, 1994, J LIPID RES, V35, P779; Verghese J, 2002, NEW ENGL J MED, V347, P1761, DOI 10.1056/NEJMoa020441; YAMASHITA S, 1990, J CLIN INVEST, V86, P688, DOI 10.1172/JCI114764	43	428	451	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	2003	290	15					2030	2040		10.1001/jama.290.15.2030	http://dx.doi.org/10.1001/jama.290.15.2030			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CX	14559957				2022-12-28	WOS:000185924200027
J	Ayoubi, JM; Fanchin, R				Ayoubi, JM; Fanchin, R			Ectopic pregnancy: which side to operate?	LANCET			English	Editorial Material									CHU Grenoble, Dept Obstet & Gynaecol, F-38042 Grenoble, France; Hop Antoine Beclere, Ctr Reprod Med, Clamart, France	CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP	Ayoubi, JM (corresponding author), CHU Grenoble, Dept Obstet & Gynaecol, F-38042 Grenoble, France.								0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 11	2003	362	9391					1183	1183		10.1016/S0140-6736(03)14540-0	http://dx.doi.org/10.1016/S0140-6736(03)14540-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568739				2022-12-28	WOS:000185924100009
J	Elwyn, G; Edwards, A; Britten, N				Elwyn, G; Edwards, A; Britten, N			"Doing prescribing": how doctors can be more effective	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SHARED DECISION-MAKING; GENERAL-PRACTICE; CARE; PRESCRIPTIONS; CONSULTATIONS; MANAGEMENT		Univ Wales Swansea, Swansea Clin Sch, Primary Care Grp, Swansea SA2 8PP, W Glam, Wales; Peninsula Med Sch, Inst Clin Educ, Exeter, Devon, England	Swansea University; University of Exeter	Elwyn, G (corresponding author), Univ Wales Swansea, Swansea Clin Sch, Primary Care Grp, Swansea SA2 8PP, W Glam, Wales.	g.elwyn@swansea.ac.uk	Elwyn, G./L-4292-2015; Elwyn, Glyn/B-4798-2009	Elwyn, Glyn/0000-0002-0917-6286				ASHCROFT A, 2001, EVIDENCE BASED PATIE; Barry CA, 2000, BRIT MED J, V320, P1246, DOI 10.1136/bmj.320.7244.1246; BEKKER H, 2003, ENCY HUMAN GENOME ET; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Britten N, 2000, BMJ-BRIT MED J, V320, P484, DOI 10.1136/bmj.320.7233.484; Britten Nicky, 2002, Health Expect, V5, P256, DOI 10.1046/j.1369-6513.2002.00187.x; Campion P, 2002, BRIT MED J, V325, P691, DOI 10.1136/bmj.325.7366.691; Carter S, 2003, QUESTION CHOICE COMP; Coulter A, 2002, AUTONOMOUS PATIENT; Cox K, 2002, SYSTEMATIC REV COMMU; DONOVAN JL, 1992, SOC SCI MED, V34, P507, DOI 10.1016/0277-9536(92)90206-6; Drew P, 2001, Health Expect, V4, P58, DOI 10.1046/j.1369-6513.2001.00125.x; Elwyn G, 1999, BRIT J GEN PRACT, V49, P477; Elwyn G, 2000, BRIT J GEN PRACT, V50, P892; Elwyn G, 2003, QUAL SAF HEALTH CARE, V12, P93, DOI 10.1136/qhc.12.2.93; Gafaranga J, 2003, FAM PRACT, V20, P242, DOI 10.1093/fampra/cmg303; Haynes R B, 2002, Cochrane Database Syst Rev, pCD000011; JENKINS L, 2002, RESOURCE PACK REV MO; Marinker M, 1997, BRIT MED J, V314, P747, DOI 10.1136/bmj.314.7082.747; McDonald HP, 2002, JAMA-J AM MED ASSOC, V288, P2868, DOI 10.1001/jama.288.22.2868; O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731; Simon GE, 2000, BRIT MED J, V320, P550, DOI 10.1136/bmj.320.7234.550; Stevenson FA, 2003, SOC SCI MED, V57, P513, DOI 10.1016/S0277-9536(02)00377-5; Stevenson FA, 2000, SOC SCI MED, V50, P829, DOI 10.1016/S0277-9536(99)00376-7; Weinstein Neil D., 1999, Journal of the National Cancer Institute Monographs, P15	25	73	74	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 11	2003	327	7419					864	867		10.1136/bmj.327.7419.864	http://dx.doi.org/10.1136/bmj.327.7419.864			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551110	Green Published			2022-12-28	WOS:000185921200032
J	Kannus, P; Parkkari, J; Khan, K				Kannus, P; Parkkari, J; Khan, K			Hip protectors need an evidence base	LANCET			English	Editorial Material							OSTEOPOROTIC FRACTURES; FALLING CONDITIONS; IMPACT; PREVENTION; FORCE		Tampere Univ, Sch Med, Dept Surg, FIN-33520 Tampere, Finland; Univ Hosp, FIN-33520 Tampere, Finland; Tampere Res Ctr Sports Med, UKK Inst Hlth Promot Res, Tampere, Finland; Univ British Columbia, Dept Family Practice, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, BC Womens Hosp Osteoporosis Program, Vancouver, BC V5Z 1M9, Canada	Tampere University; UKK Institute; University of British Columbia; University of British Columbia	Kannus, P (corresponding author), Tampere Univ, Sch Med, Dept Surg, FIN-33520 Tampere, Finland.							Birks YF, 2003, AGE AGEING, V32, P442, DOI 10.1093/ageing/32.4.442; Colon-Emeric CS, 2003, AGE AGEING, V32, P47, DOI 10.1093/ageing/32.1.47; Dennison E, 2000, HORM RES, V54, P58, DOI 10.1159/000053299; Dolan P, 1998, OSTEOPOROSIS INT, V8, P611, DOI 10.1007/s001980050107; Ekman A, 1997, LANCET, V350, P563, DOI 10.1016/S0140-6736(05)63140-6; Kannus P, 2000, NEW ENGL J MED, V343, P1506, DOI 10.1056/NEJM200011233432101; Kannus P, 1999, LANCET, V353, P802, DOI 10.1016/S0140-6736(98)04235-4; Kannus P, 1999, BONE, V25, P229, DOI 10.1016/S8756-3282(99)00154-4; LAURITZEN JB, 1993, LANCET, V341, P11, DOI 10.1016/0140-6736(93)92480-H; McColl A, 1998, J PUBLIC HEALTH MED, V20, P196, DOI 10.1093/oxfordjournals.pubmed.a024743; PARKKARI J, 1995, J BONE MINER RES, V10, P1437; Parkkari J, 1997, CALCIFIED TISSUE INT, V60, P354, DOI 10.1007/s002239900242; Parkkari J, 1998, AGE AGEING, V27, P225, DOI 10.1093/ageing/27.2.225; Parkkari J, 1999, CALCIFIED TISSUE INT, V65, P183; Wei TS, 2001, OSTEOPOROSIS INT, V12, P1050, DOI 10.1007/PL00004184	15	15	15	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 11	2003	362	9391					1168	1169		10.1016/S0140-6736(03)14554-0	http://dx.doi.org/10.1016/S0140-6736(03)14554-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568734				2022-12-28	WOS:000185924100004
J	Konje, JC; Huppertz, B; Bell, SC; Taylor, DJ; Kaufmann, P				Konje, JC; Huppertz, B; Bell, SC; Taylor, DJ; Kaufmann, P			3-dimensional colour power angiography for staging human placental development	LANCET			English	Article							ANGIOGENESIS	Maldevelopment of placental villous trees and their blood vessels results in impaired fetal growth, which can greatly compromise fetal, neonatal, childhood, and adulthood health. There are no means of directly assessing such maldevelopment. We have applied a new technique of imaging (colour power angiography [CPA]) with 3-dimensional reconstruction to assess directly villous development in human pregnancy in vivo in 20 uncomplicated pregnancies from 13 to 38 weeks' gestation. The chronology of villous trees was much the same in 3-dimensional CPA, scanning electron micrography, and classical histology from controls matched by age. This approach provides a unique opportunity to examine normal placental development directly, and should provide the bases for real-time investigation of placental pathology and a robust method for diagnosis and surveillance during pregnancy.	Univ Leicester, Dept Obstet & Gynaecol, Fetal Growth & Dev Res Grp, Leicester, Leics, England; Univ Technol, Univ Hosp, Inst Anat 2, Aachen, Germany	University of Leicester; RWTH Aachen University; RWTH Aachen University Hospital	Konje, JC (corresponding author), Univ Leicester, Dept Obstet & Gynaecol, Fetal Growth & Dev Res Grp, Leicester, Leics, England.	jck4@le.ac.uk	Huppertz, Berthold/I-2331-2019	Huppertz, Berthold/0000-0003-4814-2158				BERNISCHKE K, 2000, PATHOLOGY HUMAN PLAC; GRANNUM PAT, 1979, AM J OBSTET GYNECOL, V133, P915, DOI 10.1016/0002-9378(79)90312-0; Kadyrov M, 1998, LANCET, V352, P1747, DOI 10.1016/S0140-6736(98)02069-8; KAUFMANN P, 1987, PLACENTA, V8, P235, DOI 10.1016/0143-4004(87)90047-6; Todros T, 1999, OBSTET GYNECOL, V93, P499, DOI 10.1016/S0029-7844(98)00440-2	5	36	36	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 11	2003	362	9391					1199	1201		10.1016/S0140-6736(03)14514-X	http://dx.doi.org/10.1016/S0140-6736(03)14514-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568743				2022-12-28	WOS:000185924100013
J	Simon, SR; Fabiny, AR; Kotch, J				Simon, SR; Fabiny, AR; Kotch, J			Geriatrics training in general internal medicine fellowship programs: Current practice, barriers, and strategies for improvement	ANNALS OF INTERNAL MEDICINE			English	Article							INTEGRATING GERIATRICS; CARE; CURRICULUM; CARDIOLOGY; SOCIETY; DISEASE; CANCER	To ensure its growth and prosperity, general internal medicine will need to embrace care of the elderly, research on aging, and geriatrics education as components of its core mission. Experts agree that general internal medicine fellows could benefit from increased opportunities in research on aging and geriatrics education; however, important barriers will hamper efforts to integrate geriatrics training into general internal medicine fellowship programs. This article reviews the barriers to integration and proposes solutions for overcoming those barriers. As a result of interviews and meetings with a broad representation of general internists, geriatricians, funding agencies, and policymakers, we propose 2 interventions: 1) the development of institutional program grants to foster collaboration between general internal medicine and geriatrics faculty in the training of general internal medicine fellows and 2) the creation of a 3-year fellowship program combining general internal medicine and geriatrics. This article discusses the importance of evaluating these and other programs intended to increase the geriatrics experience of general internal medicine fellows, and it describes the potential implications of these changes for a broad array of stakeholder institutions.	Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Harvard Pilgrim Hlth Care, Boston, MA 02215 USA; Hebrew Rehabil Ctr Aged, Boston, MA 02131 USA	Harvard Pilgrim Health Care; Harvard University; Harvard Medical School	Simon, SR (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Harvard Pilgrim Hlth Care, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA.	steven_simon@hms.harvard.edu						*AM SOC CLIN ONC, GER ONC TRAIN PROGR; Applegate WB, 1997, J AM GERIATR SOC, V45, P641, DOI 10.1111/j.1532-5415.1997.tb03103.x; Beasley BW, 1998, J GEN INTERN MED, V13, P426, DOI 10.1046/j.1525-1497.1998.00127.x; BLOCK SD, 1994, NEW PATHWAYS MED ED; Caiola E, 2000, J GEN INTERN MED, V15, P656, DOI 10.1046/j.1525-1497.2000.06389.x; CALKINS E, 1993, T AM CLIN CLIMAT ASS, V105, P78; COHEN JJ, 1993, ANN INTERN MED, V119, P1125, DOI 10.7326/0003-4819-119-11-199312010-00010; Hafferty FW, 1998, ACAD MED, V73, P403, DOI 10.1097/00001888-199804000-00013; Kennedy BJ, 1997, CANCER, V80, P1270, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1270::AID-CNCR12>3.0.CO;2-4; Larson EB, 2001, ANN INTERN MED, V134, P997, DOI 10.7326/0003-4819-134-10-200105150-00013; LUDMERER KM, 2000, ED MED STUD 10 SOTR; MCCORMICK WC, 1994, J AM GERIATR SOC, V42, P517, DOI 10.1111/j.1532-5415.1994.tb04974.x; Mebane EW, 1999, J AM GERIATR SOC, V47, P579, DOI 10.1111/j.1532-5415.1999.tb02573.x; ORLANDER JD, 1991, J GEN INTERN MED, V6, P460, DOI 10.1007/BF02598172; Pantilat SZ, 1999, WESTERN J MED, V171, P253; Pepper PV, 1999, J AM GERIATR SOC, V47, P967, DOI 10.1111/j.1532-5415.1999.tb01292.x; Rich NW, 1998, J AM GERIATR SOC, V46, P921, DOI 10.1111/j.1532-5415.1998.tb02733.x; Simon SR, 1999, ACAD MED, V74, P1253, DOI 10.1097/00001888-199911000-00022; *SOC GEN INT MED, 1996, DIR GEN INT MED FELL; Society of General Internal Medicine, 1994, J GEN INTERN MED, V9, P513; Sox HC, 2001, AM J MED, V110, P745, DOI 10.1016/S0002-9343(01)00756-2; Tishler J, 2000, J AM GERIATR SOC, V48, P961, DOI 10.1111/j.1532-5415.2000.tb06895.x; TURNBERG LA, 1994, J ROY COLL PHYS LOND, V28, P194	23	11	11	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 7	2003	139	7					621	627		10.7326/0003-4819-139-7-200310070-00036	http://dx.doi.org/10.7326/0003-4819-139-7-200310070-00036			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729AP	14530246				2022-12-28	WOS:000185748800028
J	Binswanger, HP				Binswanger, HP			Willingness to pay for AIDS treatment: myths and realities	LANCET			English	Editorial Material									World Bank, Africa Reg, Washington, DC 20433 USA	The World Bank	Binswanger, HP (corresponding author), World Bank, Africa Reg, 1818 H St NW, Washington, DC 20433 USA.		Binswanger, Hans/M-6883-2013	Binswanger, Hans/0000-0002-6323-1418				BINSWANGER H, 2002, 14 C AIDS BARC JUL 7; Binswanger HP, 2001, SCIENCE, V292, P221, DOI 10.1126/science.1057504; DESCLAUX A, 2001, INITIATIVE SENEGALAI; DO M, 14 INT HIV AIDS C 20; DONNELLY J, 2001, BOSTON GLOBE BO 0607, P8; Marseille E, 2002, LANCET, V359, P1851, DOI 10.1016/S0140-6736(02)08705-6; MSELLATI P, 2002, ACCES TRAITEMENTS VI; RIVERS B, FILLING FUNDING GAP; ROSEN S, 2003, HARVARD BUSINESS FEB, P80; SIMON J, 2000, HIV AIDS COMMONWEALT, P4; *UNAIDS, FACT SHEET IMPACT HI; *UNAIDS, 2002, GLOB AIDS EP BARC JU; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; World Health Organization, 2002, SCAL ANT THER RES LT	14	9	9	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 4	2003	362	9390					1152	1153		10.1016/S0140-6736(03)14473-X	http://dx.doi.org/10.1016/S0140-6736(03)14473-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728HA	14550705				2022-12-28	WOS:000185710700026
J	Gong, SC; Zheng, C; Doughty, ML; Losos, K; Didkovsky, N; Schambra, UB; Nowak, NJ; Joyner, A; Leblanc, G; Hatten, ME; Heintz, N				Gong, SC; Zheng, C; Doughty, ML; Losos, K; Didkovsky, N; Schambra, UB; Nowak, NJ; Joyner, A; Leblanc, G; Hatten, ME; Heintz, N			A gene expression atlas of the central nervous system based on bacterial artificial chromosomes	NATURE			English	Article							ESCHERICHIA-COLI; TRANSGENIC MICE; GOOSECOID-LIKE; NEURONS; RECEPTORS; CELL; SEMAPHORINS; STRIATUM; NEUROSCIENCE; MIGRATION	The mammalian central nervous system (CNS) contains a remarkable array of neural cells, each with a complex pattern of connections that together generate perceptions and higher brain functions. Here we describe a large-scale screen to create an atlas of CNS gene expression at the cellular level, and to provide a library of verified bacterial artificial chromosome (BAC) vectors and transgenic mouse lines that offer experimental access to CNS regions, cell classes and pathways. We illustrate the use of this atlas to derive novel insights into gene function in neural cells, and into principal steps of CNS development. The atlas, library of BAC vectors and BAC transgenic mice generated in this screen provide a rich resource that allows a broad array of investigations not previously available to the neuroscience community.	Rockefeller Univ, Howard Hughes Med Inst, Mol Biol Lab, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, GENSAT Project, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, Dev Neurobiol Lab, New York, NY 10021 USA; E Tennessee State Univ, Dept Anat & Cell Biol, Johnson City, TN 37614 USA; Roswell Pk Canc Inst, Buffalo, NY 14263 USA; NYU, Sch Med, Dept Cell Biol, Skirball Inst Biomol Med,Dev Genet Program, New York, NY 10016 USA; Howard Hughes Med Inst, New York, NY 10016 USA; Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD 20892 USA	Howard Hughes Medical Institute; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; East Tennessee State University; Roswell Park Cancer Institute; New York University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Heintz, N (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Mol Biol Lab, 1230 York Ave,Box 260, New York, NY 10021 USA.	gensat@rockefeller.edu						Anderson SA, 1997, SCIENCE, V278, P474, DOI 10.1126/science.278.5337.474; BAIRD DH, 1992, J NEUROSCI, V12, P619; Bernard V, 1999, J NEUROSCI, V19, P10237; Brown A, 2000, CELL, V102, P77, DOI 10.1016/S0092-8674(00)00012-X; Cajal S.R., 1911, HISTOLOGY NERVOUS SY; Chen H, 1998, NAT NEUROSCI, V1, P436, DOI 10.1038/2154; Copeland NG, 2001, NAT REV GENET, V2, P769, DOI 10.1038/35093556; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; DERER P, 1990, NEUROSCIENCE, V36, P839, DOI 10.1016/0306-4522(90)90027-2; EDWARDS MA, 1986, J COMP NEUROL, V248, P395, DOI 10.1002/cne.902480308; EDWARDS MA, 1986, J COMP NEUROL, V248, P410, DOI 10.1002/cne.902480309; Emanuel B S, 2001, Adv Pediatr, V48, P39; Feldheim DA, 2000, NEURON, V25, P563, DOI 10.1016/S0896-6273(00)81060-0; FRANTZ GD, 1994, J NEUROSCI, V14, P5725; GERFEN CR, 1988, BRAIN RES, V460, P161, DOI 10.1016/0006-8993(88)91217-6; Gong SC, 2002, GENOME RES, V12, P1992, DOI 10.1101/gr.476202; Gottlieb S, 1998, HUM MOL GENET, V7, P1497, DOI 10.1093/hmg/7.9.1497; Gottlieb S, 1997, AM J HUM GENET, V60, P1194; Hatten ME, 2002, SCIENCE, V297, P1660, DOI 10.1126/science.1074572; Heintz N, 2001, NAT REV NEUROSCI, V2, P861, DOI 10.1038/35104049; HERSCH SM, 1995, J NEUROSCI, V15, P5222; Lavdas AA, 1999, J NEUROSCI, V19, P7881; Lee EC, 2001, GENOMICS, V73, P56, DOI 10.1006/geno.2000.6451; LEMOINE C, 1995, J COMP NEUROL, V355, P418, DOI 10.1002/cne.903550308; Marin O, 2001, NAT REV NEUROSCI, V2, P780, DOI 10.1038/35097509; Metcalf WW, 1996, PLASMID, V35, P1, DOI 10.1006/plas.1996.0001; Meyer G, 1998, J COMP NEUROL, V397, P493; Muyrers JPP, 1999, NUCLEIC ACIDS RES, V27, P1555, DOI 10.1093/nar/27.6.1555; Nakamura F, 2000, J NEUROBIOL, V44, P219, DOI 10.1002/1097-4695(200008)44:2<219::AID-NEU11>3.0.CO;2-W; Nicola SM, 2000, ANNU REV NEUROSCI, V23, P185, DOI 10.1146/annurev.neuro.23.1.185; PAXINOS G, 2001, MOUSE BRAIN STEREOTA, V132; Raper JA, 2000, CURR OPIN NEUROBIOL, V10, P88, DOI 10.1016/S0959-4388(99)00057-4; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; Rybalkin SD, 2002, CIRC RES, V90, P151, DOI 10.1161/hh0202.104108; SACHS GM, 1986, J COMP NEUROL, V246, P395, DOI 10.1002/cne.902460308; SACHS GM, 1984, J COMP NEUROL, V230, P155, DOI 10.1002/cne.902300202; Schambra UB, 1992, ATLAS PRENATAL MOUSE; Surmeier DJ, 1996, J NEUROSCI, V16, P6579, DOI 10.1523/jneurosci.16-20-06579.1996; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; Valjakka A, 1998, BRAIN RES BULL, V47, P171, DOI 10.1016/S0361-9230(98)00006-9; Valverde F, 1998, GOLGI ATLAS OF THE POSTNATAL MOUSE BRAIN, P1; Walz A, 2002, J NEUROSCI, V22, P4025, DOI 10.1523/JNEUROSCI.22-10-04025.2002; Wang X, 2002, J NEUROSCI, V22, P9185; Weimann JM, 1999, NEURON, V24, P819, DOI 10.1016/S0896-6273(00)81030-2; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859; Yates PA, 2001, J NEUROSCI, V21, P8548, DOI 10.1523/JNEUROSCI.21-21-08548.2001	46	1543	1567	2	71	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 30	2003	425	6961					917	925		10.1038/nature02033	http://dx.doi.org/10.1038/nature02033			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14586460				2022-12-28	WOS:000186230600032
J	Mackenbach, JP; Bakker, MJ				Mackenbach, JP; Bakker, MJ		European Network Interventions Pol	Tackling socioeconomic inequalities in health: analysis of European experiences	LANCET			English	Article							INTERVENTION	Effective strategies must be developed to reduce socioeconomic inequalities in health. Most efforts take place in isolation, and only the UK experience has been discussed widely in international published work. We therefore analysed policy developments on health inequalities in different European countries between 1990 and 2001. We noted that countries are in widely different phases of awareness of, and willingness to take action on, inequalities in health. We identified innovative approaches in five main areas: policy steering mechanisms; labour market and working conditions; consumption and health-related behaviour; health care; and territorial approaches. National advisory committees in the UK, the Netherlands, and Sweden have proposed comprehensive strategies to reduce health inequalities. Variations between these packages suggest that policyrnaking in this area still is largely intuitive and would benefit from incorporation of more rigorous evidence-based approaches. Further international exchanges of experiences with development, implementation, and evaluation of policies and interventions to reduce health inequalities can help to enhance learning speed.	Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Publ Hlth Fund Fonds OGZ, NL-2509 AB The Hague, Netherlands	Erasmus University Rotterdam; Erasmus MC	Mackenbach, JP (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.			Lahelma, Eero/0000-0002-1064-1333				Acheson D., 1998, INDEPENDENT INQUIRY; Benach J., 2002, REDUCING INEQUALITIE, P262; BENZEVAL M, 2002, LEARNING HLTH ACTION, P211; Benzeval M, 1995, TACKLING INEQUALITIE; Burstrom B, 2000, INT J HEALTH SERV, V30, P435, DOI 10.2190/6PP1-TDEQ-H44D-4LJQ; DAHLGREN G, 1997, 9736 SWED NAT I PUBL; *DEP HLTH, 1995, VAR HLTH WHAT CAN DE; *DEP HLTH, 1999, RED HLTH IN ACT REP; Diez E, 1995, Gac Sanit, V9, P224; Diez E, 1996, TUBERCLE LUNG DIS, V77, P420, DOI 10.1016/S0962-8479(96)90114-8; ECLERC A, 2000, INEGALITES SOCIALES; GAUNTRICHARDSON P, 1999, WOMEN LOW INCOME SMO; Kuijer PPFM, 1999, ERGONOMICS, V42, P1167, DOI 10.1080/001401399185054; Lang T, 2000, J EPIDEMIOL COMMUN H, V54, P349, DOI 10.1136/jech.54.5.349; Lang T, 1995, J EPIDEMIOL COMMUN H, V49, P610, DOI 10.1136/jech.49.6.610; Macintyre S, 2001, BRIT MED J, V322, P222, DOI 10.1136/bmj.322.7280.222; MACKENBACH J, IN PRESS INT J EPIDE; Mackenbach JP, 2002, BRIT MED J, V325, P1029, DOI 10.1136/bmj.325.7371.1029; *MIN HLTH SOC AFF, 2000, HALS LIK VILL NAT MA, P91; NAVARRO V, 1996, SOCIAL INEQUALITIES; OSTLIN P, 2001, EQUITY ORIENTED STRA, V1; PRATTALA R, 1992, EUROPEAN J CLIN NU S, V42, P16; *PROGR SOC EC GEZ, 2001, SOC EC GEZ VERKL EIN; SORGDRAGER J, 2001, SOCIAAL EC GEZONDHEI; TOWNSEND P, 1992, INEQUALITIES HLTH BL, P29; WHITEHEAD M, 1991, LANCET, V338, P1059, DOI 10.1016/0140-6736(91)91911-D; Whitehead M, 1998, MILBANK Q, V76, P469, DOI 10.1111/1468-0009.00099; *WHO, 1999, HLTH 21 ALL 21 CENT; WHO World Health Organisation, 1985, TARG HLTH ALL	29	140	144	1	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 25	2003	362	9393					1409	1414		10.1016/S0140-6736(03)14639-9	http://dx.doi.org/10.1016/S0140-6736(03)14639-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	735YX	14585645				2022-12-28	WOS:000186143300025
J	Webster, GF				Webster, GF			Laser treatment of acne	LANCET			English	Editorial Material									Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol, Philadelphia, PA 19107 USA	Jefferson University	Webster, GF (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol, Philadelphia, PA 19107 USA.							Kim J, 2002, J IMMUNOL, V169, P1535, DOI 10.4049/jimmunol.169.3.1535; KLIGMAN AM, 1974, J INVEST DERMATOL, V62, P268, DOI 10.1111/1523-1747.ep12676801; Leyden JJ, 2001, SEMIN CUTAN MED SURG, V20, P139, DOI 10.1053/sder.2001.28207; Shalita A, 2001, J EUR ACAD DERMATOL, V15, P43, DOI 10.1046/j.0926-9959.2001.00012.x; Thiboutot D, 2000, ARCH FAM MED, V9, P179, DOI 10.1001/archfami.9.2.179; Webster GF, 2002, BMJ-BRIT MED J, V325, P475, DOI 10.1136/bmj.325.7362.475	6	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 25	2003	362	9393					1342	1342		10.1016/S0140-6736(03)14670-3	http://dx.doi.org/10.1016/S0140-6736(03)14670-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	735YX	14585630				2022-12-28	WOS:000186143300002
J	Manke, IA; Lowery, DM; Nguyen, A; Yaffe, MB				Manke, IA; Lowery, DM; Nguyen, A; Yaffe, MB			BRCT repeats as phosphopeptide-binding modules involved in protein targeting	SCIENCE			English	Article							PEPTIDE LIBRARIES; DOMAIN; ATM; CHECKPOINT; 53BP1; CAFFEINE; PTIP	We used a proteomic approach to identify phosphopeptide-binding modules mediating signal transduction events in the DNA damage response pathway. Using a library of partially degenerate phosphopeptides, we identified tandem BRCT (BRCA1 carboxyl-terminal) domains in PTIP (Pax transactivation domain-interacting protein) and in BRCA1 as phosphoserine- or phosphothreonine-specific binding modules that recognize substrates phosphorylated by the kinases ATM (ataxia telangiectasia-mutated) and ATR (ataxia telangiectasia- and RAD3-related) in response to gamma-irradiation. PTIP tandem BRCT domains are responsible for phosphorylation-dependent protein localization into 53BP1- and phospho-H2AX (gamma-H2AX)-containing nuclear foci, a marker of DNA damage. These findings provide a molecular basis for BRCT domain function in the DNA damage response and may help to explain why the BRCA1 BRCT domain mutation Met(1775) --> Arg, which fails to bind phosphopeptides, predisposes women to breast and ovarian cancer.	MIT, Dept Biol, Ctr Canc Res, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Yaffe, MB (corresponding author), MIT, Dept Biol, Ctr Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060594] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60594] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Cho EA, 2003, MOL CELL BIOL, V23, P1666, DOI 10.1128/MCB.23.5.1666-1673.2003; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Huyton T, 2000, MUTAT RES-DNA REPAIR, V460, P319, DOI 10.1016/S0921-8777(00)00034-3; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lechner MS, 2000, NUCLEIC ACIDS RES, V28, P2741, DOI 10.1093/nar/28.14.2741; MANKE IA, UNPUB; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Shimizu K, 2001, MOL CELL BIOL, V21, P3901, DOI 10.1128/MCB.21.12.3901-3912.2001; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Williams RS, 2003, J BIOL CHEM, V278, P2630, DOI 10.1074/jbc.M210019200; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Yaffe MB, 2002, NAT REV MOL CELL BIO, V3, P177, DOI 10.1038/nrm759; Yaffe MB, 2000, METHOD ENZYMOL, V328, P157, DOI 10.1016/S0076-6879(00)28397-3; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	22	528	538	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					636	639		10.1126/science.1088877	http://dx.doi.org/10.1126/science.1088877			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576432				2022-12-28	WOS:000186119900057
J	Rokas, A; Williams, BL; King, N; Carroll, SB				Rokas, A; Williams, BL; King, N; Carroll, SB			Genome-scale approaches to resolving incongruence in molecular phylogenies	NATURE			English	Article							COMBINING DATA; SEQUENCE DATA; GENES; DNA; COMPLEX; DUPLICATION; EVOLUTION; POSITION; TREES	One of the most pervasive challenges in molecular phylogenetics is the incongruence between phylogenies obtained using different data sets, such as individual genes. To systematically investigate the degree of incongruence, and potential methods for resolving it, we screened the genome sequences of eight yeast species and selected 106 widely distributed orthologous genes for phylogenetic analyses, singly and by concatenation. Our results suggest that data sets consisting of single or a small number of concatenated genes have a significant probability of supporting conflicting topologies. By contrast, analyses of the entire data set of concatenated genes yielded a single, fully resolved species tree with maximum support. Comparable results were obtained with a concatenation of a minimum of 20 genes; substantially more genes than commonly used but a small fraction of any genome. These results have important implications for resolving branches of the tree of life.	Univ Wisconsin, Howard Hughes Med Inst, Mol Biol Lab, RM Bock Labs, Madison, WI 53706 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison	Carroll, SB (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, Mol Biol Lab, RM Bock Labs, 1525 Linden Dr, Madison, WI 53706 USA.	sbcarrol@wisc.edu	Rokas, Antonis/A-9775-2008	Rokas, Antonis/0000-0002-7248-6551				Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Averof M, 2000, SCIENCE, V287, P1283, DOI 10.1126/science.287.5456.1283; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; BALDAUF SL, 1993, P NATL ACAD SCI USA, V90, P11558, DOI 10.1073/pnas.90.24.11558; Bapteste E, 2002, P NATL ACAD SCI USA, V99, P1414, DOI 10.1073/pnas.032662799; Bergthorsson U, 2003, NATURE, V424, P197, DOI 10.1038/nature01743; Blair JE, 2002, BMC EVOL BIOL, V2, DOI 10.1186/1471-2148-2-7; Brown JR, 2001, NAT GENET, V28, P281, DOI 10.1038/90129; BULL JJ, 1993, SYST BIOL, V42, P384, DOI 10.2307/2992473; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; CUMMINGS MP, 1995, MOL BIOL EVOL, V12, P814; Cunningham CW, 1997, MOL BIOL EVOL, V14, P733, DOI 10.1093/oxfordjournals.molbev.a025813; Giribet G, 2001, NATURE, V413, P157, DOI 10.1038/35093097; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Graybeal A, 1998, SYST BIOL, V47, P9, DOI 10.1080/106351598260996; Hall A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [citeulike-article-id:691774, DOI 10.1021/BK-1999-0734.CH008]; Hillis DM, 1996, NATURE, V383, P130, DOI 10.1038/383130a0; Hillis DM., 1996, MOL SYSTEMATICS, V2nd; Huelsenbeck JP, 1996, TRENDS ECOL EVOL, V11, P152, DOI 10.1016/0169-5347(96)10006-9; HUELSENBECK JP, 1995, SYST BIOL, V44, P17, DOI 10.2307/2413481; Hwang UW, 2001, NATURE, V413, P154, DOI 10.1038/35093090; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Knoll AH, 1999, SCIENCE, V284, P2129, DOI 10.1126/science.284.5423.2129; Kopp A, 2002, SYST BIOL, V51, P786, DOI 10.1080/10635150290102410; Kurtzman CP, 2003, FEMS YEAST RES, V3, P417, DOI 10.1016/S1567-1356(03)00012-6; Langkjaer RB, 2003, NATURE, V421, P848, DOI 10.1038/nature01419; Lopez P, 2002, MOL BIOL EVOL, V19, P1; Loytynoja A, 2001, P NATL ACAD SCI USA, V98, P10202, DOI 10.1073/pnas.181187698; Maddison WP, 1997, SYST BIOL, V46, P523, DOI 10.2307/2413694; Martin AP, 2002, SYST BIOL, V51, P570, DOI 10.1080/10635150290069995; MasonGamer RJ, 1996, SYST BIOL, V45, P524, DOI 10.1093/sysbio/45.4.524; Moreira D, 2000, NATURE, V405, P69, DOI 10.1038/35011054; Murphy WJ, 2001, NATURE, V409, P614, DOI 10.1038/35054550; Naumov GI, 2000, INT J SYST EVOL MICR, V50, P1931, DOI 10.1099/00207713-50-5-1931; Naylor GJP, 1998, SYST BIOL, V47, P61, DOI 10.1080/106351598261030; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; PHILIPPE H, 1994, DEVELOPMENT, P15; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Rieseberg LH, 1996, ACTA BOT NEERL, V45, P243; Rokas A, 2003, EVOL DEV, V5, P346, DOI 10.1046/j.1525-142X.2003.03042.x; Sanderson MJ, 2002, ANNU REV ECOL SYST, V33, P49, DOI 10.1146/annurev.ecolsys.33.010802.150509; Satta Y, 2000, MOL PHYLOGENET EVOL, V14, P259, DOI 10.1006/mpev.2000.0704; Soltis PS, 1999, NATURE, V402, P402, DOI 10.1038/46528; Sullivan J, 1996, SYST BIOL, V45, P375, DOI 10.2307/2413571; Swofford DL, 2002, PHYLOGENETIC ANAL US; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wendel J.F., 1998, MOL SYSTEMATICS PLAN, P265, DOI 10.1007/978-1-4615-5419-6_10; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Wong S, 2002, P NATL ACAD SCI USA, V99, P9272, DOI 10.1073/pnas.142101099; YANG ZH, 1994, MOL BIOL EVOL, V11, P316	50	1117	1140	1	117	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 23	2003	425	6960					798	804		10.1038/nature02053	http://dx.doi.org/10.1038/nature02053			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574403				2022-12-28	WOS:000186118500036
J	Terkeltaub, RA				Terkeltaub, RA			Gout	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RENAL-TRANSPLANT RECIPIENTS; URIC-ACID; ADRENOCORTICOTROPIC HORMONE; SERUM URATE; HYPERTENSIVE PATIENTS; HYPERURICEMIA; COLCHICINE; ALLOPURINOL; ARTHRITIS; MANAGEMENT		Vet Affairs Med Ctr, Dept Med, Rheumatol Sect, San Diego, CA 92161 USA; Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego	Terkeltaub, RA (corresponding author), Vet Affairs Med Ctr, Dept Med, Rheumatol Sect, 111K,3350 La Jolla Village Dr, San Diego, CA 92161 USA.							AHERN MJ, 1987, AUST NZ J MED, V17, P301, DOI 10.1111/j.1445-5994.1987.tb01232.x; AXELROD D, 1988, ARTHRITIS RHEUM-US, V31, P803, DOI 10.1002/art.1780310618; BAUD FJ, 1995, NEW ENGL J MED, V332, P642, DOI 10.1056/NEJM199503093321004; BECKER MA, 1988, RHEUM DIS CLIN N AM, V14, P377; Bomalaski JS, 2002, J RHEUMATOL, V29, P1942; Bonnel RA, 2002, J EMERG MED, V22, P385, DOI 10.1016/S0736-4679(02)00430-4; BULL PW, 1989, J RHEUMATOL, V16, P1246; Campion E W, 1987, Am J Med, V82, P421, DOI 10.1016/0002-9343(87)90441-4; CARACO Y, 1992, J RHEUMATOL, V19, P494; Clive DM, 2000, J AM SOC NEPHROL, V11, P974, DOI 10.1681/ASN.V115974; Dessein PH, 2000, ANN RHEUM DIS, V59, P539, DOI 10.1136/ard.59.7.539; Ducloux D, 1997, NEPHROL DIAL TRANSPL, V12, P2389, DOI 10.1093/ndt/12.11.2389; Fam AG, 2001, ARTHRITIS RHEUM-US, V44, P231, DOI 10.1002/1529-0131(200101)44:1<231::AID-ANR30>3.0.CO;2-7; FERRAZ MB, 1995, J RHEUMATOL, V22, P1618; Getting SJ, 2002, ARTHRITIS RHEUM, V46, P2765, DOI 10.1002/art.10526; HANDE KR, 1984, AM J MED, V76, P47, DOI 10.1016/0002-9343(84)90743-5; Harris M, 2000, J RHEUMATOL, V27, P2873; Harris R, 2000, J EMERG MED, V18, P435, DOI 10.1016/S0736-4679(00)00160-8; Hsu WC, 2002, CLIN NEUROPHARMACOL, V25, P266, DOI 10.1097/00002826-200209000-00008; Johnson RJ, 1999, AM J KIDNEY DIS, V33, P225, DOI 10.1016/S0272-6386(99)70295-7; Kamper AL, 2001, TRANSPLANTATION, V72, P671, DOI 10.1097/00007890-200108270-00019; Kramer HM, 2002, AM J KIDNEY DIS, V40, P37, DOI 10.1053/ajkd.2002.33911; Lin KC, 2000, J RHEUMATOL, V27, P1045; Mazzali M, 2002, AM J PHYSIOL-RENAL, V282, pF991, DOI 10.1152/ajprenal.00283.2001; ODUFFY JD, 1975, MAYO CLIN PROC, V50, P227; Perez-Ruiz F, 2002, ARTHRIT RHEUM-ARTHR, V47, P610, DOI 10.1002/art.10792; Perez-Ruiz F, 2002, ARTHRIT RHEUM-ARTHR, V47, P356, DOI 10.1002/art.10511; Perez-Ruiz F, 1998, ANN RHEUM DIS, V57, P545, DOI 10.1136/ard.57.9.545; PUIG JG, 1991, ARCH INTERN MED, V151, P726, DOI 10.1001/archinte.151.4.726; RITTER J, 1994, J RHEUMATOL, V21, P696; Romeijnders A C M, 2002, Ned Tijdschr Geneeskd, V146, P309; Schlesinger N, 2002, J RHEUMATOL, V29, P331; Schlesinger N, 2001, CURR OPIN RHEUMATOL, V13, P240, DOI 10.1097/00002281-200105000-00016; Schmidt A, 2001, NEPHROL DIAL TRANSPL, V16, P1034, DOI 10.1093/ndt/16.5.1034; Schumacher HR, 2002, BMJ-BRIT MED J, V324, P1488, DOI 10.1136/bmj.324.7352.1488; SCHWORER H, 1994, CLIN INVESTIGATOR, V72, P811; Shahinfar S, 1999, KIDNEY INT, V56, P1879, DOI 10.1046/j.1523-1755.1999.00739.x; SHAHINFAR S, 2000, KIDNEY INT, V57, P370; Shekarriz B, 2002, J UROLOGY, V168, P1307, DOI 10.1016/S0022-5347(05)64439-4; Sica DA, 2002, CURR OPIN NEPHROL HY, V11, P475, DOI 10.1097/00041552-200209000-00001; SIEGEL LB, 1994, J RHEUMATOL, V21, P1325; Simmonds HA, 1997, J INHERIT METAB DIS, V20, P214, DOI 10.1023/A:1005308923168; Stamp L, 2000, AUST NZ J MED, V30, P567, DOI 10.1111/j.1445-5994.2000.tb00857.x; Taylor CT, 2001, ANN PHARMACOTHER, V35, P365; TERKELTAUB RA, 2001, ARTHRITIS ALLIED CON, V2, P2329; Vazquez-Mellado J, 2001, ANN RHEUM DIS, V60, P981, DOI 10.1136/ard.60.10.981; WALLACE SL, 1991, J RHEUMATOL, V18, P264; WALLER PC, 1989, J HUM HYPERTENS, V3, P457; WalterSack I, 1995, EUR J CLIN PHARMACOL, V49, P215, DOI 10.1007/BF00192382; Wortmann RL, 2002, CURR OPIN RHEUMATOL, V14, P281, DOI 10.1097/00002281-200205000-00015; WU XW, 1994, P NATL ACAD SCI USA, V91, P742, DOI 10.1073/pnas.91.2.742; Yamada H, 1998, INT OFFSHORE POLAR E, P13; Yamamoto T, 2002, J RHEUMATOL, V29, P1937	53	356	415	3	142	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	2003	349	17					1647	1655		10.1056/NEJMcp030733	http://dx.doi.org/10.1056/NEJMcp030733			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734ZT	14573737				2022-12-28	WOS:000186088400011
J	Moynihan, R				Moynihan, R			Cochrane at crossroads over drug company sponsorship	BRITISH MEDICAL JOURNAL			English	Article											Moynihan, R (corresponding author), 1312 21st St NW,Apt 4, Washington, DC 20036 USA.		Moynihan, Ray/ABC-3010-2020					Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; *COCHR COLL, COCHR REV HDB; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; MALLETT S, 2003, EVIDENCE BASED M JUL, P100; SMITH LA, 2001, COCHRANE DB SYST REV; 2003, BMJ, V326	6	3	4	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 18	2003	327	7420					924	926		10.1136/bmj.327.7420.924	http://dx.doi.org/10.1136/bmj.327.7420.924			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734RV	14563759	Green Published			2022-12-28	WOS:000186072100034
J	Campbell, DB; Black, GJ; Carter, LM; Ostro, SJ				Campbell, DB; Black, GJ; Carter, LM; Ostro, SJ			Radar evidence for liquid surfaces on Titan	SCIENCE			English	Article							DIELECTRIC-PROPERTIES; ICY SATELLITES; ATMOSPHERE; TELESCOPE	Arecibo radar observations of Titan at 13-centimeter wavelength indicate that most of the echo power is in a diffusely scattered component but that a small specular component is present for about 75% of the subearth locations observed. These specular echoes have properties consistent with those expected for areas of liquid hydrocarbons. Knowledge of the areal extent and depth of any deposits of liquid hydrocarbons could strongly constrain the history of Titan's atmosphere and surface.	Cornell Univ, Natl Astron & Ionosphere Ctr, Ithaca, NY 14853 USA; Cornell Univ, Dept Astron, Ithaca, NY 14853 USA; Univ Virginia, Dept Astron, Charlottesville, VA 22903 USA; CALTECH, Jet Prop Lab 300 233, Pasadena, CA 91109 USA	Cornell University; Cornell University; University of Virginia; California Institute of Technology	Campbell, DB (corresponding author), Cornell Univ, Natl Astron & Ionosphere Ctr, Space Sci Bldg, Ithaca, NY 14853 USA.	campbell@astro.cornell.edu	Carter, Lynn/D-2937-2012	Carter, Lynn/0000-0002-6245-4142; Black, Gregory/0000-0001-7237-8270				CAMPBELL DB, 1978, ICARUS, V34, P254, DOI 10.1016/0019-1035(78)90166-5; COUSTENIS A, 1995, ICARUS, V118, P87, DOI 10.1006/icar.1995.1179; EVANS JV, 1968, RADAR ASTRONOMY, pCH4; Ghafoor NAL, 2000, J GEOPHYS RES-PLANET, V105, P12077, DOI 10.1029/1999JE001066; Gibbard SG, 1999, ICARUS, V139, P189, DOI 10.1006/icar.1999.6095; Griffith CA, 1998, NATURE, V395, P575, DOI 10.1038/26920; Griffith CA, 2003, SCIENCE, V300, P628, DOI 10.1126/science.1081897; HAGFORS T, 1964, J GEOPHYS RES, V69, P3779, DOI 10.1029/JZ069i018p03779; Lorenz RD, 1998, ICARUS, V136, P344, DOI 10.1006/icar.1998.6017; Lorenz RD, 2001, GEOPHYS RES LETT, V28, P215, DOI 10.1029/2000GL012199; LUNINE JI, 1983, SCIENCE, V222, P1229, DOI 10.1126/science.222.4629.1229; Meier R, 2000, ICARUS, V145, P462, DOI 10.1006/icar.2000.6360; MUHLEMAN DO, 1990, SCIENCE, V248, P975, DOI 10.1126/science.248.4958.975; OSTRO SJ, 1992, J GEOPHYS RES-PLANET, V97, P18227, DOI 10.1029/92JE01992; Rodriguez S, 2003, ICARUS, V164, P213, DOI 10.1016/S0019-1035(03)00125-8; SAGAN C, 1982, NATURE, V300, P731, DOI 10.1038/300731a0; Smith PH, 1996, ICARUS, V119, P336, DOI 10.1006/icar.1996.0023; THOMPSON WR, 1990, ICARUS, V86, P336, DOI 10.1016/0019-1035(90)90224-W	18	86	86	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 17	2003	302	5644					431	434		10.1126/science.1088969	http://dx.doi.org/10.1126/science.1088969			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14526087				2022-12-28	WOS:000185963200038
J	Wilkinson, MJ; Elliott, LJ; Allainguillaume, J; Shaw, MW; Norris, C; Welters, R; Alexander, M; Sweet, J; Mason, DC				Wilkinson, MJ; Elliott, LJ; Allainguillaume, J; Shaw, MW; Norris, C; Welters, R; Alexander, M; Sweet, J; Mason, DC			Hybridization between Brassica napus and B-rapa on a national scale in the United Kingdom	SCIENCE			English	Article							OILSEED RAPE; HERBICIDE RESISTANCE; WILD RELATIVES; MOVEMENT; POLLINATION; TRANSGENE; IMPACT; CROPS	Measures blocking hybridization would prevent or reduce biotic or environmental change caused by gene flow from genetically modified (GM) crops to wild relatives. The efficacy of any such measure depends on hybrid numbers within the legislative region over the life-span of the GM cultivar. We present a national assessment of hybridization between rapeseed (Brassica napus) and B. rapa from a combination of sources, including population surveys, remote sensing, pollen dispersal profiles, herbarium data, local Floras, and other floristic databases. Across the United Kingdom, we estimate that 32,000 hybrids form annually in waterside B. rapa populations, whereas the less abundant weedy populations contain 17,000 hybrids. These findings set targets for strategies to eliminate hybridization and represent the first step toward quantitative risk assessment on a national scale.	Univ Reading, Sch Plant Sci, Reading RG6 6AS, Berks, England; Univ Reading, Nat Environm Res Council, Environm Syst Sci Ctr, Reading RG6 6AL, Berks, England; Ctr Ecol & Hydrol, Winfrith, Dorset, England	University of Reading; University of Reading; UK Centre for Ecology & Hydrology (UKCEH)	Wilkinson, MJ (corresponding author), Univ Reading, Sch Plant Sci, Reading RG6 6AS, Berks, England.	m.j.wilkinson@rdg.ac.uk	Shaw, Michael/A-1926-2011	Shaw, Michael/0000-0002-6993-048X; Wilkinson, Michael/0000-0002-9881-6993	Biotechnology and Biological Sciences Research Council [GM114202] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Dale PJ, 2002, NAT BIOTECHNOL, V20, P567, DOI 10.1038/nbt0602-567; Dandy J.E., 1975, HYBRIDIZATION FLORA, P444; Daniell H, 1998, NAT BIOTECHNOL, V16, P345, DOI 10.1038/nbt0498-345; Davenport IJ, 2000, INT J REMOTE SENS, V21, P3567, DOI 10.1080/014311600750037598; JAMES C, 2002, ISAAA BRIEFS, V27; JORGENSEN RB, 1994, AM J BOT, V81, P1620, DOI 10.2307/2445340; Metz PLJ, 1997, THEOR APPL GENET, V95, P442, DOI 10.1007/s001220050581; RAYBOULD AF, 1993, J APPL ECOL, V30, P199, DOI 10.2307/2404623; Rieger MA, 2002, SCIENCE, V296, P2386, DOI 10.1126/science.1071682; Rosellini D, 2001, EUPHYTICA, V118, P313, DOI 10.1023/A:1017568201732; SCHEFFLER JA, 1994, TRANSGENIC RES, V3, P263, DOI 10.1007/BF01973586; TIMMONS AM, 1995, EUPHYTICA, V85, P417, DOI 10.1007/BF00023975; Trewavas AJ, 2001, EMBO REP, V2, P455, DOI 10.1093/embo-reports/kve123; Waines JG, 2003, CROP SCI, V43, P451, DOI 10.2135/cropsci2003.0451; Wilkinson MJ, 2003, TRENDS PLANT SCI, V8, P208, DOI 10.1016/S1360-1385(03)00057-8; Wilkinson MJ, 2000, MOL ECOL, V9, P983, DOI 10.1046/j.1365-294x.2000.00986.x; Zuo JR, 2000, CURR OPIN BIOTECH, V11, P146, DOI 10.1016/S0958-1669(00)00073-2	17	130	145	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 17	2003	302	5644					457	459		10.1126/science.1088200	http://dx.doi.org/10.1126/science.1088200			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14551318				2022-12-28	WOS:000185963200046
J	Madsen, EB; Madsen, LH; Radutoiu, S; Olbryt, M; Rakwalska, M; Szczyglowski, K; Sato, S; Kaneko, T; Tabata, S; Sandal, N; Stougaard, J				Madsen, EB; Madsen, LH; Radutoiu, S; Olbryt, M; Rakwalska, M; Szczyglowski, K; Sato, S; Kaneko, T; Tabata, S; Sandal, N; Stougaard, J			A receptor kinase gene of the LysM type is involved in legume perception of rhizobial signals	NATURE			English	Article							LIPO-OLIGOSACCHARIDE SIGNALS; PISUM-SATIVUM-L; LOTUS-JAPONICUS; NODULE ORGANOGENESIS; NODULATION FACTORS; SYMBIOTIC MUTANTS; HOST-SPECIFICITY; MELILOTI; PEA; BACTERIAL	Plants belonging to the legume family develop nitrogen-fixing root nodules in symbiosis with bacteria commonly known as rhizobia. The legume host encodes all of the functions necessary to build the specialized symbiotic organ, the nodule, but the process is elicited by the bacteria(1-3). Molecular communication initiates the interaction, and signals, usually flavones, secreted by the legume root induce the bacteria to produce a lipochitin-oligosaccharide signal molecule (Nod-factor), which in turn triggers the plant organogenic process(4-7). An important determinant of bacterial host specificity is the structure of the Nodfactor, suggesting that a plant receptor is involved in signal perception and signal transduction initiating the plant developmental response(8,9). Here we describe the cloning of a putative Nod-factor receptor kinase gene (NFR5) from Lotus japonicus. NFR5 is essential for Nod-factor perception and encodes an unusual transmembrane serine/ threonine receptor-like kinase required for the earliest detectable plant responses to bacteria and Nod-factor. The extracellular domain of the putative receptor has three modules with similarity to LysM domains known from peptidoglycan-binding proteins and chitinases. Together with an atypical kinase domain structure this characterizes an unusual receptor-like kinase.	Univ Aarhus, Dept Mol Biol, Gene Express Lab, DK-8000 Aarhus C, Denmark; Agr & Agri Food Canada, SCPFRC, London, ON NV5 4T3, Canada; Kazusa DNA Res Inst, Chiba 2920812, Japan	Aarhus University; Agriculture & Agri Food Canada; Kazusa DNA Research Institute	Stougaard, J (corresponding author), Univ Aarhus, Dept Mol Biol, Gene Express Lab, Gustav Wieds Vej 10, DK-8000 Aarhus C, Denmark.	stougaard@mb.au.dk	Sato, Shusei/A-3616-2015; poinssot, benoit/B-2569-2009	Sato, Shusei/0000-0002-0293-5366; poinssot, benoit/0000-0001-5890-4318; Olbryt, Magdalena/0000-0001-9961-6427; Stougaard, Jens/0000-0002-9312-2685				Amon P, 1998, PLANT CELL, V10, P781; ARDOUREL M, 1994, PLANT CELL, V6, P1357, DOI 10.1105/tpc.6.10.1357; Bateman A, 2000, J MOL BIOL, V299, P1113, DOI 10.1006/jmbi.2000.3778; Bras CP, 2000, MOL PLANT MICROBE IN, V13, P475, DOI 10.1094/MPMI.2000.13.4.475; BUTLER AR, 1991, EUR J BIOCHEM, V199, P483, DOI 10.1111/j.1432-1033.1991.tb16147.x; DUC G, 1989, PLANT SCI, V60, P207, DOI 10.1016/0168-9452(89)90168-4; ENGVILD KC, 1987, THEOR APPL GENET, V74, P711, DOI 10.1007/BF00247546; HANDBERG K, 1992, PLANT J, V2, P487, DOI 10.1111/j.1365-313X.1992.00487.x; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; KNEEN BE, 1994, J HERED, V85, P129, DOI 10.1093/oxfordjournals.jhered.a111410; Krusell L, 2002, NATURE, V420, P422, DOI 10.1038/nature01207; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; Long SR, 1996, PLANT CELL, V8, P1885, DOI 10.1105/tpc.8.10.1885; LOPEZLARA IM, 1995, MOL MICROBIOL, V15, P627, DOI 10.1111/j.1365-2958.1995.tb02372.x; Nakamura Y, 2002, DNA RES, V9, P63, DOI 10.1093/dnares/9.2.63; Niwa S, 2001, MOL PLANT MICROBE IN, V14, P848, DOI 10.1094/MPMI.2001.14.7.848; Radutoiu S, 2003, NATURE, V425, P585, DOI 10.1038/nature02039; Sandal N, 2002, GENETICS, V161, P1673; Schauser L, 1998, MOL GEN GENET, V259, P414, DOI 10.1007/s004380050831; Schenk PW, 1999, BBA-MOL CELL RES, V1449, P1, DOI 10.1016/S0167-4889(98)00178-5; Schneider A, 2002, THEOR APPL GENET, V104, P1312, DOI 10.1007/s00122-002-0896-2; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; Steen A, 2003, J BIOL CHEM, V278, P23874, DOI 10.1074/jbc.M211055200; Stougaard J, 1995, Methods Mol Biol, V49, P49; Stougaard J, 2001, CURR OPIN PLANT BIOL, V4, P328, DOI 10.1016/S1369-5266(00)00181-3; Stracke S, 2002, NATURE, V417, P959, DOI 10.1038/nature00841; Szczyglowski K, 1998, MOL PLANT MICROBE IN, V11, P684, DOI 10.1094/MPMI.1998.11.7.684; TRUCHET G, 1989, MOL GEN GENET, V219, P65, DOI 10.1007/BF00261158; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; Wegel E, 1998, MOL PLANT MICROBE IN, V11, P933, DOI 10.1094/MPMI.1998.11.9.933; Wikstrom N, 2001, P ROY SOC B-BIOL SCI, V268, P2211, DOI 10.1098/rspb.2001.1782	31	648	708	7	138	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 9	2003	425	6958					637	640		10.1038/nature02045	http://dx.doi.org/10.1038/nature02045			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534591				2022-12-28	WOS:000185801000042
J	Radutoiu, S; Madsen, LH; Madsen, EB; Felle, HH; Umehara, Y; Gronlund, M; Sato, S; Nakamura, Y; Tabata, S; Sandal, N; Stougaard, J				Radutoiu, S; Madsen, LH; Madsen, EB; Felle, HH; Umehara, Y; Gronlund, M; Sato, S; Nakamura, Y; Tabata, S; Sandal, N; Stougaard, J			Plant recognition of symbiotic bacteria requires two LysM receptor-like kinases	NATURE			English	Article							LIPO-OLIGOSACCHARIDE SIGNALS; LEGUME LOTUS-JAPONICUS; ALFALFA ROOT HAIRS; RHIZOBIUM-MELILOTI; NOD FACTORS; HOST-SPECIFICITY; MUTANTS; GENE; EXPRESSION; DOMAIN	Although most higher plants establish a symbiosis with arbuscular mycorrhizal fungi, symbiotic nitrogen fixation with rhizobia is a salient feature of legumes. Despite this host range difference, mycorrhizal and rhizobial invasion shares a common plant-specified genetic programme controlling the early host interaction. One feature distinguishing legumes is their ability to perceive rhizobial-specific signal molecules. We describe here two LysM-type serine/threonine receptor kinase genes, NFR1 and NFR5, enabling the model legume Lotus japonicus to recognize its bacterial microsymbiont Mesorhizobium loti. The extracellular domains of the two transmembrane kinases resemble LysM domains of peptidoglycan- and chitin-binding proteins, suggesting that they may be involved directly in perception of the rhizobial lipochitin-oligosaccharide signal. We show that NFR1 and NFR5 are required for the earliest physiological and cellular responses to this lipochitin-oligosaccharide signal, and demonstrate their role in the mechanism establishing susceptibility of the legume root for bacterial infection.	Univ Aarhus, Dept Mol Biol, Gene Express Lab, DK-8000 Aarhus C, Denmark; Univ Giessen, Inst Bot 1, D-35390 Giessen, Germany; Kazusa DNA Res Inst, Chiba 2920812, Japan	Aarhus University; Justus Liebig University Giessen; Kazusa DNA Research Institute	Stougaard, J (corresponding author), Univ Aarhus, Dept Mol Biol, Gene Express Lab, Gustav Wieds Vej 10, DK-8000 Aarhus C, Denmark.	stougaard@mb.au.dk	poinssot, benoit/B-2569-2009; Sato, Shusei/A-3616-2015; Nakamura, Yasukazu/T-9038-2019	poinssot, benoit/0000-0001-5890-4318; Sato, Shusei/0000-0002-0293-5366; Stougaard, Jens/0000-0002-9312-2685; Nakamura, Yasukazu/0000-0002-6782-5715				Amon P, 1998, PLANT CELL, V10, P781; Bateman A, 2000, J MOL BIOL, V299, P1113, DOI 10.1006/jmbi.2000.3778; Ben Amor B, 2003, PLANT J, V34, P495, DOI 10.1046/j.1365-313X.2003.01743.x; Bras CP, 2000, MOL PLANT MICROBE IN, V13, P475, DOI 10.1094/MPMI.2000.13.4.475; BUTLER AR, 1991, EUR J BIOCHEM, V199, P483, DOI 10.1111/j.1432-1033.1991.tb16147.x; Colebatch G, 2002, MOL PLANT MICROBE IN, V15, P411, DOI 10.1094/MPMI.2002.15.5.411; DUC G, 1989, PLANT SCI, V60, P215, DOI 10.1016/0168-9452(89)90169-6; EHRHARDT DW, 1992, SCIENCE, V256, P998, DOI 10.1126/science.10744524; Endre G, 2002, NATURE, V417, P962, DOI 10.1038/nature00842; Felle HH, 2000, PLANT PHYSIOL, V124, P1373, DOI 10.1104/pp.124.3.1373; FELLE HH, 1995, PLANT J, V7, P939, DOI 10.1046/j.1365-313X.1995.07060939.x; Felle HH, 1998, PLANT J, V13, P455, DOI 10.1046/j.1365-313X.1998.00041.x; Gadkar V, 2001, PLANT PHYSIOL, V127, P1493, DOI 10.1104/pp.010783; Gerard CJ, 2000, MOL DIAGN, V5, P39, DOI 10.1016/S1084-8592(00)00009-6; GOVERS F, 1991, MOL GEN GENET, V228, P160, DOI 10.1007/BF00282461; Gressent F, 1999, P NATL ACAD SCI USA, V96, P4704, DOI 10.1073/pnas.96.8.4704; HANDBERG K, 1992, PLANT J, V2, P487, DOI 10.1111/j.1365-313X.1992.00487.x; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; JORIS B, 1992, FEMS MICROBIOL LETT, V91, P257; Kaneko T, 2003, DNA RES, V10, P27, DOI 10.1093/dnares/10.1.27; Kistner C, 2002, TRENDS PLANT SCI, V7, P511, DOI 10.1016/S1360-1385(02)02356-7; KOSUGI S, 1990, PLANT SCI, V70, P133, DOI 10.1016/0168-9452(90)90042-M; Kosuta S, 2003, PLANT PHYSIOL, V131, P952, DOI 10.1104/pp.011882; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LOPEZLARA IM, 1995, MOL MICROBIOL, V15, P627, DOI 10.1111/j.1365-2958.1995.tb02372.x; Madsen EB, 2003, NATURE, V425, P637, DOI 10.1038/nature02045; Niwa S, 2001, MOL PLANT MICROBE IN, V14, P848, DOI 10.1094/MPMI.2001.14.7.848; Parniske M, 2000, CURR OPIN PLANT BIOL, V3, P320, DOI 10.1016/S1369-5266(00)00088-1; Ponting CP, 1999, J MOL BIOL, V289, P729, DOI 10.1006/jmbi.1999.2827; Sandal N, 2002, GENETICS, V161, P1673; Schauser L, 1998, MOL GEN GENET, V259, P414, DOI 10.1007/s004380050831; Schauser L, 1999, NATURE, V402, P191, DOI 10.1038/46058; Schenk PW, 1999, BBA-MOL CELL RES, V1449, P1, DOI 10.1016/S0167-4889(98)00178-5; SCHLAMAN HRM, 1991, J BACTERIOL, V173, P4277, DOI 10.1128/JB.173.14.4277-4287.1991; Shaw SL, 2003, PLANT PHYSIOL, V131, P976, DOI 10.1104/pp.005546; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; Steen A, 2003, J BIOL CHEM, V278, P23874, DOI 10.1074/jbc.M211055200; Stougaard J, 1995, Methods Mol Biol, V49, P49; Stougaard J, 2001, CURR OPIN PLANT BIOL, V4, P328, DOI 10.1016/S1369-5266(00)00181-3; Stracke S, 2002, NATURE, V417, P959, DOI 10.1038/nature00841; Szczyglowski K, 1998, MOL PLANT MICROBE IN, V11, P684, DOI 10.1094/MPMI.1998.11.7.684; Szczyglowski K, 2003, PLANT PHYSIOL, V131, P935, DOI 10.1104/pp.017186; Timmers ACJ, 1998, DEVELOPMENT, V125, P339; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; Walker SA, 2000, P NATL ACAD SCI USA, V97, P13413, DOI 10.1073/pnas.230440097; Webb KJ, 2000, MOL PLANT MICROBE IN, V13, P606, DOI 10.1094/MPMI.2000.13.6.606; Wegel E, 1998, MOL PLANT MICROBE IN, V11, P933, DOI 10.1094/MPMI.1998.11.9.933	47	785	852	15	225	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 9	2003	425	6958					585	592		10.1038/nature02039	http://dx.doi.org/10.1038/nature02039			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534578				2022-12-28	WOS:000185801000028
J	Shamsuzzaman, ASM; Gersh, BJ; Somers, VK				Shamsuzzaman, ASM; Gersh, BJ; Somers, VK			Obstructive sleep apnea - Implications for cardiac and vascular disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							POSITIVE AIRWAY PRESSURE; C-REACTIVE PROTEIN; NEGATIVE INTRATHORACIC PRESSURE; INTIMA-MEDIA THICKNESS; DOSE-RELATED INCREASE; BLOOD-PRESSURE; ENDOTHELIAL DYSFUNCTION; HEART-FAILURE; PLATELET ACTIVATION; ATRIAL-FIBRILLATION	Context Obstructive sleep apnea (OSA) has been increasingly implicated in the initiation and progression of cardiovascular diseases. Objective To systematically review the interactions of OSA with cardiovascular pathophysiology and diseases. Data Sources and Study Selection The MEDLINE database from January 1966 to March 2003 was searched using the Medical Subject Headings sleep, sleep apnea, obesity, hypertension, heart failure, cardiac arrhythmia, coronary artery disease, stroke, sympathetic activity, endothelium, inflammation, and continuous positive airway pressure (CPAP) to identify peer-reviewed studies of OSA. Priority was given to large prospective cohort studies and to randomized controlled trials. Data Extraction We identified 154 original investigations and reviews of sleep-related breathing disorders. Data from these studies were examined for relevance and extracted by one of the authors. Data Synthesis Approximately 1 in 5 adults has at least mild OSA (apnea-hypopnea index Lie, the number of apneic and hypopneic events per hour], 5-15), and 1 in 15 adults has at least moderate OSA (apnea-hypopnea index, 15-30). Repetitive apneic events disrupt the normal physiologic interactions between sleep and the cardiovascular system. Such sleep fragmentation, as well as abnormalities evident in patients with OSA (eg, increased sympathetic activation, vascular endothelial dysfunction, increased oxidative stress, inflammation, increased platelet aggregability, metabolic dysregulation), may be implicated in the initiation and progression of cardiac and vascular disease. Persuasive data implicate OSA in the development of hypertension, and OSA also may contribute to cardiac ischemia, congestive heart failure, cardiac arrhythmias, and perhaps also to cerebrovascular disease and stroke. Conclusions Obstructive sleep apnea is common, readily diagnosed, and usually treatable. It frequently coexists undiagnosed in patients with cardiovascular disease, activates disease mechanisms known to elicit cardiac and vascular damage, and may be implicated in progression of cardiovascular disease and resistance to conventional therapeutic strategies. In the absence of definitive evidence from large-scale trials and a better understanding of potential cost-effectiveness, the likely benefits of diagnosis and treatment of OSA are presently best appraised on an individualized patient basis.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Mayo Clinic	Somers, VK (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.	somers.virend@mayo.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073211, R01HL070302, R01HL065176, R01HL061560] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64; ALEX CG, 1986, AM REV RESPIR DIS, V133, P42, DOI 10.1164/arrd.1986.133.1.42; Andreas S, 2000, SLEEP, V23, pS220; Ansell Benjamin J, 2003, Heart Dis, V5, P2, DOI 10.1097/01.HDX.0000050407.62572.DE; AZAR JJ, 1991, AM J CLIN ONCOL-CANC, V14, P530, DOI 10.1097/00000421-199112000-00013; BECK AC, 1991, WESTERN J MED, V155, P293; Becker HF, 2003, CIRCULATION, V107, P68, DOI 10.1161/01.CIR.0000042706.47107.7A; Becker HF, 1998, THORAX, V53, pS29, DOI 10.1136/thx.53.2008.S29; BLACKSHEAR JL, 1995, ARCH INTERN MED, V155, P1297, DOI 10.1001/archinte.155.12.1297; BOKINSKY G, 1995, CHEST, V108, P625, DOI 10.1378/chest.108.3.625; Bonetti PO, 2003, ARTERIOSCL THROM VAS, V23, P168, DOI 10.1161/01.ATV.0000051384.43104.FC; BRADLEY TD, 1992, CLIN CHEST MED, V13, P459; Carolan C, 1996, MOL REPROD DEV, V45, P145, DOI 10.1002/(SICI)1098-2795(199610)45:2&lt;145::AID-MRD6&gt;3.0.CO;2-T; Chan J, 1997, CHEST, V111, P1488, DOI 10.1378/chest.111.6.1488; Chin K, 1996, AM J RESP CRIT CARE, V153, P1972, DOI 10.1164/ajrccm.153.6.8665063; Chin K, 2000, AM J MED, V109, P562, DOI 10.1016/S0002-9343(00)00580-5; Chin K, 1998, QJM-MON J ASSOC PHYS, V91, P627, DOI 10.1093/qjmed/91.9.627; Chin KZ, 1999, CIRCULATION, V100, P706, DOI 10.1161/01.CIR.100.7.706; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Ciarla MV, 2001, ATHEROSCLEROSIS, V158, P241, DOI 10.1016/S0021-9150(01)00440-3; Coccagna G, 1997, SLEEP, V20, P396, DOI 10.1093/sleep/20.6.396; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; DALESSANDRO R, 1990, BRIT MED J, V300, P1557, DOI 10.1136/bmj.300.6739.1557-a; Danesh J, 2000, BMJ-BRIT MED J, V321, P199, DOI 10.1136/bmj.321.7255.199; Davi G, 2002, JAMA-J AM MED ASSOC, V288, P2008, DOI 10.1001/jama.288.16.2008; DEAN RT, 1993, SLEEP, V16, pS15, DOI 10.1093/sleep/16.suppl_8.S15; DOLLY FR, 1983, CHEST, V83, P469, DOI 10.1378/chest.83.3.469; DUBOIS JS, 1995, J IMMUNOTHER, V18, P119, DOI 10.1097/00002371-199508000-00006; Dyken ME, 1996, STROKE, V27, P401, DOI 10.1161/01.STR.27.3.401; Eisensehr I, 1998, NEUROLOGY, V51, P188, DOI 10.1212/WNL.51.1.188; El-Solh AA, 2002, CHEST, V121, P1541, DOI 10.1378/chest.121.5.1541; Elmasry A, 2001, J INTERN MED, V249, P153, DOI 10.1046/j.1365-2796.2001.00787.x; FINDLEY LJ, 1984, AM REV RESPIR DIS, V130, P937; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; FRANKLIN KA, 1995, LANCET, V345, P1085, DOI 10.1016/S0140-6736(95)90820-X; FRATTOLA A, 1993, J HYPERTENS, V11, P1133, DOI 10.1097/00004872-199310000-00019; Fung JWH, 2002, CHEST, V121, P422, DOI 10.1378/chest.121.2.422; GARRIGUE S, 1922, NEW ENGL J MED, V346, P404; George CFP, 2001, THORAX, V56, P508, DOI 10.1136/thorax.56.7.508; GOEL M, 1992, J IMMUNOTHER, V11, P225, DOI 10.1097/00002371-199204000-00010; Good DC, 1996, STROKE, V27, P252, DOI 10.1161/01.STR.27.2.252; GUILLEMINAULT C, 1983, AM J CARDIOL, V52, P490, DOI 10.1016/0002-9149(83)90013-9; HALLIWELL B, 1993, HAEMOSTASIS, V23, P118; HANLY P, 1993, AM J CARDIOL, V71, P1341, DOI 10.1016/0002-9149(93)90552-N; HANLY P, 1992, CHEST, V102, P100, DOI 10.1378/chest.102.1.100; Hanly PJ, 2001, NEW ENGL J MED, V344, P102, DOI 10.1056/NEJM200101113440204; Hartmann G, 2000, CYTOKINE, V12, P246, DOI 10.1006/cyto.1999.0533; Hasper D, 1998, EUR HEART J, V19, P761, DOI 10.1053/euhj.1997.0858; Hink U, 2001, CIRC RES, V88, pE14; Hla KM, 2002, CHEST, V122, P1125, DOI 10.1378/chest.122.4.1125; HOFFSTEIN V, 1994, CHEST, V106, P466, DOI 10.1378/chest.106.2.466; HOFFSTEIN V, 1994, CHEST, V106, P787, DOI 10.1378/chest.106.3.787; HUNG J, 1990, LANCET, V336, P261, DOI 10.1016/0140-6736(90)91799-G; Ikonomidis I, 1999, CIRCULATION, V100, P793, DOI 10.1161/01.CIR.100.8.793; Ip MSM, 2002, AM J RESP CRIT CARE, V165, P670, DOI 10.1164/ajrccm.165.5.2103001; Irwin M, 2002, BRAIN BEHAV IMMUN, V16, P503, DOI 10.1016/S0889-1591(02)00003-X; Javaheri S, 1999, NEW ENGL J MED, V341, P949, DOI 10.1056/NEJM199909233411304; Javaheri S, 1998, CIRCULATION, V97, P2154, DOI 10.1161/01.CIR.97.21.2154; Javaheri S, 1996, SLEEP, V19, pS229; Joint National Committee on Prevention Detection evaluation and treatment of high blood pressure, 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005; Kanagala R, 2003, CIRCULATION, V107, P2589, DOI 10.1161/01.CIR.0000068337.25994.21; Kaneko Y, 2003, NEW ENGL J MED, V348, P1233, DOI 10.1056/NEJMoa022479; Kato M, 2000, CIRCULATION, V102, P2607; Kennon S, 2001, J AM COLL CARDIOL, V37, P1266, DOI 10.1016/S0735-1097(01)01130-5; Koehler U, 1998, EUR RESPIR J, V11, P434, DOI 10.1183/09031936.98.11020434; Kohnlein T, 2002, THORAX, V57, P547, DOI 10.1136/thorax.57.6.547; Laaban JP, 2002, CHEST, V122, P1133, DOI 10.1378/chest.122.4.1133; Lanfranchi PA, 2003, CIRCULATION, V107, P727, DOI 10.1161/01.CIR.0000049641.11675.EE; Lee IK, 2002, INT J CLIN PRACT, P59; Leproult R, 1997, SLEEP, V20, P865; Lindberg E, 2001, AM J RESP CRIT CARE, V164, P2031, DOI 10.1164/ajrccm.164.11.2102028; Lisman Kevin A, 2002, Curr Cardiol Rep, V4, P200, DOI 10.1007/s11886-002-0051-3; Logan AG, 2003, EUR RESPIR J, V21, P241, DOI 10.1183/09031936.03.00035402; Milionis HJ, 1999, ANGIOLOGY, V50, P959, DOI 10.1177/000331979905001112; Mooe T, 1996, CORONARY ARTERY DIS, V7, P475, DOI 10.1097/00019501-199606000-00011; Mooe T, 1996, CHEST, V109, P659, DOI 10.1378/chest.109.3.659; Mooe T, 1996, AM J MED, V101, P251, DOI 10.1016/S0002-9343(96)00122-2; Morgan BJ, 1996, J APPL PHYSIOL, V80, P1627, DOI 10.1152/jappl.1996.80.5.1627; MORGAN BJ, 1993, J APPL PHYSIOL, V74, P2969, DOI 10.1152/jappl.1993.74.6.2969; Narkiewicz K, 1999, CIRCULATION, V99, P1183, DOI 10.1161/01.CIR.99.9.1183; Narkiewicz K, 1998, CIRCULATION, V98, P772, DOI 10.1161/01.CIR.98.8.772; Narkiewicz K, 1999, CIRCULATION, V100, P2332, DOI 10.1161/01.CIR.100.23.2332; Narkiewicz K, 1998, CIRCULATION, V97, P943; Narkiewicz K, 1998, CIRCULATION, V98, P1071, DOI 10.1161/01.CIR.98.11.1071; Netzer N, 1998, STROKE, V29, P87, DOI 10.1161/01.STR.29.1.87; Nobili L, 2000, CLIN HEMORHEOL MICRO, V22, P21; Ohga E, 1999, J APPL PHYSIOL, V87, P10, DOI 10.1152/jappl.1999.87.1.10; Ohga E, 2003, J APPL PHYSIOL, V94, P179, DOI 10.1152/japplphysiol.00177.2002; PALATINI P, 1992, ARCH INTERN MED, V152, P1855, DOI 10.1001/archinte.152.9.1855; PALOMAKI H, 1992, NEUROLOGY, V42, P75; PARTINEN M, 1995, J SLEEP RES, V4, P156, DOI 10.1111/j.1365-2869.1995.tb00206.x; PEDRINELLI R, 1994, LANCET, V344, P14, DOI 10.1016/S0140-6736(94)91047-2; Peker Y, 2000, AM J RESP CRIT CARE, V162, P81, DOI 10.1164/ajrccm.162.1.9905035; Peled N, 1999, J AM COLL CARDIOL, V34, P1744, DOI 10.1016/S0735-1097(99)00407-6; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; Pepperell JCT, 2002, LANCET, V359, P204, DOI 10.1016/S0140-6736(02)07445-7; PHILIP P, 1993, SLEEP, V16, P558, DOI 10.1093/sleep/16.6.558; Phillips BG, 1999, J HYPERTENS, V17, P61, DOI 10.1097/00004872-199917010-00010; Phillips BG, 2000, AM J PHYSIOL-HEART C, V279, pH234, DOI 10.1152/ajpheart.2000.279.1.H234; PHILLIPSON EA, 1993, NEW ENGL J MED, V328, P1271, DOI 10.1056/NEJM199304293281712; Plenge JK, 2002, CIRCULATION, V106, P1447, DOI 10.1161/01.CIR.0000029743.68247.31; Ponikowski P, 1997, AM J CARDIOL, V79, P1645, DOI 10.1016/S0002-9149(97)00215-4; Poredos P, 1999, ANGIOLOGY, V50, P201, DOI 10.1177/000331979905000304; Prabhakar NR, 2002, AM J RESP CRIT CARE, V165, P859, DOI 10.1164/ajrccm.165.7.2202030c; Punjabi NM, 2003, RESP PHYSIOL NEUROBI, V136, P167, DOI 10.1016/S1569-9048(03)00079-X; Punjabi NM, 2002, AM J RESP CRIT CARE, V165, P677, DOI 10.1164/ajrccm.165.5.2104087; Raitakari OT, 1999, ANN INTERN MED, V130, P578, DOI 10.7326/0003-4819-130-7-199904060-00017; RAMA PR, 1994, CLIN CARDIOL, V17, P675, DOI 10.1002/clc.4960171210; Randazzo DN, 1996, J ELECTROCARDIOL, V29, P65, DOI 10.1016/S0022-0736(96)80115-4; Redwine L, 2000, J CLIN ENDOCR METAB, V85, P3597, DOI 10.1210/jc.85.10.3597; Ridker PM, 2003, CIRCULATION, V107, P391, DOI 10.1161/01.CIR.0000055014.62083.05; Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230; Rizzoni D, 2001, J HYPERTENS, V19, P913, DOI 10.1097/00004872-200105000-00012; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAJKOV D, 1994, AM J RESP CRIT CARE, V149, P416, DOI 10.1164/ajrccm.149.2.8306039; Sanner BM, 2000, EUR RESPIR J, V16, P648, DOI 10.1034/j.1399-3003.2000.16d14.x; Schulz R, 2000, THORAX, V55, P1046, DOI 10.1136/thorax.55.12.1046; Schulz R, 2000, AM J RESP CRIT CARE, V162, P566, DOI 10.1164/ajrccm.162.2.9908091; Shahar E, 2001, AM J RESP CRIT CARE, V163, P19, DOI 10.1164/ajrccm.163.1.2001008; Shamsuzzaman ASM, 2002, CIRCULATION, V105, P2462, DOI 10.1161/01.CIR.0000018948.95175.03; Shearer WT, 2001, J ALLERGY CLIN IMMUN, V107, P165, DOI 10.1067/mai.2001.112270; SHEPARD JW, 1985, CHEST, V88, P335, DOI 10.1378/chest.88.3.335; Shepard JW, 1996, AM J RESP CRIT CARE, V153, P250, DOI 10.1164/ajrccm.153.1.8542124; SHIOMI T, 1991, CHEST, V100, P894, DOI 10.1378/chest.100.4.894; Sin DD, 1999, AM J RESP CRIT CARE, V160, P1101, DOI 10.1164/ajrccm.160.4.9903020; Sin DD, 2000, CIRCULATION, V102, P61, DOI 10.1161/01.CIR.102.1.61; Singh JP, 1998, HYPERTENSION, V32, P293, DOI 10.1161/01.HYP.32.2.293; SOMERS VK, 1993, J AUTONOM NERV SYST, V44, P253, DOI 10.1016/0165-1838(93)90038-V; SOMERS VK, 1995, J CLIN INVEST, V96, P1897, DOI 10.1172/JCI118235; SOMERS VK, 1993, NEW ENGL J MED, V328, P303, DOI 10.1056/NEJM199302043280502; Spiegel K, 2000, AM J PHYSIOL-REG I, V279, pR874, DOI 10.1152/ajpregu.2000.279.3.R874; Spiegel K, 1999, LANCET, V354, P1435, DOI 10.1016/S0140-6736(99)01376-8; SPRIGGS DA, 1992, Q J MED, V83, P555; STOOHS R, 1992, J APPL PHYSIOL, V72, P583, DOI 10.1152/jappl.1992.72.2.583; Teran-Santos J, 1999, NEW ENGL J MED, V340, P847, DOI 10.1056/NEJM199903183401104; TILKIAN AG, 1976, ANN INTERN MED, V85, P714, DOI 10.7326/0003-4819-85-6-714; Venugopal SK, 2002, CIRCULATION, V106, P1439, DOI 10.1161/01.CIR.0000033116.22237.F9; Vgontzas AN, 1999, J CLIN ENDOCR METAB, V84, P2603, DOI 10.1210/jc.84.8.2603; Vgontzas AN, 1997, J CLIN ENDOCR METAB, V82, P1313, DOI 10.1210/jc.82.5.1313; Vgontzas AN, 2000, J CLIN ENDOCR METAB, V85, P1151, DOI 10.1210/jc.85.3.1151; VIROLAINEN J, 1995, J APPL PHYSIOL, V79, P455, DOI 10.1152/jappl.1995.79.2.455; Vita JA, 2002, CIRCULATION, V106, P640, DOI 10.1161/01.CIR.0000028581.07992.56; Wallace AM, 2001, CIRCULATION, V104, P3052, DOI 10.1161/hc5001.101061; WASCHER TC, 1994, CIRCULATION, V90, P1109, DOI 10.1161/01.CIR.90.2.1109; Wessendorf TE, 2000, AM J RESP CRIT CARE, V162, P2039, DOI 10.1164/ajrccm.162.6.2001048; Wessendorf TE, 2003, NEUROLOGY, V60, P1053, DOI 10.1212/WNL.60.6.1053; WHITE SG, 1995, J APPL PHYSIOL, V79, P324, DOI 10.1152/jappl.1995.79.1.324; Wilcox I, 1998, THORAX, V53, pS33, DOI 10.1136/thx.53.2008.S33; Woollard KJ, 2002, CLIN EXP IMMUNOL, V130, P256, DOI 10.1046/j.1365-2249.2002.01978.x; Younes M., 1989, CURR PULMONOL, V10, P265; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080; ZWILLICH C, 1982, J CLIN INVEST, V69, P1286, DOI 10.1172/JCI110568	153	825	906	1	58	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2003	290	14					1906	1914		10.1001/jama.290.14.1906	http://dx.doi.org/10.1001/jama.290.14.1906			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729CB	14532320	Bronze			2022-12-28	WOS:000185752600032
J	Ehlers, MD				Ehlers, MD			Eppendorf 2003 prize-winning essay - Ubiquitin and the deconstruction of synapses	SCIENCE			English	Editorial Material							POSTSYNAPTIC DENSITY; NMDA RECEPTOR; MODULATION; PROTEINS; FAMILY		Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Duke University	Ehlers, MD (corresponding author), Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA.	ehlers@neuro.duke.edu						Adams JP, 2002, ANNU REV PHARMACOL, V42, P135, DOI 10.1146/annurev.pharmtox.42.082701.145401; Boeckers TM, 2002, J NEUROCHEM, V81, P903, DOI 10.1046/j.1471-4159.2002.00931.x; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Ehlers M.D., 2003, NAT NEUROSCI, V10, P10; GEINISMAN Y, 1991, BRAIN RES, V566, P77, DOI 10.1016/0006-8993(91)91683-R; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Meyer T, 2000, TRENDS CELL BIOL, V10, P238, DOI 10.1016/S0962-8924(00)01764-5; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Murthy VN, 2001, NEURON, V32, P673, DOI 10.1016/S0896-6273(01)00500-1; O'Brien RJ, 1998, NEURON, V21, P1067, DOI 10.1016/S0896-6273(00)80624-8; Rao A, 1997, NEURON, V19, P801, DOI 10.1016/S0896-6273(00)80962-9; Sheng M, 2002, SCIENCE, V298, P776, DOI 10.1126/science.1075333; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; Thiagarajan TC, 2002, NEURON, V36, P1103, DOI 10.1016/S0896-6273(02)01049-8; Toni N, 1999, NATURE, V402, P421, DOI 10.1038/46574; Turrigiano GG, 2000, CURR OPIN NEUROBIOL, V10, P358, DOI 10.1016/S0959-4388(00)00091-X; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Yuste R, 2001, ANNU REV NEUROSCI, V24, P1071, DOI 10.1146/annurev.neuro.24.1.1071	22	16	16	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	2003	302	5646					800	801		10.1126/science.1092546	http://dx.doi.org/10.1126/science.1092546			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593160				2022-12-28	WOS:000186258000030
J	Weinstein, LS; Simonds, WF				Weinstein, LS; Simonds, WF			HRPT2, a marker of parathyroid cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NIDDKD, Metab Dis Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Weinstein, LS (corresponding author), NIDDKD, Metab Dis Branch, Bethesda, MD 20892 USA.		Weinstein, Lee S/I-5575-2015	Weinstein, Lee/0000-0002-1899-5152	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043012, ZIADK043012] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Howell VM, 2003, J MED GENET, V40, P657, DOI 10.1136/jmg.40.9.657; SIMONDS WF, IN PRESS J CLIN ENDO	3	34	36	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 30	2003	349	18					1691	1692		10.1056/NEJMp038159	http://dx.doi.org/10.1056/NEJMp038159			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	737FJ	14585935				2022-12-28	WOS:000186219500001
J	Yamamoto, T; Pashkin, YA; Astafiev, O; Nakamura, Y; Tsai, JS				Yamamoto, T; Pashkin, YA; Astafiev, O; Nakamura, Y; Tsai, JS			Demonstration of conditional gate operation using superconducting charge qubits	NATURE			English	Article							MACROSCOPIC QUANTUM STATES; SINGLE-COOPER-PAIR; JOSEPHSON; OSCILLATIONS; ALGORITHM; JUNCTION	Following the demonstration of coherent control of the quantum state of a superconducting charge qubit(1), a variety of qubits based on Josephson junctions have been implemented(2-5). Although such solid-state devices are not currently as advanced as microscopic qubits based on nuclear magnetic resonance(6) and ion trap(7) technologies, the potential scalability of the former systems together with progress in their coherence times and read-out schemes - makes them strong candidates for the building block of a quantum computer(8). Recently, coherent oscillations(9) and microwave spectroscopy(10) of capacitively coupled superconducting qubits have been reported; the next challenging step towards quantum computation is the realization of logic gates(11,12). Here we demonstrate conditional gate operation using a pair of coupled superconducting charge qubits. Using a pulse technique, we prepare different input states and show that their amplitude can be transformed by controlled-NOT (C-NOT) gate operation, although the phase evolution during the gate operation remains to be clarified.	NEC Fundamental Res Labs, Tsukuba, Ibaraki 3058501, Japan; Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; PN Lebedev Phys Inst, Moscow 117924, Russia	NEC Corporation; RIKEN; Russian Academy of Sciences; Russian Academy of Science Lebedev Physical Institute	Yamamoto, T (corresponding author), NEC Fundamental Res Labs, Tsukuba, Ibaraki 3058501, Japan.		Pashkin, Yuri/M-8540-2015; Astafiev, Oleg/L-9771-2013; Nakamura, Yasunobu/H-1300-2012; Tsai, Jaw-Shen/I-7813-2012	Pashkin, Yuri/0000-0003-4767-8217; Nakamura, Yasunobu/0000-0003-0424-630X; 				Averin DV, 1998, SOLID STATE COMMUN, V105, P659, DOI 10.1016/S0038-1098(97)10001-1; Berkley AJ, 2003, SCIENCE, V300, P1548, DOI 10.1126/science.1084528; Bouchiat V, 1998, PHYS SCRIPTA, VT76, P165, DOI 10.1238/Physica.Topical.076a00165; Chiorescu I, 2003, SCIENCE, V299, P1869, DOI 10.1126/science.1081045; FULTON TA, 1989, PHYS REV LETT, V63, P1307, DOI 10.1103/PhysRevLett.63.1307; Gulde S, 2003, NATURE, V421, P48, DOI 10.1038/nature01336; Nakamura Y, 1999, NATURE, V398, P786, DOI 10.1038/19718; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Pashkin YA, 2003, NATURE, V421, P823, DOI 10.1038/nature01365; POTHIER H, 1992, EUROPHYS LETT, V17, P249, DOI 10.1209/0295-5075/17/3/011; Shnirman A, 1997, PHYS REV LETT, V79, P2371, DOI 10.1103/PhysRevLett.79.2371; Vandersypen LMK, 2001, NATURE, V414, P883, DOI 10.1038/414883a; Vion D, 2002, SCIENCE, V296, P886, DOI 10.1126/science.1069372; Yu Y, 2002, SCIENCE, V296, P889, DOI 10.1126/science.1069452	16	545	562	1	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	2003	425	6961					941	944		10.1038/nature02015	http://dx.doi.org/10.1038/nature02015			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14586464	Green Submitted			2022-12-28	WOS:000186230600036
J	Therrien, J; Webb, G				Therrien, J; Webb, G			Clinical update on adults with congenital heart disease	LANCET			English	Review							ATRIAL SEPTAL-DEFECTS; PULMONARY VALVE-REPLACEMENT; PATENT DUCTUS-ARTERIOSUS; RIGHT-VENTRICULAR-FUNCTION; SUDDEN CARDIAC DEATH; LONG-TERM SURVIVAL; LATE FOLLOW-UP; MUSTARD PROCEDURE; FONTAN OPERATION; NATURAL-HISTORY	The number of patients with congenital cardiac disease reaching adulthood is increasing steadily. Many adults with such disease face both medical and surgical difficulties. Most clinicians know very little about basic cardiac defects, their natural history, complications after surgery, and adequate management of these patients. We aim to provide an overview of the most frequently encountered cardiac lesions and long-term complications and to outline an up-to-date approach to their management. We present a series of hypothetical cases and discuss their management.	Univ Toronto, Congenital Cardiac Ctr Adults, Toronto Gen Hosp, Toronto, ON M5G 2C4, Canada	University of Toronto; Toronto Congenital Cardiac Centre for Adults; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Webb, G (corresponding author), Univ Toronto, Congenital Cardiac Ctr Adults, Toronto Gen Hosp, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	gary.webb@uhn.on.ca						Abd El Rahman MY, 2000, HEART, V84, P416; Attie F, 2001, J AM COLL CARDIOL, V38, P2035, DOI 10.1016/S0735-1097(01)01635-7; BALAJI S, 1994, J AM COLL CARDIOL, V23, P1209, DOI 10.1016/0735-1097(94)90613-0; Balling G, 2000, J THORAC CARDIOV SUR, V119, P745, DOI 10.1016/S0022-5223(00)70010-9; Burks JM, 1998, CLIN CARDIOL, V21, P439, DOI 10.1002/clc.4960210615; CAMPBELL M, 1970, BRIT HEART J, V32, P633; CAMPBELL M, 1968, BRIT HEART J, V30, P4; Carminati M, 2000, CARDIOL YOUNG, V10, P519; CHANG AC, 1992, CIRCULATION, V86, P140; CLARKSON PM, 1983, AM J CARDIOL, V51, P1481, DOI 10.1016/0002-9149(83)90661-6; Coon PD, 2001, ANN THORAC SURG, V71, P1990, DOI 10.1016/S0003-4975(01)02472-9; CRAIG RJ, 1968, CIRCULATION, V37, P805, DOI 10.1161/01.CIR.37.5.805; DITULLIO M, 1992, ANN INTERN MED, V117, P461, DOI 10.7326/0003-4819-117-6-461; DRISCOLL DJ, 1992, CIRCULATION, V85, P469, DOI 10.1161/01.CIR.85.2.469; Durongpisitkul K, 1998, CIRCULATION, V98, P1099, DOI 10.1161/01.CIR.98.11.1099; Fishberger SB, 1997, J THORAC CARDIOV SUR, V113, P80, DOI 10.1016/S0022-5223(97)70402-1; FISHER RG, 1986, J AM COLL CARDIOL, V8, P280, DOI 10.1016/S0735-1097(86)80040-7; FONTAN F, 1990, CIRCULATION, V81, P1520, DOI 10.1161/01.CIR.81.5.1520; Formigari R, 2001, AM J CARDIOL, V88, P586, DOI 10.1016/S0002-9149(01)01749-0; Gatzoulis MA, 1999, NEW ENGL J MED, V340, P839, DOI 10.1056/NEJM199903183401103; Gatzoulis MA, 2000, LANCET, V356, P975, DOI 10.1016/S0140-6736(00)02714-8; GATZOULIS MA, 1995, CIRCULATION, V92, P231, DOI 10.1161/01.CIR.92.2.231; Gatzoulis MA, 1996, ANN THORAC SURG, V61, P657, DOI 10.1016/0003-4975(95)01043-2; Gelatt M, 1997, J AM COLL CARDIOL, V29, P194, DOI 10.1016/S0735-1097(96)00424-X; GELATT M, 1994, J AM COLL CARDIOL, V24, P1735, DOI 10.1016/0735-1097(94)90181-3; Gentles TL, 1997, J THORAC CARDIOV SUR, V114, P376, DOI 10.1016/S0022-5223(97)70183-1; GEWILLIG M, 1991, CIRCULATION, V84, P187; GEWILLIG M, 1992, BRIT HEART J, V67, P72; Ghai A, 2002, J AM COLL CARDIOL, V40, P1675, DOI 10.1016/S0735-1097(02)02344-6; Ghai A, 2001, J AM COLL CARDIOL, V37, P585, DOI 10.1016/S0735-1097(00)01141-4; Haas F, 1999, ANN THORAC SURG, V68, P1692, DOI 10.1016/S0003-4975(99)01039-5; HAHN RT, 1992, J AM COLL CARDIOL, V19, P283, DOI 10.1016/0735-1097(92)90479-7; Hamdan MA, 2001, J AM COLL CARDIOL, V38, P1518, DOI 10.1016/S0735-1097(01)01572-8; Harrison DA, 1997, J AM COLL CARDIOL, V30, P1368, DOI 10.1016/S0735-1097(97)00316-1; Harrison DA, 1996, AM J CARDIOL, V77, P1094, DOI 10.1016/S0002-9149(96)00139-7; Harrison DA, 2001, HEART, V85, P561, DOI 10.1136/heart.85.5.561; Harrison DA, 2001, AM J CARDIOL, V87, P584, DOI 10.1016/S0002-9149(00)01435-1; Hechter SJ, 2001, AM J CARDIOL, V87, P660, DOI 10.1016/S0002-9149(00)01452-1; Helber U, 1997, J AM COLL CARDIOL, V29, P1345, DOI 10.1016/S0735-1097(97)00058-2; HELLENBRAND WE, 1990, AM J CARDIOL, V66, P207, DOI 10.1016/0002-9149(90)90590-W; Helvind MH, 1998, EUR J CARDIO-THORAC, V14, P173, DOI 10.1016/S1010-7940(98)00172-9; HORVATH KA, 1992, J AM COLL CARDIOL, V20, P1156, DOI 10.1016/0735-1097(92)90372-T; JOHN S, 1981, J THORAC CARDIOV SUR, V82, P314; KITCHINER D, 1993, INT J CARDIOL, V42, P217, DOI 10.1016/0167-5273(93)90051-H; KONSTANTINIDES S, 1995, NEW ENGL J MED, V333, P469, DOI 10.1056/NEJM199508243330801; LANDZBERG MJ, 1999, CIRCULATION S2, V84, P67; Lester SJ, 2001, AM J CARDIOL, V88, P1314, DOI 10.1016/S0002-9149(01)02098-7; Losay J, 2001, CIRCULATION, V104, pI121; Marcelletti CF, 2000, J THORAC CARDIOV SUR, V119, P340, DOI 10.1016/S0022-5223(00)70190-5; Mavroudis C, 2001, J THORAC CARDIOV SUR, V122, P863, DOI 10.1067/mtc.2001.117840; McCarthy P M, 2000, Semin Thorac Cardiovasc Surg, V12, P25; MEE RBB, 1986, J THORAC CARDIOV SUR, V92, P385; Mertens L, 1998, J THORAC CARDIOV SUR, V115, P1063, DOI 10.1016/S0022-5223(98)70406-4; MULLEN MJ, 2002, J AM COLL CARDIOL, V39, P402; MURPHY JG, 1993, NEW ENGL J MED, V329, P593, DOI 10.1056/NEJM199308263290901; MURPHY JG, 1990, NEW ENGL J MED, V323, P1645, DOI 10.1056/NEJM199012133232401; MYRIDAKIS DJ, 1994, AM J CARDIOL, V74, P1030, DOI 10.1016/0002-9149(94)90854-0; Nollert G, 1997, J AM COLL CARDIOL, V30, P1374, DOI 10.1016/S0735-1097(97)00318-5; Oechslin EN, 1999, J THORAC CARDIOV SUR, V118, P245, DOI 10.1016/S0022-5223(99)70214-X; Pape LA, 2001, CIRCULATION, V104, P354; Pedra CAC, 2000, HEART, V84, P320, DOI 10.1136/heart.84.3.320; PERLOFF JK, 1999, CLIN RECOGNITION CON, P467; Puley G, 1999, AM J CARDIOL, V83, P1080, DOI 10.1016/S0002-9149(99)00019-3; REDINGTON AN, 1988, BRIT HEART J, V60, P57; ROOSHESSELINK J, 1995, CIRCULATION, V91, P2214, DOI 10.1161/01.CIR.91.8.2214; ROSENTHAL DN, 1995, CIRCULATION, V92, P287, DOI 10.1161/01.CIR.92.9.287; ROSS D, 1991, J CARDIAC SURG, V6, P529; Sandhu SK, 1995, CATHETER CARDIO DIAG, V36, P122, DOI 10.1002/ccd.1810360207; Schaff H V, 2000, Semin Thorac Cardiovasc Surg, V12, P30; Siu SC, 2001, CIRCULATION, V104, P515, DOI 10.1161/hc3001.093437; SUTTON MGS, 1981, CIRCULATION, V64, P402, DOI 10.1161/01.CIR.64.2.402; Therrien J, 2000, J AM COLL CARDIOL, V36, P1670, DOI 10.1016/S0735-1097(00)00930-X; Therrien J, 2001, CAN J CARDIOL, V17, P940; Therrien J, 2001, CAN J CARDIOL, V17, P1029; Therrien J, 2001, CIRCULATION, V103, P2489; Therrien J, 2001, CAN J CARDIOL, V17, P1138; Veldtman GR, 2001, HEART, V86, P330, DOI 10.1136/heart.86.3.330; WARNES CA, 1987, BRIT HEART J, V58, P148; Wilson NJ, 1998, J AM COLL CARDIOL, V32, P758, DOI 10.1016/S0735-1097(98)00309-X; WRIGHT JS, 1978, J THORAC CARDIOV SUR, V75, P695; Yemets IM, 1997, ANN THORAC SURG, V64, P526, DOI 10.1016/S0003-4975(97)00577-8	81	45	46	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	2003	362	9392					1305	1313		10.1016/S0140-6736(03)14574-6	http://dx.doi.org/10.1016/S0140-6736(03)14574-6			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575977				2022-12-28	WOS:000186036900025
J	Novack, DV				Novack, DV			TSH, the bone suppressing hormone	CELL			English	Editorial Material							THYROID-HORMONE	The skeleton is a dynamic organ whose structural integrity depends on constant remodeling, controlled by many local and systemic factors. In this issue of Cell, Abe et al. (2003) identify thyroid-stimulating hormone (TSH) as an important regulator of this process.	Washington Univ, Sch Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA	Washington University (WUSTL)	Novack, DV (corresponding author), Washington Univ, Sch Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA.			Novack, Deborah/0000-0001-7101-5582				Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092-8674(03)00771-2; BRITTO JM, 1994, ENDOCRINOLOGY, V134, P169, DOI 10.1210/en.134.1.169; Davies T, 2002, J CLIN INVEST, V110, P161, DOI 10.1172/JCI200216234; Gothe S, 1999, GENE DEV, V13, P1329, DOI 10.1101/gad.13.10.1329; Greenspan SL, 1999, ANN INTERN MED, V130, P750, DOI 10.7326/0003-4819-130-9-199905040-00016; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Locklin RM, 2003, J CELL BIOCHEM, V89, P180, DOI 10.1002/jcb.10490; Samura A, 2000, ENDOCRINOLOGY, V141, P3774, DOI 10.1210/en.141.10.3774; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122	9	24	26	1	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	2003	115	2					129	130		10.1016/S0092-8674(03)00812-2	http://dx.doi.org/10.1016/S0092-8674(03)00812-2			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567908	Bronze			2022-12-28	WOS:000186039200002
J	Grol, R; Grimshaw, J				Grol, R; Grimshaw, J			From best evidence to best practice: effective implementation of change in patients' care	LANCET			English	Review							CONTINUING MEDICAL-EDUCATION; CLINICAL-PRACTICE GUIDELINES; DECISION-SUPPORT-SYSTEMS; HEALTH-CARE; HAND HYGIENE; PHYSICIAN PERFORMANCE; BUILDING BRIDGES; GENERAL-PRACTICE; INTERVENTIONS; QUALITY	Major difficulties arise when introducing evidence and clinical guidelines into routine daily practice. Data show that many patients do not receive appropriate care, or receive unnecessary or harmful care. Many approaches claim to offer solutions to this problem; which ones are as yet the most effective and efficient is unclear. We aim to provide an overview of present knowledge about initiatives to changing medical practice. Substantial evidence suggests that to change behaviour is possible, but this change generally requires comprehensive approaches at different levels (doctor, team practice, hospital, wider environment), tailored to specific settings and target groups. Plans for change should be based on characteristics of the evidence or guideline itself and barriers and facilitators to change. In general, evidence shows that none of the approaches for transferring evidence to practice is superior to all changes in all situations.	Univ Nijmegen & Univ Maastricht, Ctr Qual Care Res WOK, NL-6500 HB Nijmegen, Netherlands; Ottawa Hlth Res Inst, Clin Epidemiol Programme, Ottawa, ON, Canada	Maastricht University; Radboud University Nijmegen; University of Ottawa; Ottawa Hospital Research Institute	Grol, R (corresponding author), Univ Nijmegen & Univ Maastricht, Ctr Qual Care Res WOK, POB 9101,WOK 229, NL-6500 HB Nijmegen, Netherlands.	R.Grol@WOK.umcn.nl	Grimshaw, Jeremy/D-8726-2013; Grol, Richard/C-8523-2013	Grimshaw, Jeremy/0000-0001-8015-8243				Aiello AE, 2002, LANCET INFECT DIS, V2, P103, DOI 10.1016/S1473-3099(02)00184-6; Anderson GM, 1996, CAN MED ASSOC J, V154, P1013; AUSTIN SM, 1994, J AM MED INFORM ASSN, P121; Balas EA, 1996, ARCH FAM MED, V5, P271, DOI 10.1001/archfami.5.5.271; Balas EA, 1996, J GEN INTERN MED, V11, P584, DOI 10.1007/BF02599025; Beaudry JS, 1989, J CONTIN EDUC HEALTH, V9, P285, DOI DOI 10.1002/CHP.4750090414; Beilby JJ, 1997, MED J AUSTRALIA, V167, P89, DOI 10.5694/j.1326-5377.1997.tb138787.x; BENEY J, 2000, COCHRANE LIB; Bero LA, 1998, BMJ-BRIT MED J, V317, P465; BERTRAM DA, 1977, HEALTH EDUC QUART, V5, P330, DOI 10.1177/109019817700500404; Bodenheimer T, 1999, NEW ENGL J MED, V340, P488, DOI 10.1056/NEJM199902113400621; BOWER P, 2000, COCHRANE LIB; BUNTINX F, 1993, FAM PRACT, V10, P219, DOI 10.1093/fampra/10.2.219; BURGERS J, 2002, INT J TECHN ASS HLTH, V18, P955; Burgers JS, 2003, BRIT J GEN PRACT, V53, P15; BUSHMAN B., 1994, HDB RES SYNTHESIS; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Chaix-Couturier C, 2000, INT J QUAL HEALTH C, V12, P133, DOI 10.1093/intqhc/12.2.133; Chassin MR, 1998, MILBANK Q, V76, P565, DOI 10.1111/1468-0009.00106; Cluzeau F, 2003, QUAL SAF HEALTH CARE, V12, P18; *COCHR COLL, 2002, COCHR CONTR TRIAL RE; COHEN PA, 1992, EVAL HEALTH PROF, V15, P259, DOI 10.1177/016327879201500301; Cookson B, 1999, BRIT MED J, V318, P686; *CTR REV DISS, 1999, EFF HLTH CAR, P5; CURRELL R, 2000, COCHRANE LIB; Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; Davis DA, 1997, CAN MED ASSOC J, V157, P408; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; DEMAESENEER JM, IN PRESS LANCET; Ferlie EB, 2001, MILBANK Q, V79, P281, DOI 10.1111/1468-0009.00206; Foy R, 2002, J CLIN EPIDEMIOL, V55, P717, DOI 10.1016/S0895-4356(02)00403-1; FREEMANTLE N, 1998, COCHRANE LIB; Garside P, 1998, QUAL HEALTH CARE, V7, pS8; Gill PS, 1999, PHARM WORLD SCI, V21, P158, DOI 10.1023/A:1008719129305; GIUFFRIDA A, 1999, COCHRANE LIB; Gosden T, 1997, HEALTH POLICY, V40, P103, DOI 10.1016/S0168-8510(96)00888-3; GOSDEN T, 2000, COCHRANE LIB; GRILLI R, 1994, MED CARE, V32, P202, DOI 10.1097/00005650-199403000-00002; GRILLI R, 2000, COCHRANE LIB; Grimshaw J, 1995, Qual Health Care, V4, P55, DOI 10.1136/qshc.4.1.55; Grimshaw Jeremy M, 2002, J Contin Educ Health Prof, V22, P237, DOI 10.1002/chp.1340220408; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GRIMSHAW JM, 2001, MED CARE S, V39, P112; Grol R, 2001, MED CARE, V39, pII46; Grol R, 2001, JAMA-J AM MED ASSOC, V286, P2578, DOI 10.1001/jama.286.20.2578; Grol R, 1998, BRIT MED J, V317, P858, DOI 10.1136/bmj.317.7162.858; Grol R, 1997, BRIT MED J, V315, P418, DOI 10.1136/bmj.315.7105.418; Grol R., 2001, IMPLEMENTATION EFFEC; GURWITZ JH, 1990, J AM GERIATR SOC, V38, P542, DOI 10.1111/j.1532-5415.1990.tb02406.x; Guyatt GH, 2000, BRIT MED J, V320, P954, DOI 10.1136/bmj.320.7240.954; GYORKOS TW, 1994, CAN J PUBLIC HEALTH, V85, pS14; Haines A, 2001, EVIDENCE BASED PRACT, V2nd; HARVEY EL, 1999, COCHRANE LIB; Hearn J, 1998, PALLIATIVE MED, V12, P317, DOI 10.1191/026921698676226729; Hugonnet S, 2000, CLIN MICROBIOL INFEC, V6, P350; Hulscher MEJL, 1999, AM J PUBLIC HEALTH, V89, P737, DOI 10.2105/AJPH.89.5.737; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; JARVIS WR, 1994, LANCET, V344, P1311, DOI 10.1016/S0140-6736(94)90687-4; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; Kidd M, 2001, EVIDENCE BASED PRACT; Lancaster T, 1998, COCHRANE LIB; LANIER DC, IN PRESS LANCET; Larson EL, 1997, AM J INFECT CONTROL, V25, P3, DOI 10.1016/S0196-6553(97)90046-8; LOMAS J, 1988, American Journal of Preventive Medicine, V4, P77; MANDELBLATT J, 1995, J FAM PRACTICE, V40, P162; MUGFORD M, 1998, BMJ-BRIT MED J, V303, P398; Naikoba S, 2001, J HOSP INFECT, V47, P173, DOI 10.1053/jhin.2000.0882; O'Boyle CA, 2001, AM J INFECT CONTROL, V29, P352, DOI 10.1067/mic.2001.18405; OXMAN A, 2001, EVIDENCE BASED PRACT; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; PIPPALLA RS, 1995, J CLIN PHARM THER, V20, P189, DOI 10.1111/j.1365-2710.1995.tb00648.x; Pittet D, 2000, INFECT CONT HOSP EP, V21, P381, DOI 10.1086/501777; Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2; PRATT RJ, 2001, J HOSP INFECT, V47, P82; RUBENSTEIN L Z, 1991, Journal of the American Geriatrics Society, V39, p8S; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; Shaneyfelt TM, 2001, JAMA-J AM MED ASSOC, V286, P2600, DOI 10.1001/jama.286.20.2600; Shaneyfelt TM, 1999, JAMA-J AM MED ASSOC, V281, P1900, DOI 10.1001/jama.281.20.1900; Shea S, 1996, J AM MED INFORM ASSN, V3, P399, DOI 10.1136/jamia.1996.97084513; Shortell SM, 1998, MILBANK Q, V76, P593, DOI 10.1111/1468-0009.00107; Silagy C, 1994, Qual Health Care, V3, P193, DOI 10.1136/qshc.3.4.193; Snell JL, 1996, PREV MED, V25, P702, DOI 10.1006/pmed.1996.0109; Solberg L I, 2000, Jt Comm J Qual Improv, V26, P171; Solomon DH, 1998, JAMA-J AM MED ASSOC, V280, P2020, DOI 10.1001/jama.280.23.2020; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; Stone SP, 2001, J ROY SOC MED, V94, P278, DOI 10.1177/014107680109400606; Sulch D, 2000, AGE AGEING, V29, P349, DOI 10.1093/ageing/29.4.349; SULLIVAN F, 1995, BMJ-BRIT MED J, V311, P848, DOI 10.1136/bmj.311.7009.848; Teare L, 2001, BRIT MED J, V323, P411, DOI 10.1136/bmj.323.7310.411; Thomas LH, 1998, QUAL HEALTH CARE, V7, P183, DOI 10.1136/qshc.7.4.183; THOMSON MA, 1997, COCHRANE LIB 1; THOMSON MA, 1997, COCHRANE LIB 2; van Weel C, 2003, Ned Tijdschr Geneeskd, V147, P229; VANDERWEIJDEN T, 2000, INTERVENTIONS AIMED; Waddell D L, 1991, J Contin Educ Nurs, V22, P113; Walton R, 1999, BRIT MED J, V318, P984, DOI 10.1136/bmj.318.7189.984; Wensing M, 1998, BRIT J GEN PRACT, V48, P991; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527; WORRALL G, 1997, CMAJ, V155, P1705; ZWARENSTEIN M, 1997, COCHRANE LIB	101	2886	2908	4	253	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 11	2003	362	9391					1225	1230		10.1016/S0140-6736(03)14546-1	http://dx.doi.org/10.1016/S0140-6736(03)14546-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732CW	14568747				2022-12-28	WOS:000185924100026
J	O'Donnell, C; Donohoe, G; Sharkey, L; Owens, N; Migone, M; Harries, R; Kinsella, A; Larkin, C; O'Callaghan, E				O'Donnell, C; Donohoe, G; Sharkey, L; Owens, N; Migone, M; Harries, R; Kinsella, A; Larkin, C; O'Callaghan, E			Compliance therapy: a randomised controlled trial in schizophrenia	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICATION COMPLIANCE; INSIGHT; SCALE; NONCOMPLIANCE	Objective To evaluate the efficacy of "compliance therapy" for improving adherence to prescribed drug treatment among patients with schizophrenia. Design Randomised controlled trial. Setting Urban catchment area psychiatric service. Participants 94 consecutive admissions of patients with schizophrenia, 56 agreed to participate. Intervention Compliance therapy and non-specific counselling, each consisting of 5 sessions lasting 30-60 minutes. Main outcome measures Compliance with drug treatment at one year; attitudes to treatment, symptomatology, insight, and quality of life at one year; length of "survival" in the community, bed days, and rehospitalisation rates at two years. Results Compliance therapy did not confer a major advantage over non-specific therapy in improving compliance at one year (43% (12/28) v 54% (15/28), difference - 11% (95% confidence interval - 37% to 15%) or in any of the secondary outcome measures-symptomatology, attitudes to treatment, insight, global assessment of functioning, and quality of life. Conclusion Compliance therapy may not be of benefit to patients with schizophrenia. Attitudes to treatment at baseline predicted adherence one year later and may be a clinically useful tool.	St Vincents Univ Hosp, Univ Coll Dublin, Dept Psychiat, Dublin, Ireland; Cluain Mhuire Serv, Dept Adult Psychiat, Stanley Res Unit, Dublin, Ireland; Dublin Inst Technol, Dublin, Ireland; St John God Hosp, Stillorgan, County Dublin, Ireland	University College Dublin; Saint Vincent's University Hospital; Technological University Dublin	O'Callaghan, E (corresponding author), St Vincents Univ Hosp, Univ Coll Dublin, Dept Psychiat, Elm Pk, Dublin, Ireland.	eadbhard@iol.ie	Donohoe, Gary/J-6481-2013	Donohoe, Gary/0000-0003-3037-7426				ADAMS SG, 1993, J NERV MENT DIS, V181, P558, DOI 10.1097/00005053-199309000-00005; *AM PSYCH ASS, 1992, STRUCT CLIN INT DSM; DAVID AS, 1990, BRIT J PSYCHIAT, V156, P798, DOI 10.1192/bjp.156.6.798; Diaz E, 2001, J PSYCHIATR NEUROSCI, V26, P325; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; Fenton WS, 1997, SCHIZOPHRENIA BULL, V23, P637, DOI 10.1093/schbul/23.4.637; Garavan J, 1998, COMPR PSYCHIAT, V39, P215, DOI 10.1016/S0010-440X(98)90063-3; HAYNES RB, 1980, HYPERTENSION, V2, P757, DOI 10.1161/01.HYP.2.6.757; HEINRICHS DW, 1984, SCHIZOPHRENIA BULL, V10, P388, DOI 10.1093/schbul/10.3.388; HOGAN TP, 1983, PSYCHOL MED, V13, P177, DOI 10.1017/S0033291700050182; JOHN C, 1994, BRIT J PSYCHIAT, V165, P695; Kamali M, 2001, PSYCHIATR SERV, V52, P161, DOI 10.1176/appi.ps.52.2.161; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Kemp R, 1996, BRIT MED J, V312, P345; Kemp R, 1998, BRIT J PSYCHIAT, V172, P413, DOI 10.1192/bjp.172.5.413; Lewis CF, 1996, ACTA PSYCHIAT SCAND, V94, P416, DOI 10.1111/j.1600-0447.1996.tb09883.x; NELSON HE, 1984, NATL ADULT READING T; Olfson M, 2000, PSYCHIATR SERV, V51, P216, DOI 10.1176/appi.ps.51.2.216; ROLLNICK S, 1993, BRIT MED J, V307, P188, DOI 10.1136/bmj.307.6897.188; SELLWOOD W, 1994, SOC PSYCH PSYCH EPID, V29, P172; Smith TE, 1997, PSYCHIAT RES, V69, P123, DOI 10.1016/S0165-1781(96)03013-2	21	147	155	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 11	2003	327	7419					834	836		10.1136/bmj.327.7419.834	http://dx.doi.org/10.1136/bmj.327.7419.834			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732BP	14551096	Bronze, Green Published			2022-12-28	WOS:000185921200016
J	Warlow, C; Sudlow, C; Dennis, M; Wardlaw, J; Sandercock, P				Warlow, C; Sudlow, C; Dennis, M; Wardlaw, J; Sandercock, P			Stroke	LANCET			English	Review							ACUTE ISCHEMIC-STROKE; CASE-FATALITY; COMPUTED-TOMOGRAPHY; INTRACEREBRAL HEMORRHAGE; PREVENT STROKE; BLOOD-PRESSURE; HEART-DISEASE; EPIDEMIOLOGY; ASSOCIATION; INFARCTION	Stroke is a major public-health burden worldwide. Prevention programmes are essential to reduce the incidence of stroke and to prevent the all but inevitable stroke epidemic, which will hit less developed countries particularly hard as their populations age and adopt lifestyles of the more developed countries. Efficient, effective, and rapid diagnosis of stroke and transient ischaemic attack is crucial. The diagnosis of the exact type and cause of stroke, which requires brain imaging as well as traditional clinical skills, is also important when it will influence management. The treatment of acute stroke, the prevention and management of the many complications of stroke, and the prevention of recurrent stroke and other serious vascular events are all improving rapidly. However, stroke management will only be most effective when delivered in the context of an organised, expert, educated, and enthusiastic stroke service that can react quickly to the needs of patients at all stages from onset to recovery.	Western Gen Hosp, Div Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Warlow, C (corresponding author), Western Gen Hosp, Div Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland.	cpw@skull.dcn.ed.ac.uk	sandercock, peter/GQI-3167-2022; Wardlaw, Joanna M/Y-3456-2019; Hernandez, María/GYU-3543-2022	sandercock, peter/0000-0001-8484-0135; Wardlaw, Joanna M/0000-0002-9812-6642; Sudlow, Cathie/0000-0002-7725-7520	Wellcome Trust [063668] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Albers GW, 2002, NEW ENGL J MED, V347, P1713, DOI 10.1056/NEJMsb020987; ALGRA A, 2003, COCHRANE LIB; [Anonymous], 1996, GLOBAL BURDEN DIS CO; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; BARTON S, 2002, CLIN EVIDENCE; Bassetti C, 1999, SLEEP, V22, P217, DOI 10.1093/sleep/22.2.217; Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; BONITA R, 1993, LANCET, V342, P1470, DOI 10.1016/0140-6736(93)92938-P; Bradford Andrew, 2000, Curr Control Trials Cardiovasc Med, V1, P184, DOI 10.1186/CVM-1-3-184; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; Brown MM, 2001, LANCET, V357, P1729; Brown RD, 1996, STROKE, V27, P373; BURN J, 1998, BMJ-BRIT MED J, V315, P1582; Carolei A, 1997, STROKE, V28, P2500, DOI 10.1161/01.STR.28.12.2500; Chen ZM, 2000, STROKE, V31, P1240, DOI 10.1161/01.STR.31.6.1240; *COCHR CONTR TRIAL, COCHR LIB; COLLINS R, 1994, BRIT MED BULL, V50, P272, DOI 10.1093/oxfordjournals.bmb.a072892; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Coull BM, 2002, NEUROLOGY, V59, P13, DOI 10.1212/WNL.59.1.13; Counsell C, 2002, STROKE, V33, P1041, DOI 10.1161/hs0402.105909; COUNSELL C, 2003, COCHRANE LIB; Danesh J, 1999, AM HEART J, V138, pS434, DOI 10.1016/S0002-8703(99)70270-X; Danesh J, 1998, J Cardiovasc Risk, V5, P229, DOI 10.1097/00043798-199808000-00004; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; Davis PJ, 1999, RAMUS, V28, P1; Donnan GA, 2002, LANCET NEUROL, V1, P417, DOI 10.1016/S1474-4422(02)00189-8; Ellekjaer H, 1997, STROKE, V28, P2180, DOI 10.1161/01.STR.28.11.2180; Feigin VL, 2003, LANCET NEUROL, V2, P43, DOI 10.1016/S1474-4422(03)00266-7; FEIGIN VL, 1995, STROKE, V26, P924, DOI 10.1161/01.STR.26.6.924; Fernandes HM, 2000, STROKE, V31, P2511, DOI 10.1161/01.STR.31.10.2511; *FOOD TRIAL COLL, IN PRESS STROKE; Gilligan AK, 2002, STROKE, V33, P2236, DOI 10.1161/01.STR.0000027859.59415.66; Goldstein L B, 2000, Curr Atheroscler Rep, V2, P110, DOI 10.1007/s11883-000-0104-2; GUBITZ G, 2002, CLIN EVIDENCE; GUBITZ G, 2003, COCHRANE LIB; Hankey GJ, 1999, LANCET, V354, P1457, DOI 10.1016/S0140-6736(99)04407-4; Hankey GJ, 2000, STROKE, V31, P1779, DOI 10.1161/01.STR.31.7.1779; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Hassan A, 2000, BRAIN, V123, P1784, DOI 10.1093/brain/123.9.1784; HAWKINS GC, 1995, STROKE, V26, P1338, DOI 10.1161/01.STR.26.8.1338; HOUSE A, 1989, BMJ-BRIT MED J, V298, P991, DOI 10.1136/bmj.298.6679.991; Huxley R, 2002, LANCET, V360, P659, DOI 10.1016/S0140-6736(02)09834-3; *INT WORK PART STR, 2002, NAT CLIN GUID STROK; Jamrozik K, 1999, STROKE, V30, P2105, DOI 10.1161/01.STR.30.10.2105; Johnston SC, 2000, JAMA-J AM MED ASSOC, V284, P2901, DOI 10.1001/jama.284.22.2901; JORGENSEN HS, 1992, STROKE, V23, P1701, DOI 10.1161/01.STR.23.12.1701; Keavney B, 2000, LANCET, V355, P434; Keir SL, 2002, J NEUROL, V249, P1226, DOI 10.1007/s00415-002-0816-z; Kittusamy PK, 2001, CATHETER CARDIO INTE, V54, P221, DOI 10.1002/ccd.1273; Kolominsky-Rabas PL, 1998, STROKE, V29, P2501, DOI 10.1161/01.STR.29.12.2501; Langhorne P, 2002, AGE AGEING, V31, P365, DOI 10.1093/ageing/31.5.365; LAURIA G, 1995, STROKE, V26, P1787, DOI 10.1161/01.STR.26.10.1787; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; LIU M, 2003, COCHRANE LIB; LOVETT JK, IN PRESS J NEUROL NE; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; Mas JL, 2003, PRACT NEUROL, V3, P4; Patel SC, 2001, JAMA-J AM MED ASSOC, V286, P2830, DOI 10.1001/jama.286.22.2830; Patel SG, 2002, J NEUROL NEUROSUR PS, V73, P21, DOI 10.1136/jnnp.73.1.21; Pereira AC, 2000, CLIN RADIOL, V55, P725, DOI 10.1053/crad.2000.0118; Perry IJ, 1999, J CARDIOVASC RISK, V6, P235; Qizilbash N, 1995, LANCET, V346, P1647; RICCI S, 1994, NEUROEPIDEMIOLOGY, V13, P290, DOI 10.1159/000110393; Ridker PM, 2002, CIRCULATION, V105, P2583, DOI 10.1161/01.CIR.0000017822.82512.62; Rodgers A, 1998, LANCET, V352, P1801; Ronning OM, 1999, STROKE, V30, P2033, DOI 10.1161/01.STR.30.10.2033; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; Rothwell PM, 2001, LANCET, V357, P1612, DOI 10.1016/S0140-6736(00)04730-9; Rothwell PM, 1999, LANCET, V353, P2105, DOI 10.1016/S0140-6736(98)11415-0; Rothwell PM, 2000, STROKE, V31, P1444, DOI 10.1161/01.STR.31.6.1444; SANDERCOCK P, 2002, HLTH TECHNOL ASSESS, V6, P35; Sarti C, 2000, STROKE, V31, P1588, DOI 10.1161/01.STR.31.7.1588; SAVER JL, 2002, 27 INT STROK C; *SCOTT INT GUID NE, 2002, SCOTT INT GUID NETW, V62; *SCOTT INT GUID NE, SCOTT INT GUID NETW, V36; Scott JF, 1999, STROKE, V30, P793, DOI 10.1161/01.STR.30.4.793; Smadja D, 2001, STROKE, V32, P2741, DOI 10.1161/hs1201.099385; *STROK UN TRIAL CO, 2003, COCHR LIB; SUDLOW C, 2002, CLIN EVIDENCE; Sudlow CLM, 1997, STROKE, V28, P491, DOI 10.1161/01.STR.28.3.491; Thrift AG, 2001, STROKE, V32, P1732, DOI 10.1161/01.STR.32.8.1732; *UPD SOFTW, 2002, COCHR LIB; Vemmos KN, 1999, STROKE, V30, P363, DOI 10.1161/01.STR.30.2.363; von Kummer R, 2000, RADIOLOGY, V216, P611, DOI 10.1148/radiology.216.2.r00ma26611; Wardlaw J M, 2000, J Stroke Cerebrovasc Dis, V9, P70, DOI 10.1053/jscd.2000.0090070; Wardlaw JM, 1998, STROKE, V29, P1315, DOI 10.1161/01.STR.29.7.1315; Wardlaw JM, 2003, J NEUROL NEUROSUR PS, V74, P77, DOI 10.1136/jnnp.74.1.77; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; WARDLAW JM, 2003, COCHRANE LIB; Warlow CP, 2001, STROKE PRACTICAL GUI, P223; WARLOW CP, 2001, WHAT PATHOLOGICAL TY, P151; Warlow CP, 2001, STROKE PRACTICAL GUI, P653; Warlow CP, 2001, STROKE PRACTICAL GUI, P414; Winkley JM, 2000, AM J CARDIOL, V85, p47C; Yusuf S, 2001, NEW ENGL J MED, V345, P494; ZWEIBEL WJ, 1992, INTRO VASCULAR ULTRA, P105	96	317	345	2	44	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 11	2003	362	9391					1211	1224		10.1016/S0140-6736(03)14544-8	http://dx.doi.org/10.1016/S0140-6736(03)14544-8			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568745				2022-12-28	WOS:000185924100024
J	Luminet, JP; Weeks, JR; Riazuelo, A; Lehoucq, R; Uzan, JP				Luminet, JP; Weeks, JR; Riazuelo, A; Lehoucq, R; Uzan, JP			Dodecahedral space topology as an explanation for weak wide-angle temperature correlations in the cosmic microwave background	NATURE			English	Article							PROBE WMAP OBSERVATIONS; SPHERICAL SPACES	The current 'standard model' of cosmology posits an infinite flat universe forever expanding under the pressure of dark energy. First-year data from the Wilkinson Microwave Anisotropy Probe (WMAP) confirm this model to spectacular precision on all but the largest scales(1,2). Temperature correlations across the microwave sky match expectations on angular scales narrower than 608 but, contrary to predictions, vanish on scales wider than 60degrees. Several explanations have been proposed(3,4). One natural approach questions the underlying geometry of space-namely, its curvature(5) and topology(6). In an infinite flat space, waves from the Big Bang would fill the universe on all length scales. The observed lack of temperature correlations on scales beyond 608 means that the broadest waves are missing, perhaps because space itself is not big enough to support them. Here we present a simple geometrical model of a finite space-the Poincare' dodecahedral space-which accounts for WMAP's observations with no fine-tuning required. The predicted density is Omega(0) < 1.013 > 1, and the model also predicts temperature correlations in matching circles on the sky(7).	Observ Paris, F-92195 Meudon, France; CEA Saclay, F-91191 Gif Sur Yvette, France; Univ Paris 11, Phys Theor Lab, F-91405 Orsay, France	UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Weeks, JR (corresponding author), 15 Farmer St, Canton, NY 13617 USA.							Bennett CL, 2003, ASTROPHYS J SUPPL S, V148, P1, DOI 10.1086/377253; CLINE JM, 2003, ORGASTROPH0304558; CLINE JM, IN PRESS J COSMOL AS; Contaldi CR, 2003, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2003/07/002; Cornish NJ, 1998, CLASSICAL QUANT GRAV, V15, P2657, DOI 10.1088/0264-9381/15/9/013; Efstathiou G, 2003, MON NOT R ASTRON SOC, V343, pL95, DOI 10.1046/j.1365-8711.2003.06940.x; Gausmann E, 2001, CLASSICAL QUANT GRAV, V18, P5155, DOI 10.1088/0264-9381/18/23/311; Lehoucq R, 2002, CLASSICAL QUANT GRAV, V19, P4683, DOI 10.1088/0264-9381/19/18/305; Linde A, 2003, J COSMOL ASTROPART P; RIAZUELO A, IN PRESS PHYS REV D; RIAZUELO A, 2002, ORGASTROPH0212223; Spergel DN, 2003, ASTROPHYS J SUPPL S, V148, P175, DOI 10.1086/377226; TEGMARK M, 2003, ORGASTROPH0302496; TEGMARK M, IN PRESS PHYS REV D; UZAN JP, IN PRESS MON NOT R A	15	300	302	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2003	425	6958					593	595		10.1038/nature01944	http://dx.doi.org/10.1038/nature01944			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534579				2022-12-28	WOS:000185801000029
J	Chan, D; Janssen, JC; Whitwell, JL; Watt, HC; Jenkins, R; Frost, C; Rossor, MN; Fox, NC				Chan, D; Janssen, JC; Whitwell, JL; Watt, HC; Jenkins, R; Frost, C; Rossor, MN; Fox, NC			Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study	LANCET			English	Article							BRAIN ATROPHY; SERIAL MRI; DEMENTIA; AD	The extent to which cerebral atrophy in Alzheimer's disease changes with time is unknown. We used multiple MRI scans to measure progression of cerebral atrophy in 12 patients with Alzheimer's disease who were followed up from a presymptomatic stage through to moderately severe dementia. Analysis with hierarchical regression models with quadratic terms in time provided evidence of increasing yearly percentage losses in brain volume. At the time when patients were judged to have mild dementia (mini-mental state examination score MMSE=23), mean yearly loss of brain volume was 2.8% (95% Cl 2.3-3.3), which rose by 0.32% per year (0.15-0.50). Our findings reinforce the need for early diagnosis and therapeutic intervention in Alzheimer's disease.	UCL, Inst Neurol, Dept Clin Neurol, Dementia Res Grp, London, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Neurosci & Psychol Med, London, England; London Sch Hyg & Trop Med, Med Stat Unit, London WC1, England	University of London; University College London; Imperial College London; University of London; London School of Hygiene & Tropical Medicine	Fox, NC (corresponding author), Natl Hosp Neurol & Neurosurg, Dementia Res Grp, Queen Sq, London WC1N 3BG, England.	n.fox@dementia.ion.ucl.ac.uk	Rossor, Martin/C-1598-2008; Fox, Nick C/AAE-1849-2021; Fox, Nick C/B-1319-2009	Fox, Nick C/0000-0002-6660-657X; Fox, Nick C/0000-0002-6660-657X; Frost, Chris/0000-0003-0098-9915; Rossor, Martin/0000-0001-8215-3120	MRC [G116/143] Funding Source: UKRI; Medical Research Council [G116/143] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Fox NC, 1999, NEUROLOGY, V52, P1687, DOI 10.1212/WNL.52.8.1687; Fox NC, 1997, J MAGN RESON IMAGING, V7, P1069, DOI 10.1002/jmri.1880070620; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MURPHY DGM, 1993, BIOL PSYCHIAT, V34, P612, DOI 10.1016/0006-3223(93)90153-5; O'Brien JT, 2001, NEUROLOGY, V56, P1386, DOI 10.1212/WNL.56.10.1386	5	152	155	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 4	2003	362	9390					1121	1122		10.1016/S0140-6736(03)14469-8	http://dx.doi.org/10.1016/S0140-6736(03)14469-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728HA	14550701				2022-12-28	WOS:000185710700013
J	Clement, AM; Nguyen, MD; Roberts, EA; Garcia, ML; Boillee, S; Rule, M; McMahon, AP; Doucette, W; Siwek, D; Ferrante, RJ; Brown, RH; Julien, JP; Goldstein, LSB; Cleveland, DW				Clement, AM; Nguyen, MD; Roberts, EA; Garcia, ML; Boillee, S; Rule, M; McMahon, AP; Doucette, W; Siwek, D; Ferrante, RJ; Brown, RH; Julien, JP; Goldstein, LSB; Cleveland, DW			Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice	SCIENCE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CU/ZN SUPEROXIDE-DISMUTASE; TRANSGENIC MOUSE MODEL; DISEASE ONSET; FAMILIAL ALS; EXPRESSION; DEATH; DEGENERATION; PROGRESSION; MUTATIONS	The most common form of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease affecting adult motor neurons, is caused by dominant mutations in the ubiquitously expressed Cu-Zn superoxide dismutase (SOD1). In chimeric mice that are mixtures of normal and SOD1 mutant-expressing cells, toxicity to motor neurons is shown to require damage from mutant SOD1 acting within nonneuronal cells. Normal motor neurons in SOD1 mutant chimeras develop aspects of ALS pathology. Most important, nonneuronal cells that do not express mutant SOD1 delay degeneration and significantly extend survival of mutant-expressing motor neurons.	Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; McGill Univ, Montreal Gen Hosp, Hlth Care Ctr, Res Inst,Ctr Res Neurosci, Montreal, PQ H3G 1A4, Canada; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Massachusetts Gen Hosp E, Day Neuromuscular Res Lab, Charlestown, MA 02139 USA; Boston Univ, Sch Med, Bedford VA Med Ctr, Dept Neurol,Geriatr Res Educ & Clin Ctr, Bedford, MA 01730 USA; Boston Univ, Sch Med, Bedford VA Med Ctr, Dept Pathol,Geriatr Res Educ & Clin Ctr, Bedford, MA 01730 USA; Boston Univ, Sch Med, Bedford VA Med Ctr, Dept Psychiat,Geriatr Res Educ & Clin Ctr, Bedford, MA 01730 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; McGill University; Harvard University; Boston University; Geriatric Research Education & Clinical Center; Boston University; Geriatric Research Education & Clinical Center; Boston University; Geriatric Research Education & Clinical Center	Cleveland, DW (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, 9500 Gilman Dr, La Jolla, CA 92093 USA.	dcleveland@ucsd.edu	Boillee, Severine/J-4027-2017; McMahon, Andrew P/ABE-7520-2020; Doucette, Wilder/S-2019-2016; Cleveland, Don/AAN-9783-2021	Doucette, Wilder/0000-0003-2249-0461; Cleveland, Don/0000-0002-1934-3682; BOILLEE, Severine/0000-0001-5518-9005	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030249] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031248, R01NS027036, R01NS037912, R37NS027036, P50NS031248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG013846, P01AG012992] Funding Source: NIH RePORTER; NIA NIH HHS [AG 13846, AG 12992] Funding Source: Medline; NICHD NIH HHS [HD 30249] Funding Source: Medline; NINDS NIH HHS [R37 NS027036, NS 27036, NS 37912, NS 31248] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrus PK, 1998, J NEUROCHEM, V71, P2041; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bush AI, 2002, NAT NEUROSCI, V5, P919, DOI 10.1038/nn1002-919a; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Elliott JL, 2001, MOL BRAIN RES, V95, P172, DOI 10.1016/S0169-328X(01)00242-X; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Gong YH, 2000, J NEUROSCI, V20, P660, DOI 10.1523/JNEUROSCI.20-02-00660.2000; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hadjantonakis AK, 2001, HISTOCHEM CELL BIOL, V115, P49, DOI 10.1007/s004180000233; Hall ED, 1998, GLIA, V23, P249, DOI 10.1002/(SICI)1098-1136(199807)23:3<249::AID-GLIA7>3.0.CO;2-#; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; Jaarsma D, 2001, ACTA NEUROPATHOL, V102, P293; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; JULIEN JP, 1990, J PHYSIOLOGY PARIS, V84, P50; KAWAMATA T, 1992, AM J PATHOL, V140, P691; Kriz J, 2002, NEUROBIOL DIS, V10, P268, DOI 10.1006/nbdi.2002.0487; LEIGH PN, 1991, BRAIN, V114, P775, DOI 10.1093/brain/114.2.775; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Lino MM, 2002, J NEUROSCI, V22, P4825, DOI 10.1523/JNEUROSCI.22-12-04825.2002; Nagai M, 2001, J NEUROSCI, V21, P9246, DOI 10.1523/JNEUROSCI.21-23-09246.2001; Nagy A, 1999, GENE TARGETING PRACT, P177; Pasinelli P, 2000, P NATL ACAD SCI USA, V97, P13901, DOI 10.1073/pnas.240305897; Pramatarova A, 2001, J NEUROSCI, V21, P3369, DOI 10.1523/JNEUROSCI.21-10-03369.2001; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Van Den Bosch L, 2002, NEUROREPORT, V13, P1067, DOI 10.1097/00001756-200206120-00018; Watanabe M, 2001, NEUROBIOL DIS, V8, P933, DOI 10.1006/nbdi.2001.0443; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	35	844	884	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	2003	302	5642					113	117		10.1126/science.1086071	http://dx.doi.org/10.1126/science.1086071			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526083				2022-12-28	WOS:000185678500048
J	Lonart, G; Schoch, S; Kaeser, PS; Larkin, CJ; Sudhof, TC; Linden, DJ				Lonart, G; Schoch, S; Kaeser, PS; Larkin, CJ; Sudhof, TC; Linden, DJ			Phosphorylation of RIM1 alpha by PKA triggers presynaptic long-term potentiation at cerebellar parallel fiber synapses	CELL			English	Article							DEPENDENT PROTEIN-KINASE; CA3 PYRAMIDAL NEURONS; RAB3 EFFECTOR; ACTIVE ZONE; 2 FORMS; LTP; RIM; EXPRESSION; MECHANISMS; PLASTICITY	Presynaptic activation of protein kinase A (PKA) induces LTP in cerebellar parallel fiber synapses. Presynaptic LTP is known to require the active zone protein RIM1alpha, but the underlying induction mechanism remains unclear. We now show that PKA directly phosphorylates RIM1alpha at two sites. Using paired recordings from cultured cerebellar granule and Purkinje neurons, we demonstrate that LTP is absent in neurons from RIM1alpha KO mice but is rescued by presynaptic expression of RIM1alpha. Mutant RIM1alpha lacking the N-terminal phosphorylation site is unable to rescue LTP in RIM1alpha knockout neurons but selectively suppresses LTP in wild-type neurons. Our findings suggest that PKA-mediated phosphorylation of the active zone protein RIM1alpha at a single N-terminal site induces presynaptic LTP.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Eastern Virginia Med Sch, Dept Pathol & Anat, Norfolk, VA 23501 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Eastern Virginia Medical School; Johns Hopkins University	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	thomas.sudhof@utsouthwestern.edu; dlinden@jhmi.edu	Schoch, Susanne/F-7741-2012		NIMH NIH HHS [MH01590, MH51106, MH01505] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051106, R37MH051106, R29MH051106] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; Bear MF, 2001, SYNAPSES, P455; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; Castillo PE, 2002, NATURE, V415, P327, DOI 10.1038/415327a; Castro-Alamancos MA, 1999, J NEUROSCI, V19, P9090, DOI 10.1523/JNEUROSCI.19-20-09090.1999; Chavis P, 1998, NEURON, V20, P773, DOI 10.1016/S0896-6273(00)81015-6; Coppola T, 2001, J BIOL CHEM, V276, P32756, DOI 10.1074/jbc.M100929200; Daly C, 1997, J NEUROSCI, V17, P2365; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HAMIYA H, 2002, J NEUROSCI, V22, P10524; Hansel C, 2001, NAT NEUROSCI, V4, P467, DOI 10.1038/87419; Hibino H, 2002, NEURON, V34, P411, DOI 10.1016/S0896-6273(02)00667-0; HIRANO T, 1991, SYNAPSE, V7, P321, DOI 10.1002/syn.890070408; Hosaka M, 1999, NEURON, V24, P377, DOI 10.1016/S0896-6273(00)80851-X; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; Kapur A, 2001, NEUROSCIENCE, V107, P59, DOI 10.1016/S0306-4522(01)00293-7; KATSUKI H, 1991, NEUROSCI RES, V12, P393, DOI 10.1016/0168-0102(91)90070-F; Lev-Ram V, 2002, P NATL ACAD SCI USA, V99, P8389, DOI 10.1073/pnas.122206399; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; Linden DJ, 2001, P NATL ACAD SCI USA, V98, P14066, DOI 10.1073/pnas.241384598; Linden DJ, 1998, J NEUROPHYSIOL, V79, P3151, DOI 10.1152/jn.1998.79.6.3151; Linden DJ, 1997, NEURON, V18, P983, DOI 10.1016/S0896-6273(00)80337-2; Linden DJ, 1999, J NEUROSCI, V19, P10221; Lonart G, 1998, J NEUROSCI, V18, P634; Lonart G, 2002, TRENDS NEUROSCI, V25, P329, DOI 10.1016/S0166-2236(02)02193-8; Lonart G, 1998, NEURON, V21, P1141, DOI 10.1016/S0896-6273(00)80631-5; LopezGarcia JC, 1996, P NATL ACAD SCI USA, V93, P4712, DOI 10.1073/pnas.93.10.4712; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; Medina JF, 2000, NAT NEUROSCI, V3, P1205, DOI 10.1038/81486; Medina JF, 2000, J NEUROSCI, V20, P5516, DOI 10.1523/JNEUROSCI.20-14-05516.2000; Mellor J, 2001, NAT NEUROSCI, V4, P125, DOI 10.1038/83941; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; Ohtsuka T, 2002, J CELL BIOL, V158, P577, DOI 10.1083/jcb.200202083; Raymond JL, 1996, SCIENCE, V272, P1126, DOI 10.1126/science.272.5265.1126; REGEHR WG, 1991, NEURON, V7, P451, DOI 10.1016/0896-6273(91)90297-D; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; Salin PA, 1996, NEURON, V16, P797, DOI 10.1016/S0896-6273(00)80099-9; Schluter OM, 1999, J NEUROSCI, V19, P5834, DOI 10.1523/JNEUROSCI.19-14-05834.1999; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Sheng M, 2002, SCIENCE, V298, P776, DOI 10.1126/science.1075333; SHIBUKI K, 1992, NEUROREPORT, V3, P231, DOI 10.1097/00001756-199203000-00003; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spencer JP, 2002, NEUROSCI LETT, V329, P217, DOI 10.1016/S0304-3940(02)00659-6; SPILLANE DM, 1995, NEUROPHARMACOLOGY, V34, P1573, DOI 10.1016/0028-3908(95)00107-H; Storm DR, 1998, NEURON, V20, P1199, DOI 10.1016/S0896-6273(00)80500-0; Tong G, 1996, NEURON, V16, P1147, DOI 10.1016/S0896-6273(00)80141-5; Villacres EC, 1998, J NEUROSCI, V18, P3186; Wang XL, 2001, J BIOL CHEM, V276, P32480, DOI 10.1074/jbc.M103337200; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wang Y, 2003, GENOMICS, V81, P126, DOI 10.1016/S0888-7543(02)00024-1; Wang Y, 2002, P NATL ACAD SCI USA, V99, P14464, DOI 10.1073/pnas.182532999; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WEISSKOPF MG, 1995, NATURE, V376, P256, DOI 10.1038/376256a0; WHITTAKER VP, 1993, J NEUROCYTOL, V22, P735, DOI 10.1007/BF01181319; XIANG ZX, 1994, J NEUROPHYSIOL, V71, P2552, DOI 10.1152/jn.1994.71.6.2552; Yeckel MF, 1999, NAT NEUROSCI, V2, P625, DOI 10.1038/10180; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; Zenisek D, 2000, NEURON, V25, P229, DOI 10.1016/S0896-6273(00)80885-5; Zhen M, 1999, NATURE, V401, P371, DOI 10.1038/43886	64	174	184	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 3	2003	115	1					49	60		10.1016/S0092-8674(03)00727-X	http://dx.doi.org/10.1016/S0092-8674(03)00727-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14532002	Bronze			2022-12-28	WOS:000185815500008
J	Pagliarini, RA; Xu, T				Pagliarini, RA; Xu, T			A genetic screen in Drosophila for metastatic behavior	SCIENCE			English	Article							E-CADHERIN; ECTOPIC EXPRESSION; CELL REARRANGEMENT; GROWTH; CANCER; DEATH; SUPPRESSORS; BAZOOKA; ENCODES; MOSAICS	A genetic screen was designed in Drosophila to interrogate its genome for mutations sufficient to cause noninvasive tumors of the eye disc to invade neighboring or distant tissues. We found that cooperation between oncogenic Ras(V12) expression and inactivation of any one of a number of genes affecting cell polarity leads to metastatic behavior, including basement membrane degradation, loss of E-cadherin expression, migration, invasion, and secondary tumor formation. Inactivation of these cell polarity genes cannot drive metastatic behavior alone or in combination with other tumor-initiating alterations. These findings suggest that the oncogenic background of tissues makes a distinct contribution toward metastatic development.	Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Genet,Boyer Ctr Mol Med, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University	Xu, T (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Genet,Boyer Ctr Mol Med, 295 Congress Ave, New Haven, CT 06536 USA.	tian.xu@yale.edu			NATIONAL CANCER INSTITUTE [R01CA069408] Funding Source: NIH RePORTER; NCI NIH HHS [CA69408] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Geneva JL, 2000, DEV BIOL, V221, P181, DOI 10.1006/dbio.2000.9671; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; HAY BA, 1994, DEVELOPMENT, V120, P2121; Ito K, 1997, DEVELOPMENT, V124, P761; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Karim FD, 1998, DEVELOPMENT, V125, P1; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; Newsome TP, 2000, DEVELOPMENT, V127, P851; Pagliarini Raymond A, 2003, Methods Mol Biol, V223, P349; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Potter CJ, 2000, TRENDS GENET, V16, P33, DOI 10.1016/S0168-9525(99)01878-8; Prober DA, 2000, CELL, V100, P435, DOI 10.1016/S0092-8674(00)80679-0; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Tepass U, 1996, GENE DEV, V10, P672, DOI 10.1101/gad.10.6.672; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; XU T, 1993, DEVELOPMENT, V117, P1223; XU TA, 1995, DEVELOPMENT, V121, P1053	34	433	442	3	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 14	2003	302	5648					1227	1231		10.1126/science.1088474	http://dx.doi.org/10.1126/science.1088474			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14551319				2022-12-28	WOS:000186544300059
J	Archer, D				Archer, D			Who threw that snowball?	SCIENCE			English	Editorial Material							ATMOSPHERIC CO2		Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA	University of Chicago	Archer, D (corresponding author), Univ Chicago, Dept Geophys Sci, 5734 S Ellis Ave, Chicago, IL 60637 USA.	archer@geosci.uchicago.edu	Archer, David/K-7371-2012	Archer, David/0000-0002-4523-7912				Archer D, 1998, GLOBAL BIOGEOCHEM CY, V12, P259, DOI 10.1029/98GB00744; Berner RA, 2001, AM J SCI, V301, P182, DOI 10.2475/ajs.301.2.182; Broecker WS, 1987, GLOBAL BIOGEOCHEM CY, V1, P15, DOI 10.1029/GB001i001p00015; DOYLE AC, 1992, STRAND MAG       DEC; Hoffman PF, 2002, TERRA NOVA, V14, P129, DOI 10.1046/j.1365-3121.2002.00408.x; Kaufman AJ, 1997, P NATL ACAD SCI USA, V94, P6600, DOI 10.1073/pnas.94.13.6600; Ridgwell AJ, 2003, SCIENCE, V302, P859, DOI 10.1126/science.1088342; Urey H.C., 1952, PLANETS THEIR ORIGIN, DOI [10.1063/1.3067687, DOI 10.1063/1.3067687]; WALKER JCG, 1981, J GEOPHYS RES-OCEANS, V86, P9776, DOI 10.1029/JC086iC10p09776	9	2	3	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	2003	302	5646					791	792		10.1126/science.1091464	http://dx.doi.org/10.1126/science.1091464			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593155				2022-12-28	WOS:000186258000025
J	Artsimovitch, I; Chu, C; Lynch, AS; Landick, R				Artsimovitch, I; Chu, C; Lynch, AS; Landick, R			A new class of bacterial RNA polymerase inhibitor affects nucleotide addition	SCIENCE			English	Article							3.3 ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; TRANSCRIPTION; DNA; ELONGATION; COMPLEX; INITIATION; MECHANISM; MUTATIONS	RNA polymerase (RNAP) is the central enzyme of gene expression. Despite availability of crystal structures, details of its nucleotide addition cycle remain obscure. We describe bacterial RNAP inhibitors (the CBR703 series) whose properties illuminate this mechanism. These compounds inhibit known catalytic activities of RNAP (nucleotide addition, pyrophosphorolysis, and Gre-stimulated transcript cleavage) but not translocation of RNA or DNA when translocation is uncoupled from catalysis. CBR703-resistance substitutions occur on an outside surface of RNAP opposite its internal active site. We propose that CBR703 compounds inhibit nucleotide addition allosterically by hindering movements of active site structures that are linked to the CBR703 binding site through a bridge helix.	Cumbre Inc, Dallas, TX 75235 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Lynch, AS (corresponding author), Cumbre Inc, 1502 Viceroy Dr, Dallas, TX 75235 USA.	simon.lynch@cumbre.net; landick@bact.wisc.edu	Artsimovitch, Irina/L-3467-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038660, R29GM038660, R01GM038660] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38660] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIVAZASHVILI VA, 1982, MOL BIOL, V15, P711; Artsimovitch I, 2000, J BACTERIOL, V182, P6027, DOI 10.1128/JB.182.21.6027-6035.2000; Artsimovitch I, 2000, P NATL ACAD SCI USA, V97, P7090, DOI 10.1073/pnas.97.13.7090; Artsimovitch I, 2003, J BIOL CHEM, V278, P12344, DOI 10.1074/jbc.M211214200; ARTSIMOVITCH I, UNPUB; Bushnell DA, 2002, P NATL ACAD SCI USA, V99, P1218, DOI 10.1073/pnas.251664698; Campbell EA, 2001, CELL, V104, P901, DOI 10.1016/S0092-8674(01)00286-0; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Darst SA, 2002, P NATL ACAD SCI USA, V99, P4296, DOI 10.1073/pnas.052054099; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Ederth J, 2002, J BIOL CHEM, V277, P37456, DOI 10.1074/jbc.M207038200; Epshtein V, 2002, MOL CELL, V10, P623, DOI 10.1016/S1097-2765(02)00640-8; FENG GH, 1994, J BIOL CHEM, V269, P22282; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; PALANGAT M, UNPUB; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; Santangelo TJ, 2003, GENE DEV, V17, P1281, DOI 10.1101/gad.1082103; SEVERINOV K, 1995, J BIOL CHEM, V270, P23926, DOI 10.1074/jbc.270.41.23926; SMAGOWICZ WJ, 1978, NUCLEIC ACIDS RES, V5, P1919, DOI 10.1093/nar/5.6.1919; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816; Yuzenkova J, 2002, J BIOL CHEM, V277, P50867, DOI 10.1074/jbc.M209425200; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	27	81	84	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	2003	302	5645					650	654		10.1126/science.1087526	http://dx.doi.org/10.1126/science.1087526			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	735MV	14576436				2022-12-28	WOS:000186119900061
J	Russell, MJ				Russell, MJ			The importance of being alkaline	SCIENCE			English	Editorial Material							ORIGIN; PEPTIDES; LIFE		Scottish Univ Environm Res Ctr, Glasgow G75 0QF, Lanark, Scotland	Scottish Universities Research & Reactor Center	Russell, MJ (corresponding author), Scottish Univ Environm Res Ctr, Glasgow G75 0QF, Lanark, Scotland.							Ferris JP, 2002, ORIGINS LIFE EVOL B, V32, P311, DOI 10.1023/A:1020543312109; Geptner A, 2002, CLAY CLAY MINER, V50, P174, DOI 10.1346/000986002760832775; Hanczyc MM, 2003, SCIENCE, V302, P618, DOI 10.1126/science.1089904; Huber C, 2003, SCIENCE, V301, P938, DOI 10.1126/science.1086501; Huber C, 1998, SCIENCE, V281, P670, DOI 10.1126/science.281.5377.670; Kelley DS, 2001, NATURE, V412, P145, DOI 10.1038/35084000; Martin W, 2003, PHILOS T R SOC LON B, V358, P27; Mellersh A, 2000, ORIGINS LIFE EVOL B, V30, P3, DOI 10.1023/A:1006620421068; MELLERSH AR, 1993, ORIGINS LIFE EVOL B, V23, P261, DOI 10.1007/BF01581903; Russell MJ, 2002, GEOCHEM NEWS, V113, P6; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452; Woese C.R., 1967, GENETIC CODE MOL BAS	12	62	65	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					580	581		10.1126/science.1091765	http://dx.doi.org/10.1126/science.1091765			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576411	Green Accepted			2022-12-28	WOS:000186119900035
J	Hussey, NE; Abdel-Jawad, M; Carrington, A; Mackenzie, AP; Balicas, L				Hussey, NE; Abdel-Jawad, M; Carrington, A; Mackenzie, AP; Balicas, L			A coherent three-dimensional Fermi surface in a high-transition-temperature superconductor	NATURE			English	Article							ANGULAR MAGNETORESISTANCE OSCILLATIONS; NORMAL-STATE MAGNETOTRANSPORT; CUPRATE SUPERCONDUCTORS; TL2BA2CUO6; TRANSPORT; DEPENDENCE; FIELD; SPECTRA; VORTEX	All conventional metals are known to possess a three-dimensional Fermi surface, which is the locus in reciprocal space of the long-lived electronic excitations that govern their electronic properties at low temperatures. These excitations should have well-defined momenta with components in all three dimensions. The high-transition-temperature (high-T-c) copper oxide superconductors have unusual, highly two-dimensional properties above the superconducting transition(1). This, coupled with a lack of unambiguous evidence for a three-dimensional Fermi surface, has led to many new and exotic models for the underlying electronic ground state(2). Here we report the observation of polar angular magnetoresistance oscillations(3) in the overdoped superconductor Tl2Ba2CuO6+delta in high magnetic fields, which firmly establishes the existence of a coherent three-dimensional Fermi surface. Analysis of the oscillations reveals that at certain symmetry points, however, this surface is strictly two-dimensional. This striking form of the Fermi surface topography, long-predicted by electronic band structure calculations(4), provides a natural explanation for a wide range of anisotropic properties both in the normal(5,6) and superconducting states(7-9). Our data reveal that, despite their extreme electrical anisotropy, the high-T-c materials at high doping levels can be understood within a framework of conventional three-dimensional metal physics.	Univ Bristol, HH Wills Phys Lab, Bristol BS8 1TL, Avon, England; Univ St Andrews, Sch Phys & Astron, St Andrews KY16 9SS, Fife, Scotland; Florida State Univ, Natl High Magnet Field Lab, Tallahassee, FL 32306 USA	University of Bristol; University of St Andrews; State University System of Florida; Florida State University	Hussey, NE (corresponding author), Univ Bristol, HH Wills Phys Lab, Tyndall Ave, Bristol BS8 1TL, Avon, England.	n.e.hussey@bristol.ac.uk	Mackenzie, Andrew P/K-6742-2015; Abdel Jawad, Majed/C-5730-2016; Abdel-Jawad, Majed/ABE-3246-2020; Hussey, Nigel E/F-9699-2015; Balicas, Luis/A-3110-2008	Mackenzie, Andrew P/0000-0001-8000-4949; Abdel Jawad, Majed/0000-0003-4591-6998; Abdel-Jawad, Majed/0000-0003-4591-6998; Carrington, Antony/0000-0001-8624-6148; Hussey, Nigel/0000-0002-8590-8979				Andersen OK, 1995, J PHYS CHEM SOLIDS, V56, P1573, DOI 10.1016/0022-3697(95)00269-3; Bergemann C, 2000, PHYS REV LETT, V84, P2662, DOI 10.1103/PhysRevLett.84.2662; Damascelli A, 2003, REV MOD PHYS, V75, P473, DOI 10.1103/RevModPhys.75.473; Dragulescu A, 1999, PHYS REV B, V60, P6312, DOI 10.1103/PhysRevB.60.6312; Franz M, 1999, PHYS REV B, V60, P3581, DOI 10.1103/PhysRevB.60.3581; Hussey NE, 2002, ADV PHYS, V51, P1685, DOI 10.1080/00018730210164638; Hussey NE, 2003, EUR PHYS J B, V31, P495, DOI 10.1140/epjb/e2003-00059-9; Hussey NE, 1996, PHYS REV LETT, V76, P122, DOI 10.1103/PhysRevLett.76.122; Ioffe LB, 1998, PHYS REV B, V58, P11631, DOI 10.1103/PhysRevB.58.11631; KARTSOVNIK MV, 1992, J PHYS I, V2, P89, DOI 10.1051/jp1:1992125; KUMAR N, 1992, PHYS REV B, V45, P5001, DOI 10.1103/PhysRevB.45.5001; Mackenzie AP, 1996, PHYS REV B, V53, P5848, DOI 10.1103/PhysRevB.53.5848; MACKENZIE AP, 1993, PHYS REV LETT, V71, P1238, DOI 10.1103/PhysRevLett.71.1238; McKenzie RH, 1998, PHYS REV LETT, V81, P4492, DOI 10.1103/PhysRevLett.81.4492; Nakamae S, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.100502; ONG NP, 1994, PHYSICA C, V235, P221, DOI 10.1016/0921-4534(94)91353-6; Orenstein J, 2000, SCIENCE, V288, P468, DOI 10.1126/science.288.5465.468; Pavarini E, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.047003; Proust C, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.147003; SINGH DJ, 1992, PHYSICA C, V203, P193, DOI 10.1016/0921-4534(92)90526-I; TAMASAKU K, 1994, PHYS REV LETT, V72, P3088, DOI 10.1103/PhysRevLett.72.3088; Tyler A. W., 1997, THESIS U CAMBRIDGE; Tyler AW, 1998, PHYS REV B, V57, pR728, DOI 10.1103/PhysRevB.57.R728; van der Marel D, 1999, PHYS REV B, V60, pR765, DOI 10.1103/PhysRevB.60.R765; Wosnitza J, 1996, J PHYS I, V6, P1597, DOI 10.1051/jp1:1996177; Wu CJ, 2000, PHYS REV B, V62, P14427, DOI 10.1103/PhysRevB.62.14427; Xiang T, 1996, PHYS REV LETT, V77, P4632, DOI 10.1103/PhysRevLett.77.4632; YAMAJI K, 1989, J PHYS SOC JPN, V58, P1520, DOI 10.1143/JPSJ.58.1520; Ziman J. M., 1972, PRINCIPLES THEORY SO; [No title captured]	30	243	246	3	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 23	2003	425	6960					814	817		10.1038/nature01981	http://dx.doi.org/10.1038/nature01981			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574406				2022-12-28	WOS:000186118500039
J	De Maeseneer, JM; van Driel, ML; Green, LA; van Weel, C				De Maeseneer, JM; van Driel, ML; Green, LA; van Weel, C			The need for research in primary care	LANCET			English	Article							INTERPRETING SYSTEMATIC REVIEWS; CLINICAL-DIAGNOSIS; GENERAL-PRACTICE; CONTROLLED TRIAL; DISEASE; GUIDES; METAANALYSIS; QUALITY; ECOLOGY; BASE	Making evidence from scientific studies available to clinical practice has been expected to directly improve quality of care, but this expectation has not been realised. The notion of quality of care is complex, and quality improvement needs medical, contextual, and policy evidence. In primary care, research is needed that takes into account the specific characteristics of its population and the presentation and prevalence of illness and disease. The context of the doctor-patient encounter plays a major part, and needs better understanding. At the policy level, issues of equity must be addressed. The knowledge base for family practice must be expanded by integration of multiple methods of comprehension, so we can bridge the gap between evidence and practice.	Univ Ghent, Dept Gen Practice & Primary Hlth Care, B-9000 Ghent, Belgium; Robert Graham Ctr, Washington, DC USA; Univ Med Ctr, Dept Gen Practice, Nijmegen, Netherlands	Ghent University; Radboud University Nijmegen	De Maeseneer, JM (corresponding author), Univ Ghent, Dept Gen Practice & Primary Hlth Care, B-9000 Ghent, Belgium.	jan.demaeseneer@ugent.be	Greiver, Michelle/N-8764-2015; van Driel, Mieke/D-1167-2011; van Weel, Chris/D-4375-2009	Greiver, Michelle/0000-0001-8957-0285; van Driel, Mieke/0000-0003-1711-9553; van Weel, Chris/0000-0003-3653-4701				Bauchner H, 1997, PEDIATRICS, V99, P876, DOI 10.1542/peds.99.6.876; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; Bremberg S, 2000, FAM PRACT, V17, P124, DOI 10.1093/fampra/17.2.124; Christiaens TCM, 2002, BRIT J GEN PRACT, V52, P729; Cochrane A. L, 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; De Sutter AI, 2002, J FAM PRACTICE, V51, P317; DEMAESENEER J, 1993, HUISARTS WET, V36, P437; DEMEYERE M, 1992, EUR J CLIN PHARMACOL, V43, P581, DOI 10.1007/BF02284954; Deveugele M, 2002, BRIT MED J, V325, P472, DOI 10.1136/bmj.325.7362.472; Di Blasi Z, 2001, LANCET, V357, P757, DOI 10.1016/S0140-6736(00)04169-6; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Egger M, 1997, BMJ-BRIT MED J, V315, P1533, DOI 10.1136/bmj.315.7121.1533; Egger M, 1997, BMJ-BRIT MED J, V315, P1371, DOI 10.1136/bmj.315.7119.1371; Fishbein M, 2000, AIDS CARE, V12, P273, DOI 10.1080/09540120050042918; Green LA, 2001, NEW ENGL J MED, V344, P2021, DOI 10.1056/NEJM200106283442611; Green LA, 2001, BRIT MED J, V322, P567, DOI 10.1136/bmj.322.7286.567; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Harris JM, 1996, ANN INTERN MED, V124, P838, DOI 10.7326/0003-4819-124-9-199605010-00009; Hofmann P A, 1993, Jt Comm J Qual Improv, V19, P235; Homer CJ, 1997, NEW ENGL J MED, V337, P1461, DOI 10.1056/NEJM199711133372010; Jadad AR, 1998, ARCH PEDIAT ADOL MED, V152, P812; Karter AJ, 2002, JAMA-J AM MED ASSOC, V287, P2519, DOI 10.1001/jama.287.19.2519; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; Klassen TP, 1998, ARCH PEDIAT ADOL MED, V152, P700; Knottnerus JA, 2002, BMJ-BRIT MED J, V324, P477, DOI 10.1136/bmj.324.7335.477; LANIER DC, IN PRESS LANCET; Lannin DR, 1998, JAMA-J AM MED ASSOC, V279, P1801, DOI 10.1001/jama.279.22.1801; Lohr KN, 1990, MEDICARE STRATEGY QU; MacKay DN, 1996, J GEN INTERN MED, V11, P557, DOI 10.1007/BF02599608; Maynard A, 1997, LANCET, V349, P126, DOI 10.1016/S0140-6736(96)05153-7; MCWHINNEY IR, 2000 WONC EUR REG C; Melmed RN, 1996, ISRAEL J MED SCI, V32, P211; Moher D, 1998, ARCH PEDIAT ADOL MED, V152, P915; Mold J W, 1991, Fam Med, V23, P46; Moynihan R, 2003, BRIT MED J, V326, P45, DOI 10.1136/bmj.326.7379.45; ONG LML, 1995, SOC SCI MED, V40, P903, DOI 10.1016/0277-9536(94)00155-M; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; Ramsey SD, 2000, CHEST, V117, P33; Richards JP, 1997, BRIT MED J, V314, P525, DOI 10.1136/bmj.314.7079.525; Stange KC, 2001, FAM MED, V33, P286; SUNAERT P, 1998, HUISARTS WET, V41, P193; TASCHE M, 2001, HUISARTS WET, V44, P91; van den Akker M, 1998, J CLIN EPIDEMIOL, V51, P367, DOI 10.1016/S0895-4356(97)00306-5; van Weel C, 2001, LANCET, V357, P733, DOI 10.1016/S0140-6736(00)04176-3; Van Weel C., 1992, FUNCTIONAL STATUS AS; VANDERVELDEN J, 1998, HUISARTS WET, V41, P165; VANDRIEL M, 2001, EUR J GEN PRACT, V7, P4; VANWEEL C, 1996, EUR J GEN PRACT, V2, P17; WALLSTON BS, 1976, J CONSULT CLIN PSYCH, V44, P580, DOI 10.1037/0022-006X.44.4.580; WEBSTER F, 1995, THEORIES INFORMATION; Wensing M, 2000, EUROPEAN J GEN PRACT, V6, P82, DOI DOI 10.3109/13814780009069953; Westert GP, 2001, EUR J PUBLIC HEALTH, V11, P365, DOI 10.1093/eurpub/11.4.365; WHITE KL, 1961, NEW ENGL J MED, V265, P885, DOI 10.1056/NEJM196111022651805; White KL, 2000, LANCET, V355, P1904, DOI 10.1016/S0140-6736(00)02304-7; 2001, DRUG THER B, V39, P37	57	112	116	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	2003	362	9392					1314	1319		10.1016/S0140-6736(03)14576-X	http://dx.doi.org/10.1016/S0140-6736(03)14576-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	734CD	14575979				2022-12-28	WOS:000186036900027
J	Kisinza, WN; McCall, PJ; Mitani, H; Talbert, A; Fukunaga, M				Kisinza, WN; McCall, PJ; Mitani, H; Talbert, A; Fukunaga, M			A newly identified tick-borne Borrelia species and relapsing fever in Tanzania	LANCET			English	Article								Tick-borne relapsing fever caused by the spirochaete Borrelia duttonii is a common cause of serious illness in central Tanzania. Screening of Ornithodoros sp ticks from infested houses for the presence of B duttonii had detected a previously unidentified species of Borrelia. We investigated whether this species infected the human population in a central Tanzanian village, by use of blood slide examination and PCR. PCR was twice as sensitive in detection of infections, showing Borrelia sp in six (11%) of 54 children with fever, and in 13 (4%) of 307 otherwise healthy children. Genotyping Borrelia from 17 infections identified Borrelia duttonii and an unnamed species. Our findings show that the newly discovered species is a causal agent of tick-borne relapsing fever.	Univ Liverpool, Liverpool Sch Trop Med, Vector Res Grp, Liverpool L3 5QA, Merseyside, England; Natl Inst Med Res, Dar Es Salaam, Tanzania; Fukuyama Univ, Fac Pharm & Pharmaceut Sci, Mol Microbiol Lab, Hiroshima, Japan; Mvumi Hosp, Dodoma, Tanzania	Liverpool School of Tropical Medicine; University of Liverpool; National Institute of Medical Research; Fukuyama University	McCall, PJ (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Vector Res Grp, Pembroke Pl, Liverpool L3 5QA, Merseyside, England.			McCall, Philip J/0000-0002-0007-3985				BARCLAY AJG, 1990, T ROY SOC TROP MED H, V84, P852, DOI 10.1016/0035-9203(90)90106-O; Dennis DT, 1998, ZOONOSES, P17; Fukunaga M, 2001, VECTOR-BORNE ZOONOT, V1, P331, DOI 10.1089/15303660160025949; Talbert A, 1998, T ROY SOC TROP MED H, V92, P251, DOI 10.1016/S0035-9203(98)90998-1; TRAPE JF, 1991, LANCET, V337, P473, DOI 10.1016/0140-6736(91)93404-W	5	38	40	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 18	2003	362	9392					1283	1284		10.1016/S0140-6736(03)14609-0	http://dx.doi.org/10.1016/S0140-6736(03)14609-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575974				2022-12-28	WOS:000186036900013
J	Bradley, RS; Hughes, MK; Diaz, HF				Bradley, RS; Hughes, MK; Diaz, HF			Climate in Medieval time	SCIENCE			English	Editorial Material							ICE CORE; VOLCANISM; RECORD		Univ Massachusetts, Dept Geosci, Climate Syst Res Ctr, Amherst, MA 01003 USA; Univ Arizona, Tree Ring Res Lab, Tucson, AZ 85721 USA; NOAA, Climate Diagnost Ctr, Off Atmospher Res, Boulder, CO 80303 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Arizona; National Oceanic Atmospheric Admin (NOAA) - USA	Bradley, RS (corresponding author), Univ Massachusetts, Dept Geosci, Climate Syst Res Ctr, Amherst, MA 01003 USA.		Hughes, Malcolm/F-3350-2014; Bradley, Raymond S/P-9358-2015	Hughes, Malcolm/0000-0003-1062-3167; Bradley, Raymond S/0000-0002-4032-9519				Bard E, 2000, TELLUS B, V52, P985, DOI 10.1034/j.1600-0889.2000.d01-7.x; Cole-Dai JH, 2000, J GEOPHYS RES-ATMOS, V105, P24431, DOI 10.1029/2000JD900254; Haug GH, 2001, SCIENCE, V293, P1304, DOI 10.1126/science.1059725; HUGHES MK, 1994, CLIMATIC CHANGE, V26, P109, DOI 10.1007/BF01092410; LAMB HH, 1963, UNESCO ARID ZONE RES, V20, P125; Lamb HH, 1965, PALAEOGEOGR PALAEOCL, V1, P13, DOI DOI 10.1016/0031-0182(65)90004-0; Mann M. E., 2003, EOS, V84, P256, DOI DOI 10.1029/2003EO270003; Mann ME, 1999, GEOPHYS RES LETT, V26, P759, DOI 10.1029/1999GL900070; ROBOCK A, 1992, GEOPHYS RES LETT, V19, P2405, DOI 10.1029/92GL02627; Shindell DT, 2001, SCIENCE, V294, P2149, DOI 10.1126/science.1064363; Soon W, 2003, CLIM RES, V23, P89, DOI 10.3354/cr023089; STINE S, 1994, NATURE, V369, P546, DOI 10.1038/369546a0; ZIELINSKI GA, 1994, SCIENCE, V264, P948, DOI 10.1126/science.264.5161.948	13	343	366	2	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					404	405		10.1126/science.1090372	http://dx.doi.org/10.1126/science.1090372			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14563996				2022-12-28	WOS:000185963200029
J	Shmerling, RH				Shmerling, RH			Autoantibodies in systemic lupus erythematosus - There before you know it	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Beth Israel Deaconess Med Ctr, Dept Med, Div Rheumatol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Shmerling, RH (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Rheumatol, Boston, MA 02215 USA.			Shmerling, Robert/0000-0001-7560-1589					0	38	40	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 16	2003	349	16					1499	1500		10.1056/NEJMp038142	http://dx.doi.org/10.1056/NEJMp038142			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	731ZM	14561791				2022-12-28	WOS:000185916400003
J	Dickinson, D; Raynor, DKT				Dickinson, D; Raynor, DKT			Ask the patients - they may want to know more than you think	BRITISH MEDICAL JOURNAL			English	Article							INFORMATION; MEDICINES		Consumation, Consumer Informat Design, London SW17 7QW, England; Univ Leeds, Pharm Practice & Med Management, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Dickinson, D (corresponding author), Consumation, Consumer Informat Design, 53 Hosack Rd, London SW17 7QW, England.		Sturchio, Jeffrey/GWZ-3472-2022					Berry DC, 1997, PSYCHOL HEALTH, V12, P467, DOI 10.1080/08870449708406723; Berry DC, 2002, LANCET, V359, P853, DOI 10.1016/S0140-6736(02)07923-0; Blenkinsopp A, 1998, BRIT MED J, V317, P413; Coulter A, 1999, BRIT MED J, V318, P318, DOI 10.1136/bmj.318.7179.318; Dickinson D, 2001, PATIENT EDUC COUNS, V43, P147, DOI 10.1016/S0738-3991(00)00156-7; RAYNOR DK, IN PRESS PATIENT ED	6	70	73	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					861	861		10.1136/bmj.327.7419.861-a	http://dx.doi.org/10.1136/bmj.327.7419.861-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732BP	14551106	Green Accepted, Green Published			2022-12-28	WOS:000185921200028
J	Landskron, K; Hatton, BD; Perovic, DD; Ozin, GA				Landskron, K; Hatton, BD; Perovic, DD; Ozin, GA			Periodic mesoporous organosilicas containing interconnected [Si(CH2)](3) rings	SCIENCE			English	Article							ORGANIC GROUPS; FRAMEWORKS; SIEVES; NMR	A periodic mesoporous organosilica composed of interconnected three-ring [Si(CH (2))](3) units built of three SiO2(CH2)(2) tetrahedral subunits is reported. It represents the archetype of a previously unknown class of nanocomposite materials in which two bridging organic groups are bound to each silicon atom. It can be obtained with powder and oriented film morphologies. The nanocomposite is self-assembled from the cyclic three-ring silsesquioxane [(EtO)(2)Si(CH2)](3) precursor and a surfactant mesophase to give a well-ordered mesoporous framework. Low dielectric constants and good mechanical stability of the films were measured, making this material interesting for microelectronic applications. Methylene group reactivity of the three-ring precursor provides entry to a family of nanocomposites, exemplified by the synthesis and self-assembly of [(EtO)(2)Si(CHR)][(EtO)(2)Si(CH2)](2) (where R indicates iodine, bromine, or an ethyl group).	Univ Toronto, Dept Chem, Mat Chem Res Grp, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Mat Sci & Engn, Toronto, ON M5S 3H6, Canada	University of Toronto; University of Toronto	Ozin, GA (corresponding author), Univ Toronto, Dept Chem, Mat Chem Res Grp, 80 St George St, Toronto, ON M5S 1A1, Canada.	gozin@alchemy.chem.utoronto.ca	Hatton, Benjamin D/I-4239-2012					Asefa T, 1999, NATURE, V402, P867, DOI 10.1038/47229; Asefa T, 2002, STUD SURF SCI CATAL, V141, P1; Asefa T, 2000, ANGEW CHEM INT EDIT, V39, P1808, DOI 10.1002/(SICI)1521-3773(20000515)39:10<1808::AID-ANIE1808>3.0.CO;2-G; BRONDANI DJ, 1993, TETRAHEDRON LETT, V34, P2111, DOI 10.1016/S0040-4039(00)60358-1; DORNE L, 1995, MAGNET RESON MED, V34, P548, DOI 10.1002/mrm.1910340411; Guo WP, 2003, CHEM MATER, V15, P2295, DOI 10.1021/cm0258023; Inagaki S, 1999, J AM CHEM SOC, V121, P9611, DOI 10.1021/ja9916658; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Litvinov VM, 2002, MACROMOLECULES, V35, P4356, DOI 10.1021/ma0119124; Melde BJ, 1999, CHEM MATER, V11, P3302, DOI 10.1021/cm9903935; Yamamoto K, 2003, SCIENCE, V300, P470, DOI 10.1126/science.1081019	11	203	224	2	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					266	269		10.1126/science.1084973	http://dx.doi.org/10.1126/science.1084973			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	730HT	14551432				2022-12-28	WOS:000185825900036
J	Petitti, DB				Petitti, DB			Combination estrogen-progestin oral contraceptives	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBRAL-VEIN-THROMBOSIS; VENOUS THROMBOEMBOLISM; MYOCARDIAL-INFARCTION; OVARIAN-CANCER; YOUNG-WOMEN; CERVICAL-CANCER; CARDIOVASCULAR-DISEASE; ETHINYL ESTRADIOL; UTERINE FIBROIDS; SINUS THROMBOSIS		Kaiser Permanente So Calif, Res & Evaluat Dept, Pasadena, CA 91188 USA	Kaiser Permanente	Petitti, DB (corresponding author), Kaiser Permanente So Calif, Res & Evaluat Dept, 100 S Los Robles,2nd Fl, Pasadena, CA 91188 USA.	diana.b.petitti@kp.org						[Anonymous], 2001, INT J GYNECOL OBSTET, V75, P93; [Anonymous], 1998, Contraception, V58, P262; Bloemenkamp KWM, 1999, ARCH INTERN MED, V159, P65, DOI 10.1001/archinte.159.1.65; Bloemenkamp KWM, 2000, ARCH INTERN MED, V160, P49, DOI 10.1001/archinte.160.1.49; Burkman RT, 2001, CLIN OBSTET GYNECOL, V44, P62, DOI 10.1097/00003081-200103000-00010; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; Chang CL, 1999, BMJ-BRIT MED J, V318, P13; Chang Jeani, 2003, MMWR Surveill Summ, V52, P1; Chiaffarino F, 1999, BRIT J OBSTET GYNAEC, V106, P857, DOI 10.1111/j.1471-0528.1999.tb08409.x; Cosmi B, 2003, ARCH INTERN MED, V163, P1105, DOI 10.1001/archinte.163.9.1105; Davis A, 2000, OBSTET GYNECOL, V96, P913, DOI 10.1016/S0029-7844(00)01029-2; de Bruijn SFTM, 1998, BRIT MED J, V316, P589, DOI 10.1136/bmj.316.7131.589; de Bruijn SFTM, 1998, LANCET, V351, P1404, DOI 10.1016/S0140-6736(05)79442-3; de Bruijn SFTM, 1998, BRIT MED J, V316, P822; DELGADORODRIGUEZ M, 1992, ACTA OBSTET GYN SCAN, V71, P368, DOI 10.3109/00016349209021075; Dunn N, 1999, BRIT MED J, V318, P1579, DOI 10.1136/bmj.318.7198.1579; Farley TMM, 1998, CONTRACEPTION, V57, P211, DOI 10.1016/S0010-7824(98)00019-5; Farmer RDT, 1997, LANCET, V349, P83, DOI 10.1016/S0140-6736(96)07496-X; Fernandez E, 1998, EPIDEMIOLOGY, V9, P295, DOI 10.1097/00001648-199805000-00014; Fu HS, 1999, FAM PLANN PERSPECT, V31, P56, DOI 10.2307/2991640; Gabrick DM, 2000, JAMA-J AM MED ASSOC, V284, P1791, DOI 10.1001/jama.284.14.1791; Hannaford P, 2000, DRUG SAFETY, V22, P361, DOI 10.2165/00002018-200022050-00004; Heimdal K, 2002, CANCER DETECT PREV, V26, P23, DOI 10.1016/S0361-090X(02)00004-1; Heinemann L A, 1998, Eur J Contracept Reprod Health Care, V3, P194; Heinemann LAJ, 1997, CONTRACEPTION, V56, P275, DOI 10.1016/S0010-7824(97)00158-3; Heinemann LAJ, 1998, CONTRACEPTION, V57, P29, DOI 10.1016/S0010-7824(97)00204-7; Hennessy S, 2001, CONTRACEPTION, V64, P125, DOI 10.1016/S0010-7824(01)00234-7; Kemmeren JM, 2001, BRIT MED J, V323, P131, DOI 10.1136/bmj.323.7305.131; Kemmeren JM, 2002, STROKE, V33, P1202, DOI 10.1161/01.STR.0000015345.61324.3F; Koulianos GT, 2000, CUTIS, V66, P281; Lewis MA, 1997, CONTRACEPTION, V56, P129, DOI 10.1016/S0010-7824(97)00118-2; Lewis MA, 1996, BRIT MED J, V312, P88; Lidegaard O, 1998, CONTRACEPTION, V57, P291, DOI 10.1016/S0010-7824(98)00033-X; Marchbanks PA, 2002, NEW ENGL J MED, V346, P2025, DOI 10.1056/NEJMoa013202; Martinelli I, 1998, NEW ENGL J MED, V338, P1793, DOI 10.1056/NEJM199806183382502; Martinelli I, 1998, LANCET, V352, P326, DOI 10.1016/S0140-6736(05)60307-8; Milman N, 1998, ANN HEMATOL, V77, P13, DOI 10.1007/s002770050405; Modan B, 2001, NEW ENGL J MED, V345, P235, DOI 10.1056/NEJM200107263450401; Moreno V, 2002, LANCET, V359, P1085, DOI 10.1016/S0140-6736(02)08150-3; Narod SA, 2002, JNCI-J NATL CANCER I, V94, P1773, DOI 10.1093/jnci/94.23.1773; Narod SA, 1998, NEW ENGL J MED, V339, P424, DOI 10.1056/NEJM199808133390702; Ness RB, 2000, AM J EPIDEMIOL, V152, P233, DOI 10.1093/aje/152.3.233; Ngelangel C, 1998, JNCI-J NATL CANCER I, V90, P43, DOI 10.1093/jnci/90.1.43; Olson WH, 1998, INT J FERTIL WOMEN M, V43, P286; Parkin L, 2000, LANCET, V355, P2133, DOI 10.1016/S0140-6736(00)02382-5; POULTER NR, 1995, LANCET, V346, P1575; Poulter NR, 1996, LANCET, V348, P498; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1; RIVERA R, 1983, CONTRACEPTION, V27, P311, DOI 10.1016/0010-7824(83)90009-4; Royar J, 2001, INT J CANCER, V95, P370, DOI 10.1002/1097-0215(20011120)95:6<370::AID-IJC1065>3.0.CO;2-T; Samadi AR, 1996, AM J PUBLIC HEALTH, V86, P858, DOI 10.2105/AJPH.86.6.858; Schwartz SM, 1998, STROKE, V29, P2277, DOI 10.1161/01.STR.29.11.2277; Sidney S, 1998, CIRCULATION, V98, P1058, DOI 10.1161/01.CIR.98.11.1058; Spitzer WO, 1996, BRIT MED J, V312, P83; STAMPFER MJ, 1990, AM J OBSTET GYNECOL, V163, P285, DOI 10.1016/0002-9378(90)90569-S; Tanis BC, 2001, NEW ENGL J MED, V345, P1787, DOI 10.1056/NEJMoa003216; Thomas DB, 2001, AM J EPIDEMIOL, V153, P723, DOI 10.1093/aje/153.8.723; Thorneycroft IH, 1999, AM J OBSTET GYNECOL, V180, pS280, DOI 10.1016/S0002-9378(99)70719-2; Thorneycroft IH, 1999, CONTRACEPTION, V60, P255, DOI 10.1016/S0010-7824(99)00093-1; TZOURIO C, 1995, BMJ-BRIT MED J, V310, P830, DOI 10.1136/bmj.310.6983.830; Tzourio C, 2000, CEPHALALGIA, V20, P190, DOI 10.1046/j.1468-2982.2000.00041.x; Ursin G, 1997, CANCER RES, V57, P3678; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; Walker GR, 2002, AM J OBSTET GYNECOL, V186, P8, DOI 10.1067/mob.2002.118657; *WHO, 2000, IMPR ACC QUAL CAR FA, P1	65	179	191	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 9	2003	349	15					1443	1450		10.1056/NEJMcp030751	http://dx.doi.org/10.1056/NEJMcp030751			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729JF	14534338				2022-12-28	WOS:000185769500009
J	Turchin, A; Seifter, JL; Seely, EW				Turchin, A; Seifter, JL; Seely, EW			Mind the gap	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMARY BILIARY-CIRRHOSIS; PSEUDOHYPONATREMIA; HYPONATREMIA; PATIENT		Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Nephrol, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Turchin, A (corresponding author), Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, 221 Longwood Ave, Boston, MA 02115 USA.	aturchin@partners.org						ALBRINK MJ, 1955, J CLIN INVEST, V34, P1483, DOI 10.1172/JCI103199; COAKLEY JC, 1986, PATHOLOGY, V18, P158, DOI 10.3109/00313028609090846; *COLL AM PATH, 1982, PART SUMM REP SURV 1; Croal BL, 1997, LANCET, V350, P1402, DOI 10.1016/S0140-6736(05)65181-1; FRIER BM, 1980, ARCH DIS CHILD, V55, P771, DOI 10.1136/adc.55.10.771; Fukagawa M, 2003, CURRENT MED DIAGNOSI, P839; HICKMAN PE, 1989, J CLIN PATHOL, V42, P167, DOI 10.1136/jcp.42.2.167; Ko GTC, 1997, ANN CLIN BIOCHEM, V34, P324, DOI 10.1177/000456329703400319; LEWIS JL, 1999, MERCK MANUAL DIAGNOS, P120; MANZATO E, 1976, J CLIN INVEST, V57, P1248, DOI 10.1172/JCI108393; Robinson A. G., 2003, WILLIAMS TXB ENDOCRI, P281; ROSENSON RS, 1990, GASTROENTEROLOGY, V98, P1351, DOI 10.1016/0016-5085(90)90356-6; VANECK WF, 1952, METABOLISM, V1, P383; WEISBERG LS, 1989, AM J MED, V86, P315, DOI 10.1016/0002-9343(89)90302-1	14	56	57	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 9	2003	349	15					1465	1469		10.1056/NEJMcps031078	http://dx.doi.org/10.1056/NEJMcps031078			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729JF	14534340				2022-12-28	WOS:000185769500011
J	Petersen, MC; Palmer, FB				Petersen, MC; Palmer, FB			Birthweight and risk for cerebral palsy	LANCET			English	Editorial Material									Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Memphis, TN 38105 USA; Univ Tennessee, Hlth Sci Ctr, Boling Ctr Dev Disabil, Memphis, TN 38105 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Petersen, MC (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Memphis, TN 38105 USA.							Cohen MM, 2003, AM J MED GENET C, V117C, P49, DOI 10.1002/ajmg.c.10013; Futagi Y, 2002, PEDIATR NEUROL, V27, P111, DOI 10.1016/S0887-8994(02)00395-8; Ircha G, 1999, Ginekol Pol, V70, P795; LAFOLLA AK, 1989, J PEDIATR, V114, P1004; Levy-Reis I, 2000, J NEUROIMAGING, V10, P225; NELSON KB, 1985, AM J DIS CHILD, V139, P1031, DOI 10.1001/archpedi.1985.02140120077032	6	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 4	2003	362	9390					1089	1090		10.1016/S0140-6736(03)14497-2	http://dx.doi.org/10.1016/S0140-6736(03)14497-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728HA	14550690				2022-12-28	WOS:000185710700003
J	Magee, LA; Cham, C; Waterman, EJ; Ohlsson, A; von Dadelszen, P				Magee, LA; Cham, C; Waterman, EJ; Ohlsson, A; von Dadelszen, P			Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MAGNESIUM-SULFATE; INTRAVENOUS ISRADIPINE; ACTIVE TREATMENT; ORAL NIFEDIPINE; DIHYDRALAZINE; MANAGEMENT; LABETALOL; PREECLAMPSIA; KETANSERIN; TRIAL	Objective To review outcomes in randomised controlled trials comparing hydralazine against other antihypertensives for severe hypertension in pregnancy. Study design Meta-analysis of randomised controlled trials (published between 1966 and September 2002) of short acting antihypertensives for severe hypertension in pregnancy. Independent data abstraction by two reviewers. Data were entered into RevMan software for analysis (fixed effects model, relative risk and 95% confidence interval); in a secondary analysis, risk difference was also calculated. Results Of 21 trials (893 women), eight compared hydralazine with nifedipine and five with labetalol. Hydralazine was associated with a trend towards less persistent severe hypertension than labetalol (relative risk 0.29 (95% confidence interval 0.08 to 1.04); two trials), but more severe hypertension than nifedipine or isradipine (1.41 (0.95 to 2.09); four trials); there was significant heterogeneity in outcome between trials and differences in methodological quality. Hydralazine was associated with more maternal hypotension (3.29 (1.50 to 7.13); 13 trials); more caesarean sections (1.30 (1.08 to 1.59); 14 trials); more placental abruption (4.17 (1.19 to 14.28); five trials); more maternal oliguria (4.00 (1.22 to 12.50); three trials); more adverse effects on fetal heart rate (2.04 (1.32 to 3.16); 12 trials); and more low Apgar scores at one minute (2.70 (1.27 to 5.88); three trials). For all but Apgar scores, analysis by risk difference showed heterogeneity between trials. Hydralazine was associated with more maternal side effects (1.50 (1.16 to 1.94); 12 trials) and with less neonatal bradycardia than labetalol (risk difference -0.24 (-0.42 to -0.06); three trials). Conclusions The results are not robust enough to guide clinical practice, but they do not support use of hydralazine as first line for treatment of severe hypertension in pregnancy. Adequately powered clinical trials are needed, with a comparison of labetalol and nifedipine showing the most promise.	BC Womens Hosp & Hlth Ctr, Vancouver, BC V6H 3N1, Canada; Univ British Columbia, Fac Med, Vancouver, BC V5Z 1M9, Canada; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada	University of British Columbia; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Magee, LA (corresponding author), BC Womens Hosp & Hlth Ctr, 4500 Oak St, Vancouver, BC V6H 3N1, Canada.	LMagee@cw.bc.ca	von Dadelszen, Peter/AAP-7480-2021	von Dadelszen, Peter/0000-0003-4136-3070				Aali BS, 2002, ACTA OBSTET GYN SCAN, V81, P25, DOI 10.1034/j.1600-0412.2002.810105.x; ASHE RG, 1987, S AFR MED J, V71, P354; BENAMI M, 1994, BRIT J OBSTET GYNAEC, V101, P262, DOI 10.1111/j.1471-0528.1994.tb13126.x; BHORAT IE, 1993, AM J OBSTET GYNECOL, V168, P1292, DOI 10.1016/0002-9378(93)90383-T; Bolte AC, 1999, AM J OBSTET GYNECOL, V180, P371, DOI 10.1016/S0002-9378(99)70216-4; Bolte AC, 1998, BRIT J OBSTET GYNAEC, V105, P723, DOI 10.1111/j.1471-0528.1998.tb10202.x; BOLTE AC, 2002, HYPERTENS PREGNANCY, P9; Brown MA, 1997, MED J AUSTRALIA, V166, P640, DOI 10.5694/j.1326-5377.1997.tb123300.x; Browne J, 2001, MICROWAVES RF, V40, P133; CLARKE M, 2003, COCHRANE LIB; CLARKE M, COCHRANE LIB; Cutler JA, 1998, NEW ENGL J MED, V338, P679, DOI 10.1056/NEJM199803053381009; *DEP HLTH, 1996, REP CONF ENQ MAT DEA; *DEP HLTH, 1994, REP CONF ENQ MAT DEA; *DEP HLTH, 1991, REP CONF ENQ MAT DEA; Department of Health and Social Security, 1989, REP CONF ENQ MAT DEA; DUGGAN PM, 1992, AUST NZ J OBSTET GYN, V32, P335, DOI 10.1111/j.1479-828X.1992.tb02846.x; Duley L, 2002, LANCET, V359, P1877, DOI 10.1016/s0140-6736(02)08778-0; Duley L., 2002, COCHRANE DB SYST REV; Egger M, 2003, SYSTEMATIC REV HLTH, P23; FENAKEL K, 1991, OBSTET GYNECOL, V77, P331; GARDEN A, 1982, CLIN EXP HYPERTENS B, V1, P371, DOI 10.3109/10641958209139860; Gifford RW, 2000, AM J OBSTET GYNECOL, V183, pS1, DOI 10.1067/mob.2000.107928; HARPER A, 1991, BRIT J OBSTET GYNAEC, V98, P453, DOI 10.1111/j.1471-0528.1991.tb10339.x; Howarth GR, 1997, HYPERTENS PREGNANCY, V16, P213, DOI 10.3109/10641959709031638; IMPEY L, 1993, BRIT J OBSTET GYNAEC, V100, P959, DOI 10.1111/j.1471-0528.1993.tb15120.x; Jegasothy R, 1996, J Obstet Gynaecol Res, V22, P21; KWAWUKUME EY, 1995, INT J GYNECOL OBSTET, V49, P265, DOI 10.1016/0020-7292(95)02372-J; LEWIS G, 2001, MOTHERS DIE 1997 199; Liu LS, 1998, J HYPERTENS, V16, P1823, DOI 10.1097/00004872-199816120-00016; MABIE WC, 1987, OBSTET GYNECOL, V70, P328; Magee LA, 1999, BMJ-BRIT MED J, V318, P1332, DOI 10.1136/bmj.318.7194.1332; Maharaj B, 1994, Blood Press Suppl, V1, P54; MAHARAJ B, 1994, AM J HYPERTENS, V7, pS61, DOI 10.1093/ajh/7.7.61S; Maharaj B, 1997, HYPERTENS PREGNANCY, V16, P1, DOI 10.3109/10641959709069085; MARTINSCOSTA S, 1992, CLIN EXP HYPERTENS B, V11, P25, DOI 10.3109/10641959209031031; MOODLEY J, 1992, BRIT J OBSTET GYNAEC, V99, P727, DOI 10.1111/j.1471-0528.1992.tb13872.x; OLSEN KS, 1992, ACTA OBSTET GYN SCAN, V71, P145, DOI 10.3109/00016349209007974; *ORG SYST REV COCH, GUID REV ED; *ORG SYST REV COCH, 2002, GUID REV ED; Rey E, 1997, CAN MED ASSOC J, V157, P1245; ROSSOUW HJ, 1995, S AFR MED J, V85, P525; Schulz M, 2001, Zentralbl Gynakol, V123, P529, DOI 10.1055/s-2001-18226; SEABE SJ, 1989, S AFR MED J, V76, P248; Sibai BM, 1996, CURR OPIN OBSTET GYN, V8, P110; SNYDER SW, 1989, AM J OBSTET GYNECOL, V161, P35, DOI 10.1016/0002-9378(89)90226-3; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; STEVENS TP, 1995, J PEDIATR-US, V127, P151, DOI 10.1016/S0022-3476(95)70277-6; Steyn DW, 1997, EUR J OBSTET GYN R B, V75, P155, DOI 10.1016/S0301-2115(97)00123-1; Vermillion ST, 1999, AM J OBSTET GYNECOL, V181, P858, DOI 10.1016/S0002-9378(99)70314-5; VINK GJ, 1980, OBSTET GYNECOL, V55, P519; VINK GJ, 1982, S AFR MED J, V62, P475; WACKER J, 1993, J STEROID BIOCHEM, V45, P65, DOI 10.1016/0960-0760(93)90123-E; Wacker J, 1998, NEPHROL DIAL TRANSPL, V13, P318, DOI 10.1093/oxfordjournals.ndt.a027825; WAISMAN GD, 1988, AM J OBSTET GYNECOL, V159, P308, DOI 10.1016/S0002-9378(88)80072-3; Walss Rodriguez R J, 1993, Ginecol Obstet Mex, V61, P76	56	229	242	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 25	2003	327	7421					955	+		10.1136/bmj.327.7421.955	http://dx.doi.org/10.1136/bmj.327.7421.955			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	736AL	14576246	Green Published, Bronze			2022-12-28	WOS:000186147800016
J	Rahi, JS; Cable, N				Rahi, JS; Cable, N		BCVISG	Severe visual impairment and blindness in children in the UK	LANCET			English	Article							LOW-BIRTH-WEIGHT; CHILDHOOD BLINDNESS; VISION IMPAIRMENT; GENE-THERAPY; PREMATURITY; RETINOPATHY; SURVEILLANCE; PREVALENCE; DISABILITY; IRELAND	Background Prevention of visual impairment and blindness in childhood is an international priority. However, many countries do not have contemporary information about incidence and causes, from which the scope and priorities for prevention and treatment can be identified. Methods In the UK, children aged younger than 16 years newly diagnosed with severe visual impairment or blindness (SVI/BL, WHO criteria) during 2000 were identified through national active surveillance schemes in ophthalmology and paediatrics. From these data, we calculated yearly age-group specific incidence and cumulative incidence. Causes were classified by the anatomical site or sites affected and by timing of the insult or insults and causal factors, where known. Findings Of 439 newly diagnosed children, 336 (77%) had additional non-ophthalmic disorders or impairments (SVI/BL plus). Total yearly incidence was highest in the first year of life, being 4.0 (95% CI 3.6-4.5) per 10000, with a cumulative incidence by 16 years of age of 5.9 (5.3-6.5) per 10000. 10% (44) of all children died within 1 year of diagnosis of blindness. Prenatal causal factors affected 61% (268) of children, with perinatal or neonatal and childhood factors each affecting 18% (77). Incidence and causes varied with presence of non-ophthalmic impairments or disorders, birthweight, and ethnic orgin. At least 75% (331) of children had disorders that were neither potentially preventable nor treatable, with current knowledge. Interpretation Severe visual impairment and blindness in childhood in the UK is more common, occurs more frequently in the context of complex non-ophthalmic impairments, and has greater associated mortality, than previously assumed. An increased rate in children of low birthweight and from ethnic minority groups, together with the observed diversity and complexity of the causes, reflect recent secular changes in the population at risk, specific risk factors, and strategies available for treatment.	Great Ormond St Hosp Children, Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England; Great Ormond St Hosp Children, Inst Child Hlth, Dept Ophthalmol, Visual Sci Unit, London WC1N 1EH, England; Inst Ophthalmol, Dept Epidemiol, London, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Rahi, JS (corresponding author), Great Ormond St Hosp Children, Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, 30 Guilford St, London WC1N 1EH, England.		Cable, Noriko/B-6947-2008; Osman, Sanha A/B-4056-2012	Cable, Noriko/0000-0001-5478-1760; Rahi, Jugnoo/0000-0002-5718-9209				Alagaratnam J, 2002, EYE, V16, P557, DOI 10.1038/sj.eye.6700149; Ali RR, 1997, BRIT J OPHTHALMOL, V81, P795, DOI 10.1136/bjo.81.9.795; Breslow NE., 1987, STAT METHODS CANC RE, P81; BRYARS JH, 1977, T OPHTHAL SOC UK, V97, P26; Carstairs V., 1991, DEPRIVATION HLTH SCO; Crofts BJ, 1998, BRIT J OPHTHALMOL, V82, P9, DOI 10.1136/bjo.82.1.9; Evans J., 1995, STUDIES MED POPULATI, V57; EYLENBOSCH WJ, 1988, SURVEILLANCE HLTH DI; FRASER GR, 1967, CAUSES BLINDNESS CHI; Gilbert C, 2001, BRIT J OPHTHALMOL, V85, P1017; GILBERT C, 1993, B WORLD HEALTH ORGAN, V71, P485; Gilbert C, 2001, B WORLD HEALTH ORGAN, V79, P227; GOGGIN M, 1991, BRIT J OPHTHALMOL, V75, P425, DOI 10.1136/bjo.75.7.425; Good WV, 2001, BRIT J OPHTHALMOL, V85, P891, DOI 10.1136/bjo.85.8.891; Hook EB, 1995, EPIDEMIOL REV, V17, P243, DOI 10.1093/oxfordjournals.epirev.a036192; Hornby S J, 2000, Ophthalmic Epidemiol, V7, P127; JAY B, 1975, CHILD CARE HLTH DEV, V1, P373, DOI 10.1111/j.1365-2214.1975.tb00222.x; Kirkwood B., 1988, BR K ESSENTIALS MED; Mervis CA, 2000, PAEDIATR PERINAT EP, V14, P70, DOI 10.1046/j.1365-3016.2000.00232.x; Morton R, 2002, CHILD CARE HLTH DEV, V28, P87, DOI 10.1046/j.1365-2214.2002.00245.x; Msall ME, 2000, PEDIATRICS, V106, P998, DOI 10.1542/peds.106.5.998; Nicoll A, 2000, J ROY SOC MED, V93, P580, DOI 10.1177/014107680009301107; *OFF NAT STAT, 2002, PD 30022 CHILDH INF; *OFF NAT STAT, 2002, LIV BRIT RES 2000 01; *OFF NAT STAT, 2002, POP TRENDS, P1; PECKHAM CS, 1973, P ROY SOC MED, V66, P701, DOI 10.1177/003591577306600749; RAHI JS, 2001, RECENT ADV PAEDIAT, P97; ROBINSON GC, 1987, AM J DIS CHILD, V141, P1321, DOI 10.1001/archpedi.1987.04460120087041; Rogers M, 1996, ARCH DIS CHILD, V74, P299, DOI 10.1136/adc.74.4.299; Rosano A, 2000, J EPIDEMIOL COMMUN H, V54, P660, DOI 10.1136/jech.54.9.660; Saxena S, 2002, BMJ-BRIT MED J, V325, P520, DOI 10.1136/bmj.325.7363.520; Schendel DE, 1997, AM J EPIDEMIOL, V146, P740; Schwarz K, 2002, EYE, V16, P530, DOI 10.1038/sj.eye.6700059; Slattery MM, 2002, LANCET, V360, P1489, DOI 10.1016/S0140-6736(02)11476-0; Smith AF, 1996, BRIT J OPHTHALMOL, V80, P276, DOI 10.1136/bjo.80.4.276; Stanford MR, 2002, BRIT J OPHTHALMOL, V86, P838, DOI 10.1136/bjo.86.8.838; STEWARTBROWN SL, 1988, J EPIDEMIOL COMMUN H, V42, P17, DOI 10.1136/jech.42.1.17; Stromland K, 1996, PEDIATRICS, V97, P845; TAYLOR D, 1975, CHILD CARE HLTH DEV, V1, P291, DOI 10.1111/j.1365-2214.1975.tb00210.x; Wood NS, 2000, NEW ENGL J MED, V343, P378, DOI 10.1056/NEJM200008103430601; World Health Organization, 1992, INT STAT CLASS DIS H; ZEKI SM, 1990, BRIT J OPHTHALMOL, V74, P300, DOI 10.1136/bjo.74.5.300; [No title captured]	43	253	255	0	20	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 25	2003	362	9393					1359	1365		10.1016/S0140-6736(03)14631-4	http://dx.doi.org/10.1016/S0140-6736(03)14631-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	735YX	14585637				2022-12-28	WOS:000186143300009
J	Verbeek, JH				Verbeek, JH			Commentary: label is unhelpful	BRITISH MEDICAL JOURNAL			English	Editorial Material							REHABILITATION; REASONS; SURGERY		Univ Amsterdam, Acad Med Ctr, Coronel Inst Occupat & Environm Hlth, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Verbeek, JH (corresponding author), Univ Amsterdam, Acad Med Ctr, Coronel Inst Occupat & Environm Hlth, POB 22700,Meibergdreef 15, Amsterdam, Netherlands.		Verbeek, Jos H.A.M./F-8382-2013	Verbeek, Jos H.A.M./0000-0002-6537-6100				Fritsch EW, 1996, SPINE, V21, P626, DOI 10.1097/00007632-199603010-00017; KRAMER J, 1987, Z ORTHOP GRENZGEB, V125, P622, DOI 10.1055/s-2008-1039696; Long D M, 1991, Neurosurg Clin N Am, V2, P899; McPhillips-Tangum CA, 1998, J GEN INTERN MED, V13, P289, DOI 10.1046/j.1525-1497.1998.00093.x; Ostelo RWJG, 2003, SPINE, V28, P209; Verbeek JHAM, 2001, SCAND J WORK ENV HEA, V27, P346, DOI 10.5271/sjweh.624	6	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 25	2003	327	7421					986	987		10.1136/bmj.327.7421.986	http://dx.doi.org/10.1136/bmj.327.7421.986			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	736AL	14576255	Green Published			2022-12-28	WOS:000186147800025
J	Sollner, TH; Sequeira, S				Sollner, TH; Sequeira, S			S-nitrosylation of NSF controls membrane trafficking	CELL			English	Editorial Material								Nitric oxide is a diffusible molecule with profound effects on regulated exocytosis in several biological systems-however, the molecular targets remain elusive. In this issue of Cell, Matsushita et al. report that in aortic endothelial cells, S-nitrosylation of NSF, an ATPase essential for the activation of the membrane-fusion machinery, inhibits the exocytosis of Weibel-Palade bodies, secretory granules containing a cocktail of mediators essential to the regulation of vascular vesseltone.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Sollner, TH (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.			Sequeira, Sonia/0000-0002-3473-0736				BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Hanley JG, 2002, NEURON, V34, P53, DOI 10.1016/S0896-6273(02)00638-4; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Matsushita K, 2003, CELL, V115, P139, DOI 10.1016/S0092-8674(03)00803-1; Mirnics K, 2000, NEURON, V28, P53, DOI 10.1016/S0896-6273(00)00085-4; PALLANCK L, 1995, J BIOL CHEM, V270, P18742, DOI 10.1074/jbc.270.32.18742; Sollner TH, 2003, MOL MEMBR BIOL, V20, P209, DOI 10.1080/0968768031000104953; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0	9	7	8	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 17	2003	115	2					127	129		10.1016/S0092-8674(03)00811-0	http://dx.doi.org/10.1016/S0092-8674(03)00811-0			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567907	Bronze			2022-12-28	WOS:000186039200001
J	Baxter, GW; Olafsen, JS				Baxter, GW; Olafsen, JS			Kinetics - Gaussian statistics in granular gases	NATURE			English	Editorial Material									Penn StateErie Behrens Coll, Sch Sci, Erie, PA 16563 USA; Univ Kansas, Dept Phys & Astron, Lawrence, KS 66045 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; University of Kansas	Baxter, GW (corresponding author), Penn StateErie Behrens Coll, Sch Sci, Erie, PA 16563 USA.	jolafsen@ku.edu		Olafsen, Jeffrey/0000-0003-0184-8014				[Anonymous], 1963, STAT MECH; ATWELL J, UNPUB PHYS REV E; Batchelor G. K., 1983, INTRO FLUID DYNAMICS; Blair DL, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.050301; Grossman EL, 1997, PHYS REV E, V55, P4200, DOI 10.1103/PhysRevE.55.4200; HAFF PK, 1983, J FLUID MECH, V134, P401, DOI 10.1017/S0022112083003419; Kudrolli A, 1997, PHYS REV LETT, V78, P1383, DOI 10.1103/PhysRevLett.78.1383; Kudrolli A, 2000, PHYS REV E, V62, pR1489, DOI 10.1103/PhysRevE.62.R1489; Losert W, 1999, CHAOS, V9, P682, DOI 10.1063/1.166442; Olafsen JS, 1998, PHYS REV LETT, V81, P4369, DOI 10.1103/PhysRevLett.81.4369; OTAFSEN JS, 1999, PHYS REV E, V60, pR2468; Rouyer F, 2000, PHYS REV LETT, V85, P3676, DOI 10.1103/PhysRevLett.85.3676	12	57	58	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					680	680		10.1038/425680a	http://dx.doi.org/10.1038/425680a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562092	Bronze			2022-12-28	WOS:000185924500030
J	Marcus, GM; Atwood, JE				Marcus, GM; Atwood, JE			Images in clinical medicine: "T-U-P'' syndrome, or pseudoatrial flutter	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Calif San Francisco, San Francisco, CA 94122 USA; Walter Reed Army Med Ctr, Washington, DC 20307 USA	University of California System; University of California San Francisco; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Marcus, GM (corresponding author), Univ Calif San Francisco, San Francisco, CA 94122 USA.		Marcus, Gregory/AAN-8584-2021	Marcus, Gregory/0000-0001-5197-7696					0	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 16	2003	349	16					E15	E15		10.1056/ENEJMicm020176	http://dx.doi.org/10.1056/ENEJMicm020176			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	731ZM	14561806				2022-12-28	WOS:000185916400009
J	Sanz, EJ				Sanz, EJ			Concordance and children's use of medicines	BRITISH MEDICAL JOURNAL			English	Article								Concordance is usually established between two people, doctor and patient, but the use of drugs in children always involves a third partner, the parents. Developing concordance with children in their health care raises several questions with no straightforward answers. For example, should children have a more active role in taking decisions about health and drugs than they currently do? Should greater emphasis be placed on informing parents about the disease and its treatment or on direct communication with their sick child? From what age should children be addressed directly about their illness? What is really relevant for them? Do children's and parents' perceptions about the usefulness and risks (efficacy), rules, and use of drugs coincide? This article, based on qualitative studies of children's perceptions and attitudes to health, disease, and drug use, presents information that, though by no means providing the "right" answers to the above questions, might be useful when considering the options.	Univ La Laguna, Sch Med, Dept Pharmacol, Tenerife 38071, Spain	Universidad de la Laguna	Sanz, EJ (corresponding author), Univ La Laguna, Sch Med, Dept Pharmacol, Tenerife 38071, Spain.		Sanz Alvarez, Emilio J/M-3535-2019; Sanz, Emilio J/C-9793-2009	Sanz Alvarez, Emilio J/0000-0001-6788-4435; Sanz, Emilio J/0000-0001-6788-4435				ARAMBURUZABALA P, 1997, CHILDREN MED CULTURE, P155; Bluebond-Langner M., 1978, PRIVATE WORLDS DYING; Bush PJ, 1999, CLIN THER, V21, P1280, DOI 10.1016/S0149-2918(00)80030-2; BUSH PJ, 1996, CHILDREN MED CULTURE; Garcia M, 1997, CHILDREN MED CULTURE, P193; Haynes R B, 2002, Cochrane Database Syst Rev, pCD000011; Lewin SA, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003267; Sanz E., 1997, CHILDREN MED CULTURE, P77; SCOTT JT, 2001, COCHRANE DATABASE SY, DOI UNSP CD002969; Trakas DJ, 1992, STUDYING CHILDHOOD M; TRAKAS DJ, 1996, CHILDHOOD MED USE CR	11	36	36	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					858	860		10.1136/bmj.327.7419.858	http://dx.doi.org/10.1136/bmj.327.7419.858			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551105	Green Published			2022-12-28	WOS:000185921200027
J	Fekete, DM				Fekete, DM			Rocks that roll zebrafish	SCIENCE			English	Editorial Material							OTOCONIA		Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Fekete, DM (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.	dfekete@purdue.edu	Fekete, Donna M/B-9170-2009	Fekete, Donna M/0000-0003-0662-0246				Belcher AM, 1996, NATURE, V381, P56, DOI 10.1038/381056a0; CARLSTROM DD, 1963, BIOL BULL, V125, P441, DOI 10.2307/1539358; Falini G, 1996, SCIENCE, V271, P67, DOI 10.1126/science.271.5245.67; MANN S, 1993, SCIENCE, V261, P1286, DOI 10.1126/science.261.5126.1286; POTE KG, 1991, COMP BIOCHEM PHYS B, V98, P287, DOI 10.1016/0305-0491(91)90181-C; Sollner C, 2003, SCIENCE, V302, P282, DOI 10.1126/science.1088443; STEYGER PS, 1995, HEARING RES, V84, P61, DOI 10.1016/0378-5955(95)00013-T; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848	8	18	19	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					241	242		10.1126/science.1091171	http://dx.doi.org/10.1126/science.1091171			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551427				2022-12-28	WOS:000185825900029
J	Greer, A				Greer, A			A view of unusual peroxides	SCIENCE			English	Editorial Material							DIOXIRANES		CUNY Grad Sch & Univ Ctr, Dept Chem, CUNY Brooklyn Coll, Brooklyn, NY 11210 USA	City University of New York (CUNY) System; Brooklyn College (CUNY); City University of New York (CUNY) Graduate School	Greer, A (corresponding author), CUNY Grad Sch & Univ Ctr, Dept Chem, CUNY Brooklyn Coll, Brooklyn, NY 11210 USA.	agreer@brooklyn.cuny.edu		Greer, Alexander/0000-0003-4444-9099				ADAM W, 1989, ACCOUNTS CHEM RES, V22, P205, DOI 10.1021/ar00162a002; COLLMAN JP, 1973, J AM CHEM SOC, V95, P7868, DOI 10.1021/ja00804a054; Ho DG, 2003, SCIENCE, V302, P259, DOI 10.1126/science.1089145; Houk KN, 1997, J AM CHEM SOC, V119, P10147, DOI 10.1021/ja963847x; Ishiguro K, 2000, B CHEM SOC JPN, V73, P535, DOI 10.1246/bcsj.73.535; Kang P, 2002, J AM CHEM SOC, V124, P4865, DOI 10.1021/ja012038x; MURRAY RW, 1985, J ORG CHEM, V50, P2847, DOI 10.1021/jo00216a007; MURRAY RW, 1989, CHEM REV, V89, P1187, DOI 10.1021/cr00095a013; Sander W, 1997, J AM CHEM SOC, V119, P7265, DOI 10.1021/ja964280n; Yang J, 2002, J ORG CHEM, V67, P5057, DOI 10.1021/jo020174u	10	13	13	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					235	236						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551422				2022-12-28	WOS:000185825900024
J	Lloyd, DR				Lloyd, DR			Comment on "Salt-pump mechanism for contaminant intrusion into coastal aquifers"	SCIENCE			English	Editorial Material									Univ Dublin Trinity Coll, Dept Chem, Dublin 2, Ireland	Trinity College Dublin	Lloyd, DR (corresponding author), Univ Dublin Trinity Coll, Dept Chem, Dublin 2, Ireland.							ATKINS PW, 1986, PHYSICAL CHEM, P674; Dror I, 2003, SCIENCE, V300, P950, DOI 10.1126/science.1080075; DUNLOP PJ, 1972, TECHNIQUES CHEM, P205; LIDE DR, 2000, CRC HDB CHEM PHYSICS; 1969, LANDOLTBORNSTEIN T A, V5, P616	5	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 31	2003	302	5646												1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593151				2022-12-28	WOS:000186258000020
J	Men, T; Brennan, P; Boffetta, P; Zaridze, D				Men, T; Brennan, P; Boffetta, P; Zaridze, D			Russian mortality trends for 1991-2001: analysis by cause and region	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; EASTERN-EUROPE; HEART-DISEASE; ALCOHOL; CONSUMPTION	Objectives To investigate trends in Russian mortality for 1991-2001 with particular reference to trends since the Russian economic crisis in 1998 and to geographical differences within Russia. Design Analysis of data obtained from the Russian State statistics committee for 1991-2001. All cause mortality was compared between seven federal regions. Comparison of cause specific rates was conducted for young (15-34 years) and middle aged adults (35-69 years). The number of Russian adults who died before age 70 in the period 1992-2001 and whose deaths were attributable to increased mortality was calculated. Main outcome measures Age, sex, and cause specific mortality standardised to the world population. Results Mortality increased substantially after the economic crisis in 1998, with life expectancy falling to 58.9 years among men and 71.8 years among women by 2001. Most of these fluctuations were due to changes in mortality from vascular disease and violent deaths (mainly suicides, homicides, unintentional poisoning, and traffic incidents) among young and middle aged adults. Trends were similar in all parts of Russia. An extra 2.5-3 million Russian adults died in middle age in the period 1992-2001 than would have been expected based on 1991 mortality. Conclusions Russian mortality Was already high in 1991 and has increased further in the subsequent decade. Fluctuations in mortality seem to correlate strongly with underlying economic and societal factors. On an individual level, alcohol consumption is strongly implicated in being at least partially responsible for many of these trends.	Int Agcy Res Canc, F-69008 Lyon, France; Ctr Canc Res, Inst Carcinogenesis, Moscow 115478, Russia	World Health Organization; International Agency for Research on Cancer (IARC)	Brennan, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.		Boffetta, Paolo/AAI-7767-2021	Boffetta, Paolo/0000-0002-3811-2791				Britton A, 2000, J EPIDEMIOL COMMUN H, V54, P328, DOI 10.1136/jech.54.5.328; Chenet L, 1998, J EPIDEMIOL COMMUN H, V52, P772, DOI 10.1136/jech.52.12.772; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; Dos Santos Silva I., 1999, CANC EPIDEMIOLOGY PR; Evans C, 2000, BRIT MED J, V320, P218, DOI 10.1136/bmj.320.7229.218; Fillmore KM, 2002, J STUD ALCOHOL, V63, P436, DOI 10.15288/jsa.2002.63.436; Leon DA, 1997, LANCET, V350, P383, DOI 10.1016/S0140-6736(97)03360-6; Mazzaglia G, 2001, ADDICTION, V96, P1743, DOI 10.1046/j.1360-0443.2001.961217434.x; McKee M, 1998, J ROY SOC MED, V91, P402, DOI 10.1177/014107689809100802; McKee M, 2001, ANN EPIDEMIOL, V11, P1, DOI 10.1016/S1047-2797(00)00080-6; MESLE E, 2002, IUSSP MPIDR WORKSH J; MESLE F, 2002, IUSSP MPIDR WORKSH J; Shkolnikov V, 2001, LANCET, V357, P917, DOI 10.1016/S0140-6736(00)04212-4; Walberg P, 1998, BRIT MED J, V317, P312, DOI 10.1136/bmj.317.7154.312; World Health Organization, 1992, INT CLASS DIS REL HL; World Heath Organization, 1977, INT CLASS DIS 1975 R; ZBARSKAYA I, 2002, EC ROSSYI 21 CENTURY, V9, P12	17	132	135	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 25	2003	327	7421					964	+		10.1136/bmj.327.7421.964	http://dx.doi.org/10.1136/bmj.327.7421.964			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	736AL	14576248	Green Published, Bronze			2022-12-28	WOS:000186147800018
J	Talbot, L				Talbot, L			"Failed back surgery syndrome"	BRITISH MEDICAL JOURNAL			English	Article								An inappropriate diagnostic label may exacerbate the discomfort of patients who develop persistent and disabling symptoms after back surgery.										HELTHOFF KB, 1985, ORTHOP CLIN N AM, V16, P417; Porter RW, 1997, J ROY COLL SURG EDIN, V42, P376; RESNICK D, MEDCYCLOPAEDIA	3	27	31	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 25	2003	327	7421					985	986		10.1136/bmj.327.7421.985	http://dx.doi.org/10.1136/bmj.327.7421.985			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	736AL	14576254	Green Published			2022-12-28	WOS:000186147800024
J	Manolio, T				Manolio, T			Novel risk markers and clinical practice	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INFLAMMATION		NHLBI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Manolio, T (corresponding author), NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA.							Baldus S, 2003, CIRCULATION, V108, P1440, DOI 10.1161/01.CIR.0000090690.67322.51; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; Morrow DA, 2003, CIRCULATION, V108, P250, DOI 10.1161/01.CIR.0000078080.37974.D2; Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45; Sakkinen PA, 1999, AM J EPIDEMIOL, V149, P261; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136	6	136	144	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 23	2003	349	17					1587	1589		10.1056/NEJMp038136	http://dx.doi.org/10.1056/NEJMp038136			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734ZT	14573728				2022-12-28	WOS:000186088400001
J	Pearson, ER; Starkey, BJ; Powell, RJ; Gribble, FM; Clark, PM; Hattersley, AT				Pearson, ER; Starkey, BJ; Powell, RJ; Gribble, FM; Clark, PM; Hattersley, AT			Genetic cause of hyperglycaemia and response to treatment in diabetes	LANCET			English	Article							HEPATOCYTE NUCLEAR FACTOR-1-ALPHA; BETA-CELL FUNCTION; DOMINANT-NEGATIVE SUPPRESSION; HOMEOSTASIS MODEL ASSESSMENT; INSULIN SENSITIVITY; HNF-1-ALPHA FUNCTION; CONSORT STATEMENT; RANDOMIZED TRIALS; FACTOR-I; GLUCOSE	Background Type 2 diabetes shows evidence of underlying heterogeneity. No studies have assessed whether different causes for diabetes change the response to oral hypoglycaemic therapy. In a few cases, patients with diabetes caused by mutations in the hepatocyte nuclear factor la (HNF-1alpha) gene have been described as sensitive to the hypoglycaemic effects of sulphonylureas. We aimed to see whether the glycaemic response to the sulphonylurea gliclazide and the biguanide metformin differed in HNF-1alpha diabetes and type 2 diabetes, and to investigate the mechanism for differences in sulphonylurea sensitivity. Methods We did a randomised crossover trial of glicazide and metformin in 36 patients, either with diabetes caused by HNF-1alpha mutations or type 2 diabetes, who were matched for body-mass index and fasting plasma glucose. The primary outcome was reduction in fasting plasma glucose. Analysis was by intention to treat. We assessed possible mechanisms for sulphonylurea sensitivity through insulin sensitivity, insulin secretory response to glucose and tolbutamide, and tolbutamide clearance. Findings Patients with HNF-1alpha diabetes had a 5.2-fold greater response to gliclazide than to metformin (fasting plasma glucose reduction 4.7 vs 0.9 mmol/L, p=0.0007) and 3.9-fold greater response to gliclazide than those with type 2 diabetes (p=0.002). Patients with HNF-1alpha diabetes had a strong insulin secretory response to intravenous tolbutamide despite a small response to intravenous glucose, and were more insulin sensitive than those with type 2 diabetes. Sulphonylurea metabolism was similar in both patient groups. Interpretation The cause of hyperglycaemia changes the response to hypoglycaemic drugs; HNF-1alpha diabetes has marked sulphonylurea sensitivity. This pharmacogenetic effect is consistent with models of HNF-1alpha. deficiency, which show that the beta-cell defect is upstream of the sulphonylurea receptor. Definition of the genetic basis of hyperglycaemia has implications for patient management.	Peninsula Med Sch, Exeter EX2 5AX, Devon, England; Royal Surrey Cty Hosp, Clin Lab, Guildford, Surrey, England; Royal Devon & Exeter Hosp NHS Trust, Exeter & N Devon NHS Res & Dev Support Unit, Exeter, Devon, England; Addenbrookes Hosp, Dept Clin Biochem, Cambridge, England; Univ Hosp Birmingham NHS Trust, Reg Endocrine Lab, Birmingham, W Midlands, England	University of Exeter; Royal Surrey County Hospital; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Hattersley, AT (corresponding author), Peninsula Med Sch, Exeter EX2 5AX, Devon, England.			Powell, Roy/0000-0002-4959-5717; Pearson, Ewan/0000-0001-9237-8585; Gribble, Fiona/0000-0002-4232-2898; Hattersley, Andrew/0000-0001-5620-473X				Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Amos AF, 1997, DIABETIC MED, V14, pS7, DOI 10.1002/(SICI)1096-9136(199712)14:5+<S7::AID-DIA522>3.3.CO;2-I; Bergman RN, 2002, DIABETES, V51, pS212, DOI 10.2337/diabetes.51.2007.S212; Boileau P, 2002, DIABETES, V51, pS343, DOI 10.2337/diabetes.51.2007.S343; Byrne MM, 1996, DIABETES, V45, P1503, DOI 10.2337/diabetes.45.11.1503; Dukes ID, 1998, J BIOL CHEM, V273, P24457, DOI 10.1074/jbc.273.38.24457; Frayling TM, 2001, DIABETES, V50, pS94, DOI 10.2337/diabetes.50.2007.S94; Hansen T, 1997, DIABETES, V46, P726, DOI 10.2337/diabetes.46.4.726; Hathout EH, 1999, DIABETES CARE, V22, P867, DOI 10.2337/diacare.22.5.867; HEIERVANG E, 1989, ACTA PAEDIATR SCAND, V78, P74, DOI 10.1111/j.1651-2227.1989.tb10890.x; Hermans MP, 1999, DIABETOLOGIA, V42, P678, DOI 10.1007/s001250051215; Hom F, 1999, Diabetes Technol Ther, V1, P443, DOI 10.1089/152091599316973; Johansen K, 1999, DIABETES CARE, V22, P33, DOI 10.2337/diacare.22.1.33; KAHN SE, 1993, DIABETES, V42, P1663, DOI 10.2337/diabetes.42.11.1663; Lehto M, 1997, J CLIN INVEST, V99, P582, DOI 10.1172/JCI119199; Levy JC, 1998, DIABETES CARE, V21, P2191, DOI 10.2337/diacare.21.12.2191; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Pearson ER, 2000, DIABETIC MED, V17, P543, DOI 10.1046/j.1464-5491.2000.00305.x; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; SCOTT J, 1979, DIABETES, V28, P41, DOI 10.2337/diabetes.28.1.41; Shih DQ, 2001, DIABETES, V50, P2472, DOI 10.2337/diabetes.50.11.2472; Sovik O, 1998, DIABETOLOGIA, V41, P607, DOI 10.1007/s001250050956; STARKEY B, 2002, ASS CLIN BIOCH NAT M, P70; Stride A, 2002, ANN MED, V34, P207, DOI 10.1080/713782136; Sweetman S.C., 2002, MARTINDALE COMPLETE, V33rd; Tripathy D, 2000, DIABETOLOGIA, V43, P1476, DOI 10.1007/s001250051558; *UK PROSP DIAB STU, 1995, BMJ-BRIT MED J, V310, P83; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; Wang HY, 2000, EMBO J, V19, P4257, DOI 10.1093/emboj/19.16.4257; WHO Study Group, 1999, REP WHO CONS 1; Wobser H, 2002, J BIOL CHEM, V277, P6413, DOI 10.1074/jbc.M108390200; Yamagata K, 2002, DIABETES, V51, P114, DOI 10.2337/diabetes.51.1.114; Yang Q, 2002, DIABETES, V51, P1785, DOI 10.2337/diabetes.51.6.1785	34	387	403	1	15	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 18	2003	362	9392					1275	1281		10.1016/S0140-6736(03)14571-0	http://dx.doi.org/10.1016/S0140-6736(03)14571-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575972				2022-12-28	WOS:000186036900011
J	Mazumder, B; Sampath, P; Seshadri, V; Maitra, RK; DiCorleto, PE; Fox, PL				Mazumder, B; Sampath, P; Seshadri, V; Maitra, RK; DiCorleto, PE; Fox, PL			Regulated release of L13a from the 60S ribosomal subunit as a mechanism of transcript-specific translational control	CELL			English	Article							BINDING-PROTEIN; MESSENGER-RNAS; TYROSINE PHOSPHORYLATION; TRANSPLANTATION ANTIGEN; GAMMA-INTERFERON; CERULOPLASMIN; YEAST; EXPRESSION; COMPLEX; GENE	Transcript-specific translational control is generally directed by binding of trans-acting proteins to structural elements in the untranslated region (UTR) of the target mRNA. Here, we elucidate a translational silencing mechanism involving regulated release of an integral ribosomal protein and subsequent binding to its target mRNA. Human ribosomal protein L13a was identified as a candidate interferon-Gamma-Activated Inhibitor of Translation (GAIT) of ceruloplasmin (Cp) mRNA by a genetic screen for Cp 3' -UTR binding proteins. In vitro activity of L13a was shown by inhibition of target mRNA translation by recombinant protein. In response to interferon-gamma in vivo, the entire cellular pool of L13a was phosphorylated and released from the 60S ribosomal subunit. Released L13a specifically bound the 3'-UTR GAIT element of Cp mRNA and silenced translation. We propose a model in which the ribosome functions not only as a protein synthesis machine, but also as a depot for regulatory proteins that modulate translation.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Virus Core Facil, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Biol, Cleveland, OH 44115 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University	Fox, PL (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	foxp@ccf.org		Mazumder, Barsanjit/0000-0003-3069-7833	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582, R01HL067725] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29582, HL67725] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnold RJ, 1999, J BIOL CHEM, V274, P37035, DOI 10.1074/jbc.274.52.37035; Ballesta JPG, 1999, FEMS MICROBIOL REV, V23, P537, DOI 10.1111/j.1574-6976.1999.tb00412.x; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Ben-Asouli Y, 2002, CELL, V108, P221, DOI 10.1016/S0092-8674(02)00616-5; Bielli P, 2002, CELL MOL LIFE SCI, V59, P1413, DOI 10.1007/s00018-002-8519-2; CAMPOS F, 1990, BIOCHIM BIOPHYS ACTA, V1087, P142, DOI 10.1016/0167-4781(90)90198-B; CHAN YL, 1994, J BIOL CHEM, V269, P5589; Diaz JJ, 2002, J CHROMATOGR B, V771, P237, DOI 10.1016/S1570-0232(02)00038-7; Dominski Z, 2002, MOL CELL BIOL, V22, P6648, DOI 10.1128/MCB.22.18.6648-6660.2002; Ehrenwald E, 1996, J CLIN INVEST, V97, P884, DOI 10.1172/JCI118491; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FLEMING RE, 1991, AM J PHYSIOL, V260, pL68, DOI 10.1152/ajplung.1991.260.2.L68; Gebauer F, 2003, MOL CELL, V11, P1397, DOI 10.1016/S1097-2765(03)00176-X; Gitlin JD, 1998, PEDIATR RES, V44, P271, DOI 10.1203/00006450-199809000-00001; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kirkpatrick P, 2002, NAT REV DRUG DISCOV, V1, P99, DOI 10.1038/nrd738; KLEBANOFF SJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P302, DOI 10.1016/0003-9861(92)90522-X; Kritzik MR, 2000, J ENDOCRINOL, V165, P67, DOI 10.1677/joe.0.1650067; Law LMJ, 2003, J VIROL, V77, P1764, DOI 10.1128/JVI.77.3.1764-1771.2003; Lee SW, 2002, P NATL ACAD SCI USA, V99, P5942, DOI 10.1073/pnas.082119899; LHOEST J, 1984, EUR J BIOCHEM, V141, P585, DOI 10.1111/j.1432-1033.1984.tb08233.x; Li J, 2001, J IMMUNOL, V166, P432, DOI 10.4049/jimmunol.166.1.432; Li JX, 2002, NATURE, V418, P793, DOI 10.1038/nature00936; MADEN BEH, 1968, J MOL BIOL, V35, P333, DOI 10.1016/S0022-2836(68)80028-2; Martin F, 1997, EMBO J, V16, P769, DOI 10.1093/emboj/16.4.769; MARZOUKI A, 1990, BIOCHIM BIOPHYS ACTA, V1048, P238, DOI 10.1016/0167-4781(90)90062-7; MASSE T, 1990, MOL GEN GENET, V220, P377, DOI 10.1007/BF00391742; Mauro VP, 2002, P NATL ACAD SCI USA, V99, P12031, DOI 10.1073/pnas.192442499; Mazumder B, 1997, J IMMUNOL, V159, P1938; Mazumder B, 1999, MOL CELL BIOL, V19, P6898; Mazumder B, 2001, MOL CELL BIOL, V21, P6440, DOI 10.1128/MCB.21.19.6440-6449.2001; Mazumder B, 2003, TRENDS BIOCHEM SCI, V28, P91, DOI 10.1016/S0968-0004(03)00002-1; Mezzetti A, 1999, ARTERIOSCL THROM VAS, V19, P2659, DOI 10.1161/01.ATV.19.11.2659; Moore PB, 2003, ANNU REV BIOCHEM, V72, P813, DOI 10.1146/annurev.biochem.72.110601.135450; Muckenthaler M, 1998, MOL CELL, V2, P383, DOI 10.1016/S1097-2765(00)80282-8; Mukhopadhyay CK, 1997, P NATL ACAD SCI USA, V94, P11546, DOI 10.1073/pnas.94.21.11546; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OSAKI S, 1966, J BIOL CHEM, V241, P2746; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; Ostrowski J, 2000, J BIOL CHEM, V275, P3619, DOI 10.1074/jbc.275.5.3619; PRICE SR, 1992, GENOMICS, V14, P959, DOI 10.1016/S0888-7543(05)80117-X; REMACHA M, 1995, MOL CELL BIOL, V15, P4754; SAENZROBLES MT, 1988, EUR J BIOCHEM, V177, P531, DOI 10.1111/j.1432-1033.1988.tb14405.x; SALONEN JT, 1991, BRIT MED J, V302, P756, DOI 10.1136/bmj.302.6779.756; Sampath P, 2003, MOL CELL BIOL, V23, P1509, DOI 10.1128/MCB.23.5.1509-1519.2003; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Serganov A, 2003, EMBO J, V22, P1898, DOI 10.1093/emboj/cdg170; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; Siomi MC, 2002, MOL CELL BIOL, V22, P8438, DOI 10.1128/MCB.22.24.8438-8447.2002; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Vilardell J, 2000, MOL CELL, V5, P761, DOI 10.1016/S1097-2765(00)80255-5; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8; WOOL IG, 1996, TRANSLATIONAL CONTRO, P481; WORMINGTON M, 1991, METHOD CELL BIOL, V36, P167; Yoo JY, 1999, GENE, V229, P215, DOI 10.1016/S0378-1119(98)00604-0; Zalfa F, 2003, CELL, V112, P317, DOI 10.1016/S0092-8674(03)00079-5; ZENGEL JM, 1994, PROG NUCLEIC ACID RE, V47, P331, DOI 10.1016/S0079-6603(08)60256-1; Zhang YY, 2003, EMBO J, V22, P1801, DOI 10.1093/emboj/cdg171	62	246	263	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	2003	115	2					187	198		10.1016/S0092-8674(03)00773-6	http://dx.doi.org/10.1016/S0092-8674(03)00773-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567916	Bronze, Green Submitted			2022-12-28	WOS:000186039200010
J	Sawaya, GF; McConnell, KJ; Kulasingam, SL; Lawson, HW; Kerlikowske, K; Melnikow, J; Lee, NC; Gildengorin, G; Myers, ER; Washington, AE				Sawaya, GF; McConnell, KJ; Kulasingam, SL; Lawson, HW; Kerlikowske, K; Melnikow, J; Lee, NC; Gildengorin, G; Myers, ER; Washington, AE			Risk of cervical cancer associated with extending the interval between cervical-cancer screenings	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATURAL-HISTORY; PAPILLOMAVIRUS INFECTION; RANDOMIZED TRIAL; COSTA-RICA; WOMEN; ABNORMALITIES; CYTOLOGY; GUIDELINES; MANAGEMENT; NEOPLASIA	BACKGROUND: Although contemporary guidelines suggest that the intervals between Papanicolaou tests can be extended to three years among low-risk women with previous negative tests, the excess risk of cervical cancer associated with less frequent than annual screening is uncertain. METHODS: We determined the prevalence of biopsy-proven cervical neoplasia among 938,576 women younger than 65 years of age, stratified according to the number of previous consecutive negative Papanicolaou tests. Using a Markov model that estimates the rate at which dysplasia will progress to cancer, we estimated the risk of cancer within three years after one or more negative Papanicolaou tests, as well as the number of additional Papanicolaou tests and colposcopic examinations that would be required to avert one case of cancer given a particular interval between screenings. RESULTS: Among 31,728 women 30 to 64 years of age who had had three or more consecutive negative tests, the prevalence of biopsy-proven cervical intraepithelial neoplasia of grade 2 was 0.028 percent and the prevalence of grade 3 neoplasia was 0.019 percent; none of the women had invasive cervical cancer. According to our model, the estimated risk of cancer with annual Papanicolaou tests for three years was 2 in 100,000 among women 30 to 44 years of age, 1 in 100,000 among women 45 to 59 years of age, and 1 in 100,000 among women 60 to 64 years of age; these risks would be 5 in 100,000, 2 in 100,000, and 1 in 100,000, respectively, if screening were performed once three years after the last negative test. To avert one additional case of cancer by screening 100,000 women annually for three years rather than once three years after the last negative test, an average of 69,665 additional Papanicolaou tests and 3861 colposcopic examinations would be needed in women 30 to 44 years of age and an average of 209,324 additional Papanicolaou tests and 11,502 colposcopic examinations in women 45 to 59 years of age. CONCLUSIONS: As compared with annual screening for three years, screening performed once three years after the last negative test in women 30 to 64 years of age who have had three or more consecutive negative Papanicolaou tests is associated with an average excess risk of cervical cancer of approximately 3 in 100,000.	Dept Vet Affairs, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94121 USA; Dept Vet Affairs, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA; Dept Vet Affairs, Dept Med, San Francisco, CA 94121 USA; Dept Vet Affairs, Gen Internal Med Sect, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Oregon Hlth Sci Univ, Dept Emergency Med Publ Hlth & Prevent Med, Portland, OR 97201 USA; Duke Univ, Dept Obstet & Gynecol, Durham, NC 27710 USA; Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA; Univ Calif Davis, Dept Family & Community Med, Sacramento, CA 95817 USA	University of California System; University of California San Francisco; Oregon Health & Science University; Duke University; Centers for Disease Control & Prevention - USA; University of California System; University of California Davis	Sawaya, GF (corresponding author), Dept Vet Affairs, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94121 USA.			Kulasingam, Shalini/0000-0002-0932-9166	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U01HS007373] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K08CA074973] Funding Source: NIH RePORTER; AHRQ HHS [HS07373] Funding Source: Medline; NCI NIH HHS [K08 CA 74973-02] Funding Source: Medline; PHS HHS [282-98-0026] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AG HLTH CAR POL R, 1999, AHCPR PUBL; BEARMAN DM, 1987, OBSTET GYNECOL, V69, P660; Belinson J, 2002, GYNECOL ONCOL, V84, P355, DOI 10.1006/gyno.2001.6554; CHAN PG, IN PRESS OBSTET GYNE; CUZICK J, 1995, LANCET, V345, P1533, DOI 10.1016/S0140-6736(95)91086-7; DEVESA SS, 1989, CANCER, V64, P2184, DOI 10.1002/1097-0142(19891115)64:10<2184::AID-CNCR2820641034>3.0.CO;2-8; Duggan MA, 1998, EUR J GYNAECOL ONCOL, V19, P338; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; FAHS MC, 1992, ANN INTERN MED, V117, P520, DOI 10.7326/0003-4819-117-6-520; FINK DJ, 1988, CA-CANCER J CLIN, V38, P127, DOI 10.3322/canjclin.38.2.127; FLEISS JL, 1981, STATISTICAL METHODS, P64; Freeman-Wang T, 2001, BRIT J OBSTET GYNAEC, V108, P482, DOI 10.1016/S0306-5456(00)00121-2; Henson R M, 1996, J Public Health Manag Pract, V2, P36; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Holowaty P, 1999, JNCI-J NATL CANCER I, V91, P252, DOI 10.1093/jnci/91.3.252; Hutchinson ML, 1999, CANCER CYTOPATHOL, V87, P48, DOI 10.1002/(SICI)1097-0142(19990425)87:2&lt;48::AID-CNCR2&gt;3.0.CO;2-D; JANERICH DT, 1995, AM J PUBLIC HEALTH, V85, P791, DOI 10.2105/AJPH.85.6.791; Kulasingam SL, 2002, JAMA-J AM MED ASSOC, V288, P1749, DOI 10.1001/jama.288.14.1749; KURMAN RJ, 1994, JAMA-J AM MED ASSOC, V271, P1866, DOI 10.1001/jama.271.23.1866; Lawson HW, 1998, OBSTET GYNECOL, V92, P745, DOI 10.1016/S0029-7844(98)00257-9; Melnikow J, 1998, OBSTET GYNECOL, V92, P727, DOI 10.1016/S0029-7844(98)00245-2; Munoz N, 1996, SEX TRANSM DIS, V23, P504, DOI 10.1097/00007435-199611000-00012; Myers ER, 2000, OBSTET GYNECOL, V96, P645, DOI 10.1016/S0029-7844(00)00979-0; Myers ER, 2000, AM J EPIDEMIOL, V151, P1158, DOI 10.1093/oxfordjournals.aje.a010166; Nanda K, 2000, ANN INTERN MED, V132, P810, DOI 10.7326/0003-4819-132-10-200005160-00009; National Institutes of Health, 1996, CERV CANC NIH CONS S; PAYNE N, 2000, LIQUID BASED CYTOLOG; PRETORIUS R, 1991, GYNECOL ONCOL, V42, P48, DOI 10.1016/0090-8258(91)90229-X; *PREV SERV TASK FO, 2003, CERV CANC SCREEN; Ries LAG, 2003, SEER CANC STAT REV 1; Saslow D, 2002, CA-CANCER J CLIN, V52, P342, DOI 10.3322/canjclin.52.6.342; Sawaya GF, 2001, NEW ENGL J MED, V344, P1603, DOI 10.1056/NEJM200105243442107; Sawaya GF, 1999, OBSTET GYNECOL, V94, P307, DOI 10.1016/S0029-7844(99)00289-6; Sawaya GF, 2000, ANN INTERN MED, V133, P942, DOI 10.7326/0003-4819-133-12-200012190-00009; Sawaya GF, 2000, OBSTET GYNECOL, V96, P219, DOI 10.1016/S0029-7844(00)00882-6; Schiffman M, 2000, JAMA-J AM MED ASSOC, V283, P87, DOI 10.1001/jama.283.1.87; Schwartz PE, 1996, AM J OBSTET GYNECOL, V175, P1105, DOI 10.1016/S0002-9378(96)70012-1; Solomon D, 2001, J NATL CANCER I, V93, P293, DOI 10.1093/jnci/93.4.293; Stenkvist B, 1996, J Med Screen, V3, P204; Stoler MH, 2001, JAMA-J AM MED ASSOC, V285, P1500, DOI 10.1001/jama.285.11.1500; Swan J, 2003, CANCER, V97, P1528, DOI 10.1002/cncr.11208; SYRJANEN K, 1992, OBSTET GYNECOL, V79, P675; VANOORTMARSSEN GJ, 1991, BRIT J CANCER, V64, P559, DOI 10.1038/bjc.1991.350; Wright TC, 2002, JAMA-J AM MED ASSOC, V287, P2120, DOI 10.1001/jama.287.16.2120; Wright TC, 2003, NEW ENGL J MED, V348, P489, DOI 10.1056/NEJMp020178	45	86	107	0	9	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 16	2003	349	16					1501	1509		10.1056/NEJMoa035419	http://dx.doi.org/10.1056/NEJMoa035419			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	731ZM	14561792				2022-12-28	WOS:000185916400004
J	Braude, P; Rowell, P				Braude, P; Rowell, P			Assisted conception. II - In vitro fertilisation and intracytoplasmic sperm injection	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Guys Kings & St Thomass Sch Med, Dept Womens Hlth, London, England; Guys & St Thomass Assisted Concept Unit, London, England	University of London; King's College London	Braude, P (corresponding author), Guys Kings & St Thomass Sch Med, Dept Womens Hlth, London, England.							Ombelet W, 1995, HUM REPROD UPDATE, V1, P543, DOI 10.1093/humupd/1.6.543; Rowe PJ, 1999, WHO MANUAL STANDARDI; TEMPLETON A, 2000, MANAGEMENT INFERTILI; Winston RML, 2002, NAT CELL BIOL, V4, pS14, DOI 10.1038/ncb-nm-fertilityS14	4	32	33	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 11	2003	327	7419					852	855		10.1136/bmj.327.7419.852	http://dx.doi.org/10.1136/bmj.327.7419.852			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551103	Green Published			2022-12-28	WOS:000185921200025
J	Ho, DG; Gao, RM; Celaje, J; Chung, HY; Selke, M				Ho, DG; Gao, RM; Celaje, J; Chung, HY; Selke, M			Phosphadioxirane: A peroxide from an ortho-substituted arylphosphine and singlet dioxygen	SCIENCE			English	Article							OXYGEN; SULFIDES; PHOSPHINES; CHEMISTRY; MECHANISM	We prepared the primary adduct for the reaction of singlet dioxygen (O-1(2)) with an arylphosphine by using the sterically hindered arylphosphine tris(omethoxyphenyl) phosphine. The resulting phosphadioxirane has a dioxygen molecule triangularly bound to the phosphorus atom. Olefin trapping experiments show that the phosphadioxirane can undergo nonradical oxygen atom-transfer reactions. Under protic conditions, two different intermediates are formed during the reaction of singlet dioxygen with tris(o-methoxyphenyl) phosphine, namely, the corresponding hydroperoxy arylphosphine and a hydroxy phosphorane. Experiments with other arylphosphines possessing different electronic and steric properties demonstrate that the relative stability of the tris(o-methoxyphenyl) phosphadioxirane is due to both steric and electronic effects.	Calif State Univ Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90032 USA	California State University System; California State University Los Angeles	Selke, M (corresponding author), Calif State Univ Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90032 USA.	mselke@calstatela.edu			NIGMS NIH HHS [GM 64104, GM 08101] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM064104] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], COMMUNICATION; BOLDUC PR, 1974, J ORG CHEM, V39, P3178; Clennan EL, 2001, ACCOUNTS CHEM RES, V34, P875, DOI 10.1021/ar0100879; EAPEN KC, 1980, J FLUORINE CHEM, V15, P239, DOI 10.1016/S0022-1139(00)82580-4; Gao RM, 2001, ORG LETT, V3, P3719, DOI 10.1021/ol010195v; GORENSTEINDG, 1984, PHOSPHORUS 31 NMR PR, P14; GU CL, 1981, J AM CHEM SOC, V103, P5949, DOI 10.1021/ja00409a073; Jensen F, 1998, J AM CHEM SOC, V120, P4439, DOI 10.1021/ja973782d; LIANG JJ, 1983, J AM CHEM SOC, V105, P4717, DOI 10.1021/ja00352a033; NAHM K, 1993, J AM CHEM SOC, V115, P4879, DOI 10.1021/ja00064a057; NAHM K, 1989, J AM CHEM SOC, V111, P909; Reynolds MS, 1996, INORG CHEM, V35, P2378, DOI 10.1021/ic951212d; TSUJI S, 1993, J ORG CHEM, V58, P5055, DOI 10.1021/jo00071a012; VONITZSTEIN M, 1983, J CHEM SOC CHEM COMM, V164	14	58	59	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					259	262		10.1126/science.1089145	http://dx.doi.org/10.1126/science.1089145			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	730HT	14551430				2022-12-28	WOS:000185825900034
J	Rapp, RP; Shimizu, N; Norman, MD				Rapp, RP; Shimizu, N; Norman, MD			Growth of early continental crust by partial melting of eclogite	NATURE			English	Article							HIGH-FIELD STRENGTH; EXPERIMENTAL CONSTRAINTS; PARTITION-COEFFICIENTS; GREENSTONE-BELT; VOLCANIC-ROCKS; WEST GREENLAND; NEW-CALEDONIA; NEW-ZEALAND; MANTLE; EVOLUTION	The tectonic setting in which the first continental crust formed, and the extent to which modern processes of arc magmatism at convergent plate margins were operative on the early Earth, are matters of debate(1,2). Geochemical studies have shown that felsic rocks in both Archaean high-grade metamorphic ('grey gneiss') and low-grade granite-greenstone terranes are comprised dominantly of sodium-rich granitoids of the tonalite-trondhjemite-granodiorite (TTG) suite of rocks(3-7). Here we present direct experimental evidence showing that partial melting of hydrous basalt in the eclogite facies produces granitoid liquids with major- and trace-element compositions equivalent to Archaean TTG, including the low Nb/Ta and high Zr/Sm ratios of 'average' Archaean TTG(8), but from a source with initially subchondritic Nb/Ta. In modern environments, basalts with low Nb/Ta form by partial melting of subduction-modified depleted mantle(9,10), notably in intraoceanic arc settings in the forearc(11,12) and backarc(13,14) regimes. These observations suggest that TTG magmatism may have taken place beneath granite-greenstone complexes developing along Archaean intraoceanic island arcs by imbricate thrust-stacking(15) and tectonic accretion(16) of a diversity of subduction-related terranes. Partial melting accompanying dehydration of these generally basaltic source materials at the base of thickened, 'arc-like' crust would produce compositionally appropriate TTG granitoids in equilibrium with eclogite residues.	SUNY Stony Brook, Inst Mineral Phys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Geosci, Stony Brook, NY 11794 USA; Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA; Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Woods Hole Oceanographic Institution; Australian National University	Rapp, RP (corresponding author), Ehime Univ, Geodynam Res Ctr, 2-5 Bunkyo Cho, Matsuyama, Ehime 7908577, Japan.	rrapp@notes.cc.sunysb.edu	Facility, NENIMF/B-8811-2015	Norman, Marc/0000-0002-1357-5415				Barth MG, 2002, PRECAMBRIAN RES, V113, P323, DOI 10.1016/S0301-9268(01)00216-9; Barth MG, 2001, GEOCHIM COSMOCHIM AC, V65, P1499, DOI 10.1016/S0016-7037(00)00626-8; Bedard JH, 1999, J PETROL, V40, P1853, DOI 10.1093/petrology/40.12.1853; Boily M, 2002, PRECAMBRIAN RES, V115, P349, DOI 10.1016/S0301-9268(02)00016-5; Cluzel D, 2001, TECTONOPHYSICS, V340, P23, DOI 10.1016/S0040-1951(01)00148-2; de Wit MJ, 1998, PRECAMBRIAN RES, V91, P181, DOI 10.1016/S0301-9268(98)00043-6; FENG R, 1992, CHEM GEOL, V98, P23, DOI 10.1016/0009-2541(92)90090-R; Foley S, 2002, NATURE, V417, P837, DOI 10.1038/nature00799; GREEN TH, 1995, CHEM GEOL, V120, P347, DOI 10.1016/0009-2541(94)00145-X; Horng WS, 2000, CONTRIB MINERAL PETR, V138, P176, DOI 10.1007/s004100050016; HUNTER DR, 1992, J AFR EARTH SCI, V15, P127, DOI 10.1016/0899-5362(92)90013-3; Jacob DE, 1999, LITHOS, V48, P317, DOI 10.1016/S0024-4937(99)00034-1; Klein M, 2000, GEOCHIM COSMOCHIM AC, V64, P99, DOI 10.1016/S0016-7037(99)00178-7; Klemme S, 2002, GEOCHIM COSMOCHIM AC, V66, P3109, DOI 10.1016/S0016-7037(02)00859-1; Kreissig K, 2000, LITHOS, V50, P1, DOI 10.1016/S0024-4937(99)00037-7; Kusky TM, 1999, TECTONOPHYSICS, V305, P43, DOI 10.1016/S0040-1951(99)00014-1; LUAIS B, 1994, J PETROL, V35, P43, DOI 10.1093/petrology/35.1.43; Martin H, 1999, LITHOS, V46, P411, DOI 10.1016/S0024-4937(98)00076-0; Munker C, 1998, CHEM GEOL, V144, P23, DOI 10.1016/S0009-2541(97)00105-8; Nicholson KN, 2000, TECTONOPHYSICS, V327, P157, DOI 10.1016/S0040-1951(00)00167-0; Niu YL, 1997, EARTH PLANET SC LETT, V148, P471, DOI 10.1016/S0012-821X(97)00048-4; Nutman AP, 1999, CONTRIB MINERAL PETR, V137, P364, DOI 10.1007/s004100050556; Polat A, 2002, CHEM GEOL, V184, P231, DOI 10.1016/S0009-2541(01)00363-1; Rapp RP, 1999, CHEM GEOL, V160, P335, DOI 10.1016/S0009-2541(99)00106-0; RAPP RP, 1995, J PETROL, V36, P891, DOI 10.1093/petrology/36.4.891; RAPP RP, 1995, J GEOPHYS RES-SOL EA, V100, P15601, DOI 10.1029/95JB00913; Rollinson H, 1997, NATURE, V389, P173, DOI 10.1038/38266; Rudnick RL, 2000, SCIENCE, V287, P278, DOI 10.1126/science.287.5451.278; SEN C, 1994, CONTRIB MINERAL PETR, V117, P394, DOI 10.1007/BF00307273; Smithies RH, 2000, EARTH PLANET SC LETT, V182, P115, DOI 10.1016/S0012-821X(00)00236-3; Weyer S, 2003, EARTH PLANET SC LETT, V205, P309, DOI 10.1016/S0012-821X(02)01059-2	31	590	658	4	133	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 9	2003	425	6958					605	609		10.1038/nature02031	http://dx.doi.org/10.1038/nature02031			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534583				2022-12-28	WOS:000185801000033
J	Bloom, J; Amador, V; Bartolini, F; DeMartino, G; Pagano, M				Bloom, J; Amador, V; Bartolini, F; DeMartino, G; Pagano, M			Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation	CELL			English	Article							S-PHASE; IN-VIVO; UBIQUITINATION; PROTEIN; PROGRESSION; RESIDUE; CYCLIN; P53; INHIBITOR; P21(CIP1)	We examined the mechanism responsible for the degradation of p21, a negative regulator of the cell division cycle. We found that p21 proteolysis requires functional ubiquitin and Nedd8 systems. Ubiquitinylated forms of p21 and p21(K0), a p21 mutant missing all lysines, are detected in vivo and in vitro, showing that the presence of lysines is dispensable for p21 ubiquitinylation. Instead, the free amino group of the N-terminal methionine of p21 is a site for ubiquitinylation in vivo. Although wild-type p21 is more abundantly ubiquitinylated than p21(K0) mutant due to the presence of internal lysine residues, their rates of proteolysis are indistinguishable. These results demonstrate that proteasomal degradation of p21 is regulated by the ubiquitin pathway and suggest that the site of the ubiquitin chain is critical in making p21 a competent substrate for the proteasome.	NYU, Inst Canc, New York, NY 10016 USA; NYU, Sch Med, New York, NY 10016 USA; Univ Texas, SW Med Ctr, Dallas, TX 75390 USA	New York University; New York University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Pagano, M (corresponding author), NYU, Inst Canc, 550 1St Ave, New York, NY 10016 USA.			pagano, michele/0000-0003-3210-2442	NATIONAL CANCER INSTITUTE [R01CA076584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA76584] Funding Source: Medline; NIGMS NIH HHS [R01-GM57587] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; Fukuchi K, 2002, BIOCHEM BIOPH RES CO, V293, P120, DOI 10.1016/S0006-291X(02)00198-5; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; NISHIMOTO T, 1980, SOMAT CELL GENET, V6, P465, DOI 10.1007/BF01539150; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367	25	263	271	1	17	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 3	2003	115	1					71	82		10.1016/S0092-8674(03)00755-4	http://dx.doi.org/10.1016/S0092-8674(03)00755-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14532004	Bronze			2022-12-28	WOS:000185815500010
J	Gibb, DM; Duong, T; Tookey, PA; Sharland, M; Tudor-Williams, G; Novelli, V; Butler, K; Riordan, A; Farrelly, L; Masters, J; Peckham, CS; Dunn, DT				Gibb, DM; Duong, T; Tookey, PA; Sharland, M; Tudor-Williams, G; Novelli, V; Butler, K; Riordan, A; Farrelly, L; Masters, J; Peckham, CS; Dunn, DT		NSHPC; CHIPS	Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANTIRETROVIRAL THERAPY; HIV-INFECTION	Objective To describe changes in demographic factors, disease progression, hospital admissions, and use of antiretroviral therapy in children with HIV. Design Active surveillance through the national study of HIV in pregnancy and childhood (NSHPC and additional data from a subset of children in the collaborative HIV paediatric study (CHIPS). Setting United Kingdom and Ireland. Participants 944 children with perinatally acquired HIV-1 under clinical care. Main outcome measures Changes over time in progression to AIDS and death, hospital admission rates, and use of antiretroviral therapy. Results 944 children with perinatally acquired HIV were reported in the United Kingdom and Ireland by October 2002; 628 (67%) were black African, 205 (22%) were aged ! 10 years at last follow up, 193 (20%) are know to have died. The proportion of children presenting who were born abroad increased from 20% in 1994-5 to 60% during 2000-2. Mortality was stable before 1997 at 9.3 per 100 child years at risk but fell to 2.0 in 2001-2 (trend P < 0.001). Progression to AIDS)S also declined (P < 0.00 1). From 1997 onwards the proportion of children on three or four drug antiretroviral therapy increased. Hospital admission rates declined by 80%, but with more children in follow up the absolute number of admissions fell by only 26%. Conclusion In children with HIV infection, mortality, AIDS, and hospital admission rates have declined substantially since the introduction of three or four drug antiretroviral therapy in 1997. As infected children in the United Kingdom and Ireland are living longer, there is an increasing need to address their medical, social, and psychological needs as they enter adolescence and adult life.	MRC, Clin Trials Unit, London NW1 2DA, England; Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England; Univ London St Georges Hosp, Paediat Infect Dis Unit, London SW17 0QT, England; St Marys Hosp, Dept Paediat, London W2 1NY, England; Great Ormond St Hosp Sick Children, London WC1N 3JH, England; Our Ladys Hosp Sick Children, Dublin 12, Ireland; Birmingham Heartlands Hosp, Birmingham B9 5SS, W Midlands, England	Medical Research Council Clinical Trials Unit; University of London; University College London; St Georges University London; Imperial College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Our Ladys Children Hospital Crumlin; Heart of England NHS Foundation Trust; University of Birmingham	Gibb, DM (corresponding author), MRC, Clin Trials Unit, London NW1 2DA, England.	D.Gibb@ctu.mrc.ac.uk	Tookey, Pat A/G-2732-2010; peckham, catherine s/I-6300-2013	Tookey, Pat A/0000-0001-6258-0387; Dunn, David/0000-0003-1836-4446; sharland, mike/0000-0001-8626-8291; Gibb, Diana/0000-0002-9738-5490				Aboulker JP, 2001, ARCH DIS CHILD, V84, P230, DOI 10.1136/adc.84.3.230; ADES AE, 1993, BRIT MED J, V306, P1296, DOI 10.1136/bmj.306.6888.1296; [Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; [Anonymous], GUIDELINES USE ANTIR; *BRIT HIV ASS, GUID TREATM HIV INF; CLAYTON C, 1993, STAT MODELS EPIDEMIO; Cliffe S, 2001, BRIT MED J, V323, P376, DOI 10.1136/bmj.323.7309.376; de Martino M, 2000, JAMA-J AM MED ASSOC, V284, P190, DOI 10.1001/jama.284.2.190; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157; Kinghorn G, 2001, BMJ-BRIT MED J, V323, P243, DOI 10.1136/bmj.323.7307.243; Litalien C, 2003, PEDIATR INFECT DIS J, V22, P48, DOI 10.1097/00006454-200301000-00014; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Porter K, 2003, LANCET, V362, P1267, DOI 10.1016/S0140-6736(03)14570-9; Sharland M, 2002, HIV Med, V3, P215, DOI 10.1046/j.1468-1293.2002.00120.x; Tarwater PM, 2001, AM J EPIDEMIOL, V154, P675, DOI 10.1093/aje/154.7.675; *UNL AN SURV STEER, 2002, PREV HIV HEP INF UK; Williams AJ, 2001, AIDS, V15, P335, DOI 10.1097/00002030-200102160-00006; *WORK GROUP ANT TH, 2001, GUID US ANT AG PED H; *WORK GROUP ANT TH, MED MAN HIV INF CHIL; World Health Organization, 2002, SCAL ANT THER RES LT	22	164	171	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 1	2003	327	7422					1019	1023		10.1136/bmj.327.7422.1019	http://dx.doi.org/10.1136/bmj.327.7422.1019			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738NE	14593035	Green Submitted, Green Published, Green Accepted, Bronze			2022-12-28	WOS:000186294100020
J	Francis, CW; Berkowitz, SD; Comp, PC; Lieberman, JR; Ginsberg, JS; Paiement, G; Peters, GR; Roth, AW; McElhattan, J; Colwell, CW				Francis, CW; Berkowitz, SD; Comp, PC; Lieberman, JR; Ginsberg, JS; Paiement, G; Peters, GR; Roth, AW; McElhattan, J; Colwell, CW		EXULT A Study Grp	Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; FATAL PULMONARY-EMBOLISM; TOTAL HIP; ORAL ANTICOAGULANTS; ARTHROPLASTY; ENOXAPARIN; PROPHYLAXIS; MELAGATRAN; PHARMACOKINETICS	BACKGROUND: In a previous study of the prevention of venous thromboembolism after total knee replacement, the efficacy of ximelagatran, an oral direct thrombin inhibitor that does not require monitoring of coagulation or dose adjustment, was found to be similar to that of warfarin at a dose of 24 mg of ximelagatran twice daily. The purpose of the present study was to determine whether a higher dose of ximelagatran is superior to warfarin. METHODS: This randomized, double-blind trial compared a regimen of 7 to 12 days of oral ximelagatran, at a dose of 24 or 36 mg twice daily, starting the morning after surgery, with warfarin therapy started the evening of the day of surgery. The composite end point of venous thromboembolism and death from all causes and the incidence of bleeding were the primary outcome measures. RESULTS: Among the 1851 patients in the efficacy analysis, oral ximelagatran at a dose of 36 mg twice daily was superior to warfarin with respect to the primary composite end point of venous thromboembolism and death from all causes (20.3 percent vs. 27.6 percent; P=0.003). There were no significant differences between these two groups with respect to major bleeding (incidence, 0.8 percent and 0.7 percent, respectively), perioperative indicators of bleeding, wound characteristics, or the composite secondary end point of proximal deep-vein thrombosis, pulmonary embolism, and death (2.7 percent vs. 4.1 percent; P=0.17). CONCLUSIONS: The efficacy of oral ximelagatran, administered starting the morning after total knee replacement, was superior to that of warfarin for prevention of venous thromboembolism. Rates of hemorrhagic complications with the two drugs were similar.	Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA; Astra Zeneca, Dept Clin Dev, Wilmington, DE USA; Univ Oklahoma, Dept Med, Oklahoma City, OK USA; Univ Calif Los Angeles, Dept Orthoped Surg, Los Angeles, CA USA; McMaster Univ, Dept Med, Hamilton, ON, Canada; Univ Calif Irvine, Dept Orthoped Surg, Irvine, CA USA; Scripps Clin, Dept Orthopaed Surg, La Jolla, CA USA	University of Rochester; AstraZeneca; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of California System; University of California Los Angeles; McMaster University; University of California System; University of California Irvine; Scripps Research Institute	Francis, CW (corresponding author), Univ Rochester, Med Ctr, Dept Med, 610 Elmwood Ave,Box 610, Rochester, NY 14642 USA.	charles_francis@urmc.rochester.edu	Berkowitz, Scott Darrell/AAS-9397-2021; Kovacs, Michael/G-3315-2011; ginsberg, jeffrey s/ABC-1065-2020	Berkowitz, Scott Darrell/0000-0002-9428-4408; 				Ansari S, 1997, J ARTHROPLASTY, V12, P599, DOI 10.1016/S0883-5403(97)90131-5; Ansell J, 2001, CHEST, V119, p22S, DOI 10.1378/chest.119.1_suppl.22S; Bauer KA, 2001, NEW ENGL J MED, V345, P1305, DOI 10.1056/NEJMoa011099; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Cohen AT, 2001, THROMB HAEMOSTASIS, V85, P940; Eriksson B, 2002, LANCET, V360, P1441, DOI 10.1016/S0140-6736(02)11469-3; Eriksson BI, 2003, THROMB HAEMOSTASIS, V89, P288; Eriksson UG, 2001, CLIN PHARMACOL THER, V69, pP24; ERIKSSON UG, 2001, JCLIN PHARM THER, V62, pP24; ERIKSSONLEPKOWS.M, 2001, P 28 C INT SOC THROM; Fitzgerald RH, 2001, J BONE JOINT SURG AM, V83A, P900, DOI 10.2106/00004623-200106000-00012; Francis CW, 2002, ANN INTERN MED, V137, P648, DOI 10.7326/0003-4819-137-8-200210150-00008; Francis CW, 1996, THROMB HAEMOSTASIS, V75, P706; FRIEDMAN RJ, 1994, J BONE JOINT SURG AM, V76A, P1174; Geerts WH, 2001, CHEST, V119, p132S, DOI 10.1378/chest.119.1_suppl.132S; Gross M, 1999, CAN J SURG, V42, P457; Hamulyak K, 1995, THROMB HAEMOSTASIS, V74, P1428; Heit JA, 2001, ARCH INTERN MED, V161, P2215, DOI 10.1001/archinte.161.18.2215; Heit JA, 1997, THROMB HAEMOSTASIS, V77, P32; Hirsh J, 2001, CHEST, V119, p8S, DOI 10.1378/chest.119.1_suppl.8S; HULL R, 1993, NEW ENGL J MED, V329, P1370, DOI 10.1056/NEJM199311043291902; Johansson LC, 2003, CLIN PHARMACOKINET, V42, P381, DOI 10.2165/00003088-200342040-00006; JOHNASSON S, 2001, P 28 C INT SOC THROM; Kalebo P, 1996, THROMB HAEMOSTASIS, V76, P893; KHAW FM, 1993, J BONE JOINT SURG BR, V75, P940, DOI 10.1302/0301-620X.75B6.8245087; Klement P, 2003, J THROMB HAEMOST, V1, P587, DOI 10.1046/j.1538-7836.2003.00060.x; Leclerc JR, 1996, ANN INTERN MED, V124, P619, DOI 10.7326/0003-4819-124-7-199604010-00001; Mesko JW, 2001, J ARTHROPLASTY, V16, P679, DOI 10.1054/arth.2001.25506; MOHR DN, 1992, MAYO CLIN PROC, V67, P861, DOI 10.1016/S0025-6196(12)60825-8; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; STRINGER MD, 1989, J BONE JOINT SURG BR, V71, P492, DOI 10.1302/0301-620X.71B3.2785998; STULBERG BN, 1984, J BONE JOINT SURG AM, V66A, P194, DOI 10.2106/00004623-198466020-00005; Turpie AGG, 2002, ARCH INTERN MED, V162, P1833, DOI 10.1001/archinte.162.16.1833	33	243	264	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 30	2003	349	18					1703	1712		10.1056/NEJMoa035162	http://dx.doi.org/10.1056/NEJMoa035162			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	737FJ	14585938				2022-12-28	WOS:000186219500004
J	Roy, PM; Gras, E				Roy, PM; Gras, E			Cerebral venous thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Angers Univ Hosp, F-49033 Angers, France	Universite d'Angers; Centre Hospitalier Universitaire d'Angers	Roy, PM (corresponding author), Angers Univ Hosp, F-49033 Angers, France.		Roy, Pierre-Marie/AAA-7737-2022						0	4	5	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	2003	349	18					1730	1730		10.1056/NEJMicm010862	http://dx.doi.org/10.1056/NEJMicm010862			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	737FJ	14585941				2022-12-28	WOS:000186219500007
J	Chen, RT; Lane, JM				Chen, RT; Lane, JM			Myocarditis: the unexpected return of smallpox vaccine adverse events	LANCET			English	Editorial Material									Ctr Dis Control & Prevent, Immunizat Safety Branch, Natl Immunizat Program, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Smallpox Eradicat Program, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Chen, RT (corresponding author), Ctr Dis Control & Prevent, Immunizat Safety Branch, Natl Immunizat Program, Atlanta, GA 30333 USA.	bchen@cdc.gov	Chen, Robert T/AIA-8164-2022	Chen, Robert T/0000-0002-3094-8367				BURNET FM, 2003, AUSTRALAS ANN MED, V1, P93; Carabin H, 2003, J INFECT DIS, V187, pS29, DOI 10.1086/368038; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P639; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P248; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P88; Chen RT, 1999, VACCINE, V17, pS41, DOI 10.1016/S0264-410X(99)00292-3; Chen RT, 1998, LANCET, V351, P611, DOI 10.1016/S0140-6736(05)78423-3; Grabenstein JD, 2003, JAMA-J AM MED ASSOC, V289, P3278, DOI 10.1001/jama.289.24.3278; Halsell JS, 2003, JAMA-J AM MED ASSOC, V289, P3283, DOI 10.1001/jama.289.24.3283; Henderson DA, 2002, CLIN INFECT DIS, V34, P79, DOI 10.1086/323897; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; KARJALAINEN J, 1983, ACTA MED SCAND, V213, P65; LANE JM, 1969, NEW ENGL J MED, V281, P1220, DOI 10.1056/NEJM196911272812205; McNeill W.H., 1976, PLAGUES PEOPLES, V1st ed.; 1971, LANCET, V2, P305	15	20	21	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 25	2003	362	9393					1345	1346		10.1016/S0140-6736(03)14674-0	http://dx.doi.org/10.1016/S0140-6736(03)14674-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	735YX	14585633				2022-12-28	WOS:000186143300005
J	Pollock, AM; Price, D; Talbot-Smith, A; Mohan, J				Pollock, AM; Price, D; Talbot-Smith, A; Mohan, J			NHS and the Health and Social Care Bill: end of Bevan's vision?	BRITISH MEDICAL JOURNAL			English	Article								Although the Labour government has repeatedly pledged its commitment to the NHS, its latest reforms pave the way for multiple providers of health care.	UCL, Sch Publ Policy, Publ Hlth Policy Unit, London WC1H 9QU, England; Univ Portsmouth, Dept Geog, Portsmouth PO1 2UP, Hants, England	University of London; University College London; University of Portsmouth	Pollock, AM (corresponding author), UCL, Sch Publ Policy, Publ Hlth Policy Unit, London WC1H 9QU, England.	allyson.pollock@ucl.ac.uk		Mohan, John/0000-0002-6063-3454; pollock, allyson/0000-0002-7388-3110				*DEP HLTH, 2003, AG CHANG DRAFT CONTR; *DEP HLTH, 2002, REF NHS FIN FLOWS IN; *DEP HLTH, 2003, CMND5876; Department of Health, 2001, 200101 DEP HLTH; *HOUS COMM SEL COM, 2003, LETT SECR STAT HLTH; *HOUS COMM SEL COM, 2003, MEM KINGS FUND	6	13	13	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 25	2003	327	7421					982	985		10.1136/bmj.327.7421.982	http://dx.doi.org/10.1136/bmj.327.7421.982			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	736AL	14576253	Green Published			2022-12-28	WOS:000186147800023
J	Day, PK; LeDuc, HG; Mazin, BA; Vayonakis, A; Zmuidzinas, J				Day, PK; LeDuc, HG; Mazin, BA; Vayonakis, A; Zmuidzinas, J			A broadband superconducting detector suitable for use in large arrays	NATURE			English	Article							TRANSITION EDGE SENSORS; X-RAY-DETECTION; ENERGY RESOLUTION; ELECTROTHERMAL FEEDBACK; IMAGING SPECTROMETERS; TUNNEL-JUNCTIONS; MICROCALORIMETER; TEMPERATURE; INDUCTANCE; MULTIPLEXER	Cryogenic detectors are extremely sensitive and have a wide variety of applications(1-3) (particularly in astronomy(4-8)), but are difficult to integrate into large arrays like a modern CCD ( charge-coupled device) camera. As current detectors of the cosmic microwave background (CMB) already have sensitivities comparable to the noise arising from the random arrival of CMB photons, the further gains in sensitivity needed to probe the very early Universe will have to arise from large arrays. A similar situation is encountered at other wavelengths. Single-pixel X-ray detectors now have a resolving power of DeltaE < 5 eV for single 6-keV photons, and future X-ray astronomy missions(7) anticipate the need for 1,000-pixel arrays. Here we report the demonstration of a superconducting detector that is easily fabricated and can readily be incorporated into such an array. Its sensitivity is already within an order of magnitude of that needed for CMB observations, and its energy resolution is similarly close to the targets required for future X-ray astronomy missions.	Jet Prop Lab, Pasadena, CA 91107 USA; CALTECH, Pasadena, CA 91125 USA	National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); California Institute of Technology	Day, PK (corresponding author), Jet Prop Lab, Pasadena, CA 91107 USA.		Mazin, Ben/B-8704-2011	Mazin, Ben/0000-0003-0526-1114				Angloher G, 2001, J APPL PHYS, V89, P1425, DOI 10.1063/1.1331332; Booth NE, 1996, ANNU REV NUCL PART S, V46, P471, DOI 10.1146/annurev.nucl.46.1.471; Cabrera B, 1998, APPL PHYS LETT, V73, P735, DOI 10.1063/1.121984; CHANG WH, 1979, J APPL PHYS, V50, P8129, DOI 10.1063/1.325953; Chervenak JA, 1999, APPL PHYS LETT, V74, P4043, DOI 10.1063/1.123255; de Korte PAJ, 2000, NUCL INSTRUM METH A, V444, P163, DOI 10.1016/S0168-9002(99)01350-9; Irwin KD, 2000, NUCL INSTRUM METH A, V444, P184, DOI 10.1016/S0168-9002(99)01354-6; Irwin KD, 1996, APPL PHYS LETT, V69, P1945, DOI 10.1063/1.117630; KAPLAN SB, 1976, PHYS REV B, V14, P4854, DOI 10.1103/PhysRevB.14.4854; Kozorezov AG, 2000, PHYS REV B, V61, P11807, DOI 10.1103/PhysRevB.61.11807; KRAUS H, 1986, EUROPHYS LETT, V1, P161, DOI 10.1209/0295-5075/1/4/002; Lee SF, 1998, APPL OPTICS, V37, P3391, DOI 10.1364/AO.37.003391; Li L, 2003, J APPL PHYS, V93, P1137, DOI 10.1063/1.1533106; Li L, 2001, J APPL PHYS, V90, P3645, DOI 10.1063/1.1391422; MATTIS DC, 1958, PHYS REV, V111, P412, DOI 10.1103/PhysRev.111.412; Mazin BA, 2002, PROC SPIE, V4849, P283, DOI 10.1117/12.460456; MCMILLAN WL, 1968, PHYS REV, V167, P331, DOI 10.1103/PhysRev.167.331; MOSELEY SH, 1984, J APPL PHYS, V56, P1257, DOI 10.1063/1.334129; Newbury DE, 2000, J RADIOANAL NUCL CH, V244, P627, DOI 10.1023/A:1006777606703; Peacock A, 1996, NATURE, V381, P135, DOI 10.1038/381135a0; Rando N, 2000, REV SCI INSTRUM, V71, P4582, DOI 10.1063/1.1326055; Saab T, 2002, NUCL PHYS B-PROC SUP, V110, P100; Sergeev AV, 2002, APPL PHYS LETT, V80, P817, DOI 10.1063/1.1445462; Tinkham M., 1996, INTRO SUPERCONDUCTIV, V2nd ed.; TWERENBOLD D, 1986, EUROPHYS LETT, V1, P209, DOI 10.1209/0295-5075/1/5/002; WELLS GL, 1970, PHYS REV B, V1, P3636, DOI 10.1103/PhysRevB.1.3636; Wilson CM, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.067004; Yoon J, 2001, APPL PHYS LETT, V78, P371, DOI 10.1063/1.1338963; ZMUIDZINAS J, 1992, IEEE T MICROW THEORY, V40, P1797, DOI 10.1109/22.156607	29	1000	1020	8	178	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					817	821		10.1038/nature02037	http://dx.doi.org/10.1038/nature02037			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574407				2022-12-28	WOS:000186118500040
J	Smith-Bindman, R; Chu, PW; Miglioretti, DL; Sickles, EA; Blanks, R; Ballard-Barbash, R; Bobo, JK; Lee, NC; Wallis, NG; Patnick, J; Kerlikowske, K				Smith-Bindman, R; Chu, PW; Miglioretti, DL; Sickles, EA; Blanks, R; Ballard-Barbash, R; Bobo, JK; Lee, NC; Wallis, NG; Patnick, J; Kerlikowske, K			Comparison of screening mammography in the United States and the United Kingdom	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITIVE PREDICTIVE VALUE; BREAST-CANCER; DIAGNOSTIC MAMMOGRAPHY; MEDICAL AUDIT; 22 COUNTRIES; FOLLOW-UP; PROGRAM; PERFORMANCE; GUIDELINES; WOMEN	Context Screening mammography differs between the United States and the United Kingdom; a direct comparison may suggest methods to improve the practice. Objective To compare screening mammography performance between the United States and the United Kingdom among similar-aged women. Design, Setting, and Participants Women aged 50 years or older were identified who underwent 5.5 million mammograms from January 1, 1996, to December 31, 1999, within 3 large-scale mammography registries or screening programs: the Breast Cancer Surveillance Consortium (BCSC, n=978591) and National Breast and Cervical Cancer Early Detection Program (NBCCEDP, n=613388) in the United States; and the National Health Service Breast Screening Program (NHSBSP, n =3.94 million) in the United Kingdom. A total of 27612 women were diagnosed with breast cancer (invasive or ductal carcinoma in situ) within 12 months of screening among the 3 groups. Main Outcome Measures Recall rates (recommendation for further evaluation including diagnostic imaging, ultrasound, clinical examination, or biopsy) and cancer detection rates were calculated for first and subsequent mammograms, and within 5-year age groups. Results Recall rates were approximately twice as high in the United States than in the United Kingdom for all age groups; however, cancer rates were similar. Among women aged 50 to 54 years who underwent a first screening mammogram, 14.4% in the BCSC and 12.5% in the NBCCEDP were recalled for further evaluation vs only 7.6% in the NHSBSP. Cancer detection rates per 1000 mammogram screens were 5.8, 5.9, and 6.3, in the BCSC, NBCCEDP, and NHSBSP, respectively. Recall rates were lower for subsequent examinations in all 3 settings but remained twice as high in the United States. A similar percentage of women underwent biopsy in each setting, but rates of percutaneous biopsy were lower and open surgical biopsy higher in the United States. Open surgical biopsies not resulting in a diagnosis of cancer (negative biopsies) were twice as high in the United States than in the United Kingdom. Based on a 10-year period of screening 1000 women aged 50 to 59 years, 477, 433, and 175 women in the BCSC, NBCCEDP, and NHSBSP, respectively, would be recalled; and for women aged 60 to 69 years, 396, 334, and 1 33 women, respectively. The estimated cancer detection rates per 1000 women aged 50 to 59 years were 24.5, 23.8, and 19.4, respectively, and for women aged 60 to 69 years, 31.5, 26.6, and 27.9, respectively. Conclusions Recall and negative open surgical biopsy rates are twice as high in US settings than in the United Kingdom but cancer detection rates are similar. Efforts to improve US mammographic screening should target lowering the recall rate without reducing the cancer detection rate.	Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Vet Affairs, Gen Internal Med Sect, San Francisco, CA 94143 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ London, Inst Canc Res, Canc Screening Evaluat Unit, London WC1E 7HU, England; NCI, Appl Res Program, NIH, Bethesda, MD 20892 USA; Ctr Dis Control & Prevent, Atlanta, GA USA; Natl Hlth Serv Breast Screening Program, Sheffield, S Yorkshire, England; Warwickshire Solihull & Coventry Breast Screening, Coventry, W Midlands, England	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Centers for Disease Control & Prevention - USA	Smith-Bindman, R (corresponding author), Univ Calif San Francisco, Dept Radiol, Mt Zion Campus,1600 Divisadero St, San Francisco, CA 94115 USA.	rebecca.smith-bindman@radiology.ucsf.edu			NCI NIH HHS [CA86032, U01CA63740, U01CA86076] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K07CA086032, U01CA086076, U01CA063740] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		American College of Radiology, 1998, BREAST IM REP DAT SY, V3rd; BallardBarbash R, 1997, AM J ROENTGENOL, V169, P1001, DOI 10.2214/ajr.169.4.9308451; Bassett LW, 1994, AHCPR PUBLICATION; Beam CA, 1996, ACAD RADIOL, V3, P891, DOI 10.1016/S1076-6332(96)80296-0; Blanks RG, 2002, J MED SCREEN, V9, P11, DOI 10.1136/jms.9.1.11; Blanks RG, 2001, J MED SCREEN, V8, P24, DOI 10.1136/jms.8.1.24; Blanks RG, 2000, J MED SCREEN, V7, P195, DOI 10.1136/jms.7.4.195; Brett J, 2001, J PUBLIC HEALTH MED, V23, P292, DOI 10.1093/pubmed/23.4.292; BROWN ML, 1995, AM J ROENTGENOL, V165, P1373, DOI 10.2214/ajr.165.6.7484568; Burnside E, 2001, Clin Breast Cancer, V2, P145, DOI 10.3816/CBC.2001.n.019; Burnside ES, 2002, AM J ROENTGENOL, V179, P1173, DOI 10.2214/ajr.179.5.1791173; Carney PA, 2003, ANN INTERN MED, V138, P168, DOI 10.7326/0003-4819-138-3-200302040-00008; Christiansen CL, 2000, JNCI-J NATL CANCER I, V92, P1657, DOI 10.1093/jnci/92.20.1657; Dee KE, 2001, AM J ROENTGENOL, V176, P729, DOI 10.2214/ajr.176.3.1760729; Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601; ERNSTER VL, 2002, J NATL CANCER I, V94, P1151; Esserman L, 2002, JNCI-J NATL CANCER I, V94, P369; Feig SA, 1998, AM J ROENTGENOL, V171, P29, DOI 10.2214/ajr.171.1.9648758; Forrest APM, 1987, BREAST CANC SCREEN R, V3rd, P102; GALE A, 1999, MED IMAGING 1999 IMA, P157; Henson R M, 1996, J Public Health Manag Pract, V2, P36; HOUN F, 1994, RADIOLOGY, V190, P209, DOI 10.1148/radiology.190.1.8259406; Kan L, 2000, RADIOLOGY, V215, P563, DOI 10.1148/radiology.215.2.r00ma42563; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P39, DOI 10.1001/jama.276.1.39; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; Klabunde CN, 2002, INT J QUAL HEALTH C, V14, P449, DOI 10.1093/intqhc/14.6.449; Kopans DB, 2000, RADIOL CLIN N AM, V38, P719, DOI 10.1016/S0033-8389(05)70196-2; Leitch AM, 1997, CA-CANCER J CLIN, V47, P150, DOI 10.3322/canjclin.47.3.150; May DS, 1998, AM J ROENTGENOL, V170, P97, DOI 10.2214/ajr.170.1.9423608; MOSS M, 2002, NY TIMES        0627; *NHS BREAST SCREEN, 2000, AUD SCREEN DET BREAS; *NHS BREAST SCREEN, 1997, NAT HLTH SERV BREAST, V15; Physician Insurers Association of America, 1995, BREAST CANC STUD JUN; Salzmann P, 1997, ANN INTERN MED, V127, P955, DOI 10.7326/0003-4819-127-11-199712010-00001; Shapiro S, 1998, INT J EPIDEMIOL, V27, P735, DOI 10.1093/ije/27.5.735; Sickles EA, 2002, RADIOLOGY, V224, P861, DOI 10.1148/radiol.2243011482; SICKLES EA, 1990, RADIOLOGY, V175, P323, DOI 10.1148/radiology.175.2.2326455; Sohlich RE, 2002, AM J ROENTGENOL, V178, P681, DOI 10.2214/ajr.178.3.1780681; Suleiman OH, 1999, RADIOLOGY, V210, P345, DOI 10.1148/radiology.210.2.r99fe45345; U.S. Preventive Services Task Force, 2002, SCREEN BREAST CANC R; *UK DEP HLTH, 2001, STAT B BREAST SCREEN; *UK NAT HLTH SERV, NHS BREAST SCREEN PR; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Williams LJ, 1998, J MED SCREEN, V5, P202, DOI 10.1136/jms.5.4.202; Yankaskas BC, 2001, AM J ROENTGENOL, V177, P543, DOI 10.2214/ajr.177.3.1770543; Yood MU, 1999, CANCER EPIDEM BIOMAR, V8, P595	46	252	254	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	2003	290	16					2129	2137		10.1001/jama.290.16.2129	http://dx.doi.org/10.1001/jama.290.16.2129			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CB	14570948	Bronze			2022-12-28	WOS:000186036700022
J	Gottlieb, S				Gottlieb, S			Murderer can be forced to take medication to become sane enough to be executed	BRITISH MEDICAL JOURNAL			English	News Item																		Gottlieb S, 2003, BRIT MED J, V326, P415, DOI 10.1136/bmj.326.7386.415	1	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 18	2003	327	7420					889	889		10.1136/bmj.327.7420.889-c	http://dx.doi.org/10.1136/bmj.327.7420.889-c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734RV	14563734	Green Published			2022-12-28	WOS:000186072100013
J	Hacein-Bey-Abina, S; Von Kalle, C; Schmidt, M; McCcormack, MP; Wulffraat, N; Leboulch, P; Lim, A; Osborne, CS; Pawliuk, R; Morillon, E; Sorensen, R; Forster, A; Fraser, P; Cohen, JI; de Saint Basile, G; Alexander, I; Wintergerst, U; Frebourg, T; Aurias, A; Stoppa-Lyonnet, D; Romana, S; Radford-Weiss, I; Gross, F; Valensi, F; Delabesse, E; Macintyre, E; Sigaux, F; Soulier, J; Leiva, LE; Wissler, M; Prinz, C; Rabbitts, TH; Le Deist, F; Fischer, A; Cavazzana-Calvo, M				Hacein-Bey-Abina, S; Von Kalle, C; Schmidt, M; McCcormack, MP; Wulffraat, N; Leboulch, P; Lim, A; Osborne, CS; Pawliuk, R; Morillon, E; Sorensen, R; Forster, A; Fraser, P; Cohen, JI; de Saint Basile, G; Alexander, I; Wintergerst, U; Frebourg, T; Aurias, A; Stoppa-Lyonnet, D; Romana, S; Radford-Weiss, I; Gross, F; Valensi, F; Delabesse, E; Macintyre, E; Sigaux, F; Soulier, J; Leiva, LE; Wissler, M; Prinz, C; Rabbitts, TH; Le Deist, F; Fischer, A; Cavazzana-Calvo, M			LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1	SCIENCE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; NONHUMAN-PRIMATES; TRANSGENIC MICE; PROTEIN RBTN2; HUMAN GENOME; GAMMA-CHAIN; LEUKEMIA; TRANSLOCATIONS; LYMPHOCYTES; DELTA	We have previously shown correction of X-linked severe combined immunodeficiency [SCID-X1, also known as gamma chain (gammac) deficiency] in 9 out of 10 patients by retrovirus-mediated gammac gene transfer into autologous CD34 bone marrow cells. However, almost 3 years after gene therapy, uncontrolled exponential clonal proliferation of mature T cells (with gammadelta+ or alphabeta+ T cell receptors) has occurred in the two youngest patients. Both patients' clones showed retrovirus vector integration in proximity to the LMO2 proto-oncogene promoter, leading to aberrant transcription and expression of LMO2. Thus, retrovirus vector insertion can trigger deregulated premalignant cell proliferation with unexpected frequency, most likely driven by retrovirus enhancer activity on the LMO2 gene promoter.	INSERM, U429, F-75743 Paris 15, France; Assistance Publ Hop Paris, Dept Biotherapie, F-75743 Paris, France; Univ Paris 05, Lab Cytogenet, F-75743 Paris 15, France; Univ Paris 05, Lab Cent Hematol, F-75743 Paris 15, France; Univ Paris 05, CNRS, Unite Rech Associee 1461, F-75743 Paris 15, France; Hop Necker Enfants Malad, Unite Immunol & Hematol Pediat, F-75743 Paris 15, France; Univ Freiburg, Inst Mol Med & Cell Res, Freiburg, Germany; Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Med Ctr Utrecht, Wilhelmina Kinderziekenhuis, Utrecht, Netherlands; Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; INSERM, U277, F-75730 Paris, France; Babraham Inst, Lab Chromatin & Gene Express, Dev Genet Programme, Cambridge CB2 4AT, England; Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, New Orleans, LA 70112 USA; Childrens Hosp, New Orleans, LA 70112 USA; NIAID, Med Virol Sect, Clin Invest Lab, Bethesda, MD 20892 USA; Childrens Hosp Westmead, Sydney, NSW 2145, Australia; Univ & Childrens Hosp, D-80337 Munich, Germany; CHU, Serv Genet, F-76183 Rouen, France; Fac Med & Pharm, INSERM 9906, Equipe Mixte, F-76183 Rouen, France; Inst Curie, INSERM, U434, Paris 15, France; Inst Curie, Dept Oncol Genet, Paris 15, France; Hop St Louis, INSERM, U462, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Freiburg; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; MRC Laboratory Molecular Biology; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Children's Hospital of New Orleans; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Sydney; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; CHU de Rouen; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Fischer, A (corresponding author), INSERM, U429, F-75743 Paris 15, France.		Wilson, Matthew H/K-3193-2013; DELABESSE, Eric/I-5221-2016; Frebourg, Thierry/AAK-8390-2020; Fraser, Peter/B-7549-2009; Osborne, Cameron/N-1398-2017; de Saint Basile, Genevieve/G-9731-2017; Rabbitts, Terence/D-6262-2016	DELABESSE, Eric/0000-0002-0928-0753; Osborne, Cameron/0000-0003-4126-2499; Alexander, Ian E/0000-0002-6213-5627; Macintyre-Davi, Elizabeth Anne/0000-0003-0520-0493; Wintergerst, Uwe/0000-0002-0785-0337; Romana, Serge Pierrick/0000-0003-3435-239X; McCormack, Matthew/0000-0003-1536-5611; de Saint Basile, Genevieve/0000-0002-1913-5269; Fraser, Peter/0000-0002-0041-1227; Rabbitts, Terence/0000-0002-4982-2609	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000430, Z01AI000430] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; AURIAS A, UNPUB; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Dechanet J, 1999, J CLIN INVEST, V103, P1437, DOI 10.1172/JCI5409; DONAHUE RE, 1992, J EXP MED, V176, P1125, DOI 10.1084/jem.176.4.1125; FISCH P, 1992, ONCOGENE, V7, P2389; Freitas AA, 2000, ANNU REV IMMUNOL, V18, P83, DOI 10.1146/annurev.immunol.18.1.83; GARCIA IS, 1991, ONCOGENE, V6, P577; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; HaceinBey S, 1996, BLOOD, V87, P3108, DOI 10.1182/blood.V87.8.3108.bloodjournal8783108; Kamps WA, 1999, BLOOD, V94, P1226; Lafarge X, 2001, J INFECT DIS, V184, P533, DOI 10.1086/322843; Lantz O, 2000, NAT IMMUNOL, V1, P54, DOI 10.1038/76917; LARSON RC, 1994, ONCOGENE, V9, P3675; Li ZX, 2002, SCIENCE, V296, P497, DOI 10.1126/science.1068893; Lim A, 2002, J IMMUNOL METHODS, V261, P177, DOI 10.1016/S0022-1759(02)00004-2; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; NEALE GAM, 1995, BLOOD, V86, P3060; Neale Geoffrey A. M., 1997, Leukemia (Basingstoke), V11, P289; PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319; PRINTZ M, 1995, GENE THER, V2, P143; Rabbitts TH, 2001, ONCOGENE, V20, P5763, DOI 10.1038/sj.onc.1204597; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; Schmidt M, 2002, BLOOD, V100, P2737, DOI 10.1182/blood-2002-02-0407; Schmidt M. K., UNPUB; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Song X, 2002, P NATL ACAD SCI USA, V99, P6269, DOI 10.1073/pnas.092112199; SUGAMURA K, 1995, ADV IMMUNOL, V59, P225, DOI 10.1016/S0065-2776(08)60632-X; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VANIN EF, 1994, J VIROL, V68, P4241, DOI 10.1128/JVI.68.7.4241-4250.1994; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; [No title captured]	38	2658	2828	3	232	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					415	419		10.1126/science.1088547	http://dx.doi.org/10.1126/science.1088547			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564000				2022-12-28	WOS:000185963200033
J	O'Riordan, M; Moors, MA; Portnoy, DA				O'Riordan, M; Moors, MA; Portnoy, DA			Listeria intracellular growth and virulence require host-derived lipoic acid	SCIENCE			English	Article							PYRUVATE-DEHYDROGENASE COMPLEX; ESCHERICHIA-COLI; LIPB GENES; MONOCYTOGENES; PROTEIN; IDENTIFICATION; ANTIOXIDANT; METABOLISM; SECRETION; BIOLOGY	Listeria monocytogenes is a Gram-positive intracytosolic pathogen that causes severe disease in pregnant and immunocompromised individuals. We found that L. monocytogenes lacking the lipoate protein ligase LplA1 was defective for growth specifically in the host cytosol and was less virulent in animals by a factor of 300. A major target for LplA1, the E2 subunit of pyruvate dehydrogenase (PDH), lacked a critical lipoyl modi. cation when the DeltalplA1 strain was grown intracellularly, which suggests that abortive growth was due to loss of PDH function. Thus, the use of host-derived lipoic acid may be a critical process for in vivo replication of bacterial pathogens.	Univ Calif Berkeley, Sch Publ Hlth, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis, Berkeley, CA 94720 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Wake Forest University; Wake Forest Baptist Medical Center	O'Riordan, M (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA.		O'Riordan, Mary/D-8227-2011	O'Riordan, Mary/0000-0001-6014-4637	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029619, R01AI029619, R01AI027655] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI029619, R01 AI027655, R01 AI27655, AI29619] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROOKFIELD DE, 1991, FEBS LETT, V295, P13, DOI 10.1016/0014-5793(91)81373-G; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; CAMILLI A, 1989, P NATL ACAD SCI USA, V86, P5522, DOI 10.1073/pnas.86.14.5522; Chico-Calero I, 2002, P NATL ACAD SCI USA, V99, P431, DOI 10.1073/pnas.012363899; Dacheux D, 2002, INFECT IMMUN, V70, P3973, DOI 10.1128/IAI.70.7.3973-3977.2002; DUBENSKY T, COMMUNICATION; Gao HC, 2002, J BACTERIOL, V184, P2780, DOI 10.1128/JB.184.10.2780-2788.2002; Glaser P, 2001, SCIENCE, V294, P849; Lenz LL, 2002, MOL MICROBIOL, V45, P1043, DOI 10.1046/j.1365-2958.2002.03072.x; Lissens W, 2000, HUM MUTAT, V15, P209, DOI 10.1002/(SICI)1098-1004(200003)15:3<209::AID-HUMU1>3.0.CO;2-K; Lorenz MC, 2001, NATURE, V412, P83, DOI 10.1038/35083594; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; MORRIS TW, 1995, J BACTERIOL, V177, P1; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; O'Riordan M, 2002, TRENDS MICROBIOL, V10, P361, DOI 10.1016/S0966-842X(02)02401-0; ORIORDAN M, UNPUB; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; Portnoy DA, 2002, J CELL BIOL, V158, P409, DOI 10.1083/jcb.200205009; PREMARATNE RJ, 1991, APPL ENVIRON MICROB, V57, P3046, DOI 10.1128/AEM.57.10.3046-3048.1991; REED KE, 1993, J BACTERIOL, V175, P1325, DOI 10.1128/JB.175.5.1325-1336.1993; Stein A, 2000, J BACTERIOL, V182, P2119, DOI 10.1128/JB.182.8.2119-2124.2000	22	101	128	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					462	464		10.1126/science.1088170	http://dx.doi.org/10.1126/science.1088170			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564012				2022-12-28	WOS:000185963200048
J	Rignot, E; Rivera, A; Casassa, G				Rignot, E; Rivera, A; Casassa, G			Contribution of the Patagonia Icefields of South America to sea level rise	SCIENCE			English	Article							RECENT GLACIER VARIATIONS; NORTHERN PATAGONIA; INVENTORY	Digital elevation models of the Northern and Southern Patagonia Icefields of South America generated from the 2000 Shuttle Radar Topography Mission were compared with earlier cartography to estimate the volume change of the largest 63 glaciers. During the period 1968/1975-2000, these glaciers lost ice at a rate equivalent to a sea level rise of 0.042+/-0.002 millimeters per year. In the more recent years 1995-2000, average ice thinning rates have more than doubled to an equivalent sea level rise of 0.105+/-0.011 millimeters per year. The glaciers are thinning more quickly than can be explained by warmer air temperatures and decreased precipitation, and their contribution to sea level per unit area is larger than that of Alaska glaciers.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Chile, Dept Geog, Santiago, Chile; Univ Bristol, Sch Geog Sci, Bristol BS8 1SS, Avon, England; Ctr Estudios Cient, Valdivia, Chile	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Universidad de Chile; University of Bristol	Rignot, E (corresponding author), CALTECH, Jet Prop Lab, MS 300-227, Pasadena, CA 91109 USA.	eric.rignot@jpl.nasa.gov; andres.rivera@bristol.ac.uk; gcasassa@cecs.cl	Casassa, Gino/AAX-6142-2020; Rignot, Eric/A-4560-2014	Rignot, Eric/0000-0002-3366-0481; Rivera, Andres/0000-0002-2779-4192				Aniya M, 1999, ARCT ANTARCT ALP RES, V31, P165, DOI 10.2307/1552604; ANIYA M, 1988, ARCTIC ALPINE RES, V20, P179, DOI 10.2307/1551496; Aniya M, 1997, ARCTIC ALPINE RES, V29, P1, DOI 10.2307/1551831; Aniya M, 1996, PHOTOGRAMM ENG REM S, V62, P1361; Arendt AA, 2002, SCIENCE, V297, P382, DOI 10.1126/science.1072497; Carrasco JF, 2002, SER CENT ES, P29; Casassa G, 2002, SER CENT ES, P67; Casassa G, 1997, ANN GLACIOL, V24, P106, DOI 10.3189/S0260305500012015; DONANGELO TIY, 1996, B GLACIER RES, V14, P29; DYURGEROV M, 2002, 55 INSTAAR U COL; Haeberli W, 1999, GEOGR ANN A, V81A, P585, DOI 10.1111/1468-0459.00086; HENSLEY S, 2000, P SPIE, V4152; Meier MF, 2002, SCIENCE, V297, P350, DOI 10.1126/science.1073591; MEIER MF, 1984, SCIENCE, V226, P1418, DOI 10.1126/science.226.4681.1418; MEIER MF, 1987, J GEOPHYS RES-SOLID, V92, P9051, DOI 10.1029/JB092iB09p09051; NARUSE R, 1995, ANNALS OF GLACIOLOGY, VOL 21, 1995, P297; RASMUSSEN LA, UNPUB; RAYMOND C, 2000, EOS S, V81; Rignot E, 2001, GEOPHYS RES LETT, V28, P3501, DOI 10.1029/2000GL012484; Rivera A, 1999, GLOBAL PLANET CHANGE, V22, P233, DOI 10.1016/S0921-8181(99)00040-5; Rivera A, 2002, ANN GLACIOL, V34, P367, DOI 10.3189/172756402781817734; RIVERA A, 2001, UNPUB COMP DEMS GENE; RIVERA A, UNPUB; Rosenbluth B, 1997, INT J CLIMATOL, V17, P67, DOI 10.1002/(SICI)1097-0088(199701)17:1<67::AID-JOC120>3.0.CO;2-G; Skvarca P., 1995, B GLACIER RES, V13, P11; Warren C, 1999, GLOBAL PLANET CHANGE, V22, P59, DOI 10.1016/S0921-8181(99)00026-0; WARREN CR, 1993, ARCTIC ALPINE RES, V25, P316, DOI 10.2307/1551915; Yamaguchi S, 2003, ARCT ANTARCT ALP RES, V35, P170, DOI 10.1657/1523-0430(2003)035[0170:MVIFVA]2.0.CO;2	28	363	372	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 17	2003	302	5644					434	437		10.1126/science.1087393	http://dx.doi.org/10.1126/science.1087393			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564005	Green Submitted			2022-12-28	WOS:000185963200039
J	Darnell, RB; Posner, JB				Darnell, RB; Posner, JB			Paraneoplastic syndromes involving the nervous system	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CANCER-ASSOCIATED RETINOPATHY; EATON-MYASTHENIC-SYNDROME; CELL LUNG-CANCER; RNA-BINDING PROTEIN; ENCEPHALOMYELITIS SENSORY NEURONOPATHY; ANTI-HU ANTIBODIES; STIFF-MAN SYNDROME; CEREBELLAR DEGENERATION; HODGKINS-DISEASE; OPSOCLONUS-MYOCLONUS		Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Rockefeller University	Posner, JB (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Neurol, 1275 York Ave, New York, NY 10021 USA.		Darnell, Robert B/B-9022-2008	Darnell, Robert B/0000-0002-5134-8088	NCI NIH HHS [R01 CA85784] Funding Source: Medline; NCRR NIH HHS [M01-RR00102] Funding Source: Medline; NINDS NIH HHS [NS 026064, R01 NS34389] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085784] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034389, R01NS026064] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AlarconSegovia D, 1996, IMMUNOL TODAY, V17, P163; Albert ML, 2001, NAT IMMUNOL, V2, P1010, DOI 10.1038/ni722; Albert ML, 1998, NAT MED, V4, P1321, DOI 10.1038/3315; Albert ML, 2000, ANN NEUROL, V47, P9; ALTMAN AJ, 1976, CANCER, V37, P846, DOI 10.1002/1097-0142(197602)37:2<846::AID-CNCR2820370233>3.0.CO;2-L; Antoine JC, 1999, J NEUROL NEUROSUR PS, V67, P7, DOI 10.1136/jnnp.67.1.7; Antoine JC, 2000, ANN NEUROL, V48, P105, DOI 10.1002/1531-8249(200007)48:1<105::AID-ANA16>3.3.CO;2-7; BABIKIAN VL, 1985, LANCET, V2, P49; Bain PG, 1996, NEUROLOGY, V47, P678, DOI 10.1212/WNL.47.3.678; Barnett M, 2001, J NEUROL NEUROSUR PS, V70, P222, DOI 10.1136/jnnp.70.2.222; Bataller L, 2001, BRAIN, V124, P437, DOI 10.1093/brain/124.2.437; Blumenthal D, 1998, MUSCLE NERVE, V21, P1358, DOI 10.1002/(SICI)1097-4598(199810)21:10<1358::AID-MUS25>3.3.CO;2-W; Brown P, 1999, J NEUROL, V246, P648, DOI 10.1007/s004150050425; BUCKANOVICH RJ, 1993, NEURON, V11, P657, DOI 10.1016/0896-6273(93)90077-5; Byrne T, 1997, J NEUROL NEUROSUR PS, V62, P276, DOI 10.1136/jnnp.62.3.276; Cao YM, 1999, GYNECOL ONCOL, V75, P178, DOI 10.1006/gyno.1999.5553; Carpentier AF, 1998, CLIN CANCER RES, V4, P2819; Carpentier AF, 2001, CLIN REV ALLERG IMMU, V20, P155, DOI 10.1385/CRIAI:20:1:155; Carpentier AF, 1998, NEUROLOGY, V50, P1919, DOI 10.1212/WNL.50.6.1919; Chan KH, 2001, ANN NEUROL, V50, P301, DOI 10.1002/ana.1127; Cooper R, 2001, MED PEDIATR ONCOL, V36, P623, DOI 10.1002/mpo.1139; Corradi JP, 1997, J NEUROSCI, V17, P1406; Corriveau RA, 1998, NEURON, V21, P505, DOI 10.1016/S0896-6273(00)80562-0; Croteau D, 2001, NEUROLOGY, V57, P719, DOI 10.1212/WNL.57.4.719; DALMAU J, 1991, NEUROLOGY, V41, P1757, DOI 10.1212/WNL.41.11.1757; DALMAU J, 1992, MEDICINE, V71, P59, DOI 10.1097/00005792-199203000-00001; DALMAU J, 1990, ANN NEUROL, V27, P544, DOI 10.1002/ana.410270515; DALMAU J, 1994, NEUROLOGY, V44, P2241, DOI 10.1212/WNL.44.12.2241; Darnell JC, 2000, CANCER RES, V60, P2136; Darnell RB, 1996, P NATL ACAD SCI USA, V93, P4529, DOI 10.1073/pnas.93.10.4529; DECAMILLI P, 1993, J EXP MED, V178, P2219, DOI 10.1084/jem.178.6.2219; Denko NC, 2001, CANCER RES, V61, P795; ERLINGTON GM, 1991, J NEUROL NEUROSUR PS, V54, P764; FATHALLAHSHAYKH H, 1991, P NATL ACAD SCI USA, V88, P3451, DOI 10.1073/pnas.88.8.3451; FOLLI F, 1993, NEW ENGL J MED, V328, P546, DOI 10.1056/NEJM199302253280805; FUKUNAGA H, 1982, MUSCLE NERVE, V5, P686, DOI 10.1002/mus.880050905; FURNEAUX HF, 1990, NEUROLOGY, V40, P1085, DOI 10.1212/WNL.40.7.1085; GOLBE LI, 1989, MOVEMENT DISORD, V4, P147, DOI 10.1002/mds.870040206; Goldstein SM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1641; Graus F, 2001, BRAIN, V124, P1138, DOI 10.1093/brain/124.6.1138; Graus F, 1997, J CLIN ONCOL, V15, P2866, DOI 10.1200/JCO.1997.15.8.2866; Gultekin SH, 2000, BRAIN, V123, P1481, DOI 10.1093/brain/123.7.1481; Hart IK, 2002, BRAIN, V125, P1887, DOI 10.1093/brain/awf178; HEDGES TR, 1988, NEW ENGL J MED, V318, P903; HIYAMA E, 1994, CANCER, V74, P1821, DOI 10.1002/1097-0142(19940915)74:6<1821::AID-CNCR2820740627>3.0.CO;2-A; Inui A, 2002, CA-CANCER J CLIN, V52, P72, DOI 10.3322/canjclin.52.2.72; Jensen KB, 2000, NEURON, V25, P359, DOI 10.1016/S0896-6273(00)80900-9; Keime-Guibert F, 2000, J NEUROL NEUROSUR PS, V68, P479, DOI 10.1136/jnnp.68.4.479; LACHANCE DH, 1991, MAYO CLIN PROC, V66, P97, DOI 10.1016/S0025-6196(12)61177-X; Lahrmann H, 2001, MUSCLE NERVE, V24, P834, DOI 10.1002/mus.1078; Latov Norman, 1995, Annals of Neurology, V37, pS32; Lee HR, 2001, AM J GASTROENTEROL, V96, P373; LENNON VA, 1994, NEUROLOGY, V44, P2412, DOI 10.1212/WNL.44.12.2412; Levin MI, 1998, NEUROLOGY, V50, P764, DOI 10.1212/WNL.50.3.764; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Levy Y, 1998, SEMIN ARTHRITIS RHEU, V28, P73, DOI 10.1016/S0049-0172(98)80039-5; Lieberman FS, 1999, NEUROLOGY, V52, P414, DOI 10.1212/WNL.52.2.414; LISAK RP, 1977, ANN NEUROL, V1, P72, DOI 10.1002/ana.410010107; Luh JY, 2002, AM J CLIN ONCOL-CANC, V25, P160, DOI 10.1097/00000421-200204000-00011; LUQUE FA, 1991, ANN NEUROL, V29, P241, DOI 10.1002/ana.410290303; Maddison P, 1999, LANCET, V353, P117, DOI 10.1016/S0140-6736(05)76153-5; Maeda T, 2001, INVEST OPHTH VIS SCI, V42, P705; Mansi L, 1997, EUR J ENDOCRINOL, V137, P688, DOI 10.1530/eje.0.1370688; Musunuru K, 2001, ANNU REV NEUROSCI, V24, P239, DOI 10.1146/annurev.neuro.24.1.239; Okano HJ, 1999, GENE DEV, V13, P2087, DOI 10.1101/gad.13.16.2087; PASCUAL J, 1994, MUSCLE NERVE, V17, P694, DOI 10.1002/mus.880170626; Peltola J, 1998, ACTA NEUROL SCAND, V98, P360; PETERSON K, 1992, NEUROLOGY, V42, P1931, DOI 10.1212/wnl.42.10.1931; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; RIDLEY A, 1987, BRAIN, V110, P1699, DOI 10.1093/brain/110.6.1699; Rojas I, 2000, NEUROLOGY, V55, P713, DOI 10.1212/WNL.55.5.713; ROSENBLUM MK, 1993, BRAIN PATHOL, V3, P199, DOI 10.1111/j.1750-3639.1993.tb00747.x; Rosenfeld MR, 2001, ANN NEUROL, V50, P339, DOI 10.1002/ana.1288; Rudnicki SA, 2000, MUSCLE NERVE, V23, P1800, DOI 10.1002/1097-4598(200012)23:12<1800::AID-MUS3>3.0.CO;2-X; Saiz A, 1999, J NEUROL NEUROSUR PS, V66, P214, DOI 10.1136/jnnp.66.2.214; SAKAI K, 1994, BIOCHEM BIOPH RES CO, V199, P1200, DOI 10.1006/bbrc.1994.1358; Schneider C, 2001, EUR NEUROL, V46, P79, DOI 10.1159/000050768; SCHOLD SC, 1979, ANN NEUROL, V5, P271, DOI 10.1002/ana.410050310; SCULIER JP, 1987, CANCER, V60, P2275, DOI 10.1002/1097-0142(19871101)60:9<2275::AID-CNCR2820600929>3.0.CO;2-3; SEKIDO Y, 1994, CANCER RES, V54, P4988; Silverman IE, 1999, J NEUROL NEUROSUR PS, V67, P126, DOI 10.1136/jnnp.67.1.126; Siu LL, 1997, AM J CLIN ONCOL-CANC, V20, P558, DOI 10.1097/00000421-199712000-00004; Smitt PS, 2000, NEW ENGL J MED, V342, P21, DOI 10.1056/NEJM200001063420104; Stockton D, 2001, BRIT J CANCER, V85, P41, DOI 10.1054/bjoc.2001.1699; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; THIRKILL CE, 1992, INVEST OPHTH VIS SCI, V33, P2768; Vernino S, 1999, NEUROLOGY, V53, P1233, DOI 10.1212/WNL.53.6.1233; Vernino S, 2002, MUSCLE NERVE, V26, P702, DOI 10.1002/mus.10266; Vigliani MC, 2001, J NEUROL NEUROSUR PS, V70, P814, DOI 10.1136/jnnp.70.6.814; Vincent A, 2000, MUSCLE NERVE, V23, P655, DOI 10.1002/(SICI)1097-4598(200005)23:5<655::AID-MUS1>3.0.CO;2-E; Vital A, 2001, BRAIN PATHOL, V11, P399, DOI 10.1111/j.1750-3639.2001.tb00407.x; Voltz R, 1998, NEUROLOGY, V51, P1146, DOI 10.1212/WNL.51.4.1146; Yang YYL, 1998, P NATL ACAD SCI USA, V95, P13254, DOI 10.1073/pnas.95.22.13254; Younger DS, 2000, MUSCLE NERVE, V23, P658, DOI 10.1002/(SICI)1097-4598(200005)23:5<658::AID-MUS2>3.0.CO;2-2; Yu ZY, 2001, ANN NEUROL, V49, P146	95	647	672	1	31	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 16	2003	349	16					1543	1554		10.1056/NEJMra023009	http://dx.doi.org/10.1056/NEJMra023009			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	731ZM	14561798				2022-12-28	WOS:000185916400010
J	Congdon, NG; Friedman, DS; Lietman, T				Congdon, NG; Friedman, DS; Lietman, T			Important causes of visual impairment in the world today	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VITAMIN-A-DEFICIENCY; DIABETIC-RETINOPATHY; EYE INJURIES; RANDOMIZED-TRIAL; OCULAR INJURIES; BLINDNESS; CATARACT; GLAUCOMA; PREVALENCE; MORTALITY		Johns Hopkins Univ, Sch Med, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA; Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA; Univ Calif San Francisco, Sch Med, Francis I Proctor Fdn, San Francisco, CA USA	Johns Hopkins University; Johns Hopkins University; University of California System; University of California San Francisco	Congdon, NG (corresponding author), Wilmer 120,600 N Wolfe St, Baltimore, MD 21287 USA.	ncongdon@jhmi.edu		Friedman, David/0000-0002-2055-5797				[Anonymous], 1976, Am J Ophthalmol, V81, P383; [Anonymous], 1991, Ophthalmology, V98, P786; BRILLIANT LB, 1985, B WORLD HEALTH ORGAN, V63, P375; Congdon N G, 1999, Curr Opin Ophthalmol, V10, P464, DOI 10.1097/00055735-199912000-00016; Congdon NG, 2001, BRIT J OPHTHALMOL, V85, P516, DOI 10.1136/bjo.85.5.516; CONGDON NG, 1998, MANAGEMENT OCULAR IN, P9; Cunningham ET, 1998, NEW ENGL J MED, V339, P236, DOI 10.1056/NEJM199807233390406; Dandona L, 2001, INVEST OPHTH VIS SCI, V42, P908; DANNENBERG AL, 1992, ARCH OPHTHALMOL-CHIC, V110, P849, DOI 10.1001/archopht.1992.01080180121039; Ellwein LB, 2002, ARCH OPHTHALMOL-CHIC, V120, P804; *EYE DIS PREV STUD, IN PRESS ARCH OPHTHA; FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912; Foster PJ, 2001, BRIT J OPHTHALMOL, V85, P1277, DOI 10.1136/bjo.85.11.1277; Frick KD, 2003, AM J OPHTHALMOL, V135, P471, DOI 10.1016/S0002-9394(02)02110-4; Garrow A, 1923, Br J Ophthalmol, V7, P65, DOI 10.1136/bjo.7.2.65; GRAYSTON JT, 1975, J INFECT DIS, V132, P87, DOI 10.1093/infdis/132.1.87; Harris EW, 1998, INT OPHTHALMOL CLIN, V38, P155, DOI 10.1097/00004397-199803810-00013; Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268; HUMPHREY JH, 1992, B WORLD HEALTH ORGAN, V70, P225; Jacobson MA, 2000, CLIN INFECT DIS, V30, P231, DOI 10.1086/313612; JAVITT JC, 1991, OPHTHALMOLOGY, V98, P1565; JAVITT JC, 1994, ARCH OPHTHALMOL-CHIC, V112, P1526, DOI 10.1001/archopht.1994.01090240032022; Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; KATZ J, 1993, ARCH OPHTHALMOL-CHIC, V111, P1564, DOI 10.1001/archopht.1993.01090110130038; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1994, ARCH INTERN MED, V154, P2169, DOI 10.1001/archinte.154.19.2169; KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1217, DOI 10.1001/archopht.1994.01090210105023; KUPFER C, 1985, T OPHTHAL SOC UK, V104, P1; LARRISON WI, 1990, OPHTHALMOLOGY, V97, P1265; Lim R, 1999, INVEST OPHTH VIS SCI, V40, P3021; McCarty CA, 2000, INVEST OPHTH VIS SCI, V41, P3720; Mitchell P, 1999, OPHTHALMOLOGY, V106, P2010, DOI 10.1016/S0161-6420(99)90416-5; Narendran V, 2002, BRIT J OPHTHALMOL, V86, P1014, DOI 10.1136/bjo.86.9.1014; PARVER LM, 1993, PUBLIC HEALTH REP, V108, P625; PASHBY TJ, 1979, CAN MED ASSOC J, V121, P643; PIERRO L, 1992, RETINA-J RET VIT DIS, V12, P12, DOI 10.1097/00006982-199212010-00003; Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389; REACHER MH, 1990, BRIT J OPHTHALMOL, V74, P109, DOI 10.1136/bjo.74.2.109; REHKI GS, 1991, IND J OPHTHALMOL, V39, P108; Saint Andre AV, 2002, SCIENCE, V295, P1892, DOI 10.1126/science.1068732; Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5; SCHEIN OD, 1988, OPHTHALMOLOGY, V95, P300; SCHEIN OD, 1994, AM J OPHTHALMOL, V117, P501, DOI 10.1016/S0002-9394(14)70011-X; SCHEIN OD, 1990, CORNEA, V9, pS55; Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141; SOMMER A, 1986, LANCET, V1, P1169; SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004; SOMMER A, 1996, VITAMIN A DEFICIENCY, P6; Stulting RD, 1999, OPHTHALMOLOGY, V106, P13, DOI 10.1016/S0161-6420(99)90000-3; TAYLOR HR, 1990, SCIENCE, V250, P116, DOI 10.1126/science.2218502; TAYLOR HR, 2001, WORLD BLINDNESS ITS, V6; THYLEFORS B, 1992, AUST NZ J OPHTHALMOL, V20, P95, DOI 10.1111/j.1442-9071.1992.tb00718.x; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115; TIELSCH JM, 1990, OPHTHALMOLOGY, V97, P231; West KP, 1999, BMJ-BRIT MED J, V318, P570, DOI 10.1136/bmj.318.7183.570; WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1; 1990, JAMA, V251, P2503	59	513	604	0	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	2003	290	15					2057	2060		10.1001/jama.290.15.2057	http://dx.doi.org/10.1001/jama.290.15.2057			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CX	14559961				2022-12-28	WOS:000185924200031
J	van Weel, C				van Weel, C			Translating research into practice - a three-paper series	LANCET			English	Editorial Material									Univ Med Ctr Nijmegen, Dept Gen Practice, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	van Weel, C (corresponding author), Univ Med Ctr Nijmegen, Dept Gen Practice, NL-6500 HB Nijmegen, Netherlands.		van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				Maynard A, 1997, LANCET, V349, P126, DOI 10.1016/S0140-6736(96)05153-7; WATTON J, 1994, OXFORD MED COMPANION	2	3	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 11	2003	362	9391					1170	1170		10.1016/S0140-6736(03)14556-4	http://dx.doi.org/10.1016/S0140-6736(03)14556-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568736				2022-12-28	WOS:000185924100006
J	Phillips, P; Dalidovich, D				Phillips, P; Dalidovich, D			The elusive Bose metal	SCIENCE			English	Review							SUPERCONDUCTOR-INSULATOR TRANSITION; ORDER-PARAMETER AMPLITUDE; PHASE-TRANSITIONS; SPIN-GLASSES; QUANTUM; ABSENCE; FLUCTUATIONS; LOCALIZATION; SUPERFLUID; TRANSPORT	The conventional theory of metals is in crisis. In the past 15 years, there has been an unexpected sprouting of metallic states in low-dimensional systems, directly contradicting conventional wisdom. For example, bosons are thought to exist in one of two ground states: condensed in a superconductor or localized in an insulator. However, several experiments on thin metal-alloy films have observed that a metallic phase disrupts the direct transition between the superconductor and the insulator. We analyze the experiments on the insulator-superconductor transition and argue that the intervening metallic phase is bosonic. All relevant theoretical proposals for the Bose metal are discussed, particularly the recent idea that the metallic phase is glassy. The implications for the putative vortex-glass state in the copper oxide superconductors are examined.	Univ Illinois, Loomis Lab Phys, Urbana, IL 61801 USA; Florida State Univ, Natl High Magnet Field Lab, Tallahassee, FL 32310 USA	University of Illinois System; University of Illinois Urbana-Champaign; State University System of Florida; Florida State University	Phillips, P (corresponding author), Univ Illinois, Loomis Lab Phys, 1110 W Green St, Urbana, IL 61801 USA.	dimer@uiuc.edu						Abrahams E, 2001, REV MOD PHYS, V73, P251, DOI 10.1103/RevModPhys.73.251; ALTSHULER BL, 1980, QUANTUM THEORY SOLID; ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/science.269.5221.198; Berezinskii V. L., 1971, Zhurnal Eksperimental'noi i Teoreticheskoi Fiziki, V61, P1144; BINDER K, 1986, PHASE TRANSITIONS CR, V8, P1; Bloch F, 1929, Z PHYS, V52, P555, DOI 10.1007/BF01339455; CARDY J, 1996, SCALING RENORMALIZAT, P71; Chamon C, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.094506; Chamon C, 2000, PHYS REV LETT, V85, P5607, DOI 10.1103/PhysRevLett.85.5607; Chervenak JA, 2000, PHYS REV B, V61, pR9245, DOI 10.1103/PhysRevB.61.R9245; Christiansen C, 2002, PHYS REV LETT, V88, DOI [10.1103/PhysRevLett.88.037004, 10.1103/PhysRevB.88.037004]; Dalidovich D, 2000, PHYS REV LETT, V84, P737, DOI 10.1103/PhysRevLett.84.737; Dalidovich D, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.027001; DALIDOVICH D, 2001, PHYS REV B, V64, P1; Das D, 1999, PHYS REV B, V60, P1261, DOI 10.1103/PhysRevB.60.1261; DUNLAP DH, 1990, PHYS REV LETT, V65, P88, DOI 10.1103/PhysRevLett.65.88; Ephron D, 1996, PHYS REV LETT, V76, P1529, DOI 10.1103/PhysRevLett.76.1529; Feigel'man MV, 1998, CHEM PHYS, V235, P107, DOI 10.1016/S0301-0104(98)00075-5; FEIGELMAN MV, 1993, PHYS REV B, V48, P16641, DOI 10.1103/PhysRevB.48.16641; FEIGELMAN MV, 1979, SOV PHYS JETP, V50, P1222; FINKELSHTEIN AM, 1987, JETP LETT+, V45, P46; FISHER DS, 1991, PHYS REV B, V43, P130, DOI 10.1103/PhysRevB.43.130; FISHER MPA, 1990, PHYS REV LETT, V65, P923, DOI 10.1103/PhysRevLett.65.923; GEERLIGS LJ, 1989, PHYS REV LETT, V63, P326, DOI 10.1103/PhysRevLett.63.326; HEBARD AF, 1990, PHYS REV LETT, V65, P927, DOI 10.1103/PhysRevLett.65.927; Herbut IF, 1998, PHYS REV LETT, V81, P3916, DOI 10.1103/PhysRevLett.81.3916; HSU SY, 1995, PHYS REV LETT, V75, P132, DOI 10.1103/PhysRevLett.75.132; JAEGER HM, 1989, PHYS REV B, V40, P182, DOI 10.1103/PhysRevB.40.182; Jiang W, 1997, J PHYS-CONDENS MAT, V9, P8085, DOI 10.1088/0953-8984/9/38/014; Kapitulnik A, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.125322; Kirkpatrick TR, 1996, PHYS REV B, V53, P14364, DOI 10.1103/PhysRevB.53.14364; Kopelevich Y, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.156402; Kosterlitz JM, 1973, J PHYS C SOLID STATE, V6, P1181, DOI 10.1088/0022-3719/6/7/010; KOTLIAR G, 1986, PHYS REV B, V33, P3146, DOI 10.1103/PhysRevB.33.3146; KOTLIAR G, 1987, PHYS REV B, V35, P311, DOI 10.1103/PhysRevB.35.311; Liu Y., 1994, Modern Physics Letters B, V8, P277, DOI 10.1142/S0217984994000297; MA M, 1985, PHYS REV B, V32, P5658, DOI 10.1103/PhysRevB.32.5658; MASON N, 2001, PHYS REV B, V64, P1; MILLER J, 1993, PHYS REV LETT, V70, P3147, DOI 10.1103/PhysRevLett.70.3147; NAYAK C, IN PRESS J PHYS COND; Ng TK, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.144509; PARAMEKANTI A, 2002, PHYS REV B, V66, P1; Phillip LE, 2001, CAN J ANIM SCI, V81, P47, DOI 10.4141/A00-044; Phillips P, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.081101; Phillips P, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.104427; PRANGE E, 1987, QUANTUM HALL EFFECT; READ N, 1995, PHYS REV B, V52, P384, DOI 10.1103/PhysRevB.52.384; Reichhardt C, 2000, PHYS REV LETT, V84, P1994, DOI 10.1103/PhysRevLett.84.1994; Shimshoni E, 1998, PHYS REV LETT, V80, P3352, DOI 10.1103/PhysRevLett.80.3352; SOMPOLINSKY H, 1984, PHYS REV LETT, V52, P392, DOI 10.1103/PhysRevLett.52.392; Spivak B, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.132502; SPIVAK BI, 1991, PHYS REV B, V43, P3740, DOI 10.1103/PhysRevB.43.3740; Strachan DR, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.067007; VALLES JM, 1992, PHYS REV LETT, V69, P3567, DOI 10.1103/PhysRevLett.69.3567; Wagenblast KH, 1997, PHYS REV LETT, V78, P1779, DOI 10.1103/PhysRevLett.78.1779; YAZDANI A, 1995, PHYS REV LETT, V74, P3037, DOI 10.1103/PhysRevLett.74.3037	59	109	109	0	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					243	247		10.1126/science.1088253	http://dx.doi.org/10.1126/science.1088253			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551428	Green Submitted			2022-12-28	WOS:000185825900030
J	Derynck, R; Zhang, YE				Derynck, R; Zhang, YE			Smad-dependent and Smad-independent pathways in TGF-beta family signalling	NATURE			English	Review							GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; EPITHELIAL-CELL PLASTICITY; ANAPHASE-PROMOTING COMPLEX; CDK INHIBITOR P15(INK4B); UBIQUITIN LIGASE COMPLEX; TRANSCRIPTIONAL ACTIVATION; MESENCHYMAL TRANSDIFFERENTIATION; ADIPOCYTE DIFFERENTIATION; RECEPTOR INTERNALIZATION	Transforming growth factor-beta (TGF-beta) proteins regulate cell function, and have key roles in development and carcinogenesis. The intracellular effectors of TGF-beta signalling, the Smad proteins, are activated by receptors and translocate into the nucleus, where they regulate transcription. Although this pathway is inherently simple, combinatorial interactions in the heteromeric receptor and Smad complexes, receptor-interacting and Smad-interacting proteins, and cooperation with sequence-specific transcription factors allow substantial versatility and diversification of TGF-beta family responses. Other signalling pathways further regulate Smad activation and function. In addition, TGF-beta receptors activate Smad-independent pathways that not only regulate Smad signalling, but also allow Smad-independent TGF-beta responses.	Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Dev Biol, San Francisco, CA 94143 USA; NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Derynck, R (corresponding author), Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA.	derynck@itsa.ucsf.edu; yingz@helix.nih.gov	Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601	NATIONAL CANCER INSTITUTE [Z01BC010419, ZIABC010419] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aghdasi B, 2001, P NATL ACAD SCI USA, V98, P2425, DOI 10.1073/pnas.041614198; Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Arora K, 2001, DEV CELL, V1, P441, DOI 10.1016/S1534-5807(01)00067-3; Bai RY, 2002, NAT CELL BIOL, V4, P181, DOI 10.1038/ncb753; Bai ST, 2002, J BIOL CHEM, V277, P4176, DOI 10.1074/jbc.M105105200; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2002, J CELL SCI, V115, P3193; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Bennett D, 2002, NAT GENET, V31, P419, DOI 10.1038/ng938; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Choy L, 2003, J BIOL CHEM, V278, P9609, DOI 10.1074/jbc.M212259200; Choy L, 1998, J BIOL CHEM, V273, P31455, DOI 10.1074/jbc.273.47.31455; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Foletta VC, 2003, J CELL BIOL, V162, P1089, DOI 10.1083/jcb.200212060; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Grimm OH, 2002, NAT CELL BIOL, V4, P519, DOI 10.1038/ncb812; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Inman GJ, 2002, J BIOL CHEM, V277, P51008, DOI 10.1074/jbc.M208532200; Itoh F, 2001, EMBO J, V20, P4132, DOI 10.1093/emboj/20.15.4132; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kato Y, 2002, NATURE, V418, P641, DOI 10.1038/nature00969; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Lai YT, 2000, DEV BIOL, V222, P1, DOI 10.1006/dbio.2000.9698; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Liberati NT, 2001, J BIOL CHEM, V276, P22595, DOI 10.1074/jbc.M010778200; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Masuyama N, 1999, J BIOL CHEM, V274, P12163, DOI 10.1074/jbc.274.17.12163; Mazars A, 2001, J BIOL CHEM, V276, P36797, DOI 10.1074/jbc.M101672200; McGonigle S, 2002, BIOCHEMISTRY-US, V41, P579, DOI 10.1021/bi011407z; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Moustakas A, 2001, J CELL SCI, V114, P4359; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Pessah M, 2002, J BIOL CHEM, V277, P29094, DOI 10.1074/jbc.M202831200; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Piek E, 1999, J CELL SCI, V112, P4557; Pulaski L, 2001, J BIOL CHEM, V276, P14344, DOI 10.1074/jbc.M011019200; Razani B, 2001, J BIOL CHEM, V276, P6727, DOI 10.1074/jbc.M008340200; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sasaki A, 2001, J BIOL CHEM, V276, P17871, DOI 10.1074/jbc.M008422200; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shen X, 2001, J BIOL CHEM, V276, P15362, DOI 10.1074/jbc.M009534200; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Stroschein SL, 2001, GENE DEV, V15, P2822; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Ventura F, 1996, J BIOL CHEM, V271, P13931, DOI 10.1074/jbc.271.24.13931; Vinals F, 2001, MOL CELL BIOL, V21, P7218, DOI 10.1128/MCB.21.21.7218-7230.2001; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Watanabe M, 2000, EMBO REP, V1, P176, DOI 10.1093/embo-reports/kvd029; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Yakmovych I, 2001, FASEB J, V15, P553; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yamakawa N, 2002, EMBO J, V21, P1684, DOI 10.1093/emboj/21.7.1684; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Yao DY, 2000, J BIOL CHEM, V275, P13149, DOI 10.1074/jbc.275.17.13149; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Yue JB, 2000, METH MOL B, V142, P125; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	101	4055	4339	20	417	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 9	2003	425	6958					577	584		10.1038/nature02006	http://dx.doi.org/10.1038/nature02006			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534577				2022-12-28	WOS:000185801000027
J	Hurlstone, AFL; Haramis, APG; Wienholds, E; Begthel, H; Korving, J; van Eeden, F; Cuppen, E; Zivkovic, D; Plasterk, RHA; Clevers, H				Hurlstone, AFL; Haramis, APG; Wienholds, E; Begthel, H; Korving, J; van Eeden, F; Cuppen, E; Zivkovic, D; Plasterk, RHA; Clevers, H			The Wnt/beta-catenin pathway regulates cardiac valve formation	NATURE			English	Article							BETA-CATENIN; COLORECTAL-CANCER; CUSHION FORMATION; ZEBRAFISH; GENE; TRANSFORMATION; APC; SPECIFICATION; PHENOTYPE; MUTATION	Truncation of the tumour suppressor adenomatous polyposis coli (Apc) constitutively activates the Wnt/beta-catenin signalling pathway(1). Apc has a role in development: for example, embryos of mice with truncated Apc do not complete gastrulation(2). To understand this role more fully, we examined the effect of truncated Apc on zebrafish development. Here we show that, in contrast to mice, zebrafish do complete gastrulation. However, mutant hearts fail to loop and form excessive endocardial cushions. Conversely, overexpression of Apc or Dickkopf 1 (Dkk1), a secreted Wnt inhibitor(3), blocks cushion formation. In wild-type hearts, nuclear beta-catenin, the hallmark of activated canonical Wnt signalling(4), accumulates only in valve-forming cells, where it can activate a Tcf reporter. In mutant hearts, all cells display nuclear beta-catenin and Tcf reporter activity, while valve markers are markedly upregulated. Concomitantly, proliferation and epithelial-mesenchymal transition, normally restricted to endocardial cushions, occur throughout the endocardium. Our findings identify a novel role for Wnt/beta-catenin signalling in determining endocardial cell fate.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Clevers, H (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.		Cuppen, Edwin/H-2389-2016; Van Eeden, Freek/E-6198-2010; Cuppen, Edwin/F-5696-2011	Cuppen, Edwin/0000-0002-0400-9542; Cuppen, Edwin/0000-0002-0400-9542; Hurlstone, Adam/0000-0001-5260-9457				Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Colbert T, 2001, PLANT PHYSIOL, V126, P480, DOI 10.1104/pp.126.2.480; Dorsky RI, 2002, DEV BIOL, V241, P229, DOI 10.1006/dbio.2001.0515; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Hacker U, 1997, DEVELOPMENT, V124, P3565; Hashimoto H, 2000, DEV BIOL, V217, P138, DOI 10.1006/dbio.1999.9537; Heisenberg CP, 2001, GENE DEV, V15, P1427, DOI 10.1101/gad.194301; IWAMOTO R, 2003, P NATL ACAD SCI; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kim RY, 2001, DEV BIOL, V235, P449, DOI 10.1006/dbio.2001.0284; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Lickert H, 2002, DEV CELL, V3, P171, DOI 10.1016/S1534-5807(02)00206-X; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; Mjaatvedt CH, 1998, DEV BIOL, V202, P56, DOI 10.1006/dbio.1998.9001; Tzahor E, 2001, GENE DEV, V15, P255, DOI 10.1101/gad.871501; van de Water S, 2001, DEVELOPMENT, V128, P3877; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Walsh EC, 2001, SCIENCE, V293, P1670, DOI 10.1126/science.293.5535.1670; Westerfield M, 1995, ZEBRAFISH BOOK; Wienholds E, 2002, SCIENCE, V297, P99, DOI 10.1126/science.1071762; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8	24	315	333	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2003	425	6958					633	637		10.1038/nature02028	http://dx.doi.org/10.1038/nature02028			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534590				2022-12-28	WOS:000185801000041
J	Verschure, PFMJ; Voegtlin, T; Douglas, RJ				Verschure, PFMJ; Voegtlin, T; Douglas, RJ			Environmentally mediated synergy between perception and behaviour in mobile robots	NATURE			English	Article							PLASTICITY; CORTEX	The notion that behaviour influences perception seems self-evident, but the mechanism of their interaction is not known. Perception and behaviour are usually considered to be separate processes. In this view, perceptual learning constructs compact representations of sensory events, reflecting their statistical properties(1,2), independently of behavioural relevance(3,4). Behavioural learning(5,6), however, forms associations between perception and action, organized by reinforcement(7,8), without regard for the construction of perception. It is generally assumed that the interaction between these two processes is internal to the agent, and can be explained solely in terms of the neuronal substrate(9). Here we show, instead, that perception and behaviour can interact synergistically via the environment. Using simulated and real mobile robots, we demonstrate that perceptual learning directly supports behavioural learning and so promotes a progressive structuring of behaviour. This structuring leads to a systematic bias in input sampling, which directly affects the organization of the perceptual system. This external, environmentally mediated feedback matches the perceptual system to the emerging behavioural structure, so that the behaviour is stabilized.	Univ Swiss Fed Inst Technol ETH Zurich, Inst Neuroinformat, CH-8057 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Verschure, PFMJ (corresponding author), Univ Swiss Fed Inst Technol ETH Zurich, Inst Neuroinformat, CH-8057 Zurich, Switzerland.		verschure, paul/E-1677-2011; Verschure, Paul/AAR-2340-2021	Verschure, Paul/0000-0003-3643-9544				Arkin R. C., 1998, BEHAV BASED ROBOTICS; Bell AJ, 1999, PHILOS T ROY SOC B, V354, P2013, DOI 10.1098/rstb.1999.0540; CLANCEY WJ, 1996, SITUATED COGNITION H; Goldstone RL, 1998, ANNU REV PSYCHOL, V49, P585, DOI 10.1146/annurev.psych.49.1.585; Houde JF, 2002, J COGNITIVE NEUROSCI, V14, P1125, DOI 10.1162/089892902760807140; Kalman R.E., 1960, T ASME J BASIC ENG, V82, P35, DOI [10.1115/1.3662552, DOI 10.1115/1.3662552]; LAVOND DG, 1993, ANNU REV PSYCHOL, V44, P317, DOI 10.1146/annurev.ps.44.020193.001533; Logothetis NK, 1996, ANNU REV NEUROSCI, V19, P577, DOI 10.1146/annurev.ne.19.030196.003045; Mackintosh N. J., 1974, PSYCHOL ANIMAL LEARN; Massaro DW, 1997, PERCEIVING TALKING F; MCFARLAND D, 1993, INTELLIGENT BEHAV AN; Mehta MR, 1997, P NATL ACAD SCI USA, V94, P8918, DOI 10.1073/pnas.94.16.8918; MONDADA F, 1993, EXPT ROBOTICS, V3, P501; Olshausen BA, 1996, NATURE, V381, P607, DOI 10.1038/381607a0; Rao RPN, 1999, NAT NEUROSCI, V2, P79, DOI 10.1038/4580; Rescorla R.A., 1972, CLASSICAL CONDITION, P64, DOI DOI 10.1101/GR.110528.110; Sanchez-Montanes MA, 2000, NEURAL COMPUT, V12, P519, DOI 10.1162/089976600300015682; Scheier C, 1999, UNDERSTANDING INTELL; Schultz W, 2000, ANNU REV NEUROSCI, V23, P473, DOI 10.1146/annurev.neuro.23.1.473; Squire LR., 1999, MEMORY MIND MOL; Sur M, 2001, NAT REV NEUROSCI, V2, P251, DOI 10.1038/35067562; Thorndike E, 1898, PSYCHOL REV SER MO S, V2, P1, DOI [DOI 10.1037/0003-066X.53.10.1125, DOI 10.1037/H0092987]; TOLMAN EC, 1948, PSYCHOL REV, V55, P189, DOI 10.1037/h0061626; Verschure P. F. M. J., 1992, Robotics and Autonomous Systems, V9, P181, DOI 10.1016/0921-8890(92)90054-3; VERSCHURE PFM, 1992, ANIMALS ANIMATS, P210; Verschure PFMJ, 2003, COGNITIVE SCI, V27, P561, DOI 10.1016/S0364-0213(03)00034-X; Verschure PFMJ, 1998, NEURAL NETWORKS, V11, P1531, DOI 10.1016/S0893-6080(98)00029-X	28	138	139	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2003	425	6958					620	624		10.1038/nature02024	http://dx.doi.org/10.1038/nature02024			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	729XU	14534588				2022-12-28	WOS:000185801000038
J	Margolis, ML; Christie, JD; Silvestri, GA; Kaiser, L; Santiago, S; Hansen-Flaschen, J				Margolis, ML; Christie, JD; Silvestri, GA; Kaiser, L; Santiago, S; Hansen-Flaschen, J			Racial differences pertaining to a belief about lung cancer surgery - Results of a multicenter survey	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	96th International Conference of the American-Thoracic-Society	MAY 03-10, 2000	TORONTO, CANADA	Amer Thorac Soc			AFRICAN-AMERICANS; BREAST-CANCER; LOW-INCOME; ATTITUDES; BLACK; CARCINOMA; SURVIVAL; RACE	Background: Patients at the Philadelphia Veterans Affairs Medical Center frequently voice concern that air exposure during lung cancer surgery might cause tumor spread. Several African-American patients asserted that this belief was common in the African-American community.. I. Objective: To assess the prevalence of the belief that air exposure during lung cancer surgery might cause tumor spread and gauge the influence of this belief on the willingness of African-American and white patients to have lung cancer surgery. Design: Prospective questionnaire survey. Setting: Philadelphia Veterans Affairs Medical Center and University of Pennsylvania, Philadelphia, Pennsylvania; Los Angeles Veterans Affairs Medical Center, Los Angeles, California; and Medical University of South Carolina, Charleston, South Carolina. Patients: 626 consecutive patients in pulmonary and lung cancer clinics. Results: 38% of patients (61% of whom were African American and 29% of whom were white) stated that they believe air exposure at surgery causes tumor spread. The most significant predictor of belief was African-American race (odds ratio, 3.5 [95% Cl, 1.9 to 6.5]), even after controlling for other relevant variables in a multivariable analysis. Nineteen percent of African Americans stated that this belief was a reason for opposing surgery, and 14% would not accept their physicians' assertion that the belief is false. These rates were also statistically significantly higher among African-American than white patients. Conclusions: Belief in accelerated tumor spread at surgery is prevalent among general pulmonary outpatients and lung cancer clinic patients facing lung surgery, particularly among African-American patients. Our findings may pertain to key racial disparities in lung cancer surgery and survival rates and suggest that culturally sensitive physician training or outreach programs directed at disparate beliefs and attitudes may help to address racial discrepancies in health care outcomes.	Philadelphia Vet Affairs Med Ctr, Pulm Sect, Philadelphia, PA 19104 USA; Univ Penn, Philadelphia, PA 19104 USA; Med Univ S Carolina, Charleston, SC 29425 USA; Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Margolis, ML (corresponding author), Philadelphia Vet Affairs Med Ctr, Pulm Sect, Room 8A112,Univ & Woodland Ave, Philadelphia, PA 19104 USA.		Kaiser, Larry/L-7940-2019	Hansen-Flaschen, John/0000-0003-1989-7244				AKERLEY WL, 1993, ARCH INTERN MED, V153, P1681, DOI 10.1001/archinte.153.14.1681; ARTINIAN VS, 2002, CHEST, V122, pS7; *ASS AM MED COLL, 1994, MIN STUD MED ED FACT; Bach PB, 1999, NEW ENGL J MED, V341, P1198, DOI 10.1056/NEJM199910143411606; Cooper-Patrick L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/jama.282.6.583; Corbie-Smith G, 1999, J GEN INTERN MED, V14, P537, DOI 10.1046/j.1525-1497.1999.07048.x; DEMARKWAHNEFRIED W, 1995, UROLOGY, V46, P346, DOI 10.1016/S0090-4295(99)80218-0; Diala CC, 2001, AM J PUBLIC HEALTH, V91, P805, DOI 10.2105/AJPH.91.5.805; Earle CC, 2000, CHEST, V117, P1239, DOI 10.1378/chest.117.5.1239; Friedman L C, 1994, J Cancer Educ, V9, P105; Gadgeel SM, 2001, CHEST, V120, P55, DOI 10.1378/chest.120.1.55; Glanz K, 1996, Ethn Health, V1, P207; GRAHAM MV, 1992, J NATL CANCER I, V84, P1731, DOI 10.1093/jnci/84.22.1731; GREENBERG ER, 1988, NEW ENGL J MED, V318, P612, DOI 10.1056/NEJM198803103181006; Greenwald HP, 1998, AM J PUBLIC HEALTH, V88, P1681, DOI 10.2105/AJPH.88.11.1681; GREGG J, 1994, SOC SCI MED, V39, P519, DOI 10.1016/0277-9536(94)90094-9; King TE, 1999, NEW ENGL J MED, V341, P1231, DOI 10.1056/NEJM199910143411612; Komaromy M, 1996, NEW ENGL J MED, V334, P1305, DOI 10.1056/NEJM199605163342006; Kressin NR, 2002, MED CARE, V40, P72; Lannin DR, 1998, JAMA-J AM MED ASSOC, V279, P1801, DOI 10.1001/jama.279.22.1801; MARGOLIS ML, 2000, AM J RESP CRIT CARE, V161, pA766; MATHEWS HF, 1994, SOC SCI MED, V38, P789, DOI 10.1016/0277-9536(94)90151-1; Miller AM, 1997, WOMEN HEALTH, V26, P41, DOI 10.1300/J013v26n01_04; Okwumabua JO, 2001, J HEALTH CARE POOR U, V12, P474; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Stewart JH, 2001, CANCER-AM CANCER SOC, V91, P2476, DOI 10.1002/1097-0142(20010615)91:12<2476::AID-CNCR1283>3.0.CO;2-Z; WEESE JL, 1986, SURGERY, V100, P273; Wilson RP, 2002, AM J MED, V112, P26, DOI 10.1016/S0002-9343(01)01049-X; 1981, CA CANC J CLIN, V31, P212	29	167	168	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 7	2003	139	7					558	563		10.7326/0003-4819-139-7-200310070-00007	http://dx.doi.org/10.7326/0003-4819-139-7-200310070-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	729AP	14530226				2022-12-28	WOS:000185748800003
J	Chen, Y; Deng, LB; Maeno-Hikichi, Y; Lai, MZ; Chang, SH; Chen, G; Zhang, JF				Chen, Y; Deng, LB; Maeno-Hikichi, Y; Lai, MZ; Chang, SH; Chen, G; Zhang, JF			Formation of an endophilin-Ca2+ channel complex is critical for clathrin-mediated synaptic vesicle endocytosis	CELL			English	Article							NEURONAL CA2+ CHANNELS; NEUROTRANSMITTER RELEASE; NEUROMUSCULAR-JUNCTION; HIPPOCAMPAL SYNAPSES; PROTEIN-INTERACTION; SH3 DOMAIN; CELL; EXOCYTOSIS; SRC; SYNAPTOTAGMIN	A tight balance between synaptic vesicle exocytosis and endocytosis is fundamental to maintaining synaptic structure and function. Calcium influx through voltage-gated Ca2+ channels is crucial in regulating synaptic vesicle exocytosis. However, much less is known about how Ca2+ regulates vesicle endocytosis or how the endocytic machinery becomes enriched at the nerve terminal. We report here a direct interaction between voltage-gated Ca2+ channels and endophilin, a key regulator of clathrin-mediated synaptic vesicle endocytosis. Formation of the endophlin-Ca2+ channel complex is Ca2+ dependent. The primary Ca2+ binding domain resides within endophilin and regulates both endophilin-Ca2+ channel and endophilin-dynamin complexes. Introduction into hippocampal neurons of a dominant-negative endophilin construct, which constitutively binds to Ca2+ channels, significantly reduces endocytosis-mediated uptake of FM 4-64 dye without abolishing exocytosis. These results suggest an important role for Ca2+ channels in coordinating synaptic vesicle recycling by directly coupling to both exocytotic and endocytic machineries.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA	University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Zhang, JF (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.		Chen, Yuan/D-1462-2011	Chen, Yuan/0000-0002-9412-4623; Chen JNU, Gong/0000-0002-1857-3670	NINDS NIH HHS [NS39355] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039355] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Augustine GJ, 2001, CURR OPIN NEUROBIOL, V11, P320, DOI 10.1016/S0959-4388(00)00214-2; BABITCH J, 1990, NATURE, V346, P321, DOI 10.1038/346321b0; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; BETZ WJ, 1993, J PHYSIOL-LONDON, V460, P287, DOI 10.1113/jphysiol.1993.sp019472; Beutner D, 2001, NEURON, V29, P681, DOI 10.1016/S0896-6273(01)00243-4; BROCARD JB, 1993, NEURON, V11, P751, DOI 10.1016/0896-6273(93)90084-5; Brodin L, 2000, CURR OPIN NEUROBIOL, V10, P312, DOI 10.1016/S0959-4388(00)00097-0; Catterall WA, 1999, ANN NY ACAD SCI, V868, P144, DOI 10.1111/j.1749-6632.1999.tb11284.x; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; GonzalezGaitan M, 1997, CELL, V88, P767, DOI 10.1016/S0092-8674(00)81923-6; Griesinger CB, 2002, J NEUROSCI, V22, P3939, DOI 10.1523/JNEUROSCI.22-10-03939.2002; Guichet A, 2002, EMBO J, V21, P1661, DOI 10.1093/emboj/21.7.1661; Gundelfinger ED, 2003, NAT REV MOL CELL BIO, V4, P127, DOI 10.1038/nrm1016; Higgins MK, 2002, TRENDS BIOCHEM SCI, V27, P257, DOI 10.1016/S0968-0004(02)02089-3; Huttner WB, 2000, CURR OPIN NEUROBIOL, V10, P543, DOI 10.1016/S0959-4388(00)00126-4; Huttner WB, 2002, TRENDS CELL BIOL, V12, P155, DOI 10.1016/S0962-8924(02)02252-3; Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; Kuromi H, 2002, NEURON, V35, P333, DOI 10.1016/S0896-6273(02)00777-8; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Maeno-Hikichi Y, 2003, NAT NEUROSCI, V6, P468, DOI 10.1038/nn1041; Mayer BJ, 2001, J CELL SCI, V114, P1253; Murthy VN, 2003, ANNU REV NEUROSCI, V26, P701, DOI 10.1146/annurev.neuro.26.041002.131445; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; Neves G, 2001, P NATL ACAD SCI USA, V98, P15282, DOI 10.1073/pnas.261311698; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAMASWAMI M, 1994, NEURON, V13, P363, DOI 10.1016/0896-6273(94)90353-0; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 2001, J BIOL CHEM, V276, P40424, DOI 10.1074/jbc.M106338200; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Roos J, 1999, CURR BIOL, V9, P1411, DOI 10.1016/S0960-9822(00)80087-1; Sankaranarayanan S, 2001, NAT NEUROSCI, V4, P129, DOI 10.1038/83949; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Takei K, 2001, TRENDS CELL BIOL, V11, P385, DOI 10.1016/S0962-8924(01)02082-7; Teng HB, 2000, J NEUROSCI, V20, P7986; Tong AHY, 2002, SCIENCE, V295, P321, DOI 10.1126/science.1064987; Verstreken P, 2002, CELL, V109, P101, DOI 10.1016/S0092-8674(02)00688-8; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Yoshihara M, 2003, CURR OPIN NEUROBIOL, V13, P315, DOI 10.1016/S0959-4388(03)00063-1; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000	54	91	95	0	9	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 3	2003	115	1					37	48		10.1016/S0092-8674(03)00726-8	http://dx.doi.org/10.1016/S0092-8674(03)00726-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14532001	Bronze			2022-12-28	WOS:000185815500007
J	Lamarre, D; Anderson, PC; Bailey, M; Beaulieu, P; Bolger, G; Bonneau, P; Bos, M; Cameron, DR; Cartier, M; Cordingley, MG; Faucher, AM; Goudreau, N; Kawai, SH; Kukolj, G; Lagace, L; LaPlante, SR; Narjes, H; Poupart, MA; Rancourt, J; Sentjens, RE; St George, R; Simoneau, B; Steinmann, G; Thibeault, D; Tsantrizos, YS; Weldon, SM; Yong, CL; Llinas-Brunet, M				Lamarre, D; Anderson, PC; Bailey, M; Beaulieu, P; Bolger, G; Bonneau, P; Bos, M; Cameron, DR; Cartier, M; Cordingley, MG; Faucher, AM; Goudreau, N; Kawai, SH; Kukolj, G; Lagace, L; LaPlante, SR; Narjes, H; Poupart, MA; Rancourt, J; Sentjens, RE; St George, R; Simoneau, B; Steinmann, G; Thibeault, D; Tsantrizos, YS; Weldon, SM; Yong, CL; Llinas-Brunet, M			An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus	NATURE			English	Article							PEPTIDE-BASED INHIBITORS; SERINE-PROTEASE; VIRAL DYNAMICS; NON-A; REPLICATION	Hepatitis C virus (HCV) infection is a serious cause of chronic liver disease worldwide with more than 170 million infected individuals at risk of developing significant morbidity and mortality(1-3). Current interferon-based therapies(4) are suboptimal especially in patients infected with HCV genotype 1, and they are poorly tolerated, highlighting the unmet medical need for new therapeutics(5,6). The HCV-encoded NS3 protease is essential for viral replication(7,8) and has long been considered an attractive target for therapeutic intervention in HCV-infected patients. Here we identify a class of specific and potent NS3 protease inhibitors and report the evaluation of BILN 2061, a small molecule inhibitor biologically available through oral ingestion and the first of its class in human trials. Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive reduction of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor. Our results further illustrate the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.	Boehringer Ingelheim Canada Ltd, Res & Dev, Dept Biol Sci, Laval, PQ H7S 2G5, Canada; Boehringer Ingelheim Canada Ltd, Res & Dev, Dept Chem, Laval, PQ H7S 2G5, Canada; Boehringer Ingelheim Pharma KG, Clin Res, D-88397 Biberach, Germany; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; Boehringer Ingelheim Pharmaceut Inc, Res & Dev, Ridgefield, CT 06877 USA	Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; University of Amsterdam; Academic Medical Center Amsterdam; Boehringer Ingelheim	Lamarre, D (corresponding author), Boehringer Ingelheim Canada Ltd, Res & Dev, Dept Biol Sci, Laval, PQ H7S 2G5, Canada.	dlamarre@lav.boehringer-ingelheim.com	Rancourt, Jean/R-9482-2018	Rancourt, Jean/0000-0001-6389-2841; Cameron, Dale/0000-0001-6274-2913				Benhamou Y, 2002, HEPATOLOGY, V36, p304A; BOEHRINGER INGELHEIM, 2001, Patent No. 6323180; Chander G, 2002, HEPATOLOGY, V36, pS135, DOI 10.1053/jhep.2002.37146; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Di Bisceglie AM, 1998, LANCET, V351, P351, DOI 10.1016/S0140-6736(97)07361-3; Di Bisceglie AM, 2002, HEPATOLOGY, V35, P224, DOI 10.1053/jhep.2002.30531; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; GOUDREAU N, UNPUB J MED CHEM; HINRICHSEN H, 2002, HEPATOLOGY, V36, pA297; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LaPlante SR, 1999, J BIOL CHEM, V274, P18618, DOI 10.1074/jbc.274.26.18618; LaPlante SR, 2000, BIOORG MED CHEM LETT, V10, P2271, DOI 10.1016/S0960-894X(00)00466-2; Llinas-Brunet M, 2000, BIOORG MED CHEM LETT, V10, P2267, DOI 10.1016/S0960-894X(00)00465-0; Llinas-Brunet M, 1998, BIOORG MED CHEM LETT, V8, P2719, DOI 10.1016/S0960-894X(98)00480-6; Llinas-Brunet M, 1998, BIOORG MED CHEM LETT, V8, P1713, DOI 10.1016/S0960-894X(98)00299-6; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Mercer DF, 2001, NAT MED, V7, P927, DOI 10.1038/90968; Narjes H, 2002, HEPATOLOGY, V36, p363A; Neumann AU, 2000, J INFECT DIS, V182, P28, DOI 10.1086/315661; Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; Pause A, 2003, J BIOL CHEM, V278, P20374, DOI 10.1074/jbc.M210785200; Poupart MA, 2001, J ORG CHEM, V66, P4743, DOI 10.1021/jo010164d; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Steinkuhler C, 1998, BIOCHEMISTRY-US, V37, P8899, DOI 10.1021/bi980313v; Tan SL, 2002, NAT REV DRUG DISCOV, V1, P867, DOI 10.1038/nrd937; TSANTRISOS YS, 2003, Patent No. 6608027; Tsantrizos YS, 2003, ANGEW CHEM INT EDIT, V42, P1355, DOI 10.1002/anie.200390347; Zeuzem S, 2001, GASTROENTEROLOGY, V120, P1438, DOI 10.1053/gast.2001.24006	30	750	799	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 13	2003	426	6963					186	189		10.1038/nature02099	http://dx.doi.org/10.1038/nature02099			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14578911				2022-12-28	WOS:000186517200045
J	Alvarez-Dolado, M; Pardal, R; Garcia-Vardugo, JM; Fike, JR; Lee, HO; Pfeffer, K; Lois, C; Morrison, SJ; Alvarez-Buylla, A				Alvarez-Dolado, M; Pardal, R; Garcia-Vardugo, JM; Fike, JR; Lee, HO; Pfeffer, K; Lois, C; Morrison, SJ; Alvarez-Buylla, A			Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes	NATURE			English	Article							STEM-CELLS; MONOCLONAL-ANTIBODIES; IN-VIVO; MICE; DNA; DIFFERENTIATION; PLASTICITY; MICROGLIA; ANTIGENS; BRAIN	Recent studies have suggested that bone marrow cells possess a broad differentiation potential, being able to form new liver cells, cardiomyocytes and neurons(1,2). Several groups have attributed this apparent plasticity to 'transdifferentiation'(3-5). Others, however, have suggested that cell fusion could explain these results(6-9). Using a simple method based on Cre/lox recombination to detect cell fusion events, we demonstrate that bone-marrow-derived cells (BMDCs) fuse spontaneously with neural progenitors in vitro. Furthermore, bone marrow transplantation demonstrates that BMDCs fuse in vivo with hepatocytes in liver, Purkinje neurons in the brain and cardiac muscle in the heart, resulting in the formation of multinucleated cells. No evidence of transdifferentiation without fusion was observed in these tissues. These observations provide the first in vivo evidence for cell fusion of BMDCs with neurons and cardiomyocytes, raising the possibility that cell fusion may contribute to the development or maintenance of these key cell types.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; Univ Michigan, Dept Internal Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Valencia, Inst Cavanilles, E-46100 Valencia, Spain; Univ Dusseldorf, Inst Med Microbiol, D-40225 Dusseldorf, Germany; MIT, Picower Ctr Learning & Memory, Cambridge, MA 02139 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Valencia; Heinrich Heine University Dusseldorf; Massachusetts Institute of Technology (MIT)	Alvarez-Buylla, A (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.		Morrison, Sean/ABD-5326-2021; Alvarez-Dolado, Manuel/C-2706-2017; García-Verdugo, José Manuel/L-8421-2017; IBIS, FISIOPATOLOGIA/O-9510-2015; Pardal, Ricardo/C-4370-2015	Alvarez-Dolado, Manuel/0000-0002-0655-8289; García-Verdugo, José Manuel/0000-0001-9872-6499; Pardal, Ricardo/0000-0003-1085-0714; Morrison, Sean/0000-0003-1587-8329; Alvarez-Buylla, Arturo/0000-0003-4426-8925; Pfeffer, Klaus/0000-0002-5652-6330				Anderson JM, 2000, CURR OPIN HEMATOL, V7, P40, DOI 10.1097/00062752-200001000-00008; ARIAS IM, 2001, LIVER BIOL PATHOBIOL; Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Ianus A, 2003, J CLIN INVEST, V111, P843, DOI 10.1172/JCI200316502; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; LAPHAM LW, 1968, SCIENCE, V159, P310, DOI 10.1126/science.159.3812.310; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; Lewandoski M, 1997, COLD SPRING HARB SYM, V62, P159; LING EA, 1993, GLIA, V7, P9, DOI 10.1002/glia.440070105; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; MARES V, 1973, BRAIN RES, V53, P273, DOI 10.1016/0006-8993(73)90214-X; Morrison SJ, 2001, CURR BIOL, V11, pR7, DOI 10.1016/S0960-9822(00)00033-6; Orkin SH, 2002, NAT IMMUNOL, V3, P323, DOI 10.1038/ni0402-323; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; PALAY LP, 1974, CEREBELLAR CORTEX, P15; PIPER HM, 1989, ISOLATED ADULT CARDI; Priller J, 2001, J CELL BIOL, V155, P733, DOI 10.1083/jcb.200105103; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Spector D. L., 1998, CELLS LAB MANUAL; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; VANEWIJK W, 1981, J IMMUNOL, V127, P2594; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Weimann JM, 2003, P NATL ACAD SCI USA, V100, P2088, DOI 10.1073/pnas.0337659100; Weiss S, 1996, J NEUROSCI, V16, P7599; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	30	1250	1351	0	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	2003	425	6961					968	973		10.1038/nature02069	http://dx.doi.org/10.1038/nature02069			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14555960	Green Published			2022-12-28	WOS:000186230600043
J	Braude, P; Muhammed, S				Braude, P; Muhammed, S			ABC of subfertility - Assisted conception and the law in the United Kingdom	BRITISH MEDICAL JOURNAL			English	Review									Guys Kings & St Thomass Sch Med, Dept Womens Hlth, London, England	University of London; King's College London	Braude, P (corresponding author), Guys Kings & St Thomass Sch Med, Dept Womens Hlth, London, England.							GUNNING J, 2000, ASSISTED CONCEPTION; MORGAN D, 2001, BLACKSTONES GUIDE HU; Warnock M, 1998, INTELLIGENT PERSONS	3	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 25	2003	327	7421					978	981		10.1136/bmj.327.7421.978	http://dx.doi.org/10.1136/bmj.327.7421.978			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	736AL	14576252	Green Published			2022-12-28	WOS:000186147800022
J	Arantes-Oliveira, N; Berman, JR; Kenyon, C				Arantes-Oliveira, N; Berman, JR; Kenyon, C			Healthy animals with extreme longevity	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; LIFE-SPAN; SIGNALS; GENES		Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kenyon, C (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, Mission Bay Genentech Hall,600 16th St,Room S312D, San Francisco, CA 94143 USA.			Kenyon, Cynthia/0000-0003-3446-2636	NIA NIH HHS [R0I AG20932] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG020932] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Gems D, 1998, GENETICS, V150, P129; HEKIMI S, COMMUNICATION; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; LARSEN PL, 1995, GENETICS, V139, P1567; Partridge L, 2002, NAT REV GENET, V3, P165, DOI 10.1038/nrg753; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447	7	128	140	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					611	611		10.1126/science.1089169	http://dx.doi.org/10.1126/science.1089169			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576426				2022-12-28	WOS:000186119900049
J	Caldecott, KW				Caldecott, KW			The BRCT domain: Signaling with friends?	SCIENCE			English	Editorial Material							DNA-REPAIR; MODULE; XRCC1; P53		Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RR, E Sussex, England	University of Sussex	Caldecott, KW (corresponding author), Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RR, E Sussex, England.		Caldecott, Keith/S-4245-2019	Caldecott, Keith/0000-0003-4255-9016				Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; Huyton T, 2000, MUTAT RES-DNA REPAIR, V460, P319, DOI 10.1016/S0921-8777(00)00034-3; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Taylor RM, 1998, CURR BIOL, V8, P877, DOI 10.1016/S0960-9822(07)00350-8; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404	10	28	28	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					579	580		10.1126/science.1091463	http://dx.doi.org/10.1126/science.1091463			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576410				2022-12-28	WOS:000186119900034
J	Levy-Lahad, E; Plon, SE				Levy-Lahad, E; Plon, SE			A risky business - Assessing breast cancer risk	SCIENCE			English	Editorial Material							BRCA1; OOPHORECTOMY		Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Med Genet Unit, IL-91031 Jerusalem, Israel; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Hebrew University of Jerusalem; Shaare Zedek Medical Center; Baylor College of Medicine; Baylor College of Medicine	Levy-Lahad, E (corresponding author), Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Med Genet Unit, IL-91031 Jerusalem, Israel.	lahad@szmc.org.il; splon@bcm.tmc.edu	Levy-Lahad, Ephrat/F-2186-2018	Levy-Lahad, Ephrat/0000-0002-2637-1921				Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Astrom K, 2003, HUM GENET, V113, P228, DOI 10.1007/s00439-003-0969-6; Begg CB, 2002, J NATL CANCER I, V94, P1221; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Hamilton AS, 2003, NEW ENGL J MED, V348, P2313, DOI 10.1056/NEJMoa021293; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; Khoury MJ, 2003, NEW ENGL J MED, V348, P50, DOI 10.1056/NEJMra013182; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Scotet V, 2003, AM J EPIDEMIOL, V158, P129, DOI 10.1093/aje/kwg123	10	19	20	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	2003	302	5645					574	575		10.1126/science.1091465	http://dx.doi.org/10.1126/science.1091465			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576407				2022-12-28	WOS:000186119900031
J	Prather, MJ				Prather, MJ			An environmental experiment with H-2?	SCIENCE			English	Editorial Material							MOLECULAR-HYDROGEN; TROPOSPHERE; IMPACT; BUDGET; CH4; CO		Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA	University of California System; University of California Irvine	Prather, MJ (corresponding author), Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA.							BLAKE DR, 1995, SCIENCE, V269, P953, DOI 10.1126/science.269.5226.953; Conrad R, 1996, MICROBIOL REV, V60, P609, DOI 10.1128/MMBR.60.4.609-640.1996; Ehhalt D, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P239; Hauglustaine DA, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001156; Isaksen I., 1999, AVIATION GLOBAL ATMO, P121; Langenfelds RL, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001466; Novelli PC, 1999, J GEOPHYS RES-ATMOS, V104, P30427, DOI 10.1029/1999JD900788; Rahn T, 2003, NATURE, V424, P918, DOI 10.1038/nature01917; Schultz MG, 2003, SCIENCE, V302, P624, DOI 10.1126/science.1089527; Seinfeld J.H., 1991, RETHINKING OZONE PRO; Shine KP, 1990, CLIMATE CHANGE: THE IPCC SCIENTIFIC ASSESSMENT, P41; Tromp TK, 2003, SCIENCE, V300, P1740, DOI 10.1126/science.1085169; *US DOE, 2003, PRESIDENTS FREEDOMCA; Wild O, 2001, GEOPHYS RES LETT, V28, P1719, DOI 10.1029/2000GL012573	14	52	54	2	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					581	582		10.1126/science.1091060	http://dx.doi.org/10.1126/science.1091060			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576412				2022-12-28	WOS:000186119900036
J	Flum, DR; Cheadle, A; Prela, C; Dellinger, EP; Chan, L				Flum, DR; Cheadle, A; Prela, C; Dellinger, EP; Chan, L			Bile duct injury during cholecystectomy and survival in medicare beneficiaries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BENIGN BILIARY STRICTURES; QUALITY-OF-LIFE; LAPAROSCOPIC CHOLECYSTECTOMY; INTRAOPERATIVE CHOLANGIOGRAPHY; TRACT INJURY; MANAGEMENT; SURGERY; COMPLICATIONS; HEPATICOJEJUNOSTOMY; ANASTOMOSIS	Context Common bile duct (CBD) injury during cholecystectomy is a significant source of patient morbidity, but its impact on survival is unclear. Objective To demonstrate the relation between CBD injury and survival and to identify the factors associated with improved survival among Medicare beneficiaries. Design, Setting, and Patients Retrospective study using Medicare National Claims History Part B data(January 1, 1992, through December 31, 1999) linked to death records and to the American Medical Association's (AMA's) Physician Masterfile. Records with a procedure code for cholecystectomy were reviewed and those with an additional procedure code for repair of the CBD within 365 days were defined as having a CBD injury. Main Outcome Measure Survival after cholecystectomy, controlling for patient (sex, age, comorbidity index, disease severity) and surgeon (procedure year, case order, surgeon specialty) characteristics. Results Of the 1570361 patients identified as having had a cholecystectomy (62.9% women), 7911 patients (0.5%) had CBD injuries. The entire population had a mean (SD) age of 71.4 (10.2) years. Thirty-three percent of all patients died within the 9.2-year follow-up period (median survival, 5.6 years; interquartile range, 3.2-7.4 years), with 55.2% of patients without and 19.5% with a CBD injury remained alive. The adjusted hazard ratio (HR) for death during the follow-up period was significantly higher (2.79; 95% confidence interval [Cl]; 2.71-2.88) for patients with a CBD injury than those without CBD injury. The hazard significantly increased with advancing age and comorbidities and decreased with the experience of the repairing surgeon. The adjusted hazard of death during the follow-up period was 11% greater (HR, 1.11; 95% Cl, 1.02-1.20) if the repairing surgeon was the same as the injuring surgeon. Conclusions The association between CBD injury during cholecystectomy and survival among Medicare beneficiaries is stronger than suggested by previous reports. Referring patients with CBD injuries to surgeons or institutions with greater experience in CBD repair may represent a system-level opportunity to improve outcome.	Univ Washington, Dept Surg, Seattle, WA 98195 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Ctr Med & Med Serv, Div Clin Stand & Qual, Seattle, WA USA; Univ Washington, Robert Wood Johnson Clin Scholars Program, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Flum, DR (corresponding author), Univ Washington, Dept Surg, BB 431,1959 NE Pacific St,Box 356410, Seattle, WA 98195 USA.	daveflum@u.washington.edu	Flum, David/GPX-7976-2022					Al-Ghnaniem R, 2002, BRIT J SURG, V89, P1118, DOI 10.1046/j.1365-2168.2002.02182.x; Bauer T W, 1998, J Gastrointest Surg, V2, P61, DOI 10.1016/S1091-255X(98)80104-2; Boerma D, 2001, ANN SURG, V234, P750, DOI 10.1097/00000658-200112000-00006; Buanes T, 1998, SURG ENDOSC-ULTRAS, V12, P852, DOI 10.1007/s004649900728; Carroll BJ, 1998, SURG ENDOSC-ULTRAS, V12, P310, DOI 10.1007/s004649900660; Chaudhary A, 2002, DIGEST SURG, V19, P22, DOI 10.1159/000052001; Csendes A, 2001, WORLD J SURG, V25, P1346, DOI 10.1007/s00268-001-0121-5; CSENDES A, 1992, HEPATO-GASTROENTEROL, V39, P333; DAVIDS PHP, 1993, ANN SURG, V217, P237, DOI 10.1097/00000658-199303000-00004; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; DEZIEL DJ, 1993, AM J SURG, V165, P9, DOI 10.1016/S0002-9610(05)80397-6; Flum DR, 2003, JAMA-J AM MED ASSOC, V289, P1639, DOI 10.1001/jama.289.13.1639; Gigot JF, 1997, SURG ENDOSC-ULTRAS, V11, P1171, DOI 10.1007/s004649900563; Gouma DJ, 2002, BRIT J SURG, V89, P385, DOI 10.1046/j.0007-1323.2002.02051.x; INNES JT, 1988, AM SURGEON, V54, P27; Johnson SR, 2000, SURGERY, V128, P668, DOI 10.1067/msy.2000.108422; Kern KA, 1997, ARCH SURG-CHICAGO, V132, P392; KERN KA, 1994, AM J SURG, V168, P217, DOI 10.1016/S0002-9610(05)80189-8; Krahenbuhl L, 2001, WORLD J SURG, V25, P1325; Lillemoe KD, 2000, ANN SURG, V232, P430, DOI 10.1097/00000658-200009000-00015; Ludwig K, 2002, SURG ENDOSC, V16, P1098, DOI 10.1007/s00464-001-9183-6; MACAULAY FX, 1967, SCIENCE, V157, P1261, DOI 10.1126/science.157.3794.1261-b; MacFadyen BV, 1998, SURG ENDOSC-ULTRAS, V12, P315, DOI 10.1007/s004649900661; Mathisen O, 2002, SCAND J GASTROENTERO, V37, P476, DOI 10.1080/003655202317316123; Mirza DF, 1997, BRIT J SURG, V84, P786, DOI 10.1002/bjs.1800840614; Nealon WH, 1996, ANN SURG, V223, P639, DOI 10.1097/00000658-199606000-00002; PELLEGRINI CA, 1984, AM J SURG, V147, P175, DOI 10.1016/0002-9610(84)90054-0; PITT HA, 1989, ANN SURG, V210, P417, DOI 10.1097/00000658-198910000-00001; Russell JC, 1996, ARCH SURG-CHICAGO, V131, P382; Slater K, 2002, ANZ J SURG, V72, P83, DOI 10.1046/j.1445-2197.2002.02315.x; STEWART L, 1995, ARCH SURG-CHICAGO, V130, P1123; Targarona EM, 1998, SURG ENDOSC-ULTRAS, V12, P322, DOI 10.1007/s004649900662; Tocchi A, 2000, ARCH SURG-CHICAGO, V135, P153, DOI 10.1001/archsurg.135.2.153; Topal B, 1999, SURG ENDOSC, V13, P53, DOI 10.1007/s004649900897; Tsatis KG, 2003, SURG ENDOSC, V17, P31, DOI 10.1007/s00464-001-9230-3; Walsh R M, 1998, J Gastrointest Surg, V2, P458, DOI 10.1016/S1091-255X(98)80037-1; WOODS MS, 1994, AM J SURG, V167, P27, DOI 10.1016/0002-9610(94)90050-7; Z'graggen K, 1998, SURG ENDOSC-ULTRAS, V12, P1303, DOI 10.1007/s004649900846	38	317	352	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	2003	290	16					2168	2173		10.1001/jama.290.16.2168	http://dx.doi.org/10.1001/jama.290.16.2168			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CB	14570952	Bronze			2022-12-28	WOS:000186036700026
J	Varmus, H; Klausner, R; Zerhouni, E; Acharya, T; Daar, AS; Singer, PA				Varmus, H; Klausner, R; Zerhouni, E; Acharya, T; Daar, AS; Singer, PA			Grand challenges in global health	SCIENCE			English	Editorial Material									Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; NIH, Bethesda, MD 20892 USA; BMGF, Global Hlth Program, Seattle, WA 98102 USA; Univ Toronto, Joint Ctr Bioeth, Toronto, ON M5G 1L4, Canada	Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; University of Toronto	Varmus, H (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.							Hilbert D., 1902, B AM MATH SOC, V8, P437, DOI [DOI 10.1090/S0002-9904-1902-00923-3, 10.1090/S0002-9904-1902-00923-3]; World Health Organization, 2001, MACR HLTH INV HLTH E	2	178	181	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					398	399		10.1126/science.1091769	http://dx.doi.org/10.1126/science.1091769			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14563993	Green Published			2022-12-28	WOS:000185963200025
J	Feldman, S				Feldman, S			How often should we screen for cervical cancer?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Feldman, S (corresponding author), Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, 75 Francis St, Boston, MA 02115 USA.		Feldman, Sarah/AAJ-2457-2020; FELDMAN, SARAH/F-8423-2013	FELDMAN, SARAH/0000-0002-1671-9365				American Cancer Society, 2002, CANC FACTS FIG; Saslow D, 2002, CA-CANCER J CLIN, V52, P342, DOI 10.3322/canjclin.52.6.342	2	7	8	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 16	2003	349	16					1495	1496		10.1056/NEJMp038147	http://dx.doi.org/10.1056/NEJMp038147			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	731ZM	14561789				2022-12-28	WOS:000185916400001
J	Costello, EJ; Compton, SN; Keeler, G; Angold, A				Costello, EJ; Compton, SN; Keeler, G; Angold, A			Relationships between poverty and psychopathology - A natural experiment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDRENS MENTAL-HEALTH; INCOME-TAX EXPERIMENT; PSYCHIATRIC-DISORDERS; ADOLESCENT ADJUSTMENT; SOCIOECONOMIC-STATUS; SOCIAL-CLASS; COMORBIDITY; PREVALENCE; CAUSATION; SELECTION	Context Social causation (adversity and stress) vs social selection (downward mobility from familial liability to mental illness) are competing theories about the origins of mental illness. Objective To test the role of social selection vs social causation of childhood psychopathology using a natural experiment. Design Quasi-experimental, longitudinal study. Population and Setting A representative population sample of 1420 rural children aged 9 to 13 years at intake were given annual psychiatric assessments for 8 years (1993-2000). One quarter of the sample were American Indian, and the remaining were predominantly white. Halfway through the study, a casino opening on the Indian reservation gave every American Indian an income supplement that increased annually. This increase moved 14% of study families out of poverty, while 53% remained poor, and 32% were never poor. Incomes of non-Indian families were unaffected. Main Outcome Measures Levels of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, psychiatric symptoms in the never-poor, persistently poor, and ex-poor children were compared for the 4 years before and after the casino opened. Results Before the casino opened, the persistently poor and ex-poor children had more psychiatric symptoms (4.38 and 4.28, respectively) than the never-poor children (2.75), but after the opening levels among the ex-poor fell to those of the never-poor children, while levels among those who were persistently poor remained high (odds ratio, 1.50; 95% confidence interval, 1.08-2.09; and odds ratio, 0.91; 95% confidence interval, 0.77-1.07, respectively). The effect was specific to symptoms of conduct and oppositional defiant disorders. Anxiety and depression symptoms were unaffected. Similar results were found in non-Indian children whose families moved out of poverty during the same period. Conclusions An income intervention that moved families out of poverty for reasons that cannot be ascribed to family characteristics had a major effect on some types of children's psychiatric disorders, but not on others. Results support a social causation explanation for conduct and oppositional disorder, but not for anxiety or depression.	Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Dev Epidemiol Program, Durham, NC 27710 USA	Duke University	Costello, EJ (corresponding author), Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Dev Epidemiol Program, Box 3454, Durham, NC 27710 USA.		Compton, Scott/A-6656-2011		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063671, R01MH063970, R01MH048085] Funding Source: NIH RePORTER; NIDA NIH HHS [DA/MH11301] Funding Source: Medline; NIMH NIH HHS [MH48085, MH63970, MH63671] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Angold A, 2000, J AM ACAD CHILD PSY, V39, P39, DOI 10.1097/00004583-200001000-00015; Angold A, 1999, J CHILD PSYCHOL PSYC, V40, P57, DOI 10.1017/S0021963098003448; Barbarin OA, 1997, CHILDHOOD, V4, P193, DOI 10.1177/0907568297004002005; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bor W, 1997, AUST NZ J PSYCHIAT, V31, P664, DOI 10.3109/00048679709062679; BrooksGunn J, 1997, FUTURE CHILD, V7, P55, DOI 10.2307/1602387; BURNS BJ, 1995, HEALTH AFFAIR, V14, P147, DOI 10.1377/hlthaff.14.3.147; Burr WR, 1994, REEXAMING FAMILY STR, P52; BURTLESS G, 1978, J POLIT ECON, V86, P1103, DOI 10.1086/260730; BURTLESS G, 1995, J ECON PERSPECT, V9, P63, DOI 10.1257/jep.9.2.63; CONGER RD, 1995, CHILD DEV, V66, P80, DOI 10.2307/1131192; Conger RD, 1999, AM J COMMUN PSYCHOL, V27, P519, DOI 10.1023/A:1022133228206; COOK TD, 1994, ANNU REV PSYCHOL, V45, P545, DOI 10.1146/annurev.ps.45.020194.002553; Costello EJ, 1996, ARCH GEN PSYCHIAT, V53, P1129; Diggle PJ, 1994, ANAL LONGITUDINAL DA; DOHRENWEND BP, 1992, SCIENCE, V255, P946, DOI 10.1126/science.1546291; Elder G. H., 1999, CHILDREN GREAT DEPRE; ELESH D, 1977, J HEALTH SOC BEHAV, V18, P391, DOI 10.2307/2955347; Gennetian LA, 2002, CHILD DEV, V73, P601, DOI 10.1111/1467-8624.00426; Graham CA, 2000, DEV PSYCHOPATHOL, V12, P201, DOI 10.1017/S0954579400002054; Hollingshead August B., 1958, SOCIAL CLASS MENTAL; JARVIS E, 1971, INSANITY IDIOCY MASS; KESSLER RC, 1995, AM J PSYCHIAT, V152, P1026; Kessler RC, 1997, PSYCHOL MED, V27, P1101, DOI 10.1017/S0033291797005588; KESSLER RC, 1980, AM SOCIOL REV, V45, P463, DOI 10.2307/2095178; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; LEMKAU PV, 1986, COMMUNITY SURVEYS PS, P23; Lipman EL, 1996, SOC PSYCH PSYCH EPID, V31, P303; McLeod JD, 1996, J HEALTH SOC BEHAV, V37, P207, DOI 10.2307/2137292; MCLEOD JD, 1993, AM SOCIOL REV, V58, P351, DOI 10.2307/2095905; Miech RA, 1999, AM J SOCIOL, V104, P1096, DOI 10.1086/210137; Muntaner C, 1998, SOC SCI MED, V47, P2043, DOI 10.1016/S0277-9536(98)00309-8; POLLITT E, 1994, CHILD DEV, V65, P283; Rutter M, 2001, PSYCHOL BULL, V127, P291, DOI 10.1037//0033-2909.127.3.291; SCHAIE K W, 1965, Psychol Bull, V64, P92, DOI 10.1037/h0022371; Shaw DS, 1997, J AM ACAD CHILD PSY, V36, P1760, DOI 10.1097/00004583-199712000-00025; Silberg J, 1999, ARCH GEN PSYCHIAT, V56, P225, DOI 10.1001/archpsyc.56.3.225; SOUTHWORTH LE, 1973, HOME ECON RES J, V2, P35; SPIEGELMAN RG, 1980, J HUM RESOUR, V15, P463, DOI 10.2307/145397; Whitbeck LB, 1997, SOC PSYCHOL QUART, V60, P291, DOI 10.2307/2787091; WRIGHT S, 1975, SOC FORCES, V53, P552; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	43	687	696	3	164	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	2003	290	15					2023	2029		10.1001/jama.290.15.2023	http://dx.doi.org/10.1001/jama.290.15.2023			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732CX	14559956	Bronze			2022-12-28	WOS:000185924200026
J	Dickinson, D; Raynor, DKT; Kennedy, JG; Bonaccorso, S; Sturchio, JL				Dickinson, D; Raynor, DKT; Kennedy, JG; Bonaccorso, S; Sturchio, JL			What information do patients need about medicines?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Consumation, Consumer Informat Design, London SW17 7QW, England; Univ Leeds, Pharm Practice & Med Management Grp, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Dickinson, D (corresponding author), Consumation, Consumer Informat Design, 53 Hosack Rd, London SW17 7QW, England.		Sturchio, Jeffrey/GWZ-3472-2022						0	70	73	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					861	861		10.1136/bmj.327.7419.861-a	http://dx.doi.org/10.1136/bmj.327.7419.861-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551106	Green Accepted, Green Published			2022-12-28	WOS:000185921200029
J	Jardine, DL; Hurrell, MA; Anderson, TJ				Jardine, DL; Hurrell, MA; Anderson, TJ			A bad dose of the 'flu	LANCET			English	Editorial Material							INFLUENZA-VIRUSES; ENCEPHALOPATHY		Christchurch Hosp, Dept Gen Med, Christchurch, New Zealand; Christchurch Hosp, Dept Radiol, Christchurch, New Zealand; Christchurch Hosp, Dept Neurol, Christchurch, New Zealand	Christchurch Hospital New Zealand; Christchurch Hospital New Zealand; Christchurch Hospital New Zealand	Jardine, DL (corresponding author), Christchurch Hosp, Dept Gen Med, Private Bag 4710, Christchurch, New Zealand.							MIZUGUCHI M, 1995, J NEUROL NEUROSUR PS, V58, P555, DOI 10.1136/jnnp.58.5.555; Morishima T, 2002, CLIN INFECT DIS, V35, P512, DOI 10.1086/341407; Schlesinger RW, 1998, ADV VIRUS RES, V50, P289, DOI 10.1016/S0065-3527(08)60811-8; Seo SH, 2002, NAT MED, V8, P950, DOI 10.1038/nm757; Zambon MC, 2001, REV MED VIROL, V11, P227, DOI 10.1002/rmv.319	5	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 11	2003	362	9391					1198	1198		10.1016/S0140-6736(03)14543-6	http://dx.doi.org/10.1016/S0140-6736(03)14543-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568742				2022-12-28	WOS:000185924100012
J	Macaubas, C; de Klerk, NH; Holt, BJ; Wee, C; Kendall, G; Firth, M; Sly, PD; Holt, PG				Macaubas, C; de Klerk, NH; Holt, BJ; Wee, C; Kendall, G; Firth, M; Sly, PD; Holt, PG			Association between antenatal cytokine production and the development of atopy and asthma at age 6 years	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; INTERFERON-GAMMA; RESPIRATORY-FUNCTION; NATURAL-KILLER; PREGNANCY; FETAL; MATURATION; CHILDHOOD; BIRTH; ALPHA	Background Various lines of evidence suggest that antenatal factors are important in determining susceptibility to atopy and asthma. One possible mechanism is cytokines, production of which in the placenta is high throughout gestation and which protect placental integrity via control of local immunological homoeostasis. We investigated antenatal cytokine concentrations in a prospective birth cohort, intensively monitored for atopy and asthma outcomes at age 6 years. Methods Cryopreserved cord-blood serum samples from 407 children were assayed for interleukins 4, 5, 6, 10, 12, and 13, interferon gamma, and tumour necrosis factor alpha (TNFalpha). Associations between family, antenatal, and perinatal factors, cord-blood cytokine concentrations, and atopy or asthma outcomes were analysed by logistic regression. Causal effects of cytokines on outcomes were estimated by propensity scores based on family, antenatal, and perinatal factors. Findings Detectable cord-blood concentrations of interleukin 4 and interferon gamma were each associated with lower risk of physician-diagnosed asthma (adjusted odds ratios 0.60 [95% CI 0.37-0.99] and 0.60 [0.37-0.97] respectively), current asthma (0.59 [0.33-1.00] and 0.39 [0.22-0.71]), and current wheeze (0.55 [0.32-0.93] and 0.52 [0.31-0.90]) and atopy (sensitisation to some inhalant allergens) outcomes at 6 years. High concentrations of TNFalpha were associated with lower risk of atopy but not with asthma risk. These associations were broadly unaltered by propensity-score adjustment. Maternal smoking was associated with higher risk of both wheeze at 6 years and lower concentrations of interleukin 4 and interferon gamma in cord blood. Interpretation The mechanism underlying attenuated T-helper-1/T-helper-2 cytokine production in high-risk children also apparently operates in control of cytokine production in the fetoplacental unit. The finding that this mechanism is dysregulated by maternal smoking suggests it is a target for antenatal environmental factors relevant to asthma aetiology.	TVW Telethon Inst Child Hlth Res, Div Cell Biol, Perth, WA 6872, Australia; Univ Western Australia, Fac Med & Dent, Ctr Child Hlth Res, Perth, WA 6009, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia	Holt, PG (corresponding author), TVW Telethon Inst Child Hlth Res, Div Cell Biol, POB 855, Perth, WA 6872, Australia.		de Klerk, Nicholas H/D-8388-2016; Holt, Patrick G/H-1548-2011; Sly, Peter D/F-1486-2010; Study, Raine/K-4517-2013	de Klerk, Nicholas H/0000-0001-9223-0767; Holt, Patrick G/0000-0003-1193-0935; Sly, Peter D/0000-0001-6305-2201; Firth, Martin/0000-0002-7471-0860				Ashkar AA, 2000, J EXP MED, V192, P259, DOI 10.1084/jem.192.2.259; BUONOCORE G, 1995, BIOL NEONATE, V68, P104; Clarke JU, 1998, ENVIRON SCI TECHNOL, V32, P177, DOI 10.1021/es970521v; Gregory A, 1999, CLIN EXP ALLERGY, V29, P330; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; Holt PG, 1997, CURR OPIN IMMUNOL, V9, P782, DOI 10.1016/S0952-7915(97)80178-1; Hoo AF, 1998, AM J RESP CRIT CARE, V158, P700, DOI 10.1164/ajrccm.158.3.9711057; Leadbitter P, 1999, THORAX, V54, P905, DOI 10.1136/thx.54.10.905; Lee SM, 1996, BLOOD, V88, P945; LIN H, 1993, J IMMUNOL, V151, P4562; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; NEWNHAM JP, 1993, LANCET, V342, P887, DOI 10.1016/0140-6736(93)91944-H; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; OPSJON SL, 1993, AM J OBSTET GYNECOL, V169, P397, DOI 10.1016/0002-9378(93)90096-2; Ouyang Y, 2000, J ALLERGY CLIN IMMUN, V106, P280, DOI 10.1067/mai.2000.107751; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Rasanen M, 2000, THORAX, V55, P25, DOI 10.1136/thorax.55.1.25; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; Roth I, 1996, J EXP MED, V184, P539, DOI 10.1084/jem.184.2.539; Rothman KJ., 1986, MODERN EPIDEMIOLOGY; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Saito S, 2000, J REPROD IMMUNOL, V47, P87, DOI 10.1016/S0165-0378(00)00060-7; Schnurr M, 2000, J IMMUNOL, V165, P4704, DOI 10.4049/jimmunol.165.8.4704; SCHURMANS S, 1990, J IMMUNOL, V145, P2465; Sekhon HS, 2001, AM J RESP CRIT CARE, V164, P989, DOI 10.1164/ajrccm.164.6.2011097; SILVER RM, 1994, BIOL REPROD, V50, P1108, DOI 10.1095/biolreprod50.5.1108; Steinborn A, 1999, CLIN EXP IMMUNOL, V117, P147; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; SUZUKI K, 1980, AM J OBSTET GYNECOL, V136, P1009, DOI 10.1016/0002-9378(80)90628-6; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; TRINCHIERI G, 1994, IMMUNOL TODAY, V15, P460, DOI 10.1016/0167-5699(94)90189-9; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; Williams TJ, 2000, J ALLERGY CLIN IMMUN, V105, P951, DOI 10.1067/mai.2000.106211	33	177	183	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 11	2003	362	9391					1192	1197		10.1016/S0140-6736(03)14542-4	http://dx.doi.org/10.1016/S0140-6736(03)14542-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568741				2022-12-28	WOS:000185924100011
J	Sorensen, PS; Ross, C; Clemmesen, KM; Bendtzen, K; Frederiksen, JL; Jensen, K; Kristensen, O; Petersen, T; Rasmussen, S; Ravnborg, M; Stenager, E; Koch-Henriksen, N				Sorensen, PS; Ross, C; Clemmesen, KM; Bendtzen, K; Frederiksen, JL; Jensen, K; Kristensen, O; Petersen, T; Rasmussen, S; Ravnborg, M; Stenager, E; Koch-Henriksen, N		Danish Sclerosis Study Grp	Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis	LANCET			English	Article							PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; MAGNETIC-RESONANCE; MS PATIENTS; MULTICENTER; IFN-BETA-1A; THERAPY	Background Interferon beta is the first-line treatment for relapsing-remitting multiple sclerosis, but the drug can induce neutralising antibodies against itself, which might reduce effectiveness. We aimed to assess the clinical effect of neutralising antibodies. Methods We measured neutralising antibodies every 12 months for up to 60 months in 541 patients with multiple sclerosis, randomly selected from all patients who started treatment with interferon beta between 1996 and 1999. Patients left the study if they changed or discontinued therapy. Antibodies were measured blindly, using antiviral neutralisation bioassays with high, medium, and low sensitivity, and with different neutralising capacities as cutoff value for definition of a neutralising-antibody-positive result. Findings Patients developed neutralising antibodies independent of age, sex, disease duration, and progression index at start of treatment. Relapse rates were significantly higher during antibody-positive periods (0.64-0.70) than they were during antibody-negative periods (0.43-0.46; p<0.03). When comparing the number of relapses in the neutralising-antibody-positive and neutralising-antibody-negative periods we found odds ratios in the range 1.51 to 1.58 (p<0.03). Time to first relapse was significantly increased by 244 days in patients who were anti body-negative at 12 months (log rank test 6.83, p=0.009). During this short-term study, presence of neutralising antibodies did not affect disease progression measured with the expanded disability status scale. Interpretation Our findings suggest that the presence of neutralising antibodies against interferon beta reduces the clinical effect of the drug. In patients who are not doing well on interferon beta, the presence of such antibodies should prompt consideration about change of treatment.	Rigshosp, Dept Neurol, DK-2100 Copenhagen, Denmark; Rigshosp, Inst Inflammat Res, DK-2100 Copenhagen, Denmark; Glostrup Cty Hosp, Dept Neurol, DK-2600 Glostrup, Denmark; Cent Hosp Hillerod, Hillerod, Denmark; Odense Univ Hosp, DK-5000 Odense, Denmark; Aarhus Univ Hosp, DK-8000 Aarhus, Denmark; Esbjerg Cent Hosp, Esbjerg, Denmark; Aalborg Hosp, Aalborg, Denmark; Danish MS Treatment Register, Aalborg, Denmark; Natl Inst Publ Hlth, Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen; University of Southern Denmark; Odense University Hospital; Aarhus University; Aalborg University; Aalborg University Hospital	Sorensen, PS (corresponding author), Univ Copenhagen Hosp, Rigshosp, Dept Neurol 2082, DK-2100 Copenhagen, Denmark.		Stenager, Egon/O-2275-2017; Stenager, Egon/AAU-4463-2020; Calabrese, Massimiliano/I-6195-2012	stenager, egon/0000-0002-4877-5193; frederiksen, jette/0000-0003-1661-7438; Sorensen, Per Soelberg/0000-0002-2818-3780; Petersen, Thor/0000-0001-5633-2600				AbdulAhad AK, 1997, CYTOKINES CELL MOL T, V3, P27; Antonelli G, 1998, J INTERF CYTOK RES, V18, P345, DOI 10.1089/jir.1998.18.345; Bertolotto A, 2002, J NEUROL NEUROSUR PS, V73, P148, DOI 10.1136/jnnp.73.2.148; Bertolotto A, 2000, IMMUNOPHARMACOLOGY, V48, P95, DOI 10.1016/S0162-3109(00)00182-X; Cook SD, 2001, NEUROLOGY, V57, P1080, DOI 10.1212/WNL.57.6.1080; Deisenhammer F, 1999, NEUROLOGY, V52, P1239, DOI 10.1212/WNL.52.6.1239; DUQUETTE P, 1995, NEUROLOGY, V45, P1277; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Duquette P, 1996, NEUROLOGY, V47, P889; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Francis G, 2001, NEUROLOGY, V56, P1628; HANSEN MB, 1990, J IMMUNOL METHODS, V127, P241, DOI 10.1016/0022-1759(90)90074-6; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; Kappos L, 1998, LANCET, V352, P1491, DOI 10.1016/S0140-6736(98)10039-9; Khan OA, 1998, NEUROLOGY, V51, P1698, DOI 10.1212/WNL.51.6.1698; Kivisakk P, 2000, EUR J NEUROL, V7, P27, DOI 10.1046/j.1468-1331.2000.00002.x; Koch-Henriksen N, 2000, MULT SCLER, V6, P172, DOI 10.1191/135245800701566034; Kracke A, 2000, NEUROLOGY, V54, P193, DOI 10.1212/WNL.54.1.193; Li DKB, 1999, ANN NEUROL, V46, P197, DOI 10.1002/1531-8249(199908)46:2<197::AID-ANA9>3.0.CO;2-P; Miller DH, 1999, ANN NEUROL, V46, P850, DOI 10.1002/1531-8249(199912)46:6<850::AID-ANA7>3.0.CO;2-Q; Oger Joel J. F., 1997, Neurology, V48, pA80; Pachner AR, 1997, NEUROLOGY, V49, P647, DOI 10.1212/WNL.49.3.647; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; Rice GPA, 1999, NEUROLOGY, V52, P1277, DOI 10.1212/WNL.52.6.1277; ROSS C, 1995, J CLIN INVEST, V95, P1974, DOI 10.1172/JCI117881; Ross C, 2000, ANN NEUROL, V48, P706, DOI 10.1002/1531-8249(200011)48:5<706::AID-ANA3>3.3.CO;2-M; Rudick RA, 1997, NEUROLOGY, V49, P358, DOI 10.1212/WNL.49.2.358; Rudick RA, 1998, NEUROLOGY, V50, P1266, DOI 10.1212/WNL.50.5.1266; SCHUMACHER GA, 1965, ANN NY ACAD SCI, V122, P552; Simon JH, 1998, ANN NEUROL, V43, P79, DOI 10.1002/ana.410430114	30	293	302	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 11	2003	362	9391					1184	1191		10.1016/S0140-6736(03)14541-2	http://dx.doi.org/10.1016/S0140-6736(03)14541-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568740				2022-12-28	WOS:000185924100010
J	Gent, JF; Triche, EW; Holford, TR; Belanger, K; Bracken, MB; Beckett, WS; Leaderer, BP				Gent, JF; Triche, EW; Holford, TR; Belanger, K; Bracken, MB; Beckett, WS; Leaderer, BP			Association of low-level ozone and fine particles with respiratory symptoms in children with asthma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AFRICAN-AMERICAN CHILDREN; AIR-POLLUTION; MEDICATION USE; AMBIENT OZONE; 1ST YEAR; PARTICULATE; EXPOSURE; SUMMER; HEALTH; LIFE	Context Exposure to ozone and particulate matter of 2.5 mum or less (PM2.5) in air at levels above current US Environmental Protection Agency (EPA) standards is a risk factor for respiratory symptoms in children with asthma. Objective To examine simultaneous effects of ozone and PM2.5 at levels below EPA standards on daily respiratory symptoms and rescue medication use among children with asthma. Design, Setting, and Participants Daily respiratory symptoms and medication use were examined prospectively for 271 children younger than 12 years with physician-diagnosed, active asthma residing in southern New England. Exposure to ambient concentrations of ozone and PM2.5 from April 1 through September 30, 2001, was assessed using ozone (peak 1-hour and 8-hour) and 24-hour PM2.5. Logistic regression analyses using generalized estimating equations were performed separately for maintenance medication users (n=130) and nonusers (n=141). Associations between pollutants (adjusted for temperature, controlling for same- and previous-day levels) and respiratory symptoms and use of rescue medication were evaluated. Main Outcome Measures Respiratory symptoms and rescue medication use recorded on calendars by subjects' mothers. Results Mean (SD) levels were 59 (19) ppb (1-hour average) and 51 (16) ppb (8-hour average) for ozone and 13 (8) mug/m(3) for PM2.5. In copollutant models, ozone level but not PM2.5 was significantly associated with respiratory symptoms and rescue medication use among children using maintenance medication; a 50-ppb increase in 1-hour ozone was associated with increased likelihood of wheeze (by 35%) and chest tightness (by 47%). The highest levels of ozone (1-hour or 8-hour averages) were associated with increased shortness of breath and rescue medication use. No significant, exposure-dependent associations were observed for any outcome by any pollutant among children who did not use maintenance medication. Conclusion Asthmatic children using maintenance medication are particularly vulnerable to ozone, controlling for exposure to fine particles, at levels below EPA standards.	Yale Univ, Ctr Perinatal Pediat & Environm Epidemiol, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY USA	Yale University; University of Rochester	Gent, JF (corresponding author), Yale Univ, Ctr Perinatal Pediat & Environm Epidemiol, Sch Med, Dept Epidemiol & Publ Hlth, 1 Church St,6th Floor, New Haven, CT 06510 USA.	janneane.gent@yale.edu	Triche, Elizabeth/I-4986-2014		NIEHS NIH HHS [ES05410, ES07456, ES11013, ES01247] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007456, P30ES001247, R01ES011013] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allison P. D., 1999, LOGISTIC REGRESSION; Belanger K, 2003, AM J EPIDEMIOL, V158, P195, DOI 10.1093/aje/kwg148; *COMM MASS DEP ENV, 2000, AIR QUAL REP; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.2307/3434265; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Gent JF, 2002, ENVIRON HEALTH PERSP, V110, pA781, DOI 10.1289/ehp.021100781; Gielen MH, 1997, AM J RESP CRIT CARE, V155, P2105, DOI 10.1164/ajrccm.155.6.9196122; Gold DR, 1999, EPIDEMIOLOGY, V10, P8, DOI 10.1097/00001648-199901000-00004; Hanania NA, 1998, CHEST, V114, P752, DOI 10.1378/chest.114.3.752; Kehrl HR, 1999, J ALLERGY CLIN IMMUN, V104, P1198, DOI 10.1016/S0091-6749(99)70013-8; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Mortimer KM, 2000, AM J RESP CRIT CARE, V162, P1838, DOI 10.1164/ajrccm.162.5.9908113; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; OSTRO BD, 1995, INHAL TOXICOL, V7, P711, DOI 10.3109/08958379509014475; Peters A, 1997, ENVIRON HEALTH PERSP, V105, P430, DOI 10.2307/3433341; Romieu I, 1997, ARCH ENVIRON HEALTH, V52, P368, DOI 10.1080/00039899709602213; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300, DOI 10.1164/ajrccm.154.2.8756798; *SAS I INC, 2001, SAS VERS 8; SILVERMAN F, 1979, ENVIRON HEALTH PERSP, V29, P131, DOI 10.2307/3429055; SPEKTOR DM, 1988, AM REV RESPIR DIS, V137, P313, DOI 10.1164/ajrccm/137.2.313; *STAT CONN DEP ENV, 1999, ANN AIR QUAL SUMM; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654, DOI 10.1164/ajrccm.155.2.9032209; Ulmer C, 1997, PEDIATR PULM, V23, P344, DOI 10.1002/(SICI)1099-0496(199705)23:5<344::AID-PPUL6>3.3.CO;2-4; *US EPA, 1996, EPA600AP93004AC US E	24	324	334	1	45	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2003	290	14					1859	1867		10.1001/jama.290.14.1859	http://dx.doi.org/10.1001/jama.290.14.1859			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729CB	14532314				2022-12-28	WOS:000185752600026
J	Grzybowski, M; Clements, EA; Parsons, L; Welch, R; Tintinalli, AT; Ross, MA; Zalenski, RJ				Grzybowski, M; Clements, EA; Parsons, L; Welch, R; Tintinalli, AT; Ross, MA; Zalenski, RJ			Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy - A propensity analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; PRIMARY ANGIOPLASTY; NATIONAL REGISTRY; RANDOMIZED TRIALS; ACUTE MI; SCORES; ANGIOGRAPHY; VOLUME	Context There are no definitive recommendations for the management of acute myocardial infarction (AMI) in patients with ST-segment elevation who have contraindications to thrombolytic therapy. It is not clear whether, and the extent to which, immediate mechanical reperfusion (IMR) reduces in-hospital mortality in this population. Objective To determine whether IMR (defined as percutaneous coronary intervention or coronary artery bypass graft surgery) is associated with a mortality benefit in patients with acute ST-segment elevation AMI who are eligible for IMR but have contraindications to thrombolytic therapy. Design, Setting, and Patients From June 1994 to January 2003, the National Registry of Myocardial Infarction 2, 3, and 4 enrolled 1799704 patients with AMI. A total of 19917 patients with acute ST-segment elevation were eligible for IMR but had thrombolytic contraindications after excluding patients who were transferred in from or out to other facilities, patients who received intracoronary thrombolytics, and those who received no medications within 24 hours of arrival. Main Outcome Measure In-hospital mortality. Results Of the 19917 patients, 4705 patients (23.6%) received IMR and 5173 patients (25.9%) died. In-hospital mortality rates in the IMR and non-IMR treated groups in the unadjusted analysis were 11.1%, representing 521 of 4705 patients, and 30.6%, representing 4652 of 15212 patients, respectively, for a risk reduction of 63.7% (odds ratio [OR], 0.28; 95% confidence interval [CI], 0.26-0.31). In a further analysis using a propensity matching score to reduce the effects of bias, 3905 patients who received IMR remained at lower risk for in-hospital mortality than 3905 matched patients (10.9% vs 20.1%, respectively, for a risk reduction of 45.8%; OR, 0.48; 95% Cl, 0.43-0.55). Following a second logistic model applied to the matched groups to adjust for residual differences, a significant treatment effect persisted (OR, 0.64; 95% Cl, 0.56-0.75). Conclusions In this population, IMR was associated with a reduced risk of in-hospital mortality after appropriate adjustments. Of those we studied who were eligible for IMR, 15212 patients (76.4%) did not receive it. These results suggest that using IMR in patients with acute ST-segment elevation AMI and contrainclications to thrombolytics should be strongly considered.	Wayne State Univ, Sch Med, Dept Emergency Med, Ctr Healthcare Effectiveness, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Med, Div Cardiol, Detroit, MI 48201 USA; Spectrum Hlth Hosp, Dept Pharm, Grand Rapids, MI USA; Ovat Res Grp, Chicago, IL USA; William Beaumont Hosp, Dept Emergency Med, Royal Oak, MI 48072 USA; John D Dingell Vet Affairs Hosp, Dept Med, Sect Urgent Care, Detroit, MI USA	Wayne State University; Wayne State University; Beaumont Health	Grzybowski, M (corresponding author), Wayne State Univ, Sch Med, Dept Emergency Med, Ctr Healthcare Effectiveness, UHC 6-G,4201 St Antoine, Detroit, MI 48201 USA.							Aversano T, 2002, JAMA-J AM MED ASSOC, V287, P1943, DOI 10.1001/jama.287.15.1943; Barron HV, 2000, AM J CARDIOL, V85, P294, DOI 10.1016/S0002-9149(99)00735-3; Cannon CP, 2000, JAMA-J AM MED ASSOC, V283, P2941, DOI 10.1001/jama.283.22.2941; Canto JG, 2000, NEW ENGL J MED, V342, P1573, DOI 10.1056/NEJM200005253422106; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Every NR, 1999, J AM COLL CARDIOL, V33, P1886, DOI 10.1016/S0735-1097(99)00113-8; Grines CL, 2002, J AM COLL CARDIOL, V39, P1713, DOI 10.1016/S0735-1097(02)01870-3; HIMBERT D, 1993, AM J CARDIOL, V71, P377, DOI 10.1016/0002-9149(93)90435-F; Joffe MM, 1999, AM J EPIDEMIOL, V150, P327; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Magid DJ, 2000, JAMA-J AM MED ASSOC, V284, P3131, DOI 10.1001/jama.284.24.3131; McCullough PA, 1998, J AM COLL CARDIOL, V32, P596, DOI 10.1016/S0735-1097(98)00284-8; Moon JCC, 2002, INT J CARDIOL, V85, P199, DOI 10.1016/S0167-5273(02)00183-3; MOSES LE, 1995, MED CARE, V33, pAS8; Normand SLT, 2001, J CLIN EPIDEMIOL, V54, P387, DOI 10.1016/S0895-4356(00)00321-8; Parsons, 2001, P 26 ANN SAS US GROU; Peterson ED, 2003, J AM COLL CARDIOL, V42, P45, DOI 10.1016/S0735-1097(03)00514-X; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; Rogers WJ, 2000, J AM COLL CARDIOL, V36, P2056, DOI 10.1016/S0735-1097(00)00996-7; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Ryan TJ, 1999, J AM COLL CARDIOL, V34, P890, DOI 10.1016/S0735-1097(99)00351-4; Stone GW, 1996, CATHETER CARDIO DIAG, V39, P333, DOI 10.1002/(SICI)1097-0304(199612)39:4<333::AID-CCD1>3.0.CO;2-E; Widimsky P, 2003, EUR HEART J, V24, P94, DOI 10.1016/S0195-668X(02)00468-2; Zahn R, 1999, CATHETER CARDIO INTE, V46, P127, DOI 10.1002/(SICI)1522-726X(199902)46:2<127::AID-CCD2>3.3.CO;2-7	26	79	82	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2003	290	14					1891	1898		10.1001/jama.290.14.1891	http://dx.doi.org/10.1001/jama.290.14.1891			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729CB	14532318	Bronze			2022-12-28	WOS:000185752600030
J	Zhan, CL; Miller, MR				Zhan, CL; Miller, MR			Excess length of stay, charges, and morality attributable to medical injuries during hospitalization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE DRUG EVENTS; ICD-9-CM ADMINISTRATIVE DATA; CLINICAL COMORBIDITY INDEX; PATIENT SAFETY EFFORTS; SUBSTANDARD CARE; RISK-FACTORS; CLAIMS DATA; COMPLICATIONS; ERRORS; COSTS	Context Although medical injuries are recognized as a major hazard in the health care system, little is known about their impact. Objective To assess excess length of stay, charges, and deaths attributable to medical injuries during hospitalization. Design, Setting, and Patients The Agency for Healthcare Research and Quality (AHRQ) Patient Safety Indicators (PSIs) were used to identify medical injuries in 7.45 million hospital discharge abstracts from 994 acute-care hospitals across 28 states in 2000 in the AHRQ Healthcare Cost and Utilization Project Nationwide Inpatient Sample database. Main Outcome Measures Length of stay, charges, and mortality that were recorded in hospital discharge abstracts and were attributable to medical injuries according to 18 PSIs. Results Excess length of stay attributable to medical injuries ranged from 0 days for injury to a neonate to 10.89 days for postoperative sepsis, excess charges ranged from $0 for obstetric trauma (without vaginal instrumentation) to $57727 for postoperative sepsis, and excess mortality ranged from 0% for obstetric trauma to 21.96% for postoperative sepsis (P<.001). Following postoperative sepsis, the second most serious event was postoperative wound dehiscence, with 9.42 extra days in the hospital, 40323 in excess charges, and 9.63% attributable mortality. Infection due to medical care was associated with 9.58 extra days, $38656 in excess charges, and 4.31% attributable mortality. Conclusion Some injuries incurred during hospitalization pose a significant threat to patients and costs to society, but the impact of such injury is highly variable.	Agcy Healthcare Res & Qual Safety, Ctr Qual Improvement & Patient Safety, US Dept HHS, Rockville, MD 20850 USA; Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA	Johns Hopkins University	Zhan, CL (corresponding author), Agcy Healthcare Res & Qual Safety, Ctr Qual Improvement & Patient Safety, US Dept HHS, 540 Gaither Rd, Rockville, MD 20850 USA.							*AG HEALTHC RES QU, 2003, AHRQ QUAL IND PAT SA; BATES DW, 1995, MED CARE, V33, P452, DOI 10.1097/00005650-199505000-00002; Bates DW, 1999, ARCH INTERN MED, V159, P2553, DOI 10.1001/archinte.159.21.2553; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1991, JAMA-J AM MED ASSOC, V265, P3265, DOI 10.1001/jama.265.24.3265; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; *DEP HLTH HUM SERV, 2000, CHALL POT ASS QUAL H; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Fleming S T, 1996, Clin Perform Qual Health Care, V4, P137; Friedman Bernard, 2002, J Health Care Finance, V29, P1; Geraci JM, 1997, MED CARE, V35, P589, DOI 10.1097/00005650-199706000-00005; Ghali WA, 1996, J CLIN EPIDEMIOL, V49, P273, DOI 10.1016/0895-4356(95)00564-1; Hayward RA, 2001, JAMA-J AM MED ASSOC, V286, P415, DOI 10.1001/jama.286.4.415; HSIA D, 1988, NEW ENGL J MED, V11, P303; Hurtado M.P., 2001, ENVISIONING NATL HLT; HYSLOP JW, 1982, SOUTH MED J, V75, P657, DOI 10.1097/00007611-198206000-00006; Iezzoni L I, 1992, QRB Qual Rev Bull, V18, P361; IEZZONI LI, 1997, RISK ADJUSTMENT MEAS, P43; IEZZONI LI, 1997, RISK ADJUSTMENT MEAS, P169; Jason R S, 1979, J Natl Med Assoc, V71, P501; Jensen AG, 1999, ARCH INTERN MED, V159, P1437, DOI 10.1001/archinte.159.13.1437; Johantgen M, 1998, Jt Comm J Qual Improv, V24, P88; JOHNSON WG, 1992, JAMA-J AM MED ASSOC, V267, P2487, DOI 10.1001/jama.267.18.2487; Kalish R L, 1995, Am J Med Qual, V10, P48, DOI 10.1177/0885713X9501000108; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, VVolume 600; Kozak LJ, 2002, VITAL HLTH STAT, V13, P1; KRAVITZ RL, 1991, JAMA-J AM MED ASSOC, V266, P2087, DOI 10.1001/jama.266.15.2087; Lawthers AG, 2000, MED CARE, V38, P785, DOI 10.1097/00005650-200008000-00003; Layde PM, 2002, JAMA-J AM MED ASSOC, V287, P1993, DOI 10.1001/jama.287.15.1993; Leape L, 1999, Image J Nurs Sch, V31, P281; Leape LL, 2000, JAMA-J AM MED ASSOC, V284, P95, DOI 10.1001/jama.284.1.95; Leape LL, 2002, JAMA-J AM MED ASSOC, V288, P501, DOI 10.1001/jama.288.4.501; Leape LL, 2002, NEW ENGL J MED, V347, P1633, DOI 10.1056/NEJMNEJMhpr011493; Littel R., 1996, SYSTEM MIXED MODELS; Mark DH, 2001, JAMA-J AM MED ASSOC, V285, P337, DOI 10.1001/jama.285.3.337; McCarthy EP, 2000, MED CARE, V38, P868, DOI 10.1097/00005650-200008000-00010; McDonald CJ, 2000, JAMA-J AM MED ASSOC, V284, P93, DOI 10.1001/jama.284.1.93; McNutt RA, 2002, JAMA-J AM MED ASSOC, V287, P1997, DOI 10.1001/jama.287.15.1997; Ming KW, 2000, BIOMETRICS, V56, P118, DOI 10.1111/j.0006-341X.2000.00118.x; MITCHELL JB, 1994, MED CARE, V32, pJS38; President's Advisory Commission on Consumer Protection and Quality in the Health Care Industry, 1998, QUAL 1 BETT HLTH CAR; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1085, DOI 10.1016/0895-4356(93)90106-B; Romano PS, 2000, HEALTH SERV RES, V34, P1469; Romano PS, 2003, HEALTH AFFAIR, V22, P154, DOI 10.1377/hlthaff.22.2.154; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; Romano PS, 2002, MED CARE, V40, P856, DOI 10.1097/00005650-200210000-00004; ROSENBAUM PR, 1989, J AM STAT ASSOC, V84, P1024, DOI 10.2307/2290079; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; RUBIN DB, 1979, J AM STAT ASSOC, V74, P318, DOI 10.2307/2286330; RUBIN DB, 1973, BIOMETRICS, V29, P159, DOI 10.2307/2529684; Shojania KG, 2002, JAMA-J AM MED ASSOC, V288, P508, DOI 10.1001/jama.288.4.508; SIMBORG DW, 1981, NEW ENGL J MED, V304, P1602, DOI 10.1056/NEJM198106253042611; Smith HL, 1997, SOCIOL METHODOL, V27, P325, DOI 10.1111/1467-9531.271030; Thomas EJ, 1999, INQUIRY-J HEALTH CAR, V36, P255; Thomas EJ, 2000, MED CARE, V38, P261, DOI 10.1097/00005650-200003000-00003; *U CA SAN FRANC ST, 2002, EV REP MEAS PAT SAF; Weingart SN, 2000, MED CARE, V38, P796, DOI 10.1097/00005650-200008000-00004; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; Whitfield M D, 2000, J Wound Care, V9, P261; Zarling E J, 1999, Am J Med Qual, V14, P242, DOI 10.1177/106286069901400603; MEASURES PATIENT SAF; NATIONWIDE INPATIENT	66	703	732	1	31	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2003	290	14					1868	1874		10.1001/jama.290.14.1868	http://dx.doi.org/10.1001/jama.290.14.1868			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729CB	14532315	Bronze			2022-12-28	WOS:000185752600027
J	He, WZ; Cowin, P; Stokes, DL				He, WZ; Cowin, P; Stokes, DL			Untangling desmosomal knots with electron tomography	SCIENCE			English	Article							CELL-CELL ADHESION; PEMPHIGUS-VULGARIS ANTIGEN; E-CADHERIN; MOLECULE UVOMORULIN; CYTOPLASMIC DOMAIN; STRUCTURAL BASIS; BINDING; IDENTIFICATION; SUPERFAMILY; ACTIN	Cell adhesion by adherens junctions and desmosomes relies on interactions between cadherin molecules. However, the molecular interfaces that de. ne molecular specificity and that mediate adhesion remain controversial. We used electron tomography of plastic sections from neonatal mouse skin to visualize the organization of desmosomes in situ. The resulting three-dimensional maps reveal individual cadherin molecules forming discrete groups and interacting through their tips. Fitting of an x-ray crystal structure for C-cadherin to these maps is consistent with a flexible intermolecular interface mediated by an exchange of amino-terminal tryptophans. This flexibility suggests a novel mechanism for generating both cis and trans interactions and for propagating these adhesive interactions along the junction.	NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; New York Struct Biol Ctr, New York, NY 10027 USA	New York University; New York University	Stokes, DL (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, 540 1st Ave, New York, NY 10016 USA.	stokes@saturn.med.nyu.edu		Cowin, Pamela/0000-0002-1827-1154	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047429] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM47429] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; Angst BD, 2001, J CELL SCI, V114, P629; Baumeister W, 2002, CURR OPIN STRUC BIOL, V12, P679, DOI 10.1016/S0959-440X(02)00378-0; Birchmeier C, 1996, ACTA ANAT, V156, P217; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; Chappuis-Flament S, 2001, J CELL BIOL, V154, P231, DOI 10.1083/jcb.200103143; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; DEROSIER DJ, 1980, NATURE, V287, P291, DOI 10.1038/287291a0; Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6; GEIGER B, 1990, CELL DIFFER DEV, V32, P343, DOI 10.1016/0922-3371(90)90049-3; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hatsell S, 2001, NAT CELL BIOL, V3, pE270, DOI 10.1038/ncb1201-e270; Huber O, 1999, J CELL SCI, V112, P4415; Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013; LELOUP R, 1979, BIOL CELLULAIRE, V34, P137; McDonald K, 1999, METH MOL B, V117, P77; McEwen BF, 2001, J HISTOCHEM CYTOCHEM, V49, P553, DOI 10.1177/002215540104900502; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; Medalia O, 2002, SCIENCE, V298, P1209, DOI 10.1126/science.1076184; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, MECH DEVELOP, V33, P49, DOI 10.1016/0925-4773(90)90134-8; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; ROH JY, 1995, J CELL BIOL, V128, P939, DOI 10.1083/jcb.128.5.939; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHAPIRO L, 1995, P NATL ACAD SCI USA, V92, P6793, DOI 10.1073/pnas.92.15.6793; Sivasankar S, 2001, BIOPHYS J, V80, P1758, DOI 10.1016/S0006-3495(01)76146-2; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Taylor KA, 1999, CELL, V99, P421, DOI 10.1016/S0092-8674(00)81528-7; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; Tselepis C, 1998, P NATL ACAD SCI USA, V95, P8064, DOI 10.1073/pnas.95.14.8064; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; WAGNER G, 1995, SCIENCE, V267, P342, DOI 10.1126/science.7824932; WINKELMANN DA, 1991, J CELL BIOL, V114, P701, DOI 10.1083/jcb.114.4.701; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	46	192	195	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	2003	302	5642					109	113		10.1126/science.1086957	http://dx.doi.org/10.1126/science.1086957			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526082				2022-12-28	WOS:000185678500047
J	Tadokoro, S; Shattil, SJ; Eto, K; Tai, V; Liddington, RC; de Pereda, JM; Ginsberg, MH; Calderwood, DA				Tadokoro, S; Shattil, SJ; Eto, K; Tai, V; Liddington, RC; de Pereda, JM; Ginsberg, MH; Calderwood, DA			Talin binding to integrin beta tails: A final common step in integrin activation	SCIENCE			English	Article							AFFINITY MODULATION; CYTOPLASMIC DOMAIN; ALPHA(IIB)BETA(3); LIGAND; CELLS; IIIA; IIB	Control of integrin affinity for ligands (integrin activation) is essential for normal cell adhesion, migration, and assembly of an extracellular matrix. Integrin activation is usually mediated through the integrin beta subunit cytoplasmic tail and can be regulated by many different biochemical signaling pathways. We report that specific binding of the cytoskeletal protein talin to integrin beta subunit cytoplasmic tails leads to the conformational rearrangements of integrin extracellular domains that increase their affinity. Thus, regulated binding of talin to integrin beta tails is a final common element of cellular signaling cascades that control integrin activation.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Burnham Inst, Program Cell Adhes, La Jolla, CA 92037 USA	Scripps Research Institute; Sanford Burnham Prebys Medical Discovery Institute	Ginsberg, MH (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.	ginsberg@scripps.edu	de Pereda, Jose M/F-1733-2010; Calderwood, David A/AAC-6954-2019; de Pereda, Jose M/AAE-5226-2022	de Pereda, Jose M/0000-0002-8912-6739; Calderwood, David A/0000-0002-0791-4142; de Pereda, Jose M/0000-0002-8912-6739				Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Eto K, 2002, P NATL ACAD SCI USA, V99, P12819, DOI 10.1073/pnas.202380099; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kashiwagi H, 1997, J CELL BIOL, V137, P1433, DOI 10.1083/jcb.137.6.1433; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; TAPLEY P, 1989, ONCOGENE, V4, P325; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200	23	945	969	6	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	2003	302	5642					103	106		10.1126/science.1086652	http://dx.doi.org/10.1126/science.1086652			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526080				2022-12-28	WOS:000185678500045
J	Laxon, S; Peacock, N; Smith, D				Laxon, S; Peacock, N; Smith, D			High interannual variability of sea ice thickness in the Arctic region	NATURE			English	Article							CLIMATE; OCEAN; MODEL; REGIMES; DRAFT; BASIN	Possible future changes in Arctic sea ice cover and thickness, and consequent changes in the ice-albedo feedback, represent one of the largest uncertainties in the prediction of future temperature rise(1,2). Knowledge of the natural variability of sea ice thickness is therefore critical for its representation in global climate models(3,4). Numerical simulations suggest that Arctic ice thickness varies primarily on decadal timescales(3,5,6) owing to changes in wind and ocean stresses on the ice(7-10), but observations have been unable to provide a synoptic view of sea ice thickness, which is required to validate the model results(3,6,9). Here we use an eight-year time-series of Arctic ice thickness, derived from satellite altimeter measurements of ice freeboard, to determine the mean thickness field and its variability from 65degrees N to 81.5degrees N. Our data reveal a high-frequency interannual variability in mean Arctic ice thickness that is dominated by changes in the amount of summer melt(11), rather than by changes in circulation. Our results suggest that a continued increase in melt season length would lead to further thinning of Arctic sea ice.	UCL, Ctr Polar Observat & Modelling, London WC1E 6BT, England; Met Off Hadley Ctr Climate Predict & Res, Exeter EX1 3PB, Devon, England	University of London; University College London; Met Office - UK; Hadley Centre	Laxon, S (corresponding author), UCL, Ctr Polar Observat & Modelling, Gower St, London WC1E 6BT, England.	swl@cpom.ucl.ac.uk	Smith, Doug/ABD-5204-2021; Laxon, Seymour/C-1644-2008					BABKO O, 2002, J GEOPHYS RES, V107; Battisti DS, 1997, J CLIMATE, V10, P1909, DOI 10.1175/1520-0442(1997)010<1909:DGCMUT>2.0.CO;2; BEAVEN SG, 1995, INT J REMOTE SENS, V16, P851, DOI 10.1080/01431169508954448; BOURKE RH, 1992, J GEOPHYS RES-OCEANS, V97, P17715, DOI 10.1029/92JC01857; Carson DJ, 1999, Q J ROY METEOR SOC, V125, P1, DOI 10.1002/qj.49712555303; CHAPMAN WL, 1994, J GEOPHYS RES-OCEANS, V99, P919, DOI 10.1029/93JC02564; Eicken H, 2001, ANN GLACIOL-SER, V33, P194, DOI 10.3189/172756401781818356; GREGORY JM, 2002, GEOPHYS RES LETT, V29; Haas C, 2001, J GEOPHYS RES-OCEANS, V106, P4449, DOI 10.1029/1999JC000088; Hilmer M, 2000, GEOPHYS RES LETT, V27, P3751, DOI 10.1029/2000GL011403; Holloway G, 2002, J CLIMATE, V15, P1691, DOI 10.1175/1520-0442(2002)015<1691:HASIRT>2.0.CO;2; Houghton J. T., 2001, CLIMATE CHANGE 2001; LINDSAY RW, 1995, J GEOPHYS RES-OCEANS, V100, P4533, DOI 10.1029/94JC02393; MANABE S, 1991, J CLIMATE, V4, P785, DOI 10.1175/1520-0442(1991)004<0785:TROACO>2.0.CO;2; PEACOCK NR, IN PRESS J GEOPHYS R; Polyakov IV, 1999, J GEOPHYS RES-OCEANS, V104, P25761, DOI 10.1029/1999JC900208; Polyakov IV, 2000, GEOPHYS RES LETT, V27, P4097, DOI 10.1029/2000GL011909; RADIONOV VF, 1996, SNOW COVER ARCTIC BA; Rind D, 1997, GEOPHYS RES LETT, V24, P1491, DOI 10.1029/97GL01433; Rothrock DA, 1999, GEOPHYS RES LETT, V26, P3469, DOI 10.1029/1999GL010863; ROTHROCK DA, 2003, J GEOPHYS RES, V108; Smith DM, 1998, GEOPHYS RES LETT, V25, P655, DOI 10.1029/98GL00251; STEELE M, 2000, FRESHWATER BUDGET AR; Tucker WB, 2001, GEOPHYS RES LETT, V28, P2851, DOI 10.1029/2001GL012967; Wadhams P, 2000, GEOPHYS RES LETT, V27, P3973, DOI 10.1029/2000GL011802; WADHAMS P, 1992, J GEOPHYS RES-OCEANS, V97, P20325, DOI 10.1029/92JC02014; WADHAMS P, 1980, J GLACIOL, V25, P401, DOI 10.3189/S0022143000015264; Warren SG, 1999, J CLIMATE, V12, P1814, DOI 10.1175/1520-0442(1999)012<1814:SDOASI>2.0.CO;2; Zhang JL, 2000, J CLIMATE, V13, P3099, DOI 10.1175/1520-0442(2000)013<3099:RCIASI>2.0.CO;2; Zhang YX, 2001, J GEOPHYS RES-OCEANS, V106, P4369, DOI 10.1029/2000JC900159	30	392	426	3	91	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 30	2003	425	6961					947	950		10.1038/nature02050	http://dx.doi.org/10.1038/nature02050			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14586466				2022-12-28	WOS:000186230600038
J	Yagi, H; Furutani, Y; Hamada, H; Sasaki, T; Asakawa, S; Minoshima, S; Ichida, F; Joo, K; Kimura, M; Imamura, S; Kamatani, N; Momma, K; Takao, A; Nakazawa, M; Shimizu, N; Matsuoka, R				Yagi, H; Furutani, Y; Hamada, H; Sasaki, T; Asakawa, S; Minoshima, S; Ichida, F; Joo, K; Kimura, M; Imamura, S; Kamatani, N; Momma, K; Takao, A; Nakazawa, M; Shimizu, N; Matsuoka, R			Role of TBX1 in human del22q11.2 syndrome	LANCET			English	Article							T-BOX GENE; DELETION; DEFECTS; MUTANT; FGF8; ARCH	Background Del22q11.2 syndrome is the most frequent known chromosomal microdeletion syndrome, with an incidence of 1 in 4000-5000 livebirths. It is characterised by a 3-Mb deletion on chromosome 22q11.2, cardiac abnormalities, T-cell deficits, cleft palate facial anomalies, and hypocalcaemia. At least 30 genes have been mapped to the deleted region. However, the association of these genes with the cause of this syndrome is not clearly understood. Methods To test for the chromosomal deletion at 22q11.2, we did fluorescence in-situ hybridisation analysis with ten probes on 22q11.2 in 235 unrelated patients with clinically diagnosed del22q11.2 syndrome. To investigate mutations in the coding sequence of TBX1, we also did genetic analysis in 13 patients from ten families who have the 22q11.2 syndrome phenotype but no detectable deletion of 22q11.2. Findings 96% (225 of 235) of patients had a defined 1.5-3-Mb deletion at 22q11.2. We identified three mutations of TBX1 in two unrelated patients without the 22q11.2 deletion-one with sporadic conotruncal anomaly face syndrome/velocardiofacial syndrome and one with sporadic DiGeorge's syndrome-and in three patients from a family with conotruncal anomaly face syndrome/velocardiofacial syndrome. We did not record these three mutations in 555 healthy controls (1110 chromosomes; p<0.0001). Interpretation Our results suggest that the TBX1 mutation is responsible for five major phenotypes in del22q11.2 syndrome. Therefore, we conclude that TBX1 is a major genetic determinant of the del22q11.2 syndrome.	Tokyo Womens Med Univ, Grad Sch Med, Inst Adv Biomed Engn & Sci, Div Genom Med,Shinjuku Ku, Tokyo, Japan; Tokyo Womens Med Univ, Heart Inst Japan, Shinjuku Ku, Tokyo, Japan; Chiba Univ, Grad Sch Med, Dept Paediat, Chiba, Japan; Keio Univ, Sch Med, Dept Mol Biol, Tokyo, Japan; Toyama Med & Pharmaceut Univ, Dept Paediat, Toyama, Japan; Kyushu Welf Pens Hosp, Dept Paediat, Fukuoka, Japan	Tokyo Women's Medical University; Tokyo Women's Medical University; Chiba University; Keio University; University of Toyama	Matsuoka, R (corresponding author), Tokyo Womens Med Univ, Grad Sch Med, Inst Adv Biomed Engn & Sci, Div Genom Med,Shinjuku Ku, 8-1 Kawada Cho, Tokyo, Japan.	rumiko@imcir.twmu.ac.jp	Sasaki, Takashi/AAD-1461-2019	Sasaki, Takashi/0000-0002-6275-046X; Yagi, Hisato/0000-0003-1460-4043				Abu-Issa R, 2002, DEVELOPMENT, V129, P4613; Asakawa S, 1997, GENE, V191, P69, DOI 10.1016/S0378-1119(97)00044-9; BURN J, 1995, DEVELOPMENTAL MECHANISMS OF HEART DISEASE, P559; Conti E, 2003, EUR J HUM GENET, V11, P349, DOI 10.1038/sj.ejhg.5200956; FIREMAN P, 1965, J PEDIATR-US, V67, P907; Frank DU, 2002, DEVELOPMENT, V129, P4591; Gong W, 2001, J Med Genet, V38, pE45, DOI 10.1136/jmg.38.12.e45; Jerome LA, 2001, NAT GENET, V27, P286, DOI 10.1038/85845; Kinouchi A, 1976, SHONIKA PEDIAT JPN, V17, P84; Lindsay EA, 2001, NAT REV GENET, V2, P858, DOI 10.1038/35098574; Lindsay EA, 2001, NATURE, V410, P97, DOI 10.1038/35065105; MATSUOKA R, 1994, AM J MED GENET, V53, P285, DOI 10.1002/ajmg.1320530314; Matsuoka R, 1998, HUM GENET, V103, P70, DOI 10.1007/s004390050786; Matsuoka R, 2000, ETIOLOGY MORPHOGENES, P341; McQuade L, 1999, AM J MED GENET, V86, P27, DOI 10.1002/(SICI)1096-8628(19990903)86:1<27::AID-AJMG6>3.0.CO;2-7; Merscher S, 2001, CELL, V104, P619, DOI 10.1016/S0092-8674(01)00247-1; Packham EA, 2003, HUM MOL GENET, V12, pR37, DOI 10.1093/hmg/ddg077; Papaioannou VE, 1998, BIOESSAYS, V20, P9, DOI 10.1002/(SICI)1521-1878(199801)20:1<9::AID-BIES4>3.0.CO;2-Q; Paxton C, 2002, GENE, V283, P117, DOI 10.1016/S0378-1119(01)00878-2; Scambler PJ, 2000, HUM MOL GENET, V9, P2421, DOI 10.1093/hmg/9.16.2421; SHPRINTZEN RJ, 1994, J MED GENET, V31, P423, DOI 10.1136/jmg.31.5.423-b; SHPRINTZEN RJ, 1978, CLEFT PALATE J, V15, P56; Tada M, 2001, DEV GROWTH DIFFER, V43, P1; TAKAO A, 1980, ETIOLOGY MORPHOGENES, P253; Vitelli F, 2002, DEVELOPMENT, V129, P4605; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; Yamagishi H, 2003, GENE DEV, V17, P269, DOI 10.1101/gad.1048903; Yamagishi H, 1998, AM J MED GENET, V78, P319, DOI 10.1002/(SICI)1096-8628(19980724)78:4<319::AID-AJMG3>3.0.CO;2-G; Yamagishi Hiroyuki, 2002, Keio Journal of Medicine, V51, P77; YOSHIDA MC, 1986, JPN J CANCER RES, V77, P1059	30	572	609	0	35	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 25	2003	362	9393					1366	1373		10.1016/S0140-6736(03)14632-6	http://dx.doi.org/10.1016/S0140-6736(03)14632-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	735YX	14585638				2022-12-28	WOS:000186143300010
J	Allsop, DJ; West, SA				Allsop, DJ; West, SA			Changing sex at the same relative body size - Similar forces may select for gender switching across taxa in all animals with this facility	NATURE			English	Editorial Material							AGE		Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Allsop, DJ (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, Kings Bldg,W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.	david.allsop@ed.ac.uk	West, Stuart A/M-3608-2014	West, Stuart A/0000-0003-2152-3153				Allsop DJ, 2003, J EVOLUTION BIOL, V16, P921, DOI 10.1046/j.1420-9101.2003.00590.x; CHARNOV E L, 1982; Charnov EL, 2000, EVOL ECOL RES, V2, P1067; Charnov Eric L., 1993, P1; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; Frank, 1998, FDN SOCIAL EVOLUTION; Gemmill AW, 1999, J EVOLUTION BIOL, V12, P1148, DOI 10.1046/j.1420-9101.1999.00117.x; Harvey P.H., 1991, COMP METHOD EVOLUTIO; LEIGH EG, 1976, P NATL ACAD SCI USA, V73, P3655, DOI DOI 10.1111/J.1420-9101.2006.01156.X; WEST PA, 1985, J ROY SOC HEALTH, V1, P15	10	53	55	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 23	2003	425	6960					783	784		10.1038/425783a	http://dx.doi.org/10.1038/425783a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574399	Green Submitted			2022-12-28	WOS:000186118500032
J	Ashton, CM; Souchek, J; Petersen, NJ; Menke, TJ; Collins, TC; Kizer, KW; Wright, SM; Wray, NP				Ashton, CM; Souchek, J; Petersen, NJ; Menke, TJ; Collins, TC; Kizer, KW; Wright, SM; Wray, NP			Hospital use and survival among Veterans Affairs beneficiaries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE SYSTEM; QUALITY; VA; ADMISSIONS; OUTCOMES; IMPACT; RATES	BACKGROUND: Initiatives to reduce hospital care were part of the reorganization of the Department of Veterans Affairs (VA) medical care system undertaken in the mid-1990s. We examined changes in the use of VA health services and survival from 1994 through 1998 among VA beneficiaries with serious chronic diseases. We postulated that if access to hospital care was reduced too much, or if decreased hospital use was not offset by improvements in ambulatory care, urgent care visits would increase or survival rates would fall. METHODS: We tracked changes in risk-adjusted VA bed-day rates, rates of medical visits, rates of visits for testing and consultation, and rates of urgent care visits per patient-year among VA beneficiaries in nine disease cohorts (a total of 342,300 beneficiaries). Trends in non-VA hospital use by VA beneficiaries 65 years of age or older who were enrolled in fee-for-service Medicare were also studied. VA and Medicare vital-status data were used to calculate one-year survival rates. RESULTS: From 1994 through 1998, VA bed-day rates fell by 50 percent, rates of medical-clinic visits and visits for testing and consultation increased moderately, and rates of urgent care visits fell by 35 percent. The sharp decline in the use of VA hospitals was not compensated for by increases in the use of Medicare-reimbursed non-VA hospital care by veterans eligible for both VA care and Medicare, and the use of non-VA hospitals actually declined in four cohorts. The survival rates were essentially unchanged over the study period. CONCLUSIONS: The marked decline in VA hospital use from 1994 through 1998 did not curtail access to needed services and was not associated with serious consequences for chronically ill VA beneficiaries.	Vet Affairs Med Ctr, Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA; Vet Hlth Adm Headquarters, Washington, DC USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ashton, CM (corresponding author), Vet Affairs Med Ctr, Ctr Qual Care & Utilizat Studies, 152,2002 Holcombe Blvd, Houston, TX 77030 USA.	carol.ashton@med.va.gov						Ashton CM, 1999, NEW ENGL J MED, V340, P32, DOI 10.1056/NEJM199901073400106; ASHTON CM, 1994, MED CARE, V32, P447, DOI 10.1097/00005650-199405000-00004; BLUMENTHAL D, 1995, HEALTH SERV RES, V30, P253; BOOTH BM, 1991, MED CARE, V29, pAS40; COX DR, 1972, J R STAT SOC B, V34, P187; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; Forrest CB, 1996, J FAM PRACTICE, V43, P40; GARG R, 1995, JAMA-J AM MED ASSOC, V274, P462; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; GRAVES EJ, 1997, VITAL HLTH STAT 13, V128; Iglehart JK, 1996, NEW ENGL J MED, V335, P1407, DOI 10.1056/NEJM199610313351821; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; Kizer KW, 1999, AM J MED QUAL, V14, P3, DOI 10.1177/106286069901400103; Kizer KW, 1997, HOSP HEALTH SERV ADM, V42, P283; Kizer KW, 2001, HLTH INFORMAT SER, P79; LUFT HS, 1990, JAMA-J AM MED ASSOC, V263, P2899, DOI 10.1001/jama.263.21.2899; Menke TJ, 1998, MED CARE, V36, P1126, DOI 10.1097/00005650-199808000-00003; MILLER MG, 1994, JAMA-J AM MED ASSOC, V271, P1493, DOI 10.1001/jama.271.19.1493; NAJI S, 1994, BRIT MED J, V308, P1208; *NAT CTR HLTH STAT, 2002, PROV TABL BIRTHS MAR, V47; Page WF, 1996, ANN EPIDEMIOL, V6, P102, DOI 10.1016/1047-2797(95)00126-3; POPOVIC JR, 2000, VITAL HLTH STAT 13, V148; Smith CB, 1996, MED CARE, V34, P85, DOI 10.1097/00005650-199601000-00007; SNEDECOR GW, 1980, STATISTICAL METHODS, P288; STARFIELD B, 1994, LANCET, V344, P1129, DOI 10.1016/S0140-6736(94)90634-3; *VET HLTH ADM OFF, 1997, VET EQ RES ALL SYST; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; Wilson NJ, 1997, HEALTH AFFAIR, V16, P200, DOI 10.1377/hlthaff.16.4.200; Wray NP, 1999, HEALTH SERV RES, V34, P777; Wray NP, 1997, MED CARE, V35, P768, DOI 10.1097/00005650-199708000-00003; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	31	75	76	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 23	2003	349	17					1637	1646		10.1056/NEJMsa003299	http://dx.doi.org/10.1056/NEJMsa003299			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	734ZT	14573736				2022-12-28	WOS:000186088400010
J	Seminara, SB; Messager, S; Chatzidaki, EE; Thresher, RR; Acierno, JS; Shagoury, JK; Bo-Abbas, Y; Kuohung, W; Schwinof, KM; Hendrick, AG; Zahn, D; Dixon, J; Kaiser, UB; Slaugenhaupt, SA; Gusella, JF; O'Rahilly, S; Carlton, MBL; Crowley, WF; Aparicio, SAJR; Colledge, WH				Seminara, SB; Messager, S; Chatzidaki, EE; Thresher, RR; Acierno, JS; Shagoury, JK; Bo-Abbas, Y; Kuohung, W; Schwinof, KM; Hendrick, AG; Zahn, D; Dixon, J; Kaiser, UB; Slaugenhaupt, SA; Gusella, JF; O'Rahilly, S; Carlton, MBL; Crowley, WF; Aparicio, SAJR; Colledge, WH			The GPR54 gene as a regulator of puberty	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GONADOTROPIN-RELEASING-HORMONE; IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM; METASTASIS-SUPPRESSOR GENE; PROTEIN-COUPLED RECEPTOR; LUTEINIZING-HORMONE; KALLMANNS-SYNDROME; MENSTRUAL-CYCLE; GNRH RECEPTOR; KISS-1; MEN	BACKGROUND: Puberty, a complex biologic process involving sexual development, accelerated linear growth, and adrenal maturation, is initiated when gonadotropin-releasing hormone begins to be secreted by the hypothalamus. We conducted studies in humans and mice to identify the genetic factors that determine the onset of puberty. METHODS: We used complementary genetic approaches in humans and in mice. A consanguineous family with members who lacked pubertal development (idiopathic hypogonadotropic hypogonadism) was examined for mutations in a candidate gene, GPR54, which encodes a G protein-coupled receptor. Functional differences between wild-type and mutant GPR54 were examined in vitro. In parallel, a Gpr54-deficient mouse model was created and phenotyped. Responsiveness to exogenous gonadotropin-releasing hormone was assessed in both the humans and the mice. RESULTS: Affected patients in the index pedigree were homozygous for an L148S mutation in GPR54, and an unrelated proband with idiopathic hypogonadotropic hypogonadism was determined to have two separate mutations, R331X and X399R. The in vitro transfection of COS-7 cells with mutant constructs demonstrated a significantly decreased accumulation of inositol phosphate. The patient carrying the compound heterozygous mutations (R331X and X399R) had attenuated secretion of endogenous gonadotropin-releasing hormone and a left-shifted dose-response curve for gonadotropin-releasing hormone as compared with six patients who had idiopathic hypogonadotropic hypogonadism without GPR54 mutations. The Gpr54-deficient mice had isolated hypogonadotropic hypogonadism (small testes in male mice and a delay in vaginal opening and an absence of follicular maturation in female mice), but they showed responsiveness to both exogenous gonadotropins and gonadotropin-releasing hormone and had normal levels of gonadotropin-releasing hormone in the hypothalamus. CONCLUSIONS: Mutations in GPR54, a G protein-coupled receptor gene, cause autosomal recessive idiopathic hypogonadotropic hypogonadism in humans and mice, suggesting that this receptor is essential for normal gonadotropin-releasing hormone physiology and for puberty.	Paradigm Therapeut, Cambridge CB4 0WA, England; Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Human Genet Res, Mol Neurogenet Unit, Boston, MA 02114 USA; Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA; Harvard Univ, Sch Med, Harvard Inst Human Genet, Boston, MA USA; Univ Cambridge, Dept Physiol, Cambridge, England; Univ Cambridge, Dept Oncol, Cambridge, England; Univ Cambridge, Dept Clin Biochem, Cambridge, England; Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 2QQ, England; Kuwait Univ, Fac Med, Al Jabriyah, Kuwait	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Cambridge; University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Kuwait University	Colledge, WH (corresponding author), Paradigm Therapeut, 214 Cambridge Sci Pk,Milton Rd, Cambridge CB4 0WA, England.		Oka, Yoshitaka/C-9670-2010; O'Rahilly, Stephen/ABF-6509-2020; Colledge, William/X-4976-2019	Oka, Yoshitaka/0000-0002-3482-3051; O'Rahilly, Stephen/0000-0003-2199-4449; Colledge, William/0000-0002-9603-4429; Acierno, James/0000-0002-5301-4970; Hendrick, Alan/0000-0002-8604-0462; Kuohung, Wendy/0000-0003-1764-2264; Aparicio, Samuel/0000-0002-0487-9599	NCRR NIH HHS [3M01 RR01066-22S2] Funding Source: Medline; NICHD NIH HHS [5R01 HD15788-17, U54 HD029164, R01 HD043341, R01 HD015788, U54 HD28138-13, U54 HD028138, T32 HD40135] Funding Source: Medline; NIGMS NIH HHS [GM61354] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD015788, T32HD040135, R01HD043341, U54HD028138] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD029164] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM061354] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acierno JS, 2003, J CLIN ENDOCR METAB, V88, P2947, DOI 10.1210/jc.2003-030423; Antonarakis SE, 1998, HUM MUTAT, V11, P1; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Bedecarrats GY, 2003, J CLIN ENDOCR METAB, V88, P834, DOI 10.1210/jc.2002-020806; Bo-Abbas Y, 2003, J CLIN ENDOCR METAB, V88, P2730, DOI 10.1210/jc.2002-021948; CAMERON JL, 1985, BIOL REPROD, V33, P147, DOI 10.1095/biolreprod33.1.147; CARATY A, 1995, ENDOCRINOLOGY, V136, P3452, DOI 10.1210/en.136.8.3452; COLLINS TJ, 1981, NEUROBIOL AGING, V2, P125, DOI 10.1016/0197-4580(81)90010-5; CROWLEY WF, 1980, J CLIN ENDOCR METAB, V51, P173, DOI 10.1210/jcem-51-1-173; de Roux N, 2003, P NATL ACAD SCI USA, V100, P10972, DOI 10.1073/pnas.1834399100; FILICORI M, 1986, J CLIN ENDOCR METAB, V62, P1136, DOI 10.1210/jcem-62-6-1136; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; Frischmeyer PA, 2002, SCIENCE, V295, P2258, DOI 10.1126/science.1067338; HOFFMAN AR, 1982, NEW ENGL J MED, V307, P1237, DOI 10.1056/NEJM198211113072003; Horikoshi Y, 2003, J CLIN ENDOCR METAB, V88, P914, DOI 10.1210/jc.2002-021235; Kotani M, 2001, J BIOL CHEM, V276, P34631, DOI 10.1074/jbc.M104847200; Lee DK, 1999, FEBS LETT, V446, P103, DOI 10.1016/S0014-5793(99)00009-5; Lee JH, 1997, CANCER RES, V57, P2384; Lee JH, 1997, INT J CANCER, V71, P1035, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1035::AID-IJC20>3.3.CO;2-T; Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731; LEE JH, 1997, J NATL CANCER I, V89, P1549; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LEGOUIS R, 1993, P NATL ACAD SCI USA, V90, P2461, DOI 10.1073/pnas.90.6.2461; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; MCDOWELL IFW, 1982, J ENDOCRINOL, V95, P331, DOI 10.1677/joe.0.0950331; MCDOWELL IFW, 1982, J ENDOCRINOL, V95, P321, DOI 10.1677/joe.0.0950321; Muir AI, 2001, J BIOL CHEM, V276, P28969, DOI 10.1074/jbc.M102743200; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; SANTEN RJ, 1973, J CLIN INVEST, V52, P2617, DOI 10.1172/JCI107454; SANTORO N, 1986, ENDOCR REV, V7, P11, DOI 10.1210/edrv-7-1-11; Seminara SB, 1998, ENDOCR REV, V19, P521, DOI 10.1210/er.19.5.521; SPRATT DI, 1987, J CLIN ENDOCR METAB, V64, P283, DOI 10.1210/jcem-64-2-283; SPRATT DI, 1988, AM J PHYSIOL, V254, pE658, DOI 10.1152/ajpendo.1988.254.5.E658; *UCSC, 2002, UCSC GEN BROWS; van Hoof A, 2002, SCIENCE, V295, P2262, DOI 10.1126/science.1067272; WHITCOMB RW, 1990, J CLIN ENDOCR METAB, V70, P3, DOI 10.1210/jcem-70-1-3; WIEMANN JN, 1989, ENDOCRINOLOGY, V124, P1760, DOI 10.1210/endo-124-4-1760	37	1859	1937	5	106	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	2003	349	17					1614	U8		10.1056/NEJMoa035322	http://dx.doi.org/10.1056/NEJMoa035322			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734ZT	14573733				2022-12-28	WOS:000186088400006
J	Hemingway, H; Shipley, M; Britton, A; Page, M; Macfarlane, P; Marmot, M				Hemingway, H; Shipley, M; Britton, A; Page, M; Macfarlane, P; Marmot, M			Prognosis of angina with and without a diagnosis: 11 year follow up in the Whitehall II prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							ABNORMALITIES; MORTALITY; SYMPTOMS	Objective To investigate the prognosis of angina among people with and without diagnosis by a doctor and an abnormal cardiovascular test result. Design Prospective cohort study with a median follow up of 11 years. Setting 20 civil service departments originally located in London. Participants 10 308 civil servants aged 35-55 years at baseline. Main outcome measures Recurrent reports of angina; quality of life (SF-36 physical functioning); non-fatal myocardial infarction; death from any cause (n = 344). Results 1158 (11.4%) participants developed angina, and 813 (70%) had no evidence of diagnosis by a doctor at the time of the initial report. Participants without a diagnosis had an increased risk of impaired physical functioning (age and sex adjusted odds ratio of 2.36 (95% confidence interval 1.91 to 2.90)) compared with those who had neither angina nor myocardial infarction throughout follow up. Among reported cases of angina without a diagnosis, the 15.5% with an abnormality on a study electrocardiogram had an increased risk of death (hazard ratio 2.37 (1.16 to 4.87)). These effects were similar in magnitude to those in participants with a diagnosis of angina. Conclusion Undiagnosed angina was common and had an adverse impact on prognosis comparable to that of diagnosed angina, particularly among people with electrocardiographic abnormalities. Efforts to improve prognosis among people with angina should take account of this submerged clinical iceberg.	UCL, Sch Med, Dept Epidemiol & Publ Hlth, Int Ctr Hlth & Soc, London WC1E 6BT, England; Univ Glasgow, Royal Infirm, Dept Med Cardiol, Glasgow G31 2ER, Lanark, Scotland	University of London; University College London; UCL Medical School; Royal Infirmary of Edinburgh; University of Glasgow	Hemingway, H (corresponding author), UCL, Sch Med, Dept Epidemiol & Publ Hlth, Int Ctr Hlth & Soc, London WC1E 6BT, England.	h.hemingway@public-health.ucl.ac.uk	Hemingway, Harry/C-1219-2009; Marmot, M G/Y-3920-2019; Greiver, Michelle/N-8764-2015	Hemingway, Harry/0000-0003-2279-0624; Marmot, M G/0000-0002-2431-6419; Greiver, Michelle/0000-0001-8957-0285	AHRQ HHS [5 R01 HS06516] Funding Source: Medline; Medical Research Council [G19/35, G8802774, G0100222] Funding Source: Medline; NHLBI NIH HHS [2R01 HL36310] Funding Source: Medline; NIA NIH HHS [R01 AG13196-02] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006516] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013196] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Daviglus ML, 1999, JAMA-J AM MED ASSOC, V281, P530, DOI 10.1001/jama.281.6.530; *DEP HLTH, 2000, NAT SERV FRAM COR HE; Gardner K, 1999, BRIT MED J, V319, P418, DOI 10.1136/bmj.319.7207.418; Gibbons RJ, 2003, CIRCULATION, V107, P149, DOI 10.1161/01.CIR.0000047041.66447.29; Hemingway H, 2000, J EPIDEMIOL COMMUN H, V54, P510, DOI 10.1136/jech.54.7.510; Lampe FC, 1999, J CLIN EPIDEMIOL, V52, P73, DOI 10.1016/S0895-4356(98)00146-2; Lampe FC, 2001, AM J EPIDEMIOL, V153, P1173, DOI 10.1093/aje/153.12.1173; LAST JM, 1963, LANCET, P28; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MCCORMICK A, 1995, MORBIDITY STAT GEN P; Rose G, 1982, CARDIOVASCULAR SURVE; Stafford M, 1998, J EPIDEMIOL COMMUN H, V52, P353, DOI 10.1136/jech.52.6.353; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583	13	47	50	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 18	2003	327	7420					895	898		10.1136/bmj.327.7420.895	http://dx.doi.org/10.1136/bmj.327.7420.895			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734RV	14563744	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000186072100016
J	Arbuckle, MR; McClain, MT; Rubertone, MV; Scofield, RH; Dennis, GJ; James, JA; Harley, JB				Arbuckle, MR; McClain, MT; Rubertone, MV; Scofield, RH; Dennis, GJ; James, JA; Harley, JB			Development of autoantibodies before the clinical onset of systemic lupus erythematosus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTI-DNA ANTIBODIES; CONGENITAL HEART-BLOCK; SJOGRENS-SYNDROME; WILCOXON TEST; SM; DSDNA; ANTINUCLEAR; MOTHERS; AUTOIMMUNITY; CHILDREN	BACKGROUND: Although much is known about the natural history of systemic lupus erythematosus (SLE), the development of SLE autoantibodies before the diagnosis of the disease has not been extensively explored. We investigated the onset and progression of autoantibody development before the clinical diagnosis. METHODS: The Department of Defense Serum Repository contains approximately 30 million specimens prospectively collected from more than 5 million U.S. Armed Forces personnel. We evaluated serum samples obtained from 130 persons before they received a diagnosis of SLE, along with samples from matched controls. RESULTS: In 115 of the 130 patients with SLE (88 percent), at least one SLE autoantibody tested was present before the diagnosis (up to 9.4 years earlier; mean, 3.3 years). Antinuclear antibodies were present in 78 percent (at a dilution of 1:120 or more), anti-double-stranded DNA antibodies in 55 percent, anti-Ro antibodies in 47 percent, anti-La antibodies in 34 percent, anti-Sm antibodies in 32 percent, anti-nuclear ribonucleoprotein antibodies in 26 percent, and antiphospholipid antibodies in 18 percent. Antinuclear, antiphospholipid antibodies, anti-Ro, and anti-La antibodies were present earlier than anti-Sm and anti-nuclear ribonucleoprotein antibodies (a mean of 3.4 years before the diagnosis vs. 1.2 years, P=0.005). Anti-double-stranded DNA antibodies, with a mean onset 2.2 years before the diagnosis, were found later than antinuclear antibodies (P=0.06) and earlier than anti-nuclear ribonucleoprotein antibodies (P=0.005). For many patients, the earliest available serum sample was positive; therefore, these measures of the average time from the first positive antibody test to the diagnosis are underestimates of the time from the development of antibodies to the diagnosis. Of the 130 initial matched controls, 3.8 percent were positive for one or more autoantibodies. CONCLUSIONS: Autoantibodies are typically present many years before the diagnosis of SLE. Furthermore, the appearance of autoantibodies in patients with SLE tends to follow a predictable course, with a progressive accumulation of specific autoantibodies before the onset of SLE, while patients are still asymptomatic.	Oklahoma Med Res Fdn, Arthrit & Immunol Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA; Dept Vet Affairs, Oklahoma City, OK USA; Walter Reed Army Med Ctr, Dept Rheumatol, Bethesda, MD USA; NIAMSD, NIH, Bethesda, MD 20892 USA; USA, Ctr Hlth Promot & Prevent Med, Washington, DC 20310 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; United States Department of Defense; United States Army; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	James, JA (corresponding author), Oklahoma Med Res Fdn, Arthrit & Immunol Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.		Scofield, Robert Hal/AEJ-8314-2022		NCRR NIH HHS [RR14467, RR15577] Funding Source: Medline; NIAID NIH HHS [AI31584, AI24717] Funding Source: Medline; NIAMS NIH HHS [AR45084, AR01981, AR4904, AR48940, AR42460, AR45231] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015577, M01RR014467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031584, R01AI024717, R37AI024717] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042460, K08AR001981, P50AR045231, P50AR048940, R03AR045084] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AARDEN LA, 1975, ANN NY ACAD SCI, V254, P505, DOI 10.1111/j.1749-6632.1975.tb29197.x; AHO K, 1991, J RHEUMATOL, V18, P1282; AHO K, 1992, J RHEUMATOL, V19, P1377; Arbuckle MR, 1999, SCAND J IMMUNOL, V50, P447; Arbuckle MR, 2001, SCAND J IMMUNOL, V54, P211, DOI 10.1046/j.1365-3083.2001.00959.x; AVINAZUBIETA JA, 1995, LUPUS, V4, P370, DOI 10.1177/096120339500400507; Azizah MR, 1996, ASIAN PAC J ALLERGY, V14, P125; Batstra M R, 2001, Clin Lab, V47, P497; DUBOIS EL, 1974, LUPUS ERYTHEMATOSUS, P613; ELKON KB, 1998, RHEUMATOLOGY, V2; GAITHER KK, 1987, J CLIN INVEST, V79, P841, DOI 10.1172/JCI112892; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.2307/2333825; GEHAN EA, 1965, BIOMETRIKA, V52, P650, DOI 10.1093/biomet/52.3-4.650; GHARAVI AE, 1987, ANN RHEUM DIS, V46, P1, DOI 10.1136/ard.46.1.1; HARVEY AM, 1954, MEDICINE, V33, P291, DOI 10.1097/00005792-195412000-00001; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; ISENBERG DA, 1987, ANN RHEUM DIS, V46, P448, DOI 10.1136/ard.46.6.448; JAMES JA, 1995, J EXP MED, V181, P453, DOI 10.1084/jem.181.2.453; JULKUNEN H, 1993, ARTHRITIS RHEUM-US, V36, P1588, DOI 10.1002/art.1780361114; Julkunen H, 2001, ARTHRITIS RHEUM, V44, P647, DOI 10.1002/1529-0131(200103)44:3<647::AID-ANR113>3.3.CO;2-9; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lee E, 2013, STAT METHODS SURVIVA; McClain MT, 2002, J IMMUNOL, V168, P2054, DOI 10.4049/jimmunol.168.4.2054; Mosca M, 1998, LUPUS, V7, P95, DOI 10.1191/096120398678919787; Press J, 1996, AM J MED, V100, P328, DOI 10.1016/S0002-9343(97)89492-2; Reichlin M., 2002, DUBOISLUPUS ERYTHEMA, V6th ed, P467; Ruiz-Irastorza G, 2001, LANCET, V357, P1027, DOI 10.1016/S0140-6736(00)04239-2; SATOH M, 1995, LUPUS, V4, P63, DOI 10.1177/096120339500400113; SIMMONSOBRIEN E, 1995, MEDICINE, V74, P109, DOI 10.1097/00005792-199505000-00001; SPRONK PE, 1995, LUPUS, V4, P86, DOI 10.1177/096120339500400202; Vlachoyiannopoulos PG, 1998, J RHEUMATOL, V25, P886; ZARMBINSKI MA, 1992, J RHEUMATOL, V19, P1380	32	1704	1794	1	101	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 16	2003	349	16					1526	1533		10.1056/NEJMoa021933	http://dx.doi.org/10.1056/NEJMoa021933			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	731ZM	14561795				2022-12-28	WOS:000185916400007
J	Salvador, JR; Gu, F; Hogan, T; Kanatzidis, MG				Salvador, JR; Gu, F; Hogan, T; Kanatzidis, MG			Zero thermal expansion in YbGaGe due to an electronic valence transition	NATURE			English	Article								Most materials expand upon heating. Although rare, some materials expand on cooling, and are said to exhibit negative thermal expansion (NTE); but the property is exhibited in only one crystallographic direction. Such materials include silicon and germanium(1) at very low temperature (<100 K) and, at room temperature, glasses in the titania-silica family(2), Kevlar, carbon fibres, anisotropic Invar Fe-Ni alloys(3), ZrW2O3 (ref. 4) and certain molecular networks'. NTE materials can be combined with materials demonstrating a positive thermal expansion coefficient to fabricate composites exhibiting an overall zero thermal expansion (ZTE). ZTE materials are useful because they do not undergo thermal shock on rapid heating or cooling. The need for such composites could be avoided if ZTE materials were available in a pure form. Here we show that an electrically conductive intermetallic compound, YbGaGe, can exhibit nearly ZTE-that is, negligible volume change between 100 and 400 K. We suggest that this response is due to a temperature-induced valence transition in the Yb atoms. ZTE materials are desirable to prevent or reduce resulting strain or internal stresses in systems subject to large temperature fluctuations, such as in space applications and thermomechanical actuators.	Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; Michigan State Univ, Ctr Fundamental Mat Res, E Lansing, MI 48824 USA; Michigan State Univ, Dept Elect & Comp Engn, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University	Kanatzidis, MG (corresponding author), Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA.							Attfield MP, 1998, CHEM MATER, V10, P2013, DOI 10.1021/cm9801587; BAUGHMAN RH, 1993, NATURE, V365, P735, DOI 10.1038/365735a0; CZYBULKA A, 1989, Z ANORG ALLG CHEM, V579, P151, DOI 10.1002/zaac.19895790119; DEVISSER A, 1993, PHYSICA B, V186-88, P577, DOI 10.1016/0921-4526(93)90640-R; HAUSCH G, 1989, PHYSICA B, V161, P22, DOI 10.1016/0921-4526(89)90094-X; Hoffmann RD, 2001, Z KRISTALLOGR, V216, P127, DOI 10.1524/zkri.216.3.127.20327; HORMILLOSA C, 1993, VALENCE BOND CALCULA; KAGAYA HM, 1993, SOLID STATE COMMUN, V85, P617, DOI 10.1016/0038-1098(93)90320-M; LANG M, 1987, J MAGN MAGN MATER, V63-4, P79, DOI 10.1016/0304-8853(87)90528-2; Oomi G, 2001, J MAGN MAGN MATER, V226, P1182, DOI 10.1016/S0304-8853(00)00727-7; Schultz P. C, 1970, AMORPHOUS MAT; TSUYOSHI M, 1987, PHYS REV B, V35, P6051	14	172	177	8	156	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					702	705		10.1038/nature02011	http://dx.doi.org/10.1038/nature02011			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562099				2022-12-28	WOS:000185924500037
J	Ueshima, R; Asami, T				Ueshima, R; Asami, T			Single-gene speciation by left-right reversal - A land-snail species of polyphyletic origin results from chirality constraints on mating.	NATURE			English	Editorial Material							SYMPATRIC SPECIATION; PARTULA-SUTURALIS; POLYMORPHISM; EVOLUTION; COIL		Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130033, Japan; Shinshu Univ, Dept Biol, Matsumoto, Nagano 3608621, Japan; Japan Sci & Technol, PRESTO, Kawaguchi 3320012, Japan	University of Tokyo; Shinshu University; Japan Science & Technology Agency (JST)	Ueshima, R (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130033, Japan.	asami99@gipac.shinshu-u.ac.jp						Asami T, 1998, AM NAT, V152, P225, DOI 10.1086/286163; Dobzhansky T., 1937; FREEMAN G, 1982, ROUX ARCH DEV BIOL, V191, P69, DOI 10.1007/BF00848443; GITTENBERGER E, 1988, EVOLUTION, V42, P826, DOI 10.1111/j.1558-5646.1988.tb02502.x; Harrison RG, 1998, ENDLESS FORMS, P19; JOHNSON MS, 1990, EVOLUTION, V44, P459, DOI 10.1111/j.1558-5646.1990.tb05215.x; JOHNSON MS, 1982, HEREDITY, V49, P145, DOI 10.1038/hdy.1982.80; LIPTON CS, 1979, MALACOLOGIA, V19, P129; Muller HJ, 1942, BIOL S, V6, P71; ORR HA, 1991, EVOLUTION, V45, P764, DOI 10.1111/j.1558-5646.1991.tb04345.x; VANHATENBURG FHO, 1996, HEREDITY, V76, P278; VERMEIJ GJ, 1975, NATURE, V254, P419, DOI 10.1038/254419a0	12	130	138	2	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	2003	425	6959					679	679		10.1038/425679a	http://dx.doi.org/10.1038/425679a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562091	Bronze			2022-12-28	WOS:000185924500029
J	Lewin, MR; Bouyer, DH; Walker, DH; Musher, DM				Lewin, MR; Bouyer, DH; Walker, DH; Musher, DM			Rickettsia sibirica infection in members of scientific expeditions to northern Asia	LANCET			English	Article							INNER-MONGOLIA	The risk of acquiring North Asian tick typhus (infection by Rickettsia sibirica) during travel to regions of Asia where this disease is endemic is unknown. We investigated prospectively 13 paleontologists on expedition to Mongolia. Four paleontologists had acute illness characterised by fever, rash, headache, and lymphadenoparthy. All had IgM and IgG antibodies to R sibirica. Paleontologists with no illness and people who went on expeditions in other parts of the world did not have antibodies to R sibirica. Only two of the four infected persons were aware of tick bites. Travellers to regions endemic for R sibirica are at risk of contracting North Asian tick typhus even in the absence of recognised tick-bites.	Univ Calif San Francisco, Fresno, CA USA; Univ Texas, Med Branch, Galveston, TX 77550 USA; Vet Affairs Med Ctr, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA	University of California System; University of California San Francisco; University of California San Francisco at Fresno; University of Texas System; University of Texas Medical Branch Galveston; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine	Lewin, MR (corresponding author), Dept Emergency Med, Room 275,445 S Cedar Ave, Fresno, CA 93702 USA.	aplysia99@yahoo.com		Lewin, Matthew/0000-0003-4480-9891				ANTONOV NI, 1936, DALNEVOST MED ZH, V5, P77; Lankester T, 1997, LANCET, V349, P656, DOI 10.1016/S0140-6736(05)61613-3; LIU QH, 1990, ANN NY ACAD SCI, V590, P237, DOI 10.1111/j.1749-6632.1990.tb42225.x; LIU QH, 1995, EPIDEMIOL INFECT, V115, P177, DOI 10.1017/S0950268800058246; Lyskovtsev MM, 1968, MISCELLANEOUS PUBLIC, V6, P42	5	18	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 11	2003	362	9391					1201	1202		10.1016/S0140-6736(03)14515-1	http://dx.doi.org/10.1016/S0140-6736(03)14515-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568744				2022-12-28	WOS:000185924100014
J	Mukhopadhyay, S; Kim, BS; Chipman, PR; Rossmann, MG; Kuhn, RJ				Mukhopadhyay, S; Kim, BS; Chipman, PR; Rossmann, MG; Kuhn, RJ			Structure of West Nile virus	SCIENCE			English	Article							ENVELOPE GLYCOPROTEIN; DENGUE VIRUS; ENCEPHALITIS		Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Kuhn, RJ (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.	kuhnr@purdue.edu	Kuhn, Richard/AAR-2722-2021	Kuhn, Richard/0000-0003-4148-1026; Chipman, Paul/0000-0003-3652-4087	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI045976] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 45976] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beasley DWC, 2002, J VIROL, V76, P13097, DOI 10.1128/JVI.76.24.13097-13100.2002; Berthet FX, 1997, J GEN VIROL, V78, P2293, DOI 10.1099/0022-1317-78-9-2293; Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8; Lanciotti RS, 1999, SCIENCE, V286, P2333, DOI 10.1126/science.286.5448.2333; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0	6	284	307	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					248	248		10.1126/science.1089316	http://dx.doi.org/10.1126/science.1089316			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551429				2022-12-28	WOS:000185825900031
J	Wilschanski, M; Yahav, Y; Yaacov, Y; Blau, H; Bentur, L; Rivlin, J; Aviram, M; Bdolah-Abram, T; Bebok, Z; Shushi, L; Kerem, B; Kerem, E				Wilschanski, M; Yahav, Y; Yaacov, Y; Blau, H; Bentur, L; Rivlin, J; Aviram, M; Bdolah-Abram, T; Bebok, Z; Shushi, L; Kerem, B; Kerem, E			Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NASAL POTENTIAL DIFFERENCE; NONSENSE MUTATION; SUPPRESSION; DISEASE; STREPTOMYCIN; ACCUMULATION; TERMINATION; EFFICIENCY; CELLS; COLI	BACKGROUND: Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene containing a premature termination signal cause a deficiency or absence of functional chloride-channel activity. Aminoglycoside antibiotics can suppress premature termination codons, thus permitting translation to continue to the normal end of the transcript. We assessed whether topical administration of gentamicin to the nasal epithelium of patients with cystic fibrosis could result in the expression of functional CFTR channels. METHODS: In a double-blind, placebo-controlled, crossover trial, patients with stop mutations in CFTR or patients homozygous for the (Delta)F508 mutation received two drops containing gentamicin (0.3 percent, or 3 mg per milliliter) or placebo in each nostril three times daily for two consecutive periods of 14 days. Nasal potential difference was measured at base line and after each treatment period. Nasal epithelial cells were obtained before and after gentamicin treatment from patients carrying stop mutations, and the C-terminal of surface CFTR was stained. RESULTS: Gentamicin treatment caused a significant reduction in basal potential difference in the 19 patients carrying stop mutations (from -45+/-8 to -34+/-11 mV, P=0.005) and a significant response to chloride-free isoproterenol solution (from 0+/-3.6 to -5+/-2.7 mV, P<0.001). This effect of gentamicin on nasal potential difference occurred both in patients who were homozygous for stop mutations and in those who were heterozygous, but not in patients who were homozygous for (Delta)F508. After gentamicin treatment, a significant increase in peripheral and surface staining for CFTR was observed in the nasal epithelial cells of patients carrying stop mutations. CONCLUSIONS: In patients with cystic fibrosis who have premature stop codons, gentamicin can cause translational ``read through,'' resulting in the expression of full-length CFTR protein at the apical cell membrane, and thus can correct the typical electrophysiological abnormalities caused by CFTR dysfunction.	Hebrew Univ Jerusalem, Sch Med, Shaare Zedek Med Ctr, Cyst Fibrosis Ctr,Dept Pediat, IL-91010 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Med, Hadassah Univ Hosp, IL-91010 Jerusalem, Israel; Chaim Sheba Med Ctr, Cyst Fibrosis Ctr, IL-52621 Tel Hashomer, Israel; Schneider Childrens Med Ctr Israel, Graub Cyst Fibrosis Ctr, Petah Tiqwa, Israel; Rambam Med Ctr, Cyst Fibrosis Ctr, Haifa, Israel; Carmel Hosp, Cyst Fibrosis Ctr, Haifa, Israel; Soroka Med Ctr, Cyst Fibrosis Ctr, IL-84101 Beer Sheva, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, Jerusalem, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Dept Med Stat, Jerusalem, Israel; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL USA	Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Chaim Sheba Medical Center; Rambam Health Care Campus; Technion Israel Institute of Technology; Clalit Health Services; Carmel Medical Center; Ben Gurion University; Soroka Medical Center; Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Wilschanski, M (corresponding author), Hebrew Univ Jerusalem, Sch Med, Shaare Zedek Med Ctr, Cyst Fibrosis Ctr,Dept Pediat, IL-91010 Jerusalem, Israel.							Barton-Davis ER, 1999, J CLIN INVEST, V104, P375, DOI 10.1172/JCI7866; Bedwell DM, 1997, NAT MED, V3, P1280, DOI 10.1038/nm1197-1280; BONETTI B, 1995, J MOL BIOL, V251, P334, DOI 10.1006/jmbi.1995.0438; BUCHANAN JH, 1987, EUR J CELL BIOL, V43, P141; BURKE JF, 1985, NUCLEIC ACIDS RES, V13, P6265, DOI 10.1093/nar/13.17.6265; Clancy JP, 2001, AM J RESP CRIT CARE, V163, P1683, DOI 10.1164/ajrccm.163.7.2004001; Fleiss JL, 1986, DESIGN ANAL CLIN EXP, P263; GORINI L, 1964, P NATL ACAD SCI USA, V51, P487, DOI 10.1073/pnas.51.3.487; HAMOSH A, 1993, NEW ENGL J MED, V329, P1308; Helip-Wooley A, 2002, MOL GENET METAB, V75, P128, DOI 10.1006/mgme.2001.3272; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; Howard M, 1996, NAT MED, V2, P467, DOI 10.1038/nm0496-467; Keeling KM, 2002, J MOL MED-JMM, V80, P367, DOI 10.1007/s00109-001-0317-z; Keeling KM, 2001, HUM MOL GENET, V10, P291, DOI 10.1093/hmg/10.3.291; KNOWLES MR, 1995, HUM GENE THER, V6, P445, DOI 10.1089/hum.1995.6.4-445; KOPELOWITZ J, 1992, J MOL BIOL, V225, P261, DOI 10.1016/0022-2836(92)90920-F; POOLE ES, 1995, EMBO J, V14, P151, DOI 10.1002/j.1460-2075.1995.tb06985.x; Rubenstein RC, 1998, AM J RESP CRIT CARE, V157, P484, DOI 10.1164/ajrccm.157.2.9706088; RUUSALA T, 1984, MOL GEN GENET, V198, P100, DOI 10.1007/BF00328707; SHOSHANI T, 1992, AM J HUM GENET, V50, P222; Sleat D E, 2001, Eur J Paediatr Neurol, V5 Suppl A, P57, DOI 10.1053/ejpn.2000.0436; Wagner KR, 2001, ANN NEUROL, V49, P706, DOI 10.1002/ana.1023.abs; WELSH MJ, 1995, METABOLIC MOL BASES, V3, P3799; Wilschanski M, 2000, AM J RESP CRIT CARE, V161, P860, DOI 10.1164/ajrccm.161.3.9904116; Wilschanski M, 2001, EUR RESPIR J, V17, P1208, DOI 10.1183/09031936.01.00092501; Zsembery A, 2002, HEPATOLOGY, V35, P95, DOI 10.1053/jhep.2002.30423	26	392	412	0	26	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	2003	349	15					1433	1441		10.1056/NEJMoa022170	http://dx.doi.org/10.1056/NEJMoa022170			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729JF	14534336				2022-12-28	WOS:000185769500006
J	Wai, SN; Lindmark, B; Soderblom, T; Takade, A; Westermark, M; Oscarsson, J; Jass, J; Richter-Dahlfors, A; Mizunoe, Y; Uhlin, BE				Wai, SN; Lindmark, B; Soderblom, T; Takade, A; Westermark, M; Oscarsson, J; Jass, J; Richter-Dahlfors, A; Mizunoe, Y; Uhlin, BE			Vesicle-mediated export and assembly of pore-forming oligomers of the enterobacterial ClyA cytotoxin	CELL			English	Article							HEAT-LABILE ENTEROTOXIN; OUTER-MEMBRANE VESICLES; ESCHERICHIA-COLI; SECRETORY PATHWAY; PROTEIN SECRETION; CRYSTAL-STRUCTURE; HEMOLYSIN-E; IN-VITRO; SHEA; EXPRESSION	The ClyA protein is a pore-forming cytotoxin expressed by Escherichia coli and some other enterobacteria. It confers cytotoxic activity toward mammalian cells, but it has remained unknown how ClyA is surface exposed and exported from bacterial cells. Outer-membrane vesicles (OMVs) released from the bacteria were shown to contain ClyA protein. ClyA formed oligomeric pore assemblies in the OMVs, and the cytotoxic activity toward mammalian cells was considerably higher than that of ClyA protein purified from the bacterial periplasm. The redox status of ClyA correlated with its ability to form the oligomeric pore assemblies. In bacterial cells with a defective periplasmic disulphide oxidoreductase system, the ClyA protein was phenotypically expressed in a constitutive manner. The results define a vesicle-mediated transport mechanism in bacteria, and our findings show that the localization of proteins to OMVs directly may contribute to the activation and delivery of pathogenic effector proteins.	Umea Univ, Dept Mol Biol, SE-90187 Umea, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Kyushu Univ, Fac Med Sci, Dept Bacteriol, Fukuoka 8128582, Japan	Umea University; Karolinska Institutet; Kyushu University	Wai, SN (corresponding author), Umea Univ, Dept Mol Biol, SE-90187 Umea, Sweden.	sun.nyunt.wai@molbiol.umu.se	Uhlin, Bernt Eric/AAO-6292-2021; Jass, Jana/D-1617-2013	Uhlin, Bernt Eric/0000-0002-2991-8072; Jass, Jana/0000-0001-7957-0310; Richter-Dahlfors, Agneta/0000-0002-5479-7591; Wai, Sun Nyunt/0000-0003-4793-4671				AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; Atkins A, 2000, J BIOL CHEM, V275, P41150, DOI 10.1074/jbc.M005420200; Beveridge TJ, 1999, J BACTERIOL, V181, P4725, DOI 10.1128/JB.181.16.4725-4733.1999; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Chen LY, 1996, J BIOL CHEM, V271, P2703, DOI 10.1074/jbc.271.5.2703; Christie PJ, 2000, TRENDS MICROBIOL, V8, P354, DOI 10.1016/S0966-842X(00)01792-3; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; del Castillo FJ, 2001, FEMS MICROBIOL LETT, V204, P281, DOI 10.1016/S0378-1097(01)00413-X; delCastillo FJ, 1997, MOL MICROBIOL, V25, P107, DOI 10.1046/j.1365-2958.1997.4391813.x; Fiocca R, 1999, J PATHOL, V188, P220, DOI 10.1002/(SICI)1096-9896(199906)188:2<220::AID-PATH307>3.0.CO;2-C; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Green J, 1997, MICROBIOL-SGM, V143, P3785, DOI 10.1099/00221287-143-12-3785; Henderson IR, 2000, TRENDS MICROBIOL, V8, P529, DOI 10.1016/S0966-842X(00)01853-9; HENNING U, 1979, ANAL BIOCHEM, V97, P153, DOI 10.1016/0003-2697(79)90339-7; Horstman AL, 2000, J BIOL CHEM, V275, P12489, DOI 10.1074/jbc.275.17.12489; Horstman AL, 2002, J BIOL CHEM, V277, P32538, DOI 10.1074/jbc.M203740200; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Kadokura H, 2000, P NATL ACAD SCI USA, V97, P10884, DOI 10.1073/pnas.97.20.10884; Kadurugamuwa JL, 1998, ANTIMICROB AGENTS CH, V42, P1476, DOI 10.1128/AAC.42.6.1476; Kato S, 2002, MICROB PATHOGENESIS, V32, P1, DOI 10.1006/mpat.2001.0474; KORONAKIS V, 1991, EMBO J, V10, P3263, DOI 10.1002/j.1460-2075.1991.tb04890.x; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai XH, 2000, INFECT IMMUN, V68, P4363, DOI 10.1128/IAI.68.7.4363-4367.2000; LARSSON S, 1986, AM J PHYSIOL, V251, pC455, DOI 10.1152/ajpcell.1986.251.3.C455; Ludwig A, 1999, MOL MICROBIOL, V31, P557, DOI 10.1046/j.1365-2958.1999.01196.x; Oscarsson J, 2002, INFECT IMMUN, V70, P5759, DOI 10.1128/IAI.70.10.5759-5769.2002; Oscarsson J, 2002, INT J MED MICROBIOL, V291, P625, DOI 10.1078/1438-4221-00176; Oscarsson J, 1999, MOL MICROBIOL, V32, P1226, DOI 10.1046/j.1365-2958.1999.01435.x; Oscarsson J, 1996, MOL MICROBIOL, V20, P191, DOI 10.1111/j.1365-2958.1996.tb02500.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; Sandkvist M, 2001, MOL MICROBIOL, V40, P271, DOI 10.1046/j.1365-2958.2001.02403.x; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Tauschek M, 2002, P NATL ACAD SCI USA, V99, P7066, DOI 10.1073/pnas.092152899; Thanabalu T, 1998, EMBO J, V17, P6487, DOI 10.1093/emboj/17.22.6487; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; UHLIN BE, 1994, J CELL BIOCH S A, V18, P71; WAI SN, 1995, MICROBIOL IMMUNOL, V39, P451, DOI 10.1111/j.1348-0421.1995.tb02228.x; Wai SN, 2003, J BACTERIOL, V185, P5491, DOI 10.1128/JB.185.18.5491-5499.2003; Wai SN, 1998, APPL ENVIRON MICROB, V64, P3648; Wallace AJ, 2000, CELL, V100, P265, DOI 10.1016/S0092-8674(00)81564-0; Westermark M, 2000, J BACTERIOL, V182, P6347, DOI 10.1128/JB.182.22.6347-6357.2000; WHITTAM TS, 1988, J INFECT DIS, V157, P1124, DOI 10.1093/infdis/157.6.1124; Xia Y, 2000, EMBO J, V19, P1450, DOI 10.1093/emboj/19.7.1450	48	350	365	6	49	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 3	2003	115	1					25	35		10.1016/S0092-8674(03)00754-2	http://dx.doi.org/10.1016/S0092-8674(03)00754-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14532000	Bronze			2022-12-28	WOS:000185815500006
J	Papa, FR; Zhang, C; Shokat, K; Walter, P				Papa, FR; Zhang, C; Shokat, K; Walter, P			Bypassing a kinase activity with an ATP-competitive drug	SCIENCE			English	Article							UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM; RNASE-L; TRANSMEMBRANE PROTEIN; TYROSINE KINASES; NUCLEUS; IRE1P; ER; PHOSPHORYLATION; DIMERIZATION	Unfolded proteins in the endoplasmic reticulum cause trans-autophosphorylation of the bifunctional transmembrane kinase Ire1, which induces its endoribonuclease activity. The endoribonuclease initiates nonconventional splicing of HAC1 messenger RNA to trigger the unfolded-protein response (UPR). We explored the role of Ire1's kinase domain by sensitizing it through site-directed mutagenesis to the ATP-competitive inhibitor 1NM-PP1. Paradoxically, rather than being inhibited by 1NM-PP1, drug-sensitized Ire1 mutants required 1NM-PP1 as a cofactor for activation. In the presence of 1NM-PP1, drug-sensitized Ire1 bypassed mutations that inactivate its kinase activity and induced a full UPR. Thus, rather than through phosphorylation per se, a conformational change in the kinase domain triggered by occupancy of the active site with a ligand leads to activation of all known downstream functions.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Papa, FR (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.		Longo, Kenneth A/A-5631-2010	Papa, Feroz/0000-0002-3684-9108	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032384, R01GM032384] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44009] Funding Source: Medline; NIGMS NIH HHS [GM32384] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Bishop AC, 1998, CURR BIOL, V8, P257, DOI 10.1016/S0960-9822(98)70198-8; Carroll AS, 2001, P NATL ACAD SCI USA, V98, P12578, DOI 10.1073/pnas.211195798; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dong BH, 1999, NUCLEIC ACIDS RES, V27, P439, DOI 10.1093/nar/27.2.439; Dong BH, 2001, RNA, V7, P361, DOI 10.1017/S1355838201002230; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kroiher M, 2001, BIOESSAYS, V23, P69, DOI 10.1002/1521-1878(200101)23:1<69::AID-BIES1009>3.3.CO;2-B; MORI K, 1993, CELL, V74, P743; Naik S, 1998, NUCLEIC ACIDS RES, V26, P1522, DOI 10.1093/nar/26.6.1522; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; Ruegsegger U, 2001, CELL, V107, P103, DOI 10.1016/S0092-8674(01)00505-0; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Schuit F, 1999, J BIOL CHEM, V274, P32803, DOI 10.1074/jbc.274.46.32803; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; Stevens FJ, 1999, SEMIN CELL DEV BIOL, V10, P443, DOI 10.1006/scdb.1999.0315; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Urano F, 2000, J CELL SCI, V113, P3697; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Weiss EL, 2000, NAT CELL BIOL, V2, P677, DOI 10.1038/35036300	29	195	205	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 28	2003	302	5650					1533	1537		10.1126/science.1090031	http://dx.doi.org/10.1126/science.1090031			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	747JV	14564015				2022-12-28	WOS:000186802200033
J	Pak, DTS; Sheng, M				Pak, DTS; Sheng, M			Targeted protein degradation and synapse remodeling by an inducible protein kinase	SCIENCE			English	Article							LONG-TERM POTENTIATION; POLO-LIKE KINASES; DENDRITIC SPINES; EXCITATORY SYNAPSES; PLASTICITY; ACTIN; UBIQUITIN; MITOSIS	Synaptic plasticity involves the reorganization of synapses at the protein and the morphological levels. Here, we report activity-dependent remodeling of synapses by serum-inducible kinase (SNK). SNK was induced in hippocampal neurons by synaptic activity and was targeted to dendritic spines. SNK bound to and phosphorylated spine-associated Rap guanosine triphosphatase activating protein (SPAR), a postsynaptic actin regulatory protein, leading to degradation of SPAR. Induction of SNK in hippocampal neurons eliminated SPAR protein, depleted postsynaptic density-95 and Bassoon clusters, and caused loss of mature dendritic spines. These results implicate SNK as a mediator of activity-dependent change in the molecular composition and morphology of synapses.	MIT, Howard Hughes Med Inst, Neurosci Res Ctr, RIKEN,Picower Ctr Learning & Memory, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); RIKEN	Pak, DTS (corresponding author), MIT, Howard Hughes Med Inst, Neurosci Res Ctr, RIKEN,Picower Ctr Learning & Memory, Cambridge, MA 02139 USA.			Sheng, Morgan/0000-0002-8703-5366				BAILEY CH, 1989, J NEUROBIOL, V20, P356, DOI 10.1002/neu.480200508; Bi GQ, 2001, ANNU REV NEUROSCI, V24, P139, DOI 10.1146/annurev.neuro.24.1.139; Colicos MA, 2001, CELL, V107, P605, DOI 10.1016/S0092-8674(01)00579-7; El-Hussein AE, 2000, SCIENCE, V290, P1364; Feng Y, 2001, CELL GROWTH DIFFER, V12, P29; Frey U, 1998, TRENDS NEUROSCI, V21, P181, DOI 10.1016/S0166-2236(97)01189-2; Gao QS, 1999, MOL CELL BIOL, V19, P733; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Hegde AN, 2002, NAT REV NEUROSCI, V3, P854, DOI 10.1038/nrn961; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Kim CH, 1999, J NEUROSCI, V19, P4314; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Martin KC, 2000, CURR OPIN NEUROBIOL, V10, P587, DOI 10.1016/S0959-4388(00)00128-8; Matus A, 2000, HIPPOCAMPUS, V10, P555, DOI 10.1002/1098-1063(2000)10:5<555::AID-HIPO5>3.0.CO;2-Z; Murphey RK, 2002, NEURON, V36, P5, DOI 10.1016/S0896-6273(02)00943-1; Nedivi E, 1999, J NEUROBIOL, V41, P135, DOI 10.1002/(SICI)1097-4695(199910)41:1<135::AID-NEU17>3.0.CO;2-F; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Sheng M, 2002, SCIENCE, V298, P776, DOI 10.1126/science.1075333; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Star EN, 2002, NAT NEUROSCI, V5, P239, DOI 10.1038/nn811; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; Turrigiano GG, 2000, CURR OPIN NEUROBIOL, V10, P358, DOI 10.1016/S0959-4388(00)00091-X; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Yuste R, 2001, ANNU REV NEUROSCI, V24, P1071, DOI 10.1146/annurev.neuro.24.1.1071; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	28	233	244	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 21	2003	302	5649					1368	1373		10.1126/science.1082475	http://dx.doi.org/10.1126/science.1082475			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14576440				2022-12-28	WOS:000186683500044
J	Feng, JL				Feng, JL			Searching for gravity's hidden strength	SCIENCE			English	Editorial Material							DIMENSIONS		Univ Calif Irvine, Dept Phys & Astron, Irvine, CA 92697 USA	University of California System; University of California Irvine	Feng, JL (corresponding author), Univ Calif Irvine, Dept Phys & Astron, Irvine, CA 92697 USA.	jlf@uci.edu		Feng, Jonathan/0000-0002-7713-2138				Alvarez-Muniz J, 2002, PHYS REV D, V65, DOI 10.1103/PhysRevD.65.124015; Anchordoqui L, 2002, PHYS REV D, V65, DOI 10.1103/PhysRevD.65.047502; Arkani-Hamed N, 1998, PHYS LETT B, V429, P263, DOI 10.1016/S0370-2693(98)00466-3; Cullen S, 1999, PHYS REV LETT, V83, P268, DOI 10.1103/PhysRevLett.83.268; Dimopoulos S, 2001, PHYS REV LETT, V87, part. no., DOI 10.1103/PhysRevLett.87.161602; Eardley DM, 2002, PHYS REV D, V66, DOI 10.1103/PhysRevD.66.044011; Feng JL, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.021303; Giddings SB, 2002, PHYS REV D, V65, DOI 10.1103/PhysRevD.65.056010; Hall LJ, 1999, PHYS REV D, V60, DOI 10.1103/PhysRevD.60.085008; Kowalski M, 2002, PHYS LETT B, V529, P1, DOI 10.1016/S0370-2693(02)01235-2; Yoshino H, 2002, PHYS REV D, V66, DOI 10.1103/PhysRevD.66.065004	11	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	2003	302	5646					795	797						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593158				2022-12-28	WOS:000186258000028
J	Buller, HR; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Piovella, F; Prins, MH; Raskob, G; van den Berg-Segers, AEM; Cariou, R; Leeuwenkamp, O; Lensing, AWA				Buller, HR; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Piovella, F; Prins, MH; Raskob, G; van den Berg-Segers, AEM; Cariou, R; Leeuwenkamp, O; Lensing, AWA		Matisse Investigators	Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOLECULAR-WEIGHT HEPARIN; PROXIMAL-VEIN THROMBOSIS; VENOUS THROMBOEMBOLIC DISEASE; FACTOR XA; THERAPY	BACKGROUND: The standard initial treatment of hemodynamically stable patients with pulmonary embolism is intravenous unfractionated heparin, requiring laboratory monitoring and hospitalization. METHODS: We conducted a randomized, open-label trial involving 2213 patients with acute symptomatic pulmonary embolism to compare the efficacy and safety of the synthetic antithrombotic agent fondaparinux with those of unfractionated heparin and to document noninferiority in terms of efficacy. Patients received either fondaparinux (5.0, 7.5, or 10.0 mg in patients weighing less than 50, 50 to 100, or more than 100 kg, respectively) subcutaneously once daily or a continuous intravenous infusion of unfractionated heparin (ratio of the activated partial-thromboplastin time to a control value, 1.5 to 2.5), both given for at least five days and until the use of vitamin K antagonists resulted in an international normalized ratio above 2.0. The primary efficacy outcome was the three-month incidence of the composite end point of symptomatic, recurrent pulmonary embolism (nonfatal or fatal) and new or recurrent deep-vein thrombosis. RESULTS: Forty-two of the 1103 patients randomly assigned to receive fondaparinux (3.8 percent) had recurrent thromboembolic events, as compared with 56 of the 1110 patients randomly assigned to receive unfractionated heparin (5.0 percent), for an absolute difference of -1.2 percent in favor of fondaparinux (95 percent confidence interval, -3.0 to 0.5). Major bleeding occurred in 1.3 percent of the patients treated with fondaparinux and 1.1 percent of those treated with unfractionated heparin. Mortality rates at three months were similar in the two groups. Of the patients in the fondaparinux group, 14.5 percent received the drug in part on an outpatient basis. CONCLUSIONS: Once-daily, subcutaneous administration of fondaparinux without monitoring is at least as effective and is as safe as adjusted-dose, intravenous administration of unfractionated heparin in the initial treatment of hemodynamically stable patients with pulmonary embolism.	Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Buller, HR (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, F4-211,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Piovella, Franco/AAM-8305-2020	Gallus, Alexander/0000-0001-7347-9989; Shah, Pallav/0000-0002-9052-4638				Anand SS, 1999, ARCH INTERN MED, V159, P2029, DOI 10.1001/archinte.159.17.2029; BARRITT DW, 1960, LANCET, V1, P1309; BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; Buller HR, 2000, CIRCULATION, V102, P2726; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Goldhaber SZ, 1998, NEW ENGL J MED, V339, P93, DOI 10.1056/NEJM199807093390207; Graafsma YP, 1997, THROMB HAEMOSTASIS, V78, P1189; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; Hyers TM, 2001, CHEST, V119, p176S, DOI 10.1378/chest.119.1_suppl.176S; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Lensing AWA, 1999, LANCET, V353, P479, DOI 10.1016/S0140-6736(98)04298-6; Merli G, 2001, ANN INTERN MED, V134, P191, DOI 10.7326/0003-4819-134-3-200102060-00009; Petitou M, 2002, SEMIN THROMB HEMOST, V28, P393, DOI 10.1055/s-2002-34309; PRANDONI P, 1993, CIRCULATION, V88, P1730, DOI 10.1161/01.CIR.88.4.1730; Prandoni P, 2002, THROMB HAEMOSTASIS, V88, P402; REILLY BM, 1993, J GEN INTERN MED, V8, P536, DOI 10.1007/BF02599634; Simonneau G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002; tenCate JW, 1997, NEW ENGL J MED, V337, P657; van Den Belt A.G., 2000, COCHRANE DB SYST REV, V2; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003	20	607	637	1	15	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	2003	349	18					1695	1702						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	737FJ	14585937				2022-12-28	WOS:000186219500003
J	Bromm, V; Loeb, A				Bromm, V; Loeb, A			The formation of the first low-mass stars from gas with low carbon and oxygen abundances	NATURE			English	Article							SUPERNOVAE; FRAGMENTATION; ELEMENTS	The first stars in the Universe are predicted to have been much more massive than the Sun(1-3). Gravitational condensation, accompanied by cooling of the primordial gas via molecular hydrogen, yields a minimum fragmentation scale of a few hundred solar masses. Numerical simulations indicate that once a gas clump acquires this mass it undergoes a slow, quasihydrostatic contraction without further fragmentation(1,2); lowermass stars cannot form. Here we show that as soon as the primordial gas - left over from the Big Bang - is enriched by elements ejected from supernovae to a carbon or oxygen abundance as small as similar to0.01 - 0.1 per cent of that found in the Sun, cooling by singly ionized carbon or neutral oxygen can lead to the formation of low-mass stars by allowing cloud fragmentation to smaller clumps. This mechanism naturally accommodates the recent discovery(4) of solar-mass stars with unusually low iron abundances (10(-5.3) solar) but with relatively high (10(-1.3) solar) carbon abundance. The critical abundances that we derive can be used to identify those metal-poor stars in our Galaxy with elemental patterns imprinted by the first supernovae. We also find that the minimum stellar mass at early epochs is partially regulated by the temperature of the cosmic microwave background.	Harvard Univ, Dept Astron, Cambridge, MA 02138 USA	Harvard University	Bromm, V (corresponding author), Harvard Univ, Dept Astron, 60 Garden St, Cambridge, MA 02138 USA.	loeb@cfa.harvard.edu						Abel T, 2002, SCIENCE, V295, P93, DOI 10.1126/science.1063991; AKERMAN CJ, UNPUB ASTRON ASTROPH; Bromm V, 2003, ASTROPHYS J, V596, P34, DOI 10.1086/377529; Bromm V, 2002, ASTROPHYS J, V564, P23, DOI 10.1086/323947; Bromm V, 2001, MON NOT R ASTRON SOC, V328, P969, DOI 10.1046/j.1365-8711.2001.04915.x; BROMM V, 2003, IN PRESS ASTROPHYS J; CAYREL R, UNPUB ASTRON ASTROPH; Cen RY, 2003, ASTROPHYS J, V591, pL5, DOI 10.1086/377068; Clarke CJ, 2003, MON NOT R ASTRON SOC, V343, P1224, DOI 10.1046/j.1365-8711.2003.06765.x; Heger A, 2002, ASTROPHYS J, V567, P532, DOI 10.1086/338487; HOLLENBACH D, 1989, ASTROPHYS J, V342, P306, DOI 10.1086/167595; Kogut A, 2003, ASTROPHYS J SUPPL S, V148, P161, DOI 10.1086/377219; Larson RB, 1998, MON NOT R ASTRON SOC, V301, P569, DOI 10.1046/j.1365-8711.1998.02045.x; Mackey J, 2003, ASTROPHYS J, V586, P1, DOI 10.1086/367613; McKee CF, 2002, NATURE, V416, P59, DOI 10.1038/416059a; Nakamura F, 2002, ASTROPHYS J, V569, P549, DOI 10.1086/339392; Qian YZ, 2002, ASTROPHYS J, V567, P515, DOI 10.1086/338277; Qian YZ, 2002, ASTROPHYS J, V569, pL61, DOI 10.1086/340641; REES MJ, 1976, MON NOT R ASTRON SOC, V176, P483, DOI 10.1093/mnras/176.3.483; Schneider R, 2002, ASTROPHYS J, V571, P30, DOI 10.1086/339917; Sneden C, 2003, SCIENCE, V299, P70, DOI 10.1126/science.1077506; SOKASIAN A, 2003, UNPUB MON NOT R ASTR; Tumlinson J, 2000, ASTROPHYS J, V528, pL65, DOI 10.1086/312432; Umeda H, 2003, NATURE, V422, P871, DOI 10.1038/nature01571; Umeda H, 2002, ASTROPHYS J, V565, P385, DOI 10.1086/323946; Wyithe JSB, 2003, ASTROPHYS J, V588, pL69, DOI 10.1086/375682	30	343	343	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 23	2003	425	6960					812	814		10.1038/nature02071	http://dx.doi.org/10.1038/nature02071			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574405	Green Submitted			2022-12-28	WOS:000186118500038
J	Huxter, J; Burgess, N; O'Keefe, J				Huxter, J; Burgess, N; O'Keefe, J			Independent rate and temporal coding in hippocampal pyramidal cells	NATURE			English	Article							THETA-PHASE PRECESSION; PLACE CELLS; NEURONAL-ACTIVITY; OSCILLATIONS; MEMORY; EXPERIENCE; EXPANSION; SEQUENCES; DYNAMICS; POSITION	In the brain, hippocampal pyramidal cells use temporal(1) as well as rate(2) coding to signal spatial aspects of the animal's environment or behaviour. The temporal code takes the form of a phase relationship to the concurrent cycle of the hippocampal electroencephalogram theta rhythm(1). These two codes could each represent a different variable(3,4). However, this requires the rate and phase to vary independently, in contrast to recent suggestions(5,6) that they are tightly coupled, both reflecting the amplitude of the cell's input. Here we show that the time of firing and firing rate are dissociable, and can represent two independent variables: respectively the animal's location within the place field, and its speed of movement through the field. Independent encoding of location together with actions and stimuli occurring there may help to explain the dual roles of the hippocampus in spatial and episodic memory(7,8), or may indicate a more general role of the hippocampus in relational/declarative memory(9,10).	UCL, Dept Anat & Dev Biol, London WC1E 6BT, England; UCL, Inst Cognit Neurosci, London WC1E 6BT, England	University of London; University College London; University of London; University College London	O'Keefe, J (corresponding author), UCL, Dept Anat & Dev Biol, Gower St, London WC1E 6BT, England.	j.okeefe@ucl.ac.uk	Burgess, Neil/B-2420-2009	Burgess, Neil/0000-0003-0646-6584	Medical Research Council [G0501672, G0501672(76328), G117/433] Funding Source: Medline; Wellcome Trust [071248] Funding Source: Medline; MRC [G117/433] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BURGESS N, 1994, NEURAL NETWORKS, V7, P1065, DOI 10.1016/S0893-6080(05)80159-5; Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9; Buzsaki G, 2002, NEURON, V33, P325, DOI 10.1016/S0896-6273(02)00586-X; Eichenbaum HE, 2001, CONDITIONING CONSCIO; Ekstrom AD, 2001, NEURON, V31, P631, DOI 10.1016/S0896-6273(01)00401-9; Harris KD, 2002, NATURE, V417, P738, DOI 10.1038/nature00808; Hirase H, 1999, EUR J NEUROSCI, V11, P4373, DOI 10.1046/j.1460-9568.1999.00853.x; Jensen O, 1996, LEARN MEMORY, V3, P279, DOI 10.1101/lm.3.2-3.279; Jensen O, 2000, J NEUROPHYSIOL, V83, P2602, DOI 10.1152/jn.2000.83.5.2602; Kahana MJ, 1999, NATURE, V399, P781, DOI 10.1038/21645; Kamondi A, 1998, HIPPOCAMPUS, V8, P244, DOI 10.1002/(SICI)1098-1063(1998)8:3<244::AID-HIPO7>3.0.CO;2-J; Lengyel M, 2003, HIPPOCAMPUS, V13, P700, DOI 10.1002/hipo.10116; MCNAUGHTON BL, 1983, EXP BRAIN RES, V52, P41; Mehta MR, 2002, NATURE, V417, P741, DOI 10.1038/nature00807; Mehta MR, 1997, P NATL ACAD SCI USA, V94, P8918, DOI 10.1073/pnas.94.16.8918; Moita MAP, 2003, NEURON, V37, P485, DOI 10.1016/S0896-6273(03)00033-3; Muller R, 1996, NEURON, V17, P813, DOI 10.1016/S0896-6273(00)80214-7; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKeefe J, 1996, NATURE, V381, P425, DOI 10.1038/381425a0; OKEEFE J, 1976, EXP NEUROL, V51, P78, DOI 10.1016/0014-4886(76)90055-8; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; OKeefe J, 1991, BRAIN SPACE, P273, DOI DOI 10.1016/j.neuron.2015.06.011; Pike FG, 2000, J PHYSIOL-LONDON, V529, P205, DOI 10.1111/j.1469-7793.2000.00205.x; Skaggs WE, 1996, HIPPOCAMPUS, V6, P149, DOI 10.1002/(SICI)1098-1063(1996)6:2<149::AID-HIPO6>3.0.CO;2-K; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Tsodyks MV, 1996, HIPPOCAMPUS, V6, P271, DOI 10.1002/(SICI)1098-1063(1996)6:3<271::AID-HIPO5>3.3.CO;2-Q; Wallenstein GV, 1997, J NEUROPHYSIOL, V78, P393, DOI 10.1152/jn.1997.78.1.393; WIENER SI, 1989, J NEUROSCI, V9, P2737; Wood ER, 1999, NATURE, V397, P613, DOI 10.1038/17605; Yamaguchi Y, 2002, J NEUROPHYSIOL, V87, P2629, DOI 10.1152/jn.2002.87.6.2629	30	417	427	1	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					828	832		10.1038/nature02058	http://dx.doi.org/10.1038/nature02058			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574410	Green Accepted			2022-12-28	WOS:000186118500043
J	Couzin, J				Couzin, J			Aging research - Is long life in the blood?	SCIENCE			English	News Item																			0	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					373	+						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14563979				2022-12-28	WOS:000185963200006
J	Xu, W; Angell, CA				Xu, W; Angell, CA			Solvent-free electrolytes with aqueous solution - Like conductivities	SCIENCE			English	Article							TEMPERATURE MOLTEN-SALTS; IONIC LIQUIDS; DERIVATIVES; TECHNOLOGY	Aqueous solutions are generally assumed to be superior electrolytic conductors because of the unique dielectric and fluid properties of water. We show that their conductivities can be matched by liquid electrolytes that contain no solvent. These are proton transfer salts that are liquid at ambient temperature. The high conductivities are due to the high fluidity and ionicity rather than some sort of Grotthus mechanism, although in certain cases a mobile proton population may make a non-negligible contribution. The highest conductivities have been obtained when both cations and anions contain protons. At 25degreesC, values of >150 millisiemens per centimeter (mS cm(-1)) appear possible; at 100degreesC, 470 mS cm(-1) has been measured. Because of the combination of high ionicity and proton exchange kinetics with low vapor pressure, the systems we describe also make excellent fuel cell electrolytes.	Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Angell, CA (corresponding author), Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA.			Xu, Wu/0000-0002-2685-8684				Angell C. A., 2003, IONIC LIQUIDS FRONT, P43; Angell C.A., 2003, P INT S ION LIQ HON, P389; ANGELL CA, 1983, SOLID STATE IONICS, V9-10, P3, DOI 10.1016/0167-2738(83)90206-0; ANGELL CA, 1995, SCIENCE, V267, P1924, DOI 10.1126/science.267.5206.1924; Arrhenius S., 1887, Z PHYS CHEM, V1U, P631, DOI [10.1515/zpch-1887-0164, DOI 10.1515/ZPCH-1887-0164]; BARTHEL J, 1983, TOP CURR CHEM, V111, P33; Barthel J, 1999, PURE APPL CHEM, V71, P1705, DOI 10.1351/pac199971091705; Bernal JD, 1933, J CHEM PHYS, V1, P515, DOI 10.1063/1.1749327; BRESSEL RD, 1972, THESIS PURDUE U; Carlin R. T., 1994, CHEM NONAQUEOUS SOLU, P277; EVANS DF, 1982, J COLLOID INTERF SCI, V88, P69; Fuller J, 1997, J ELECTROCHEM SOC, V144, P3881, DOI 10.1149/1.1838106; Gurney R.W., 1953, IONIC PROCESSES SOLU; Hagiwara R, 2002, J ELECTROCHEM SOC, V149, pD1, DOI 10.1149/1.1421606; Lu W, 2002, SCIENCE, V297, P983, DOI 10.1126/science.1072651; Noda A, 2003, J PHYS CHEM B, V107, P4024, DOI 10.1021/jp022347p; Papageorgiou N, 1996, J ELECTROCHEM SOC, V143, P3099, DOI 10.1149/1.1837171; ROBINSON RA, 1959, ELECTROLYTE SOLUTION, P465; Rogers R., 2003, GREEN IND APPL IONIC; Rogers R.D., 2002, ACS S SERIES, V818, DOI 10.1021/bk-2002-0818.fw001; Sun J, 1998, J PHYS CHEM B, V102, P8858, DOI 10.1021/jp981159p; SUTTER EJ, 1971, J PHYS CHEM-US, V75, P1826; SUTTER EJ, 1971, THESIS PURDUE U; Walden P, 1906, Z PHYS CHEM-STOCH VE, V55, P207; Walden P, 1914, B ACAD IMPER SCI ST, P405; Walden P. Z., 1906, Z PHYS CHEM, V55, P246; Xu W, 2003, J PHYS CHEM B, V107, P6170, DOI 10.1021/jp0275894; Xu W, 2001, ELECTROCHEM SOLID ST, V4, pE1, DOI 10.1149/1.1344281; Yoshizawa M, 2001, ELECTROCHEM SOLID ST, V4, pE25, DOI 10.1149/1.1369218; YOSHIZAWA M, IN PRESS J AM CHEM S	30	440	451	4	153	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					422	425		10.1126/science.1090287	http://dx.doi.org/10.1126/science.1090287			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564002				2022-12-28	WOS:000185963200035
J	Finney, SJ; Zekveld, C; Elia, A; Evans, TW				Finney, SJ; Zekveld, C; Elia, A; Evans, TW			Glucose control and mortality in critically ill patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	99th International Conference of the American-Thoracic-Society	MAY, 2003	SEATTLE, WASHINGTON	Amer Thorac Soc			ACUTE MYOCARDIAL-INFARCTION; INTENSIVE INSULIN THERAPY; ADMISSION PLASMA-GLUCOSE; INDEPENDENT RISK-FACTOR; DIABETIC-PATIENTS; HYPERGLYCEMIA; INFUSION; TRIAL; MODULATION; FAILURE	Context Hyperglycemia is common in critically ill patients, even in those without diabetes mellitus. Aggressive glycemic control may reduce mortality in this population. However, the relationship between mortality, the control of hyperglycemia, and the administration of exogenous insulin is unclear. Objective To determine whether blood glucose level or quantity of insulin administered is associated with reduced mortality in critically ill patients. Design, Setting, and Patients Single-center, prospective, observational study of 531 patients (median age, 64 years) newly admitted over the first 6 months of 2002 to an adult intensive care unit (ICU) in a UK national referral center for cardiorespiratory surgery and medicine. Main Outcome Measures The primary end point was intensive care unit (ICU) mortality. Secondary end points were hospital mortality, ICU and hospital length of stay, and predicted threshold glucose level associated with risk of death.. Results Of 531 patients admitted to the ICU, 523 underwent analysis of their glycemic control. Twenty-four-hour control of blood glucose levels was variable. Rates of ICU and hospital mortality were 5.2% and 5.7%, respectively; median lengths of stay were 1.8 (interquartile range, 0.9-3.7) days and 6 (interquartile range, 4.5-8.3) days, respectively. Multivariable logistic regression demonstrated that increased administration of insulin was positively and significantly associated with ICU mortality (odds ratio, 1.02 [95% confidence interval, 1.01-1.04] at a prevailing glucose level of 111-144 mg/dL [6.1-8.0 mmol/L] for a 1-IU/d increase), suggesting that mortality benefits are attributable to glycemic control rather than increased administration of insulin. Also, the regression models suggest that a mortality benefit accrues below a predicted threshold glucose level of 144 to 200 mg/dL (8.0-11.1 mmol/L), with a speculative upper limit of 145 mg/dL (8.0 mmol/L) for the target blood glucose level. Conclusions increased insulin administration is positively associated with death in the ICU regardless of the prevailing blood glucose level. Thus, control of glucose levels rather than of absolute levels of exogenous insulin appear to account for the mortality benefit associated with intensive insulin therapy demonstrated by others.	Royal Brompton Hosp, Adult Intens Care Unit, London SW3 6LY, England; Royal Brompton Hosp, Dept Occupat & Environm Med, London SW3 6LY, England; Royal Brompton Hosp, Dept Biomed Engn, London SW3 6LY, England	Royal Brompton Hospital; Royal Brompton Hospital; Royal Brompton Hospital	Evans, TW (corresponding author), Royal Brompton Hosp, Adult Intens Care Unit, Sydney St, London SW3 6LY, England.		Finney, Simon/A-2168-2012	Finney, Simon/0000-0001-8219-1952				Annane D, 2003, CRIT CARE MED, V31, P634, DOI 10.1097/01.CCM.0000045569.14948.F2; British Association for Parenteral and Enteral Nutrition, 1996, STAND GUID NUTR SUPP; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; *DEP HLTH, 2000, HOSP ACT STAT; Dhatariya K, 2003, JAMA-J AM MED ASSOC, V289, P1244, DOI 10.1001/jama.289.10.1244-a; Diaz R, 1998, CIRCULATION, V98, P2227, DOI 10.1161/01.CIR.98.21.2227; Evans TW, 2001, NEW ENGL J MED, V345, P1417, DOI 10.1056/NEJM200111083451910; Furnary AP, 1999, ANN THORAC SURG, V67, P352, DOI 10.1016/S0003-4975(99)00014-4; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Malmberg K, 1999, CIRCULATION, V99, P2626, DOI 10.1161/01.CIR.99.20.2626; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; McManus LM, 2001, J LEUKOCYTE BIOL, V70, P395; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; Montori VM, 2002, JAMA-J AM MED ASSOC, V288, P2167, DOI 10.1001/jama.288.17.2167; Norhammar AM, 1999, DIABETES CARE, V22, P1827, DOI 10.2337/diacare.22.11.1827; Scott JF, 1999, STROKE, V30, P793, DOI 10.1161/01.STR.30.4.793; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; Van den Berghe G, 2003, CRIT CARE MED, V31, P359, DOI 10.1097/01.CCM.0000045568.12881.10; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156; Wass CT, 1996, MAYO CLIN PROC, V71, P801; Zindrou D, 2001, DIABETES CARE, V24, P1634, DOI 10.2337/diacare.24.9.1634	23	688	730	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	2003	290	15					2041	2047		10.1001/jama.290.15.2041	http://dx.doi.org/10.1001/jama.290.15.2041			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CX	14559958	Bronze			2022-12-28	WOS:000185924200028
J	Hughes, TP; Kaeda, J; Branford, S; Rudzki, Z; Hochhaus, A; Hensley, ML; Gathmann, I; Bolton, AE; van Hoomissen, IC; Goldman, JM; Radich, JP; Taylor, K; Durrant, S; Schwarer, A; Joske, D; Seymour, J; Grigg, A; Ma, D; Arthur, C; Bradstock, K; Joshua, D; Lechner, K; Verhoef, G; Louwagie, A; Martiat, P; Straetmans, N; Bosly, A; Shepherd, J; Shustik, C; Lipton, J; Kovacs, DM; Turner, AR; Nielsen, JL; Birgens, H; Bjerrum, OW; Guilhot, F; Reiffers, J; Rousselot, P; Facon, T; Harousseau, JL; Tulliez, M; Guerci, A; Blaise, D; Maloisel, F; Michallet, M; Fischer, T; Hossfeld, D; Mertelsmann, R; Andreesen, R; Nerl, C; Freund, M; Gattermann, N; Hoeffken, K; Ehninger, G; Deininger, M; Ottmann, O; Peschel, C; Fruehauf, S; Neubauer, A; Le Coutre, P; Aulitzky, W; Baccarani, M; Saglio, G; Fanin, R; Rosti, G; Mandelli, F; Morra, E; Carella, A; Lazzarino, M; Petrini, M; Ferrini, PR; Nobile, F; Liso, V; Ferrara, F; Rizzoli, V; Fioritoni, G; Martinelli, G; Cornelissen, J; Ossenkoppele, G; Browett, P; Gedde-Dahl, T; Tangen, JM; Dahl, I; Cervantes, F; Odriozola, J; Boluda, JCH; Steegmann, JL; Canizo, C; Sureda, A; Diaz, J; Granena, A; Fernandez, MN; Simonsson, B; Stenke, L; Paul, C; Bjoreman, M; Malm, C; Wadenvik, H; Nilsson, PG; Turesson, I; Gratwohl, A; Hess, U; Solenthaler, M; O'Brien, SG; Russell, N; Mufti, G; Cavenagh, J; Clark, RE; Green, AR; Holyoake, TL; Lucas, GS; Smith, G; Milligan, DW; Rule, SJ; Burnett, AK; Druker, BJ; Larson, RA; Moroose, R; Wetzler, M; Bearden, J; Brown, R; Lobell, M; Cataland, S; Rabinowitz, I; Meisenberg, B; Gabrilove, J; Thompson, K; Graziano, S; Emanuel, P; Gross, H; Cobb, P; Bhatia, R; Dakhil, S; Irwin, D; Issell, B; Pavletic, S; Kuebler, P; Layhe, E; Butera, P; Glass, J; Moore, J; Grant, B; Niell, H; Herzig, R; Burris, H; Kantarjian, H; Peterson, B; Powell, B; Kalaycio, M; Stirewalt, D; Samlowski, W; Berman, E; Limentani, S; Seay, T; Shea, T; Akard, L; Smith, G; Becker, P; DeVine, S; Hart, R; Veith, R; Wade, J; Brunvand, M; Silver, R; Kalman, I; Strickland, D; Shurafa, M; Bashey, A; Shadduck, R; Cooper, S; Safah, H; Rubenstein, M; Collins, R; Keller, A; Stone, R; Tallman, M; Stevens, D; Pecora, A; Agha, M; Holmes, H				Hughes, TP; Kaeda, J; Branford, S; Rudzki, Z; Hochhaus, A; Hensley, ML; Gathmann, I; Bolton, AE; van Hoomissen, IC; Goldman, JM; Radich, JP; Taylor, K; Durrant, S; Schwarer, A; Joske, D; Seymour, J; Grigg, A; Ma, D; Arthur, C; Bradstock, K; Joshua, D; Lechner, K; Verhoef, G; Louwagie, A; Martiat, P; Straetmans, N; Bosly, A; Shepherd, J; Shustik, C; Lipton, J; Kovacs, DM; Turner, AR; Nielsen, JL; Birgens, H; Bjerrum, OW; Guilhot, F; Reiffers, J; Rousselot, P; Facon, T; Harousseau, JL; Tulliez, M; Guerci, A; Blaise, D; Maloisel, F; Michallet, M; Fischer, T; Hossfeld, D; Mertelsmann, R; Andreesen, R; Nerl, C; Freund, M; Gattermann, N; Hoeffken, K; Ehninger, G; Deininger, M; Ottmann, O; Peschel, C; Fruehauf, S; Neubauer, A; Le Coutre, P; Aulitzky, W; Baccarani, M; Saglio, G; Fanin, R; Rosti, G; Mandelli, F; Morra, E; Carella, A; Lazzarino, M; Petrini, M; Ferrini, PR; Nobile, F; Liso, V; Ferrara, F; Rizzoli, V; Fioritoni, G; Martinelli, G; Cornelissen, J; Ossenkoppele, G; Browett, P; Gedde-Dahl, T; Tangen, JM; Dahl, I; Cervantes, F; Odriozola, J; Boluda, JCH; Steegmann, JL; Canizo, C; Sureda, A; Diaz, J; Granena, A; Fernandez, MN; Simonsson, B; Stenke, L; Paul, C; Bjoreman, M; Malm, C; Wadenvik, H; Nilsson, PG; Turesson, I; Gratwohl, A; Hess, U; Solenthaler, M; O'Brien, SG; Russell, N; Mufti, G; Cavenagh, J; Clark, RE; Green, AR; Holyoake, TL; Lucas, GS; Smith, G; Milligan, DW; Rule, SJ; Burnett, AK; Druker, BJ; Larson, RA; Moroose, R; Wetzler, M; Bearden, J; Brown, R; Lobell, M; Cataland, S; Rabinowitz, I; Meisenberg, B; Gabrilove, J; Thompson, K; Graziano, S; Emanuel, P; Gross, H; Cobb, P; Bhatia, R; Dakhil, S; Irwin, D; Issell, B; Pavletic, S; Kuebler, P; Layhe, E; Butera, P; Glass, J; Moore, J; Grant, B; Niell, H; Herzig, R; Burris, H; Kantarjian, H; Peterson, B; Powell, B; Kalaycio, M; Stirewalt, D; Samlowski, W; Berman, E; Limentani, S; Seay, T; Shea, T; Akard, L; Smith, G; Becker, P; DeVine, S; Hart, R; Veith, R; Wade, J; Brunvand, M; Silver, R; Kalman, I; Strickland, D; Shurafa, M; Bashey, A; Shadduck, R; Cooper, S; Safah, H; Rubenstein, M; Collins, R; Keller, A; Stone, R; Tallman, M; Stevens, D; Pecora, A; Agha, M; Holmes, H		IRIS Study Grp	Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	44th Annual Meeting of the American-Society-of-Hematology	DEC 06-10, 2002	PHILADELPHIA, PA	Amer Soc Hematol			POLYMERASE-CHAIN-REACTION; CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL TRANSCRIPTS; BONE-MARROW TRANSPLANT; RESIDUAL DISEASE; TYROSINE KINASE; CYTOGENETIC RESPONSES; REACTION PREDICTS; THERAPY; MESYLATE	BACKGROUND: In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy. We measured levels of BCR-ABL transcripts in the blood of all patients in this trial who had a complete cytogenetic remission. METHODS: Levels of BCR-ABL transcripts were measured by a quantitative real-time polymerase-chain-reaction assay. Results were expressed relative to the median level of BCR-ABL transcripts in the blood of 30 patients with untreated CML in chronic phase. RESULTS: In patients who had a complete cytogenetic remission, levels of BCR-ABL transcripts after 12 months of treatment had fallen by at least 3 log in 57 percent of those in the imatinib group and 24 percent of those in the group given interferon plus cytarabine (P=0.003). On the basis of the rates of complete cytogenetic remission of 68 percent in the imatinib group and 7 percent in the group given interferon plus cytarabine at 12 months, an estimated 39 percent of all patients treated with imatinib but only 2 percent of all those given interferon plus cytarabine had a reduction in BCR-ABL transcript levels of at least 3 log (P<0.001). For patients who had a complete cytogenetic remission and a reduction in transcript levels of at least 3 log at 12 months, the probability of remaining progression-free was 100 percent at 24 months, as compared with 95 percent for such patients with a reduction of less than 3 log and 85 percent for patients who were not in complete cytogenetic remission at 12 months (P<0.001). CONCLUSIONS: The proportion of patients with CML who had a reduction in BCR-ABL transcript levels of at least 3 log by 12 months of therapy was far greater with imatinib treatment than with treatment with interferon plus cytarabine. Patients in the imatinib group with this degree of molecular response had a negligible risk of disease progression during the subsequent 12 months.	Inst Med & Vet Sci, Div Haematol, Adelaide, SA 5000, Australia; Hammersmith Hosp, London, England; Heidelberg Univ, Klinikum Mannheim, Med Klin 3, Mannheim, Germany; Novartis Pharmaceut, Basel, Switzerland; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	Institute Medical & Veterinary Science Australia; Imperial College London; Ruprecht Karls University Heidelberg; Novartis; Fred Hutchinson Cancer Center	Hughes, TP (corresponding author), Inst Med & Vet Sci, Div Haematol, Adelaide, SA 5000, Australia.	timothy.hughes@imvs.sa.gov.au	Agha, Mounzer/AAC-2520-2022; Hughes, Tim/AAO-9975-2021; Fernandez, Manuel/M-9168-2013; Kovacs, Michael/G-3315-2011; Seymour, John/K-7326-2019; Branford, Susan/X-7733-2019; Devine, Steven/AAS-7644-2021; Blaise, Didier/R-2483-2016; Bjerrum, Ole Weis/AAF-9999-2019; Arthur, Chris/ABG-7286-2022	Seymour, John/0000-0003-2188-6835; Blaise, Didier/0000-0002-5684-9447; Arthur, Chris/0000-0002-9147-9090; Branford, Susan/0000-0002-5095-7981; Hochhaus, Andreas/0000-0003-0626-0834				Baccarani M, 2002, BLOOD, V99, P1527, DOI 10.1182/blood.V99.5.1527; Bonifazi F, 2001, BLOOD, V98, P3074, DOI 10.1182/blood.V98.10.3074; Branford S, 1999, BRIT J HAEMATOL, V107, P587; Buchdunger E, 1996, CANCER RES, V56, P100; CROSS NCP, 1993, BLOOD, V82, P1929; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Delannoy A, 1997, J NATL CANCER I, V89, P1616; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Emig M, 1999, LEUKEMIA, V13, P1825, DOI 10.1038/sj.leu.2401566; Goldman JM, 2001, BLOOD, V98, P2039, DOI 10.1182/blood.V98.7.2039; Guilhot F, 1997, NEW ENGL J MED, V337, P223, DOI 10.1056/NEJM199707243370402; Hasford J, 1998, JNCI-J NATL CANCER I, V90, P850, DOI 10.1093/jnci/90.11.850; Hochhaus A, 2000, BLOOD, V95, P62; Hochhaus A, 1996, BLOOD, V87, P1549, DOI 10.1182/blood.V87.4.1549.bloodjournal8741549; Hughes T, 2003, SEMIN HEMATOL, V40, P62, DOI 10.1053/shem.2003.50044; HUGHES TP, 1991, BLOOD, V77, P874; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Kantarjian HM, 2003, BLOOD, V101, P97, DOI 10.1182/blood-2002-02-0545; Kurzrock R, 1998, J CLIN ONCOL, V16, P1526, DOI 10.1200/JCO.1998.16.4.1526; Lin F, 1996, BLOOD, V87, P4473, DOI 10.1182/blood.V87.10.4473.bloodjournal87104473; LION T, 1995, LEUKEMIA, V9, P1353; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Mackinnon S, 1996, BONE MARROW TRANSPL, V17, P643; Mahon FX, 2002, J CLIN ONCOL, V20, P214, DOI 10.1200/JCO.20.1.214; Merx K, 2002, LEUKEMIA, V16, P1579, DOI 10.1038/sj.leu.2402680; MIYAMURA K, 1993, BLOOD, V81, P1089; Morley A, 1998, NEW ENGL J MED, V339, P627, DOI 10.1056/NEJM199808273390911; Mughal TI, 2001, BRIT J HAEMATOL, V115, P569, DOI 10.1046/j.1365-2141.2001.03155.x; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Olavarria E, 2001, BLOOD, V97, P1560, DOI 10.1182/blood.V97.6.1560; Preudhomme C, 1999, LEUKEMIA, V13, P957, DOI 10.1038/sj.leu.2401426; Radich JP, 2001, BLOOD, V98, P1701, DOI 10.1182/blood.V98.6.1701; ROTH MS, 1992, BLOOD, V79, P276; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; SOKAL JE, 1988, SEMIN HEMATOL, V25, P49; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; VANRHEE F, 1995, LEUKEMIA, V9, P329; Wang L, 2002, BRIT J HAEMATOL, V118, P771, DOI 10.1046/j.1365-2141.2002.03705.x	40	948	1001	1	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 9	2003	349	15					1423	1432		10.1056/NEJMoa030513	http://dx.doi.org/10.1056/NEJMoa030513			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	729JF	14534335				2022-12-28	WOS:000185769500005
J	Deng, YB; Ren, XY; Yang, L; Lin, YH; Wu, XW				Deng, YB; Ren, XY; Yang, L; Lin, YH; Wu, XW			A JNK-dependent pathway is required for TNF alpha-induced apoptosis	CELL			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION PATHWAY; INDUCED CELL-DEATH; CYTOCHROME-C; CASPASE ACTIVATION; MITOCHONDRIA; INDUCTION; INHIBITION; PROMOTES; PROTEIN	Tumor necrosis factor (TNFalpha) receptor signaling can simultaneously activate caspase 8, the transcription factor, NF-KB and the kinase, JNK. While activation of caspase 8 is required for TNFalpha-induced apoptosis, and induction of NF-KB inhibits cell death, the precise function of JNK activation in TNFa signaling is not clearly understood. Here, we report that TNFalpha-mediated caspase 8 cleavage and apoptosis require a sequential pathway involving JNK, Bid, and Smac/DIABLO. Activation of JNK induces caspase 8-independent cleavage of Bid at a distinct site to generate the Bid cleavage product jBid. Translocation of jBid to mitochondria leads to preferential release of Smac/DIABLO, but not cytochrome c. The released Smac/DIABLO then disrupts the TRAF2-cIAP1 complex. We propose that the JNK pathway described here is required to relieve the inhibition imposed by TRAF2-cIAP1 on caspase 8 activation and induction of apoptosis. Further, our findings define a mechanism for crosstalk between intrinsic and extrinsic cell death pathways.	Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Wu, XW (corresponding author), Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA.		ren, xianyan/J-3165-2018	Deng, Yibin/0000-0001-5711-3565				Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hunter AM, 2003, J BIOL CHEM, V278, P7494, DOI 10.1074/jbc.C200695200; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LUO ZG, 1996, CELL, V94, P481; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Moreno E, 2002, CURR BIOL, V12, P1263, DOI 10.1016/S0960-9822(02)00954-5; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; Rennefahrt UEE, 2002, J BIOL CHEM, V277, P29510, DOI 10.1074/jbc.M203010200; Reuther JY, 1999, J BIOL CHEM, V274, P20664, DOI 10.1074/jbc.274.29.20664; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; VAN AD, 1996, SCIENCE, V274, P787; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XD, 2001, GENE DEV, V15, P2922; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	44	474	494	1	34	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 3	2003	115	1					61	70		10.1016/S0092-8674(03)00757-8	http://dx.doi.org/10.1016/S0092-8674(03)00757-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14532003	Bronze			2022-12-28	WOS:000185815500009
J	Kim, D; Park, D; Choi, S; Lee, S; Sun, M; Kim, C; Shin, HS				Kim, D; Park, D; Choi, S; Lee, S; Sun, M; Kim, C; Shin, HS			Thalamic control of visceral nociception mediated by T-type Ca2+ channels	SCIENCE			English	Article							THALAMOCORTICAL RELAY; CALCIUM CHANNELS; DORSAL COLUMN; SPINAL-CORD; NEURONS; BURST; RESPONSES; PATHWAY; NUCLEUS; RATS	Sensations from viscera, like fullness, easily become painful if the stimulus persists. Mice lacking alpha1GT-typeCa(2+) channels show hyperalgesia to visceral pain. Thalamic infusion of a T-type blocker induced similar hyperalgesia in wild-type mice. In response to visceral pain, the ventroposterolateral thalamic neurons evoked a surge of single spikes, which then slowly decayed as T type-dependent burst spikes gradually increased. In alpha1G-deficient neurons, the single-spike response persisted without burst spikes. These results indicate that T-type Ca2+ channels underlie an antinociceptive mechanism operating in the thalamus and support the idea that burst. ring plays a critical role in sensory gating in the thalamus.	Korea Inst Sci & Technol, Natl Creat Res Initiat Ctr Calcium & Learning, Seoul 136791, South Korea	Korea Institute of Science & Technology (KIST)	Shin, HS (corresponding author), Korea Inst Sci & Technol, Natl Creat Res Initiat Ctr Calcium & Learning, Seoul 136791, South Korea.	shin@kist.re.kr	Kim, Daesoo/C-1625-2011	Kim, Daesoo/0000-0001-9915-1463				AlChaer ED, 1996, J NEUROPHYSIOL, V76, P2661, DOI 10.1152/jn.1996.76.4.2661; BAL T, 1993, J PHYSIOL-LONDON, V468, P669, DOI 10.1113/jphysiol.1993.sp019794; Clozel JP, 1997, J HYPERTENS, V15, pS17, DOI 10.1097/00004872-199715055-00004; CRUNELLI V, 1989, J PHYSIOL-LONDON, V413, P543, DOI 10.1113/jphysiol.1989.sp017668; Dogrul A, 1998, GEN PHARMACOL-VASC S, V30, P613, DOI 10.1016/S0306-3623(97)00335-2; GUIDO W, 1992, J NEUROPHYSIOL, V68, P2199, DOI 10.1152/jn.1992.68.6.2199; Huguenard JR, 1996, ANNU REV PHYSIOL, V58, P329, DOI 10.1146/annurev.physiol.58.1.329; JAHNSEN H, 1984, J PHYSIOL-LONDON, V349, P205, DOI 10.1113/jphysiol.1984.sp015153; Jeanmonod D, 1996, BRAIN, V119, P363, DOI 10.1093/brain/119.2.363; Kim D, 2001, NEURON, V31, P35, DOI 10.1016/S0896-6273(01)00343-9; Le Masson G, 2002, NATURE, V417, P854, DOI 10.1038/nature00825; Llinas R, 2001, ANN NY ACAD SCI, V929, P166; LLINAS R, 1982, NATURE, V297, P406, DOI 10.1038/297406a0; Matthews EA, 2001, EUR J PHARMACOL, V415, P141, DOI 10.1016/S0014-2999(01)00812-3; MCCORMICK DA, 1990, NEUROSCIENCE, V39, P103, DOI 10.1016/0306-4522(90)90225-S; Millan MJ, 1999, PROG NEUROBIOL, V57, P1, DOI 10.1016/S0301-0082(98)00048-3; Mogil JS, 1999, PAIN, V80, P67, DOI 10.1016/S0304-3959(98)00197-3; Montero VM, 1999, NEUROSCIENCE, V91, P805, DOI 10.1016/S0306-4522(98)00632-0; SEYBOLD VS, 1995, CAN J PHYSIOL PHARM, V73, P1007, DOI 10.1139/y95-141; Sherman SM, 2001, TRENDS NEUROSCI, V24, P122, DOI 10.1016/S0166-2236(00)01714-8; Sherman SM, 2001, NAT NEUROSCI, V4, P344, DOI 10.1038/85973; STERIADE M, 1988, PHYSIOL REV, V68, P649, DOI 10.1152/physrev.1988.68.3.649; STERIADE M, 1984, BRAIN RES REV, V8, P1, DOI 10.1016/0165-0173(84)90017-1; Steriade M, 2001, NAT NEUROSCI, V4, P671, DOI 10.1038/89434; Steriade M., 1997, THALAMUS; Talley EM, 1999, J NEUROSCI, V19, P1895; Todorovic SM, 2002, BRAIN RES, V951, P336, DOI 10.1016/S0006-8993(02)03350-4; Todorovic SM, 2001, NEURON, V31, P75, DOI 10.1016/S0896-6273(01)00338-5; Willis WD, 1999, P NATL ACAD SCI USA, V96, P7675, DOI 10.1073/pnas.96.14.7675	29	190	200	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	2003	302	5642					117	119		10.1126/science.1088886	http://dx.doi.org/10.1126/science.1088886			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526084				2022-12-28	WOS:000185678500049
J	Nease, DE; Aikens, JE				Nease, DE; Aikens, JE			DSM depression and anxiety criteria and severity of symptoms in primary care: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							DISORDERS		Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Nease, DE (corresponding author), Univ Michigan, Dept Family Med, 1018 Fuller St, Ann Arbor, MI 48109 USA.		Nease, Donald/B-6206-2013	Nease, Donald/0000-0001-8323-3720	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [D32PE016033, D32PE010158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R03AA009496] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09496] Funding Source: Medline; BHP HRSA HHS [D32-PE16033, D32-PE10158] Funding Source: Medline	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); BHP HRSA HHS		Goldberg D, 1996, BRIT J PSYCHIAT, V168, P44, DOI 10.1192/S0007125000298401; Goldberg D., 2000, COMPR PSYCHIAT S1, V41, pS8; Nease D E Jr, 1999, J Am Board Fam Pract, V12, P21; Nease DE, 2002, J FAM PRACTICE, V51, P1065; Volk RJ, 1997, ALCOHOL CLIN EXP RES, V21, P899, DOI 10.1111/j.1530-0277.1997.tb03855.x	5	11	12	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 1	2003	327	7422					1030	+		10.1136/bmj.327.7422.1030	http://dx.doi.org/10.1136/bmj.327.7422.1030			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738NE	14593040	Green Published, Bronze			2022-12-28	WOS:000186294100025
J	Hoang, QQ; Sicheri, F; Howard, AJ; Yang, DSC				Hoang, QQ; Sicheri, F; Howard, AJ; Yang, DSC			Bone recognition mechanism of porcine osteocalcin from crystal structure	NATURE			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; PROTEIN	Osteocalcin is the most abundant noncollagenous protein in bone(1), and its concentration in serum is closely linked to bone metabolism and serves as a biological marker for the clinical assessment of bone disease(2). Although its precise mechanism of action is unclear, osteocalcin influences bone mineralization(3,4), in part through its ability to bind with high affinity to the mineral component of bone, hydroxyapatite(5). In addition to binding to hydroxyapatite, osteocalcin functions in cell signalling and the recruitment of osteoclasts(6) and osteoblasts(7), which have active roles in bone resorption and deposition, respectively. Here we present the X-ray crystal structure of porcine osteocalcin at 2.0 Angstrom resolution, which reveals a negatively charged protein surface that coordinates five calcium ions in a spatial orientation that is complementary to calcium ions in a hydroxyapatite crystal lattice. On the basis of our findings, we propose a model of osteocalcin binding to hydroxyapatite and draw parallels with other proteins that engage crystal lattices.	McMaster Univ, Fac Hlth Sci, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; Microstar Biotech Inc, Flamborough, ON L9H 7H9, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; IIT, Dept Biol Chem & Phys Sci, Chicago, IL 60616 USA	McMaster University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Illinois Institute of Technology	Yang, DSC (corresponding author), McMaster Univ, Fac Hlth Sci, Dept Biochem, Hamilton, ON L8N 3Z5, Canada.	yang@mcmaster.ca	ID, IMCACAT/D-5867-2014; Sicheri, Frank/F-8856-2013					ATKINSON RA, 1995, EUR J BIOCHEM, V232, P515, DOI 10.1111/j.1432-1033.1995.515zz.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bodine PVN, 1999, BONE, V25, P535, DOI 10.1016/S8756-3282(99)00213-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calvo MS, 1996, ENDOCR REV, V17, P333, DOI 10.1210/er.17.4.333; CHENU C, 1994, J CELL BIOL, V127, P1149, DOI 10.1083/jcb.127.4.1149; COLOMBO G, 1993, J BONE MINER RES, V8, P733; Davies PL, 2002, PHILOS T R SOC B, V357, P927, DOI 10.1098/rstb.2002.1081; DeLano W.L, PYMOL MOL GRAPHICS S; Dowd TL, 2003, BIOCHEMISTRY-US, V42, P7769, DOI 10.1021/bi034470s; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Eppell SJ, 2001, J ORTHOPAED RES, V19, P1027, DOI 10.1016/S0736-0266(01)00034-1; HAUSCHKA PV, 1978, DEV BIOL, V65, P426, DOI 10.1016/0012-1606(78)90038-6; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; HOHM L, 1993, J MOL BIOL, V233, P123; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KAY MI, 1964, NATURE, V204, P1050, DOI 10.1038/2041050a0; Klein C., 1999, MANUAL MINERALOGY, V21st; Laue TM, 1992, BIOCH POLYM SCI; MUNDY GR, 1983, CALCIFIED TISSUE INT, V35, P164, DOI 10.1007/BF02405025; ONUMA K, 1995, J CRYST GROWTH, V154, P118, DOI 10.1016/0022-0248(95)00201-4; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PASTOUREAU P, 1993, J BONE MINER RES, V8, P1417; POSER JW, 1979, J BIOL CHEM, V254, P431; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Yang DSC, 1998, BIOPHYS J, V74, P2142, DOI 10.1016/S0006-3495(98)77923-8; Ziv V, 1996, BONE, V18, P417, DOI 10.1016/8756-3282(96)00049-X	30	406	420	5	112	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 30	2003	425	6961					977	980		10.1038/nature02079	http://dx.doi.org/10.1038/nature02079			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14586470				2022-12-28	WOS:000186230600045
J	Wharton, B; Bishop, N				Wharton, B; Bishop, N			Rickets	LANCET			English	Review							VITAMIN-D DEFICIENCY; BONE-MINERAL CONTENT; SERUM 25(OH)D CONCENTRATION; BIRTH-WEIGHT INFANTS; NUTRITIONAL RICKETS; RISK-FACTORS; ALKALINE-PHOSPHATASE; SUNSHINE EXPOSURE; D SUPPLEMENTATION; AFRICAN-AMERICAN	Rickets, once thought vanquished, is reappearing. In some less developed countries it hardly went away. This seminar reviews the effects of genes, stage of development, and environment on clinical expression of the disease. Rickets can be secondary to disorders of the gut, pancreas, liver, kidney, or metabolism; however, it is mostly due to nutrient deficiency and we concentrate on this form. Although calcium deficiency contributes in communities where little cows' milk is consumed, deficiency of vitamin D is the main cause. There are three major problems: the promotion of exclusive breastfeeding for long periods without vitamin D supplementation, particularly for babies whose mothers are vitamin D deficient; reduced opportunities for production of the vitamin in the skin because of female modesty and fear of skin cancer; and the high prevalence of rickets in immigrant groups in more temperate regions. A safety net of extra dietary vitamin D should be re-emphasised, not only for children but also for pregnant women. The reason why many immigrant children in temperate zones have vitamin D deficiency is unclear. We speculate that in addition to differences in genetic factors, sun exposure, and skin pigmentation, iron deficiency may affect vitamin D handling in the skin or gut or its intermediary metabolism.	Inst Child Hlth, MRC, Childhood Nutr Res Ctr, London WC1N 1EH, England; Univ Sheffield, Sheffield Childrens Hosp, Acad Unit Child Hlth, Sheffield, S Yorkshire, England	University of London; University College London; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Sheffield	Wharton, B (corresponding author), Inst Child Hlth, MRC, Childhood Nutr Res Ctr, 30 Guilford St, London WC1N 1EH, England.	bwharton@ich.ucl.ac.uk						ABRAMS SA, 1988, J PEDIATR-US, V112, P956, DOI 10.1016/S0022-3476(88)80226-9; Agarwal KS, 2002, ARCH DIS CHILD, V87, P111, DOI 10.1136/adc.87.2.111; Akpede GO, 1999, J R SOC PROMO HEALTH, V119, P216, DOI 10.1177/146642409911900403; Al-Jurayyan NA, 2002, SAUDI MED J, V23, P182; ALAGEEL A, 1993, CLIN ENDOCRINOL, V39, P229, DOI 10.1111/j.1365-2265.1993.tb01779.x; Albar MA, 2002, SAUDI MED J, V23, P627; Andiran N, 2002, NUTRITION, V18, P47, DOI 10.1016/S0899-9007(01)00724-9; [Anonymous], 1991, Rep Health Soc Subj (Lond), V41, P1; Awumey EMK, 1998, J CLIN ENDOCR METAB, V83, P169, DOI 10.1210/jc.83.1.169; Bailey DA, 2000, J BONE MINER RES, V15, P2245, DOI 10.1359/jbmr.2000.15.11.2245; BEGUM R, 1968, LANCET, V1, P1048; Bereket A, 2000, EUR J PEDIATR, V159, P70, DOI 10.1007/PL00013807; BEYERS N, 1994, BONE, V15, P5, DOI 10.1016/8756-3282(94)90884-2; Bischof F, 2002, DEV MED CHILD NEUROL, V44, P119, DOI 10.1017/S0012162201001773; Bishop N, 1999, NEW ENGL J MED, V341, P602, DOI 10.1056/NEJM199908193410810; BISHOP N, 1989, ARCH DIS CHILD, V64, P1403, DOI 10.1136/adc.64.10_Spec_No.1403; BISHOP NJ, 1993, ARCH DIS CHILD-FETAL, V68, P573, DOI 10.1136/adc.68.5_Spec_No.573; BLOC BH, 2000, NZ MED J, V113, P374; BROOKE OG, 1981, BMJ-BRIT MED J, V283, P1024, DOI 10.1136/bmj.283.6298.1024; Bulloch B, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e48; Carvalho NF, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.4.e46; Chali D, 1998, ETHIOPIAN MED J, V36, P227; Cheney M C, 2000, Public Health Rev, V28, P171; Chesney R W, 2001, Rev Endocr Metab Disord, V2, P145, DOI 10.1023/A:1010071426415; CHESNEY RW, 1998, ARCH PEDIAT ADOLESC, V152, P1243; Chick H, 1922, LANCET, V2, P7; CLAYTON BE, 1994, CLIN BIOCH SICK CHIL; CLEMENS TL, 1982, LANCET, V1, P74; CLEMENTS MR, 1992, CLIN ENDOCRINOL, V37, P17, DOI 10.1111/j.1365-2265.1992.tb02278.x; CLEMENTS MR, 1987, NATURE, V325, P62, DOI 10.1038/325062a0; CONGDON PJ, 1990, ARCH DIS CHILD-FETAL, V65, P1038, DOI 10.1136/adc.65.10_Spec_No.1038; Cornish Daryl A., 2000, Biofactors, V11, P35; Daniels ED, 2000, EUR J PEDIATR, V159, P730, DOI 10.1007/PL00008336; Darnton-Hill I, 2002, P NUTR SOC, V61, P231, DOI 10.1079/PNS2002150; Davies PSW, 1999, EUR J CLIN NUTR, V53, P195, DOI 10.1038/sj.ejcn.1600697; de Beur SMJ, 2002, J CLIN ENDOCR METAB, V87, P2467, DOI 10.1210/jc.87.6.2467; DELARCO C, 1992, J INTELL DISABIL RES, V36, P251; DICKERSON JWT, 1962, BIOCHEM J, V82, P56, DOI 10.1042/bj0820056; DOXIADIS S, 1976, ARCH DIS CHILD, V51, P83, DOI 10.1136/adc.51.2.83; Du XQ, 2001, AM J CLIN NUTR, V74, P494; Duplechin RY, 1999, ANN EMERG MED, V34, P399, DOI 10.1016/S0196-0644(99)70137-X; EEK S, 1957, PEDIATRICS, V20, P63; Faerk J, 2000, PEDIATR RES, V47, P148, DOI 10.1203/00006450-200001000-00025; Faerk J, 2002, ARCH DIS CHILD-FETAL, V87, pF133, DOI 10.1136/fn.87.2.F133; FEILLET F, 1988, PEDIATRIE, V43, P775; Fewtrell MS, 2000, J PEDIATR-US, V137, P668, DOI 10.1067/mpd.2000.108953; Fischer PR, 2000, J BONE MINER RES, V15, P2206, DOI 10.1359/jbmr.2000.15.11.2206; FOMON SJ, 1982, AM J CLIN NUTR, V35, P1169, DOI 10.1093/ajcn/35.5.1169; Gaffney P, 2001, Eur J Emerg Med, V8, P159; Gartner LM, 2003, PEDIATRICS, V111, P908, DOI 10.1542/peds.111.4.908; Gartner LM, 1997, PEDIATRICS, V100, P1035, DOI 10.1542/peds.100.6.1035; Glendenning P, 2003, AM J CLIN NUTR, V77, P522, DOI 10.1093/ajcn/77.2.522; Grant WB, 2002, CANCER-AM CANCER SOC, V94, P272, DOI 10.1002/cncr.10196; GREGORY J, 2000, NATL DIET NUTR SURVE, P796; GREGORY JR, 1995, NATIONAL DIET NUTR S, P1; GRINDULIS H, 1986, ARCH DIS CHILD, V61, P843, DOI 10.1136/adc.61.9.843; Guillemant J, 1998, ARCH PEDIATRIE, V5, P1211, DOI 10.1016/S0929-693X(98)81235-9; HANAFY M. MAMDOUH, 1967, J TROP PEDIAT AFR CHILD HEALTH, V13, P19; Haschke F, 1983, Acta Paediatr Scand Suppl, V307, P1; HELDENBERG D, 1992, AM J CLIN NUTR, V56, P533, DOI 10.1093/ajcn/56.3.533; HO ML, 1985, J PEDIATR-US, V107, P928, DOI 10.1016/S0022-3476(85)80192-X; Holick MF, 2003, J CELL BIOCHEM, V88, P296, DOI 10.1002/jcb.10338; HOLICK MF, 1981, J INVEST DERMATOL, V77, P51, DOI 10.1111/1523-1747.ep12479237; Huldschinsky K., 1920, Z ORTHOP CHIR, V39, P426; Hypponen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140-6736(01)06580-1; Jablonski NG, 2000, J HUM EVOL, V39, P57, DOI 10.1006/jhev.2000.0403; JACOBI A, 1985, EUR J PEDIATR, V143, P219; Karrar ZA, 1998, ANN TROP PAEDIATR, V18, pS89, DOI 10.1080/02724936.1998.11833490; Klein GL, 2002, PEDIATR TRANSPLANT, V6, P136, DOI 10.1034/j.1399-3046.2002.01060.x; KOO WWK, 1989, J PEDIATR ORTHOPED, V9, P326, DOI 10.1097/01202412-198909030-00012; Kreiter SR, 2000, J PEDIATR-US, V137, P153, DOI 10.1067/mpd.2000.109009; KUOPPALA T, 1986, HUM NUTR-CLIN NUTR, V40C, P287; Kutluk G, 2002, J TROP PEDIATRICS, V48, P351, DOI 10.1093/tropej/48.6.351; LADIZESKY M, 1995, J BONE MINER RES, V10, P545; Lawson M, 1999, BRIT MED J, V318, P28, DOI 10.1136/bmj.318.7175.28; Lehtonen-Veromaa M, 2002, EUR J CLIN NUTR, V56, P431, DOI 10.1038/sj.ejcn.1601330; LO CW, 1986, AM J CLIN NUTR, V44, P683, DOI 10.1093/ajcn/44.5.683; Looker AC, 2002, BONE, V30, P771, DOI 10.1016/S8756-3282(02)00692-0; Lopez Segura N, 2002, An Esp Pediatr, V57, P227; LUCAS A, 1989, ARCH DIS CHILD-FETAL, V64, P902, DOI 10.1136/adc.64.7_Spec_No.902; Lulseged S, 1999, E AFR MED J, V76, P457; Madelenat P, 2001, J Gynecol Obstet Biol Reprod (Paris), V30, P761; MAHOMED K, 2003, COCHRANE LIB; MALMBERG N., 1942, Acta Paediatrica, V28, P367, DOI 10.1111/j.1651-2227.1942.tb16394.x; MARKS R, 1995, ARCH DERMATOL, V131, P415, DOI 10.1001/archderm.131.4.415; MARX SJ, 1986, CLIN ENDOCRINOL, V25, P373, DOI 10.1111/j.1365-2265.1986.tb01703.x; McGrath J, 2001, MED HYPOTHESES, V56, P367, DOI 10.1054/mehy.2000.1226; Mellanby E, 1919, LANCET, V1, P407; MILLS AM, 1992, FOOD NUTR INTAKES BR, P1; Molla AM, 2000, PEDIATR INT, V42, P280, DOI 10.1046/j.1442-200x.2000.01230.x; Moyer-Mileur LJ, 2000, PEDIATRICS, V106, P1088, DOI 10.1542/peds.106.5.1088; Mughal MZ, 1999, BRIT MED J, V318, P39, DOI 10.1136/bmj.318.7175.39; Muhe L, 1997, LANCET, V349, P1801, DOI 10.1016/S0140-6736(96)12098-5; Narchi H, 2001, ARCH DIS CHILD, V84, P501, DOI 10.1136/adc.84.6.501; Narchi H, 2001, J PEDIATR ENDOCR MET, V14, P329; Nesby-O'Dell S, 2002, AM J CLIN NUTR, V76, P187, DOI 10.1093/ajcn/76.1.187; Ness AR, 1999, BRIT MED J, V319, P114, DOI 10.1136/bmj.319.7202.114; Nozza JM, 2001, MED J AUSTRALIA, V175, P253, DOI 10.5694/j.1326-5377.2001.tb143559.x; Oginni LM, 1999, LANCET, V353, P296, DOI 10.1016/S0140-6736(05)74931-X; Olson E B Jr, 1973, World Rev Nutr Diet, V17, P164; Ozsoylu S, 2000, EUR J PEDIATR, V159, P931; Parfitt A. M., 1997, Vitamin D., P645; Park MJ, 1998, J PEDIATR-US, V132, P641, DOI 10.1016/S0022-3476(98)70353-1; PARK W, 1987, EUR J PEDIATR, V146, P292, DOI 10.1007/BF00716477; Pettifor JM, 1996, S AFR MED J, V86, P1270; PETTIFOR JM, 1984, S AFR MED J, V65, P549; Pettifor JM, 2002, CALCIFIED TISSUE INT, V70, P398, DOI 10.1007/s00223-001-0046-x; PETTIFOR JM, 1978, J PEDIATR-US, V92, P320, DOI 10.1016/S0022-3476(78)80035-3; PITTARD WB, 1990, AM J DIS CHILD, V144, P36, DOI 10.1001/archpedi.1990.02150250042028; PURVIS RJ, 1973, LANCET, V2, P811; Rowe PM, 2001, LANCET, V357, P1100, DOI 10.1016/S0140-6736(00)04315-4; RUBINACCI A, 1993, ACTA PAEDIATR, V82, P711, DOI 10.1111/j.1651-2227.1993.tb12543.x; Rucker D, 2002, CAN MED ASSOC J, V166, P1517; Salle BL, 2000, AM J CLIN NUTR, V71, p1317S, DOI 10.1093/ajcn/71.5.1317s; Sanchez CP, 2001, SEMIN NEPHROL, V21, P441, DOI 10.1053/snep.2001.24938; SCOTT JH, 1982, INTRO DENT ANATOMY, P122; SCRIVER CR, 1978, NEW ENGL J MED, V299, P976, DOI 10.1056/NEJM197811022991803; Shaw NJ, 2002, ARCH DIS CHILD, V86, P147, DOI 10.1136/adc.86.3.147; Sifarns G, 1936, J PEDIATR-US, V9, P1, DOI 10.1016/S0022-3476(36)80032-8; SWEET RA, 1980, ANN INTERN MED, V93, P279, DOI 10.7326/0003-4819-93-2-279; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; Tanner JM., 1983, ASSESSMENT SKELETAL; Thacher TD, 2000, J TROP PEDIATRICS, V46, P132, DOI 10.1093/tropej/46.3.132; Thacher TD, 1999, NEW ENGL J MED, V341, P563, DOI 10.1056/NEJM199908193410803; Uysal S, 1999, PEDIATR CARDIOL, V20, P283, DOI 10.1007/s002469900464; van der Mei IAF, 2001, NEUROEPIDEMIOLOGY, V20, P168, DOI 10.1159/000054783; Vieth R, 2000, J BONE MINER RES, V15, pS231; VONSYDOW G, 1946, ACTA PAEDIATR SCA S2, V33, P1; WEBB AR, 1988, J CLIN ENDOCR METAB, V67, P373, DOI 10.1210/jcem-67-2-373; WHARTON BA, 1982, ADVERSE EFFECTS FOOD, P397; WILTON P, 1995, CAN MED ASSOC J, V153, P740; Wu SX, 2002, ENDOCRINOLOGY, V143, P4135, DOI 10.1210/en.2002-220568; Youl P, 2002, INT J CANCER, V98, P92, DOI 10.1002/ijc.10117; Zamora SA, 1999, J CLIN ENDOCR METAB, V84, P4541, DOI 10.1210/jc.84.12.4541; Zhang ZB, 2000, J ANIM SCI, V78, P2868; ZIEGLER EE, 1976, GROWTH, V40, P329	139	226	251	0	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 25	2003	362	9393					1389	1400		10.1016/S0140-6736(03)14636-3	http://dx.doi.org/10.1016/S0140-6736(03)14636-3			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	735YX	14585642				2022-12-28	WOS:000186143300022
J	Hanczyc, MM; Fujikawa, SM; Szostak, JW				Hanczyc, MM; Fujikawa, SM; Szostak, JW			Experimental models of primitive cellular compartments: Encapsulation, growth, and division	SCIENCE			English	Article							MURCHISON CARBONACEOUS CHONDRITE; LARGE UNILAMELLAR VESICLES; FATTY-ACID MEMBRANES; MONTMORILLONITE CATALYSIS; SIZE DISTRIBUTION; EXTRUSION; SURFACE; RNA; POLYMERIZATION; COMPONENTS	The clay montmorillonite is known to catalyze the polymerization of RNA from activated ribonucleotides. Here we report that montmorillonite accelerates the spontaneous conversion of fatty acid micelles into vesicles. Clay particles often become encapsulated in these vesicles, thus providing a pathway for the prebiotic encapsulation of catalytically active surfaces within membrane vesicles. In addition, RNA adsorbed to clay can be encapsulated within vesicles. Once formed, such vesicles can grow by incorporating fatty acid supplied as micelles and can divide without dilution of their contents by extrusion through small pores. These processes mediate vesicle replication through cycles of growth and division. The formation, growth, and division of the earliest cells may have occurred in response to similar interactions with mineral particles and inputs of material and energy.	Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital	Szostak, JW (corresponding author), Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA.			Hanczyc, Martin/0000-0002-5453-2139	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Apel CL, 2002, BBA-BIOMEMBRANES, V1559, P1, DOI 10.1016/S0005-2736(01)00400-X; Aranda-Espinoza H, 1999, SCIENCE, V285, P394, DOI 10.1126/science.285.5426.394; Berclaz N, 2001, J PHYS CHEM B, V105, P1056, DOI 10.1021/jp001298i; Blochliger E, 1998, J PHYS CHEM B, V102, P10383, DOI 10.1021/jp981234w; CLERC SG, 1994, BIOPHYS J, V67, P475, DOI 10.1016/S0006-3495(94)80503-X; DEAMER DW, 1985, NATURE, V317, P792, DOI 10.1038/317792a0; DEAMER DW, 1989, ORIGINS LIFE EVOL B, V19, P21, DOI 10.1007/BF01808285; Dworkin JP, 2001, P NATL ACAD SCI USA, V98, P815, DOI 10.1073/pnas.98.3.815; Ertem G, 1997, J AM CHEM SOC, V119, P7197, DOI 10.1021/ja970422h; FERRIS JP, 1993, J AM CHEM SOC, V115, P12270, DOI 10.1021/ja00079a006; FERRIS JP, 1992, SCIENCE, V257, P1387, DOI 10.1126/science.1529338; Franchi M, 2003, ORIGINS LIFE EVOL B, V33, P1, DOI 10.1023/A:1023982008714; Frisken BJ, 2000, LANGMUIR, V16, P928, DOI 10.1021/la9905113; GEBICKI JM, 1973, NATURE, V243, P232, DOI 10.1038/243232a0; GEBICKI JM, 1976, CHEM PHYS LIPIDS, V16, P142, DOI 10.1016/0009-3084(76)90006-2; HAINES TH, 1983, P NATL ACAD SCI-BIOL, V80, P160, DOI 10.1073/pnas.80.1.160; HARGREAVES WR, 1978, BIOCHEMISTRY-US, V17, P3759, DOI 10.1021/bi00611a014; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Hunter DG, 1998, BIOPHYS J, V74, P2996, DOI 10.1016/S0006-3495(98)78006-3; Johnston WK, 2001, SCIENCE, V292, P1319, DOI 10.1126/science.1060786; Korgel BA, 1998, BIOPHYS J, V74, P3264, DOI 10.1016/S0006-3495(98)78033-6; Malinin VS, 2001, BIOCHEMISTRY-US, V40, P8292, DOI 10.1021/bi010570r; MAYER L, 1986, BIOCHIM BIOPHYS ACTA, V858, P61; McCollom TM, 1999, ORIGINS LIFE EVOL B, V29, P153, DOI 10.1023/A:1006592502746; Monnard PA, 2002, ASTROBIOLOGY, V2, P139, DOI 10.1089/15311070260192237; MUI BLS, 1995, BIOPHYS J, V69, P930, DOI 10.1016/S0006-3495(95)79967-2; NAYER R, 1989, BIOCHIM BIOPHYS ACTA, V986, P200; Ramos L, 1999, SCIENCE, V286, P2325, DOI 10.1126/science.286.5448.2325; Rushdi AI, 2001, ORIGINS LIFE EVOL B, V31, P103, DOI 10.1023/A:1006702503954; SMITH R, 1973, P NATL ACAD SCI USA, V70, P289, DOI 10.1073/pnas.70.2.289; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; Szostak JW, 2001, NATURE, V409, P387, DOI 10.1038/35053176; Traikia M, 2002, BIOPHYS J, V83, P1443, DOI 10.1016/S0006-3495(02)73915-5; WALDE P, 1994, J AM CHEM SOC, V116, P11649, DOI 10.1021/ja00105a004	34	576	593	11	215	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					618	622		10.1126/science.1089904	http://dx.doi.org/10.1126/science.1089904			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576428	Green Accepted			2022-12-28	WOS:000186119900051
J	King, MC; Marks, JH; Mandell, JB				King, MC; Marks, JH; Mandell, JB		New York Breast Canc Study Grp	Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2	SCIENCE			English	Article							ASHKENAZI JEWISH CARRIERS; FAMILY-HISTORY; PENETRANCE; WOMEN; PREVALENCE; FREQUENCY; SERIES; OOPHORECTOMY; INDIVIDUALS; MASTECTOMY	Risks of breast and ovarian cancer were determined for Ashkenazi Jewish women with inherited mutations in the tumor suppressor genes BRCA1 and BRCA2. We selected 1008 index cases, regardless of family history of cancer, and carried out molecular analysis across entire families. The lifetime risk of breast cancer among female mutation carriers was 82%, similar to risks in families with many cases. Risks appear to be increasing with time: Breast cancer risk by age 50 among mutation carriers born before 1940 was 24%, but among those born after 1940 it was 67%. Lifetime risks of ovarian cancer were 54% for BRCA1 and 23% for BRCA2 mutation carriers. Physical exercise and lack of obesity in adolescence were associated with significantly delayed breast cancer onset.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Sarah Lawrence Coll, Grad Program Human Genet, Bronxville, NY 10708 USA; Albert Einstein Coll Med, Montefiore Med Ctr, Bronx, NY USA; Beth Israel Med Ctr, New York, NY 10003 USA; Columbia Univ, Columbia Presbyterian Med Ctr, New York, NY 10027 USA; Englewood Hosp & Med Ctr, Englewood, NJ 07631 USA; Greenwich Hosp, Yale Canc Ctr, Greenwich, CT 06830 USA; Hackensack Univ, Med Ctr, Hackensack, NJ 07601 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; NYU, Med Ctr, New York, NY 10016 USA; N Shore Univ Hosp, Manhasset, NY 11030 USA; Stamford Hosp, Bennett Canc Ctr, Stamford, CT 06902 USA; Strang Canc Prevent Ctr, New York, NY USA; Univ Washington, Seattle, WA 98195 USA; White Plains Hosp Ctr, White Plains, NY 10601 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Sarah Lawrence College; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Beth Israel Deaconess Medical Center; Columbia University; NewYork-Presbyterian Hospital; Englewood Hospital & Medical Center; Hackensack University Medical Center; Memorial Sloan Kettering Cancer Center; New York University; Northwell Health; North Shore University Hospital; Stamford Hospital; University of Washington; University of Washington Seattle	King, MC (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.			Robson, Mark/0000-0002-3109-1692; King, Mary-Claire/0000-0001-9426-1743; Walsh, Tom/0000-0002-8875-0310; Norton, Larry/0000-0003-3701-9250				Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Begg CB, 2002, J NATL CANCER I, V94, P1221; Brose MS, 2002, J NATL CANCER I, V94, P1365, DOI 10.1093/jnci/94.18.1365; Carpenter CL, 2003, INT J CANCER, V106, P96, DOI 10.1002/ijc.11186; Colditz GA, 1996, J NATL CANCER I, V88, P365, DOI 10.1093/jnci/88.6.365; Fodor FH, 1998, AM J HUM GENET, V63, P45, DOI 10.1086/301903; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Foulkes WD, 2002, J MED GENET, V39, P407, DOI 10.1136/jmg.39.6.407; Frank TS, 2002, J CLIN ONCOL, V20, P1480, DOI 10.1200/JCO.20.6.1480; Hartmann LC, 2001, JNCI-J NATL CANCER I, V93, P1633, DOI 10.1093/jnci/93.21.1633; Hopper JL, 1999, CANCER EPIDEM BIOMAR, V8, P741; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; LevyLahad E, 1997, AM J HUM GENET, V60, P1059; Meijers-Heijboer H, 2001, NEW ENGL J MED, V345, P159, DOI 10.1056/NEJM200107193450301; Narod SA, 2002, NAT REV CANCER, V2, P113, DOI 10.1038/nrc726; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; Ponder BAJ, 2000, BRIT J CANCER, V83, P1301; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Ries LA, 2002, SEER CANC STAT REV 1; Risch HA, 2001, AM J HUM GENET, V68, P700, DOI 10.1086/318787; Satagopan JM, 2002, CLIN CANCER RES, V8, P3776; Satagopan JM, 2001, CANCER EPIDEM BIOMAR, V10, P467; Scheuer L, 2002, J CLIN ONCOL, V20, P1260, DOI 10.1200/JCO.2002.20.5.1260; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Thorlacius S, 1998, LANCET, V352, P1337, DOI 10.1016/S0140-6736(98)03300-5; Warner E, 1999, J NATL CANCER I, V91, P1241, DOI 10.1093/jnci/91.14.1241	27	1590	1648	2	168	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					643	646		10.1126/science.1088759	http://dx.doi.org/10.1126/science.1088759			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576434				2022-12-28	WOS:000186119900059
J	Brennan, M; Penn, MS; Van Lente, F; Nambi, V; Shishehbor, MH; Aviles, RJ; Goormastic, M; Pepoy, ML; McErlean, ES; Topol, EJ; Nissen, SE; Hazen, SL				Brennan, M; Penn, MS; Van Lente, F; Nambi, V; Shishehbor, MH; Aviles, RJ; Goormastic, M; Pepoy, ML; McErlean, ES; Topol, EJ; Nissen, SE; Hazen, SL			Prognostic value of myeloperoxidase in patients with chest pain	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE CORONARY SYNDROMES; UNSTABLE ANGINA-PECTORIS; C-REACTIVE PROTEIN; TROPONIN-I; INFLAMMATION; ATHEROSCLEROSIS; NEUTROPHIL; INHIBITOR; LESIONS; SERUM	BACKGROUND: Inflammation is linked to adverse outcomes in acute coronary syndromes. Myeloperoxidase, an abundant leukocyte enzyme, is elevated in culprit lesions that have fissured or ruptured in patients with sudden death from cardiac causes. Numerous lines of evidence suggest mechanistic links between myeloperoxidase and both inflammation and cardiovascular disease. METHODS: We assessed the value of plasma levels of myeloperoxidase as a predictor of the risk of cardiovascular events in 604 sequential patients presenting to the emergency department with chest pain. RESULTS: Initial plasma myeloperoxidase levels predicted the risk of myocardial infarction, even in patients who are negative for troponin T (<0.1 ng per milliliter) at base line (P<0.001). Myeloperoxidase levels at presentation also predicted the risk of major adverse cardiac events (myocardial infarction, the need for revascularization, or death) within 30 days and 6 months after presentation (P<0.001). In patients without evidence of myocardial necrosis (defined as those who were negative for troponin T), the base-line myeloperoxidase levels independently predicted the risk of major adverse coronary events at 30 days (unadjusted 2nd, 3rd, and 4th quartile odds ratios, 2.2 [95 percent confidence interval, 1.1 to 4.6], 4.2 [95 percent confidence interval, 2.1 to 8.4], and 4.1 [95 percent confidence interval, 2.0 to 8.4], respectively) and at 6 months. CONCLUSIONS: A single initial measurement of plasma myeloperoxidase independently predicts the early risk of myocardial infarction, as well as the risk of major adverse cardiac events in the ensuing 30-day and 6-month periods. Myeloperoxidase levels, in contrast to troponin T, creatine kinase MB isoform, and C-reactive protein levels, identified patients at risk for cardiac events in the absence of myocardial necrosis, highlighting its potential usefulness for risk stratification among patients who present with chest pain.	Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Clin Pathol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Internal Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Hazen, SL (corresponding author), Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, 9500 Euclid Ave,NC10, Cleveland, OH 44195 USA.	hazens@ccf.org	Hazen, Stanley L/ABD-5845-2021	Topol, Eric/0000-0002-1478-4729	NATIONAL CANCER INSTITUTE [F32CA096348] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR018390] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061878, R01HL062526, R01HL070621] Funding Source: NIH RePORTER; NCI NIH HHS [CA96348] Funding Source: Medline; NCRR NIH HHS [M01 RR018390] Funding Source: Medline; NHLBI NIH HHS [HL61878, HL62526, HL70621] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524; Agner K., 1972, STRUCTURE FUNCTION O, P329; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Biasucci L M, 2001, Ital Heart J, V2, P164; Buffon A, 2002, NEW ENGL J MED, V347, P5, DOI 10.1056/NEJMoa012295; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; deServi S, 1996, AM J CARDIOL, V78, P564, DOI 10.1016/S0002-9149(96)00367-0; DINERMAN JL, 1990, J AM COLL CARDIOL, V15, P1559, DOI 10.1016/0735-1097(90)92826-N; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; McErlean ES, 2000, AM J CARDIOL, V85, P421, DOI 10.1016/S0002-9149(99)00766-3; Naruko T, 2002, CIRCULATION, V106, P2894, DOI 10.1161/01.CIR.0000042674.89762.20; Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200; Sabatine MS, 2002, CIRCULATION, V105, P1760, DOI 10.1161/01.CIR.0000015464.18023.0A; Schmitt D, 1999, BIOCHEMISTRY-US, V38, P16904, DOI 10.1021/bi991623w; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Shabani F, 1998, FREE RADICAL RES, V28, P115, DOI 10.3109/10715769809065797; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136	25	798	882	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 23	2003	349	17					1595	1604		10.1056/NEJMoa035003	http://dx.doi.org/10.1056/NEJMoa035003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734ZT	14573731	Bronze			2022-12-28	WOS:000186088400004
J	Gordon, AL; Susanto, RD; Vranes, K				Gordon, AL; Susanto, RD; Vranes, K			Cool Indonesian throughflow as a consequence of restricted surface layer flow	NATURE			English	Article							INDIAN-OCEAN; MAKASSAR STRAIT; HEAT-TRANSPORT; CLIMATE SYSTEM; PACIFIC; CIRCULATION; BUDGET; WATER; FLUXES; SEAS	Approximately 10 million m(3) s(-1) of water flow from the Pacific Ocean into the Indian Ocean through the Indonesian seas(1). Within the Makassar Strait, the primary pathway of the flow(2), the Indonesian throughflow is far cooler than estimated earlier, as pointed out recently on the basis of ocean current and temperature measurements(3,4). Here we analyse ocean current and stratification data along with satellite-derived wind measurements, and find that during the boreal winter monsoon, the wind drives buoyant, low-salinity Java Sea surface water into the southern Makassar Strait, creating a northward pressure gradient in the surface layer of the strait. This surface layer 'freshwater plug' inhibits the warm surface water from the Pacific Ocean from flowing southward into the Indian Ocean, leading to a cooler Indian Ocean sea surface(5-7), which in turnmay weaken the Asian monsoon(8). The summer wind reversal eliminates the obstructing pressure gradient, by transferring more- saline Banda Sea surface water into the southern Makassar Strait. The coupling of the southeast Asian freshwater budget to the Pacific and Indian Ocean surface temperatures by the proposed mechanism may represent an important negative feedback within the climate system.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA	Columbia University	Gordon, AL (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA.		Gordon, Arnold L/H-1049-2011; Susanto, Raden Dwi/ABE-2222-2021	Gordon, Arnold L/0000-0001-6480-6095; Susanto, Raden Dwi/0000-0003-1495-5951				Conkright M. E., 1998, 15 NAT OC DAT CTR; Ffield A, 2000, GEOPHYS RES LETT, V27, P237, DOI 10.1029/1999GL002377; Ganachaud A, 2003, J CLIMATE, V16, P696, DOI 10.1175/1520-0442(2003)016<0696:LSOHAF>2.0.CO;2; Ganachaud A, 2000, NATURE, V408, P453, DOI 10.1038/35044048; GODFREY S, 1996, J GEOPHYS RES, V101, P12217, DOI DOI 10.1029/95JC03860; Gordon A. L., 2001, OCEAN CIRCULATION CL, P303, DOI [10.1016/s0074-6142(01)80125-x, DOI 10.1016/S0074-6142(01)80125-X]; Gordon AL, 1999, GEOPHYS RES LETT, V26, P3325, DOI 10.1029/1999GL002340; Gordon AL, 1996, NATURE, V379, P146, DOI 10.1038/379146a0; HIRST AC, 1993, J PHYS OCEANOGR, V23, P1057, DOI 10.1175/1520-0485(1993)023<1057:TROITI>2.0.CO;2; Ilahude AG, 1996, J GEOPHYS RES-OCEANS, V101, P12401, DOI 10.1029/95JC03798; Lee T, 2002, J PHYS OCEANOGR, V32, P1404, DOI 10.1175/1520-0485(2002)032<1404:EOTITO>2.0.CO;2; MACDONALD AM, 1993, J GEOPHYS RES-OCEANS, V98, P6851, DOI 10.1029/92JC02964; MARIANO AJ, 1995, MARIANO GLOBAL SURFA, V55; Molcard R, 1996, J GEOPHYS RES-OCEANS, V101, P12411, DOI 10.1029/95JC03565; Molcard R, 2001, DEEP-SEA RES PT I, V48, P1237, DOI 10.1016/S0967-0637(00)00084-4; MURRAY SP, 1988, NATURE, V333, P444, DOI 10.1038/333444a0; Oberhuber J.M., 1988, 15 MAX PLANCK I MET; PIOLA AR, 1986, J PHYS OCEANOGR, V16, P2184, DOI 10.1175/1520-0485(1986)016<2184:OOHAFF>2.0.CO;2; Robbins PE, 1997, DEEP-SEA RES PT I, V44, P879, DOI 10.1016/S0967-0637(96)00126-4; Saji NH, 1999, NATURE, V401, P360, DOI 10.1038/43854; Schneider N, 1998, J CLIMATE, V11, P676, DOI 10.1175/1520-0442(1998)011<0676:TITATG>2.0.CO;2; Susanto RD, 2001, GEOPHYS RES LETT, V28, P1599, DOI 10.1029/2000GL011844; TOOLE JM, 1993, DEEP-SEA RES PT I, V40, P1973, DOI 10.1016/0967-0637(93)90042-2; VANAKEN HM, 1988, NETH J SEA RES, V22, P315, DOI 10.1016/0077-7579(88)90003-8; Vranes K, 2002, DEEP-SEA RES PT II, V49, P1391, DOI 10.1016/S0967-0645(01)00150-3; Wajsowicz RC, 2002, CLIM DYNAM, V18, P437, DOI 10.1007/s00382-001-0187-7; Wajsowicz RC, 2001, J CLIMATE, V14, P3029, DOI 10.1175/1520-0442(2001)014<3029:TITSEO>2.0.CO;2; Wajsowicz RC, 2001, J CLIMATE, V14, P1199, DOI 10.1175/1520-0442(2001)014<1199:OIOTSC>2.0.CO;2; Wyrtki K., 1961, PHYS OCEANOGR SE ASI, V2, P195	29	193	217	5	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					824	828		10.1038/nature02038	http://dx.doi.org/10.1038/nature02038			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574409				2022-12-28	WOS:000186118500042
J	Strom, BL; Schinnar, R; Apter, AJ; Margolis, DJ; Lautenbach, E; Hennessy, S; Bilker, WB; Pettitt, D				Strom, BL; Schinnar, R; Apter, AJ; Margolis, DJ; Lautenbach, E; Hennessy, S; Bilker, WB; Pettitt, D			Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK FACTOR; SELECTION; DATABASE; ALLERGY; SENSITIVITY; PREVALENCE; VALIDATION; CELECOXIB; PROFILE; ATOPY	BACKGROUND: The safety of sulfonamide nonantibiotics is unclear in patients with prior allergic reactions to sulfonamide antibiotics. METHODS: We conducted a retrospective cohort study using the General Practice Research Database in the United Kingdom, examining the risk of allergic reactions within 30 days after the receipt of a sulfonamide nonantibiotic. Patients with evidence of prior hypersensitivity after the receipt of a sulfonamide antibiotic were compared with those without such evidence. Similar analyses were also performed with the use of penicillins instead of sulfonamides, to determine whether any risk was specific to sulfonamide cross-reactivity. RESULTS: Of 969 patients with an allergic reaction after a sulfonamide antibiotic, 96 (9.9 percent) had an allergic reaction after subsequently receiving a sulfonamide nonantibiotic. Of 19,257 who had no allergic reaction after a sulfonamide antibiotic, 315 (1.6 percent) had an allergic reaction after receiving a sulfonamide nonantibiotic (adjusted odds ratio, 2.8; 95 percent confidence interval, 2.1 to 3.7). However, the risk of allergic reactions was even greater after the receipt of a penicillin among patients with a prior hypersensitivity reaction to a sulfonamide antibiotic, as compared with patients with no such history (adjusted odds ratio, 3.9; 95 percent confidence interval, 3.5 to 4.3). Furthermore, among those with a prior hypersensitivity reaction after the receipt of a sulfonamide antibiotic, the risk of an allergic reaction after the subsequent receipt of a sulfonamide nonantibiotic was lower than the risk of an allergic reaction after the subsequent receipt of a penicillin (adjusted odds ratio, 0.7; 95 percent confidence interval, 0.5 to 0.9). Finally, the risk of an allergic reaction after the receipt of a sulfonamide nonantibiotic was lower among patients with a history of hypersensitivity to sulfonamide antibiotics than among patients with a history of hypersensitivity to penicillins (adjusted odds ratio, 0.6; 95 percent confidence interval, 0.5 to 0.8). CONCLUSIONS: There is an association between hypersensitivity after the receipt of sulfonamide antibiotics and a subsequent allergic reaction after the receipt of a sulfonamide nonantibiotic, but this association appears to be due to a predisposition to allergic reactions rather than to cross-reactivity with sulfonamide-based drugs.	Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Dermatol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA; Pfizer, Dept Outcomes Res, New York, NY USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pfizer	Strom, BL (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, 824 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.		Bilker, Warren/AAS-3515-2021					ADKINSON NF, 1984, J ALLERGY CLIN IMMUN, V74, P567, DOI 10.1016/0091-6749(84)90108-8; BIGBY M, 1986, JAMA-J AM MED ASSOC, V256, P3358; BRETZA JA, 1982, WISC MED J, V81, P21; Cribb AE, 1996, ADVERSE DRUG REACT T, V15, P9; Demoly P, 2001, CURR OPIN ALLERGY CL, V1, P305, DOI 10.1097/01.all.0000011031.16814.e0; DITTO AM, 2002, PATTERSONS ALLERGIC, P295; ENRIGHT T, 1989, ANN ALLERGY, V62, P302; Garcia Rodriguez L A, 2000, PHARMACOEPIDEM DR S, P375; GREENBERGER PA, 2002, PATTERSONS ALLERGIC, P335; HANSBROUGH JR, 1987, J ALLERGY CLIN IMMUN, V80, P538, DOI 10.1016/0091-6749(87)90004-2; HOIGNE R, 1993, MONOGR ALLERGY, V31, P147; Holtzer CD, 1998, PHARMACOTHERAPY, V18, P831; HOSMER DW, 1989, APPL LOGISTIC REGRES; Hosoya T, 2000, Radiat Med, V18, P39; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Knowles S, 2001, DRUG SAFETY, V24, P239, DOI 10.2165/00002018-200124040-00001; LANDOR M, 1993, ANN ALLERGY, V70, P196; Lawrenson R, 2000, BRIT J CLIN PHARMACO, V49, P591, DOI 10.1046/j.1365-2125.2000.00199.x; Lewis JD, 2002, PHARMACOEPIDEM DR S, V11, P211, DOI 10.1002/pds.698; LIEBERMAN P, 1997, ALLERGIC DIS DIAGNOS, P289; LIS Y, 1995, J CLIN EPIDEMIOL, V48, P431, DOI 10.1016/0895-4356(94)00137-F; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; Margolis DJ, 2002, J AM ACAD DERMATOL, V46, P381, DOI 10.1067/mjd.2002.121739; Margolis DJ, 2002, ANN EPIDEMIOL, V12, P321, DOI 10.1016/S1047-2797(01)00255-1; MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462; Park J, 2000, Can J Clin Pharmacol, V7, P38; Pastorello EA, 1998, ALLERGY, V53, P880, DOI 10.1111/j.1398-9995.1998.tb03995.x; Patterson R, 1999, CLIN THER, V21, P2065, DOI 10.1016/S0149-2918(00)87238-0; ROBINS JM, 1986, AM J EPIDEMIOL, V123, P392, DOI 10.1093/oxfordjournals.aje.a114254; RYTEL MW, 1963, JAMA-J AM MED ASSOC, V186, P894; Sanchez-Borges N, 2000, ANN ALLERG ASTHMA IM, V84, P101, DOI 10.1016/S1081-1206(10)62748-2; *SAS I, 2000, SAS VERS 8 0; SMITH JW, 1966, NEW ENGL J MED, V274, P998, DOI 10.1056/NEJM196605052741804	35	212	216	0	12	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	2003	349	17					1628	U9		10.1056/NEJMoa022963	http://dx.doi.org/10.1056/NEJMoa022963			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734ZT	14573734				2022-12-28	WOS:000186088400007
J	Landi, F; Aloe, L; Russo, A; Cesari, M; Onder, G; Bonini, S; Carbonin, PU; Bernabei, R				Landi, F; Aloe, L; Russo, A; Cesari, M; Onder, G; Bonini, S; Carbonin, PU; Bernabei, R			Topical treatment of pressure ulcers with nerve growth factor - A randomized clinical trial	ANNALS OF INTERNAL MEDICINE			English	Article							NURSING-HOME; MESSENGER-RNA; NGF; EXPRESSION; SKIN; INNERVATION; RECEPTORS; DISEASES; THERAPY; QUALITY	Background: The prevalence of pressure ulcers of the foot is a major health care problem in frail elderly patients. A pressure sore dramatically increases the cost of medical and nursing care, and effective treatment has always been an essential nursing concern. Management options for pressure ulcers include local wound care; surgical repair; and, more recently, topical application of growth factors. Objective: To examine the effects of topical treatment with nerve growth factor in patients with severe, noninfected pressure ulcers of the foot. Design: Randomized, double-blind, placebo-controlled trial. Setting: Teaching nursing home of Catholic University of the Sacred Heart, Italy. Patients: 36 persons with pressure ulcers of the foot. Intervention: 18 patients received nerve growth factor treatment, and 18 patients received only conventional topical treatment. Measurements: The course of the ulcers during follow-up was evaluated by tracing the perimeter of the wound onto sterile, transparent block paper and determining the stage. Results: At baseline, the treatment and control groups did not differ across demographic variables, clinical characteristics, and functional measures. The mean area (+/-SD) of the ulcers was 1012 +/- 633 mm(2) in the treatment group and 1012 +/- 655 mm(2) in the control group (P > 0.2). The average reduction in pressure ulcer area at 6 weeks was statistically significantly greater in the treatment group than in the control group (738 +/- 393 mm(2) VS. 485 +/- 384 mm(2); P = 0.034). Conclusion: Topical application of nerve growth factor may be an effective therapy for patients with severe pressure ulcers.	Univ Cattolica Sacro Cuore, Dept Geriatr, I-00168 Rome, Italy; Univ Sacred Heart, Fontecchio, Italy; CNR, Inst Neurobiol & Mol Med, Rome, Italy; Wake Forest Univ, Baptist Med Ctr, J Paul Sticht Ctr Aging & Rehabil, Winston Salem, NC 27109 USA; Bietti Fdn, Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; Consiglio Nazionale delle Ricerche (CNR); Wake Forest University; Wake Forest Baptist Medical Center; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in Oftalmologia	Landi, F (corresponding author), Univ Cattolica Sacro Cuore, Dept Geriatr, Largo Agostino Gemelli 8, I-00168 Rome, Italy.	francesco_landi@rm.unicatt.it	Bernabei, Roberto/AAB-2704-2019; Bonini, Sergio/T-6594-2019; Cesari, Matteo/A-4649-2008; Bonini, Stefano/A-2250-2012	Bernabei, Roberto/0000-0002-9197-004X; Bonini, Sergio/0000-0003-0079-3031; Cesari, Matteo/0000-0002-0348-3664; Bonini, Stefano/0000-0002-7787-2144				Belmin J, 2002, J AM GERIATR SOC, V50, P269, DOI 10.1046/j.1532-5415.2002.50058.x; Berlowitz DR, 2000, J AM GERIATR SOC, V48, P59, DOI 10.1111/j.1532-5415.2000.tb03029.x; Bernabei R, 1999, LANCET, V354, P307, DOI 10.1016/S0140-6736(99)02784-1; Bernabei R., 1996, MINIMUM DATA SET NUR; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; Calza L, 2001, P NATL ACAD SCI USA, V98, P4160, DOI 10.1073/pnas.051626998; DONNERER J, 1992, NEUROSCIENCE, V49, P693, DOI 10.1016/0306-4522(92)90237-V; EBENDAL T, 1992, J NEUROSCI RES, V32, P461, DOI 10.1002/jnr.490320402; Flour M, 1998, SEMIN CUTAN MED SURG, V17, P260, DOI 10.1016/S1085-5629(98)80022-9; Gambassi G, 1998, MED CARE, V36, P167, DOI 10.1097/00005650-199802000-00006; HAMMES HP, 1995, MOL MED, V1, P527, DOI 10.1007/BF03401589; HAWES C, 1995, GERONTOLOGIST, V35, P172, DOI 10.1093/geront/35.2.172; HEFTI F, 1994, J NEUROBIOL, V25, P1418, DOI 10.1002/neu.480251109; Higashiyama Mari, 1992, Journal of Dermatology (Tokyo), V19, P676; Kantor J, 1998, ARCH DERMATOL, V134, P1571, DOI 10.1001/archderm.134.12.1571; Lambiase A, 1998, NEW ENGL J MED, V338, P1174, DOI 10.1056/NEJM199804233381702; Levi-Montalcini R, 1998, NEUROREPORT, V9, pR71; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LI AKC, 1980, P NATL ACAD SCI-BIOL, V77, P4379, DOI 10.1073/pnas.77.7.4379; Matsuda H, 1998, J EXP MED, V187, P297, DOI 10.1084/jem.187.3.297; MEAROW KM, 1993, NEUROREPORT, V4, P351, DOI 10.1097/00001756-199304000-00002; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; Mogi M, 2000, LIFE SCI, V67, P1197, DOI 10.1016/S0024-3205(00)00705-0; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; MOULIN V, 1995, EUR J CELL BIOL, V68, P1; Mukamel DB, 2000, MED CARE, V38, P78, DOI 10.1097/00005650-200001000-00009; Pincelli C, 2000, EUR J DERMATOL, V10, P85; Pozza M, 2000, J RHEUMATOL, V27, P1121; Pullen R, 2002, AGE AGEING, V31, P126, DOI 10.1093/ageing/31.2.126; REYNOLDS ML, 1995, J COMP NEUROL, V358, P487, DOI 10.1002/cne.903580403; Riaz SS, 1996, PROG NEUROBIOL, V49, P125; Rice FL, 1998, DEV BIOL, V198, P57, DOI 10.1006/dbio.1998.8861; Robson MC, 2000, ANN SURG, V231, P600, DOI 10.1097/00000658-200004000-00020; ROTHE M, 1989, ARCH DERMATOL, V125, P1390, DOI 10.1001/archderm.125.10.1390; ROTHE MJ, 1991, CLIN DERMATOL, V9, P553, DOI 10.1016/0738-081X(91)90084-X; Samii A, 1999, NEUROSCI LETT, V262, P159, DOI 10.1016/S0304-3940(99)00064-6; SMITH DM, 1995, ANN INTERN MED, V123, P433, DOI 10.7326/0003-4819-123-6-199509150-00008; Sondell M, 1999, BRAIN RES, V846, P219, DOI 10.1016/S0006-8993(99)02056-9; STEAD RH, 1987, IMMUNOL REV, V100, P333, DOI 10.1111/j.1600-065X.1987.tb00538.x; Tuveri M, 2000, LANCET, V356, P1739, DOI 10.1016/S0140-6736(00)03212-8; VERGE VMK, 1992, J NEUROSCI, V12, P4011; Waldorf H, 1995, Adv Dermatol, V10, P77; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; YARKONY GM, 1990, ARCH DERMATOL, V126, P1218, DOI 10.1001/archderm.126.9.1218	44	84	86	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 21	2003	139	8					635	641		10.7326/0003-4819-139-8-200310210-00006	http://dx.doi.org/10.7326/0003-4819-139-8-200310210-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734DW	14568851				2022-12-28	WOS:000186040800001
J	Chitnis, V; Chitnis, S; Patil, S; Chitnis, D				Chitnis, V; Chitnis, S; Patil, S; Chitnis, D			Solar disinfection of infectious biomedical waste: a new approach for developing countries	LANCET			English	Article							DRINKING-WATER	Poor developing countries cannot afford expensive technologies such as incineration for management of infectious biomedical waste. We assessed solar heating as an alternative technology. We immersed simulated infectious waste with added challenge bacteria in water in a box-type solar cooker, which was left in the sun for 6 h. In 24 sets of observations, the amount of viable bacteria was reduced by about 7 log. We also tested infectious medical waste with a heavy load of bacteria (10(8)-10(9)/g) from our hospital's burn U nit for solar heat disinfection in 20 experiments. Our results showed a similar 7 log reduction in the amount of viable bacteria. Solar heating thus seems to be a cheap method to disinfect infectious medical waste in less economically developed countries.	Choithram Hosp & Res Ctr, Dept Microbiol, Indore 452001, Madhya Pradesh, India; Devi Ahilya Vishwavidyalaya, Sch Life Sci, Dept Microbiol, Indore, Madhya Pradesh, India	Devi Ahilya University	Chitnis, V (corresponding author), Choithram Hosp & Res Ctr, Dept Microbiol & Immunol, Indore 452001, Madhya Pradesh, India.							Conroy RM, 1996, LANCET, V348, P1695, DOI 10.1016/S0140-6736(96)02309-4; GRAHAM W, 1983, TOPLEY WILSONS PRINC, P70; Reed RH, 2000, LETT APPL MICROBIOL, V30, P432, DOI [10.1046/j.1472-765x.2000.00741.x, 10.1046/j.1472-765X.2000.00741.x]; Rijal GK, 2001, WATER SCI TECHNOL, V43, P155, DOI 10.2166/wst.2001.0728; *UNICEF REG OFF MI, 1984, SOL DIS DRINK WAT OR	5	10	10	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 18	2003	362	9392					1285	1286		10.1016/S0140-6736(03)14610-7	http://dx.doi.org/10.1016/S0140-6736(03)14610-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575975				2022-12-28	WOS:000186036900014
J	Gomes, MER; Deinum, J; Timmers, HJLM; Lenders, JWM				Gomes, MER; Deinum, J; Timmers, HJLM; Lenders, JWM			Occam's razor; anaemia and orthostatic hypotension	LANCET			English	Editorial Material							ERYTHROPOIETIN		St Radboud Univ Med Ctr, Dept Internal Med, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Lenders, JWM (corresponding author), St Radboud Univ Med Ctr, Dept Internal Med, NL-6500 HB Nijmegen, Netherlands.		Deinum, J./L-4261-2015; Lenders, J.W.M./L-4487-2015; Timmers, Henri JLM/A-4641-2010	Deinum, J./0000-0003-2465-1986; Lenders, J.W.M./0000-0002-7658-4466; 				ANO Y, 1996, J AUTONOM NERV SYST, V61, P145; HOELDTKE RD, 1993, NEW ENGL J MED, V329, P611, DOI 10.1056/NEJM199308263290904; MATHIAS CJ, 1990, Q J MED, V75, P617; MATHIAS CJ, 1999, AUTONOMIC FAILURE TX, P387; ROBERTSON D, 1994, ACTA ASTRONAUT, V33, P137, DOI 10.1016/0094-5765(94)90118-X	5	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 18	2003	362	9392					1282	1282		10.1016/S0140-6736(03)14572-2	http://dx.doi.org/10.1016/S0140-6736(03)14572-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575973				2022-12-28	WOS:000186036900012
J	Mellor, D				Mellor, D			Commentary: Recruitment is ethical	BRITISH MEDICAL JOURNAL			English	Editorial Material									Dept Hlth, Leeds LS7 2EU, W Yorkshire, England		Mellor, D (corresponding author), Dept Hlth, Leeds LS7 2EU, W Yorkshire, England.							*DEP HLTH, INT RECR AG; *DEP HLTH, COMP NHS CONTR DEV N	2	7	7	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 18	2003	327	7420					928	928		10.1136/bmj.327.7420.928	http://dx.doi.org/10.1136/bmj.327.7420.928			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734RV	14563761	Green Published			2022-12-28	WOS:000186072100036
J	Bogan, JS; Hendon, N; McKee, AE; Tsao, TS; Lodish, HF				Bogan, JS; Hendon, N; McKee, AE; Tsao, TS; Lodish, HF			Functional cloning of TUG as a regulator of GLUT4 glucose transporter trafficking	NATURE			English	Article							3T3-L1 ADIPOCYTES; INSULIN; PROTEINS; CELLS; COMPARTMENTS; INTERACTS; MEMBRANE; DOMAIN; GENE; P47	Insulin stimulates glucose uptake in fat and muscle by mobilizing the GLUT4 glucose transporter. GLUT4 is sequestered intracellularly in the absence of insulin, and is redistributed to the plasma membrane within minutes of insulin stimulation(1,2). But the trafficking mechanisms that control GLUT4 sequestration have remained elusive. Here we describe a functional screen to identify proteins that modulate GLUT4 distribution, and identify TUG as a putative tether, containing a UBX domain, for GLUT4. In truncated form, TUG acts in a dominant-negative manner to inhibit insulin-stimulated GLUT4 redistribution in Chinese hamster ovary cells and 3T3-L1 adipocytes. Full-length TUG forms a complex specifically with GLUT4; in 3T3-L1 adipocytes, this complex is present in unstimulated cells and is largely disassembled by insulin. Endogenous TUG is localized with the insulin-mobilizable pool of GLUT4 in unstimulated 3T3-L1 adipocytes, and is not mobilized to the plasma membrane by insulin. Distinct regions of TUG are required to bind GLUT4 and to retain GLUT4 intracellularly in transfected, non-adipose cells. Our data suggest that TUG traps endocytosed GLUT4 and tethers it intracellularly, and that insulin mobilizes this pool of retained GLUT4 by releasing this tether.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Massachusetts Gen Hosp, Dept Med, Diabet Unit, Boston, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Bogan, JS (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St,Box 208020, New Haven, CT 06520 USA.		Bogan, Jonathan S/A-1575-2010	Bogan, Jonathan S/0000-0001-6463-8466; Tsao, Tsu-Shuen/0000-0002-1041-9687				Becker K, 1997, FEBS LETT, V412, P102, DOI 10.1016/S0014-5793(97)00758-8; Bogan JS, 1999, J CELL BIOL, V146, P609, DOI 10.1083/jcb.146.3.609; Bogan JS, 2001, MOL CELL BIOL, V21, P4785, DOI 10.1128/MCB.21.14.4785-4806.2001; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Buchberger A, 2001, J MOL BIOL, V307, P17, DOI 10.1006/jmbi.2000.4462; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Holman GD, 2001, TRENDS CELL BIOL, V11, P173, DOI 10.1016/S0962-8924(01)01953-5; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Ladanyi M, 2001, ONCOGENE, V20, P48, DOI 10.1038/sj.onc.1204074; Lalioti VS, 2002, J BIOL CHEM, V277, P19783, DOI 10.1074/jbc.M110294200; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Perera HKI, 2003, MOL BIOL CELL, V14, P2946, DOI 10.1091/mbc.E02-11-0722; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; Wilson VG, 2001, EXP CELL RES, V271, P57, DOI 10.1006/excr.2001.5366; Wright DA, 1996, J BIOL CHEM, V271, P31037, DOI 10.1074/jbc.271.49.31037; Yuan XM, 2001, J MOL BIOL, V311, P255, DOI 10.1006/jmbi.2001.4864	22	143	148	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					727	733		10.1038/nature01989	http://dx.doi.org/10.1038/nature01989			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562105				2022-12-28	WOS:000185924500044
J	Pui, CH; Sandlund, JT; Pei, DQ; Rivera, GK; Howard, SC; Ribeiro, RC; Rubnitz, JE; Razzouk, BI; Hudson, MM; Cheng, C; Raimondi, SC; Behm, FG; Downing, JR; Relling, MV; Evans, WE				Pui, CH; Sandlund, JT; Pei, DQ; Rivera, GK; Howard, SC; Ribeiro, RC; Rubnitz, JE; Razzouk, BI; Hudson, MM; Cheng, C; Raimondi, SC; Behm, FG; Downing, JR; Relling, MV; Evans, WE			Results of therapy for acute lymphoblastic leukemia in black and white children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PEDIATRIC-ONCOLOGY-GROUP; CENTRAL-NERVOUS-SYSTEM; CANCER SURVIVAL; RACIAL-DIFFERENCES; CHILDHOOD-CANCER; LUMBAR PUNCTURE; TRIALS; RISK; INTENSIFICATION; DIAGNOSIS	Context Treatment results for acute lymphoblastic leukemia (ALL) clearly have improved over the past decade, but black children have not fared as well as white children in large national trials. Objective To compare the clinical outcomes of therapy for black and white children with ALL treated at a single institution. Design, Setting, and Patients A retrospective analysis of 412 children and adolescents (68 black, 338 white, and 6 other race) with newly diagnosed ALL who were treated consecutively at a pediatric cancer center in Memphis, Tenn. Patients were enrolled from December 1991 to July 1998 in successive Total Therapy studies regardless of race, ethnicity, or ability to pay and received risk-directed therapy according to stringent criteria. Interventions All patients received the same intensive, remission-induction therapy followed by 120 weeks of risk-assigned postremission therapy that included reinduction treatment, pulses of high-dose methotrexate, and early intensification of intrathecal chemotherapy. Main Outcome Measures Event-free and overall survival rates for black and white children were estimated by the method of Kaplan and Meier and compared with the Mantel-Haenszel test and by Cox proportional hazards regression analysis, adjusting for known prognostic factors. Results The 68 black children were significantly more likely than the 338 white children to have higher-risk prognostic features, including an initial leukocyte count greater than 100 X 10(3)/muL, a T-cell immunophenotype, and the t(1;19) chromosomal translocation with E2A-PBX1 fusion, and were less likely to have hyperdiploid blast cells, a favorable prognostic factor in childhood ALL. However, the clinical outcomes for these 2 cohorts were not significantly different: 5-year event-free and overall survival rates were 80.7% (95% confidence interval [CI], 70.3%-91.1%) and 86.2% (95% Cl, 77.2%-95.2%) for black children vs 79.4% (95% CI, 74.7%-84.1%) and 85.0% (95% Cl, 80.9%-89.1%) for white children. Ten-year results also were comparable, but the Cls were wide because of the small numbers of patients who had been followed up for 10 years or more. The lack of a racial effect on the long-term outcome of therapy was still apparent in a multivariate Cox regression analysis, adjusting for sex, age, presenting leukocyte count, leukemic cell DNA index, immunophenotype, and central nervous system status. Conclusion With equal access to effective antileukemic therapy, black and white children with ALL can expect the same high rate of cure.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Coll Med, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Pui, CH (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	ching-hon.pui@stjude.org	Howard, Scott C/K-3401-2013; Pui, Ching-Hon/N-8076-2018; Relling, Mary/N-5032-2018; Evans, William E./C-2069-2012; Downing, James R./N-8102-2018; Hudson, Melissa M/N-4441-2018; Cheng, Cheng/N-8075-2018; Raimondi, Susana C/N-8166-2018	Howard, Scott C/0000-0003-2244-1686; Pui, Ching-Hon/0000-0003-0303-5658; Evans, William E./0000-0002-9333-5322; Hudson, Melissa M/0000-0001-6984-2407; Razzouk, Bassem/0000-0003-0536-6135	NATIONAL CANCER INSTITUTE [P30CA021765, R37CA036401, R01CA051001, R01CA078224, R29CA051001, R01CA036401] Funding Source: NIH RePORTER; NCI NIH HHS [CA-51001, CA-36401, CA-21765, CA-78224] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agresti A., 1996, INTRO CATEGORICAL DA; Bach PB, 2002, JAMA-J AM MED ASSOC, V287, P2106, DOI 10.1001/jama.287.16.2106; Bhatia S, 2002, BLOOD, V100, P1957, DOI 10.1182/blood-2002-02-0395; Clarke M, 2003, J CLIN ONCOL, V21, P1798, DOI 10.1200/JCO.2003.08.047; ELEY JW, 1994, JAMA-J AM MED ASSOC, V272, P947, DOI 10.1001/jama.272.12.947; FALLETTA JM, 1984, PROG CANCER RES THER, V27, P191; Gajjar A, 2000, BLOOD, V96, P3381; Gaynon PS, 2000, LEUKEMIA, V14, P2223, DOI 10.1038/sj.leu.2401939; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Gustafsson G, 2000, LEUKEMIA, V14, P2267, DOI 10.1038/sj.leu.2401961; HOWARD J, 1992, CANCER, V69, P2349, DOI 10.1002/1097-0142(19920501)69:9&lt;2349::AID-CNCR2820690925&gt;3.0.CO;2-7; Howard SC, 2002, JAMA-J AM MED ASSOC, V288, P2001, DOI 10.1001/jama.288.16.2001; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P169; KALWINSKY DK, 1985, LEUKEMIA RES, V9, P817, DOI 10.1016/0145-2126(85)90300-5; MAHMOUD HH, 1993, NEW ENGL J MED, V329, P314, DOI 10.1056/NEJM199307293290504; Maloney KW, 2000, LEUKEMIA, V14, P2276, DOI 10.1038/sj.leu.2401965; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Matherly LH, 1997, BLOOD, V90, P578, DOI 10.1182/blood.V90.2.578.578_578_589; NOVAKOVIC B, 1994, MED PEDIATR ONCOL, V23, P480, DOI 10.1002/mpo.2950230606; PINKEL D, 1993, LEUKEMIA, V7, pS146; Pollock BH, 2000, J CLIN ONCOL, V18, P813, DOI 10.1200/JCO.2000.18.4.813; Pui CH, 2000, LEUKEMIA, V14, P2286, DOI 10.1038/sj.leu.2401938; PUI CH, 1988, J CLIN ONCOL, V6, P56, DOI 10.1200/JCO.1988.6.1.56; PUI CH, 1995, JAMA-J AM MED ASSOC, V273, P633, DOI 10.1001/jama.273.8.633; Pui CH, 2003, J CLIN ONCOL, V21, P179, DOI 10.1200/JCO.2003.10.032; PUI CH, 1992, LEUKEMIA, V6, P150; PUI CH, 1986, BLOOD, V67, P1688; Pui CH, 2003, NEW ENGL J MED, V349, P640, DOI 10.1056/NEJMoa035091; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407; Pui CH, 2000, BRIT J HAEMATOL, V109, P13, DOI 10.1046/j.1365-2141.2000.01843.x; Pui CH, 1998, BLOOD, V92, P411, DOI 10.1182/blood.V92.2.411.414k34_411_415; PUI CH, IN PRESS N ENGL J ME; RAGLAND KE, 1991, AM J EPIDEMIOL, V133, P672; REAMAN GH, 1984, PROG CANCER RES THER, V27, P163; Relling MV, 2003, BLOOD, V101, P3862, DOI 10.1182/blood-2002-08-2405; Ries L. A. G., 1999, SEER CANC STAT REV 1; RIES LA, 1999, PUBLICATION NIH; SATHER H, 1984, PROG CANCER RES THER, V27, P179; Schrappe M, 2000, LEUKEMIA, V14, P2205, DOI 10.1038/sj.leu.2401973; WALTERS TR, 1972, CANCER, V29, P210, DOI 10.1002/1097-0142(197201)29:1<210::AID-CNCR2820290131>3.0.CO;2-U; Wilson JF, 2001, NAT GENET, V29, P265, DOI 10.1038/ng761	43	130	134	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	2003	290	15					2001	2007		10.1001/jama.290.15.2001	http://dx.doi.org/10.1001/jama.290.15.2001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CX	14559953				2022-12-28	WOS:000185924200023
J	Johnstone, R				Johnstone, R			Commentary: A small study, but the results ring true	BRITISH MEDICAL JOURNAL			English	Editorial Material									Arthrit & Rheumatism Int, Skelmersdale WN9 6UN, Lancs, England		Johnstone, R (corresponding author), Arthrit & Rheumatism Int, 14 Hazel Lane, Skelmersdale WN9 6UN, Lancs, England.								0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					844	845		10.1136/bmj.327.7419.844	http://dx.doi.org/10.1136/bmj.327.7419.844			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551100	Green Published, Bronze			2022-12-28	WOS:000185921200020
J	McIntire, JJ; Umetsu, SE; Macaubas, C; Hoyte, EG; Cinnioglu, C; Cavalli-Sforza, LL; Barsh, GS; Hallmayer, JF; Underhill, PA; Risch, NJ; Freeman, GJ; DeKruyff, RH; Umetsu, DT				McIntire, JJ; Umetsu, SE; Macaubas, C; Hoyte, EG; Cinnioglu, C; Cavalli-Sforza, LL; Barsh, GS; Hallmayer, JF; Underhill, PA; Risch, NJ; Freeman, GJ; DeKruyff, RH; Umetsu, DT			Hepatitis A virus link to atopic disease	NATURE			English	Editorial Material							HAY-FEVER; INFECTION; MARKERS		Stanford Univ, Dept Pediat, Div Immunol & Allergy, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; Harvard Univ, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Stanford University; Stanford University; Stanford University; Harvard University; Dana-Farber Cancer Institute	McIntire, JJ (corresponding author), Stanford Univ, Dept Pediat, Div Immunol & Allergy, Stanford, CA 94305 USA.		Jones, Jennifer/C-8691-2015; Freeman, Gordon/AAC-5380-2019	Jones, Jennifer/0000-0002-9488-7719; Freeman, Gordon/0000-0002-7210-5616				Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bower WA, 2000, J INFECT DIS, V182, P12, DOI 10.1086/315701; Feigelstock D, 1998, J VIROL, V72, P6621, DOI 10.1128/JVI.72.8.6621-6628.1998; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739; Silberstein E, 2003, J VIROL, V77, P8765, DOI 10.1128/JVI.77.16.8765-8774.2003; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259	10	166	185	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2003	425	6958					576	576		10.1038/425576a	http://dx.doi.org/10.1038/425576a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534576				2022-12-28	WOS:000185801000026
J	Berry, LL; Seiders, K; Wilder, SS				Berry, LL; Seiders, K; Wilder, SS			Innovations in access to care: A patient-centered approach	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; 5 MINUTE CONSULTATION; NURSE-PRACTITIONERS; E-MAIL; FOLLOW-UP; TIME CONSTRAINT; UNITED-STATES; TELEPHONE; INTERNET; MANAGEMENT	To receive health care, patients with nonemergent problems must gain access to a complex, interdependent ambulatory care system currently structured around the conventional office appointment model. The system does not effectively accommodate diverse patient needs and preferences, contributing to both overuse and underuse of health care resources. A patient-centered access model would help patients secure appropriate and preferred medical assistance when and where it is needed. Characteristics of patient-centered access include availability, appropriateness, preference, and timeliness. One or more of these characteristics often is missing in patients' health care experiences. The goal of this paper is to present patient-centered access as an integrated concept and philosophy to provide context for evaluating specific access initiatives. on the basis of an assessment of existing literature, 3 organizing principles of patient-centered access are proposed and discussed: work at the high end of expertise; align care with need and preference; and serve when service is needed. Patient-centered access warrants serious consideration, given the stakes involved for patients, providers, and payers. Few concepts support all 6 of the Institute of Medicine's aims for the 21st century: safety, effectiveness, patient-centeredness, timeliness, efficiency, and equitability. Patient-centered access is such a concept.	Texas A&M Univ, Mays Business Sch, Dept Mkt, College Stn, TX 77843 USA; Boston Coll, Chestnut Hill, MA 02167 USA; Mayo Clin Scottsdale, Scottsdale, AZ USA	Texas A&M University System; Texas A&M University College Station; Mays Business School; Boston College; Mayo Clinic; Mayo Clinic Phoenix	Berry, LL (corresponding author), Texas A&M Univ, Mays Business Sch, Dept Mkt, 4112 TAMU, College Stn, TX 77843 USA.	BerryLe@tamu.edu						*AM COLL PHYS, 2003, CHANG FAC AMB MED RE; [Anonymous], 2002, HARRIS INTERACTIVE H, V2; Ayanian JZ, 2000, JAMA-J AM MED ASSOC, V284, P2061, DOI 10.1001/jama.284.16.2061; BA H, 2001, EFFECTIVE LOW INCOME; Baker L, 2003, JAMA-J AM MED ASSOC, V289, P2400, DOI 10.1001/jama.289.18.2400; Barry HC, 2001, J FAM PRACTICE, V50, P589; Bauchner H, 2002, PEDIATRICS, V109, P954, DOI 10.1542/peds.109.5.954; Beck A, 1997, J AM GERIATR SOC, V45, P543, DOI 10.1111/j.1532-5415.1997.tb03085.x; BEISECKER AE, 1990, MED CARE, V28, P19, DOI 10.1097/00005650-199001000-00004; BELFIGLIO G, 2001, MODERN PHYSICIAN, V5, P34; BELLUCK P, 2002, NY TIMES        1204, pA1; Berti L C, 2001, J Pediatr Health Care, V15, P244, DOI 10.1016/S0891-5245(01)37459-X; BERWICK D, 2002, MOD HEALTHC S2, V27, P1999; Boulanger B, 2001, J AM COLL SURGEONS, V192, P447, DOI 10.1016/S1072-7515(01)00796-7; Brennan TA, 2002, NEW ENGL J MED, V346, P1165, DOI 10.1056/NEJM200204113461513; Brown SA, 1995, NURS RES, V44, P332; Buckwalter KC, 2002, FAM COMMUNITY HEALTH, V25, P31, DOI 10.1097/00003727-200210000-00007; CHIN T, 2002, AM MED NEWS, V45, P23; CHRISTIANSON JB, 2001, ADDRESS ISSUES BUSIN; Coleman E A, 2001, Eff Clin Pract, V4, P49; Cooper RA, 1998, JAMA-J AM MED ASSOC, V280, P795, DOI 10.1001/jama.280.9.795; CUMMINGSLAWRENC.S, IMPROVING CLIN TRIAG; Cunningham PJ, 1995, MED CARE RES REV, V52, P453, DOI 10.1177/107755879505200402; DARVES B, 2002, PHYSICIANS PRACT JAN, P18; Davidoff F, 1997, ANN INTERN MED, V127, P483, DOI 10.7326/0003-4819-127-6-199709150-00011; DORSCHNER J, 2002, KNIGHT RIDER NE 0616, pA11; FOX S, INT HLTH RESOURCES P; FREUDENHEIM M, 2002, NY TIMES        0609, pC1; Grover F, 2002, J FAM PRACTICE, V51, P570; Hanson KL, 2001, J URBAN HEALTH, V78, P112, DOI 10.1093/jurban/78.1.112; Hauber Roxanne Pickett, 2002, Rehabil Nurs, V27, P142; Hooker RS, 2002, HEALTH AFFAIR, V21, P174, DOI 10.1377/hlthaff.21.5.174; Howie JGR, 1997, MEASURING QUALITY GE; Institute of Medicine, 2001, CROSSING QUALITY CHA; JANCIN B, 2003, INTERNAL MED NEWS, V36, P58; Kaiser Family Foundation, 2000, NAT SURV CONS EXP HL; KOLATA G, 2001, NY TIMES        0720, pA1; Kuppersmith RB, 1999, ARCH OTOLARYNGOL, V125, P468, DOI 10.1001/archotol.125.4.468; Leatherman S, 2003, HEALTH AFFAIR, V22, P17, DOI 10.1377/hlthaff.22.2.17; Lee TH, 2002, NEW ENGL J MED, V346, P529, DOI 10.1056/NEJM200202143460715; Lorig KR, 2002, ARCH INTERN MED, V162, P792, DOI 10.1001/archinte.162.7.792; MAGUIRE P, 2002, MED BENEFITS, V19, P6; Marvel M K, 1993, Fam Med, V25, P337; Masley S, 2001, J FAM PRACTICE, V50, P235; MORRELL DC, 1986, BMJ-BRIT MED J, V292, P870, DOI 10.1136/bmj.292.6524.870; Mundinger MO, 2000, JAMA-J AM MED ASSOC, V283, P59, DOI 10.1001/jama.283.1.59; Murray M, 2003, JAMA-J AM MED ASSOC, V289, P1035, DOI 10.1001/jama.289.8.1035; Murray M, 2003, JAMA-J AM MED ASSOC, V289, P1042, DOI 10.1001/jama.289.8.1042; Murray M, 2000, Fam Pract Manag, V7, P45; Murray Mark, 2002, Fam Pract Manag, V9, P39; MYDANS S, 2002, NYT, pA6; NORBUT M, 2003, AM MED NEWS, P46; PENNACHIO DL, 2002, MED ECON, V79, P68; PENNACHIO DL, 2002, MED ECON, V79, P71; Pennachio Dorothy L, 2002, Med Econ, V79, P71; Pinnock H, 2003, BMJ-BRIT MED J, V326, P477, DOI 10.1136/bmj.326.7387.477; Roan C, 2002, HEALTH AFFAIR, V21, P250, DOI 10.1377/hlthaff.21.6.250; Robinson C, 1999, JAMA-J AM MED ASSOC, V281, P988, DOI 10.1001/jama.281.11.988-a; ROLAND MO, 1986, BRIT MED J, V292, P874, DOI 10.1136/bmj.292.6524.874; SILVERMAN J, 2002, INTERNAL MED NEWS, V35, P42; Simon GE, 2000, BRIT MED J, V320, P550, DOI 10.1136/bmj.320.7234.550; Sox HC, 2000, JAMA-J AM MED ASSOC, V283, P106, DOI 10.1001/jama.283.1.106; Suhayda L, 1997, Cancer Pract, V5, P105; Tamblyn R, 1997, ANN INTERN MED, V127, P429, DOI 10.7326/0003-4819-127-6-199709150-00003; Tate DF, 2003, JAMA-J AM MED ASSOC, V289, P1833, DOI 10.1001/jama.289.14.1833; Trento M, 2001, DIABETES CARE, V24, P995, DOI 10.2337/diacare.24.6.995; Wagner EH, 2001, DIABETES CARE, V24, P695, DOI 10.2337/diacare.24.4.695; Walker SP, 1996, ANN HUM BIOL, V23, P23, DOI 10.1080/03014469600004242; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; WEBER J, 2002, NY TIMES        0906, P90; Weinger K, 2003, DIABETES SPECTRUM, V16, P104, DOI DOI 10.2337/	72	84	85	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 7	2003	139	7					568	574		10.7326/0003-4819-139-7-200310070-00009	http://dx.doi.org/10.7326/0003-4819-139-7-200310070-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	729AP	14530228				2022-12-28	WOS:000185748800005
J	Scally, G; Oliver, I				Scally, G; Oliver, I			Putting Jenner back in his place	LANCET			English	Editorial Material									Govt Off SW, Reg Publ Hlth Grp, Bristol BS1 6ED, Avon, England; Avon Hlth Protect Unit, Bristol, Avon, England		Scally, G (corresponding author), Govt Off SW, Reg Publ Hlth Grp, Bristol BS1 6ED, Avon, England.			Oliver, Isabel/0000-0002-6106-1734				*DEP HLTH, 2002, INT GUID SMALLP RESP; Empson J, 1996, J ROY SOC MED, V89, P514, DOI 10.1177/014107689608900910; Jezek Z, 1988, HUMAN MONKEYPOX; 1858, BMJ, V1, P395; 2003, SHORTLIST INT ARTIST; 2003, MAYOR CALLS WESTMINS	6	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 4	2003	362	9390					1092	1092		10.1016/S0140-6736(03)14500-X	http://dx.doi.org/10.1016/S0140-6736(03)14500-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728HA	14550693				2022-12-28	WOS:000185710700006
J	Ball, C; Kirkby, M; Williams, S				Ball, C; Kirkby, M; Williams, S			Effect of the critical care outreach team on patient survival to discharge from hospital and readmission to critical care: non-randomised population based study	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL EMERGENCY TEAM; INTENSIVE-CARE; MORTALITY; ADMISSIONS; ARRESTS; DEATHS; UNITS	Objectives To determine the effect of the critical care outreach team on patient survival to discharge from hospital after discharge from critical care and readmission to critical care. Design Non-randomised population based study. Setting Tertiary referral teaching hospital with 1200 beds. Participants Patients discharged from the critical care unit after their first or only admission for two study periods, 26 February 2000 to 25 February 2001 and 26 February 2001 to 25 February 2002. Main outcome measures Survival to discharge from hospital after discharge from critical care and readmission to critical care. Results The introduction of a critical care outreach team increased survival to discharge from hospital after discharge from critical care by 6.8% (risk ratio 1.08). Readmission to critical care decreased by 6.4% (0.48). Conclusions The activity of the critical care outreach team seems to improve patient survival to discharge from hospital and may reduce the number of readmissions to critical care.	Royal Free Hampstead NHS Trust, Crit Care Unit, London NW3 2QG, England	University of London; University College London	Ball, C (corresponding author), Royal Free Hampstead NHS Trust, Crit Care Unit, London NW3 2QG, England.							Bristow PJ, 2000, MED J AUSTRALIA, V173, P236, DOI 10.5694/j.1326-5377.2000.tb125627.x; Buist MD, 2002, BRIT MED J, V324, P387, DOI 10.1136/bmj.324.7334.387; Cuthbertson BH, 2003, BRIT J ANAESTH, V90, P4, DOI 10.1093/bja/aeg004; DALY K, 2001, BRIT MED J, V322, P1; *DEP HLTH, 2001, COMPR CRIT CAR; Garrard C, 1998, BMJ-BRIT MED J, V316, P1841; Goldhill DR, 1999, ANAESTHESIA, V54, P853; Goldhill DR, 1996, INTENS CARE MED, V22, P415, DOI 10.1007/BF01712157; Goldhill DR, 2002, CURR ANAESTH CRIT CA, V13, P356, DOI DOI 10.1054/cacc.2003.0433; Hillman K, 2003, BRIT J ANAESTH, V90, P808, DOI 10.1093/bja/aeg573; *ICNARC, 1997, INT CAR NAT AUD RES; *INT CAR NAT AUD R, 1997, INT CAR NAT AUD RES; Leary T, 2003, ANAESTHESIA, V58, P328, DOI 10.1046/j.1365-2044.2003.03077.x; McGloin H, 1999, J ROY COLL PHYS LOND, V33, P255; McQuillan P, 1998, BMJ-BRIT MED J, V316, P1853; Metnitz PGH, 2003, INTENS CARE MED, V29, P241, DOI 10.1007/s00134-002-1584-z; Patel PA, 1999, INTENS CARE MED, V25, P977, DOI 10.1007/s001340050992; Rosenberg AL, 2000, CHEST, V118, P492, DOI 10.1378/chest.118.2.492; *SCOTT EX HLTH DEP, 2000, BETT CRIT CAR REP SH; Trivedi M, 2001, ANAESTHESIA, V56, P841, DOI 10.1046/j.1365-2044.2001.02174.x	20	174	177	0	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 1	2003	327	7422					1014	1016A		10.1136/bmj.327.7422.1014	http://dx.doi.org/10.1136/bmj.327.7422.1014			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738NE	14593033	Bronze, Green Published			2022-12-28	WOS:000186294100017
J	Sikora, K; Bosanquet, N				Sikora, K; Bosanquet, N			Cancer care in the United Kingdom: new solutions are needed	BRITISH MEDICAL JOURNAL			English	Article							WAITING-TIMES		Hammersmith Hosp, Imperial Coll Sch Sci Med & Technol, London W12 0NN, England; Imperial Coll Sch Sci Med & Technol, London SW7 2BX, England	Imperial College London; Imperial College London	Sikora, K (corresponding author), Hammersmith Hosp, Imperial Coll Sch Sci Med & Technol, London W12 0NN, England.							BERRINO F, 1999, SCI PUBLICATIONS, V151; Brown ML, 1999, MED CARE, V37, P1249, DOI 10.1097/00005650-199912000-00008; *CANC SERV COLL, NAT MONTHL PROGR REP; *DEP HLTH, 1999, NEW OPP FUND; *DEP HLTH, 2003, DEL NHS PLAN EXP REP; Department of Health, 2000, NHS CANC PLAN; Downer M C, 1998, Community Dent Health, V15, P72; Kerr D, 2002, BMJ-BRIT MED J, V324, P164, DOI 10.1136/bmj.324.7330.164; Kunkler IH, 2000, J ROY COLL PHYS LOND, V34, P230; *NAT CANC CONTR IN, 2003, OPT CANC CAR AUSTR S; O'Rourke N, 2000, CLIN ONCOL-UK, V12, P141, DOI 10.1053/clon.2000.9139; Patel RS, 2000, EUR J SURG ONCOL, V26, P452, DOI 10.1053/ejso.1999.0920; RICHARDS M, 2003, INV CANC 2001 2002 2; Robinson D, 2003, BRIT J CANCER, V89, P492, DOI 10.1038/sj.bjc.6601149; *ROYAL COLL PATH, 2002, SUBM NICE LIQ BAS CY; Sikora K, 2002, DRUG DISCOV TODAY, V7, P951, DOI 10.1016/S1359-6446(02)02434-0; *UK REN REG, 2002, REP 2002; 2002, LANCET ONCOL, V3, P385	18	6	6	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 1	2003	327	7422					1044	1046		10.1136/bmj.327.7422.1044	http://dx.doi.org/10.1136/bmj.327.7422.1044			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738NE	14593044	Green Published			2022-12-28	WOS:000186294100029
J	Dellavalle, RP; Hester, EJ; Heilig, LF; Drake, AL; Kuntzman, JW; Graber, M; Schilling, LM				Dellavalle, RP; Hester, EJ; Heilig, LF; Drake, AL; Kuntzman, JW; Graber, M; Schilling, LM			Information science - Going, going, gone: Lost Internet references	SCIENCE			English	Editorial Material									Dept Vet Affairs Med Ctr, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Denison Mem Lib, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Dellavalle, RP (corresponding author), Dept Vet Affairs Med Ctr, Denver, CO 80220 USA.	robert.dellavalle@uchsc.edu	Dellavalle, Robert/L-2020-2013	Dellavalle, Robert/0000-0001-8132-088X; Hill, Lauren/0000-0002-9443-2167	NCI NIH HHS [K-07 CA92550, R25 CA49981] Funding Source: Medline; NIAMS NIH HHS [T32 AR07411] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K07CA092550, R25CA049981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007411] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CAPLAN P, 1998, PUBLIC ACCESS COMPUT, V9; DEE M, 1998, QUOTE UNQUOTE HARVAR; Fichter D, 1999, ONLINE, V23, P77; Grogg J. E., 2002, Searcher, V10, P56; *I SCI INF, 2001, J CIT REP JCR SCI ED; Jacso P., 2002, Information Today, V19, P30; Machrone B, 1999, PC WEEK, V16, P81; Markwell J, 2003, BIOCHEM MOL BIOL EDU, V31, P69, DOI 10.1002/bmb.2003.494031010165; Markwell J., 2002, J SCI EDUC TECHNOL, V11, P105; *MOD LANG ASS, 1998, MLA STYL MAN GUID SC; *OCLC PURL SERV OC, 2003, PERS URL HOM PAG; OLSEN S, 2003, CNET NEWS COM   0709; Pearson D, 2001, Health Info Libr J, V18, P139, DOI 10.1046/j.1471-1842.2001.00329.x; *PURD U ONL WRIT L, 2003, US MOD LANG ASS MLA; Shafer K. E., 2001, Journal of Library Administration, V34, P123, DOI 10.1300/J111v34n01_19; *STAFF U CHIC PRES, 2003, CHIC MAN STYL, P646; Veronin MA, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.2.e10; [No title captured]	18	111	115	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	2003	302	5646					787	788		10.1126/science.1088234	http://dx.doi.org/10.1126/science.1088234			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	737XQ	14593153				2022-12-28	WOS:000186258000023
J	Hudson, PJ; Bjornstad, ON				Hudson, PJ; Bjornstad, ON			Vole stranglers and lemming cycles	SCIENCE			English	Editorial Material							POPULATION-DYNAMICS; PREDATION; PATTERNS; HYPOTHESIS; IMPACT; PREY		Penn State Univ, Dept Biol, University Pk, PA 16802 USA; Penn State Univ, Dept Entomol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Hudson, PJ (corresponding author), Penn State Univ, Dept Biol, University Pk, PA 16802 USA.		Bjornstad, Ottar N/I-4518-2012; Hudson, Peter/AAB-8080-2020	Hudson, Peter/0000-0003-0468-3403				Bjornstad ON, 1998, RES POPUL ECOL, V40, P77, DOI 10.1007/BF02765223; Gilg O, 2003, SCIENCE, V302, P866, DOI 10.1126/science.1087509; Graham IM, 2002, J ANIM ECOL, V71, P946, DOI 10.1046/j.1365-2656.2002.00657.x; HANSKI I, 1991, J ANIM ECOL, V60, P353, DOI 10.2307/5465; HANSKI I, 1987, TRENDS ECOL EVOL, V2, P55, DOI 10.1016/0169-5347(87)90146-7; Hudson PJ, 1998, SCIENCE, V282, P2256, DOI 10.1126/science.282.5397.2256; Hudson PJ, 2002, PHILOS T R SOC B, V357, P1259, DOI 10.1098/rstb.2002.1126; Korpimaki E, 1998, ECOLOGY, V79, P2448, DOI 10.2307/176834; KREBS CJ, 1995, SCIENCE, V269, P1112, DOI 10.1126/science.269.5227.1112; McCauley E, 1999, NATURE, V402, P653, DOI 10.1038/45223; Mougeot F, 2003, NATURE, V421, P737, DOI 10.1038/nature01395; Murdoch W.W., 2013, CONSUMER RESOURCE DY; Nielsen OK, 1999, J ANIM ECOL, V68, P1034, DOI 10.1046/j.1365-2656.1999.00351.x; Reid DG, 1997, ECOL MONOGR, V67, P89, DOI 10.2307/2963506; Sinclair ARE, 2003, NATURE, V425, P288, DOI 10.1038/nature01934; Sundell J, 2003, OIKOS, V101, P416, DOI 10.1034/j.1600-0706.2003.12236.x	16	19	20	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 31	2003	302	5646					797	798		10.1126/science.1092366	http://dx.doi.org/10.1126/science.1092366			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593159				2022-12-28	WOS:000186258000029
J	Dorenkamp, M; Weikert, U; Meyer, R; Schwimmbeck, PL; Morguet, AJ				Dorenkamp, M; Weikert, U; Meyer, R; Schwimmbeck, PL; Morguet, AJ			Heart failure in acute febrile neutrophilic dermatosis	LANCET			English	Article							SWEETS-SYNDROME; PATIENT		Benjamin Franklin Univ Hosp, Dept Cardiol & Pneumol, D-12200 Berlin, Germany; German Heart Inst, Dept Pathol, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Heart Center Berlin	Morguet, AJ (corresponding author), Benjamin Franklin Univ Hosp, Dept Cardiol & Pneumol, D-12200 Berlin, Germany.							Callen JP, 2002, DERMATOL CLIN, V20, P409, DOI 10.1016/S0733-8635(02)00006-2; DELABIE J, 1991, BRIT J DERMATOL, V124, P348, DOI 10.1111/j.1365-2133.1991.tb00595.x; Hayashi I, 2001, SURG TODAY, V31, P810, DOI 10.1007/s005950170053; Shimizu K, 1998, AM J HEMATOL, V58, P337, DOI 10.1002/(SICI)1096-8652(199808)58:4<337::AID-AJH16>3.0.CO;2-4; SWEET RD, 1964, BRIT J DERMATOL, V76, P349, DOI 10.1111/j.1365-2133.1964.tb14541.x	5	13	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 25	2003	362	9393					1374	1374		10.1016/S0140-6736(03)14633-8	http://dx.doi.org/10.1016/S0140-6736(03)14633-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	735YX	14585639				2022-12-28	WOS:000186143300011
J	Toh, CH; Dennis, M				Toh, CH; Dennis, M			Disseminated intravascular coagulation: old disease, new hope	BRITISH MEDICAL JOURNAL			English	Review							PROTEIN-C ACTIVATION; SEVERE SEPSIS; THROMBIN; DYSFUNCTION; PURPURA; HEPARIN; COMPLEX; PLASMA	Disseminated intravascular coagulation has long been associated with increased mortality in patients with sepsis. An effective treatment is now available, and the authors of this review describe how improved understanding and earlier diagnosis could lead to targeted treatment and improved prognosis	Royal Liverpool Univ Hosp, Haemostasis & Thrombosis Ctr, Liverpool L7 8XP, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Toh, CH (corresponding author), Royal Liverpool Univ Hosp, Haemostasis & Thrombosis Ctr, Liverpool L7 8XP, Merseyside, England.							Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Combes V, 1999, J CLIN INVEST, V104, P93, DOI 10.1172/JCI4985; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Dupuy M, 1834, GAZ MED PARIS, V2, P524; Faust SN, 2001, NEW ENGL J MED, V345, P408, DOI 10.1056/NEJM200108093450603; FEINSTEIN DI, 1982, BLOOD, V60, P284; Gando S, 1998, THROMB HAEMOSTASIS, V79, P1111; Gando S, 1996, THROMB HAEMOSTASIS, V75, P224; GILES AR, 1984, J CLIN INVEST, V74, P2219, DOI 10.1172/JCI111648; Hazelzet JA, 1996, THROMB HAEMOSTASIS, V76, P932; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; KALAFATIS M, 1994, BBA-MOL BASIS DIS, V1227, P113, DOI 10.1016/0925-4439(94)90086-8; Liaw PCY, 2003, J THROMB HAEMOST, V1, P662, DOI 10.1046/j.1538-7836.2003.00153.x; SATTA N, 1994, J IMMUNOL, V153, P3245; SHIMAMURA K, 1983, ARCH PATHOL LAB MED, V107, P543; Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887; Smith OP, 1997, LANCET, V350, P1590, DOI 10.1016/S0140-6736(97)06356-3; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327, DOI 10.1055/s-0037-1616068; Toh CH, 2002, BLOOD, V100, P2522, DOI 10.1182/blood.V100.7.2522; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302; VONDEMBORNE PAK, 1995, BLOOD, V86, P3035; Warren BL, 2001, JAMA-J AM MED ASSOC, V286, P1869, DOI 10.1001/jama.286.15.1869; Westendorp RGJ, 1997, LANCET, V349, P1912, DOI 10.1016/S0140-6736(05)63910-4	25	67	72	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 25	2003	327	7421					974	977		10.1136/bmj.327.7421.974	http://dx.doi.org/10.1136/bmj.327.7421.974			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	736AL	14576251	Green Published			2022-12-28	WOS:000186147800021
J	Burke, MD; Berger, EM; Schreiber, SL				Burke, MD; Berger, EM; Schreiber, SL			Generating diverse skeletons of small molecules combinatorially	SCIENCE			English	Article							FURAN COMPOUNDS; LIBRARY	Lack of efficient access to collections of synthetic compounds that have skeletal diversity is a key bottleneck in the small-molecule discovery process. We report a synthesis strategy that involves transforming substrates with different appendages that pre-encode skeletal information, named sigma elements, into products that have different skeletons with the use of common reaction conditions. With this approach, split-pool synthesis can be used to pre-encode skeletal diversity combinatorially and thereby generate such small molecules very efficiently. A split-pool synthesis of more than 1000 compounds produced overlapping, combinatorial matrices of molecular skeletons and appended building blocks in both enantiomeric and diastereomeric forms.	Harvard Univ, Inst Chem & Cell Biol, Howard Hughes Med Inst, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University; Howard Hughes Medical Institute	Schreiber, SL (corresponding author), Harvard Univ, Inst Chem & Cell Biol, Howard Hughes Med Inst, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.	sls@slsiris.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080436] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM080436] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHMATOWICZ O, 1971, TETRAHEDRON, V27, P1973, DOI 10.1016/S0040-4020(01)98229-8; Bach T, 1999, EUR J ORG CHEM, V1999, P2045; Blackwell HE, 2001, CHEM BIOL, V8, P1167, DOI 10.1016/S1074-5521(01)00085-0; Breinbauer R, 2002, ANGEW CHEM INT EDIT, V41, P2879; BUNIN BA, 1992, J AM CHEM SOC, V114, P10997, DOI 10.1021/ja00053a067; BURGESS K, 1994, J MED CHEM, V37, P2985, DOI 10.1021/jm00045a001; CLAUSONKAAS N, 1953, ACTA CHEM SCAND, V7, P845, DOI 10.3891/acta.chem.scand.07-0845; DEWITT SH, 1993, P NATL ACAD SCI USA, V90, P6909, DOI 10.1073/pnas.90.15.6909; Ding S, 2002, J AM CHEM SOC, V124, P1594, DOI 10.1021/ja0170302; Dolle RE, 2002, J COMB CHEM, V4, P369, DOI 10.1021/cc020039v; EVANS DA, 1981, J AM CHEM SOC, V103, P2127, DOI 10.1021/ja00398a058; Furka A, 1988, HIGHLIGHTS MODERN BI, P47; Harris JM, 2000, TETRAHEDRON LETT, V41, P183, DOI 10.1016/S0040-4039(99)02050-X; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; Kobayashi Y, 1998, J ORG CHEM, V63, P7505, DOI 10.1021/jo980942a; Kwon O, 2002, J AM CHEM SOC, V124, P13402, DOI 10.1021/ja028086e; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; Lee DS, 2000, ORG LETT, V2, P709, DOI 10.1021/ol005574n; NESTLER HP, 1994, J ORG CHEM, V59, P4723, DOI 10.1021/jo00096a008; NEWTH FH, 1951, ADV CARBOHYD CHEM, V6, P83; Schreiber SL, 2003, CHEM ENG NEWS, V81, P51, DOI 10.1021/cen-v081n009.p051; Schreiber SL, 2000, SCIENCE, V287, P1964, DOI 10.1126/science.287.5460.1964; Tan DS, 1998, J AM CHEM SOC, V120, P8565, DOI 10.1021/ja981746o; Taniguchi T, 1998, TETRAHEDRON-ASYMMETR, V9, P1451, DOI 10.1016/S0957-4166(98)00117-7; Weber L, 2000, CURR OPIN CHEM BIOL, V4, P295, DOI 10.1016/S1367-5931(00)00092-2; [No title captured]	26	336	342	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	2003	302	5645					613	618		10.1126/science.1089946	http://dx.doi.org/10.1126/science.1089946			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576427				2022-12-28	WOS:000186119900050
J	Penna, C; Deroide, GA				Penna, C; Deroide, GA			Splenic sarcoidosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Hop Ambroise Pare, F-92100 Boulogne, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	Penna, C (corresponding author), Hop Ambroise Pare, F-92100 Boulogne, Paris, France.								0	7	7	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	2003	349	17					E16	E16		10.1056/ENEJMicm020110	http://dx.doi.org/10.1056/ENEJMicm020110			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734ZT	14573747				2022-12-28	WOS:000186088400009
J	Wilson, JF				Wilson, JF			Should doctors prescribe alcohol to adults?	ANNALS OF INTERNAL MEDICINE			English	News Item							CONSUMPTION; DRINKING; MORTALITY						Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136				Abramson JL, 2001, JAMA-J AM MED ASSOC, V285, P1971, DOI 10.1001/jama.285.15.1971; Ellison RC, 2002, ANN NY ACAD SCI, V957, P1, DOI 10.1111/j.1749-6632.2002.tb02900.x; FUCHS CS, 1995, NEW ENGL J MED, V332, P1245, DOI 10.1056/NEJM199505113321901; Goldberg IJ, 2003, NEW ENGL J MED, V348, P163, DOI 10.1056/NEJMe020163; Mukamal KJ, 2003, NEW ENGL J MED, V348, P109, DOI 10.1056/NEJMoa022095; Nicolas JM, 2002, ANN INTERN MED, V136, P192, DOI 10.7326/0003-4819-136-3-200202050-00007; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401	7	5	6	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 21	2003	139	8					711	714		10.7326/0003-4819-139-8-200310210-00036	http://dx.doi.org/10.7326/0003-4819-139-8-200310210-00036			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734DW	14568873				2022-12-28	WOS:000186040800022
J	Gu, Y; Filippi, MD; Cancelas, JA; Siefring, JE; Williams, EP; Jasti, AC; Harris, CE; Lee, AW; Prabhakar, R; Atkinson, SJ; Kwiatkowski, DJ; Williams, DA				Gu, Y; Filippi, MD; Cancelas, JA; Siefring, JE; Williams, EP; Jasti, AC; Harris, CE; Lee, AW; Prabhakar, R; Atkinson, SJ; Kwiatkowski, DJ; Williams, DA			Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases	SCIENCE			English	Article							RHO-GTPASES; MAST-CELLS; STEM-CELLS; T-CELLS; BINDING; GENE; EXPRESSION; ACTIVATION; DELETION; ADHESION	The Rho guanosine triphosphatases (GTPases) Rac1 and Rac2 are critical signaling regulators in mammalian cells. The deletion of both Rac1 and Rac2 murine alleles leads to a massive egress of hematopoietic stem/progenitor cells (HSC/Ps) into the blood from the marrow, whereas Rac1(-/-) but not Rac2(-/-) HSC/Ps fail to engraft in the bone marrow of irradiated recipient mice. In contrast, Rac2, but not Rac1, regulates superoxide production and directed migration in neutrophils, and in each cell type, the two GTPases play distinct roles in actin organization, cell survival, and proliferation. Thus, Rac1 and Rac2 regulate unique aspects of hematopoietic development and function.	Cincinnati Childrens Hosp, Med Ctr, Div Expt Hematol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Hoxworth Blood Ctr, Cincinnati, OH 45267 USA; Indiana Univ, Dept Med, Indianapolis, IN 46202 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Indiana University System; Indiana University-Purdue University Indianapolis; Harvard University; Brigham & Women's Hospital	Williams, DA (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Expt Hematol, Cincinnati, OH 45229 USA.		Cancelas, Jose/AAR-9324-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062757] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK62757] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Croker BA, 2002, J IMMUNOL, V168, P3376, DOI 10.4049/jimmunol.168.7.3376; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Glogauer M, 2003, J IMMUNOL, V170, P5652, DOI 10.4049/jimmunol.170.11.5652; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Gu Y, 2002, MOL CELL BIOL, V22, P7645, DOI 10.1128/MCB.22.21.7645-7657.2002; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Li BY, 2000, SCIENCE, V288, P2219, DOI 10.1126/science.288.5474.2219; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MOLL J, 1991, ONCOGENE, V6, P863; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Palacios R, 1996, P NATL ACAD SCI USA, V93, P5247, DOI 10.1073/pnas.93.11.5247; Papayannopoulou T, 1997, ACTA HAEMATOL-BASEL, V97, P97; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; SHIRSAT NV, 1990, ONCOGENE, V5, P769; Sugihara K, 1998, ONCOGENE, V17, P3427, DOI 10.1038/sj.onc.1202595; VAN AL, 1997, GENE DEV, V11, P2295; van der Loo JCM, 1998, J CLIN INVEST, V102, P1051, DOI 10.1172/JCI3687; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; Yang FC, 2001, P NATL ACAD SCI USA, V98, P5614, DOI 10.1073/pnas.101546898	25	396	417	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					445	449		10.1126/science.1088485	http://dx.doi.org/10.1126/science.1088485			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564009				2022-12-28	WOS:000185963200043
J	Markowitz, AJ; McPhee, S				Markowitz, AJ; McPhee, S			Complexities in prognostication in advanced cancer - "To help them live their lives the way they want to"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Lamont EB, 2003, JAMA-J AM MED ASSOC, V290, P98, DOI 10.1001/jama.290.1.98	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	2003	290	15					2056	2056		10.1001/jama.290.15.2056	http://dx.doi.org/10.1001/jama.290.15.2056			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CX	14559960				2022-12-28	WOS:000185924200030
J	Bonaccorso, S; Sturchio, JL				Bonaccorso, S; Sturchio, JL			Perspectives from the pharmaceutical industry	BRITISH MEDICAL JOURNAL			English	Article									Merck & Co Inc, Mkt & Med Serv, Whitehouse Stn, NJ 08889 USA; Merck & Co Inc, External Affairs Europe Middle E & Africa, Whitehouse Stn, NJ 08889 USA	Merck & Company; Merck & Company	Bonaccorso, S (corresponding author), Merck & Co Inc, Mkt & Med Serv, 1 Merck Dr, Whitehouse Stn, NJ 08889 USA.							Bonaccorso SN, 2002, BRIT MED J, V324, P910, DOI 10.1136/bmj.324.7342.910; Calfee JE, 2002, J LAW ECON, V45, P673, DOI 10.1086/374704; Coulter A, 2003, EUROPEAN PATIENT FUT; *EUR FED PHARM IND, 2001, GUID INT WEB SIT AV; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; Organization WH, 2003, ADHERENCE LONG TERM	6	14	14	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					863	864		10.1136/bmj.327.7419.863	http://dx.doi.org/10.1136/bmj.327.7419.863			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551109	Green Published			2022-12-28	WOS:000185921200031
J	Narayan, KMV; Boyle, JP; Thompson, TJ; Sorensen, SW; Williamson, DF				Narayan, KMV; Boyle, JP; Thompson, TJ; Sorensen, SW; Williamson, DF			Lifetime risk for diabetes mellitus in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; BREAST-CANCER; US; PREVALENCE; POPULATION; MORTALITY; PERSPECTIVE; IMPACT; ADULTS; BURDEN	Context Although diabetes mellitus is one of the most prevalent and costly chronic diseases in the United States, no estimates have been published of individuals' average lifetime risk of developing diabetes. Objective Toe stimate age-, sex-, and race/ethnicity-specific lifetime risk. of diabetes in the cohort born in 2000 in the United States. Design, Setting, and Participants Data from the National Health Interview Survey (1984-2000) were used to estimate age-, sex-, and race/ethnicity-specific prevalence and incidence in 2000. US Census Bureau data. and data from a previous study of diabetes as a cause of death were used to estimate age-, sex-, and race/ethnicity- specific mortality rates for diabetic and nondiabetic populations. Main Outcome Measures, Residual (remaining) lifetime risk of diabetes (from birth to 80, years in 1-year intervals), duration with diabetes, and life-years and quality-adjusted life-years lost from diabetes. Results the estimated lifetime risk of developing diabetes for individuals born in 2000 is 32.8% for males and 38.5% for females. Females have higher residual lifetime risks at all ages. The highest. estimated lifetime risk for diabetes is among Hispanics (males, 45.4% and females, 515%) Individuals diagnosed as having diabetes have large reductions in life expectancy. For example, we estimate that if an individual is diagnosed at age 40 years, men will lose 11.6 life-years and 18.6 quality-adjusted life-years and women will lose 14.3 life-years and 22.0 quality-adjusted life-years. Conclusions, For individuals born in the United States in 2000, the lifetime probability of being diagnosed with diabetes mellitus is substantial. Primary prevention of diabetes and its complications are important public health priorities.	Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Narayan, KMV (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, 4770 Buford Hwy NE,MSK-10, Atlanta, GA 30341 USA.							[Anonymous], 1995, DIABETES AM; Botman S, 2000, VITAL HLTH STAT, V2; Boyle JP, 2001, DIABETES CARE, V24, P1936, DOI 10.2337/diacare.24.11.1936; Briggs AH, 2000, PHARMACOECONOMICS, V17, P479, DOI 10.2165/00019053-200017050-00006; *BUR CENS, 2000, COMP ASS RES POP AG; Burke JP, 1999, ARCH INTERN MED, V159, P1450, DOI 10.1001/archinte.159.13.1450; Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5; Clarke P, 2002, MED DECIS MAKING, V22, P340, DOI 10.1177/027298902400448902; Coffey JT, 2002, DIABETES CARE, V25, P2238, DOI 10.2337/diacare.25.12.2238; CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445; Davidson MB, 2002, DIABETES CARE, V25, P1, DOI 10.2337/diacare.25.1.1; *DEP HLTH HUM SERV, 1998, SUMM HLTH STAT US CH; Engelgau MM, 2000, DIABETES CARE, V23, P1563, DOI 10.2337/diacare.23.10.1563; Fagot-Campagna A, 2000, J PEDIATR-US, V136, P664, DOI 10.1067/mpd.2000.105141; FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Gu K, 1998, DIABETES CARE, V21, P1138, DOI 10.2337/diacare.21.7.1138; HARRIS MI, 1995, NIH PUBLICATION, P1; HOEL PG, 1972, INTRO STOCHASTIC PRO; Honeycutt Amanda A, 2003, Health Care Manag Sci, V6, P155, DOI 10.1023/A:1024467522972; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; Jagger C, 2003, J PUBLIC HEALTH MED, V25, P42, DOI 10.1093/pubmed/fdg009; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Leibson CL, 1997, AM J EPIDEMIOL, V146, P12, DOI 10.1093/oxfordjournals.aje.a009187; Lloyd-Jones DM, 1999, LANCET, V353, P89, DOI 10.1016/S0140-6736(98)10279-9; Mokdad AH, 2000, DIABETES CARE, V23, P1278, DOI 10.2337/diacare.23.9.1278; Mokdad AH, 2001, DIABETES CARE, V24, P412, DOI 10.2337/diacare.24.2.412; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; NARAYAN KM, 2002, EPIDEMIOLOGY DIABETE; Narayan KMV, 2000, DIABETES CARE, V23, P1794, DOI 10.2337/diacare.23.12.1794; Narayan KMV, 2000, DIABETES RES CLIN PR, V50, pS77; *NAT CTR HLTH STAT, 2002, HLTH US; *NAT CTR HLTH STAT, 2000 NAT HLTH INT SU; *NAT CTR HLTH STAT, 1993, CD ROM SERIES, V10; O'Connor PJ, 1998, AM J MANAG CARE, V4, P335; Phillips KA, 1999, NEW ENGL J MED, V340, P141, DOI 10.1056/NEJM199901143400211; Ray NF, 1998, DIABETES CARE, V21, P296; Rothman K., 1998, MODERN EPIDEMIOLOGY; Sasieni PD, 1999, AM J EPIDEMIOL, V149, P869; Saydah SH, 2002, AM J EPIDEMIOL, V156, P714, DOI 10.1093/aje/kwf111; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; Seshadri S, 1997, NEUROLOGY, V49, P1498, DOI 10.1212/WNL.49.6.1498; Tierney EF, 2001, AM J PUBLIC HEALTH, V91, P84, DOI 10.2105/AJPH.91.1.84; Vasan RS, 2002, JAMA-J AM MED ASSOC, V287, P1003, DOI 10.1001/jama.287.8.1003	44	1021	1045	0	43	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2003	290	14					1884	1890		10.1001/jama.290.14.1884	http://dx.doi.org/10.1001/jama.290.14.1884			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729CB	14532317	Bronze			2022-12-28	WOS:000185752600029
J	Vlahov, D; Galea, S				Vlahov, D; Galea, S			Urban health: a new discipline	LANCET			English	Editorial Material							DISEASE; WORLD; ABUSE		New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY 10029 USA	New York Academy of Medicine	Vlahov, D (corresponding author), New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY 10029 USA.	dvlahov@nyam.org	Galea, Sandro/GLR-6066-2022	Galea, Sandro/0000-0002-7534-0945				[Anonymous], 1993, HIST PUBLIC HLTH; Cornish JW, 1996, ANNU REV PUBL HEALTH, V17, P259; Freudenberg N, 2000, J URBAN HEALTH, V77, P443, DOI 10.1007/BF02386753; Gelbard A, 1999, POPUL BULL, V54, P3; Gould WTS, 1998, HEALTH PLACE, V4, P171, DOI 10.1016/S1353-8292(98)00009-4; *INT SOC URB HLTH, 2003, 2 INT C URB HLTH OCT; McMichael AJ, 2000, B WORLD HEALTH ORGAN, V78, P1117; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; SATTERTHWAITE D, 2002, LEADING EDGE SERIES; *UN POP DIV, 2000, WORLD URB PROSP 1999; Vlahov D, 2002, J URBAN HEALTH, V79, pS1, DOI 10.1093/jurban/79.suppl_1.S1	11	35	36	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 4	2003	362	9390					1091	1092		10.1016/S0140-6736(03)14499-6	http://dx.doi.org/10.1016/S0140-6736(03)14499-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	728HA	14550692	Green Submitted			2022-12-28	WOS:000185710700005
J	Martina, BEE; Haagmans, BL; Kuiken, T; Fouchier, RAM; Rimmelzwaan, GF; van Amerongen, G; Peiris, JSM; Lim, W; Osterhaus, ADME				Martina, BEE; Haagmans, BL; Kuiken, T; Fouchier, RAM; Rimmelzwaan, GF; van Amerongen, G; Peiris, JSM; Lim, W; Osterhaus, ADME			SARS virus infection of cats and ferrets	NATURE			English	Article							ACUTE RESPIRATORY SYNDROME; CORONAVIRUS		Erasmus Med Ctr, Inst Virol, NL-3015 GE Rotterdam, Netherlands; Queen Mary Hosp, Dept Pathol & Microbiol, Hong Kong, Hong Kong, Peoples R China; Govt Virus Unit, Kowloon, Hong Kong, Peoples R China	Erasmus University Rotterdam; Erasmus MC; University of Hong Kong	Martina, BEE (corresponding author), Erasmus Med Ctr, Inst Virol, NL-3015 GE Rotterdam, Netherlands.		Fouchier, Ron A/A-1911-2014; Haagmans, Bart/E-9791-2015	Fouchier, Ron A/0000-0001-8095-2869; Haagmans, Bart/0000-0001-6221-2015; Osterhaus, Albert/0000-0002-6074-1172				Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2	5	424	459	65	246	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	2003	425	6961					915	915		10.1038/425915a	http://dx.doi.org/10.1038/425915a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14586458	Green Published, Bronze			2022-12-28	WOS:000186230600030
J	Griffin, AS; West, SA				Griffin, AS; West, SA			Kin discrimination and the benefit of helping in cooperatively breeding vertebrates	SCIENCE			English	Article							PUBLICATION BIAS; EVOLUTION; BEHAVIOR; ECOLOGY; KINSHIP; SELECTION; FILL; TRIM	In many cooperatively breeding vertebrates, a dominant breeding pair is assisted in offspring care by nonbreeding helpers. A leading explanation for this altruistic behavior is Hamilton's idea that helpers gain indirect fitness benefits by rearing relatives (kin selection). Many studies have shown that helpers typically provide care for relatives, but relatively few have shown that helpers provide closer kin with preferential care ( kin discrimination), fueling the suggestion that kin selection only poorly accounts for the evolution of cooperative breeding in vertebrates. We used meta-analysis to show that (i) individuals consistently discriminate between kin, and (ii) stronger discrimination occurs in species where the benefits of helping are greater. These results suggest a general role for kin selection and that the relative importance of kin selection varies across species, as predicted by Hamilton's rule.	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Griffin, AS (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, Kings Bldg,W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.	a.griffin@ed.ac.uk	Griffin, Ashleigh/C-6244-2014; West, Stuart A/M-3608-2014	Griffin, Ashleigh/0000-0001-7674-9825; West, Stuart A/0000-0003-2152-3153				ARNQVIST G, 1995, TRENDS ECOL EVOL, V10, P236, DOI 10.1016/S0169-5347(00)89073-4; Bourke A. F., 1995, SOCIAL EVOLUTION ANT; Clutton-Brock T, 2002, SCIENCE, V296, P69, DOI 10.1126/science.296.5565.69; Clutton-Brock TH, 2000, P ROY SOC B-BIOL SCI, V267, P301, DOI 10.1098/rspb.2000.1000; Clutton-Brock TH, 1999, SCIENCE, V284, P1640, DOI 10.1126/science.284.5420.1640; Cockburn A, 1998, ANNU REV ECOL SYST, V29, P141, DOI 10.1146/annurev.ecolsys.29.1.141; DUGATKIN LA, 1997, OXFORD SERIES ETHOLO; DUNN PO, 1995, P ROY SOC B-BIOL SCI, V259, P339, DOI 10.1098/rspb.1995.0050; DUPLESSIS MA, 1993, BEHAVIOUR, V127, P49, DOI 10.1163/156853993X00425; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; EMLEN ST, 1988, BEHAV ECOL SOCIOBIOL, V23, P305, DOI 10.1007/BF00300577; EMLEN ST, 1995, P NATL ACAD SCI USA, V92, P8092, DOI 10.1073/pnas.92.18.8092; Emlen Stephen T., 1997, P228; GASTON AJ, 1978, AM NAT, V112, P1091, DOI 10.1086/283348; GRAFEN A, 1990, ANIM BEHAV, V39, P42, DOI 10.1016/S0003-3472(05)80724-9; Griffin AS, 2002, TRENDS ECOL EVOL, V17, P15, DOI 10.1016/S0169-5347(01)02355-2; HAMILTON WD, 1963, AM NAT, V97, P354, DOI 10.1086/497114; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Jennions MD, 2002, BIOL REV, V77, P211, DOI 10.1017/S1464793101005875; KELLER L, 2002, KIN SELECTION; Kokko H, 2002, BEHAV ECOL, V13, P291, DOI 10.1093/beheco/13.3.291; Kokko H, 2001, P ROY SOC B-BIOL SCI, V268, P187, DOI 10.1098/rspb.2000.1349; Komdeur J, 1999, TRENDS ECOL EVOL, V14, P237, DOI 10.1016/S0169-5347(98)01573-0; KOMDEUR J, 1994, P ROY SOC B-BIOL SCI, V256, P47, DOI 10.1098/rspb.1994.0047; Moller AP, 2002, OECOLOGIA, V132, P492, DOI 10.1007/s00442-002-0952-2; RABENOLD KN, 1985, BEHAV ECOL SOCIOBIOL, V17, P1, DOI 10.1007/BF00299422; Rosenberg MS, 2000, METAWIN STAT SOFTWAR; Rosenthal R, 1991, METAANALYTIC PROCEDU; Russell AF, 2001, P ROY SOC B-BIOL SCI, V268, P2169, DOI 10.1098/rspb.2001.1790; Stacey P.B., 1990, COOPERATIVE BREEDING	30	296	301	2	229	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	2003	302	5645					634	636		10.1126/science.1089402	http://dx.doi.org/10.1126/science.1089402			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576431	Green Submitted			2022-12-28	WOS:000186119900056
J	Finn, AV; Antman, EM				Finn, AV; Antman, EM			Isolated right ventricular infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Boston, MA 02114 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital	Finn, AV (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.								0	15	16	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	2003	349	17					1636	1636		10.1056/NEJMicm030315	http://dx.doi.org/10.1056/NEJMicm030315			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734ZT	14573735				2022-12-28	WOS:000186088400008
J	Khot, UN; Jia, G; Moliterno, DJ; Lincoff, AM; Khot, MB; Harrington, RA; Topol, EJ				Khot, UN; Jia, G; Moliterno, DJ; Lincoff, AM; Khot, MB; Harrington, RA; Topol, EJ			Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes - The enduring value of Killip classification	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; PLATELET GLYCOPROTEIN IIB/IIIA; ACUTE ISCHEMIC SYNDROMES; UNSTABLE ANGINA; RISK STRATIFICATION; SEGMENT ELEVATION; DOPPLER-ECHOCARDIOGRAPHY; CARDIAC AUSCULTATION; CARDIOGENIC-SHOCK; EJECTION FRACTION	Context In acute myocardial infarction, the presence and severity of heart failure at the time of initial presentation have been formally categorized by the Killip classification. Although well studied in ST-elevation myocardial infarction, the prognostic importance of Killip classification in non-ST-elevation acute coronary syndromes is not well established. Objectives To determine the prognostic importance of physical examination for heart failure analyzed according to Killip classification in non-ST-elevation acute coronary syndromes and to understand its predictive value relative to other variables. Design, Setting, and Patients From April 2001 to September 2003, We analyzed information from 26090 patients with non-ST-elevation acute coronary syndromes enrolled in the GUSTO IIb, PURSUIT, PARAGON A, and PARAGON B trials. Demographic information was categorized by Killip class. Killip classes III and IV were combined into 1 category. Multivariate Cox proportional hazard models were developed to determine the prognostic importance of Killip classification in comparison with other variables. Main Outcome Measure Association between Killip classification and all-cause mortality at 30 days and 6 months. Results Patients in Killip class II (n =2513) and III/IV (n =390) were older than those in Killip class I (n =23 187), with higher rates of diabetes, prior myocardial infarction, ST depression, and elevated cardiac enzymes (all P<.001). Higher Killip class was associated with higher mortality at 30 days (2.8% in Killip class I vs 8.8% in class II vs 14.4% in class III/IV; P<.001) and 6 months (5.0% vs 14.7% vs 23.0%, respectively; P<.001). Patients with Killip class II, III, or IV constituted 11% of the overall population but accounted for approximately 30% of the deaths at both time points. In multivariate analysis, Killip class III/IV was the most powerful predictor of mortality at 30 days (hazard ratio [HR], 2.35; 95% confidence interval [CI], 1.69-3.26; P<.001) and 6 months (HR, 2.12; 95% Cl, 1.63-2.75; P<.001). Killip class 11 was predictive of mortality at 30 days (HR, 1.73; 95% Cl, 1.44-2.09; P<.001) and 6 months (HR, 1.52; 95% Cl, 1.31-1.76; P<.001). Five factors-age, Killip classification, heart rate, systolic blood pressure, and ST depression-provided more than 70% of the prognostic information for 30-day and 6-month mortality. Conclusions Killip classification is a powerful independent predictor of all-cause mortality in patients with non-ST-elevation acute coronary syndromes. Age, Killip classification, heart rate, systolic blood pressure, and ST depression should receive particular attention in the initial assessment of these patients.	Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Duke Clin Res Inst, Durham, NC USA	Cleveland Clinic Foundation; Duke University	Khot, UN (corresponding author), Indiana Heart Phys, 112 N 17th Ave,Suite 300, Beech Grove, IN 46107 USA.			Topol, Eric/0000-0002-1478-4729				Alexander JH, 2000, JAMA-J AM MED ASSOC, V283, P347, DOI 10.1001/jama.283.3.347; Antman EM, 2000, JAMA-J AM MED ASSOC, V284, P835, DOI 10.1001/jama.284.7.835; Armstrong PW, 1998, CIRCULATION, V98, P1860, DOI 10.1161/01.CIR.98.18.1860; Bazzino O, 1999, AM HEART J, V137, P322, DOI 10.1053/hj.1999.v137.93029; Braunwald E, 2000, J AM COLL CARDIOL, V36, P970, DOI 10.1016/S0735-1097(00)00889-5; Braunwald E, 1994, UNSTABLE ANGINA DIAG; BROWN KA, 1991, J AM COLL CARDIOL, V17, P1053, DOI 10.1016/0735-1097(91)90829-X; CHATTERJEE K, 2002, TXB CARDIOVASCULAR M, P273; COL NF, 1994, AM J CARDIOL, V73, P149, DOI 10.1016/0002-9149(94)90206-2; Collinson J, 2000, EUR HEART J, V21, P1450, DOI 10.1053/euhj.1999.1995; Coronado BE, 1997, J AM COLL CARDIOL, V29, P1490, DOI 10.1016/S0735-1097(97)00077-6; de Lemos JA, 2001, NEW ENGL J MED, V345, P1014, DOI 10.1056/NEJMoa011053; de Sa EL, 2002, MEDICINE, V81, P434, DOI 10.1097/00005792-200211000-00004; DeGeare VS, 2001, AM J CARDIOL, V87, P1035, DOI 10.1016/S0002-9149(01)01457-6; Diderholm E, 2002, AM HEART J, V143, P760, DOI 10.1067/mhj.2002.121733; Drazner MH, 2001, NEW ENGL J MED, V345, P574, DOI 10.1056/NEJMoa010641; Gigli G, 2002, Eur J Echocardiogr, V3, P59, DOI 10.1053/euje.2001.0119; Harrington RA, 2002, CIRCULATION, V105, P316; Holmes DR, 1999, CIRCULATION, V100, P2067, DOI 10.1161/01.CIR.100.20.2067; JAFFE WM, 1988, CIRCULATION, V78, P267, DOI 10.1161/01.CIR.78.2.267; Katz DA, 1996, JAMA-J AM MED ASSOC, V276, P1568; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; LAUNBJERG J, 1992, CARDIOLOGY, V80, P375, DOI 10.1159/000175028; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; Mangione S, 1999, AM J RESP CRIT CARE, V159, P1119, DOI 10.1164/ajrccm.159.4.9806083; Mangione S, 1997, JAMA-J AM MED ASSOC, V278, P717, DOI 10.1001/jama.278.9.717; Moller JE, 2001, J AM SOC ECHOCARDIOG, V14, P757, DOI 10.1067/mje.2001.113367; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; Neskovic AN, 1999, AM HEART J, V137, P361, DOI 10.1053/hj.1999.v137.89744; NICOD P, 1988, AM J CARDIOL, V61, P1165, DOI 10.1016/0002-9149(88)91148-4; Roe MT, 2000, CIRCULATION, V102, P1101, DOI 10.1161/01.CIR.102.10.1101; Rott D, 1997, AM J CARDIOL, V80, P859, DOI 10.1016/S0002-9149(97)00536-5; Savonitto S, 2002, J AM COLL CARDIOL, V39, P22, DOI 10.1016/S0735-1097(01)01706-5; Schneiderman H, 2001, AM J MED, V110, P233, DOI 10.1016/S0002-9343(00)00736-1; Seres L, 1999, AM J CARDIOL, V84, P963, DOI 10.1016/S0002-9149(99)00481-6; Solomon DH, 2001, J AM COLL CARDIOL, V38, P969, DOI 10.1016/S0735-1097(01)01503-0; Tavel ME, 1996, CIRCULATION, V93, P1250, DOI 10.1161/01.CIR.93.6.1250; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol E, 1998, CIRCULATION, V97, P2386; Topol EJ, 1996, NEW ENGL J MED, V335, P775; WARNOWICZ MA, 1983, CIRCULATION, V67, P330, DOI 10.1161/01.CIR.67.2.330	41	154	165	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	2003	290	16					2174	2181		10.1001/jama.290.16.2174	http://dx.doi.org/10.1001/jama.290.16.2174			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CB	14570953	Bronze			2022-12-28	WOS:000186036700027
J	Pichler, WJ				Pichler, WJ			Delayed drug hypersensitivity reactions	ANNALS OF INTERNAL MEDICINE			English	Review							T-CELL-CLONES; TOXIC EPIDERMAL NECROLYSIS; GENERALIZED EXANTHEMATOUS PUSTULOSIS; BETA-LACTAM ANTIBIOTICS; INDUCED CUTANEOUS ERUPTIONS; HERPESVIRUS 6 INFECTION; ALLERGIC REACTIONS; SKIN-LESIONS; CONTACT HYPERSENSITIVITY; INTERSTITIAL NEPHRITIS	Immune reactions to small molecular compounds, such as drugs, can cause a variety of diseases involving the skin, liver, kidney, and lungs. In many drug hypersensitivity reactions, drug-specific CD4(+) and CD8(+) T cells recognize drugs through their alphabeta T-cell receptors in an MHC-dependent way. Drugs stimulate T cells if they act as haptens and bind covalently to peptides or if they have structural features that allow them to interact with certain T-cell receptors directly. Immunohistochemical and functional studies of drug-reactive T cells in patients with distinct forms of exanthema reveal that distinct T-cell functions lead to different clinical phenotypes. In maculopapular exanthema, perforin-positive and granzyme B-positive CD4(+) T cells kill activated keratinocytes, while a large number of cytotoxic CD8(+) T cells in the epidermis is associated with formation of vesicles and bullae. Drug-specific T cells also orchestrate inflammatory skin reactions through the release of various cytokines (for example, interleukin-5, interferon) and chemokines (such as interieukin-8). Activation of T cells with a particular function seems to lead to a specific clinical picture (for example, bullous or pustular exanthema). Taken together, these data allow delayed hypersensitivity reactions (type IV) to be further subclassified into T-cell reactions, which through the release of certain cytokines and chemokines preferentially activate and recruit monocytes (type lVa), eosinophils (type lVb), or neutrophils (type lVd). Moreover, cytotoxic functions by either CD4(+) or CD8(+) T cells (type IVc) seem to participate in all type IV reactions.	Univ Bern, Inselspital, Clin Rheumatol & Clin Immunol Allergol, Div Allergol, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern	Pichler, WJ (corresponding author), Univ Bern, Inselspital, Clin Rheumatol & Clin Immunol Allergol, Div Allergol, CH-3010 Bern, Switzerland.	werner.pichler@insel.ch		Pichler, Werner J./0000-0002-8117-359X				ALANKO K, 1993, CONTACT DERMATITIS, V29, P254, DOI 10.1111/j.1600-0536.1993.tb03560.x; Antonen JA, 1999, SCAND J RHEUMATOL, V28, P157; Arakawa M, 2001, INTERNAL MED, V40, P331, DOI 10.2169/internalmedicine.40.331; Austyn JM, 1999, NAT MED, V5, P1232, DOI 10.1038/15182; Barbaud AM, 1998, ARCH DERMATOL, V134, P1040, DOI 10.1001/archderm.134.8.1040; Barbaud AM, 1997, ARCH DERMATOL, V133, P481, DOI 10.1001/archderm.133.4.481; Behrendt C, 2000, EUR J DERMATOL, V10, P365; BEYLOT C, 1980, ANN DERMATOL VENER, V107, P37; BIGBY M, 1986, JAMA-J AM MED ASSOC, V256, P3358; BLANCA M, 1994, J ALLERGY CLIN IMMUN, V94, P562, DOI 10.1016/0091-6749(94)90218-6; Bourezane Y, 1998, CLIN INFECT DIS, V27, P1321, DOI 10.1086/517713; BRANDER C, 1995, J IMMUNOL, V155, P2670; Britschgi M, 2001, J CLIN INVEST, V107, P1433, DOI 10.1172/JCI12118; Brugnolo F, 1999, J IMMUNOL, V163, P1053; Burkhart C, 2001, BRIT J PHARMACOL, V132, P623, DOI 10.1038/sj.bjp.0703845; Carroll MC, 2001, PEDIATRICS, V108, P485, DOI 10.1542/peds.108.2.485; Choquet-Kastylevsky G, 1998, BRIT J DERMATOL, V139, P1026, DOI 10.1046/j.1365-2133.1998.02559.x; Coombs P.R., 1968, CLIN ASPECTS IMMUNOL, P575; COOPMAN SA, 1993, NEW ENGL J MED, V328, P1670, DOI 10.1056/NEJM199306103282304; CRIBB AE, 1992, CLIN PHARMACOL THER, V51, P522, DOI 10.1038/clpt.1992.57; Descamps V, 2001, ARCH DERMATOL, V137, P301; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; FELLNER MJ, 1970, J INVEST DERMATOL, V55, P390, DOI 10.1111/1523-1747.ep12260501; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; Gerber BO, 1997, CURR BIOL, V7, P836, DOI 10.1016/S0960-9822(06)00371-X; Girolomoni G, 2001, CURR OPIN IMMUNOL, V13, P733, DOI 10.1016/S0952-7915(01)00287-4; Griem P, 1998, IMMUNOL TODAY, V19, P133, DOI 10.1016/S0167-5699(97)01219-X; Hari Y, 2001, CLIN EXP ALLERGY, V31, P1398, DOI 10.1046/j.1365-2222.2001.01164.x; Hari Y, 1999, INT ARCH ALLERGY IMM, V120, P225, DOI 10.1159/000024271; Hashimoto K, 2003, CURR OPIN ALLERGY CL, V3, P255, DOI [10.1097/00130832-200308000-00004, 10.1097/01.all.0000083949.99396.af]; Heller HM, 2000, CLIN DERMATOL, V18, P485, DOI 10.1016/S0738-081X(99)00144-3; HERTL M, 1993, J INVEST DERMATOL, V101, P794, DOI 10.1111/1523-1747.ep12371697; HERTL M, 1995, BRIT J DERMATOL, V132, P215; HERTL M, 1993, BRIT J DERMATOL, V128, P619, DOI 10.1111/j.1365-2133.1993.tb00255.x; HOUWERZIJL J, 1977, CLIN EXP IMMUNOL, V29, P272; Hunziker T, 1997, ALLERGY, V52, P388, DOI 10.1111/j.1398-9995.1997.tb01017.x; Hunziker T, 2002, PHARMACOEPIDEM DR S, V11, P159, DOI 10.1002/pds.669; Janeway CA, 2001, IMMUNOBIOLOGY; Kamradt T, 2001, NEW ENGL J MED, V344, P655, DOI 10.1056/NEJM200103013440907; Kehren J, 1999, J EXP MED, V189, P779, DOI 10.1084/jem.189.5.779; Knowles SR, 2000, LANCET, V356, P1587, DOI 10.1016/S0140-6736(00)03137-8; Knowles SR, 1999, DRUG SAFETY, V21, P489, DOI 10.2165/00002018-199921060-00005; Landsteiner K, 1935, J EXP MED, V61, P643, DOI 10.1084/jem.61.5.643; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Le Cleach L, 2000, CLIN EXP IMMUNOL, V119, P225, DOI 10.1046/j.1365-2249.2000.01119.x; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Maria VAJ, 1997, GUT, V41, P534, DOI 10.1136/gut.41.4.534; MATSON JR, 1985, HUM PATHOL, V16, P94, DOI 10.1016/S0046-8177(85)80220-3; MauriHellweg D, 1996, J IMMUNOL, V157, P1071; MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462; McFadden JP, 2000, CONTACT DERMATITIS, V42, P123, DOI 10.1034/j.1600-0536.2000.042003123.x; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; MEYS E, 1992, J RHEUMATOL, V19, P807; Mochizuki M, 1997, J DERMATOL SCI, V15, P9, DOI 10.1016/S0923-1811(96)00588-9; Naisbitt DJ, 2003, J ALLERGY CLIN IMMUN, V111, P1393, DOI 10.1067/mai.2003.1507; Naisbitt DJ, 2003, MOL PHARMACOL, V63, P732, DOI 10.1124/mol.63.3.732; Naisbitt DJ, 2001, BRIT J PHARMACOL, V133, P295, DOI 10.1038/sj.bjp.0704074; Naisbitt DJ, 2000, DRUG SAFETY, V23, P483, DOI 10.2165/00002018-200023060-00002; Nassif A, 2002, J INVEST DERMATOL, V118, P728, DOI 10.1046/j.1523-1747.2002.01622.x; Neukomm CB, 2001, J INVEST ALLERG CLIN, V11, P275; ORENTAS RJ, 1990, SCIENCE, V248, P1234, DOI 10.1126/science.2190315; Padovan E, 1997, EUR J IMMUNOL, V27, P1303, DOI 10.1002/eji.1830270602; Park BE, 1998, CHEM RES TOXICOL, V11, P969, DOI 10.1021/tx980058f; Pichler WJ, 2002, CURR OPIN ALLERGY CL, V2, P301, DOI 10.1097/00130832-200208000-00003; Pichler Werner J, 2002, Am J Clin Dermatol, V3, P229, DOI 10.2165/00128071-200203040-00001; Pichler WJ, 1998, ALLERGY, V53, P225, DOI 10.1111/j.1398-9995.1998.tb03881.x; Pichler WJ, 1997, INT ARCH ALLERGY IMM, V113, P177, DOI 10.1159/000237539; Pichler WJ, 2001, TOXICOLOGY, V158, P31, DOI 10.1016/S0300-483X(00)00399-1; PIRMOHAMED M, 1994, DRUG SAFETY, V11, P114, DOI 10.2165/00002018-199411020-00006; Pirmohamed M, 2001, TRENDS PHARMACOL SCI, V22, P298, DOI 10.1016/S0165-6147(00)01717-X; Posadas SJ, 2000, J ALLERGY CLIN IMMUN, V106, P769, DOI 10.1067/mai.2000.109828; Pouyanne P, 2000, BRIT MED J, V320, P1036, DOI 10.1136/bmj.320.7241.1036; Reilly TP, 2000, J INVEST DERMATOL, V114, P1164, DOI 10.1046/j.1523-1747.2000.00985.x; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; ROUJEAU JC, 1991, ARCH DERMATOL, V127, P1333, DOI 10.1001/archderm.127.9.1333; ROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906; Schaub N, 2000, ALLERGY, V55, P191, DOI 10.1034/j.1398-9995.2000.00467.x; Schmid S, 2002, AM J PATHOL, V161, P2079, DOI 10.1016/S0002-9440(10)64486-0; SCHNEIDE.CH, 1965, NATURE, V208, P57, DOI 10.1038/208057a0; Schnyder B, 1998, CLIN EXP ALLERGY, V28, P1412, DOI 10.1046/j.1365-2222.1998.00419.x; Schnyder B, 1997, J CLIN INVEST, V100, P136, DOI 10.1172/JCI119505; Schnyder B, 2000, J IMMUNOL, V164, P6647, DOI 10.4049/jimmunol.164.12.6647; Sharma K, 2000, PHARMACOL THERAPEUT, V88, P333, DOI 10.1016/S0163-7258(00)00096-6; Sieben S, 2002, J ALLERGY CLIN IMMUN, V109, P1005, DOI 10.1067/mai.2002.123872; Stepp SE, 2000, IMMUNOL TODAY, V21, P254, DOI 10.1016/S0167-5699(00)01622-4; Suzuki Y, 1998, ARCH DERMATOL, V134, P1108, DOI 10.1001/archderm.134.9.1108; SWANBECK G, 1992, ARCH DERMATOL RES, V284, P215, DOI 10.1007/BF00375796; TSUTSUI H, 1992, J IMMUNOL, V149, P706; Uetrecht JP, 2000, CURR DRUG METAB, V1, P133, DOI 10.2174/1389200003339081; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; von Greyerz S, 1999, J IMMUNOL, V162, P595; von Greyerz S, 2001, INT IMMUNOL, V13, P877, DOI 10.1093/intimm/13.7.877; von Greyerz S, 1999, INT ARCH ALLERGY IMM, V119, P173, DOI 10.1159/000024192; Wang BH, 2001, J LEUKOCYTE BIOL, V70, P185; Weltzien HU, 1996, TOXICOLOGY, V107, P141, DOI 10.1016/0300-483X(95)03253-C; Wolkenstein P, 1996, CONTACT DERMATITIS, V35, P234, DOI 10.1111/j.1600-0536.1996.tb02364.x; Yawalkar N, 2000, CLIN EXP ALLERGY, V30, P847; Yawalkar N, 2000, J ALLERGY CLIN IMMUN, V106, P1171, DOI 10.1067/mai.2000.110922; Yawalkar N, 2001, AM J PATHOL, V158, P803, DOI 10.1016/S0002-9440(10)64027-8; Yawalkar N, 2000, J INVEST DERMATOL, V115, P647, DOI 10.1046/j.1523-1747.2000.00105.x; Yawalkar N, 2001, CURR OPIN ALLERGY CL, V1, P299; Zanni MP, 1998, J CLIN INVEST, V102, P1591, DOI 10.1172/JCI3544; Zanni MP, 1999, J INVEST DERMATOL, V112, P197, DOI 10.1046/j.1523-1747.1999.00484.x; Zanni MP, 1997, J IMMUNOL, V158, P1139; Zanni MP, 1998, INT IMMUNOL, V10, P507, DOI 10.1093/intimm/10.4.507	105	502	524	1	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 21	2003	139	8					683	693		10.7326/0003-4819-139-8-200310210-00012	http://dx.doi.org/10.7326/0003-4819-139-8-200310210-00012			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734DW	14568857				2022-12-28	WOS:000186040800006
J	Vasan, RS; Sullivan, LM; D'Agostino, RB; Roubenoff, R; Harris, T; Sawyer, DB; Levy, D; Wilson, PWF				Vasan, RS; Sullivan, LM; D'Agostino, RB; Roubenoff, R; Harris, T; Sawyer, DB; Levy, D; Wilson, PWF			Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: The Framingham Heart Study	ANNALS OF INTERNAL MEDICINE			English	Article							DILATED CARDIOMYOPATHY; BODY-COMPOSITION; TRANSGENIC MICE; OLDER WOMEN; WALL STRESS; HYPERTROPHY; HORMONE; OVEREXPRESSION; DISEASE; EPIDEMIOLOGY	Background: several experimental investigations have emphasized the favorable effects of insulin-like growth factor I (IGF-1) on left ventricular remodeling, partly through its antiapoptotic effects. Cross-sectional clinical studies have reported that low serum IGF-I levels in patients with heart failure correlate with cachexia and severity of ventricular dysfunction. it is unclear whether low serum IGF-I is a risk factor for heart failure. Objective: To prospectively study the association between serum IGF-I level and the incidence of congestive heart failure. Design: Community-based, prospective cohort study. Setting: Framingham, Massachusetts. Participants: 717 elderly individuals (mean age, 78.4 years; 67% women) who did not have myocardial infarction and congestive heart failure at baseline. Measurement: Incidence of a first episode of congestive heart failure on follow-up. Results: During follow-up (mean, 5.2 years), 56 participants (35 women) developed congestive heart failure. In multivarlable Cox regression models adjusting for established risk factors at baseline, there was a 27% decrease in risk for heart failure for every 1 standard. deviation increment in log IGF-I. Individuals with serum IGF-I level at or above the median value (140 mug/L) had half the risk for heart failure (hazard ratio, 0.49 [95% Cl, 0.26 to 0.92]) of those with serum IGF-I levels below the median. These comparisons were maintained in analyses adjusting for the occurrence of a myocardial infarction on follow-up. Conclusions: In our prospective, community-based investigation, serum IGF-I level was inversely related to the risk for congestive heart failure in elderly people without a previous myocardial infarction. Additional investigations are warranted to confirm these findings.	NHLBI, Framingham Heart Study, Framingham, MA 01702 USA; Boston Univ, Boston, MA 02215 USA; Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; NHLBI, Bethesda, MD 20892 USA; NIA, Bethesda, MD 20892 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Tufts University; United States Department of Agriculture (USDA); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Vasan, RS (corresponding author), NHLBI, Framingham Heart Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.		Levy, Daniel/ABF-6873-2021; Levy, Daniel/ABB-2752-2021; Ramachandran, Vasan/Y-2527-2019; Wilson, Peter W.F./J-2455-2016	Levy, Daniel/0000-0003-1843-8724; Ramachandran, Vasan/0000-0001-7357-5970; Roubenoff, Ronenn/0000-0002-3959-3179; Sullivan, Lisa/0000-0003-0726-7149	NHLBI NIH HHS [1K24 HL04334, N01-HC-25195] Funding Source: Medline; NIA NIH HHS [AG15797] Funding Source: Medline; NIDDK NIH HHS [DK02120] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL004334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG015797] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMBLER GR, 1993, CARDIOVASC RES, V27, P1368, DOI 10.1093/cvr/27.7.1368; Anker SD, 2001, J AM COLL CARDIOL, V38, P443, DOI 10.1016/S0735-1097(01)01385-7; Anversa P, 1996, CARDIOVASC RES, V32, P484, DOI 10.1016/S0008-6363(96)00036-3; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Benbassat CA, 1997, J CLIN ENDOCR METAB, V82, P1484, DOI 10.1210/jc.82.5.1484; Bruch C, 2002, AM HEART J, V144, P538, DOI 10.1067/mhj.2002.123572; BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; Cappola AR, 2001, J CLIN ENDOCR METAB, V86, P4139, DOI 10.1210/jc.86.9.4139; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Cox D. R., 1984, ANAL SURVIVAL DATA; Cupples LA, 1987, FRAMINGHAM STUDY EPI; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Donath MY, 1998, J CLIN ENDOCR METAB, V83, P3177, DOI 10.1210/jc.83.9.3177; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; GoodmanGruen D, 1997, AM J EPIDEMIOL, V145, P970, DOI 10.1093/oxfordjournals.aje.a009065; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Harris TB, 1997, J AM GERIATR SOC, V45, P133, DOI 10.1111/j.1532-5415.1997.tb04497.x; HINTZ RL, 1988, HORM METAB RES, V20, P344, DOI 10.1055/s-2007-1010832; Juul A, 2002, CIRCULATION, V106, P939, DOI 10.1161/01.CIR.0000027563.44593.CC; Khan AS, 2002, CARDIOVASC RES, V54, P25, DOI 10.1016/S0008-6363(01)00533-8; Lee WL, 1999, ENDOCRINOLOGY, V140, P4831, DOI 10.1210/en.140.10.4831; Leri A, 1999, CIRC RES, V84, P752; Li Q, 1997, J CLIN INVEST, V100, P1991, DOI 10.1172/JCI119730; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; McMurray JJ, 2000, HEART, V83, P596, DOI 10.1136/heart.83.5.596; Mosterd A, 1997, EUR J EPIDEMIOL, V13, P491; Niebauer J, 1998, J AM COLL CARDIOL, V32, P393, DOI 10.1016/S0735-1097(98)00226-5; Osterziel KJ, 1998, LANCET, V351, P1233, DOI 10.1016/S0140-6736(97)11329-0; Parkhouse WS, 2000, MECH AGEING DEV, V113, P75, DOI 10.1016/S0047-6374(99)00103-7; Redaelli G, 1998, CIRC RES, V82, P594, DOI 10.1161/01.RES.82.5.594; Ren J, 1999, J MOL CELL CARDIOL, V31, P2049, DOI 10.1006/jmcc.1999.1036; Serneri GGN, 1999, CIRC RES, V85, P57; Tai BC, 2001, STAT MED, V20, P661, DOI 10.1002/sim.711; Vasan RS, 2003, CIRCULATION, V107, P1486, DOI 10.1161/01.CIR.0000057810.48709.F6; Vecchione C, 2001, HYPERTENSION, V37, P1480, DOI 10.1161/01.HYP.37.6.1480; Wang L, 1998, CIRC RES, V83, P516, DOI 10.1161/01.RES.83.5.516; Wang PH, 2001, CIRC RES, V88, P552, DOI 10.1161/01.RES.88.6.552; Welch S, 2002, CIRC RES, V90, P641, DOI 10.1161/01.RES.0000013780.77774.75	38	218	226	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 21	2003	139	8					642	648		10.7326/0003-4819-139-8-200310210-00007	http://dx.doi.org/10.7326/0003-4819-139-8-200310210-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734DW	14568852				2022-12-28	WOS:000186040800002
J	Cross, SS; Harrison, RF; Sanders, DS				Cross, SS; Harrison, RF; Sanders, DS			Supporting decisions in clinical medicine: neural networks in lower gastrointestinal haemorrhage	LANCET			English	Editorial Material							SYSTEMS; OUTCOMES; BENEFIT		Univ Sheffield, Sch Med & Biomed Sci, Div Genom Med, Acad Unit Pathol, Sheffield S10 2UL, S Yorkshire, England; Univ Sheffield, Dept Automat Control & Syst Engn, Sheffield S10 2UL, S Yorkshire, England; Sheffield Teaching Hosp NHS Trust, Dept Gastroenterol, Sheffield, S Yorkshire, England	University of Sheffield; University of Sheffield; University of Sheffield	Cross, SS (corresponding author), Univ Sheffield, Sch Med & Biomed Sci, Div Genom Med, Acad Unit Pathol, Sheffield S10 2UL, S Yorkshire, England.		Harrison, Robert/B-9034-2008	Harrison, Robert/0000-0002-9323-8637; Cross, Simon/0000-0003-2044-1754				CROSS SS, 1995, LANCET, V346, P1075, DOI 10.1016/S0140-6736(95)91746-2; Downs J, 1996, ARTIF INTELL MED, V8, P403, DOI 10.1016/0933-3657(95)00044-5; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; Kennedy RL, 1997, COMPUT METH PROG BIO, V52, P93, DOI 10.1016/S0169-2607(96)01782-8; Kollef MH, 1997, CRIT CARE MED, V25, P1125, DOI 10.1097/00003246-199707000-00011; Lisboa PJG, 2002, NEURAL NETWORKS, V15, P11, DOI 10.1016/S0893-6080(01)00111-3; Sanders DS, 2002, AM J GASTROENTEROL, V97, P630; Sintchenko V, 2003, INT J MED INFORM, V70, P309, DOI 10.1016/S1386-5056(03)00040-6; Walker AJ, 1999, LANCET, V354, P1518, DOI 10.1016/S0140-6736(99)02186-8; WYATT J, 1995, LANCET, V346, P1175, DOI 10.1016/S0140-6736(95)92893-6; Wyatt J, 1997, INT J MED INFORM, V47, P165, DOI 10.1016/S1386-5056(97)00100-7; Wyatt JC, 2000, J ROY SOC MED, V93, P629, DOI 10.1177/014107680009301206	12	3	3	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 18	2003	362	9392					1250	1251		10.1016/S0140-6736(03)14612-0	http://dx.doi.org/10.1016/S0140-6736(03)14612-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575963				2022-12-28	WOS:000186036900002
J	Wilcken, NRC; Stockler, MTR				Wilcken, NRC; Stockler, MTR			Fulvestrant: spreading the word, but not too thinly	LANCET			English	Editorial Material							ADVANCED BREAST-CANCER; POSTMENOPAUSAL WOMEN; ANASTROZOLE		Westmead Hosp, NSW Breast Canc Inst, Sydney, NSW, Australia; Westmead Hosp, Dept Med Oncol, Sydney, NSW, Australia; NHMRC Clin Trials Ctr, Sydney, NSW, Australia; Sydney Canc Ctr, RPA & Concord Hosp, Sydney, NSW, Australia; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney; University of Sydney; University of Sydney; University of Sydney	Wilcken, NRC (corresponding author), Westmead Hosp, NSW Breast Canc Inst, Sydney, NSW, Australia.	nicholasw@westgate.wh.usyd.edu.au	Stockler, Martin R/N-3859-2016	Stockler, Martin R/0000-0003-3793-8724				[Anonymous], 1988, LANCET, V2, P349; *ASTR, 2002, FASL FULV INJ HORM T; Fletcher RH, 2003, LANCET, V361, P10, DOI 10.1016/S0140-6736(03)12185-X; Howell A, 2002, J CLIN ONCOL, V20, P3396, DOI 10.1200/JCO.2002.10.057; Mauriac L, 2003, EUR J CANCER, V39, P1228, DOI 10.1016/S0959-8049(03)00199-0; Osborne CK, 2002, J CLIN ONCOL, V20, P3386, DOI 10.1200/JCO.2002.10.058; STOCKLER M, 1993, MED J AUSTRALIA, V159, P291, DOI 10.5694/j.1326-5377.1993.tb137859.x; Tannock IF, 1996, J NATL CANCER I, V88, P206, DOI 10.1093/jnci/88.3-4.206	8	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	2003	362	9392					1254	1254		10.1016/S0140-6736(03)14616-8	http://dx.doi.org/10.1016/S0140-6736(03)14616-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575967				2022-12-28	WOS:000186036900006
J	Bushman, FD				Bushman, FD			Targeting survival: Integration site selection by retroviruses and LTR-retrotransposons	CELL			English	Review							TRANSPOSABLE ELEMENTS; ACTIVE GENES; HUMAN GENOME; YEAST; SPECIFICITY; INSTABILITY	Replication of retroviruses and retrotransposons depends on selecting a favorable chromosomal site for integration of their genomic DNA. Different retroelements; meet this challenge by targeting distinctive chromosomal regions. Despite these differences, recent data hints at a common targeting mechanism-tethering of integration complexes to proteins bound at favorable sites.	Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA	Salk Institute	Bushman, FD (corresponding author), Salk Inst Biol Studies, Infect Dis Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Boeke JD, 1998, CELL, V93, P1087, DOI 10.1016/S0092-8674(00)81450-6; Bushman F, 2002, MOL THER, V6, P570, DOI 10.1006/mthe.2002.0724; Check E, 2002, NATURE, V420, P116, DOI 10.1038/420116a; Coffin J, 1997, RETROVIRUSES; Gilbert N, 2002, CELL, V110, P315, DOI 10.1016/S0092-8674(02)00828-0; Kazazian HH, 2002, CELL, V110, P277, DOI 10.1016/S0092-8674(02)00868-1; KIRCHNER J, 1995, SCIENCE, V267, P1488, DOI 10.1126/science.7878467; Nakai H, 2003, NAT GENET, V34, P297, DOI 10.1038/ng1179; Sandmeyer S, 2003, P NATL ACAD SCI USA, V100, P5586, DOI 10.1073/pnas.1031802100; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Singleton TL, 2002, EUKARYOT CELL, V1, P44, DOI 10.1128/EC.01.1.44-55.2002; Smit AFA, 1999, CURR OPIN GENET DEV, V9, P657, DOI 10.1016/S0959-437X(99)00031-3; Symer DE, 2002, CELL, V110, P327, DOI 10.1016/S0092-8674(02)00839-5; Vigdal TJ, 2002, J MOL BIOL, V323, P441, DOI 10.1016/S0022-2836(02)00991-9; Weidhaas JB, 2000, J VIROL, V74, P8382, DOI 10.1128/JVI.74.18.8382-8389.2000; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Zhu YX, 1999, GENE DEV, V13, P2738, DOI 10.1101/gad.13.20.2738; Zhu YX, 2003, P NATL ACAD SCI USA, V100, P5891, DOI 10.1073/pnas.1036705100	18	165	173	0	12	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 17	2003	115	2					135	138		10.1016/S0092-8674(03)00760-8	http://dx.doi.org/10.1016/S0092-8674(03)00760-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567911	Bronze			2022-12-28	WOS:000186039200005
J	Williams, DA; Baum, C				Williams, DA; Baum, C			Gene therapy - New challenges ahead	SCIENCE			English	Editorial Material							HEMATOPOIETIC STEM-CELLS; HUMAN GENOME; INTEGRATION		Cincinnati Childrens Hosp, Med Ctr, Div Expt Hematol, Cincinnati, OH 45229 USA; Hannover Med Sch, Dept Hematol & Oncol, D-3000 Hannover, Germany	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Hannover Medical School	Williams, DA (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Expt Hematol, Cincinnati, OH 45229 USA.				NHLBI NIH HHS [HL53586] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053586] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Baum C, 2003, BLOOD, V101, P2099, DOI 10.1182/blood-2002-07-2314; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Kohn DB, 2003, MOL THER, V8, P180, DOI 10.1016/S1525-0016(03)00212-0; Li ZX, 2002, SCIENCE, V296, P497, DOI 10.1126/science.1068893; Schmidt M, 2002, BLOOD, V100, P2737, DOI 10.1182/blood-2002-02-0407; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413	9	91	97	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					400	401		10.1126/science.1091258	http://dx.doi.org/10.1126/science.1091258			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14563994				2022-12-28	WOS:000185963200026
J	Colavita, A; Tessier-Lavigne, M				Colavita, A; Tessier-Lavigne, M			A neurexin-related protein, BAM-2, terminates axonal branches in C-elegans	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; NEURONS	Neuronal axons connect to multiple target cells through the formation of collateral branches, but the mechanisms that regulate this process are largely unknown. We show that BAM-2, a neurexin-related transmembrane protein, is required for development of VC motoneuron branches in the worm Caenorhabditis elegans. Expression analysis and ectopic expression experiments suggest that BAM-2 functions as a branch termination cue and reveal a mechanism for selective control of branches that sprout off a primary axon.	Stanford Univ, Howard Hughes Med Inst, Dept Biol Sci, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Tessier-Lavigne, M (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	marctl@gene.com		Colavita, Antonio/0000-0001-9391-5282				Acebes A, 2000, TRENDS NEUROSCI, V23, P557, DOI 10.1016/S0166-2236(00)01646-5; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; Dean C, 2003, NAT NEUROSCI, V6, P708, DOI 10.1038/nn1074; Duerr JS, 1999, J NEUROSCI, V19, P72, DOI 10.1523/JNEUROSCI.19-01-00072.1999; GARRIGA G, 1993, DEVELOPMENT, V117, P1071; LI C, 1990, NEURON, V4, P681, DOI 10.1016/0896-6273(90)90195-L; Luo LQ, 2002, ANNU REV CELL DEV BI, V18, P601, DOI 10.1146/annurev.cellbio.18.031802.150501; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; OLSEN PT, COMMUNICATION; PELES E, COMMUNICATION; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Soussi-Yanicostas N, 2002, CELL, V109, P217, DOI 10.1016/S0092-8674(02)00713-4; TAKAO I, 2002, GENE EXPR PATTERNS, V2, P235; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; Waggoner LE, 1998, NEURON, V21, P203, DOI 10.1016/S0896-6273(00)80527-9; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; WEINSHENKER D, 1995, J NEUROSCI, V15, P6975; Yates PA, 2001, J NEUROSCI, V21, P8548, DOI 10.1523/JNEUROSCI.21-21-08548.2001	18	24	35	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					293	296		10.1126/science.1089163	http://dx.doi.org/10.1126/science.1089163			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551437				2022-12-28	WOS:000185825900044
J	Whitfield, CW; Cziko, AM; Robinson, GE				Whitfield, CW; Cziko, AM; Robinson, GE			Gene expression profiles in the brain predict behavior in individual honey bees	SCIENCE			English	Article							MICROARRAYS; GENOMICS	We show that the age-related transition by adult honey bees from hive work to foraging is associated with changes in messenger RNA abundance in the brain for 39% of similar to5500 genes tested. This result, discovered using a highly replicated experimental design involving 72 microarrays, demonstrates more extensive genomic plasticity in the adult brain than has yet been shown. Experimental manipulations that uncouple behavior and age revealed that messenger RNA changes were primarily associated with behavior. Individual brain messenger RNA profiles correctly predicted the behavior of 57 out of 60 bees, indicating a robust association between brain gene expression in the individual and naturally occurring behavioral plasticity.	Univ Illinois, Dept Entomol, 320 Morrill Hall,505 S Goodwin Ave, Urbana, IL 61801 USA; Univ Illinois, Neurosci Program, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Robinson, GE (corresponding author), Univ Illinois, Dept Entomol, 320 Morrill Hall,505 S Goodwin Ave, Urbana, IL 61801 USA.	generobi@life.uiuc.edu						Alcock J., 2001, ANIMAL BEHAV EVOLUTI; Becker JB, 1992, BEHAV ENDOCRINOLOGY; Ben-Shahar Y, 2002, SCIENCE, V296, P741, DOI 10.1126/science.1069911; Brett M, 2002, NAT REV NEUROSCI, V3, P243, DOI 10.1038/nrn756; CASH AC, UNPUB; Cavallaro S, 2002, NEUROCHEM RES, V27, P1201, DOI 10.1023/A:1020933627597; Chung CH, 2002, NAT GENET, V32, P533, DOI 10.1038/ng1038; Churchill GA, 2002, NAT GENET, V32, P490, DOI 10.1038/ng1031; Dubnau J, 2003, CURR BIOL, V13, P286, DOI 10.1016/S0960-9822(03)00064-2; Etter PD, 2002, BIOESSAYS, V24, P494, DOI 10.1002/bies.10109; Gibson G, 2002, MOL ECOL, V11, P17, DOI 10.1046/j.0962-1083.2001.01425.x; Greenspan RJ, 1997, CURR OPIN NEUROBIOL, V7, P805, DOI 10.1016/S0959-4388(97)80139-0; Hofmann HA, 2000, J NEUROSCI, V20, P4740, DOI 10.1523/JNEUROSCI.20-12-04740.2000; Korol DL, 1998, AM J CLIN NUTR, V67, p764S, DOI 10.1093/ajcn/67.4.764S; Kucharski R, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-2-research0007; Mong JA, 2003, P NATL ACAD SCI USA, V100, P318, DOI 10.1073/pnas.262663799; Oster G.F., 1978, Monographs in Population Biology, pi; Robinson GE, 2002, AM NAT, V160, pS160, DOI 10.1086/342901; Robinson GE, 2002, GENES BRAIN BEHAV, V1, P197, DOI 10.1034/j.1601-183X.2002.10401.x; Slonim DK, 2002, NAT GENET, V32, P502, DOI 10.1038/ng1033; Sun MK, 2002, TRENDS PHARMACOL SCI, V23, P83, DOI 10.1016/S0165-6147(02)01899-0; Toma DP, 2002, NAT GENET, V31, P349, DOI 10.1038/ng893; Townsend JP, 2002, GENOME BIOL, V3; Wahlsten D, 2003, J NEUROBIOL, V54, P283, DOI 10.1002/neu.10173; Whitfield CW, 2002, GENOME RES, V12, P555, DOI 10.1101/gr.5302; Winston M.L., 1991, BIOL HONEY BEE; 2003, NATURE NEUROSCI, V6, P647	27	445	468	1	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					296	299		10.1126/science.1086807	http://dx.doi.org/10.1126/science.1086807			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551438				2022-12-28	WOS:000185825900045
J	Priplata, AA; Niemi, JB; Harry, JD; Lipsitz, LA; Collins, JJ				Priplata, AA; Niemi, JB; Harry, JD; Lipsitz, LA; Collins, JJ			Vibrating insoles and balance control in elderly people	LANCET			English	Article								Somatosensory function declines with age, and such changes have been associated with diminished motor performance. Input noise can enhance sensory and motor function. We asked young and elderly participants to stand quietly on vibrating gel-based insoles, and calculated sway parameters and random-walk variables. In our 27 participants, application of noise resulted in a reduction in seven of eight sway parameters in young participants and all of the sway variables in elderly participants. Elderly participants showed greater improvement than young people in two variables, mediolateral range (p=0.008), and critical mean square displacement (p=0.012). Noise-based devices, such as randomly vibrating insoles, could ameliorate age-related impairments in balance control.	Boston Univ, Ctr Biodynam, Boston, MA 02215 USA; Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA; Afferent Corp, Providence, RI USA; Hebrew Rehabil Ctr Aged, Res & Training Inst, Boston, MA USA; Beth Israel Deaconess Med Ctr, Gerontol Div, Boston, MA 02215 USA; Harvard Univ, Sch Med, Div Aging, Boston, MA 02115 USA	Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Collins, JJ (corresponding author), Boston Univ, Ctr Biodynam, Boston, MA 02215 USA.			Niemi, James/0000-0003-2136-0681	NIA NIH HHS [AG04390, AG08812] Funding Source: Medline; NICHD NIH HHS [HD37880, HD40035] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037880, R43HD040035, R44HD040035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG008812, P60AG008812, P01AG004390] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		COLLINS JJ, 1995, EXP BRAIN RES, V104, P480, DOI 10.1007/BF00231982; JUDGE JO, 1995, J GERONTOL, V50, P263; Liu W, 2002, ARCH PHYS MED REHAB, V83, P171, DOI 10.1053/apmr.2002.28025; MAKI BE, 1994, J GERONTOL, V49, P72	5	379	392	1	56	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 4	2003	362	9390					1123	1124		10.1016/S0140-6736(03)14470-4	http://dx.doi.org/10.1016/S0140-6736(03)14470-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728HA	14550702				2022-12-28	WOS:000185710700014
J	Sigwart, U				Sigwart, U			Drug-delivering coronary artery stents: bare metal threatened by extinction?	LANCET			English	Editorial Material							RESTENOSIS		Univ Hosp, Ctr Cardiol, CH-1211 Geneva, Switzerland	University of Geneva	Sigwart, U (corresponding author), Univ Hosp, Ctr Cardiol, CH-1211 Geneva, Switzerland.							Gruntzig A., 1977, PERKUTANE TRANSLUMIN; HOLMES DR, 2003, J AM COLL CARDIOL SA, V41; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Pache J, 2003, J AM COLL CARDIOL, V41, P1283, DOI 10.1016/S0735-1097(03)00119-0; ROGERS C, 1995, CIRCULATION, V91, P2995, DOI 10.1161/01.CIR.91.12.2995; SERRUYS P, 2003, COMMUNICATION; Sigwart U, 1999, LANCET, V354, P269, DOI 10.1016/S0140-6736(99)00137-3; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; STONE G, 2003, COMMUNICATION	9	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 4	2003	362	9390					1088	1089		10.1016/S0140-6736(03)14496-0	http://dx.doi.org/10.1016/S0140-6736(03)14496-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728HA	14550689				2022-12-28	WOS:000185710700002
J	Varaldi, J; Fouillet, P; Ravallec, M; Lopez-Ferber, M; Bouletreau, M; Fleury, F				Varaldi, J; Fouillet, P; Ravallec, M; Lopez-Ferber, M; Bouletreau, M; Fleury, F			Infectious behavior in a parasitoid	SCIENCE			English	Article							SUPERPARASITISM		Univ Lyon 1, Lab Biometrie & Biol Evolut, CNRS, UMR 5558, F-69622 Villeurbanne, France; Univ Montpellier 2, INRA, Lab Pathol Comparee, CNRS,UMR 5087, F-30380 St Christol Les Ales, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup; Centre National de la Recherche Scientifique (CNRS); INRAE; Universite de Montpellier	Varaldi, J (corresponding author), Univ Lyon 1, Lab Biometrie & Biol Evolut, CNRS, UMR 5558, 43 Bld 11 Novembre 1918, F-69622 Villeurbanne, France.	varaldi@biomserv.univ-lyon1.fr	Lopez-Ferber, Miguel/F-5465-2012	Lopez-Ferber, Miguel/0000-0002-3850-1703; varaldi, julien/0000-0002-2100-1542				Allemand R, 2002, ANN SOC ENTOMOL FR, V38, P319, DOI 10.1080/00379271.2002.10697346; Poulin R, 1995, INT J PARASITOL, V25, P1371, DOI 10.1016/0020-7519(95)00100-X; VANALPHEN JJM, 1990, ANNU REV ENTOMOL, V35, P59, DOI 10.1146/annurev.en.35.010190.000423; Vinson SB, 1998, J INSECT PHYSIOL, V44, P703, DOI 10.1016/S0022-1910(98)00003-1	4	62	65	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 12	2003	302	5652					1930	1930		10.1126/science.1088798	http://dx.doi.org/10.1126/science.1088798			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	752NL	14564013				2022-12-28	WOS:000187174000050
J	Liotta, LA; Ferrari, M; Petricoin, E				Liotta, LA; Ferrari, M; Petricoin, E			Written in blood	NATURE			English	Article									NCI, Bethesda, MD 20892 USA; Ohio State Univ, Dorothy M Davis Heart & Lung Res Inst, Dept Internal Med, Columbus, OH 43210 USA; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Ohio; Ohio State University; US Food & Drug Administration (FDA)	Liotta, LA (corresponding author), NCI, 10 Ctr Dr, Bethesda, MD 20892 USA.							Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200; Liu J, 2002, DIS MARKERS, V18, P175, DOI 10.1155/2002/874157; Mehta AI, 2003, DIS MARKERS, V19, P1; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Tirumalai RS, 2003, MOL CELL PROTEOMICS, V2, P1096, DOI 10.1074/mcp.M300031-MCP200	5	410	450	2	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	2003	425	6961					905	905		10.1038/425905a	http://dx.doi.org/10.1038/425905a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14586448	Bronze, Green Published			2022-12-28	WOS:000186230600022
J	Nelson, KB				Nelson, KB			Can we prevent cerebral palsy?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CESAREAN-SECTION; BIRTH-WEIGHT; RISK-FACTORS; INFANTS; STROKE; INTRAPARTUM; DELIVERY; TRENDS		NINDS, Neuroepidemiol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Nelson, KB (corresponding author), NINDS, Neuroepidemiol Branch, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002863] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrew M E, 2001, Hematology Am Soc Hematol Educ Program, P358; Clark SL, 2003, AM J OBSTET GYNECOL, V188, P628, DOI 10.1067/mob.2003.204; Golomb MR, 2001, ANN NEUROL, V50, P163, DOI 10.1002/ana.1078; GRANT A, 1989, LANCET, V2, P1233; Grether JK, 1998, JAMA-J AM MED ASSOC, V279, P118; Grether JK, 2003, ARCH PEDIAT ADOL MED, V157, P26, DOI 10.1001/archpedi.157.1.26; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Jackson N, 2001, BEST PRACT RES CL OB, V15, P49, DOI 10.1053/beog.2000.0148; Lanska DJ, 2000, STROKE, V31, P1274, DOI 10.1161/01.STR.31.6.1274; LILFORD RJ, 1990, BRIT J OBSTET GYNAEC, V97, P883, DOI 10.1111/j.1471-0528.1990.tb02442.x; Lynch JK, 2001, CURR OPIN PEDIATR, V13, P499, DOI 10.1097/00008480-200112000-00002; MacDorman MF, 2002, PEDIATRICS, V110, P1037, DOI 10.1542/peds.110.6.1037; Meis PJ, 2003, NEW ENGL J MED, V348, P2379, DOI 10.1056/NEJMoa035140; Mello MM, 2003, NEW ENGL J MED, V348, P2281, DOI 10.1056/NEJMp030064; Nelson KB, 1996, NEW ENGL J MED, V334, P613, DOI 10.1056/NEJM199603073341001; Nelson KB, 1998, AM J OBSTET GYNECOL, V179, P507, DOI 10.1016/S0002-9378(98)70387-4; PETTERSON B, 1993, BRIT MED J, V307, P1239, DOI 10.1136/bmj.307.6914.1239; Ros HS, 2002, AM J OBSTET GYNECOL, V186, P198, DOI 10.1067/mob.2002.119177; SHY KK, 1990, NEW ENGL J MED, V322, P588, DOI 10.1056/NEJM199003013220904; STANLEY F, 2000, CLIN DEV MED, V151; Surman G, 2003, DEV MED CHILD NEUROL, V45, P456, DOI 10.1017/S0012162203000859; THACKER SB, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000063; Walstab J, 2002, AUST NZ J OBSTET GYN, V42, P138, DOI 10.1111/j.0004-8666.2002.00138.x; Willoughby RE, 2002, CLIN PERINATOL, V29, P603, DOI 10.1016/S0095-5108(02)00058-1; Winter S, 2002, PEDIATRICS, V110, P1220, DOI 10.1542/peds.110.6.1220	25	131	137	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 30	2003	349	18					1765	1769		10.1056/NEJMsb035364	http://dx.doi.org/10.1056/NEJMsb035364			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	737FJ	14585946				2022-12-28	WOS:000186219500013
J	Duyk, G				Duyk, G			Attrition and translation	SCIENCE			English	Article							DRUG DEVELOPMENT; UNITED-STATES	The recently published NIH Roadmap proposes that public-sector science should place increased emphasis on the development of new therapeutics and diagnostics based on the fruits of fundamental research. Such "translational research" activities, traditionally the province of the private sector, have long been compromised by high rates of attrition (failure during the course of preclinical or clinical development of therapeutics). Attrition has led to growing financial costs, as well as opportunity costs. The new focus offers a way to reverse these trends, especially if the scientific community can improve on its ability to reconcile molecular genetic research with integrative organ- and organism-based research.	Exelixis Inc, San Francisco, CA 94083 USA	Exelixis, Inc.	Duyk, G (corresponding author), Exelixis Inc, 170 Harbor Way, San Francisco, CA 94083 USA.							*BILL MEL GAT FDN, GLOB HLTH PROGR; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; Collins FS, 2003, SCIENCE, V300, P286, DOI 10.1126/science.1084564; DiMasi JA, 2001, CLIN PHARMACOL THER, V69, P286, DOI 10.1067/mcp.2001.115132; DIMASI JA, 1991, CLIN PHARMACOL THER, V50, P471, DOI 10.1038/clpt.1991.172; DiMasi Joseph A., 1996, Am J Ther, V3, P647, DOI 10.1097/00045391-199609000-00008; Eisenberg RS, 2003, SCIENCE, V299, P1018, DOI 10.1126/science.1081790; FALK M, 2003, STATUS FUTURE INTEGR; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; KAITIN KI, 2003, TUFTS CTR STUDY DRUG, V5; *LEHM BROTH, 2001, FRUITS GEN DRUG PIP; Malakoff D, 2003, SCIENCE, V300, P1635; MCCLELLAN MB, 2003, COMMUNICATION   0609; MILNE CP, 2002, PHARMACOECONOMICS S3, V20; Wellcome Trust, 2003, SHAR DAT LARG SCAL B; Zerhouni E, 2003, SCIENCE, V302, P63, DOI 10.1126/science.1091867	16	72	74	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					603	605		10.1126/science.1090521	http://dx.doi.org/10.1126/science.1090521			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576424				2022-12-28	WOS:000186119900047
J	Hoefen, TM; Clark, RN; Bandfield, JL; Smith, MD; Pearl, JC; Christensen, PR				Hoefen, TM; Clark, RN; Bandfield, JL; Smith, MD; Pearl, JC; Christensen, PR			Discovery of olivine in the Nili Fossae region of Mars	SCIENCE			English	Article							SURFACE; TES	We have detected a 30,000-square-kilometer area rich in olivine in the Nili Fossae region of Mars. Nili Fossae has been interpreted as a complex of grabens and fractures related to the formation of the Isidis impact basin. We propose that post-impact faulting of this area has exposed subsurface layers rich in olivine. Linear mixture analysis of Thermal Emission Spectrometer spectra shows surface exposures of 30% olivine, where the composition of the olivine ranges from Fo(30) to Fo(70).	US Geol Survey, Denver, CO 80225 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Arizona State Univ, Tempe, AZ 85287 USA	United States Department of the Interior; United States Geological Survey; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Arizona State University; Arizona State University-Tempe	Hoefen, TM (corresponding author), US Geol Survey, Box 25046, Denver, CO 80225 USA.	thoefen@usgs.gov	Smith, Michael/C-8875-2012	Bandfield, Joshua/0000-0003-3571-3716				Albee AL, 1998, SCIENCE, V279, P1671, DOI 10.1126/science.279.5357.1671; Bandfield JL, 2003, ICARUS, V161, P47, DOI 10.1016/S0019-1035(02)00025-8; BANDFIELD JL, 2002, J GEOPHYS RES, V107; Christensen PR, 2000, J GEOPHYS RES-PLANET, V105, P9609, DOI 10.1029/1999JE001127; CHRISTENSEN PR, 1992, J GEOPHYS RES-PLANET, V97, P7719, DOI 10.1029/92JE00453; Christensen PR, 2003, SCIENCE, V300, P2056, DOI 10.1126/science.1080885; Christensen PR, 1998, SCIENCE, V279, P1692, DOI 10.1126/science.279.5357.1692; CLARK RN, 2002, AVIRIS WORKSH P NASA; CLARK RN, IN PRESS J GEOPHYS R; CLARK RN, 1999, MANUAL REMOTE SENSIN, pCH1; COLMAN SM, 1986, RATES CHEM WEATHERIN, P25; DEER WA, 1963, ROCK FORMING MINER A, V1; GAO BC, 1993, REMOTE SENS ENVIRON, V44, P165, DOI 10.1016/0034-4257(93)90014-O; Green RO, 1998, REMOTE SENS ENVIRON, V65, P227, DOI 10.1016/S0034-4257(98)00064-9; Hamilton VE, 2003, METEORIT PLANET SCI, V38, P871, DOI 10.1111/j.1945-5100.2003.tb00284.x; Hamilton VE, 1997, J GEOPHYS RES-PLANET, V102, P25593, DOI 10.1029/97JE01874; Hartmann WK, 2001, SPACE SCI REV, V96, P165, DOI 10.1023/A:1011945222010; HIESINGER H, 2002, P LUNAR PLANET SCI C, V32; KIEFFER HH, 1992, MARS, P363; KING TVV, 1987, J GEOPHYS RES-SOLID, V92, P11457, DOI 10.1029/JB092iB11p11457; KRAAL ER, 1998, P LUNAR PLANET SCI C, V29; MCKINNON WB, 1980, ICARUS, V44, P454, DOI 10.1016/0019-1035(80)90037-8; PIETERS CM, 1985, J GEOPHYS RES, V90, pC415, DOI 10.1029/JB090iS02p0C415; Salisbury J.W., 1991, INFRARED 2 1 25 MU M; Smith MD, 2000, J GEOPHYS RES-PLANET, V105, P9589, DOI 10.1029/1999JE001105	25	229	229	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	2003	302	5645					627	630		10.1126/science.1089647	http://dx.doi.org/10.1126/science.1089647			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576430	Green Submitted			2022-12-28	WOS:000186119900054
J	Kane, TJ				Kane, TJ			The long road to race-blindness	SCIENCE			English	Editorial Material																		Bowen William G, 1998, SHAPE RIVER; CAMPBELL JR, 2000, 2000469 NCES US DEP; Carnevale AP., 2003, SOCIOECONOMIC STATUS; HORN CL, 2003, PERCENT PLANS COLL A; KAHLENBERG RD, 2003, WASHINGTON POST 0331, pA13; KAHLENBERG RD, 1996, REMEDY CLASS RACE AF; Kane T., 1998, BLACK WHITE TEST SCO; Liu G, 2002, MICH LAW REV, V100, P1045, DOI 10.2307/1290503; LONG M, IN PRESS J ECONOMETR; Tienda M., 2003, CLOSING GAP ADMISSIO; *US COMM CIL RIGHT, 2003, US DEP ED RAC NEUTR	11	7	7	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					571	573		10.1126/science.1089944	http://dx.doi.org/10.1126/science.1089944			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	735MV	14576406				2022-12-28	WOS:000186119900030
J	Baumgart, T; Hess, ST; Webb, WW				Baumgart, T; Hess, ST; Webb, WW			Imaging coexisting fluid domains in biomembrane models coupling curvature and line tension	NATURE			English	Article							GIANT PHOSPHOLIPID-VESICLES; INTRAMEMBRANE DOMAINS; MEMBRANES; SHAPE; FISSION; TRANSITIONS; MONOLAYERS; DYNAMICS	Lipid bilayer membranes - ubiquitous in biological systems and closely associated with cell function - exhibit rich shape-transition behaviour, including bud formation(1) and vesicle fission(2). Membranes formed from multiple lipid components can laterally separate into coexisting liquid phases, or domains, with distinct compositions. This process, which may resemble raft formation in cell membranes, has been directly observed in giant unilamellar vesicles(3,4). Detailed theoretical frameworks(5-11) link the elasticity of domains and their boundary properties to the shape adopted by membranes and the formation of particular domain patterns, but it has been difficult to experimentally probe and validate these theories. Here we show that high-resolution fluorescence imaging using two dyes preferentially labelling different fluid phases directly provides a correlation between domain composition and local membrane curvature. Using freely suspended membranes of giant unilamellar vesicles, we are able to optically resolve curvature and line tension interactions of circular, stripe and ring domains. We observe long-range domain ordering in the form of locally parallel stripes and hexagonal arrays of circular domains, curvature-dependent domain sorting, and membrane fission into separate vesicles at domain boundaries. By analysing our observations using available membrane theory, we are able to provide experimental estimates of boundary tension between fluid bilayer domains.	Cornell Univ, Ithaca, NY 14853 USA; NICHHD, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA	Cornell University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Webb, WW (corresponding author), Cornell Univ, Ithaca, NY 14853 USA.		Webb, Watt W./B-5905-2011					ANDELMAN D, 1992, EUROPHYS LETT, V19, P57, DOI 10.1209/0295-5075/19/1/010; ANDELMAN D, 1987, J CHEM PHYS, V86, P3673, DOI 10.1063/1.451970; BARZIV R, 1994, PHYS REV LETT, V73, P1392, DOI 10.1103/PhysRevLett.73.1392; BENVEGNU DJ, 1992, J PHYS CHEM-US, V96, P6820, DOI 10.1021/j100195a053; Chen CM, 1997, PHYS REV LETT, V79, P1579, DOI 10.1103/PhysRevLett.79.1579; Debregeas G, 1998, SCIENCE, V279, P1704, DOI 10.1126/science.279.5357.1704; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; DOBEREINER HG, 1993, BIOPHYS J, V65, P1396; DUWE HP, 1990, PHYSICA A, V163, P410, DOI 10.1016/0378-4371(90)90349-W; HELFRICH W, 1984, NUOVO CIMENTO D, V3, P137, DOI 10.1007/BF02452208; HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693, DOI 10.1515/znc-1973-11-1209; Huttner WB, 2001, CURR OPIN CELL BIOL, V13, P478, DOI 10.1016/S0955-0674(00)00239-8; JENKINS JT, 1977, J MATH BIOL, V4, P149, DOI 10.1007/BF00275981; Jiang Y, 2000, PHYS REV E, V61, pR57, DOI 10.1103/PhysRevE.61.R57; Julicher F, 1996, PHYS REV E, V53, P2670, DOI 10.1103/PhysRevE.53.2670; KAS J, 1991, BIOPHYS J, V60, P825, DOI 10.1016/S0006-3495(91)82117-8; Kumar PBS, 2001, PHYS REV LETT, V86, P3911, DOI 10.1103/PhysRevLett.86.3911; LEIBLER S, 1987, J PHYS-PARIS, V48, P2013, DOI 10.1051/jphys:0198700480110201300; LIPOWSKY R, 1992, J PHYS II, V2, P1825, DOI 10.1051/jp2:1992238; Lipowsky R, 2003, J PHYS-CONDENS MAT, V15, pS31, DOI 10.1088/0953-8984/15/1/304; Mathivet L, 1996, BIOPHYS J, V70, P1112, DOI 10.1016/S0006-3495(96)79693-5; Mukherjee S, 2000, TRAFFIC, V1, P203, DOI 10.1034/j.1600-0854.2000.010302.x; Samsonov AV, 2001, BIOPHYS J, V81, P1486, DOI 10.1016/S0006-3495(01)75803-1; SCHNEIDER MB, 1984, J PHYS-PARIS, V45, P1457, DOI 10.1051/jphys:019840045090145700; SEIFERT U, 1993, PHYS REV LETT, V70, P1335, DOI 10.1103/PhysRevLett.70.1335; SEUL M, 1995, SCIENCE, V267, P476, DOI 10.1126/science.267.5197.476; Veatch SL, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.268101; Wintz W, 1996, EUROPHYS LETT, V33, P403, DOI 10.1209/epl/i1996-00353-8	29	1230	1254	7	325	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					821	824		10.1038/nature02013	http://dx.doi.org/10.1038/nature02013			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574408				2022-12-28	WOS:000186118500041
J	Kris, MG; Natale, RB; Herbst, RS; Lynch, TJ; Prager, D; Belani, CP; Schiller, JH; Kelly, K; Spiridonidis, H; Sandler, A; Albain, KS; Cella, D; Wolf, MK; Averbuch, SD; Ochs, JJ; Kay, AC				Kris, MG; Natale, RB; Herbst, RS; Lynch, TJ; Prager, D; Belani, CP; Schiller, JH; Kelly, K; Spiridonidis, H; Sandler, A; Albain, KS; Cella, D; Wolf, MK; Averbuch, SD; Ochs, JJ; Kay, AC			Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FUNCTIONAL ASSESSMENT; CHEMOTHERAPY REGIMENS; IMATINIB MESYLATE; ZD1839 IRESSA(TM); THERAPY; EXPRESSION; DOCETAXEL; PLATINUM; TUMORS; EGFR	Context More persons in the United States die from non-small cell lung cancer (NSCLC) than from breast, colorectal, and prostate cancer combined. In preclinical testing, oral gefitinib inhibited the growth of NSCLC tumors that express the epidermal growth factor receptor (EGFR), a mediator of cell signaling, and phase 1 trials have demonstrated that a fraction of patients with NSCLC progressing after chemotherapy experience both a decrease in lung cancer symptoms and radiographic tumor shrinkages with gefitinib. Objective To assess differences in symptomatic and radiographic response among patients with NSCLC receiving 250-mg and 500-mg daily doses of gefitinib. Design, Setting, and Patients Double-blind, randomized phase 2 trial conducted from November 2000 to April 2001 in 30 US academic and community oncology centers. Patients (N =221) had either stage IIIB or IV NSCLC for which they had received at least 2 chemotherapy regimens. Intervention Daily oral gefitinib, either 500 mg (administered as two 250-mg gefitinib tablets) or 250 mg (administered as one 250-mg gefitinib tablet and 1 matching placebo). Main Outcome Measures Improvement of NSCLC symptoms (2-point or greater increase in score on the summed lung cancer subscale of the Functional Assessment of Cancer Therapy-Lung [FACT-L] instrument) and tumor regression (>50% decrease in lesion size on imaging studies). Results Of 221 patients enrolled, 216 received gefitinib as randomized. Symptoms of NSCLC improved in 43% (95% confidence interval [CI], 33%-53%) of patients receiving 250 mg of gefitinib and in 35% (95% Cl, 26%-45%) of patients receiving 500 mg. These benefits were observed within 3 weeks in 75% of patients. Partial radiographic responses occurred in 12% (95% Cl, 6%-20%) of individuals receiving 250 mg of gefitinib and in 9% (95% Cl, 4%-16%) of those receiving 500 mg. Symptoms improved in 96% of patients with partial radiographic responses. The overall survival at 1 year was 25%. There were no significant differences between the 250-mg and 500-mg doses in rates of symptom improvement (P=.26), radiographic tumor regression (P=.51), and projected 1-year survival (P=.54). The 500-mg dose was associated more frequently with transient acne-like rash (P=.04) and diarrhea (P=.006). Conclusions Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy.	Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Thorac Oncol Serv, New York, NY 10021 USA; Cornell Univ, Weil Med Coll, New York, NY USA; Cedars Sinai Comprehens Canc Ctr, Los Angeles, CA USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA; Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA; Univ Wisconsin Hosp, Madison, WI USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Hematol Oncol Consultants Inc, Columbus, OH USA; Vanderbilt Univ, Nashville, TN USA; Loyola Univ, Med Ctr, Maywood, IL 60153 USA; Northwestern Univ, Evanston, IL USA; AstraZeneca, Wilmington, DE USA	Memorial Sloan Kettering Cancer Center; Cornell University; Cedars Sinai Medical Center; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Massachusetts General Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Wisconsin System; University of Wisconsin Madison; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Vanderbilt University; Loyola University Chicago; Northwestern University; AstraZeneca	Kris, MG (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Thorac Oncol Serv, 1275 York Ave, New York, NY 10021 USA.			Belani, Chandra/0000-0001-5049-5329; Kelly, Karen/0000-0002-2235-6636; Kris, Mark/0000-0002-7317-5341				Al Hazaa A, 2000, CLIN CANCER RES, V6, p4542S; Albanell J, 2002, J CLIN ONCOL, V20, P110, DOI 10.1200/JCO.20.1.110; Allen LF, 2000, CLIN CANCER RES, V6, p4543S; Arteaga CL, 2001, J CLIN ONCOL, V19, p32S; BAILEY R, 2003, P AM ASSOC CANC RES, P1362; Baselga J, 2002, J CLIN ONCOL, V20, P4292, DOI 10.1200/JCO.2002.03.100; Bergeron A, 2002, J CLIN ONCOL, V20, P4271, DOI 10.1200/JCO.2002.99.179; Brabender J, 2001, CLIN CANCER RES, V7, P1850; Cella D, 2002, J CLIN EPIDEMIOL, V55, P285, DOI 10.1016/S0895-4356(01)00477-2; CELLA DF, 1995, LUNG CANCER-J IASLC, V12, P199, DOI 10.1016/0169-5002(95)00450-F; CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; COOPER JAD, 1986, AM REV RESPIR DIS, V133, P321; Eton DT, 2003, J CLIN ONCOL, V21, P1536, DOI 10.1200/JCO.2003.07.128; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Fossella FV, 2000, J CLIN ONCOL, V18, P2354, DOI 10.1200/JCO.2000.18.12.2354; Fujino S, 1996, EUR J CANCER, V32A, P2070, DOI 10.1016/S0959-8049(96)00243-2; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; GREEN S, 1992, INVEST NEW DRUG, V10, P239, DOI 10.1007/BF00944177; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Heinrich MC, 2002, J CLIN ONCOL, V20, P1692, DOI 10.1200/JCO.2002.20.6.1692; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; HEINRICH MC, 2002, P AN M AM SOC CLIN, V21, pA2; Herbst RS, 2002, J CLIN ONCOL, V20, P3815, DOI 10.1200/JCO.2002.03.038; HIRSCH FR, IN PRESS J CLIN ONCO; Inoue A, 2003, LANCET, V361, P137, DOI 10.1016/S0140-6736(03)12190-3; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kris MG, 2000, LUNG CANCER, V29, P72; Kusaba H, 2000, CLIN CANCER RES, V6, p4543S; Massarelli E, 2003, LUNG CANCER-J IASLC, V39, P55, DOI 10.1016/S0169-5002(02)00308-2; Mauro MJ, 2002, J CLIN ONCOL, V20, P325, DOI 10.1200/JCO.20.1.325; Mendelsohn J, 2000, CLIN CANCER RES, V6, P747; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; Moyer JD, 1997, CANCER RES, V57, P4838; NATALE RB, 2002, P AN M AM SOC CLIN, V21, pA292; OCONNELL JP, 1986, J CLIN ONCOL, V4, P1604, DOI 10.1200/JCO.1986.4.11.1604; PEREZSOLER R, 2001, AM SOC CLIN ONC ANN; Pfeiffer P, 1996, BRIT J CANCER, V74, P86, DOI 10.1038/bjc.1996.320; RUSCH V, 1993, CANCER RES, V53, P2379; Rusch V, 1997, CLIN CANCER RES, V3, P515; Saltz L, 2001, CLIN CANCER RES, V7, p3766S; Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; SHAH NT, 2003, P AN M AM SOC CLIN, V2, P628; Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095; Singh B, 2002, GENE DEV, V16, P984, DOI 10.1101/gad.973602; Sirotnak FM, 2000, CLIN CANCER RES, V6, P4885; Soria JC, 2002, CLIN CANCER RES, V8, P1178; STALLINGSMANN M, 2002, P AN M AM SOC CLIN, V21, pA19; Wakeling AE, 2002, CANCER RES, V62, P5749	50	2135	2304	2	116	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	2003	290	16					2149	2158		10.1001/jama.290.16.2149	http://dx.doi.org/10.1001/jama.290.16.2149			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CB	14570950	Bronze			2022-12-28	WOS:000186036700024
J	McManus, DP; Zhang, WB; Li, J; Bartley, PB				McManus, DP; Zhang, WB; Li, J; Bartley, PB			Echinococcosis	LANCET			English	Review							LINKED-IMMUNOSORBENT-ASSAY; HUMAN CYSTIC ECHINOCOCCOSIS; ALVEOLAR ECHINOCOCCOSIS; HYDATID-DISEASE; PERCUTANEOUS TREATMENT; GRANULOSUS INFECTION; SERUM ANTIBODIES; VACCINE ANTIGEN; HIGH PREVALENCE; DIAGNOSIS	Echinococcosis is a near-cosmopolitan zoonosis caused by adult or larval stages of cestodes belonging to the genus Echinococcus (family Taenlidae). The two major species of medical and public health importance are Echinococcus granulosus and Echinococcus multilocularis, which cause cystic echinococcosis and alveolar echinococcosis, respectively. Both are serious and severe diseases, the latter especially so, with high fatality rates and poor prognosis if managed incorrectly. Several reports have shown that both diseases are of increasing public health concern and that both can be regarded as emerging or re-emerging diseases. In this review we discuss aspects of the biology, life cycle, aetiology, distribution, and transmission of the Echinococcus organisms, and the epidemiology, clinical features, treatment, and diagnosis of the diseases they cause. We also discuss the countermeasures available for the control and prevention of these diseases. E granulosus still has a wide geographical distribution, although effective control against cystic echinococcosis has been achieved in some regions. E multilocularis and alveolar echinococcosis are more problematic, since the primary transmission cycle is almost always sylvatic so that efficient and cost-effective methods for control are unavailable.	Queensland Inst Med Res, Mol Parasitol Lab, Australian Ctr Int & Trop Hlth & Nutr, Brisbane, Qld 4029, Australia; Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, Brisbane, Qld 4029, Australia; Univ Queensland, Brisbane, Qld 4029, Australia; Xinjiang Acad Anim Sci, Vet Res Inst, Urumqi, Xinjiang, Peoples R China	QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical Research Institute; University of Queensland	McManus, DP (corresponding author), Queensland Inst Med Res, Mol Parasitol Lab, Australian Ctr Int & Trop Hlth & Nutr, Brisbane, Qld 4029, Australia.	donM@qimr.edu.au	McManus, Don/AAC-5394-2020; Bartley, Paul/ABE-6528-2020; McManus, Donald P./G-2678-2013; Bartley, Paul/C-2178-2016	McManus, Don/0000-0001-6443-1449; Bartley, Paul/0000-0001-6748-1775; Bartley, Paul/0000-0001-6748-1775				ALKARAWI MA, 1990, HEPATO-GASTROENTEROL, V37, P327; AMMANN R, 1988, KLIN WOCHENSCHR, V66, P1060, DOI 10.1007/BF01711918; Ammann RW, 1996, GASTROENTEROL CLIN N, V25, P655, DOI 10.1016/S0889-8553(05)70268-5; Aygun E, 2001, CAN J SURG, V44, P203; BABBA H, 1994, AM J TROP MED HYG, V50, P64, DOI 10.4269/ajtmh.1994.50.64; Bartholomot B, 2002, AM J TROP MED HYG, V66, P23, DOI 10.4269/ajtmh.2002.66.23; BOWLES J, 1995, PARASITOLOGY, V110, P317, DOI 10.1017/S0031182000080902; Bresson-Hadni S, 2000, EUR J GASTROEN HEPAT, V12, P327, DOI 10.1097/00042737-200012030-00011; Cabrera M, 2002, DIAGN MICR INFEC DIS, V44, P29, DOI 10.1016/S0732-8893(02)00414-5; CASTELLANO G, 1994, HEPATO-GASTROENTEROL, V41, P458; Castrodale LJ, 2002, AM J TROP MED HYG, V66, P325, DOI 10.4269/ajtmh.2002.66.325; Conchedda M, 2002, NATO SCI SER I LIFE, V341, P343; Craig P., 1997, COMPENDIUM CYSTIC EC, P85; CRAIG PS, 1992, LANCET, V340, P826, DOI 10.1016/0140-6736(92)92693-A; CRAIG PS, 1986, PARASITE IMMUNOL, V8, P171, DOI 10.1111/j.1365-3024.1986.tb00843.x; CRAIG PS, 1988, T ROY SOC TROP MED H, V82, P268, DOI 10.1016/0035-9203(88)90445-2; DAlessandro A, 1997, ACTA TROP, V67, P43, DOI 10.1016/S0001-706X(97)00048-X; Danson FM, 2002, NATO SCI SER I LIFE, V341, P237; DEPLAZES P, 1992, PARASITOL RES, V78, P303, DOI 10.1007/BF00937088; Deplazes P., 1996, Applied Parasitology, V37, P245; Doi R, 1987, JAP J PUBL HLTH, V34, P357; Eckert J, 2001, WHO/OIE MANUAL ON ECHINOCOCCOSIS IN HUMANS AND ANIMALS: A PUBLIC HEALTH PROBLEM OF GLOBAL CONCERN, P100; Eckert J, 2001, WHO/OIE MANUAL ON ECHINOCOCCOSIS IN HUMANS AND ANIMALS: A PUBLIC HEALTH PROBLEM OF GLOBAL CONCERN, P72; Eckert J, 2000, INT J PARASITOL, V30, P1283, DOI 10.1016/S0020-7519(00)00130-2; Eiermann TH, 1998, TISSUE ANTIGENS, V52, P124, DOI 10.1111/j.1399-0039.1998.tb02275.x; Filice C, 2000, GUT, V47, P156, DOI 10.1136/gut.47.1.156b; Filice C, 1997, ACTA TROP, V64, P95, DOI 10.1016/S0001-706X(96)00642-0; Franchi C, 1999, CLIN INFECT DIS, V29, P304, DOI 10.1086/520205; Frider B, 1999, J HEPATOL, V30, P228, DOI 10.1016/S0168-8278(99)80066-X; GARGOURI M, 1990, CARDIOVASC INTER RAD, V13, P169, DOI 10.1007/BF02575469; GASSER RB, 1988, AUST VET J, V65, P369, DOI 10.1111/j.1751-0813.1988.tb14274.x; GASSER RB, 1991, RES VET SCI, V50, P340, DOI 10.1016/0034-5288(91)90135-B; GASSER RB, 1990, AUST VET J, V67, P145, DOI 10.1111/j.1751-0813.1990.tb07735.x; Gauci C, 2002, INFECT IMMUN, V70, P3969, DOI 10.1128/IAI.70.7.3969-3972.2002; Gemmell M. A., 1995, P333; Gemmell MA, 2001, WHO/OIE MANUAL ON ECHINOCOCCOSIS IN HUMANS AND ANIMALS: A PUBLIC HEALTH PROBLEM OF GLOBAL CONCERN, P195; GILBERT D, 2001, TABLE 6 RISK CATEGOR, P55; GILGRANDE LA, 1993, LANCET, V342, P1269, DOI 10.1016/0140-6736(93)92361-V; Giraudoux P, 2002, NATO SCI SER I LIFE, V341, P251; Godot V, 2000, CLIN EXP IMMUNOL, V121, P491, DOI 10.1046/j.1365-2249.2000.01309.x; GOTTSTEIN B, 1992, CLIN MICROBIOL REV, V5, P248, DOI 10.1128/CMR.5.3.248-261.1992; GOTTSTEIN B, 1991, J VET MED B, V38, P161, DOI 10.1111/j.1439-0450.1991.tb00858.x; GOTTSTEIN B, 1993, J CLIN MICROBIOL, V31, P373, DOI 10.1128/JCM.31.2.373-376.1993; Gottstein B, 2001, EMERG INFECT DIS, V7, P408; GOTTSTEIN B, 1985, PARASITE IMMUNOL, V7, P201, DOI 10.1111/j.1365-3024.1985.tb00070.x; GOTTSTEIN B, 1994, J INFECT DIS, V169, P1416, DOI 10.1093/infdis/169.6.1416; Gottstein B., 1995, ECHINOCOCCUS HYDATID, P355; Haag KL, 1997, PARASITOLOGY, V115, P521, DOI 10.1017/S0031182097001649; Heath DD, 1997, ACTA TROP, V67, P37, DOI 10.1016/S0001-706X(97)00054-5; HELBIG M, 1993, J CLIN MICROBIOL, V31, P3211, DOI 10.1128/JCM.31.12.3211-3215.1993; Hildreth MB, 2000, J PARASITOL, V86, P75, DOI 10.1645/0022-3395(2000)086[0075:FTIAEI]2.0.CO;2; Horton RJ, 1997, ACTA TROP, V64, P79, DOI 10.1016/S0001-706X(96)00640-7; ITO A, 1995, AM J TROP MED HYG, V52, P41, DOI 10.4269/ajtmh.1995.52.41; Ito A, 2002, PARASITOL INT, V51, P221, DOI 10.1016/S1383-5769(02)00036-3; Ito A, 2003, ACTA TROP, V85, P173, DOI 10.1016/S0001-706X(02)00221-8; Ito A, 2003, ACTA TROP, V86, P3, DOI 10.1016/S0001-706X(02)00269-3; Ito A, 2002, J CLIN MICROBIOL, V40, P4161, DOI 10.1128/JCM.40.11.4161-4165.2002; JENKINS DJ, 1986, AUST VET J, V63, P40, DOI 10.1111/j.1751-0813.1986.tb02918.x; Kern P, 2003, EMERG INFECT DIS, V9, P343, DOI 10.3201/eid0903.020341; Khuroo MS, 1997, NEW ENGL J MED, V337, P881, DOI 10.1056/NEJM199709253371303; Kittelberger R, 2002, VET PARASITOL, V110, P57, DOI 10.1016/S0304-4017(02)00308-4; LARRIEU E, 1999, ARCH INT HIDATID, V33, P122; Larrieu EJ, 2001, ANN TROP MED PARASIT, V95, P679, DOI 10.1080/00034980120094730; Le TH, 2002, PARASITOLOGY, V124, P97, DOI 10.1017/S0031182001008976; Lightowlers MW, 1999, INT J PARASITOL, V29, P531, DOI 10.1016/S0020-7519(99)00003-X; Lightowlers MW, 2000, PARASITOL TODAY, V16, P191, DOI 10.1016/S0169-4758(99)01633-6; LIU YH, 1997, ARCH INT HIDATIDOSIS, V32, P171; Lorenzo C, 2003, BIOCHEM J, V369, P191, DOI 10.1042/BJ20021402; Ma L, 1997, T ROY SOC TROP MED H, V91, P476, DOI 10.1016/S0035-9203(97)90291-1; MACPHERSON CNL, 1983, AM J TROP MED HYG, V32, P397, DOI 10.4269/ajtmh.1983.32.397; Marsland BJ, 2003, ARCH VIROL, V148, P555, DOI 10.1007/s00705-002-0948-6; Mathis A, 2002, NATO SCI SER I LIFE, V341, P195; Mboti B, 1996, ACTA CHIR BELG, V96, P229; McManus D P, 2002, Trans R Soc Trop Med Hyg, V96 Suppl 1, pS151, DOI 10.1016/S0035-9203(02)90068-4; McManus D. P., 1995, BIOL ECHINOCOCCUS HY, P355; McManus DP, 2002, AM J TROP MED HYG, V67, P296, DOI 10.4269/ajtmh.2002.67.296; Men S, 1999, AM J ROENTGENOL, V172, P83, DOI 10.2214/ajr.172.1.9888745; Menghebat L., 1993, Compendium on cystic echinococcosis: with special reference to the Xinjiang Uygur Autonomous Region, The People's Republic of China., P135; Mohamed AE, 1998, HEPATO-GASTROENTEROL, V45, P1690; Nakao M, 2002, MITOCHONDRION, V1, P497, DOI 10.1016/S1567-7249(02)00040-5; Pawlowski ZS, 2001, WHO/OIE MANUAL ON ECHINOCOCCOSIS IN HUMANS AND ANIMALS: A PUBLIC HEALTH PROBLEM OF GLOBAL CONCERN, P20; Pelaez V, 2000, ACTA TROP, V75, P197, DOI 10.1016/S0001-706X(00)00058-9; Poretti D, 1999, AM J TROP MED HYG, V60, P193, DOI 10.4269/ajtmh.1999.60.193; Rausch RL, 2002, NATO SCI SER I LIFE, V341, P107; Ravinder PT, 1997, J MED MICROBIOL, V46, P859, DOI 10.1099/00222615-46-10-859; Rickard M.D., 1986, P217; Rigano R, 1999, CLIN EXP IMMUNOL, V118, P95; Rinder H, 1997, J PARASITOL, V83, P1045, DOI 10.2307/3284359; ROBERTS MG, 1995, VET PARASITOL, V56, P67, DOI 10.1016/0304-4017(94)00655-V; Sako Y, 2002, J CLIN MICROBIOL, V40, P2760, DOI 10.1128/JCM.40.8.2760-2765.2002; Sarciron EM, 1997, PARASITE IMMUNOL, V19, P61, DOI 10.1046/j.1365-3024.1997.d01-183.x; Sato N, 1997, J GASTROENTEROL, V32, P351, DOI 10.1007/BF02934492; Sato N., 1993, ALVEOLAR ECHINOCOCCO, P63; Schipper HG, 2002, GUT, V50, P718, DOI 10.1136/gut.50.5.718; Sreter T, 2003, EMERG INFECT DIS, V9, P384, DOI 10.3201/eid0903.020320; Thompson R. C. A., 1995, P1; THOMPSON RCA, 1988, ADV PARASIT, V27, P209, DOI 10.1016/S0065-308X(08)60356-5; Thompson RCA, 2002, TRENDS PARASITOL, V18, P452, DOI 10.1016/S1471-4922(02)02358-9; Thompson RCA, 2001, WHO/OIE MANUAL ON ECHINOCOCCOSIS IN HUMANS AND ANIMALS: A PUBLIC HEALTH PROBLEM OF GLOBAL CONCERN, P1; THOMPSON RCA, 1990, INT J PARASITOL, V20, P457, DOI 10.1016/0020-7519(90)90193-Q; Torgerson P, 2002, NATO SCI SER I LIFE, V341, P221; Tsukada H, 2002, PARASITOLOGY, V125, P119, DOI 10.1017/S0031182002001968; Utrilla JG., 1991, ARCH HYDATIDOSIS, V30, P721; Vuitton DA, 1996, B WORLD HEALTH ORGAN, V74, P231; Wang DL, 2002, IEEE T SYST MAN CY B, V32, P254, DOI 10.1109/TSMCB.2002.999803; WILSON JF, 1992, CLIN INFECT DIS, V15, P234, DOI 10.1093/clinids/15.2.234; Yamashita J., 1973, Progress of medical parasitology in Japan. Volume 5., P65; YONG WK, 1984, RES VET SCI, V36, P24, DOI 10.1016/S0034-5288(18)31996-9; Zhang S, 2003, EUR J IMMUNOGENET, V30, P133, DOI 10.1046/j.1365-2370.2003.00375.x; Zhang WB, 2003, CLIN MICROBIOL REV, V16, P18, DOI 10.1128/CMR.16.1.18-36.2003; 2000, THERAPEUTIC GUIDELIN, P238	111	679	812	1	73	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	2003	362	9392					1295	1304		10.1016/S0140-6736(03)14573-4	http://dx.doi.org/10.1016/S0140-6736(03)14573-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575976				2022-12-28	WOS:000186036900024
J	Porter, K; Babiker, AG; Darbyshire, JH; Pezzotti, P; Bhaskaran, K; Walker, AS				Porter, K; Babiker, AG; Darbyshire, JH; Pezzotti, P; Bhaskaran, K; Walker, AS		CASCADE Collaboration	Determinants of survival following HIV-1 seroconversion after the introduction of HAART	LANCET			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; DRUG-USE; MORTALITY; AIDS; ADHERENCE; PROGRESSION; PREDICTORS; INFECTION; RECOVERY; OUTCOMES	Background Highly active antiretroviral therapy (HAART) was introduced in 1997. We aimed to assess the continuing effect of this treatment on survival and progression to AIDS after HIV-1 seroconversion. Methods We used Cox models to estimate the effect of calendar year on time to AIDS and death in 22 cohorts of people from Europe, Australia, and Canada who had seroconverted. Retrospective and prospective data were used. We compared the effects of age at seroconversion, exposure category, sex, and presentation during acute HIV-1 infection pre-1997 (pre-HAART), in 1997-98 (limited use of HAART), and 1999-2001 (widespread use of HAART). Findings Of 7740 seroconverters, 2000 (26%) had died. Compared with pre-1997 data, the hazard ratio (HR) for death fell sharply to 0.47 [95% Cl 0.39-0-56] in 1997, dropping further to 0.16 [0.12-0.22] in 2001. Correspondingly, the proportion of person-time on HAART increased from 22% in 1997 to 57% in 2001. By contrast with the pre-HAART era, injecting drug users had significantly higher mortality in 1999-2001 than did men infected through sex with men (HR 4.28 [2.86-6.41]). However, whereas pre-1997 the risk of AIDS was higher in those aged 45 years or older at seroconversion than in people who were 16-24 years (2.03 [1.67-2.47]), in 1999-2001 there was little evidence of a difference in risk by age (HR=1.17 [0.60-2.30]; interaction p=0.06). No such attenuation in the effect of age on survival was observed (p=0.63). Interpretation Predicted survival for people with HIV-1 has continued to increase, since the introduction of HAART; however. the importance of age and exposure category as determinants of progression seems to have changed.	MRC, Clin Trials Unit, London NW1 2DA, England	Medical Research Council Clinical Trials Unit	Porter, K (corresponding author), MRC, Clin Trials Unit, 222 Euston Rd, London NW1 2DA, England.	kp@ctu.mrc.ac.uk	PEZZOTTI, PATRIZIO/C-6480-2016; VALLET, Yannick/F-9979-2011	PEZZOTTI, PATRIZIO/0000-0002-0805-2927; Bhaskaran, Krishnan/0000-0001-5364-8757; Johnson, Anne/0000-0003-1330-7100; Porter, Kholoud/0000-0002-9226-6206				Babiker A, 2000, LANCET, V355, P1131, DOI 10.1016/S0140-6736(00)02061-4; BROOKMEYER R, 1987, AM J EPIDEMIOL, V126, P14, DOI 10.1093/oxfordjournals.aje.a114646; CASCADE Collaboration, 2000, LANCET, V355, P1158, DOI 10.1016/S0140-6736(00)02069-9; CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) Collaboration, 2000, HIV Med, V1, P224; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; Celentano DD, 2001, AIDS, V15, P1707, DOI 10.1097/00002030-200109070-00015; CLAYTON C, 1993, STAT MODELS EPIDEMIO; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; Cunningham WE, 2000, J ACQ IMMUN DEF SYND, V25, P115, DOI 10.1097/00126334-200010010-00005; Darby SC, 1997, LANCET, V350, P1425, DOI 10.1016/S0140-6736(97)05413-5; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Gordillo V, 1999, AIDS, V13, P1763, DOI 10.1097/00002030-199909100-00021; Greub G, 2000, LANCET, V356, P1800, DOI 10.1016/S0140-6736(00)03232-3; Jacobson LP, 2001, J CLIN EPIDEMIOL, V54, P149, DOI 10.1016/S0895-4356(00)00274-2; Le Moing V, 2001, J ACQ IMMUN DEF SYND, V27, P372, DOI 10.1097/00126334-200108010-00007; Lindsey J. K., 1996, PARAMETRIC STAT INFE; Lucas GM, 2002, AIDS, V16, P767, DOI 10.1097/00002030-200203290-00012; Lucas GM, 2001, J ACQ IMMUN DEF SYND, V27, P251, DOI 10.1097/00126334-200107010-00006; Mocroft A, 1999, J ACQ IMMUN DEF SYND, V22, P369; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mocroft A, 1997, BRIT MED J, V314, P409, DOI 10.1136/bmj.314.7078.409; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; PEREZHOYOZ S, 2002, 14 INT AIDS C BARC J; PEZZOTTI P, 14 INT AIDS C BARC J, P2; Porta D, 1999, AIDS, V13, P2125, DOI 10.1097/00002030-199910220-00016; Porter K, 1999, AIDS, V13, P1943, DOI 10.1097/00002030-199910010-00018; Porter K, 2000, AIDS, V14, P1899; Poundstone KE, 2001, AIDS, V15, P1115, DOI 10.1097/00002030-200106150-00006; Sabin CA, 2001, EPIDEMIOL INFECT, V127, P91; Steinmann G G, 1986, Curr Top Pathol, V75, P43; Strathdee SA, 1998, JAMA-J AM MED ASSOC, V280, P547, DOI 10.1001/jama.280.6.547; Tarwater PM, 2001, AM J EPIDEMIOL, V154, P675, DOI 10.1093/aje/154.7.675; Turner BJ, 2001, J GEN INTERN MED, V16, P625, DOI 10.1046/j.1525-1497.2001.016009625.x; Viard JP, 2001, J INFECT DIS, V183, P1290, DOI 10.1086/319678; Whitman S, 2000, ARCH INTERN MED, V160, P365, DOI 10.1001/archinte.160.3.365; Wilson TE, 2002, CLIN INFECT DIS, V34, P529, DOI 10.1086/338397	38	280	294	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	2003	362	9392					1267	1274						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575971				2022-12-28	WOS:000186036900010
J	Khvorova, A; Reynolds, A; Jayasena, SD				Khvorova, A; Reynolds, A; Jayasena, SD			Functional siRNAs and rniRNAs exhibit strand bias	CELL			English	Article							RNA-INTERFERENCE; MESSENGER-RNA; EXPRESSION; DICER; RIBONUCLEASE; MICRORNA; CLEAVAGE	Both microRNAs (miRNA) and small interfering RNAs (siRNA) share a common set of cellular proteins (Dicer and the RNA-induced silencing complex [RISC]) to elicit RNA interference. In the following work, a statistical analysis of the internal stability of published miRNA sequences in the context of miRNA precursor hairpins revealed enhanced flexibility of miRNA precursors, especially at the 5'-anti-sense (AS) terminal base pair. The same trend was observed in siRNA, with functional duplexes displaying a lower internal stability (Delta0.5 kcal/mol) at the 5'-AS end than nonfunctional duplexes. Average internal stability of siRNA molecules retrieved from plant cells after introduction of long RNA sequences also shows this characteristic thermodynamic signature. Together, these results suggest that the thermodynamic properties of siRNA play a critical role in determining the molecule's function and longevity, possibly biasing the steps involved in duplex unwinding and strand retention by RISC.	Amgen Inc, Thousand Oaks, CA 91320 USA; Dharmacon Inc, Lafayette, CO 80026 USA	Amgen	Jayasena, SD (corresponding author), Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.	sumedhaj@amgen.com						Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Collins ML, 1997, NUCLEIC ACIDS RES, V25, P2979, DOI 10.1093/nar/25.15.2979; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; LARGOSQUINTANA M, 2001, SCIENCE, V294, P853; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; Llave C, 2002, PLANT CELL, V14, P1605, DOI 10.1105/tpc.003210; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Nicholson RH, 2002, MAMM GENOME, V13, P67, DOI 10.1007/s00335-001-2119-6; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Plasterk RHA, 2002, SCIENCE, V296, P1263, DOI 10.1126/science.1072148; SAXENA S, 2003, IN PRESS J BIOL CHEM, DOI DOI 10.1074/JBCM307089200; Scaringe SA, 2000, METHOD ENZYMOL, V317, P3; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100	29	1815	2131	4	137	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	2003	115	2					209	216		10.1016/S0092-8674(03)00801-8	http://dx.doi.org/10.1016/S0092-8674(03)00801-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567918	Bronze, Green Published			2022-12-28	WOS:000186039200012
J	Lee, S; Sowa, ME; Watanabe, YH; Sigler, PB; Chiu, W; Yoshida, M; Tsai, FTF				Lee, S; Sowa, ME; Watanabe, YH; Sigler, PB; Chiu, W; Yoshida, M; Tsai, FTF			The structure of clpB: A molecular chaperone that rescues proteins from an aggregated state	CELL			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; HSP100 CHAPERONE; LEUCINE-ZIPPER; BINDING; ATPASE; DNAK; TRANSLOCATION; SOFTWARE; SYSTEM	Molecular chaperones assist protein folding by facilitating their "forward" folding and preventing aggregation. However, once aggregates have formed, these chaperones cannot facilitate protein disaggregation. Bacterial ClpB and its eukaryotic homolog Hsp104 are essential proteins of the heat-shock response, which have the remarkable capacity to rescue stress-damaged proteins from an aggregated state. We have determined the structure of Thermus thermophilus ClpB (TClpB) using a combination of X-ray crystallography and cryo-electron microscopy (cryo-EM). Our single-particle reconstruction shows that TClpB forms a two-tiered hexameric ring. The ClpB/Hsp104-linker consists of an 85 Angstrom long and mobile coiled coil that is located on the outside of the hexamer. Our mutagenesis and biochemical data show that both the relative position and motion of this coiled coil are critical for chaperone function. Taken together, we propose a mechanism by which an ATP-driven conformational change is coupled to a large coiled-coil motion, which is indispensable for protein disaggregation.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06511 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06511 USA	Baylor College of Medicine; Tokyo Institute of Technology; Yale University; Howard Hughes Medical Institute; Yale University	Tsai, FTF (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA.	ftsai@bcm.tmc.edu			NCRR NIH HHS [P41RR02250] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002250] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barnett ME, 2000, J BIOL CHEM, V275, P37565, DOI 10.1074/jbc.M005211200; Beinker P, 2002, J BIOL CHEM, V277, P47160, DOI 10.1074/jbc.M207853200; Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; Clarke AK, 2000, J BACTERIOL, V182, P7092, DOI 10.1128/JB.182.24.7092-7096.2000; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Ishikawa T, 2001, P NATL ACAD SCI USA, V98, P4328, DOI 10.1073/pnas.081543698; Jiang W, 2001, J MOL BIOL, V308, P1033, DOI 10.1006/jmbi.2001.4633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1991, MOL REPLACEMENT, P91; Kim KI, 2000, J MOL BIOL, V303, P655, DOI 10.1006/jmbi.2000.4165; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li JZ, 2003, STRUCTURE, V11, P323, DOI 10.1016/S0969-2126(03)00030-3; Li JZ, 2002, J MOL BIOL, V318, P1127, DOI 10.1016/S0022-2836(02)00188-2; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Neuwald AF, 1999, GENOME RES, V9, P27; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Ortega J, 2000, MOL CELL, V6, P1515, DOI 10.1016/S1097-2765(00)00148-9; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARK SK, 1993, J BIOL CHEM, V268, P20170; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schlee S, 2001, J MOL BIOL, V306, P889, DOI 10.1006/jmbi.2001.4455; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; Stiggall D L, 1979, Methods Enzymol, V55, P308; Tek V, 2002, PROTEIN SCI, V11, P1192, DOI 10.1110/ps.4860102; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang J, 2001, STRUCTURE, V9, P1107, DOI 10.1016/S0969-2126(01)00670-0; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083; Zolkiewski M, 1999, PROTEIN SCI, V8, P1899, DOI 10.1110/ps.8.9.1899	53	349	356	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	2003	115	2					229	240		10.1016/S0092-8674(03)00807-9	http://dx.doi.org/10.1016/S0092-8674(03)00807-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567920	Bronze			2022-12-28	WOS:000186039200014
J	Prodan, E; Radloff, C; Halas, NJ; Nordlander, P				Prodan, E; Radloff, C; Halas, NJ; Nordlander, P			A hybridization model for the plasmon response of complex nanostructures	SCIENCE			English	Article							CORE-SHELL PARTICLES; METALLIC NANOSHELLS; OPTICAL-PROPERTIES; SILVER NANOPARTICLES; CHEMICAL-SYNTHESIS; SILICA SPHERES; GOLD; SIZE; POLARIZABILITY; RESONANCES	We present a simple and intuitive picture, an electromagnetic analog of molecular orbital theory, that describes the plasmon response of complex nanostructures of arbitrary shape. Our model can be understood as the interaction or "hybridization" of elementary plasmons supported by nanostructures of elementary geometries. As an example, the approach is applied to the important case of a four-layer concentric nanoshell, where the hybridization of the plasmons of the inner and outer nanoshells determines the resonant frequencies of the multilayer nanostructure.	Rice Univ, Dept Chem, Houston, TX 77251 USA; Rice Univ, Dept Phys, Houston, TX 77251 USA; Rice Univ, Dept Elect & Comp Engn, Houston, TX 77251 USA; Rice Univ, Rice Quantum Inst, Houston, TX 77251 USA	Rice University; Rice University; Rice University; Rice University	Halas, NJ (corresponding author), Rice Univ, Dept Chem, POB 1892, Houston, TX 77251 USA.	halas@rice.edu	Nordlander, Peter J. A./A-2560-2008; Prodan, Emil V/A-2589-2008; Halas, Naomi/D-2935-2011	Nordlander, Peter J. A./0000-0002-1633-2937; Prodan, Emil V/0000-0001-8940-6629; Halas, Naomi/0000-0002-8461-8494				ADEN AL, 1951, J APPL PHYS, V22, P1242, DOI 10.1063/1.1699834; Aizpurua J, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.057401; Charnay C, 2003, J PHYS CHEM B, V107, P7327, DOI 10.1021/jp034309r; Graf C, 2002, LANGMUIR, V18, P524, DOI 10.1021/la011093g; Jackson JB, 2001, J PHYS CHEM B, V105, P2743, DOI 10.1021/jp003868k; Jana NR, 2001, J PHYS CHEM B, V105, P4065, DOI 10.1021/jp0107964; Kelly KL, 2003, J PHYS CHEM B, V107, P668, DOI 10.1021/jp026731y; Kobayashi Y, 2001, CHEM MATER, V13, P1630, DOI 10.1021/cm001240g; Liz-Marzan LM, 1996, LANGMUIR, V12, P4329, DOI 10.1021/la9601871; Love JC, 2002, NANO LETT, V2, P891, DOI 10.1021/nl025633l; Maier SA, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.193408; Maillard M, 2003, J PHYS CHEM B, V107, P2466, DOI 10.1021/jp022357q; Malinsky MD, 2001, J AM CHEM SOC, V123, P1471, DOI 10.1021/ja003312a; Nicewarner-Pena SR, 2001, SCIENCE, V294, P137, DOI 10.1126/science.294.5540.137; Oldenburg SJ, 1998, CHEM PHYS LETT, V288, P243, DOI 10.1016/S0009-2614(98)00277-2; Prodan E, 2002, CHEM PHYS LETT, V352, P140, DOI 10.1016/S0009-2614(01)01409-9; Prodan E, 2002, CHEM PHYS LETT, V360, P325, DOI 10.1016/S0009-2614(02)00850-3; Prodan E, 2003, NANO LETT, V3, P543, DOI 10.1021/nl034030m; STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021-9797(68)90272-5; Sun YG, 2002, SCIENCE, V298, P2176, DOI 10.1126/science.1077229; Sun YG, 2002, ANAL CHEM, V74, P5297, DOI 10.1021/ac0258352; Westcott SL, 2001, J PHYS CHEM B, V105, P9913, DOI 10.1021/jp011213t	22	3175	3242	61	1392	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					419	422		10.1126/science.1089171	http://dx.doi.org/10.1126/science.1089171			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564001				2022-12-28	WOS:000185963200034
J	Walmsley, MJ; Ooi, SKT; Reynolds, LF; Smith, SH; Ruf, S; Mathiot, A; Vanes, L; Williams, DA; Cancro, MP; Tybulewicz, VLJ				Walmsley, MJ; Ooi, SKT; Reynolds, LF; Smith, SH; Ruf, S; Mathiot, A; Vanes, L; Williams, DA; Cancro, MP; Tybulewicz, VLJ			Critical roles for Rac1 and Rac2 GTPases in B cell development and signaling	SCIENCE			English	Article							RECEPTOR RESPONSES; B-1 CELLS; BAFF-R; ACTIVATION; EXPRESSION; SELECTION; KINASE	The Rac1 guanosine triphosphatase (GTPase) has been implicated in multiple cellular functions, including actin dynamics, proliferation, apoptosis, adhesion, and migration resulting from signaling by multiple receptors, including the B cell antigen receptor (BCR). We used conditional gene targeting to generate mice with specific Rac1 deficiency in the B cell lineage. In the absence of both Rac1 and the highly related Rac2, B cell development was almost completely blocked. Both GTPases were required to transduce BCR signals leading to proliferation, survival and upregulation of BAFF-R, a receptor for BAFF, a key survival molecule required for B cell development and maintenance.	Natl Inst Med Res, Div Immune Cell Biol, London NW7 1AA, England; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Cincinnati Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA	MRC National Institute for Medical Research; University of Pennsylvania; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Tybulewicz, VLJ (corresponding author), Natl Inst Med Res, Div Immune Cell Biol, Ridgeway,Mill Hill, London NW7 1AA, England.	vtybule@nimr.mrc.ac.uk		Tybulewicz, Victor/0000-0003-2439-0798; Cancro, Michael/0000-0002-8659-3227; Ooi, Steen/0000-0003-4198-9014	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062757] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI054488] Funding Source: Medline; NIDDK NIH HHS [R01 DK62757] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amanna IJ, 2003, J IMMUNOL, V170, P4593, DOI 10.4049/jimmunol.170.9.4593; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Croker BA, 2002, J IMMUNOL, V168, P3376, DOI 10.4049/jimmunol.168.7.3376; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Grill B, 2002, BLOOD, V100, P3183, DOI 10.1182/blood-2002-01-0154; Hayakawa K, 2000, CURR OPIN IMMUNOL, V12, P346, DOI 10.1016/S0952-7915(00)00098-4; Inabe K, 2002, J EXP MED, V195, P189, DOI 10.1084/jem.20011571; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; Lentz VM, 1998, J IMMUNOL, V160, P3743; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Nosaka Y, 2001, BIOCHEM BIOPH RES CO, V285, P675, DOI 10.1006/bbrc.2001.5222; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Rickert RC, 1997, NUCLEIC ACIDS RES, V25, P1317, DOI 10.1093/nar/25.6.1317; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Smith SH, 2003, J IMMUNOL, V170, P5820, DOI 10.4049/jimmunol.170.12.5820; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; Su TT, 2002, J IMMUNOL, V168, P2101, DOI 10.4049/jimmunol.168.5.2101; Sugihara K, 1998, ONCOGENE, V17, P3427, DOI 10.1038/sj.onc.1202595; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Turner M, 1997, J EXP MED, V186, P2013, DOI 10.1084/jem.186.12.2013; WALMSLEY MJ, UNPUB; Yan MH, 2001, CURR BIOL, V11, P1547, DOI 10.1016/S0960-9822(01)00481-X; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043	26	208	211	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 17	2003	302	5644					459	462		10.1126/science.1089709	http://dx.doi.org/10.1126/science.1089709			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564011				2022-12-28	WOS:000185963200047
J	Solanki, SK; Lagg, A; Woch, J; Krupp, N; Collados, M				Solanki, SK; Lagg, A; Woch, J; Krupp, N; Collados, M			Three-dimensional magnetic field topology in a region of solar coronal heating	NATURE			English	Article							EVOLVING FIELDS; NEUTRAL SHEETS; LINE; INVERSION; ORIGIN; VECTOR; SUN	Flares and X-ray jets on the Sun arise in active regions where magnetic flux emerges from the solar interior amd interacts with the ambient magnetic field(1,2). The interactions are believed to occur in electric current sheets separating regions of opposite magnetic polarity. The current sheets located in the corona or upper chromosphere have long been thought to act as an important source of coronal heating(3-6), requiring their location in the corona or upper chromosphere. The dynamics and energetics of these sheets are governed by a complex magnetic field structure that, until now, has been difficult to measure. Here we report the determination of the full magnetic vector in an interaction region near the base of the solar corona. The observations reveal two magnetic features that characterize young active regions on the Sun: a set of rising magnetic loops and a tangential discontinuity of the magnetic field direction, the latter being the observational signature of an electric current sheet. This provides strong support for coronal heating models based on the dissipation of magnetic energy at current sheets.	Max Planck Inst Aeron, D-37191 Katlenburg Lindau, Germany; Inst Astrofis Canarias, Tenerife, Spain	Max Planck Society; Instituto de Astrofisica de Canarias	Solanki, SK (corresponding author), Max Planck Inst Aeron, D-37191 Katlenburg Lindau, Germany.		Korpi-Lagg, Andreas/W-8166-2019; Collados, Manuel/Z-5865-2019; Solanki, Sami K/E-2487-2013	Korpi-Lagg, Andreas/0000-0003-1459-7074; Solanki, Sami K/0000-0002-3418-8449; Collados, Manuel/0000-0002-6210-9648				AVRETT EH, 1994, IAU S, V154, P35; COBO BR, 1992, ASTROPHYS J, V398, P375, DOI 10.1086/171862; Frutiger C, 2000, ASTRON ASTROPHYS, V358, P1109; Galsgaard K, 1999, ASTROPHYS J, V510, P444, DOI 10.1086/306559; GIOVANELLI RG, 1977, SOL PHYS, V52, P211, DOI 10.1007/BF00935803; Gudiksen BV, 2002, ASTROPHYS J, V572, pL113, DOI 10.1086/341600; Handy BN, 1999, SOL PHYS, V187, P229, DOI 10.1023/A:1005166902804; Harvey J, 1971, IAU S, V43, P279; KURUCZ RL, 1992, REV MEX ASTRON ASTR, V23, P181; LAGG A, UNPUB ASTRON ASTROPH; Lites BW, 1998, ASTRON ASTROPHYS, V333, P1053; PARKER EN, 1983, ASTROPHYS J, V264, P635, DOI 10.1086/160636; PARKER EN, 1983, ASTROPHYS J, V264, P642, DOI 10.1086/160637; PARKER EN, 1988, ASTROPHYS J, V330, P474, DOI 10.1086/166485; PENN MJ, 1995, ASTROPHYS J, V441, pL51, DOI 10.1086/187787; Pillet VM, 1999, ASTR SOC P, V183, P264; RACHKOVSKY DN, 1967, IZV KRYMSK ASTROFIZ, V37, P56; RUEDI I, 1995, ASTRON ASTROPHYS, V293, P252; Ruedi I, 1996, SOL PHYS, V164, P265, DOI 10.1007/BF00146639; Schmidt W, 2000, ASTROPHYS J, V544, P567, DOI 10.1086/317169; Trujillo Bueno J, 2002, NATURE, V415, P403, DOI 10.1038/415403a; ULMSHNEIDER P, 1991, MECH CHROMOSPHERIC C; YOKOYAMA T, 1995, NATURE, V375, P42, DOI 10.1038/375042a0; ZIRIN H, 1993, NATURE, V363, P426, DOI 10.1038/363426a0	24	148	152	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					692	695		10.1038/nature02035	http://dx.doi.org/10.1038/nature02035			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562096				2022-12-28	WOS:000185924500034
J	Lewis, DK; Robinson, J; Wilkinson, E				Lewis, DK; Robinson, J; Wilkinson, E			Factors involved in deciding to start preventive treatment: qualitative study of clinicians' and lay people's attitudes	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANTIHYPERTENSIVE DRUGS; DECISION-MAKING; RECOMMENDATIONS; HYPERTENSION; PREFERENCES; THRESHOLDS; DISEASE; IMPACT	Objectives To explore the views of clinicians and lay people about the minimum benefit needed to justify drug treatment to prevent heart attacks, and to explore the rationale behind treatment decisions. Design Qualitative study using semi-structured interviews. Participants 4 general practitioners, 4 practice nurses, and 18 lay people. Setting 8 general practices and 6 community settings across Liverpool. Results Participants varied widely in the minimum acceptable benefits chosen. Most people found the concepts difficult initially, and few appreciated that increased length of treatment should increase absolute benefits. Lay people usually wanted to make decisions for themselves, and clinicians supported this. Participants wanted to consider adverse effects and costs of treatment. Dislike of drug taking was common, and many people preferred lifestyle change to an imperfect treatment. Quality of life and personal views were more important than an individual's age. Conclusions Evidence based guidelines make assumptions about people's preferences, and, by using 10 year estimates of risk, inflate the apparent benefits of treatment. It is unlikely that guidelines could incorporate the wide range of people's preferences, and true dialogue is necessary between clinicians and patients before starting long term preventive treatment.	Cent Liverpool Primary Care Trust, Dept Publ Hlth, Liverpool L3 6AL, Merseyside, England; Univ Liverpool, Hlth & Community Care Res Unit, Liverpool L69 3GB, Merseyside, England	University of Liverpool; University of Liverpool	Lewis, DK (corresponding author), Vauxhall Primary Hlth Care, Liverpool L5 8XR, Merseyside, England.	David.Lewis@gp-N82115.nhs.uk	Robinson, Jude/R-5877-2016	Robinson, Jude/0000-0001-5491-4893				ALDERMAN MH, 1990, J CLIN EPIDEMIOL, V43, P195, DOI 10.1016/0895-4356(90)90185-R; BARBER N, 1995, BRIT MED J, V310, P923, DOI 10.1136/bmj.310.6984.923; Benson J, 2002, BRIT MED J, V325, P873, DOI 10.1136/bmj.325.7369.873; Britten N, 2000, BMJ-BRIT MED J, V320, P484, DOI 10.1136/bmj.320.7233.484; Britton A, 1998, HLTH TECHNOLOGY ASSE, V2, P1; COFFREY A, 1996, MAKING SENSE QUALITA; *DEP HLTH, 2000, NAT SERV FRAM COR HE; FORROW L, 1988, JAMA-J AM MED ASSOC, V259, P3161, DOI 10.1001/jama.259.21.3161; Haynes R Brian, 2002, ACP J Club, V136, pA11; HAYNES RB, 1978, NEW ENGL J MED, V299, P741, DOI 10.1056/NEJM197810052991403; KJELLGREN KI, 1995, INT J CARDIOL, V47, P257, DOI 10.1016/0167-5273(94)02203-U; Lewis DK, 2003, J EPIDEMIOL COMMUN H, V57, P241, DOI 10.1136/jech.57.4.241; Lupton D, 1995, Nurs Inq, V2, P157; Man-Son-Hing M, 2000, MED DECIS MAKING, V20, P394, DOI 10.1177/0272989X0002000403; McAlister FA, 2000, CAN MED ASSOC J, V163, P403; McKinstry B, 2000, BRIT MED J, V321, P867, DOI 10.1136/bmj.321.7265.867; Montgomery AA, 2001, FAM PRACT, V18, P309, DOI 10.1093/fampra/18.3.309; Protheroe J, 2000, BRIT MED J, V320, P1380, DOI 10.1136/bmj.320.7246.1380; PYORALA K, 1994, EUR HEART J, V15, P1300; Royal Pharmaceutical Society of Great Britain, 1997, COMPL CONC ACH SHAR; Shepherd J, 1996, LANCET, V348, P1339; Skolbekken JA, 1998, BMJ-BRIT MED J, V316, P1956, DOI 10.1136/bmj.316.7149.1956; Steel N, 2000, BRIT MED J, V320, P1446, DOI 10.1136/bmj.320.7247.1446; Svensson S, 2000, INT J CARDIOL, V76, P157, DOI 10.1016/S0167-5273(00)00374-0; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Wood D, 1998, HEART, V80, pS1	26	57	60	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 11	2003	327	7419					841	844		10.1136/bmj.327.7419.841	http://dx.doi.org/10.1136/bmj.327.7419.841			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551099	Bronze, Green Published			2022-12-28	WOS:000185921200019
J	Scholefield, JH; Moss, S				Scholefield, JH; Moss, S			Screening sigmoidoscopy for colorectal cancer	LANCET			English	Editorial Material							DEBATE; COSTS		Univ Nottingham Hosp, Div GI Surg, Nottingham NG7 2UH, England; Canc Screening Evaluat Unit, Surrey, England	University of Nottingham	Scholefield, JH (corresponding author), Univ Nottingham Hosp, Div GI Surg, Nottingham NG7 2UH, England.	john.scholefield@nottingham.ac.uk						Atkin WS, 2002, LANCET, V359, P1291, DOI 10.1016/s0140-6736(02)08268-5; Atkin WS, 2003, GUT, V52, P321, DOI 10.1136/gut.52.3.321; Cronin KA, 1998, J NATL CANCER I, V90, P498, DOI 10.1093/jnci/90.7.498; Lund JN, 2001, GUT, V49, P91, DOI 10.1136/gut.49.1.91; Macafee DAL, 2003, GUT, V52, P323, DOI 10.1136/gut.52.3.323; MILBURN A, 2002, BRIT CANC C LOND NOV; Newcomb PA, 2003, J NATL CANCER I, V95, P622, DOI 10.1093/jnci/95.8.622; Rex DK, 2000, AM J GASTROENTEROL, V95, P868, DOI 10.1111/j.1572-0241.2000.02059.x; Schoen RE, 2003, JAMA-J AM MED ASSOC, V290, P41, DOI 10.1001/jama.290.1.41; Steele RJC, 2001, J MED SCREEN, V8, P197, DOI 10.1136/jms.8.4.197; WHYNES DK, 1992, J EPIDEMIOL COMMUN H, V46, P577, DOI 10.1136/jech.46.6.577	12	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 11	2003	362	9391					1167	1168		10.1016/S0140-6736(03)14553-9	http://dx.doi.org/10.1016/S0140-6736(03)14553-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568733				2022-12-28	WOS:000185924100003
J	Dar, MS; Daoud, S				Dar, MS; Daoud, S			Epidural lipomatosis causing spinal cord compression	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Cleveland Clin Fdn, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Dar, MS (corresponding author), Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA.								0	5	5	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	2003	349	15					E14	E14		10.1056/ENEJMicm020007	http://dx.doi.org/10.1056/ENEJMicm020007			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729JF	14534350				2022-12-28	WOS:000185769500008
J	Fenn, KM; Nusbaum, HC; Margoliash, D				Fenn, KM; Nusbaum, HC; Margoliash, D			Consolidation during sleep of perceptual learning of spoken language	NATURE			English	Article							SYNTHETIC SPEECH; MOTOR CORTEX; MEMORY; SKILL; IMPROVEMENT; PERFORMANCE; PLASTICITY	Memory consolidation resulting from sleep has been seen broadly: in verbal list learning(1), spatial learning(2,3), and skill acquisition in visual(4-8) and motor(9-11) tasks. These tasks do not generalize across spatial locations or motor sequences, or to different stimuli in the same location(5,11,12). Although episodic rote learning constitutes a large part of any organism's learning, generalization is a hallmark of adaptive behaviour(13). In speech, the same phoneme often has different acoustic patterns depending on context. Training on a small set of words improves performance on novel words using the same phonemes but with different acoustic patterns, demonstrating perceptual generalization(14). Here we show a role of sleep in the consolidation of a naturalistic spoken-language learning task that produces generalization of phonological categories across different acoustic patterns. Recognition performance immediately after training showed a significant improvement that subsequently degraded over the span of a day's retention interval, but completely recovered following sleep. Thus, sleep facilitates the recovery and subsequent retention of material learned opportunistically at any time throughout the day. Performance recovery indicates that representations and mappings associated with generalization are refined and stabilized during sleep.	Univ Chicago, Dept Psychol, Chicago, IL 60637 USA; Univ Chicago, Dept Organismal Biol & Anat, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Fenn, KM (corresponding author), Univ Chicago, Dept Psychol, 5848 S Univ Ave, Chicago, IL 60637 USA.							BrashersKrug T, 1996, NATURE, V382, P252, DOI 10.1038/382252a0; EGAN JP, 1948, LARYNGOSCOPE, V58, P955, DOI 10.1288/00005537-194809000-00002; Estes W. K., 1978, HDB LEARNING COGNITI, V6, P167; Ficca G, 2000, BEHAV BRAIN RES, V112, P159, DOI 10.1016/S0166-4328(00)00177-7; Gabrieli JDE, 1998, ANNU REV PSYCHOL, V49, P87, DOI 10.1146/annurev.psych.49.1.87; GREENSPAN SL, 1988, J EXP PSYCHOL LEARN, V14, P421, DOI 10.1037/0278-7393.14.3.421; Johnson M P, 1992, J Sleep Res, V1, P24; KARNI A, 1993, NATURE, V365, P250, DOI 10.1038/365250a0; KARNI A, 1994, SCIENCE, V265, P679, DOI 10.1126/science.8036518; KARNI A, 1995, NATURE, V377, P155; Karni A, 1998, P NATL ACAD SCI USA, V95, P861, DOI 10.1073/pnas.95.3.861; Karni A, 1997, CURR OPIN NEUROBIOL, V7, P530, DOI 10.1016/S0959-4388(97)80033-5; KOLERS PA, 1969, PERCEPT PSYCHOPHYS, V5, P265, DOI 10.3758/BF03209559; LIBERMAN AM, 1967, PSYCHOL REV, V74, P431, DOI 10.1037/h0020279; Mednick SC, 2002, NAT NEUROSCI, V5, P677, DOI 10.1038/nn864; Nusbaum H. C., 1987, Computer Speech and Language, V2, P87, DOI 10.1016/0885-2308(87)90002-7; OHMAN SEG, 1966, J ACOUST SOC AM, V39, P151, DOI 10.1121/1.1909864; Plihal W, 1999, PSYCHOPHYSIOLOGY, V36, P571, DOI 10.1111/1469-8986.3650571; RUDNICKY AI, 1978, J EXP PSYCHOL HUMAN, V4, P638; SCHWAB EC, 1985, HUM FACTORS, V27, P395, DOI 10.1177/001872088502700404; Smith C, 1997, BEHAV NEUROSCI, V111, P1197, DOI 10.1037/0735-7044.111.6.1197; Stickgold R, 2000, NAT NEUROSCI, V3, P1237, DOI 10.1038/81756; Stickgold R, 2000, J COGNITIVE NEUROSCI, V12, P246, DOI 10.1162/089892900562075; Walker MP, 2002, NEURON, V35, P205, DOI 10.1016/S0896-6273(02)00746-8	24	276	282	2	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2003	425	6958					614	616		10.1038/nature01951	http://dx.doi.org/10.1038/nature01951			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	729XU	14534586				2022-12-28	WOS:000185801000036
J	Jepson, PD; Arbelo, M; Deaville, R; Patterson, IAP; Castro, P; Baker, JR; Degollada, E; Ross, HM; Herraez, P; Pocknell, AM; Rodriguez, F; Howie, FE; Espinosa, A; Reid, RJ; Jaber, JR; Martin, V; Cunningham, AA; Fernandez, A				Jepson, PD; Arbelo, M; Deaville, R; Patterson, IAP; Castro, P; Baker, JR; Degollada, E; Ross, HM; Herraez, P; Pocknell, AM; Rodriguez, F; Howie, FE; Espinosa, A; Reid, RJ; Jaber, JR; Martin, V; Cunningham, AA; Fernandez, A			Gas-bubble lesions in stranded cetaceans - Was sonar responsible for a spate of whale deaths after an Atlantic military exercise?	NATURE			English	Editorial Material							COLLAPSE; GROWTH		Zool Soc London, Inst Zool, London NW1 4RY, England; Univ Las Palmas de Gran Canaria, Sch Vet, Inst Anim Hlth, Histol & Pathol Unit, Las Palmas Gran Canaria, Spain; SAC Vet Sci Div Inverness, Wildlife Unit, Inverness IV2 4JZ, Scotland; Univ Liverpool, Dept Vet Pathol, Wirral CH64 7TE, Merseyside, England; SAC Vet Sci Div Edinburgh, Penicuik EH26 0QE, Midlothian, Scotland	Zoological Society of London; Universidad de Las Palmas de Gran Canaria; Scottish Agricultural College; University of Liverpool; Scottish Agricultural College	Jepson, PD (corresponding author), Zool Soc London, Inst Zool, Regents Pk, London NW1 4RY, England.		Castro, Pedro Luis/ABF-6635-2021; Arbelo, Manuel/D-6789-2013; Jepson, Paul D/G-1840-2013; Cunningham, Andrew A/E-7536-2010; Langhamer, Olivia/J-3425-2012; Fernandez, Antonio/G-3448-2015; Rodriguez Guisado, Francisco/L-6874-2014	Arbelo, Manuel/0000-0002-1623-5010; Fernandez, Antonio/0000-0001-5281-0521; Castro, Pedro Luis/0000-0002-0395-899X; Rodriguez Guisado, Francisco/0000-0002-4968-5333; Herraez, Pedro/0000-0001-9316-2882				Crum LA, 1996, J ACOUST SOC AM, V99, P2898, DOI 10.1121/1.414859; FALKE KJ, 1985, SCIENCE, V229, P556, DOI 10.1126/science.4023700; Francis T. J. R., 2003, BENNETT ELLIOTTS PHY, P530; Frantzis A, 1998, NATURE, V392, P29, DOI 10.1038/32068; HARRISON R. J., 1956, PROC ZOOL SOC LONDON, V126, P205; Houser DS, 2001, J THEOR BIOL, V213, P183, DOI 10.1006/jtbi.2001.2415; Knight B., 1996, FORENSIC PATHOLOGY, V2nd ed.; Ponganis P. J., 2003, BENNETT ELLIOTTS PHY, P211; RIDGWAY SH, 1982, SCIENCE, V216, P651, DOI 10.1126/science.216.4546.651; RIDGWAY SH, 1979, SCIENCE, V206, P1182, DOI 10.1126/science.505001; SIMMONDS MP, 1991, NATURE, V351, P448, DOI 10.1038/351448a0; *USN, 2001, JOINT INT REP BAH MA	12	305	324	9	210	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2003	425	6958					575	576		10.1038/425575a	http://dx.doi.org/10.1038/425575a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534575				2022-12-28	WOS:000185801000025
J	Stelfox, HT; Bates, DW; Redelmeier, DA				Stelfox, HT; Bates, DW; Redelmeier, DA			Safety of patients isolated for infection control	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; ADVERSE; EVENTS; STOP; CARE	Context Hospital infection control policies that use patient isolation prevent nosocomial transmission of infectious diseases, but may inadvertently lead to patient neglect and errors. Objective To examine the quality of medical care received by patients isolated for infection control. Design, Setting, and Patients We identified consecutive adults who were isolated for methicillin-resistant Staphylococcus aureus colonization or infection at 2 large North American teaching hospitals: a general cohort (patients admitted with all diagnoses between January 1, 1999, and January 1, 2000; n = 78); and a disease-specific cohort (patients admitted with a diagnosis of congestive heart failure between January 1, 1999, and July 1, 2002; n = 72). Two matched controls were selected for each isolated patient (n = 156 general cohort controls and n = 144 disease-specific cohort controls). Main Outcome Measures Quality-of-care measures encompassing processes, outcomes, and satisfaction. Adjustments for study cohort and patient demographic, hospital, and clinical characteristics were conducted using multivariable regression. Results Isolated and control patients generally had similar baseline characteristics; however, isolated patients were twice as likely as control patients to experience adverse events during their hospitalization (31 vs 15 adverse events per 1000 days; P<.001). This difference in adverse events reflected preventable events (20 vs 3 adverse events per 1000 days; P<.001) as opposed to nonpreventable events (11 vs 12 adverse events per 1000 days; P=.98). Isolated patients were also more likely to formally complain to the hospital about their care than control patients (8% vs 1%; P<.001), to have their vital signs not recorded as ordered (51% vs 31%; P<.001), and more likely to have days with no physician progress note (26% vs 13%; P<.001). No differences in hospital mortality were observed for the 2 groups (17% vs 10%; P=16). Conclusion Compared with controls, patients isolated for infection control precautions experience more preventable adverse events, express greater dissatisfaction with their treatment, and have less documented care.	Brigham & Womens Hosp, Div Gen Med, Boston, MA 02120 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02120 USA; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Clin Epidemiol Unit, Toronto, ON, Canada; Harvard Univ, Grad Sch Arts & Sci, Cambridge, MA 02138 USA; Partners HealthCare Syst, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Harvard University; Partners Healthcare System	Stelfox, HT (corresponding author), Brigham & Womens Hosp, Div Gen Med, 1620 Tremont St, Boston, MA 02120 USA.	stelfox@fas.harvard.edu		Stelfox, Henry/0000-0003-1231-1490	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P01HS011534] Funding Source: NIH RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Andrews LB, 1997, LANCET, V349, P309, DOI 10.1016/S0140-6736(96)08268-2; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Brown L H, 1997, Prehosp Emerg Care, V1, P145, DOI 10.1080/10903129708958808; Burke JP, 2003, NEW ENGL J MED, V348, P651, DOI 10.1056/NEJMhpr020557; Centers for Disease Control and Prevention, SEV AC RESP SYNDR SA; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Garner Julia S., 1996, Infection Control and Hospital Epidemiology, V17, P53; Gawande AA, 2003, NEW ENGL J MED, V348, P229, DOI 10.1056/NEJMsa021721; Harvard Medical Practice study, 1990, PAT DOCT LAW STUD ME, VI; HICKSON G, 1997, LAW CONTEMP PROBL, V27, P8; Hickson GB, 2002, JAMA-J AM MED ASSOC, V287, P2951, DOI 10.1001/jama.287.22.2951; HIGGINS L, 2001, J GEN INTERN MED S1, V16, P200; Kirkland KB, 1999, LANCET, V354, P1177, DOI 10.1016/S0140-6736(99)04196-3; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Knowles H E, 1993, Nurs Times, V89, P53; Kohn KT, 2000, ERR IS HUMAN BUILDIN; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Krumholz HM, 2000, CIRCULATION, V101, pE122, DOI 10.1161/01.CIR.101.12.e122; Krumholz HM, 2000, CIRCULATION, V101, P1483; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Montecalvo MA, 1999, ANN INTERN MED, V131, P269, DOI 10.7326/0003-4819-131-4-199908170-00006; Nettleman M D, 1994, Clin Perform Qual Health Care, V2, P67; ONEIL AC, 1993, ANN INTERN MED, V119, P370, DOI 10.7326/0003-4819-119-5-199309010-00004; Ostrowsky BE, 2001, NEW ENGL J MED, V344, P1427, DOI 10.1056/NEJM200105103441903; Peel RK, 1997, BRIT MED J, V315, P58; Pichert J W, 1999, Jt Comm J Qual Improv, V25, P288; Reason J., 1997, MANAGING RISK ORG AC; Reason J., 1990, HUMAN ERROR; Rosenberg AL, 2000, CHEST, V118, P492, DOI 10.1378/chest.118.2.492; Smalley W, 2000, JAMA-J AM MED ASSOC, V284, P3036, DOI 10.1001/jama.284.23.3036; Sobie J M, 2000, J Emerg Nurs, V26, P549, DOI 10.1067/men.2000.110891; Teare EL, 1997, BRIT MED J, V314, P665, DOI 10.1136/bmj.314.7081.665; WEICK KE, 1987, CALIF MANAGE REV, V29, P112, DOI 10.2307/41165243; World Health Organization, HOSP INF CONTR GUID; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	36	405	406	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2003	290	14					1899	1905		10.1001/jama.290.14.1899	http://dx.doi.org/10.1001/jama.290.14.1899			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	729CB	14532319	Bronze			2022-12-28	WOS:000185752600031
J	Jackson, JL; O'Malley, PG; Kroenke, K				Jackson, JL; O'Malley, PG; Kroenke, K			Evaluation of acute knee pain in primary care	ANNALS OF INTERNAL MEDICINE			English	Review							ANTERIOR CRUCIATE LIGAMENT; FAST-SPIN-ECHO; ARTICULAR-CARTILAGE ABNORMALITIES; CLINICAL DECISION RULES; DIHYDRATE CRYSTAL DEPOSITION; ACUTE TRAUMATIC HEMARTHROSIS; RESONANCE-IMAGING FINDINGS; DISCOID LATERAL MENISCI; BUCKET-HANDLE TEARS; MAGNETIC-RESONANCE	Background: The evaluation of acute knee pain often includes radiography of the knee. Objective: To synthesize the literature to determine the role of radiologic procedures in evaluating common causes of acute knee pain: fractures, meniscal or ligamentous injuries, osteoarthritis, and pseudogout. Data Sources: MEDLINE search from 1966 to October 2002. Study Selection: We included all published, peer-reviewed studies of decision rules for fractures. We included studies that used arthroscopy as the gold standard for measuring the accuracy of the physical examination and magnetic resonance imaging (MRI) for meniscal and ligamentous knee damage. We included all studies on the use of radiographs in pseudogout. Data Extraction: We extracted all data in duplicate and abstracted physical examination and MRI results into 2 x 2 tables. Data Synthesis: Among the 5 decision rules for deciding when to use plain films in knee fractures, the Ottawa knee rules (injury due to trauma and age >55 years, tenderness at the head of the fibula or the patella, inability to bear weight for 4 steps, or inability to flex the knee to 90 degrees) have the strongest supporting evidence. When the history suggests a potential meniscal or ligamentous injury, the physical examination is moderately sensitive (meniscus, 87%; anterior cruciate ligament, 74%; and posterior cruciate ligament, 81%) and specific (meniscus, 92%; anterior cruciate ligamen, 95%; and posterior cruciate ligament, 95%). The Lachman test is more sensitive and specific for ligamentous tears than is the drawer sign. For meniscal tears, joint line tenderness is sensitive (75%) but not specific (27%), while the McMurray test is specific (97%) but not sensitive (52%). Compared with the physical examination, MRI is more sensitive for ligamentous and meniscal damage but less specific. When the differential diagnosis for acute knee pain includes an exacerbation of osteoarthritis, clinical features (age >50 years, morning stiffness <30 minutes, crepitus, or bony enlargement) are 89% sensitive and 88% specific for underlying chronic arthritis. Adding plain films improves sensitivity slightly but not specificity. Plain films for pseudogout are not sensitive or specific, according to limited-quality studies. Conclusions: We recommend the Ottawa knee rules to decide when to obtain plain films for suspected knee fracture. A careful physical examination should be sufficient to decide whether to refer patients with potential meniscal and ligament injuries, and we prefer clinical criteria rather than plain films for evaluating osteoarthritis. We do not recommend using plain films to diagnose pseudogout.	Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; Walter Reed Army Med Ctr, Washington, DC 20307 USA; Indiana Univ, Sch Med, Indianapolis, IN 46204 USA; Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc	Jackson, JL (corresponding author), Med EDP, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.		Jackson, Jeffrey/AAA-3519-2019; anand, amit/A-7222-2009	Jackson, Jeffrey/0000-0002-9820-5834; Kroenke, Kurt/0000-0002-0114-4669				ABDON P, 1989, ACTA ORTHOP SCAND, V60, P453, DOI 10.3109/17453678909149318; Adalberth T, 1997, AM J SPORT MED, V25, P231, DOI 10.1177/036354659702500217; ADAMS ME, 1991, J RHEUMATOL, V18, P1573; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; ANDERSON AF, 1986, AM J SPORT MED, V14, P291, DOI 10.1177/036354658601400408; ANDERSON MW, 1995, ACAD RADIOL, V2, P209, DOI 10.1016/S1076-6332(05)80166-7; ARAKI Y, 1992, AM J ROENTGENOL, V158, P587, DOI 10.2214/ajr.158.3.1739000; ARAKI Y, 1994, EUR J RADIOL, V18, P92, DOI 10.1016/0720-048X(94)90271-2; Araki Y, 1998, EUR J RADIOL, V27, P153, DOI 10.1016/S0720-048X(97)00044-2; AUBEL S, 1992, MAGN RESON IMAGING, V10, P531, DOI 10.1016/0730-725X(92)90004-J; Bachmann GF, 1999, EUR RADIOL, V9, P145, DOI 10.1007/s003300050646; BAKER CL, 1984, AM J SPORT MED, V12, P204, DOI 10.1177/036354658401200307; BARRONIAN A D, 1989, Arthroscopy, V5, P187, DOI 10.1016/0749-8063(89)90169-2; Barry KP, 1996, SKELETAL RADIOL, V25, P365, DOI 10.1007/s002560050096; BARRY OCD, 1983, IRISH J MED SCI, V152, P149, DOI 10.1007/BF02960058; BAUER SJ, 1994, ACAD EMERG MED, V1, pA64; BELTRAN J, 1986, RADIOLOGY, V159, P747, DOI 10.1148/radiology.159.3.3704154; BODEN SD, 1992, CLIN ORTHOP RELAT R, P177; BOEREE NR, 1991, INJURY, V22, P291, DOI 10.1016/0020-1383(91)90008-3; BOEREE NR, 1991, J BONE JOINT SURG BR, V73, P452, DOI 10.1302/0301-620X.73B3.1670448; BONAMO JJ, 1988, ORTHOPEDICS, V11, P1041; Brandser EA, 1996, AM J ROENTGENOL, V167, P121, DOI 10.2214/ajr.167.1.8659355; BRANDT KD, 1991, ARTHRITIS RHEUM, V34, P1381; BRAUNSTEIN EM, 1982, AM J ROENTGENOL, V138, P423, DOI 10.2214/ajr.138.3.423; BRODERICK LS, 1994, AM J ROENTGENOL, V162, P99, DOI 10.2214/ajr.162.1.8273700; BRUNNER MC, 1989, INVEST RADIOL, V24, P72, DOI 10.1097/00004424-198901000-00015; BuiMansfield LT, 1997, AM J ROENTGENOL, V168, P913, DOI 10.2214/ajr.168.4.9124139; BURK DL, 1986, AM J ROENTGENOL, V147, P293, DOI 10.2214/ajr.147.2.293; CHAN WP, 1994, AM J ROENTGENOL, V162, P355, DOI 10.2214/ajr.162.2.8310927; CHEN MC, 1995, J FORMOS MED ASSOC, V94, P605; Cheung LP, 1997, RADIOLOGY, V203, P508, DOI 10.1148/radiology.203.2.9114113; Cibere J, 2000, CAN MED ASSOC J, V162, P1577; CLAESSENS AAMC, 1990, ANN RHEUM DIS, V49, P771, DOI 10.1136/ard.49.10.771; CRUES JV, 1987, RADIOLOGY, V164, P445, DOI 10.1148/radiology.164.2.3602385; DAHLSTEDT LJ, 1989, ACTA ORTHOP SCAND, V60, P181, DOI 10.3109/17453678909149249; DANDY DJ, 1975, J BONE JOINT SURG BR, V57, P349, DOI 10.1302/0301-620X.57B3.349; DANIEL D, 1982, CLIN ORTHOP RELAT R, V163, P218; DAVIS MA, 1992, J RHEUMATOL, V19, P1943; DEHAVEN KE, 1980, AM J SPORT MED, V8, P9, DOI 10.1177/036354658000800102; DELAUCHE MC, 1977, REV RHUM, V44, P555; DESMET AA, 1993, AM J ROENTGENOL, V160, P555, DOI 10.2214/ajr.160.3.8430552; DIEPPE PA, 1982, ANN RHEUM DIS, V41, P371, DOI 10.1136/ard.41.4.371; DISLER DG, 1995, AM J ROENTGENOL, V165, P377, DOI 10.2214/ajr.165.2.7618561; Disler DG, 1996, AM J ROENTGENOL, V167, P127, DOI 10.2214/ajr.167.1.8659356; DONALDSON WF, 1985, AM J SPORT MED, V13, P5, DOI 10.1177/036354658501300102; Eckstein F, 1998, CLIN ORTHOP RELAT R, P137; ELLMAN MH, 1975, ARTHRITIS RHEUM, V18, P43, DOI 10.1002/art.1780180109; ELLMAN MH, 1981, J AM GERIATR SOC, V29, P189, DOI 10.1111/j.1532-5415.1981.tb01764.x; Emparanza JI, 2001, ANN EMERG MED, V38, P364, DOI 10.1067/mem.2001.118011; ETTINGER WH, 1994, J CLIN EPIDEMIOL, V47, P809, DOI 10.1016/0895-4356(94)90178-3; Fagan DJT, 2000, INJURY, V31, P723, DOI 10.1016/S0020-1383(00)00075-9; FALCONIERO RP, 1994, ORTHOP T, V18, P1013; FELSON DT, 1989, J RHEUMATOL, V16, P1241; FIFE RS, 1991, ARTHRITIS RHEUM-US, V34, P377, DOI 10.1002/art.1780340402; FITZGERALD SW, 1993, AM J ROENTGENOL, V160, P1233, DOI 10.2214/ajr.160.6.8498224; FOWLER P J, 1989, Arthroscopy, V5, P184, DOI 10.1016/0749-8063(89)90168-0; Franklin PD, 1997, AM J SPORT MED, V25, P382; GAGLIARDI JA, 1994, AM J ROENTGENOL, V163, P629, DOI 10.2214/ajr.163.3.8079858; Gelb HJ, 1996, AM J SPORT MED, V24, P99, DOI 10.1177/036354659602400118; GENTILI A, 1994, RADIOLOGY, V193, P835, DOI 10.1148/radiology.193.3.7972834; GILLIES H, 1979, J BONE JOINT SURG AM, V61, P343, DOI 10.2106/00004623-197961030-00004; GLASHOW JL, 1989, J BONE JOINT SURG AM, V71A, P113, DOI 10.2106/00004623-198971010-00017; GLIMET T, 1979, REV RHUM, V46, P589; GOOD AE, 1967, NEW ENGL J MED, V277, P286, DOI 10.1056/NEJM196708102770603; Grassi W, 1998, EUR J RADIOL, V27, pS18, DOI 10.1016/S0720-048X(98)00038-2; GRATTON MC, 1990, ANN EMERG MED, V19, P497, DOI 10.1016/S0196-0644(05)82175-4; Gray SD, 1997, SKELETAL RADIOL, V26, P298, DOI 10.1007/s002560050239; GREVITT MP, 1992, INJURY, V23, P410, DOI 10.1016/0020-1383(92)90019-O; GUCCIONE AA, 1990, AM J PUBLIC HEALTH, V80, P945, DOI 10.2105/AJPH.80.8.945; Guckel C, 1995, EUR J RADIOL, V21, P25, DOI 10.1016/0720-048X(95)00681-F; GURTLER RA, 1987, CLIN ORTHOP RELAT R, P141; Ha TPT, 1998, AM J ROENTGENOL, V170, P1215, DOI 10.2214/ajr.170.5.9574587; HAMADA M, 1994, ARTHROSCOPY, V10, P645, DOI 10.1016/S0749-8063(05)80063-5; HANSEN SE, 1984, SCAND J RHEUMATOL, V13, P85, DOI 10.3109/03009748409102672; HARAMATI N, 1994, SKELETAL RADIOL, V23, P211; HARDAKER WT, 1990, SOUTH MED J, V83, P640, DOI 10.1097/00007611-199006000-00011; HARILAINEN A, 1988, INJURY, V19, P21, DOI 10.1016/0020-1383(88)90168-4; HERNBORG J, 1977, GERIATRICS, V32, P123; HERON CW, 1992, RADIOLOGY, V183, P839, DOI 10.1148/radiology.183.3.1584944; HODLER J, 1992, J COMPUT ASSIST TOMO, V16, P597, DOI 10.1097/00004728-199207000-00020; HOPPENFELD S, 1976, PHYSICAL EXAMINATION; HUGHSTON JC, 1976, J BONE JOINT SURG AM, V58, P159, DOI 10.2106/00004623-197658020-00001; Hutchinson C H, 1995, Am J Knee Surg, V8, P93; Hyer K, 1991, Diagn Imaging (San Franc), V13, P82; IKE RW, 1995, ARTHRITIS RHEUM, V38, P917, DOI 10.1002/art.1780380707; JACKSON DW, 1988, AM J SPORT MED, V16, P29, DOI 10.1177/036354658801600105; JACKSON R W, 1972, Journal of Bone and Joint Surgery British Volume, V54, P310; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Jee WH, 1998, J COMPUT ASSIST TOMO, V22, P814, DOI 10.1097/00004728-199809000-00028; JOHNSON LL, 1982, CLIN ORTHOP RELAT R, P75; JONSSON T, 1982, AM J SPORT MED, V10, P100, DOI 10.1177/036354658201000207; JUSTICE WW, 1995, RADIOLOGY, V196, P617, DOI 10.1148/radiology.196.3.7644620; KALUNIAN K, 1989, Arthritis and Rheumatism, V32, pS20; KATZ JW, 1986, AM J SPORT MED, V14, P88, DOI 10.1177/036354658601400115; Kawahara Y, 1998, ACTA RADIOL, V39, P120; Keefe FJ, 1997, PAIN, V73, P191, DOI 10.1016/S0304-3959(97)00109-7; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; KELLY M A, 1991, Arthroscopy, V7, P78, DOI 10.1016/0749-8063(91)90083-A; Ketelslegers E, 2002, EUR RADIOL, V12, P1218, DOI 10.1007/s00330-001-1198-9; KINNUNEN J, 1994, MAGN RESON IMAGING, V12, P1155, DOI 10.1016/0730-725X(94)90080-B; KLADNY B, 1995, ARCH ORTHOP TRAUM SU, V114, P281, DOI 10.1007/BF00452088; KORNICK J, 1990, RADIOLOGY, V177, P463, DOI 10.1148/radiology.177.2.2217786; Kroenke K, 1998, FAM PRACT, V15, P398, DOI 10.1093/fampra/15.5.398; Lanyon P, 1998, ANN RHEUM DIS, V57, P595, DOI 10.1136/ard.57.10.595; LAPRADE RF, 1994, AM J SPORT MED, V22, P739, DOI 10.1177/036354659402200603; LAWRENCE RC, 1989, J RHEUMATOL, V16, P427; LEE JK, 1988, RADIOLOGY, V166, P861, DOI 10.1148/radiology.166.3.3340785; LEIGH JH, 1988, RADIOLOY, V167, P775; LERMAN JE, 1995, J COMPUT ASSIST TOMO, V19, P604, DOI 10.1097/00004728-199507000-00019; LEVINSOHN EM, 1980, AM J ROENTGENOL, V134, P107, DOI 10.2214/ajr.134.1.107; LIU SH, 1995, J BONE JOINT SURG BR, V77B, P586; LOOS WC, 1981, AM J SPORT MED, V9, P86, DOI 10.1177/036354658100900203; Lundberg M, 1996, INT J SPORTS MED, V17, P218, DOI 10.1055/s-2007-972835; MACKENZIE R, 1995, BRIT J RADIOL, V68, P1045, DOI 10.1259/0007-1285-68-814-1045; Mackenzie R, 1996, CLIN RADIOL, V51, P245, DOI 10.1016/S0009-9260(96)80340-0; Magee TH, 1998, SKELETAL RADIOL, V27, P495, DOI 10.1007/s002560050426; MANCO LG, 1989, CRIT REV DIAGN IMAG, V29, P151; MANDELBAUM BR, 1986, AM J SPORT MED, V14, P361, DOI 10.1177/036354658601400503; MCALINDON TE, 1992, BRIT J RHEUMATOL, V31, P189; MCALINDON TE, 1992, ANN RHEUM DIS, V51, P844, DOI 10.1136/ard.51.7.844; MCCARTY DJ, 1985, ARTHRITIS RHEUM, V28, P717, DOI 10.1002/art.1780280623; MCCAULEY TR, 1994, AM J ROENTGENOL, V162, P115, DOI 10.2214/ajr.162.1.8273648; MCCAULEY TR, 1992, AM J ROENTGENOL, V158, P101, DOI 10.2214/ajr.158.1.1727333; MCCRAIG LF, 1994, ADV DATA, V245, P1; Miller GK, 1996, ARTHROSCOPY, V12, P406, DOI 10.1016/S0749-8063(96)90033-X; MINK JH, 1988, RADIOLOGY, V167, P769, DOI 10.1148/radiology.167.3.3363138; MITROVIC DR, 1988, J RHEUMATOL, V15, P633; MITSOU A, 1988, INJURY, V19, P427, DOI 10.1016/0020-1383(88)90139-8; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; Muellner T, 1997, AM J SPORT MED, V25, P7, DOI 10.1177/036354659702500103; Munk B, 1998, ARTHROSCOPY, V14, P171, DOI 10.1016/S0749-8063(98)70036-2; Murao H, 1998, J Orthop Sci, V3, P10, DOI 10.1007/s007760050016; NEGENDANK WG, 1990, J ORTHOPAED RES, V8, P311, DOI 10.1002/jor.1100080302; NEWMAN AP, 1994, AM J KNEE SURG, V7, P42; Nichol G, 1999, ANN EMERG MED, V34, P438, DOI 10.1016/S0196-0644(99)80044-4; NIITSU M, 1991, RADIOLOGY, V178, P859, DOI 10.1148/radiology.178.3.1994433; NOBLE J, 1980, J BONE JOINT SURG BR, V62, P7, DOI 10.1302/0301-620X.62B1.7351438; NOYES FR, 1980, J BONE JOINT SURG AM, V62, P687, DOI 10.2106/00004623-198062050-00001; OBERLANDER MA, 1993, AM J SPORT MED, V21, P773, DOI 10.1177/036354659302100603; OROURKE KS, 1992, ARTHRITIS RHEUM, V35, pS322; OShea KJ, 1996, AM J SPORT MED, V24, P164, DOI 10.1177/036354659602400208; POLLACK MS, 1987, SKELETAL RADIOL, V16, P121, DOI 10.1007/BF00367759; POLLY DW, 1988, J BONE JOINT SURG AM, V70A, P192, DOI 10.2106/00004623-198870020-00005; Potter HG, 1998, J BONE JOINT SURG AM, V80A, P1276, DOI 10.2106/00004623-199809000-00005; QUINN SF, 1992, RADIOLOGY, V185, P577, DOI 10.1148/radiology.185.2.1410376; QUINN SF, 1991, RADIOLOGY, V181, P843, DOI 10.1148/radiology.181.3.1947108; RANGGER C, 1996, CLIN ORTHOP RELAT R, V330, P133; Rappeport ED, 1997, ACTA ORTHOP SCAND, V68, P277, DOI 10.3109/17453679708996701; RAUNEST J, 1991, J BONE JOINT SURG AM, V73A, P11, DOI 10.2106/00004623-199173010-00003; RAUNEST J, 1994, ARTHROSCOPY, V10, P634, DOI 10.1016/S0749-8063(05)80061-1; Recht MP, 1996, RADIOLOGY, V198, P209, DOI 10.1148/radiology.198.1.8539380; REICHER MA, 1987, RADIOLOGY, V162, P547, DOI 10.1148/radiology.162.2.3797670; REICHER MA, 1985, AM J ROENTGENOL, V145, P903, DOI 10.2214/ajr.145.5.903; REICHER MA, 1986, RADIOLOGY, V159, P753, DOI 10.1148/radiology.159.3.3754645; REISER MF, 1988, SKELETAL RADIOL, V17, P465, DOI 10.1007/BF00364038; REMER EM, 1992, RADIOGRAPHICS, V12, P901, DOI 10.1148/radiographics.12.5.1529133; Richman Peter B., 1997, Journal of Emergency Medicine, V15, P459, DOI 10.1016/S0736-4679(97)00073-5; Riel KA, 1999, KNEE SURG SPORT TR A, V7, P37, DOI 10.1007/s001670050118; RIESTRA JL, 1985, J RHEUMATOL, V12, P1154; ROBERTSON PL, 1994, RADIOLOGY, V193, P829, DOI 10.1148/radiology.193.3.7972833; Rose NE, 1996, ARTHROSCOPY, V12, P398, DOI 10.1016/S0749-8063(96)90032-8; ROSE PM, 1994, RADIOLOGY, V193, P437, DOI 10.1148/radiology.193.2.7972759; Roychowdhury S, 1997, AM J ROENTGENOL, V168, P1487, DOI 10.2214/ajr.168.6.9168712; RUBIN DA, 1994, AM J ROENTGENOL, V162, P1131, DOI 10.2214/ajr.162.5.8165997; Rubin DA, 1998, AM J ROENTGENOL, V170, P1207, DOI 10.2214/ajr.170.5.9574586; Ruwe P A, 1994, Magn Reson Imaging Clin N Am, V2, P475; Ryan PJ, 1998, CLIN NUCL MED, V23, P803, DOI 10.1097/00003072-199812000-00002; Ryu KN, 1998, AM J ROENTGENOL, V171, P963, DOI 10.2214/ajr.171.4.9762976; SANCHISALFONSO V, 1993, EUR J RADIOL, V16, P126, DOI 10.1016/0720-048X(93)90009-C; SAXENA AC, 1992, ANN EMERG MED, V21, P658; SCHLESINGER I, 1988, ORTHOP T, V12, P544; SCHWEITZER ME, 1995, RADIOLOGY, V194, P825, DOI 10.1148/radiology.194.3.7862987; Seaberg DC, 1998, ANN EMERG MED, V32, P8, DOI 10.1016/S0196-0644(98)70092-7; SEABERG DC, 1994, AM J EMERG MED, V12, P541, DOI 10.1016/0735-6757(94)90274-7; SILVA I, 1988, J BONE JOINT SURG AM, V70A, P199, DOI 10.2106/00004623-198870020-00006; SIMONSEN O, 1984, INJURY, V16, P96, DOI 10.1016/S0020-1383(84)80007-8; Smith DK, 1996, AM J ROENTGENOL, V166, P411, DOI 10.2214/ajr.166.2.8553957; SONIN AH, 1994, RADIOLOGY, V190, P455, DOI 10.1148/radiology.190.2.8284399; SPECTOR TD, 1993, ANN RHEUM DIS, V52, P790, DOI 10.1136/ard.52.11.790; SPEER KP, 1991, AM J SPORT MED, V19, P396, DOI 10.1177/036354659101900414; SPIERS ASD, 1993, J BONE JOINT SURG BR, V75, P49, DOI 10.1302/0301-620X.75B1.8421033; Stanitski CL, 1998, AM J SPORT MED, V26, P2, DOI 10.1177/03635465980260012001; STIELL IG, 1995, ACAD EMERG MED, V2, P966, DOI 10.1111/j.1553-2712.1995.tb03123.x; Stiell IG, 1996, JAMA-J AM MED ASSOC, V275, P611, DOI 10.1001/jama.275.8.611; STIELL IG, 1995, ANN EMERG MED, V26, P405, DOI 10.1016/S0196-0644(95)70106-0; STOCKMAN A, 1980, ANN RHEUM DIS, V39, P7, DOI 10.1136/ard.39.1.7; STOLLER DW, 1987, RADIOLOGY, V163, P731, DOI 10.1148/radiology.163.3.3575724; Suh JS, 1996, JMRI-J MAGN RESON IM, V6, P884, DOI 10.1002/jmri.1880060608; SYKES J T, 1990, Australasian Radiology, V34, P207, DOI 10.1111/j.1440-1673.1990.tb02633.x; TERRY GC, 1995, ARTHROSCOPY, V11, P568, DOI 10.1016/0749-8063(95)90134-5; Tigges S, 1999, AM J ROENTGENOL, V172, P1069, DOI 10.2214/ajr.172.4.10587149; Torg J S, 1976, Am J Sports Med, V4, P84, DOI 10.1177/036354657600400206; Trieshmann HW, 1996, ARTHROSCOPY, V12, P550, DOI 10.1016/S0749-8063(96)90193-0; TURNER DA, 1985, RADIOLOGY, V154, P717, DOI 10.1148/radiology.154.3.3969476; TYRRELL RL, 1988, RADIOLOGY, V166, P865, DOI 10.1148/radiology.166.3.3340786; UMANS H, 1995, AM J ROENTGENOL, V165, P893, DOI 10.2214/ajr.165.4.7676988; UTSINGER PD, 1975, J RHEUMATOL, V2, P258; Vallotton J A, 1995, Knee Surg Sports Traumatol Arthrosc, V3, P157, DOI 10.1007/BF01565475; VELLET A D, 1989, Arthroscopy, V5, P287, DOI 10.1016/0749-8063(89)90143-6; VELLET AD, 1995, RADIOLOGY, V197, P826, DOI 10.1148/radiology.197.3.7480763; Verma A, 2001, ACAD RADIOL, V8, P392, DOI 10.1016/S1076-6332(03)80546-9; WALDROP JI, 1988, AM J SPORT MED, V16, P492, DOI 10.1177/036354658801600511; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WEBER JE, 1995, ANN EMERG MED, V26, P429, DOI 10.1016/S0196-0644(95)70109-5; Weinstabl R, 1997, WORLD J SURG, V21, P363, DOI 10.1007/PL00012254; WERTHEIM SB, 1994, ORTHOP T, V18, P1013; WOJTYS E, 1987, AM J SPORT MED, V15, P455, DOI 10.1177/036354658701500505; WRIGHT DH, 1995, AM J ROENTGENOL, V165, P621, DOI 10.2214/ajr.165.3.7645481; Yang BY, 1996, J RHEUMATOL, V23, P883; YAO L, 1995, SKELETAL RADIOL, V24, P247; Yoon YS, 1997, INT ORTHOP, V21, P223, DOI 10.1007/s002640050155; 1996, NATL AMBULATORY MED	213	110	115	1	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 7	2003	139	7					575	588		10.7326/0003-4819-139-7-200310070-00010	http://dx.doi.org/10.7326/0003-4819-139-7-200310070-00010			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729AP	14530229				2022-12-28	WOS:000185748800006
J	Aguzzi, A; Haass, C				Aguzzi, A; Haass, C			Games played by rogue proteins in prion disorders and Alzheimer's disease	SCIENCE			English	Review							CREUTZFELDT-JAKOB-DISEASE; GAMMA-SECRETASE ACTIVITY; FOLLICULAR DENDRITIC CELLS; MICE EXPRESSING HUMAN; TRANSGENIC MICE; SCRAPIE AGENT; BETA-APP; SPONGIFORM ENCEPHALOPATHIES; INCUBATION PERIOD; PRECURSOR PROTEIN	The incidence of Alzheimer's disease (AD) and that of prion disorders (PrD) could not be more different. One-third of octogenarians succumb to AD, whereas Creutzfeldt-Jakob disease typically affects one individual in a million each year. However, these diseases have many common features impinging on the metabolism of neuronal membrane proteins: the amyloid precursor protein APP in the case of AD, and the cellular prion protein PrPC in PrD. APP begets the Abeta peptide, whereas PrPC begets the malignant prion protein PrPSc. Both Abeta and PrPSc are associated with disease, but we do not know what triggers their accumulation and neurotoxicity. A great deal has been learned, however, about protein folding, misfolding, and aggregation; an entirely new class of intramembrane proteases has been identified; and unsuspected roles for the immune system have been uncovered. There is reason to expect that prion research will profit from advances in the understanding of AD, and vice versa.	Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Univ Munich, Dept Biochem, Adolf Butenandt Inst, Lab Alzheimers Parkinsons Dis Res, Munich, Germany	University of Zurich; University Zurich Hospital; University of Munich	Haass, C (corresponding author), Univ Zurich Hosp, Inst Neuropathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.		Aguzzi, Adriano/A-3351-2008	Aguzzi, Adriano/0000-0002-0344-6708				Aguzzi A, 2003, J EXP MED, V198, P1, DOI 10.1084/jem.20030732; Aguzzi A, 2003, NATURE, V423, P127, DOI 10.1038/423127a; Aguzzi A, 1998, BRAIN PATHOL, V8, P695, DOI 10.1111/j.1750-3639.1998.tb00195.x; Aguzzi A, 1997, NATURE, V389, P795, DOI 10.1038/39758; Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; Asante EA, 2002, EMBO J, V21, P6358, DOI 10.1093/emboj/cdf653; Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; Behrens A, 2002, TRENDS NEUROSCI, V25, P150, DOI 10.1016/S0166-2236(00)02089-0; Behrens A, 2002, EMBO J, V21, P3652, DOI 10.1093/emboj/cdf386; Behrens A, 2001, EMBO REP, V2, P347, DOI 10.1093/embo-reports/kve088; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BRUCE ME, 1987, J GEN VIROL, V68, P79, DOI 10.1099/0022-1317-68-1-79; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; Caughey B, 2003, J VIROL, V77, P5499, DOI 10.1128/JVI.77.9.5499-5502.2003; CAUGHEY B, 1992, J NEUROCHEM, V59, P768, DOI 10.1111/j.1471-4159.1992.tb09437.x; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; Cervantes S, 2001, FEBS LETT, V505, P81, DOI 10.1016/S0014-5793(01)02785-5; CHESEBRO B, 1985, NATURE, V315, P331, DOI 10.1038/315331a0; Collins SJ, 2002, ANN NEUROL, V52, P503, DOI 10.1002/ana.10336; Cooper E, 2002, BRIT MED J, V324, P239; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Dickinson A. G., 1979, Slow transmissible diseases of the nervous system. Volume 1., P367; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; DICKINSON AG, 1988, CIBA F SYMP, V135, P63; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; DUFFY P, 1974, NEW ENGL J MED, V290, P692; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Farquhar C, 1999, LANCET, V353, P117, DOI 10.1016/S0140-6736(98)05395-1; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Glatzel M, 2001, NEURON, V31, P25, DOI 10.1016/S0896-6273(01)00331-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Jackson GS, 2001, NATURE, V414, P269, DOI 10.1038/35104694; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; KIMBERLIN RH, 1994, ANN NY ACAD SCI, V724, P210, DOI 10.1111/j.1749-6632.1994.tb38911.x; KIMBERLIN RH, 1978, J COMP PATHOL, V88, P39, DOI 10.1016/0021-9975(78)90059-2; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; KIMBERLY WT, 2003, PNAS, DOI UNSP 1037392100; Klein MA, 1998, NAT MED, V4, P1429, DOI 10.1038/4022; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; Korth C, 2001, P NATL ACAD SCI USA, V98, P9836, DOI 10.1073/pnas.161274798; Lai MT, 2003, J BIOL CHEM, V278, P22475, DOI 10.1074/jbc.M300974200; LaPointe CF, 2000, J BIOL CHEM, V275, P1502, DOI 10.1074/jbc.275.2.1502; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Li T, 2003, J NEUROSCI, V23, P3272; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Mabbott NA, 2000, NAT MED, V6, P719, DOI 10.1038/77401; Mead S, 2003, SCIENCE, V300, P640, DOI 10.1126/science.1083320; Meier P, 2003, CELL, V113, P49, DOI 10.1016/S0092-8674(03)00201-0; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; Pepys MB, 2003, LANCET, V361, P487, DOI 10.1016/S0140-6736(03)12455-5; POCCHIARI M, 1987, J GEN VIROL, V68, P219, DOI 10.1099/0022-1317-68-1-219; Prinz M, 2002, P NATL ACAD SCI USA, V99, P919, DOI 10.1073/pnas.022626399; Priola SA, 2000, SCIENCE, V287, P1503, DOI 10.1126/science.287.5457.1503; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; RACE RE, 1995, NEURON, V15, P1183, DOI 10.1016/0896-6273(95)90105-1; Scoazec JY, 2003, ANN NEUROL, V53, P546, DOI 10.1002/ana.10530; SCOTT JR, 1993, VET MICROBIOL, V34, P305, DOI 10.1016/0378-1135(93)90055-C; SELKOE D, 2003, ANN REV NEUROSCI; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Soto C, 2000, LANCET, V355, P192, DOI 10.1016/S0140-6736(99)11419-3; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Supattapone S, 2001, J VIROL, V75, P3453, DOI 10.1128/JVI.75.7.3453-3461.2001; Tagliavini F, 1997, SCIENCE, V276, P1119, DOI 10.1126/science.276.5315.1119; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Weissmann C, 1999, SCIENCE, V286, P914, DOI 10.1126/science.286.5441.914; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0; WELLS GAH, 1987, VET REC, V121, P419, DOI 10.1136/vr.121.18.419; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	104	184	194	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 31	2003	302	5646					814	818		10.1126/science.1087348	http://dx.doi.org/10.1126/science.1087348			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593165				2022-12-28	WOS:000186258000035
J	Rappuoli, R; Covacci, A				Rappuoli, R; Covacci, A			Reverse vaccinology and genomics	SCIENCE			English	Article							SEQUENCE	The genomic revolution has had a dramatic effect on our ability to find new vaccine targets and develop effective vaccines.	IRIS, Chiron Vaccines, I-53100 Siena, Italy	Novartis	Rappuoli, R (corresponding author), IRIS, Chiron Vaccines, I-53100 Siena, Italy.							FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Foster I, 1999, GRID: BLUEPRINT FOR A NEW COMPUTING INFRASTRUCTURE, P15; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; Rappuoli R, 2000, CURR OPIN MICROBIOL, V3, P445, DOI 10.1016/S1369-5274(00)00119-3; RAPPUOLI R, UNPUB; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; IN PRESS BIOTECHNOLO	9	75	86	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	2003	302	5645					602	602		10.1126/science.1092329	http://dx.doi.org/10.1126/science.1092329			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576423				2022-12-28	WOS:000186119900046
J	Yan, LJL; Liu, K; Matthews, KA; Daviglus, ML; Ferguson, TF; Kiefe, CI				Yan, LJL; Liu, K; Matthews, KA; Daviglus, ML; Ferguson, TF; Kiefe, CI			Psychosocial factors and risk of hypertension - The Coronary Artery Risk Development in Young Adults (CARDIA) study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							A-BEHAVIOR PATTERN; NUTRITION EXAMINATION SURVEY; BLOOD-PRESSURE; HEART-DISEASE; PSYCHOLOGICAL PREDICTORS; CARDIOVASCULAR-DISEASE; NATIONAL-HEALTH; HOSTILITY; SYMPTOMS; PREVENTION	Context Although psychosocial factors are correlated, previous studies on risk factors for hypertension have typically examined psychosocial factors individually and have yielded inconsistent findings. Objective To examine the role of psychosocial factors of time urgency/impatience (TUI), achievement striving/competitiveness (ASC), hostility, depression, and anxiety on long-term risk of hypertension. Design, Setting, and Study Population A population-based, prospective, observational study using participant data from the Coronary Artery Risk Development in Young Adults (CARDIA) study. A total of 3308 black and white adults aged 18 to 30 years (when recruited in 1985 and 1986) from 4 US metropolitan areas and followed up through 2000 to 2001. Main Outcome Measures Fifteen-year cumulative incidence of hypertension (systolic blood pressure of 140 mm Hg or higher, diastolic blood pressure of 90 mm Hg or higher, or taking anti hypertensive medication). Results The incidence of hypertension at year 15 was 15% from baseline and 13.6% from year 5. After adjusting for the same set of hypertension risk factors and each of the psychosocial factors of TUI, ASC, hostility, depression, and anxiety in 5 separate logistic regression models, higher TUI and hostility were significantly associated with risk of developing hypertension at 15-year follow-up for the total sample. Compared with the lowest score group, the adjusted odds ratio (OR) for TUI was 1.51 (95% confidence interval [CI], 1.12-2.03) for a score of 1; 1.47 (95% Cl, 1.08-2.02) for a score of 2; and 1.84 (95% Cl, 1.29-2.62) for a score of 3 to 4 (P for trend =.001). Compared with the lowest quartile group, the adjusted OR for hostility was 1.06 (95% Cl, 0.76-1.47) for quartile 2; 1.38 (95% Cl, 1.00-1.91) for quartile 3; and 1.84 (95% Cl, 1.33-2.54) for quartile 4 (P for trend <.001). No consistent patterns were found for ASC, depression, or anxiety. Race- and sex-specific analyses and multivariable models with simultaneous adjustment for all 5 psychosocial factors and other hypertension risk factors had generally similar results. Conclusion Among young adults, TUI and hostility were associated with a dose-response increase in the long-term risk of hypertension.	Northwestern Univ, Feinberg Sch Med, Dept Prevent Dent, Chicago, IL 60611 USA; Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA; Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA; Birmingham Vet Affairs Med Ctr, Birmingham, AL USA	Northwestern University; Feinberg School of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham	Yan, LJL (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Prevent Dent, 680 N Lake Shore Dr,Suite 1102, Chicago, IL 60611 USA.	lijing@northwestern.edu			DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC095095, N01HC048050, N01HC048047, N01HC048048, N01HC048049] Funding Source: NIH RePORTER	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adams Jann H., 1999, Ethnicity and Disease, V9, P359; BOOTHKEWLEY S, 1987, PSYCHOL BULL, V101, P343, DOI 10.1037/0033-2909.101.3.343; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cole SR, 2001, INT J EPIDEMIOL, V30, P363, DOI 10.1093/ije/30.2.363; Cook WW, 1954, J APPL PSYCHOL, V38, P414, DOI 10.1037/h0060667; Davidson K, 2000, ARCH INTERN MED, V160, P1495, DOI 10.1001/archinte.160.10.1495; DEMBROSKI TM, 1989, PSYCHOSOM MED, V51, P514, DOI 10.1097/00006842-198909000-00003; DYER AR, 1990, J CLIN EPIDEMIOL, V43, P1, DOI 10.1016/0895-4356(90)90050-Y; EDWARDS JR, 1991, J APPL PSYCHOL, V76, P276, DOI 10.1037/0021-9010.76.2.276; FRIEDMAN GD, 1988, J CLIN EPIDEMIOL, V41, P1105, DOI 10.1016/0895-4356(88)90080-7; GARRITY TF, 1990, AM J PUBLIC HEALTH, V80, P1354, DOI 10.2105/AJPH.80.11.1354; GOLDBERG EL, 1980, PSYCHOL MED, V10, P243, DOI 10.1017/S0033291700044007; Harris KF, 2003, PSYCHOSOM MED, V65, P402, DOI 10.1097/01.PSY.0000035720.08842.9F; Hart KE, 1997, J CLIN PSYCHOL, V53, P905, DOI 10.1002/(SICI)1097-4679(199712)53:8<905::AID-JCLP15>3.0.CO;2-O; HAYNES SG, 1978, AM J EPIDEMIOL, V107, P362, DOI 10.1093/oxfordjournals.aje.a112556; Hemingway H, 1999, BMJ-BRIT MED J, V318, P1460, DOI 10.1136/bmj.318.7196.1460; Hosmer DavidW., 2000, APPL LOGISTIC REGRES; Jacobs David R Jr, 1989, J Cardiopulm Rehabil, V9, P448, DOI 10.1097/00008483-198911000-00003; JOHNSON EH, 1987, J PSYCHOSOM RES, V31, P731, DOI 10.1016/0022-3999(87)90022-5; JOHNSON EH, 1992, PERSONALITY ELEVATED; Joint National Committee on Prevention Detection evaluation and treatment of high blood pressure, 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005; Jonas BS, 2000, PSYCHOSOM MED, V62, P188, DOI 10.1097/00006842-200003000-00006; Jonas BS, 1997, ARCH FAM MED, V6, P43, DOI 10.1001/archfami.6.1.43; JonesWebb R, 1996, ALCOHOL CLIN EXP RES, V20, P420, DOI 10.1111/j.1530-0277.1996.tb01069.x; JULIUS S, 1995, CLIN EXP HYPERTENS, V17, P375, DOI 10.3109/10641969509087078; Kannel WB, 1996, JAMA-J AM MED ASSOC, V275, P1571, DOI 10.1001/jama.275.20.1571; Kawachi I, 1998, CIRCULATION, V98, P405, DOI 10.1161/01.CIR.98.5.405; KRANTZ DS, 1984, PSYCHOL BULL, V96, P435, DOI 10.1037/0033-2909.96.3.435; Krantz DS, 2002, ANNU REV PSYCHOL, V53, P341, DOI 10.1146/annurev.psych.53.100901.135208; KRANTZ DS, 1987, CIRCULATION, V76, P184; LIGHT KC, 1983, SCIENCE, V220, P429, DOI 10.1126/science.6836285; Liu K, 1996, CIRCULATION, V93, P60, DOI 10.1161/01.CIR.93.1.60; MARKOVITZ JH, 1991, J HYPERTENS, V9, P399, DOI 10.1097/00004872-199105000-00003; MARKOVITZ JH, 1993, JAMA-J AM MED ASSOC, V270, P2439; MATTHEWS KA, 1986, AM J EPIDEMIOL, V123, P923, DOI 10.1093/oxfordjournals.aje.a114347; Miller TQ, 1996, PSYCHOL BULL, V119, P322, DOI 10.1037/0033-2909.119.2.322; Pickering TG., 1991, AMBULATORY MONITORIN; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Raikkonen K, 1999, HEALTH PSYCHOL, V18, P44, DOI 10.1037/0278-6133.18.1.44; Raikkonen K, 2001, HYPERTENSION, V38, P798, DOI 10.1161/hyp.38.4.798; ROSENMAN RH, 1975, JAMA-J AM MED ASSOC, V233, P872, DOI 10.1001/jama.233.8.872; ROSNER B, 1983, AM J EPIDEMIOL, V117, P429, DOI 10.1093/oxfordjournals.aje.a113561; Rozanski A, 1999, CIRCULATION, V99, P2192, DOI 10.1161/01.CIR.99.16.2192; SHEPHERD JT, 1987, CIRCULATION, V76, P150; Shinn EH, 2001, AM J HYPERTENS, V14, P660, DOI 10.1016/S0895-7061(01)01304-8; SIEGLER IC, 1992, AM J EPIDEMIOL, V136, P146, DOI 10.1093/oxfordjournals.aje.a116481; SPARROW D, 1982, CIRCULATION, V65, P789, DOI 10.1161/01.CIR.65.4.789; Spector PE., 1996, STRESS EMOTION ANXIE, V16, P127; SPENCE JT, 1987, J APPL PSYCHOL, V72, P522, DOI 10.1037/0021-9010.72.4.522; Spicer J, 1996, J PSYCHOSOM RES, V40, P359, DOI 10.1016/0022-3999(95)00546-3; Steptoe A, 2000, ANN MED, V32, P371, DOI 10.3109/07853890008995940; Wolz M, 2000, AM J HYPERTENS, V13, P103, DOI 10.1016/S0895-7061(99)00241-1; WRIGHT L, 1988, AM PSYCHOL, V43, P2, DOI 10.1037/0003-066X.43.1.2	55	249	264	0	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	2003	290	16					2138	2148		10.1001/jama.290.16.2138	http://dx.doi.org/10.1001/jama.290.16.2138			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	734CB	14570949				2022-12-28	WOS:000186036700023
J	Crane, J; Cheshire, N				Crane, J; Cheshire, N			Recent developments in vascular surgery	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ABDOMINAL AORTIC-ANEURYSM; INTERMITTENT CLAUDICATION; POWERED PHLEBECTOMY; CEREBRAL PROTECTION; TREATMENT EFFICACY; NO TREATMENT; REPAIR; REGISTRY; THERAPY; TRIAL		St Marys Hosp, Reg Vasc Unit, London W2 1NY, England	Imperial College London	Crane, J (corresponding author), St Marys Hosp, Reg Vasc Unit, Praed St, London W2 1NY, England.	j.crane@imperial.ac.uk		Crane, Jeremy/0000-0001-6018-4567				Angelini A, 2002, STROKE, V33, P456, DOI 10.1161/hs0202.102337; Arumugasamy M, 2002, EUR J VASC ENDOVASC, V23, P180, DOI 10.1053/ejvs.2001.1553; Ashton HA, 2002, LANCET, V360, P1531, DOI 10.1016/S0140-6736(02)11522-4; Ashton HA, 2002, BMJ-BRIT MED J, V325, P1135; BACHOO P, 2003, COCHRANE DB SYST REV, P3228, DOI DOI 10.1002/14651858CD003228; BEARD J, 2001, VASCULAR ENDOVASCULA; Beard JD, 2003, BRIT J SURG, V90, P515, DOI 10.1002/bjs.4140; Biasi GM, 2001, J ENDOVASC THER, V8, P46, DOI 10.1583/1545-1550(2001)008<0046:TIROCA>2.0.CO;2; Bicknell CD, 2003, EUR J VASC ENDOVASC, V26, P17, DOI 10.1053/ejvs.2002.1859; Brown MM, 2001, LANCET, V357, P1729; Burns P, 2002, EUR J VASC ENDOVASC, V24, P6, DOI 10.1053/ejvs.2002.1684; Cheshire N, 2002, ANN VASC SURG, V16, P488, DOI 10.1007/s10016-001-0100-1; Collins R, 2002, INT J CLIN PRACT, V56, P53; Criado FJ, 2002, J VASC SURG, V36, P1121, DOI 10.1067/mva.2002.129649; Cusi C, 2003, NEUROEPIDEMIOLOGY, V22, P153, DOI 10.1159/000068749; Dimakakos P, 1995, INT SURG, V80, P267; DONNELLY R, 2001, ABC VASCULAR SURG; Gelin J, 2001, EUR J VASC ENDOVASC, V22, P107, DOI 10.1053/ejvs.2001.1413; Golledge J, 2003, EUR J VASC ENDOVASC, V25, P319, DOI 10.1053/ejvs.2002.1843; GREENHALGH RM, 2002, 29 GLOB C VASC END I; HALLIDAY AW, 1994, EUR J VASCULAR SURG, V8, P703; Hennessy MJ, 2000, INT J CLIN PRACT, V54, P432; Hinchliffe RJ, 2003, EUR J VASC ENDOVASC, V25, P191, DOI 10.1053/ejvs.2002.1846; Jordan WD, 2003, ANN SURG, V237, P623, DOI 10.1097/00000658-200305000-00004; Karkos CD, 2003, CARDIOVASC SURG, V11, P6, DOI 10.1016/S0967-2109(02)00110-2; Khaw KT, 1999, BRIT MED J, V319, P1350, DOI 10.1136/bmj.319.7221.1350; Laheij RJF, 2000, BRIT J SURG, V87, P1666, DOI 10.1046/j.1365-2168.2000.01661.x; Laxdal E, 2003, EUR J VASC ENDOVASC, V25, P578, DOI 10.1053/ejvs.2002.1899; Lee TY, 2002, SURGERY, V132, P399, DOI 10.1067/msy.2002.126510; Lindholt JS, 1999, EUR J VASC ENDOVASC, V17, P472, DOI 10.1053/ejvs.1999.0835; Logason Karl, 2002, Vasc Endovascular Surg, V36, P9, DOI 10.1177/153857440203600103; Powell JT, 1998, LANCET, V352, P1649; Reimers B, 2001, CIRCULATION, V104, P12, DOI 10.1161/hc2601.092495; ROBLESS P, 2003, BR J SURG S1, V90; Rothwell PM, 2003, STROKE, V34, P514, DOI 10.1161/01.STR.0000054671.71777.C7; Scott RAP, 2002, BRIT J SURG, V89, P283, DOI 10.1046/j.0007-1323.2001.02014.x; Stanley JC, 1996, J VASC SURG, V23, P172, DOI 10.1016/S0741-5214(05)80050-3; Sybrandy JEM, 2002, J VASC SURG, V36, P1207, DOI 10.1067/mva.2002.128936; Taft C, 2001, EUR J VASC ENDOVASC, V22, P114, DOI 10.1053/ejvs.2001.1406; Tisi PV, 2002, EUR J VASC ENDOVASC, V24, P417, DOI 10.1053/ejvs.2002.1754; Tu JV, 2001, J VASC SURG, V33, P447, DOI 10.1067/mva.2001.113487; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035	42	7	7	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 18	2003	327	7420					911	915		10.1136/bmj.327.7420.911	http://dx.doi.org/10.1136/bmj.327.7420.911			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734RV	14563751	Green Published			2022-12-28	WOS:000186072100024
J	Ota, S; Ueoka, H; Tanimoto, M				Ota, S; Ueoka, H; Tanimoto, M			Clinical picture - Retroperitoneal paraganglioma	LANCET			English	Editorial Material									Okayama Univ, Sch Med & Dent, Dept Internal Med 2, Okayama 7008558, Japan	Okayama University	Ota, S (corresponding author), Okayama Univ, Sch Med & Dent, Dept Internal Med 2, Okayama 7008558, Japan.								0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 18	2003	362	9392					1266	1266		10.1016/S0140-6736(03)14569-2	http://dx.doi.org/10.1016/S0140-6736(03)14569-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575970				2022-12-28	WOS:000186036900009
J	Heritage, J				Heritage, J			Will GM rapeseed cut the mustard?	SCIENCE			English	Editorial Material									Univ Leeds, Div Microbiol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Heritage, J (corresponding author), Univ Leeds, Div Microbiol, Leeds LS2 9JT, W Yorkshire, England.							Bilsborrow PE, 1998, J SCI FOOD AGR, V76, P17, DOI 10.1002/(SICI)1097-0010(199801)76:1&lt;17::AID-JSFA903&gt;3.0.CO;2-9; *DEP ENV FOOD RUR, 2003, FARM SCAL EV GM CROP; *GM SCI REV PAN, 2003, 1 GM SCI REV; *OECD, 2003, BIOT DAT; ORSON J, 2002, 443 ENGL NAT RES; Wilkinson MJ, 2003, SCIENCE, V302, P457, DOI 10.1126/science.1088200	6	2	3	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					401	+		10.1126/science.1091475	http://dx.doi.org/10.1126/science.1091475			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14563995				2022-12-28	WOS:000185963200027
J	Goodman, A; Wilbur, DC				Goodman, A; Wilbur, DC			Case 32-2003: A 37-year-old woman with atypical squamous cells on a Papanicolaou smear - Atypical squamous cells of unknown significance (on the Papanicolaou smear), with a negative test for high-risk human papillomavirus. The patient is currently not at increased risk for cervical cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							UNDETERMINED SIGNIFICANCE; NATURAL-HISTORY; MANAGEMENT; GUIDELINES; CYTOLOGY; WOMEN; TRIAL		Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Gynecol Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Cytopathol Div, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Goodman, A (corresponding author), Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Boston, MA 02114 USA.							Davey DD, 2002, AM J CLIN PATHOL, V118, P714; Holowaty P, 1999, JNCI-J NATL CANCER I, V91, P252, DOI 10.1093/jnci/91.3.252; *IARC, 1995, IARC MON EV CARC RIS, V64; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; KURMAN RJ, 1994, JAMA-J AM MED ASSOC, V271, P1866, DOI 10.1001/jama.271.23.1866; Kurman RJ, 1994, BETHESDA SYSTEM REPO; Manos MM, 1999, JAMA-J AM MED ASSOC, V281, P1605, DOI 10.1001/jama.281.17.1605; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; *NAT CANC I, 1973, SEER CANC STAT REV; Papanicolaou GN, 1941, AM J OBSTET GYNECOL, V42, P193; Sherman ME, 2002, J NATL CANCER I, V94, P102, DOI 10.1093/jnci/94.2.102; Solomon D, 2003, AM J OBSTET GYNECOL, V188, P1383, DOI 10.1067/mob.2003.457; Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114; Woodman CBJ, 2001, LANCET, V357, P1831, DOI 10.1016/S0140-6736(00)04956-4; Wright TC, 2002, JAMA-J AM MED ASSOC, V287, P2120, DOI 10.1001/jama.287.16.2120	15	8	10	1	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 16	2003	349	16					1555	1564		10.1056/NEJMcpc030026	http://dx.doi.org/10.1056/NEJMcpc030026			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	731ZM	14561799	Green Published			2022-12-28	WOS:000185916400011
J	Schwartz, E; Parise, M; Kozarsky, P; Cetron, M				Schwartz, E; Parise, M; Kozarsky, P; Cetron, M			Delayed onset of malaria - Implications for chemoprophylaxis in travelers	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMODIUM-FALCIPARUM MALARIA; PLACEBO-CONTROLLED TRIAL; UNITED-STATES TROOPS; DOUBLE-BLIND; ATOVAQUONE-PROGUANIL; VIVAX MALARIA; NONIMMUNE TRAVELERS; PYRIMETHAMINE-SULFADOXINE; CHLOROQUINE-PROGUANIL; AMERICAN TRAVELERS	BACKGROUND: Most antimalarial agents used by travelers act on the parasite's blood stage and therefore do not prevent late-onset illness, particularly that due to species that cause relapsing malaria. We examined the magnitude of this problem among Israeli and American travelers. METHODS: We examined malaria surveillance data from Israel and the United States to determine the traveler's destination, the infecting species, the type of chemoprophylaxis used, and the incubation period. RESULTS: In Israel, from 1994 through 1999, there were 300 cases of malaria among returning travelers in which one species of plasmodium could be identified. In 134 of these cases (44.7 percent), the illness developed more than two months after the traveler's return; nearly all of these cases were due to infection with Plasmodium vivax or P. ovale. In 108 of the 134 cases (80.6 percent), the patient had used an antimalarial regimen according to national guidelines. In the United States, from 1992 through 1998, there were 2822 cases of malaria among travelers in which the cause could be evaluated. Late illness developed in 987 (35.0 percent) of these travelers. The infection was due to P. vivax in 811 travelers, P. ovale in 66, P. falciparum in 59, and P. malariae in 51; 614 (62.2 percent) of those with late-onset illness had appropriately taken an effective antimalarial agent. CONCLUSIONS: In more than one third of malaria-infected travelers, the illness developed more than two months after their return. Most of these late-onset illnesses are not prevented by the commonly used and effective blood schizonticides. Agents that act on the liver phase of malaria parasites are needed for more effective prevention of malaria in travelers.	Chaim Sheba Med Ctr, Ctr Geog Med, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Med, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; CDCP, Malaria Epidemiol Branch, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA USA; CDCP, Surveillance & Epidemiol Branch, Div Global Migrat & Quarantine, Natl Ctr Infect Dis, Atlanta, GA USA; US PHS, US Dept HHS, Atlanta, GA USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA USA	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; United States Public Health Service; Emory University	Schwartz, E (corresponding author), Chaim Sheba Med Ctr, Ctr Geog Med, IL-52621 Tel Hashomer, Israel.							ALVING AS, 1952, JAMA-J AM MED ASSOC, V149, P1558, DOI 10.1001/jama.1952.72930340017010; Anabwani G, 1999, PEDIATR INFECT DIS J, V18, P456, DOI 10.1097/00006454-199905000-00011; Baird JK, 2001, CLIN INFECT DIS, V33, P1990, DOI 10.1086/324085; Baudon D, 1999, T ROY SOC TROP MED H, V93, P302, DOI 10.1016/S0035-9203(99)90030-5; Berman JD, 2001, T ROY SOC TROP MED H, V95, P429, DOI 10.1016/S0035-9203(01)90206-8; Brueckner RP, 1998, AM J TROP MED HYG, V58, P645, DOI 10.4269/ajtmh.1998.58.645; Bustos DG, 1999, J INFECT DIS, V179, P1587, DOI 10.1086/314770; *CDCP, 2001, HLTH INF INT TRAV 20; Croft A, 1997, BRIT MED J, V315, P1412, DOI 10.1136/bmj.315.7120.1412; Croft AMJ, 1996, LANCET, V347, P326, DOI 10.1016/S0140-6736(96)90500-0; deAlencar FEC, 1997, J INFECT DIS, V175, P1544, DOI 10.1086/516497; FRYAUFF DJ, 1995, LANCET, V346, P1190, DOI 10.1016/S0140-6736(95)92898-7; HATTON CSR, 1986, LANCET, V1, P411; HENNEQUIN C, 1994, ARCH INTERN MED, V154, P2360, DOI 10.1001/archinte.154.20.2360; Hogh B, 2000, LANCET, V356, P1888, DOI 10.1016/S0140-6736(00)03260-8; Lacy MD, 2002, CLIN INFECT DIS, V35, pE92, DOI 10.1086/343750; Lell B, 2000, LANCET, V355, P2041, DOI 10.1016/S0140-6736(00)02352-7; Lell B, 1998, LANCET, V351, P709, DOI 10.1016/S0140-6736(97)09222-2; Ling J, 2002, CLIN INFECT DIS, V35, P825, DOI 10.1086/342578; LOBEL HO, 1990, B WORLD HEALTH ORGAN, V68, P209; Looareesuwan S, 1999, T ROY SOC TROP MED H, V93, P637, DOI 10.1016/S0035-9203(99)90079-2; Looareesuwan S, 1996, AM J TROP MED HYG, V54, P62, DOI 10.4269/ajtmh.1996.54.62; Looareesuwan S, 1999, AM J TROP MED HYG, V60, P526, DOI 10.4269/ajtmh.1999.60.526; MILLER KD, 1986, AM J TROP MED HYG, V35, P451, DOI 10.4269/ajtmh.1986.35.451; Mulenga M, 1999, CLIN THER, V21, P841, DOI 10.1016/S0149-2918(99)80006-X; NEFTEL KA, 1986, BRIT MED J, V292, P721, DOI 10.1136/bmj.292.6522.721; Ohrt C, 1997, ANN INTERN MED, V126, P963, DOI 10.7326/0003-4819-126-12-199706150-00006; Overbosch D, 2001, CLIN INFECT DIS, V33, P1015, DOI 10.1086/322694; PHILLIPSHOWARD PA, 1986, BRIT MED J, V293, P932, DOI 10.1136/bmj.293.6552.932; Radloff PD, 1996, LANCET, V347, P1511, DOI 10.1016/S0140-6736(96)90671-6; Sabchareon A, 1998, T ROY SOC TROP MED H, V92, P201, DOI 10.1016/S0035-9203(98)90749-0; SANCHEZ JL, 1993, LANCET, V341, P1021, DOI 10.1016/0140-6736(93)91107-W; Schwartz E, 1998, CLIN INFECT DIS, V26, P1089, DOI 10.1086/520279; Schwartz E, 1999, CLIN INFECT DIS, V29, P1502, DOI 10.1086/313527; Shanks GD, 1999, J TRAVEL MED, V6, pS21; Shanks GD, 1998, CLIN INFECT DIS, V27, P494, DOI 10.1086/514710; Shapiro TA, 1999, AM J TROP MED HYG, V60, P831, DOI 10.4269/ajtmh.1999.60.831; Soto J, 1998, ANN INTERN MED, V129, P241, DOI 10.7326/0003-4819-129-3-199808010-00013; STEFFEN R, 1990, B WORLD HEALTH ORGAN, V68, P313; Sukwa TY, 1999, AM J TROP MED HYG, V60, P521, DOI 10.4269/ajtmh.1999.60.521; Taylor WRJ, 1999, CLIN INFECT DIS, V28, P74, DOI 10.1086/515071; Wallace MR, 1996, AM J MED, V100, P49, DOI 10.1016/S0002-9343(96)90011-X; *WHO, 2000, INT TRAV HLTH VACC R	43	116	120	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 16	2003	349	16					1510	1516		10.1056/NEJMoa021592	http://dx.doi.org/10.1056/NEJMoa021592			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	731ZM	14561793				2022-12-28	WOS:000185916400005
J	Taylor, GK; Nudds, RL; Thomas, ALR				Taylor, GK; Nudds, RL; Thomas, ALR			Flying and swimming animals cruise at a Strouhal number tuned for high power efficiency	NATURE			English	Article							LOCUSTA-MIGRATORIA L; OSCILLATING FOILS; INTERMITTENT FLIGHT; WINGBEAT FREQUENCY; NEUROMUSCULAR CONTROL; FLAPPING FLIGHT; NATURAL FLIGHT; WIDE-RANGE; KINEMATICS; PROPULSION	Dimensionless numbers are important in biomechanics because their constancy can imply dynamic similarity between systems, despite possible differences in medium or scale(1). A dimensionless parameter that describes the tail or wing kinematics of swimming and flying animals is the Strouhal number(1), St = fA/U, which divides stroke frequency (f) and amplitude (A) by forward speed (U)(2-8). St is known to govern a well-defined series of vortex growth and shedding regimes for airfoils undergoing pitching and heaving motions(6,8). Propulsive efficiency is high over a narrow range of St and usually peaks within the interval 0.2 < St < 0.4 (refs 3-8). Because natural selection is likely to tune animals for high propulsive efficiency, we expect it to constrain the range of St that animals use. This seems to be true for dolphins(2-5), sharks(3-5) and bony fish(3-5), which swim at 0.2 < St < 0.4. Here we show that birds, bats and insects also converge on the same narrow range of St, but only when cruising. Tuning cruise kinematics to optimize St therefore seems to be a general principle of oscillatory lift-based propulsion.	Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Taylor, GK (corresponding author), Univ Oxford, Dept Zool, Tinbergen Bldg,S Parks Rd, Oxford OX1 3PS, England.		tay, wee beng/B-1095-2010; Taylor, Graham/A-5041-2010; Usoh, Chigozie/H-5517-2011					Alexander RM., 2003, PRINCIPLES ANIMAL LO; Anderson JM, 1998, J FLUID MECH, V360, P41, DOI 10.1017/S0022112097008392; BAKER PS, 1981, J COMP PHYSIOL, V141, P233, DOI 10.1007/BF01342669; BAKER PS, 1979, J COMP PHYSIOL, V131, P79, DOI 10.1007/BF00613086; Bandyopadhyay PR, 2000, J FLUID ENG-T ASME, V122, P219, DOI 10.1115/1.483274; Bullen RD, 2002, J EXP BIOL, V205, P2615; DUDLEY R, 1990, J COMP PHYSIOL A, V167, P145; GOPALKRISHNAN R, 1994, J FLUID MECH, V274, P1, DOI 10.1017/S0022112094002016; Huang RF, 2001, J FLUID MECH, V441, P265, DOI 10.1017/S002211200100489X; Motani R, 2002, NATURE, V415, P309, DOI 10.1038/415309a; PENNYCUICK CJ, 1989, J EXP BIOL, V142, P1; Pennycuick CJ, 2001, J EXP BIOL, V204, P3283; PENNYCUICK CJ, 1990, J EXP BIOL, V150, P171; Pennycuick CJ, 1996, J EXP BIOL, V199, P1613; RAYNER JMV, 1987, CURRENT ORNITHOLOGY, V5, P1; Read DA, 2003, J FLUID STRUCT, V17, P163, DOI 10.1016/S0889-9746(02)00115-9; ROHR JJ, 1998, 1769 SPAC NAV WARF S; SCHOLEY KD, 1983, THESIS U BRISTOL; Tobalske BW, 1996, AUK, V113, P151, DOI 10.2307/4088943; Tobalske BW, 1999, J EXP BIOL, V202, P1725; Tobalske BW, 1996, J EXP BIOL, V199, P263; TOBALSKE BW, 1995, J EXP BIOL, V198, P1259; TOBALSKE BW, 1994, J EXP BIOL, V187, P1; TRIANTAFYLLOU GS, 1993, J FLUID STRUCT, V7, P205, DOI 10.1006/jfls.1993.1012; Triantafyllou MS, 2000, ANNU REV FLUID MECH, V32, P33, DOI 10.1146/annurev.fluid.32.1.33; TRIANTAFYLLOU MS, 1991, PHYS FLUIDS A-FLUID, V3, P2835, DOI 10.1063/1.858173; VIDELER JJ, 1988, J EXP BIOL, V134, P185; Wang ZJ, 2000, J FLUID MECH, V410, P323, DOI 10.1017/S0022112099008071; WITHERS PC, 1977, J EXP BIOL, V70, P13; Wolfgang MJ, 1999, J EXP BIOL, V202, P2303	30	566	579	10	211	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					707	711		10.1038/nature02000	http://dx.doi.org/10.1038/nature02000			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562101				2022-12-28	WOS:000185924500039
J	Teri, L; Gibbons, LE; McCurry, SM; Logsdon, RG; Buchner, DM; Barlow, WE; Kukull, WA; LaCroix, AZ; McCormick, W; Larson, EB				Teri, L; Gibbons, LE; McCurry, SM; Logsdon, RG; Buchner, DM; Barlow, WE; Kukull, WA; LaCroix, AZ; McCormick, W; Larson, EB			Exercise plus behavioral management in patients with Alzheimer disease - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED CLINICAL-TRIAL; NURSING-HOME RESIDENTS; OLDER ADULTS; DEPRESSIVE SYMPTOMS; DEMENTIA PATIENTS; PHYSICAL-ACTIVITY; FUNCTIONAL REACH; FALLS; REHABILITATION; ASSOCIATION	Context Exercise training for patients with Alzheimer disease combined with teaching caregivers how to manage behavioral problems may help decrease the frailty and behavioral impairment that are often prevalent in patients with Alzheimer disease. Objective To determine whether a home-based exercise program combined with caregiver training in behavioral management techniques would reduce functional dependence and delay institutionalization among patients with Alzheimer disease. Design, Setting, and Patients Randomized controlled trial of 153 community-dwelling patients meeting National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer Disease and Related Disorders Association criteria for Alzheimer disease, conducted between June 1994 and April 1999. Interventions Patient-caregiver dyads were randomly assigned to the combined exercise and caregiver training progam, Reducing Disability in Alzheimer Disease (RDAD), or to routine medical care (RMC). The RDAD program was conducted in the patients' home over 3 months. Main Outcome Measures Physical health and function (36-item Short-Form Health Survey's [SF-36] physical functioning and physical role functioning subscales and Sickness Impact Profile's Mobility subscale), and affective status (Hamilton Depression Rating Scale and Cornell Depression Scale for Depression in Dementia). Results At 3 months, in comparison with the routine care patients, more patients in the RDAD group exercised at least 60 min/wk (odds ratio [OR], 2.82; 95% confidence interval [CI], 1.25-6.39; P=.01) and had fewer days of restricted activity (OR, 3.10; 95% Cl, 1.08-8.95; P<.001). Patients in the RDAD group also had improved scores for physical role functioning compared with worse scores for patients in the RMC group (mean difference, 19.29; 95% Cl, 8.75-29.83; P<.001). Patients in the RDAD group had improved Cornell Depression Scale for Depression in Dementia scores while the patients in the RMC group had worse scores (mean difference, -1.03; 95% Cl, -0.17 to -1.91; P=.02). At 2 years, the RDAD patients continued to have better physical role functioning scores than the RMC patients (mean difference, 10.89; 95% Cl, 3.62-18.16; P=.003) and showed a trend (19% vs 50%) for less institutionalization due to behavioral disturbance. For patients with higher depression scores at baseline, those in the RDAD group improved significantly more at 3 months on the Hamilton Depression Rating Scale (mean difference, 2.21; 95% Cl, 0.22-4.20; P=.04) and maintained that improvement at 24 months (mean difference, 2.14; 95% Cl, 0.14-4.17; P=.04). Conclusion Exercise training combined with teaching caregivers behavioral management techniques improved physical health and depression in patients with Alzheimer disease.	Univ Washington, Dept Psychosocial & Community Hlth, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Ctr Dis Control & Prevent, Div Nutr & Phys Act, Atlanta, GA USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centers for Disease Control & Prevention - USA; Group Health Cooperative	Teri, L (corresponding author), Univ Washington, Dept Psychosocial & Community Hlth, POB 358733, Seattle, WA 98195 USA.	lteri@u.washington.edu	McCurry, Susan M/E-4731-2015; Janson, Patrick/AAC-7581-2022	McCurry, Susan M/0000-0001-8624-3772; Kukull, Walter/0000-0001-8761-9014	NATIONAL INSTITUTE ON AGING [R01AG010845, R01AG014777] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALEXOPOULOS GS, 1988, BIOL PSYCHIAT, V23, P271, DOI 10.1016/0006-3223(88)90038-8; Arkin SM, 1999, GERONTOLOGIST, V39, P729, DOI 10.1093/geront/39.6.729; Blumenthal JA, 1999, ARCH INTERN MED, V159, P2349, DOI 10.1001/archinte.159.19.2349; BRILL PA, 1995, GERONTOLOGIST, V35, P263; BUCHNER DM, 1987, JAMA-J AM MED ASSOC, V257, P1492, DOI 10.1001/jama.257.11.1492; BUCHNER DM, 1993, J AM GERIATR SOC, V41, P321, DOI 10.1111/j.1532-5415.1993.tb06711.x; DUNCAN PW, 1990, J GERONTOL, V45, pM192, DOI 10.1093/geronj/45.6.M192; Dvorak RV, 1998, NEUROLOGY, V51, P1386, DOI 10.1212/WNL.51.5.1386; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hamilton M., 1967, BRIT J SOC CLIN PSYC, V6, P278, DOI [10.1111/j.2044-8260.1967.tb00530.x, DOI 10.1111/J.2044-8260.1967.TB00530.X]; KRENZ C, 1988, MED CARE, V26, P453, DOI 10.1097/00005650-198805000-00002; Larson E B, 1990, Aging (Milano), V2, P404; Lazowski DA, 1999, J GERONTOL A-BIOL, V54, pM621, DOI 10.1093/gerona/54.12.M621; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LIANG MH, 1985, ARTHRITIS RHEUM, V28, P542, DOI 10.1002/art.1780280513; LOGSDON RG, 1995, J AM GERIATR SOC, V43, P150, DOI 10.1111/j.1532-5415.1995.tb06380.x; MacRae PG, 1996, J AM GERIATR SOC, V44, P175, DOI 10.1111/j.1532-5415.1996.tb02435.x; MAGAZINER J, 1990, J GERONTOL, V45, pM101, DOI 10.1093/geronj/45.3.M101; Mather AS, 2002, BRIT J PSYCHIAT, V180, P411, DOI 10.1192/bjp.180.5.411; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Meuleman JR, 2000, ARCH PHYS MED REHAB, V81, P312, DOI 10.1053/apmr.2000.0810312; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; MORRIS JC, 1987, J GERONTOL, V42, P412, DOI 10.1093/geronj/42.4.412; Morris JN, 1999, J GERONTOL A-BIOL, V54, pM494, DOI 10.1093/gerona/54.10.M494; *NAT CTR HLTH STAT, 1986, VIT HLTH STAT, V10; OLESKE DM, 1995, J AM GERIATR SOC, V43, P741, DOI 10.1111/j.1532-5415.1995.tb07042.x; Penninx BWJH, 2002, J GERONTOL B-PSYCHOL, V57, pP124, DOI 10.1093/geronb/57.2.P124; SCHOLES D, 1991, AM J PUBLIC HEALTH, V81, P485, DOI 10.2105/AJPH.81.4.485; Singh NA, 2001, J GERONTOL A-BIOL, V56, pM497, DOI 10.1093/gerona/56.8.M497; Small GW, 1997, JAMA-J AM MED ASSOC, V278, P1363, DOI 10.1001/jama.278.16.1363; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; TERI L, 1992, J CONSULT CLIN PSYCH, V60, P379, DOI 10.1037/0022-006X.60.3.379; Teri L, 1998, PSYCHOTHERAPY, V35, P436, DOI 10.1037/h0087766; Teri L, 2000, NEUROLOGY, V55, P1271, DOI 10.1212/WNL.55.9.1271; Teri L, 2002, MED CLIN N AM, V86, P641, DOI 10.1016/S0025-7125(02)00006-8; Teri L, 1997, J GERONTOL B-PSYCHOL, V52, pP159, DOI 10.1093/geronb/52B.4.P159; TERI L, 1992, PSYCHOL AGING, V7, P622, DOI 10.1037/0882-7974.7.4.622; Teri L, 1998, J REHABIL RES DEV, V35, P411; TINETTI ME, 1995, J AM GERIATR SOC, V43, P1214, DOI 10.1111/j.1532-5415.1995.tb07396.x; WAGNER EH, 1993, J AM GERIATR SOC, V41, P241, DOI 10.1111/j.1532-5415.1993.tb06700.x; WEINER DK, 1993, ARCH PHYS MED REHAB, V74, P796, DOI 10.1016/0003-9993(93)90003-S; Wolf-Klein G P, 1994, Int Psychogeriatr, V6, P135, DOI 10.1017/S1041610294001705	44	504	531	2	74	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	2003	290	15					2015	2022		10.1001/jama.290.15.2015	http://dx.doi.org/10.1001/jama.290.15.2015			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732CX	14559955	Green Published			2022-12-28	WOS:000185924200025
J	Blanco, P; Viallard, JF; Parrens, M; Mercie, P; Pellegrin, JL				Blanco, P; Viallard, JF; Parrens, M; Mercie, P; Pellegrin, JL			Bone-marrow fibrin-ring granuloma	LANCET			English	Editorial Material									Hop Haut Leveque, Clin Med Interne & Malad Infect, F-33604 Pessac, France; Hop Haut Leveque, Lab Anatomopathol, F-33604 Pessac, France	CHU Bordeaux; CHU Bordeaux	Blanco, P (corresponding author), Hop Haut Leveque, Clin Med Interne & Malad Infect, F-33604 Pessac, France.								0	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 11	2003	362	9391					1224	1224		10.1016/S0140-6736(03)14545-X	http://dx.doi.org/10.1016/S0140-6736(03)14545-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568746				2022-12-28	WOS:000185924100025
J	Hardy, R; Kuh, D; Langenberg, C; Wadsworth, MEJ				Hardy, R; Kuh, D; Langenberg, C; Wadsworth, MEJ			Birthweight, childhood social class, and change in adult blood pressure in the 1946 British birth cohort	LANCET			English	Article							FETAL ORIGINS HYPOTHESIS; CARDIOVASCULAR-DISEASE; BODY-MASS; FOLLOW-UP; GROWTH; CHILDREN; ASSOCIATION; SIZE; RISK	Background The negative effect of birthweight on systolic blood pressure has been suggested to be initiated in utero and amplified with age. We aimed to investigate this hypothesis. Methods A sample of 3634 people from a birth cohort study of men and women born in Britain in 1946 were included in analyses. Cohort members have been contacted regularly since birth, and systolic and diastolic blood pressures were measured at ages 36, 43, and 53 years. Multilevel models, with blood pressure as a repeated outcome, were used to test the amplification hypothesis and to compare results for birthweight with those for childhood social class. Findings Considering both men and women together, a consistent negative association between birthweight and systolic blood pressure was noted from age 36 to 53 years, but no evidence was recorded of substantial amplification with age. A 1 kg higher birthweight was associated with a slower mean increase in systolic blood pressure by -0.4 mm Hg (95% CI -1.3 to 0.4; p=0.3) per 10-year increase in age. Birthweight was not associated with diastolic blood pressure at any age. People from a manual social class in childhood had higher systolic and diastolic blood pressure than did those from a non-manual class. The effect on systolic blood pressure rose with age, by 1.0 mm Hg (95% Cl 0.1 to 2.0; p=0.03) per 10 years, but was largely accounted for by current body-mass index, which was an increasingly strong determinant of blood pressure. Interpretation These findings suggest that weight control throughout life is key to prevention of raised blood pressure during middle age. Understanding the link between the early childhood socioeconomic environment and adult obesity could make this strategy more effective.	UCL Royal Free & Univ Coll Med Sch, Dept Epidemiol & Publ Hlth, MRC, Natl Survey Hlth & Dev, London WC1E 6BT, England	University of London; University College London; UCL Medical School	Hardy, R (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Epidemiol & Publ Hlth, MRC, Natl Survey Hlth & Dev, London WC1E 6BT, England.	rebecca.hardy@ucl.ac.uk	Langenberg, Claudia/ABG-9067-2021; Hardy, Rebecca/AFR-1989-2022; Kuh, Diana/L-6019-2014	Langenberg, Claudia/0000-0002-5017-7344; Kuh, Diana/0000-0001-7386-2857; Hardy, Rebecca/0000-0001-9949-0799				Bavdekar A, 1999, DIABETES, V48, P2422, DOI 10.2337/diabetes.48.12.2422; Blane D, 1996, BMJ-BRIT MED J, V313, P1434, DOI 10.1136/bmj.313.7070.1434; COLHOUN H, 2002, LIFE COURSE APPROACH; Falkner B, 1998, HYPERTENSION, V31, P145, DOI 10.1161/01.HYP.31.1.145; Forsen T, 1998, J HUM HYPERTENS, V12, P397, DOI 10.1038/sj.jhh.1000643; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; Goldstein H., 1998, USERS GUIDE MLWIN MU; Hardy R, 2000, INT J OBESITY, V24, P725, DOI 10.1038/sj.ijo.0801238; Huxley R, 2002, LANCET, V360, P659, DOI 10.1016/S0140-6736(02)09834-3; Huxley RR, 2000, J HYPERTENS, V18, P815, DOI 10.1097/00004872-200018070-00002; Koupilova Ilona, 1997, Blood Pressure, V6, P223, DOI 10.3109/08037059709062073; LAUNER LJ, 1993, BMJ-BRIT MED J, V307, P1451, DOI 10.1136/bmj.307.6917.1451; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LEON DA, 2000, FETAL ORIGINS CARDIO, P23; Lucas A, 1999, BRIT MED J, V319, P245, DOI 10.1136/bmj.319.7204.245; Moore VM, 1999, J HYPERTENS, V17, P883, DOI 10.1097/00004872-199917070-00003; Plewis I, 1996, BRIT J MATH STAT PSY, V49, P25, DOI 10.1111/j.2044-8317.1996.tb01073.x; Taittonen L, 1996, PEDIATR RES, V40, P627, DOI 10.1203/00006450-199610000-00019; Thame M, 2000, HYPERTENSION, V35, P662, DOI 10.1161/01.HYP.35.2.662; Uiterwaal CSPM, 1997, HYPERTENSION, V30, P267, DOI 10.1161/01.HYP.30.2.267; Wadsworth M. E. J., 1991, IMPRINT TIME CHILDHO; WADSWORTH MEJ, 1992, J EPIDEMIOL COMMUN H, V46, P300, DOI 10.1136/jech.46.3.300; Wadsworth MEJ, 1997, PAEDIATR PERINAT EP, V11, P2, DOI 10.1046/j.1365-3016.1997.d01-7.x; WADSWORTH MEJ, 1985, BRIT MED J, V291, P1534, DOI 10.1136/bmj.291.6508.1534; WADSWORTH MEJ, IN PRESS SOC SCI MED; WADSWORTH MEJ, 2003, CHANGING BRITAIN CHA; Wannamethee SG, 1996, LANCET, V348, P1259, DOI 10.1016/S0140-6736(96)02465-8; WHINCUP P, 1995, BRIT MED J, V311, P773, DOI 10.1136/bmj.311.7008.773; Williams S, 2002, AM J EPIDEMIOL, V155, P849, DOI 10.1093/aje/155.9.849	29	90	94	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 11	2003	362	9391					1178	1183		10.1016/S0140-6736(03)14539-4	http://dx.doi.org/10.1016/S0140-6736(03)14539-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732CW	14568738				2022-12-28	WOS:000185924100008
J	Heath, I				Heath, I			A wolf in sheep's clothing: a critical look at the ethics of drug taking	BRITISH MEDICAL JOURNAL			English	Article							CONCORDANCE; WOMEN	In 1997 a report of a working party of the Royal Pharmaceutical Society of Great Britain acknowledged that prescribing is "a technically difficult, and morally complex, problem" and that compliance is an ethically dubious aspiration.(1) The report proposed the use of a new term-concordance-which was intended to describe the creation, during the process of prescribing, of an agreement that respected the beliefs and wishes of the patient.(2) The intention of the working party was to foster a distinct change in culture in the relation between prescribing and drug taking and between patient and prescriber. The intention was honourable, but the initiative seems to be foundering.	Caversham Grp Practice, London NW5 2UP, England		Heath, I (corresponding author), Caversham Grp Practice, Kentish Town, London NW5 2UP, England.							Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Bashir A, 2001, INT J PHARM PRACT S, V9, pR78; Butler CC, 2001, J ANTIMICROB CHEMOTH, V48, P435, DOI 10.1093/jac/48.3.435; Carter S, 2003, QUESTION CHOICE COMP; COL N, 1990, ARCH INTERN MED, V150, P841, DOI 10.1001/archinte.150.4.841; DONALDSON MR, 1992, ALL ER, V4, P649; Dowell J, 2002, BRIT J GEN PRACT, V52, P24; Hodgkin P, 1996, BRIT MED J, V313, P1568, DOI 10.1136/bmj.313.7072.1568; Marinker M, 2003, BRIT MED J, V326, P348, DOI 10.1136/bmj.326.7385.348; METCALFE D, 1986, J ROY COLL GEN PRACT, V36, P349; POLLOCK AM, 2003, BRIT MED J, V377, P571; Rochon PA, 1997, BMJ-BRIT MED J, V315, P1096, DOI 10.1136/bmj.315.7115.1096; Royal Pharmaceutical Society of Great Britain, 1997, COMPL CONC ACH SHAR; Thornton H, 2003, BMJ-BRIT MED J, V327, P101, DOI 10.1136/bmj.327.7406.101; Tuckett D., 1985, M EXPERTS APPROACH S; ZBIGNIEW H, 1983, REPORT BESIEGED CITY	16	23	23	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					856	858		10.1136/bmj.327.7419.856	http://dx.doi.org/10.1136/bmj.327.7419.856			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551104	Green Published			2022-12-28	WOS:000185921200026
J	Eisenberger, NI; Lieberman, MD; Williams, KD				Eisenberger, NI; Lieberman, MD; Williams, KD			Does rejection hurt? An fMRI study of social exclusion	SCIENCE			English	Article							ANTERIOR CINGULATE CORTEX; BRAIN ACTIVITY; PAIN; CONNECTIONS; ACTIVATION; RESPONSES; MONKEYS; NETWORK	A neuroimaging study examined the neural correlates of social exclusion and tested the hypothesis that the brain bases of social pain are similar to those of physical pain. Participants were scanned while playing a virtual ball-tossing game in which they were ultimately excluded. Paralleling results from physical pain studies, the anterior cingulate cortex (ACC) was more active during exclusion than during inclusion and correlated positively with self-reported distress. Right ventral prefrontal cortex (RVPFC) was active during exclusion and correlated negatively with self-reported distress. ACC changes mediated the RVPFC-distress correlation, suggesting that RVPFC regulates the distress of social exclusion by disrupting ACC activity.	Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA; Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia	University of California System; University of California Los Angeles; Macquarie University	Eisenberger, NI (corresponding author), Univ Calif Los Angeles, Dept Psychol, Franz Hall, Los Angeles, CA 90095 USA.	neisenbe@ucla.edu	Li, Chong/F-4265-2015; Lieberman, Matthew/ABD-8197-2020; Tudusciuc, Oana/C-1339-2011; Williams, Kipling D/B-2620-2012	Lieberman, Matthew/0000-0002-4447-7359; 	NATIONAL INSTITUTE OF MENTAL HEALTH [R21MH066709] Funding Source: NIH RePORTER; NIMH NIH HHS [R21MH66709-01] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Brown JL, 2003, PSYCHOSOM MED, V65, P276, DOI 10.1097/01.PSY.0000030388.62434.46; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Carmichael ST, 1995, J COMP NEUROL, V363, P615, DOI 10.1002/cne.903630408; Carter CS, 2000, P NATL ACAD SCI USA, V97, P1944, DOI 10.1073/pnas.97.4.1944; Cavada C, 2000, CEREB CORTEX, V10, P220, DOI 10.1093/cercor/10.3.220; FOLTZ EL, 1962, J NEUROSURG, V19, P89, DOI 10.3171/jns.1962.19.2.0089; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Hariri AR, 2000, NEUROREPORT, V11, P43, DOI 10.1097/00001756-200001170-00009; Kimbrell TA, 1999, BIOL PSYCHIAT, V46, P454, DOI 10.1016/S0006-3223(99)00103-1; Leary M.R., 2001, HURT FEELINGS NEGLEC; LIEBERMAN ML, UNPUB; Lorberbaum JP, 1999, DEPRESS ANXIETY, V10, P99, DOI 10.1002/(SICI)1520-6394(1999)10:3<99::AID-DA2>3.0.CO;2-#; MACLEAN PD, 1988, BRAIN RES, V450, P111, DOI 10.1016/0006-8993(88)91550-8; MURPHY MR, 1981, SCIENCE, V213, P459, DOI 10.1126/science.7244642; Nelson EE, 1998, NEUROSCI BIOBEHAV R, V22, P437, DOI 10.1016/S0149-7634(97)00052-3; PANKSEPP J, 1998, AFFECTIVE NEUROSCIEC; Petrovic P, 2002, SCIENCE, V295, P1737, DOI 10.1126/science.1067176; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; Sawamoto N, 2000, J NEUROSCI, V20, P7438; Small DM, 2001, BRAIN, V124, P1720, DOI 10.1093/brain/124.9.1720; Williams KD, 2000, J PERS SOC PSYCHOL, V79, P748, DOI 10.1037/0022-3514.79.5.748; ZADRO L, IN PRESS RESPONDING; Zhang YQ, 1997, PAIN, V72, P127, DOI 10.1016/S0304-3959(97)00025-0	23	2170	2227	13	483	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					290	292		10.1126/science.1089134	http://dx.doi.org/10.1126/science.1089134			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	730HT	14551436				2022-12-28	WOS:000185825900043
J	Gillett, NP; Thompson, DWJ				Gillett, NP; Thompson, DWJ			Simulation of recent Southern Hemisphere climate change	SCIENCE			English	Article							OZONE DEPLETION; ANNULAR MODES; STRATOSPHERE; CIRCULATION; VARIABILITY; WEATHER; TRENDS; GCM	Recent observations indicate that climate change over the high latitudes of the Southern Hemisphere is dominated by a strengthening of the circumpolar westerly flow that extends from the surface to the stratosphere. Here we demonstrate that the seasonality, structure, and amplitude of the observed climate trends are simulated in a state-of-the-art atmospheric model run with high vertical resolution that is forced solely by prescribed stratospheric ozone depletion. The results provide evidence that anthropogenic emissions of ozone-depleting gases have had a distinct impact on climate not only at stratospheric levels but at Earth's surface as well.	Univ Victoria, Sch Earth & Ocean Sci, Victoria, BC V8W 3P6, Canada; Colorado State Univ, Dept Atmospher Sci, Ft Collins, CO 80523 USA	University of Victoria; Colorado State University	Gillett, NP (corresponding author), Univ Victoria, Sch Earth & Ocean Sci, POB 3055, Victoria, BC V8W 3P6, Canada.	gillett@uvic.ca	Thompson, David W J/F-9627-2012	Thompson, David W J/0000-0002-5413-4376				Baldwin MP, 2003, SCIENCE, V301, P317, DOI 10.1126/science.1085688; Baldwin MP, 1999, J GEOPHYS RES-ATMOS, V104, P30937, DOI 10.1029/1999JD900445; Baldwin MP, 2001, SCIENCE, V294, P581, DOI 10.1126/science.1063315; BOVILLE BA, 1984, J ATMOS SCI, V41, P1132, DOI 10.1175/1520-0469(1984)041<1132:TIOTPN>2.0.CO;2; Fyfe JC, 1999, GEOPHYS RES LETT, V26, P1601, DOI 10.1029/1999GL900317; Gillett NP, 2003, Q J ROY METEOR SOC, V129, P947, DOI 10.1256/qj.02.102; Hartmann DL, 1998, J ATMOS SCI, V55, P1303, DOI 10.1175/1520-0469(1998)055<1303:WDZFVI>2.0.CO;2; Hoerling MP, 2001, SCIENCE, V292, P90, DOI 10.1126/science.1058582; HURRELL JW, 1994, TELLUS A, V46, P325, DOI 10.1034/j.1600-0870.1994.t01-1-00007.x; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Karoly D. J., 1990, Tellus, Series A (Dynamic Meteorology and Oceanography), V42A, P41, DOI 10.1034/j.1600-0870.1990.00005.x; Kidson JW, 1988, J CLIMATE, V1, P1177, DOI 10.1175/1520-0442(1988)001<1177:IVITSH>2.0.CO;2; KIEHL JT, 1988, J ATMOS SCI, V45, P1798, DOI 10.1175/1520-0469(1988)045<1798:TRDROA>2.0.CO;2; Kindem IT, 2001, GEOPHYS RES LETT, V28, P1547, DOI 10.1029/2000GL012552; Kushner PJ, 2001, J CLIMATE, V14, P2238, DOI 10.1175/1520-0442(2001)014<0001:SHACRT>2.0.CO;2; LAL M, 1987, Tellus Series B Chemical and Physical Meteorology, V39, P326, DOI 10.1111/j.1600-0889.1987.tb00103.x; LI DM, 1995, 35 UK U GLOB ATM MOD; Limpasuvan V, 2000, J CLIMATE, V13, P4414, DOI 10.1175/1520-0442(2000)013<4414:WMAMOC>2.0.CO;2; Lorenz DJ, 2001, J ATMOS SCI, V58, P3312, DOI 10.1175/1520-0469(2001)058<3312:EZFFIT>2.0.CO;2; MAHLMAN JD, 1994, J ATMOS SCI, V51, P489, DOI 10.1175/1520-0469(1994)051<0489:TRADEO>2.0.CO;2; Polvani LM, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014284; Ramaswamy V, 2001, REV GEOPHYS, V39, P71, DOI 10.1029/1999RG000065; Randel WJ, 1999, GEOPHYS RES LETT, V26, P3089, DOI 10.1029/1999GL900615; Randel WJ, 1999, J CLIMATE, V12, P1467, DOI 10.1175/1520-0442(1999)012<1467:COTAAA>2.0.CO;2; Sexton DMH, 2001, GEOPHYS RES LETT, V28, P3697, DOI 10.1029/2001GL013376; SHINE KP, 1986, GEOPHYS RES LETT, V13, P1331, DOI 10.1029/GL013i012p01331; THOMPSON DH, UNPUB; Thompson DWJ, 2002, SCIENCE, V296, P895, DOI 10.1126/science.1069270; Thompson DWJ, 2000, J CLIMATE, V13, P1000, DOI 10.1175/1520-0442(2000)013<1018:AMITEC>2.0.CO;2; Vaughan DG, 2001, SCIENCE, V293, P1777, DOI 10.1126/science.1065116; Waugh DW, 1999, J GEOPHYS RES-ATMOS, V104, P27191, DOI 10.1029/1999JD900795; Zhou ST, 2000, GEOPHYS RES LETT, V27, P1123, DOI 10.1029/1999GL011018	32	459	482	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					273	275		10.1126/science.1087440	http://dx.doi.org/10.1126/science.1087440			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551433				2022-12-28	WOS:000185825900038
J	Karoly, DJ				Karoly, DJ			Ozone and climate change	SCIENCE			English	Editorial Material									Univ Oklahoma, Sch Meteorol, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Karoly, DJ (corresponding author), Univ Oklahoma, Sch Meteorol, Norman, OK 73019 USA.	dkaroly@ou.edu	Karoly, David J/C-8262-2011	Karoly, David J/0000-0002-8671-2994				Baldwin MP, 2003, SCIENCE, V301, P317, DOI 10.1126/science.1085688; CAL W, 2003, J CLIMATOL, V16, P1525; Fyfe JC, 2003, J CLIMATE, V16, P2802, DOI 10.1175/1520-0442(2003)016<2802:ESHCHO>2.0.CO;2; Gillett NP, 2003, SCIENCE, V302, P273, DOI 10.1126/science.1087440; HOUGHTON JT, 2001, CLIMATE CHANGE 2001; Indian Ocean Climate Initiative Panel, 2002, CLIM VAR CHANG S W W; Thompson DWJ, 2002, SCIENCE, V296, P895, DOI 10.1126/science.1069270	7	34	37	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					236	237		10.1126/science.1090851	http://dx.doi.org/10.1126/science.1090851			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551423				2022-12-28	WOS:000185825900025
J	Lowenberg, B				Lowenberg, B			Minimal residual disease in chronic myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Erasmus Univ, Med Ctr, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Lowenberg, B (corresponding author), Erasmus Univ, Med Ctr, Rotterdam, Netherlands.								0	48	49	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	2003	349	15					1399	1401		10.1056/NEJMp038130	http://dx.doi.org/10.1056/NEJMp038130			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729JF	14534331				2022-12-28	WOS:000185769500001
J	Walker, MP; Brakefield, T; Hobson, JA; Stickgold, R				Walker, MP; Brakefield, T; Hobson, JA; Stickgold, R			Dissociable stages of human memory consolidation and reconsolidation	NATURE			English	Article							PROTEIN-SYNTHESIS; MOTOR MEMORY; SLEEP; SKILL; NEUROSCIENCE; REACTIVATION; HYPOTHESIS; SYSTEMS; SHOCK	Historically, the term 'memory consolidation' refers to a process whereby a memory becomes increasingly resistant to interference from competing or disrupting factors with the continued passage of time(1). Recent findings regarding the learning of skilled sensory and motor tasks ('procedural learning') have refined this definition, suggesting that consolidation can be more strictly determined by time spent in specific brain states such as wake, sleep or certain stages of sleep(2-8). There is also renewed interest(9) in the possibility that recalling or 'reactivating' a previously consolidated memory renders it once again fragile and susceptible to interference(10-12), therefore requiring periods of reconsolidation(13-15). Using a motor skill finger-tapping task, here we provide evidence for at least three different stages of human motor memory processing after initial acquisition. We describe the unique contributions of wake and sleep in the development of different forms of consolidation, and show that waking reactivation can turn a previously consolidated memory back into a labile state requiring subsequent reconsolidation.	Harvard Univ, Sch Med, Dept Psychiat, Lab Neurophysiol,Massachusetts Mental Hlth Ctr, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Walker, MP (corresponding author), Harvard Univ, Sch Med, Dept Psychiat, Lab Neurophysiol,Massachusetts Mental Hlth Ctr, 74 Fenwood Rd, Boston, MA 02115 USA.	mwalker@hms.harvard.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH092638] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BrashersKrug T, 1996, NATURE, V382, P252, DOI 10.1038/382252a0; Debiec J, 2002, NEURON, V36, P527, DOI 10.1016/S0896-6273(02)01001-2; Fischer S, 2002, P NATL ACAD SCI USA, V99, P11987, DOI 10.1073/pnas.182178199; Goedert KM, 2002, LEARN MEMORY, V9, P279, DOI 10.1101/lm.50102; GORDON WC, 1973, PHYSIOL BEHAV, V10, P1071, DOI 10.1016/0031-9384(73)90190-X; Hobson JA, 2002, NAT REV NEUROSCI, V3, P679, DOI 10.1038/nrn915; KARNI A, 1994, SCIENCE, V265, P679, DOI 10.1126/science.8036518; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; Milekic MH, 2002, NEURON, V36, P521, DOI 10.1016/S0896-6273(02)00976-5; MISANIN JR, 1968, SCIENCE, V160, P554, DOI 10.1126/science.160.3827.554; Muellbacher W, 2002, NATURE, V415, P640, DOI 10.1038/nature712; Nader K, 2003, TRENDS NEUROSCI, V26, P65, DOI 10.1016/S0166-2236(02)00042-5; Nader K, 2000, NATURE, V406, P722, DOI 10.1038/35021052; Pace-Schott EF, 2002, NAT REV NEUROSCI, V3, P591, DOI 10.1038/nrn895; RUBIN RD, 1976, CAN PSYCHIAT ASSOC J, V21, P87, DOI 10.1177/070674377602100205; SMITH C, 1994, J SLEEP RES, V3, P206, DOI 10.1111/j.1365-2869.1994.tb00133.x; Stickgold R, 2000, NAT NEUROSCI, V3, P1237, DOI 10.1038/81756; Walker MP, 2003, LEARN MEMORY, V10, P275, DOI 10.1101/lm.58503; Walker MP, 2002, NEURON, V35, P205, DOI 10.1016/S0896-6273(02)00746-8	19	720	734	3	147	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 9	2003	425	6958					616	620		10.1038/nature01930	http://dx.doi.org/10.1038/nature01930			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534587				2022-12-28	WOS:000185801000037
J	Jarvis, S; Glinianaia, SV; Torrioli, MG; Platt, MJ; Miceli, M; Jouk, PS; Johnson, A; Hutton, J; Hemming, K; Hagberg, G; Dolk, H; Chalmers, J				Jarvis, S; Glinianaia, SV; Torrioli, MG; Platt, MJ; Miceli, M; Jouk, PS; Johnson, A; Hutton, J; Hemming, K; Hagberg, G; Dolk, H; Chalmers, J		SCPE Collaboration European Cerebr	Cerebral palsy and intrauterine growth in single births: European collaborative study	LANCET			English	Article							GESTATIONAL-AGE; PERINATAL-MORTALITY; WEIGHT STANDARD; FETAL-GROWTH; ASSOCIATION; CHILDREN; INFANTS; CURVES	Background Cerebral palsy seems to be more common in term babies whose birthweight is low for their gestational age at delivery, but past analyses have been hampered by small datasets and Z-score calculation methods. Methods We compared data from ten European registers for 4503 singleton children with cerebral palsy born between 1976 and 1990 with the number of births in each study population. Weight and gestation of these children were compared with reference standards for the normal spread of gestation and weight-for-gestational age at birth. Findings Babies of 32-42 weeks' gestation with a birthweight for gestational age below the 10th percentile (using fetal growth standards) were 4-6 times more likely to have cerebral palsy than were children in a reference band between the 25th and 75th percentiles. In children with a weight above the 97th percentile, the increased risk was smaller (from 1.6 to 3.1), but still significant. Those with a birthweight about 1 SD above average always had the lowest risk of cerebral palsy. A similar pattern was seen in those with unilateral or bilateral spasticity, as in those with a dyskinetic or ataxic disability. In babies of less than 32 weeks' gestation, the relation between weight and risk was less clear. Interpretation The risk of cerebral palsy, like the risk of perinatal death, is lowest in babies who are of above average weight-for-gestation at birth, but risk rises when weight is well above normal as well as when it is well below normal. Whether deviant growth is the cause or a consequence of the disability remains to be determined.	Univ Newcastle, Inst Child Hlth, Newcastle Upon Tyne, Tyne & Wear, England; Univ Newcastle, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne, Tyne & Wear, England; Univ Sacred Heart, I-00168 Rome, Italy; Univ Liverpool, Dept Publ Hlth, Liverpool L69 3BX, Merseyside, England; Agenzia Sanita Pubbl Reg Lazio, Rome, Italy; CHU Grenoble, F-38043 Grenoble, France; Univ Oxford, Natl Perinatal Epidemiol Unit, Oxford, England; Univ Warwick, Dept Stat, Coventry CV4 7AL, W Midlands, England; Univ Gothenburg, Queen Silvia Childrens Hosp, Gothenburg, Sweden; Univ Ulster, Fac Life & Hlth Sci, Jordanstown, North Ireland; Natl Hlth Serv Scotland, Informat & Stat Div, Edinburgh, Midlothian, Scotland	Newcastle University - UK; Newcastle University - UK; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Liverpool; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); University of Oxford; University of Warwick; Queen Silvia Children's Hospital; University of Gothenburg; Ulster University; NHS National Services Scotland	Jarvis, S (corresponding author), Univ Newcastle Upon Tyne, Royal Victoria Infirm, Sch Clin Med Sci Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.		Jouk, Pierre-Simon/M-7367-2014; Jarvis, Stephen/AAT-3127-2021; Jouk, Pierre-Simon/AAB-5262-2022; Hemming, karla/AAB-3391-2021; Platt, MJ/K-4588-2012	Jarvis, Stephen/0000-0002-1249-2167; Jouk, Pierre-Simon/0000-0001-8301-320X; Hemming, karla/0000-0002-2226-6550; Platt, MJ/0000-0002-9372-9575; Johnson, Anne/0000-0003-1330-7100				BLAIR E, 1990, AM J OBSTET GYNECOL, V162, P229, DOI 10.1016/0002-9378(90)90856-3; BLAIR E, 1992, EARLY HUM DEV, V28, P91, DOI 10.1016/0378-3782(92)90104-O; Bonellie SR, 1996, STAT MED, V15, P2657; Cans C, 2000, DEV MED CHILD NEUROL, V42, P816, DOI 10.1111/j.1469-8749.2000.tb00695.x; ELLENBERG JH, 1979, AM J DIS CHILD, V133, P1044, DOI 10.1001/archpedi.1979.02130100068014; FOLEY J, 1995, EARLY HUM DEV, V40, P145, DOI 10.1016/0378-3782(94)01602-L; GARDOSI J, 1995, ULTRASOUND OBST GYN, V6, P168, DOI 10.1046/j.1469-0705.1995.06030168.x; GOLDSTEIN H, 1976, BIOL HUMAN FETAL GRO, V15; GOULD J, 1986, HUMAN GROWTH COMPREH, V1; Grether JK, 1997, JAMA-J AM MED ASSOC, V278, P207, DOI 10.1001/jama.278.3.207; HADLOCK FP, 1991, RADIOLOGY, V181, P129, DOI 10.1148/radiology.181.1.1887021; JARVIS SN, 1985, ARCH DIS CHILD, V60, P1113, DOI 10.1136/adc.60.12.1113; KALLEN B, 1995, EUR J EPIDEMIOL, V11, P601, DOI 10.1007/BF01719316; KYLLERMAN M, 1982, ACTA PAEDIATR SCAND, V71, P543, DOI 10.1111/j.1651-2227.1982.tb09472.x; Lackman F, 2001, AM J OBSTET GYNECOL, V184, P946, DOI 10.1067/mob.2001.111719; Liu JM, 2000, INT J EPIDEMIOL, V29, P292, DOI 10.1093/ije/29.2.292; Marsal K, 1996, ACTA PAEDIATR, V85, P843, DOI 10.1111/j.1651-2227.1996.tb14164.x; Mongelli M, 2000, CURR OPIN OBSTET GYN, V12, P111, DOI 10.1097/00001703-200004000-00009; MORRIS J, 1989, STAT CONFIDENCE CONF; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; PATTERSON RM, 1986, OBSTET GYNECOL, V68, P459; Pharoah POD, 1997, DEV MED CHILD NEUROL, V39, P292; Skjaerven R, 2000, ACTA OBSTET GYN SCAN, V79, P440, DOI 10.1034/j.1600-0412.2000.079006440.x; STANLEY R, 2000, CEREBRAL PALSIES EPI; Thorarensen O, 1997, ANN NEUROL, V42, P372, DOI 10.1002/ana.410420316; Tin W, 1997, BRIT J OBSTET GYNAEC, V104, P180, DOI 10.1111/j.1471-0528.1997.tb11041.x; Topp M, 1996, EARLY HUM DEV, V44, P27, DOI 10.1016/0378-3782(96)82791-5; UVEBRANT P, 1992, ACTA PAEDIATR, V81, P407, DOI 10.1111/j.1651-2227.1992.tb12259.x; WILCOX AJ, 1983, INT J EPIDEMIOL, V12, P319, DOI 10.1093/ije/12.3.319; WOLSTENHOLME J, 1994, PRENATAL DIAG, V14, P345, DOI 10.1002/pd.1970140505	30	240	245	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 4	2003	362	9390					1106	1111		10.1016/S0140-6736(03)14466-2	http://dx.doi.org/10.1016/S0140-6736(03)14466-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728HA	14550698				2022-12-28	WOS:000185710700010
J	Schofer, J; Schluter, M; Gershlick, AH; Wijns, W; Garcia, E; Schampaert, E; Breithardt, G				Schofer, J; Schluter, M; Gershlick, AH; Wijns, W; Garcia, E; Schampaert, E; Breithardt, G		E-SIRIUS Investigators	Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS)	LANCET			English	Article							INTRACORONARY BETA-RADIATION; BALLOON ANGIOPLASTY; INTRAVASCULAR ULTRASOUND; RESTENOSIS; IMPLANTATION; INHIBIT; DISEASE; RECURRENCE; PLACEMENT; THERAPY	Background Sirolimus-eluting stents have been developed to prevent restenosis in the treatment of coronary artery disease. We investigated the risk of restenosis with use of sirolimus-eluting stents compared with bare-metal stents to assess possible differences. Methods We enrolled 352 patients in whom one coronary artery required treatment, with diameter 2.5-3.0 mm and esion length 15-32 mm. We randomly assigned patients sirolimus-eluting stents (n=175) or bare-metal stents control, n=177). At 8 months we assessed differences in minimum lumen diameter and binary restenosis within the esion (restenosis of greater than or equal to50% diameter, including 5 mm vessel segments proximal and distal to stented segment). Patients were also followed up for 9 months for major adverse cardiac events. Analysis was by intention to treat. Findings Stent implantation was successful in 100% of sirolimus-stent patients and 99.4% of controls. The mean diameter of treated coronary arteries was 2.55 mm (SD) 0.37) and mean lesion length was 15.0 mm (6.0). Multiple stents were implanted in 170 (48%) patients. At 8 months, minimum lumen diameter was significantly higher with sirolimus-eluting stents than with control stents (2.22 vs L.33 mm, p<0.0001). The rate of binary restenosis was significantly reduced with sirolimus-eluting stents compared with control stents (5.9 vs 42.3%, p=0.0001). Significantly newer patients with sirolimus-eluting stents had major adverse cardiac events at 9 months than did controls (8.0 vs 22.6%, p=0.0002), due mainly to a lower need for target-lesion revascularisations (4.0 vs 20.9%, p<0.0001). Interpretation Sirolimus-eluting stents are better than bareinetal stents for treatment of single long atherosclerotic lesions in a coronary vessel smaller than 3 mm in diameter.	Ctr Cardiol & Vasc Intervent, D-22763 Hamburg, Germany; Glenfield Gen Hosp, Leicester LE3 9QP, Leics, England; Onze Lieve Vrouw Hosp, Aalst, Belgium; Hosp Univ Gregorio Maranon, Madrid, Spain; Hop Sacre Coeur, Montreal, PQ H4J 1C5, Canada; Hosp Univ Munster, Dept Cardiol & Angiol, Munster, Germany	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; General University Gregorio Maranon Hospital; Universite de Montreal; University of Munster	Schofer, J (corresponding author), Ctr Cardiol & Vasc Intervent, Othmarscher Hirchenweg 168, D-22763 Hamburg, Germany.			Wijns, William/0000-0002-7267-4376; Schampaert, Erick/0000-0002-7607-1214				Al Suwaidi J, 2000, JAMA-J AM MED ASSOC, V284, P1828, DOI 10.1001/jama.284.14.1828; Bauters C, 1998, J AM COLL CARDIOL, V31, P1291, DOI 10.1016/S0735-1097(98)00076-X; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; Edelman ER, 1996, CIRCULATION, V94, P1199, DOI 10.1161/01.CIR.94.6.1199; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Hamm CW, 2000, CIRCULATION, V102, P118, DOI 10.1161/01.CIR.102.1.118; Hoffmann R, 1996, CIRCULATION, V94, P1247, DOI 10.1161/01.CIR.94.6.1247; Kastrati A, 1997, J AM COLL CARDIOL, V30, P1428, DOI 10.1016/S0735-1097(97)00334-3; Laham RJ, 1996, J AM COLL CARDIOL, V28, P820, DOI 10.1016/S0735-1097(96)00244-6; Leon MB, 2001, NEW ENGL J MED, V344, P250, DOI 10.1056/NEJM200101253440402; Marx SO, 2001, CIRCULATION, V104, P852, DOI 10.1161/01.CIR.104.8.852; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Serruys PW, 1998, LANCET, V352, P673, DOI 10.1016/S0140-6736(97)11128-X; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Sousa JE, 2001, CIRCULATION, V104, P2007, DOI 10.1161/hc4201.098056; Sousa JE, 2003, CIRCULATION, V107, P2383, DOI 10.1161/01.CIR.0000069331.67148.2F; Teirstein PS, 1997, NEW ENGL J MED, V336, P1697, DOI 10.1056/NEJM199706123362402; Waksman R, 2000, CIRCULATION, V101, P1895, DOI 10.1161/01.CIR.101.16.1895; Waksman R, 2002, LANCET, V359, P551, DOI 10.1016/S0140-6736(02)07741-3	19	722	813	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 4	2003	362	9390					1093	1099		10.1016/S0140-6736(03)14462-5	http://dx.doi.org/10.1016/S0140-6736(03)14462-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728HA	14550694				2022-12-28	WOS:000185710700007
J	Leung, GC; Sicheri, F				Leung, GC; Sicheri, F			A polo match for Plk1	CELL			English	Editorial Material							SUBCELLULAR-LOCALIZATION; CELL-DIVISION; KINASES; DOMAIN; BOX; REGULATORS	New work by Elia et al. in this issue of Cell reveals the molecular basis of phosphopeptide recognition by the polo domain and the domain's dual function to promote substrate recognition by targeting the kinase to subcellular structures and to autoregulate the adjacent protein kinase catalytic domain.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Leung, GC (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Sicheri, Frank/F-8856-2013					Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Song S, 2000, MOL CELL BIOL, V20, P286, DOI 10.1128/MCB.20.1.286-298.2000	11	5	5	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 3	2003	115	1					3	4		10.1016/S0092-8674(03)00761-X	http://dx.doi.org/10.1016/S0092-8674(03)00761-X			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14531994	Bronze			2022-12-28	WOS:000185815500003
J	Bagshawe, A; Taylor, A				Bagshawe, A; Taylor, A			ABC of subfertility - Counselling	BRITISH MEDICAL JOURNAL			English	Review									Guys & St Thomass Assisted Concept Unit, London, England		Bagshawe, A (corresponding author), Guys & St Thomass Assisted Concept Unit, London, England.							[Anonymous], HUMAN FERTILISATION; CAMPION MJ, 1995, WHOS FIT PARENT; READ J, 1995, COUNSELLING FERTILIT	3	6	6	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 1	2003	327	7422					1038	1040		10.1136/bmj.327.7422.1038	http://dx.doi.org/10.1136/bmj.327.7422.1038			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738NE	14593042	Green Published			2022-12-28	WOS:000186294100027
J	Vigod, SN; Bell, CM; Bohnen, JMA				Vigod, SN; Bell, CM; Bohnen, JMA			Privacy of patients' information in hospital lifts: observational study	BRITISH MEDICAL JOURNAL			English	Article									Univ Toronto, St Michaels Hosp, Dept Surg, Toronto, ON M5B 1W8, Canada; Univ Toronto, St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada; Univ Toronto, St Michaels Hosp, Dept Hlth Policy Management & Evalut, Toronto, ON M5B 1W8, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Bohnen, JMA (corresponding author), Univ Toronto, St Michaels Hosp, Dept Surg, 30 Bond St, Toronto, ON M5B 1W8, Canada.		Bell, Chaim/C-4611-2015	Bell, Chaim/0000-0002-3778-9469; Vigod, Simone/0000-0002-2736-9639				Grady C, 1991, J Clin Ethics, V2, P25; Hasman A, 1997, Ugeskr Laeger, V159, P6819; UBEL PA, 1995, AM J MED, V99, P190, DOI 10.1016/S0002-9343(99)80139-9	3	15	15	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 1	2003	327	7422					1024	1025		10.1136/bmj.327.7422.1024	http://dx.doi.org/10.1136/bmj.327.7422.1024			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738NE	14593037	Bronze, Green Published			2022-12-28	WOS:000186294100022
J	Klose, R; Bird, A				Klose, R; Bird, A			MeCP2 repression goes nonglobal	SCIENCE			English	Editorial Material							RETT-SYNDROME; DNA		Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland	University of Edinburgh	Klose, R (corresponding author), Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Kings Bldg, Edinburgh EH9 3JR, Midlothian, Scotland.	a.bird@ed.ac.uk		Bird, Adrian/0000-0002-8600-0372				Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Hutchins AS, 2002, MOL CELL, V10, P81, DOI 10.1016/S1097-2765(02)00564-6; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kriaucionis S, 2003, HUM MOL GENET, V12, pR221, DOI 10.1093/hmg/ddg286; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Stancheva I, 2003, MOL CELL, V12, P425, DOI 10.1016/S1097-2765(03)00276-4; Tudor M, 2002, P NATL ACAD SCI USA, V99, P15536, DOI 10.1073/pnas.242566899; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298	12	52	58	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	2003	302	5646					793	795		10.1126/science.1091762	http://dx.doi.org/10.1126/science.1091762			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593157	Green Submitted			2022-12-28	WOS:000186258000027
J	Rak, A; Pylypenko, O; Durek, T; Watzke, A; Kushnir, S; Brunsveld, L; Waldmann, H; Goody, RS; Alexandrov, K				Rak, A; Pylypenko, O; Durek, T; Watzke, A; Kushnir, S; Brunsveld, L; Waldmann, H; Goody, RS; Alexandrov, K			Structure of Rab GDP-dissociation inhibitor in complex with prenylated YPT1 GTPase	SCIENCE			English	Article							IN-VITRO; PROTEINS; DOMAIN; GERANYLGERANYLTRANSFERASE; GDI1	Rab/Ypt guanosine triphosphatases (GTPases) represent a family of key membrane traffic regulators in eukaryotic cells whose function is governed by the guanosine diphosphate (GDP) dissociation inhibitor (RabGDI). Using a combination of chemical synthesis and protein engineering, we generated and crystallized the monoprenylated Ypt1: RabGDI complex. The structure of the complex was solved to 1.5 angstrom resolution and provides a structural basis for the ability of RabGDI to inhibit the release of nucleotide by Rab proteins. Isoprenoid binding requires a conformational change that opens a cavity in the hydrophobic core of its domain II. Analysis of the structure provides a molecular basis for understanding a RabGDI mutant that causes mental retardation in humans.	Max Planck Inst Mol Physiol, Dept Phys Biochem, D-44227 Dortmund, Germany; Max Planck Inst Mol Physiol, Dept Biol Chem, D-44227 Dortmund, Germany; Max Planck Inst Med Res, Dept Biomol Mech, D-69120 Heidelberg, Germany; Univ Dortmund, Dept Organ Chem, D-44227 Dortmund, Germany	Max Planck Society; Max Planck Society; Max Planck Society; Dortmund University of Technology	Alexandrov, K (corresponding author), Max Planck Inst Mol Physiol, Dept Phys Biochem, Otto Hahn Str 11, D-44227 Dortmund, Germany.		Alexandrov, Kirill/A-5830-2013; Durek, Thomas/I-8715-2014; Waldmann, Herbert/B-7406-2017; Goody, Roger S/J-8845-2014	Alexandrov, Kirill/0000-0002-0957-6511; Durek, Thomas/0000-0003-0686-227X; Waldmann, Herbert/0000-0002-9606-7247; Goody, Roger S/0000-0002-0772-0444; Brunsveld, Luc/0000-0001-5675-511X; Pylypenko, Olena/0000-0001-7073-5238				Alexandrov K, 2002, J AM CHEM SOC, V124, P5648, DOI 10.1021/ja017799e; Alory C, 2001, TRAFFIC, V2, P532, DOI 10.1034/j.1600-0854.2001.20803.x; An Y, 2003, STRUCTURE, V11, P347, DOI 10.1016/S0969-2126(03)00034-0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; Constantinescu AT, 2002, STRUCTURE, V10, P569, DOI 10.1016/S0969-2126(02)00737-2; D'Adamo P, 1998, NAT GENET, V19, P134, DOI 10.1038/487; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; Gilbert PM, 2001, J BIOL CHEM, V276, P8014, DOI 10.1074/jbc.M008845200; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; HORIUCHI H, 1995, METHOD ENZYMOL, V257, P9; Kalinin A, 2001, PROTEIN EXPRES PURIF, V22, P84, DOI 10.1006/prep.2001.1423; Luan P, 2000, TRAFFIC, V1, P270, DOI 10.1034/j.1600-0854.2000.010309.x; Ludolph B, 2002, J AM CHEM SOC, V124, P5954, DOI 10.1021/ja025768t; Muir TW, 2003, ANNU REV BIOCHEM, V72, P249, DOI 10.1146/annurev.biochem.72.121801.161900; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Pylypenko O, 2003, MOL CELL, V11, P483, DOI 10.1016/S1097-2765(03)00044-3; RAK A, UNPUB; Ricard CS, 2001, GENESIS, V31, P17, DOI 10.1002/gene.10000; Sakisaka T, 2002, EMBO J, V21, P6125, DOI 10.1093/emboj/cdf603; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Shen F, 1996, J BIOL CHEM, V271, P3692; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	25	158	163	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					646	650		10.1126/science.1087761	http://dx.doi.org/10.1126/science.1087761			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576435				2022-12-28	WOS:000186119900060
J	Chapman, T				Chapman, T			Seeing is believing	NATURE			English	Article																			0	1	2	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					867	+		10.1038/425867a	http://dx.doi.org/10.1038/425867a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574416	Bronze			2022-12-28	WOS:000186118500051
J	Hypponen, E; Smith, GD; Power, C				Hypponen, E; Smith, GD; Power, C			Effects of grandmothers' smoking in pregnancy on birth weight: intergenerational cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY REVASCULARIZATION; FOLLOW-UP; ANGINA; WHITEHALL; ABNORMALITIES; TRANSMISSION; ASSOCIATION; VARIABILITY; MANAGEMENT; GUIDELINE	Objective To investigate the influences on birth weight of maternal smoking during pregnancy across generations. Design Intergenerational cohort study. Participants Members of the 1958 birth cohort and their offspring and mothers. Setting England, Scotland, and Wales. Main outcome measure Birth weight. Results Information on grandmothers' smoking during pregnancy was available for 9028 singleton offspring of 4302 female cohort members. Assuming heritable transmission through the intergenerational birth weight association, grandmothers' smoking was predicted to result in a 34 g reduction (95% confidence interval - 41 g to - 28 g) in the birth weight of grandchildren. Random effects models showed a negative association between grandmothers' smoking and birth weight of grandchildren (Beta regression coefficient - 24 g, - 50 g to 3 g), but this effect was eliminated after adjustment for maternal smoking (0 g, - 26 g to 26 g). No association was evident among if the offspring of non-smoking mothers G 105; 14 17 g to 46 g), and after adjustment for maternal birth weight and height and body mass index as adults, grandmothers' smoking was positively associated with the birth weight of grandchildren (45 g, 10 g to 80 g). Conclusion Deficits in mothers' birth weight attributable to their mother smoking was not evident in the grandchildren.	Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of London; University College London; University of Bristol	Hypponen, E (corresponding author), Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, 30 Guilford St, London WC1N 1EH, England.	e.hypponen@ich.ucl.ac.uk	Hypponen, Elina/B-2596-2014; Davey Smith, George/A-7407-2013	Hypponen, Elina/0000-0003-3670-9399; Davey Smith, George/0000-0002-1407-8314				Butler N.R., 1963, PERINATAL MORTALITY; BUTLER NR, 1969, PERINATAL PROBLEMS; CLARKE KW, 1994, BRIT HEART J, V71, P38; *CTR LONG STUD I E, 1994, SN3148 CTR LONG STUD; Daviglus ML, 1999, JAMA-J AM MED ASSOC, V281, P530, DOI 10.1001/jama.281.6.530; *DEP HLTH, 2000, NAT SERV RAM COR HEA; Eccles M, 2001, FAM PRACT, V18, P217, DOI 10.1093/fampra/18.2.217; EMANUEL I, 1992, BRIT J OBSTET GYNAEC, V99, P67, DOI 10.1111/j.1471-0528.1992.tb14396.x; FERRI E, 1993, LIFE 33 5 FOLLOW UP; FERRI E, 1993, LIFE 33 5 FOLLOW NAT; FOGELMAN KR, 1988, BRIT MED J, V297, P1233, DOI 10.1136/bmj.297.6658.1233; Gardner K, 1999, BRIT MED J, V319, P418, DOI 10.1136/bmj.319.7207.418; Gibbons RJ, 2003, CIRCULATION, V107, P149, DOI 10.1161/01.CIR.0000047041.66447.29; Hemingway H, 2000, J EPIDEMIOL COMMUN H, V54, P510, DOI 10.1136/jech.54.7.510; Hemingway H, 2001, NEW ENGL J MED, V344, P645, DOI 10.1056/NEJM200103013440906; Hennessy E, 1998, PAEDIATR PERINAT EP, V12, P45, DOI 10.1046/j.1365-3016.1998.0120s1045.x; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; Lake JK, 1997, ARCH DIS CHILD, V77, P376, DOI 10.1136/adc.77.5.376; Lampe FC, 1999, J CLIN EPIDEMIOL, V52, P73, DOI 10.1016/S0895-4356(98)00146-2; Lampe FC, 2001, AM J EPIDEMIOL, V153, P1173, DOI 10.1093/aje/153.12.1173; LAST JM, 1963, LANCET, V2, P28; LUMEY LH, 1994, INT J EPIDEMIOL, V23, P1006, DOI 10.1093/ije/23.5.1006; Macfarlane PW, 1996, J ELECTROCARDIOL, V29, P29, DOI 10.1016/S0022-0736(96)80016-1; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; Martin RM, 2002, HEART, V88, P627, DOI 10.1136/heart.88.6.627; MCCORMICK A, 1995, MORBIDITY STAT GEN P; OUNSTED M, 1986, ANN HUM BIOL, V13, P143, DOI 10.1080/03014468600008281; Pocock SJ, 2000, J AM COLL CARDIOL, V35, P907, DOI 10.1016/S0735-1097(99)00637-3; Power C, 2002, INT J EPIDEMIOL, V31, P413, DOI 10.1093/ije/31.2.413; Price KC, 1999, OBSTET GYNECOL, V94, P128, DOI 10.1016/S0029-7844(99)00269-0; Ramakrishnan U, 1999, J NUTR, V129, p544S, DOI 10.1093/jn/129.2.544S; Richards H, 2000, J EPIDEMIOL COMMUN H, V54, P714, DOI 10.1136/jech.54.9.714; ROSE G, 1968, BRIT J PREV SOC MED, V22, P12; Rose G, 1982, CARDIOVASCULAR SURVE; Sanderson M, 1998, AM J EPIDEMIOL, V147, P136; Stafford M, 1998, J EPIDEMIOL COMMUN H, V52, P353, DOI 10.1136/jech.52.6.353; Stein AD, 2000, HUM BIOL, V72, P641; SUSSER M, 1994, NUTR REV, V52, P84, DOI 10.1111/j.1753-4887.1994.tb01395.x; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; Ware JE, 1993, SF36 HLTH SURVEY MAN	40	27	27	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 18	2003	327	7420					898	900A		10.1136/bmj.327.7420.898	http://dx.doi.org/10.1136/bmj.327.7420.898			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734RV	14563745	Green Published, Bronze			2022-12-28	WOS:000186072100017
J	Schiestl, FP; Peakall, R; Mant, JG; Ibarra, F; Schulz, C; Franke, S; Francke, W				Schiestl, FP; Peakall, R; Mant, JG; Ibarra, F; Schulz, C; Franke, S; Francke, W			The chemistry of sexual deception in an orchid-wasp pollination system	SCIENCE			English	Article							ORGANIC MASS SPECTROMETRY; ATTRACTION; VOLATILES	The "sexually deceptive" orchid Chiloglottis trapeziformis attracts males of its pollinator species, the thynnine wasp Neozeleboria cryptoides, by emitting a unique volatile compound, 2-ethyl-5-propylcyclohexan-1,3-dione, which is also produced by female wasps as a male-attracting sex pheromone.	Univ Hamburg, Inst Organ Chem, D-20146 Hamburg, Germany; Australian Natl Univ, Sch Bot & Zool, Canberra, ACT 0200, Australia	University of Hamburg; Australian National University	Francke, W (corresponding author), Univ Hamburg, Inst Organ Chem, Martin Luther King Pl 6, D-20146 Hamburg, Germany.		Peakall, Rod/C-9623-2009	Peakall, Rod/0000-0001-9407-8404; Schiestl, Florian/0000-0001-7637-6918				ATTYGALLE AB, 1988, ANGEW CHEM INT EDIT, V27, P460, DOI 10.1002/anie.198804601; ATTYGALLE AB, 1994, PURE APPL CHEM, V66, P2323, DOI 10.1351/pac199466102323; Ayasse M, 2003, P ROY SOC B-BIOL SCI, V270, P517, DOI 10.1098/rspb.2002.2271; Bower CC, 1996, AUST J BOT, V44, P15, DOI 10.1071/BT9960015; DAFNI A, 1990, EVOL BIOL, V24, P193; Kullenberg B., 1961, STUDIES OPHRYS POLLI; Mant JG, 2002, EVOLUTION, V56, P888; Pichersky E, 2002, CURR OPIN PLANT BIOL, V5, P237, DOI 10.1016/S1369-5266(02)00251-0; RAGUSO RA, COGNITIVE ECOLOGY PO, p8O; Schiestl FP, 1999, NATURE, V399, P421, DOI 10.1038/20829; Schiestl FP, 2000, J COMP PHYSIOL A, V186, P567, DOI 10.1007/s003590000112; Schiestl FP, 2002, MOLEC METH PLAN ANAL, V21, P173; Stensmyr MC, 2002, NATURE, V420, P625, DOI 10.1038/420625a; VANDEWAL.M, 1967, B SOC CHIM BELG, V76, P111; VANDEWALLE M, 1967, B SOC CHIM BELG, V76, P123; VOGEL S, 1983, ENCY PLANT PHYSL C, V12, P560; Wong BBM, 2002, P ROY SOC B-BIOL SCI, V269, P1529, DOI 10.1098/rspb.2002.2052	17	256	275	2	114	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					437	438		10.1126/science.1087835	http://dx.doi.org/10.1126/science.1087835			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564006				2022-12-28	WOS:000185963200040
J	Deleault, NR; Lucassen, RW; Supattapone, S				Deleault, NR; Lucassen, RW; Supattapone, S			RNA molecules stimulate prion protein conversion	NATURE			English	Article							NUCLEOCAPSID PROTEIN; AMPLIFICATION; HIV-1	Much evidence supports the hypothesis that the infectious agents of prion diseases are devoid of nucleic acid, and instead are composed of a specific infectious protein(1). This protein, PrPSc, seems to be generated by template-induced conformational change of a normally expressed glycoprotein, PrPC (ref. 2). Although numerous studies have established the conversion of PrPC to PrPSc as the central pathogenic event of prion disease, it is unknown whether cellular factors other than PrPC might be required to stimulate efficient PrPSc production. We investigated the biochemical amplification of protease-resistant PrPSc-like protein (PrPres) using a modified version(3) of the protein-misfolding cyclic amplification method(4). Here we report that stoichiometric transformation of PrPC to PrPres in vitro requires specific RNA molecules. Notably, whereas mammalian RNA preparations stimulate in vitro amplification of PrPres, RNA preparations from invertebrate species do not. Our findings suggest that host-encoded stimulatory RNA molecules may have a role in the pathogenesis of prion disease. They also provide a practical approach to improve the sensitivity of diagnostic techniques based on PrPres amplification.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Supattapone, S (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.							BANKS GR, 1974, EUR J BIOCHEM, V47, P499, DOI 10.1111/j.1432-1033.1974.tb03718.x; Caughey B, 1999, METHOD ENZYMOL, V309, P122; Chapon C, 1997, RNA, V3, P1337; Cordeiro Y, 2001, J BIOL CHEM, V276, P49400, DOI 10.1074/jbc.M106707200; Derrington E, 2002, CR BIOL, V325, P17, DOI 10.1016/S1631-0691(02)01388-4; Gabus C, 2001, J BIOL CHEM, V276, P19301, DOI 10.1074/jbc.M009754200; Gabus C, 2001, J MOL BIOL, V307, P1011, DOI 10.1006/jmbi.2001.4544; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; LOCKARD RE, 1981, NUCLEIC ACIDS RES, V9, P5125, DOI 10.1093/nar/9.19.5125; Lucassen R, 2003, BIOCHEMISTRY-US, V42, P4127, DOI 10.1021/bi027218d; Moscardini M, 2002, J MOL BIOL, V318, P149, DOI 10.1016/S0022-2836(02)00092-X; Nandi PK, 2002, J MOL BIOL, V322, P153, DOI 10.1016/S0022-2836(02)00750-7; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1999, PRION BIOL DIS; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0	16	411	438	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					717	720		10.1038/nature01979	http://dx.doi.org/10.1038/nature01979			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562104				2022-12-28	WOS:000185924500042
J	Machens, A; Niccoli-Sire, P; Hoegel, J; Frank-Raue, K; van Vroonhoven, TJ; Roeher, HD; Wahl, RA; Lamesch, P; Raue, F; Conte-Devolx, B; Dralle, H				Machens, A; Niccoli-Sire, P; Hoegel, J; Frank-Raue, K; van Vroonhoven, TJ; Roeher, HD; Wahl, RA; Lamesch, P; Raue, F; Conte-Devolx, B; Dralle, H		EUROMEN Study Grp	Early malignant progression of hereditary medullary thyroid cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEOPLASIA TYPE 2A; C-CELL HYPERPLASIA; RET PROTOONCOGENE; PROPHYLACTIC THYROIDECTOMY; HIRSCHSPRUNGS-DISEASE; TRANSGENIC MICE; POINT MUTATION; MEN 2A; CARCINOMA; PHENOTYPE	BACKGROUND: An age-related progression from C-cell hyperplasia to medullary thyroid carcinoma is associated with various germ-line mutations in the rearranged during transfection (RET) proto-oncogene that could be used to identify the optimal time for prophylactic surgery. METHODS: In this European multicenter study conducted from July 1993 to February 2001, we enrolled patients who had a RET point mutation in the germ line, were 20 years of age or younger, were asymptomatic, and had undergone total thyroidectomy after confirmation of the RET mutation. Exclusion criteria were medullary thyroid carcinomas of more than 10 mm in greatest dimension and distant metastasis. RESULTS: Altogether, 207 patients from 145 families were identified. There was a significant age-related progression from C-cell hyperplasia to medullary thyroid carcinoma and, ultimately, nodal metastasis in patients whose RET mutations were grouped according to the extracellular- and intracellular-domain codons affected and in those with the codon 634 genotype. No lymph-node metastases were noted in patients younger than 14 years of age. The age-related penetrance was unaffected by the type of amino acid substitution encoded by the various codon 634 mutations. The codon-specific differences in the age at presentation of cancer and the familial rates of concomitant adrenal and parathyroid involvement suggest that the risk of progression was based on the transforming potential of the individual RET mutation. CONCLUSIONS: These data provide initial guidelines for the timing of prophylactic thyroidectomy in asymptomatic carriers of RET gene mutations.	Univ Halle Wittenberg, Klin Allgemein Viszeral & Gefasschirurg, D-06097 Halle An Der Saale, Saale, Germany; Ctr Hosp Reg & Univ Marseille, Serv Endocrinol & Malad Metab, Marseille, France; Univ Ulm, Abt Biometrie & Med Dokumentat, Ulm, Germany; Endokrinol Gemeinschaftspraxis, Heidelberg, Germany; Univ Utrecht Hosp, Dept Surg, Utrecht, Netherlands; Univ Dusseldorf, Klin Allgemeine & Unfallchirurg, D-4000 Dusseldorf, Germany; Burgerhosp Frankfurt Main, Chirurg Klin, Frankfurt, Germany; Univ Leipzig, Chirurg Klin, Leipzig, Germany; Univ Leipzig, Poliklin Abdominal Transplantat & Gefasschirurg, Leipzig, Germany	Martin Luther University Halle Wittenberg; UDICE-French Research Universities; Aix-Marseille Universite; Ulm University; Utrecht University; Utrecht University Medical Center; Heinrich Heine University Dusseldorf; Leipzig University; Leipzig University	Machens, A (corresponding author), Univ Halle Wittenberg, Klin Allgemein Viszeral & Gefasschirurg, Ernst Grube Str 40, D-06097 Halle An Der Saale, Saale, Germany.	gensurg@medizin.uni-halle.de	Dralle, Henning/ABD-4454-2020; Raue, Friedhelm/ABD-6150-2021; Raue, Friedhelm/AAC-4405-2020	Raue, Friedhelm/0000-0002-7700-1648; 				Acton DS, 2000, ONCOGENE, V19, P3121, DOI 10.1038/sj.onc.1203648; Berndt I, 1998, J CLIN ENDOCR METAB, V83, P770, DOI 10.1210/jc.83.3.770; Brandi ML, 2001, J CLIN ENDOCR METAB, V86, P5658, DOI 10.1210/jc.86.12.5658; BROWN KS, 1998, ENCY BIOSTATISTICS, V1, P146; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; Decker RA, 1997, CANCER, V80, P557, DOI 10.1002/(SICI)1097-0142(19970801)80:3+<557::AID-CNCR5>3.0.CO;2-6; Diaz-Cano SJ, 2001, J CLIN ENDOCR METAB, V86, P3948, DOI 10.1210/jc.86.8.3948; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Dralle H, 1998, WORLD J SURG, V22, P744, DOI 10.1007/s002689900463; Eng C, 1996, NEW ENGL J MED, V335, P943, DOI 10.1056/NEJM199609263351307; ENG C, 1995, ONCOGENE, V10, P509; Feldman GL, 2000, SURGERY, V128, P93, DOI 10.1067/msy.2000.107103; Fitze G, 2002, ANN SURG, V236, P570, DOI 10.1097/00000658-200211000-00006; Frohnauer MK, 2000, SURGERY, V128, P1052, DOI 10.1067/msy.2000.11/6/111080; Grosfeld F J, 1996, Oncology (Williston Park), V10, P141; Grosfeld FJ, 1996, ONCOLOGY HUNTINGT, V10, P141; Grosfeld FJ, 1996, ONCOLOGY HUNTINGT, V10, P141; Hansen HS, 2000, CANCER-AM CANCER SOC, V89, P863, DOI 10.1002/1097-0142(20000815)89:4<863::AID-CNCR19>3.0.CO;2-Z; Hofstra RMW, 1997, J CLIN ENDOCR METAB, V82, P4176, DOI 10.1210/jc.82.12.4176; Ito S, 1997, CANCER RES, V57, P2870; JACKSON CE, 1973, ANN INTERN MED, V78, P845, DOI 10.7326/0003-4819-78-6-845; Kawai K, 2000, CANCER RES, V60, P5254; Kitamura Y, 1997, ONCOGENE, V14, P3103, DOI 10.1038/sj.onc.1201102; KRAMER CY, 1956, BIOMETRICS, V12, P307, DOI 10.2307/3001469; Krueger JE, 2000, AM J SURG PATHOL, V24, P853, DOI 10.1097/00000478-200006000-00011; LIPS CJM, 1994, NEW ENGL J MED, V331, P828, DOI 10.1056/NEJM199409293311302; Machens A, 2001, J CLIN ENDOCR METAB, V86, P1104, DOI 10.1210/jc.86.3.1104; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Niccoli-Sire P, 2001, J CLIN ENDOCR METAB, V86, P3746, DOI 10.1210/jc.86.8.3746; O'Keeffe DA, 1998, IRISH J MED SCI, V167, P226, DOI 10.1007/BF02937418; Routledge R, 1998, ENCY BIOSTATISTICS, V2, P1519; Russo A, 2000, ANTICANCER RES, V20, P4841; Sanso GE, 2002, CANCER, V94, P323, DOI 10.1002/cncr.10228; Sasaki Y, 2001, EUR J SURG, V167, P467; Schuffenecker I, 1997, AM J HUM GENET, V60, P233; Simon S, 2002, J PEDIATR SURG, V37, P897, DOI 10.1053/jpsu.2002.32906; Smith-Hicks CL, 2000, EMBO J, V19, P612, DOI 10.1093/emboj/19.4.612; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; van Heurn LWE, 1999, J PEDIATR SURG, V34, P568, DOI 10.1016/S0022-3468(99)90075-1; WELLS SA, 1994, ANN SURG, V220, P237, DOI 10.1097/00000658-199409000-00002; WOLFE HJ, 1973, NEW ENGL J MED, V289, P437, DOI 10.1056/NEJM197308302890901	42	354	377	2	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 16	2003	349	16					1517	1525		10.1056/NEJMoa012915	http://dx.doi.org/10.1056/NEJMoa012915			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	731ZM	14561794				2022-12-28	WOS:000185916400006
J	Wellems, TE; Miller, LH				Wellems, TE; Miller, LH			Two worlds of malaria	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NIAID, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Wellems, TE (corresponding author), NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000241, Z01AI000483, Z01AI000241, ZIAAI000483] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))			0	43	45	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 16	2003	349	16					1496	1498		10.1056/NEJMp038127	http://dx.doi.org/10.1056/NEJMp038127			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	731ZM	14561790				2022-12-28	WOS:000185916400002
J	Nisar, PJ; Scholefield, JH				Nisar, PJ; Scholefield, JH			Managing haemorrhoids	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED-TRIAL; RUBBER BAND LIGATION; MILLIGAN-MORGAN HEMORRHOIDECTOMY; STAPLED HEMORRHOIDECTOMY; CIRCUMFERENTIAL MUCOSECTOMY; DIATHERMY HEMORRHOIDECTOMY; EXCISION HEMORRHOIDECTOMY; INJECTION SCLEROTHERAPY; CLINICAL-TRIAL; PAIN		Univ Nottingham Hosp, Queens Med Ctr, Sect Gastrointestinal Surg, Nottingham NG7 2UH, England	University of Nottingham	Nisar, PJ (corresponding author), Univ Nottingham Hosp, Queens Med Ctr, Sect Gastrointestinal Surg, Nottingham NG7 2UH, England.	pasha.nisar@nottingham.ac.uk						BAT L, 1993, DIS COLON RECTUM, V36, P287, DOI 10.1007/BF02053512; Bayer I, 1996, J CLIN GASTROENTEROL, V23, P50, DOI 10.1097/00004836-199607000-00014; BLEDAY R, 1992, DIS COLON RECTUM, V35, P477, DOI 10.1007/BF02049406; Boccasanta P, 2001, AM J SURG, V182, P64, DOI 10.1016/S0002-9610(01)00654-7; Brown S R, 2001, Colorectal Dis, V3, P175, DOI 10.1046/j.1463-1318.2001.00224.x; Carapeti EA, 1998, LANCET, V351, P169, DOI 10.1016/S0140-6736(97)09003-X; Ceulemans R, 2000, EUR J SURG, V166, P808, DOI 10.1080/110241500447452; Cheetham MJ, 2003, DIS COLON RECTUM, V46, P491, DOI 10.1007/s10350-004-6588-z; Cheetham MJ, 2000, LANCET, V356, P730, DOI 10.1016/S0140-6736(00)02632-5; Corman M L, 2003, Colorectal Dis, V5, P304, DOI 10.1046/j.1463-1318.2003.00483.x; Correa-Rovelo JM, 2002, DIS COLON RECTUM, V45, P1367, DOI 10.1007/s10350-004-6426-3; CUELEMANS R, 2000, EUR J SURG, V166, P813; *DEP HLTH, 2000, HOSP EP STAT; Ganio E, 2001, BRIT J SURG, V88, P669, DOI 10.1046/j.0007-1323.2001.01772.x; GAZET JC, 1970, P ROY SOC MED, V63, P78; Hayssen TK, 1999, DIS COLON RECTUM, V42, P909, DOI 10.1007/BF02237100; Hetzer FH, 2002, ARCH SURG-CHICAGO, V137, P337, DOI 10.1001/archsurg.137.3.337; Ho YH, 1997, BRIT J SURG, V84, P1729, DOI 10.1002/bjs.1800841223; Ho YH, 2000, DIS COLON RECTUM, V43, P1666, DOI 10.1007/BF02236847; HO YH, 1995, BRIT J SURG, V82, P1034, DOI 10.1002/bjs.1800820809; Hulme-Moir M, 2001, GASTROENTEROL CLIN N, V30, P183, DOI 10.1016/S0889-8553(05)70173-4; Hunt L, 1999, BRIT J SURG, V86, P255, DOI 10.1046/j.1365-2168.1999.01024.x; JENSEN SL, 1988, ACTA CHIR SCAND, V154, P395; JOHANSON JF, 1990, GASTROENTEROLOGY, V98, P380, DOI 10.1016/0016-5085(90)90828-O; Kairaluoma M, 2003, DIS COLON RECTUM, V46, P93, DOI 10.1007/s10350-004-6502-8; Law WL, 1999, DIS COLON RECTUM, V42, P363, DOI 10.1007/BF02236354; LEE HH, 1994, DIS COLON RECTUM, V37, P37, DOI 10.1007/BF02047212; LONGO A, 1998, 6 WORLD C END SURG R; MacRae HM, 1997, CAN J SURG, V40, P14; Mehigan BJ, 2000, LANCET, V355, P782, DOI 10.1016/S0140-6736(99)08362-2; MOESGAARD F, 1982, DIS COLON RECTUM, V25, P454, DOI 10.1007/BF02553653; Moore BA, 2001, DIS COLON RECTUM, V44, P1079, DOI 10.1007/BF02234625; Morandi E, 1999, DIS COLON RECTUM, V42, P1140, DOI 10.1007/BF02238565; Ortiz H, 2002, BRIT J SURG, V89, P1376, DOI 10.1046/j.1365-2168.2002.02237.x; Palimento D, 2003, WORLD J SURG, V27, P203, DOI 10.1007/s00268-002-6459-5; Pavlidis T, 2002, INT J COLORECTAL DIS, V17, P50, DOI 10.1007/s003840100342; Rowsell M, 2000, LANCET, V355, P779, DOI 10.1016/S0140-6736(99)06122-X; SANTOS G, 1993, DIS COLON RECTUM, V36, P958, DOI 10.1007/BF02050633; SENAPATI A, 1988, INT J COLORECTAL DIS, V3, P124, DOI 10.1007/BF01645317; Shalaby R, 2001, BRIT J SURG, V88, P1049, DOI 10.1046/j.0007-1323.2001.01830.x; Smyth EF, 2003, LANCET, V361, P1437, DOI 10.1016/S0140-6736(03)13106-6; THOMSON WHF, 1975, BRIT J SURG, V62, P542, DOI 10.1002/bjs.1800620710; Wilson MS, 2002, DIS COLON RECTUM, V45, P1437, DOI 10.1007/s10350-004-6446-z	43	60	61	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 11	2003	327	7419					847	851		10.1136/bmj.327.7419.847	http://dx.doi.org/10.1136/bmj.327.7419.847			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551102	Green Published			2022-12-28	WOS:000185921200022
J	Yang, H; Luo, GB; Karnchanaphanurach, P; Louie, TM; Rech, I; Cova, S; Xun, LY; Xie, XS				Yang, H; Luo, GB; Karnchanaphanurach, P; Louie, TM; Rech, I; Cova, S; Xun, LY; Xie, XS			Protein conformational dynamics probed by single-molecule electron transfer	SCIENCE			English	Article							NAD(P)H-FLAVIN OXIDOREDUCTASE; ANOMALOUS DIFFUSION; ESCHERICHIA-COLI; KINETICS; PHOTON; RELAXATION	Electron transfer is used as a probe for angstrom-scale structural changes in single protein molecules. In a flavin reductase, the fluorescence of flavin is quenched by a nearby tyrosine residue by means of photo-induced electron transfer. By probing the fluorescence lifetime of the single flavin on a photon-by-photon basis, we were able to observe the variation of flavin-tyrosine distance over time. We could then determine the potential of mean force between the flavin and the tyrosine, and a correlation analysis revealed conformational fluctuation at multiple time scales spanning from hundreds of microseconds to seconds. This phenomenon suggests the existence of multiple interconverting conformers related to the fluctuating catalytic reactivity.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; Politecn Milan, Dept Elect & Informat, I-20133 Milan, Italy; CNR, Ctr Elettron Quantist & Strumentaz Elettron, I-20133 Milan, Italy	Harvard University; Washington State University; Polytechnic University of Milan; Consiglio Nazionale delle Ricerche (CNR)	Xie, XS (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.	xie@chemistry.harvard.edu	Pakawatpanurut, Pasit/E-5419-2010; Yang, Haw/AHD-0857-2022	Pakawatpanurut, Pasit/0000-0002-7657-4161; Yang, Haw/0000-0003-0268-6352; Rech, Ivan/0000-0002-1430-1010	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061577] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM61577-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROSE WP, 1994, SCIENCE, V265, P364, DOI 10.1126/science.265.5170.364; ANGELL CA, 1995, SCIENCE, V267, P1924, DOI 10.1126/science.267.5206.1924; BOUCHAUD JP, 1990, PHYS REP, V195, P127, DOI 10.1016/0370-1573(90)90099-N; COVA S, 1989, REV SCI INSTRUM, V60, P1104, DOI 10.1063/1.1140324; Cova S, 1996, APPL OPTICS, V35, P1956, DOI 10.1364/AO.35.001956; Duan Y, 1998, SCIENCE, V282, P740, DOI 10.1126/science.282.5389.740; Edman L, 1996, P NATL ACAD SCI USA, V93, P6710, DOI 10.1073/pnas.93.13.6710; Eggeling C, 1998, P NATL ACAD SCI USA, V95, P1556, DOI 10.1073/pnas.95.4.1556; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; GEHLEN JN, 1994, SCIENCE, V263, P499, DOI 10.1126/science.263.5146.499; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; Ingelman M, 1999, BIOCHEMISTRY-US, V38, P7040, DOI 10.1021/bi982849m; JACKSON TA, 1994, CHEM PHYS, V180, P131, DOI 10.1016/0301-0104(93)E0414-Q; Jia YW, 1997, P NATL ACAD SCI USA, V94, P7932, DOI 10.1073/pnas.94.15.7932; Jortner J., 1999, ELECT TRANSFER ISOLA, V106; KLEINFELD D, 1984, BIOCHEMISTRY-US, V23, P5780, DOI 10.1021/bi00319a017; KOLLNER M, 1992, CHEM PHYS LETT, V200, P199, DOI 10.1016/0009-2614(92)87068-Z; Louie TM, 2002, J BIOL CHEM, V277, P39450, DOI 10.1074/jbc.M206339200; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; Lu HP, 1997, J PHYS CHEM B, V101, P2753, DOI 10.1021/jp9634518; MARCHI M, 1993, J AM CHEM SOC, V115, P4178, DOI 10.1021/ja00063a041; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; Mataga N, 2000, J PHYS CHEM B, V104, P10667, DOI 10.1021/jp002145y; MCCAMMON JA, 1979, BIOCHEMISTRY-US, V18, P927, DOI 10.1021/bi00573a001; Metzler R, 2000, PHYS REP, V339, P1, DOI 10.1016/S0370-1573(00)00070-3; Metzler R, 1999, PHYS REV LETT, V82, P3563, DOI 10.1103/PhysRevLett.82.3563; Moerner WE, 1999, SCIENCE, V283, P1670, DOI 10.1126/science.283.5408.1670; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Nie SM, 1997, ANNU REV BIOPH BIOM, V26, P567, DOI 10.1146/annurev.biophys.26.1.567; SIDERS P, 1984, J CHEM PHYS, V81, P5613, DOI 10.1063/1.447665; Van Den Berg PAW, 2001, SPR S FLUOR, V1, P457; van Oijen AM, 2003, SCIENCE, V301, P1235, DOI 10.1126/science.1084387; Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676; XIE XS, 1994, SCIENCE, V265, P361, DOI 10.1126/science.265.5170.361; Xie XS, 1998, ANNU REV PHYS CHEM, V49, P441, DOI 10.1146/annurev.physchem.49.1.441; Yang H, 2002, J CHEM PHYS, V117, P10965, DOI 10.1063/1.1521154; Zhong DP, 2001, P NATL ACAD SCI USA, V98, P11867, DOI 10.1073/pnas.211440398; Zhuang XW, 2000, SCIENCE, V288, P2048, DOI 10.1126/science.288.5473.2048	39	736	748	2	228	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					262	266		10.1126/science.1086911	http://dx.doi.org/10.1126/science.1086911			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551431				2022-12-28	WOS:000185825900035
J	Ho, AS; Sung, JJY; Chan-Yeung, M				Ho, AS; Sung, JJY; Chan-Yeung, M			An outbreak of severe acute respiratory syndrome among hospital workers in a community hospital in Hong Kong	ANNALS OF INTERNAL MEDICINE			English	Article							CORONAVIRUS; SARS; IDENTIFICATION; TRANSMISSION	Background: During outbreaks, hospital workers are at high risk for nosocomial infection with severe acute respiratory syndrome (SARS)-associated coronavirus. Objective: To examine how hospital workers became infected and whether they transmit the virus to their families. Design: Retrospective descriptive study. Setting: 529-bed community hospital in Hong Kong. Patients: 40 hospital workers infected with SARS-associated coronavirus over a 6-week period (25 March through 5 May 2003). Measurements: Percentage of infected hospital workers according to job category. Results: The cumulative incidence was highest among health care assistants, followed by physicians and nurses (8%, 5%, and 4%, respectively). Most hospital workers were infected from direct contact with patients with SARS, who primarily were in general wards and had unsuspected infection. At the time of contact, all hospital workers had used masks but not necessarily other protective devices. Affected hospital workers did not infect their families. Conclusion: Before isolation of all patients with clinically confirmed or suspected SARS, routine use of several protective devices, and training of staff in infection control, many health care workers were infected with SARS from patients with unsuspected cases.	Chinese Univ Hong Kong, Alice Ho Miu Ling Nethersole Hosp, Sha Tin 100083, Peoples R China; Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China	Alice Ho Miu Ling Nethersole Hospital; Chinese University of Hong Kong; University of Hong Kong	Chan-Yeung, M (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, 4-F Professorial Block, Hong Kong, Hong Kong, Peoples R China.	mmwchan@hkucc.hku.hk	Sung, Joseph J. Y./R-3203-2018	Sung, Joseph J. Y./0000-0003-3125-5199				*CDCP, 2003, CDC LAB SEQ GEN NEW; *DEP HLTH, AT PNEUM; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Dwosh HA, 2003, CAN MED ASSOC J, V168, P1415; *HOSP AUTH HONG KO, 2003, SEV AC RESP SYND CAS; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; *PPHB, SUMM SEV AC RESP SAR; Riley S, 2003, SCIENCE, V300, P1961, DOI 10.1126/science.1086478; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Seto WH, 2003, LANCET, V361, P1519, DOI 10.1016/S0140-6736(03)13168-6; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666	16	78	79	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 7	2003	139	7					564	567		10.7326/0003-4819-139-7-200310070-00008	http://dx.doi.org/10.7326/0003-4819-139-7-200310070-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729AP	14530227				2022-12-28	WOS:000185748800004
J	Gravel, S; Jackson, SP				Gravel, S; Jackson, SP			Increased genome instability in aging yeast	CELL			English	Editorial Material								In the September 26 issue of Science, McMurray and Gottschling (2003) report that aged yeast cells display high rates of loss of heterozygosity. Furthermore, they show that this reflects an impaired ability to correctly detect and repair DNA double-strand breaks. These results provide insights into how aging can engender genomic instability in eukaryotic cells.	Univ Cambridge, Inst Canc & Dev Biol, Wellcome Trust Canc Res UK, Cambridge CB2 1QR, England	Cancer Research UK; University of Cambridge	Gravel, S (corresponding author), Univ Cambridge, Inst Canc & Dev Biol, Wellcome Trust Canc Res UK, Cambridge CB2 1QR, England.		Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019	Jackson, Stephen Philip/0000-0001-9317-7937				Aguilaniu H, 2003, SCIENCE, V299, P1751, DOI 10.1126/science.1080418; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Kraus E, 2001, P NATL ACAD SCI USA, V98, P8255, DOI 10.1073/pnas.151008198; LOEB LA, 1991, CANCER RES, V51, P3075; McMurray MA, 2003, SCIENCE, V301, P1908, DOI 10.1126/science.1087706; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6	6	2	2	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 3	2003	115	1					1	2		10.1016/S0092-8674(03)00766-9	http://dx.doi.org/10.1016/S0092-8674(03)00766-9			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14531992	Bronze			2022-12-28	WOS:000185815500001
J	Ono, T; Losada, A; Hirano, M; Myers, MP; Neuwald, AF; Hirano, T				Ono, T; Losada, A; Hirano, M; Myers, MP; Neuwald, AF; Hirano, T			Differential contributions of condensin I and condensin II to mitotic chromosome architecture in vertebrate cells	CELL			English	Article							CHROMATID SEGREGATION; SISTER CHROMATIDS; 13S CONDENSIN; SMC PROTEINS; COMPLEX; COHESIN; XENOPUS; DNA; IDENTIFICATION; ORGANIZATION	The canonical condensin complex (henceforth condensin I) plays an essential role in mitotic chromosome assembly and segregation from yeast to humans. We report here the identification of a second condensin complex (condensin II) from vertebrate cells. Condensins I and II share the same pair of structural maintenance of chromosomes (SMC) subunits but contain different sets of non-SMC subunits. siRNA-mediated depletion of condensin I- or condensin II-specific subunits in HeLa cells produces a distinct, highly characteristic defect in chromosome morphology. Simultaneous depletion of both complexes causes the severest defect. In Xenopus egg extracts, condensin I function is predominant, but lack of condensin II results in the formation of irregularly shaped chromosomes. Condensins I and II show different distributions along the axis of chromosomes assembled in vivo and in vitro. We propose that the two condensin complexes make distinct mechanistic contributions to mitotic chromosome architecture in vertebrate cells.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Hirano, T (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd,POB 100, Cold Spring Harbor, NY 11724 USA.	hirano@cshl.org	Hirano, Tatsuya/F-6008-2011; Ono, Takao/C-6065-2017; Losada, Ana/H-5917-2015	Hirano, Tatsuya/0000-0002-4219-6473; Ono, Takao/0000-0002-0498-8293; Losada, Ana/0000-0001-5251-3383	NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053926] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM006747] Funding Source: NIH RePORTER; NCI NIH HHS [CA45508] Funding Source: Medline; NIGMS NIH HHS [GM53926] Funding Source: Medline; NLM NIH HHS [LM06747, R01 LM006747] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Anderson DE, 2002, J CELL BIOL, V156, P419, DOI 10.1083/jcb.200111002; Bazett-Jones DP, 2002, MOL CELL, V9, P1183, DOI 10.1016/S1097-2765(02)00546-4; BELMONT AS, 1987, J CELL BIOL, V105, P77, DOI 10.1083/jcb.105.1.77; Bhalla N, 2002, MOL BIOL CELL, V13, P632, DOI 10.1091/mbc.01-05-0264; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; Dietzel S, 2001, NAT CELL BIOL, V3, P767, DOI 10.1038/35087089; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Freeman L, 2000, J CELL BIOL, V149, P811, DOI 10.1083/jcb.149.4.811; Hagstrom KA, 2003, NAT REV GENET, V4, P520, DOI 10.1038/nrg1110; Hagstrom KA, 2002, GENE DEV, V16, P729, DOI 10.1101/gad.968302; Hirano M, 2001, EMBO J, V20, P3238, DOI 10.1093/emboj/20.12.3238; Hirano M, 1998, EMBO J, V17, P7139, DOI 10.1093/emboj/17.23.7139; Hirano T, 2002, GENE DEV, V16, P399, DOI 10.1101/gad.955102; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Jessberger R, 2002, NAT REV MOL CELL BIO, V3, P767, DOI 10.1038/nrm930; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Kimura K, 2000, P NATL ACAD SCI USA, V97, P11972, DOI 10.1073/pnas.220326097; Kitajima TS, 2003, SCIENCE, V300, P1152, DOI 10.1126/science.1083634; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Lavoie BD, 2002, J CELL BIOL, V156, P805, DOI 10.1083/jcb.200109056; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; MacCallum DE, 2002, MOL BIOL CELL, V13, P25, DOI 10.1091/mbc.01-09-0441; Maeshima K, 2003, DEV CELL, V4, P467, DOI 10.1016/S1534-5807(03)00092-3; Marshall WF, 2001, CURR BIOL, V11, P569, DOI 10.1016/S0960-9822(01)00180-4; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Neuwald AF, 2000, GENOME RES, V10, P1445, DOI 10.1101/gr.147400; OHNUKI Y, 1968, CHROMOSOMA, V25, P402, DOI 10.1007/BF02327721; Poirier MG, 2002, MOL BIOL CELL, V13, P2170, DOI 10.1091/mbc.01-08-0401; Prieto I, 2001, NAT CELL BIOL, V3, P761, DOI 10.1038/35087082; RATTNER JB, 1985, CELL, V42, P291, DOI 10.1016/S0092-8674(85)80124-0; Revenkova E, 2001, MOL CELL BIOL, V21, P6984, DOI 10.1128/MCB.21.20.6984-6998.2001; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; Sakai A, 2003, EMBO J, V22, P2764, DOI 10.1093/emboj/cdg247; Schleiffer A, 2003, MOL CELL, V11, P571, DOI 10.1016/S1097-2765(03)00108-4; Schmiesing JA, 2000, MOL CELL BIOL, V20, P6996, DOI 10.1128/MCB.20.18.6996-7006.2000; Siddiqui NU, 2003, DEVELOPMENT, V130, P3283, DOI 10.1242/dev.00542; Stear JH, 2002, GENE DEV, V16, P1498, DOI 10.1101/gad.989102; Steffensen S, 2001, CURR BIOL, V11, P295, DOI 10.1016/S0960-9822(01)00096-3; Stray JE, 2003, J BIOL CHEM, V278, P26238, DOI 10.1074/jbc.M302699200; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; Sumner AT., 2003, CHROMOSOMES ORG FUNC; Sutani T, 1999, GENE DEV, V13, P2271, DOI 10.1101/gad.13.17.2271; Swedlow JR, 2003, MOL CELL, V11, P557, DOI 10.1016/S1097-2765(03)00103-5; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	52	381	408	1	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 3	2003	115	1					109	121		10.1016/S0092-8674(03)00724-4	http://dx.doi.org/10.1016/S0092-8674(03)00724-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14532007	Bronze			2022-12-28	WOS:000185815500013
J	Ringler, P; Schulz, GE				Ringler, P; Schulz, GE			Self-assembly of proteins into designed networks	SCIENCE			English	Article							CRYSTAL-STRUCTURE; RESOLUTION; DNA	A C-4-symmetric tetrameric aldolase was used to produce a quadratic network consisting of the enzyme as a rigid four-way connector and stiff streptavidin rods as spacers. Each aldolase subunit was furnished with a His 6 tag for oriented binding to a planar surface and two tethered biotins for binding streptavidin in an oriented manner. The networks were improved by starting with composite units and also by binding to nickel-nitrilotriacetic acid-lipid monolayers. The mesh was adjustable in 5-nanometer increments. The production of a net with switchable mesh was initiated with the use of a calcium ion-containing beta-helix spacer that denatured on calcium ion depletion.	Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany	University of Freiburg	Schulz, GE (corresponding author), Univ Freiburg, Inst Organ Chem & Biochem, Albertstr 21, D-79104 Freiburg, Germany.	schulz@bio.chemie.uni-freiburg.de						BAUMANN U, 1994, J MOL BIOL, V242, P244, DOI 10.1006/jmbi.1994.1576; Bischler N, 1998, BIOPHYS J, V74, P1522, DOI 10.1016/S0006-3495(98)77864-6; CHALCROFT JP, 1987, FEBS LETT, V211, P53, DOI 10.1016/0014-5793(87)81273-5; Dotan N, 1999, ANGEW CHEM INT EDIT, V38, P2363, DOI 10.1002/(SICI)1521-3773(19990816)38:16<2363::AID-ANIE2363>3.3.CO;2-4; Drexler KE, 1999, TRENDS BIOTECHNOL, V17, P5, DOI 10.1016/S0167-7799(98)01278-5; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; Keren K, 2002, SCIENCE, V297, P72, DOI 10.1126/science.1071247; Kroemer M, 2002, ACTA CRYSTALLOGR D, V58, P824, DOI 10.1107/S0907444902004614; Michl J, 2002, P NATL ACAD SCI USA, V99, P4788, DOI 10.1073/pnas.052016299; MORALES P, 1995, MAT SCI ENG C-BIOMIM, V2, P173, DOI 10.1016/0928-4931(95)00056-9; Padilla JE, 2001, P NATL ACAD SCI USA, V98, P2217, DOI 10.1073/pnas.041614998; Piner RD, 1999, SCIENCE, V283, P661, DOI 10.1126/science.283.5402.661; Reviakine I, 1998, J STRUCT BIOL, V121, P356, DOI 10.1006/jsbi.1998.4003; Richard C, 2003, SCIENCE, V300, P775, DOI 10.1126/science.1080848; Ringler P, 2002, CHEMBIOCHEM, V3, P463, DOI 10.1002/1439-7633(20020503)3:5<463::AID-CBIC463>3.0.CO;2-P; Scheuring S, 1999, J MICROSC-OXFORD, V193, P28, DOI 10.1046/j.1365-2818.1999.00434.x; Seeman NC, 2003, NATURE, V421, P427, DOI 10.1038/nature01406; Service RF, 2002, SCIENCE, V298, P2322, DOI 10.1126/science.298.5602.2322; Sleytr UB, 2002, PROG COLL POL SCI S, V121, P57; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; Whitesides GM, 2002, P NATL ACAD SCI USA, V99, P4769, DOI 10.1073/pnas.082065899; WIESMANN C, 1995, STRUCTURE, V3, P961, DOI 10.1016/S0969-2126(01)00230-1; Yeates TO, 2002, CURR OPIN STRUC BIOL, V12, P464, DOI 10.1016/S0959-440X(02)00350-0	24	238	255	0	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	2003	302	5642					106	109		10.1126/science.1088074	http://dx.doi.org/10.1126/science.1088074			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526081				2022-12-28	WOS:000185678500046
J	Dermitzakis, ET; Reymond, A; Scamuffa, N; Ucla, C; Kirkness, E; Rossier, C; Antonarakis, SE				Dermitzakis, ET; Reymond, A; Scamuffa, N; Ucla, C; Kirkness, E; Rossier, C; Antonarakis, SE			Evolutionary discrimination of mammalian conserved non-genic sequences (CNGs)	SCIENCE			English	Article							FACTOR-BINDING SITES; REGULATORY REGIONS; PLACENTAL MAMMALS; MOUSE GENOME; DNA; IDENTIFICATION	Analysis of the human and mouse genomes identified an abundance of conserved non-genic sequences (CNGs). The significance and evolutionary depth of their conservation remain unanswered. We have quantified levels and patterns of conservation of 191 CNGs of human chromosome 21 in 14 mammalian species. We found that CNGs are significantly more conserved than protein-coding genes and noncoding RNAS (ncRNAs) within the mammalian class from primates to monotremes to marsupials. The pattern of substitutions in CNGs differed from that seen in protein-coding and ncRNA genes and resembled that of protein-binding regions. About 0.3% to 1% of the human genome corresponds to a previously unknown class of extremely constrained CNGs shared among mammals.	Univ Geneva, Sch Med, Div Med Genet, CH-1211 Geneva, Switzerland; Univ Geneva, Sch Med, Natl Ctr Competence Res Frontiers Genet, CH-1211 Geneva, Switzerland; Univ Hosp, CH-1211 Geneva, Switzerland; TIGR, Rockville, MD 20850 USA	University of Geneva; University of Geneva; University of Geneva; J. Craig Venter Institute	Dermitzakis, ET (corresponding author), Univ Geneva, Sch Med, Div Med Genet, CH-1211 Geneva, Switzerland.		Kutalik, Zoltan/HHZ-5697-2022; Dermitzakis, Emmanouil/B-7687-2013; Antonarakis, Stylianos E/N-8866-2014	Kutalik, Zoltan/0000-0001-8285-7523; Antonarakis, Stylianos E/0000-0001-8907-5823; Reymond, Alexandre/0000-0003-1030-8327				Boffelli D, 2003, SCIENCE, V299, P1391, DOI 10.1126/science.1081331; Chiaromonte F, 2001, P NATL ACAD SCI USA, V98, P14503, DOI 10.1073/pnas.251423898; Dermitzakis ET, 2003, MOL BIOL EVOL, V20, P703, DOI 10.1093/molbev/msg077; Dermitzakis ET, 2002, NATURE, V420, P578, DOI 10.1038/nature01251; Dermitzakis ET, 2002, MOL BIOL EVOL, V19, P1114, DOI 10.1093/oxfordjournals.molbev.a004169; DERMITZAKIS ET, UNPUB; Dubchak I, 2000, GENOME RES, V10, P1304, DOI 10.1101/gr.142200; Elnitski L, 2003, GENOME RES, V13, P64, DOI 10.1101/gr.817703; Frank AC, 1999, GENE, V238, P65, DOI 10.1016/S0378-1119(99)00297-8; Frazer KA, 2001, GENOME RES, V11, P1651, DOI 10.1101/gr.198201; Green P, 2003, NAT GENET, V33, P514, DOI 10.1038/ng1103; Leung JY, 2000, P NATL ACAD SCI USA, V97, P6614, DOI 10.1073/pnas.97.12.6614; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Madsen O, 2001, NATURE, V409, P610, DOI 10.1038/35054544; Mural RJ, 2002, SCIENCE, V296, P1661, DOI 10.1126/science.1069193; Murphy WJ, 2001, SCIENCE, V294, P2348, DOI 10.1126/science.1067179; Murphy WJ, 2001, NATURE, V409, P614, DOI 10.1038/35054550; Shabalina SA, 2001, TRENDS GENET, V17, P373, DOI 10.1016/S0168-9525(01)02344-7; Springer MS, 2003, P NATL ACAD SCI USA, V100, P1056, DOI 10.1073/pnas.0334222100; Stojanovic N, 1999, NUCLEIC ACIDS RES, V27, P3899, DOI 10.1093/nar/27.19.3899; Tang H, 1999, GENETICS, V153, P485; Wasserman WW, 2000, NAT GENET, V26, P225, DOI 10.1038/79965; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555	24	153	160	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 7	2003	302	5647					1033	1035		10.1126/science.1087047	http://dx.doi.org/10.1126/science.1087047			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14526086				2022-12-28	WOS:000186396300044
J	Chung, DC; Mino, M; Shannon, KM; Isselbacher, KJ; Harris, NL				Chung, DC; Mino, M; Shannon, KM; Isselbacher, KJ; Harris, NL			Case 34-2003: A 45-year-old woman with a family history of colonic polyps and cancer - Attenuated familial adenomatous polyposis syndrome with a germ-line truncating mutation of the APC gene at codon 169	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NONPOLYPOSIS COLORECTAL-CANCER; CYCLOOXYGENASE-2 INHIBITOR; SULINDAC; EXPRESSION; DIAGNOSIS; CELECOXIB; ALLELES; COLI; AFAP		Massachusetts Gen Hosp, Dept Med, Gastrointestinal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Canc Risk Anal, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Chung, DC (corresponding author), Massachusetts Gen Hosp, Dept Med, Gastrointestinal Unit, Boston, MA 02114 USA.							Aktan-Collan K, 2000, INT J CANCER, V89, P44, DOI 10.1002/(SICI)1097-0215(20000120)89:1<44::AID-IJC8>3.3.CO;2-V; Ao A, 1998, J ASSIST REPROD GEN, V15, P140, DOI 10.1023/A:1023008921386; Chung DC, 2003, ANN INTERN MED, V138, P560, DOI 10.7326/0003-4819-138-7-200304010-00012; COOPER HS, 1998, PATHOLOGY GASTROINTE, P819; Cromwell DM, 1998, GASTROENTEROLOGY, V114, P893, DOI 10.1016/S0016-5085(98)70308-7; Cruz-Correa M, 2002, GASTROENTEROLOGY, V122, P641, DOI 10.1053/gast.2002.31890; Dihlmann S, 1999, CANCER RES, V59, P1857; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Esplen MJ, 2001, AM J MED GENET, V103, P9, DOI 10.1002/ajmg.1493; Giardiello FM, 1997, NEW ENGL J MED, V336, P823, DOI 10.1056/NEJM199703203361202; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Giardiello FM, 2002, NEW ENGL J MED, V346, P1054, DOI 10.1056/NEJMoa012015; Goss KH, 2002, P NATL ACAD SCI USA, V99, P8161, DOI 10.1073/pnas.112072199; Hernegger GS, 2002, DIS COLON RECTUM, V45, P127; Johns LE, 2001, AM J GASTROENTEROL, V96, P2992, DOI 10.1111/j.1572-0241.2001.04677.x; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Laurent-Puig P, 1998, NUCLEIC ACIDS RES, V26, P269, DOI 10.1093/nar/26.1.269; LYNCH HT, 1990, CANCER, V66, P909, DOI 10.1002/1097-0142(19900901)66:5<909::AID-CNCR2820660516>3.0.CO;2-H; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; LYNCH HT, 1995, CANCER, V76, P2427, DOI 10.1002/1097-0142(19951215)76:12<2427::AID-CNCR2820761205>3.0.CO;2-B; Lynch HT, 1998, GUT, V43, P451, DOI 10.1136/gut.43.4.451a; LYNCH HT, 1993, CANCER, V71, P2709, DOI 10.1002/1097-0142(19930501)71:9<2709::AID-CNCR2820710904>3.0.CO;2-T; Matsumoto T, 2002, GUT, V50, P402, DOI 10.1136/gut.50.3.402; Nowlan W, 2002, SCIENCE, V297, P195, DOI 10.1126/science.1070987; Phillips RKS, 2002, GUT, V50, P857, DOI 10.1136/gut.50.6.857; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RUSTGI AK, 1994, NEW ENGL J MED, V331, P1694, DOI 10.1056/NEJM199412223312507; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; Spirio LN, 1998, NAT GENET, V20, P385, DOI 10.1038/3865; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stephenson J, 1999, JAMA-J AM MED ASSOC, V282, P2197, DOI 10.1001/jama.282.23.2197; WILLIAMS AR, 1982, GUT, V23, P835, DOI 10.1136/gut.23.10.835; Yang VW, 1998, CANCER RES, V58, P1750; Zwick A, 1997, GASTROENTEROLOGY, V113, P659, DOI 10.1053/gast.1997.v113.pm9247488	34	8	9	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	2003	349	18					1750	1760		10.1056/NEJMcpc030023	http://dx.doi.org/10.1056/NEJMcpc030023			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	737FJ	14585944				2022-12-28	WOS:000186219500011
J	Molofsky, AV; Pardal, R; Iwashita, T; Park, IK; Clarke, MF; Morrison, SJ				Molofsky, AV; Pardal, R; Iwashita, T; Park, IK; Clarke, MF; Morrison, SJ			Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation	NATURE			English	Article							ADULT MAMMALIAN FOREBRAIN; TRANSGENIC MICE; TRANSFORMATION; TUMORIGENESIS; P16(INK4A); SENESCENCE; REPRESSION; EXPRESSION; P19(ARF); MEMBERS	Stem cells persist throughout life by self-renewing in numerous tissues including the central(1) and peripheral(2) nervous systems. This raises the issue of whether there is a conserved mechanism to effect self-renewing divisions. Deficiency in the polycomb family transcriptional repressor Bmi-1 leads to progressive postnatal growth retardation and neurological defects(3). Here we show that Bmi-1 is required for the self-renewal of stem cells in the peripheral and central nervous systems but not for their survival or differentiation. The reduced self-renewal of Bmi-1-deficient neural stem cells leads to their postnatal depletion. In the absence of Bmi-1, the cyclin-dependent kinase inhibitor gene p16(Ink4a) is upregulated in neural stem cells, reducing the rate of proliferation. p16(Ink4a) deficiency partially reverses the self-renewal defect in Bmi-1(-/-) neural stem cells. This conserved requirement for Bmi-1 to promote self-renewal and to repress p16(Ink4a) expression suggests that a common mechanism regulates the self-renewal and postnatal persistence of diverse types of stem cell. Restricted neural progenitors from the gut and forebrain proliferate normally in the absence of Bmi-1. Thus, Bmi-1 dependence distinguishes stem cell self-renewal from restricted progenitor proliferation in these tissues.	Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Morrison, SJ (corresponding author), Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.		Morrison, Sean/ABD-5326-2021; Pardal, Ricardo/C-4370-2015; Molofsky, Anna Victoria/P-2506-2018; Nam, Jae Do/F-2201-2013; IBIS, FISIOPATOLOGIA/O-9510-2015	Pardal, Ricardo/0000-0003-1085-0714; Molofsky, Anna Victoria/0000-0002-4709-2411; Morrison, Sean/0000-0003-1587-8329	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040750] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS040750, R01 NS040750-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Bixby S, 2002, NEURON, V35, P643, DOI 10.1016/S0896-6273(02)00825-5; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; HAUPT Y, 1993, ONCOGENE, V8, P3161; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Kruger GM, 2002, NEURON, V35, P657, DOI 10.1016/S0896-6273(02)00827-9; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Morshead CM, 1998, DEVELOPMENT, V125, P2251; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Rietze RL, 2001, NATURE, V412, P736, DOI 10.1038/35089085; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; STRITT TN, 1995, CELL, V80, P661; vanderLugt NMT, 1996, MECH DEVELOP, V58, P153, DOI 10.1016/S0925-4773(96)00570-9; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	27	1045	1133	2	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	2003	425	6961					962	967		10.1038/nature02060	http://dx.doi.org/10.1038/nature02060			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14574365	Green Accepted, Green Published			2022-12-28	WOS:000186230600042
J	Pirozzo, S; Papinczak, T; Glasziou, P				Pirozzo, S; Papinczak, T; Glasziou, P			Whispered voice test for screening for hearing impairment in adults and children: systematic review	BRITISH MEDICAL JOURNAL			English	Review							OLDER ADULTS; GENERAL-PRACTICE; PREVALENCE; IMPACT	Objective To determine the accuracy of the whispered voice test in detecting hearing impairment in adults and children. Design Systematic review of studies of test accuracy. Data sources Medline, Embase, Science Citation Index, unpublished theses, manual searching of bibliographies of known primary and review articles, and contact with authors. Study selection Two reviewers independently selected and extracted data on study characteristics, quality, and accuracy of studies. Studies were included if they had cross sectional designs, at least one of the index tests was the whispered voice test, and the reference test (audiometry) was performed on at least 80% of the participants. Data extraction Data were used to form 2x2 contingency tables with hearing impairment by audiometry as the reference standard. Data synthesis The eight studies that were found used six different techniques. The sensitivity in the four adult studies was 90% or 100% and the specificity was 70% to 87%. The sensitivity in the four childhood studies ranged from 80% to 96% and specificity ranged from 90% to 98%. Conclusion The whispered voice test is a simple and accurate test for detecting hearing impairment. There is some concern regarding the lower sensitivity in children and the overall reproducibility of the test, particularly in primary care settings. Further studies should be conducted in primary care settings to explore the influence of components of the testing procedure to optimise test sensitivity and to promote standardisation of the testing procedure.	Univ Queensland, Royal Brisbane Hosp, Sch Populat Hlth, Herston, Qld 4029, Australia	Royal Brisbane & Women's Hospital; University of Queensland	Pirozzo, S (corresponding author), Univ Queensland, Royal Brisbane Hosp, Sch Populat Hlth, Herston, Qld 4029, Australia.		Glasziou, Paul/A-7832-2008; Papinczak, Tracey/F-2721-2010; Papinczak, Tracey/B-6360-2017	Glasziou, Paul/0000-0001-7564-073X; Papinczak, Tracey/0000-0002-0177-3086				ABUTAN BB, 1993, FAM PRACT, V10, P391, DOI 10.1093/fampra/10.4.391; Burkey JM, 1998, AM J OTOL, V19, P59; CROSS AW, 1985, J PEDIATR-US, V107, P487, DOI 10.1016/S0022-3476(85)80003-2; Cruickshanks KJ, 1998, AM J EPIDEMIOL, V148, P879; Davis A, 1999, INT J PEDIATR OTORHI, V49, pS51, DOI 10.1016/S0165-5876(99)00213-X; DEMPSTER JH, 1992, CLIN OTOLARYNGOL, V17, P54, DOI 10.1111/j.1365-2273.1992.tb00988.x; Eekhof JAH, 1996, BRIT J GEN PRACT, V46, P473; FLEMING KC, 1995, MAYO CLIN PROC, V70, P890; Fortnum HM, 2001, BRIT MED J, V323, P536, DOI 10.1136/bmj.323.7312.536; GROEN JJ, 1973, ORL J OTO-RHINO-LARY, V35, P65, DOI 10.1159/000275089; GROEN JJ, 1973, ORL J OTORHINOLARYNG, V33, P65; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; Mulrow C.D., 1991, HOSP PRACT, V26, P83; MULROW CD, 1990, ANN INTERN MED, V113, P188, DOI 10.7326/0003-4819-113-3-188; MULROW CD, 1991, HOSP PRACT, V26, P79; NADOL JB, 1993, NEW ENGL J MED, V329, P1092, DOI 10.1056/NEJM199310073291507; Nondahl DM, 1998, AUDIOLOGY, V37, P295; Prescott CAJ, 1999, INT J PEDIATR OTORHI, V51, P165, DOI 10.1016/S0165-5876(99)00263-3; Sindhusake D, 2001, INT J EPIDEMIOL, V30, P1371, DOI 10.1093/ije/30.6.1371; *STAARD GROUP, 2001, COMPL ACC REP STUD D; Strawbridge WJ, 2000, GERONTOLOGIST, V40, P320, DOI 10.1093/geront/40.3.320; SWAN IRC, 1985, J ROY COLL GEN PRACT, V35, P197; UHLMANN RF, 1989, J GEN INTERN MED, V4, P90, DOI 10.1007/BF02602346; Wallhagen MI, 2001, J AM GERIATR SOC, V49, P1086, DOI 10.1046/j.1532-5415.2001.49213.x	24	88	91	0	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 25	2003	327	7421					967	+		10.1136/bmj.327.7421.967	http://dx.doi.org/10.1136/bmj.327.7421.967			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	736AL	14576249	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000186147800019
J	Wall, NR; Shi, Y				Wall, NR; Shi, Y			Small RNA: can RNA interference be exploited for therapy?	LANCET			English	Review							ABL GENE-EXPRESSION; ELEGANS GENOME; INHIBITION; SYSTEM; INDUCTION; APOPTOSIS; VECTORS; CELLS; MICE	Context RNA interference (RNAi) is the sequence specific gene-silencing induced by double-stranded: RNA (dsRNA), and gives information about gene function quickly, easily, and inexpensively. The use of RNAi for genetic-based therapies is widely studied, especially in viral infections,, cancers, and inherited genetic disorders. RNAi has been used to make tissue-specific knockdown mice for studying,gene function in a whole animal. Combined with genomics data, RNAi-directed gene-silencing could allow functional determination of any gene expressed in a cell or pathway. The term RNAi came from the discovery that the injection of dsRNAs into Caenorhabditis elegans interferes with the expression of specific genes containing a complementary region to the delivered dsRNA. Although stalled for a time by the non-gene-specific interferon; response elicited by dsRNA molecules longer than about 30-nucleotides in mammalian cells, Tom Tuschl's group found that, transfection of synthetic 21-nucleotide small-interfering RNA, (siRNA) duplexes were highly selective and sequence-specific inhibitors of endogenous genes. Starting point siRNA expression has been studied with siRNA from plasmid and viral vectors that efficiently deliver siRNAs into both dividing and non-dividing cells, stem cells, zygotes, and their differentiated progeny. A collection of RNA interference vectors that suppress 50 human de-ubiquitinating enzymes allowed Thijn Brummelkamp and colleagues to study this gene family and to-identify de-ubiquitinating enzymes in cancer-relevant pathways (Nature 2003; 424: 797-801). These researchers found that the familial cylindromatosis tumour suppressor gene, (CYLD), previously of unknown function, could enhance the activation of the transcription factor NF-kappaB, leading to increased resistance to apoptosis. They have now started to-investigate the use of CYLD inhibitors in clinical trials. Where next The ability to efficiently and stably produce and deliver sufficient amounts of siRNA to the proper target; tissues require refinement before this new technology can be tried clinically. Initial in-vivo studies reported effective trans gene suppression in adult mice by chemically synthesised siRNAs. More recently many researchers have used plasmid and viral vectors for transcription of short-hairpin RNAs, both in vitro and in vivo. With these expression systems, gene expression was more stably inhibited than with the transient; knockdown recorded with chemically synthesised siRNA. Human trials exploiting these latest findings are likely to soon follow.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Shi, Y (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Warren Alpert Bldg Rm 120,200 Longwood Ave, Boston, MA 02115 USA.	yang_shi@hms.harvard.edu	Wall, Nathan R./H-7368-2015	Wall, Nathan R./0000-0002-3235-4386	NCI NIH HHS [F32 CA097802] Funding Source: Medline; NIGMS NIH HHS [R01GM53874] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA097802] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Brantl S, 2002, BBA-GENE STRUCT EXPR, V1575, P15, DOI 10.1016/S0167-4781(02)00280-4; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Carmell MA, 2003, NAT STRUCT BIOL, V10, P91, DOI 10.1038/nsb896; Chen YC, 2003, CANCER RES, V63, P4801; Chi JT, 2003, P NATL ACAD SCI USA, V100, P6343, DOI 10.1073/pnas.1037853100; Coburn GA, 2002, J VIROL, V76, P9225, DOI 10.1128/JVI.76.18.9225-9231.2002; Ding HL, 2003, AGING CELL, V2, P209, DOI 10.1046/j.1474-9728.2003.00054.x; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ford KG, 2001, GENE THER, V8, P1, DOI 10.1038/sj.gt.3301383; Frankish H, 2003, LANCET, V361, P584, DOI 10.1016/S0140-6736(03)12552-4; Ge Q, 2003, P NATL ACAD SCI USA, V100, P2718, DOI 10.1073/pnas.0437841100; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Matsukura S, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng077; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Pothof J, 2003, GENE DEV, V17, P443, DOI 10.1101/gad.1060703; Reid T, 2002, CANCER GENE THER, V9, P979, DOI 10.1038/sj.cgt.7700539; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Scherr M, 2003, BLOOD, V101, P1566, DOI 10.1182/blood-2002-06-1685; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; Shinagawa T, 2003, GENE DEV, V17, P1340, DOI 10.1101/gad.1073003; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; SONG E, 2001, NAT MED, V9, P347; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Wang J, 2003, P NATL ACAD SCI USA, V100, P5103, DOI 10.1073/pnas.0931345100; Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653; Wohlbold L, 2003, BLOOD, V102, P2236, DOI 10.1182/blood-2002-12-3899; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zender L, 2003, P NATL ACAD SCI USA, V100, P7797, DOI 10.1073/pnas.1330920100	38	155	194	2	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 25	2003	362	9393					1401	1403		10.1016/S0140-6736(03)14637-5	http://dx.doi.org/10.1016/S0140-6736(03)14637-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	735YX	14585643				2022-12-28	WOS:000186143300023
J	Blankenberg, S; Rupprecht, HJ; Bickel, C; Torzewski, M; Hafner, G; Tiret, L; Smieja, M; Cambien, F; Meyer, J; Lackner, KJ				Blankenberg, S; Rupprecht, HJ; Bickel, C; Torzewski, M; Hafner, G; Tiret, L; Smieja, M; Cambien, F; Meyer, J; Lackner, KJ		AtheroGene Investigators	Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ERYTHROCYTE GLUTATHIONE-PEROXIDASE; ISCHEMIC-HEART-DISEASE; ENDOTHELIAL DYSFUNCTION; MYOCARDIAL-INFARCTION; ANTIOXIDANT ENZYMES; SERUM SELENIUM; ATHEROSCLEROSIS; CELLS; 5-LIPOXYGENASE; EXPRESSION	BACKGROUND: Cellular antioxidant enzymes such as glutathione peroxidase 1 and superoxide dismutase have a central role in the control of reactive oxygen species. In vitro data and studies in animal models suggest that these enzymes may protect against atherosclerosis, but little is known about their relevance to human disease. METHODS: We conducted a prospective study among 636 patients with suspected coronary artery disease, with a median follow-up period of 4.7 years (maximum, 5.4) to assess the risk of cardiovascular events associated with base-line erythrocyte glutathione peroxidase 1 and superoxide dismutase activity. RESULTS: Glutathione peroxidase 1 activity was among the strongest univariate predictors of the risk of cardiovascular events, whereas superoxide dismutase activity had no association with risk. The risk of cardiovascular events was inversely associated with increasing quartiles of glutathione peroxidase 1 activity (P for trend <0.001); patients in the highest quartile of glutathione peroxidase 1 activity had a hazard ratio of 0.29 (95 percent confidence interval, 0.15 to 0.58; P<0.001), as compared with those in the lowest quartile. Glutathione peroxidase 1 activity was affected by sex and smoking status but retained its predictive power in these subgroups. After adjustment for these and other cardiovascular risk factors, the inverse association between glutathione peroxidase 1 activity and cardiovascular events remained nearly unchanged. CONCLUSIONS: In patients with coronary artery disease, a low level of activity of red-cell glutathione peroxidase 1 is independently associated with an increased risk of cardiovascular events. Glutathione peroxidase 1 activity may have prognostic value in addition to that of traditional risk factors. Furthermore, increasing glutathione peroxidase 1 activity might lower the risk of cardiovascular events.	Johannes Gutenberg Univ Mainz, Dept Med 2, D-55131 Mainz, Germany; Johannes Gutenberg Univ Mainz, Dept Clin Chem & Lab Med, D-55131 Mainz, Germany; Univ Paris 06, INSERM, U525, Paris, France; Bundeswehrzent Krankenhaus, Innere Abt, Koblenz, Germany; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; McMaster University	Blankenberg, S (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med 2, Langenbeckstr 1, D-55131 Mainz, Germany.	stefan.blankenberg@uni-mainz.de; lackner@zentrallabor.klinik.uni-mainz.de		Blankenberg, Stefan/0000-0001-6488-2362				Alissa EM, 2003, MED SCI MONITOR, V9, pRA9; Andersen HR, 1997, CLIN CHEM, V43, P562; Arthur JR, 2000, CELL MOL LIFE SCI, V57, P1825; Blankenberg S, 2002, CIRCULATION, V106, P24, DOI 10.1161/01.CIR.0000020546.30940.92; Blankenberg S, 2001, CIRCULATION, V104, P1336, DOI 10.1161/hc3701.095949; Dayal S, 2002, ARTERIOSCL THROM VAS, V22, P1996, DOI 10.1161/01.ATV.0000041629.92741.DC; Flohe L, 1988, Basic Life Sci, V49, P663; Forgione MA, 2002, CIRCULATION, V106, P1154, DOI 10.1161/01.CIR.0000026820.87824.6A; Forgione MA, 2002, AM J PHYSIOL-HEART C, V282, pH1255, DOI 10.1152/ajpheart.00598.2001; Forsberg L, 2001, ARCH BIOCHEM BIOPHYS, V389, P84, DOI 10.1006/abbi.2001.2295; Forsberg L, 2000, BLOOD CELL MOL DIS, V26, P423, DOI 10.1006/bcmd.2000.0325; Fukai T, 2002, CARDIOVASC RES, V55, P239, DOI 10.1016/S0008-6363(02)00328-0; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Guo ZM, 2001, ARTERIOSCL THROM VAS, V21, P1131, DOI 10.1161/hq0701.092092; Hussein O, 1997, TRANSPLANTATION, V63, P679, DOI 10.1097/00007890-199703150-00012; Kardinaal AFM, 1997, AM J EPIDEMIOL, V145, P373, DOI 10.1093/oxfordjournals.aje.a009115; Lapenna D, 1998, CIRCULATION, V97, P1930, DOI 10.1161/01.CIR.97.19.1930; Liu DJ, 2000, CHINESE MED J-PEKING, V113, P771; Massafra C, 2002, CLIN ENDOCRINOL, V57, P663, DOI 10.1046/j.1365-2265.2002.01657.x; Mehrabian M, 2002, CIRC RES, V91, P120, DOI 10.1161/01.RES.0000028008.99774.7F; Mulholland CW, 1999, QJM-INT J MED, V92, P579, DOI 10.1093/qjmed/92.10.579; OSTER O, 1982, CLIN CHIM ACTA, V124, P277, DOI 10.1016/0009-8981(82)90422-3; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; RAES M, 1987, FREE RADICAL BIO MED, V3, P3, DOI 10.1016/0891-5849(87)90032-3; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rupprecht HJ, 2001, CIRCULATION, V104, P25, DOI 10.1161/hc2601.091703; SALONEN JT, 1988, ATHEROSCLEROSIS, V70, P155, DOI 10.1016/0021-9150(88)90109-8; SALVINI S, 1995, AM J CARDIOL, V76, P1218, DOI 10.1016/S0002-9149(99)80344-0; SHINGU M, 1985, INFLAMMATION, V9, P309, DOI 10.1007/BF00916279; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Spanbroek R, 2003, P NATL ACAD SCI USA, V100, P1238, DOI 10.1073/pnas.242716099; Steinberg D, 2002, CIRCULATION, V105, P2107, DOI 10.1161/01.CIR.0000014762.06201.06; Straif D, 2000, BIOCHEM J, V349, P455, DOI 10.1042/0264-6021:3490455; Su YC, 1998, AM J RESP CELL MOL, V19, P819, DOI 10.1165/ajrcmb.19.5.3091; SUADICANI P, 1992, ATHEROSCLEROSIS, V96, P33, DOI 10.1016/0021-9150(92)90035-F; URSINI F, 1995, METHOD ENZYMOL, V252, P38	37	453	475	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 23	2003	349	17					1605	1613		10.1056/NEJMoa030535	http://dx.doi.org/10.1056/NEJMoa030535			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734ZT	14573732				2022-12-28	WOS:000186088400005
J	Ubersax, JA; Woodbury, EL; Quang, PN; Paraz, M; Blethrow, JD; Shah, K; Shokat, KM; Morgan, DO				Ubersax, JA; Woodbury, EL; Quang, PN; Paraz, M; Blethrow, JD; Shah, K; Shokat, KM; Morgan, DO			Targets of the cyclin-dependent kinase Cdk1	NATURE			English	Article							UNNATURAL NUCLEOTIDE SPECIFICITY; ANAPHASE-PROMOTING COMPLEX; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; PHOSPHORYLATION; CDC28; UBIQUITINATION; IDENTIFICATION; LOCALIZATION; REPLICATION	The events of cell reproduction are governed by oscillations in the activities of cyclin-dependent kinases (Cdks)(1). Cdks control the cell cycle by catalysing the transfer of phosphate from ATP to specific protein substrates. Despite their importance in cell-cycle control, few Cdk substrates have been identified(2). Here, we screened a budding yeast proteomic library for proteins that are directly phosphorylated by Cdk1 in whole-cell extracts. We identified about 200 Cdk1 substrates, several of which are phosphorylated in vivo in a Cdk1-dependent manner. The identities of these substrates reveal that Cdk1 employs a global regulatory strategy involving phosphorylation of other regulatory molecules as well as phosphorylation of the molecular machines that drive cell-cycle events. Detailed analysis of these substrates is likely to yield important insights into cell-cycle regulation.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Novartis Fdn, Genom Inst, San Diego, CA 92121 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Novartis	Morgan, DO (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.			Morgan, David/0000-0001-8753-4416				Agarwal R, 2002, GENE DEV, V16, P1371, DOI 10.1101/gad.971402; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Cross FR, 1999, MOL CELL, V4, P11, DOI 10.1016/S1097-2765(00)80183-5; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Elsasser S, 1999, MOL BIOL CELL, V10, P3263, DOI 10.1091/mbc.10.10.3263; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Gartner A, 1998, MOL CELL BIOL, V18, P3681, DOI 10.1128/MCB.18.7.3681; Habelhah H, 2001, J BIOL CHEM, V276, P18090, DOI 10.1074/jbc.M011396200; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Kraybill BC, 2002, J AM CHEM SOC, V124, P12118, DOI 10.1021/ja0264798; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; Masumoto H, 2002, NATURE, V415, P651, DOI 10.1038/nature713; McMillan JN, 2002, MOL BIOL CELL, V13, P3560, DOI 10.1091/mbc.E02-05-0283; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Mortensen EM, 2002, MOL BIOL CELL, V13, P2091, DOI 10.1091/mbc.01-10-0500; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Niswender CM, 2002, J BIOL CHEM, V277, P28916, DOI 10.1074/jbc.M203327200; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Roberts JM, 1999, CELL, V98, P129, DOI 10.1016/S0092-8674(00)81007-7; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; Shah K, 2002, CHEM BIOL, V9, P35, DOI 10.1016/S1074-5521(02)00086-8; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Sullivan M, 2001, NAT CELL BIOL, V3, P771, DOI 10.1038/ncb0901-771; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Witucki LA, 2002, CHEM BIOL, V9, P25, DOI 10.1016/S1074-5521(02)00091-1; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	30	717	773	1	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					859	864		10.1038/nature02062	http://dx.doi.org/10.1038/nature02062			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574415				2022-12-28	WOS:000186118500050
J	Li, L; Parsons, TJ; Power, C				Li, L; Parsons, TJ; Power, C			Breast feeding and obesity in childhood: cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OVERWEIGHT; DURATION; PROTECT		Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England	University of London; University College London	Li, L (corresponding author), Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, 30 Guilford St, London WC1N 1EH, England.	L.Li@ich.ucl.ac.uk						BARROS FC, 1990, PAEDIATR PERINAT EP, V4, P267; Beral V, 2003, LANCET, V361, P177, DOI 10.1016/S0140-6736(03)12209-X; BLOCK G, 1989, J NUTR EDUC, V21, P199; Butte NE, 2001, PEDIATR CLIN N AM, V48, P189, DOI 10.1016/S0031-3955(05)70293-5; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; Dewey Kathryn G, 2003, J Hum Lact, V19, P9; Dietz WH, 2001, JAMA-J AM MED ASSOC, V285, P2506, DOI 10.1001/jama.285.19.2506; Elliott KG, 1997, OBES RES, V5, P538, DOI 10.1002/j.1550-8528.1997.tb00574.x; FERRI E, 1993, LIFE 33 5 FOLLOW UP; Gillman MW, 2001, JAMA-J AM MED ASSOC, V285, P2461, DOI 10.1001/jama.285.19.2461; Hediger ML, 2001, JAMA-J AM MED ASSOC, V285, P2453, DOI 10.1001/jama.285.19.2453; HUTTLY SRA, 1990, AM J EPIDEMIOL, V132, P572, DOI 10.1093/oxfordjournals.aje.a115693; KRAMER MS, 1981, J PEDIATR-US, V98, P883, DOI 10.1016/S0022-3476(81)80579-3; Parsons TJ, 2003, ARCH DIS CHILD, V88, P793, DOI 10.1136/adc.88.9.793; Tulldahl J, 1999, OBES RES, V7, P431, DOI 10.1002/j.1550-8528.1999.tb00430.x; VANITALLIE TB, 1990, AM J CLIN NUTR, V52, P953, DOI 10.1093/ajcn/52.6.953; Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5; VICTORA CG, 2003, IN PRESS CAD SAUDE P; von Kries R, 2000, ADV EXP MED BIOL, V478, P29; WELLS JCK, 2003, INT J BODY COMPOSITI, V1, P1; *WHO DIV DIARRH AC, 1991, IND ASS BREAST FEED; *WHO EXP COMM NUTR, 1995, WHO TECHN REP SER, V854	22	72	79	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 18	2003	327	7420					904	905		10.1136/bmj.327.7420.904	http://dx.doi.org/10.1136/bmj.327.7420.904			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734RV	14563747	Green Published, Bronze			2022-12-28	WOS:000186072100019
J	Townsend, A; Hunt, K; Wyke, S				Townsend, A; Hunt, K; Wyke, S			Managing multiple morbidity in mid-life: a qualitative study of attitudes to drug use	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; PRIMARY-CARE; MEDICATIONS; DECISIONS; MEDICINES	Objective To examine attitudes towards drug use among middle aged respondents with high levels of chronic morbidity. Design Qualitative study with detailed interviews. Setting West of Scotland. Participants 23 men and women aged about 50 years with four or more chronic illnesses. Main outcome measure Participants' feelings about long term use of drugs to manage chronic multiple morbidity. Results Drugs occupied a central place in the way people managed their comorbidities. Respondents expressed an aversion to taking drugs, despite acknowledging that they depended on drugs to live as "normal" a life as possible. Respondents expressed ambivalence to their drugs in various ways. Firstly, they adopted both regular and more flexible regimens and might adhere to a regular regimen in treating one condition (such as hypertension) while adopting a flexible regimen in relation to others, in response to their experience of symptoms or varying demands of their daily life. Secondly, they expressed reluctance to take drugs, but an inability to be free of them. Thirdly, drugs both facilitated performance of social roles and served as evidence of an inability to perform such roles. Conclusions Insight into the considerable tension experienced by people managing complex drug regimens to manage multiple chronic illness may help medical carets to support self care practices among patients and to optimise concordance in their use of prescribed drugs.	Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland; NHS Educ Scotland, Scottish Sch Primary Care, Edinburgh EH8 9DR, Midlothian, Scotland	MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Glasgow; NHS Education for Scotland	Hunt, K (corresponding author), Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland.			Hunt, Kate/0000-0002-5873-3632				[Anonymous], MED ANTHR Q; Benson J, 2002, BRIT MED J, V325, P873, DOI 10.1136/bmj.325.7369.873; Britten N, 2000, BMJ-BRIT MED J, V320, P484, DOI 10.1136/bmj.320.7233.484; BRITTEN N, 1994, BRIT J GEN PRACT, V44, P465; BRITTEN N, 1995, FAM PRACT, V12, P104, DOI 10.1093/fampra/12.1.104; Britten N, 1996, MODERN MED LAY PERSP, P48; Britten Nicky, 2002, Health Expect, V5, P256, DOI 10.1046/j.1369-6513.2002.00187.x; CONRAD P, 1985, SOC SCI MED, V20, P29, DOI 10.1016/0277-9536(85)90308-9; Department of Health, 2001, EXP PAT NEW APPR CHR; DONOVAN JL, 1992, SOC SCI MED, V34, P507, DOI 10.1016/0277-9536(92)90206-6; FORD G, 1994, SOC SCI MED, V39, P1037, DOI 10.1016/0277-9536(94)90375-1; Haynes RB, 1996, LANCET, V348, P383; HUNT K, 2000, J EPIDEMIOL COMMUNIT, V54, P786; Macintyre S, 1999, SOC SCI MED, V48, P89, DOI 10.1016/S0277-9536(98)00292-5; Macintyre S, 1989, READINGS NEW PUBLIC, P56; Marinker M, 2003, BRIT MED J, V326, P348, DOI 10.1136/bmj.326.7385.348; Morgan M., 1996, MODERN MED LAY PERSP, P95; *OFF NAT STAT, 2000, LIV BRIT RES 1998 GE; Rogers A, 1998, SOC SCI MED, V47, P1313, DOI 10.1016/S0277-9536(98)00209-3; Royal Pharmaceutical Society of Great Britain, 1997, COMPL CONC ACH SHAR; Starfield B, 2001, BRIT J GEN PRACT, V51, P303; Strauss A., 1998, BASICS QUALITATIVE R; Wyke Sally, 2003, Eur J Gen Pract, V9, P48	23	118	120	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					837	840		10.1136/bmj.327.7419.837	http://dx.doi.org/10.1136/bmj.327.7419.837			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732BP	14551097	Bronze, Green Published, Green Accepted			2022-12-28	WOS:000185921200017
J	Lisse, JR; Perlman, M; Johansson, G; Shoemaker, JR; Schechtman, J; Skalky, CS; Dixon, ME; Polls, AB; Mollen, AJ; Geba, GP				Lisse, JR; Perlman, M; Johansson, G; Shoemaker, JR; Schechtman, J; Skalky, CS; Dixon, ME; Polls, AB; Mollen, AJ; Geba, GP			Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CARDIOVASCULAR THROMBOTIC EVENTS; COX-2 INHIBITOR ROFECOXIB; CYCLOOXYGENASE-2; TOXICITY; IBUPROFEN; EFFICACY; ASPIRIN; NSAIDS; HEALTH	Background: Gastrointestinal (GI) toxicity mediated by dual cyclooxygenase (COX)-1 and COX-2 inhibition of nonsteroidal antiinflammatory drugs (NSAIDs) can cause serious alterations of mucosal integrity or, more commonly, intolerable GI symptoms that may necessitate discontinuation of therapy. Unlike NSAIDs, rofecoxib targets only the COX-2 isoform. Objective: To assess the tolerability of rofecoxib compared with naproxen for treatment of osteoarthritis. Design: Randomized, controlled trial. Setting: 600 office and clinical research sites. Patients: 5557 patients (mean age, 63 years) with a baseline diagnosis of osteoarthritis of the knee, hip, hand, or spine. Intervention: Rofecoxib, 25 mg/d, or naproxen, 500 mg twice daily. Use of routine medications, including aspirin, was permitted. Measurements: Discontinuation due to GI adverse events (primary end point) and use of concomitant medication to treat GI symptoms (secondary end point). Efficacy was determined by patient-reported global assessment of disease status and the Australian/Canadian Osteoarthritis Hand Index, as well as discontinuations due to lack of efficacy. Patients were evaluated at baseline and at weeks 6 and 12. Results: Rates of cumulative discontinuation due to GI adverse events were statistically significantly lower in the rofecoxib group than in the naproxen group (5.9% vs. 8.1%; relative risk, 0.74 [95% Cl, 0.60 to 0.92]; P = 0.005), as were rates of cumulative use of medication to treat GI symptoms (9.1 % vs. 11.2%; relative risk, 0.79 [Cl, 0.66 to 0.96]; P = 0.014]). Subgroup analysis of patients who used low-dose aspirin (13%) and those who previously discontinued using arthritis medication because of GI symptoms (15%) demonstrated a relative risk similar to the overall sample for discontinuation due to GI adverse events (relative risk, 0.56 [Cl, 0.31 to 1.01] and 0.53 [Cl, 0.34 to 0.84], respectively). No statistically significant difference was observed between treatments for efficacy in treating osteoarthritis or for occurrence of other adverse events. Conclusions: in patients with osteoarthritis treated for 12 weeks, rofecoxib, 25 mg/d, was as effective as naproxen, 500 mg twice daily, but had statistically significantly superior GI tolerability and led to less use of concomitant GI medications. Benefits of rofecoxib in subgroup analyses were consistent with findings in the overall sample.	Merck & Co Inc, West Point, PA 19486 USA; Univ Arizona, Tucson, AZ USA; Sun Valley Arthrit Ctr Ltd, Glendale, AZ USA; SW Hlth Inst, Phoenix, AZ USA; Scripps Clin, La Jolla, CA USA; Uppsala Univ, Uppsala, Sweden; Ormond Med Arts, Ormond Beach, FL USA	Merck & Company; University of Arizona; Scripps Research Institute; Uppsala University	Geba, GP (corresponding author), Merck & Co Inc, HM-202,POB 4, West Point, PA 19486 USA.	gregory_geba@merck.com	Polls, Artur/K-7643-2014	Polls, Artur/0000-0002-3272-106X				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Brater DC, 2001, AM J NEPHROL, V21, P1, DOI 10.1159/000046212; Cappell MS, 2000, GASTROENTEROL CLIN N, V29, P97, DOI 10.1016/S0889-8553(05)70109-6; CHEYAT C, 2001, PHARMACOECONOMICS S1, V19, P17; Day R, 2000, ARCH INTERN MED, V160, P1781, DOI 10.1001/archinte.160.12.1781; Dieppe P, 1998, RHEUMATOLOGY, V2nd; Felson DT, 1998, OSTEOARTHRITIS, P13; FELSON DT, 1993, RHEUM DIS CLIN N AM, V19, P607; Fendrick AM, 2002, CLEV CLIN J MED, V69, P59, DOI 10.3949/ccjm.69.Suppl_1.SI59; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GRAHAM DY, 1989, GASTROENTEROLOGY, V96, P675, DOI 10.1016/S0016-5085(89)80064-2; Griffin Marie R., 1998, American Journal of Medicine, V104, p23S, DOI 10.1016/S0002-9343(97)00207-6; GRIFFIN MR, 1998, AM J MED, V104, pS41; Hawkey CJ, 1996, SCAND J GASTROENTERO, V31, P124, DOI 10.3109/00365529609094763; Hochberg MC, 2000, OSTEOARTHR CARTILAGE, V8, pS38; Juni P, 2002, BRIT MED J, V324, P1287, DOI 10.1136/bmj.324.7349.1287; Konstam MA, 2001, CIRCULATION, V104, P2280, DOI 10.1161/hc4401.100078; Langman MJ, 1999, JAMA-J AM MED ASSOC, V282, P1929, DOI 10.1001/jama.282.20.1929; Lanza FL, 1999, ALIMENT PHARM THERAP, V13, P761, DOI 10.1046/j.1365-2036.1999.00529.x; LEE SH, 1992, J BIOL CHEM, V267, P25934; Lichtenstein DR, 2000, JAMA-J AM MED ASSOC, V284, P1297, DOI 10.1001/jama.284.10.1297; Marshall JK, 2001, PHARMACOECONOMICS, V19, P1039, DOI 10.2165/00019053-200119100-00005; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Pincus T, 2000, J RHEUMATOL, V27, P1020; Reicin AS, 2002, AM J CARDIOL, V89, P204, DOI 10.1016/S0002-9149(01)02201-9; Saag K, 2000, ARCH FAM MED, V9, P1124, DOI 10.1001/archfami.9.10.1124; SEIBERT K, 1995, AGENT ACTION SUPPL, V46, P41; Sheen Christopher L, 2002, Expert Opin Pharmacother, V3, P265; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Singh G, 1998, J RHEUMATOL, V25, P8; Singh G, 2002, AM J MANAG CARE, V8, pS383; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Vane JR, 1996, SCAND J RHEUMATOL, P9; Watson DJ, 2000, ARCH INTERN MED, V160, P2998, DOI 10.1001/archinte.160.19.2998; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407	38	117	121	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 7	2003	139	7					539	546		10.7326/0003-4819-139-7-200310070-00005	http://dx.doi.org/10.7326/0003-4819-139-7-200310070-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729AP	14530224				2022-12-28	WOS:000185748800001
J	Reilly, BM				Reilly, BM			Physical examination in the care of medical inpatients: an observational study	LANCET			English	Article							CLINICAL SKILLS; RESIDENTS; DIAGNOSIS; HISTORY; AUTOPSY; ERROR	Background Little is known about the clinical importance of skilled physical examination in the care of patients in hospital. Methods Hospital records of a systematic consecutive sample of patients admitted to a general medical inpatient service were reviewed retrospectively to determine whether physical findings by the attending physician led to important changes in clinical management. Patients with pivotal physical findings were defined by an outcomes adjudication panel as those whose diagnosis and treatment in hospital changed substantially as a result of the attending physician's physical examination. Pivotal findings were classed as validated if the resulting treatment change involved the active collaboration of a consulting specialist. Findings were classed as discoverable if subsequent diagnostic testing (other than physical examination) would probably have led to the correct diagnosis. Class 1 findings were those deemed validated but not discoverable. Findings Among 100 patients, 26 had pivotal physical findings (26%; 95% Cl 18-36). 15 of these (58%; 95% Cl 37-77) were validated (13 with urgent surgical or other invasive procedures) and 14 were discoverable (54%; 95% Cl 33-73). Seven patients had class 1 findings (7%; 95% Cl 3-14). Interpretation Physical examination can have a substantial effect on the care of medical inpatients. If replicated in other settings, these findings might have important implications for medical educators and quality improvement initiatives.	Cook Cty Hosp, Dept Med, Chicago, IL 60612 USA; Rush Med Coll, Chicago, IL 60612 USA	John H Stroger Junior Hospital Cook County; Rush University	Reilly, BM (corresponding author), Cook Cty Hosp, Dept Med, Room 2129,1901 W Harrison St,A-1502, Chicago, IL 60612 USA.							Bates DW, 1999, J AM MED INFORM ASSN, V6, P313, DOI 10.1136/jamia.1999.00660313; Burroughs T E, 2000, Jt Comm J Qual Improv, V26, P439; Cassell E.J., 1985, TALKING PATIENTS, VVol. 1; CROMBIE D L, 1963, J Coll Gen Pract, V6, P579; Feinstein AR., 1967, CLIN JUDGMENT; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; HAMPTON JR, 1975, BRIT MED J, V2, P486, DOI 10.1136/bmj.2.5969.486; Haynes R Brian, 2002, ACP J Club, V136, pA11; Institute of Medicine, 2001, CROSSING QUALITY CHA; Institute of Medicine, 2000, ERR IS HUM BUILD SAF; Kassirer JP., 2009, LEARNING CLIN REASON; KERN DC, 1985, JAMA-J AM MED ASSOC, V254, P70, DOI 10.1001/jama.254.1.70; LANDEFELD CS, 1988, NEW ENGL J MED, V318, P1249, DOI 10.1056/NEJM198805123181906; LI JTC, 1994, ACAD MED, V69, P296, DOI 10.1097/00001888-199404000-00013; LINFORS EW, 1980, NEW ENGL J MED, V303, P1230, DOI 10.1056/NEJM198011203032110; MANGIONE S, 1994, J GEN INTERN MED, V9, P213, DOI 10.1007/BF02600127; NOEL GL, 1992, ANN INTERN MED, V117, P757, DOI 10.7326/0003-4819-117-9-757; ODDONE EZ, 1993, AM J MED, V95, P389, DOI 10.1016/0002-9343(93)90308-C; Osler W., 1903, MED NEWS NEW YORK, V82, P49; PETERSON MC, 1992, WESTERN J MED, V156, P163; PETRUSA ER, 1987, AM J MED, V83, P34, DOI 10.1016/0002-9343(87)90494-3; Sackett D., 2000, EVIDENCE BASED MED P, DOI DOI 10.1136/BMJ.H3089; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; Sapira JD, 1990, ART SCI BEDSIDE DIAG; Sim I, 2002, J GEN INTERN MED, V17, P302, DOI 10.1046/j.1525-1497.2002.10518.x; Simel DL, 1997, JAMA-J AM MED ASSOC, V277, P572, DOI 10.1001/jama.277.7.572; Sox HC, 1988, MED DECISION MAKING; STCLAIR EW, 1992, ANN INTERN MED, V117, P751, DOI 10.7326/0003-4819-117-9-751; STILLMAN P, 1991, ANN INTERN MED, V114, P393, DOI 10.7326/0003-4819-114-5-393; WIENER S, 1976, JAMA-J AM MED ASSOC, V236, P852, DOI 10.1001/jama.236.7.852; Wood JM, 1997, ACAD MED, V72, P71; WRAY NP, 1983, JAMA-J AM MED ASSOC, V249, P1035, DOI 10.1001/jama.249.8.1035	32	124	130	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 4	2003	362	9390					1100	1105		10.1016/S0140-6736(03)14464-9	http://dx.doi.org/10.1016/S0140-6736(03)14464-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728HA	14550696				2022-12-28	WOS:000185710700008
J	Gardai, SJ; Xiao, YQ; Dickinson, M; Nick, JA; Voelker, DR; Greene, KE; Henson, PM				Gardai, SJ; Xiao, YQ; Dickinson, M; Nick, JA; Voelker, DR; Greene, KE; Henson, PM			By binding SIRP alpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation	CELL			English	Article							SURFACTANT-PROTEIN-A; CARBOHYDRATE-RECOGNITION DOMAINS; CELL-SURFACE; ALVEOLAR MACROPHAGES; PSEUDOMONAS-AERUGINOSA; APOPTOTIC CELLS; DEFICIENT MICE; RAT LUNG; C1Q; RECEPTOR	Surfactant proteins A and D (SP-A and SP-D) are lung collectins composed of two regions, a globular head domain that binds PAMPs and a collagenous tail domain that initiates phagocytosis. We provide evidence that SP-A and SP-D act in a dual manner, to enhance or suppress inflammatory mediator production depending on binding orientation. SP-A and SP-D bind SIRPalpha through their globular heads to initiate a signaling pathway that blocks proinflammatory mediator production. In contrast, their collagenous tails stimulate proinflammatory mediator production through binding to calreticulin/CD91. Together a model is implied in which SP-A and SP-D help maintain a non/anti-inflammatory lung environment by stimulating SIRPalpha on resident cells through their globular heads. However, interaction of these heads with PAMPs on foreign organisms or damaged cells and presentation of the collagenous tails in an aggregated state to calreticulin/CD91, stimulates phagocytosis and proinflammatory responses.	Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Henson, PM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048211, R01GM061031] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48211, GM61031] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen MJ, 2001, INFECT IMMUN, V69, P2037, DOI 10.1128/IAI.69.4.2037-2044.2001; Arias-Diaz J, 2000, SHOCK, V14, P300, DOI 10.1097/00024382-200014030-00010; Arosa FA, 1999, J BIOL CHEM, V274, P16917, DOI 10.1074/jbc.274.24.16917; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; BLAU S, 1994, AM J PHYSIOL, V266, pL148; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Bridges JP, 2000, J BIOL CHEM, V275, P38848, DOI 10.1074/jbc.M005322200; Carter KB, 2000, J BIOL CHEM, V275, P27858; Chiba H, 2001, INFECT IMMUN, V69, P1587, DOI 10.1128/IAI.69.3.1587-1592.2001; Coppolino MG, 1998, INT J BIOCHEM CELL B, V30, P553, DOI 10.1016/S1357-2725(97)00153-2; EGGLETON P, 1994, CLIN IMMUNOL IMMUNOP, V72, P405, DOI 10.1006/clin.1994.1160; Ernst M, 2002, J EXP MED, V196, P589, DOI 10.1084/jem.20020873; Fadok VA, 2001, J IMMUNOL, V166, P6847, DOI 10.4049/jimmunol.166.11.6847; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; Goicoechea S, 2000, J BIOL CHEM, V275, P36358, DOI 10.1074/jbc.M005951200; GREENE KE, 1996, AM J RESP CRIT CARE, V153, pA662; GREENE KE, 2000, AM THOR SOC 2000 INT; GREENE KE, 1998, AM J RESP CRIT CARE, V157, pA562; Harrod KS, 1999, AM J PHYSIOL-LUNG C, V277, pL580, DOI 10.1152/ajplung.1999.277.3.L580; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KREMLEV SG, 1994, AM J PHYSIOL-LUNG C, V267, pL712, DOI 10.1152/ajplung.1994.267.6.L712; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; LeVine AM, 1999, AM J RESP CELL MOL, V20, P279, DOI 10.1165/ajrcmb.20.2.3303; LeVine AM, 1998, AM J RESP CELL MOL, V19, P700, DOI 10.1165/ajrcmb.19.4.3254; LeVine AM, 2000, J IMMUNOL, V165, P3934, DOI 10.4049/jimmunol.165.7.3934; Murakami S, 2002, J BIOL CHEM, V277, P6830, DOI 10.1074/jbc.M106671200; Ofek I, 2001, INFECT IMMUN, V69, P24, DOI 10.1128/IAI.69.1.24-33.2001; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; OGASAWARA Y, 1995, J BIOL CHEM, V270, P19052, DOI 10.1074/jbc.270.32.19052; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Orr AW, 2002, J BIOL CHEM, V277, P20453, DOI 10.1074/jbc.M112091200; Poornima S, 2002, LUNG, V180, P33, DOI 10.1007/s004080000079; REID KBM, 1976, BIOCHEM J, V155, P5, DOI 10.1042/bj1550005; Restrepo CI, 1999, AM J RESP CELL MOL, V21, P576, DOI 10.1165/ajrcmb.21.5.3334; Rosseau S, 1999, J IMMUNOL, V163, P4495; Sano H, 1999, J IMMUNOL, V163, P387; Sano H, 1998, J BIOL CHEM, V273, P4783, DOI 10.1074/jbc.273.8.4783; Sano H, 2000, J BIOL CHEM, V275, P22442, DOI 10.1074/jbc.M001107200; Schagat TL, 2001, J IMMUNOL, V166, P2727, DOI 10.4049/jimmunol.166.4.2727; Sim RB, 1998, IMMUNOBIOLOGY, V199, P208, DOI 10.1016/S0171-2985(98)80028-4; Stuart GR, 1997, IMMUNOPHARMACOLOGY, V38, P73, DOI 10.1016/S0162-3109(97)00076-3; Su HP, 2002, J BIOL CHEM, V277, P11772, DOI 10.1074/jbc.M109336200; Tenner AJ, 1998, IMMUNOBIOLOGY, V199, P250, DOI 10.1016/S0171-2985(98)80031-4; van den Berg RH, 1998, J IMMUNOL, V161, P6924; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; WARD JM, 1978, VET PATHOL, V15, P170, DOI 10.1177/030098587801500203; White MK, 2002, EXP CELL RES, V280, P270, DOI 10.1006/excr.2002.5646; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200	50	529	565	0	26	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 3	2003	115	1					13	23		10.1016/S0092-8674(03)00758-X	http://dx.doi.org/10.1016/S0092-8674(03)00758-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14531999	Bronze			2022-12-28	WOS:000185815500005
J	Yu, XH; Yu, YK; Liu, BD; Luo, K; Kong, W; Mao, PY; Yu, XF				Yu, XH; Yu, YK; Liu, BD; Luo, K; Kong, W; Mao, PY; Yu, XF			Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VIRAL VIF PROTEIN; SOR GENE-PRODUCT; HTLV-III/LAV; TYPE-1 VIF; DNA; SCF; IDENTIFICATION; HYPERMUTATION; LYMPHOCYTES	Human immunodeficiency virus-1 (HIV-1) Vif is essential for viral evasion of host antiviral factor CEM15/APOBEC3G. We report that Vif interacts with cellular proteins Cul5, elongins B and C, and Rbx1 to form an Skp1-cullin-F-box (SCF)-like complex. The ability of Vif to suppress antiviral activity of APOBEC3G was specifically dependent on Cul5-SCF function, allowing Vif to interact with APOBEC3G and induce its ubiquitination and degradation. A Vif mutant that interacted with APOBEC3G but not with Cul5-SCF was functionally inactive. The Cul5-SCF was also required for Vif function in distantly related simian immunodeficiency virus mac. These results indicate that the conserved Cul5-SCF pathway used by Vif is a potential target for antiviral development.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Jilin Univ, Changchun, Peoples R China; Zhejiang Univ, Hangzhou 310027, Peoples R China	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Jilin University; Zhejiang University	Yu, XF (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014702] Funding Source: NIH RePORTER; NCRR NIH HHS [1S10-RR14702] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dettenhofer M, 2000, J VIROL, V74, P8938, DOI 10.1128/JVI.74.19.8938-8945.2000; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P607, DOI 10.1089/aid.1994.10.607; Gray WM, 2002, PLANT CELL, V14, P2137, DOI 10.1105/tpc.003178; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KAN NC, 1986, SCIENCE, V231, P1553, DOI 10.1126/science.3006245; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; LEE TH, 1986, SCIENCE, V231, P1546, DOI 10.1126/science.3006243; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; SODROSKI J, 1986, SCIENCE, V231, P1549, DOI 10.1126/science.3006244; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	27	959	1004	2	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 7	2003	302	5647					1056	1060		10.1126/science.1089591	http://dx.doi.org/10.1126/science.1089591			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14564014				2022-12-28	WOS:000186396300052
J	Moorthy, K; Munz, Y; Sarker, SK; Darzi, A				Moorthy, K; Munz, Y; Sarker, SK; Darzi, A			Objective assessment of technical skills in surgery	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SURGICAL COMPETENCE; MASTER SURGEONS; VIRTUAL-REALITY; MOTION ANALYSIS; PERFORMANCE; TRAINEES		St Marys Hosp, Imperial Coll, Dept Surg Oncol & Technol, London W2 1NY, England	Imperial College London	Moorthy, K (corresponding author), St Marys Hosp, Imperial Coll, Dept Surg Oncol & Technol, Praed St, London W2 1NY, England.	k.moorthy@imperial.ac.uk		Moorthy, Krishna/0000-0001-8960-465X				Bridges M, 1999, AM J SURG, V177, P28, DOI 10.1016/S0002-9610(98)00289-X; Bridgewater B, 2003, BMJ-BRIT MED J, V327, P13, DOI 10.1136/bmj.327.7405.13; Cuschieri A, 2001, AM J SURG, V182, P110, DOI 10.1016/S0002-9610(01)00667-5; Darzi A, 2001, AM J SURG, V181, P484, DOI 10.1016/S0002-9610(01)00624-9; Darzi A, 1999, BRIT MED J, V318, P887, DOI 10.1136/bmj.318.7188.887; Datta V, 2002, AM J SURG, V184, P70, DOI 10.1016/S0002-9610(02)00891-7; Datta V, 2001, J AM COLL SURGEONS, V193, P479, DOI 10.1016/S1072-7515(01)01041-9; Datta V, 2002, SURGERY, V131, P318, DOI 10.1067/msy.2002.120235; Emam TA, 2000, DIGEST SURG, V17, P120, DOI 10.1159/000018813; Francis NK, 2002, ARCH SURG-CHICAGO, V137, P841, DOI 10.1001/archsurg.137.7.841; Hanna GB, 1997, AM J SURG, V174, P410, DOI 10.1016/S0002-9610(97)00129-3; KOPTA JA, 1971, SURGERY, V70, P297; Martin JA, 1997, BRIT J SURG, V84, P273, DOI 10.1046/j.1365-2168.1997.02502.x; McCloy R, 2001, BRIT MED J, V323, P912, DOI 10.1136/bmj.323.7318.912; Regehr G, 1998, ACAD MED, V73, P993, DOI 10.1097/00001888-199809000-00020; Reznick R, 1997, AM J SURG, V173, P226, DOI 10.1016/S0002-9610(97)89597-9; REZNICK RK, 1993, AM J SURG, V165, P358, DOI 10.1016/S0002-9610(05)80843-8; Ross DG, 2002, BRIT J SURG, V89, P60, DOI 10.1046/j.1365-2168.89.s.1.17_2.x; Satava R M, 2003, Surg Endosc, V17, P220, DOI 10.1007/s00464-002-8869-8; Scott DJ, 2000, SURGERY, V128, P613, DOI 10.1067/msy.2000.108115; Skidmore FD, 1997, BRIT MED J, V314, P1281, DOI 10.1136/bmj.314.7089.1281; Smith SGT, 2002, SURG ENDOSC, V16, P640, DOI 10.1007/s004640080081; Szalay D, 2000, AM J SURG, V180, P234, DOI 10.1016/S0002-9610(00)00470-0; Taffinder N, 1998, ST HEAL T, V50, P124; Taffinder NJ, 1999, SURG ENDOSC-ULTRAS, V13, P814, DOI 10.1007/s004649901107	25	437	447	1	29	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 1	2003	327	7422					1032	1037		10.1136/bmj.327.7422.1032	http://dx.doi.org/10.1136/bmj.327.7422.1032			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738NE	14593041	Green Published			2022-12-28	WOS:000186294100026
J	Zhong, NS; Zheng, BJ; Li, YM; Poon, LLM; Xie, ZH; Chan, KH; Li, PH; Tan, SY; Chang, Q; Xie, JP; Liu, XQ; Xu, J; Li, DX; Yuen, KY; Peiris, JSM; Guan, Y				Zhong, NS; Zheng, BJ; Li, YM; Poon, LLM; Xie, ZH; Chan, KH; Li, PH; Tan, SY; Chang, Q; Xie, JP; Liu, XQ; Xu, J; Li, DX; Yuen, KY; Peiris, JSM; Guan, Y			Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003	LANCET			English	Article							HONG-KONG; CORONAVIRUS	Background An epidemic of severe acute respiratory syndrome (SARS) has been associated with an outbreak of atypical pneumonia originating in Guangdong Province, People's Republic of China. We aimed to identify the causative agent in the Guangdong outbreak and describe the emergence and spread of the disease within the province. Methods We analysed epidemiological information and collected serum and nasopharyngeal aspirates from patients with SARS in Guangdong in mid-February, 2003. We did virus isolation, serological tests, and molecular assays to identify the causative agent. Findings SARS had been circulating in other cities of Guangdong Province for about 2 months before causing a major outbreak in Guangzhou, the province's capital. A novel coronavirus, SARS coronavirus (CoV), was isolated from specimens from three patients with SARS. Viral antigens were also directly detected in nasopharyngeal aspirates from these patients. 48 of 55 (87%) patients had antibodies to SARS CoV in their convalescent sera. Genetic analysis showed that the SARS CoV isolates from Guangzhou shared the same origin with those in other countries, and had a phylogenetic pathway that matched the spread of SARS to the other parts of the world. Interpretation SARS CoV is the infectious agent responsible for the epidemic outbreak of SARS in Guangdong. The virus isolated from patients in Guangdong is the prototype of the SARS CoV in other regions and countries.	Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Guangzhou Med Coll, Guangzhou Inst Resp Dis, Guangzhou, Guangdong Prov, Peoples R China; Guangzhou Chest Hosp, Guangzhou, Guangdong Prov, Peoples R China; Guangzhou Childrens Hosp, Guangzhou, Guangdong Prov, Peoples R China	University of Hong Kong; Guangzhou Medical University	Guan, Y (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Univ Pathol Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.		Poon, Leo Lit Man/C-4382-2009; Chan, Kwok Hung/ABD-5399-2021; Poon, Leo/AAP-6887-2020; Yuen, Kwok Yung/C-4465-2009; Peiris, Joseph Sriyal Malik/C-4380-2009	Poon, Leo Lit Man/0000-0002-9101-7953; Yuen, Kwok-yung/0000-0002-2083-1552; Guan, Yi/0000-0001-6057-9243; Peiris, Joseph Sriyal Malik/0000-0001-8217-5995; li, yimin/0000-0003-0810-5256	PHS HHS [A195357] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 2003, WKLY EPIDEMIOL REC, V78, P81; DEJONG JC, 1997, NATURE, V389, P544; Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151; Guan Y, 2002, P NATL ACAD SCI USA, V99, P8950, DOI 10.1073/pnas.132268999; *GUANGD PUBL HLTH, 2003, 2 GUANGD PUBL HLTH O; HOLLAND JJ, 1991, J VIROL, V65, P1960; Knipe D, 2001, FIELDS VIROLOGY, P1187; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; [彭国文 Peng Guowen], 2003, [中华流行病学杂志, Chinese Journal of Epidemiology], V24, P350; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; SHORTRIDGE KF, 1982, LANCET, V2, P812; Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666; *WHO, CAS DEF SURV SEV AC; World Health Organization, CUM NUMB REP PROB CA; 2003, MMWR MORB MORT WKL R, V52, P241	20	874	936	17	178	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 25	2003	362	9393					1353	1358		10.1016/S0140-6736(03)14630-2	http://dx.doi.org/10.1016/S0140-6736(03)14630-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	735YX	14585636	Green Published, Bronze			2022-12-28	WOS:000186143300008
J	Ray, WA				Ray, WA			Population-based studies of adverse drug effects	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Vet Affairs Med Ctr, Dept Prevent Med, Div Pharmacoepidemiol, Nashville, TN 37212 USA; Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Nashville, TN 37212 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Ray, WA (corresponding author), Vet Affairs Med Ctr, Dept Prevent Med, Div Pharmacoepidemiol, Nashville, TN 37212 USA.				AHRQ HHS [HS1-0384] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS010384] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)			0	68	69	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	2003	349	17					1592	1594		10.1056/NEJMp038145	http://dx.doi.org/10.1056/NEJMp038145			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734ZT	14573730				2022-12-28	WOS:000186088400003
J	Soto, O; Cros, DP; Hedley-Whyte, ET				Soto, O; Cros, DP; Hedley-Whyte, ET			A 37-year-old man with a history of alcohol and drug abuse and sudden onset of leg weakness - Colchicine myoneuropathy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INDUCED RHABDOMYOLYSIS; AXOPLASMIC-TRANSPORT; INDUCED MYOPATHY; SKELETAL-MUSCLE; TOXICITY; NEUROPATHY; DISEASE; NEUROMYOPATHY; MYOTONIA; NERVE		Univ Navarra Clin, Dept Neurol, Navarra, Spain; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA	University of Navarra; Harvard University; Massachusetts General Hospital; Harvard University	Soto, O (corresponding author), Univ Navarra Clin, Dept Neurol, Navarra, Spain.		Hedley-Whyte, E Tessa/AAJ-9975-2021	Hedley-Whyte, E Tessa/0000-0002-1687-8905				BESANA C, 1987, LANCET, V2, P1271; BOSCH EP, 1979, MUSCLE NERVE, V2, P133, DOI 10.1002/mus.880020208; Chattopadhyay I, 2001, POSTGRAD MED J, V77, P191, DOI 10.1136/pmj.77.905.191; Dawson TM, 1997, J RHEUMATOL, V24, P2045; Duarte J, 1998, MUSCLE NERVE, V21, P550, DOI 10.1002/(SICI)1097-4598(199804)21:4<550::AID-MUS19>3.0.CO;2-0; GENDRON Y, 1989, PRESSE MED, V18, P1256; HED R, 1962, ACTA MED SCAND, V171, P585; HED R, 1955, ACTA MED SCAND, V152, P459; HOFMANN WW, 1975, EXP NEUROL, V46, P355, DOI 10.1016/0014-4886(75)90141-7; HOFMANN WW, 1972, EUR J PHARMACOL, V20, P256, DOI 10.1016/0014-2999(72)90182-3; Hsia AW, 2001, MUSCLE NERVE, V24, P1692, DOI 10.1002/mus.1204; INESTROSA NC, 1976, J NEUROPHYSIOL, V39, P1236, DOI 10.1152/jn.1976.39.6.1236; JONSSON J, 1992, TRANSPLANTATION, V53, P1369, DOI 10.1097/00007890-199206000-00039; KONTOS HA, 1962, NEW ENGL J MED, V266, P38, DOI 10.1056/NEJM196201042660111; KUNCL RW, 1989, MUSCLE NERVE, V12, P360, DOI 10.1002/mus.880120504; KUNCL RW, 1987, NEW ENGL J MED, V316, P1562, DOI 10.1056/NEJM198706183162502; LEQUINTREC JS, 1991, BAILLIERE CLIN RHEUM, V5, P21, DOI 10.1016/S0950-3579(05)80294-8; MARKAND ON, 1971, ARCH NEUROL-CHICAGO, V24, P72, DOI 10.1001/archneur.1971.00480310100010; MARTIN JB, 1971, NEUROLOGY, V21, P1160, DOI 10.1212/WNL.21.11.1160; Montseny JJ, 1996, NEPHROL DIAL TRANSPL, V11, P2055, DOI 10.1093/oxfordjournals.ndt.a027096; MURRAY SS, 1983, MAYO CLIN PROC, V58, P528; MYERSON RM, 1970, MED CLIN N AM, V54, P723, DOI 10.1016/S0025-7125(16)32639-6; NAIDUS RM, 1977, ARCH INTERN MED, V137, P394, DOI 10.1001/archinte.137.3.394; PAULSON JC, 1975, ANN NY ACAD SCI, V253, P517, DOI 10.1111/j.1749-6632.1975.tb19225.x; PERKOFF GT, 1967, ANN INTERN MED, V67, P481, DOI 10.7326/0003-4819-67-3-481; Proske U, 1998, EXP BRAIN RES, V119, P391, DOI 10.1007/s002210050354; RIEGER EH, 1990, TRANSPLANTATION, V49, P1196; RIGGS JE, 1986, ARCH NEUROL-CHICAGO, V43, P521, DOI 10.1001/archneur.1986.00520050091033; RINGEL SP, 1979, HDB CLIN NEUROLOGY, V40, P295; Rutkove SB, 1996, MUSCLE NERVE, V19, P870, DOI 10.1002/(SICI)1097-4598(199607)19:7<870::AID-MUS9>3.0.CO;2-6; SCHIFF D, 1992, ARTHRITIS RHEUM, V35, P1535, DOI 10.1002/art.1780351218; SLOTWINER P, 1966, ARCH NEUROL-CHICAGO, V15, P172, DOI 10.1001/archneur.1966.00470140062008; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701; VANDERNAALT J, 1992, ANN RHEUM DIS, V51, P1267, DOI 10.1136/ard.51.11.1267; VICTOR M, 1994, MYOLOGY, V2, P1697; WELCH KMA, 1972, NEUROLOGY, V22, P697; WILBOURN AJ, 1993, J CLIN NEUROPHYSIOL, V10, P132, DOI 10.1097/00004691-199304000-00002	37	4	4	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 23	2003	349	17					1656	1663		10.1056/NEJMcpc030008	http://dx.doi.org/10.1056/NEJMcpc030008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734ZT	14573738				2022-12-28	WOS:000186088400012
J	Reynolds, EE; Singer, DE				Reynolds, EE; Singer, DE			A 60-year-old woman with atrial fibrillation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; ORAL ANTICOAGULATION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ANTITHROMBOTIC THERAPY; STROKE PREVENTION; RHYTHM MANAGEMENT; MAZE PROCEDURE; WARFARIN; THROMBOEMBOLISM; ASPIRIN		Massachusetts Gen Hosp, Clin Epidemiol Unit, Div Gen Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Reynolds, EE (corresponding author), Massachusetts Gen Hosp, Clin Epidemiol Unit, Div Gen Med, S 50-9, Boston, MA 02114 USA.				NATIONAL INSTITUTE ON AGING [R01AG015478] Funding Source: NIH RePORTER; NIA NIH HHS [AG15478] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Al-Khatib SM, 2000, AM HEART J, V140, P142, DOI 10.1067/mhj.2000.107547; Al-Saady NM, 1999, HEART, V82, P547, DOI 10.1136/hrt.82.5.547; Albers GW, 2001, CHEST, V119, p194S, DOI 10.1378/chest.119.1_suppl.194S; [Anonymous], 2001, CIRCULATION, V104, P2118; [Anonymous], 1997, Arch Intern Med, V157, P1237; Ansell JE, 1997, ANN PHARMACOTHER, V31, P604, DOI 10.1177/106002809703100516; ANSELL JE, 2003, MANAGING ORAL ANTICO, pCH44; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; BJERKELUND CJ, 1969, AM J CARDIOL, V23, P208, DOI 10.1016/0002-9149(69)90068-X; Blackshear JL, 1996, LANCET, V348, P633; Blackshear JL, 1996, ANN THORAC SURG, V61, P755, DOI 10.1016/0003-4975(95)00887-X; Brugada R, 1997, NEW ENGL J MED, V336, P905, DOI 10.1056/NEJM199703273361302; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P128; CHEVALIER H, 1979, AM HEART J, V98, P361, DOI 10.1016/0002-8703(79)90049-8; Cox JL, 1998, AM HEART J, V136, P934, DOI 10.1016/S0002-8703(98)70143-7; Cox JL, 1999, J THORAC CARDIOV SUR, V118, P833, DOI 10.1016/S0022-5223(99)70052-8; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; Epstein AE, 2002, J CARDIOVASC ELECTR, V13, P667, DOI 10.1046/j.1540-8167.2002.00667.x; EVANS W, 1954, BRIT HEART J, V16, P189; Ezekowitz M, 1998, ARCH INTERN MED, V158, P1316; Falk RH, 2001, NEW ENGL J MED, V344, P1067, DOI 10.1056/NEJM200104053441407; FLAKER GC, 1995, AM J CARDIOL, V76, P355, DOI 10.1016/S0002-9149(99)80100-3; Francis CW, 2002, ANN INTERN MED, V137, P648, DOI 10.7326/0003-4819-137-8-200210150-00008; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; Go AS, 2002, CIRCULATION, V106, P515; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Go AS, 1999, ANN INTERN MED, V131, P927, DOI 10.7326/0003-4819-131-12-199912210-00004; Go AS, 2000, CIRCULATION, V102, P11, DOI 10.1161/01.CIR.102.1.11; Haissaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003; Hart RG, 1999, STROKE, V30, P1223, DOI 10.1161/01.STR.30.6.1223; Hart RG, 2000, J AM COLL CARDIOL, V35, P183, DOI 10.1016/S0735-1097(99)00489-1; Hylek EM, 2003, NEW ENGL J MED, V349, P1019, DOI 10.1056/NEJMoa022913; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; JOSEPHSON ME, 1994, HARRISONS PRINCIPLES, P1022; Klein AL, 2001, NEW ENGL J MED, V344, P1411, DOI 10.1056/NEJM200105103441901; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; LAKE FR, 1989, AUST NZ J MED, V19, P321, DOI 10.1111/j.1445-5994.1989.tb00271.x; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Levy S, 1999, CIRCULATION, V99, P3028, DOI 10.1161/01.CIR.99.23.3028; Longstreth WT, 2001, NEUROLOGY, V56, P368, DOI 10.1212/WNL.56.3.368; Man-Son-Hing M, 2000, MED DECIS MAKING, V20, P394, DOI 10.1177/0272989X0002000403; Manning WJ, 1996, PROG CARDIOVASC DIS, V39, P33, DOI 10.1016/S0033-0620(96)80039-9; MANNING WJ, 1995, ARCH INTERN MED, V155, P2193, DOI 10.1001/archinte.155.20.2193; ManSonHing M, 1996, ARCH INTERN MED, V156, P1841, DOI 10.1001/archinte.156.16.1841; Monette J, 1997, J AM GERIATR SOC, V45, P1060, DOI 10.1111/j.1532-5415.1997.tb05967.x; MULROW CD, 1994, JAMA-J AM MED ASSOC, V272, P1932, DOI 10.1001/jama.272.24.1932; Ommen SR, 1997, NEW ENGL J MED, V336, P1429, DOI 10.1056/NEJM199705153362006; Page RL, 2003, CIRCULATION, V107, P1141, DOI 10.1161/01.CIR.0000051455.44919.73; PAGE RL, 1994, CIRCULATION, V89, P224, DOI 10.1161/01.CIR.89.1.224; Ricard P, 1997, AM J CARDIOL, V79, P815, DOI 10.1016/S0002-9149(96)00879-X; Saksena S, 2002, J AM COLL CARDIOL, V40, P1140, DOI 10.1016/S0735-1097(02)02068-5; SANDLER G, 1959, Q J MED, V28, P347; Sawicki PT, 1999, JAMA-J AM MED ASSOC, V281, P145, DOI 10.1001/jama.281.2.145; Sievert H, 2002, CIRCULATION, V105, P1887, DOI 10.1161/01.CIR.0000015698.54752.6D; Stein PD, 2001, CHEST, V119, p220S, DOI 10.1378/chest.119.1_suppl.220S; Stollberger C, 1998, ANN INTERN MED, V128, P630, DOI 10.7326/0003-4819-128-8-199804150-00004; Stroke Prevention in Atrial Fibrillation Investigators, 1995, J Stroke Cerebrovasc Dis, V5, P147, DOI 10.1016/S1052-3057(10)80166-1; Umana E, 2003, AM J MED, V114, P51, DOI 10.1016/S0002-9343(02)01472-9; Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375; van Walraven C, 2002, JAMA-J AM MED ASSOC, V288, P2441, DOI 10.1001/jama.288.19.2441; VAZIRI SM, 1994, CIRCULATION, V89, P724, DOI 10.1161/01.CIR.89.2.724; WALDO AL, 1995, AM HEART MONOGR S, P213; Wang TJ, 2003, JAMA-J AM MED ASSOC, V290, P1049, DOI 10.1001/jama.290.8.1049; WIJFFELS MCEF, 1995, CIRCULATION, V92, P1954, DOI 10.1161/01.CIR.92.7.1954; Williams Mathew R, 2002, Semin Thorac Cardiovasc Surg, V14, P232; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328; Zabalgoitia M, 1998, ANN INTERN MED, V128, P639, DOI 10.7326/0003-4819-128-8-199804150-00005; Zabalgoitia M, 1998, J AM COLL CARDIOL, V31, P1622, DOI 10.1016/S0735-1097(98)00146-6	71	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	2003	290	16					2182	2189						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CB	14570954				2022-12-28	WOS:000186036700028
J	Steffes, MW; Chavers, BM; Molitch, ME; Cleary, PA; Lachin, JM; Genuth, S; Nathan, DM; Genuth, S; Nathan, D; Engel, S; Martinez, H; Shamoon, H; Engel, H; Dahms, W; Mayer, L; Pendegras, S; Zegarra, H; Miller, D; Singerman, L; Smith-Brewer, S; Genuth, S; Brillion, D; Lackaye, M; Heinemann, M; Repucci, V; Lee, T; Whitehouse, F; Kruger, D; Galpern, A; Carey, JD; Bergenstal, R; Johnson, M; Kendell, D; Spencer, M; Noller, D; Morgan, K; Etzwiler, D; Jacobson, A; Golden, E; Sharuk, G; ARrigg, P; Baeser, R; Ganda, O; Rosenzweig, J; Wolpert, H; Economides, P; Handy, O; Rand, L; Nathan, D; Fritz, S; Godine, J; McKitrick, C; Lou, P; Service, FJ; Ziegler, G; Pach, J; Lindsey, J; Colwell, J; Wood, D; Mayfield, R; Hermayer, K; Szpiech, M; Lyons, T; Parker, J; Farr, A; Elsing, S; Thompson, T; Selby, J; Bracey, M; Molitch, M; Schaefer, B; Jampol, L; Weinberg, D; Lyon, A; Strugula, Z; Shankle, J; Astlesford, P; Kolterman, O; Lorenzi, G; Goldbaum, M; Sivitz, W; Bayless, M; Zeither, R; Weingeist, T; Stone, E; Boidt, HC; Gehres, K; Russell, S; Counts, D; Kowarski, A; Ostrowski, D; Donner, T; Steidl, S; Jones, B; Herman, W; Greene, D; Martin, C; Stevens, MJ; Vine, AK; Elner, S; Bantle, J; Rogness, B; Olsen, T; Steuer, E; Goldstein, D; Hitt, S; Giangiacomo, J; Hainsworth, D; Schade, D; Burge, M; Canady, J; Schluter, M; Das, A; Hornbeck, D; Schwartz, S; Bourne, PA; Maschak-Carey, BJ; Baker, L; Braunstein, S; Brucker, A; Orchard, T; Silvers, N; Songer, T; Doft, B; Olson, S; Bergren, RL; Lobes, L; Fineman, M; Drash, A; Malone, J; Vaccaro-Kish, J; Berger, C; Gstalder, R; Pavan, PR; Morrison, A; Dagogo-Jack, S; Schussler, S; Kitabchi, A; Lambeth, H; Murphy, MB; Mosesr, S; Meyer, D; Iannacone, A; Bryer-Ash, M; Raskin, P; Strowig, S; Edwards, A; Alappatt, J; Wilson, C; Park, S; Ye, H; Zinman, B; Barnie, A; MacLean, S; Devenyi, R; Mandelcorn, M; Brent, M; Palmer, J; Catton, S; Kinyoun, J; Van Ottingham, L; Ginsberg, J; Dupre, J; Harth, J; Nicolle, D; May, M; Lorenz, R; Lipps, J; Survant, L; Feman, S; Tawansy, K; Agarwal, A; Adkins, T; White, N; Santiago, J; Levandoski, L; Boniuk, I; Grand, G; Thomas, M; Burgess, D; Joseph, D; Blinder, K; Shah, G; Tamborlane, W; Gatcomb, P; Stoessel, K; Taylor, K; Dahms, B; Trail, R; Quin, J; Lachin, J; Cleary, P; Kenny, D; Backlund, J; Diminick, L; Determan, A; Klump, K; Hawkins, M; Cowie, C; Fradkin, J; Siebert, C; Eastman, R; Davis, M; Hubbard, L; Geithman, P; Kastorff, L; Neider, M; Badal, D; Esser, B; Miner, K; Wabers, H; Glander, K; Joyce, J; Robinson, N; Hurtenbach, C; Hannon, C; Steffes, M; Bucksa, J; Chavers, B; O'Leary, D; Funk, L; Polak, J; Crow, R; O'Donnell, C; Gloeb, B; Thomas, S; Detrano, R; Wong, N; Fox, M; Kim, L; Oudiz, R; Weir, G; Clark, C; D'Agostino, R; Espeland, M; Klein, B; Manolio, T; Rand, L; Singer, D; Stern, M; Garvey, WT; Lyons, TJ; Jenkins, A; Klein, R; Lopes-Virella, M; Virella, G; Jaffa, AA; Zheng, D; Lackland, D; McGee, D; Mayfield, RK; Brabham, M; Boright, A; Paterson, A; Scherere, S; Zinman, B; Bruznell, J; Hokanson, J; Marcovina, S; Purnell, J; Sibley, S; Deeb, S; Edwards, K; Nathan, D				Steffes, MW; Chavers, BM; Molitch, ME; Cleary, PA; Lachin, JM; Genuth, S; Nathan, DM; Genuth, S; Nathan, D; Engel, S; Martinez, H; Shamoon, H; Engel, H; Dahms, W; Mayer, L; Pendegras, S; Zegarra, H; Miller, D; Singerman, L; Smith-Brewer, S; Genuth, S; Brillion, D; Lackaye, M; Heinemann, M; Repucci, V; Lee, T; Whitehouse, F; Kruger, D; Galpern, A; Carey, JD; Bergenstal, R; Johnson, M; Kendell, D; Spencer, M; Noller, D; Morgan, K; Etzwiler, D; Jacobson, A; Golden, E; Sharuk, G; ARrigg, P; Baeser, R; Ganda, O; Rosenzweig, J; Wolpert, H; Economides, P; Handy, O; Rand, L; Nathan, D; Fritz, S; Godine, J; McKitrick, C; Lou, P; Service, FJ; Ziegler, G; Pach, J; Lindsey, J; Colwell, J; Wood, D; Mayfield, R; Hermayer, K; Szpiech, M; Lyons, T; Parker, J; Farr, A; Elsing, S; Thompson, T; Selby, J; Bracey, M; Molitch, M; Schaefer, B; Jampol, L; Weinberg, D; Lyon, A; Strugula, Z; Shankle, J; Astlesford, P; Kolterman, O; Lorenzi, G; Goldbaum, M; Sivitz, W; Bayless, M; Zeither, R; Weingeist, T; Stone, E; Boidt, HC; Gehres, K; Russell, S; Counts, D; Kowarski, A; Ostrowski, D; Donner, T; Steidl, S; Jones, B; Herman, W; Greene, D; Martin, C; Stevens, MJ; Vine, AK; Elner, S; Bantle, J; Rogness, B; Olsen, T; Steuer, E; Goldstein, D; Hitt, S; Giangiacomo, J; Hainsworth, D; Schade, D; Burge, M; Canady, J; Schluter, M; Das, A; Hornbeck, D; Schwartz, S; Bourne, PA; Maschak-Carey, BJ; Baker, L; Braunstein, S; Brucker, A; Orchard, T; Silvers, N; Songer, T; Doft, B; Olson, S; Bergren, RL; Lobes, L; Fineman, M; Drash, A; Malone, J; Vaccaro-Kish, J; Berger, C; Gstalder, R; Pavan, PR; Morrison, A; Dagogo-Jack, S; Schussler, S; Kitabchi, A; Lambeth, H; Murphy, MB; Mosesr, S; Meyer, D; Iannacone, A; Bryer-Ash, M; Raskin, P; Strowig, S; Edwards, A; Alappatt, J; Wilson, C; Park, S; Ye, H; Zinman, B; Barnie, A; MacLean, S; Devenyi, R; Mandelcorn, M; Brent, M; Palmer, J; Catton, S; Kinyoun, J; Van Ottingham, L; Ginsberg, J; Dupre, J; Harth, J; Nicolle, D; May, M; Lorenz, R; Lipps, J; Survant, L; Feman, S; Tawansy, K; Agarwal, A; Adkins, T; White, N; Santiago, J; Levandoski, L; Boniuk, I; Grand, G; Thomas, M; Burgess, D; Joseph, D; Blinder, K; Shah, G; Tamborlane, W; Gatcomb, P; Stoessel, K; Taylor, K; Dahms, B; Trail, R; Quin, J; Lachin, J; Cleary, P; Kenny, D; Backlund, J; Diminick, L; Determan, A; Klump, K; Hawkins, M; Cowie, C; Fradkin, J; Siebert, C; Eastman, R; Davis, M; Hubbard, L; Geithman, P; Kastorff, L; Neider, M; Badal, D; Esser, B; Miner, K; Wabers, H; Glander, K; Joyce, J; Robinson, N; Hurtenbach, C; Hannon, C; Steffes, M; Bucksa, J; Chavers, B; O'Leary, D; Funk, L; Polak, J; Crow, R; O'Donnell, C; Gloeb, B; Thomas, S; Detrano, R; Wong, N; Fox, M; Kim, L; Oudiz, R; Weir, G; Clark, C; D'Agostino, R; Espeland, M; Klein, B; Manolio, T; Rand, L; Singer, D; Stern, M; Garvey, WT; Lyons, TJ; Jenkins, A; Klein, R; Lopes-Virella, M; Virella, G; Jaffa, AA; Zheng, D; Lackland, D; McGee, D; Mayfield, RK; Brabham, M; Boright, A; Paterson, A; Scherere, S; Zinman, B; Bruznell, J; Hokanson, J; Marcovina, S; Purnell, J; Sibley, S; Deeb, S; Edwards, K; Nathan, D			Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy - The Epidemiology of Diabetes Interventions and Complications (EDIC) study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRODUCTS	Context The Diabetes Control and Complications Trial (DCCT) demonstrated the benefits of intensive treatment of diabetes in reducing glycemic levels and slowing the progression of diabetic nephropathy. The DCCT cohort has been examined annually for another 8 years as part of the follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) study. During the EDIC study, glycemic levels no longer differed substantially between the 2 original treatment groups. Objective To determine the long-term effects of intensive vs conventional diabetes treatment during the DCCT on kidney function during the EDIC study. Design, Setting, and Participants Observational study begun in 1993 (following DCCT closeout) in 28 medical centers in the United States and Canada. Participants were 1349 (of 1375) EDIC volunteers who had kidney evaluation at years 7 or 8. Main Outcome Measures Development of microalbuminuria, clinical-grade albuminuria, hypertension, or increase in serum creatinine level. Results Results were analyzed by intention-to-treat analyses, comparing the 2 original DCCT treatment groups. New cases of microalbuminuria occurred during the EDIC study in 39 (6.8%) of the participants originally assigned to the intensive-treatment group vs 87 (15.8%) of those assigned to the conventional-treatment group, for a 59% (95% confidence interval [CI], 39%-73%) reduction in odds, adjusted for baseline values, compared with a 59% (95% Cl, 36%-74%) reduction at the end of the DCCT (P<.001 for both comparisons). New cases of clinical albuminuria occurred in 9 (1.4%) of the participants in the original intensive-treatment group vs 59 (9.4%) of those in the original conventional-treatment group, representing an 84% reduction in odds (95% Cl, 67%-92%), compared with a reduction of 57% (95% Cl, -1% to +81%) at the end of the DCCT. Fewer cases of hypertension (prevalence at year 8, 29.9% vs 40.3%; P<.001) developed in the original intensive-treatment group. Significantly fewer participants reached a serum creatinine level of 2 mg/dL or greater in the intensive-treatment vs the conventional-treatment group (5 vs 19, P=.004), but there were no differences in mean log clearance values. Although small numbers of patients required dialysis and/or transplantation, fewer patients experienced either of these outcomes in the intensive group (4 vs 7, P=36). Conclusions The persistent beneficial effects on albumin excretion and the reduced incidence of hypertension 7 to 8 years after the end of the DCCT suggest that previous intensive treatment of diabetes with near-normal glycemia during the DCCT has an extended benefit in delaying progression of diabetic nephropathy.	Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA; Northwestern Univ, Feinberg Sch Med, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA; George Washington Univ, Ctr Biostat, Rockville, MD USA; Case Western Reserve Univ, Sch Med, Div Clin & Mol Endocrinol, Cleveland, OH USA; Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Northwestern University; Feinberg School of Medicine; George Washington University; Case Western Reserve University; Harvard University; Massachusetts General Hospital	Nathan, D (corresponding author), Massachusetts Gen Hosp, Diabet Unit, 32 Fruit St, Boston, MA 02114 USA.	dnathan@partners.org	Goldbaum, Michael/AAG-4258-2020; Pavan, Peter/B-6473-2013; Zinman, Bernard/E-7266-2013	Goldbaum, Michael/0000-0002-7721-2736; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK062204] Funding Source: NIH RePORTER; NIDDK NIH HHS [N01 DK062204-007] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1997, DIABETES, V46, P271, DOI 10.2337/diab.46.2.271; [Anonymous], 1996, DIABETES, V45, P1289; [Anonymous], 1995, DIABETES, V44, P968; [Anonymous], 1995, ANN INTERN MED, V122, P561, DOI 10.7326/0003-4819-122-8-199504150-00001; BORCHJOHNSEN K, 1987, DIABETIC MED, V4, P201, DOI 10.1111/j.1464-5491.1987.tb00863.x; BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; CERAMI A, 1988, DIABETES CARE, V11, P73; De Giorgio L, 2000, NEW ENGL J MED, V342, P1376; Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703; Diabet Control Complications Trial DCCT Res Grp, 1995, AM J CARDIOL, V75, P894; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Genuth S, 1999, DIABETES CARE, V22, P99; Genuth S, 2002, JAMA-J AM MED ASSOC, V287, P2563; Hovind P, 2003, DIABETES CARE, V26, P1258, DOI 10.2337/diacare.26.4.1258; King GL, 1996, ENDOCRIN METAB CLIN, V25, P255, DOI 10.1016/S0889-8529(05)70324-8; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; Lachin J. M., 2000, WILEY SER PROB STAT; LEVEY AS, 1993, J AM SOC NEPHROL, V4, P1159; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MOGENSEN CE, 1982, BRIT MED J, V285, P685, DOI 10.1136/bmj.285.6343.685; MOLITCH ME, 1993, KIDNEY INT, V43, P668, DOI 10.1038/ki.1993.96; Monnier VM, 1999, DIABETES, V48, P870, DOI 10.2337/diabetes.48.4.870; PARVING HH, 1983, LANCET, V1, P1175; SHAMOON H, 1995, ARCH OPHTHALMOL-CHIC, V113, P36; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shannon H, 2000, NEW ENGL J MED, V342, P381; Snedecor GW, 1980, STAT METHODS, V7th	27	794	809	1	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	2003	290	16					2159	2167						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CB	14570951	Green Accepted, Bronze			2022-12-28	WOS:000186036700025
J	McGuigan, KG; Kehoe, SC				McGuigan, KG; Kehoe, SC			Cooking the waste	LANCET			English	Editorial Material							WATER; PASTEURIZATION; INACTIVATION		Royal Coll Surgeons Ireland, Dept Phys & Surg, Dublin 2, Ireland	Royal College of Surgeons - Ireland	McGuigan, KG (corresponding author), Royal Coll Surgeons Ireland, Dept Phys & Surg, Dublin 2, Ireland.		McGuigan, Kevin G/A-3656-2010	McGuigan, Kevin G/0000-0002-3775-8339				Anderson WA, 1996, J APPL BACTERIOL, V80, P283, DOI 10.1111/j.1365-2672.1996.tb03221.x; Cho HY, 1999, BIOTECHNOL BIOENG, V62, P368, DOI 10.1002/(SICI)1097-0290(19990205)62:3<368::AID-BIT14>3.0.CO;2-0; CIOCHETTI DA, 1984, APPL ENVIRON MICROB, V47, P223, DOI 10.1128/AEM.47.2.223-228.1984; *EAWAG SWISS FED I, SOL WAT DIS SANDEC; KERR BP, 1999, EXPANDING WORLD SOLA; McGuigan KG, 1999, J MED MICROBIOL, V48, P785, DOI 10.1099/00222615-48-9-785; Safapour N, 1999, APPL ENVIRON MICROB, V65, P859; Sommer B, 1997, J WATER SUPPLY RES T, V46, P127	8	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 18	2003	362	9392					1251	1252		10.1016/S0140-6736(03)14613-2	http://dx.doi.org/10.1016/S0140-6736(03)14613-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575964				2022-12-28	WOS:000186036900003
J	Strachan, MWJ				Strachan, MWJ			Insulin and cognitive function	LANCET			English	Editorial Material							ALZHEIMERS-DISEASE; HYPERINSULINEMIA; POPULATION; MEMORY		Western Gen Hosp, Metab Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Strachan, MWJ (corresponding author), Western Gen Hosp, Metab Unit, Edinburgh EH4 2XU, Midlothian, Scotland.							Craft S, 1996, NEUROBIOL AGING, V17, P123, DOI 10.1016/0197-4580(95)02002-0; Craft S, 1998, NEUROLOGY, V50, P164, DOI 10.1212/WNL.50.1.164; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Galasko D, 2003, NEUROLOGY, V60, P1886, DOI 10.1212/WNL.60.12.1886; KALMIJN S, 1995, DIABETOLOGIA, V38, P1096, DOI 10.1007/BF00402181; KUUSISTO J, 1993, HYPERTENSION, V22, P771, DOI 10.1161/01.HYP.22.5.771; Kuusisto J, 1997, BRIT MED J, V315, P1045, DOI 10.1136/bmj.315.7115.1045; Park CR, 2000, PHYSIOL BEHAV, V68, P509, DOI 10.1016/S0031-9384(99)00220-6; Stolk RP, 1997, DIABETES CARE, V20, P792, DOI 10.2337/diacare.20.5.792; Watson GS, 2003, NEUROLOGY, V60, P1899, DOI 10.1212/01.WNL.0000065916.25128.25	10	44	44	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 18	2003	362	9392					1253	1253		10.1016/S0140-6736(03)14615-6	http://dx.doi.org/10.1016/S0140-6736(03)14615-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575966				2022-12-28	WOS:000186036900005
J	Abe, E; Marians, RC; Yu, WQ; Wu, XB; Ando, T; Li, YN; Iqbal, J; Eldeiry, L; Rajendren, G; Blair, HC; Davies, TF; Zaidi, M				Abe, E; Marians, RC; Yu, WQ; Wu, XB; Ando, T; Li, YN; Iqbal, J; Eldeiry, L; Rajendren, G; Blair, HC; Davies, TF; Zaidi, M			TSH is a negative regulator of skeletal remodeling	CELL			English	Article							STIMULATING HORMONE-RECEPTOR; THYROID-HORMONE; THYROTROPIN RECEPTOR; OSTEOCLAST DIFFERENTIATION; PHOSPHATASE-ACTIVITY; BONE-MARROW; RANK LIGAND; KAPPA-B; EXPRESSION; CELLS	The established function of thyroid stimulating hormone (TSH) is to promote thyroid follicle development and hormone secretion. The osteoporosis associated with hyperthyroidism is traditionally viewed as a secondary consequence of altered thyroid function. We provide evidence for direct effects of TSH on both components of skeletal remodeling, osteoblastic bone formation, and osteoclastic bone resorption, mediated via the TSH receptor (TSHR) found on osteoblast and osteoclast precursors. Even a 50% reduction in TSHR expression produces profound osteoporosis (bone loss) together with focal osteosclerosis (localized bone formation). TSH inhibits osteoclast formation and survival by attenuating JNK/c-jun and NFkappaB signaling triggered in response to RANK-L and TNFalpha. TSH also inhibits osteoblast differentiation and type 1 collagen expression in a Runx-2- and osterix-independent manner by downregulating Wnt (LRP-5) and VEGF (Flk) signaling. These studies define a role for TSH as a single molecular switch in the independent control of both bone formation and resorption.	CUNY Mt Sinai Sch Med, Dept Med, Mt Sinai Bone Program, New York, NY 10029 USA; Vet Affairs Med Ctr, Bronx, NY 10463 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA; Vet Affairs Med Ctr, Pittsburgh, PA 15213 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Zaidi, M (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Mt Sinai Bone Program, New York, NY 10029 USA.	mone.zaidi@mssm.edu			NIA NIH HHS [AG-14917-8, AG23176-01] Funding Source: Medline; NIDDK NIH HHS [DK52464, DK45011, DK07646] Funding Source: Medline; PHS HHS [A124671] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007646, R01DK052464, R01DK045011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014917, R01AG023176] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663; Ando T, 2002, J CLIN INVEST, V110, P1667, DOI 10.1172/JCI200216991; Bagriacik EU, 2000, J IMMUNOL, V164, P6158, DOI 10.4049/jimmunol.164.12.6158; Blair HC, 2002, BIOCHEM J, V364, P329, DOI 10.1042/BJ20020165; BORDIER P, 1967, P ROY SOC MED, V60, P1132, DOI 10.1177/003591576706011P130; BRITTO JM, 1994, ENDOCRINOLOGY, V134, P169, DOI 10.1210/en.134.1.169; Davies T, 2002, J CLIN INVEST, V110, P161, DOI 10.1172/JCI200216234; ENDO T, 1995, J BIOL CHEM, V270, P10833, DOI 10.1074/jbc.270.18.10833; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gothe S, 1999, GENE DEV, V13, P1329, DOI 10.1101/gad.13.10.1329; Greenspan SL, 1999, ANN INTERN MED, V130, P750, DOI 10.7326/0003-4819-130-9-199905040-00016; Hofbauer LC, 2002, J CELL BIOCHEM, V86, P642, DOI 10.1002/jcb.10242; Inoue M, 1998, THYROID, V8, P1059, DOI 10.1089/thy.1998.8.1059; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kawaida R, 2003, J EXP MED, V197, P1029, DOI 10.1084/jem.20021321; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Kohn L D, 1995, Vitam Horm, V50, P287, DOI 10.1016/S0083-6729(08)60658-5; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Lecka-Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Marians RC, 2002, P NATL ACAD SCI USA, V99, P15776, DOI 10.1073/pnas.242322099; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153; Prummel MF, 2000, J CLIN ENDOCR METAB, V85, P4347, DOI 10.1210/jc.85.11.4347; Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279; SATO K, 1987, ENDOCRINOLOGY, V120, P1873, DOI 10.1210/endo-120-5-1873; Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197; Sims NA, 2003, J CLIN INVEST, V111, P1319, DOI 10.1172/JCI200317246; Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200; Sun L, 2003, FASEB J, V17, P369, DOI 10.1096/fj.02-0205com; Takahashi N, 2003, METH MOLEC MED, V80, P129; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Valyasevi RW, 1999, J CLIN ENDOCR METAB, V84, P2557, DOI 10.1210/jc.84.7.2557; Vincent BL, 2001, J BONE MINER RES, V16, pS268; Wang HC, 2003, BLOOD, V101, P119, DOI 10.1182/blood-2002-02-0544; WANG J, 1995, CELL IMMUNOL, V161, P299, DOI 10.1006/cimm.1995.1040; WEBBER DM, 1988, HISTOCHEM J, V20, P269, DOI 10.1007/BF01745605; Wei S, 2001, ENDOCRINOLOGY, V142, P1290, DOI 10.1210/en.142.3.1290; Zaidi M, 2003, J BONE MINER RES, V18, P599, DOI 10.1359/jbmr.2003.18.4.599; Zelzer E, 2002, DEVELOPMENT, V129, P1893	42	461	506	2	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	2003	115	2					151	162		10.1016/S0092-8674(03)00771-2	http://dx.doi.org/10.1016/S0092-8674(03)00771-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567913	Bronze			2022-12-28	WOS:000186039200007
J	Eysel, UT				Eysel, UT			Illusions and perceived images in the primate brain	SCIENCE			English	Editorial Material							MACAQUE MONKEY; CORTEX; AREA; DIRECTION; SIGNALS; NEURONS		Ruhr Univ Bochum, Dept Neurophysiol, D-44780 Bochum, Germany	Ruhr University Bochum	Eysel, UT (corresponding author), Ruhr Univ Bochum, Dept Neurophysiol, D-44780 Bochum, Germany.			Eysel, Ulf/0000-0001-6087-957X				Chen LM, 2003, SCIENCE, V302, P881, DOI 10.1126/science.1087846; CHEN LM, 2003, SCIENCE         0918; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; KAAS JH, 1979, SCIENCE, V204, P521, DOI 10.1126/science.107591; Macknik SL, 1999, P NATL ACAD SCI USA, V96, P15208, DOI 10.1073/pnas.96.26.15208; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; Movshon JA, 1996, J NEUROSCI, V16, P7733; Penfield W., 1950, CEREBRAL CORTEX MAN; Ramsden BM, 2001, CEREB CORTEX, V11, P648, DOI 10.1093/cercor/11.7.648; SAITO H, 1986, J NEUROSCI, V6, P145; TOOTELL RBH, 1982, SCIENCE, V218, P902, DOI 10.1126/science.7134981; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; WADE N, 2000, HELMHOLTZS TREATISE; Whitney D, 2003, SCIENCE, V302, P878, DOI 10.1126/science.1087839; WHITNEY D, 2003, SCIENCE         0918	16	12	13	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 31	2003	302	5646					789	791		10.1126/science.1091065	http://dx.doi.org/10.1126/science.1091065			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593154				2022-12-28	WOS:000186258000024
J	Dasen, JS; Liu, JP; Jessell, TM				Dasen, JS; Liu, JP; Jessell, TM			Motor neuron columnar fate imposed by sequential phases of Hox-c activity	NATURE			English	Article							SPINAL-CORD; HOMEODOMAIN PROTEIN; SUBTYPE IDENTITY; HOMEOTIC TRANSFORMATIONS; TRANSCRIPTIONAL CODES; POSITIONAL IDENTITY; GENES; EXPRESSION; MICE; SPECIFICATION	The organization of neurons into columns is a prominent feature of central nervous systemstructure and function. In many regions of the central nervous system the grouping of neurons into columns links cell-body position to axonal trajectory, thus contributing to the establishment of topographic neural maps. This link is prominent in the developing spinal cord, where columnar sets of motor neurons innervate distinct targets in the periphery. We show here that sequential phases of Hox-c protein expression and activity control the columnar differentiation of spinal motor neurons. Hox expression in neural progenitors is established by graded fibroblast growth factor signalling and translated into a distinct motor neuron Hox pattern. Motor neuron columnar fate then emerges through cell autonomous repressor and activator functions of Hox proteins. Hox proteins also direct the expression of genes that establish motor topographic projections, thus implicating Hox proteins as critical determinants of spinal motor neuron identity and organization.	Columbia Univ, Ctr Neurobiol & Behav, Dept Biochem & Mol Biophys, Howard Hughes Med Inst, New York, NY 10032 USA; Univ Virginia, Sch Med, Dept Neurosci, Charlottesville, VA 22908 USA	Columbia University; Howard Hughes Medical Institute; University of Virginia	Jessell, TM (corresponding author), Columbia Univ, Ctr Neurobiol & Behav, Dept Biochem & Mol Biophys, Howard Hughes Med Inst, 701 W 168th St, New York, NY 10032 USA.							Arber S, 1999, NEURON, V23, P659, DOI 10.1016/S0896-6273(01)80026-X; Bel-Vialar S, 2002, DEVELOPMENT, V129, P5103; Bell E, 1999, SCIENCE, V284, P2168, DOI 10.1126/science.284.5423.2168; Brend T, 2003, DEVELOPMENT, V130, P2717, DOI 10.1242/dev.00471; Briscoe J, 2001, CURR OPIN NEUROBIOL, V11, P43, DOI 10.1016/S0959-4388(00)00172-0; Briscoe J, 2000, CELL, V101, P435, DOI 10.1016/S0092-8674(00)80853-3; Cai J, 2000, GENESIS, V27, P6, DOI 10.1002/1526-968X(200005)27:1<6::AID-GENE20>3.3.CO;2-F; Carpenter EM, 2002, DEV NEUROSCI-BASEL, V24, P24, DOI 10.1159/000064943; Chen F, 1999, P NATL ACAD SCI USA, V96, P541, DOI 10.1073/pnas.96.2.541; Cohn MJ, 1997, NATURE, V387, P97, DOI 10.1038/387097a0; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Cooper KL, 2003, DEV BIOL, V253, P200, DOI 10.1016/S0012-1606(02)00018-0; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; Ensini M, 1998, DEVELOPMENT, V125, P969; Gabay L, 1997, DEVELOPMENT, V124, P3535; Garcia-Gasca A, 2000, DEV DYNAM, V219, P261, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1048>3.0.CO;2-3; Goddard JM, 1996, DEVELOPMENT, V122, P3217; GUTMAN CR, 1993, BRAIN RES, V609, P129, DOI 10.1016/0006-8993(93)90865-K; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; HOLLYDAY M, 1980, J COMP NEUROL, V194, P143, DOI 10.1002/cne.901940108; HOLLYDAY M, 1990, J COMP NEUROL, V302, P575, DOI 10.1002/cne.903020313; Hollyday M., 1980, Current Topics in Developmental Biology, V15, P181; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Kania A, 2003, NEURON, V38, P581, DOI 10.1016/S0896-6273(03)00292-7; Kmita M, 2003, SCIENCE, V301, P331, DOI 10.1126/science.1085753; KOSTIC D, 1994, MECH DEVELOP, V46, P231, DOI 10.1016/0925-4773(94)90073-6; Lance-Jones C, 2001, DEVELOPMENT, V128, P2255; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P371, DOI 10.1113/jphysiol.1978.sp012545; Li XL, 1999, P NATL ACAD SCI USA, V96, P6802, DOI 10.1073/pnas.96.12.6802; Liu JP, 2001, NEURON, V32, P997, DOI 10.1016/S0896-6273(01)00544-X; Mann RS, 1998, CURR OPIN GENET DEV, V8, P423, DOI 10.1016/S0959-437X(98)80113-5; Mountcastle VB, 1997, BRAIN, V120, P701, DOI 10.1093/brain/120.4.701; Muhr J, 2001, CELL, V104, P861, DOI 10.1016/S0092-8674(01)00283-5; Nelson CE, 1996, DEVELOPMENT, V122, P1449; Niederreither K, 1997, MECH DEVELOP, V62, P67, DOI 10.1016/S0925-4773(96)00653-3; PRASAD A, 1991, J COMP NEUROL, V307, P237, DOI 10.1002/cne.903070207; Rossel M, 1999, DEVELOPMENT, V126, P5027; Sanders TA, 2002, J NEUROSCI, V22, P10742; Shirasaki R, 2002, ANNU REV NEUROSCI, V25, P251, DOI 10.1146/annurev.neuro.25.112701.142916; Sockanathan S, 2003, NEURON, V40, P97, DOI 10.1016/S0896-6273(03)00532-4; Sockanathan S, 1998, CELL, V94, P503, DOI 10.1016/S0092-8674(00)81591-3; Studer M, 1996, NATURE, V384, P630, DOI 10.1038/384630a0; Suemori H, 2000, DEV BIOL, V220, P333, DOI 10.1006/dbio.2000.9651; Tiret L, 1998, DEVELOPMENT, V125, P279; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Wahba GM, 2001, DEV BIOL, V231, P87, DOI 10.1006/dbio.2000.0130; William CM, 2003, DEVELOPMENT, V130, P1523, DOI 10.1242/dev.00358	49	262	268	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	2003	425	6961					926	933		10.1038/nature02051	http://dx.doi.org/10.1038/nature02051			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14586461				2022-12-28	WOS:000186230600033
J	Finkelstein, I; Piasetzky, E				Finkelstein, I; Piasetzky, E			Comment on "C-14 dates from Tel Rehov: Iron-Age chronology, Pharaohs, and Hebrew kings"	SCIENCE			English	Editorial Material									Tel Aviv Univ, Archaeol Inst, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sch Phys & Astron, IL-69978 Tel Aviv, Israel	Tel Aviv University; Tel Aviv University	Finkelstein, I (corresponding author), Tel Aviv Univ, Archaeol Inst, IL-69978 Tel Aviv, Israel.							BIRAN A, 1995, ISRAEL EXPLOR J, V45, P1; Bruins HJ, 2003, SCIENCE, V300, P315, DOI 10.1126/science.1082776; FINKELSTEIN I, IN PRESS ANTIQUITY; Finkelstein Israel, 1996, LEVANT, V28, P177, DOI DOI 10.1179/LEV.1996.28.1.177; Gilboa A, 2001, RADIOCARBON, V43, P1343; Mazar A, 2001, RADIOCARBON, V43, P1333; Ussishkin D., 1990, BASOR, V277-278, P71	7	15	15	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645												1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576405				2022-12-28	WOS:000186119900027
J	Lamb, S; Davis, P				Lamb, S; Davis, P			Cenozoic climate change as a possible cause for the rise of the Andes	NATURE			English	Article							VERTICAL AXIS ROTATION; SUBDUCTION EROSION; BOLIVIAN OROCLINE; CONVERGENT MARGIN; NAZCA FARALLON; FAULT ZONE; NORTHERN; CHILE; EARTHQUAKE; PLATEAU	Causal links between the rise of a large mountain range and climate have often been considered to work in one direction, with significant uplift provoking climate change. Here we propose a mechanism by which Cenozoic climate change could have caused the rise of the Andes. Based on considerations of the force balance in the South American lithosphere, we suggest that the height of, and tectonics in, the Andes are strongly controlled both by shear stresses along the plate interface in the subduction zone and by buoyancy stress contrasts between the trench and highlands, and shear stresses in the subduction zone depend on the amount of subducted sediments. We propose that the dynamics of subduction and mountain-building in this region are controlled by the processes of erosion and sediment deposition, and ultimately climate. In central South America, climate-controlled sediment starvation would then cause high shear stress, focusing the plate boundary stresses that support the high Andes.	Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England; Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA	University of Oxford; University of California System; University of California Los Angeles	Lamb, S (corresponding author), Univ Oxford, Dept Earth Sci, Parks Rd, Oxford OX1 3PR, England.	simon.lamb@earth.ox.ac.uk	Davis, Paul/E-7151-2012; DAVIS, Paul/HCH-8889-2022					Allmendinger RW, 1997, ANNU REV EARTH PL SC, V25, P139, DOI 10.1146/annurev.earth.25.1.139; Angermann D, 1999, EARTH PLANET SC LETT, V171, P329, DOI 10.1016/S0012-821X(99)00173-9; Bangs NL, 1997, TECTONICS, V16, P489, DOI 10.1029/97TC00494; BARRIENTOS SE, 1990, GEOPHYS J INT, V103, P589, DOI 10.1111/j.1365-246X.1990.tb05673.x; Beck SL, 1996, GEOLOGY, V24, P407, DOI 10.1130/0091-7613(1996)024<0407:CTVITC>2.3.CO;2; Brink KH., 1998, COAST SEGMENT, P273; CAHILL T, 1992, J GEOPHYS RES-SOL EA, V97, P17503, DOI 10.1029/92JB00493; Cembrano J, 1996, TECTONOPHYSICS, V259, P55, DOI 10.1016/0040-1951(95)00066-6; CLADOUHOS TT, 1994, J S AM EARTH SCI, V7, P209, DOI 10.1016/0895-9811(94)90008-6; Clapperton CM, 1993, QUATERNARY GEOLOGY G; CROUGH ST, 1983, TECTONOPHYSICS, V94, P23, DOI 10.1016/0040-1951(83)90007-0; Delouis B, 1996, TECTONOPHYSICS, V259, P81, DOI 10.1016/0040-1951(95)00065-8; DOSER DI, 1987, GEOPHYS J ROY ASTR S, V91, P57, DOI 10.1111/j.1365-246X.1987.tb05213.x; GIESE P, 1998, SONDERFORSCHUNGSBERE, V267, P15; Gregory-Wodzicki KM, 2000, GEOL SOC AM BULL, V112, P1091, DOI 10.1130/0016-7606(2000)112<1091:UHOTCA>2.0.CO;2; GUBBELS TL, 1993, GEOLOGY, V21, P695, DOI 10.1130/0091-7613(1993)021<0695:HLSPUA>2.3.CO;2; Gutscher MA, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000787; Hartley AJ, 2003, J GEOL SOC LONDON, V160, P7, DOI 10.1144/0016-764902-083; Hindle D, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013757; Horton BK, 2002, J SEDIMENT RES, V72, P711, DOI 10.1306/020702720711; HYNDMAN RD, 1993, J GEOPHYS RES-SOL EA, V98, P2039, DOI 10.1029/92JB02279; JUDGE AV, 1991, J GEOPHYS RES-SOL EA, V96, P16625, DOI 10.1029/90JB01772; Keller G, 1997, MAR MICROPALEONTOL, V31, P97, DOI 10.1016/S0377-8398(96)00061-8; Klotz J, 1999, PURE APPL GEOPHYS, V154, P709, DOI 10.1007/s000240050249; KULM LD, 1977, M EWING SERIES, V1, P285; Lamb S, 1997, TECTONICS, V16, P623, DOI 10.1029/97TC00495; Lamb S, 2000, J GEOPHYS RES-SOL EA, V105, P25627, DOI 10.1029/2000JB900187; Lamb S, 1997, GEOL SOC SPEC PUBL, V121, P237, DOI 10.1144/GSL.SP.1997.121.01.10; Lamb S, 2001, J GEOPHYS RES-SOL EA, V106, P26633, DOI 10.1029/2001JB000203; Lamb S, 2001, J GEOPHYS RES-SOL EA, V106, P26605, DOI 10.1029/2001JB900012; MERCIER JL, 1992, J GEOPHYS RES-SOL EA, V97, P11945, DOI 10.1029/90JB02473; MOLNAR P, 1990, J GEOPHYS RES-SOLID, V95, P4833, DOI 10.1029/JB095iB04p04833; Montgomery DR, 2001, GEOLOGY, V29, P579, DOI 10.1130/0091-7613(2001)029<0579:CTATMO>2.0.CO;2; Muller RD, 1997, J GEOPHYS RES-SOL EA, V102, P3211, DOI 10.1029/96JB01781; *NAT EARTHQ INF CT, 2003, EARTHQ CAT; PARDOCASAS F, 1987, TECTONICS, V6, P233, DOI 10.1029/TC006i003p00233; Peacock S.M., 1996, SUBDUCTION TOP BOTTO, V96, P119, DOI DOI 10.1029/GM096P0119; Rind D, 1998, J GEOPHYS RES-ATMOS, V103, P5943, DOI 10.1029/97JD03649; RUFF LJ, 1989, PURE APPL GEOPHYS, V129, P263, DOI 10.1007/BF00874629; SCHWARTZ DP, 1988, J GEOPHYS RES-SOLID, V93, P4712, DOI 10.1029/JB093iB05p04712; SCHWERDTFEGER W, 1976, CLIMATES CENTRAL S A, P1; SMITH AG, 1981, GEOLOGICAL SOC LONDO, V9, P111; Somoza R, 1998, J S AM EARTH SCI, V11, P211, DOI 10.1016/S0895-9811(98)00012-1; Springer M, 1998, TECTONOPHYSICS, V291, P123, DOI 10.1016/S0040-1951(98)00035-3; SUAREZ G, 1983, J GEOPHYS RES, V88, P403, DOI 10.1029/JB088iB12p10403; THORNBURG TM, 1987, GEOL SOC AM BULL, V98, P33, DOI 10.1130/0016-7606(1987)98<33:SITCTD>2.0.CO;2; TICHELAAR BW, 1993, J GEOPHYS RES-SOL EA, V98, P2017, DOI 10.1029/92JB02045; *U LEEDS GET, 1998, DIG EL MOD 3M 3M S A; von Huene R, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB001569; VONHUENE R, 1991, REV GEOPHYS, V29, P279, DOI 10.1029/91RG00969; WATTS AB, 1995, EARTH PLANET SC LETT, V134, P9, DOI 10.1016/0012-821X(95)00095-T; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412	52	351	368	5	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 23	2003	425	6960					792	797		10.1038/nature02049	http://dx.doi.org/10.1038/nature02049			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574402				2022-12-28	WOS:000186118500035
J	Mungall, AJ; Palmer, SA; Sims, SK; Edwards, CA; Ashurst, JL; Wilming, L; Jones, MC; Horton, R; Hunt, SE; Scott, CE; Gilbert, JGR; Clamp, ME; Bethel, G; Milne, S; Ainscough, R; Almeida, JP; Ambrose, KD; Andrews, TD; Ashwell, RIS; Babbage, AK; Bagguley, CL; Bailey, J; Banerjee, R; Barker, DJ; Barlow, KF; Bates, K; Beare, DM; Beasley, H; Beasley, O; Bird, CP; Blakey, S; Bray-Allen, S; Brook, J; Brown, AJ; Brown, JY; Burford, DC; Burrill, W; Burton, J; Carder, C; Carter, NP; Chapman, JC; Clark, SY; Clark, G; Clee, CM; Clegg, S; Cobley, V; Collier, RE; Collins, JE; Colman, LK; Corby, NR; Coville, GJ; Culley, KM; Dhami, P; Davies, J; Dunn, M; Earthrowl, ME; Ellington, AE; Evans, KA; Faulkner, L; Francis, MD; Frankish, A; Frankland, J; French, L; Garner, P; Garnett, J; Ghori, MJR; Gilby, LM; Gillson, CJ; Glithero, RJ; Grafham, DV; Grant, M; Gribble, S; Griffiths, C; Griffiths, M; Hall, R; Halls, KS; Hammond, S; Harley, JL; Hart, EA; Heath, PD; Heathcott, R; Holmes, SJ; Howden, PJ; Howe, KL; Howell, GR; Huckle, E; Humphray, SJ; Humphries, MD; Hunt, AR; Johnson, CM; Joy, AA; Kay, M; Keenan, SJ; Kimberley, AM; King, A; Laird, GK; Langford, C; Lawlor, S; Leongamornlert, DA; Leversha, M; Lloyd, CR; Lloyd, DM; Loveland, JE; Lovell, J; Martin, S; Mashreghi-Mohammadi, M; Maslen, GL; Matthews, L; McCann, OT; McLaren, SJ; McLay, K; McMurray, A; Moore, MJF; Mullikin, JC; Niblett, D; Nickerson, T; Novik, KL; Oliver, K; Overton-Larty, EK; Parker, A; Patel, R; Pearce, AV; Peck, AI; Phillimore, B; Phillips, S; Plumb, RW; Porter, KM; Ramsey, Y; Ranby, SA; Rice, CM; Ross, MT; Searle, SM; Sehra, HK; Sheridan, E; Skuce, CD; Smith, S; Smith, M; Spraggon, L; Squares, SL; Steward, CA; Sycamore, N; Tamlyn-Hall, G; Tester, J; Theaker, AJ; Thomas, DW; Thorpe, A; Tracey, A; Tromans, A; Tubby, B; Wall, M; Wallis, JM; West, AP; White, SS; Whitehead, SL; Whittaker, H; Wild, A; Willey, DJ; Wilmer, TE; Wood, JM; Wray, PW; Wyatt, JC; Young, L; Younger, RM; Bentley, DR; Coulson, A; Durbin, R; Hubbard, T; Sulston, JE; Dunham, I; Rogers, J; Beck, S				Mungall, AJ; Palmer, SA; Sims, SK; Edwards, CA; Ashurst, JL; Wilming, L; Jones, MC; Horton, R; Hunt, SE; Scott, CE; Gilbert, JGR; Clamp, ME; Bethel, G; Milne, S; Ainscough, R; Almeida, JP; Ambrose, KD; Andrews, TD; Ashwell, RIS; Babbage, AK; Bagguley, CL; Bailey, J; Banerjee, R; Barker, DJ; Barlow, KF; Bates, K; Beare, DM; Beasley, H; Beasley, O; Bird, CP; Blakey, S; Bray-Allen, S; Brook, J; Brown, AJ; Brown, JY; Burford, DC; Burrill, W; Burton, J; Carder, C; Carter, NP; Chapman, JC; Clark, SY; Clark, G; Clee, CM; Clegg, S; Cobley, V; Collier, RE; Collins, JE; Colman, LK; Corby, NR; Coville, GJ; Culley, KM; Dhami, P; Davies, J; Dunn, M; Earthrowl, ME; Ellington, AE; Evans, KA; Faulkner, L; Francis, MD; Frankish, A; Frankland, J; French, L; Garner, P; Garnett, J; Ghori, MJR; Gilby, LM; Gillson, CJ; Glithero, RJ; Grafham, DV; Grant, M; Gribble, S; Griffiths, C; Griffiths, M; Hall, R; Halls, KS; Hammond, S; Harley, JL; Hart, EA; Heath, PD; Heathcott, R; Holmes, SJ; Howden, PJ; Howe, KL; Howell, GR; Huckle, E; Humphray, SJ; Humphries, MD; Hunt, AR; Johnson, CM; Joy, AA; Kay, M; Keenan, SJ; Kimberley, AM; King, A; Laird, GK; Langford, C; Lawlor, S; Leongamornlert, DA; Leversha, M; Lloyd, CR; Lloyd, DM; Loveland, JE; Lovell, J; Martin, S; Mashreghi-Mohammadi, M; Maslen, GL; Matthews, L; McCann, OT; McLaren, SJ; McLay, K; McMurray, A; Moore, MJF; Mullikin, JC; Niblett, D; Nickerson, T; Novik, KL; Oliver, K; Overton-Larty, EK; Parker, A; Patel, R; Pearce, AV; Peck, AI; Phillimore, B; Phillips, S; Plumb, RW; Porter, KM; Ramsey, Y; Ranby, SA; Rice, CM; Ross, MT; Searle, SM; Sehra, HK; Sheridan, E; Skuce, CD; Smith, S; Smith, M; Spraggon, L; Squares, SL; Steward, CA; Sycamore, N; Tamlyn-Hall, G; Tester, J; Theaker, AJ; Thomas, DW; Thorpe, A; Tracey, A; Tromans, A; Tubby, B; Wall, M; Wallis, JM; West, AP; White, SS; Whitehead, SL; Whittaker, H; Wild, A; Willey, DJ; Wilmer, TE; Wood, JM; Wray, PW; Wyatt, JC; Young, L; Younger, RM; Bentley, DR; Coulson, A; Durbin, R; Hubbard, T; Sulston, JE; Dunham, I; Rogers, J; Beck, S			The DNA sequence and analysis of human chromosome 6	NATURE			English	Article							GENETIC-VARIATION; SEGMENTAL DUPLICATIONS; MEIOTIC RECOMBINATION; 6P22.3 GENE; LARGE-SCALE; RNA GENES; MAP; SCHIZOPHRENIA; MUTATIONS; DYSBINDIN	Chromosome 6 is a metacentric chromosome that constitutes about 6% of the human genome. The finished sequence comprises 166,880,988 base pairs, representing the largest chromosome sequenced so far. The entire sequence has been subjected to high-quality manual annotation, resulting in the evidence-supported identification of 1,557 genes and 633 pseudogenes. Here we report that at least 96% of the protein-coding genes have been identified, as assessed by multi-species comparative sequence analysis, and provide evidence for the presence of further, otherwise unsupported exons/ genes. Among these are genes directly implicated in cancer, schizophrenia, autoimmunity and many other diseases. Chromosome 6 harbours the largest transfer RNA gene cluster in the genome; we show that this cluster co-localizes with a region of high transcriptional activity. Within the essential immune loci of the major histocompatibility complex, we find HLA-B to be the most polymorphic gene on chromosome 6 and in the human genome.	Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England	Wellcome Trust Sanger Institute	Mungall, AJ (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.	ajm@sanger.ac.uk	Mungall, Andrew J./U-7067-2018; Hubbard, Tim J.P./AAT-4571-2020; Frankish, Adam/G-6545-2011; Durbin, Richard/AAE-7178-2019; Hubbard, Tim J/C-2567-2008; Barker, David JP/A-5671-2013; Andrews, Dan/ABG-4815-2020; Spraggon, Lee/E-5900-2012	Mungall, Andrew J./0000-0002-0905-2742; Hubbard, Tim J.P./0000-0002-1767-9318; Durbin, Richard/0000-0002-9130-1006; Hubbard, Tim J/0000-0002-1767-9318; Wass, Elizabeth/0000-0002-8605-9921; Fosker, Christine/0000-0002-3799-9474; Gilbert, James/0000-0001-8079-3159; Andrews, Dan/0000-0003-3922-6376; Davidson, Claire/0000-0002-4910-8202; Hunt, Sarah/0000-0002-8350-1235; Edwards, Carol/0000-0002-1887-1280; Wilming, Laurens/0000-0002-4154-7358; Hunt, Adrienne/0000-0002-1227-0310; Martin, Sancha/0000-0001-6213-5259; Frankish, Adam/0000-0002-4333-628X; Howe, Kevin/0000-0002-1751-9226; Keenan, Stephen/0000-0002-9141-7690; Loveland, Jane/0000-0002-7669-2934; Steward, Charles/0000-0001-8829-5349; Maslen, Gareth/0000-0001-7318-3678; Dunham, Ian/0000-0003-2525-5598; Kay, Mike/0000-0002-3282-0834; Leongamornlert, Daniel/0000-0002-3486-3168				Acquati F, 2001, ONCOGENE, V20, P980, DOI 10.1038/sj.onc.1204178; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Beck S, 1999, NATURE, V401, P921, DOI 10.1038/44853; Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573; Bentley DR, 2001, NATURE, V409, P942, DOI 10.1038/35057165; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; CEPELLINI R, 1967, HISTOCOMPATIBILITY T, P149; Collins JE, 2003, GENOME RES, V13, P27, DOI 10.1101/gr.695703; Courseaux A, 2003, GENOME RES, V13, P369, DOI 10.1101/gr.490303; Cullen M, 2002, AM J HUM GENET, V71, P759, DOI 10.1086/342973; DAVIES AF, 1995, HUM MOL GENET, V4, P121; Deloukas P, 2001, NATURE, V414, P865, DOI 10.1038/414865a; Eddy SR, 2001, NAT REV GENET, V2, P919, DOI 10.1038/35103511; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Felsenfeld A, 1999, GENOME RES, V9, P1; Gu X, 2002, NAT GENET, V31, P205, DOI 10.1038/ng902; Heilig R, 2003, NATURE, V421, P601, DOI 10.1038/nature01348; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Jeffreys AJ, 2001, NAT GENET, V29, P217, DOI 10.1038/ng1001-217; Jeffries AR, 2003, MOL PSYCHIATR, V8, P654, DOI 10.1038/sj.mp.4001382; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kolomietz E, 2002, GENE CHROMOSOME CANC, V35, P97, DOI 10.1002/gcc.10111; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lehmann OJ, 2002, INVEST OPHTH VIS SCI, V43, P1843; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Minassian BA, 1998, NAT GENET, V20, P171, DOI 10.1038/2470; Mungall AJ, 1997, DNA SEQUENCE, V8, P151, DOI 10.3109/10425179709034066; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; Novik K. L., 2002, Current Issues in Molecular Biology, V4, P111; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Radosavljevic M, 2002, GENOMICS, V79, P114, DOI 10.1006/geno.2001.6673; Robinson J, 2003, NUCLEIC ACIDS RES, V31, P311, DOI [10.1093/nar/gkg070, 10.1093/nar/GKG070]; Roest Crollius H, 2000, NAT GENET, V25, P235, DOI 10.1038/76118; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Schwab SG, 2003, AM J HUM GENET, V72, P185, DOI 10.1086/345463; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Schwartz S, 2003, GENOME RES, V13, P103, DOI 10.1101/gr.809403; Sokal R.R., 1995, BIOMETRY PRINCIPLES, P803; Straub RE, 2002, AM J HUM GENET, V71, P337, DOI 10.1086/341750; Syvanen AC, 2001, NAT REV GENET, V2, P930, DOI 10.1038/35103535; Thomas JW, 2003, NATURE, V424, P788, DOI 10.1038/nature01858; Tiwari J.L., 1985, HLA DIS ASS; Trowsdale J, 2002, GENOME BIOL, V3; Volpi EV, 2000, J CELL SCI, V113, P1565; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; Wain HM, 2002, NUCLEIC ACIDS RES, V30, P169, DOI 10.1093/nar/30.1.169; Yu A, 2001, NATURE, V409, P951, DOI 10.1038/35057185	49	220	1250	3	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 23	2003	425	6960					805	U1		10.1038/nature02055	http://dx.doi.org/10.1038/nature02055			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574404	Bronze			2022-12-28	WOS:000186118500037
J	Duke, T				Duke, T			Sources of error: from procedures to end-of-life decisions	LANCET			English	Editorial Material									Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia	University of Melbourne	Duke, T (corresponding author), Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 18	2003	362	9392					1313	1313		10.1016/S0140-6736(03)14575-8	http://dx.doi.org/10.1016/S0140-6736(03)14575-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575978				2022-12-28	WOS:000186036900026
J	Matsushita, K; Morrell, CN; Cambien, B; Yang, SX; Yamakuchi, M; Bao, C; Hara, MR; Quick, RA; Cao, W; O'Rourke, B; Lowenstein, JM; Pevsner, J; Wagner, DD; Lowenstein, CJ				Matsushita, K; Morrell, CN; Cambien, B; Yang, SX; Yamakuchi, M; Bao, C; Hara, MR; Quick, RA; Cao, W; O'Rourke, B; Lowenstein, JM; Pevsner, J; Wagner, DD; Lowenstein, CJ			Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimdide-sensitive factor	CELL			English	Article							WEIBEL-PALADE BODIES; HUMAN-ENDOTHELIAL-CELLS; VON-WILLEBRAND-FACTOR; MEMBRANE-FUSION; TRANSPORT VESICLES; YEAST VACUOLES; KNOCKOUT MICE; P-SELECTIN; PROTEIN; NSF	Nitric oxide (NO) inhibits vascular inflammation, but the molecular basis for its anti-inflammatory properties is unknown. We show that NO inhibits exocytosis of Weibel-Palade bodies, endothelial granules that mediate vascular inflammation and thrombosis, by regulating the activity of N-ethylmaleimide-sensitive factor (NSF). NO inhibits NSF disassembly of soluble NSF attachment protein receptor (SNARE) complexes by nitrosylating critical cysteine residues of NSF. NO may regulate exocytosis in a variety of physiological processes, including vascular inflammation, neuro-transmission, thrombosis, and cytotoxic T lymphocyte cell killing.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Comparat Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Kennedy Krieger Institute; Brandeis University; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Lowenstein, CJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.			Lowenstein, Charles/0000-0003-0485-7514; Cambien, Beatrice/0000-0002-6914-0525; O'Rourke, Brian/0000-0002-5548-4853	NCRR NIH HHS [T32 RR007002, RR07002] Funding Source: Medline; NHLBI NIH HHS [R01 HL074061-04, HL074945, P01 HL065608, P01 HL56091, R37 HL41002, R01 HL63706-04, K08 HL074945, P01 HL056091-100003, R01 HL063706, R37 HL041002, P01 HL65608, R01 HL074061, R01 HL078635, P01 HL056091, R01 HL078635-04, P01 HL065608-050003] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [T32RR007002] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063706, R01HL074061, R37HL041002, R01HL078635, K08HL074945, P01HL056091, P01HL065608] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andre P, 2000, BLOOD, V96, P3322, DOI 10.1182/blood.V96.10.3322.h8003322_3322_3328; Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BONFANTI R, 1989, BLOOD, V73, P1109; Burgoyne RD, 1998, BIOESSAYS, V20, P328, DOI 10.1002/(SICI)1521-1878(199804)20:4<328::AID-BIES9>3.0.CO;2-L; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; Denis C, 1998, P NATL ACAD SCI USA, V95, P9524, DOI 10.1073/pnas.95.16.9524; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Huber D, 2002, BLOOD, V99, P3637, DOI 10.1182/blood.V99.10.3637; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; JAFFREY SR, 2001, SCI STKE; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Kuhlencordt PJ, 2001, CIRCULATION, V103, P3099, DOI 10.1161/01.CIR.103.25.3099; Kuhlencordt PJ, 2001, CIRCULATION, V104, P448, DOI 10.1161/hc2901.091399; Littleton JT, 1995, INVERTEBR NEUROSCI, V1, P3, DOI 10.1007/BF02331827; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; May AP, 2001, J BIOL CHEM, V276, P21991, DOI 10.1074/jbc.R100013200; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Ni HY, 2000, J CLIN INVEST, V106, P385, DOI 10.1172/JCI9896; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Papapetropoulos A, 1999, CARDIOVASC RES, V43, P509, DOI 10.1016/S0008-6363(99)00161-3; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Qian ZP, 2001, CIRCULATION, V104, P2369, DOI 10.1161/hc4401.098471; RADOMSKI MW, 1993, THROMB HAEMOSTASIS, V70, P36; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Ruggeri ZM, 1997, J CLIN INVEST, V100, pS41; Saura M, 1999, IMMUNITY, V10, P21, DOI 10.1016/S1074-7613(00)80003-5; Schweizer FE, 1998, SCIENCE, V279, P1203, DOI 10.1126/science.279.5354.1203; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; VISCHER UM, 1993, BLOOD, V82, P1184, DOI 10.1182/blood.V82.4.1184.1184; WAGNER DD, 1982, J CELL BIOL, V95, P355, DOI 10.1083/jcb.95.1.355; WAGNER DD, 1993, THROMB HAEMOSTASIS, V70, P105; Walev I, 2001, P NATL ACAD SCI USA, V98, P3185, DOI 10.1073/pnas.051429498; WEIBEL ER, 1964, J CELL BIOL, V23, P101, DOI 10.1083/jcb.23.1.101; Weiss EJ, 2002, BLOOD, V100, P3240, DOI 10.1182/blood-2002-05-1470; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247	51	358	379	0	14	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 17	2003	115	2					139	150		10.1016/S0092-8674(03)00803-1	http://dx.doi.org/10.1016/S0092-8674(03)00803-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567912	Green Accepted, Bronze			2022-12-28	WOS:000186039200006
J	Ponnuraj, K; Bowden, MG; Davis, S; Gurusiddappa, S; Moore, D; Choe, D; Xu, Y; Hook, M; Narayana, SVL				Ponnuraj, K; Bowden, MG; Davis, S; Gurusiddappa, S; Moore, D; Choe, D; Xu, Y; Hook, M; Narayana, SVL			A "dock, lock, and latch" structural model for a staphylococcal adhesin binding to fibrinogen	CELL			English	Article							BOVINE THROMBIN; CLUMPING FACTOR; EXTRACELLULAR-MATRIX; CRYSTAL-STRUCTURE; FIBRINOPEPTIDE-B; SURFACE PROTEIN; AUREUS; INFECTIONS; CLEAVAGE; RESIDUES	Gram-positive pathogens such as staphylococci contain multiple cell wall-anchored proteins that serve as an interface between the microbe and its environment. Some of these proteins act as adhesins and mediate bacterial attachment to host tissues. SdrG is a cell wall-anchored adhesin from Staphylococcus epidermidis that binds to the BP chain of human fibrinogen (Fg) and is necessary and sufficient for bacterial attachment to Fg-coated biomaterials. Here, we present the crystal structures of the ligand binding region of SdrG as an apoprotein and in complex with a synthetic peptide analogous to its binding site in Fg. Analysis of the crystal structures, along with mutational studies of both the protein and of the peptide, reveals that SdrG binds to its ligand with a dynamic "dock, lock, and latch" mechanism. We propose that this mechanism represents a general mode of ligand binding for structurally related cell wall-anchored proteins of gram-positive bacteria.	Texas A&M Univ, Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Inst Biosci & Technol, Houston, TX 77030 USA; Univ Alabama Birmingham, Sch Optometry, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Narayana, SVL (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Inst Biosci & Technol, Houston, TX 77030 USA.	mhook@ibt.tamu.edu; narayana@uab.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020624] Funding Source: NIH RePORTER; NIAID NIH HHS [AI10629, AI20624] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BINNIE CG, 1993, BLOOD, V81, P3186; BLOMBACK B, 1986, ANN NY ACAD SCI, V485, P120, DOI 10.1111/j.1749-6632.1986.tb34573.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; Davis SL, 2001, J BIOL CHEM, V276, P27799, DOI 10.1074/jbc.M103873200; Deivanayagam CCS, 1999, ACTA CRYSTALLOGR D, V55, P554, DOI 10.1107/S0907444998012426; Deivanayagam CCS, 2002, EMBO J, V21, P6660, DOI 10.1093/emboj/cdf619; Donlan RM, 2001, EMERG INFECT DIS, V7, P277, DOI 10.3201/eid0702.010226; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Huebner J, 1999, ANNU REV MED, V50, P223, DOI 10.1146/annurev.med.50.1.223; Hussain M, 2001, J BACTERIOL, V183, P6778, DOI 10.1128/JB.183.23.6778-6786.2001; JONSSON K, 1995, J BIOL CHEM, V270, P21457, DOI 10.1074/jbc.270.37.21457; KAY AB, 1974, BRIT J HAEMATOL, V27, P669, DOI 10.1111/j.1365-2141.1974.tb06633.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LORD ST, 1990, J BIOL CHEM, V265, P838; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Malkowski MG, 1997, BIOCHEM J, V326, P815, DOI 10.1042/bj3260815; MARTIN PD, 1992, J BIOL CHEM, V267, P7911; Martin PD, 1996, BIOCHEMISTRY-US, V35, P13030, DOI 10.1021/bi960656y; McAleese FM, 2001, J BIOL CHEM, V276, P29969, DOI 10.1074/jbc.M102389200; McCrea KW, 2000, MICROBIOL-SGM, V146, P1535, DOI 10.1099/00221287-146-7-1535; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palma M, 1999, J BACTERIOL, V181, P2840, DOI 10.1128/JB.181.9.2840-2845.1999; Palma M, 2001, J BIOL CHEM, V276, P31691, DOI 10.1074/jbc.M104554200; PATTI JM, 1994, CURR OPIN CELL BIOL, V6, P752, DOI 10.1016/0955-0674(94)90104-X; Perkins S, 2001, J BIOL CHEM, V276, P44721, DOI 10.1074/jbc.M106741200; Richards MJ, 2000, INFECT CONT HOSP EP, V21, P510, DOI 10.1086/501795; RICHARDSON DL, 1976, BRIT J HAEMATOL, V32, P507, DOI 10.1111/j.1365-2141.1976.tb00953.x; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; SCHERAGA HA, 1986, ANN NY ACAD SCI, V485, P124, DOI 10.1111/j.1749-6632.1986.tb34574.x; Schwarz-Linek U, 2003, NATURE, V423, P177, DOI 10.1038/nature01589; SENIOR RM, 1986, J CLIN INVEST, V77, P1014, DOI 10.1172/JCI112353; SKOGEN WF, 1988, BLOOD, V71, P1475; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839	38	225	234	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	2003	115	2					217	228		10.1016/S0092-8674(03)00809-2	http://dx.doi.org/10.1016/S0092-8674(03)00809-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567919	Bronze			2022-12-28	WOS:000186039200013
J	Huh, WK; Falvo, JV; Gerke, LC; Carroll, AS; Howson, RW; Weissman, JS; O'Shea, EK				Huh, WK; Falvo, JV; Gerke, LC; Carroll, AS; Howson, RW; Weissman, JS; O'Shea, EK			Global analysis of protein localization in budding yeast	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE GENOME; SUBCELLULAR-LOCALIZATION; FLUORESCENT PROTEIN; MASS-SPECTROMETRY; GENE DELETION; CELL-WALL; SCALE; ORGANIZATION; PHOSPHATASE; EXPRESSION	A fundamental goal of cell biology is to define the functions of proteins in the context of compartments that organize them in the cellular environment. Here we describe the construction and analysis of a collection of yeast strains expressing full-length, chromosomally tagged green fluorescent protein fusion proteins. We classify these proteins, representing 75% of the yeast proteome, into 22 distinct subcellular localization categories, and provide localization information for 70% of previously unlocalized proteins. Analysis of this high-resolution, high-coverage localization data set in the context of transcriptional, genetic, and protein-protein interaction data helps reveal the logic of transcriptional co-regulation, and provides a comprehensive view of interactions within and between organelles in eukaryotic cells.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	O'Shea, EK (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, 600 16th St, San Francisco, CA 94143 USA.		Huh, Won-Ki/AAQ-6767-2021	Weissman, Jonathan/0000-0003-2445-670X				Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Bergmann S, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.031902; BHATTACHARYA S, 1995, P NATL ACAD SCI USA, V92, P2984, DOI 10.1073/pnas.92.7.2984; Breitkreutz BJ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r22; Breitkreutz BJ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r23; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Cope MJTV, 1999, J CELL BIOL, V144, P1203, DOI 10.1083/jcb.144.6.1203; DeMarini DJ, 1997, J CELL BIOL, V139, P75, DOI 10.1083/jcb.139.1.75; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DOLINSKI K, 2003, GENOME DATABASE; Drawid A, 2000, TRENDS GENET, V16, P426, DOI 10.1016/S0168-9525(00)02108-9; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hodges PE, 2002, NUCLEIC ACIDS RES, V30, P137, DOI 10.1093/nar/30.1.137; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Ihmels J, 2002, NAT GENET, V31, P370, DOI 10.1038/ng941; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Koc EC, 2001, J BIOL CHEM, V276, P43958, DOI 10.1074/jbc.M106510200; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Madden K, 1998, ANNU REV MICROBIOL, V52, P687, DOI 10.1146/annurev.micro.52.1.687; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; Rabitsch KP, 2003, DEV CELL, V4, P535, DOI 10.1016/S1534-5807(03)00086-8; Ross-Macdonald P, 1999, NATURE, V402, P413, DOI 10.1038/46558; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; San-Segundo PA, 1999, CELL, V97, P313, DOI 10.1016/S0092-8674(00)80741-2; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Taylor SW, 2003, TRENDS BIOTECHNOL, V21, P82, DOI 10.1016/S0167-7799(02)00037-9; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Trilla JA, 1999, J CELL BIOL, V145, P1153, DOI 10.1083/jcb.145.6.1153; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; VANBERKEL MAA, 1994, FEBS LETT, V349, P135, DOI 10.1016/0014-5793(94)00631-8; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Wigge PA, 1998, J CELL BIOL, V141, P967, DOI 10.1083/jcb.141.4.967; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	48	3156	5246	11	396	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					686	691		10.1038/nature02026	http://dx.doi.org/10.1038/nature02026			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562095				2022-12-28	WOS:000185924500033
J	Sollner, C; Burghammer, M; Busch-Nentwich, E; Berger, J; Schwarz, H; Riekel, C; Nicolson, T				Sollner, C; Burghammer, M; Busch-Nentwich, E; Berger, J; Schwarz, H; Riekel, C; Nicolson, T			Control of crystal size and lattice formation by starmaker in otolith biomineralization	SCIENCE			English	Article							EAR DEVELOPMENT; FISH OTOLITHS; MAJOR PROTEIN; ZEBRAFISH; MACROMOLECULES; DIMENSIONS; MUTATIONS; OTOCONIA; MATRIX; DSPP	The stone-like otoliths from the ears of teleost fishes are involved in balance and hearing and consist of calcium carbonate crystallites embedded in a protein framework. We report that a previously unknown gene, starmaker, is required in zebrafish for otolith morphogenesis. Reduction of starmaker activity by injection of modified antisense oligonucleotides causes a change in the crystal lattice structure and thus a change in otolith morphology. The expression pattern of starmaker, along with the presence of the protein on the growing otolith, suggest that the expression levels of starmaker control the shape of the otoliths.	Max Planck Inst Entwicklungsbiol, Microscopy Unit, D-72076 Tubingen, Germany; European Synchrotron Radiat Facil, F-38073 Grenoble, France	Max Planck Society; European Synchrotron Radiation Facility (ESRF)	Nicolson, T (corresponding author), Oregon Hlth & Sci Univ, Oregon Hearing Res Ctr, Portland, OR 97201 USA.	nicolson@ohsu.edu						Bekele H, 1999, J AM CHEM SOC, V121, P7266, DOI 10.1021/ja991416j; Belcher AM, 1996, NATURE, V381, P56, DOI 10.1038/381056a0; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Borelli G, 2001, CALCIFIED TISSUE INT, V69, P356, DOI 10.1007/s00223-001-2016-8; Campana SE, 1999, MAR ECOL PROG SER, V188, P263, DOI 10.3354/meps188263; Draper BW, 2001, GENESIS, V30, P154, DOI 10.1002/gene.1053; Everett LA, 2001, HUM MOL GENET, V10, P153, DOI 10.1093/hmg/10.2.153; Falini G, 1996, SCIENCE, V271, P67, DOI 10.1126/science.271.5245.67; FAY RR, 1984, SCIENCE, V225, P951, DOI 10.1126/science.6474161; Haddon C, 1996, J COMP NEUROL, V365, P113, DOI 10.1002/(SICI)1096-9861(19960129)365:1<113::AID-CNE9>3.0.CO;2-6; Hurle B, 2003, HUM MOL GENET, V12, P777, DOI 10.1093/hmg/ddg087; LOWENSTAM HA, 1981, SCIENCE, V211, P1126, DOI 10.1126/science.7008198; Lowenstam HA, 1989, BIOMINERALIZATION; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; NEILSON JD, 1985, FISH B-NOAA, V83, P81; PANNELLA G, 1971, SCIENCE, V173, P1124, DOI 10.1126/science.173.4002.1124; Pisam M, 2002, CELL TISSUE RES, V310, P163, DOI 10.1007/s00441-002-0622-z; POPPER A, 1993, INNER EAR LATERAL LI, P99; POTE KG, 1993, BIOCHEMISTRY-US, V32, P5017, DOI 10.1021/bi00070a007; RADTKE RL, 1982, FISH B-NOAA, V80, P201; Riekel C, 2000, REP PROG PHYS, V63, P233, DOI 10.1088/0034-4885/63/3/201; Riley BB, 1997, DEV BIOL, V191, P191, DOI 10.1006/dbio.1997.8736; Verpy E, 1999, P NATL ACAD SCI USA, V96, P529, DOI 10.1073/pnas.96.2.529; Wang YX, 1998, P NATL ACAD SCI USA, V95, P15345, DOI 10.1073/pnas.95.26.15345; WEINER S, 1991, TRENDS BIOCHEM SCI, V16, P252, DOI 10.1016/0968-0004(91)90098-G; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765	27	228	231	2	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					282	286		10.1126/science.1088443	http://dx.doi.org/10.1126/science.1088443			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551434				2022-12-28	WOS:000185825900041
J	Eremtchenko, M; Schaefer, JA; Tautz, FS				Eremtchenko, M; Schaefer, JA; Tautz, FS			Understanding and tuning the epitaxy of large aromatic adsorbates by molecular design	NATURE			English	Article							THIN-FILM TRANSISTORS; ORGANIC SEMICONDUCTOR; QUASIEPITAXIAL GROWTH; DIANHYDRIDE; MONOLAYERS; INTERFACES; TRANSPORT; SURFACES; DIODES	If the rich functionality of organic molecules is to be exploited in devices such as light-emitting diodes or field-effect transistors(1-7), interface properties of organic materials with various (metallic and insulating) substrates must be tailored carefully(7-10). In many cases, this calls for well-ordered interfaces. Organic epitaxy(11-13) that is, the growth of molecular films with a commensurate structural relationship to their crystalline substrates-relies on successful recognition of preferred epitaxial sites. For some large pi-conjugated molecules ('molecular platelets') this works surprisingly well(14,15), even if the substrate exhibits no template structure into which the molecules can lock(13, 15,16). Here we present an explanation for site recognition in non-templated organic epitaxy, and thus resolve a long-standing puzzle(11).We propose that this form of site recognition relies on the existence of a local molecular reaction centre in the extended pi-electron system of the molecule. Its activity can be controlled by appropriate side groups and-in a certain regime-may also be probed by molecularly sensitized scanning tunnelling microscopy. Our results open the possibility of engineering epitaxial interfaces, as well as other interfacial nanostructures for which specific site recognition is essential.	Int Univ Bremen, Sch Sci & Engn, D-28725 Bremen, Germany; Tech Univ Ilmenau, Inst Phys, D-98684 Ilmenau, Germany; Tech Univ Ilmenau, Zentrum Mikro & Nanotechnol, D-98684 Ilmenau, Germany	Jacobs University; Technische Universitat Ilmenau; Technische Universitat Ilmenau	Tautz, FS (corresponding author), Int Univ Bremen, Sch Sci & Engn, POB 750561, D-28725 Bremen, Germany.		Tautz, Frank Stefan/L-4500-2016	Tautz, Frank Stefan/0000-0003-3583-2379				Bohringer M, 1998, SURF SCI, V408, P72, DOI 10.1016/S0039-6028(98)00151-4; Chen Q, 2002, CHEM MATER, V14, P743, DOI 10.1021/cm011185r; Crone B, 2000, NATURE, V403, P521, DOI 10.1038/35000530; Dimitrakopoulos CD, 2002, ADV MATER, V14, P99, DOI 10.1002/1521-4095(20020116)14:2<99::AID-ADMA99>3.0.CO;2-9; Dimitrakopoulos CD, 1999, SCIENCE, V283, P822, DOI 10.1126/science.283.5403.822; Dodabalapur A, 1997, SOLID STATE COMMUN, V102, P259, DOI 10.1016/S0038-1098(96)00714-4; Fink R, 1999, PHYS REV B, V60, P2818, DOI 10.1103/PhysRevB.60.2818; FORREST SR, 1984, J APPL PHYS, V56, P543, DOI 10.1063/1.333944; Forrest SR, 1997, CHEM REV, V97, P1793, DOI 10.1021/cr941014o; FORREST SR, 1994, PHYS REV B, V49, P11309, DOI 10.1103/PhysRevB.49.11309; Frisch M. J., 1998, GAUSSIAN 98; Heringdorf FJMZ, 2001, NATURE, V412, P517, DOI 10.1038/35087532; Hill IG, 2000, APPL SURF SCI, V166, P354, DOI 10.1016/S0169-4332(00)00449-9; Hillier AC, 1996, PHYS REV B, V54, P14037, DOI 10.1103/PhysRevB.54.14037; HIROSE Y, 1995, APPL PHYS LETT, V66, P944, DOI 10.1063/1.113605; HIROSE Y, 1995, PHYS REV B, V52, P14040, DOI 10.1103/PhysRevB.52.14040; Horowitz G, 1998, ADV MATER, V10, P365, DOI 10.1002/(SICI)1521-4095(199803)10:5<365::AID-ADMA365>3.0.CO;2-U; HOROWITZ G, 1992, SYNTHETIC MET, V51, P419, DOI 10.1016/0379-6779(92)90297-V; Katz HE, 2000, NATURE, V404, P478, DOI 10.1038/35006603; MOBUS M, 1992, J CRYST GROWTH, V116, P495, DOI 10.1016/0022-0248(92)90658-6; SchmitzHubsch T, 1997, PHYS REV B, V55, P7972, DOI 10.1103/PhysRevB.55.7972; Schoonveld WA, 2000, NATURE, V404, P977, DOI 10.1038/35010073; Soukopp A, 1998, PHYS REV B, V58, P13882, DOI 10.1103/PhysRevB.58.13882; Taborski J, 1995, J ELECTRON SPECTROSC, V75, P129, DOI 10.1016/0368-2048(95)02397-6; TADA H, 1992, SURF SCI, V268, P387, DOI 10.1016/0039-6028(92)90978-F; Tautz FS, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.125405; Tautz FS, 2002, SURF SCI, V502, P176, DOI 10.1016/S0039-6028(01)01930-6; Umbach E, 1998, SURF SCI, V402, P20, DOI 10.1016/S0039-6028(98)00014-4; Wagner V, 2001, PHYS STATUS SOLIDI A, V188, P1297, DOI 10.1002/1521-396X(200112)188:4<1297::AID-PSSA1297>3.0.CO;2-X; ZHANG Y, 1993, PHYS REV LETT, V71, P2765, DOI 10.1103/PhysRevLett.71.2765	30	224	224	0	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2003	425	6958					602	605		10.1038/nature01901	http://dx.doi.org/10.1038/nature01901			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534582				2022-12-28	WOS:000185801000032
J	Lukacs, GL; Durie, PR				Lukacs, GL; Durie, PR			Pharmacologic approaches to correcting the basic defect in cystic fibrosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Hosp Sick Children, Res Inst, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Program Integrat Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto	Lukacs, GL (corresponding author), Hosp Sick Children, Res Inst, Cell Biol Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.			Lukacs, Gergely/0000-0003-0900-0675				SCRIVER CR, 2001, METABOLIC MOL BASES, V3, P5152; Yang H, 2003, J BIOL CHEM, V278, P35079, DOI 10.1074/jbc.M303098200	2	15	15	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	2003	349	15					1401	1404		10.1056/NEJMp038113	http://dx.doi.org/10.1056/NEJMp038113			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729JF	14534332				2022-12-28	WOS:000185769500002
J	Sears, MR; Greene, JM; Willan, AR; Wiecek, EM; Taylor, DR; Flannery, EM; Cowan, JO; Herbison, GP; Silva, PA; Poulton, R				Sears, MR; Greene, JM; Willan, AR; Wiecek, EM; Taylor, DR; Flannery, EM; Cowan, JO; Herbison, GP; Silva, PA; Poulton, R			A longitudinal, population-based, cohort study of childhood asthma followed to adulthood	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; LUNG-FUNCTION; AIRWAY HYPERRESPONSIVENESS; NEW-ZEALAND; WHEEZING ILLNESS; BIRTH COHORT; ATOPY; PREVALENCE; CHILDREN; LIFE	BACKGROUND: The outcome of childhood asthma in adults has been described in high-risk cohorts, but few population-based studies have reported the risk factors for persistence and relapse. METHODS: We assessed children born from April 1972 through March 1973 in Dunedin, New Zealand, repeatedly from 9 to 26 years of age with questionnaires, pulmonary-function tests, bronchial-challenge testing, and allergy testing. RESULTS: By the age of 26 years, 51.4 percent of 613 study members with complete respiratory data had reported wheezing at more than one assessment. Eighty-nine study members (14.5 percent) had wheezing that persisted from childhood to 26 years of age, whereas 168 (27.4 percent) had remission, but 76 (12.4 percent) subsequently relapsed by the age of 26. Sensitization to house dust mites predicted the persistence of wheezing (odds ratio, 2.41; P=0.001) and relapse (odds ratio, 2.18; P=0.01), as did airway hyperresponsiveness (odds ratio for persistence, 3.00; P<0.001; odds ratio for relapse, 3.03; P<0.001). Female sex predicted the persistence of wheezing (odds ratio, 1.71; P=0.03), as did smoking at the age of 21 years (odds ratio, 1.84; P=0.01). The earlier the age at onset, the greater the risk of relapse (odds ratio, 0.89 per year of increase in the age at onset; P<0.001). Pulmonary function was consistently lower in those with persistent wheezing than in those without persistent wheezing. CONCLUSIONS: In an unselected birth cohort, more than one in four children had wheezing that persisted from childhood to adulthood or that relapsed after remission. The factors predicting persistence or relapse were sensitization to house dust mites, airway hyperresponsiveness, female sex, smoking, and early age at onset. These findings, together with persistently low lung function, suggest that outcomes in adult asthma may be determined primarily in early childhood.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand; Univ Otago, Dunedin Multidisciplinary Hlth & Dev Res Unit, Dunedin, New Zealand	McMaster University; McMaster University; University of Otago; University of Otago	Sears, MR (corresponding author), McMaster Univ & St Josephs Healthcare, Firestone Inst Resp Hlth, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.			Herbison, Graham Peter/0000-0002-5684-024X				Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BRONNIMANN S, 1986, CHEST, V90, P480, DOI 10.1378/chest.90.4.480; BURNEY PGJ, 1987, CHEST, V91, P79; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Downs SH, 2001, ARCH DIS CHILD, V84, P20, DOI 10.1136/adc.84.1.20; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Grol MH, 1996, ALLERGY, V51, P855; Grol MH, 1999, AM J RESP CRIT CARE, V160, P1830, DOI 10.1164/ajrccm.160.6.9812100; JENKINS MA, 1994, BRIT MED J, V309, P90, DOI 10.1136/bmj.309.6947.90; JONES DT, 1987, BRIT J DIS CHEST, V81, P332, DOI 10.1016/0007-0971(87)90181-1; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176, DOI 10.1164/ajrccm.165.2.2104032; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Sears MR, 1996, ARCH DIS CHILD, V75, P392, DOI 10.1136/adc.75.5.392; Sears MR, 1997, EUR RESPIR J, V10, P51, DOI 10.1183/09031936.97.10010051; SEARS MR, 1994, BRIT MED J, V309, P72, DOI 10.1136/bmj.309.6947.72; Silva P., 1996, CHILD ADULT DUNEDIN; SINCLAIR SW, 1980, NEW ZEAL MED J, V91, P1; Strachan DP, 1996, BRIT MED J, V312, P1195; Strachan DP, 1996, AM J RESP CRIT CARE, V154, P1629, DOI 10.1164/ajrccm.154.6.8970346; Ulrik CS, 1999, EUR RESPIR J, V13, P904, DOI 10.1034/j.1399-3003.1999.13d35.x; Ulrik CS, 1996, RESP MED, V90, P623, DOI 10.1016/S0954-6111(96)90021-9; Xuan W, 2000, AM J RESP CRIT CARE, V161, P1820, DOI 10.1164/ajrccm.161.6.9809118; Xuan W, 2002, THORAX, V57, P104, DOI 10.1136/thorax.57.2.104	28	914	934	1	60	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	2003	349	15					1414	1422		10.1056/NEJMoa022363	http://dx.doi.org/10.1056/NEJMoa022363			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729JF	14534334				2022-12-28	WOS:000185769500004
J	Romagnuolo, J; Bardou, M; Rahme, E; Joseph, L; Reinhold, C; Barkun, AN				Romagnuolo, J; Bardou, M; Rahme, E; Joseph, L; Reinhold, C; Barkun, AN			Magnetic resonance cholangiopancreatography: A meta-analysis of test performance in suspected biliary disease	ANNALS OF INTERNAL MEDICINE			English	Review							ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; COMMON BILE-DUCT; PRIMARY SCLEROSING CHOLANGITIS; HALF-FOURIER ACQUISITION; FAST SPIN-ECHO; ORTHOTOPIC LIVER-TRANSPLANTATION; PANCREATIC EXOCRINE FUNCTION; HOLD MR CHOLANGIOGRAPHY; DIAGNOSTIC-ACCURACY; LAPAROSCOPIC CHOLECYSTECTOMY	Background: Magnetic resonance cholangiopancreatography (MRCP) is one of many newer noninvasive tests that can image the biliary tree. Purpose: To precisely estimate the overall sensitivity and specificity of MRCP in suspected biliary obstruction and to evaluate clinically important subgroups. Data Sources, MEDLINE search (January 1987 to March 2003) for studies in English or French, bibliographies, and subject matter experts. Study Selection: Studies were included if they allowed construction of 2 x 2 contingency tables of MRCP compared with a reasonable gold standard for at least 1 of the following: the presence, level, or cause of biliary obstruction. Data Extraction: Two independent observers graded study quality, which included consecutive enrollment, blinding, use of a single (versus composite) gold standard, and nonselective use of the gold standard. Logistic regression was used to examine the influence of publication year, quality score, proportion of patients having a "direct" gold standard, and clinical context on diagnostic performance. Data Synthesis: Of 498 studies identified, 67 were included (4711 patients). Mixed-effect models were used to estimate the sensitivity and specificity, and quantitative receiver-operating characteristic analysis was performed. Magnetic resonance cholangiopancreatography had a high overall pooled sensitivity (95% [+/-1.96 SD: spread of SD, 75% to 99%]) and specificity (97% [spread of SD, 86% to 99%]). The procedure was less sensitive for stones (92%; odds ratio, 0.51 [Cl, 0.35 to 0.75]) and malignant conditions (88%; odds ratio, 0.28 [Cl, 0.18 to 0.44]) than for the presence of obstruction. In addition, diagnostic performance was higher in studies that were larger, did not use consecutive enrollment, and did not use gold standard assessment for some patients. Conclusions: Magentic resonance cholangiopancreatography is a noninvasive imaging test with excellent overall sensitivity and specificity for demonstrating the level and presence of biliary obstruction; however, it seems less sensitive for detecting stones or differentiating malignant from benign obstruction.	Univ Calgary, Med Clin, Calgary, AB T2N 4N1, Canada; McGill Univ, Montreal, PQ, Canada	University of Calgary; McGill University	Romagnuolo, J (corresponding author), Univ Calgary, Med Clin, 3350 Hosp Dr NW,G-179, Calgary, AB T2N 4N1, Canada.	j.romagnuolo@ucalgary.ca		Romagnuolo, Joseph/0000-0002-5630-3022				Adamek HE, 2000, LANCET, V356, P190, DOI 10.1016/S0140-6736(00)02479-X; Adamek HE, 1998, GUT, V43, P680, DOI 10.1136/gut.43.5.680; Angulo P, 2000, J HEPATOL, V33, P520, DOI 10.1034/j.1600-0641.2000.033004520.x; Arguedas MR, 2001, AM J GASTROENTEROL, V96, P2892; Aube C, 1998, J RADIOL, V79, P1487; Barish MA, 1999, NEW ENGL J MED, V341, P258, DOI 10.1056/NEJM199907223410407; BARISH MA, 1995, AM J ROENTGENOL, V165, P295, DOI 10.2214/ajr.165.2.7618543; BARTEAU JA, 1995, SURG ENDOSC-ULTRAS, V9, P490; Bearcroft PW, 1997, GUT, V41, P135, DOI 10.1136/gut.41.2.135; Becker CD, 1997, RADIOLOGY, V205, P523, DOI 10.1148/radiology.205.2.9356639; BEGG CB, 1987, STAT MED, V6, P411, DOI 10.1002/sim.4780060402; Boraschi P, 1999, MAGN RESON IMAGING, V17, P1245, DOI 10.1016/S0730-725X(99)00075-2; Boraschi P, 2002, ACTA RADIOL, V43, P593, DOI 10.1034/j.1600-0455.2002.430610.x; Boraschi P, 1999, EUR J RADIOL, V32, P171, DOI 10.1016/S0720-048X(99)00002-9; Bret PM, 1996, RADIOLOGY, V199, P99, DOI 10.1148/radiology.199.1.8633179; Calvo MM, 2002, MAYO CLIN PROC, V77, P422; Cannon ME, 1999, GASTROINTEST ENDOSC, V50, P27, DOI 10.1016/S0016-5107(99)70340-8; Cappeliez O, 2000, RADIOLOGY, V215, P358, DOI 10.1148/radiology.215.2.r00ma10358; Coakley FV, 1998, RADIOLOGY, V209, P141, DOI 10.1148/radiology.209.1.9769825; Czako L, 2001, PANCREAS, V23, P323, DOI 10.1097/00006676-200110000-00015; David V, 1998, AM J ROENTGENOL, V170, P1055, DOI 10.2214/ajr.170.4.9530058; de Ledinghen V, 1999, GASTROINTEST ENDOSC, V49, P26, DOI 10.1016/S0016-5107(99)70441-4; Demartines N, 2000, ARCH SURG-CHICAGO, V135, P148, DOI 10.1001/archsurg.135.2.148; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Deviere J, 1999, GASTROINTEST ENDOSC, V50, P136, DOI 10.1016/S0016-5107(99)70367-6; Dwerryhouse SJ, 1998, BRIT J SURG, V85, P1364; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Farrell RJ, 2001, ENDOSCOPY, V33, P668, DOI 10.1055/s-2001-16218; Feldman DR, 1997, ANN SURG ONCOL, V4, P634, DOI 10.1007/BF02303747; Freeman ML, 1996, NEW ENGL J MED, V335, P909, DOI 10.1056/NEJM199609263351301; FREEMAN ML, 1999, GASTROENTEROLOGY, V116, pA825; Fulcher AS, 1999, RADIOLOGY, V211, P715, DOI 10.1148/radiology.211.3.r99jn17715; Fulcher AS, 1998, J COMPUT ASSIST TOMO, V22, P845, DOI 10.1097/00004728-199811000-00001; Fulcher AS, 2000, RADIOLOGY, V215, P71, DOI 10.1148/radiology.215.1.r00ap2671; Fulcher AS, 2002, GASTROINTEST ENDOSC, V56, pS178, DOI 10.1067/mge.2002.129029; Fulcher AS, 1999, RADIOGRAPHICS, V19, P25, DOI 10.1148/radiographics.19.1.g99ja0525; Fulcher AS, 1999, SEMIN ULTRASOUND CT, V20, P294, DOI 10.1016/S0887-2171(99)90061-6; Fulcher AS, 1998, RADIOLOGY, V207, P21, DOI 10.1148/radiology.207.1.9530295; Fulcher AS, 1999, RADIOGRAPHICS, V19, P41; Georgopoulos SK, 1999, ARCH SURG-CHICAGO, V134, P1002, DOI 10.1001/archsurg.134.9.1002; GUIBAUD L, 1995, RADIOLOGY, V197, P109, DOI 10.1148/radiology.197.1.7568807; Hakansson K, 2002, ACTA RADIOL, V43, P80, DOI 10.1034/j.1600-0455.2002.430116.x; HALLCRAGGS MA, 1993, RADIOLOGY, V189, P423, DOI 10.1148/radiology.189.2.8210370; Halme L, 1999, ANN CHIR GYNAECOL FE, V88, P127; Hintze RE, 1997, ENDOSCOPY, V29, P182, DOI 10.1055/s-2007-1004160; Hochwald S N, 1998, J Gastrointest Surg, V2, P573, DOI 10.1016/S1091-255X(98)80059-0; Holzknecht N, 1998, RADIOLOGY, V206, P657, DOI 10.1148/radiology.206.3.9494483; Hussein Fawzia M Y, 2002, Australas Radiol, V46, P41, DOI 10.1046/j.1440-1673.2001.00992.x; IRWIG L, 1995, J CLIN EPIDEMIOL, V48, P119, DOI 10.1016/0895-4356(94)00099-C; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; ISHIZAKI Y, 1993, AM J GASTROENTEROL, V88, P2072; Kats J, 2003, DIGEST SURG, V20, P32, DOI 10.1159/000068863; Kim JH, 2002, RADIOLOGY, V224, P410, DOI 10.1148/radiol.2241011223; Kim MJ, 2000, RADIOLOGY, V215, P395, DOI 10.1148/radiology.215.2.r00ma04395; Kim MJ, 2000, RADIOLOGY, V214, P173, DOI 10.1148/radiology.214.1.r00ja35173; Kim TK, 2002, AM J ROENTGENOL, V179, P429, DOI 10.2214/ajr.179.2.1790429; Kok T, 1996, J CLIN ULTRASOUND, V24, P103, DOI 10.1002/(SICI)1097-0096(199603)24:3<103::AID-JCU1>3.0.CO;2-L; Kuo YT, 1999, J FORMOS MED ASSOC, V98, P97; LACHS MS, 1992, ANN INTERN MED, V117, P135, DOI 10.7326/0003-4819-117-2-135; Laghi A, 1999, AM J ROENTGENOL, V172, P1541, DOI 10.2214/ajr.172.6.10350286; Laokpessi A, 2001, AM J GASTROENTEROL, V96, P2354; Lee MG, 1997, RADIOLOGY, V202, P663, DOI 10.1148/radiology.202.3.9051013; Liu TH, 1999, AM J SURG, V178, P480, DOI 10.1016/S0002-9610(99)00224-X; Lomanto D, 1997, AM J SURG, V174, P33, DOI 10.1016/S0002-9610(97)00022-6; Lomas DJ, 1999, EUR RADIOL, V9, P1411, DOI 10.1007/s003300050859; Lopera JE, 2001, RADIOLOGY, V220, P90, DOI 10.1148/radiology.220.1.r01jl3990; Loperfido S, 1998, GASTROINTEST ENDOSC, V48, P1, DOI 10.1016/S0016-5107(98)70121-X; Macaskill P, 2001, STAT MED, V20, P641, DOI 10.1002/sim.698; Magnuson TH, 1999, J AM COLL SURGEONS, V189, P63, DOI 10.1016/S1072-7515(99)00082-4; Magnuson TH, 1999, J AM COLL SURGEONS, V189, P72; Materne R, 2000, ENDOSCOPY, V32, P3, DOI 10.1055/s-2000-86; Matos C, 2001, GASTROINTEST ENDOSC, V53, P728, DOI 10.1067/mge.2001.114784; MATZEN P, 1981, GASTROENTEROLOGY, V81, P237; McAuley L, 2000, LANCET, V356, P1228, DOI 10.1016/S0140-6736(00)02786-0; Mehta S N, 1997, Gastrointest Endosc Clin N Am, V7, P247; Mendler MH, 1998, AM J GASTROENTEROL, V93, P2482, DOI 10.1016/S0002-9270(98)00589-9; Miyazaki T, 1996, AM J ROENTGENOL, V166, P1297, DOI 10.2214/ajr.166.6.8633435; MORIMOTO K, 1992, RADIOLOGY, V183, P578, DOI 10.1148/radiology.183.2.1561373; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; Musella M, 1998, BRIT J SURG, V85, P16; OCONNOR KW, 1983, GASTROENTEROLOGY, V84, P1498; Patel RS, 2000, GASTROINTEST ENDOSC, V51, pAB198, DOI 10.1016/S0016-5107(00)14515-8; Pavone P, 1997, AM J ROENTGENOL, V169, P807, DOI 10.2214/ajr.169.3.9275901; Pavone P, 1997, SURG ENDOSC-ULTRAS, V11, P982, DOI 10.1007/s004649900507; Pavone P, 1996, EUR RADIOL, V6, P147, DOI 10.1007/BF00181131; Pavone P, 1996, ITAL J GASTROENTEROL, V28, P63; Pickuth D, 2000, ABDOM IMAGING, V25, P618, DOI 10.1007/s002610000137; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; Rawat B, 1996, CAN ASSOC RADIOL J, V47, P265; Regan F, 1996, AM J ROENTGENOL, V167, P1441, DOI 10.2214/ajr.167.6.8956574; Reinhold C, 1998, RADIOLOGY, V209, P435, DOI 10.1148/radiology.209.2.9807570; Reuther G, 1996, RADIOLOGY, V198, P561, DOI 10.1148/radiology.198.2.8596866; Romagnuolo J, 2000, GASTROINTEST ENDOSC, V51, pAB199, DOI 10.1016/S0016-5107(00)14518-3; Rondeau Y, 1998, J RADIOL, V79, P147; Rosch T, 2002, GASTROINTEST ENDOSC, V55, P870, DOI 10.1067/mge.2002.124206; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; Sahai AV, 2001, AM J GASTROENTEROL, V96, P2074, DOI 10.1016/S0002-9270(01)02528-X; Scheiman JM, 2001, AM J GASTROENTEROL, V96, P2900; Schwartz LH, 1998, AM J ROENTGENOL, V170, P1491, DOI 10.2214/ajr.170.6.9609160; SEMELKA RC, 1992, GASTROINTEST RADIOL, V17, P347, DOI 10.1007/BF01888585; SHARMA AK, 1993, ANN ROY COLL SURG, V75, P245; Sheridan MB, 1999, AM J ROENTGENOL, V173, P583, DOI 10.2214/ajr.173.3.10470884; Sica GT, 1999, RADIOLOGY, V210, P605, DOI 10.1148/radiology.210.3.r99fe55605; Song FJ, 2002, INT J EPIDEMIOL, V31, P88, DOI 10.1093/ije/31.1.88; Soto JA, 1996, GASTROENTEROLOGY, V110, P589, DOI 10.1053/gast.1996.v110.pm8566608; Soto JA, 2000, RADIOLOGY, V215, P737, DOI 10.1148/radiology.215.3.r00ma12737; Stiris MG, 2000, ACTA RADIOL, V41, P269, DOI 10.1034/j.1600-0455.2000.041003269.x; Sugiyama M, 1997, GASTROINTEST ENDOSC, V45, P143, DOI 10.1016/S0016-5107(97)70237-2; Sugiyama M, 1998, AM J GASTROENTEROL, V93, P1886; Takehara Y, 1999, EUR J RADIOL, V29, P211, DOI 10.1016/S0720-048X(98)00177-6; Tandon M, 2001, AM J GASTROENTEROL, V96, P705; Textor HJ, 2002, ENDOSCOPY, V34, P984, DOI 10.1055/s-2002-35830; Urban M, 2002, WORLD J SURG, V26, P353, DOI 10.1007/s00268-001-0232-z; Varghese JC, 2000, CLIN RADIOL, V55, P25, DOI 10.1053/crad.1999.0319; Varghese JC, 1999, CLIN RADIOL, V54, P604, DOI 10.1016/S0009-9260(99)90023-5; Varghese JC, 1999, CLIN RADIOL, V54, P513, DOI 10.1016/S0009-9260(99)90848-6; Walter SD, 2002, STAT MED, V21, P1237, DOI 10.1002/sim.1099; Zidi SH, 2000, GUT, V46, P103, DOI 10.1136/gut.46.1.103; Zidi SH, 1999, GUT, V44, P118, DOI 10.1136/gut.44.1.118	119	255	272	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 7	2003	139	7					547	557		10.7326/0003-4819-139-7-200310070-00006	http://dx.doi.org/10.7326/0003-4819-139-7-200310070-00006			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729AP	14530225				2022-12-28	WOS:000185748800002
J	Zachos, JC; Wara, MW; Bohaty, S; Delaney, ML; Petrizzo, MR; Brill, A; Bralower, TJ; Premoli-Silva, I				Zachos, JC; Wara, MW; Bohaty, S; Delaney, ML; Petrizzo, MR; Brill, A; Bralower, TJ; Premoli-Silva, I			A transient rise in tropical sea surface temperature during the Paleocene-Eocene Thermal Maximum	SCIENCE			English	Article							OCEANIC METHANE HYDRATE; PLANKTONIC-FORAMINIFERA; LATEST PALEOCENE; ATMOSPHERIC CO2; CLIMATE-CHANGE; MG/CA; DISSOCIATION; SEAWATER; CARBON; SENSITIVITY	The Paleocene-Eocene Thermal Maximum (PETM) has been attributed to a rapid rise in greenhouse gas levels. If so, warming should have occurred at all latitudes, although amplified toward the poles. Existing records reveal an increase in high-latitude sea surface temperatures (SSTs) (8degrees to 10 degreesC) and in bottom water temperatures (4degrees to 5 degreesC). To date, however, the character of the tropical SST response during this event remains unconstrained. Here we address this deficiency by using paired oxygen isotope and minor element (magnesium/calcium) ratios of planktonic foraminifera from a tropical Pacific core to estimate changes in SST. Using mixed-layer foraminifera, we found that the combined proxies imply a 4degrees to 5 degreesC rise in Pacific SST during the PETM. These results would necessitate a rise in atmospheric pCO(2) to levels three to four times as high as those estimated for the late Paleocene.	Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Dept Ocean Sci, Santa Cruz, CA 95064 USA; Univ Milan, Dipartimento Sci Terra Ardito Desio, I-20133 Milan, Italy; Univ N Carolina, Dept Geol Sci, Chapel Hill, NC 27599 USA; Penn State Univ, Dept Geosci, University Pk, PA 16802 USA	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz; University of Milan; University of North Carolina; University of North Carolina Chapel Hill; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Zachos, JC (corresponding author), Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA.		Zachos, James C/A-7674-2008; Petrizzo, Maria Rose/U-6464-2019; Petrizzo, Maria Rose/M-8672-2013	Zachos, James C/0000-0001-8439-1886; Petrizzo, Maria Rose/0000-0002-9584-8471; Petrizzo, Maria Rose/0000-0002-9584-8471				Alexeev VA, 2003, CLIM DYNAM, V20, P775, DOI 10.1007/s00382-003-0312-x; Anand P, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000846; Billups K, 2003, EARTH PLANET SC LETT, V209, P181, DOI 10.1016/S0012-821X(03)00067-0; BOUVIERSOUMAGNAC Y, 1985, J FORAMIN RES, V15, P302, DOI 10.2113/gsjfr.15.4.302; Bralower TJ, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2002PA000832; Bralower TJ, 1997, GEOLOGY, V25, P963, DOI 10.1130/0091-7613(1997)025<0963:HRROTL>2.3.CO;2; CLYDE WC, 1998, GEOLOGY; Crouch EM, 2001, GEOLOGY, V29, P315, DOI 10.1130/0091-7613(2001)029<0315:GDEAWT>2.0.CO;2; DEKENS PS, 2002, GEOCHEM GEOPHYS GEOS, V3; DHONDT S, 1994, PALEOBIOLOGY, V20, P391, DOI 10.1017/S0094837300012847; Dickens GR, 1997, GEOLOGY, V25, P259, DOI 10.1130/0091-7613(1997)025<0259:ABOGIT>2.3.CO;2; DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087; Dickens GR, 2000, B SOC GEOL FR, V171, P37; EREZ J, 1983, GEOCHIM COSMOCHIM AC, V47, P1025, DOI 10.1016/0016-7037(83)90232-6; Farley KA, 2003, EARTH PLANET SC LETT, V208, P135, DOI 10.1016/S0012-821X(03)00017-7; Kelly DC, 1998, PALAEOGEOGR PALAEOCL, V141, P139, DOI 10.1016/S0031-0182(98)00017-0; Kelly DC, 1996, GEOLOGY, V24, P423; KENNETT JP, 1991, NATURE, V353, P225, DOI 10.1038/353225a0; Malone M. J, 2002, P ODP INITIAL REPORT, V198; Nurnberg D, 1996, GEOCHIM COSMOCHIM AC, V60, P803, DOI 10.1016/0016-7037(95)00446-7; ROBERT C, 1994, GEOLOGY, V22, P211, DOI 10.1130/0091-7613(1994)022<0211:ASHEAT>2.3.CO;2; Rohl U, 2000, GEOLOGY, V28, P927, DOI 10.1130/0091-7613(2000)28<927:NCFTLP>2.0.CO;2; Rosenthal Y, 2000, PALEOCEANOGRAPHY, V15, P135, DOI 10.1029/1999PA000415; Rosenthal Y, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2001PA000749; Royer DL, 2001, SCIENCE, V292, P2310, DOI 10.1126/science.292.5525.2310; Schmidt GA, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000757; SCHRAG DP, 1995, GEOCHIM COSMOCHIM AC, V59, P2265, DOI 10.1016/0016-7037(95)00105-9; Shellito CJ, 2003, PALAEOGEOGR PALAEOCL, V193, P113, DOI 10.1016/S0031-0182(02)00718-6; Sloan LC, 1999, RECONSTRUCTING OCEAN HISTORY, P273; Spero HJ, 1997, NATURE, V390, P497, DOI 10.1038/37333; Stott LD, 1992, PALEOCEANOGRAPHY, V7, P395, DOI 10.1029/92PA01183; Thomas DJ, 1999, PALEOCEANOGRAPHY, V14, P561, DOI 10.1029/1999PA900031; Thomas DJ, 2002, GEOLOGY, V30, P1067, DOI 10.1130/0091-7613(2002)030<1067:WTFFTF>2.0.CO;2; Thomas E., 1996, Geological Society Special Publication, V101, P401, DOI 10.1144/GSL.SP.1996.101.01.20; Thomas E, 1998, LATE PALEOCENE-EARLY EOCENE CLIMATIC AND BIOTIC EVENTS IN THE MARINE AND TERRESTRIAL RECORDS, P214; Wara MW, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2003GC000525; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412; ZACHOS JC, 1994, PALEOCEANOGRAPHY, V9, P353, DOI 10.1029/93PA03266; Zeebe RE, 2001, PALAEOGEOGR PALAEOCL, V170, P49, DOI 10.1016/S0031-0182(01)00226-7	39	456	487	7	239	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 28	2003	302	5650					1551	1554		10.1126/science.1090110	http://dx.doi.org/10.1126/science.1090110			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	747JV	14576441				2022-12-28	WOS:000186802200039
J	Bell, J				Bell, J		working grp Acad Medical Sci	Education and debate - Resuscitating clinical research in the United Kingdom	BRITISH MEDICAL JOURNAL			English	Article									John Radcliffe Hosp, Off Regius Prof, Oxford PX3 9DU, England	University of Oxford	Bell, J (corresponding author), John Radcliffe Hosp, Off Regius Prof, Oxford PX3 9DU, England.							Chalmers I, 2003, BRIT MED J, V327, P1017, DOI 10.1136/bmj.327.7422.1017; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; *NUFF TRUST RES PO, 2002, LEARN EXP PRIV SEC U	4	68	68	1	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 1	2003	327	7422					1041	1043		10.1136/bmj.327.7422.1041	http://dx.doi.org/10.1136/bmj.327.7422.1041			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	738NE	14593043	Green Published			2022-12-28	WOS:000186294100028
J	Ofri, D				Ofri, D			Tools of the trade	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NYU, Sch Med, Bellebue Hosp, New York, NY 10016 USA	New York University	Ofri, D (corresponding author), NYU, Sch Med, Bellebue Hosp, New York, NY 10016 USA.			Ofri, Danielle/0000-0001-9865-7104					0	0	0	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	2003	349	18					1693	1694		10.1056/NEJMp038170	http://dx.doi.org/10.1056/NEJMp038170			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	737FJ	14585936				2022-12-28	WOS:000186219500002
J	Prinz, M; Heikenwalder, M; Junt, T; Schwarz, P; Glatzel, M; Heppner, FL; Fu, YX; Lipp, M; Aguzzi, A				Prinz, M; Heikenwalder, M; Junt, T; Schwarz, P; Glatzel, M; Heppner, FL; Fu, YX; Lipp, M; Aguzzi, A			Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion	NATURE			English	Article							CREUTZFELDT-JAKOB-DISEASE; SYMPATHETIC INNERVATION; GERMINAL-CENTERS; MICE; SCRAPIE; REPLICATION; SUSCEPTIBILITY; EXPRESSION; INFECTION; RECEPTOR	Peripheral infection is the natural route of transmission in most prion diseases(1). Peripheral prion infection is followed by rapid prion replication in lymphoid organs, neuroinvasion(2) and progressive neurological disease. Both immune cells and nerves are involved in pathogenesis(3,4), but the mechanisms of prion transfer from the immune to the nervous system are unknown. Here we show that ablation of the chemokine receptor CXCR5 juxtaposes follicular dendritic cells (FDCs) to major splenic nerves, and accelerates the transfer of intraperitoneally administered prions into the spinal cord. Neuroinvasion velocity correlated exclusively with the relative locations of FDCs and nerves: transfer of CXCR5(-/-) bone marrow to wild-type mice induced perineural FDCs and enhanced neuroinvasion, whereas reciprocal transfer to CXCR5(-/-) mice abolished them and restored normal efficiency of neuroinvasion. Suppression of lymphotoxin signalling depleted FDCs, abolished splenic infectivity, and suppressed acceleration of pathogenesis in CXCR5(-/-) mice. This suggests that prion neuroimmune transition occurs between FDCs and sympathetic nerves, and relative positioning of FDCs and nerves controls the efficiency of peripheral prion infection.	Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Inst Expt Immunol, CH-8091 Zurich, Switzerland; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Comm Immunol, Chicago, IL 60637 USA; Max Delbruck Ctr Mol Med, Dept Mol Tumor Genet & Immunogenet, D-13092 Berlin, Germany	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Chicago; University of Chicago; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Aguzzi, A (corresponding author), Univ Zurich Hosp, Inst Neuropathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.		Glatzel, Markus/V-8844-2019; Lipp, Martin/G-2235-2010; Junt, Tobias/AAE-4389-2021; Heppner, Frank/ABH-8393-2020; Heikenwalder, Mathias/AAA-2269-2020; Glatzel, Markus/G-3356-2011; Aguzzi, Adriano/A-3351-2008	Glatzel, Markus/0000-0002-7720-8817; Heppner, Frank/0000-0001-9816-8917; Glatzel, Markus/0000-0002-7720-8817; Aguzzi, Adriano/0000-0002-0344-6708; Lipp, Martin/0000-0002-0087-2672; fu, yang-xin/0000-0001-8441-6617				Aguzzi A, 1997, LANCET, V349, P742, DOI 10.1016/S0140-6736(97)22011-8; Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Aguzzi A, 2001, NAT REV NEUROSCI, V2, P745, DOI 10.1038/35094590; Ansel KM, 2000, NATURE, V406, P309, DOI 10.1038/35018581; Beekes M, 1996, J GEN VIROL, V77, P1925, DOI 10.1099/0022-1317-77-8-1925; CARLSON SL, 1995, J NEUROSCI, V15, P5892; EKLUND CM, 1967, J INFECT DIS, V117, P15, DOI 10.1093/infdis/117.1.15; FELTEN D L, 1988, Brain Behavior and Immunity, V2, P293, DOI 10.1016/0889-1591(88)90031-1; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; Glatzel M, 2001, NEURON, V31, P25, DOI 10.1016/S0896-6273(01)00331-2; HEINEN E, 1995, CURR TOP MICROBIOL, V201, P15; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hill AF, 2000, P NATL ACAD SCI USA, V97, P10248, DOI 10.1073/pnas.97.18.10248; Hilton DA, 1998, LANCET, V352, P703, DOI 10.1016/S0140-6736(98)24035-9; Kaeser PS, 2001, J VIROL, V75, P7097, DOI 10.1128/JVI.75.15.7097-7106.2001; Karrer U, 2000, J IMMUNOL, V164, P768, DOI 10.4049/jimmunol.164.2.768; KIMBERLIN RH, 1989, VIRUS RES, V12, P201, DOI 10.1016/0168-1702(89)90039-7; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; Klein MA, 1998, NAT MED, V4, P1429, DOI 10.1038/4022; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; Mackay F, 1998, NATURE, V395, P26, DOI 10.1038/25630; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; Oldstone MBA, 2002, J VIROL, V76, P4357, DOI 10.1128/JVI.76.9.4357-4363.2002; Prinz M, 2002, P NATL ACAD SCI USA, V99, P919, DOI 10.1073/pnas.022626399; Prusiner S B, 1981, Adv Exp Med Biol, V134, P385; Race R, 2000, J VIROL, V74, P828, DOI 10.1128/JVI.74.2.828-833.2000; Voigt I, 2000, EUR J IMMUNOL, V30, P560, DOI 10.1002/1521-4141(200002)30:2<560::AID-IMMU560>3.0.CO;2-T; Wu Q, 2001, J EXP MED, V193, P1327, DOI 10.1084/jem.193.11.1327	29	170	175	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	2003	425	6961					957	962		10.1038/nature02072	http://dx.doi.org/10.1038/nature02072			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14562059				2022-12-28	WOS:000186230600041
J	Lanier, DC; Roland, M; Burstin, H; Knottnerus, JA				Lanier, DC; Roland, M; Burstin, H; Knottnerus, JA			Doctor performance and public accountability	LANCET			English	Article							QUALITY-OF-CARE; CLINICAL GOVERNANCE; GENERAL-PRACTICE; IMPROVEMENT; IMPLEMENTATION; INFORMATION; RELEASE	Public concern about the quality of health care has motivated governments, health-care funders, and clinicians to expand efforts to improve professional performance. In this paper, we illustrate such efforts from the perspective of three countries, the UK, the USA, and the Netherlands. The earliest strategies, which included continuing professional education, clinical audits, and peer review, were aimed at the individual doctor, and produced only modest effects. Other efforts, such as national implementation of practice guidelines, effective use of information technologies, and intensive involvement by doctors in continuous quality-improvement activities, are aimed more broadly at health-care systems. Much is yet unknown about whether these or other strategies-such as centralised supervision or regulation of quality improvement, or use of financial incentives-are effective. As demands for greater public accountability rise, continuing performance improvement efforts of each of our countries offer us opportunities to learn from one another.	Agcy Healthcare Res & Qual, Ctr Primary Care Prevent & Clin Partnerships, Rockville, MD 20850 USA; Natl Primary Care Res & Dev Ctr, Manchester, Lancs, England; Netherlands Sch Primary Care Res, Maastricht, Netherlands	Agency for Healthcare Research & Quality; University of Manchester; Maastricht University	Lanier, DC (corresponding author), Agcy Healthcare Res & Qual, Ctr Primary Care Prevent & Clin Partnerships, 540 Gaither Rd, Rockville, MD 20850 USA.	dlanier@ahrq.gov	Knottnerus, Andre/F-4866-2013; Knottnerus, Johannes A/A-3829-2009					Brennan T., 1996, NEW RULES REGULATION; Brennan TA, 1998, MILBANK Q, V76, P709, DOI 10.1111/1468-0009.00111; Buetow SA, 1999, QUAL HEALTH CARE, V8, P184, DOI 10.1136/qshc.8.3.184; BURGERS JS, 2002, HUISARTS WET, V45, P349; Campbell SM, 2002, QUAL SAF HEALTH CARE, V11, P9, DOI 10.1136/qhc.11.1.9; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867; *DEP HLTH, NHS PERF RAT; *DEP HLTH, 2000, NHS PLAN; Galvin R, 2002, NEW ENGL J MED, V347, P939, DOI 10.1056/NEJMsb012850; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Grol R, 2001, MED CARE, V39, pII46; Health Council of the Netherlands, 2000, HLTH COUNC NETH PUBL; Hofer TP, 1999, JAMA-J AM MED ASSOC, V281, P2098, DOI 10.1001/jama.281.22.2098; Horbar JD, 2001, PEDIATRICS, V107, P14, DOI 10.1542/peds.107.1.14; Jans MP, 2001, INT J QUAL HEALTH C, V13, P17, DOI 10.1093/intqhc/13.1.17; Knottnerus JA, 1996, LANCET, V347, P1236; Knottnerus JA, 1999, METHOD INFORM MED, V38, P350; Marshall MN, 2000, JAMA-J AM MED ASSOC, V283, P1866, DOI 10.1001/jama.283.14.1866; Marshall MN, 2002, BRIT MED J, V325, P1278, DOI 10.1136/bmj.325.7375.1278; MECHANIC D, 2002, J HLTH SERV RES P S1, V7, P35; Mukamel DB, 1998, MED CARE, V36, P945, DOI 10.1097/00005650-199807000-00002; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; RELMAN AS, 1988, NEW ENGL J MED, V319, P1220, DOI 10.1056/NEJM198811033191810; Renders CM, 2001, DIABETES CARE, V24, P1365, DOI 10.2337/diacare.24.8.1365; Schneider EC, 1998, JAMA-J AM MED ASSOC, V279, P1638, DOI 10.1001/jama.279.20.1638; Shekelle P, 2003, BRIT MED J, V326, P457, DOI 10.1136/bmj.326.7387.457; Solberg LI, 1997, JOINT COMM J QUAL IM, V23, P135, DOI 10.1016/S1070-3241(16)30305-4; Van der Weijden T, 1999, INT J QUAL HEALTH C, V11, P131, DOI 10.1093/intqhc/11.2.131	29	42	43	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 25	2003	362	9393					1404	1408		10.1016/S0140-6736(03)14638-7	http://dx.doi.org/10.1016/S0140-6736(03)14638-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	735YX	14585644				2022-12-28	WOS:000186143300024
J	MacMicking, JD; Taylor, GA; McKinney, JD				MacMicking, JD; Taylor, GA; McKinney, JD			Immune control of tuberculosis by IFN-gamma-inducible LRG-47	SCIENCE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; INTERFERON-GAMMA; ENDOPLASMIC-RETICULUM; NITRIC-OXIDE; MACROPHAGES; RESISTANCE; RESPONSES; ROLES	Interferon-gamma (IFN-gamma) provides an essential component of immunity to tuberculosis by activating infected host macrophages to directly inhibit the replication of Mycobacterium tuberculosis (Mtb). IFN-gamma-inducible nitric oxide synthase 2 (NOS2) is considered a principal effector mechanism, although other pathways may also exist. Here, we identify one member of a newly emerging 47-kilodalton (p47) guanosine triphosphatase family, LRG-47, that acts independently of NOS2 to protect against disease. Mice lacking LRG-47 failed to control Mtb replication, unlike those missing the related p47 guanosine triphosphatases IRG-47 or IGTP. Defective bacterial killing in IFN-gamma-activated LRG-47(-/-) macrophages was associated with impaired maturation of Mtb-containing phagosomes, vesicles that otherwise recruited LRG-47 in wild-type cells. Thus, LRG-47 may serve as a critical vacuolar trafficking component used to dispose of intracellular pathogens like Mtb.	Rockefeller Univ, Lab Infect Biol, New York, NY 10021 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27705 USA; Duke Univ, Med Ctr, Dept Immunol, Div Geriatr, Durham, NC 27705 USA; Duke Univ, Med Ctr, Ctr Aging & Human Dev, Durham, NC 27705 USA; Durham Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27705 USA	Rockefeller University; Duke University; Duke University; Duke University; Geriatric Research Education & Clinical Center	MacMicking, JD (corresponding author), Rockefeller Univ, Lab Infect Biol, 1230 York Ave, New York, NY 10021 USA.	macmicj@mail.rockefeller.edu			PHS HHS [R01 A1051702] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Boehm U, 1998, J IMMUNOL, V161, P6715; Buchmeier N, 2000, MOL MICROBIOL, V35, P1375, DOI 10.1046/j.1365-2958.2000.01797.x; Casanova JL, 2002, ANNU REV IMMUNOL, V20, P581, DOI 10.1146/annurev.immunol.20.081501.125851; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; Clemens DL, 1996, J EXP MED, V184, P1349, DOI 10.1084/jem.184.4.1349; Collazo CM, 2001, J EXP MED, V194, P181, DOI 10.1084/jem.194.2.181; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dye C, 2002, SCIENCE, V295, P2042, DOI 10.1126/science.1063814; Ehrt S, 2001, J EXP MED, V194, P1123, DOI 10.1084/jem.194.8.1123; Fisher MA, 2002, J BACTERIOL, V184, P4025, DOI 10.1128/JB.184.14.4025-4032.2002; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Hackam DJ, 1998, J EXP MED, V188, P351, DOI 10.1084/jem.188.2.351; HART PD, 1991, J EXP MED, V174, P881, DOI 10.1084/jem.174.4.881; Hayashi T, 2001, INFECT IMMUN, V69, P6156, DOI 10.1128/IAI.69.10.6156-6164.2001; Kincaid EZ, 2003, J IMMUNOL, V171, P2042, DOI 10.4049/jimmunol.171.4.2042; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MacMicking JD, 2003, HANDB EXP PHARM, V158, P409; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; Mazurek GH, 2001, JAMA-J AM MED ASSOC, V286, P1740, DOI 10.1001/jama.286.14.1740; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; OLAKAMNI O, 2003, J BIOL CHEM, V277, P49727; Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Taylor GA, 1997, J BIOL CHEM, V272, P10639; Taylor GA, 2000, P NATL ACAD SCI USA, V97, P751, DOI 10.1073/pnas.97.2.751; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106; Ward TH, 2001, J CELL BIOL, V155, P557, DOI 10.1083/jcb.200107045; Zerrahn J, 2002, J IMMUNOL, V168, P3428, DOI 10.4049/jimmunol.168.7.3428	31	519	547	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	2003	302	5645					654	659		10.1126/science.1088063	http://dx.doi.org/10.1126/science.1088063			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576437				2022-12-28	WOS:000186119900062
J	Weatherall, DJ				Weatherall, DJ			Genomics and global health: Time for a reappraisal	SCIENCE			English	Article							HEMOGLOBIN DISORDERS; FUTURE	Although currently there are only a limited number of genomic technologies that are applicable to health care in the developing countries, this is unlikely to be the case in the near future. If, however, the full potential of genomics for health care is to be fulfilled, there will have to be a complete change of emphasis in education and research in the richer countries toward a more global view of disease and its consequences.	Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England	University of Oxford	Weatherall, DJ (corresponding author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England.							Alberti G, 2001, B WORLD HEALTH ORGAN, V79, P907; Angastiniotis M, 1998, ANN NY ACAD SCI, V850, P251, DOI 10.1111/j.1749-6632.1998.tb10482.x; [Anonymous], WORLD HLTH REP 2002; Collins FS, 2001, JAMA-J AM MED ASSOC, V285, P540, DOI 10.1001/jama.285.5.540; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; de Silva S, 2000, LANCET, V355, P786, DOI 10.1016/S0140-6736(99)08246-X; Djimde A, 2001, LANCET, V358, P890, DOI 10.1016/S0140-6736(01)06040-8; Harris E, 2000, BRIT MED J, V321, P817, DOI 10.1136/bmj.321.7264.817; Keusch GT, 2003, NATURE, V422, P561, DOI 10.1038/422561a; Pang T, 2003, LANCET, V361, P716, DOI 10.1016/S0140-6736(03)12668-2; Schaeffeler E, 2001, LANCET, V358, P383, DOI 10.1016/S0140-6736(01)05579-9; Subramanian G, 2001, JAMA-J AM MED ASSOC, V286, P2296, DOI 10.1001/jama.286.18.2296; Weatherall D, 2002, GENES IMMUN, V3, P331, DOI 10.1038/sj.gene.6363878; Weatherall D.J., 2001, THALASSAEMIA SYNDROM, Vfourth; Weatherall DJ, 2001, B WORLD HEALTH ORGAN, V79, P704; WHO, 2002, GEN WORLD HLTH; WHO Commission on Macroeconomics and Health, 2001, MACR HLTH INV HLTH E; *WORLD BANK, 2002, 2002 WORLD DEV IND	18	35	36	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					597	599		10.1126/science.1089864	http://dx.doi.org/10.1126/science.1089864			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576421				2022-12-28	WOS:000186119900044
J	Sivars, U; Aivazian, D; Pfeffer, SR				Sivars, U; Aivazian, D; Pfeffer, SR			Yip3 catalyses the dissociation of endosomal Rab-GDI complexes	NATURE			English	Article							GOLGI MEMBRANE-PROTEIN; PRENYLATED RAB; NUCLEOTIDE EXCHANGE; BINDING PROTEIN; GTPASES; INHIBITOR; IDENTIFICATION; TRANSPORT; INTERACTS; RECEPTOR	Human cells contain more than 60 small G proteins of the Rab family, which are localized to the surfaces of distinct membrane compartments and regulate transport vesicle formation, motility, docking and fusion(1-3). Prenylated Rabs also occur in the cytosol bound to GDI(4,5) (guanine nucleotide dissociation inhibitor), which binds to Rabs in their inactive state. Prenyl Rab-GDI complexes contain all of the information necessary to direct Rab delivery onto distinct membrane compartments(6-8). The late endosomal, prenyl Rab9 binds GDI with very high affinity(9), which led us to propose that there might be a 'GDI-displacement factor' to catalyse dissociation of Rab-GDI complexes and to enable transfer of Rabs from GDI onto membranes(6,10). Indeed, we have previously shown that endosomal membranes contain a proteinaceous factor that can act in this manner(10). Here we show that the integral membrane protein, Yip3, acts catalytically to dissociate complexes of endosomal Rabs bound to GDI, and to deliver them onto membranes. We propose that the conserved Yip proteins serve as GDI-displacement factors for the targeting of Rab GTPases in eukaryotic cells.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Stanford University	Pfeffer, SR (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.							Abdul-Ghani M, 2001, J BIOL CHEM, V276, P6225, DOI 10.1074/jbc.M009073200; BARROWMAN J, 2002, J BIOL CHEM, V278, P1978; Bucci C, 1999, BIOCHEM BIOPH RES CO, V258, P657, DOI 10.1006/bbrc.1999.0651; Calero M, 2002, BIOCHEM BIOPH RES CO, V290, P676, DOI 10.1006/bbrc.2001.6242; Calero M, 2002, FEBS LETT, V515, P89, DOI 10.1016/S0014-5793(02)02442-0; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Figueroa C, 2001, J BIOL CHEM, V276, P28219, DOI 10.1074/jbc.M101763200; Hutt DM, 2000, J BIOL CHEM, V275, P18511, DOI 10.1074/jbc.M909309199; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lin JL, 2001, J BIOL CHEM, V276, P41733, DOI 10.1074/jbc.M103475200; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; Matern H, 2000, EMBO J, V19, P4485, DOI 10.1093/emboj/19.17.4485; Otte S, 2001, J CELL BIOL, V152, P503, DOI 10.1083/jcb.152.3.503; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; SHAPIRO AD, 1995, J BIOL CHEM, V270, P11085, DOI 10.1074/jbc.270.19.11085; SOLDATI T, 1995, J BIOL CHEM, V270, P25541, DOI 10.1074/jbc.270.43.25541; SOLDATI T, 1995, METHOD ENZYMOL, V257, P253; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; Tang BL, 2001, J BIOL CHEM, V276, P40008, DOI 10.1074/jbc.M106189200; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; Yang XP, 1998, EMBO J, V17, P4954, DOI 10.1093/emboj/17.17.4954; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	26	195	207	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					856	859		10.1038/nature02057	http://dx.doi.org/10.1038/nature02057			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574414				2022-12-28	WOS:000186118500049
J	Zhang, JW; Niu, C; Ye, L; Huang, HY; He, X; Tong, WG; Ross, J; Haug, J; Johnson, T; Feng, JQ; Harris, S; Wiedemann, LM; Mishina, Y; Li, LH				Zhang, JW; Niu, C; Ye, L; Huang, HY; He, X; Tong, WG; Ross, J; Haug, J; Johnson, T; Feng, JQ; Harris, S; Wiedemann, LM; Mishina, Y; Li, LH			Identification of the haematopoietic stem cell niche and control of the niche size	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-2; DROSOPHILA-OVARY; IN-VIVO; DIFFERENTIATION; OSTEOBLAST; CADHERIN; LINEAGES; PROLIFERATION; MESODERM; MARROW	Haematopoietic stem cells (HSCs) are a subset of bone marrow cells that are capable of self-renewal and of forming all types of blood cells (multi-potential)(1). However, the HSC 'niche'-the in vivo regulatory microenvironment where HSCs reside-and the mechanisms involved in controlling the number of adult HSCs remain largely unknown. The bone morphogenetic protein (BMP) signal has an essential role in inducing haematopoietic tissue during embryogenesis(2,3). We investigated the roles of the BMP signalling pathway in regulating adult HSC development in vivo by analysing mutant mice with conditional inactivation of BMP receptor type IA (BMPRIA). Here we show that an increase in the number of spindle-shaped N-cadherin(+)CD45(-) osteoblastic (SNO) cells correlates with an increase in the number of HSCs. The long-term HSCs are found attached to SNO cells. Two adherens junction molecules, N-cadherin and beta-catenin, are asymmetrically localized between the SNO cells and the long-term HSCs. We conclude that SNO cells lining the bone surface function as a key component of the niche to support HSCs, and that BMP signalling through BMPRIA controls the number of HSCs by regulating niche size.	Stowers Inst Med Res, Kansas City, MO 64110 USA; Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO 64108 USA; NIEHS, Reprod & Dev Toxicol Lab, Res Triangle Pk, NC 27709 USA; Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA	Stowers Institute for Medical Research; University of Missouri System; University of Missouri Kansas City; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Kansas; University of Kansas Medical Center	Li, LH (corresponding author), Stowers Inst Med Res, Kansas City, MO 64110 USA.		Wiedemann, Leanne/E-3316-2010	Li, Linheng/0000-0001-9963-430X; Wiedemann, Leanne/0000-0002-0964-4676	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071004] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Askenasy N, 2002, STEM CELLS, V20, P501, DOI 10.1634/stemcells.20-6-501; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Charbord P, 2001, THERAPIE, V56, P383; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Davidson AJ, 2000, CURR TOP DEV BIOL, V50, P45, DOI 10.1016/S0070-2153(00)50003-9; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; El-Badri NS, 1998, EXP HEMATOL, V26, P110; Hay E, 2001, J BIOL CHEM, V276, P29028, DOI 10.1074/jbc.M011265200; Hay E, 2000, J CELL PHYSIOL, V183, P117, DOI 10.1002/(SICI)1097-4652(200004)183:1<117::AID-JCP14>3.0.CO;2-#; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lagasse E, 2001, IMMUNITY, V14, P425, DOI 10.1016/S1074-7613(01)00123-6; Maeno M, 1996, BLOOD, V88, P1965, DOI 10.1182/blood.V88.6.1965.bloodjournal8861965; Mishina Y, 2002, GENESIS, V32, P69, DOI 10.1002/gene.10038; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293; Puch S, 2001, J CELL SCI, V114, P1567; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; Simmons PJ, 2001, HEMATOPOIESIS DEV AP, P718; Song XQ, 2002, P NATL ACAD SCI USA, V99, P14813, DOI 10.1073/pnas.232389399; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; SZILVASSY SJ, 2002, HAEMATOPOIETIC STEM, P167; Taichman RUSSELL S., 2000, Hematology, V4, P421; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Visnjic D, 2001, J BONE MINER RES, V16, P2222, DOI 10.1359/jbmr.2001.16.12.2222; WEISSMAN IL, 1994, CELL, V76, P207, DOI 10.1016/0092-8674(94)90329-8; Xie T, 2000, SCIENCE, V290, P328, DOI 10.1126/science.290.5490.328	31	2194	2341	4	167	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					836	841		10.1038/nature02041	http://dx.doi.org/10.1038/nature02041			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574412	Bronze			2022-12-28	WOS:000186118500045
J	Hadjikoutis, S; Pickersgill, TP; Smith, PEM				Hadjikoutis, S; Pickersgill, TP; Smith, PEM			Weight loss associated with levetiracetam	BMJ-BRITISH MEDICAL JOURNAL			English	Letter									Univ Wales Hosp, Dept Neurol, Epilepsy Unit, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Smith, PEM (corresponding author), Univ Wales Hosp, Dept Neurol, Epilepsy Unit, Cardiff CF14 4XN, S Glam, Wales.	smithpe@cardiff.ac.uk						*BRIT MED ASS, 2003, BRIT NAT FORM, P231; Faught E, 2001, NEUROLOGY, V57, P1774, DOI 10.1212/WNL.57.10.1774; GLANSER TA, 1999, EPILIPSIA, V40, pS71; Shorvon SD, 2000, HDB EPILEPSY TREATME	4	15	15	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 18	2003	327	7420					905	905		10.1136/bmj.327.7420.905	http://dx.doi.org/10.1136/bmj.327.7420.905			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734RV	14563748	Bronze, Green Published			2022-12-28	WOS:000186072100021
J	Zimmermann, RA				Zimmermann, RA			The double life of ribosomal proteins	CELL			English	Editorial Material							SUBUNIT; RESOLUTION	Many integral proteins of the ribosome also carry out extra-ribosomal functions as independent polypeptides, raising questions as to their evolutionary derivation. In this issue of Cell, Mazumder et al. report a surprising new twist in the dual life of these molecules: as part of a cellular response to interferon, a large-subunit protein dramatically exits the ribosome to bind and inhibit the translation of a specific mRNA.	Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Zimmermann, RA (corresponding author), Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA.							Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; Cukras AR, 2003, MOL CELL, V12, P321, DOI 10.1016/S1097-2765(03)00275-2; Gabashvili IS, 2001, MOL CELL, V8, P181, DOI 10.1016/S1097-2765(01)00293-3; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Mazumder B, 2003, CELL, V115, P187, DOI 10.1016/S0092-8674(03)00773-6; Nakatogawa H, 2002, CELL, V108, P629, DOI 10.1016/S0092-8674(02)00649-9; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8; Wower IK, 1998, J BIOL CHEM, V273, P19847, DOI 10.1074/jbc.273.31.19847; ZENGEL JM, 1994, PROG NUCLEIC ACID RE, V47, P331, DOI 10.1016/S0079-6603(08)60256-1	10	33	37	0	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 17	2003	115	2					130	132		10.1016/S0092-8674(03)00804-3	http://dx.doi.org/10.1016/S0092-8674(03)00804-3			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567909	Bronze			2022-12-28	WOS:000186039200003
J	Kadan-Lottick, NS; Ness, KK; Bhatia, S; Gurney, JG				Kadan-Lottick, NS; Ness, KK; Bhatia, S; Gurney, JG			Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE LYMPHOID LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; RACIAL-DIFFERENCES; CHILDREN; CANCER; WHITE; BLACK; CURE	Context The role of race/ethnicity in survival of children with acute lymphoblastic leukemia (ALL) is unclear, with some studies reporting poorer survival among minority children and others reporting equivalent survival across race/ethnicity in the modern, risk-stratified treatment era. Objective To investigate the relation between race/ethnicity and survival in a large, population-based analysis of incident ALL cases in the United States. Design, Population, and Setting This study included 4952 individuals diagnosed with ALL between 1973 and 1999 at age 19 years or younger. ALL cases were identified from 9 population-based registries of the National Cancer Institute's Surveillance, Epidemiology, and End Results program. Main Outcome Measures Survival probabilities were compared among white, black, Hispanic, Asian/Pacific Islander, and American Indian/Alaskan Native children. Kaplan-Meier curves and proportional hazard ratios from Cox regression analysis were calculated, accounting for treatment era (1973-1982, 1983-1989, and 1990-1999), age at diagnosis (<1, 1-9, and 10-19 years), and sex. Results Although overall 5-year survival probabilities improved with each successive treatment era, differences according to race/ethnicity persisted. For 1990-1999, 5-year survival was 84% for white children, 81 % for Asian/Pacific Islander children, 75% for black children, and 72% for both American Indian/Alaskan Native children and Hispanic children. The largest difference by race/ethnicity was observed among children diagnosed between ages 1 and 9 years. Compared with white children, after adjusting for treatment era, age at diagnosis, and sex, children of black, Hispanic, and American Indian/Alaskan Native descent had hazard ratios of 1.50 (95% Cl, 1.0-2.2; P=.03), 1.83 (95% Cl, 1.4-2.4; P<.001), and 1.90 (95% Cl, 0.8-4.6; P=.16). Conclusions Black, Hispanic, and American Indian/Alaskan Native children with ALL have worse survival than white and Asian/Pacific Islander children, even in the contemporary treatment era. Future work must delineate the social and biological factors, including any differences in pharmacokinetics associated with chemotherapeutic agents, that account for disparities in outcome.	Univ Minnesota, Div Pediat Epidemiol & Clin Res, Minneapolis, MN 55455 USA; Yale Univ, Div Pediat Hematol Oncol, New Haven, CT USA; City Hope Natl Med Ctr, Div Pediat, Duarte, CA 91010 USA	University of Minnesota System; University of Minnesota Twin Cities; Yale University; City of Hope	Gurney, JG (corresponding author), Univ Minnesota, Div Pediat Epidemiol & Clin Res, Mayo Mail Code 715,420 Delaware St SE, Minneapolis, MN 55455 USA.		Kadan-Lottick, Nina Singh/HGE-5850-2022; Ness, Kirsten K/N-2550-2018	Kadan-Lottick, Nina Singh/0000-0002-6857-396X; Ness, Kirsten K/0000-0002-2084-1507				ALLISON PD, 1999, LOGISTIC REGRESSION, P30; ALLISON PD, 1999, LOGISTIC REGRESSION, P113; Bach PB, 2002, JAMA-J AM MED ASSOC, V287, P2106, DOI 10.1001/jama.287.16.2106; Bhatia S, 2002, BLOOD, V100, P1957, DOI 10.1182/blood-2002-02-0395; Brenner MK, 1999, SEMIN HEMATOL, V36, P73; COLLETT D, 1991, MODELING BINARY DATA, P16; *DCCPS NAT CANC I, 2002, SURV EP END RES PROG; FALLETTA JM, 1984, PATHOGENESIS LEUKEMI, P191; FOUCAR K, 1991, CANCER-AM CANCER SOC, V67, P2125, DOI 10.1002/1097-0142(19910415)67:8<2125::AID-CNCR2820670820>3.0.CO;2-A; Hord MH, 1996, CANCER-AM CANCER SOC, V77, P563; MARUBINI E, 1985, ANAL SURVIVAL DATA C, P41; McKinney PA, 1999, BRIT J CANCER, V80, P1844, DOI 10.1038/sj.bjc.6690609; MCLEOD HL, 1994, CLIN PHARMACOL THER, V55, P15, DOI 10.1038/clpt.1994.4; *NCI, SEER STAT VERS 4 2; *NCI, CANC CONTR POP SCI S; NOVAKOVIC B, 1994, MED PEDIATR ONCOL, V23, P480, DOI 10.1002/mpo.2950230606; Percy C., 1990, INT CLASSIFICATION D; PINKEL D, 1993, LEUKEMIA, V7, pS146; Pollock BH, 2000, J CLIN ONCOL, V18, P813, DOI 10.1200/JCO.2000.18.4.813; Powell JE, 2000, BRIT J CANCER, V82, P1568; PRATT JA, 1988, J CLIN EPIDEMIOL, V41, P367, DOI 10.1016/0895-4356(88)90144-8; PUI CH, 1995, JAMA-J AM MED ASSOC, V273, P633, DOI 10.1001/jama.273.8.633; REAMAN GH, 1984, PATHOGENESIS LEUKEMI, P163; Ries LA, 2002, SEER CANC STAT REV 1; Rivera-Luna R, 2000, J CLIN ONCOL, V18, P2349; *SAS I, SAS VERS 8 2; SATHER H, 1984, PATHOGENESIS LEUKEMI, P179; Smith M, 1996, J CLIN ONCOL, V14, P18, DOI 10.1200/JCO.1996.14.1.18; SMITH MA, 1999, NIH PUB; Walker A H, 1998, Hum Mutat, V12, P289; WALTERS TR, 1972, CANCER, V29, P210, DOI 10.1002/1097-0142(197201)29:1<210::AID-CNCR2820290131>3.0.CO;2-U; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C	32	163	164	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	2003	290	15					2008	2014		10.1001/jama.290.15.2008	http://dx.doi.org/10.1001/jama.290.15.2008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732CX	14559954	Bronze			2022-12-28	WOS:000185924200024
J	Lawton, B; Rose, S; McLeod, D; Dowell, A				Lawton, B; Rose, S; McLeod, D; Dowell, A			Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users	BRITISH MEDICAL JOURNAL			English	Editorial Material									Wellington Sch Med & Hlth Sci, Dept Gen Practice, Wellington, New Zealand	University of Otago	Lawton, B (corresponding author), Wellington Sch Med & Hlth Sci, Dept Gen Practice, POB 7343, Wellington, New Zealand.			Lawton, Beverley/0000-0003-2447-8386				Ballard K, 2002, BRIT J GEN PRACT, V52, P835; Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; International Menopause Society, INT MEN SOC DEV CONS; North FM, 2001, NEW ZEAL MED J, V114, P250; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321	5	106	107	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					845	846		10.1136/bmj.327.7419.845	http://dx.doi.org/10.1136/bmj.327.7419.845			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551101	Green Published, Bronze			2022-12-28	WOS:000185921200021
J	Apesteguia, S; Novas, FE				Apesteguia, S; Novas, FE			Large Cretaceous sphenodontian from Patagonia provides insight into lepidosaur evolution in Gondwana	NATURE			English	Article							JURASSIC KOTA FORMATION; CENTRAL MEXICO; DIAPSIDA; REPTILIA; RHYNCHOCEPHALIA	Sphenodontian reptiles successfully radiated during Triassic and Jurassic times, but were driven almost to extinction during the Cretaceous period(1). The sparse Early Cretaceous record of sphenodontians has been interpreted as reflecting the decline of the group in favour of lizards, their suspected ecological successors(2). However, recent discoveries in Late Cretaceous beds in Patagonia partially modify this interpretation. Numerous skeletons of a new sphenodontian, Priosphenodon avelasi gen. et sp. nov., were collected from a single locality in the Cenomanian-Turonian Candeleros Formation, where it is more abundant than any other tetrapod group recorded in the quarry (for example, Crocodyliformes, Serpentes, Dinosauria and Mammalia)(3,4). Adult specimens of Priosphenodon reached one metre in length, larger than any previously known terrestrial sphenodontian. Here we propose, using available evidence, that sphenodontians were not a minor component of the Cretaceous terrestrial ecosystems of South America, and that their ecological replacement by squamates was delayed until the early Tertiary. The new discovery helps to bridge the considerable gap in the fossil record (around 120 million years) that separates the Early Cretaceous sphenodontians(5-7) from their living relatives (Sphenodon).	Museo Argentino Ciencias Nat Bernardino Rivadavia, RA-1405 Buenos Aires, DF, Argentina	Museo Argentino de Ciencias Naturales Bernardino Rivadavia (MACN)	Apesteguia, S (corresponding author), Museo Argentino Ciencias Nat Bernardino Rivadavia, Av Angel Gallardo 470, RA-1405 Buenos Aires, DF, Argentina.		Apesteguía, Sebastian/F-4034-2018	Apesteguía, Sebastian/0000-0002-0414-0524				ALBINO A, 1 C OA REIG VERT BAS; APESTEGUIA S, IN PRESS C ARG PAL B; APESTEGUIA S, IN PRESS 1 C OA REIG; APESTEGUIA S, 2002, AMEGHINIANA, V39, pR5; Baez A. M., 1977, ACTA GEOLOGICA LILLO, V14, P149; Barbera C., 1992, Memorie della Societa Geologica Italiana, V41, P567; Broschinski Annette, 1996, Annales de Paleontologie, V82, P147; Carroll RL, 1988, VERTEBRATE PALEONTOL; Estes R., 1985, GREAT AM BIOTIC INTE, P139; Evans SE, 2002, J VERTEBR PALEONTOL, V22, P299, DOI 10.1671/0272-4634(2002)022[0299:FLFTJK]2.0.CO;2; Evans SE, 1997, J VERTEBR PALEONTOL, V17, P45, DOI 10.1080/02724634.1997.10010952; Evans SE, 2001, ZOOL J LINN SOC-LOND, V133, P309, DOI 10.1006/zjls.2000.0266; Evans Susan E., 1998, Neues Jahrbuch fuer Geologie und Palaeontologie Monatshefte, V6, P349; FRASER NC, 1988, PHILOS T ROY SOC B, V321, P125, DOI 10.1098/rstb.1988.0092; FRASER NC, 1989, ZOOL J LINN SOC-LOND, V96, P413, DOI 10.1111/j.1096-3642.1989.tb02521.x; GALLINA P.A., 2002, AMEGHINIANA, V39, p10R; Haeckel Ernst, 1866, GENERELLE MORPHOLOGI; HUGO C, 1999, I GEOL REC NAT SEGEM, V309, P1; Novas F. E., 1999, AMEGHINIANA, V36, p16R; POL D, IN PRESS C ARG PALEO; RASMUSSEN TE, 1981, J PALEONTOL, V55, P1109; Reynoso VH, 1997, J VERTEBR PALEONTOL, V17, P52, DOI 10.1080/02724634.1997.10010953; Reynoso VH, 2000, J PALEONTOL, V74, P133, DOI 10.1666/0022-3360(2000)074<0133:AUASRD>2.0.CO;2; Rich T.H.V., 1983, Transactions of the Geological Society of South Africa, V86, P281; Smith Krister T., 2001, Journal of Vertebrate Paleontology, V21, p102A; THROCKMORTON GS, 1981, J PALEONTOL, V55, P586; WILLISTON S. W., 1925, OSTEOLOGY REPTILES; Wu X.-C., 1991, THESIS MCGILL U; Zils Wolfgang, 1995, Documenta Naturae, V97, P1	29	85	88	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2003	425	6958					609	612		10.1038/nature01995	http://dx.doi.org/10.1038/nature01995			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534584				2022-12-28	WOS:000185801000034
J	Jansen, PLM; Sturm, E				Jansen, PLM; Sturm, E			Paediatric cholestasis: is villin the villain?	LANCET			English	Editorial Material							BILIARY ATRESIA; ACTIN CYTOSKELETON; IN-VIVO; MORPHOGENESIS; DISRUPTION		Univ Groningen Hosp, Dept Pediat, NL-9713 GZ Groningen, Netherlands; Univ Groningen Hosp, Dept Gastroenterol & Hepatol, NL-9713 GZ Groningen, Netherlands	University of Groningen; University of Groningen	Jansen, PLM (corresponding author), Univ Groningen Hosp, Dept Pediat, NL-9713 GZ Groningen, Netherlands.		Jansen, Peter LM/I-4509-2013					Athman R, 2002, AM J PHYSIOL-GASTR L, V283, pG496, DOI 10.1152/ajpgi.00207.2002; ATHMAN R, 2003, MOL BIOL CELL   0822; Chen LM, 2003, HEPATOLOGY, V38, P567, DOI 10.1053/jhep.2003.50363; Ferrary E, 1999, J CELL BIOL, V146, P819, DOI 10.1083/jcb.146.4.819; Friederich E, 1999, J BIOL CHEM, V274, P26751, DOI 10.1074/jbc.274.38.26751; LAURENT J, 1990, GASTROENTEROLOGY, V99, P1793, DOI 10.1016/0016-5085(90)90489-N; Lauwaet T, 2003, J BIOL CHEM, V278, P22650, DOI 10.1074/jbc.M300142200; Perlmutter DH, 2002, HEPATOLOGY, V35, P1297, DOI 10.1053/jhep.2002.34170; Pinson KI, 1998, DEV DYNAM, V211, P109, DOI 10.1002/(SICI)1097-0177(199801)211:1<109::AID-AJA10>3.0.CO;2-7	9	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 4	2003	362	9390					1090	1091		10.1016/S0140-6736(03)14498-4	http://dx.doi.org/10.1016/S0140-6736(03)14498-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728HA	14550691				2022-12-28	WOS:000185710700004
J	Phillips, MJ; Azuma, T; Meredith, SLM; Squire, JA; Ackerley, CA; Pluthero, FG; Roberts, EA; Superina, RA; Levy, GA; Marsden, PA				Phillips, MJ; Azuma, T; Meredith, SLM; Squire, JA; Ackerley, CA; Pluthero, FG; Roberts, EA; Superina, RA; Levy, GA; Marsden, PA			Abnormalities in villin gene expression and canalicular microvillus structure in progressive cholestatic liver disease of childhood	LANCET			English	Article							FAMILIAL INTRAHEPATIC CHOLESTASIS; BILE CANALICULI; F-ACTIN; DISRUPTION; CELLS; CONTRACTILITY; CYTOSKELETON; MECHANISMS; MUTATIONS	Background The molecular basis of clinical cholestasis is a subject of intense investigation. Villin is an actin binding, bundling, and severing protein needed for maintenance of structural integrity of canalicular microvilli, in which membrane transporters required for bile secretion are located. We aimed to investigate the role of canalicular cytoskeletal proteins in three genetically unrelated children with a biliary atresia-like clinical disorder, each of whom developed liver failure requiring liver transplantation. Methods Explanted livers from the three patients were examined by standard pathological methods followed by transmission and cryoimmunoelectron microscopy. With archival tissue samples, a panel of cytoskeletal proteins was investigated by immunohistochemistry and western blotting, with purified canalicular membrane preparations. Villin mRNA analyses were undertaken on liver homogenates, with primers from coding regions of the human villin gene. Classic biliary atresia, other types of cholestasis, and normal livers served as controls. Findings In patients, pronounced ultrastructural deformities of canaliculi and especially of their microvilli were noted, which correlated with absence of villin protein by immunostaining of liver tissue sections and by western blot analysis. Additionally, villin mRNA was strikingly reduced or absent. These results differed greatly from those in controls. Interpretation These results suggest that the disorder described mimics biliary atresia, but structural and molecular pathological findings differ. We propose that a functional abnormality in villin gene expression is key to the mechanism of cholestasis in patients with progressive cholestasis and hepatic failure.	Toronto Gen Hosp, Univ Hlth Network, Dept Multiorgan Transplantat Res, Toronto, ON, Canada; Hosp Sick Children, Div Pathol, Toronto, ON M5G 1X8, Canada; Keio Univ, Dept Surg, Tokyo, Japan; Univ Hlth Network, Ontario Canc Inst, Dvi Cellular & Mol Biol, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Northwestern Univ, Dept Surg, Chicago, IL 60611 USA; St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Keio University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Northwestern University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Phillips, MJ (corresponding author), Hosp Sick Children, Univ Hlth Network, Wlm Str Wing,Room 3125,555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Marsden, Philip A/B-1441-2012; Squire, Jeremy A/A-9352-2012; Pluthero, Fred/T-8593-2019; Squire, Jeremy A/F-4437-2012	Squire, Jeremy A/0000-0002-9863-468X; Pluthero, Fred/0000-0002-0451-5840				Blanquicett C, 2002, ANAL BIOCHEM, V303, P209, DOI 10.1006/abio.2001.5570; Bove KE, 2000, PEDIATR DEVEL PATHOL, V3, P1, DOI 10.1007/s100240050001; BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X; Bull LN, 1998, NAT GENET, V18, P219, DOI 10.1038/ng0398-219; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Cutz E, 1997, PEDIATR PATHOL LAB M, V17, P335, DOI 10.1080/107710497174688; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; EZZELL RM, 1989, DEVELOPMENT, V106, P407; Ferrary E, 1999, J CELL BIOL, V146, P819, DOI 10.1083/jcb.146.4.819; Flowers MA, 1995, AM J PHYSIOL-HEART C, V269, pH1988, DOI 10.1152/ajpheart.1995.269.6.H1988; FRIEDERICH E, 1989, CELL, V59, P461, DOI 10.1016/0092-8674(89)90030-5; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; Jansen PLM, 2001, HEPATOLOGY, V34, P1067, DOI 10.1053/jhep.2001.29625; LINARELLI LG, 1972, J PEDIATR-US, V81, P484, DOI 10.1016/S0022-3476(72)80174-4; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; MAUROURY R, 1988, EMBO J, V7, P3321; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; OSHIO C, 1981, SCIENCE, V212, P1041, DOI 10.1126/science.7015506; Phillips M. James, 1994, P19; Phillips MJ., 1987, LIVER ATLAS TEXT ULT; Pinson KI, 1998, DEV DYNAM, V211, P109, DOI 10.1002/(SICI)1097-0177(199801)211:1<109::AID-AJA10>3.0.CO;2-7; Pinto D, 1999, J BIOL CHEM, V274, P6476, DOI 10.1074/jbc.274.10.6476; PRINGAULT E, 1991, P NATL ACAD SCI USA, V88, P10811, DOI 10.1073/pnas.88.23.10811; PRINGAULT E, 1986, EMBO J, V5, P3119, DOI 10.1002/j.1460-2075.1986.tb04618.x; Setchell KDR, 2001, LIVER DIS CHILDREN, P701; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; SUCHY FJ, 2001, LIVER DIS CHILDREN, P187; Thompson RJ, 2001, J HEPATOL, V34, P184, DOI 10.1016/S0168-8278(01)80678-4; TSUKADA N, 1995, HEPATOLOGY, V21, P1106, DOI 10.1002/hep.1840210433; TSUKADA N, 1994, P NATL ACAD SCI USA, V91, P6919, DOI 10.1073/pnas.91.15.6919; WATANABE N, 1991, J CELL BIOL, V113, P1069, DOI 10.1083/jcb.113.5.1069	34	25	27	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 4	2003	362	9390					1112	1119		10.1016/S0140-6736(03)14467-4	http://dx.doi.org/10.1016/S0140-6736(03)14467-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728HA	14550699				2022-12-28	WOS:000185710700011
J	Bertsch, DN; Lindsley, JE				Bertsch, DN; Lindsley, JE			Does it take two to untangle?	CELL			English	Editorial Material							MITOSIS; PROTEIN; CONDENSATION; SEGREGATION; CHROMOSOMES; COMPLEXES; MEIOSIS	The structural integrity of mitotic chromosomes is essential for proper chromatid segregation. In this issue of Cell, Ono et al. (2003) show that vertebrates contain two distinct condensin complexes, both of which are required for normal mitotic chromosome morphology.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Bertsch, DN (corresponding author), Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA.							Hagstrom KA, 2002, GENE DEV, V16, P729, DOI 10.1101/gad.968302; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; Hudson DF, 2003, DEV CELL, V5, P323, DOI 10.1016/S1534-5807(03)00199-0; Kaitna S, 2002, CURR BIOL, V12, P798, DOI 10.1016/S0960-9822(02)00820-5; Kitajima TS, 2003, SCIENCE, V300, P1152, DOI 10.1126/science.1083634; Maeshima K, 2003, DEV CELL, V4, P467, DOI 10.1016/S1534-5807(03)00092-3; Ono T, 2003, CELL, V115, P109, DOI 10.1016/S0092-8674(03)00724-4; Schleiffer A, 2003, MOL CELL, V11, P571, DOI 10.1016/S1097-2765(03)00108-4; Steffensen S, 2001, CURR BIOL, V11, P295, DOI 10.1016/S0960-9822(01)00096-3; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587	10	1	1	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 3	2003	115	1					4	6		10.1016/S0092-8674(03)00763-3	http://dx.doi.org/10.1016/S0092-8674(03)00763-3			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14531995	Bronze			2022-12-28	WOS:000185815500004
J	Ito, S; Stuphorn, V; Brown, JW; Schall, JD				Ito, S; Stuphorn, V; Brown, JW; Schall, JD			Performance monitoring by the anterior cingulate cortex during saccade countermanding	SCIENCE			English	Article							SUPPLEMENTARY EYE FIELD; REWARD; MOVEMENT; MACAQUE; DOPAMINE; MONKEY	Consensus is emerging that the medial frontal lobe of the brain is involved in monitoring performance, but precisely what is monitored remains unclear. A saccade-countermanding task affords an experimental dissociation of neural signals of error, reinforcement, and conflict. Single-unit activity was monitored in the anterior cingulate cortex of monkeys performing this task. Neurons that signaled errors were found, half of which responded to the omission of earned reinforcement. A further diversity of neurons signaled earned or unexpected reinforcement. No neurons signaled the form of conflict engendered by interruption of saccade preparation produced in this task. These results are consistent with the hypothesis that the anterior cingulate cortex monitors the consequences of actions.	Vanderbilt Univ, Dept Psychol, Vanderbilt Vis Res Ctr, Ctr Integrat & Cognit Neurosci, Nashville, TN 37203 USA; Washington Univ, Dept Psychol, St Louis, MO 63130 USA	Vanderbilt University; Washington University (WUSTL)	Schall, JD (corresponding author), Vanderbilt Univ, Dept Psychol, Vanderbilt Vis Res Ctr, Ctr Integrat & Cognit Neurosci, Wilson Hall, Nashville, TN 37203 USA.	jeffrey.d.schall@vanderbilt.edu	Brown, Joshua/G-2867-2011		NEI NIH HHS [P30-EY008126] Funding Source: Medline; NIMH NIH HHS [R01-MH55806] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY008126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH055806] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BECKER W, 1979, VISION RES, V19, P967, DOI 10.1016/0042-6989(79)90222-0; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Brown J, 1999, J NEUROSCI, V19, P10502; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Dayan P, 2002, NEURON, V36, P285, DOI 10.1016/S0896-6273(02)00963-7; Gehring WJ, 2002, SCIENCE, V295, P2279, DOI 10.1126/science.1066893; HANES DP, 1995, VISUAL NEUROSCI, V12, P929, DOI 10.1017/S0952523800009482; Hanes DP, 1998, J NEUROPHYSIOL, V79, P817, DOI 10.1152/jn.1998.79.2.817; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI 10.1037/0033-295X.109.4.679; HUERTA MF, 1990, J COMP NEUROL, V293, P299, DOI 10.1002/cne.902930211; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Luppino G, 2003, EUR J NEUROSCI, V17, P559, DOI 10.1046/j.1460-9568.2003.02476.x; McPeek RM, 2003, J NEUROPHYSIOL, V89, P2577, DOI 10.1152/jn.00657.2002; Montague PR, 2002, NEURON, V36, P265, DOI 10.1016/S0896-6273(02)00974-1; NIKI H, 1979, BRAIN RES, V171, P213, DOI 10.1016/0006-8993(79)90328-7; Pare M, 2003, J NEUROSCI, V23, P6480; Paus T, 2001, NAT REV NEUROSCI, V2, P417, DOI 10.1038/35077500; SCHALL JD, 1993, VISUAL NEUROSCI, V10, P385, DOI 10.1017/S0952523800003771; Scheffers MK, 2000, J EXP PSYCHOL HUMAN, V26, P141, DOI 10.1037/0096-1523.26.1.141; Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4; Shidara M, 2002, SCIENCE, V296, P1709, DOI 10.1126/science.1069504; Shima K, 1998, SCIENCE, V282, P1335, DOI 10.1126/science.282.5392.1335; Stuphorn V, 2000, NATURE, V408, P857, DOI 10.1038/35048576	23	427	433	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	2003	302	5642					120	122		10.1126/science.1087847	http://dx.doi.org/10.1126/science.1087847			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526085				2022-12-28	WOS:000185678500050
J	Goss, PE; Ingle, JN; Martino, S; Robert, NJ; Muss, HB; Piccart, MJ; Castiglione, M; Tu, D; Shepherd, LE; Pritchard, KI; Livingston, RB; Davidson, NE; Norton, L; Perez, EA; Abrams, JS; Therasse, P; Palmer, MJ; Pater, JL				Goss, PE; Ingle, JN; Martino, S; Robert, NJ; Muss, HB; Piccart, MJ; Castiglione, M; Tu, D; Shepherd, LE; Pritchard, KI; Livingston, RB; Davidson, NE; Norton, L; Perez, EA; Abrams, JS; Therasse, P; Palmer, MJ; Pater, JL			A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ONCOLOGY TECHNOLOGY-ASSESSMENT; AROMATASE INHIBITOR LETROZOLE; SURGICAL ADJUVANT BREAST; BONE-MINERAL DENSITY; CELL-PROLIFERATION; AMERICAN-SOCIETY; ESTROGEN; PREVENTION; COMBINATION; MECHANISMS	BACKGROUND: In hormone-dependent breast cancer, five years of postoperative tamoxifen therapy -- but not tamoxifen therapy of longer duration -- prolongs disease-free and overall survival. The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy. METHODS: We conducted a double-blind, placebo-controlled trial to test the effectiveness of five years of letrozole therapy in postmenopausal women with breast cancer who have completed five years of tamoxifen therapy. The primary end point was disease-free survival. RESULTS: A total of 5187 women were enrolled (median follow-up, 2.4 years). At the first interim analysis, there were 207 local or metastatic recurrences of breast cancer or new primary cancers in the contralateral breast -- 75 in the letrozole group and 132 in the placebo group -- with estimated four-year disease-free survival rates of 93 percent and 87 percent, respectively, in the two groups (P lessthan/equal 0.001 for the comparison of disease-free survival). A total of 42 women in the placebo group and 31 women in the letrozole group died (P=0.25 for the comparison of overall survival). Low-grade hot flashes, arthritis, arthralgia, and myalgia were more frequent in the letrozole group, but vaginal bleeding was less frequent. There were new diagnoses of osteoporosis in 5.8 percent of the women in the letrozole group and 4.5 percent of the women in the placebo group (P=0.07); the rates of fracture were similar. After the first interim analysis, the independent data and safety monitoring committee recommended termination of the trial and prompt communication of the results to the participants. CONCLUSIONS: As compared with placebo, letrozole therapy after the completion of standard tamoxifen treatment significantly improves disease-free survival.	Princess Margaret Hosp, Div Hematol Oncol, Toronto, ON M5G 2M9, Canada; Mayo Clin, Rochester, MN USA; John Wayne Canc Inst, Santa Monica, CA USA; Inova Fairfax Hosp, Falls Church, VA USA; Univ Vermont, Burlington, VT USA; Inst Jules Bordet, B-1000 Brussels, Belgium; Int Breast Canc Study Grp Coordinating Ctr, Bern, Switzerland; Natl Canc Inst Canada, Clin Trials Grp, Kingston, ON, Canada; Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada; Univ Washington, Seattle, WA 98195 USA; Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Mayo Clin, Jacksonville, FL 32224 USA; NCI, Canc Therapy Evaluat Program, Clin Invest Branch, Rockville, MD USA; European Org Res Treatment Canc, Ctr Data, Brussels, Belgium	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Mayo Clinic; John Wayne Cancer Institute; Inova Fairfax Hospital; University of Vermont; Institut Jules Bordet; International Breast Cancer Study Group; Queens University - Canada; Canadian Cancer Trials Group; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Washington; University of Washington Seattle; Johns Hopkins University; Johns Hopkins Medicine; Memorial Sloan Kettering Cancer Center; Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); European Organisation for Research & Treatment of Cancer	Goss, PE (corresponding author), Princess Margaret Hosp, Div Hematol Oncol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	pegoss@interlog.com	Pritchard, Kathleen I/I-2184-2014	Pritchard, Kathleen I/0000-0003-0758-9666; Norton, Larry/0000-0003-3701-9250	NATIONAL CANCER INSTITUTE [U10CA038926, U10CA025224, U10CA021115, U10CA032102, U10CA031946] Funding Source: NIH RePORTER; NCI NIH HHS [CA38926, CA25224, CA32102, CA31946, CA21115] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE O, 1992, LANCET, V339, P71; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Baum M, 2002, LANCET, V359, P2131; Baum M, 2002, LANCET, V360, P1520; Bilimoria MM, 1996, J STEROID BIOCHEM, V58, P479, DOI 10.1016/0960-0760(96)00078-7; Clarke M, 1998, LANCET, V351, P1451; Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407; Dowsett M, 1997, EUR J CANCER, V33, P1177, DOI 10.1016/S0959-8049(97)00100-7; EASTELL R, 2002, ANN ONCOL, V13, P32; Elisaf MS, 2001, EUR J CANCER, V37, P1510, DOI 10.1016/S0959-8049(01)00155-1; Fisher B, 2001, JNCI-J NATL CANCER I, V93, P684, DOI 10.1093/jnci/93.9.684; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; Goss PE, 2003, AM J CLIN ONCOL-CANC, V26, pS27, DOI 10.1097/00000421-200308001-00005; Goss PE, 2001, J CLIN ONCOL, V19, P881, DOI 10.1200/JCO.2001.19.3.881; GOTTARDIS MM, 1988, CANCER RES, V48, P5183; Hamilton A, 1999, ANN ONCOL, V10, P377, DOI 10.1023/A:1008368300827; Harper-Waynne C, 2001, BREAST CANCER RES TR, V69, P225; Harper-Wynne C, 2002, CANCER EPIDEM BIOMAR, V11, P614; HENDERSON BE, 1989, AM J OBSTET GYNECOL, V161, P1859, DOI 10.1016/S0002-9378(89)80007-9; Hilditch JR, 1996, MATURITAS, V25, P231; Klein JP., 2003, SURVIVAL ANAL TECHNI; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LOVE RR, 1988, BREAST CANCER RES TR, V12, P297, DOI 10.1007/BF01811242; LOVE RR, 1990, JNCI-J NATL CANCER I, V82, P1327, DOI 10.1093/jnci/82.16.1327; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MACMAHON B, 1974, Gynecologic Oncology, V2, P122, DOI 10.1016/0090-8258(74)90003-1; MASAMURA S, 1995, J CLIN ENDOCR METAB, V80, P2918, DOI 10.1210/jc.80.10.2918; MCGUIRE WL, 1991, MOL ENDOCRINOL, V5, P1571, DOI 10.1210/mend-5-11-1571; *NAT CANC I, 1995, CLIN ANN ADJ THER BR; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; OSBORNE CK, 1991, J NATL CANCER I, V83, P1477, DOI 10.1093/jnci/83.20.1477; OSBORNE CK, 1993, J STEROID BIOCHEM, V47, P83; Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763; STEIN RC, 1990, BRIT J CANCER, V62, P679, DOI 10.1038/bjc.1990.356; Tu D., 2003, ENCY BIOPHARMACEUTIC, P614; WAKELING AE, 1984, J STEROID BIOCHEM, V20, P111, DOI 10.1016/0022-4731(84)90197-3; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Winer EP, 2002, J CLIN ONCOL, V20, P3317, DOI 10.1200/JCO.2002.06.020; Winer EP, 2003, J CLIN ONCOL, V21, P2597, DOI 10.1200/JCO.2003.04.596	41	1379	1422	0	56	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 6	2003	349	19					1793	1802		10.1056/NEJMoa032312	http://dx.doi.org/10.1056/NEJMoa032312			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739NR	14551341				2022-12-28	WOS:000186353800003
J	Pfortner, J; Hovel, M				Pfortner, J; Hovel, M			Bony ghosts - Residual effects of severe growth arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Klinikum Essen, D-45122 Essen, Germany	University of Duisburg Essen	Pfortner, J (corresponding author), Univ Klinikum Essen, D-45122 Essen, Germany.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	2003	349	18					E17	E17		10.1056/ENEJMicm030278	http://dx.doi.org/10.1056/ENEJMicm030278			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	737FJ	14585954				2022-12-28	WOS:000186219500008
J	Dosani, S; Schroter, S; MacDonald, R; Connor, J				Dosani, S; Schroter, S; MacDonald, R; Connor, J			Recruitment of doctors to non-standard grades in the NHS: analysis of job advertisements and survey of advertisers	BRITISH MEDICAL JOURNAL			English	Article								Objectives To estimate die proportion of advertised non-consultant hospital posts that do not conform to nationally recognised terms and conditions of service and to investigate why these posts exist, who fills them, and what the doctors in such jobs do. Design Analysis of job advertisements and a cross sectional survey of advertisers. Setting Job advertisements in one of the leading UK publications listing hospital doctor vacancies (BMJ Careers). Results Nearly a quarter of non-consultant posts advertised in the two study periods (23% and 21%) were for non-standard grade posts. A questionnaire was sent to die medical staffing officer for each post. Of 430 questionnaires sent out 192 (45%) were returned. 98 trusts said they advertised non-standard grades because there was no more funding from the deanery for approved posts and 75 because service needs Could not be met by doctors in training grades. In 132 posts (69%) the post holder would be required to do on-call work, and 50 advertisers (26%) required on-call duty for I in 5 or more frequently, which would conflict with the European Working Time Directive. 131 advertisers (68%) expected the posts to be filled by doctors from outside the European Economic Area. Conclusions Non-standard grade posts are mostly being created to meet service requirements when there is no more funding for standard training posts and are expected to be filled by doctors from overseas. Doctors in such posts can be more easily exploited and their careers hindered. The Department of Health's annual census should include non-standard grade doctors.	BMJ, London WC1H 9JR, England		Dosani, S (corresponding author), BMJ, London WC1H 9JR, England.		Dosani, Sabina/GRR-9014-2022; Dosani, Sabina/GQQ-9273-2022; Schroter, Sara/G-3427-2012	Dosani, Sabina/0000-0001-5981-5616; Schroter, Sara/0000-0002-8791-8564				Cooper N, 2002, BRIT MED J, V325, P491, DOI 10.1136/bmj.325.7362.491; *DEP HLTH, 1996, GUID SPEC REG TRAIN; *DEP HLTH, 2003, CHOIC OPP MOD MED CA; *DEP HLTH, 1991, JUN DOCT NEW DEAL; DILLMAN DA, 1908, MAIL TELEPHONE SURVE; Edwards P, 2002, BRIT MED J, V324, P1183, DOI 10.1136/bmj.324.7347.1183; Norcliffe G., 2001, BMJ S, V323, pS2	7	6	6	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 25	2003	327	7421					961	964		10.1136/bmj.327.7421.961	http://dx.doi.org/10.1136/bmj.327.7421.961			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	736AL	14576247	Green Published, Bronze			2022-12-28	WOS:000186147800017
J	Seaton, ED; Charakida, A; Mouser, PE; Grace, I; Clement, RM; Chu, AC				Seaton, ED; Charakida, A; Mouser, PE; Grace, I; Clement, RM; Chu, AC			Pulsed-dye laser treatment for inflammatory acne vulgaris: randomised controlled trial	LANCET			English	Article							ANTIBIOTIC-RESISTANT PROPIONIBACTERIA; THERAPY; ISOTRETINOIN; LIGHT; BLUE; SKIN; NM	Background Low-fluence (low irradiation energy density) pulsed-dye lasers (PDLs) have been used for atrophic acne scarring, and anecdotal experience suggests that long-term improvements in inflammatory acne can be seen after one PDL treatment. Our aim was to compare the efficacy and tolerability of such PDL treatment with sham treatment in patients with facial inflammatory acne in a double-blind, randomised controlled trial. Methods We recruited 41 adults with mild-to-moderate facial inflammatory acne. We randomly assigned patients to PDL (n=31) or sham treatment (n=10). Treatment was given at baseline and patients were seen after 2, 4, 8, and 12 weeks. Assessors and participants were unaware of treatment allocations. Primary outcome measures were acne severity after 12 weeks and adverse events at any time. Secondary measures were change in lesion counts after 12 weeks and change in acne severity with time. Analysis was by intention-to-treat. Findings After 12 weeks, acne severity (measured by Leeds revised grading system) was reduced from 3.8 (SD 1.5) to 1.9 (1.5) in the PDL group and 3.6 (1.8) to 3.5 (1.9) in the sham group (p=0.007). Treatment was well tolerated. Total lesion counts fell by 53% (IQR 19 to 64) in PDL patients and 9% (-16 to 38) in controls (p=0.023), and inflammatory lesion counts reduced by 49% (30 to 75) in PDL patients and 10% (-8 to 49) in controls (p=0.024). The most rapid improvements were seen in the first 4 weeks after treatment. Interpretation PDL therapy improves inflammatory facial acne 12 weeks after one treatment with no serious adverse effects.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Dermatol, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Primary Care & Populat Hlth Sci, London, England; Univ Coll Swansea, Sch Engn, Swansea, W Glam, Wales	Imperial College London; Imperial College London; Swansea University	Seaton, ED (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Dermatol, Hammersmith Hosp Campus, London W12 0NN, England.							Altman D.G., 1991, PRACTICAL STAT MED R; Bjerring P, 2000, J Cutan Laser Ther, V2, P9, DOI 10.1080/14628830050516542; BJERRING P, 2002, J COSMET LASER THER, V3, P39; *CDCP FDA NIH, PUBL HLTH ACT PLAN C; Coates P, 2002, BRIT J DERMATOL, V146, P840, DOI 10.1046/j.1365-2133.2002.04690.x; Cotterill JA, 1997, BRIT J DERMATOL, V137, P246, DOI 10.1046/j.1365-2133.1997.18131897.x; CRAWFORD WW, 1979, J INVEST DERMATOL, V72, P187, DOI 10.1111/1523-1747.ep12676385; CUNLIFFE WJ, 1986, BRIT J DERMATOL, V115, P386, DOI 10.1111/j.1365-2133.1986.tb05757.x; *DEP HLTH UK, 2000, ANT RES STRAT ACT PL, P23; EADY EA, 1993, BRIT MED J, V306, P555, DOI 10.1136/bmj.306.6877.555; GREENWOOD R, 1986, BRIT J DERMATOL, V114, P353, DOI 10.1111/j.1365-2133.1986.tb02827.x; Gupta MA, 1998, BRIT J DERMATOL, V139, P846; JOWETT S, 1985, SOC SCI MED, V20, P425, DOI 10.1016/0277-9536(85)90021-8; KJELDSTAD B, 1986, PHOTOCHEM PHOTOBIOL, V43, P67, DOI 10.1111/j.1751-1097.1986.tb05592.x; Lehmann HP, 2002, J AM ACAD DERMATOL, V47, P231, DOI 10.1067/mjd.2002.120912; LEYDEN JJ, 1975, J INVEST DERMATOL, V65, P382, DOI 10.1111/1523-1747.ep12607634; Lucky AW, 1996, J AM ACAD DERMATOL, V35, P559, DOI 10.1016/S0190-9622(96)90680-5; MELO TB, 1987, Z NATURFORSCH C, V42, P123; MITCHELL AA, 1995, NEW ENGL J MED, V333, P101, DOI 10.1056/NEJM199507133330206; MOUSER PE, IN PRESS J INVEST DE; NORRIS JFB, 1988, BRIT J DERMATOL, V118, P651, DOI 10.1111/j.1365-2133.1988.tb02566.x; O'Brien SC, 1998, J DERMATOL TREAT, V9, P215, DOI 10.3109/09546639809160698; OLSEN TG, 1982, MED CLIN N AM, V66, P851, DOI 10.1016/S0025-7125(16)31398-0; Ortonne JP, 1997, DERMATOLOGY, V195, P34, DOI 10.1159/000246018; Papageorgiou P, 2000, BRIT J DERMATOL, V142, P973, DOI 10.1046/j.1365-2133.2000.03481.x; Patel N, 2002, DERMATOL SURG, V28, P942, DOI 10.1046/j.1524-4725.2002.02062.x; STILLMAN S, 2000, J EUR ACAD DERMAT S1, V14, P47; TAN OT, 1989, NEW ENGL J MED, V320, P416, DOI 10.1056/NEJM198902163200702; *US FDA CTR DRUG E, ACC LAB REV 2002 DRU	29	134	136	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 25	2003	362	9393					1347	1352		10.1016/S0140-6736(03)14629-6	http://dx.doi.org/10.1016/S0140-6736(03)14629-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	735YX	14585635				2022-12-28	WOS:000186143300007
J	Britten, N				Britten, N			Commentary: Does a prescribed treatment match a patient's priorities?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Exeter, Peninsula Med Sch, Inst Clin Educ, Exeter EX1 2LU, Devon, England; Univ Plymouth, Peninsula Med Sch, Inst Clin Educ, Exeter EX1 2LU, Devon, England	University of Exeter; University of Exeter; University of Plymouth	Britten, N (corresponding author), Univ Exeter, Peninsula Med Sch, Inst Clin Educ, St Lukes Campus, Exeter EX1 2LU, Devon, England.	nicky.britten@pms.ac.uk						BRITTEN N, IN PRESS OXFORD TXB; Haynes R B, 2002, Cochrane Database Syst Rev, pCD000011; HORNUNG MR, 1999, MICROSYSTEMS, V4, P1	3	12	12	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 11	2003	327	7419					840	840		10.1136/bmj.327.7419.840	http://dx.doi.org/10.1136/bmj.327.7419.840			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551098	Bronze, Green Published			2022-12-28	WOS:000185921200018
J	Hocker, M; Hohenberger, P				Hocker, M; Hohenberger, P			Helicobacter pylori virulence factors - one part of a big picture	LANCET			English	Review							CLINICAL-RELEVANCE; BABA2; ADHESIN; VACA; CAGA; ATTACHMENT; INFECTION; GENES; RISK	Context At least half the world's population is infected with Helicobacter pylori, although only 10-20% of carriers develop gastric diseases, ranging from ulcer to MALT-lymphoma and adenocarcinoma (MALT is mucosa-associated lymphoid tissue). The clinical outcome of H pylori infection is determined by a complex interaction of environmental influences and host and microbial virulence factors'. H pylori genotypes carrying the babA2 gene, encoding a bacterial adhesin mediating interaction With gastric epithelial cells, have enhanced pathogenicity. Moreover, coexistence of babA2 with other, bacterial virulence factors further worsens clinical outcomes. Starting point To further elucidate the clinical relevance of babA2-genopositive H pylori strains, Carlo-Frederico Zambon and colleagues analysed the association of babA2 genotypes with gastritis, gastroduodenal ulcer disease, or intestinal metaplasia in 167 infected Italian individuals. The coexistence of babA2 with other potentially disease-related H pylori genes, such as cag4, vacA, or oipA, correlated with clinical outcome. 36% of H pylori strains were babA2 genopositive, and abundance of babA2 was associated with the genomic presence of the other potential virulence-factor genes. H pylon strains carrying babA2, cagA, and the vacA genotype s1m1 were associated with the highest risk of developing intestinal metaplasia, whereas this condition was rarely (<10%) associated with strains with a cagA-, babA2-, vacA s2m2 genotype. Whilst the risk-of developing more serious gastric lesions increased as the number of virulence factor genes accumulated in a given H pylori strain, there was no indication of any one specific bacterial gene-pattern being associated with a particular clinical disease. Where next? Identifying the factors responsible for the enhanced pathogenicity of H pylori leading to development of life-threatening diseases in a subset of infected individuals is a mandatory task for the future. Identification of virulence-associated H pylori genes and investigation of their clinical relevance in large prospective studies will help to define such, strains with increased pathogenicity. The value of H pylori genotypes as predictors of disease outcome is limited, because the pathogenic impact of bacterial virulence factors, is greatly influenced by coexisting environmental and host factors.	Charite Univ Med Berlin, Robert Rossle Klin, Div Surg & Surg Oncol, D-13125 Berlin, Germany; Charite Univ Med Berlin, Dept Gastroenterol & Hepatol, D-13125 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hohenberger, P (corresponding author), Charite Univ Med Berlin, Robert Rossle Klin, Div Surg & Surg Oncol, Campus Berlin Buch, D-13125 Berlin, Germany.	hohenberger@rrk.charite-buch.de						Bjorkholm B, 2003, J INTERN MED, V253, P102, DOI 10.1046/j.1365-2796.2003.01119.x; Blaser MJ, 2001, J CLIN INVEST, V107, P767, DOI 10.1172/JCI12672; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Gerhard M, 1999, P NATL ACAD SCI USA, V96, P12778, DOI 10.1073/pnas.96.22.12778; Guruge JL, 1998, P NATL ACAD SCI USA, V95, P3925, DOI 10.1073/pnas.95.7.3925; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Israel DA, 2001, ALIMENT PHARM THER, V15, P1271, DOI 10.1046/j.1365-2036.2001.01052.x; Maeda S, 1998, GUT, V42, P338, DOI 10.1136/gut.42.3.338; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; Megraud F, 2001, DIGEST DIS, V19, P99, DOI 10.1159/000050662; Mizushima T, 2001, J CLIN MICROBIOL, V39, P2463, DOI 10.1128/JCM.39.7.2463-2465.2001; Nogueira C, 2001, AM J PATHOL, V158, P647, DOI 10.1016/S0002-9440(10)64006-0; Parsonnent J., 1998, GUT               S1, V43, P3247; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Podzorski RP, 2003, DIAGN MICR INFEC DIS, V46, P83, DOI 10.1016/S0732-8893(03)00034-8; Prinz C, 2001, CANCER RES, V61, P1903; Rad R, 2003, J INFECT DIS, V188, P272, DOI 10.1086/376458; Sheu BS, 2003, GUT, V52, P927, DOI 10.1136/gut.52.7.927; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Webb PM, 2001, GUT, V49, P347, DOI 10.1136/gut.49.3.347; Zambon CF, 2003, J CLIN PATHOL, V56, P287, DOI 10.1136/jcp.56.4.287	24	92	101	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 11	2003	362	9391					1231	1233		10.1016/S0140-6736(03)14547-3	http://dx.doi.org/10.1016/S0140-6736(03)14547-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568748				2022-12-28	WOS:000185924100027
J	Thomas, DC; Leipzig, RM; Smith, LG; Dunn, K; Sullivan, G; Callahan, E				Thomas, DC; Leipzig, RM; Smith, LG; Dunn, K; Sullivan, G; Callahan, E			Improving geriatrics training in internal medicine residency programs: Best practices and sustainable solutions	ANNALS OF INTERNAL MEDICINE			English	Article							FAMILY-PRACTICE RESIDENCY; TEACHING NURSING-HOME; CURRICULUM RECOMMENDATIONS; ACUTE-CARE; EXPERIENCE; KNOWLEDGE; ROTATION	National surveys indicate a need for additional training in geriatrics during internal medicine residencies. This paper describes 1) "best practices" for integrating geriatrics education into internal medicine residency programs, 2) barriers to implementation of these practices, and 3) possible ways to improve geriatrics training for internal medicine residents. These best practices were determined by a systematic review of the literature and through interviews with leaders of 26 residency and geriatrics programs concerned with geriatrics training for residents. The most successful programs have clinical experiences with 3 key elements: model geriatric care in 1 or more settings (for example, in the hospital or in ambulatory practice), patient care across sites or transitions of care, and interdisciplinary teamwork. Barriers include attitudes, few faculty, need for relationships with nontraditional training sites, and lack of funding. Local solutions include engaging the internal medicine program director to accomplish a mutual goal-for example, by creating a model geriatrics training experience in which residents demonstrate their skill in a new Accreditation Council of Graduate Medical Education competency (such as systems-based practice). National solutions include reaching consensus on the competencies in geriatrics that should be achieved by board-eligible internists. This may mean increasing the number of questions that test geriatrics competency in the certifying and in-training examinations, increasing numbers of faculty members able to teach and model geriatric care, developing "effective medical resident teaching" courses for nonphysician faculty, and lobbying for improved systems of care.	Mt Sinai Sch Med, New York, NY 10029 USA; NYU, Sch Med, New York, NY USA; Univ Connecticut, Hlth Sci Ctr, Farmington, CT USA	Icahn School of Medicine at Mount Sinai; New York University; University of Connecticut	Thomas, DC (corresponding author), Mt Sinai Sch Med, 1 Gustave Levy Pl,Box 1087, New York, NY 10029 USA.	david.thomas@msnyuhealth.org		Dunn, Kathel/0000-0002-6967-130X				*ACCR COUNC GRAD M, 2003, PROGR REQ RES ED INT; Barbour G L, 1987, Gerontol Geriatr Educ, V7, P29; BARRY PP, 1991, AM J MED, V91, P447, DOI 10.1016/0002-9343(91)90177-Y; Blumenthal D, 2001, JAMA-J AM MED ASSOC, V286, P1027, DOI 10.1001/jama.286.9.1027; CHODOSH J, 1997, GERONTOL GERIATR ED, V18, P3; CLARFIELD AM, 1982, J AM GERIATR SOC, V30, P457, DOI 10.1111/j.1532-5415.1982.tb03384.x; COLENDA CC, 1994, AM J MED, V97, P15; COUNSELL SR, 1994, J AM GERIATR SOC, V42, P1200, DOI 10.1111/j.1532-5415.1994.tb06989.x; COUNSELL SR, 1994, J AM GERIATR SOC, V42, P1193, DOI 10.1111/j.1532-5415.1994.tb06988.x; Counsell SR, 1999, J AM GERIATR SOC, V47, P1145, DOI 10.1111/j.1532-5415.1999.tb05242.x; Degelau J., 1997, Journal of the American Geriatrics Society, V45, pS61; EUBANKS P, 1991, HOSPITALS, V65, P74; EVE SB, 1986, EDUC GERONTOL, V12, P59; *FCIM INT MED CURR, RES GUID CURR DEV; Friend T., 1996, Journal of the American Geriatrics Society, V44, pS65; GARRELL M, 1983, J MED EDUC, V58, P482; JAHNIGEN D, 1994, AM J MED, V97, P43; KATZ PR, 1992, J GEN INTERN MED, V7, P52, DOI 10.1007/BF02599103; KELLY JT, 1977, J FAM PRACTICE, V4, P1103; Koenig H G, 1986, Gerontol Geriatr Educ, V7, P15; Leipzig RM, 2001, GERONTOL GERIATR ED, V21, P63; Lindberg MC, 1996, J GEN INTERN MED, V11, P397, DOI 10.1007/BF02600185; Long C C, 1982, Gerontol Geriatr Educ, V2, P219; McNabney M., 1996, Journal of the American Geriatrics Society, V44, pS74; MOON JB, 1990, J FAM PRACTICE, V30, P594; Murden RA, 1996, J GEN INTERN MED, V11, P776, DOI 10.1007/BF02599002; PALMER RM, 1994, J AM GERIATR SOC, V42, P545, DOI 10.1111/j.1532-5415.1994.tb04978.x; REUBEN DB, 1990, ACAD MED, V65, P382, DOI 10.1097/00001888-199006000-00006; Reuben DB, 1997, J GEN INTERN MED, V12, P450, DOI 10.1046/j.1525-1497.1997.00078.x; Reuben DB, 1997, AM J MED, V103, P260; ROBBINS JA, 1983, J MED EDUC, V58, P811; RODRIGUEZ JD, 1998, GERONTOL GERIATR ED, V19, P67; Rubin CD, 2003, ANN INTERN MED, V139, P615, DOI 10.7326/0003-4819-139-7-200310070-00035; Sullivan GM, 1998, J AM GERIATR SOC, V46, P1166, DOI 10.1111/j.1532-5415.1998.tb06660.x; Swamy L, 1997, J AM GERIATR SOC, V45, pP77; WALKER L, 1998, GERONTOL GERIATR ED, V19, P79; WARSHAW G, 2003, IN PRESS J GEN INTER; WEILER PG, 1987, EDUC GERONTOL, V13, P1, DOI 10.1080/0380127870130101; WIELAND D, 1986, JAMA-J AM MED ASSOC, V255, P2622, DOI 10.1001/jama.255.19.2622; 1982, JAMA, V247, P2787	40	55	57	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 7	2003	139	7					628	634		10.7326/0003-4819-139-7-200310070-00037	http://dx.doi.org/10.7326/0003-4819-139-7-200310070-00037			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729AP	14530247				2022-12-28	WOS:000185748800029
J	Ruefli-Brasse, AA; French, DM; Dixit, VM				Ruefli-Brasse, AA; French, DM; Dixit, VM			Regulation of NF-kappa B-dependent lymphocyte activation and development by paracaspase	SCIENCE			English	Article							MALT LYMPHOMA; MARGINAL-ZONE; IMMUNE-RESPONSES; BCL10; CARMA1; CELLS; PROLIFERATION; PROTEINS	Paracaspase (MALT1), a member of an evolutionarily conserved superfamily of caspase-like proteins, has been shown to bind and colocalize with the protein Bcl10 in vitro and, because of this association, has been suggested to be involved in the CARMA1-Bcl10 pathway of antigen-induced nuclear factor kappaB (NF-kappaB) activation. We demonstrate that primary T and B lymphocytes from para-caspase-deficient mice are defective in antigen-receptor-induced NF-kappaB activation, cytokine production, and proliferation. Paracaspase acts downstream of Bcl10 to induce NF-kappaB activation and is required for the normal development of B cells, indicating that paracaspase provides the missing link between Bcl10 and activation of the IkappaB kinase complex.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Dixit, VM (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.		dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326				Bertoni Francesco, 2002, Hematol J, V3, P10, DOI 10.1038/sj.thj.6200146; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Martin F, 2002, NAT REV IMMUNOL, V2, P323, DOI 10.1038/nri799; McAllister-Lucas LM, 2001, J BIOL CHEM, V276, P30589, DOI 10.1074/jbc.M103824200; Newton K, 2003, CURR BIOL, V13, P1247, DOI 10.1016/S0960-9822(03)00458-5; Pohl T, 2002, P NATL ACAD SCI USA, V99, P4514, DOI 10.1073/pnas.072071599; RUEFLIBRASSE AA, UNPUB; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Thome M, 2003, TRENDS IMMUNOL, V24, P419, DOI 10.1016/S1471-4906(03)00177-7; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Vega F, 2001, ADV ANAT PATHOL, V8, P313, DOI 10.1097/00125480-200111000-00001; Xue LQ, 2003, NAT IMMUNOL, V4, P857, DOI 10.1038/ni963; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767	18	293	316	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 28	2003	302	5650					1581	1584		10.1126/science.1090769	http://dx.doi.org/10.1126/science.1090769			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	747JV	14576442				2022-12-28	WOS:000186802200049
J	Baldini, A				Baldini, A			DiGeorge's syndrome: a gene at last	LANCET			English	Editorial Material							SYNDROME REGION; TBX1 GENE; DEFECTS; MICE		Baylor Coll Med, Dept Pediat Cardiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Baldini, A (corresponding author), Baylor Coll Med, Dept Pediat Cardiol, Houston, TX 77030 USA.		genes, anthony/F-2541-2012; Baldini, Antonio/M-2355-2015	Baldini, Antonio/0000-0002-5330-0256				Chieffo C, 1997, GENOMICS, V43, P267, DOI 10.1006/geno.1997.4829; Conti E, 2003, EUR J HUM GENET, V11, P349, DOI 10.1038/sj.ejhg.5200956; Gong W, 2001, J Med Genet, V38, pE45, DOI 10.1136/jmg.38.12.e45; Jerome LA, 2001, NAT GENET, V27, P286, DOI 10.1038/85845; Lindsay EA, 2001, NAT REV GENET, V2, P858, DOI 10.1038/35098574; Lindsay EA, 2001, NATURE, V410, P97, DOI 10.1038/35065105; Lindsay EA, 1999, NATURE, V401, P379, DOI 10.1038/43900; Merscher S, 2001, CELL, V104, P619, DOI 10.1016/S0092-8674(01)00247-1; Scambler PJ, 2000, HUM MOL GENET, V9, P2421, DOI 10.1093/hmg/9.16.2421	9	19	19	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 25	2003	362	9393					1342	1343		10.1016/S0140-6736(03)14671-5	http://dx.doi.org/10.1016/S0140-6736(03)14671-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	735YX	14585631				2022-12-28	WOS:000186143300003
J	Merikangas, KR; Risch, N				Merikangas, KR; Risch, N			Genomic priorities and public health	SCIENCE			English	Article							GENETIC EPIDEMIOLOGY; ADOLESCENT SMOKING; DIABETES-MELLITUS; ALZHEIMER-DISEASE; COMPLEX TRAITS; FAMILY-HISTORY; LIFE-STYLE; STRATEGIES; CANCER; RISK	Given the continuing difficulty of identifying genes for complex disorders in a robust, replicable manner, and the extensive resources devoted to this effort, it is becoming increasingly important to analyze the relative benefits of genomics research for public health applications and for the understanding of disease pathogenesis. To establish priorities for genetics research, we review and evaluate several characteristics of selected exemplary complex diseases, including phenotypic accuracy, knowledge of specific and nonspecific genetic and environmental risk factors, and population prevalence and impact. We propose that complex diseases with the strongest evidence for genetic etiology, limited ability to modify exposure or risk factors, and high public health impact should have the highest priority for genetics research.	NIMH, Sec Dev Genet Epidemiol, Mood & Anxiety Disorders Progrma, NIH,Dept Hlth & Human Serv, Bethesda, MD 20892 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Kaiser Permanente, Div Res, Oakland, CA 94612 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Stanford University; Kaiser Permanente	Merikangas, KR (corresponding author), NIMH, Sec Dev Genet Epidemiol, Mood & Anxiety Disorders Progrma, NIH,Dept Hlth & Human Serv, 15K N Dr,Mail Stop Code 2670, Bethesda, MD 20892 USA.	kathleen.merikangas@nih.gov		Merikangas, Kathkeen/0000-0002-4667-2414	NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002804, Z01MH002804] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Akerblom HK, 2002, AM J MED GENET, V115, P18, DOI 10.1002/ajmg.10340; *AM CANC SOC, 2003, CANC FACTS FIG 2003; Avenevoli S, 2003, ADDICTION, V98, P1, DOI 10.1046/j.1360-0443.98.s1.2.x; Baird P, 2001, Community Genet, V4, P77, DOI 10.1159/000051161; Baird PA, 2002, PERSPECT BIOL MED, V45, P516, DOI 10.1353/pbm.2002.0061; BOOMSMA DI, 1994, ADDICTION, V89, P219, DOI 10.1111/j.1360-0443.1994.tb00881.x; Breslau N, 2001, ARCH GEN PSYCHIAT, V58, P810, DOI 10.1001/archpsyc.58.9.810; Calabrese EJ, 1997, ENVIRON HEALTH PERSP, V105, P1354, DOI 10.2307/3433755; Carrington M, 2003, ANNU REV MED, V54, P535, DOI 10.1146/annurev.med.54.101601.152346; *CDC, 2001, SURV EP AIDS SURV SP; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; Glazier AM, 2002, SCIENCE, V298, P2345, DOI 10.1126/science.1076641; GOLDMAN D, 1993, RECENT DEV ALCOHOLIS, V2; Goldner EM, 2002, CAN J PSYCHIAT, V47, P833, DOI 10.1177/070674370204700904; Gottesman I. I., 1972, SCHIZOPHRENIA GENETI; Haga SB, 2003, NAT GENET, V34, P347, DOI 10.1038/ng0803-347; HANLEY AJG, 1995, INT J EPIDEMIOL, V24, P255, DOI 10.1093/ije/24.2.255; Harrison TA, 2003, AM J PREV MED, V24, P152, DOI 10.1016/S0749-3797(02)00588-3; Hendrie HC, 1998, AM J GERIAT PSYCHIAT, V6, pS3, DOI 10.1097/00019442-199821001-00002; Ishibe N, 1997, CANCER CAUSE CONTROL, V8, P504, DOI 10.1023/A:1018421724776; Kenny S.J., 1995, NIH PUBLICATION, P47; Khoury MJ, 2003, GENET MED, V5, P261, DOI 10.1097/01.GIM.0000076977.90682.A5; Khoury MJ, 1996, AM J PUBLIC HEALTH, V86, P1717, DOI 10.2105/AJPH.86.12.1717; KIDD K, COMMUNICATION; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kobus K, 2003, ADDICTION, V98, P37, DOI 10.1046/j.1360-0443.98.s1.4.x; Lantz PM, 2000, TOB CONTROL, V9, P47, DOI 10.1136/tc.9.1.47; Little J, 2003, AM J EPIDEMIOL, V157, P667, DOI 10.1093/aje/kwg048; MERIKANGAS KR, 1990, PSYCHOL MED, V20, P11, DOI 10.1017/S0033291700013192; MERIKANGAS KR, UNPUB AM J EPIDEMIOL; Newschaffer CJ, 2002, EPIDEMIOL REV, V24, P137, DOI 10.1093/epirev/mxf010; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Pociot F, 2002, GENES IMMUN, V3, P235, DOI 10.1038/sj.gene.6363875; Pollitt RJ, 2001, J INHERIT METAB DIS, V24, P299, DOI 10.1023/A:1010339606265; RAVUSSIN E, 1994, DIABETES CARE, V17, P1067, DOI 10.2337/diacare.17.9.1067; REWERS M, 1995, NIH PUBLICATION, P179; Rich SS, 2002, DIABETES, V51, pS288, DOI 10.2337/diabetes.51.2007.S288; RISCH N, 1990, AM J HUM GENET, V46, P222; Risch N, 2001, CANCER EPIDEM BIOMAR, V10, P733; ROSE G, 1997, STRATEGY PREVENTIVE; Rose JS, 1999, MERRILL PALMER QUART, V45, P62; Sadovnick AD, 2002, CLIN NEUROL NEUROSUR, V104, P199, DOI 10.1016/S0303-8467(02)00038-0; SHAPER AG, 1991, ACTA PAEDIATR SCAND, P73; Shostak S, 2003, SOC SCI MED, V56, P2327, DOI 10.1016/S0277-9536(02)00231-9; SLATTERY ML, 1993, JAMA-J AM MED ASSOC, V270, P1563, DOI 10.1001/jama.270.13.1563; Slooter AJC, 1997, EPIDEMIOL REV, V19, P107, DOI 10.1093/oxfordjournals.epirev.a017933; Sobngwi E, 2003, LANCET, V361, P1861, DOI 10.1016/S0140-6736(03)13505-2; Susser M, 1996, AM J PUBLIC HEALTH, V86, P668, DOI 10.2105/AJPH.86.5.668; Susser M, 1998, J EPIDEMIOL COMMUN H, V52, P608, DOI 10.1136/jech.52.10.608; Trevisan R, 1998, NEPHROL DIAL TRANSPL, V13, P2, DOI 10.1093/ndt/13.suppl_8.2; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20	51	185	190	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	2003	302	5645					599	601		10.1126/science.1091468	http://dx.doi.org/10.1126/science.1091468			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	735MV	14576422				2022-12-28	WOS:000186119900045
J	Van Laere, AS; Nguyen, M; Braunschweig, M; Nezer, C; Collette, C; Moreau, L; Archibald, AL; Haley, CS; Buys, N; Tally, M; Andersson, G; Georges, M; Andersson, L				Van Laere, AS; Nguyen, M; Braunschweig, M; Nezer, C; Collette, C; Moreau, L; Archibald, AL; Haley, CS; Buys, N; Tally, M; Andersson, G; Georges, M; Andersson, L			A regulatory mutation in IGF2 causes a major QTL effect on muscle growth in the pig	NATURE			English	Article							QUANTITATIVE TRAIT LOCI; INCREASED OVULATION RATE; GENETIC DISSECTION; IDENTIFICATION; DELETION; MASS; PHENOTYPE; SKELETAL; ELEMENT; CATTLE	Most traits and disorders have a multifactorial background indicating that they are controlled by environmental factors as well as an unknown number of quantitative trait loci (QTLs)(1,2). The identification of mutations underlying QTLs is a challenge because each locus explains only a fraction of the phenotypic variation(3,4). A paternally expressed QTL affecting muscle growth, fat deposition and size of the heart in pigs maps to the IGF2 (insulin-like growth factor 2) region(5,6). Here we show that this QTL is caused by a nucleotide substitution in intron 3 of IGF2. The mutation occurs in an evolutionarily conserved CpG island that is hypomethylated in skeletal muscle. The mutation abrogates in vitro interaction with a nuclear factor, probably a repressor, and pigs inheriting the mutation from their sire have a threefold increase in IGF2 messenger RNA expression in postnatal muscle. Our study establishes a causal relationship between a single-base-pair substitution in a non-coding region and a QTL effect. The result supports the long-held view that regulatory mutations are important for controlling phenotypic variation(7).	Swedish Univ Agr Sci, Dept Anim Breeding & Genet, BMC, SE-75124 Uppsala, Sweden; Uppsala Univ, Dept Med Biochem & Microbiol, BMC, SE-75124 Uppsala, Sweden; Univ Liege, Fac Vet Med, Dept Genet, B-4000 Liege, Belgium; Roslin Inst, Roslin EH25 9PS, Midlothian, Scotland; Gentec, B-9255 Buggenhout, Belgium; Tally Consulting, SE-11458 Stockholm, Sweden	Swedish University of Agricultural Sciences; Uppsala University; University of Liege; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Georges, M (corresponding author), Swedish Univ Agr Sci, Dept Anim Breeding & Genet, BMC, Box 597, SE-75124 Uppsala, Sweden.		Haley, Chris S/F-3110-2013; Van+Laere, Anne-Sophie/ADZ-7821-2022; Andersson, Goran/AAK-6564-2020	Andersson, Goran/0000-0001-5131-3144; Archibald, Alan/0000-0001-9213-1830; Haley, Chris/0000-0002-9811-0210; Buys, Nadine/0000-0002-7313-3088; Georges, Michel/0000-0003-4124-2375				Amarger V, 2002, MAMM GENOME, V13, P388, DOI 10.1007/s00335-001-3059-x; Anderson SI, 2000, MAMM GENOME, V11, P811, DOI 10.1007/s003350010155; Andersson L, 2001, NAT REV GENET, V2, P130, DOI 10.1038/35052563; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Constancia M, 2000, NAT GENET, V26, P203, DOI 10.1038/79930; Darvasi A, 2002, TRENDS GENET, V18, P489, DOI 10.1016/S0168-9525(02)02767-1; de Koning DJ, 2000, P NATL ACAD SCI USA, V97, P7947, DOI 10.1073/pnas.140216397; Eden S, 2001, EMBO J, V20, P3518, DOI 10.1093/emboj/20.13.3518; ENGEMANN S, 2002, METHODS MOL BIOL, V181; Evans GJ, 2003, GENETICS, V164, P621; Florini JR, 1995, DIABETES REV, V3, P73; Freking BA, 2002, GENOME RES, V12, P1496, DOI 10.1101/gr.571002; Galloway SM, 2000, NAT GENET, V25, P279, DOI 10.1038/77033; Giuffra E, 2000, GENETICS, V154, P1785; Glazier AM, 2002, SCIENCE, V298, P2345, DOI 10.1126/science.1076641; Greally JM, 1997, MAMM GENOME, V8, P805, DOI 10.1007/s003359900583; Grisart B, 2002, GENOME RES, V12, P222, DOI 10.1101/gr.224202; Grobet L, 1997, NAT GENET, V17, P71, DOI 10.1038/ng0997-71; HALEY CS, 1994, GENETICS, V136, P1195; Jeon JT, 1999, NAT GENET, V21, P157, DOI 10.1038/5938; Kashuk C, 2002, GENOME RES, V12, P333, DOI 10.1101/gr.211202; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Mackay TFC, 2001, NAT REV GENET, V2, P11, DOI 10.1038/35047544; Milan D, 2000, SCIENCE, V288, P1248, DOI 10.1126/science.288.5469.1248; Mulsant P, 2001, P NATL ACAD SCI USA, V98, P5104, DOI 10.1073/pnas.091577598; Nezer C, 1999, NAT GENET, V21, P155, DOI 10.1038/5935; Nezer C, 2003, GENETICS, V165, P277; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Pailhoux E, 2001, NAT GENET, V29, P453, DOI 10.1038/ng769	29	673	725	2	100	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					832	836		10.1038/nature02064	http://dx.doi.org/10.1038/nature02064			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574411				2022-12-28	WOS:000186118500044
J	Garfield, R				Garfield, R			Challenges to health service development in Iraq	LANCET			English	Editorial Material									Columbia Univ, New York, NY 10032 USA	Columbia University	Garfield, R (corresponding author), Columbia Univ, New York, NY 10032 USA.							DIAZ J, 2003, IRAQ HLTH NUTR WATCH; Valenciano M, 2003, JAMA-J AM MED ASSOC, V290, P654, DOI 10.1001/jama.290.5.654	2	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 18	2003	362	9392					1324	1324		10.1016/S0140-6736(03)14578-3	http://dx.doi.org/10.1016/S0140-6736(03)14578-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14579815				2022-12-28	WOS:000186036900029
J	Loya, WM; Pregitzer, KS; Karberg, NJ; King, JS; Giardina, CP				Loya, WM; Pregitzer, KS; Karberg, NJ; King, JS; Giardina, CP			Reduction of soil carbon formation by tropospheric ozone under increased carbon dioxide levels	NATURE			English	Article							GROWTH; TREES; ALLOCATION; PLANTS; ASPEN	In the Northern Hemisphere, ozone levels in the troposphere have increased by 35 per cent over the past century(1), with detrimental impacts on forest(2,3) and agricultural(4) productivity, even when forest productivity has been stimulated by increased carbon dioxide levels'. In addition to reducing productivity, increased tropospheric ozone levels could alter terrestrial carbon cycling by lowering the quantity and quality of carbon inputs to soils. However, the influence of elevated ozone levels on soil carbon formation and decomposition are unknown. Here we examine the effects of elevated ozone levels on the formation rates of total and decay-resistant acid-insoluble soil carbon under conditions of elevated carbon dioxide levels in experimental aspen (Populus tremuloides) stands and mixed aspen-birch (Betula papyrifera) stands. With ambient concentrations of ozone and carbon dioxide both raised by 50 per cent, we find that the formation rates of total and acid-insoluble soil carbon are reduced by 50 per cent relative to the amounts entering the soil when the forests were exposed to increased carbon dioxide alone. Our results suggest that, in a world with elevated atmospheric carbon dioxide concentrations, global-scale reductions in plant productivity due to elevated ozone levels will also lower soil carbon formation rates significantly.	Michigan Technol Univ, Sch Forest Resources & Environm Sci, Houghton, MI 49931 USA; US Forest Serv, USDA, N Cent Res Stn, Houghton, MI 49931 USA	Michigan Technological University; United States Department of Agriculture (USDA); United States Forest Service	Loya, WM (corresponding author), Michigan Technol Univ, Sch Forest Resources & Environm Sci, Houghton, MI 49931 USA.		Giardina, Christian P/C-3120-2011	Giardina, Christian P/0000-0002-3431-5073				Andersen CP, 2003, NEW PHYTOL, V157, P213, DOI 10.1046/j.1469-8137.2003.00674.x; CHAMEIDES WL, 1994, SCIENCE, V264, P74, DOI 10.1126/science.264.5155.74; COLEMAN MD, 1995, TREE PHYSIOL, V15, P593, DOI 10.1093/treephys/15.9.593; DICKSON RE, 2000, NC214 USDA; Findlay S, 1996, ECOL APPL, V6, P269, DOI 10.2307/2269570; Gregg JW, 2003, NATURE, V424, P183, DOI 10.1038/nature01728; *IPCC SECR, 2001, IPCC CLIM CHANG 2001; King JS, 2001, OECOLOGIA, V128, P237, DOI 10.1007/s004420100656; Larson JL, 2002, SOIL SCI SOC AM J, V66, P1848, DOI 10.2136/sssaj2002.1848; Leavitt SW, 1996, RADIOCARBON, V38, P231, DOI 10.1017/S0033822200017604; MCLAUGHLIN SB, 1995, NATURE, V374, P252, DOI 10.1038/374252a0; Paul EA, 1997, SOIL SCI SOC AM J, V61, P1058, DOI 10.2136/sssaj1997.03615995006100040011x; Percy KE, 2002, NATURE, V420, P403, DOI 10.1038/nature01028; Phillips RL, 2002, OECOLOGIA, V131, P236, DOI 10.1007/s00442-002-0868-x; *US EPA, LAT FIND NAT AIR QUA	15	105	113	4	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					705	707		10.1038/nature02047	http://dx.doi.org/10.1038/nature02047			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562100				2022-12-28	WOS:000185924500038
J	Holberg, CJ; Halonen, M				Holberg, CJ; Halonen, M			Cytokines, atopy, and asthma	LANCET			English	Editorial Material									Univ Arizona, Arizona Resp Ctr, Tucson, AZ 85724 USA	University of Arizona	Holberg, CJ (corresponding author), Univ Arizona, Arizona Resp Ctr, Tucson, AZ 85724 USA.	cathy@resp-sci.arizona.edu		Halonen, Marilyn/0000-0001-9606-935X				Bunnin N., 1996, BLACKWELL COMPANION; Christodoulopoulos P, 2000, J ALLERGY CLIN IMMUN, V105, P211, DOI 10.1016/S0091-6749(00)90068-X; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Ideker T, 2001, ANNU REV GENOM HUM G, V2, P343, DOI 10.1146/annurev.genom.2.1.343; Joffe MM, 1999, AM J EPIDEMIOL, V150, P327; KIM J, 1995, CAMBRIDGE DICT PHILO; LAST JM, 1995, DICT EPIDEMIOLOGY; Rothman K, 1986, MODERN EPIDEMIOLOGY, P7; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064	9	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 11	2003	362	9391					1166	1167		10.1016/S0140-6736(03)14552-7	http://dx.doi.org/10.1016/S0140-6736(03)14552-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568732				2022-12-28	WOS:000185924100002
J	Ashida, H; Saito, Y; Kojima, C; Kobayashi, K; Ogasawara, N; Yokota, A				Ashida, H; Saito, Y; Kojima, C; Kobayashi, K; Ogasawara, N; Yokota, A			A functional link between RuBisCO-like protein of Bacillus and photosynthetic RuBisCO	SCIENCE			English	Article							METHIONINE SALVAGE PATHWAY; COMPLETE GENOME SEQUENCE; RIBULOSE 1,5-BISPHOSPHATE CARBOXYLASE/OXYGENASE; CHLOROBIUM-TEPIDUM; ARCHAEON; SITE	The genomes of several nonphotosynthetic bacteria, such as Bacillus subtilis, and some Archaea include genes for proteins with sequence homology to the large subunit of ribulose bisphosphate carboxylase/oxygenase (RuBisCO). We found that such a RuBisCO-like protein (RLP) from B. subtilis catalyzed the 2,3-diketo-5-methylthiopentyl-1-phosphate enolase reaction in the methionine salvage pathway. A growth-defective mutant, in which the gene for this RLP had been disrupted, was rescued by the gene for RuBisCO from the photosynthetic bacterium Rhodospirillum rubrum. Thus, the photosynthetic RuBisCO from R. rubrum retains the ability to function in the methionine salvage pathway in B. subtilis.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Res Inst Innovat Technol Earth, Plant Mol Physiol Lab, Kyoto 6190292, Japan	Nara Institute of Science & Technology; Research Institute of Innovative Technology for the Earth	Yokota, A (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.	yokota@bs.aist-nara.ac.jp	Kojima, Chojiro/AFV-4592-2022; Saito, Yohtaro/C-9838-2017; Ogasawara, Naotake/B-7971-2011	Saito, Yohtaro/0000-0002-1024-5154; Kojima, Chojiro/0000-0003-2723-8249				Andrews T.J., 1987, BIOCH PLANTS, P131, DOI 10.1016/B978-0-12-675410-0.50009-9; ASHIDA H, UNPUB; Avigad G, 1975, Methods Enzymol, V41, P27; CHEN YR, 1995, J BIOL CHEM, V270, P11741, DOI 10.1074/jbc.270.20.11741; Cleland WW, 1998, CHEM REV, V98, P549, DOI 10.1021/cr970010r; Dai Y, 2001, BIOCHEMISTRY-US, V40, P6379, DOI 10.1021/bi010110y; Eisen JA, 2002, P NATL ACAD SCI USA, V99, P9509, DOI 10.1073/pnas.132181499; ELLIS RJ, 1979, TRENDS BIOCHEM SCI, V4, P241, DOI 10.1016/0968-0004(79)90212-3; Ezaki S, 1999, J BIOL CHEM, V274, P5078, DOI 10.1074/jbc.274.8.5078; FURFINE ES, 1988, J BIOL CHEM, V263, P9598; GRUNDY JF, 2002, BACILLUS SUBTILIS IT, P245; Hanson TE, 2001, P NATL ACAD SCI USA, V98, P4397, DOI 10.1073/pnas.081610398; Hartman H, 1998, ORIGINS LIFE EVOL B, V28, P515, DOI 10.1023/A:1006548904157; Heilbronn J, 1999, J BACTERIOL, V181, P1739, DOI 10.1128/JB.181.6.1739-1747.1999; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Kyrpides NC, 1998, P NATL ACAD SCI USA, V95, P224, DOI 10.1073/pnas.95.1.224; LARSON EM, 1995, BIOCHEMISTRY-US, V34, P4531, DOI 10.1021/bi00014a005; Moszer I, 1999, CURR OPIN MICROBIOL, V2, P524, DOI 10.1016/S1369-5274(99)00011-9; Murphy BA, 2002, J BACTERIOL, V184, P2314, DOI 10.1128/JB.184.8.2314-2318.2002; MYERS RW, 1993, J BIOL CHEM, V268, P24785; Roy Harry, 2000, VVolume 9, P53; Sekowska A, 2001, BMC Microbiol, V1, P15, DOI 10.1186/1471-2180-1-15; Sekowska A, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-8; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; Watson GMF, 1997, FEMS MICROBIOL LETT, V146, P13, DOI 10.1016/S0378-1097(96)00417-X; Watson GMF, 1999, J BACTERIOL, V181, P1569, DOI 10.1128/JB.181.5.1569-1575.1999; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WRAY JW, 1995, J BIOL CHEM, V270, P3147, DOI 10.1074/jbc.270.7.3147	29	143	155	3	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					286	290		10.1126/science.1086997	http://dx.doi.org/10.1126/science.1086997			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551435				2022-12-28	WOS:000185825900042
J	Quackenbush, J				Quackenbush, J			Microarrays - Guilt by association	SCIENCE			English	Editorial Material							GENE-EXPRESSION PATTERNS; CDNA MICROARRAYS; DESIGN		Inst Genom Res, Rockville, MD 20850 USA	J. Craig Venter Institute	Quackenbush, J (corresponding author), Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	johnq@tigr.org		Quackenbush, John/0000-0002-2702-5879				Churchill GA, 2002, NAT GENET, V32, P490, DOI 10.1038/ng1031; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Kerr MK, 2001, GENET RES, V77, P123; LIPSHUTZ RJ, 1995, BIOTECHNIQUES, V19, P442; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Simon R, 2002, GENET EPIDEMIOL, V23, P21, DOI 10.1002/gepi.202; Staudt LM, 2000, ANNU REV IMMUNOL, V18, P829, DOI 10.1146/annurev.immunol.18.1.829; Stuart JM, 2003, SCIENCE, V302, P249, DOI 10.1126/science.1087447	8	116	120	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					240	241		10.1126/science.1090887	http://dx.doi.org/10.1126/science.1090887			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551426				2022-12-28	WOS:000185825900028
J	Sappol, M				Sappol, M			The anatomical mission to Burma	SCIENCE			English	Editorial Material									Natl Lib Med, Hist Med Div, Bethesda, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Sappol, M (corresponding author), Natl Lib Med, Hist Med Div, Bethesda, MD 20894 USA.	michael_sappol@nlm.nih.gov						ALCOTT WA, 1834, HOUSE I LIVE 1; CUTTER C, 1872, ANATOMY PHYSL HYGIEN; RIDDER E, 1999, DISSECTING CORPSE 20; SAPPOL M, 2001, TRAFFIC DEAD BODIES; TORBET RG, 1955, VENTURE FAITH STORY, P2; 1843, LU KUIY KHAN DHA AIM	6	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					232	233		10.1126/science.1086308	http://dx.doi.org/10.1126/science.1086308			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551420				2022-12-28	WOS:000185825900022
J	Harris, JP; Weisman, MH; Derebery, JM; Espeland, MA; Gantz, BJ; Gulya, AJ; Hammerschlag, PE; Hannley, M; Hughes, GB; Moscicki, R; Nelson, RA; Niparko, JK; Rauch, SD; Telian, SA; Brookhouser, PE				Harris, JP; Weisman, MH; Derebery, JM; Espeland, MA; Gantz, BJ; Gulya, AJ; Hammerschlag, PE; Hannley, M; Hughes, GB; Moscicki, R; Nelson, RA; Niparko, JK; Rauch, SD; Telian, SA; Brookhouser, PE			Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RHEUMATOID-ARTHRITIS; INFLIXIMAB; EFFICACY; THERAPY	Context A number of therapies have been proposed for the long-term management of corticosteroid-responsive, rapidly progressive, bilateral sensorineural hearing loss (autoimmune inner ear disease [AIED]). Methotrexate has emerged as the benchmark agent but has not been rigorously evaluated for hearing improvement in patients with AIED. Objective To assess the efficacy of long-term methotrexate in maintaining hearing improvements achieved with glucocorticoid (prednisone) therapy in patients with AIED. Design, Setting, and Participants A randomized, double-blind, placebo-controlled trial conducted from February 3, 1998, to November 5, 2001, of 67 patients with rapidly progressive, bilateral sensorineural hearing loss at 10 tertiary care centers in the United States. Intervention Randomization to either oral methotrexate (15 to 20 mg/wk; n=33) or placebo (n=34), in combination with an 18-week prednisone taper. Follow-up examinations, including audiometric evaluation, were performed at 4, 8,12, 24, 36, 48, and 52 weeks, or until hearing loss was documented. Main Outcome Measure Maintenance of hearing improvement achieved from prednisone treatment. Results Sixty-seven patients (57.8%) enrolled in the prednisone challenge experienced hearing improvement. Twenty-five patients (37%) experienced hearing improvements in both ears. Of the individuals who reached study end points, 24 (80%) of 30 end points were because of measured hearing loss in the methotrexate group and 29 (93.5%) of 31 end points were because of measured hearing loss in the placebo group (P=.15). Methotrexate was no more effective than placebo in maintaining the hearing improvement achieved with prednisone treatment (hazard ratio, 1.31 95% confidence, interval, 0.79-2.17; P=30). Conclusion Methotrexate does not appear to be effective in maintaining the hearing improvement achieved with prednisone therapy in patients with AIED.	Univ Calif San Diego, Div Otolaryngol Head & Neck Surg, San Diego, CA 92103 USA; Cedars Sinai Med Ctr, Div Rheumatol, Los Angeles, CA 90048 USA; House Ear Res Inst, Los Angeles, CA USA; Wake Forest Univ, Dept Publ Hlth Sci, Winston Salem, NC 27109 USA; Univ Iowa, Dept Otolaryngol Head & Neck Surg, Iowa City, IA 52242 USA; Natl Inst Deafness & Other Commun Disorders, Bethesda, MD USA; NYU, Dept Otolaryngol Head & Neck Surg, New York, NY USA; Amer Acad Otolaryngol Head & Neck Surg, Res Dev, Alexandria, VA USA; Cleveland Clin, Cleveland, OH 44106 USA; Massachusetts Gen Hosp, Dept Allergy & Immunol, Boston, MA 02114 USA; Johns Hopkins Univ, Dept Otolaryngol, Baltimore, MD USA; Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA; Univ Michigan, Dept Otolaryngol Head & Neck Surg, Ann Arbor, MI 48109 USA; Boys Town Natl Res Hosp, Omaha, NE 68131 USA	University of California System; University of California San Diego; Cedars Sinai Medical Center; House Research Institute; Wake Forest University; University of Iowa; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); New York University; Cleveland Clinic Foundation; Harvard University; Massachusetts General Hospital; Johns Hopkins University; Harvard University; Massachusetts Eye & Ear Infirmary; University of Michigan System; University of Michigan; Boys Town National Research Hospital	Harris, JP (corresponding author), Univ Calif San Diego, Div Otolaryngol Head & Neck Surg, 200 W Arbor Dr,Mail Code 8895, San Diego, CA 92103 USA.	jpharris@ucsd.edu		Gantz, Bruce/0000-0002-9916-6048; Hammerschlag, Paul/0000-0003-3251-077X	NIDCD NIH HHS [5 U01 DC03209] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [U01DC003209] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201; BEICKERT P, 1961, Z Laryngol Rhinol Otol, V40, P837; BULMAN CH, 1985, J LARYNGOL OTOL, V99, P941, DOI 10.1017/S0022215100097978; COX DR, 1972, J R STAT SOC B, V34, P187; Cronstein BN, 1996, ARTHRITIS RHEUM-US, V39, P1951, DOI 10.1002/art.1780391203; DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308; KAPLAN E, 1958, J AM STAT ASSOC, V8, P699; KEYSTONE E, 2002, J MUSCULOSKELETAL ME, V19, P53; Kilpatrick J K, 2000, Ear Nose Throat J, V79, P82; Kilpatrick JK, 2000, ENT-EAR NOSE THROAT, V79, P86; Kilpatrick JK, 2000, ENT-EAR NOSE THROAT, V79, P91; KITAHARA M, 1989, MENIERES DIS PATHOGE, P411; Kremer JM, 1997, ARTHRITIS RHEUM, V40, P984, DOI 10.1002/art.1780400533; Lee DM, 2001, LANCET, V358, P903, DOI 10.1016/S0140-6736(01)06075-5; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; LUETJE CM, 1989, LARYNGOSCOPE, V99, P1137; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; Matteson EL, 2001, ARTHRIT RHEUM-ARTHR, V45, P146; Matteson EL., 2001, PRIMER RHEUMATIC DIS, P225; MCCABE BF, 1989, AM J OTOL, V10, P196; MCCABE BF, 1979, ANN OTO RHINOL LARYN, V88, P585, DOI 10.1177/000348947908800501; Pyykko I, 1997, ACTA OTO-LARYNGOL, P83; SARACAYDIN A, 1993, J INT MED RES, V21, P192, DOI 10.1177/030006059302100404; SCHIFF M, 1974, LARYNGOSCOPE, V84, P1959, DOI 10.1002/lary.5540841113; Sismanis A, 1997, OTOLARYNG HEAD NECK, V116, P146, DOI 10.1016/S0194-5998(97)70316-4; Tirzaman O, 2000, ANN OTO RHINOL LARYN, V109, P710, DOI 10.1177/000348940010900802; Weinblatt ME, 1998, J RHEUMATOL, V25, P238; WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303; YOSHIHIKO T, 1964, Acta Otolaryngol, V58, P49; 1996, ARTHRITIS RHEUM, V39, P1951	30	115	137	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2003	290	14					1875	1883		10.1001/jama.290.14.1875	http://dx.doi.org/10.1001/jama.290.14.1875			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729CB	14532316	Bronze			2022-12-28	WOS:000185752600028
J	Shattuck, TM; Valimaki, S; Obara, T; Gaz, RD; Clark, OH; Shoback, D; Wierman, ME; Tojo, K; Robbins, CM; Carpten, JD; Farnebo, LO; Larsson, C; Arnold, A				Shattuck, TM; Valimaki, S; Obara, T; Gaz, RD; Clark, OH; Shoback, D; Wierman, ME; Tojo, K; Robbins, CM; Carpten, JD; Farnebo, LO; Larsson, C; Arnold, A			Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							JAW TUMOR SYNDROME; HEREDITARY HYPERPARATHYROIDISM; SUPPRESSOR GENES; RETINOBLASTOMA; DIAGNOSIS; MANAGEMENT; HISTORY; CANCER; BRCA2	BACKGROUND: We looked for mutations of the HRPT2 gene, which encodes the parafibromin protein, in sporadic parathyroid carcinoma because germ-line inactivating HRPT2 mutations have been found in a type of familial hyperparathyroidism -- hyperparathyroidism-jaw tumor (HPT-JT) syndrome -- that carries an increased risk of parathyroid cancer. METHODS: We directly sequenced the full coding and flanking splice-junctional regions of the HRPT2 gene in 21 parathyroid carcinomas from 15 patients who had no known family history of primary hyperparathyroidism or the HPT-JT syndrome at presentation. We also sought to confirm the somatic nature of the identified mutations and tested the carcinomas for tumor-specific loss of heterozygosity at HRPT2. RESULTS: Parathyroid carcinomas from 10 of the 15 patients had HRPT2 mutations, all of which were predicted to inactivate the encoded parafibromin protein. Two distinct HRPT2 mutations were found in tumors from five patients, and biallelic inactivation as a result of a mutation and loss of heterozygosity was found in one tumor. At least one HRPT2 mutation was demonstrably somatic in carcinomas from six patients. Unexpectedly, HRPT2 mutations in the parathyroid carcinomas of three patients were identified as germ-line mutations. CONCLUSIONS: Sporadic parathyroid carcinomas frequently have HRPT2 mutations that are likely to be of pathogenetic importance. Certain patients with apparently sporadic parathyroid carcinoma carry germ-line mutations in HRPT2 and may have the HPT-JT syndrome or a phenotypic variant.	Univ Connecticut, Sch Med, Ctr Mol Med, Farmington, CT 06030 USA; Univ Connecticut, Sch Med, Div Endocrinol & Metab, Farmington, CT 06030 USA; Karolinska Hosp, Dept Mol Med, S-10401 Stockholm, Sweden; Karolinska Hosp, Dept Surg Sci, S-10401 Stockholm, Sweden; Tokyo Womens Med Univ, Dept Endocrine Surg, Sinjuku Ku, Tokyo, Japan; Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; Univ Calif San Francisco, Mt Zion Med Ctr, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Vet Affairs Med Ctr, Endocrine Res Unit, San Francisco, CA 94143 USA; Univ Colorado, Vet Affairs Med Ctr, Div Endocrinol, Denver, CO 80202 USA; Jikei Univ, Sch Med, Dept Internal Med, Div Diabet & Endocrinol, Tokyo, Japan; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA	University of Connecticut; University of Connecticut; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Tokyo Women's Medical University; Harvard University; Massachusetts General Hospital; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jikei University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Arnold, A (corresponding author), Univ Connecticut, Sch Med, Ctr Mol Med, 263 Farmington Ave, Farmington, CT 06030 USA.	catharina.larsson@cmm.ki.se; molecularmedicine@uchc.edu						Agarwal SK, 1998, CANCER GENET CYTOGEN, V106, P30, DOI 10.1016/S0165-4608(98)00049-1; ANDERSON BJ, 1983, SURGERY, V94, P906; Arnold A, 2002, J BONE MINER RES, V17, pN30; BONDESON L, 1993, AM J SURG PATHOL, V17, P820, DOI 10.1097/00000478-199308000-00007; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; COSTA J, 2003, J ENDOCR GENET, V3, P57; CRYNS VL, 1994, NEW ENGL J MED, V330, P757, DOI 10.1056/NEJM199403173301105; Dotzenrath C, 1996, J CLIN ENDOCR METAB, V81, P3194, DOI 10.1210/jc.81.9.3194; EVERSOLE LR, 1985, ORAL SURG ORAL MED O, V60, P505, DOI 10.1016/0030-4220(85)90239-7; FITKO R, 1990, HUM PATHOL, V21, P234, DOI 10.1016/0046-8177(90)90136-S; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Haven CJ, 2000, J CLIN ENDOCR METAB, V85, P1449, DOI 10.1210/jc.85.4.1449; Imanishi Y, 1999, J BONE MINER RES, V14, pS421; JACKSON CE, 1990, SURGERY, V108, P1006; KENNETT S, 1971, ORAL SURG ORAL MED O, V31, P502, DOI 10.1016/0030-4220(71)90347-1; Kytola S, 2000, AM J PATHOL, V157, P579, DOI 10.1016/S0002-9440(10)64568-3; Marx SJ, 2000, NEW ENGL J MED, V343, P1863, DOI 10.1056/NEJM200012213432508; Marx SJ, 2002, J BONE MINER RES, V17, pN37; Marx SJ, 2001, NEW ENGL J MED, V344, P696; Marx SJ, 2001, NEW ENGL J MED, V344, P240; Pearce SHS, 1996, CLIN ENDOCRINOL, V45, P195, DOI 10.1046/j.1365-2265.1996.d01-1561.x; ROTH SI, 1962, ARCH PATHOL, V73, P495; SANDELIN K, 1991, SURGERY, V110, P978; SANDELIN K, 1992, WORLD J SURG, V16, P724, DOI 10.1007/BF02067369; SCHANTZ A, 1973, CANCER-AM CANCER SOC, V31, P600, DOI 10.1002/1097-0142(197303)31:3<600::AID-CNCR2820310316>3.0.CO;2-0; Shane E, 2001, J CLIN ENDOCR METAB, V86, P485, DOI 10.1210/jc.86.2.485; Shattuck TM, 2003, CLIN ENDOCRINOL, V59, P180, DOI 10.1046/j.1365-2265.2003.01814.x; Shattuck TM, 2002, J CLIN ENDOCR METAB, V87, P3911, DOI 10.1210/jc.87.8.3911; Simonds WF, 2002, MEDICINE, V81, P1, DOI 10.1097/00005792-200201000-00001; SZABO J, 1995, AM J HUM GENET, V56, P944; Teh BT, 1996, J CLIN ENDOCR METAB, V81, P4204, DOI 10.1210/jc.81.12.4204; VETTO JT, 1993, SURGERY, V114, P882; WANG CA, 1985, AM J SURG, V149, P522, DOI 10.1016/S0002-9610(85)80050-7; Wassif WS, 1999, CLIN ENDOCRINOL, V50, P191, DOI 10.1046/j.1365-2265.1999.00633.x	34	384	400	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 30	2003	349	18					1722	1729		10.1056/NEJMoa031237	http://dx.doi.org/10.1056/NEJMoa031237			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	737FJ	14585940				2022-12-28	WOS:000186219500006
J	Panageas, KS; Schrag, D; Riedel, E; Bach, PB; Begg, CB				Panageas, KS; Schrag, D; Riedel, E; Bach, PB; Begg, CB			The effect of clustering of outcomes on the association of procedure volume and surgical outcomes	ANNALS OF INTERNAL MEDICINE			English	Article							NEW-YORK-STATE; HOSPITAL VOLUME; SURGEON VOLUME; RADICAL PROSTATECTOMY; CANCER RESECTION; BREAST-CANCER; COLON-CANCER; MORTALITY; SURVIVAL; MODELS	Background: A large body of literature documents associations between the volume of cases a hospital or surgeon treats and clinical outcomes. Most of these studies have used conventional statistical methods that do not recognize the fact that hospitals or surgeons with similar volumes may have very different outcomes because of systematic differences in processes of care, a phenomenon that exaggerates the true statistical significance of the effect of volume on outcome. Objective: To describe methods to assess the degree of this "clustering" of outcomes and to explore the impact of available statistical techniques that correct for clustering. Design: Reanalysis of 3 previously published volume-outcome studies. Setting: Medicare beneficiaries 65 years of age or older undergoing surgery for colon, prostate, or rectal cancer in the population defined by the Surveillance, Epidemiology, and End Results cancer registries during 1992 to 1996. Patients: 3 data sets were analyzed to assess the impact of surgeon volume on outcomes: 1) 24 166 colectomies performed by 2682 surgeons, 2) 10 737 prostatectomies performed by 999 surgeons, and 3) 2603 rectal resections performed by 1141 surgeons. Measurements: Volume-outcome trends were analyzed by a conventional method (logistic regression) and corrected for clustering. Two widely used statistical methods for analyzing clustered data, a random-effects model and generalized estimating equations, were used and compared, and the degree of clustering was presented graphically. Results: Substantial clustering was observed in the analyses involving morbidity end points. The 2 statistical techniques produced noticeably different results in some analyses. Conclusions: The presence of clustering represents variations in outcomes among providers with similar volumes. Thus, in volume-outcome studies, the degree of clustering of outcomes should be characterized because it may provide insight into variations in quality of care.	Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Begg, CB (corresponding author), Mem Sloan Kettering Canc Ctr, 307 E 63rd St 3rd Floor, New York, NY 10021 USA.	beggc@mskcc.org		Schrag, Deborah/0000-0002-4334-5717	NCI NIH HHS [CA08748, CA83950, CA90226] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, R01CA090226, K07CA083950] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM MED ASS, 1999, CURR PROC TERM; ASHBY M, 1992, STAT MED, V11, P67, DOI 10.1002/sim.4780110108; Bach PB, 2001, NEW ENGL J MED, V345, P181, DOI 10.1056/NEJM200107193450306; Begg CB, 1998, JAMA-J AM MED ASSOC, V280, P1747, DOI 10.1001/jama.280.20.1747; Begg CB, 2003, J CLIN ONCOL, V21, P393, DOI 10.1200/JCO.2003.11.022; Begg CB, 2002, NEW ENGL J MED, V346, P1138, DOI 10.1056/NEJMsa011788; Birkmeyer JD, 1999, SURGERY, V126, P178, DOI 10.1016/S0039-6060(99)70152-2; Birkmeyer JD, 2001, SURGERY, V130, P415, DOI 10.1067/msy.2001.117139; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; BRESLOW NE, 1993, J AM STAT ASSOC, V88, P9, DOI 10.1080/01621459.1993.10594284; Choti M A, 1998, J Gastrointest Surg, V2, P11, DOI 10.1016/S1091-255X(98)80098-X; Dimick JB, 2001, ANN THORAC SURG, V72, P334, DOI 10.1016/S0003-4975(01)02781-3; DONNER A, 1987, STAT MED, V6, P43, DOI 10.1002/sim.4780060106; Edwards EB, 1999, NEW ENGL J MED, V341, P2049, DOI 10.1056/NEJM199912303412703; Glasgow RE, 1999, ARCH SURG-CHICAGO, V134, P30, DOI 10.1001/archsurg.134.1.30; Glasgow RE, 1996, WESTERN J MED, V165, P294; GREEN SB, 1995, AM J EPIDEMIOL, V142, P587, DOI 10.1093/oxfordjournals.aje.a117679; Greenfield S, 2002, ANN INTERN MED, V136, P111, DOI 10.7326/0003-4819-136-2-200201150-00008; Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012; Hannan EL, 1998, STROKE, V29, P2292, DOI 10.1161/01.STR.29.11.2292; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; HANNAN EL, 1994, ANN THORAC SURG, V58, P1852, DOI 10.1016/0003-4975(94)91726-4; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; Hannan EL, 1997, JAMA-J AM MED ASSOC, V277, P892, DOI 10.1001/jama.277.11.892; HOSMER DW, 1989, APPL LOGISTIC REGRES; Hu JC, 2003, J CLIN ONCOL, V21, P401, DOI 10.1200/JCO.2003.05.169; Kee F, 1999, BRIT MED J, V318, P1381, DOI 10.1136/bmj.318.7195.1381; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; McGrath PD, 2000, JAMA-J AM MED ASSOC, V284, P3139, DOI 10.1001/jama.284.24.3139; Polednak AP, 1999, AM J PUBLIC HEALTH, V89, P946, DOI 10.2105/AJPH.89.6.946; POTOSKY AL, 1993, MED CARE, V31, P732; RODRIGUEZ G, 1995, J ROY STAT SOC A STA, V158, P73, DOI 10.2307/2983404; Roohan PJ, 1998, AM J PUBLIC HEALTH, V88, P454, DOI 10.2105/AJPH.88.3.454; Schrag D, 2000, JAMA-J AM MED ASSOC, V284, P3028, DOI 10.1001/jama.284.23.3028; Schrag D, 2003, J SURG ONCOL, V83, P68, DOI 10.1002/jso.10244; Schrag D, 2002, ANN SURG, V236, P583, DOI 10.1097/00000658-200211000-00008; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; *WHO, 1990, INT CLASS DIS ONC; Yao SL, 1999, J NATL CANCER I, V91, P1950, DOI 10.1093/jnci/91.22.1950	42	275	276	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 21	2003	139	8					658	665		10.7326/0003-4819-139-8-200310210-00009	http://dx.doi.org/10.7326/0003-4819-139-8-200310210-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734DW	14568854				2022-12-28	WOS:000186040800004
J	Cordner, S; Coupland, R				Cordner, S; Coupland, R			Missing people and mass graves in Iraq	LANCET			English	Editorial Material									ICRC, Legal Div, Geneva, Switzerland		Cordner, S (corresponding author), Assistance Div ICRC, 19 Ave Paix, CH-1202 Geneva, Switzerland.							BOUCKAERT P, 2003, MASS GRAVES AL MAHAW; Coupland R, 2003, BRIT MED J, V326, P943, DOI 10.1136/bmj.326.7396.943; *ICRC, MISS; STOVER E, 2003, JAMA-J AM MED ASSOC, V5, P663	4	6	6	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 18	2003	362	9392					1325	1326		10.1016/S0140-6736(03)14579-5	http://dx.doi.org/10.1016/S0140-6736(03)14579-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14579816				2022-12-28	WOS:000186036900030
J	Henke, M; Laszig, R; Rube, C; Schafer, U; Haase, KD; Schilcher, B; Mose, S; Beer, KGT; Burger, U; Dougherty, C; Frommhold, H				Henke, M; Laszig, R; Rube, C; Schafer, U; Haase, KD; Schilcher, B; Mose, S; Beer, KGT; Burger, U; Dougherty, C; Frommhold, H			Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial	LANCET			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; QUALITY-OF-LIFE; EPOETIN-ALPHA; RECEPTOR EXPRESSION; HEMOGLOBIN LEVELS; LOCAL-CONTROL; CHEMOTHERAPY; THERAPY; IMPACT; OXYGENATION	Background Anaemia is associated with poor cancer control, particularly in patients undergoing radiotherapy. We investigated whether anaemia correction with epoetin beta could improve outcome of curative radiotherapy among patients with head and neck cancer. Methods We did a multicentre, double-blind, randomised, placebo-controlled trial in 351 patients (haemoglobin <120 g/L in women or <130 g/L in men) with carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Patients received curative radiotherapy at 60 Gy for completely (R0) and histologically incomplete (R1) resected disease, or 70 Gy for macroscopically incompletely resected (R2) advanced disease (T3, T4, or nodal involvement) or for primary definitive treatment. All patients were assigned to subcutaneous placebo (n=171) or epoetin beta 300 IU/kg (n=180) three times weekly, from 10-14 days before and continuing throughout radiotherapy. The primary endpoint was locoregional progress ion-free survival. We assessed also time to locoregional progression and survival. Analysis was by intention to treat. Findings 148 (82%) patients given epoetin beta achieved haemoglobin concentrations higher than 140 g/L (women) or 150 g/L (men) compared with 26 (15%) given placebo. However, locoregional progression-free survival was poorer with epoetin 0 than with placebo (adjusted relative risk 1.62 [95% Cl 1.22-2.14); p=0.0008). For locoregional progression the relative risk was 1.69 (1.16-2.47, p=0.007) and for survival was 1.39 (1.05-1.84, p=0.02). Interpretation Epoetin beta corrects anaemia but does not improve cancer control or survival. Disease control might even be impaired. Patients receiving curative cancer treatment and given erythropoietin should be studied in carefully controlled trials.	Univ Freiburg, Radiol Klin, Abt Strahlenheilkunde, D-79106 Freiburg, Germany; Univ Munster, Hals Nasen & Ohrenheilkunde, Munster, Germany; Univ Klinikum, Klin Strahlentherapie & Radioonkol, Munster, Germany; Univ Witten Herdecke, Klin Strahlentherapie & Radioonkol, Wuppertal, Germany; Univ Frankfurt Klinikum, Klin Strahlentherapie, D-6000 Frankfurt, Germany; Univ Bern, Inselspital, Klin Radioonkol, CH-3010 Bern, Switzerland; F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland	University of Freiburg; University of Munster; University of Munster; Witten Herdecke University; Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Bern; University Hospital of Bern; Roche Holding	Henke, M (corresponding author), Univ Freiburg, Radiol Klin, Abt Strahlenheilkunde, Hugstetter Str 55, D-79106 Freiburg, Germany.	henke@uni-freiburg.de						ABELS RI, 1992, ACTA HAEMATOL-BASEL, V87, P4, DOI 10.1159/000204780; Acs G, 2001, CANCER RES, V61, P3561; Arcasoy MO, 2002, LAB INVEST, V82, P911, DOI 10.1097/01.LAB.0000020415.72863.40; Becker A, 2000, INT J RADIAT ONCOL, V46, P459, DOI 10.1016/S0360-3016(99)00384-3; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Brizel DM, 1998, NEW ENGL J MED, V338, P1798, DOI 10.1056/NEJM199806183382503; CASE DC, 1993, J NATL CANCER I, V85, P801, DOI 10.1093/jnci/85.10.801; COX DR, 1972, J R STAT SOC B, V34, P187; Demetri GD, 1998, J CLIN ONCOL, V16, P3412, DOI 10.1200/JCO.1998.16.10.3412; Frommhold H, 1998, STRAHLENTHER ONKOL, V174, P31; Glaser CM, 2001, INT J RADIAT ONCOL, V50, P705, DOI 10.1016/S0360-3016(01)01488-2; Glaspy J, 1997, J CLIN ONCOL, V15, P1218, DOI 10.1200/JCO.1997.15.3.1218; Grau C, 2000, SIGNIFICANCE HEMOGLO; GRAY LH, 1953, BRIT J RADIOL, V26, P638, DOI 10.1259/0007-1285-26-312-638; GUTTENBERGER R, 1997, EJC SUPPL, V33, P102; Hasenclever D, 1998, NEW ENGL J MED, V339, P1506, DOI 10.1056/NEJM199811193392104; HENKE M, 1999, ERYTHROPOIETIN PATIE; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; KRANTZ SB, 1991, BLOOD, V77, P419; LAVEY RS, 1993, INT J RADIAT ONCOL, V27, P1147, DOI 10.1016/0360-3016(93)90536-5; Leyland-Jones B, 2003, LANCET ONCOL, V4, P459, DOI 10.1016/S1470-2045(03)01163-X; Littlewood TJ, 2001, J CLIN ONCOL, V19, P2865, DOI 10.1200/JCO.2001.19.11.2865; Littlewood TJ, 2001, SEMIN ONCOL, V28, P49, DOI 10.1016/S0093-7754(01)90213-1; LUDWIG H, 1990, NEW ENGL J MED, V322, P1693, DOI 10.1056/NEJM199006143222402; Lutterbach J, 2000, INT J RADIAT ONCOL, V48, P1345, DOI 10.1016/S0360-3016(00)01382-1; Marti HH, 1997, KIDNEY INT, V51, P416, DOI 10.1038/ki.1997.55; MILLER CB, 1992, J NATL CANCER I, V84, P98, DOI 10.1093/jnci/84.2.98; OSTER W, 1990, J CLIN ONCOL, V8, P956, DOI 10.1200/JCO.1990.8.6.956; OVERGAARD J, 1986, INT J RADIAT ONCOL, V12, P515, DOI 10.1016/0360-3016(86)90058-1; Silver DF, 1999, GYNECOL ONCOL, V73, P280, DOI 10.1006/gyno.1999.5368; Thews O, 1998, BRIT J CANCER, V78, P752, DOI 10.1038/bjc.1998.572; VAUPEL P, 1991, CANCER RES, V51, P3316; VIGARIO G, 1973, RADIOLOGY, V106, P649, DOI 10.1148/106.3.649; Yasuda Y, 2003, CARCINOGENESIS, V24, P1021, DOI 10.1093/carcin/bgg060; YU L, 1995, CANCER INVEST, V13, P567, DOI 10.3109/07357909509024924	36	977	1023	0	42	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	2003	362	9392					1255	1260		10.1016/S0140-6736(03)14567-9	http://dx.doi.org/10.1016/S0140-6736(03)14567-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575968				2022-12-28	WOS:000186036900007
J	Dahan, M; Levi, S; Luccardini, C; Rostaing, P; Riveau, B; Triller, A				Dahan, M; Levi, S; Luccardini, C; Rostaing, P; Riveau, B; Triller, A			Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking	SCIENCE			English	Article							LATERAL MOVEMENTS; IN-VIVO; SYNAPSES; GEPHYRIN; MEMBRANE; MICROSCOPY; NEURONS	Semiconductor quantum dots (QDs) are nanometer-sized fluorescent probes suitable for advanced biological imaging. We used QDs to track individual glycine receptors (GlyRs) and analyze their lateral dynamics in the neuronal membrane of living cells for periods ranging from milliseconds to minutes. We characterized multiple diffusion domains in relation to the synaptic, perisynaptic, or extrasynaptic GlyR localization. The entry of GlyRs into the synapse by diffusion was observed and further confirmed by electron microscopy imaging of QD-tagged receptors.	Ecole Normale Super, CNRS, UMR 8552, Lab Kastler Brossel, F-75005 Paris, France; Univ Paris 06, F-75005 Paris, France; Ecole Normale Super, INSERM, U497, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; College de France; Ecole Normale Superieure (ENS); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Dahan, M (corresponding author), Ecole Normale Super, CNRS, UMR 8552, Lab Kastler Brossel, 24 Rue Lhomond, F-75005 Paris, France.		Dahan, Maxime/F-1740-2010; LEVI, SABINE/AAX-5607-2020	Dahan, Maxime/0000-0002-4943-2491; TRILLER, Antoine/0000-0002-7530-1233; Levi, Sabine/0000-0002-9927-0945				Borgdorff AJ, 2002, NATURE, V417, P649, DOI 10.1038/nature00780; Chan WCW, 2002, CURR OPIN BIOTECH, V13, P40, DOI 10.1016/S0958-1669(02)00282-3; Choquet D, 2003, NAT REV NEUROSCI, V4, P251, DOI 10.1038/nrn1077; Dubertret B, 2002, SCIENCE, V298, P1759, DOI 10.1126/science.1077194; Dumoulin A, 2000, EUR J NEUROSCI, V12, P3883, DOI 10.1046/j.1460-9568.2000.00271.x; Empedocles S, 1999, ACCOUNTS CHEM RES, V32, P389, DOI 10.1021/ar9501939; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; Gready JE, 1997, PROTEIN SCI, V6, P983, DOI 10.1002/pro.5560060504; Harms GS, 2001, BIOPHYS J, V80, P2396, DOI 10.1016/S0006-3495(01)76209-1; HARVEY K, 2002, RECEPTOR ION CHANNEL, pCH8; HURTLEY SM, 2003, SCIENCE, V300; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; Larson DR, 2003, SCIENCE, V300, P1434, DOI 10.1126/science.1083780; Meier J, 2001, NAT NEUROSCI, V4, P253, DOI 10.1038/85099; Nirmal M, 1996, NATURE, V383, P802, DOI 10.1038/383802a0; Rasmussen H, 2002, MOL CELL NEUROSCI, V19, P201, DOI 10.1006/mcne.2001.1074; Saxton MJ, 1997, ANNU REV BIOPH BIOM, V26, P373, DOI 10.1146/annurev.biophys.26.1.373; SCHRODER S, 1991, BIOCHEMISTRY-US, V30, P42, DOI 10.1021/bi00215a007; Serge A, 2002, J NEUROSCI, V22, P3910, DOI 10.1523/JNEUROSCI.22-10-03910.2002; Tardin C, 2003, EMBO J, V22, P4656, DOI 10.1093/emboj/cdg463; Thompson RE, 2002, BIOPHYS J, V82, P2775, DOI 10.1016/S0006-3495(02)75618-X; TRILLER A, 1985, J CELL BIOL, V101, P683, DOI 10.1083/jcb.101.2.683; Ueda M, 2001, SCIENCE, V294, P864, DOI 10.1126/science.1063951; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1; Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764	25	1221	1285	2	232	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					442	445		10.1126/science.1088525	http://dx.doi.org/10.1126/science.1088525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564008				2022-12-28	WOS:000185963200042
J	Baughman, RH				Baughman, RH			Avoiding the shrink	NATURE			English	Editorial Material									Univ Texas, NanoTech Inst, Richardson, TX 75083 USA; Univ Texas, Dept Chem, Richardson, TX 75083 USA	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas	Baughman, RH (corresponding author), Univ Texas, NanoTech Inst, Richardson, TX 75083 USA.		Baughman, Ray/A-8628-2018	Baughman, Ray/0000-0001-5845-5137				Baughman RH, 1998, SCIENCE, V279, P1522, DOI 10.1126/science.279.5356.1522; Baughman RH, 2000, SCIENCE, V288, P2018, DOI 10.1126/science.288.5473.2018; Bowick M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.148103; Evans KE, 2000, ADV MATER, V12, P617, DOI 10.1002/(SICI)1521-4095(200005)12:9<617::AID-ADMA617>3.0.CO;2-3; Gibson LJ, 1988, CELLULAR SOLIDS; LAKES R, 1993, ADV MATER, V5, P293, DOI 10.1002/adma.19930050416; Macdonald AG, 1999, COMP BIOCHEM PHYS A, V122, P13, DOI 10.1016/S1095-6433(98)10173-3	7	104	126	0	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					667	667		10.1038/425667a	http://dx.doi.org/10.1038/425667a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562080				2022-12-28	WOS:000185924500020
J	Goldman, JM; Melo, JV				Goldman, JM; Melo, JV			Mechanisms of disease - Chronic myeloid leukemia - Advances in biology and new approaches to treatment	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHRONIC MYELOGENOUS LEUKEMIA; ABL TYROSINE KINASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; GROWTH-FACTOR RECEPTOR; BONE-MARROW-TRANSPLANTATION; COLONY-STIMULATING FACTOR; BCR-ABL; CLINICAL RESISTANCE; CHRONIC-PHASE; IMATINIB MESYLATE		Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Haematol, London SW7 2AZ, England	Imperial College London	Goldman, JM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Du Cane Rd, London W12 0NN, England.	jgoldman@imperial.ac.uk						Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Baccarani M, 2002, BLOOD, V99, P1527, DOI 10.1182/blood.V99.5.1527; Barnes DJ, 2002, ACTA HAEMATOL-BASEL, V108, P180, DOI 10.1159/000065655; Barrett AJ, 1996, BRIT J HAEMATOL, V93, P754, DOI 10.1046/j.1365-2141.1996.d01-1713.x; Barrett J, 2003, SEMIN HEMATOL, V40, P59, DOI 10.1053/shem.2003.50003; BEDI A, 1994, BLOOD, V83, P2038; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; BIERNAUX C, 1995, BLOOD, V86, P3118; Bose S, 1998, BLOOD, V92, P3362, DOI 10.1182/blood.V92.9.3362; Branford S, 2002, BLOOD, V99, P3472, DOI 10.1182/blood.V99.9.3472; Branford S, 2003, BLOOD, V102, P276, DOI 10.1182/blood-2002-09-2896; Buchdunger E, 1996, CANCER RES, V56, P100; CARELLA AM, 1993, BONE MARROW TRANSPL, V12, P267; Chase A, 2000, BLOOD, V96, P777; Chomel JC, 2000, BLOOD, V95, P404, DOI 10.1182/blood.V95.2.404; Clark RE, 2001, BLOOD, V98, P2887, DOI 10.1182/blood.V98.10.2887; Corbin AS, 2003, BLOOD, V101, P4611, DOI 10.1182/blood-2002-12-3659; CORTES JE, 1995, CANCER-AM CANCER SOC, V75, P464, DOI 10.1002/1097-0142(19950115)75:2<464::AID-CNCR2820750209>3.0.CO;2-E; COULOMBEL L, 1983, NEW ENGL J MED, V308, P1493, DOI 10.1056/NEJM198306233082502; Cross NCP, 1997, BAILLIERE CLIN HAEM, V10, P389, DOI 10.1016/S0950-3536(97)80014-5; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; Dai ZH, 2001, J BIOL CHEM, V276, P28954, DOI 10.1074/jbc.M101170200; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; de la Fuente J, 2001, BLOOD, V98, P2879, DOI 10.1182/blood.V98.9.2879; Deininger M, 2000, BLOOD, V96, P778; Deininger MWN, 1998, CANCER RES, V58, P421; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Delannoy A, 1997, J NATL CANCER I, V89, P1616; Dierov JK, 2002, BLOOD, V100, p204A; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Druker BJ, 2001, NEW ENGL J MED, V345, P232; Eaves CJ, 1997, BAILLIERE CLIN HAEM, V10, P233, DOI 10.1016/S0950-3536(97)80005-4; EAVES CJ, 2001, CHRONIC MYELOID LEUK, P73; ERNST TJ, 1994, J BIOL CHEM, V269, P5764; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; FIALKOW PJ, 1981, BLOOD, V58, P158, DOI 10.1182/blood.V58.1.158.158; Gale RP, 1998, BLOOD, V91, P1810; Gao LQ, 2000, BLOOD, V95, P2198, DOI 10.1182/blood.V95.7.2198.007k38_2198_2203; Geary CG, 2000, BRIT J HAEMATOL, V110, P2, DOI 10.1046/j.1365-2141.2000.02137.x; Giralt S, 2001, BLOOD, V97, P631, DOI 10.1182/blood.V97.3.631; GOLDMAN JM, 1993, BLOOD, V82, P2235; Goldman JM, 2001, BLOOD, V98, P2039, DOI 10.1182/blood.V98.7.2039; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gorre ME, 2002, BLOOD, V100, P3041, DOI 10.1182/blood-2002-05-1361; GOTOH A, 1995, EXP HEMATOL, V23, P1153; GOTOH A, 1994, LEUKEMIA, V8, P115; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Gratwohl A, 1998, LANCET, V352, P1087, DOI 10.1016/S0140-6736(98)03030-X; Guilhot F, 1997, NEW ENGL J MED, V337, P223, DOI 10.1056/NEJM199707243370402; Hasford J, 1998, JNCI-J NATL CANCER I, V90, P850, DOI 10.1093/jnci/90.11.850; Hochhaus A, 2002, LEUKEMIA, V16, P2190, DOI 10.1038/sj.leu.2402741; Hochhaus A, 2001, SCIENCE, V293, P2163; Hofmann WK, 2002, BLOOD, V99, P1860, DOI 10.1182/blood.V99.5.1860; Holyoake TL, 2001, BLOOD, V97, P720, DOI 10.1182/blood.V97.3.720; Hoover RR, 2002, BLOOD, V100, P1068, DOI 10.1182/blood.V100.3.1068; Huntly BJP, 2001, BLOOD, V98, P1732, DOI 10.1182/blood.V98.6.1732; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; Johansson B, 2002, ACTA HAEMATOL-BASEL, V107, P76, DOI 10.1159/000046636; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Li SG, 2001, EMBO J, V20, P6793, DOI 10.1093/emboj/20.23.6793; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Marin D, 2003, LANCET, V362, P617, DOI 10.1016/S0140-6736(03)14182-7; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MELO JV, 1994, LEUKEMIA, V8, P208; MELO JV, 1993, BLOOD, V81, P158; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; Molldrem JJ, 2000, NAT MED, V6, P1018, DOI 10.1038/79526; Mow BMF, 2002, BLOOD, V99, P664, DOI 10.1182/blood.V99.2.664; Neves H, 1999, BLOOD, V93, P1197, DOI 10.1182/blood.V93.4.1197.404k33_1197_1207; NOWELL PC, 1960, SCIENCE, V132, P1497; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; ODA T, 1994, J BIOL CHEM, V269, P22925; Ogawa S, 1996, Hum Cell, V9, P323; Okuda K, 2001, BLOOD, V97, P2440, DOI 10.1182/blood.V97.8.2440; Or R, 2003, BLOOD, V101, P441, DOI 10.1182/blood-2002-02-0535; Passweg J, 2002, BONE MARROW TRANSPL, V29, pS33; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Pinilla-Ibarz J, 2000, BLOOD, V95, P1781, DOI 10.1182/blood.V95.5.1781.005k46_1781_1787; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; PRESTON DL, 1994, RADIAT RES, V139, P129; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Roche-Lestienne C, 2002, BLOOD, V100, P1014, DOI 10.1182/blood.V100.3.1014; Rotoli B, 1997, BLOOD, V89, P4240; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Saglio G, 2002, P NATL ACAD SCI USA, V99, P9882, DOI 10.1073/pnas.152171299; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; SALGIA R, 1995, ONCOGENE, V11, P1149; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sattler M, 1996, ONCOGENE, V12, P839; Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schultheis B, 2001, BLOOD, V98, p618A; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shi CS, 1999, BLOOD, V93, P1338, DOI 10.1182/blood.V93.4.1338.404k27_1338_1345; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SILL H, 1995, BLOOD, V85, P2013, DOI 10.1182/blood.V85.8.2013.bloodjournal8582013; Sinclair PB, 2000, BLOOD, V95, P738, DOI 10.1182/blood.V95.3.738.003k21_738_743; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Smedley Damian, 1999, Neoplasia (New York), V1, P349, DOI 10.1038/sj.neo.7900035; Smith KM, 2003, MOL CELL, V12, P27, DOI 10.1016/S1097-2765(03)00274-0; SOKAL JE, 1984, BLOOD, V63, P789, DOI 10.1182/blood.V63.4.789.789; Steer EJ, 2002, ACTA HAEMATOL-BASEL, V107, P113, DOI 10.1159/000046641; Stryckmans P, 1995, BLOOD, V86, P3118; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; Tanabe T, 2000, NATURE, V406, P473, DOI 10.1038/35020190; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; TOWATARI M, 1991, BLOOD, V78, P2178, DOI 10.1182/blood.V78.9.2178.bloodjournal7892178; Traxler P, 2001, MED RES REV, V21, P499, DOI 10.1002/med.1022; Uzunel M, 2003, BLOOD, V101, P469, DOI 10.1182/blood-2002-02-0571; vanRhee F, 1997, BONE MARROW TRANSPL, V20, P553, DOI 10.1038/sj.bmt.1700933; Verfaillie CM, 1999, J HEMATOTHER, V8, P3, DOI 10.1089/106161299320523; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; von Bubnoff N, 2002, LANCET, V359, P487, DOI 10.1016/S0140-6736(02)07679-1; Wadhwa J, 2002, BLOOD, V99, P2304, DOI 10.1182/blood.V99.7.2304; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; Wilbanks AM, 2000, EXP HEMATOL, V28, P584, DOI 10.1016/S0301-472X(00)00138-7; Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653; Wisniewski D, 2002, CANCER RES, V62, P4244; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Xu D, 2001, BLOOD, V98, p146A; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	136	683	760	0	62	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 9	2003	349	15					1451	1464		10.1056/NEJMra020777	http://dx.doi.org/10.1056/NEJMra020777			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729JF	14534339				2022-12-28	WOS:000185769500010
J	Volkmar, FR; Pauls, D				Volkmar, FR; Pauls, D			Autism	LANCET			English	Review							PLACEBO-CONTROLLED TRIAL; LATENT-CLASS ANALYSIS; LINKAGE-DISEQUILIBRIUM; RUBELLA VACCINE; FAMILY-HISTORY; PERSONALITY-CHARACTERISTICS; DEVELOPMENTAL DYSLEXIA; SEGREGATION ANALYSIS; SPECTRUM DISORDERS; POPULATION-SAMPLE	Autism is a disorder characterised by severe difficulties in social interaction and communication, and with unusual behaviours. Once thought of as rare, autism is now recognised as being common. The role of CNS factors in pathogenesis is suggested by high rates of seizure disorder; research has highlighted the role of several specific brain regions in syndrome pathogenesis. Autism is a strongly genetic disorder and probably arises because of multiple genes; recurrence rates in families with one child are high. Early intervention with various techniques is helpful in many cases. Some pharmacological agents may help with certain problematic behaviours but do not address the underlying cause of the disorder.	Yale Univ, Ctr Child Study, New Haven, CT 06520 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Charlestown, MA USA	Yale University; Harvard University; Massachusetts General Hospital	Volkmar, FR (corresponding author), Yale Univ, Ctr Child Study, POB 207900, New Haven, CT 06520 USA.	fred.volkmar@yale.edu	Volkmar, Fred/AEB-0666-2022					Allen G, 2003, AM J PSYCHIAT, V160, P262, DOI 10.1176/appi.ajp.160.2.262; Alsobrook JP, 1999, AM J MED GENET, V88, P669, DOI 10.1002/(SICI)1096-8628(19991215)88:6<669::AID-AJMG17>3.0.CO;2-N; Alsobrook JP, 2002, AM J PSYCHIAT, V159, P291, DOI 10.1176/appi.ajp.159.2.291; Anderson G. M, 1997, HDB AUTISM PERVASIVE, P325; [Anonymous], 1980, DIAGNOSTIC STAT MANU; [Anonymous], 1994, DIAGNOSTIC STAT MANU; Bailey A, 1998, HUM MOL GENET, V7, P571; Bailey A, 1996, J CHILD PSYCHOL PSYC, V37, P89, DOI 10.1111/j.1469-7610.1996.tb01381.x; BAILEY A, 1995, PSYCHOL MED, V25, P63, DOI 10.1017/S0033291700028099; BAKER P, 1994, J AUTISM DEV DISORD, V24, P529, DOI 10.1007/BF02172133; Baron-Cohen S, 1999, EUR J NEUROSCI, V11, P1891, DOI 10.1046/j.1460-9568.1999.00621.x; Baron-Cohen S, 2000, NEUROSCI BIOBEHAV R, V24, P355, DOI 10.1016/S0149-7634(00)00011-7; BARONCOHEN S, 1989, BRIT J DISORD COMMUN, V24, P199; BaronCohen S, 1997, VIS COGN, V4, P311, DOI 10.1080/713756761; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; Barrett S, 1999, AM J MED GENET, V88, P609; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOLTON P, 1994, J CHILD PSYCHOL PSYC, V35, P877, DOI 10.1111/j.1469-7610.1994.tb02300.x; BOWLER DM, 1992, J CHILD PSYCHOL PSYC, V33, P877, DOI 10.1111/j.1469-7610.1992.tb01962.x; Bradford Y, 2001, AM J MED GENET, V105, P539, DOI 10.1002/ajmg.1497; BREGMAN JD, 1997, HDB AUTISM PERVASIVE, P606; BROTHERS L, 1993, BEHAV BRAIN RES, V57, P53, DOI 10.1016/0166-4328(93)90061-T; BRYSON SE, 1997, HDB AUTISM PERVASIVE, P41; Buitelaar JK, 1999, DEV PSYCHOPATHOL, V11, P39, DOI 10.1017/S0954579499001947; Buitelaar JK, 1998, J AM ACAD CHILD PSY, V37, P800, DOI 10.1097/00004583-199808000-00006; BUNDEY S, 1994, DEV MED CHILD NEUROL, V36, P736; Buxbaum JD, 2001, AM J HUM GENET, V68, P1514, DOI 10.1086/320588; CHAWARSKA K, IN PRESS CHILD DEV; Chen RT, 1998, LANCET, V351, P611, DOI 10.1016/S0140-6736(05)78423-3; Chez MG, 2000, J AUTISM DEV DISORD, V30, P87, DOI 10.1023/A:1005443119324; COLLINS FS, 1991, CLIN RES, V39, P615; Cook EH, 1998, AM J HUM GENET, V62, P1077, DOI 10.1086/301832; COURCHESNE E, 1988, NEW ENGL J MED, V318, P1349, DOI 10.1056/NEJM198805263182102; Dahlgren SO, 1996, J CHILD PSYCHOL PSYC, V37, P759, DOI 10.1111/j.1469-7610.1996.tb01469.x; Dales L, 2001, JAMA-J AM MED ASSOC, V285, P1183, DOI 10.1001/jama.285.9.1183; Davidovitch M, 2000, J AUTISM DEV DISORD, V30, P113, DOI 10.1023/A:1005403421141; Dawson G, 1998, CHILD DEV, V69, P1276, DOI 10.2307/1132265; Dawson JE, 1998, RES DEV DISABIL, V19, P439, DOI 10.1016/S0891-4222(98)00016-X; De Giacomo A, 1998, EUR CHILD ADOLES PSY, V7, P131, DOI 10.1007/s007870050058; Elgar K, 2001, J CHILD PSYCHOL PSYC, V42, P705, DOI 10.1111/1469-7610.00767; Feinstein C, 1998, J AUTISM DEV DISORD, V28, P393, DOI 10.1023/A:1026000404855; Filipek PA, 2000, NEUROLOGY, V55, P468, DOI 10.1212/WNL.55.4.468; FOLSTEIN S, 1977, J CHILD PSYCHOL PSYC, V18, P297, DOI 10.1111/j.1469-7610.1977.tb00443.x; Folstein SE, 1999, J CHILD PSYCHOL PSYC, V40, P1117, DOI 10.1111/1469-7610.00528; Fombonne E, 2003, MOL PSYCHIATR, V8, P133, DOI 10.1038/sj.mp.4001266; Fombonne E, 2002, MOL PSYCHIATR, V7, pS4, DOI 10.1038/sj.mp.4001162; Fombonne E, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e58; Frith U., 1989, AUTISM EXPLAINING EN, V6th; Ghaziuddin M, 2002, EUR CHILD ADOLES PSY, V11, P142, DOI 10.1007/s00787-002-0271-5; GILLBERG C, 1991, J AM ACAD CHILD PSY, V30, P489, DOI 10.1097/00004583-199105000-00022; GILLBERG C, 1995, DEV MED CHILD NEUROL, V37, P239; Grigorenko EL, 2000, AM J HUM GENET, V66, P715, DOI 10.1086/302755; Grigorenko EL, 1997, AM J HUM GENET, V60, P27; Grigorenko EL, 2001, AM J MED GENET, V105, P120, DOI 10.1002/1096-8628(20010108)105:1<120::AID-AJMG1075>3.3.CO;2-K; Grossman JB, 1997, ANN NY ACAD SCI, V807, P440, DOI 10.1111/j.1749-6632.1997.tb51938.x; GURLING H, 1986, PSYCHIAT DEV, V4, P289; Haxby JV, 2002, BIOL PSYCHIAT, V51, P59, DOI 10.1016/S0006-3223(01)01330-0; HEFLIN LJ, 1998, FOCUS AUTISM DEV DIS, V14, P194; HERMELIN B, 2001, BRIGHT SPLINTERS MIN, P176; HOBSON RP, 1988, BRIT J PSYCHOL, V79, P441, DOI 10.1111/j.2044-8295.1988.tb02745.x; Horvath K, 1998, J Assoc Acad Minor Phys, V9, P9; HOWLIN P, 1994, CHILD ABUSE NEGLECT, V18, P529, DOI 10.1016/0145-2134(94)90006-X; HOWLIN P, 1997, AUTISM PERVASIVE DEV; Hughes C, 1997, PSYCHOL MED, V27, P209, DOI 10.1017/S0033291796004308; JORDE LB, 1991, AM J HUM GENET, V49, P932; KANNER L, 1971, J AUTISM CHILD SCHIZ, V1, P119, DOI 10.1007/BF01537953; Kanner L, 1943, NERV CHILD, V2, P217; Kastner JL, 2001, PEDIATR ANN, V30, P408, DOI 10.3928/0090-4481-20010701-08; Kaye JA, 2001, BRIT MED J, V322, P460, DOI 10.1136/bmj.322.7284.460; Kemper TL, 1998, J NEUROPATH EXP NEUR, V57, P645, DOI 10.1097/00005072-199807000-00001; Klin A, 2002, AM J PSYCHIAT, V159, P895, DOI 10.1176/appi.ajp.159.6.895; Klin A, 2002, ARCH GEN PSYCHIAT, V59, P809, DOI 10.1001/archpsyc.59.9.809; KLIN A, 1992, J CHILD PSYCHOL PSYC, V33, P861, DOI 10.1111/j.1469-7610.1992.tb01961.x; Klin A, 2000, J CHILD PSYCHOL PSYC, V41, P831, DOI 10.1111/1469-7610.00671; Krause I, 2002, J AUTISM DEV DISORD, V32, P337, DOI 10.1023/A:1016391121003; LANDA R, 1992, PSYCHOL MED, V22, P245, DOI 10.1017/S0033291700032918; LANDA R, 1991, J SPEECH HEAR RES, V34, P1339, DOI 10.1044/jshr.3406.1339; LeCouteur A, 1996, J CHILD PSYCHOL PSYC, V37, P785; Liu JJ, 2001, AM J HUM GENET, V69, P327, DOI 10.1086/321980; LORD C, 1993, INF MENTAL HLTH J, V14, P234, DOI 10.1002/1097-0355(199323)14:3<234::AID-IMHJ2280140308>3.0.CO;2-F; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Lord C, 1996, J CHILD PSYCHOL PSYC, V36, P1065; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Machado CJ, 2003, J CHILD PSYCHOL PSYC, V44, P64, DOI 10.1111/1469-7610.00103; Maestro S, 2002, J AM ACAD CHILD PSY, V41, P1239, DOI 10.1097/00004583-200210000-00014; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; Mendola P, 2002, MENT RETARD DEV D R, V8, P188, DOI 10.1002/mrdd.10033; MINDERAA RB, 1989, J AM ACAD CHILD PSY, V28, P190, DOI 10.1097/00004583-198903000-00007; Minshew NJ, 1997, HDB AUTISM PERVASIVE, P344; NARAYAN M, 1993, BIOL PSYCHIAT, V33, P630, DOI 10.1016/0006-3223(93)90102-J; National Research Council (U.S.), 2001, ED YOUNG CHILDR AUT, P307; Neuman RJ, 2001, J CHILD PSYCHOL PSYC, V42, P933, DOI 10.1111/1469-7610.00789; Nurmi EL, 2001, GENOMICS, V77, P105, DOI 10.1006/geno.2001.6617; Owley T, 2001, J AM ACAD CHILD PSY, V40, P1293, DOI 10.1097/00004583-200111000-00009; Ozonoff S., 1997, HDB AUTISM PERVASIVE, P868; Palferman S, 2001, AM J HUM GENET, V69, P570; Paul R, 2003, CHILD ADOL PSYCH CL, V12, P87, DOI 10.1016/S1056-4993(02)00047-0; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Philippe A, 1999, HUM MOL GENET, V8, P805, DOI 10.1093/hmg/8.5.805; PICKLES A, 1995, AM J HUM GENET, V57, P717; Piven J, 1997, J CHILD PSYCHOL PSYC, V38, P1011, DOI 10.1111/j.1469-7610.1997.tb01618.x; PIVEN J, 1995, AM J PSYCHIAT, V152, P1145; PIVEN J, 1994, PSYCHOL MED, V24, P783, DOI 10.1017/S0033291700027938; Piven J, 1997, NEUROLOGY, V49, P546, DOI 10.1212/WNL.49.2.546; PIVEN J, 1990, AM J PSYCHIAT, V147, P734; Piven J, 1997, AM J PSYCHIAT, V154, P185; Piven J, 1997, AM J MED GENET, V74, P398, DOI 10.1002/(SICI)1096-8628(19970725)74:4<398::AID-AJMG11>3.3.CO;2-K; PIVEN J, 1995, NEUROLOGY, V45, P398, DOI 10.1212/WNL.45.2.398-a; Piven J, 1996, J AM ACAD CHILD PSY, V35, P530, DOI 10.1097/00004583-199604000-00020; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Risch N, 1999, AM J HUM GENET, V65, P493, DOI 10.1086/302497; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; RITVO ER, 1986, AM J PSYCHIAT, V143, P862; RITVO ER, 1985, AM J PSYCHIAT, V142, P187; Rodier PM, 2002, DEV PSYCHOPATHOL, V14, P537, DOI 10.1017/S0954579402003085; Rogers T, 1999, J AUTISM DEV DISORD, V29, P195, DOI 10.1023/A:1023075904742; RUTTER M, 1994, J CHILD PSYCHOL PSYC, V35, P311, DOI 10.1111/j.1469-7610.1994.tb01164.x; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Santangelo SL, 1999, DEV COGN NEUROSCI, P431; SANTANGELO SL, 1995, AM J HUM GENET, V57, P89; Schroer RJ, 1998, AM J MED GENET, V76, P327, DOI 10.1002/(SICI)1096-8628(19980401)76:4<327::AID-AJMG8>3.0.CO;2-M; Schuler A., 1997, HDB AUTISM PERVASIVE, P539; Schultz RT, 2000, ARCH GEN PSYCHIAT, V57, P331, DOI 10.1001/archpsyc.57.4.331; Shao YJ, 2002, AM J MED GENET, V114, P99, DOI 10.1002/ajmg.10153; Siegal M, 2002, NAT REV NEUROSCI, V3, P463, DOI 10.1038/nrn844; Sigman M, 1999, MONOGR SOC RES CHILD, V64, P1, DOI 10.1111/1540-5834.00002; SMALLEY S, 1991, ANN NY ACAD SCI, V615, P382; Smalley SL, 1998, J AUTISM DEV DISORD, V28, P407, DOI 10.1023/A:1026052421693; Sparrow S, 1997, HDB AUTISM PERVASIVE, P411; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; STEFFENBURG S, 1989, J CHILD PSYCHOL PSYC, V30, P405, DOI 10.1111/j.1469-7610.1989.tb00254.x; STONE WL, 1994, ARCH PEDIAT ADOL MED, V148, P174, DOI 10.1001/archpedi.1994.02170020060010; Sweeten TL, 2002, PHARMACOL BIOCHEM BE, V71, P449, DOI 10.1016/S0091-3057(01)00697-9; SZATMARI P, 1993, J AM ACAD CHILD PSY, V32, P1264, DOI 10.1097/00004583-199311000-00022; TANZI RE, 1998, MOL NEUROLOGY, P55; Taylor B, 1999, LANCET, V353, P2026, DOI 10.1016/S0140-6736(99)01239-8; Todd RD, 2001, AM J PSYCHIAT, V158, P1891, DOI 10.1176/appi.ajp.158.11.1891; Torres AR, 2002, HUM IMMUNOL, V63, P311, DOI 10.1016/S0198-8859(02)00374-9; TSAI L, 1981, J AUTISM DEV DISORD, V11, P165, DOI 10.1007/BF01531682; Uhlmann V, 2002, J CLIN PATHOL-MOL PA, V55, P84, DOI 10.1136/mp.55.2.84; Unis AS, 2002, J AM ACAD CHILD PSY, V41, P1315, DOI 10.1097/00004583-200211000-00012; VOLKMAR F, 2003, SOCIAL BRAIN EVOLUTI; Volkmar FR, 1999, NEW ENGL J MED, V341, P1842, DOI 10.1056/NEJM199912093412412; VOLKMAR FR, 1990, J AM ACAD CHILD PSY, V29, P127, DOI 10.1097/00004583-199001000-00020; VOLKMAR FR, 1994, AM J PSYCHIAT, V151, P1361; VOLKMAR FR, 1997, HDB AUTISM PERVASIVE, P5; Volkmar FR., 1997, HDB AUTISM PERVASIVE, P195; Volkmar Fred, 1999, Journal of the American Academy of Child and Adolescent Psychiatry, V38, p32S; WAKEFIELD A, 1998, ISR MED ASSOC J, V1, P183; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; Wakefield AJ, 1999, LANCET, V354, P949, DOI 10.1016/S0140-6736(05)75696-8; *WHO, 1994, DIAGN CRIT RES; Williams PG, 1998, J AUTISM DEV DISORD, V28, P567, DOI 10.1023/A:1026012414193; WING L, 1984, J AUTISM DEV DISORD, V14, P211, DOI 10.1007/BF02409664; Wing L, 2002, MENT RETARD DEV D R, V8, P151, DOI 10.1002/mrdd.10029; WING L, 1991, AUTISM ASPERGER SYND; WING L, 1997, HDB AUTISM PERVASIVE, P148; WOLFF S, 1988, J CHILD PSYCHOL PSYC, V29, P143, DOI 10.1111/j.1469-7610.1988.tb00699.x; Woods CG, 1997, AM J HUM GENET, V61, pA117; [No title captured]; [No title captured]	162	223	231	2	53	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 4	2003	362	9390					1133	1141		10.1016/S0140-6736(03)14471-6	http://dx.doi.org/10.1016/S0140-6736(03)14471-6			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	728HA	14550703				2022-12-28	WOS:000185710700024
J	Miller, SI; Bader, M; Guina, T				Miller, SI; Bader, M; Guina, T			Bacterial vesicle formation as a mechanism of protein transfer to animals	CELL			English	Editorial Material							LIPOPOLYSACCHARIDE; SECRETION; RELEASE; EXPORT	Gram-negative bacterial vesicle formation is a mechanism for specific secretion and transfer of a protein toxin to animals. This discovery should stimulate work on the mechanism of protein sorting into vesicles and the role of vesicles in bacterial pathogenesis.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Miller, SI (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.							Baron C, 2002, MOL MICROBIOL, V43, P1359, DOI 10.1046/j.1365-2958.2002.02816.x; Beveridge TJ, 1999, J BACTERIOL, V181, P4725, DOI 10.1128/JB.181.16.4725-4733.1999; DEVOE IW, 1973, J EXP MED, V138, P1156, DOI 10.1084/jem.138.5.1156; FORSBERG CW, 1981, APPL ENVIRON MICROB, V42, P886, DOI 10.1128/AEM.42.5.886-896.1981; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Horstman AL, 2002, J BIOL CHEM, V277, P32538, DOI 10.1074/jbc.M203740200; Kolling GL, 1999, APPL ENVIRON MICROB, V65, P1843; Pugsley AP, 1997, GENE, V192, P13, DOI 10.1016/S0378-1119(96)00803-7; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Wai SN, 2003, CELL, V115, P25, DOI 10.1016/S0092-8674(03)00754-2	10	11	12	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 3	2003	115	1					2	3		10.1016/S0092-8674(03)00767-0	http://dx.doi.org/10.1016/S0092-8674(03)00767-0			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14531993	Bronze			2022-12-28	WOS:000185815500002
J	Giannini, A; Saravanan, R; Chang, P				Giannini, A; Saravanan, R; Chang, P			Oceanic forcing of Sahel rainfall on interannual to interdecadal time scales	SCIENCE			English	Article							EASTERN EQUATORIAL ATLANTIC; TROPICAL NORTH-AFRICA; SUMMER RAINFALL; LAND-USE; CLIMATE; DESERTIFICATION; PRECIPITATION; CIRCULATION; VARIABILITY; ANOMALIES	We present evidence, based on an ensemble of integrations with NSIPP1 (version 1 of the atmospheric general circulation model developed at NASA's Goddard Space Flight Center in the framework of the Seasonal-to-Interannual Prediction Project) forced only by the observed record of sea surface temperature from 1930 to 2000, to suggest that variability of rainfall in the Sahel results from the response of the African summer monsoon to oceanic forcing, amplified by land-atmosphere interaction. The recent drying trend in the semi-arid Sahel is attributed to warmer-than-average low-latitude waters around Africa, which, by favoring the establishment of deep convection over the ocean, weaken the continental convergence associated with the monsoon and engender widespread drought from Senegal to Ethiopia.	Natl Ctr Atmospher Res, Boulder, CO 80305 USA; Texas A&M Univ, Dept Oceanog, College Stn, TX 77843 USA	National Center Atmospheric Research (NCAR) - USA; Texas A&M University System; Texas A&M University College Station	Giannini, A (corresponding author), Int Res Inst Climate Predict, Palisades, NY 10964 USA.		Giannini, Alessandra/F-7163-2016; Giannini, Alessandra/H-4403-2013; Noojipady, Praveen/B-2511-2010; Chang, Ping/A-1642-2013; Saravanan, Ramalingam/G-8879-2012	Giannini, Alessandra/0000-0001-5425-4995; Chang, Ping/0000-0002-9085-0759; Saravanan, Ramalingam/0000-0002-0005-6907				BACMEISTER JT, 2000, 104606 NASA, V17; CHARNEY JG, 1975, Q J ROY METEOR SOC, V101, P193, DOI 10.1002/qj.49710142802; Chiang JCH, 2002, J CLIMATE, V15, P2616, DOI 10.1175/1520-0442(2002)015<2616:TTTVCB>2.0.CO;2; Chou C, 2001, Q J ROY METEOR SOC, V127, P1869, DOI 10.1002/qj.49712757602; COOK KH, 1994, J CLIMATE, V7, P400, DOI 10.1175/1520-0442(1994)007<0400:MBWSDP>2.0.CO;2; FAIRHEAD J, 1998, DEFORESTATION GLOBAL; FOLLAND CK, 1986, NATURE, V320, P602, DOI 10.1038/320602a0; Fontaine B, 1996, J CLIMATE, V9, P2935, DOI 10.1175/1520-0442(1996)009<2935:SSTFAW>2.0.CO;2; GIANNINI A, UNPUB; GLANTZ MH, 1985, AMBIO, V14, P334; HASTENRATH S, 1977, MON WEATHER REV, V105, P1019, DOI 10.1175/1520-0493(1977)105<1019:SAOCAC>2.0.CO;2; Janicot S, 1998, J CLIMATE, V11, P1874, DOI 10.1175/1520-0442-11.8.1874; KOSTER RD, 1995, J GEOPHYS RES-ATMOS, V100, P13775, DOI 10.1029/95JD00176; Koster RD, 2000, J HYDROMETEOROL, V1, P26, DOI 10.1175/1525-7541(2000)001<0026:VAPOPA>2.0.CO;2; LAMB PJ, 1978, MON WEATHER REV, V106, P482, DOI 10.1175/1520-0493(1978)106<0482:CSOTAS>2.0.CO;2; Lambin EF, 2001, GLOBAL ENVIRON CHANG, V11, P261, DOI 10.1016/S0959-3780(01)00007-3; NICHOLSON SE, 1980, MON WEATHER REV, V108, P473, DOI 10.1175/1520-0493(1980)108<0473:TNORFI>2.0.CO;2; OTTERMAN J, 1974, SCIENCE, V186, P531, DOI 10.1126/science.186.4163.531; PALMER TN, 1986, NATURE, V322, P251, DOI 10.1038/322251a0; Peixoto J. P., 1992, PHYS CLIMATE, DOI DOI 10.1063/1.2809772; Preisendorfer R.W., 1988, DEV ATMOS SCI, V17; Rasmussen K, 2001, GLOBAL ENVIRON CHANG, V11, P271, DOI 10.1016/S0959-3780(01)00005-X; RAYNER NA, IN PRESS; RAYNER NA, 1996, CLIMATE RES TECHNICA, V74; REYNOLDS RW, 1994, J CLIMATE, V7, P929, DOI 10.1175/1520-0442(1994)007<0929:IGSSTA>2.0.CO;2; ROWELL DP, 1995, Q J ROY METEOR SOC, V121, P669, DOI 10.1256/smsqj.52310; SUD YC, 1982, J CLIMATOL, V2, P105, DOI 10.1002/joc.3370020202; Taylor CM, 2002, J CLIMATE, V15, P3615, DOI [10.1175/1520-0442(2002)015<3615:TIOLUC>2.0.CO;2, 10.1175/1520-0442(2002)015&lt;3615:TIOLUC&gt;2.0.CO;2]; TUCKER CJ, 1991, SCIENCE, V253, P299, DOI 10.1126/science.253.5017.299; Vizy EK, 2001, J CLIMATE, V14, P795, DOI 10.1175/1520-0442(2001)014<0795:MBWGOG>2.0.CO;2; VIZY EK, 2002, J GEOPHYS RES, V107; vonsStorch H., 1999, STAT ANAL CLIMATE RE, DOI DOI 10.1017/CBO9780511612336; VOSE RS, 1992, ORNLCDIAC53NDP041; Ward MN, 1998, J CLIMATE, V11, P3167, DOI 10.1175/1520-0442(1998)011<3167:DASLTP>2.0.CO;2; XUE YK, 1993, J CLIMATE, V6, P2232, DOI 10.1175/1520-0442(1993)006<2232:TIOLSP>2.0.CO;2; Zeng N, 1999, SCIENCE, V286, P1537, DOI 10.1126/science.286.5444.1537	36	723	740	3	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 7	2003	302	5647					1027	1030		10.1126/science.1089357	http://dx.doi.org/10.1126/science.1089357			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14551320				2022-12-28	WOS:000186396300042
J	Chalmers, I; Rounding, C; Lock, K				Chalmers, I; Rounding, C; Lock, K			Descriptive survey of non-commercial randomised controlled trials in the United Kingdom, 1980-2002	BRITISH MEDICAL JOURNAL			English	Article								Objectives To describe the characteristics of randomised controlled trials supported by the main non-commercial sources of funding in the United Kingdom between 1980 and 2002. Design Descriptive survey. Setting Randomised controlled trials funded by the Medical Research Council, NHS research and development programme, Department of Health, Chief Scientist Office in Scotland, and medical research charities. Participants 1464 randomised controlled trials supported by the main non-commercial sources of funding. Results Support for randomised controlled trials by the main sources of non-commercial funding in the United Kingdom has fallen in recent years, without any concomitant increase in the sample sizes of these studies. Drug trials in a limited range of health problems have dominated among the studies supported by the Medical Research Council and medical research charities. Until recently, the NHS research and development programme supported randomised controlled trials of various healthcare interventions, in a wide range of health problems, but between 1999 and 2002 many of the subprogrammes that had commissioned trials were discontinued. Conclusions The future of non-commercial randomised controlled trials in the United Kingdom has been threatened by the discontinuation or demise of national and regional NHS research and development programmes. Support also seems to be declining from the Medical Research Council and the medical research charities. It is unclear what the future holds for randomised controlled trials that address issues of no interest to industry but are of great importance to patients and practitioners.	UK Cochrane Ctr, UK Randomised Controlled Trial Registrat Project, Oxford OX2 7LG, England	Cochrane Centre	Chalmers, I (corresponding author), UK Cochrane Ctr, UK Randomised Controlled Trial Registrat Project, Oxford OX2 7LG, England.							[Anonymous], 2003, LANCET, V361, P2167; [Anonymous], 2020, CLIN RES TRIALS, V6, DOI [10.15761/CRT.1000298, DOI 10.15761/CRT.1000298]; Chalmers I, 2000, LANCET, V356, P774, DOI 10.1016/S0140-6736(05)73681-3; CHALMERS I, 2000, UK RCT REGISTRATION; Chalmers L, 2000, J ROY SOC MED, V93, P555, DOI 10.1177/014107680009301101; Ernst E, 2002, BRIT MED J, V325, P1245, DOI 10.1136/bmj.325.7374.1245; Hanley B, 2001, BRIT MED J, V322, P519, DOI 10.1136/bmj.322.7285.519; *MED RES COUNC, 2003, PAT PAP MED RES COUN; *MED RES COUNC, 2003, REP CLIN TRIALS TOM; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; *PHARM IND COMP TA, 2003, CLIN RES REP; Rothwell PM, 1997, BMJ-BRIT MED J, V314, P1580, DOI 10.1136/bmj.314.7094.1580; Tallon D, 2000, LANCET, V355, P2037, DOI 10.1016/S0140-6736(00)02351-5	13	43	44	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 1	2003	327	7422					1017	1019		10.1136/bmj.327.7422.1017	http://dx.doi.org/10.1136/bmj.327.7422.1017			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738NE	14593034	Bronze, Green Published			2022-12-28	WOS:000186294100019
J	Smeeth, L; Fletcher, AE; Hanciles, S; Evans, J; Wormald, R				Smeeth, L; Fletcher, AE; Hanciles, S; Evans, J; Wormald, R			Screening older people for impaired vision in primary care: cluster randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; MRC TRIAL; VISUAL IMPAIRMENT; EYE DISEASE; MANAGEMENT; COMMUNITY; ACUITY; QUESTIONNAIRE; POPULATION; PREVALENCE	Objective To determine the effectiveness of screening for visual impairment in people aged 75 or over as part of a multidimensional screening programme. Design Cluster randomised trial. Setting General practices in the United Kingdom participating in the MRC trial of assessment and management of older people in the community. Participants 4340 people aged 75 years or over randomly sampled from 20 general practices, excluding people resident in hospitals or nursing homes. Intervention Visual acuity testing and referral to eye services for people with visual impairment. Universal screening (assessment and visual acuity testing) was compared with targeted screening, in which only participants with a range of health related problems were offered an assessment that included acuity screening. Main outcome measures Proportion of people with visual acuity less than 6/18 in either eye; mean composite score of 25 item version of the National Eye Institute visual function questionnaire. Results Three to five years after screening, the relative risk of having visual acuity < 6/18 in either eye, comparing universal with targeted screening, was 1.07 (95% confidence interval 0.84 to 1.36; P = 0.58). The mean composite score of the visual function questionnaire was 85.6 in the targeted screening group and 86.0 in the universal group (difference 0.4, 95% confidence interval - 1.7 to 2.5, P = 0.69). Conclusions Including a vision screening component by a practice nurse in a pragmatic trial of multidimensional screening for older people did not lead to improved visual outcomes.	Univ London London Sch Hyg & Trop Med, Ctr Ageing & Publ Hlth, London WC1E 7HT, England; Moorfields Eye Hosp, London EC1V 2PD, England; Inst Ophthalmol, London EC1V 2PD, England	University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of London; University College London	Smeeth, L (corresponding author), Univ London London Sch Hyg & Trop Med, Ctr Ageing & Publ Hlth, Keppel St, London WC1E 7HT, England.	liam.smeeth@lshtm.ac.uk	Evans, Jennifer/F-4672-2012; Smeeth, Liam/X-5862-2018	Evans, Jennifer/0000-0002-6137-2030; Smeeth, Liam/0000-0002-9168-6022				Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Aminzadeh F, 2000, AGE AGEING, V29, P401, DOI 10.1093/ageing/29.5.401; CARABELLESE C, 1993, J AM GERIATR SOC, V41, P401, DOI 10.1111/j.1532-5415.1993.tb06948.x; DargentMolina P, 1996, LANCET, V348, P145, DOI 10.1016/S0140-6736(96)01440-7; *DEP HLTH WELS OFF, 1989, GEN PRACT NAT HLTH S; *DEP HLTH WELSH OF, 1989, GEN PRACT NAT HLTH S; Department of Health, 2001, NAT SERV FRAM OLD PE; Evans JR, 2002, BRIT J OPHTHALMOL, V86, P795, DOI 10.1136/bjo.86.7.795; Fletcher AE, 2002, BMC HEALTH SERV RES, V2, DOI 10.1186/1472-6963-2-21; HITCHINGS RA, 1989, BRIT MED J, V298, P1126, DOI 10.1136/bmj.298.6681.1126; LOEWENSTEIN JI, 1985, ARCH OPHTHALMOL-CHIC, V103, P222; Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050; Massof RW, 2001, VISION RES, V41, P397, DOI 10.1016/S0042-6989(00)00249-2; MCGRAW PV, 1993, OPHTHAL PHYSL OPT, V13, P400, DOI 10.1111/j.1475-1313.1993.tb00499.x; Reidy A, 1998, BRIT MED J, V316, P1643, DOI 10.1136/bmj.316.7145.1643; Rovner BW, 1996, J AM GERIATR SOC, V44, P181, DOI 10.1111/j.1532-5415.1996.tb02436.x; SCOTT IU, 1994, ARCH OPHTHALMOL-CHIC, V112, P329, DOI 10.1001/archopht.1994.01090150059023; Smeeth L, 1998, FAM PRACT, V15, pS24; Smeeth L, 2001, BRIT MED J, V323, P1403, DOI 10.1136/bmj.323.7326.1403; SMEETH L, 2003, COCHRANE DATABASE SY; SMEETH L, 2000, COCHRANE DATABASE SY, V2; STRAHLMAN E, 1990, ARCH INTERN MED, V150, P2159, DOI 10.1001/archinte.150.10.2159; van der Pols JC, 2000, BRIT J OPHTHALMOL, V84, P165, DOI 10.1136/bjo.84.2.165; WANG F, 1994, ARCH INTERN MED, V154, P1821, DOI 10.1001/archinte.154.16.1821; WORMALD RPL, 1992, BRIT MED J, V304, P1226, DOI 10.1136/bmj.304.6836.1226; Wun YT, 1997, FAM PRACT, V14, P289, DOI 10.1093/fampra/14.4.289	26	31	31	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 1	2003	327	7422					1027	1030A		10.1136/bmj.327.7422.1027	http://dx.doi.org/10.1136/bmj.327.7422.1027			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738NE	14593039	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000186294100024
J	Rogers, RD; Seddon, KR				Rogers, RD; Seddon, KR			Ionic liquids - Solvents of the future?	SCIENCE			English	Editorial Material									Univ Alabama, Ctr Green Mfg, Tuscaloosa, AL 35487 USA; Queens Univ Belfast, Queens Univ Ion Liquid Labs, Belfast BT9 5AG, Antrim, North Ireland	University of Alabama System; University of Alabama Tuscaloosa; Queens University Belfast	Rogers, RD (corresponding author), Univ Alabama, Ctr Green Mfg, Tuscaloosa, AL 35487 USA.		Rogers, Robin D./C-8265-2013; Rogers, Robin D./N-4067-2019	Rogers, Robin D./0000-0001-9843-7494; Rogers, Robin D./0000-0001-9843-7494				Bosmann A, 2001, CHEM COMMUN, P2494, DOI 10.1039/b108411a; Freemantle M, 1998, CHEM ENG NEWS, V76, P32, DOI 10.1021/cen-v076n013.p032; Gamero-Castano M, 2001, J PROPUL POWER, V17, P977, DOI 10.2514/2.5858; Gutowski KE, 2003, J AM CHEM SOC, V125, P6632, DOI 10.1021/ja0351802; Liu WM, 2002, TRIBOL LETT, V13, P81, DOI 10.1023/A:1020148514877; Majewski P, 2003, ACTA HISTOCHEM, V105, P135, DOI 10.1078/0065-1281-00707; Ohno H., 2003, IONIC LIQUIDS FRONT; Poliakoff M, 2002, SCIENCE, V297, P807, DOI 10.1126/science.297.5582.807; Rogers R. D., 2002, ACS S SER, V818; ROGERS RD, 2003, ACS S SER, V0856; ROGERS RD, 2002, IND APPL IONIC LIQUI, V92; Seddon K. R, 1999, INT G PAP S P, P131; Seddon KR, 2003, NAT MATER, V2, P363, DOI 10.1038/nmat907; Sheldon RA, 2002, GREEN CHEM, V4, P147, DOI 10.1039/b110008b; Wasserscheid P., 2003, IONIC LIQUIDS SYNTHE, DOI 10.1002/3527600701; 2003, ACS FALL M 7 11 SEPT	16	3376	3537	29	1125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 31	2003	302	5646					792	793		10.1126/science.1090313	http://dx.doi.org/10.1126/science.1090313			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593156				2022-12-28	WOS:000186258000026
J	Kenet, T; Bibitchkov, D; Tsodyks, M; Grinvald, A; Arieli, A				Kenet, T; Bibitchkov, D; Tsodyks, M; Grinvald, A; Arieli, A			Spontaneously emerging cortical representations of visual attributes	NATURE			English	Article							OBLIQUE CONTOURS; ONGOING ACTIVITY; IN-VIVO; CORTEX; VARIABILITY; RESPONSES; DYNAMICS; CELLS; SYNCHRONIZATION; CIRCUITS	Spontaneous cortical activity - ongoing activity in the absence of intentional sensory input - has been studied extensively(1), using methods ranging from EEG (electroencephalography)(2-4), through voltage sensitive dye imaging(5-7), down to recordings from single neurons(8,9). Ongoing cortical activity has been shown to play a critical role in development(10-14), and must also be essential for processing sensory perception, because it modulates stimulus-evoked activity(5,15,16), and is correlated with behaviour(17). Yet its role in the processing of external information and its relationship to internal representations of sensory attributes remains unknown. Using voltage sensitive dye imaging, we previously established a close link between ongoing activity in the visual cortex of anaesthetized cats and the spontaneous firing of a single neuron(6). Here we report that such activity encompasses a set of dynamically switching cortical states, many of which correspond closely to orientation maps. When such an orientation state emerged spontaneously, it spanned several hypercolumns and was often followed by a state corresponding to a proximal orientation. We suggest that dynamically switching cortical states could represent the brain's internal context, and therefore reflect or influence memory, perception and behaviour.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Kenet, T (corresponding author), Univ Calif San Francisco, Keck Ctr Integrat Neurosci, 513 Parnassus Ave,Box 0732, San Francisco, CA 94143 USA.		tsodyks, misha/J-4430-2013; GRINVALD, AMIRAM/AAH-9919-2019	Tsodyks, Misha/0000-0002-5661-4349				Adrian ED, 1934, BRAIN, V57, P355, DOI 10.1093/brain/57.4.355; ARIELI A, 1995, J NEUROPHYSIOL, V73, P2072, DOI 10.1152/jn.1995.73.5.2072; Arieli A, 1996, SCIENCE, V273, P1868, DOI 10.1126/science.273.5283.1868; Azouz R, 1999, J NEUROSCI, V19, P2209; BENYISHAI R, 1995, P NATL ACAD SCI USA, V92, P3844, DOI 10.1073/pnas.92.9.3844; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; Chapman B, 1998, P NATL ACAD SCI USA, V95, P2609, DOI 10.1073/pnas.95.5.2609; Chiu CY, 2002, NEURON, V35, P1123, DOI 10.1016/S0896-6273(02)00867-X; Coppola DM, 1998, P NATL ACAD SCI USA, V95, P2621, DOI 10.1073/pnas.95.5.2621; CREUTZFELDT OD, 1966, ELECTROEN CLIN NEURO, V20, P19, DOI 10.1016/0013-4694(66)90137-4; Elul R, 1971, Int Rev Neurobiol, V15, P227; Ernst UA, 2001, NAT NEUROSCI, V4, P431, DOI 10.1038/86089; Fries P, 2001, NAT NEUROSCI, V4, P194, DOI 10.1038/84032; Grinvald A, 1999, MODERN TECHNIQUES NE, P893, DOI 10.1007/978-3-642-58552-4_34; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kisley MA, 1999, J NEUROSCI, V19, P10451; Kohonen T., 2000, SELF ORG MAPS; Lestienne R, 2001, PROG NEUROBIOL, V65, P545, DOI 10.1016/S0301-0082(01)00019-3; Li BW, 2003, J NEUROPHYSIOL, V90, P204, DOI 10.1152/jn.00954.2002; McCormick DA, 1999, SCIENCE, V285, P541, DOI 10.1126/science.285.5427.541; NODA H, 1970, BRAIN RES, V18, P513, DOI 10.1016/0006-8993(70)90134-4; Petersen CCH, 2003, J NEUROSCI, V23, P1298, DOI 10.1523/JNEUROSCI.23-04-01298.2003; Scherrer J, 1976, Prog Brain Res, V45, P309, DOI 10.1016/S0079-6123(08)60996-6; Shoham D, 1999, NEURON, V24, P791, DOI 10.1016/S0896-6273(00)81027-2; SOFTKY WR, 1993, J NEUROSCI, V13, P334; SOMERS DC, 1995, J NEUROSCI, V15, P5448; Sur M, 1999, J NEUROBIOL, V41, P33, DOI 10.1002/(SICI)1097-4695(199910)41:1<33::AID-NEU6>3.0.CO;2-1; Thompson I, 1997, CURR BIOL, V7, pR324, DOI 10.1016/S0960-9822(06)00150-3; Tsodyks M, 1999, SCIENCE, V286, P1943, DOI 10.1126/science.286.5446.1943; Wang G, 2003, NEUROSCI LETT, V338, P77, DOI 10.1016/S0304-3940(02)01355-1	30	617	622	3	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	2003	425	6961					954	956		10.1038/nature02078	http://dx.doi.org/10.1038/nature02078			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14586468				2022-12-28	WOS:000186230600040
J	Witmer, LM; Chatterjee, S; Franzosa, J; Rowe, T				Witmer, LM; Chatterjee, S; Franzosa, J; Rowe, T			Neuroanatomy of flying reptiles and implications for flight, posture and behaviour	NATURE			English	Article							PIGEONS	Comparison of birds and pterosaurs, the two archosaurian flyers, sheds light on adaptation to an aerial lifestyle. The neurological basis of control holds particular interest in that flight demands on sensory integration, equilibrium, and muscular coordination are acute(1-8). Here we compare the brain and vestibular apparatus in two pterosaurs based on high-resolution computed tomographic (CT) scans from which we constructed digital endocasts. Although general neural organization resembles birds, pterosaurs had smaller brains relative to body mass than do birds. This difference probably has more to do with phylogeny than flight, in that birds evolved from nonavian theropods that had already established trends for greater encephalization(5,9). Orientation of the osseous labyrinth relative to the long axis of the skull was different in these two pterosaur species, suggesting very different head postures and reflecting differing behaviours. Their enlarged semicircular canals reflect a highly refined organ of equilibrium, which is concordant with pterosaurs being visually based, aerial predators. Their enormous cerebellar floccular lobes may suggest neural integration of extensive sensory information from the wing, further enhancing eye- and neck-based reflex mechanisms for stabilizing gaze.	Ohio Univ, Coll Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA; Texas Tech Univ Museum, Lubbock, TX 79409 USA; Univ Texas, Jackson Sch Geosci, Austin, TX 78712 USA	University System of Ohio; Ohio University; Texas Tech University System; Texas Tech University; University of Texas System; University of Texas Austin	Witmer, LM (corresponding author), Ohio Univ, Coll Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA.	witmerL@ohio.edu						Bennett S. Christopher, 2001, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V260, P1; BLANKS RHI, 1972, AM J PHYSIOL, V223, P55, DOI 10.1152/ajplegacy.1972.223.1.55; Brochu CA, 2001, J PALEONTOL, V75, P1185, DOI 10.1666/0022-3360(2001)075<1185:PAFDIA>2.0.CO;2; BUTLER AB, 1996, COMP VERTEBRATE NEUR, P514; CHATTERJEE S, IN PRESS GEOL SOC AM; de Beer G. R., 1947, Proceedings of the Linnean Society of London, V159, P125; Duijm M., 1951, Proceedings of the Koninklijke Nederlandse Akademie van Wetenschappen, V54C, P202; Duijm M., 1951, P KONINKL NEDERL A C, V54, P260; Edinger T, 1941, AM J SCI, V239, P665, DOI 10.2475/ajs.239.9.665; EDINGER T, 1927, Z ANAT ENTWICKLUNGS, V82, P105; ERICHSEN JT, 1989, BRAIN BEHAV EVOLUT, V33, P268, DOI 10.1159/000115935; Hopson J.A., 1979, P39; HURLBURT GR, 1996, THESIS U TORONTO, P250; Jerison H.J., 1973, EVOLUTION BRAIN INTE, P482; JONES GM, 1963, PROC R SOC SER B-BIO, V157, P403, DOI 10.1098/rspb.1963.0019; Kellner Alexander Wilhelm Armin, 1996, American Museum Novitates, V3175, P1; Kellner AWA, 2000, NATL SCI MUSEUM MONO, V17, P1, DOI 10.1159/000061634; Larsson HCE, 2000, J VERTEBR PALEONTOL, V20, P615, DOI 10.1671/0272-4634(2000)020[0615:FEANTD]2.0.CO;2; LEBEDKIN S, 1924, ANAT ANZEIGER, V58, P447; Newton E.T., 1888, PHILOS T R SOC B, V179, P503; Proctor N. S., 1993, MANUAL ORNITHOLOGY A, V340; Romer A.S, 1956, OSTEOLOGY REPTILES; Spoor F, 2002, NATURE, V417, P163, DOI 10.1038/417163a; Spoor F, 1998, YEARB PHYS ANTHROPOL, V41, P211; Tischlinger H., 2002, ARCHAEOPTERYX, V20, P1; TURKEWITSCH B. G., 1934, ZEITSCHR ANAT U ENTWICKLUNGSGESCH, V103, P551, DOI 10.1007/BF02118934; Unwin David M., 2000, Mitteilungen aus dem Museum fuer Naturkunde in Berlin Geowissenschaftliche Reihe, V3, P181; Wellnhofer P., 1975, PALAONTOGRAPHICA A, V148, P1; Wellnhofer P., 1991, ILLUSTRATED ENCY PTE, P192; WHARTON DS, 2002, THESIS U BRISTOL, P343; Winship IR, 2003, J COMP NEUROL, V456, P127, DOI 10.1002/cne.10507	31	197	204	2	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	2003	425	6961					950	953		10.1038/nature02048	http://dx.doi.org/10.1038/nature02048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14586467	Green Published			2022-12-28	WOS:000186230600039
J	Fehr, E; Fischbacher, U				Fehr, E; Fischbacher, U			The nature of human altruism	NATURE			English	Review							INDIRECT RECIPROCITY; GROUP SELECTION; EVOLUTION; COOPERATION; FAIRNESS; PEOPLE; TRUST; ENFORCEMENT; PREFERENCES; PUNISHMENT	Some of the most fundamental questions concerning our evolutionary origins, our social relations, and the organization of society are centred around issues of altruism and selfishness. Experimental evidence indicates that human altruism is a powerful force and is unique in the animal world. However, there is much individual heterogeneity and the interaction between altruists and selfish individuals is vital to human cooperation. Depending on the environment, a minority of altruists can force a majority of selfish individuals to cooperate or, conversely, a few egoists can induce a large number of altruists to defect. Current gene-based evolutionary theories cannot explain important patterns of human altruism, pointing towards the importance of both theories of cultural evolution as well as gene-culture co-evolution.	Univ Zurich, Inst Empir Res Econ, Blumlisalpstr 10, CH-8006 Zurich, Switzerland	University of Zurich	Fehr, E (corresponding author), Univ Zurich, Inst Empir Res Econ, Blumlisalpstr 10, CH-8006 Zurich, Switzerland.	efehr@iew.unizh.ch	Fischbacher, Urs/H-2693-2014	Fischbacher, Urs/0000-0002-5115-8815				Alexander R., 1987, BIOL MORAL SYSTEMS; ANDREONI J, 1993, ECON J, V103, P570, DOI 10.2307/2234532; Andreoni J, 2002, ECONOMETRICA, V70, P737, DOI 10.1111/1468-0262.00302; AOKI K, 1982, EVOLUTION, V36, P832, DOI [10.2307/2407896, 10.1111/j.1558-5646.1982.tb05449.x]; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; BATSON DC, 1991, ALTRUISM QUESTION; Bendor J, 2001, AM J SOCIOL, V106, P1493, DOI 10.1086/321298; BERG J, 1995, GAME ECON BEHAV, V10, P122, DOI 10.1006/game.1995.1027; Bolton GE, 2000, AM ECON REV, V90, P166, DOI 10.1257/aer.90.1.166; BOLTON GE, 1995, GAME ECON BEHAV, V10, P95, DOI 10.1006/game.1995.1026; BORNSTEIN G, 1994, J EXP SOC PSYCHOL, V30, P52, DOI 10.1006/jesp.1994.1003; BOWLES S, IN PRESS J THEOR BIO; Boyd R, 2003, P NATL ACAD SCI USA, V100, P3531, DOI 10.1073/pnas.0630443100; BOYD R, 1988, J THEOR BIOL, V132, P337, DOI 10.1016/S0022-5193(88)80219-4; BOYD R, IN PRESS NATURE CULT; BROWN M, IN PRESS ECONOMETRIC; Buchan NR, 2002, AM J SOCIOL, V108, P168, DOI 10.1086/344546; Cameron LA, 1999, ECON INQ, V37, P47, DOI 10.1111/j.1465-7295.1999.tb01415.x; CHAUDHURI A, 2003, EVOLUTION CONVENTION; COSMIDES L, 1992, ADAPTED MIND; DALY M, 1988, SCIENCE, V242, P519, DOI 10.1126/science.3175672; DAWES RM, 1980, ANNU REV PSYCHOL, V31, P169, DOI 10.1146/annurev.ps.31.020180.001125; ENGELMANN D, 2002, 132 U ZUR I EMP RES; Falk A., 2001, ANN EC STAT, P111; Fehr E, 2002, NATURE, V415, P137, DOI 10.1038/415137a; Fehr E, 2002, HUM NATURE-INT BIOS, V13, P1, DOI 10.1007/s12110-002-1012-7; Fehr E, 2003, DAHL WS ENV, P55; Fehr E, 1999, Q J ECON, V114, P817, DOI 10.1162/003355399556151; FEHR E, 1993, Q J ECON, V108, P437, DOI 10.2307/2118338; Fehr E, 2002, SCHMOLLERS JB, V122, P519; FEHR E, IN PRESS EVOL HUM BE; FEHR F, 2002, 125 U ZUR I EMP RES; Fischbacher U, 2001, ECON LETT, V71, P397, DOI 10.1016/S0165-1765(01)00394-9; FORSYTHE R, 1994, GAME ECON BEHAV, V6, P347, DOI 10.1006/game.1994.1021; Gachter S, 2002, SCAND J ECON, V104, P1, DOI 10.1111/1467-9442.00269; Gintis H, 2003, J THEOR BIOL, V220, P407, DOI 10.1006/jtbi.2003.3104; Gintis H, 2001, J THEOR BIOL, V213, P103, DOI 10.1006/jtbi.2001.2406; Gintis H, 2000, J THEOR BIOL, V206, P169, DOI 10.1006/jtbi.2000.2111; Gurven M, 2000, EVOL HUM BEHAV, V21, P263, DOI 10.1016/S1090-5138(00)00032-5; GUTH W, 1982, J ECON BEHAV ORGAN, V3, P367, DOI 10.1016/0167-2681(82)90011-7; Hammerstein P, 2003, DAHL WS ENV, P1; HARBAUGH WT, 2000, CHILDRENS BARGAINING; HAUSER MD, IN PRESS P R SOC L B; Hayashi N, 1999, RATION SOC, V11, P27, DOI 10.1177/104346399011001002; Henrich J, 2001, AM ECON REV, V91, P73, DOI 10.1257/aer.91.2.73; Henrich J, 2001, J THEOR BIOL, V208, P79, DOI 10.1006/jtbi.2000.2202; Hill K, 2002, HUM NATURE-INT BIOS, V13, P105, DOI 10.1007/s12110-002-1016-3; HOFFMAN E, 1994, GAME ECON BEHAV, V7, P346, DOI 10.1006/game.1994.1056; ISAAC RM, 1988, Q J ECON, V103, P179, DOI 10.2307/1882648; JORGENSEN JG, 1980, INDIANS COMP ENV LAN; Kaplan H, 2000, EVOL ANTHROPOL, V9, P156, DOI 10.1002/1520-6505(2000)9:4<156::AID-EVAN5>3.0.CO;2-7; Kelly Raymond C., 1985, NUER CONQUEST STRUCT; Kiyonari T, 2000, EVOL HUM BEHAV, V21, P411, DOI 10.1016/S1090-5138(00)00055-6; Ledyard JO, 1995, HDB EXPT EC, P111, DOI DOI 10.3987/CONTENTS-12-85-7; Leimar O, 2001, P ROY SOC B-BIOL SCI, V268, P745, DOI 10.1098/rspb.2000.1573; Levine DK, 1998, REV ECON DYNAM, V1, P593; LONG JC, 1986, GENETICS, V112, P629; Messick D., 1983, REV PERSONALITY SOCI; Milinski M, 2002, NATURE, V415, P424, DOI 10.1038/415424a; Milinski M, 2001, P ROY SOC B-BIOL SCI, V268, P2495, DOI 10.1098/rspb.2001.1809; Nowak MA, 2000, SCIENCE, V289, P1773, DOI 10.1126/science.289.5485.1773; Nowak MA, 1998, NATURE, V393, P573, DOI 10.1038/31225; OSTROM E, 1992, AM POLIT SCI REV, V86, P404, DOI 10.2307/1964229; Otterbein KF., 1985, EVOLUTION WAR CROSS, V2nd edn; RABIN M, 1993, AM ECON REV, V83, P1281; Rilling JK, 2002, NEURON, V35, P395, DOI 10.1016/S0896-6273(02)00755-9; ROTH AE, 1991, AM ECON REV, V81, P1068; Schotter A, 2003, AM ECON REV, V93, P196, DOI 10.1257/000282803321947047; Sethi R, 1996, AM ECON REV, V86, P766; SILK JB, 1980, AM ANTHROPOL, V82, P799, DOI 10.1525/aa.1980.82.4.02a00050; Slonim R, 1998, ECONOMETRICA, V66, P569, DOI 10.2307/2998575; Smith EA, 2003, BEHAV ECOL, V14, P116, DOI 10.1093/beheco/14.1.116; Sober E., 1998, OTHERS EVOLUTION PSY; SOLTIS J, 1995, CURR ANTHROPOL, V36, P473, DOI 10.1086/204381; Stephens DW, 2002, SCIENCE, V298, P2216, DOI 10.1126/science.1078498; Thibaut J., 1959, SOCIAL PSYCHOL GROUP; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; Wedekind C, 2000, SCIENCE, V288, P850, DOI 10.1126/science.288.5467.850; Williams G. C., 1966, P307; YAMAGISHI T, 1986, J PERS SOC PSYCHOL, V51, P110, DOI 10.1037/0022-3514.51.1.110; ZAHAVI A, 1995, J AVIAN BIOL, V26, P1, DOI 10.2307/3677205	81	1892	1949	27	1147	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 23	2003	425	6960					785	791		10.1038/nature02043	http://dx.doi.org/10.1038/nature02043			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	735ME	14574401				2022-12-28	WOS:000186118500034
J	Meyerhardt, JA; Catalano, PJ; Schrag, D; Ayanian, JZ; Haller, DG; Mayer, RJ; Macdonald, JS; Benson, AB; Fuchs, CS				Meyerhardt, JA; Catalano, PJ; Schrag, D; Ayanian, JZ; Haller, DG; Mayer, RJ; Macdonald, JS; Benson, AB; Fuchs, CS			Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY IMPROVEMENT PROGRAM; 8 COMMON OPERATIONS; SURGICAL VOLUME; COLORECTAL-CANCER; BREAST-CANCER; MORTALITY; COMORBIDITY; SURVIVAL; IMPACT; OLDER	Background: Studies that use registry data have demonstrated superior long-term overall survival after curative surgical resection of colon cancer at hospitals where the volume of such surgeries is high. However, because such administrative data lack information on cancer recurrence, the true nature of this relation remains uncertain. Objective: To determine whether hospital procedure volume predicts long-term outcomes of colon cancer surgery. Design: Nested cohort study within a randomized clinical trial. Setting: Intergroup 0089 national adjuvant colon cancer study conducted between 1988 and 1992. Patients: 3161 patients with high-risk stage II and stage III colon cancer. Measurements: overall survival and recurrence-free survival, by hospital procedure volume as defined by Medicare claims data. Results: With a median follow-up of 9.4 years, 5-year overall survival significantly differed across tertiles of hospital procedure volume (63.8% for patients who had resection at low-volume hospitals compared with 67.3% at high-volume hospitals; P = 0.04). After adjustment for other predictors of colon cancer outcome, the hazard ratio for overall mortality in patients treated at low-volume centers was 1.16 (95% Cl, 1.03 to 1.32). However, the risk for cancer recurrence was not associated with hospital procedure volume. Five-year recurrence-free survival was 63.9% for patients who had resection at low-volume hospitals compared with 63.0% at high-volume hospitals (adjusted hazard ratio, 1.03 [Cl, 0.89 to 1.18]). These findings did not materially change after stratification by other potential demographic and clinical predictors of outcome. Conclusions: According to prospectively recorded data from a large clinical trial, patients whose colon cancer was resected at low-volume hospitals experienced a higher risk for long-term mortality; however, this increased mortality was not attributable to differences in colon cancer recurrences.	Dana Farber Canc Inst, Eastern Cooperat Oncol Grp Stat Ctr, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; St Vincent Clin Canc Ctr, New York, NY USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; Northwestern Univ, Chicago, IL 60611 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Northwestern University	Meyerhardt, JA (corresponding author), Dana Farber Canc Inst, Eastern Cooperat Oncol Grp Stat Ctr, 44 Binney St, Boston, MA 02115 USA.			Schrag, Deborah/0000-0002-4334-5717	NCI NIH HHS [1K07CA097992-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K07CA097992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bach PB, 2001, NEW ENGL J MED, V345, P181, DOI 10.1056/NEJM200107193450306; Begg CB, 1998, JAMA-J AM MED ASSOC, V280, P1747, DOI 10.1001/jama.280.20.1747; Birkmeyer JD, 1999, SURGERY, V126, P178, DOI 10.1016/S0039-6060(99)70152-2; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Brennan MF, 1999, ANN SURG, V230, P411; COX DR, 1972, J R STAT SOC B, V34, P187; Dardik A, 1998, J VASC SURG, V28, P413, DOI 10.1016/S0741-5214(98)70126-0; *E COOP ONC GROUP, E COOP ONC GROUP PER; Epstein AM, 2002, NEW ENGL J MED, V346, P1161, DOI 10.1056/NEJM200204113461512; Extermann M, 2000, EUR J CANCER, V36, P453, DOI 10.1016/S0959-8049(99)00319-6; Extermann M, 2000, CRIT REV ONCOL HEMAT, V35, P181, DOI 10.1016/S1040-8428(00)00090-1; HALLER DG, 1998, P AM SOC CLIN ONC; HALLER DG, 1997, P AM SOC CLIN ONC; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; Harmon JW, 1999, ANN SURG, V230, P404, DOI 10.1097/00000658-199909000-00013; Hillner BE, 2000, J CLIN ONCOL, V18, P2327, DOI 10.1200/JCO.2000.18.11.2327; Hodgson DC, 2001, JNCI-J NATL CANCER I, V93, P501, DOI 10.1093/jnci/93.7.501; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kee F, 1999, BRIT MED J, V318, P1381, DOI 10.1136/bmj.318.7195.1381; KELLY JV, 1986, MED CARE, V24, P785, DOI 10.1097/00005650-198609000-00001; Khuri SF, 1999, ANN SURG, V230, P429; Khuri SF, 1999, ANN SURG, V230, P414, DOI 10.1097/00000658-199909000-00014; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; McCollum AD, 2002, JNCI-J NATL CANCER I, V94, P1160; Meyerkardt JA, 2003, J CLIN ONCOL, V21, P433, DOI 10.1200/JCO.2003.07.125; Robison JG, 1998, J VASC SURG, V28, P420; Roohan PJ, 1998, AM J PUBLIC HEALTH, V88, P454, DOI 10.2105/AJPH.88.3.454; Schrag D, 2000, JAMA-J AM MED ASSOC, V284, P3028, DOI 10.1001/jama.284.23.3028; Sosa JA, 1998, ANN SURG, V228, P429, DOI 10.1097/00000658-199809000-00016; Yancik R, 1998, CANCER, V82, P2123, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2123::AID-CNCR6>3.0.CO;2-W; Yancik R, 2001, JAMA-J AM MED ASSOC, V285, P885, DOI 10.1001/jama.285.7.885; Yao SL, 1999, J NATL CANCER I, V91, P1950, DOI 10.1093/jnci/91.22.1950	33	94	96	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 21	2003	139	8					649	657		10.7326/0003-4819-139-8-200310210-00008	http://dx.doi.org/10.7326/0003-4819-139-8-200310210-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734DW	14568853				2022-12-28	WOS:000186040800003
J	Jansen, R; Yu, HY; Greenbaum, D; Kluger, Y; Krogan, NJ; Chung, SB; Emili, A; Snyder, M; Greenblatt, JF; Gerstein, M				Jansen, R; Yu, HY; Greenbaum, D; Kluger, Y; Krogan, NJ; Chung, SB; Emili, A; Snyder, M; Greenblatt, JF; Gerstein, M			A Bayesian networks approach for predicting protein-protein interactions from genomic data	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; EXPRESSION DATA; COMPLEXES; POB3; TOOL; DNA	We have developed an approach using Bayesian networks to predict protein-protein interactions genome-wide in yeast. Our method naturally weights and combines into reliable predictions genomic features only weakly associated with interaction (e.g., messenger RNA coexpression, coessentiality, and colocalization). In addition to de novo predictions, it can integrate often noisy, experimental interaction data sets. We observe that at given levels of sensitivity, our predictions are more accurate than the existing high-throughput experimental data sets. We validate our predictions with TAP (tandem affinity purification) tagging experiments. Our analysis, which gives a comprehensive view of yeast interactions, is available at genecensus.org/intint.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Comp Sci, New Haven, CT 06520 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Res, Toronto, ON M5G 1L6, Canada	Yale University; Yale University; Yale University; University of Toronto; University of Toronto	Gerstein, M (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 266 Whitney Ave,POB 208114, New Haven, CT 06520 USA.	mark.gerstein@yale.edu	Greenbaum, Dov/ABG-8539-2021	Greenbaum, Dov/0000-0003-4440-3090; Snyder, Michael/0000-0003-0784-7987				Anand M, 2003, J BIOL CHEM, V278, P6985, DOI 10.1074/jbc.M209224200; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bader GD, 2002, NAT BIOTECHNOL, V20, P991, DOI 10.1038/nbt1002-991; Bader GD, 2001, NUCLEIC ACIDS RES, V29, P242, DOI 10.1093/nar/29.1.242; Bash RC, 2001, J BIOL CHEM, V276, P861, DOI 10.1074/jbc.M007070200; Brewster NK, 2001, MOL CELL BIOL, V21, P3491, DOI 10.1128/MCB.21.10.3491-3502.2001; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Deane CM, 2002, MOL CELL PROTEOMICS, V1, P349, DOI 10.1074/mcp.M100037-MCP200; Drawid A, 2000, J MOL BIOL, V301, P1059, DOI 10.1006/jmbi.2000.3968; Edwards AM, 2002, TRENDS GENET, V18, P529, DOI 10.1016/S0168-9525(02)02763-4; Formosa T, 2002, GENETICS, V162, P1557; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jansen R, 2002, GENOME RES, V12, P37, DOI 10.1101/gr.205602; Jansen Ronald, 2002, Journal of Structural and Functional Genomics, V2, P71, DOI 10.1023/A:1020495201615; Kovalchuke O, 1998, EUR J BIOCHEM, V258, P986, DOI 10.1046/j.1432-1327.1998.2580986.x; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; Kumar A, 2002, NATURE, V415, P123, DOI 10.1038/415123a; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Steffen M, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-34; Travers AA, 2003, EMBO REP, V4, P131, DOI 10.1038/sj.embor.embor741; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Xenarios I, 2002, NUCLEIC ACIDS RES, V30, P303, DOI 10.1093/nar/30.1.303; Yu YX, 2003, MOL CELL BIOL, V23, P1910, DOI 10.1128/MCB.23.6.1910-1921.2003	30	942	990	5	153	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 17	2003	302	5644					449	453		10.1126/science.1087361	http://dx.doi.org/10.1126/science.1087361			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564010	Green Submitted			2022-12-28	WOS:000185963200044
J	Schwarz, DS; Hutvagner, G; Du, T; Xu, ZS; Aronin, N; Zamore, PD				Schwarz, DS; Hutvagner, G; Du, T; Xu, ZS; Aronin, N; Zamore, PD			Asymmetry in the assembly of the RNAi enzyme complex	CELL			English	Article							DOUBLE-STRANDED-RNA; SHORT-INTERFERING RNAS; MESSENGER-RNA; GENE-EXPRESSION; HAIRPIN RNAS; C-ELEGANS; DROSOPHILA; SIRNAS; DICER; MICRORNAS	A key step in RNA interference (RNAi) is assembly of the RISC, the protein-siRNA complex that mediates target RNA cleavage. Here, we show that the two strands of an siRNA duplex are not equally eligible for assembly into RISC. Rather, both the absolute and relative stabilities of the base pairs at the 5' ends of the two siRNA strands determine the degree to which each strand participates in the RNAi pathway. siRNA duplexes can be functionally asymmetric, with only one of the two strands able to trigger RNAi. Asymmetry is the hallmark of a related class of small, single-stranded, noncoding RNAs, microRNAs (miRNAs). We suggest that single-stranded miRNAs are initially generated as siRNA-like duplexes whose structures predestine one strand to enter the RISC and the other strand to be destroyed. Thus, the common step of RISC assembly is an unexpected source of asymmetry for both siRNA function and miRNA biogenesis.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Zamore, PD (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA.	phillip.zamore@umassmed.edu	Zamore, Phillip D/A-8941-2013	Zamore, Phillip/0000-0002-4505-9618; Hutvagner, Gyorgy/0000-0002-7231-9446	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062862, R01GM065236, R37GM062862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038194, R21NS044952] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62862-01, GM65236-01] Funding Source: Medline; NINDS NIH HHS [R01 NS38194, R21 NS44952-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amarzguioui M, 2003, NUCLEIC ACIDS RES, V31, P589, DOI 10.1093/nar/gkg147; Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803; Aravin AA, 2003, DEV CELL, V5, P337, DOI 10.1016/S1534-5807(03)00228-4; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Billy E, 2001, P NATL ACAD SCI USA, V98, P14428, DOI 10.1073/pnas.261562698; Boutla A, 2001, CURR BIOL, V11, P1776, DOI 10.1016/S0960-9822(01)00541-3; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Catalanotto C, 2002, GENE DEV, V16, P790, DOI 10.1101/gad.222402; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; Chiu YL, 2003, RNA, V9, P1034, DOI 10.1261/rna.5103703; Chiu YL, 2002, MOL CELL, V10, P549, DOI 10.1016/S1097-2765(02)00652-4; Crow JP, 1997, J NEUROCHEM, V69, P1936; Dalmay T, 2001, EMBO J, V20, P2069, DOI 10.1093/emboj/20.8.2069; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Doi N, 2003, CURR BIOL, V13, P41, DOI 10.1016/S0960-9822(02)01394-5; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Haley B, 2003, METHODS, V30, P330, DOI 10.1016/S1046-2023(03)00052-5; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kennerdell JR, 2002, GENE DEV, V16, P1884, DOI 10.1101/gad.990802; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE SK, 1993, LAND DEGRAD REHABIL, V4, P1, DOI 10.1002/ldr.3400040102; Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; Mallory AC, 2002, P NATL ACAD SCI USA, V99, P15228, DOI 10.1073/pnas.232434999; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; McManus MT, 2002, RNA, V8, P842, DOI 10.1017/S1355838202024032; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Myers JW, 2003, NAT BIOTECHNOL, V21, P324, DOI 10.1038/nbt792; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Park W, 2002, CURR BIOL, V12, P1484, DOI 10.1016/S0960-9822(02)01017-5; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Schwarz DS, 2002, MOL CELL, V10, P537, DOI 10.1016/S1097-2765(02)00651-2; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; Tijsterman M, 2002, SCIENCE, V295, P694, DOI 10.1126/science.1067534; TURNER DH, 1987, J AM CHEM SOC, V109, P3783, DOI 10.1021/ja00246a047; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Wu-Scharf D, 2000, SCIENCE, V290, P1159, DOI 10.1126/science.290.5494.1159; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100; Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582; ZUKER M, 2003, NUCLEIC ACIDS RES, V31, P1	71	1986	2317	5	272	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	2003	115	2					199	208		10.1016/S0092-8674(03)00759-1	http://dx.doi.org/10.1016/S0092-8674(03)00759-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567917	Bronze			2022-12-28	WOS:000186039200011
J	Ghaemmaghami, S; Huh, W; Bower, K; Howson, RW; Belle, A; Dephoure, N; O'Shea, EK; Weissman, JS				Ghaemmaghami, S; Huh, W; Bower, K; Howson, RW; Belle, A; Dephoure, N; O'Shea, EK; Weissman, JS			Global analysis of protein expression in yeast	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; GENE DELETION; GENOME; IDENTIFICATION; ORGANIZATION	The availability of complete genomic sequences and technologies that allow comprehensive analysis of global expression profiles of messenger RNA(1-3) have greatly expanded our ability to monitor the internal state of a cell. Yet biological systems ultimately need to be explained in terms of the activity, regulation and modification of proteins-and the ubiquitous occurrence of posttranscriptional regulation makes mRNA an imperfect proxy for such information. To facilitate global protein analyses, we have created a Saccharomyces cerevisiae fusion library where each open reading frame is tagged with a high-affinity epitope and expressed from its natural chromosomal location. Through immunodetection of the common tag, we obtain a census of proteins expressed during log-phase growth and measurements of their absolute levels. We find that about 80% of the proteome is expressed during normal growth conditions, and, using additional sequence information, we systematically identify misannotated genes. The abundance of proteins ranges from fewer than 50 to more than 10(6) molecules per cell. Many of these molecules, including essential proteins and most transcription factors, are present at levels that are not readily detectable by other proteomic techniques nor predictable by mRNA levels or codon bias measurements.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weissman, JS (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	jsw1@itsa.ucsf.edu	Dephoure, Noah/N-7818-2014; Huh, Won-Ki/AAQ-6767-2021	Dephoure, Noah/0000-0001-5802-2657; Weissman, Jonathan/0000-0003-2445-670X; Ghaemmaghami, Sina/0000-0002-8696-2950				Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Bergmann S, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.031902; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; Das S, 1997, NATURE, V385, P29, DOI 10.1038/385029a0; Futcher B, 1999, MOL CELL BIOL, V19, P7357; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Goffeau A, 2000, FEBS LETT, V480, P37, DOI 10.1016/S0014-5793(00)01775-0; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; GRANTHAM R, 1980, NUCLEIC ACIDS RES, V8, P1893, DOI 10.1093/nar/8.9.1893; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Harrison PM, 2002, NUCLEIC ACIDS RES, V30, P1083, DOI 10.1093/nar/30.5.1083; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Ihmels J, 2002, NAT GENET, V31, P370, DOI 10.1038/ng941; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Kowalczuk M, 1999, YEAST, V15, P1031, DOI 10.1002/(SICI)1097-0061(199908)15:11<1031::AID-YEA431>3.0.CO;2-G; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Washburn MP, 2003, P NATL ACAD SCI USA, V100, P3107, DOI 10.1073/pnas.0634629100; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zhang CT, 2000, NUCLEIC ACIDS RES, V28, P2804, DOI 10.1093/nar/28.14.2804	29	2872	6775	9	586	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	2003	425	6959					737	741		10.1038/nature02046	http://dx.doi.org/10.1038/nature02046			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562106				2022-12-28	WOS:000185924500046
J	Jones, JM; Datta, P; Srinivasula, SM; Ji, WZ; Gupta, S; Zhang, ZJ; Davies, E; Hajnoczky, G; Saunders, TL; Van Keuren, ML; Fernandes-Alnemri, T; Meisler, MH; Alnemri, ES				Jones, JM; Datta, P; Srinivasula, SM; Ji, WZ; Gupta, S; Zhang, ZJ; Davies, E; Hajnoczky, G; Saunders, TL; Van Keuren, ML; Fernandes-Alnemri, T; Meisler, MH; Alnemri, ES			Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice	NATURE			English	Article							APOPTOSIS-INDUCING FACTOR; SERINE-PROTEASE; REGULATES APOPTOSIS; CASPASE ACTIVITY; CHROMOSOME 2P13; CELL-DEATH; INHIBITOR; OMI/HTRA2; SEQUENCE; XIAP	The mouse mutant mnd2 (motor neuron degeneration 2) exhibits muscle wasting, neurodegeneration, involution of the spleen and thymus, and death by 40 days of age(1,2). Degeneration of striatal neurons, with astrogliosis and microglia activation, begins at around 3 weeks of age, and other neurons are affected at later stages'. Here we have identified the mnd2 mutation as the missense mutation Ser276Cys in the protease domain of the nuclear-encoded mitochondrial serine protease Omi (also known as HtrA2 or Prss25). Protease activity of Omi is greatly reduced in tissues of mnd2 mice but is restored in mice rescued by a bacterial artificial chromosome transgene containing the wildtype Omi gene. Deletion of the PDZ domain partially restores protease activity to the inactive recombinant Omi protein carrying the Ser276Cys mutation, suggesting that the mutation impairs substrate access or binding to the active site pocket. Loss of Omi protease activity increases the susceptibility of mitochondria to induction of the permeability transition, and increases the sensitivity of mouse embryonic fibroblasts to stress-induced cell death. The neurodegeneration and juvenile lethality in mnd2 mice result from this defect in mitochondrial Omi protease.	Thomas Jefferson Univ Hosp, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ Hosp, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ Hosp, Dept Pathol & Cell Biol, Philadelphia, PA 19107 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Div Med & Mol Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Biomed Res Core Facil, Transgen Anim Model Core, Ann Arbor, MI 48109 USA	Jefferson University; Jefferson University; Jefferson University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Alnemri, ES (corresponding author), Thomas Jefferson Univ Hosp, Ctr Apoptosis Res, Philadelphia, PA 19107 USA.		Gupta, Sanjeev/AAG-9749-2020; gupta, sanjeev/B-2824-2008; Alnemri, Emad S/B-4526-2010	Gupta, Sanjeev/0000-0002-4691-6853; gupta, sanjeev/0000-0002-4691-6853; Saunders, Thom/0000-0003-2015-101X				Brustovetsky N, 2003, J NEUROSCI, V23, P4858; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Jang KH, 1996, J MICROBIOL BIOTECHN, V6, P36; Jang W, 1999, GENOME RES, V9, P53; Jang W, 1997, BIOCHEM BIOPH RES CO, V231, P344, DOI 10.1006/bbrc.1997.6095; Jang WH, 1997, GENOMICS, V40, P506, DOI 10.1006/geno.1996.4593; Ji WZ, 2001, MAMM GENOME, V12, P456, DOI 10.1007/s003350020032; JONES JM, 1993, GENOMICS, V16, P669, DOI 10.1006/geno.1993.1246; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Maurizi MR, 2002, NAT STRUCT BIOL, V9, P410, DOI 10.1038/nsb0602-410; Rathke-Hartlieb S, 2002, EXP NEUROL, V175, P87, DOI 10.1006/exnr.2002.7868; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Van Dyck L, 1999, CELL MOL LIFE SCI, V56, P825, DOI 10.1007/s000180050029; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Walsh NP, 2003, CELL, V113, P61, DOI 10.1016/S0092-8674(03)00203-4; Weber JS, 1998, GENOMICS, V54, P107, DOI 10.1006/geno.1998.5496; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903	29	297	309	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					721	727		10.1038/nature02052	http://dx.doi.org/10.1038/nature02052			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14534547	Green Published			2022-12-28	WOS:000185924500043
J	de Waal, A; Whiteside, A				de Waal, A; Whiteside, A			New variant famine: AIDS and food crisis in southern Africa	LANCET			English	Article							MORTALITY	Southern Africa is undergoing a food crisis of surprising scale and novelty. The familiar culprits of drought and mismanagement of national strategies are implicated. However, this crisis is distinct from conventional drought-induced food shortages with respect to those vulnerable to starvation, and the course of impoverishment and recovery. We propose that these new aspects to the food crisis can be attributed largely to the HIV/AIDS epidemic in the region. We present evidence that we are facing a new variant famine. We have used frameworks drawn from famine theory to examine the implications. HIV/AIDS has created a new category of highly vulnerable households-namely, those with Ill adults or those whose adults have died. The general burden of care in both AIDS-affected and non-AIDS-affected households has reduced the viability of farming livelihoods. The sensitivity of rural communities to external shocks such as drought has increased, and their resilience has declined. The prospects for a sharp decline into severe famine are increased, and possibilities for recovery reduced.	Univ Natal, Hlth Econ & HIV AIDS Res Div, ZA-4041 Durban, South Africa; UN Econ Commiss Africa, Commiss HIV AIDS & Governance Africa, Addis Ababa, Ethiopia	University of Kwazulu Natal; UN Economic Commission for Africa (UNECA)	Whiteside, A (corresponding author), Univ Natal, Hlth Econ & HIV AIDS Res Div, ZA-4041 Durban, South Africa.							[Anonymous], 1992, AIDS AFRICA; Barnett T., 2002, AIDS 21 CENTURY DIS; Baylies C, 2002, DEV CHANGE, V33, P611, DOI 10.1111/1467-7660.00272; CALDWELL JC, 1977, DROUGHT AFRICA, V2; Coutsoudis A, 1999, LANCET, V354, P471, DOI 10.1016/S0140-6736(99)01101-0; DAVIES S, 1995, ADAPTABLE LIVELIHOOD; de Waal A., 1989, FAMINE KILLS DARFUR; DEVEREUX S, 2002, IDS B, V33, P88; DEWAAL A, 1990, DEV CHANGE, V21, P469, DOI 10.1111/j.1467-7660.1990.tb00384.x; DEWAAL A, 1989, POP STUD-J DEMOG, V43, P5, DOI 10.1080/0032472031000143826; Dyson T., 2002, FAMINE DEMOGRAPHY PE; Eldridge C, 2002, IDS BULL-I DEV STUD, V33, P79, DOI 10.1111/j.1759-5436.2002.tb00047.x; HADDAD L, 2001, 112 INT FOOD POL RES; KWARAMBA P, 1998, 19 EC ADV PROJ; Macintyre Kate, 2002, FAMINE DEMOGRAPHY PE; ROSEN S, 2002, SHIFTING BURDEN HIV; Rugalema G., 2000, Review of African Political Economy, P537, DOI 10.1080/03056240008704488; *SAV CHILDR FUND, 2002, HARARE           MAR; Semba RD, 1999, BRIT J NUTR, V81, P181, DOI 10.1017/S0007114599000379; Sen A., 1983, POVERTY FAMINES ESSA; *SO AFR DEV COMM, 2003, UNPUB VULN ASS COMM; STANECKI K, 2003, M EMP EV DEM SOC IMP; SWIFT J, 1993, IDS BULL-I DEV STUD, V24, P1, DOI 10.1111/j.1759-5436.1993.mp24004001.x; *UN ADM COMM COORD, 1998, SCN NEWS, V17, P3; *UNICEF USAID UNAI, 2002, CHILDR BRINK 2002 JO; WATKINS SC, 1985, POPUL DEV REV, V11, P647, DOI 10.2307/1973458; WEBB D, 1999, SAFAIDS NEWS; World Development Movement, 2002, STRUCT DAM CAUS CONS	28	212	214	0	39	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 11	2003	362	9391					1234	1237		10.1016/S0140-6736(03)14548-5	http://dx.doi.org/10.1016/S0140-6736(03)14548-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732CW	14568749				2022-12-28	WOS:000185924100028
J	Peggs, KS; Verfuerth, S; Pizzey, A; Khan, N; Guiver, M; Moss, PA; Mackinnon, S				Peggs, KS; Verfuerth, S; Pizzey, A; Khan, N; Guiver, M; Moss, PA; Mackinnon, S			Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines	LANCET			English	Article							DENDRITIC CELLS; RECONSTITUTION; ANTIGEN	Adoptive transfer of CMV-specific T cells offers the potential for reconstitution of viral immunity after allogeneic transplantation. However, the logistics of producing virus-specific T-cell clones has limited the application of cellular therapies. We treated 16 patients for CMV infection with polyclonal CMV-specific T-cell lines generated by short-term culture. Massive in-vivo expansions of CMV-specific cytotoxic T lymphocytes were observed, resulting in reconstitution of viral immunity. In eight cases antiviral drugs were not required, and subsequent episodes of reactivation occurred in only two patients. Our findings indicate that application of CMV-specific cell lines is both feasible and effective in a clinical environment.	UCL Royal Free & UCL Med Sch, Dept Haematol, London WC1E 6HX, England; Univ Birmingham, CR UK Inst Canc Studies, Birmingham, W Midlands, England; Publ Hlth Lab Serv, Dept Virol, Manchester, Lancs, England	University of London; University College London; University of Birmingham	Peggs, KS (corresponding author), UCL Royal Free & UCL Med Sch, Dept Haematol, London WC1E 6HX, England.	kpeggs@hotmail.com	Mackinnon, Stephen/C-5559-2008; Wilson, Matthew H/K-3193-2013; Moss, Paul/D-1728-2009; PEGGS, Karl/B-3869-2009; Pizzey, Arnold/E-6301-2015	Moss, Paul/0000-0002-6895-1967; Pizzey, Arnold/0000-0003-1850-1121				Chakrabarti S, 2002, BLOOD, V99, P4357, DOI 10.1182/blood.V99.12.4357; Cwynarski K, 2001, BLOOD, V97, P1232, DOI 10.1182/blood.V97.5.1232; Peggs K, 2002, BLOOD, V99, P213, DOI 10.1182/blood.V99.1.213; Peggs K, 2001, BLOOD, V97, P994, DOI 10.1182/blood.V97.4.994; RIDDELL SR, 1992, SCIENCE, V257, P238	5	377	388	2	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 25	2003	362	9393					1375	1377		10.1016/S0140-6736(03)14634-X	http://dx.doi.org/10.1016/S0140-6736(03)14634-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	735YX	14585640				2022-12-28	WOS:000186143300012
J	Sibbett, CH; Thompson, WT; Crawford, M; McKnight, A				Sibbett, CH; Thompson, WT; Crawford, M; McKnight, A			Evaluation of extended training for general practice in Northern Ireland: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							EDUCATION	Objective To evaluate participants' perceptions of the impact on them of an additional six months' training beyond the standard 12 month general practice vocational training scheme. Design Qualitative stud), rising focus groups. Setting General practice vocational training in Northern Ireland. Participants 13 general practitioner registrars, six of whom participated in the additional six months' training, and four trainers involved in the additional six months' training. Main outcome measures: Participants' views about their experiences in 18 month and 12 month courses. Results Participants reported that the 12 month course was generally positive but was too pressurised and focused on examinations, and also that it had a negative impact on self care. The nature of the learning and assessment was reported to have left participants feeling averse to further continuing education and lacking in confidence. In contrast, the extended six month component was reported to have restimulated learning by focusing more on patient care and promoting self directed learning. It developed confidence, promoted teamwork, and gave experience of two practice contexts, and was reported as valuable by both ex-registrars and trainers. However, both the 12 and 18 month courses left participants feeling under-prepared for practice management and self care. Conclusions 12 months' training in general practice does not provide doctors with the necessary competencies and confidence to enter independent practice. The extended period was reported to promote greater professional development, critical evaluation skills, and orientation to lifelong learning but does not fill all the gaps.	Queens Univ Belfast, Grad Sch Educ, Belfast BT7 1HL, Antrim, North Ireland; DPO Consultants, Belfast BT7 1LN, Antrim, North Ireland; No Ireland Council Postgrad Med & Dent Educ, Belfast BT7 3JH, Antrim, North Ireland	Queens University Belfast	Sibbett, CH (corresponding author), Queens Univ Belfast, Grad Sch Educ, Belfast BT7 1HL, Antrim, North Ireland.							BAHRAMI J, 1994, BRIT MED J, V309, P284, DOI 10.1136/bmj.309.6950.284; Cupples M. E., 2002, BMJ CAREER FOCUS, V324, pS139; Field S, 2000, BRIT MED J, V321, pS2; Glaser B.G., 1965, AWARENESS DYING; HARRISON J, 1998, BMJ S, V316, pS2; Johnson N, 1998, BRIT J GEN PRACT, V48, P1755; Lipman T, 2000, BRIT J GEN PRACT, V50, P743; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; MCKINSTRY B, 1999, EXT GP TRAIN YEAR EX; MILLAR RL, 2000, RES LIFE STORIES FAM; *ROYAL COLL GEN PR, 1966, EV COLL ROYAL COMM; Royal College of General Practitioners, 2000, PRIMARY CARE WORKFOR; Thompson WT, 2001, BRIT MED J, V323, P728, DOI 10.1136/bmj.323.7315.728; van Zwanenberg T, 2001, BRIT J GEN PRACT, V51, P349	14	24	24	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 25	2003	327	7421					971	973		10.1136/bmj.327.7421.971	http://dx.doi.org/10.1136/bmj.327.7421.971			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	736AL	14576250	Bronze, Green Published			2022-12-28	WOS:000186147800020
J	Fahnestock, M				Fahnestock, M			Glacial flow goes seismic	SCIENCE			English	Editorial Material							RADAR INTERFEROMETRY; GREENLAND		Univ New Hampshire, Inst Study Earth Oceans & Space, Durham, NH 03824 USA	University System Of New Hampshire; University of New Hampshire	Fahnestock, M (corresponding author), Univ New Hampshire, Inst Study Earth Oceans & Space, Durham, NH 03824 USA.		Fahnestock, Mark/N-2678-2013					Abdalati W, 2001, J GEOPHYS RES-ATMOS, V106, P33729, DOI 10.1029/2001JD900192; ANANDAKRISHNAN S, 1993, J GLACIOL, V39, P455, DOI 10.3189/S0022143000016348; Ekstrom G, 2003, SCIENCE, V302, P622, DOI 10.1126/science.1088057; Joughin I, 1996, SCIENCE, V274, P228, DOI 10.1126/science.274.5285.228; Mohr JJ, 1998, NATURE, V391, P273, DOI 10.1038/34635	5	6	6	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					578	579		10.1126/science.1091766	http://dx.doi.org/10.1126/science.1091766			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576409				2022-12-28	WOS:000186119900033
J	Yu, XC; Chini, CCS; He, M; Mer, G; Chen, JJ				Yu, XC; Chini, CCS; He, M; Mer, G; Chen, JJ			The BRCT domain is a phospho-protein binding domain	SCIENCE			English	Article							DNA-DAMAGE; CHECKPOINT; REPAIR; FHA	The carboxyl-terminal domain (BRCT) of the Breast Cancer Gene 1 (BRCA1) protein is an evolutionarily conserved module that exists in a large number of proteins from prokaryotes to eukaryotes. Although most BRCT domain-containing proteins participate in DNA-damage checkpoint or DNA-repair pathways, or both, the function of the BRCT domain is not fully understood. We show that the BRCA1 BRCT domain directly interacts with phosphorylated BRCA1-Associated Carboxyl-terminal Helicase (BACH1). This specific interaction between BRCA1 and phosphorylated BACH1 is cell cycle regulated and is required for DNA damage-induced checkpoint control during the transition from G(2) to M phase of the cell cycle. Further, we show that two other BRCT domains interact with their respective physiological partners in a phosphorylation-dependent manner. Thirteen additional BRCT domains also preferentially bind phospho-peptides rather than nonphosphorylated control peptides. These data imply that the BRCT domain is a phospho-protein binding domain involved in cell cycle control.	Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med Genet, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Chen, JJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA.		Mer, Georges/AAT-4946-2021	Mer, Georges/0000-0002-1900-1578	NATIONAL CANCER INSTITUTE [R01CA089239, R01CA092312] Funding Source: NIH RePORTER; NCI NIH HHS [CA92312, CA89239] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Chen YM, 1996, CANCER RES, V56, P3168; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; Taylor RM, 2000, MOL CELL BIOL, V20, P735, DOI 10.1128/MCB.20.2.735-740.2000; Tseng HM, 2002, J BIOL CHEM, V277, P45630, DOI 10.1074/jbc.M206861200; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zhao S, 2002, NUCLEIC ACIDS RES, V30, P4815, DOI 10.1093/nar/gkf612	15	659	670	3	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					639	642		10.1126/science.1088753	http://dx.doi.org/10.1126/science.1088753			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576433				2022-12-28	WOS:000186119900058
J	Amin, NMM; Khoshnaw, MQ				Amin, NMM; Khoshnaw, MQ			Medical education and training in Iraq	LANCET			English	Editorial Material									Univ Sulaimani, Sulaimani, Kurdistan Reg, Iraq; Minist Hlth, Kurdistan Reg Govt, Sulaimani, Iraq	University of Sulimanyah; Ministry of Health Iraq	Amin, NMM (corresponding author), Univ Sulaimani, Sulaimani, Kurdistan Reg, Iraq.								0	19	19	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 18	2003	362	9392					1326	1326						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14579817				2022-12-28	WOS:000186036900031
J	Braude, P; Rowell, P				Braude, P; Rowell, P			ABC of subfertility - Assisted conception. III - Problems with assisted conception	BRITISH MEDICAL JOURNAL			English	Review									Guys & St Thomass Assisted Concept Unit, London, England		Braude, P (corresponding author), Guys & St Thomass Assisted Concept Unit, London, England.							Balen A. H., 1997, INFERTILITY PRACTICE; Meniru G. I., 1997, HDB INTRAUTERINE INS; Mortimer D., 1994, PRACTICAL LAB ANDROL; *ROYAL COLL OBST G, 1998, EV BAS GUID IN INV M; TEMPLETON A, 2000, MANAGEMENT INFERT MR	5	7	8	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 18	2003	327	7420					920	923		10.1136/bmj.327.7420.920	http://dx.doi.org/10.1136/bmj.327.7420.920			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734RV	14563758	Green Published			2022-12-28	WOS:000186072100033
J	Toroyan, T; Roberts, I; Oakley, A; Laing, G; Mugford, M; Frost, C				Toroyan, T; Roberts, I; Oakley, A; Laing, G; Mugford, M; Frost, C			Effectiveness of out-of-home day care for disadvantaged families: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							INFECTIONS	Objective To assess the effects of providing daycare facilities for young children on the health and welfare of disadvantaged families. Design Randomised controlled trial. Eligible children from the application list to a daycare facility were randomly allocated to receive a daycare place or not. Setting Early Years daycare centre in Borough of Hackney, London. Participants 120 mothers and 143 eligible children (aged between 6 months and 3.5 years). Intervention A place at the centre, which provided high quality day care. Control families used other child care that they secured for themselves. Main outcome measures Maternal paid employment, household income, child health and development. Results At 18 months' follow up, 67% of intervention group mothers and 60% of control group mothers were in paid employment (adjusted risk ratio 1.23 (95% confidence interval 0.99 to 1.52)), but were no more likely to have a weekly household income of above pound200 (risk ratio 0.88 (0.70 to 1.09)). Intervention group children had more otitis media with effusion (risk ratio 1.74 (1.02 to 2.96)) and used more health services (1.58 (1.05 to 2.38)), but both estimates were imprecise. Conclusion The provision of child day care may have increased maternal employment, but it did not seem to increase household income. The results suggest that providing day care may be insufficient as a strategy to reduce poverty. The study shows how random allocation can be used to ration and evaluate interventions where demand exceeds supply.	London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Publ Hlth Intervent Res Unit, London WC1B 3DP, England; Univ London, Inst Educ, Social Sci Res Unit, London WC1N 1AZ, England; St Leonards City & Hackney Primary Care Trust, Child & Adolescent Serv, St Leonards On Sea, England; Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England; London Sch Hyg & Trop Med, Med Stat Unit, London WC1, England	University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; UCL Institute of Education; University of East Anglia; University of London; London School of Hygiene & Tropical Medicine	Toroyan, T (corresponding author), London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Publ Hlth Intervent Res Unit, London WC1B 3DP, England.			Frost, Chris/0000-0003-0098-9915				Acheson D., 1998, INDEPENDENT INQUIRY; Bennett KE, 1999, ARCH DIS CHILD, V80, P28, DOI 10.1136/adc.80.1.28; Cohen B, 1991, CHILDCARE MODERN WEL; COLLET JP, 1994, PEDIATRICS, V94, P997; DUNCAN A, 1995, EQUAL OPPORTUNITIES, V13; *E LOND CITY HLTH, 1999, HLTH E END ANN PUBL; *LOND BOR HACKN, 2001, TRANSF EARL YEARS HA; *LOND SCH HYG TROP, DAYC RES STUD; OAKLEY A, 2002, FEASIBILITY STUDY RA; Oppenheim C., 1996, POVERTY FACTS; PARADISE JL, 1981, PEDIATRICS, V68, P869; Perrons D, 2000, FEM ECON, V6, P105, DOI 10.1080/135457000337714; Roberts I, 1996, BRIT MED J, V313, P784; Toroyan T, 2000, J MED ETHICS, V26, P319, DOI 10.1136/jme.26.5.319; WALD ER, 1988, J PEDIATR-US, V112, P540, DOI 10.1016/S0022-3476(88)80164-1; Ward C, 1996, J SOC POLICY, V25, P223, DOI 10.1017/S0047279400000325; ZORITCH B, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000564; 2002, SPENDING REV 2002 OP; [No title captured]	19	16	16	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 18	2003	327	7420					906	909		10.1136/bmj.327.7420.906	http://dx.doi.org/10.1136/bmj.327.7420.906			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	734RV	14563749	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000186072100022
J	He, SG; Dong, W; Deng, QD; Weng, SJ; Sun, WZ				He, SG; Dong, W; Deng, QD; Weng, SJ; Sun, WZ			Seeing more clearly: Recent advances in understanding retinal circuitry	SCIENCE			English	Review							STARBURST AMACRINE CELLS; GANGLION-CELLS; MAMMALIAN RETINA; DIRECTIONAL SELECTIVITY; RABBIT RETINA; RETINOHYPOTHALAMIC TRACT; VISUAL INFORMATION; CALCIUM SIGNALS; BIPOLAR CELLS; GAP-JUNCTION	Among 10 breakthroughs that Science announced at the end of 2002 was the discovery of a photosensing (melanopsin-containing) retinal ganglion cell (RGC) and its role in entraining the circadian clock. This breakthrough exemplifies the ultimate goal of neuroscience: to understand the nervous system from molecules to behavior. Light-sensing RGCs constitute one of a dozen discrete RGC populations coding various aspects of visual scenes by virtue of their unique morphology, physiology, and coverage of the retina. Interestingly, the function of the melanopsin-containing RGCs in entraining the circadian clock need not involve much retinal processing, making it the simplest form of processing in the retina. This review focuses on recent advances in our understanding of retinal circuitry, visual processing, and retinal development demonstrated by innovative experimental techniques. It also discusses the advantages of using the retina as a model system to address some of the key questions in neuroscience.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	He, SG (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.		Deng, Qiudong/D-2446-2010; Sun, Wenzhi/C-4031-2011	Dong, Wei/0000-0002-8151-9407				Amthor FR, 2002, VISUAL NEUROSCI, V19, P495, DOI 10.1017/S0952523802194119; Bansal A, 2000, J NEUROSCI, V20, P7672; Belenky MA, 2003, J COMP NEUROL, V460, P380, DOI 10.1002/cne.10652; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; Berson DM, 2003, TRENDS NEUROSCI, V26, P314, DOI 10.1016/S0166-2236(03)00130-9; Borg-Graham LJ, 2001, NAT NEUROSCI, V4, P176, DOI 10.1038/84007; Chiao CC, 2002, J NEUROSCI, V22, P10509; Das T, 2003, NEURON, V37, P597, DOI 10.1016/S0896-6273(03)00066-7; Deans MR, 2002, NEURON, V36, P703, DOI 10.1016/S0896-6273(02)01046-2; Denk W, 1999, P NATL ACAD SCI USA, V96, P7035, DOI 10.1073/pnas.96.12.7035; Dermietzel R, 2000, J NEUROSCI, V20, P8331, DOI 10.1523/JNEUROSCI.20-22-08331.2000; DeVries SH, 1997, J NEUROPHYSIOL, V78, P2048, DOI 10.1152/jn.1997.78.4.2048; DeVries SH, 1999, J NEUROPHYSIOL, V81, P908, DOI 10.1152/jn.1999.81.2.908; DeVries SH, 2000, NEURON, V28, P847, DOI 10.1016/S0896-6273(00)00158-6; DIAO L, 2003, INT BRAIN RES ORG WH; DUNN F, 2002, ARVO M ABSTR, V43, P2982; Euler T, 2002, NATURE, V418, P845, DOI 10.1038/nature00931; Feigenspan A, 2001, J NEUROSCI, V21, P230, DOI 10.1523/JNEUROSCI.21-01-00230.2001; Feller MB, 1997, NEURON, V19, P293, DOI 10.1016/S0896-6273(00)80940-X; Freedman MS, 1999, SCIENCE, V284, P502, DOI 10.1126/science.284.5413.502; Fried SI, 2002, NATURE, V420, P411, DOI 10.1038/nature01179; Goldberg JL, 2002, SCIENCE, V296, P1860, DOI 10.1126/science.1068428; Gooley JJ, 2001, NAT NEUROSCI, V4, P1165, DOI 10.1038/nn768; Guldenagel M, 2001, J NEUROSCI, V21, P6036, DOI 10.1523/JNEUROSCI.21-16-06036.2001; Hannibal J, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-01-j0002.2002; Hattar S, 2003, NATURE, V424, P76, DOI 10.1038/nature01761; Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609; He SG, 1997, NATURE, V389, P378, DOI 10.1038/38723; Iwakabe H, 1997, NEUROPHARMACOLOGY, V36, P135, DOI 10.1016/S0028-3908(96)00167-0; Lohmann C, 2002, NATURE, V418, P177, DOI 10.1038/nature00850; Lom B, 2002, J NEUROSCI, V22, P7639; Lucas RJ, 2003, SCIENCE, V299, P245, DOI 10.1126/science.1077293; Lucas RJ, 2001, BEHAV BRAIN RES, V125, P97, DOI 10.1016/S0166-4328(01)00274-1; MASLAND RH, 1986, TRENDS NEUROSCI, V9, P218, DOI 10.1016/0166-2236(86)90062-7; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MEISTER M, 1995, SCIENCE, V270, P1207, DOI 10.1126/science.270.5239.1207; Mills SL, 2000, J NEUROSCI, V20, P8629, DOI 10.1523/JNEUROSCI.20-22-08629.2000; Mills SL, 2001, J COMP NEUROL, V436, P336; NELSON RJ, 1981, COMP BIOCHEM PHYS A, V69, P145, DOI 10.1016/0300-9629(81)90651-4; OBrien J, 1996, MOL BIOL CELL, V7, P233, DOI 10.1091/mbc.7.2.233; OYSTER CW, 1968, J PHYSIOL-LONDON, V199, P613, DOI 10.1113/jphysiol.1968.sp008671; Panda S, 2003, SCIENCE, V301, P525, DOI 10.1126/science.1086179; Panda S, 2002, SCIENCE, V298, P2213, DOI 10.1126/science.1076848; Provencio I, 2002, NATURE, V415, P493, DOI 10.1038/415493a; Provencio I, 2000, J NEUROSCI, V20, P600, DOI 10.1523/JNEUROSCI.20-02-00600.2000; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; Ruby NF, 2002, SCIENCE, V298, P2211, DOI 10.1126/science.1076701; Schnitzer MJ, 2003, NEURON, V37, P499, DOI 10.1016/S0896-6273(03)00004-7; SIMPSON JI, 1984, ANNU REV NEUROSCI, V7, P13, DOI 10.1146/annurev.ne.07.030184.000305; Stacy RC, 2003, J COMP NEUROL, V456, P154, DOI 10.1002/cne.10509; Taylor WR, 2000, SCIENCE, V289, P2347, DOI 10.1126/science.289.5488.2347; Taylor WR, 2002, J NEUROSCI, V22, P7712; Tokuoka H, 2002, J NEUROSCI, V22, P10324; Trexler EB, 2001, J COMP NEUROL, V437, P408, DOI 10.1002/cne.1292; Vaney D.I., 1990, PROGR RETINAL RES, V9, P49, DOI [10.1016/0278-4327(90)90004-2, DOI 10.1016/0278-4327(90)90004-2]; VANEY DI, 2003, VISION, P13; Veruki ML, 2002, J NEUROSCI, V22, P10558; Warland DK, 1997, J NEUROPHYSIOL, V78, P2336, DOI 10.1152/jn.1997.78.5.2336; Wong WT, 2001, NAT NEUROSCI, V4, P351, DOI 10.1038/85987; Wong WT, 2000, J NEUROSCI, V20, P5024; Yoshida K, 2001, NEURON, V30, P771, DOI 10.1016/S0896-6273(01)00316-6	61	34	39	2	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					408	411		10.1126/science.1085457	http://dx.doi.org/10.1126/science.1085457			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14563998				2022-12-28	WOS:000185963200031
J	Nobrega, MA; Ovcharenko, I; Afzal, V; Rubin, EM				Nobrega, MA; Ovcharenko, I; Afzal, V; Rubin, EM			Scanning human gene deserts for long-range enhancers	SCIENCE			English	Article							DROSOPHILA DACHSHUND; EXPRESSION		US Dept Energy Joint Genome Inst, Walnut Creek, CA 94598 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Genome Sci Dept, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Nobrega, MA (corresponding author), US Dept Energy Joint Genome Inst, Walnut Creek, CA 94598 USA.				NHLBI NIH HHS [HL66728] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066728] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Caubit X, 1999, DEV DYNAM, V214, P66, DOI 10.1002/(SICI)1097-0177(199901)214:1<66::AID-DVDY7>3.0.CO;2-7; Davis RJ, 1999, DEV GENES EVOL, V209, P526, DOI 10.1007/s004270050285; Ghanem N, 2003, GENOME RES, V13, P533, DOI 10.1101/gr.716103; KOTHARY R, 1988, NATURE, V335, P435, DOI 10.1038/335435a0; Lettice LA, 2002, P NATL ACAD SCI USA, V99, P7548, DOI 10.1073/pnas.112212199; Machon O, 2002, NEUROSCIENCE, V112, P951, DOI 10.1016/S0306-4522(02)00053-2	6	464	484	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					413	413		10.1126/science.1088328	http://dx.doi.org/10.1126/science.1088328			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14563999	Green Submitted			2022-12-28	WOS:000185963200032
J	Mesulam, MM				Mesulam, MM			Current concepts - Primary progressive aphasiam - A language-based Dementia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FRONTOTEMPORAL LOBAR DEGENERATION; NONFAMILIAL DYSPHASIC DEMENTIA; ALZHEIMERS-DISEASE; CORTICAL ATROPHY; SEMANTIC DEMENTIA; CEREBRAL-CORTEX; PICKS-DISEASE; TAU; DYSFUNCTION; CONSENSUS		Northwestern Univ, Freinberg Sch Med,Dept Neurol, Cognit Neurol & Alzheimers Dis Ctr, Northwestern Cognit Brain Mapping Grp, Chicago, IL 60611 USA; Northwestern Univ, Freinberg Sch Med,Dept Psychiat & Behav Sci, Cognit Neurol & Alzheimers Dis Ctr, Northwestern Cognit Brain Mapping Grp, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Mesulam, MM (corresponding author), Northwestern Univ, Freinberg Sch Med,Dept Neurol, Cognit Neurol & Alzheimers Dis Ctr, Northwestern Cognit Brain Mapping Grp, 320 E Superior St, Chicago, IL 60611 USA.	mmesulam@northwestern.edu			NIA NIH HHS [AG13854] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG013854] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abe K, 1997, NEURORADIOLOGY, V39, P556, DOI 10.1007/s002340050466; ALBERCA R, IN PRESS ARCH NEUROL; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Basun H, 1997, ARCH NEUROL-CHICAGO, V54, P539, DOI 10.1001/archneur.1997.00550170021010; Bird TD, 1998, NEUROLOGY, V50, P1526, DOI 10.1212/WNL.50.6.1526; Braak H, 1996, ACTA NEUROL SCAND, V93, P3; Broussolle E, 1996, J NEUROL SCI, V144, P44, DOI 10.1016/S0022-510X(96)00096-2; Catani M, 2003, ANN NEUROL, V53, P242, DOI 10.1002/ana.10445; CHAWLUK JB, 1986, ANN NEUROL, V19, P68, DOI 10.1002/ana.410190112; Chin SS-M, 1994, BRAIN PATHOL, V4, P515; DAMASIO AR, 1992, NEW ENGL J MED, V326, P531, DOI 10.1056/NEJM199202203260806; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Galton CJ, 2000, BRAIN, V123, P484, DOI 10.1093/brain/123.3.484; Geschwind DH, 2001, ANN NEUROL, V50, P741, DOI 10.1002/ana.10024; Grossman M, 2001, NEUROLOGY, V56, pS1, DOI 10.1212/WNL.56.suppl_4.S1; Harasty JA, 1996, BRAIN, V119, P181, DOI 10.1093/brain/119.1.181; Ikeda K, 1996, ACTA NEUROPATHOL, V92, P534, DOI 10.1007/s004010050558; KEMPLER D, 1990, J NEUROL NEUROSUR PS, V53, P987, DOI 10.1136/jnnp.53.11.987; KERTESZ A, 1994, NEUROLOGY, V44, P2065, DOI 10.1212/WNL.44.11.2065; Kinoshita A, 1996, ACTA NEUROPATHOL, V92, P520, DOI 10.1007/s004010050555; KLAWANS HL, 1981, NEUROLOGY, V31, P625, DOI 10.1212/WNL.31.5.625; Krefft TA, 2003, ALZ DIS ASSOC DIS, V17, P106, DOI 10.1097/00002093-200304000-00009; Lendon CL, 1998, NEUROLOGY, V50, P1546, DOI 10.1212/WNL.50.6.1546; LIPPA CF, 1991, NEUROLOGY, V41, P882, DOI 10.1212/WNL.41.6.882; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; MEHLER MF, 1987, NEUROLOGY, V37, P1448, DOI 10.1212/WNL.37.9.1448; MEHLER MF, 1988, CORTEX, V24, P545, DOI 10.1016/S0010-9452(88)80048-0; Mesulam M.-M., 2000, PRINCIPLES BEHAV COG, P439; Mesulam MM, 1997, NEUROLOGY, V49, P51, DOI 10.1212/WNL.49.1.51; Mesulam MM, 2001, ANN NEUROL, V49, P425, DOI 10.1002/ana.91.abs; MESULAM MM, 1987, ANN NEUROL, V22, P533, DOI 10.1002/ana.410220414; MESULAM MM, 1992, BALLIERE CLINICAL NE, P583; Miller BL, 1999, NEUROLOGIST, V5, P205, DOI 10.1097/00127893-199907000-00004; Molina JA, 1998, EUR NEUROL, V40, P71, DOI 10.1159/000007961; Mummery CJ, 1999, BRAIN, V122, P61, DOI 10.1093/brain/122.1.61; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Otsuki M, 1998, EUR NEUROL, V39, P135, DOI 10.1159/000007923; PRICE BH, 1993, ARCH NEUROL-CHICAGO, V50, P931, DOI 10.1001/archneur.1993.00540090038008; Ratnavalli E, 2002, NEUROLOGY, V58, P1615, DOI 10.1212/WNL.58.11.1615; Rossor MN, 2000, BRAIN, V123, P267, DOI 10.1093/brain/123.2.267; Snowden JS, 1999, DEMENT GERIATR COGN, V10, P33, DOI 10.1159/000051209; SNOWDEN JS, 1992, ANN NEUROL, V31, P174, DOI 10.1002/ana.410310208; Sobrido MJ, 2003, NEUROLOGY, V60, P862, DOI 10.1212/01.WNL.0000049473.36612.F2; Sonty SP, 2003, ANN NEUROL, V53, P35, DOI 10.1002/ana.10390; Thompson CK, 1997, APHASIOLOGY, V11, P297, DOI 10.1080/02687039708248473; Turner RS, 1996, ANN NEUROL, V39, P166, DOI 10.1002/ana.410390205; TYRRELL PJ, 1990, BRAIN, V113, P1321, DOI 10.1093/brain/113.5.1321; WEINTRAUB S, 1990, ARCH NEUROL-CHICAGO, V47, P1329, DOI 10.1001/archneur.1990.00530120075013; WEINTRAUB S, 1996, DEMENCE POURQUOI, P75; Wilhelmsen KC, 1997, ANN NEUROL, V41, P139, DOI 10.1002/ana.410410202; Zhukareva V, 2001, ANN NEUROL, V49, P165, DOI 10.1002/1531-8249(20010201)49:2<165::AID-ANA36>3.0.CO;2-3; [No title captured]	52	286	304	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 16	2003	349	16					1535	1542		10.1056/NEJMra022435	http://dx.doi.org/10.1056/NEJMra022435			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	731ZM	14561797				2022-12-28	WOS:000185916400030
J	Stenner, MD; Gauthier, DJ; Neifeld, MA				Stenner, MD; Gauthier, DJ; Neifeld, MA			The speed of information in a 'fast-light' optical medium	NATURE			English	Article							NEGATIVE GROUP-VELOCITY; PULSE-PROPAGATION; SUPERLUMINAL SIGNALS; GROUP DELAY; CAUSALITY; SLOW	One consequence of the special theory of relativity is that no signal can cause an effect outside the source light cone, the space-time surface on which light rays emanate from the source(1). Violation of this principle of relativistic causality leads to paradoxes, such as that of an effect preceding its cause(2). Recent experiments on optical pulse propagation in so-called 'fastlight' media-which are characterized by a wave group velocity v(g) exceeding the vacuum speed of light c or taking on negative values'-have led to renewed debate about the definition of the information velocity v(i). One view is that v(i) = v(g) (ref. 4), which would violate causality, while another is that vi = c in all situations', which would preserve causality. Here we find that the time to detect information propagating through a fast-light medium is slightly longer than the time required to detect the same information travelling through a vacuum, even though vg in the medium vastly exceeds c. Our observations are therefore consistent with relativistic causality and help to resolve the controversies surrounding superluminal pulse propagation.	Duke Univ, Dept Phys, Durham, NC 27708 USA; Fitzpatrick Ctr Photon & Commun Syst, Durham, NC 27708 USA; Univ Arizona, Ctr Opt Sci, Dept Elect & Comp Engn, Tucson, AZ 85721 USA	Duke University; University of Arizona	Gauthier, DJ (corresponding author), Duke Univ, Dept Phys, Durham, NC 27708 USA.		Gauthier, Daniel J/G-1336-2011	Gauthier, Daniel J/0000-0002-4473-217X				Agrawal G. P., 2001, NONLINEAR FIBER OPTI; Akulshin AM, 2002, QUANTUM ELECTRON+, V32, P567, DOI 10.1070/QE2002v032n07ABEH002249; Bigelow MS, 2003, SCIENCE, V301, P200, DOI 10.1126/science.1084429; Born M, 2005, PRINCIPLES OPTICS, V7th edn; Boyd RW, 2002, PROG OPTICS, V43, P497, DOI 10.1016/S0079-6638(02)80030-0; Brillouin L, 1914, ANN PHYS-BERLIN, V44, P203; Brillouin L., 1960, WAVE PROPAGATION GRO; Cao H, 2003, IEEE J SEL TOP QUANT, V9, P52, DOI 10.1109/JSTQE.2002.807974; CAVES CM, 1994, REV MOD PHYS, V66, P481, DOI 10.1103/RevModPhys.66.481; Chiao RY, 1997, PROG OPTICS, V37, P345, DOI 10.1016/S0079-6638(08)70341-X; CHU S, 1982, PHYS REV LETT, V48, P738, DOI 10.1103/PhysRevLett.48.738; Diener G, 1996, PHYS LETT A, V223, P327, DOI 10.1016/S0375-9601(96)00767-0; GARRETT CGB, 1970, PHYS REV A, V1, P305, DOI 10.1103/PhysRevA.1.305; Garrison JC, 1998, PHYS LETT A, V245, P19, DOI 10.1016/S0375-9601(98)00381-8; Harris SE, 1997, PHYS TODAY, V50, P36, DOI 10.1063/1.881806; Jackson J.D., 1999, CLASSICAL ELECTRODYN; Kuzmich A, 2001, PHYS REV LETT, V86, P3925, DOI 10.1103/PhysRevLett.86.3925; Macke B, 2003, EUR PHYS J D, V23, P125, DOI 10.1140/epjd/e2003-00022-0; Mitchell MW, 1997, PHYS LETT A, V230, P133, DOI 10.1016/S0375-9601(97)00244-2; Nakanishi T, 2002, AM J PHYS, V70, P1117, DOI 10.1119/1.1503378; Nimtz G, 2002, ANN PHYS-BERLIN, V11, P163, DOI 10.1002/1521-3889(200202)11:2<163::AID-ANDP163>3.0.CO;2-Q; Peatross J, 2000, PHYS REV LETT, V84, P2370, DOI 10.1103/PhysRevLett.84.2370; SEGARD B, 1985, PHYS LETT A, V109, P213, DOI 10.1016/0375-9601(85)90305-6; Solli D, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.056601; Sommerfeld A, 1914, ANN PHYS-BERLIN, V44, P177, DOI 10.1002/andp.19143491002; STEINBERG AM, 1994, PHYS REV A, V49, P2071, DOI 10.1103/PhysRevA.49.2071; Stenner MD, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.063801; Wang LJ, 2000, NATURE, V406, P277, DOI 10.1038/35018520; Wynne K, 2002, OPT COMMUN, V209, P85, DOI 10.1016/S0030-4018(02)01638-3	29	281	293	1	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					695	698		10.1038/nature02016	http://dx.doi.org/10.1038/nature02016			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562097				2022-12-28	WOS:000185924500035
J	Wiesenfeld, HC; Guido, RS				Wiesenfeld, HC; Guido, RS			Intraabdominal pregnancy after hysterectomy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wiesenfeld, HC (corresponding author), Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA.								0	5	5	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 16	2003	349	16					1534	1534		10.1056/NEJMicm020681	http://dx.doi.org/10.1056/NEJMicm020681			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	731ZM	14561796				2022-12-28	WOS:000185916400008
J	Taha, TE; Kumwenda, NI; Gibbons, A; Broadhead, RL; Fiscus, S; Lema, V; Liomba, G; Nkhoma, C; Miotti, PG; Hoover, DR				Taha, TE; Kumwenda, NI; Gibbons, A; Broadhead, RL; Fiscus, S; Lema, V; Liomba, G; Nkhoma, C; Miotti, PG; Hoover, DR			Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL PROPHYLAXIS; VERTICAL TRANSMISSION; ORAL ZIDOVUDINE; COTE-DIVOIRE; DOUBLE-BLIND; NEVIRAPINE; EFFICACY; AFRICA; INTRAPARTUM	Background In sub-Saharan Africa, most women present late for delivery with unknown HIV status, which limits the use of intrapartum nevirapine to prevent mother-to-child transmission of HIV. We aimed to determine whether post-exposure prophylaxis of nevirapine plus zidovudine given to babies only reduced transmission of HIV more than did a regimen of nevirapine alone. Methods We randomly assigned 1119 babies of Malawian women with HIV-1 who presented late (ie, within 2 h of expected delivery) to either nevirapine alone or nevirapine and zidovudine. Both drugs were given immediately after birth: one dose of nevirapine (2 mg/kg weight) was given as a single dose; babies in the nevirapine plus zidovudine group also received zidovudine twice daily for 1 week (4 mg/kg weight). Infant HIV infection was determined at birth and at 6-8 weeks. Primary outcome was HIV infection in babies at 6-8 weeks in those not infected at birth. Analysis was by intention to treat. Findings The overall rate of mother-to-child transmission at 6-8 weeks was 15.3% in 484 babies who received nevirapine and zidovudine and 20.9% in 468 babies who received nevirapine only (p=0.03). At 6-8 weeks, in babies who were HIV negative at birth, 34 (7-7%) babies who had nevirapine and zidovudine and 51 (12.1%) who received nevirapine only were infected (p=0.03 -a protective efficacy of 36%. This finding remained after controlling for maternal viral load and other factors at baseline. Adverse events were mild and of similar frequency in the two groups. Interpretation Postexposure prophylaxis can offer protection against HIV infection to babies of women who missed opportunities to be counselled and tested before or during pregnancy. The nevirapine and zidovudine regimen is safe and easy to implement.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Univ Malawi, Coll Med, Blantyre, Malawi; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA; Johns Hopkins Univ, Blantyre, Malawi; Coll Med, Blantyre, Malawi; Minist Hlth Res Project, Blantyre, Malawi; NIH, Off AIDS Res, Bethesda, MD 20892 USA; Rutgers State Univ, Dept Stat, Piscataway, NJ USA; Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, Piscataway, NJ USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Malawi; University of North Carolina; University of North Carolina Chapel Hill; University of Malawi; University of Malawi; National Institutes of Health (NIH) - USA; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Taha, TE (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Rm E7138, Baltimore, MD 21205 USA.		Kumwenda, Newton/ADL-6890-2022	Kumwenda, Newton/0000-0003-2622-4339; Taha, Taha/0000-0001-9814-4894	FIC NIH HHS [5R03TW01199] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001199] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Biggar RJ, 1997, J ACQ IMMUN DEF SYND, V14, P368, DOI 10.1097/00042560-199704010-00010; Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5; Biggar RJ, 1997, AIDS, V11, P1375, DOI 10.1097/00002030-199711000-00012; *BOEHR ING, 2000, INV BROCH NEV BI RG; *CDC, 1998, MMWR-MORBID MORTAL W, V47, P22; *CDC, 1995, MMWR-MORBID MORTAL W, V44, P929; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Leroy V, 2002, AIDS, V16, P631, DOI 10.1097/00002030-200203080-00016; MIROCHNICK M, 2001, 3 C GLOB STRAT PREV; Moodley D, 2003, J INFECT DIS, V187, P725, DOI 10.1086/367898; Nolan M, 2002, J ACQ IMMUN DEF SYND, V30, P216, DOI [10.1097/01.QAI.0000018365.28828.5D, 10.1097/00042560-200206010-00011]; OWOR M, 2000, 13 INT AIDS C JUL 9; Rice J., 1995, MATH STAT DATA ANAL; Saba J, 2002, LANCET, V359, P1178; Semba RD, 1999, J INFECT DIS, V180, P93, DOI 10.1086/314854; Taha TE, 2002, AIDS, V16, P851, DOI 10.1097/00002030-200204120-00004; VANROMPAY KKA, 1995, ANTIMICROB AGENTS CH, V39, P125, DOI 10.1128/AAC.39.1.125; Wade NA, 1998, NEW ENGL J MED, V339, P1409, DOI 10.1056/NEJM199811123392001; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9	21	138	142	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 11	2003	362	9391					1171	1177		10.1016/S0140-6736(03)14538-2	http://dx.doi.org/10.1016/S0140-6736(03)14538-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568737				2022-12-28	WOS:000185924100007
J	Doiron-Leyraud, N; Walker, IR; Taillefer, L; Steiner, MJ; Julian, SR; Lonzarich, GG				Doiron-Leyraud, N; Walker, IR; Taillefer, L; Steiner, MJ; Julian, SR; Lonzarich, GG			Fermi-liquid breakdown in the paramagnetic phase of a pure metal	NATURE			English	Article							SPIN FLUCTUATIONS; ELECTRON; MNSI; TRANSITION; POINTS; STATE	Fermi-liquid theory(1) (the standard model of metals) has been challenged by the discovery of anomalous properties in an increasingly large number of metals. The anomalies often occur near a quantum critical point-a continuous phase transition in the limit of absolute zero, typically between magnetically ordered and paramagnetic phases. Although not understood in detail, unusual behaviour in the vicinity of such quantum critical points was anticipated nearly three decades ago by theories going beyond the standard model(2-5). Here we report electrical resistivity measurements of the 3d metal MnSi, indicating an unexpected breakdown of the Fermi-liquid model-not in a narrow crossover region close to a quantum critical point(6,7) where it is normally expected to fail, but over a wide region of the phase diagram near a first-order magnetic transition. In this regime, corrections to the Fermi-liquid model are expected to be small. The range in pressure, temperature and applied magnetic field over which we observe an anomalous temperature dependence of the electrical resistivity in MnSi is not consistent with the crossover behaviour widely seen in quantum critical systems(8,9,31). This may suggest the emergence of a well defined but enigmatic quantum phase of matter.	Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England; Univ Sherbrooke, Dept Phys, Sherbrooke, PQ J1K 2R1, Canada	University of Cambridge; University of Sherbrooke	Doiron-Leyraud, N (corresponding author), Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England.	nd223@cam.ac.uk						Altshuler B. L., 1985, Electron-electron interactions in disordered systems, P1; Anderson PW, 2002, PHYSICA B, V318, P28, DOI 10.1016/S0921-4526(02)00770-6; Belitz D, 2000, PHYS REV LETT, V85, P4602, DOI 10.1103/PhysRevLett.85.4602; BLOCH D, 1975, PHYS LETT A, VA 51, P259, DOI 10.1016/0375-9601(75)90438-7; Custers J, 2003, NATURE, V424, P524, DOI 10.1038/nature01774; HERTZ JA, 1976, PHYS REV B, V14, P1165, DOI 10.1103/PhysRevB.14.1165; ISHIKAWA Y, 1985, PHYS REV B, V31, P5884, DOI 10.1103/PhysRevB.31.5884; LANDAU LD, 1965, COLLETED PAPERS, pCH90; LANGER JS, 1969, ANN PHYS-NEW YORK, V54, P258, DOI 10.1016/0003-4916(69)90153-5; Laughlin RB, 2001, ADV PHYS, V50, P361, DOI 10.1080/00018730110098534; Lebech B., 1993, RECENT ADV MAGNETISM, P167; LONZARICH GG, 1985, J PHYS C SOLID STATE, V18, P4339, DOI 10.1088/0022-3719/18/22/017; Millis AJ, 2002, PHYSICA B, V312, P1, DOI 10.1016/S0921-4526(01)01528-9; MILLIS AJ, 1993, PHYS REV B, V48, P7183, DOI 10.1103/PhysRevB.48.7183; MORIYA T, 1973, J PHYS SOC JPN, V34, P639, DOI 10.1143/JPSJ.34.639; Moriya T., 1985, SPIN FLUCTUATIONS IT; MURATA KK, 1972, PHYS REV LETT, V29, P285, DOI 10.1103/PhysRevLett.29.285; Pfleiderer C, 1997, PHYS REV B, V55, P8330, DOI 10.1103/PhysRevB.55.8330; Pfleiderer C, 2003, PHYSICA B, V328, P100, DOI 10.1016/S0921-4526(02)01818-5; Pfleiderer C, 2001, NATURE, V414, P427, DOI 10.1038/35106527; RAMAKRISHNAN TV, 1974, PHYS REV B, V10, P4014, DOI 10.1103/PhysRevB.10.4014; Rivadulla F, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.165110; Schroder A, 2000, NATURE, V407, P351, DOI 10.1038/35030039; TAILLEFER L, 1986, J MAGN MAGN MATER, V54-7, P957, DOI 10.1016/0304-8853(86)90332-X; Thessieu C, 1997, J PHYS-CONDENS MAT, V9, P6677, DOI 10.1088/0953-8984/9/31/019; Thessieu C, 1998, J MAGN MAGN MATER, V177, P609, DOI 10.1016/S0304-8853(97)00478-2; THOMPSON JD, 1989, PHYSICA B, V161, P317, DOI 10.1016/0921-4526(89)90155-5; Varma CM, 2002, PHYS REP, V361, P267, DOI 10.1016/S0370-1573(01)00060-6; Vojta T, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.052404; Walker IR, 1999, REV SCI INSTRUM, V70, P3402, DOI 10.1063/1.1149927; Yamada H, 1999, PHYS REV B, V59, P9342, DOI 10.1103/PhysRevB.59.9342	31	159	160	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 9	2003	425	6958					595	599		10.1038/nature01968	http://dx.doi.org/10.1038/nature01968			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534580				2022-12-28	WOS:000185801000030
J	Pearson, BJ; Doe, CQ				Pearson, BJ; Doe, CQ			Regulation of neuroblast competence in Drosophila	NATURE			English	Article							CELL-FATE DETERMINATION; CENTRAL-NERVOUS-SYSTEM; TRANSCRIPTION FACTORS; CEREBRAL-CORTEX; RETINA; CNS; PROJECTIONS; SEQUENCE; LINEAGES; BINDING	Individual neural progenitors generate different cell types in a reproducible order in the retina(1-3), cerebral cortex(4-6) and probably in the spinal cord(7). It is unknown how neural progenitors change over time to generate different cell types. It has been proposed that progenitors undergo progressive restriction(8) or transit through distinct competence states(9,10); however, the underlying molecular mechanisms remain unclear. Here we investigate neural progenitor competence and temporal identity using an in vivo genetic system-Drosophila neuroblasts-where the Hunchback transcription factor is necessary and sufficient to specify early-born cell types(11). We show that neuroblasts gradually lose competence to generate early-born fates in response to Hunchback, similar to progressive restriction models(8), and that competence to acquire early-born fates is present in mitotic precursors but is lost in post-mitotic neurons. These results match those observed in vertebrate systems, and establish Drosophila neuroblasts as a model system for the molecular genetic analysis of neural progenitor competence and plasticity.	Univ Oregon 1254, Howard Hughes Med Inst, Inst Neurosci & Mol Biol, Eugene, OR 97403 USA	Howard Hughes Medical Institute; University of Oregon	Doe, CQ (corresponding author), Univ Oregon 1254, Howard Hughes Med Inst, Inst Neurosci & Mol Biol, Eugene, OR 97403 USA.			Pearson, Bret/0000-0002-3473-901X				ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; Bossing T, 1996, DEV BIOL, V179, P41, DOI 10.1006/dbio.1996.0240; BUENZOW DE, 1995, DEV BIOL, V170, P338, DOI 10.1006/dbio.1995.1219; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Desai AR, 2000, DEVELOPMENT, V127, P2863; Isshiki T, 2001, CELL, V106, P511, DOI 10.1016/S0092-8674(01)00465-2; Kambadur R, 1998, GENE DEV, V12, P246, DOI 10.1101/gad.12.2.246; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Landgraf M, 1997, J NEUROSCI, V17, P9642; Livesey FJ, 2001, NAT REV NEUROSCI, V2, P109, DOI 10.1038/35053522; MCCONNELL SK, 1989, TRENDS NEUROSCI, V12, P342, DOI 10.1016/0166-2236(89)90041-6; Perron M, 1998, DEV BIOL, V199, P185, DOI 10.1006/dbio.1998.8939; Qian XM, 2000, NEURON, V28, P69, DOI 10.1016/S0896-6273(00)00086-6; Rapaport DH, 2001, J NEUROBIOL, V49, P129, DOI 10.1002/neu.1070; Sabbattini P, 2001, EMBO J, V20, P2812, DOI 10.1093/emboj/20.11.2812; Schmid A, 1999, DEVELOPMENT, V126, P4653; Skeath JB, 1998, DEVELOPMENT, V125, P1857; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; Yang XH, 1997, GENE DEV, V11, P1396, DOI 10.1101/gad.11.11.1396; ZHANG CC, 1992, P NATL ACAD SCI USA, V89, P7511, DOI 10.1073/pnas.89.16.7511; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	23	160	162	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2003	425	6958					624	628		10.1038/nature01910	http://dx.doi.org/10.1038/nature01910			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534589				2022-12-28	WOS:000185801000039
J	Winter, Y; Lopez, J; von Helversen, O				Winter, Y; Lopez, J; von Helversen, O			Ultraviolet vision in a bat	NATURE			English	Article							PHOTORECEPTORS; SENSITIVITY; LIGHT	Most mammals, with the exception of primates, have dichromatic vision and correspondingly limited colour perception(1). Ultraviolet vision was discovered in mammals only a decade ago(2), and in the few rodents and marsupials where it has been found, ultraviolet light is detected by an independent photoreceptor(2,3). Bats orient primarily by echolocation, but they also use vision. Here we show that a phyllostomid flower bat, Glossophaga soricina, is colour-blind but sensitive to ultraviolet light down to a wavelength of 310 nm. Behavioural experiments revealed a spectral-sensitivity function with maxima at 510 nm (green) and above 365 nm (ultraviolet). A test for colour vision was negative. Chromatic adaptation had the same threshold-elevating effects on ultraviolet and visible test lights, indicating that the same photoreceptor is responsible for both response peaks (ultraviolet and green). Thus, excitation of the beta-band of the visual pigment is the most likely cause of ultraviolet sensitivity. This is a mechanism for ultraviolet vision that has not previously been demonstrated in intact mammalian visual systems.	Univ Munich, Dept Biol, D-80333 Munich, Germany; Max Planck Res Ctr Ornithol, D-82305 Seewiesen, Germany; Univ San Carlos, Escuela Biol, Guatemala City 01012, Guatemala; Univ Erlangen Nurnberg, Inst Zool, D-91058 Erlangen, Germany	University of Munich; Max Planck Society; Universidad de San Carlos de Guatemala; University of Erlangen Nuremberg	Winter, Y (corresponding author), Univ Munich, Dept Biol, Luisenstr 14, D-80333 Munich, Germany.	winter@zi.biologie.uni-muenchen.de	Vazquez-Dominguez, Guillermo GVD/L-7818-2014	Winter, York/0000-0002-7828-1872				Arrese CA, 2002, CURR BIOL, V12, P657, DOI 10.1016/S0960-9822(02)00772-8; Biedinger N, 1993, TROP SUBTROP PFLANZE, V86, P1; CHASE J, 1983, ANIM BEHAV, V31, P526, DOI 10.1016/S0003-3472(83)80075-X; Douglas R.H., 1999, P95; Dyer AG, 1999, J COMP PHYSIOL A, V185, P445, DOI 10.1007/s003590050405; Govardovskii VI, 2000, VISUAL NEUROSCI, V17, P509, DOI 10.1017/S0952523800174036; GRISWOLD MS, 1992, VISION RES, V32, P1739, DOI 10.1016/0042-6989(92)90166-G; JACOBS GH, 1992, AM ZOOL, V32, P544; JACOBS GH, 1994, VISION RES, V34, P1433, DOI 10.1016/0042-6989(94)90144-9; JACOBS GH, 1991, NATURE, V353, P655, DOI 10.1038/353655a0; JACOBS GH, 1993, BIOL REV, V68, P413, DOI 10.1111/j.1469-185X.1993.tb00738.x; KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061; MORTON RA, 1972, HDB SENSORY PHYSIOLO, V7, P33; NEUMEYER C, 1988, FARBENSEHEN GOLDFISC; REMY M, 1989, BEHAV NEUROSCI, V103, P170, DOI 10.1037/0735-7044.103.1.170; SMITH H, 1982, ANNU REV PLANT PHYS, V33, P481, DOI 10.1146/annurev.pp.33.060182.002405; SUTHERS R, 1969, BIOL BULL, V137, P535, DOI 10.2307/1540174; VONCAMPENHAUSE C, 1986, NATURWISSENSCHAFTEN, V73, P674; Winter Y, 1999, J EXP BIOL, V202, P1917	19	103	107	3	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 9	2003	425	6958					612	614		10.1038/nature01971	http://dx.doi.org/10.1038/nature01971			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534585				2022-12-28	WOS:000185801000035
J	Landefeld, CS; Callahan, CM; Woolard, N				Landefeld, CS; Callahan, CM; Woolard, N			General internal medicine and geriatrics: Building a foundation to improve the training of general internists in the care of older adults	ANNALS OF INTERNAL MEDICINE			English	Article							PROGRAMS; 21ST-CENTURY; RESIDENTS; FACULTY	Internists-"doctors for adults"-provide most of the medical care given to older Americans, especially those with serious chronic disease. Nonetheless, the United States lacks an adequate physician workforce with mastery in caring for older persons and with expertise in building knowledge about how best to provide this care. This supplement aims to strengthen the physician workforce by fostering incremental and sustained improvements in the training of internal medicine residents in the care of older adults and in the development of geriatrics-oriented general internal medicine faculty. It identifies 3 major barriers to these improvements: lack of adequately trained teachers and mentors, the belief that explicit training in geriatrics has little to offer the generalist, and inadequate funding. Three strategies offer particular promise in over-coming these barriers: engaging directors of internal medicine residency programs, funding centers to promote collaboration between teaching and research programs in general internal medicine and geriatrics, and providing substantial incremental funding on the national level to pay for the time required to care for frail older patients and to teach and do research about this care. The barriers and strategies identified in this supplement may also inform efforts to enhance the skills of practicing physicians and improve training and faculty development in family medicine and other disciplines.	Univ Calif San Francisco, San Francisco, CA 94143 USA; San Francisco VA Med Ctr, San Francisco, CA USA; Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA; Indiana Univ, Indianapolis, IN 46204 USA; Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Indiana University System; Indiana University-Purdue University Indianapolis; Wake Forest University	Landefeld, CS (corresponding author), Univ Calif San Francisco, Box 1265, San Francisco, CA 94143 USA.	sethl@medicine.ucsf.edu			NIA NIH HHS [K07 AG000912, K-07 AG00912] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K07AG000912] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 2001, AM J MED, V110, P507, DOI 10.1016/S0002-9343(01)00685-4; BURTLER RN, 1975, WHY SURVIVE BEING OL; HAZZARD WR, 1994, AM J MED, pS1; *I MED, 1978, AG MED ED REP STUD; *I MED COMM LEAD A, 1987, ACAD GER YEAR 2000; *INT LONG CTR, 2002, NAT CRIS NEED GER FA; JAHNIGEN D, 1994, AM J MED, V97, P43; Kennedy J, 1998, INT J HEALTH SERV, V28, P757, DOI 10.2190/3C1X-TQAE-7UDM-2NWQ; Larson EB, 2001, ANN INTERN MED, V134, P997, DOI 10.7326/0003-4819-134-10-200105150-00013; LIBOW LS, 1990, J AM GERIATR SOC, V38, P79, DOI 10.1111/j.1532-5415.1990.tb01603.x; Medina-Walpole A, 2002, J AM GERIATR SOC, V50, P949, DOI 10.1046/j.1532-5415.2002.50225.x; *NAT CTR HLTH STAT, DAT WAR TRENDS HLTH; REUBEN DB, 1993, J AM GERIATR SOC, V41, P560, DOI 10.1111/j.1532-5415.1993.tb01896.x; REUBEN DB, 1993, J AM GERIATR SOC, V41, P444, DOI 10.1111/j.1532-5415.1993.tb06955.x; Rubin CD, 2003, ANN INTERN MED, V139, P615, DOI 10.7326/0003-4819-139-7-200310070-00035; Simon SR, 2003, ANN INTERN MED, V139, P621, DOI 10.7326/0003-4819-139-7-200310070-00036; Solomon DH, 2002, J AM GERIATR SOC, V50, P5, DOI 10.1046/j.1532-5415.2002.50038.x; Sox HC, 2001, AM J MED, V110, P745, DOI 10.1016/S0002-9343(01)00756-2; Thomas DC, 2003, ANN INTERN MED, V139, P628, DOI 10.7326/0003-4819-139-7-200310070-00037; *US DEP HHS ADM AG, 2001, PROF OLD AM; Warshaw G, 2003, FAM MED, V35, P24; Warshaw GA, 2002, JAMA-J AM MED ASSOC, V288, P2313, DOI 10.1001/jama.288.18.2313; Warshaw GA., 2002, GERIATRIC MED TRAINI	23	38	38	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 7	2003	139	7					609	614		10.7326/0003-4819-139-7-200310070-00034	http://dx.doi.org/10.7326/0003-4819-139-7-200310070-00034			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729AP	14530244				2022-12-28	WOS:000185748800026
J	Sharma, MR; Koc, EC; Datta, PP; Booth, TM; Spremulli, LL; Agrawal, RK				Sharma, MR; Koc, EC; Datta, PP; Booth, TM; Spremulli, LL; Agrawal, RK			Structure of the mammalian mitochondrial ribosome reveals an expanded functional role for its component proteins	CELL			English	Article							COLI 70S RIBOSOME; 3-DIMENSIONAL CRYOELECTRON MICROSCOPY; TRANSFER-RNA; ANGSTROM RESOLUTION; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; COMPARATIVE SEQUENCE; TRANSLATION SYSTEM; CRYSTAL-STRUCTURE; MESSENGER-RNA	The mitochondrial ribosome is responsible for the biosynthesis of protein components crucial to the generation of ATP in the eukaryotic cell. Because the protein:RNA ratio in the mitochondrial ribosome (similar to69:similar to31) is the inverse of that of its prokaryotic counterpart (similar to33:similar to67), it was thought that the additional and/or larger proteins of the mitochondrial ribosome must compensate for the shortened rRNAs. Here, we present a three-dimensional cryo-electron microscopic map of the mammalian mitochondrial 55S ribosome carrying a tRNA at its P site, and we find that instead, many of the proteins occupy new positions in the ribosome. Furthermore, unlike cytoplasmic ribosomes, the mitochondrial ribosome possesses inter-subunit bridges composed largely of proteins; it has a gatelike structure at its mRNA entrance, perhaps involved in recruiting unique mitochondrial mRNAs; and it has a polypeptide exit tunnel that allows access to the solvent before the exit site, suggesting a unique nascent-polypeptide exit mechanism.	New York State Dept Hlth, Wadsworth Ctr, Div Mol Med, Albany, NY 12201 USA; Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12222 USA	State University of New York (SUNY) System; Wadsworth Center; University of North Carolina; University of North Carolina Chapel Hill; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Agrawal, RK (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Div Mol Med, Empire State Plaza, Albany, NY 12201 USA.	agrawal@wadsworth.org			NIGMS NIH HHS [R01 GM061576, GM61576, GM32734] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032734, R01GM061576] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 2000, J CELL BIOL, V150, P447, DOI 10.1083/jcb.150.3.447; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; ATTARDI G, 1985, INT REV CYTOL, V93, P93, DOI 10.1016/S0074-7696(08)61373-X; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BASAVAPPA R, 1991, EMBO J, V10, P3105, DOI 10.1002/j.1460-2075.1991.tb07864.x; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Cannone JJ, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-2; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; Dube P, 1998, J MOL BIOL, V279, P403, DOI 10.1006/jmbi.1998.1804; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; Frank J, 2000, METHOD ENZYMOL, V317, P276; FRANK J, 2001, S QUANT BIOL, V66, P67; Gabashvili IS, 2000, CELL, V100, P537, DOI 10.1016/S0092-8674(00)80690-X; Gabashvili IS, 2001, MOL CELL, V8, P181, DOI 10.1016/S1097-2765(01)00293-3; Gomez-Lorenzo MG, 2000, EMBO J, V19, P2710, DOI 10.1093/emboj/19.11.2710; Gray MW, 2001, GENOME BIOL, V2; Hanada T, 2001, GENES CELLS, V6, P1019, DOI 10.1046/j.1365-2443.2001.00491.x; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koc EC, 2000, J BIOL CHEM, V275, P32585, DOI 10.1074/jbc.M003596200; Koc EC, 2001, FEBS LETT, V492, P166, DOI 10.1016/S0014-5793(01)02250-5; Koc EC, 2001, J BIOL CHEM, V276, P43958, DOI 10.1074/jbc.M106510200; MATTHEWS DE, 1982, J BIOL CHEM, V257, P8788; Mears JA, 2002, J MOL BIOL, V321, P215, DOI 10.1016/S0022-2836(02)00568-5; O'Brien TW, 2002, GENE, V286, P73, DOI 10.1016/S0378-1119(01)00808-3; O'Brien TW, 2000, J BIOL CHEM, V275, P18153, DOI 10.1074/jbc.M909762199; OBRIEN TW, 1990, BIOCHIM BIOPHYS ACTA, V1050, P174, DOI 10.1016/0167-4781(90)90162-U; OBRIEN TW, 1971, J BIOL CHEM, V246, P3409; Ohtsuki T, 2002, FEBS LETT, V514, P37, DOI 10.1016/S0014-5793(02)02328-1; OJALA DK, 1980, NATURE, V287, P79, DOI 10.1038/287079a0; Orlova EV, 1997, J MOL BIOL, V271, P417, DOI 10.1006/jmbi.1997.1182; Patel VB, 2001, J BIOL CHEM, V276, P6739, DOI 10.1074/jbc.M005781200; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; REMME J, 1989, EUR J BIOCHEM, V183, P281, DOI 10.1111/j.1432-1033.1989.tb14925.x; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; Spahn CMT, 2000, STRUCTURE, V8, P937, DOI 10.1016/S0969-2126(00)00185-4; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; Stuart RA, 2002, BBA-MOL CELL RES, V1592, P79, DOI 10.1016/S0167-4889(02)00266-5; Suzuki T, 2001, J BIOL CHEM, V276, P33181, DOI 10.1074/jbc.M103236200; Suzuki T, 2001, J BIOL CHEM, V276, P21724, DOI 10.1074/jbc.M100432200; Valle M, 2002, EMBO J, V21, P3557, DOI 10.1093/emboj/cdf326; WAGENKNECHT T, 1988, J MOL BIOL, V199, P137, DOI 10.1016/0022-2836(88)90384-1; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Wittmann-Liebold B., 1985, STRUCTURE FUNCTION G, P326; WOLSTENHOLME D, 1992, ANIMAL MITOCHONDRIAL, P173; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4	54	274	287	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 3	2003	115	1					97	108		10.1016/S0092-8674(03)00762-1	http://dx.doi.org/10.1016/S0092-8674(03)00762-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14532006	Green Published, Bronze			2022-12-28	WOS:000185815500012
J	Calvi, LM; Adams, GB; Weibrecht, KW; Weber, JM; Olson, DP; Knight, MC; Martin, RP; Schipani, E; Divieti, P; Bringhurst, FR; Milner, LA; Kronenberg, HM; Scadden, DT				Calvi, LM; Adams, GB; Weibrecht, KW; Weber, JM; Olson, DP; Knight, MC; Martin, RP; Schipani, E; Divieti, P; Bringhurst, FR; Milner, LA; Kronenberg, HM; Scadden, DT			Osteoblastic cells regulate the haematopoietic stem cell niche	NATURE			English	Article							BONE-MARROW; GROWTH-FACTOR; SELF-RENEWAL; NOTCH; LINEAGE	Stem cell fate is influenced by specialized microenvironments that remain poorly defined in mammals(1-3). To explore the possibility that haematopoietic stem cells derive regulatory information from bone, accounting for the localization of haematopoiesis in bone marrow, we assessed mice that were genetically altered to produce osteoblast-specific, activated PTH/PTHrP receptors (PPRs)(4). Here we show that PPR-stimulated osteoblastic cells that are increased in number produce high levels of the Notch ligand jagged 1 and support an increase in the number of haematopoietic stem cells with evidence of Notch1 activation in vivo. Furthermore, ligand-dependent activation of PPR with parathyroid hormone (PTH) increased the number of osteoblasts in stromal cultures, and augmented ex vivo primitive haematopoietic cell growth that was abrogated by gamma-secretase inhibition of Notch activation. An increase in the number of stem cells was observed in wild-type animals after PTH injection, and survival after bone marrow transplantation was markedly improved. Therefore, osteoblastic cells are a regulatory component of the haematopoietic stem cell niche in vivo that influences stem cell function through Notch activation. Niche constituent cells or signalling pathways provide pharmacological targets with therapeutic potential for stem-cell-based therapies.	Harvard Univ, Massachusetts Gen Hosp, Sch Med,Canc Ctr, Partners AIDS Res Ctr,Ctr Regenerat Med & Technol, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA 02114 USA; Univ Rochester, Sch Med, Dept Med, Endocrine Unit, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Pediat, Ctr Human Genet & Mol Pediat Dis, Rochester, NY 14642 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Rochester; University of Rochester	Scadden, DT (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Canc Ctr, Partners AIDS Res Ctr,Ctr Regenerat Med & Technol, Boston, MA 02114 USA.	scadden.david@mgh.harvard.edu	Calvi, Laura/P-6988-2019	Calvi, Laura/0000-0001-6969-239X; Divieti Pajevic, Paola/0000-0001-9853-9837; Weber, Jonathan/0000-0002-6015-8454	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK064381] Funding Source: NIH RePORTER; NIDDK NIH HHS [K08 DK064381, K08 DK064381-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cui YF, 1996, CELL PROLIFERAT, V29, P243, DOI 10.1046/j.1365-2184.1996.00999.x; Giri N, 2001, EXP HEMATOL, V29, P779, DOI 10.1016/S0301-472X(01)00646-4; GONG JK, 1978, SCIENCE, V199, P1443, DOI 10.1126/science.75570; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Karanu FN, 2001, BLOOD, V97, P1960, DOI 10.1182/blood.V97.7.1960; Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365; Kiger AA, 2000, NATURE, V407, P750, DOI 10.1038/35037606; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; LORD BI, 1990, INT J CELL CLONING, V8, P317, DOI 10.1002/stem.5530080501; LORD BI, 1975, BLOOD, V46, P65; Pereira RMR, 2002, J CELL BIOCHEM, V85, P252, DOI 10.1002/jcb.10125; PLOEMACHER RE, 1991, BLOOD, V78, P2527; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Stier S, 2002, BLOOD, V99, P2369, DOI 10.1182/blood.V99.7.2369; Taichman RS, 1996, BLOOD, V87, P518, DOI 10.1182/blood.V87.2.518.bloodjournal872518; TAICHMAN RS, 1994, J EXP MED, V179, P1677, DOI 10.1084/jem.179.5.1677; Taichman RS, 2001, BRIT J HAEMATOL, V112, P438, DOI 10.1046/j.1365-2141.2001.02568.x; Taichman RUSSELL S., 2000, Hematology, V4, P421; Tran J, 2000, NATURE, V407, P754, DOI 10.1038/35037613; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Varnum-Finney B, 2003, BLOOD, V101, P1784, DOI 10.1182/blood-2002-06-1862; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	26	2587	2743	5	188	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 23	2003	425	6960					841	846		10.1038/nature02040	http://dx.doi.org/10.1038/nature02040			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574413	Bronze			2022-12-28	WOS:000186118500046
J	Koller, J; Baumer, U; Kaup, Y; Schmid, M; Weser, U				Koller, J; Baumer, U; Kaup, Y; Schmid, M; Weser, U			Ancient materials - Analysis of a pharaonic embalming tar	NATURE			English	Editorial Material									Bayer Staatsgemaldesammlungen, Doerner Inst, D-80799 Munich, Germany; Univ Tubingen, Inst Physiol Chem, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Koller, J (corresponding author), Bayer Staatsgemaldesammlungen, Doerner Inst, D-80799 Munich, Germany.							Charnov EL, 2000, EVOL ECOL RES, V2, P1067; David A.R., 2000, ANCIENT EGYPTIAN MAT, P372; FORBES RJ, 1965, STUDIES ANCIENT TECH, V3, P190; Griffiths J. G. A., 1937, ANALYST, V62, P703; Herodotus, 1954, HISTORIES, P160; KAUP Y, 2001, J AM RES CTR EGYPT, V38, P115; Lucas A., 1931, J EGYPT ARCHAEOL, V17, P13; PAIX O, 1990, HOLZ ALS ROH WERKSTO, V48, P281; Pliny the Elder, 1960, NATURAL HIST, V4; TOTH L, 1985, CHEM UNSERER ZEIT, V19, P48, DOI 10.1002/ciuz.19850190204	10	26	27	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 23	2003	425	6960					784	784		10.1038/425784a	http://dx.doi.org/10.1038/425784a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	735ME	14574400	Bronze			2022-12-28	WOS:000186118500033
J	Mao, WL; Mao, HK; Eng, PJ; Trainor, TP; Newville, M; Kao, CC; Heinz, DL; Shu, JF; Meng, Y; Hemley, RJ				Mao, WL; Mao, HK; Eng, PJ; Trainor, TP; Newville, M; Kao, CC; Heinz, DL; Shu, JF; Meng, Y; Hemley, RJ			Bonding changes in compressed superhard graphite	SCIENCE			English	Article							X-RAY-DIFFRACTION; HIGH-PRESSURE; HEXAGONAL DIAMOND; TRANSPARENT PHASE; ROOM-TEMPERATURE; CARBON; TRANSFORMATION; GPA	Compressed under ambient temperature, graphite undergoes a transition at similar to17 gigapascals. The near K-edge spectroscopy of carbon using synchrotron x-ray inelastic scattering reveals that half of the pi-bonds between graphite layers convert to sigma-bonds, whereas the other half remain as pi-bonds in the high-pressure form. The x-ray diffraction pattern of the high-pressure form is consistent with a distorted graphite structure in which bridging carbon atoms between graphite layers pair and form sigma-bonds, whereas the nonbridging carbon atoms remain unpaired with pi-bonds. The high-pressure form is superhard, capable of indenting cubic-diamond single crystals.	Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA; Univ Chicago, Consortium Adv Radiat Sources, Chicago, IL 60637 USA; Univ Chicago, James Franck Inst, Chicago, IL 60637 USA; Carnegie Inst Washington, Geophys Lab, Washington, DC 20015 USA; Brookhaven Natl Lab, Natl Synchrotron Light Source, Upton, NY 11973 USA; Argonne Natl Lab, Adv Photon Source, High Pressure Coolaborat Access Team, Argonne, IL 60439 USA; Univ Alabama, Dept Chem & Biochem, Fairbanks, AK 99775 USA	University of Chicago; University of Chicago; University of Chicago; Carnegie Institution for Science; State University of New York (SUNY) System; United States Department of Energy (DOE); Brookhaven National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory; University of Alabama System	Mao, WL (corresponding author), Univ Chicago, Dept Geophys Sci, 5734 S Ellis Ave, Chicago, IL 60637 USA.		Newville, Matthew G/B-3372-2009; Mao, Wendy/D-1885-2009; Eng, Peter/ABA-8842-2021; Newville, Matthew/GNP-3282-2022	Newville, Matthew G/0000-0001-6938-1014; Eng, Peter/0000-0002-8072-3203; 				BUNDY FP, 1967, J CHEM PHYS, V46, P3437, DOI 10.1063/1.1841236; Bundy FP, 1996, CARBON, V34, P141, DOI 10.1016/0008-6223(96)00170-4; Cody GD, 1998, ORG GEOCHEM, V28, P441, DOI 10.1016/S0146-6380(98)00010-2; Goncharov AF, 1992, HIGH PRESSURE RES, V8, P607; GONCHAROV AF, 1989, ZH EKSP TEOR FIZ, V69, P380; HANFLAND M, 1989, PHYS REV B, V39, P12598, DOI 10.1103/PhysRevB.39.12598; HANFLAND M, 1989, PHYS REV B, V40, P1951, DOI 10.1103/PhysRevB.40.1951; Miller ED, 1997, CHEM MATER, V9, P18, DOI 10.1021/cm960288k; Sung J, 2000, J MATER SCI, V35, P6041, DOI 10.1023/A:1026779802263; Takemura K, 2001, J APPL PHYS, V89, P662, DOI 10.1063/1.1328410; UTSUMI W, 1991, SCIENCE, V252, P1542; Xu JA, 2002, J PHYS-CONDENS MAT, V14, P11549, DOI 10.1088/0953-8984/14/44/514; YAGI T, 1992, PHYS REV B, V46, P6031, DOI 10.1103/PhysRevB.46.6031; Zha CS, 2000, P NATL ACAD SCI USA, V97, P13494, DOI 10.1073/pnas.240466697; ZHAO YX, 1989, PHYS REV B, V40, P993, DOI 10.1103/PhysRevB.40.993	15	525	533	8	218	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					425	427		10.1126/science.1089713	http://dx.doi.org/10.1126/science.1089713			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564003				2022-12-28	WOS:000185963200036
J	Fromme, E; Billings, JA				Fromme, E; Billings, JA			Care of the dying doctor - On the other end of the stethoscope	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN-PATIENT; MEDICAL-PRACTICE; ROLE REVERSAL; HEAL THYSELF; PERSPECTIVE; FAMILIES; ANXIETY; SICK; ILLNESS; QUALITY	The challenges of caring for a dying doctor reflect both common issues in helping the terminally ill and unique problems in working with a physician-patient. The dying doctor must deal with a familiar environment and set of problems from a radically different perspective and must negotiate overlapping and conflicting personal and professional roles. Some of the cardinal virtues of physicians-professional identity, expertise, perfectionism, selflessness, and stoicism-may pose both strengths and liabilities in the patient's role. The treating physicians may also encounter new strains in caring for a colleague. They must guard against both overinvolvement and underinvolvement, and, as with all dying persons, they must serve as a guide through unfamiliar territory for dying patient and family-a companion who is not afraid to listen to or explore the most upsetting matters, a person who can speak frankly when others may be ignoring "the horse on the dining room table." The case of Dr B, an internist dying of myelofibrosis and congestive heart failure, whose son is also a physician, offers the reader the opportunity to reflect on these challenges and to draw lessons about how to best care for fellow physicians at a time of great need. We suggest strategies for negotiating the patient-physician relationship when the patient is also a physician.	Massachusetts Gen Hosp, Palliat Care Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Ctr Palliat Care, Boston, MA USA; Oregon Hlth Sci Univ, Portland, OR 97201 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Oregon Health & Science University; Harvard University; Harvard Medical School	Billings, JA (corresponding author), Massachusetts Gen Hosp, Palliat Care Serv, FND 600,55 Fruit St, Boston, MA 02114 USA.				NATIONAL CANCER INSTITUTE [R25CA082174, R25CA066818] Funding Source: NIH RePORTER; NCI NIH HHS [R25 CA 66818-04, R25 CA 82174-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLIBONE A, 1990, PRACTITIONER, V234, P984; Allibone A, 1981, J R Coll Gen Pract, V31, P728; *AM MED ASS, 1847, DUT PHYS EACH OTH PR, P9; AOUN H, 1992, ANN INTERN MED, V116, P335, DOI 10.7326/0003-4819-116-4-335; Back Anthony L, 2003, Ann Intern Med, V138, P439; Baldwin PJ, 1997, SOC SCI MED, V45, P41, DOI 10.1016/S0277-9536(96)00307-3; Bean RB, 1950, W OSLER APHORISMS HI; Bennet G, 1997, BRIT MED J, V314, P1908, DOI 10.1136/bmj.314.7098.1908; Berwick DM, 1996, ANN INTERN MED, V125, P839, DOI 10.7326/0003-4819-125-10-199611150-00009; BILLINGS J, IN PRESS CECIL TXB M; Bone RC, 1996, JAMA-J AM MED ASSOC, V276, P1931, DOI 10.1001/jama.276.24.1931; BONE RC, 1995, JAMA-J AM MED ASSOC, V274, P1656, DOI 10.1001/jama.274.21.1656; BOWES D, 1984, CAN MED ASSOC J, V131, P1343; British Medical Association, 1995, ETH RESP INV TREAT D; Cassell EJ, 1999, ANN INTERN MED, V131, P531, DOI 10.7326/0003-4819-131-7-199910050-00009; CASSELL EJ, 1991, MYSTERIOUS RELATIONS, P66; Chen FM, 2001, J FAM PRACTICE, V50, P762; Choa RG, 1998, BRIT MED J, V316, P1089; COHN KH, 1982, LANCET, V1, P1006; EDELSTEIN EL, 1982, PSYCHIAT CLIN, V15, P177, DOI 10.1159/000283938; ELLARD J, 1974, MED J AUSTRALIA, V2, P318, DOI 10.5694/j.1326-5377.1974.tb70807.x; ENDE J, 1990, J GEN INTERN MED, V5, P506, DOI 10.1007/BF02600881; ENGLISH TL, 1991, JAMA-J AM MED ASSOC, V265, P964, DOI 10.1001/jama.265.8.964; Forsythe M, 1999, BRIT MED J, V319, P605, DOI 10.1136/bmj.319.7210.605; GABBARD GO, 1985, JAMA-J AM MED ASSOC, V254, P2926, DOI 10.1001/jama.254.20.2926; GABBARD GO, 1995, JAMA-J AM MED ASSOC, V273, P1445, DOI 10.1001/jama.273.18.1445; Gallegos K V, 1990, Md Med J, V39, P1007; GLASS GS, 1975, PSYCHIATRY, V38, P132, DOI 10.1080/00332747.1975.11023843; GOLD N, 1972, AUST NZ J PSYCHIAT, V6, P209, DOI 10.3109/00048677209159712; Goldberger JJ, 1997, AM HEART J, V134, P119, DOI 10.1016/S0002-8703(97)70115-7; GROOPMAN J, 1998, NEW YORKER      1026, P78; Gross CP, 2000, ARCH INTERN MED, V160, P3209, DOI 10.1001/archinte.160.21.3209; GROVES JE, 1978, NEW ENGL J MED, V298, P883, DOI 10.1056/NEJM197804202981605; HAEFNER HK, 1994, ANN INTERN MED, V120, P806, DOI 10.7326/0003-4819-120-9-199405010-00013; HEY S, 1994, BRIT MED J, V309, P1235, DOI 10.1136/bmj.309.6963.1235; Horn MO, 1999, ANN INTERN MED, V130, P940, DOI 10.7326/0003-4819-130-11-199906010-00020; HORN MO, 1996, AM J GASTROENTEROL, V91, P1299; INGELFINGER FJ, 1980, NEW ENGL J MED, V303, P1507, DOI 10.1056/NEJM198012253032604; KANE AC, 1985, OMEGA-J DEATH DYING, V16, P11; Kastenbaum R. J., 2001, DEATH SOC HUMAN EXPE; Klein MC, 1997, CAN MED ASSOC J, V156, P53; Lamberg L, 1999, JAMA-J AM MED ASSOC, V282, P13, DOI 10.1001/jama.282.1.13; LAPUMA J, 1992, JAMA-J AM MED ASSOC, V267, P1810, DOI 10.1001/jama.267.13.1810; MARZUK PM, 1987, NEW ENGL J MED, V317, P1409, DOI 10.1056/NEJM198711263172209; MCCUE JD, 1982, NEW ENGL J MED, V306, P458, DOI 10.1056/NEJM198202253060805; Meier DE, 2001, JAMA-J AM MED ASSOC, V286, P3007, DOI 10.1001/jama.286.23.3007; Miller MN, 2000, SOUTH MED J, V93, P966; MOR S, 1995, COGNITIVE THER RES, V19, P207, DOI 10.1007/BF02229695; MORGAN P, 1997, CANC PERSONAL VOYAGE; Mount B M, 1994, J Palliat Care, V10, P24; MULLAN F, 1985, NEW ENGL J MED, V313, P270, DOI 10.1056/NEJM198507253130421; Mullan F, 1983, VITAL SIGNS YOUNG DO; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; OSLER W, 1932, AEQUANIMITAS OTHER A, P2; Poulson J, 1998, NEW ENGL J MED, V338, P1844, DOI 10.1056/NEJM199806183382512; PULLEN D, 1995, MED J AUSTRALIA, V162, P481, DOI 10.5694/j.1326-5377.1995.tb140011.x; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; QUILL TE, 1995, ARCH INTERN MED, V155, P1250, DOI 10.1001/archinte.155.12.1250; RABIN D, 1982, NEW ENGL J MED, V307, P506, DOI 10.1056/NEJM198208193070827; ROBBINS GF, 1953, CANCER, V6, P624, DOI 10.1002/1097-0142(195305)6:3<624::AID-CNCR2820060320>3.0.CO;2-0; Rosen IM, 2000, J GEN INTERN MED, V15, P116, DOI 10.1046/j.1525-1497.2000.11218.x; ROSENBAUM EE, 1988, DOCTOR, P42; Scally G, 1996, LANCET, V347, P1059, DOI 10.1016/S0140-6736(96)90273-1; Schneck SA, 1998, JAMA-J AM MED ASSOC, V280, P2039, DOI 10.1001/jama.280.23.2039; SCHWARTZ JS, 1991, ANN INTERN MED, V114, P46, DOI 10.7326/0003-4819-114-1-46; Sontag Susan, 1983, ILLNESS METAPHOR AID, P59; Spiro HM, 1998, ANN INTERN MED, V128, P152, DOI 10.7326/0003-4819-128-2-199801150-00014; STETTEN D, 1981, NEW ENGL J MED, V305, P458, DOI 10.1056/NEJM198108203050811; STILLMAN AE, 1995, NEW ENGL J MED, V333, P1086, DOI 10.1056/NEJM199510193331618; STOUDEMIRE A, 1983, ANN INTERN MED, V98, P654, DOI 10.7326/0003-4819-98-5-654; Thompson WT, 2001, BRIT MED J, V323, P728, DOI 10.1136/bmj.323.7315.728; Tierney WM, 2002, MED CARE, V40, P20; Toyry S, 2000, ARCH FAM MED, V9, P1079, DOI 10.1001/archfami.9.10.1079; Vachon MLS, 2001, OXFORD TXB PALLIATIV, P919; VAILLANT GE, 1972, NEW ENGL J MED, V287, P372, DOI 10.1056/NEJM197208242870802; Villarosa L, 2001, NY TIMES; Viner E D, 1994, Trends Health Care Law Ethics, V9, P43; Waldron HA, 1996, LANCET, V347, P1558, DOI 10.1016/S0140-6736(96)90712-6; Waldron HA, 1996, ANN OCCUP HYG, V40, P391, DOI 10.1093/annhyg/40.4.391; WEINTRAUB W, 1964, J NERV MENT DIS, V138, P181, DOI 10.1097/00005053-196402000-00012; Wines AP, 1998, AUST NZ J SURG, V68, P778, DOI 10.1111/j.1445-2197.1998.tb04675.x; ZINN WM, 1988, JAMA-J AM MED ASSOC, V259, P3296, DOI 10.1001/jama.259.22.3296; ZINN WM, 1990, ANN INTERN MED, V113, P293, DOI 10.7326/0003-4819-113-4-293; 1972, MED WORLD NEWS, P56	84	23	24	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	2003	290	15					2048	2055		10.1001/jama.290.15.2048	http://dx.doi.org/10.1001/jama.290.15.2048			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732CX	14559959				2022-12-28	WOS:000185924200029
J	Panksepp, J				Panksepp, J			Feeling the pain of social loss	SCIENCE			English	Editorial Material							FUNCTIONAL NEUROANATOMY; BRAIN ACTIVITY; REWARD; RESPONSES; FMRI		Bowling Green State Univ, Dept Psychol, JP Scott Ctr Neurosci Mind & Behav, Bowling Green, OH 43403 USA; Northwestern Univ, Dept Biomed Engn, Falk Ctr Mol Therapeut, Evanston, IL 60201 USA	University System of Ohio; Bowling Green State University; Northwestern University	Panksepp, J (corresponding author), Bowling Green State Univ, Dept Psychol, JP Scott Ctr Neurosci Mind & Behav, Bowling Green, OH 43403 USA.	jpankse@bgnet.bgsu.edu						Aharon I, 2001, NEURON, V32, P537, DOI 10.1016/S0896-6273(01)00491-3; Blood AJ, 2001, P NATL ACAD SCI USA, V98, P11818, DOI 10.1073/pnas.191355898; Carter CS, 2000, P NATL ACAD SCI USA, V97, P1944, DOI 10.1073/pnas.97.4.1944; Damasio AR, 2000, NAT NEUROSCI, V3, P1049, DOI 10.1038/79871; Decety J, 2003, NEUROPSYCHOLOGIA, V41, P127, DOI 10.1016/S0028-3932(02)00143-4; Eisenberger NI, 2003, SCIENCE, V302, P290, DOI 10.1126/science.1089134; HERMAN BH, 1981, SCIENCE, V211, P1060, DOI 10.1126/science.7466377; Kern MK, 2001, AM J PHYSIOL-GASTR L, V281, pG1512, DOI 10.1152/ajpgi.2001.281.6.G1512; Knutson B, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-16-j0002.2001; Liotti M, 2001, P NATL ACAD SCI USA, V98, P2035, DOI 10.1073/pnas.98.4.2035; Mayberg HS, 2002, AM J PSYCHIAT, V159, P728, DOI 10.1176/appi.ajp.159.5.728; MILLER A, 1995, ROAD BEYOND LOSS; Panksepp J, 2003, PSYCHOL REV, V110, P376, DOI 10.1037/0033-295X.110.2.376; PANKSEPP J, 1980, NEUROSCI BIOBEHAV R, V4, P473, DOI 10.1016/0149-7634(80)90036-6; PANKSEPP J, 1980, PSYCHOPHARMACOLOGY, V72, P111, DOI 10.1007/BF00433816; Panksepp J., 2000, CONSCIOUSNESS EMOTIO, V1, P17; Panksepp J., 1981, PROGR THEORY PSYCHOP, P149; Panksepp J., 1988, PHYSL CONTROL MAMMAL, P263, DOI 10.1007/978-1-4613-1051-8_15; Panksepp J., 1998, AFFECTIVE NEUROSCIEN; Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087; Redoute J, 2000, HUM BRAIN MAPP, V11, P162, DOI 10.1002/1097-0193(200011)11:3<162::AID-HBM30>3.0.CO;2-A; Small DM, 2001, BRAIN, V124, P1720, DOI 10.1093/brain/124.9.1720	22	170	174	1	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					237	239		10.1126/science.1091062	http://dx.doi.org/10.1126/science.1091062			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	730HT	14551424				2022-12-28	WOS:000185825900026
J	Wapner, R; Thom, E; Simpson, JL; Pergament, E; Silver, R; Filkins, K; Platt, L; Mahoney, M; Johnson, A; Hogge, WA; Wilson, RD; Mohide, P; Hershey, D; Krantz, D; Zachary, J; Snijders, R; Greene, N; Sabbagha, R; MacGregor, S; Hill, L; Gagnon, A; Hallahan, T; Jackson, L				Wapner, R; Thom, E; Simpson, JL; Pergament, E; Silver, R; Filkins, K; Platt, L; Mahoney, M; Johnson, A; Hogge, WA; Wilson, RD; Mohide, P; Hershey, D; Krantz, D; Zachary, J; Snijders, R; Greene, N; Sabbagha, R; MacGregor, S; Hill, L; Gagnon, A; Hallahan, T; Jackson, L		BUN Study Grp	First-trimester screening for trisomies 21 and 18	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NUCHAL TRANSLUCENCY MEASUREMENT; HUMAN CHORIONIC-GONADOTROPIN; DOWNS-SYNDROME; FIRST-TRIMESTER; MATERNAL SERUM; FETAL DNA; TRISOMY-21; FETUSES; BLOOD; RISK	BACKGROUND: Screening for aneuploid pregnancies is routinely performed after 15 weeks of gestation and has a sensitivity of approximately 65 percent, with a false positive rate of 5 percent. First-trimester markers of aneuploidy have been developed, but their use in combination has not been adequately evaluated in clinical practice. METHODS: We conducted a multicenter study of screening for trisomies 21 and 18 among patients with pregnancies between 74 and 97 days of gestation, based on maternal age, maternal levels of free (beta) human chorionic gonadotropin and pregnancy-associated plasma protein A, and ultrasonographic measurement of fetal nuchal translucency. A screening result was considered to be positive for trisomy 21 if the calculated risk was at least 1 in 270 pregnancies and positive for trisomy 18 if the risk was at least 1 in 150. RESULTS: Screening was completed in 8514 patients with singleton pregnancies. This approach to screening identified 85.2 percent of the 61 cases of Down's syndrome (95 percent confidence interval, 73.8 to 93.0), with a false positive rate of 9.4 percent (95 percent confidence interval, 8.8 to 10.1). At a false positive rate of 5 percent, the detection rate was 78.7 percent (95 percent confidence interval, 66.3 to 88.1). Screening identified 90.9 percent of the 11 cases of trisomy 18 (95 percent confidence interval, 58.7 to 99.8), with a 2 percent false positive rate. Among women 35 years of age or older, screening identified 89.8 percent of fetuses with trisomy 21, with a false positive rate of 15.2 percent, and 100 percent of fetuses with trisomy 18. CONCLUSIONS: First-trimester screening for trisomies 21 and 18 on the basis of maternal age, maternal levels of free (beta) human chorionic gonadotropin and pregnancy-associated plasma protein A, and measurement of fetal nuchal translucency has good sensitivity at an acceptable false positive rate.	Drexel Univ, Coll Med, Dept Obstet & Gynecol, Philadelphia, PA 19102 USA; George Washington Univ, Ctr Biostat, Washington, DC USA; Baylor Coll Med, Houston, TX 77030 USA; Northwestern Univ, Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA; Northwestern Univ, Evanston Hosp, Sch Med, Fetal Diagnost Ctr, Evanston, IL 60201 USA; Univ Calif Los Angeles, Ctr Hlth Sci, Los Angeles, CA 90024 USA; Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Los Angeles, CA 90048 USA; Yale Univ, New Haven, CT USA; Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI USA; Magee Womens Hosp, Pittsburgh, PA USA; BC Womens Hosp, Vancouver, BC, Canada; McMaster Univ, Med Ctr, Hamilton, ON, Canada; Prenatal Diag No Calif Med Grp, Sacramento, CA USA; NTD Labs, Huntington Stn, NY USA	Drexel University; George Washington University; Baylor College of Medicine; Northwestern University; NorthShore University Health System; Northwestern University; University of California System; University of California Los Angeles; Cedars Sinai Medical Center; Yale University; Wayne State University; University of British Columbia; McMaster University	Wapner, R (corresponding author), Drexel Univ, Coll Med, Dept Obstet & Gynecol, 245 N 15th St,MS 495, Philadelphia, PA 19102 USA.			Snijders, Rosalinde/0000-0003-1809-7886	NICHD NIH HHS [R01 HD31991, R01 HD32109] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031991, R01HD032109] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bianchi DW, 1997, AM J HUM GENET, V61, P822, DOI 10.1086/514885; Borrell A, 1998, AM J OBSTET GYNECOL, V179, P1612, DOI 10.1016/S0002-9378(98)70034-1; *CDCP, 1999, LIV BIRTH DAT 1999 C, V21; Cicero S, 2001, LANCET, V358, P1665, DOI 10.1016/S0140-6736(01)06709-5; CUCKLE H, 1995, PRENATAL DIAG, V15, P1057, DOI 10.1002/pd.1970151111; CUCKLE H, 1996, EARLY HUM DEV, V47, P27; De Biasio P, 1999, PRENATAL DIAG, V19, P360, DOI 10.1002/(SICI)1097-0223(199904)19:4<360::AID-PD556>3.0.CO;2-U; Dunstan FDJ, 1998, ANN CLIN BIOCHEM, V35, P57, DOI 10.1177/000456329803500106; Haddow JE, 1998, NEW ENGL J MED, V338, P955, DOI 10.1056/NEJM199804023381404; HADDOW JE, 1994, NEW ENGL J MED, V330, P1114, DOI 10.1056/NEJM199404213301603; Krantz DA, 1996, AM J OBSTET GYNECOL, V174, P612, DOI 10.1016/S0002-9378(96)70436-2; Krantz DA, 2000, OBSTET GYNECOL, V96, P207, DOI 10.1016/S0029-7844(00)00881-4; Lo YMD, 1999, CLIN CHEM, V45, P1747; Macri JN, 1996, AM J OBSTET GYNECOL, V174, P566, DOI 10.1016/S0002-9378(96)70429-5; Morris JK, 1999, PRENATAL DIAG, V19, P142, DOI 10.1002/(SICI)1097-0223(199902)19:2<142::AID-PD486>3.3.CO;2-Z; Schuchter K, 2001, ULTRASOUND OBST GYN, V18, P23, DOI 10.1046/j.1469-0705.2001.00458.x; Snijders RJM, 2002, ULTRASOUND OBST GYN, V19, P353, DOI 10.1046/j.1469-0705.2002.00637.x; Snijders RJM, 1998, LANCET, V352, P343, DOI 10.1016/S0140-6736(97)11280-6; Snijders RJM, 1999, ULTRASOUND OBST GYN, V13, P167, DOI 10.1046/j.1469-0705.1999.13030167.x; Wald NJ, 2003, LANCET, V361, P835, DOI 10.1016/S0140-6736(03)12680-3; Wald NJ, 1999, NEW ENGL J MED, V341, P461, DOI 10.1056/NEJM199908123410701; Zhang DD, 2002, STAT MED, V21, P701, DOI 10.1002/sim.1011; Zhong XY, 2000, PRENATAL DIAG, V20, P795	23	369	442	0	14	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	2003	349	15					1405	1413		10.1056/NEJMoa025273	http://dx.doi.org/10.1056/NEJMoa025273			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729JF	14534333				2022-12-28	WOS:000185769500003
J	Denning, DW				Denning, DW			Echinocandin antifungal drugs	LANCET			English	Review							IN-VITRO ACTIVITY; AMPHOTERICIN-B; ASPERGILLUS-FUMIGATUS; DISSEMINATED CANDIDIASIS; INVASIVE ASPERGILLOSIS; DOUBLE-BLIND; CELL-WALL; PNEUMOCYSTIS-CARINII; MOUSE MODELS; PULMONARY ASPERGILLOSIS	The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp. They are not active at clinically relevant concentrations against Zygomycetes, Cryptococcus neoformans, or Fusarium spp. No drug target is present in mammalian cells. The first of the class to be licensed was caspofungin, for refractory invasive aspergillosis (about 40% response rate) and the second was micafungin. Adverse events are generally mild, including (for caspofungin) local phlebitis, fever, abnormal liver function tests, and mild haemolysis. Poor absorption after oral administration limits use to the intravenous route. Dosing is once daily and drug interactions are few. The echinocandins are widely distributed in the body, and are metabolised by the liver. Results of studies of caspofungin in candidaemia and invasive candidiasis suggest equivalent efficacy to amphotericin B, with substantially fewer toxic effects. Absence of antagonism in combination with other antifungal drugs suggests that combination antifungal therapy could become a general feature of the echinocandins, particularly for invasive aspergillosis.	Wythenshawe Hosp, Educ & Res Ctr, Manchester M23 9LT, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Denning, DW (corresponding author), Wythenshawe Hosp, Educ & Res Ctr, Southmoor Rd, Manchester M23 9LT, Lancs, England.	ddenning@man.ac.uk	Denning, David/AAC-6931-2019	Denning, David/0000-0001-5626-2251				Abruzzo GK, 2000, ANTIMICROB AGENTS CH, V44, P2310, DOI 10.1128/AAC.44.9.2310-2318.2000; Abruzzo GK, 1997, ANTIMICROB AGENTS CH, V41, P2333, DOI 10.1128/AAC.41.11.2333; Aliff TB, 2003, CANCER-AM CANCER SOC, V97, P1025, DOI 10.1002/cncr.11115; Ally R, 2001, CLIN INFECT DIS, V33, P1447, DOI 10.1086/322653; Arathoon EG, 2002, ANTIMICROB AGENTS CH, V46, P451, DOI 10.1128/AAC.46.2.451-457.2002; Arikan S, 2002, ANTIMICROB AGENTS CH, V46, P245, DOI 10.1128/AAC.46.1.245-247.2002; BACHMANN SP, 2002, 42 INT C ANT AG CHEM; Barchiesi F, 1999, EUR J CLIN MICROBIOL, V18, P302; Bartizal K, 1997, ANTIMICROB AGENTS CH, V41, P2326, DOI 10.1128/AAC.41.11.2326; Beauvais A, 2001, J BACTERIOL, V183, P2273, DOI 10.1128/JB.183.7.2273-2279.2001; Bernard M, 2001, MED MYCOL, V39, P9, DOI 10.1080/mmy.39.1.9.17; Bowman JC, 2002, ANTIMICROB AGENTS CH, V46, P3001, DOI 10.1128/AAC.46.9.3001-3012.2002; Bowman JC, 2001, ANTIMICROB AGENTS CH, V45, P3474, DOI 10.1128/AAC.45.12.3474-3481.2001; BROWN GL, 2000, 40 INT C ANT AG CHEM, P371; Cabello M. Angeles, 2001, International Microbiology, V4, P93; Chiller T, 2000, ANTIMICROB AGENTS CH, V44, P3302, DOI 10.1128/AAC.44.12.3302-3305.2000; Chiou CC, 2001, ANTIMICROB AGENTS CH, V45, P3310, DOI 10.1128/AAC.45.12.3310-3321.2001; Cuenca-Estrella M, 2000, J ANTIMICROB CHEMOTH, V46, P475, DOI 10.1093/jac/46.3.475; CURRENT WL, 1995, DISCOVERY MODE ACTIO, P143; Del Poeta M, 2000, ANTIMICROB AGENTS CH, V44, P739, DOI 10.1128/AAC.44.3.739-746.2000; Denning DW, 2002, CLIN INFECT DIS, V34, P563, DOI 10.1086/324620; DENNING DW, 1994, AM J MED, V97, P135, DOI 10.1016/0002-9343(94)90023-X; Denning DW, 1998, CLIN INFECT DIS, V26, P781, DOI 10.1086/513943; Douglas CM, 1997, ANTIMICROB AGENTS CH, V41, P2471, DOI 10.1128/AAC.41.11.2471; Douglas CM, 2001, MED MYCOL, V39, P55, DOI 10.1080/mmy.39.1.55.66; Espinel-Ingroff A, 1998, J CLIN MICROBIOL, V36, P2950, DOI 10.1128/JCM.36.10.2950-2956.1998; *FDA ADV COMM, CASP AC FDA ADV COMM; Franzot SP, 1997, ANTIMICROB AGENTS CH, V41, P331, DOI 10.1128/AAC.41.2.331; GEISS HK, 2002, 42 INT C ANT AG CHEM; Gonzalez GM, 2001, ANTIMICROB AGENTS CH, V45, P1854, DOI 10.1128/AAC.45.6.1854-1859.2001; Grant AD, 1997, AIDS, V11, P1357, DOI 10.1097/00002030-199711000-00010; Graybill JR, 1997, ANTIMICROB AGENTS CH, V41, P1775, DOI 10.1128/AAC.41.8.1775; Graybill JR, 1997, ANTIMICROB AGENTS CH, V41, P1937, DOI 10.1128/AAC.41.9.1937; Green LJ, 1999, ANTIMICROB AGENTS CH, V43, P830, DOI 10.1128/AAC.43.4.830; Groll AH, 1996, J INFECTION, V33, P23, DOI 10.1016/S0163-4453(96)92700-0; Groll AH, 2001, ANTIMICROB AGENTS CH, V45, P2845, DOI 10.1128/AAC.45.10.2845-2855.2001; HEIMENZ J, 1999, 39 INT C ANT AG CHEM; Herbrecht R, 2002, NEW ENGL J MED, V347, P408, DOI 10.1056/NEJMoa020191; HOLLAND S, 2001, 41 INT C ANT AG CHEM; Ikeda F, 2000, ANTIMICROB AGENTS CH, V44, P614, DOI 10.1128/AAC.44.3.614-618.2000; Ito M, 2000, ANTIMICROB AGENTS CH, V44, P2259, DOI 10.1128/AAC.44.9.2259-2262.2000; IWAMOTO T, 1994, J ANTIBIOT, V47, P1084; Ju JY, 2002, ANTIMICROB AGENTS CH, V46, P1240, DOI 10.1128/AAC.46.5.1240-1245.2002; Kartsonis N, 2002, JAIDS-J ACQ IMM DEF, V31, P183, DOI 10.1097/00126334-200210010-00009; Kirkpatrick WR, 2002, ANTIMICROB AGENTS CH, V46, P2564, DOI 10.1128/AAC.46.8.2564-2568.2002; Klis FM, 2001, MED MYCOL, V39, P1, DOI 10.1080/744118876; Kohler S, 2000, ANTIMICROB AGENTS CH, V44, P1850, DOI 10.1128/AAC.44.7.1850-1854.2000; KOHNO S, 2001, 41 INT C ANT AG CHEM, P384; KONTOYIANNIS DP, 2002, 42 INT C ANT AG CHEM; Kottom TJ, 2000, J BIOL CHEM, V275, P40628, DOI 10.1074/jbc.M002103200; KRAUSE D, 2002, 42 INT C ANT AG CHEM; KRAUSE D, 2003, P 13 EUR C CLIN MICR, P73; Kuhn DM, 2002, ANTIMICROB AGENTS CH, V46, P1773, DOI 10.1128/AAC.46.6.1773-1780.2002; Kurtz MB, 2001, ADV PROTEIN CHEM, V56, P423; KURTZ MB, 1994, ANTIMICROB AGENTS CH, V38, P1480, DOI 10.1128/AAC.38.7.1480; LUCAS R, 1996, 36 INT C ANT AG CHEM; MAERTENS J, 2002, 42 INT C ANT AG CHEM, P388; Maesaki S, 2000, ANTIMICROB AGENTS CH, V44, P1728, DOI 10.1128/AAC.44.6.1728-1730.2000; MAESAKI S, 2000, 40 INT C ANT AG CHEM, P388; Marchetti O, 2000, ANTIMICROB AGENTS CH, V44, P2373, DOI 10.1128/AAC.44.9.2373-2381.2000; Marr KA, 2000, BLOOD, V96, P2055; MASUREKAR PS, 1992, J ANTIBIOT, V45, P1867, DOI 10.7164/antibiotics.45.1867; Matsumoto S, 2000, ANTIMICROB AGENTS CH, V44, P619, DOI 10.1128/AAC.44.3.619-621.2000; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; Mikamo H, 2000, J ANTIMICROB CHEMOTH, V46, P485, DOI 10.1093/jac/46.3.485; Moore CB, 2000, J INFECTION, V41, P203, DOI 10.1053/jinf.2000.0747; Moore CB, 2001, CLIN MICROBIOL INFEC, V7, P11, DOI 10.1046/j.1469-0691.2001.00158.x; MOORE CB, 2002, 42 INT C ANT AG CHEM; Moore RD, 1996, ANN INTERN MED, V124, P633, DOI 10.7326/0003-4819-124-7-199604010-00003; Mora-Duarte J, 2002, NEW ENGL J MED, V347, P2020, DOI 10.1056/NEJMoa021585; Nyfeler R, 1974, Helv Chim Acta, V57, P2459; Oakley KL, 1998, ANTIMICROB AGENTS CH, V42, P2726, DOI 10.1128/AAC.42.10.2726; Ohyama T, 2000, J ANTIBIOT, V53, P1108, DOI 10.7164/antibiotics.53.1108; Osherov N, 2002, ANTIMICROB AGENTS CH, V46, P2462, DOI 10.1128/AAC.46.8.2462-2469.2002; PARENT SA, 1993, J GEN MICROBIOL, V139, P2973, DOI 10.1099/00221287-139-12-2973; Pelaez F, 2000, SYST APPL MICROBIOL, V23, P333, DOI 10.1016/S0723-2020(00)80062-4; Perea S, 2002, ANTIMICROB AGENTS CH, V46, P3039, DOI 10.1128/AAC.46.9.3039-3041.2002; PETER J, 2002, 42 INT C ANT AG CHEM; Petraitiene R, 1999, ANTIMICROB AGENTS CH, V43, P2148, DOI 10.1128/AAC.43.9.2148; Petraitiene R, 2002, ANTIMICROB AGENTS CH, V46, P12, DOI 10.1128/AAC.46.1.12-23.2002; PETRAITIENE R, 2002, 42 INT C ANT AG CHEM, P385; Petraitis V, 2002, ANTIMICROB AGENTS CH, V46, P1857, DOI 10.1128/AAC.46.6.1857-1869.2002; Petraitis V, 2001, ANTIMICROB AGENTS CH, V45, P471, DOI 10.1128/AAC.45.2.471-479.2001; PETTENGELL K, 2000, 40 INT C ANT AG CHEM, P371; Pfaller MA, 1999, DIAGN MICR INFEC DIS, V35, P19, DOI 10.1016/S0732-8893(99)00046-2; Phillips P, 1997, EUR J CLIN MICROBIOL, V16, P337, DOI 10.1007/BF01726360; Popolo L, 2001, MED MYCOL, V39, P111, DOI 10.1080/744118881; Powles MA, 1998, ANTIMICROB AGENTS CH, V42, P1985, DOI 10.1128/AAC.42.8.1985; RAJMAN I, 1996, 36 INT C ANT AG CHEM; RATANATHARATHOR.V, 2002, P 44 ANN AM SOC HEM; REX JH, 1994, NEW ENGL J MED, V331, P1325, DOI 10.1056/NEJM199411173312001; Ribaud P, 1999, CLIN INFECT DIS, V28, P322, DOI 10.1086/515116; Roberts J, 2000, ANTIMICROB AGENTS CH, V44, P3381, DOI 10.1128/AAC.44.12.3381-3388.2000; Roling EE, 2002, DIAGN MICR INFEC DIS, V43, P13, DOI 10.1016/S0732-8893(02)00361-9; Rubin MA, 2002, CLIN INFECT DIS, V34, P1160, DOI 10.1086/339755; Sanglard D, 2002, LANCET INFECT DIS, V2, P73, DOI 10.1016/S1473-3099(02)00181-0; SCHMATZ DM, 1991, J PROTOZOOL, V38, pS151; SCHWARTZ C, 2000, 40 INT C ANT AG CHEM; SHEPHERD B, 2001, 41 INT C ANT AG CHEM; SIROHI B, 2001, 41 INT C ANT AG CHEM; Steinbach WJ, 2003, CLIN INFECT DIS, V37, pS188, DOI 10.1086/376524; Stone JA, 2002, ANTIMICROB AGENTS CH, V46, P739, DOI 10.1128/AAC.46.3.739-745.2002; SUPPARATPINYO K, 1994, LANCET, V344, P110, DOI 10.1016/S0140-6736(94)91287-4; TAMADA S, 2000, 40 INT C ANT AG CHEM, P387; Tawara S, 2000, ANTIMICROB AGENTS CH, V44, P57, DOI 10.1128/AAC.44.1.57-62.2000; THYE D, 2001, 41 INT C ANT AG CHEM; THYE D, 2002, 42 INT C ANT AG CHEM; TOWNSEND R, 2002, P AM COLL CLIN PHARM; ULLMANN AJ, 2003, P 13 EUR C CLIN MICR; VANBURIK J, 2002, 42 INT C ANT AG CHEM, P401; vanderHorst CM, 1997, NEW ENGL J MED, V337, P15, DOI 10.1056/NEJM199707033370103; Verweij PE, 1998, ANTIMICROB AGENTS CH, V42, P873, DOI 10.1128/AAC.42.4.873; Villanueva A, 2002, AM J MED, V113, P294, DOI 10.1016/S0002-9343(02)01191-9; Villanueva A, 2001, CLIN INFECT DIS, V33, P1529, DOI 10.1086/323401; Vogeser M, 1997, EUR J CLIN MICROBIOL, V16, P1, DOI 10.1007/BF01575110; WALSH TJ, 2002, 42 INT C ANT AG CHEM; Warn PA, 2003, J ANTIMICROB CHEMOTH, V51, P913, DOI 10.1093/jac/dkg185; WARN PA, 2002, 42 INT C ANT AG CHEM; ZHANEL G, 1998, 38 INT C ANT AG CHEM	120	768	824	2	107	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 4	2003	362	9390					1142	1151		10.1016/S0140-6736(03)14472-8	http://dx.doi.org/10.1016/S0140-6736(03)14472-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728HA	14550704				2022-12-28	WOS:000185710700025
J	Elia, AEH; Rellos, P; Haire, LF; Chao, JW; Ivins, FJ; Hoepker, K; Mohammad, D; Cantley, LC; Smerdon, SJ; Yaffe, MB				Elia, AEH; Rellos, P; Haire, LF; Chao, JW; Ivins, FJ; Hoepker, K; Mohammad, D; Cantley, LC; Smerdon, SJ; Yaffe, MB			The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain	CELL			English	Article							PHOSPHOSERINE/THREONINE-BINDING DOMAINS; SACCHAROMYCES-CEREVISIAE CDC5; TYROSINE KINASE HCK; CELL-CYCLE; STRUCTURAL BASIS; PROTEIN-KINASE; M-PHASE; CRYSTAL-STRUCTURE; UBIQUITIN LIGASE; MAMMALIAN-CELLS	Polo-like kinases (Plks) perform crucial functions in cell-cycle progression and multiple stages of mitosis. Plks are characterized by a C-terminal noncatalytic region containing two tandem Polo boxes, termed the Polo-box domain (PBD), which has recently been implicated in phosphodependent substrate targeting. We show that the PBDs of human, Xenopus, and yeast Plks all recognize similar phosphoserine/threonine-containing motifs. The 1.9 Angstrom X-ray structure of a human Plk1 PBD-phosphopeptide complex shows that the Polo boxes each comprise beta(6)alpha structures that associate to form a 12-stranded beta sandwich domain. The phosphopeptide binds along a conserved, positively charged cleft located at the edge of the Polo-box interface. Mutations that specifically disrupt phosphodependent interactions abolish cell-cycle-dependent localization and provide compelling phenotypic evidence that PBD-phospholigand binding is necessary for proper mitotic progression. In addition, phosphopeptide binding to the PBD stimulates kinase activity in full-length Plk1, suggesting a conformational switching mechanism for Plk regulation and a dual functionality for the PBD.	Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England; MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Beth Israel Deaconess Hosp, Sch Med, Dept Cell Biol,Div Signal Transduct, Boston, MA 02215 USA	MRC National Institute for Medical Research; Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Smerdon, SJ (corresponding author), Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Smerdon, Stephen/0000-0001-5688-8465	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060594, R01GM056203] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60594, R01 GM056203] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1998, J CELL SCI, V111, P1751; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Conn CW, 2000, CANCER RES, V60, P6826; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Elez R, 2000, BIOCHEM BIOPH RES CO, V269, P352, DOI 10.1006/bbrc.2000.2291; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Grallert A, 2002, EMBO J, V21, P3096, DOI 10.1093/emboj/cdf294; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee KS, 1999, P NATL ACAD SCI USA, V96, P14360, DOI 10.1073/pnas.96.25.14360; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; LIU XQ, 1993, ONCOGENE, V8, P1119; Ma S, 2003, MOL CANCER RES, V1, P376; May KM, 2002, J CELL BIOL, V156, P23, DOI 10.1083/jcb.200106150; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Reynolds N, 2003, J CELL SCI, V116, P1377, DOI 10.1242/jcs.00314; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Sonnhammer ELL, 1998, NUCLEIC ACIDS RES, V26, P320, DOI 10.1093/nar/26.1.320; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2002, CELL CYCLE, V1, P424, DOI 10.4161/cc.1.6.271; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 2000, METHOD ENZYMOL, V328, P157, DOI 10.1016/S0076-6879(00)28397-3; Yaffe MB, 2001, STRUCTURE, V9, pR33, DOI 10.1016/S0969-2126(01)00580-9; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7	50	589	606	1	39	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 3	2003	115	1					83	95		10.1016/S0092-8674(03)00725-6	http://dx.doi.org/10.1016/S0092-8674(03)00725-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14532005	Bronze			2022-12-28	WOS:000185815500011
J	Thompson, T; Barbour, R; Schwartz, L				Thompson, T; Barbour, R; Schwartz, L			Adherence to advance directives in critical care decision making: vignette study	BRITISH MEDICAL JOURNAL			English	Article							PROFESSIONALS; ATTITUDES; VIEWS	Objective To explore health professionals' decision making in a critical care scenario when there is an advance directive. Design Qualitative study. Setting Scotland. Participants Interviewees (n = 12) comprising general practitioners, hospital specialists, and nurses, and six focus groups (n = 34 participants) comprising general practitioners, geriatricians (consultants and specialist registrars), hospital nurses, and hospice nurses. Results When presented with an advance directive that applied to the same hypothetical scenario, health professionals came to divergent conclusions as to the "right thing to do' " Arguments opposing treatment centred on the supremacy of autonomy as an ethical principle. Other arguments were that the decision to treat was consistent with the terms of the advance directive, or that, notwithstanding the advance directive, the patients quality of life was sufficient to warrant treatment. Conclusion Advance directives are open to widely varying interpretation. Some of this variability is related to the ambiguity of the directive's terminology whereas some is related to the willingness of health professionals to make subjective value judgments concerning quality of life.	Univ Bristol, Div Primary Hlth Care, Bristol BS6 6JL, Avon, England; Univ Dundee, Sch Nursing & Midwifery, Dundee DD1 4HJ, Scotland; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; Univ Glasgow, Dept Gen Practice, Glasgow G12 8QQ, Lanark, Scotland	University of Bristol; University of Dundee; McMaster University; University of Glasgow	Thompson, T (corresponding author), Univ Bristol, Div Primary Hlth Care, Bristol BS6 6JL, Avon, England.			Schwartz, Lisa/0000-0002-4959-225X				Barbour RS, 2000, FAM PRACT, V17, P83, DOI 10.1093/fampra/17.1.83; Barbour RS, 2001, BMJ-BRIT MED J, V322, P1115, DOI 10.1136/bmj.322.7294.1115; *BRIT MED ASS, 1999, WITHH WITHDR LIF PRO; Charles C, 1999, BRIT MED J, V319, P780, DOI 10.1136/bmj.319.7212.780; Collins K, 1999, BRIT J GEN PRACT, V49, P641; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; Ditto PH, 2001, ARCH INTERN MED, V161, P421, DOI 10.1001/archinte.161.3.421; Docker C, 2000, BMJ-BRIT MED J, V320, P54; DOWNIE RS, 2000, CLIN JUDGEMENT; DOWNIE RS, 1994, HLTH RESPECT, P51; DOWNIE RS, 1994, HLTH RESPECT, P141; Hojat M, 2001, ACAD MED, V76, P669, DOI 10.1097/00001888-200107000-00001; *HOUS LORDS, 1994, REP SEL COMM MED ETH, V1, P54; Ikonomidis S, 1999, J MED ETHICS, V25, P522, DOI 10.1136/jme.25.6.522; KELNER M, 1993, CAN MED ASSOC J, V148, P1331; Mallik M, 1997, J ADV NURS, V25, P130, DOI 10.1046/j.1365-2648.1997.1997025130.x; MCLEAN S, 2000, ETHICS LAW INTENSIVE, P68; MUHR T, 1997, ATLAS SHORT USERS GU; NEUBERGER J, 1999, DYING WELL GUIDE ENA; Ritchie J., 1994, ANAL QUALITATIVE DAT, P173, DOI [10.4324/9780203413081, DOI 10.4324/9780203413081_CHAPTER_9]; SOMMERVILLE A, 1995, BRIT MED J, V310, P1663; Swartz R, 1998, Adv Ren Replace Ther, V5, P109; Thompson TDB, 2003, PALLIATIVE MED, V17, P403, DOI 10.1191/0269216303pm784oa	24	60	60	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 1	2003	327	7422					1011	1014		10.1136/bmj.327.7422.1011	http://dx.doi.org/10.1136/bmj.327.7422.1011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738NE	14593032	Bronze, Green Published			2022-12-28	WOS:000186294100016
J	Collins, NC; Thordal-Christensen, H; Lipka, V; Bau, S; Kombrink, E; Qiu, JL; Huckelhoven, R; Stein, M; Freialdenhoven, A; Somerville, SC; Schulze-Lefert, P				Collins, NC; Thordal-Christensen, H; Lipka, V; Bau, S; Kombrink, E; Qiu, JL; Huckelhoven, R; Stein, M; Freialdenhoven, A; Somerville, SC; Schulze-Lefert, P			SNARE-protein-mediated disease resistance at the plant cell wall	NATURE			English	Article							POWDERY MILDEW FUNGUS; PAPILLA FORMATION; BARLEY; COMPLEX; GENES; SPECIFICITY; IDENTIFICATION; SYNTAXIN; FUSION; HORDEI	Failure of pathogenic fungi to breach the plant cell wall constitutes a major component of immunity of non-host plant species species outside the pathogen host range - and accounts for a proportion of aborted infection attempts on 'susceptible' host plants (basal resistance)(1-4). Neither form of penetration resistance is understood at the molecular level. We developed a screen for penetration ( pen) mutants of Arabidopsis, which are disabled in non-host penetration resistance against barley powdery mildew, Blumeria graminis f. sp. hordei, and we isolated the PEN1 gene. We also isolated barley ROR2 (ref. 2), which is required for basal penetration resistance against B. g. hordei. The genes encode functionally homologous syntaxins, demonstrating a mechanistic link between non-host resistance and basal penetration resistance in monocotyledons and dicotyledons. We show that resistance in barley requires a SNAP-25 (synaptosome-associated protein, molecular mass 25 kDa) homologue capable of forming a binary SNAP receptor ( SNARE) complex with ROR2. Genetic control of vesicle behaviour at penetration sites, and plasma membrane location of PEN1/ROR2, is consistent with a proposed involvement of SNARE-complex-mediated exocytosis and/or homotypic vesicle fusion events in resistance. Functions associated with SNARE-dependent penetration resistance are dispensable for immunity mediated by race-specific resistance (R) genes, highlighting fundamental differences between these two resistance forms.	Max Planck Inst Plant Breeding Res, Dept Plant Microbe Interact, D-50829 Cologne, Germany; John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England; Riso Natl Lab, Plant Res Dept, DK-4000 Roskilde, Denmark; Univ Giessen, Inst Phytopathol & Appl Zool, D-35392 Giessen, Germany; Carnegie Inst Washington, Dept Plant Biol, Stanford, CA 94305 USA	Max Planck Society; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Technical University of Denmark; Justus Liebig University Giessen; Carnegie Institution for Science	Schulze-Lefert, P (corresponding author), Max Planck Inst Plant Breeding Res, Dept Plant Microbe Interact, D-50829 Cologne, Germany.		Huckelhoven, Ralph/H-6676-2013; Schulze-Lefert, Paul/B-6707-2011; Thordal-Christensen, Hans/F-6281-2014; Schulze-Lefert, Paul/A-7746-2008; Lipka, Volker/C-5874-2009; Bruening, Stefan/B-8505-2011	Huckelhoven, Ralph/0000-0001-5632-5451; Thordal-Christensen, Hans/0000-0001-8813-0157; Stein, Monica/0000-0002-1926-4212; Qiu, Jin-Long/0000-0001-8054-2552				Adam L, 1996, PLANT J, V9, P341, DOI 10.1046/j.1365-313X.1996.09030341.x; Betz WJ, 2000, NAT NEUROSCI, V3, P636, DOI 10.1038/76579; Blatt MR, 2002, NEW PHYTOL, V153, P405, DOI 10.1046/j.0028-646X.2001.00341.x; Emans N, 2002, PLANT CELL, V14, P71, DOI 10.1105/tpc.010339; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Freialdenhoven A, 1996, PLANT CELL, V8, P5, DOI 10.1105/tpc.8.1.5; Hammond-Kosack KE, 2003, CURR OPIN BIOTECH, V14, P177, DOI 10.1016/S0958-1669(03)00035-1; Hoogkamp TJH, 1998, PHYTOPATHOLOGY, V88, P856, DOI 10.1094/PHYTO.1998.88.8.856; Huckelhoven R, 1999, PLANT PHYSIOL, V119, P1251, DOI 10.1104/pp.119.4.1251; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; JOHNSON LEB, 1982, CAN J BOT, V60, P1068, DOI 10.1139/b82-137; KOGA H, 1990, CAN J BOT, V68, P2344, DOI 10.1139/b90-299; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; Lauber MH, 1997, J CELL BIOL, V139, P1485, DOI 10.1083/jcb.139.6.1485; Lerman JC, 2000, BIOCHEMISTRY-US, V39, P8470, DOI 10.1021/bi0003994; Mellersh DG, 2002, PLANT J, V29, P257, DOI 10.1046/j.0960-7412.2001.01215.x; Misura KMS, 2001, J BIOL CHEM, V276, P13273, DOI 10.1074/jbc.M009636200; Munson M, 2000, NAT STRUCT BIOL, V7, P894; Peterhansel C, 1997, PLANT CELL, V9, P1397, DOI 10.1105/tpc.9.8.1397; Sanderfoot AA, 2000, PLANT PHYSIOL, V124, P1558, DOI 10.1104/pp.124.4.1558; Shen QH, 2003, PLANT CELL, V15, P732, DOI 10.1105/tpc.009258; SNYDER BA, 1990, SCIENCE, V248, P1637, DOI 10.1126/science.248.4963.1637; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Yu Y, 2000, THEOR APPL GENET, V101, P1093, DOI 10.1007/s001220051584	24	696	734	5	139	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	2003	425	6961					973	977		10.1038/nature02076	http://dx.doi.org/10.1038/nature02076			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14586469				2022-12-28	WOS:000186230600044
J	Mandel, O; Greiner, M; Widera, A; Rom, T; Hansch, TW; Bloch, I				Mandel, O; Greiner, M; Widera, A; Rom, T; Hansch, TW; Bloch, I			Controlled collisions for multi-particle entanglement of optically trapped atoms	NATURE			English	Article							NEUTRAL ATOMS; QUANTUM; LATTICES; ARRAYS	Entanglement lies at the heart of quantum mechanics, and in recent years has been identified as an essential resource for quantum information processing and computation(1-4). The experimentally challenging production of highly entangled multi-particle states is therefore important for investigating both fundamental physics and practical applications. Here we report the creation of highly entangled states of neutral atoms trapped in the periodic potential of an optical lattice. Controlled collisions between individual neighbouring atoms are used to realize an array of quantum gates, with massively parallel operation. We observe a coherent entangling - disentangling evolution in the many-body system, depending on the phase shift acquired during the collision between neighbouring atoms. Such dynamics are indicative of highly entangled many-body states; moreover, these are formed in a single operational step, independent of the size of the system(5,6).	Univ Munich, Sekt Phys, D-80799 Munich, Germany; Max Planck Inst Quantum Opt, D-85748 Garching, Germany	University of Munich; Max Planck Society	Bloch, I (corresponding author), Univ Munich, Sekt Phys, Schellingstr 4-3, D-80799 Munich, Germany.	imb@mpq.mpg.de	Bloch, Immanuel/N-9169-2019; Bloch, Immanuel/G-3174-2010; Widera, Artur/D-1032-2017; Greiner, Markus/E-9512-2017; Greiner, Markus/A-8502-2010	Bloch, Immanuel/0000-0002-0679-4759; Widera, Artur/0000-0002-0338-9969; 				Anderson BP, 1998, SCIENCE, V282, P1686, DOI 10.1126/science.282.5394.1686; Batrouni GG, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.117203; Brennen GK, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.050302; Brennen GK, 1999, PHYS REV LETT, V82, P1060, DOI 10.1103/PhysRevLett.82.1060; Briegel HJ, 2000, J MOD OPTIC, V47, P415, DOI 10.1080/095003400148303; Cataliotti FS, 2001, SCIENCE, V293, P843, DOI 10.1126/science.1062612; Feynman R. P., 1985, OPT NEWS, V11, P11, DOI 10.1364/ON.11.2.000011; FEYNMAN RP, 1986, FOUND PHYS, V16, P507, DOI 10.1007/BF01886518; Greiner M, 2002, NATURE, V419, P51, DOI 10.1038/nature00968; Grimm R, 2000, ADV ATOM MOL OPT PHY, V42, P95, DOI 10.1016/S1049-250X(08)60186-X; Jaksch D, 1999, PHYS REV LETT, V82, P1975, DOI 10.1103/PhysRevLett.82.1975; JAKSCH D, 1999, THESIS L FRANZENS U, P97; Jane E, 2003, QUANTUM INF COMPUT, V3, P15; Jessen PS, 1996, ADV ATOM MOL OPT PHY, V37, P95; Kashurnikov VA, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.031601; Mandel O, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.010407; PACHOS JK, 2003, QUANTUM COMPUTATION; Sorensen A, 1999, PHYS REV LETT, V83, P2274, DOI 10.1103/PhysRevLett.83.2274; Stauffer D., 1991, INTRO PERCOLATION TH; Terhal BM, 2003, PHYS TODAY, V56, P46, DOI 10.1063/1.1580049	26	637	649	2	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 30	2003	425	6961					937	940		10.1038/nature02008	http://dx.doi.org/10.1038/nature02008			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14586463	Green Submitted			2022-12-28	WOS:000186230600035
J	Cullimore, J; Denarie, J				Cullimore, J; Denarie, J			How legumes select their sweet talking symbionts	SCIENCE			English	Editorial Material							RECEPTOR-LIKE KINASES; SIGNAL-TRANSDUCTION; PERCEPTION; DOMAIN; GENE		CNRS, INRA, Lab Interact Plantes Microorganismes, F-31326 Castanet Tolosan, France	INRAE; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS)	Cullimore, J (corresponding author), CNRS, INRA, Lab Interact Plantes Microorganismes, F-31326 Castanet Tolosan, France.			Cullimore, Julie/0000-0001-8804-4849				Bateman A, 2000, J MOL BIOL, V299, P1113, DOI 10.1006/jmbi.2000.3778; Ben Amor B, 2003, PLANT J, V34, P495, DOI 10.1046/j.1365-313X.2003.01743.x; Catoira R, 2000, PLANT CELL, V12, P1647, DOI 10.1105/tpc.12.9.1647; Geurts R, 2002, PLANT CELL, V14, pS239, DOI 10.1105/tpc.002451; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Kistner C, 2002, TRENDS PLANT SCI, V7, P511, DOI 10.1016/S1360-1385(02)02356-7; Limpens E, 2003, SCIENCE, V302, P630, DOI 10.1126/science.1090074; Madsen EB, 2003, NATURE, V425, P637, DOI 10.1038/nature02045; Radutoiu S, 2003, NATURE, V425, P585, DOI 10.1038/nature02039; Shiu SH, 2001, P NATL ACAD SCI USA, V98, P10763, DOI 10.1073/pnas.181141598; Steen A, 2003, J BIOL CHEM, V278, P23874, DOI 10.1074/jbc.M211055200; Walker SA, 2000, P NATL ACAD SCI USA, V97, P13413, DOI 10.1073/pnas.230440097	12	44	47	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					575	+		10.1126/science.1091269	http://dx.doi.org/10.1126/science.1091269			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576408				2022-12-28	WOS:000186119900032
J	Horne-Badovinac, S; Rebagliati, M; Stainier, DYR				Horne-Badovinac, S; Rebagliati, M; Stainier, DYR			A cellular framework for gut-looping morphogenesis in zebrafish	SCIENCE			English	Article							LEFT-RIGHT ASYMMETRY; RIGHT AXIS FORMATION; ENDODERM FORMATION; HEART; PATHWAYS; PROTEIN; GENES; LIVER; ROLES; SOUL	Many vertebrate organs adopt asymmetric positions with respect to the midline, but little is known about the cellular changes and tissue movements that occur downstream of left-right gene expression to produce this asymmetry. Here, we provide evidence that the looping of the zebrafish gut results from the asymmetric migration of the neighboring lateral plate mesoderm (LPM). Mutations that disrupt the epithelial structure of the LPM perturb this asymmetric migration and inhibit gut looping. Asymmetric LPM migration still occurs when the endoderm is ablated from the gut-looping region, suggesting that the LPM can autonomously provide a motive force for gut displacement. Finally, reducing left-sided Nodal activity randomizes the pattern of LPM migration and gut looping. These results reveal a cellular framework for the regulation of organ laterality by asymmetrically expressed genes.	Univ Calif San Francisco, Dept Biochem & Biophys, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, Genet Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, Program Human Genet, San Francisco, CA 94143 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Anat & Cell Biol, Iowa City, IA 52242 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Iowa	Stainier, DYR (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, Program Dev Biol, San Francisco, CA 94143 USA.			Stainier, Didier/0000-0002-0382-0026				Alexander J, 1999, DEV BIOL, V215, P343, DOI 10.1006/dbio.1999.9441; Bisgrove BW, 2000, DEVELOPMENT, V127, P3567; Burdine RD, 2000, GENE DEV, V14, P763; Campione M, 1999, DEVELOPMENT, V126, P1225; Chen JN, 1997, DEVELOPMENT, V124, P4373; Chin AJ, 2000, DEV BIOL, V227, P403, DOI 10.1006/dbio.2000.9924; Field HA, 2003, DEV BIOL, V253, P279, DOI 10.1016/S0012-1606(02)00017-9; Heasman J, 2000, DEV BIOL, V222, P124, DOI 10.1006/dbio.2000.9720; Horne-Badovinac S, 2001, CURR BIOL, V11, P1492, DOI 10.1016/S0960-9822(01)00458-4; Kikuchi Y, 2000, GENE DEV, V14, P1279; Liang JO, 2000, DEVELOPMENT, V127, P5101; Long S, 2003, DEVELOPMENT, V130, P2303, DOI 10.1242/dev.00436; Mercola M, 2001, ANNU REV CELL DEV BI, V17, P779, DOI 10.1146/annurev.cellbio.17.1.779; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Ober EA, 2003, MECH DEVELOP, V120, P5, DOI 10.1016/S0925-4773(02)00327-1; Odenthal J, 1998, DEV GENES EVOL, V208, P245, DOI 10.1007/s004270050179; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Peterson RT, 2001, CURR BIOL, V11, P1481, DOI 10.1016/S0960-9822(01)00482-1; Tabin CJ, 2003, GENE DEV, V17, P1, DOI 10.1101/gad.1053803; Wei XY, 2002, NAT GENET, V31, P150, DOI 10.1038/ng883; Yan YT, 1999, GENE DEV, V13, P2527, DOI 10.1101/gad.13.19.2527	21	105	108	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					662	665		10.1126/science.1085397	http://dx.doi.org/10.1126/science.1085397			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576439				2022-12-28	WOS:000186119900064
J	Schultz, MG; Diehl, T; Brasseur, GP; Zittel, W				Schultz, MG; Diehl, T; Brasseur, GP; Zittel, W			Air pollution and climate-forcing impacts of a global hydrogen economy	SCIENCE			English	Article							MOLECULAR-HYDROGEN; TROPOSPHERE	If today's surface traffic fleet were powered entirely by hydrogen fuel cell technology, anthropogenic emissions of the ozone precursors nitrogen oxide (NOx) and carbon monoxide could be reduced by up to 50%, leading to significant improvements in air quality throughout the Northern Hemisphere. Model simulations of such a scenario predict a decrease in global OH and an increased lifetime of methane, caused primarily by the reduction of the NOx emissions. The sign of the change in climate forcing caused by carbon dioxide and methane depends on the technology used to generate the molecular hydrogen. A possible rise in atmospheric hydrogen concentrations is unlikely to cause significant perturbations of the climate system.	Max Planck Inst Meteorol, D-20146 Hamburg, Germany; Ludwig Bolkow Syst Tech, D-85521 Ottobrunn, Germany	Max Planck Society	Schultz, MG (corresponding author), Max Planck Inst Meteorol, Bundesstr 55, D-20146 Hamburg, Germany.		Schultz, Martin G/I-9512-2012	Schultz, Martin G/0000-0003-3455-774X				[Anonymous], 2001, CLIMATE CHANGE 2001; [Anonymous], 2002, 47 WORLD MET ORG; GRANIER C, COMMUNICATION; GRETZ J, 1992, P 9 WORLD HYDR EN C, P1821; Hauglustaine DA, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001156; HOROWITZ LW, 2003, J GEOPHYS RES, V108; Logan JA, 1999, J GEOPHYS RES-ATMOS, V104, P26373, DOI 10.1029/1999JD900300; LOGAN JA, 1981, J GEOPHYS RES-OCEANS, V86, P7210, DOI 10.1029/JC086iC08p07210; Novelli PC, 1999, J GEOPHYS RES-ATMOS, V104, P30427, DOI 10.1029/1999JD900788; Olivier J. G. J., 2001, CLIMATE SYSTEM, P33; OONK IJ, 1995, R95168 TNO MIL EN PR; Prather M, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016285; Tromp TK, 2003, SCIENCE, V300, P1740, DOI 10.1126/science.1085169; Volz-Thomas A., 2003, CLEANER AIR EUROPE 1, P73; *WHO, 2000, 187 WHO; ZITTEL W, 1996, P 11 WORLD HYDR EN C, P71	16	280	291	9	141	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					624	627		10.1126/science.1089527	http://dx.doi.org/10.1126/science.1089527			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576429				2022-12-28	WOS:000186119900053
J	Balk, EM; Lau, J; Goudas, LC; Jordan, HS; Kupelnick, B; Kim, LU; Karas, RH				Balk, EM; Lau, J; Goudas, LC; Jordan, HS; Kupelnick, B; Kim, LU; Karas, RH			Effects of statins on nonlipid serum markers associated with cardiovascular disease - A systematic review	ANNALS OF INTERNAL MEDICINE			English	Review							C-REACTIVE PROTEIN; LOW-DENSITY-LIPOPROTEIN; COA REDUCTASE INHIBITORS; LIPID-LOWERING THERAPY; PLASMINOGEN-ACTIVATOR INHIBITOR; ENDOTHELIAL-CELL MARKERS; PLASMA-FIBRINOGEN LEVEL; CORONARY-ARTERY-DISEASE; INTIMA MEDIA THICKNESS; BLOOD RHEOLOGY	Background: Statins reduce cardiovascular events to a greater extent than can be explained by their effect on lipids. Several studies have attempted to elucidate mechanisms by which statins reduce cardiovascular risk. Purpose: To summarize the effects of statins on nonlipid serum markers and to correlate statins' effect on serum markers with lipid levels and cardiovascular outcomes. Data Sources: MEDLINE (1980 to 2003) search limited to English-language articles. Study Selection: Studies reporting original data in at least 10 participants on the effect of statins on outcomes of interest, excluding studies of cerivastatin, drug combinations, and patients with organ transplants. Data Extraction: Study design, sample size, treatment, and outcome data extracted on the basis of preestablished criteria. When appropriate, meta-analysis was performed by using a random-effects model. Data Synthesis: All statins are effective at lowering C-reactive protein levels, and the effect is not dose-dependent. Studies do not demonstrate a correlation between statins' effects on C-reactive protein levels and on lipids or cardiovascular outcomes. Statins do not affect fibrinogen levels, and limited data suggest little effect on lipid oxidation, tissue plasminogen activator, or plasminogen activator inhibitor. Platelet aggregation data are inconclusive. Conclusions: Among nonlipid serum markers examined, only C-reactive protein levels are statistically significantly affected by statins. These findings suggest that statin-mediated anti-inflammatory effects may contribute to the ability of statins to reduce risk for cardiovascular disease. Overall, however, available data are insufficient to support recommendations for using nonlipid serum markers in decisions regarding statin therapy for individual patients.	Tufts Univ New England Med Ctr, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Lau, J (corresponding author), Tufts Univ New England Med Ctr, Box 63,750 Washington St, Boston, MA 02111 USA.		Balk, Ethan/AAJ-2547-2020	Goudas, Leonidas C./0000-0002-3614-3455				Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64; Aoki I, 1997, J AM COLL CARDIOL, V30, P91, DOI 10.1016/S0735-1097(97)00129-0; Arai Y, 2002, ANGIOLOGY, V53, P57, DOI 10.1177/000331970205300108; Athyros VG, 2002, J CARDIOVASC RISK, V9, P33, DOI 10.1097/00043798-200202000-00005; AVELLONE G, 1994, CURR THER RES CLIN E, V55, P1335, DOI 10.1016/S0011-393X(05)80318-2; Bairaktari ET, 1999, J CARDIOVASC RISK, V6, P113; Ballantyne CM, 2003, CIRCULATION, V107, P2409, DOI 10.1161/01.CIR.0000068312.21969.C8; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; Baller D, 1999, CIRCULATION, V99, P2871, DOI 10.1161/01.CIR.99.22.2871; Banyai S, 2001, ATHEROSCLEROSIS, V159, P513, DOI 10.1016/S0021-9150(01)00532-9; Bays HE, 2002, AM J CARDIOL, V90, P942, DOI 10.1016/S0002-9149(02)02658-9; BEIGEL Y, 1991, J INTERN MED, V230, P23, DOI 10.1111/j.1365-2796.1991.tb00402.x; BEIGEL Y, 1991, J CLIN PHARMACOL, V31, P512, DOI 10.1002/j.1552-4604.1991.tb03729.x; Bevilacqua M, 1997, AM J CARDIOL, V79, P84, DOI 10.1016/S0002-9149(96)00684-4; Blann AD, 2001, AM J CARDIOL, V88, P89, DOI 10.1016/S0002-9149(01)01597-1; BO M, 1991, ANGIOLOGY, V42, P106, DOI 10.1177/000331979104200204; Bo M, 2001, NUTR METAB CARDIOVAS, V11, P17; Bonetti PO, 2003, EUR HEART J, V24, P225, DOI 10.1016/S0195-668X(02)00419-0; BRANCHI A, 1993, THROMB HAEMOSTASIS, V70, P241; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; BROIJERSEN A, 1994, EUR J CLIN INVEST, V24, P488; Castano G, 1999, INT J CLIN PHARM RES, V19, P105; Chan DC, 2002, CLIN CHEM, V48, P877; Chang JW, 2002, AM J KIDNEY DIS, V39, P1213, DOI 10.1053/ajkd.2002.33393; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Cortellaro M, 2000, THROMB HAEMOSTASIS, V83, P549; Dangas G, 1999, J AM COLL CARDIOL, V33, P1294, DOI 10.1016/S0735-1097(99)00018-2; Davis M, 2000, CURR MED RES OPIN, V16, P198, DOI 10.1185/0300799009117026; de Lorgeril M, 1999, J CARDIOVASC PHARM, V33, P473, DOI 10.1097/00005344-199903000-00018; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Di Garbo V, 2000, EUR J CLIN PHARMACOL, V56, P277, DOI 10.1007/s002280000135; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Dujovne CA, 2000, AM J CARDIOL, V85, P350, DOI 10.1016/S0002-9149(99)00745-6; Dupuis J, 1999, CIRCULATION, V99, P3227, DOI 10.1161/01.CIR.99.25.3227; Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008; Ernst E, 1997, Vasc Med, V2, P115; FARRER M, 1994, DIABETES RES CLIN PR, V23, P111, DOI 10.1016/0168-8227(94)90018-3; Gavish D, 2000, J INTERN MED, V247, P563, DOI 10.1046/j.1365-2796.2000.00646.x; Giral P, 2001, ATHEROSCLEROSIS, V154, P421, DOI 10.1016/S0021-9150(00)00474-3; Gomez-Gerique JA, 2002, ATHEROSCLEROSIS, V162, P245, DOI 10.1016/S0021-9150(01)00708-0; Gottsater A, 1999, BLOOD COAGUL FIBRIN, V10, P133, DOI 10.1097/00001721-199904000-00004; Goudevenos JA, 2001, CURR MED RES OPIN, V16, P269, DOI 10.1185/030079901750120204; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Gurevich V S, 1993, Clin Ter, V142, P329; Haak E, 2001, ATHEROSCLEROSIS, V155, P395, DOI 10.1016/S0021-9150(00)00567-0; Harb TS, 2003, AM J CARDIOL, V91, P1120, DOI 10.1016/S0002-9149(03)00162-0; HOCHGRAF E, 1994, METABOLISM, V43, P11, DOI 10.1016/0026-0495(94)90151-1; Hussein O, 1997, ATHEROSCLEROSIS, V128, P11, DOI 10.1016/S0021-9150(96)05972-2; HUSSEIN O, 1997, BR J CLIN PHARM, V44, P77; ISAACSOHN JL, 1994, AM J CARDIOL, V74, P735, DOI 10.1016/0002-9149(94)90322-0; JACOBS H, 1992, ACTA CLIN BELG, V47, P82, DOI 10.1080/17843286.1992.11718214; Jialal I, 2001, CIRCULATION, V103, P1933; John S, 1998, CIRCULATION, V98, P211, DOI 10.1161/01.CIR.98.3.211; Joukhadar C, 2001, THROMB HAEMOSTASIS, V85, P47, DOI 10.1055/s-0037-1612902; Jula A, 2002, JAMA-J AM MED ASSOC, V287, P598, DOI 10.1001/jama.287.5.598; Kalela A, 2001, AM J CARDIOL, V88, P173, DOI 10.1016/S0002-9149(01)01616-2; Karas, 1997, J Thromb Thrombolysis, V4, P167, DOI 10.1023/A:1008862026972; Kent Steven M, 2003, Am Heart J, V145, pe8, DOI 10.1067/mhj.2003.34; KLEINVELD HA, 1993, EUR J CLIN INVEST, V23, P289, DOI 10.1111/j.1365-2362.1993.tb00776.x; KOENIG W, 1992, J CLIN PHARMACOL, V32, P539, DOI 10.1177/009127009203200609; Koh KK, 2001, CORONARY ARTERY DIS, V12, P305, DOI 10.1097/00019501-200106000-00006; Kontopoulos AG, 1996, CORONARY ARTERY DIS, V7, P843, DOI 10.1097/00019501-199611000-00009; KOPPENSTEINER R, 1990, ATHEROSCLEROSIS, V83, P53, DOI 10.1016/0021-9150(90)90130-B; Lauer MS, 2002, NEW ENGL J MED, V346, P1468, DOI 10.1056/NEJMcp012672; Leonhardt W, 1997, EUR J CLIN PHARMACOL, V53, P65, DOI 10.1007/s002280050338; Lin Tsung-Hsien, 2000, Kaohsiung Journal of Medical Sciences, V16, P600; Lowe G, 2000, THROMB HAEMOSTASIS, V84, P553, DOI 10.1055/s-0037-1614066; Ma Li-Ping, 2002, J Assoc Acad Minor Phys, V13, P23; MacMahon M, 2000, NUTR METAB CARDIOVAS, V10, P195; Malik J, 2001, CARDIOVASC RES, V52, P290, DOI 10.1016/S0008-6363(01)00382-0; Malminiemi K, 2000, FREE RADICAL RES, V33, P581, DOI 10.1080/10715760000301111; Martinez M, 1996, HAEMOSTASIS, V26, P171; MAYER J, 1992, ANN HEMATOL, V64, P196, DOI 10.1007/BF01696223; MCDOWELL IFW, 1991, BRIT J CLIN PHARMACO, V31, P340, DOI 10.1111/j.1365-2125.1991.tb05539.x; Miossec P, 1999, DIABETIC MED, V16, P424, DOI 10.1046/j.1464-5491.1999.00083.x; Mitropoulos KA, 1997, EUR HEART J, V18, P235; Mohrschladt MF, 2001, ATHEROSCLEROSIS, V157, P491, DOI 10.1016/S0021-9150(00)00754-1; Morishita Eriko, 2002, J Atheroscler Thromb, V9, P72; Musial J, 2001, THROMB HAEMOSTASIS, V85, P221; Musial J, 2001, INT J CARDIOL, V77, P247, DOI 10.1016/S0167-5273(00)00439-3; NOTARBARTOLO A, 1995, ARTERIOSCL THROM VAS, V15, P247, DOI 10.1161/01.ATV.15.2.247; Orem C, 2002, CORONARY ARTERY DIS, V13, P65, DOI 10.1097/00019501-200202000-00009; Palomaki A, 1998, J LIPID RES, V39, P1430; Palomaki A, 1997, FEBS LETT, V410, P254, DOI 10.1016/S0014-5793(97)00609-1; Palomaki A, 1999, ARTERIOSCL THROM VAS, V19, P1541, DOI 10.1161/01.ATV.19.6.1541; Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45; PEDERSEN TR, 1994, LANCET, V344, P1383; Pintaric I, 2001, ATHEROSCLEROSIS, V154, P493, DOI 10.1016/S0021-9150(00)00505-0; Plenge JK, 2002, CIRCULATION, V106, P1447, DOI 10.1161/01.CIR.0000029743.68247.31; Porreca E, 2000, THROMB HAEMOSTASIS, V84, P789; Portal Vera Lúcia, 2003, Arq. Bras. Cardiol., V80, P156, DOI 10.1590/S0066-782X2003000200004; PORTAL VL, 2003, ARQ BRAS CARDIOL, V80, P150; Rauch U, 2000, ATHEROSCLEROSIS, V153, P181, DOI 10.1016/S0021-9150(00)00397-X; Ridker PM, 2003, CIRCULATION, V107, P363, DOI 10.1161/01.CIR.0000053730.47739.3C; Ridker PM, 2002, CIRCULATION, V105, P1776, DOI 10.1161/01.CIR.0000014447.06099.FB; Ridker PM, 2001, NEW ENGL J MED, V344, P1959, DOI 10.1056/NEJM200106283442601; Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230; Riesen WF, 2002, EUR HEART J, V23, P794, DOI 10.1053/euhj.2001.2967; Rizos E, 2002, CURR MED RES OPIN, V18, P154, DOI 10.1185/030079902125000480; Rosenson RS, 2001, ATHEROSCLEROSIS, V155, P463, DOI 10.1016/S0021-9150(00)00590-6; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; SANDSET PM, 1991, ARTERIOSCLER THROMB, V11, P138, DOI 10.1161/01.ATV.11.1.138; Sbarouni E, 2000, AM J CARDIOL, V86, P80, DOI 10.1016/S0002-9149(00)00831-6; Seljeflot I, 2002, ATHEROSCLEROSIS, V162, P179, DOI 10.1016/S0021-9150(01)00696-7; Seljeflot I, 2002, THROMB RES, V105, P285, DOI 10.1016/S0049-3848(02)00034-8; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Smith S C Jr, 2000, Circulation, V101, P111; Szczeklik A, 1999, J AM COLL CARDIOL, V33, P1286, DOI 10.1016/S0735-1097(99)00023-6; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; Tan KCB, 1999, AM J CARDIOL, V84, P934, DOI 10.1016/S0002-9149(99)00471-3; Taylor AJ, 2002, CIRCULATION, V106, P2055, DOI 10.1161/01.CIR.0000034508.55617.65; Tsuda Y, 1996, ATHEROSCLEROSIS, V122, P225, DOI 10.1016/0021-9150(95)05757-9; Undas A, 2001, CIRCULATION, V103, P2248; van de Ree MA, 2003, ATHEROSCLEROSIS, V166, P129, DOI 10.1016/S0021-9150(02)00316-7; van Wissen S, 2002, ATHEROSCLEROSIS, V165, P361, DOI 10.1016/S0021-9150(02)00280-0; Vigna GB, 1999, NUTR METAB CARDIOVAS, V9, P234; WADA H, 1993, AM J HEMATOL, V44, P112, DOI 10.1002/ajh.2830440208; Wiklund O, 2002, J INTERN MED, V251, P338, DOI 10.1046/j.1365-2796.2002.00966.x; Wright RS, 2002, MAYO CLIN PROC, V77, P1085, DOI 10.4065/77.10.1085; YOSHIDA H, 1995, CLIN THER, V17, P379, DOI 10.1016/0149-2918(95)80103-0; Youssef F, 2002, EUR J VASC ENDOVASC, V23, P358, DOI 10.1053/ejvs.2002.1611	123	153	161	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 21	2003	139	8					670	682		10.7326/0003-4819-139-8-200310210-00011	http://dx.doi.org/10.7326/0003-4819-139-8-200310210-00011			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734DW	14568856				2022-12-28	WOS:000186040800005
J	Bjermer, L; Bisgaard, H; Bousquet, J; Fabbri, LM; Greening, AP; Haahtela, T; Holgate, ST; Picado, C; Menten, J; Dass, SB; Leff, JA; Polos, PG				Bjermer, L; Bisgaard, H; Bousquet, J; Fabbri, LM; Greening, AP; Haahtela, T; Holgate, ST; Picado, C; Menten, J; Dass, SB; Leff, JA; Polos, PG			Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EOSINOPHILIC INFLAMMATION; BETA(2)-AGONISTS; PROVIDES; DISEASE; MARKERS	Objectives To assess the effect of montelukast versus salmeterol added to inhaled fluticasone propionate on asthma exacerbation in patients whose symptoms are inadequately controlled with fluticasone alone. Design and setting A 52 week, two period, double blind, multicentre trial during which patients whose symptoms remained uncontrolled by inhaled corticosteroids were randomised to add montelukast or salmeterol. Participants Patients (15-72 years; n = 1490) had a clinical history of chronic asthma for greater than or equal to1 year, a baseline forced expiratory volume in one second (FEV1) value 50-90% predicted, and a beta agonist improvement of greater than or equal to 12% in FEV1. Main outcome measures The primary end point was the percentage of patients with at least one asthma exacerbation. Results 20.1% of the patients in the group receiving montelukast and fluticasone had an asthma exacerbation compared with 19.1% in the group receiving salmeterol and fluticasone; the difference was 1% (95% confidence interval - 3.1% to 5.0%). With a risk ratio (montelukast-fluticasone/ salmeterol-fluticasone) of 1.05 (0.86 to 1.29), treatment with montelukast and fluticasone was shown to be non-inferior to treatment with salmeterol and fluticasone. Salmeterol and fluticasonc significantly increased FEV1 before a beta agonist was used and morning peak expiratory flow compared with montelukast and fluticasone (P less than or equal to0.001), whereas FEV1 after a beta agonist was used and improvements in asthma specific quality of life and nocturnal awakenings were similar between the groups. Montelukast and fluticasone significantly (P = 0.011) reduced peripheral blood eosinophil counts compared with salmeterol and fluticasone. Both treatments were generally well tolerated. Conclusion The addition of montelukast in patients whose symptoms remain uncontrolled by inhaled fluticasone could provide equivalent clinical control to salmeterol.	Merck & Co Inc, Whitehouse Stn, NJ 08889 USA; Univ Hosp, Dept Resp Med & Allergol, SE-22185 Lund, Sweden; Univ Copenhagen Hosp, Dept Paediat, DK-2900 Copenhagen, Denmark; Hosp Arnaud Villeneuve, Serv Malad Resp, F-34295 Montpellier 5, France; Univ Modena, Dept Resp Dis, I-41100 Modena, Italy; Western Gen Hosp, Resp Med Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Helsinki Univ Hosp, Dept Allergol, FIN-00029 Helsinki, Finland; Southampton Gen Hosp, Resp Cell & Mol Biol Res Div, Southampton SO16 6YD, Hants, England; Univ Barcelona, Hosp Clin, Inst Pneumol, Serv Pneumol, E-08036 Barcelona, Spain	Merck & Company; Lund University; Skane University Hospital; University of Copenhagen; Universite de Montpellier; CHU de Montpellier; Universita di Modena e Reggio Emilia; University of Edinburgh; University of Helsinki; Helsinki University Central Hospital; University of Southampton; University of Barcelona; Hospital Clinic de Barcelona	Polos, PG (corresponding author), Merck & Co Inc, WS3D-50 1 Merck Dr, Whitehouse Stn, NJ 08889 USA.	peter_polos@merck.com	Fabbri, Leonardo M/I-4055-2012; Bisgaard, Hans/N-4761-2016; Kronow, Joern/B-1054-2011; Bjermer, Leif H/I-4899-2014; /AFX-9519-2022; /AAL-7347-2021	Fabbri, Leonardo M/0000-0001-8894-1689; Bisgaard, Hans/0000-0003-4131-7592; Bjermer, Leif H/0000-0002-3441-8099; 				Barnes PJ, 2001, RESP MED, V95, pS12, DOI 10.1053/rmed.2001.1140; Barnes PJ, 1998, J ALLERGY CLIN IMMUN, V102, P531, DOI 10.1016/S0091-6749(98)70268-4; Bisgaard H, 2000, PEDIATR PULM, V29, P221, DOI 10.1002/(SICI)1099-0496(200003)29:3<221::AID-PPUL11>3.3.CO;2-G; BOUSQUET J, 1994, AM J RESP CRIT CARE, V150, pS33, DOI 10.1164/ajrccm/150.5_Pt_2.S33; Busse WW, 1998, J ALLERGY CLIN IMMUN, V102, pS17, DOI 10.1016/S0091-6749(98)70002-8; Crimi E, 2001, SCI TOTAL ENVIRON, V270, P57, DOI 10.1016/S0048-9697(00)00785-3; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953, DOI 10.1164/ajrccm.149.4.8143061; El-Radhi AS, 2000, ARCH DIS CHILD, V83, P158, DOI 10.1136/adc.83.2.158; *EXP WORK GROUP, 1999, STAT MED, V18, P1905; Fish JE, 2001, CHEST, V120, P423, DOI 10.1378/chest.120.2.423; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Jarvis B, 2000, DRUGS, V59, P891, DOI 10.2165/00003495-200059040-00015; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Kraft M, 2001, AM J RESP CRIT CARE, V163, P1551, DOI 10.1164/ajrccm.163.7.2008013; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Metso T, 2001, RESP MED, V95, P48, DOI 10.1053/rmed.2000.0970; Minoguchi K, 2002, CHEST, V121, P732, DOI 10.1378/chest.121.3.732; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V106, P1088, DOI 10.1067/mai.2000.110920; *NIH NAT HEART LUN, 1995, NIH PUBL; OSHAUGHNESSY KM, 1993, AM REV RESPIR DIS, V147, P1472, DOI 10.1164/ajrccm/147.6_Pt_1.1472; Pang LH, 2001, FASEB J, V15, P261, DOI 10.1096/fj.00-0103com; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pearson MG, 1997, THORAX, V52, pS1; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; Reiss TF, 1997, THORAX, V52, P45, DOI 10.1136/thx.52.1.45; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Villaran C, 1999, J ALLERGY CLIN IMMUN, V104, P547, DOI 10.1016/S0091-6749(99)70322-2; Wilson AM, 2001, CHEST, V119, P1021, DOI 10.1378/chest.119.4.1021; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590	30	140	153	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 18	2003	327	7420					891	895		10.1136/bmj.327.7420.891	http://dx.doi.org/10.1136/bmj.327.7420.891			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734RV	14563743	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000186072100015
J	Victora, CG; Barros, FC; Lima, RC; Horta, BL; Wells, J				Victora, CG; Barros, FC; Lima, RC; Horta, BL; Wells, J			Anthropometry and body composition of 18 year old men according to duration of breast feeding: birth cohort study from Brazil	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OVERWEIGHT	Objective To assess the association between duration of breast feeding and measures of adiposity in adolescence. Design Population based birth cohort study. Setting Pelotas, a city of 320 000 inhabitants in a relatively developed area in southern Brazil. Participants All newborn infants in the city's hospitals were enrolled in 1982; 78.8% (2250) of all male participants were located at age 18 years when enrolling in the national army. Main outcome measures Weight, height, sitting height, subscapular and triceps skinfolds, and body composition (body fat, lean mass). Results Neither the duration of total breast feeding nor that of predominant breast feeding (breast milk plus non-nutritive fluids) showed consistent associations with anthropometric or body composition indices. After adjustment for confounding factors, the only significant associations were a greater than 50% reduction in obesity among participants breast fed for three to five months compared with all other breastfeeding categories (P = 0.007) and a linear decreasing trend in obesity with increasing duration of predominant breast feeding (P = 0.03). Similar significant effects were not observed for other measures of adiposity. Borderline direct associations also occurred between total duration of breast feeding and adult height (P = 0.06). Conclusions The significant reduction in obesity among children breast fed for three to five months is difficult to interpret, as no a priori hypothesis existed regarding a protective effect of intermediate duration of breast feeding. The findings indicate that, in this population, breast feeding has no marked protective effect against adolescent adiposity.	Univ Fed Pelotas, Post Grad Programme Epidemiol, BR-96001970 Pelotas, RS, Brazil; PAHO WHO, Latin Amer Ctr Perinatol & Human Dev, Montevideo, Uruguay; Univ Catolica Pelotas, Fac Med, Pelotas, RS, Brazil; Univ London, Inst Child Hlth, London WC1N 1EH, England	Universidade Federal de Pelotas; Universidade Catolica de Pelotas; Universidade Federal de Pelotas; University of London; University College London	Victora, CG (corresponding author), Univ Fed Pelotas, Post Grad Programme Epidemiol, CP 464, BR-96001970 Pelotas, RS, Brazil.	cvictora@terra.com.br	Horta, Bernardo/A-7604-2008; Victora, Cesar Gomes/Y-2455-2019; Barros, Fernando C/D-4857-2013; Wells, Jonathan/A-4604-2009; Victora, Cesar G/D-4476-2013	Horta, Bernardo/0000-0001-9843-412X; Victora, Cesar Gomes/0000-0002-2465-2180; Wells, Jonathan/0000-0003-0411-8025; Victora, Cesar G/0000-0002-2465-2180				BARROS FC, 1990, PAEDIATR PERINAT EP, V4, P267; Beral V, 2003, LANCET, V361, P177, DOI 10.1016/S0140-6736(03)12209-X; BLOCK G, 1989, J NUTR EDUC, V21, P199; Butte NE, 2001, PEDIATR CLIN N AM, V48, P189, DOI 10.1016/S0031-3955(05)70293-5; Dewey Kathryn G, 2003, J Hum Lact, V19, P9; Dietz WH, 2001, JAMA-J AM MED ASSOC, V285, P2506, DOI 10.1001/jama.285.19.2506; Elliott KG, 1997, OBES RES, V5, P538, DOI 10.1002/j.1550-8528.1997.tb00574.x; Gillman MW, 2001, JAMA-J AM MED ASSOC, V285, P2461, DOI 10.1001/jama.285.19.2461; Hediger ML, 2001, JAMA-J AM MED ASSOC, V285, P2453, DOI 10.1001/jama.285.19.2453; KRAMER MS, 1981, J PEDIATR-US, V98, P883, DOI 10.1016/S0022-3476(81)80579-3; Tulldahl J, 1999, OBES RES, V7, P431, DOI 10.1002/j.1550-8528.1999.tb00430.x; Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5; VICTORA CG, 2003, IN PRESS CAD SAUDE P; *WHO DIV DIARRH AC, 1991, IND ASS BREAST FEED; *WHO EXP COMM NUTR, 1995, WHO TECHN REP SER, V854	15	99	110	1	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 18	2003	327	7420					901	904		10.1136/bmj.327.7420.901	http://dx.doi.org/10.1136/bmj.327.7420.901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734RV	14563746	Green Published, Bronze			2022-12-28	WOS:000186072100018
J	Hu, QD; Ang, BT; Karsak, M; Hu, WP; Cui, XY; Duka, T; Takeda, Y; Chia, W; Sankar, N; Ng, YK; Ling, EA; Maciag, T; Small, D; Trifonova, R; Kopan, R; Okano, H; Nakafuku, M; Chiba, S; Hirai, H; Aster, JC; Schachner, M; Pallen, CJ; Watanabe, K; Xiao, ZC				Hu, QD; Ang, BT; Karsak, M; Hu, WP; Cui, XY; Duka, T; Takeda, Y; Chia, W; Sankar, N; Ng, YK; Ling, EA; Maciag, T; Small, D; Trifonova, R; Kopan, R; Okano, H; Nakafuku, M; Chiba, S; Hirai, H; Aster, JC; Schachner, M; Pallen, CJ; Watanabe, K; Xiao, ZC			F3/contactin acts as a functional ligand for notch during oligodendrocyte maturation	CELL			English	Article							ADHESION MOLECULE; NEURITE OUTGROWTH; FYN KINASE; RECEPTOR; EXPRESSION; CELLS; CONTACTIN; MOUSE; DIFFERENTIATION; F3	Axon-derived molecules are temporally and spatially required as positive or negative signals to coordinate oligodendrocyte differentiation. Increasing evidence suggests that, in addition to the inhibitory Jagged1/ Notch1 signaling cascade, other pathways act via Notch to mediate oligodendrocyte differentiation. The GPI-linked neural cell recognition molecule F3/contactin is clustered during development at the paranodal region, a vital site for axoglial interaction. Here, we show that F3/contactin acts as a functional ligand of Notch. This trans-extracellular interaction triggers gamma-secre-tase-dependent nuclear translocation of the Notch intracellular domain. F3/Notch signaling promotes oligodendrocyte precursor cell differentiation and upregulates the myelin-related protein MAG in OLN-93 cells. This can be blocked by dominant negative Notch1, Notch2, and two Deltex1 mutants lacking the RING-H2 finger motif, but not by dominant-negative RBP-J or Hes1 antisense oligonucleotides. Expression of constitutively active Notch1 or Notch2 does not upregulate MAG. Thus, F3/contactin specifically initiates a Notch/Deltex1 signaling pathway that promotes oligodendrocyte maturation and myelination.	Tokyo Metropolitan Inst Gerontol, Dept Cell Recognit, Tokyo 1730015, Japan; Singapore Gen Hosp, Dept Clin Res, Singapore 169608, Singapore; Natl Univ Singapore, Dept Anat, Singapore 117597, Singapore; Natl Inst Neurosci, Dept Neurosurg, Singapore 306433, Singapore; Univ Hamburg, Zentrum Mol Neurobiol, D-20251 Hamburg, Germany; Singapore Gen Hosp, Dept Obstet & Gynecol, Singapore 169608, Singapore; Natl Canc Ctr, Singapore 169610, Singapore; Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04469 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Div Dermatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, Div Dermatol, St Louis, MO 63110 USA; Keio Univ, Sch Med, Dept Physiol, Tokyo 1608582, Japan; Univ Tokyo, Grad Sch Med, Tokyo 1130033, Japan; Univ Tokyo, Dept Cell Therapy Transplantat Med & Hematol, Tokyo 1138655, Japan; Univ Tokyo, Dept Oncol, Tokyo 1138655, Japan; Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA; Univ British Columbia, Dept Pediat, Vancouver, BC V5Z 1M9, Canada	Tokyo Metropolitan Institute of Gerontology; Singapore General Hospital; National University of Singapore; National Neuroscience Institute (NNI); University of Hamburg; University Medical Center Hamburg-Eppendorf; Singapore General Hospital; National Cancer Centre Singapore (NCCS); Maine Medical Center; Washington University (WUSTL); Washington University (WUSTL); Keio University; University of Tokyo; University of Tokyo; University of Tokyo; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of British Columbia	Xiao, ZC (corresponding author), Tokyo Metropolitan Inst Gerontol, Dept Cell Recognit, Tokyo 1730015, Japan.		Kopan, Raphael/AFG-3275-2022; Kopan, Raphael/AAF-1357-2022; Okano, Hideyuki/I-7584-2019; xiao, zhicheng/A-1529-2011; Nakafuku, Masato/J-3068-2013	Pallen, Catherine/0000-0002-3576-5295; Nakafuku, Masato/0000-0001-7783-9005; Kopan, Raphael/0000-0002-0350-2730; Karsak, Meliha/0000-0001-6612-6317	NCRR NIH HHS [RR 15555] Funding Source: Medline; NHLBI NIH HHS [HL35627, HL32348] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015555] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035627, R01HL032348] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2; Berglund EO, 1999, NEURON, V24, P739, DOI 10.1016/S0896-6273(00)81126-5; BOGLER O, 1997, CURRENT PROTOCOLS NE, DOI UNSP 3.4.1-3.4.9; COLELLO RJ, 1998, CURRENT PROTOCOLS NE, DOI UNSP 3.12.7-3.12.10; Dale JK, 2003, BIOESSAYS, V25, P200, DOI 10.1002/bies.10253; Dawson MRL, 2000, J NEUROSCI RES, V61, P471, DOI 10.1002/1097-4547(20000901)61:5<471::AID-JNR1>3.3.CO;2-E; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Faivre-Sarrailh C, 2000, J CELL BIOL, V149, P491, DOI 10.1083/jcb.149.2.491; GENNARINI G, 1991, NEURON, V6, P595, DOI 10.1016/0896-6273(91)90062-5; Genoud S, 2002, J CELL BIOL, V158, P709, DOI 10.1083/jcb.200202002; Girault JA, 2002, CURR OPIN NEUROBIOL, V12, P476, DOI 10.1016/S0959-4388(02)00370-7; HEMANN C, 1994, DNA CELL BIOL, V13, P437, DOI 10.1089/dna.1994.13.437; Hirata H, 2002, SCIENCE, V298, P840, DOI 10.1126/science.1074560; Holm J, 1996, EUR J NEUROSCI, V8, P1613, DOI 10.1111/j.1460-9568.1996.tb01306.x; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Izon DJ, 2002, IMMUNITY, V16, P231, DOI 10.1016/S1074-7613(02)00271-6; Jack C, 2001, MOL BRAIN RES, V87, P166, DOI 10.1016/S0169-328X(01)00010-9; John GR, 2002, NAT MED, V8, P1115, DOI 10.1038/nm781; Kabos P, 2002, J BIOL CHEM, V277, P8763, DOI 10.1074/jbc.C100758200; Kaneta M, 2000, J IMMUNOL, V164, P256, DOI 10.4049/jimmunol.164.1.256; Kato H, 1997, DEVELOPMENT, V124, P4133; Kazarinova-Noyes K, 2001, J NEUROSCI, V21, P7517, DOI 10.1523/JNEUROSCI.21-19-07517.2001; Kishi N, 2001, INT J DEV NEUROSCI, V19, P21, DOI 10.1016/S0736-5748(00)00071-X; Klein C, 2002, J NEUROSCI, V22, P698, DOI 10.1523/JNEUROSCI.22-03-00698.2002; Koch T, 1997, GLIA, V19, P199, DOI 10.1002/(SICI)1098-1136(199703)19:3<199::AID-GLIA3>3.0.CO;2-V; Kramer EM, 1999, J BIOL CHEM, V274, P29042, DOI 10.1074/jbc.274.41.29042; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Matsuno K, 2002, DEVELOPMENT, V129, P1049; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Revest JM, 1999, ADV EXP MED BIOL, V468, P309; RichterLandsberg C, 1996, J NEUROSCI RES, V45, P161, DOI 10.1002/(SICI)1097-4547(19960715)45:2<161::AID-JNR8>3.0.CO;2-8; Sakurai T, 1997, J CELL BIOL, V136, P907, DOI 10.1083/jcb.136.4.907; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shimazaki K, 1998, NEUROSCI LETT, V245, P117, DOI 10.1016/S0304-3940(98)00179-7; Shimizu K, 1999, J BIOL CHEM, V274, P32961, DOI 10.1074/jbc.274.46.32961; Small D, 2001, J BIOL CHEM, V276, P32022, DOI 10.1074/jbc.M100933200; TSIOTRA PC, 1993, GENOMICS, V18, P562, DOI 10.1016/S0888-7543(05)80357-X; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; Xiao ZC, 1996, EUR J NEUROSCI, V8, P766, DOI 10.1111/j.1460-9568.1996.tb01262.x; Yamamoto N, 2001, J BIOL CHEM, V276, P45031, DOI 10.1074/jbc.M105245200; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707	44	289	302	1	21	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 17	2003	115	2					163	175		10.1016/S0092-8674(03)00810-9	http://dx.doi.org/10.1016/S0092-8674(03)00810-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567914	Bronze			2022-12-28	WOS:000186039200008
J	Biju, SD; Bossuyt, F				Biju, SD; Bossuyt, F			New frog family from India reveals an ancient biogeographical link with the Seychelles	NATURE			English	Article							PHYLOGENETIC-RELATIONSHIPS; MADAGASCAN; AMPHIBIA	About 96% of the more than 4,800 living anuran species(1) belong to the Neobatrachia or advanced frogs(2-4). Because of the extremely poor representation of these animals in the Mesozoic fossil record, hypotheses on their early evolution have to rely largely on extant taxa(5-7). Here we report the discovery of a burrowing frog from India that is noticeably distinct from known taxa in all anuran families. Phylogenetic analyses of 2.8 kilobases of mitochondrial and nuclear DNA unambiguously designate this frog as the sister taxon of Sooglossidae, a family exclusively occurring on two granitic islands of the Seychelles archipelago(8). Furthermore, molecular clock analyses(9) uncover the branch leading to both taxa as an ancient split in the crown-group Neobatrachia. Our discovery discloses a lineage that may have been more diverse on Indo-Madagascar in the Cretaceous period, but now only comprises four species on the Seychelles and a sole survivor in India. Because of its very distinct morphology and an inferred origin that is earlier than several neobatrachian families(10), we recognize this frog as a new family.	Free Univ Brussels, Dept Biol, Unit Ecol & Systemat, B-1050 Brussels, Belgium; Trop Bot Garden & Res Inst, Thiruvananthapuram 695562, Kerala, India	Universite Libre de Bruxelles; Vrije Universiteit Brussel; KSCSTE-Jawaharlal Nehru Tropical Botanic Garden & Research Institute (JNTBGRI)	Bossuyt, F (corresponding author), Free Univ Brussels, Dept Biol, Unit Ecol & Systemat, Pleinlaan 2, B-1050 Brussels, Belgium.	fbossuyt@vub.ac.be		Bossuyt, Franky/0000-0001-6804-9271				Avise JC, 1999, P NATL ACAD SCI USA, V96, P7358, DOI 10.1073/pnas.96.13.7358; BENTON MJ, 1997, VERTEBRATE PALAEONTO, P1; Bossuyt F, 2000, P NATL ACAD SCI USA, V97, P6585, DOI 10.1073/pnas.97.12.6585; Bossuyt F, 2001, SCIENCE, V292, P93, DOI 10.1126/science.1058875; COFFIN MF, 1992, AAPG MEMOIR, V53, P207; Duellman WE, 1986, BIOL AMPHIBIANS, P1; Feller AE, 1998, MOL PHYLOGENET EVOL, V9, P509, DOI 10.1006/mpev.1998.0500; Ford Linda S., 1993, Herpetological Monographs, V7, P94, DOI 10.2307/1466954; FROST DR, 2002, AMPHIBIAN SPECIES WO; Gao KQ, 2003, NATURE, V422, P424, DOI 10.1038/nature01491; HAY JM, 1995, MOL BIOL EVOL, V12, P928; Hay WW, 1999, GEOL S AM S, P1; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Krause DW, 2001, NATURE, V412, P497, DOI 10.1038/35087649; Krause DW, 1997, NATURE, V390, P504, DOI 10.1038/37343; Lemmon AR, 2002, P NATL ACAD SCI USA, V99, P10516, DOI 10.1073/pnas.162224399; Lynch J. D., 1971, Misc Publs Mus nat Hist Univ Kansas, VNo. 53, P1; NUSSBAUM RA, 1980, HERPETOLOGICA, V36, P1; NUSSBAUM RA, 1979, CARYOLOGIA, V32, P279, DOI 10.1080/00087114.1979.10796793; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Ruta M, 2003, BIOL REV, V78, P251, DOI 10.1017/S1464793102006103; Ruvinsky I, 1996, MOL PHYLOGENET EVOL, V5, P533, DOI 10.1006/mpev.1996.0048; Savage J.M., 1973, EVOLUTIONARY BIOL AN, P351; SPINAR Z V, 1985, Amphibia-Reptilia, V6, P363, DOI 10.1163/156853885X00353; Swofford D.L., 2002, PAUP PHYLOGENETIC AN; Thorne JL, 2002, SYST BIOL, V51, P689, DOI 10.1080/10635150290102456; TYLER MJ, 1985, HERPETOLOGICA, V41, P173; Wilkinson M, 2002, MOL PHYLOGENET EVOL, V23, P401, DOI 10.1016/S1055-7903(02)00031-3	28	248	269	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	2003	425	6959					711	714		10.1038/nature02019	http://dx.doi.org/10.1038/nature02019			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562102				2022-12-28	WOS:000185924500040
J	Kubatkin, S; Danilov, A; Hjort, M; Cornil, J; Bredas, JL; Stuhr-Hansen, N; Hedegard, P; Bjornholm, T				Kubatkin, S; Danilov, A; Hjort, M; Cornil, J; Bredas, JL; Stuhr-Hansen, N; Hedegard, P; Bjornholm, T			Single-electron transistor of a single organic molecule with access to several redox states	NATURE			English	Article							TRANSPORT; OLIGOMERS	A combination of classical Coulomb charging, electronic level spacings, spin, and vibrational modes determines the single-electron transfer reactions through nanoscale systems connected to external electrodes by tunnelling barriers(1). Coulomb charging effects have been shown to dominate such transport in semiconductor quantum dots(2), metallic(3) and semiconducting, nanoparticles, carbon nanotubes(5,6), and single molecules(7-9). Recently, transport has been shown to be also influenced by spin-through the Kondo effect-for both nanotubes(10) and single molecules(8,9), as well as by vibrational fine structure(7,11). Here we describe a single-electron transistor where the electronic levels of a single pi-conjugated molecule in several distinct charged states control the transport properties. The molecular electronic levels extracted from the single-electron-transistor measurements are strongly perturbed compared to those of the molecule in solution, leading to a very significant reduction of the gap between the highest occupied molecular orbital and the lowest unoccupied molecular orbital. We suggest, and verify by simple model calculations, that this surprising effect could be caused by image charges generated in the source and drain electrodes resulting in a strong localization of the charges on the molecule.	Univ Copenhagen, Dept Chem, Nanosci Ctr, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Niels Bohr Inst, DK-2100 Copenhagen, Denmark; Chalmers Univ Technol, Dept Microtechnol & Nanosci MC2, S-41296 Gothenburg, Sweden; Univ Arizona, Dept Chem, Tucson, AZ 85721 USA; Univ Mons, Ctr Res Mol Elect & Photon, Lab Chem Novel Mat, B-7000 Mons, Belgium	University of Copenhagen; University of Copenhagen; Niels Bohr Institute; Chalmers University of Technology; University of Arizona; University of Mons	Bjornholm, T (corresponding author), Univ Copenhagen, Dept Chem, Nanosci Ctr, Univ Pk 5, DK-2100 Copenhagen, Denmark.	tb@nano.ku.dk	Kubatkin, Sergey/O-6092-2014; Danilov, Andrey/AAC-7475-2022; Hedegård, Per/C-1954-2015; Bredas, Jean-Luc E/A-3431-2008	Kubatkin, Sergey/0000-0001-8551-9247; Danilov, Andrey/0000-0001-7838-8613; Hedegård, Per/0000-0002-6328-7462; Bredas, Jean-Luc E/0000-0001-7278-4471; Bjornholm, Thomas/0000-0002-2981-8290; Stuhr-Hansen, Nicolai/0000-0001-7497-8915				Averin D., 1991, MESOSCOPIC PHENOMENA, P173, DOI DOI 10.1016/B978-0-444-88454-1.50012-7; Cobden DH, 1998, PHYSICA B, V249, P132, DOI 10.1016/S0921-4526(98)00083-0; Cobden DH, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.046803; Comoretto D, 2000, PHYS REV B, V62, P10173, DOI 10.1103/PhysRevB.62.10173; Danilov AV, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.125312; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; HEINZE J, 1987, J CHEM SOC CHEM COMM, P701, DOI 10.1039/c39870000701; KLAMT A, 1993, J CHEM SOC PERK T 2, P799, DOI 10.1039/p29930000799; Klein DL, 1997, NATURE, V389, P699, DOI 10.1038/39535; Kouwenhoven LP, 2001, REP PROG PHYS, V64, P701, DOI 10.1088/0034-4885/64/6/201; Kouwenhoven LP, 1997, NATO ADV SCI I E-APP, V345, P105; Kubatkin SE, 2000, J LOW TEMP PHYS, V118, P307, DOI 10.1023/A:1004629630942; Liang WJ, 2002, NATURE, V417, P725, DOI 10.1038/nature00790; Likharev KK, 1999, P IEEE, V87, P606, DOI 10.1109/5.752518; Nygard J, 2000, NATURE, V408, P342, DOI 10.1038/35042545; Park H, 1999, APPL PHYS LETT, V75, P301, DOI 10.1063/1.124354; Park H, 2000, NATURE, V407, P57, DOI 10.1038/35024031; Pourtois G, 2002, J AM CHEM SOC, V124, P4436, DOI 10.1021/ja017150+; Ralph DC, 1997, PHYS REV LETT, V78, P4087, DOI 10.1103/PhysRevLett.78.4087; Stuhr-Hansen N, 2003, J ORG CHEM, V68, P1275, DOI 10.1021/jo0263770; Tans SJ, 1998, NATURE, V394, P761, DOI 10.1038/29494; van Houten H., 1992, SINGLE CHARGE TUNNEL; Vondrak T, 1999, J PHYS CHEM B, V103, P3449, DOI 10.1021/jp9846983; Zhitenev NB, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.226801	24	727	732	3	243	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	2003	425	6959					698	701		10.1038/nature02010	http://dx.doi.org/10.1038/nature02010			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562098				2022-12-28	WOS:000185924500036
J	Orrit, M				Orrit, M			The motions of an enzyme soloist	SCIENCE			English	Editorial Material							PROTEIN DYNAMICS		Leiden Univ, Leiden Inst Phys, Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Orrit, M (corresponding author), Leiden Univ, Leiden Inst Phys, POB 9504, Leiden, Netherlands.	orrit@molphys.leidenuniv.nl						Bockmann RA, 2002, NAT STRUCT BIOL, V9, P198, DOI 10.1038/nsb760; Columbus L, 2002, TRENDS BIOCHEM SCI, V27, P288, DOI 10.1016/S0968-0004(02)02095-9; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Ishima R, 2000, NAT STRUCT BIOL, V7, P740, DOI 10.1038/78963; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; Parak FG, 2003, REP PROG PHYS, V66, P103, DOI 10.1088/0034-4885/66/2/201; Weiss S, 2000, NAT STRUCT BIOL, V7, P724, DOI 10.1038/78941; Yang H, 2003, SCIENCE, V302, P262, DOI 10.1126/science.1086911; 1999, SCIENCE, V283, P1593	9	17	17	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					239	240		10.1126/science.1090850	http://dx.doi.org/10.1126/science.1090850			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551425				2022-12-28	WOS:000185825900027
J	Schibler, U				Schibler, U			Liver regeneration clocks on	SCIENCE			English	Editorial Material									Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland	University of Geneva	Schibler, U (corresponding author), Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland.	ueli.schibler@molbio.unige.ch						Bjarnason GA, 2002, CHRONOBIOL INT, V19, P129, DOI 10.1081/CBI-120002595; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3; Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271; Mori T, 1996, P NATL ACAD SCI USA, V93, P10183, DOI 10.1073/pnas.93.19.10183; OConnor PM, 1997, CANCER SURV, V29, P151; Potten CS, 2002, CELL PROLIFERAT, V35, P1, DOI 10.1046/j.1365-2184.35.s1.1.x; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Schernhammer ES, 2001, J NATL CANCER I, V93, P1563, DOI 10.1093/jnci/93.20.1563; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4	10	41	45	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					234	235		10.1126/science.1090810	http://dx.doi.org/10.1126/science.1090810			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551421				2022-12-28	WOS:000185825900023
J	Vaidya, JS; Lalude, O; Grant, D; Mukhtar, H				Vaidya, JS; Lalude, O; Grant, D; Mukhtar, H			Gallstone ileus	LANCET			English	Editorial Material									Whittington Hosp, Royal Free & Univ Coll Med Sch, Dept Surg, London N19 5NF, England; Whittington Hosp, Royal Free & Univ Coll Med Sch, Dept Radiol, London N19 5NF, England	University of London; University College London; University of London; University College London	Vaidya, JS (corresponding author), Whittington Hosp, Royal Free & Univ Coll Med Sch, Dept Surg, London N19 5NF, England.		de Mey, Johan/F-3602-2011; Panda, Nikhil/W-7798-2019; van der Vliet, J. Adam/L-4721-2015; Vaidya, Jayant S/A-7218-2008; Vaidya, Jayant S/F-7717-2010; Besselink, Marc/H-3294-2019; Samarkos, Michael/Q-5104-2019; Eglinton, Tim W/H-8606-2019	Vaidya, Jayant S/0000-0003-1760-1278; Vaidya, Jayant S/0000-0003-1760-1278; Samarkos, Michael/0000-0001-9630-9712; 					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 4	2003	362	9390					1105	1105		10.1016/S0140-6736(03)14465-0	http://dx.doi.org/10.1016/S0140-6736(03)14465-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728HA	14550697	Bronze			2022-12-28	WOS:000185710700009
J	Langley, JD; Kypri, K; Stephenson, SCR				Langley, JD; Kypri, K; Stephenson, SCR			Secondhand effects of alcohol use among university students: computerised survey	BRITISH MEDICAL JOURNAL			English	Article							DRINKING		Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Injury Prevent Res Unit, Dunedin 9000, New Zealand	University of Otago	Langley, JD (corresponding author), Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Injury Prevent Res Unit, Dunedin 9000, New Zealand.		Kypri, Kypros/D-2809-2009	Kypri, Kypros/0000-0002-9657-9904				Kypri K, 2003, ALCOHOL ALCOHOLISM, V38, P437, DOI 10.1093/alcalc/agg107; Kypri K, 2002, ALCOHOL ALCOHOLISM, V37, P457, DOI 10.1093/alcalc/37.5.457; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Turner CF, 1998, SCIENCE, V280, P867, DOI 10.1126/science.280.5365.867; Wechsler H, 2002, J AM COLL HEALTH, V50, P203, DOI 10.1080/07448480209595713	5	55	56	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 1	2003	327	7422					1023	1024		10.1136/bmj.327.7422.1023	http://dx.doi.org/10.1136/bmj.327.7422.1023			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738NE	14593036	Bronze, Green Published			2022-12-28	WOS:000186294100021
J	Clarkson, TW; Magos, L; Myers, GJ				Clarkson, TW; Magos, L; Myers, GJ			The toxicology of mercury - Current exposures and clinical manifestations	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PRENATAL METHYLMERCURY EXPOSURE; DENTAL AMALGAM FILLINGS; MYOCARDIAL-INFARCTION; RISK; POPULATION; VACCINES; DISEASE; FISH; MEN; ETHYLMERCURY		Univ Rochester, Sch Med, Dept Environm Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Neurol, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Pediat, Rochester, NY 14642 USA; MRC Labs, Carshalton, Surrey, England	University of Rochester; University of Rochester; University of Rochester	Clarkson, TW (corresponding author), Univ Rochester, Sch Med, Dept Environm Med, Box EHSC, Rochester, NY 14642 USA.		Myers, Gary J/I-4901-2013	Myers, Gary J/0000-0003-4317-015X	NIEHS NIH HHS [P30 ES01247, R01 ES10219] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010219, P30ES001247] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agency for Toxic Substances and Disease Registry, 1999, TOX PROF MERC; Ahlqwist M, 1999, ACTA ODONTOL SCAND, V57, P168; BAKIR F, 1973, SCIENCE, V181, P230, DOI 10.1126/science.181.4096.230; Ball LK, 2001, PEDIATRICS, V107, P1147, DOI 10.1542/peds.107.5.1147; Bjorkman L, 1996, COMMUNITY DENT ORAL, V24, P260, DOI 10.1111/j.1600-0528.1996.tb00856.x; BLUHM RE, 1992, HUM EXP TOXICOL, V11, P201, DOI 10.1177/096032719201100308; Bolger PM, 2002, NEW ENGL J MED, V347, P1735, DOI 10.1056/NEJMp020139; BRUNE D, 1991, SCI TOTAL ENVIRON, V100, P235, DOI 10.1016/0048-9697(91)90380-W; Centers for Disease Control and Prevention (CDC), 2003, 2 CDCP; Clarkson TW, 2002, ENVIRON HEALTH PERSP, V110, P11, DOI 10.1289/ehp.02110s111; *ENV PROT AG, 2001, REF DOS CHRON EXP ME; *ENV PROT AG, 2001, EPA823R01001; ETO K, 1992, MOL CHEM NEUROPATHOL, V16, P171, DOI 10.1007/BF03159968; Forman J, 2000, ENVIRON HEALTH PERSP, V108, P575, DOI 10.2307/3454622; Freed GL, 2002, PEDIATRICS, V109, P1153, DOI 10.1542/peds.109.6.1153; Gibson R, 2000, CHICAGO TRIBUNE 0914, P1; Goldwater L., 1972, MERCURY HIST QUICKSI; GOSSEL TA, 1990, PRINCIPLES CLIN TOXI; GRANDJEAN P, 1992, ARCH ENVIRON HEALTH, V47, P185, DOI 10.1080/00039896.1992.9938348; Grandjean P, 1997, NEUROTOXICOL TERATOL, V19, P417, DOI 10.1016/S0892-0362(97)00097-4; Guallar E, 2002, NEW ENGL J MED, V347, P1747, DOI 10.1056/NEJMoa020157; HUNTER D, 1969, DIS OCCUPATIONS, P314; IPCS, 1990, ENV HLTH CRIT 101 ME; JEMELOV A, 1969, CHEM FALLOUT CURRENT, P68; Johnels A. G., 1969, CHEM FALLOUT CURRENT, P221; *JOINT FAO WHO EXP, 1978, WHO TECH REP SER, V631, P1; Kingman A, 1998, J DENT RES, V77, P461, DOI 10.1177/00220345980770030501; Kjellstrom T., 1989, 3642 SOLN NAT SWED E; Leong CCW, 2001, NEUROREPORT, V12, P733, DOI 10.1097/00001756-200103260-00024; LIKOSKY WH, 1970, ORGANIC MERCURY POIS, V20, P401; Magos L, 2001, J APPL TOXICOL, V21, P1, DOI 10.1002/jat.721; MAGOS L, 1985, ARCH TOXICOL, V57, P260, DOI 10.1007/BF00324789; MOLIN M, 1990, ACTA ODONTOL SCAND, V48, P189, DOI 10.3109/00016359009005875; Myers GJ, 2003, LANCET, V361, P1686, DOI 10.1016/S0140-6736(03)13371-5; National Research Council, 2000, TOX EFF METH MERC; Nierenberg DW, 1998, NEW ENGL J MED, V338, P1672, DOI 10.1056/NEJM199806043382305; Pfab R, 1996, J TOXICOL-CLIN TOXIC, V34, P453, DOI 10.3109/15563659609013818; Pichichero ME, 2002, LANCET, V360, P1737, DOI 10.1016/S0140-6736(02)11682-5; Ramazzini B, 1964, DIS WORKERS; Riley DM, 2001, ENVIRON HEALTH PERSP, V109, P779, DOI 10.2307/3454819; Sallsten G, 1996, J DENT RES, V75, P594, DOI 10.1177/00220345960750011301; Salonen JT, 2000, ATHEROSCLEROSIS, V148, P265, DOI 10.1016/S0021-9150(99)00272-5; SALONEN JT, 1995, CIRCULATION, V91, P645, DOI 10.1161/01.CIR.91.3.645; SAXE SR, 1995, J AM DENT ASSOC, V126, P1495, DOI 10.14219/jada.archive.1995.0078; Smith JC, 1996, TOXICOL APPL PHARM, V137, P245, DOI 10.1006/taap.1996.0078; Sorensen N, 1999, EPIDEMIOLOGY, V10, P370, DOI 10.1097/00001648-199907000-00006; *STRAT ADV GROUP E, 2002, WKLY EPIDEMIOL REC, V77, P305; *US PHARM CONV, 1999, USP, V24; WARKANY J, 1953, J PEDIATR-US, V42, P365, DOI 10.1016/S0022-3476(53)80195-2; World Health Organization, 1991, ENV HLTH CRIT, V118; Yoshizawa K, 2002, NEW ENGL J MED, V347, P1755, DOI 10.1056/NEJMoa021437; 2001, JAMA, V4285, P1436	52	1276	1339	14	349	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	2003	349	18					1731	1737		10.1056/NEJMra022471	http://dx.doi.org/10.1056/NEJMra022471			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	737FJ	14585942				2022-12-28	WOS:000186219500009
J	Genzel, R; Schodel, R; Ott, T; Eckart, A; Alexander, T; Lacombe, F; Rouan, D; Aschenbach, B				Genzel, R; Schodel, R; Ott, T; Eckart, A; Alexander, T; Lacombe, F; Rouan, D; Aschenbach, B			Near-infrared flares from accreting gas around the supermassive black hole at the Galactic Centre	NATURE			English	Article							SAGITTARIUS-A-ASTERISK; X-RAY FLARE; SGR-A; VARIABILITY; GALAXY; STAR; VLT	Recent measurements of stellar orbits(1-3) provide compelling evidence that the compact radio source Sagittarius A* ( refs 4, 5) at the Galactic Centre is a 3.6-million-solar-mass black hole. Sgr A* is remarkably faint in all wavebands other than the radio region(6,7), however, which challenges current theories of matter accretion and radiation surrounding black holes(8). The black hole's rotation rate is not known, and therefore neither is the structure of space-time around it. Here we report high-resolution infrared observations of Sgr A* that reveal 'quiescent' emission and several flares. The infrared emission originates from within a few milliarcseconds of the black hole, and traces very energetic electrons or moderately hot gas within the innermost accretion region. Two flares exhibit a 17-minute quasi-periodic variability. If the periodicity arises from relativistic modulation of orbiting gas, the emission must come from just outside the event horizon, and the black hole must be rotating at about half of the maximum possible rate.	Max Planck Inst Extraterr Phys, Giessenbachstr 1, D-85748 Garching, Germany; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Cologne, Inst Phys 1, D-50937 Cologne, Germany; Weizmann Inst Sci, Fac Phys, IL-76100 Rehovot, Israel; Observ Paris, Sect Meudon, F-92195 Meudon, France	Max Planck Society; University of California System; University of California Berkeley; University of Cologne; Weizmann Institute of Science; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris	Genzel, R (corresponding author), Max Planck Inst Extraterr Phys, Giessenbachstr 1, D-85748 Garching, Germany.	genzel@mpe-garching.mpg.de	Schoedel, Rainer/D-4751-2014	Schoedel, Rainer/0000-0001-5404-797X				Alexander T, 1999, ASTROPHYS J, V520, P137, DOI 10.1086/307446; Backer DC, 1999, ASTROPHYS J, V524, P805, DOI 10.1086/307857; Baganoff FK, 2003, ASTROPHYS J, V591, P891, DOI 10.1086/375145; Baganoff FK, 2001, NATURE, V413, P45, DOI 10.1038/35092510; BAGANOFF FK, 2003, HIGH EN ASTR DIV HEA, P35; BARDEEN JM, 1972, ASTROPHYS J, V178, P347, DOI 10.1086/151796; BARDEEN JM, 1975, ASTROPHYS J, V105, pL65; Benlloch S, 2001, ASTROPHYS J, V562, pL121, DOI 10.1086/338252; DEVILLIERS JP, 2003, UNPUB ASTROPHYS J; Doeleman SS, 2001, ASTRON J, V121, P2610, DOI 10.1086/320376; Eisenhauer F, 2003, ASTROPHYS J, V597, pL121, DOI 10.1086/380188; Ghez AM, 2003, ASTROPHYS J, V586, pL127, DOI 10.1086/374804; GHEZ AM, 2003, UNPUB ASTROPHYS J LE; Hollywood JM, 1997, ASTROPHYS J SUPPL S, V112, P423, DOI 10.1086/313036; Hornstein SD, 2002, ASTROPHYS J, V577, pL9, DOI 10.1086/344098; Lenzen R, 1998, P SOC PHOTO-OPT INS, V3354, P606, DOI 10.1117/12.317287; Liu SM, 2001, ASTROPHYS J, V561, pL77, DOI 10.1086/324514; Markoff S, 2001, ASTRON ASTROPHYS, V379, pL13, DOI 10.1051/0004-6361:20011346; Melia F, 2001, ANNU REV ASTRON ASTR, V39, P309, DOI 10.1146/annurev.astro.39.1.309; Melia F, 2001, ASTROPHYS J, V554, pL37, DOI 10.1086/320918; Miyazaki A, 2003, ASTRON NACHR, V324, P363, DOI 10.1002/asna.200385071; NAYAKSHIN S, 2003, IN PRESS ASTRON ASTR; Nowak MA, 1997, ASTROPHYS J, V477, pL91, DOI 10.1086/310534; Porquet D, 2003, ASTRON ASTROPHYS, V407, pL17, DOI 10.1051/0004-6361:20030983; Rousset G, 1998, P SOC PHOTO-OPT INS, V3353, P508, DOI 10.1117/12.321686; Schodel R, 2002, NATURE, V419, P694, DOI 10.1038/nature01121; Yuan F, 2002, ASTRON ASTROPHYS, V383, P854, DOI 10.1051/0004-6361:20011709; YUAN F, 2003, UNPUB ASTROPHYS J; Zhao JH, 2003, ASTROPHYS J, V586, pL29, DOI 10.1086/374581	29	507	510	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 30	2003	425	6961					934	937		10.1038/nature02065	http://dx.doi.org/10.1038/nature02065			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14586462				2022-12-28	WOS:000186230600034
J	Herschman, HR				Herschman, HR			Molecular imaging: Looking at problems, seeing solutions	SCIENCE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; GENE-EXPRESSION; DRUG DISCOVERY; MICE; LIGHT	Noninvasive molecular-imaging technologies are providing researchers with exciting new opportunities to study small-animal models of human disease. With continued improvements in instrumentation, identification of better imaging targets by genome-based approaches, and design of better imaging probes by innovative chemistry, these technologies promise to play increasingly important roles in disease diagnosis and therapy.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol Med Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Herschman, HR (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, 341 Boyer Hall,611 Charles E Young Dr E, Los Angeles, CA 90095 USA.	hherschman@mednet.ucla.edu			NATIONAL CANCER INSTITUTE [R01CA084572] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA88306, R01 CA84572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JY, 2002, NAT MED, V8, P891, DOI 10.1038/nm743; Blasberg RG, 2003, J CLIN INVEST, V111, P1620, DOI 10.1172/JCI200318855; Burns HD, 1999, CURR OPIN CHEM BIOL, V3, P388, DOI 10.1016/S1367-5931(99)80059-3; Contag CH, 2002, ANNU REV BIOMED ENG, V4, P235, DOI 10.1146/annurev.bioeng.4.111901.093336; Dubey P, 2003, P NATL ACAD SCI USA, V100, P1232, DOI 10.1073/pnas.0337418100; Funovics M, 2003, ANAL BIOANAL CHEM, V377, P956, DOI 10.1007/s00216-003-2199-0; GAMBHIR SS, COMMUNICATION; Halldin C, 2001, CURR PHARM DESIGN, V7, P1907, DOI 10.2174/1381612013396871; Herschman HR, 2002, J CELL BIOCHEM, P36, DOI 10.1002/jcb.10402; HERSCHMAN HR, 2002, VECTOR TARGETING THE, P661; Koehne G, 2003, NAT BIOTECHNOL, V21, P405, DOI 10.1038/nbt805; Laxman B, 2002, P NATL ACAD SCI USA, V99, P16551, DOI 10.1073/pnas.252644499; Liang QW, 2002, MOL THER, V6, P73, DOI 10.1006/mthe.2002.0626; Mahmood U, 2002, RADIOLOGY, V224, P446, DOI 10.1148/radiol.2242011589; Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403; Ntziachristos V, 2003, EUR RADIOL, V13, P195, DOI 10.1007/s00330-002-1524-x; Rudin M, 2003, NAT REV DRUG DISCOV, V2, P123, DOI 10.1038/nrd1007; Tai YC, 2003, PHYS MED BIOL, V48, P1519, DOI 10.1088/0031-9155/48/11/303; Volkow ND, 2001, BIOL PSYCHIAT, V49, P211, DOI 10.1016/S0006-3223(00)01112-4; Vooijs M, 2002, CANCER RES, V62, P1862; Wagenaar DJ, 2001, ACAD RADIOL, V8, P409, DOI 10.1016/S1076-6332(03)80549-4; Weissleder R, 2003, NAT MED, V9, P123, DOI 10.1038/nm0103-123; Zhang WS, 2001, TRANSGENIC RES, V10, P423, DOI 10.1023/A:1012042506002	23	321	351	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	2003	302	5645					605	608		10.1126/science.1090585	http://dx.doi.org/10.1126/science.1090585			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576425				2022-12-28	WOS:000186119900048
J	Wang, L				Wang, L			Expanding the genetic code	SCIENCE			English	Editorial Material							UNNATURAL AMINO-ACID; ESCHERICHIA-COLI; TRANSFER-RNA; GENERATION; PROTEINS		Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Wang, L (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.		Wang, Lei/E-7912-2011	Wang, Lei/0000-0002-5859-2526				BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; Knight RD, 2001, NAT REV GENET, V2, P49, DOI 10.1038/35047500; Liu HT, 2003, J AM CHEM SOC, V125, P1702, DOI 10.1021/ja029433n; Mehl RA, 2003, J AM CHEM SOC, V125, P935, DOI 10.1021/ja0284153; Sakamoto K, 2002, NUCLEIC ACIDS RES, V30, P4692, DOI 10.1093/nar/gkf589; Srinivasan G, 2002, SCIENCE, V296, P1459, DOI 10.1126/science.1069588; Walsh CT, 2001, CURR OPIN CHEM BIOL, V5, P525, DOI 10.1016/S1367-5931(00)00235-0; Wang L, 2001, CHEM BIOL, V8, P883, DOI 10.1016/S1074-5521(01)00063-1; Wang L, 2001, SCIENCE, V292, P498, DOI 10.1126/science.1060077; Wang L, 2003, P NATL ACAD SCI USA, V100, P56, DOI 10.1073/pnas.0234824100; Wang L, 2000, J AM CHEM SOC, V122, P5010, DOI 10.1021/ja000595y; Wang L, 2003, J ORG CHEM, V68, P174, DOI 10.1021/jo026570u; Wang L, 2002, J AM CHEM SOC, V124, P1836, DOI 10.1021/ja012307j; Wang L, 2002, THESIS U CALIFORNIA	15	7	8	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					584	585		10.1126/science.302.5645.584	http://dx.doi.org/10.1126/science.302.5645.584			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	14576413				2022-12-28	WOS:000186119900037
J	Das, A; Ben-Menachem, T; Cooper, GS; Chak, A; Sivak, MV; Gonet, JA; Wong, RCK				Das, A; Ben-Menachem, T; Cooper, GS; Chak, A; Sivak, MV; Gonet, JA; Wong, RCK			Prediction of outcome in acute lower-gastrointestinal haemorrhage based on an artificial neural network: internal and external validation of a predictive model	LANCET			English	Article; Proceedings Paper	Digestive Disease Week Meeting/102nd Annual Meeting of the American-Gastroenterological-Association	MAY 20-23, 2001	ATLANTA, GA	Amer Gastroenterol Assoc			DIAGNOSIS; DECISION	Background Models based on artificial neural networks (ANN) are useful in predicting outcome of various disorders. There is currently no useful predictive model for risk assessment in acute lower-gastrointestinal haemorrhage. We investigated whether ANN models using information available during triage could predict clinical outcome in patients with this disorder. Methods ANN and multiple-logistic-regression (MLR) models were constructed from non-endoscopic data of patients admitted with acute lower-gastrointestinal haemorrhage. The performance of ANN in classifying patients into high-risk and low-risk groups was compared with that of another validated scoring system (BLEED), with the outcome variables recurrent bleeding, death, and therapeutic interventions for control of haemorrhage. The ANN models were trained with data from patients admitted to the primary institution during the first 12 months (n=120) and then internally validated with data from patients admitted to the same institution during the next 6 months (n=70). The ANN models were then externally validated and direct comparison made with MLR in patients admitted to an independent institution in another US state (n=142). Findings Clinical features were similar for training and validation groups. The predictive accuracy of ANN was significantly better than that of BLEED (predictive accuracy in internal validation group for death 87% vs 21%; for recurrent bleeding 89% vs 41%; and for intervention 96% vs 46%) and similar to MLR. During external validation, ANN performed well in predicting death (97%), recurrent bleeding (93%), and need for intervention (94%), and it was superior to MLR (70%. 73%, and 70%, respectively). Interpretation ANN can accurately predict the outcome for patients presenting with acute lower-gastrointestinal haemorrhage and may be generally useful for the risk stratification of these patients.	Case Western Reserve Univ, Univ Hosp Cleveland, Dept Med, Div Gastroenterol, Cleveland, OH 44106 USA; Henry Ford Hosp, Div Gastroenterol, Detroit, MI 48202 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Henry Ford Health System; Henry Ford Hospital	Wong, RCK (corresponding author), Univ Hosp Cleveland, Div Gastroenterol Wearn 247, 11100 Euclid Ave, Cleveland, OH 44106 USA.	rxw16@po.cwru.edu						BAXT WG, 1992, ANN EMERG MED, V21, P1439, DOI 10.1016/S0196-0644(05)80056-3; BAXT WG, 1995, LANCET, V346, P1135, DOI 10.1016/S0140-6736(95)91804-3; BAXT WG, 1991, ANN INTERN MED, V115, P843, DOI 10.7326/0003-4819-115-11-843; BLAKELEY DD, 1995, ANN INTERN MED, V122, P360, DOI 10.7326/0003-4819-122-5-199503010-00007; Blatchford O, 2000, LANCET, V356, P1318, DOI 10.1016/S0140-6736(00)02816-6; Bottaci L, 1997, LANCET, V350, P469, DOI 10.1016/S0140-6736(96)11196-X; CROSS SS, 1995, LANCET, V346, P1075, DOI 10.1016/S0140-6736(95)91746-2; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hay JA, 1997, JAMA-J AM MED ASSOC, V278, P2151, DOI 10.1001/jama.278.24.2151; Haykin S., 1994, NEURAL NETWORKS, DOI 10.5555/521706; Heden B, 1997, CIRCULATION, V96, P1798, DOI 10.1161/01.CIR.96.6.1798; Jensen DM, 2000, NEW ENGL J MED, V342, P78, DOI 10.1056/NEJM200001133420202; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; Klenzak JS, 1996, GASTROINTEST ENDOSC, V43, P247; Kollef MH, 1997, CRIT CARE MED, V25, P1125, DOI 10.1097/00003246-199707000-00011; Lapuerta P, 1997, HEPATOLOGY, V25, P302; Morris AH, 2000, ANN INTERN MED, V132, P373, DOI 10.7326/0003-4819-132-5-200003070-00007; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; SCHROCK TR, 1989, SURG CLIN N AM, V69, P1309; Selaru FM, 2002, GASTROENTEROLOGY, V122, P606, DOI 10.1053/gast.2002.31904; Sinha M, 2001, J TRAUMA, V50, P308, DOI 10.1097/00005373-200102000-00018; TOURASSI GD, 1993, RADIOLOGY, V189, P555, DOI 10.1148/radiology.189.2.8210389; Vreeburg EM, 1999, GUT, V44, P331, DOI 10.1136/gut.44.3.331; Zuckerman GR, 1999, GASTROINTEST ENDOSC, V49, P228, DOI 10.1016/S0016-5107(99)70491-8; Zuckerman GR, 1998, GASTROINTEST ENDOSC, V48, P606, DOI 10.1016/S0016-5107(98)70043-4	25	135	139	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	2003	362	9392					1261	1266		10.1016/S0140-6736(03)14568-0	http://dx.doi.org/10.1016/S0140-6736(03)14568-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	734CD	14575969				2022-12-28	WOS:000186036900008
J	Duke, T; Molyneux, EM				Duke, T; Molyneux, EM			Intravenous fluids for seriously ill children: time to reconsider	LANCET			English	Editorial Material							ARGININE-VASOPRESSIN; HYPONATREMIC ENCEPHALOPATHY; ANTIDIURETIC-HORMONE; MENINGITIS; RESTRICTION; MANAGEMENT; SODIUM; SECRETION; SEPSIS; PLASMA		Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Ctr Int Child Hlth, Parkville, Vic 3052, Australia; Coll Med, Dept Paediat, Blantyre, Malawi	Royal Children's Hospital Melbourne; University of Melbourne; University of Malawi	Duke, T (corresponding author), Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Ctr Int Child Hlth, Flemington Rd, Parkville, Vic 3052, Australia.	Trevor.duke@rch.org.au						ARIEFF AI, 2002, NEW ENGL J MED, V314, P1529; BILBREY GL, 1973, ANN SURG, V177, P112, DOI 10.1097/00000658-197301000-00020; COOKE RE, 1972, CLIN PEDIATR, V11, P493; DHAWAN A, 1992, ANN TROP PAEDIATR, V12, P455, DOI 10.1080/02724936.1992.11747614; Duke T, 2002, ANN TROP PAEDIATR, V22, P145, DOI 10.1179/027249302125000878; Dunn K, 1997, J PAEDIATR CHILD H, V33, P26, DOI 10.1111/j.1440-1754.1997.tb00986.x; English MC, 1996, ARCH DIS CHILD, V74, P201, DOI 10.1136/adc.74.3.201; Halberthal M, 2001, BRIT MED J, V322, P780, DOI 10.1136/bmj.322.7289.780; HANNON RJ, 1990, J PEDIATR SURG, V25, P599, DOI 10.1016/0022-3468(90)90342-7; Hughes PD, 1998, AUST NZ J SURG, V68, P165, DOI 10.1111/j.1445-2197.1998.tb04735.x; Jackson J, 2000, AM J EMERG MED, V18, P269, DOI 10.1016/S0735-6757(00)90119-0; Jensen AG, 1999, ARCH INTERN MED, V159, P1437, DOI 10.1001/archinte.159.13.1437; KANAKRIYEH M, 1987, CLIN PEDIATR, V26, P126, DOI 10.1177/000992288702600304; Levine JP, 2001, PLAST RECONSTR SURG, V108, P1501, DOI 10.1097/00006534-200111000-00009; McJunkin JE, 2001, NEW ENGL J MED, V344, P801, DOI 10.1056/NEJM200103153441103; Moller K, 2001, SCAND J INFECT DIS, V33, P13; MOR J, 1975, AM J DIS CHILD, V129, P133, DOI 10.1001/archpedi.1975.02120380101024; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Paut O, 2000, ANN FR ANESTH, V19, P467; Poddar U, 1995, Indian Pediatr, V32, P59; POTTS FL, 1986, ANN EMERG MED, V15, P834, DOI 10.1016/S0196-0644(86)80385-7; POWELL KR, 1990, J PEDIATR-US, V117, P515, DOI 10.1016/S0022-3476(05)80682-1; Schwenk A, 2000, CLIN NUTR, V19, P35, DOI 10.1054/clnu.1999.0070; SHARPLES PM, 1992, ARCH DIS CHILD, V67, P998, DOI 10.1136/adc.67.8.998; SINGHI SC, 1995, PEDIATR INFECT DIS J, V14, P495, DOI 10.1097/00006454-199506000-00006; SOWUNMI A, 2002, AFR J MED SCI, V25, P47; STERNS RH, 1986, NEW ENGL J MED, V314, P1535, DOI 10.1056/NEJM198606123142402; THOMAS TH, 1979, BRIT J SURG, V66, P540, DOI 10.1002/bjs.1800660806; Vajda Z, 2001, NEUROSURGERY, V49, P697, DOI 10.1097/00006123-200109000-00031; von Vigier RO, 2001, AM J NEPHROL, V21, P87, DOI 10.1159/000046229; *WHO, 2000, MAN CHILD SER INF SE, P64; WINTERS RW, 1973, BODY FLUIDS PEDIATRI, P113; Zornow M H, 1995, New Horiz, V3, P488	33	88	93	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	2003	362	9392					1320	1323		10.1016/S0140-6736(03)14577-1	http://dx.doi.org/10.1016/S0140-6736(03)14577-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575980				2022-12-28	WOS:000186036900028
J	Foerster, K; Delhey, K; Johnsen, A; Lifjeld, JT; Kempenaers, B				Foerster, K; Delhey, K; Johnsen, A; Lifjeld, JT; Kempenaers, B			Females increase offspring heterozygosity and fitness through extra-pair matings	NATURE			English	Article							TIT PARUS-CAERULEUS; BLUE TIT; MATE CHOICE; GENETIC SIMILARITY; PATERNITY; MICROSATELLITES; POPULATIONS; POLYANDRY; PARENTAGE; BENEFITS	Females in a variety of species commonly mate with multiple males, and there is evidence that they benefit by producing offspring of higher genetic quality(1-3); however, the nature of these genetic benefits is debated(1-4). Enhanced offspring survival or quality can result from intrinsic effects of paternal genes- 'good genes'-or from interactions between the maternal and paternal genomes-'compatible genes'(1-5). Evidence for the latter process is accumulating(2,6): matings between relatives lead to decreased reproductive success, and the individual level of inbreeding-measured as average heterozygosity-is a strong fitness predictor(7-13). Females should thus benefit from mating with genetically dissimilar males(2,14). In many birds, social monogamy restricts mate choice, but females may circumvent this by pursuing extra-pair copulations(15,16). Here we show that female blue tits, Parus caeruleus, increase the heterozygosity of their progeny through extra-pair matings. Females thereby produce offspring of higher reproductive value, because less inbred individuals have increased survival chances, a more elaborate male secondary sexual trait (crown colour) and higher reproductive success. The cost of inbreeding may therefore be an important factor driving the evolution of female extra-pair mating.	Max Planck Res Ctr Ornithol, D-82305 Starnberg, Germany; Univ Oslo, Zool Museum, N-0318 Oslo, Norway	Max Planck Society; University of Oslo	Kempenaers, B (corresponding author), Max Planck Res Ctr Ornithol, POB 1564, D-82305 Starnberg, Germany.		Lifjeld, Jan T/B-1978-2008; Delhey, Kaspar/AAZ-5362-2020; Delhey, Kaspar/F-6515-2010; Foerster, Katharina/AAX-3894-2020	Lifjeld, Jan T/0000-0002-9172-9985; Delhey, Kaspar/0000-0001-5190-5406; Johnsen, Arild/0000-0003-4864-6284; Kempenaers, Bart/0000-0002-7505-5458				Amos W, 2001, P ROY SOC B-BIOL SCI, V268, P2021, DOI 10.1098/rspb.2001.1751; Andersson S, 1998, P ROY SOC B-BIOL SCI, V265, P445, DOI 10.1098/rspb.1998.0315; Aparicio JM, 2001, ANIM BEHAV, V62, P1001, DOI 10.1006/anbe.2001.1840; Bensch S, 1997, MOL ECOL, V6, P91, DOI 10.1046/j.1365-294X.1997.00150.x; Blomqvist D, 2002, NATURE, V419, P613, DOI 10.1038/nature01104; Brown JL, 1997, BEHAV ECOL, V8, P60, DOI 10.1093/beheco/8.1.60; Coltman DW, 1998, P ROY SOC B-BIOL SCI, V265, P803, DOI 10.1098/rspb.1998.0363; Dawson DA, 2000, MOL ECOL, V9, P1941, DOI 10.1046/j.1365-294x.2000.01094-14.x; Fridolfsson AK, 1997, HEREDITAS, V126, P127, DOI 10.1111/j.1601-5223.1997.00127.x; Hansson B, 2001, P ROY SOC B-BIOL SCI, V268, P1287, DOI 10.1098/rspb.2001.1640; Hansson B, 2002, MOL ECOL, V11, P2467, DOI 10.1046/j.1365-294X.2002.01644.x; Hoglund J, 2002, P ROY SOC B-BIOL SCI, V269, P711, DOI 10.1098/rspb.2001.1937; Hunt S, 1999, ANIM BEHAV, V58, P809, DOI 10.1006/anbe.1999.1214; JAMIESON A, 1994, ANIM GENET, V25, P37, DOI 10.1111/j.1365-2052.1994.tb00401.x; Jennions MD, 2000, BIOL REV, V75, P21, DOI 10.1017/S0006323199005423; Kempenaers B, 1997, BEHAV ECOL, V8, P481, DOI 10.1093/beheco/8.5.481; Kempenaers B, 1996, P ROY SOC B-BIOL SCI, V263, P179, DOI 10.1098/rspb.1996.0029; KEMPENAERS B, 1992, NATURE, V357, P494, DOI 10.1038/357494a0; MITTON JB, 1993, HEREDITY, V71, P59, DOI 10.1038/hdy.1993.107; Pemberton J.M., 1999, MICROSATELLITES EVOL, P151; Petrie M, 1998, TRENDS ECOL EVOL, V13, P52, DOI 10.1016/S0169-5347(97)01232-9; Pusey A, 1996, TRENDS ECOL EVOL, V11, P201, DOI 10.1016/0169-5347(96)10028-8; Sheldon BC, 1999, NATURE, V402, P874, DOI 10.1038/47239; STOCKLEY P, 1993, P ROY SOC B-BIOL SCI, V254, P173, DOI 10.1098/rspb.1993.0143; Thornhill N.W., 1993, NATURAL HIST INBREED; Tregenza T, 2002, NATURE, V415, P71, DOI 10.1038/415071a; Tregenza T, 2000, MOL ECOL, V9, P1013, DOI 10.1046/j.1365-294x.2000.00964.x; TURELLI M, 1983, GENETICS, V104, P191; Zeh JA, 1996, P ROY SOC B-BIOL SCI, V263, P1711, DOI 10.1098/rspb.1996.0250; Zeh JA, 2001, ANIM BEHAV, V61, P1051, DOI 10.1006/anbe.2000.1705	30	396	402	6	245	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					714	717		10.1038/nature01969	http://dx.doi.org/10.1038/nature01969			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562103				2022-12-28	WOS:000185924500041
J	Grynszpan, D				Grynszpan, D			Lessons from the French heatwave	LANCET			English	Editorial Material							MORTALITY; WAVE		The Lancet, London NW1 7BY, England		Grynszpan, D (corresponding author), The Lancet, London NW1 7BY, England.							*COMM AFF CULT FAM, 2003, COMPT REND, V58; Hemon D., 2003, SURMORTALITE LIEE CA; *I VEILL SAN, 2003, IMP SAN VAG CHAL FRA; Klinenberg E., 2002, HEAT WAVE SOCIAL AUT; Lalande F., 2003, MISSION EXPERTISE EV; Naughton MP, 2002, AM J PREV MED, V22, P221, DOI 10.1016/S0749-3797(02)00421-X; Weisskopf MG, 2002, AM J PUBLIC HEALTH, V92, P830, DOI 10.2105/AJPH.92.5.830	7	33	33	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 11	2003	362	9391					1169	1170		10.1016/S0140-6736(03)14555-2	http://dx.doi.org/10.1016/S0140-6736(03)14555-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568735				2022-12-28	WOS:000185924100005
J	Kennedy, JG				Kennedy, JG			"Doc, tell me what I need to know" - a doctor's perspective	BRITISH MEDICAL JOURNAL			English	Article									Cedar Brook Practice, Middlesex UB4 8DD, England		Kennedy, JG (corresponding author), Cedar Brook Practice, 11 Kingshill Close, Middlesex UB4 8DD, England.							*DEP HLTH, 2001, EXP PAT NEW APPR CHR, P12; Edwards A, 2002, BMJ-BRIT MED J, V324, P827, DOI 10.1136/bmj.324.7341.827; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; National Audit Office, 1993, REP PRESCR GEN MED P; Say RE, 2003, BMJ-BRIT MED J, V327, P542, DOI 10.1136/bmj.327.7414.542	5	8	10	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					862	863		10.1136/bmj.327.7419.862	http://dx.doi.org/10.1136/bmj.327.7419.862			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551108	Green Published			2022-12-28	WOS:000185921200030
